CZ295843B6 - Multi-funkční chimérní agonisté hematopoietických receptorů - Google Patents
Multi-funkční chimérní agonisté hematopoietických receptorů Download PDFInfo
- Publication number
- CZ295843B6 CZ295843B6 CZ19991323A CZ132399A CZ295843B6 CZ 295843 B6 CZ295843 B6 CZ 295843B6 CZ 19991323 A CZ19991323 A CZ 19991323A CZ 132399 A CZ132399 A CZ 132399A CZ 295843 B6 CZ295843 B6 CZ 295843B6
- Authority
- CZ
- Czechia
- Prior art keywords
- xaa
- leu
- seq
- ser
- arg
- Prior art date
Links
- 230000003394 haemopoietic effect Effects 0.000 title claims abstract 48
- 239000000018 receptor agonist Substances 0.000 title claims abstract 16
- 229940044601 receptor agonist Drugs 0.000 title claims abstract 16
- 108090000623 proteins and genes Proteins 0.000 claims abstract 49
- 102000004169 proteins and genes Human genes 0.000 claims abstract 46
- 238000000034 method Methods 0.000 claims abstract 6
- 102000039446 nucleic acids Human genes 0.000 claims 474
- 108020004707 nucleic acids Proteins 0.000 claims 474
- 150000007523 nucleic acids Chemical class 0.000 claims 474
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 249
- 235000001014 amino acid Nutrition 0.000 claims 228
- 150000001413 amino acids Chemical class 0.000 claims 218
- BUZMZDDKFCSKOT-CIUDSAMLSA-N Glu-Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O BUZMZDDKFCSKOT-CIUDSAMLSA-N 0.000 claims 139
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 claims 108
- 108010055341 glutamyl-glutamic acid Proteins 0.000 claims 103
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 claims 99
- 108010050848 glycylleucine Proteins 0.000 claims 98
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims 87
- HDHZCEDPLTVHFZ-GUBZILKMSA-N Asn-Leu-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O HDHZCEDPLTVHFZ-GUBZILKMSA-N 0.000 claims 70
- 108010025198 decaglycine Proteins 0.000 claims 48
- YOKVEHGYYQEQOP-QWRGUYRKSA-N Leu-Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O YOKVEHGYYQEQOP-QWRGUYRKSA-N 0.000 claims 46
- 108010026333 seryl-proline Proteins 0.000 claims 43
- 235000018102 proteins Nutrition 0.000 claims 42
- XCIGOVDXZULBBV-DCAQKATOSA-N Ala-Val-Lys Chemical compound CC(C)[C@H](NC(=O)[C@H](C)N)C(=O)N[C@@H](CCCCN)C(O)=O XCIGOVDXZULBBV-DCAQKATOSA-N 0.000 claims 41
- 108010002311 N-glycylglutamic acid Proteins 0.000 claims 40
- 108010001064 glycyl-glycyl-glycyl-glycine Proteins 0.000 claims 39
- WZDCVAWMBUNDDY-KBIXCLLPSA-N Ile-Glu-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)O)N WZDCVAWMBUNDDY-KBIXCLLPSA-N 0.000 claims 38
- 108010091871 leucylmethionine Proteins 0.000 claims 38
- 101150014526 Gla gene Proteins 0.000 claims 37
- SQUTUWHAAWJYES-GUBZILKMSA-N Met-Asp-Arg Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SQUTUWHAAWJYES-GUBZILKMSA-N 0.000 claims 37
- 125000003275 alpha amino acid group Chemical group 0.000 claims 35
- UPLYXVPQLJVWMM-KKUMJFAQSA-N Ser-Phe-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O UPLYXVPQLJVWMM-KKUMJFAQSA-N 0.000 claims 34
- YBPLKDWJFYCZSV-ZLUOBGJFSA-N Ala-Asn-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CS)C(=O)O)N YBPLKDWJFYCZSV-ZLUOBGJFSA-N 0.000 claims 33
- SENJXOPIZNYLHU-UHFFFAOYSA-N L-leucyl-L-arginine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CCCN=C(N)N SENJXOPIZNYLHU-UHFFFAOYSA-N 0.000 claims 32
- YVKSMSDXKMSIRX-GUBZILKMSA-N Leu-Glu-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O YVKSMSDXKMSIRX-GUBZILKMSA-N 0.000 claims 32
- 108010087924 alanylproline Proteins 0.000 claims 32
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 claims 32
- 108010000761 leucylarginine Proteins 0.000 claims 32
- ZMUQQMGITUJQTI-CIUDSAMLSA-N Asn-Leu-Asn Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O ZMUQQMGITUJQTI-CIUDSAMLSA-N 0.000 claims 31
- MMEDVBWCMGRKKC-GARJFASQSA-N Leu-Asp-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N MMEDVBWCMGRKKC-GARJFASQSA-N 0.000 claims 31
- RIAKPZVSNBBNRE-BJDJZHNGSA-N Ser-Ile-Leu Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O RIAKPZVSNBBNRE-BJDJZHNGSA-N 0.000 claims 31
- SPIPSJXLZVTXJL-ZLUOBGJFSA-N Asn-Cys-Ser Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(O)=O SPIPSJXLZVTXJL-ZLUOBGJFSA-N 0.000 claims 29
- XAJRHVUUVUPFQL-ACZMJKKPSA-N Asp-Glu-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O XAJRHVUUVUPFQL-ACZMJKKPSA-N 0.000 claims 29
- -1 His Chemical group 0.000 claims 29
- IDAHFEPYTJJZFD-PEFMBERDSA-N Ile-Asp-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N IDAHFEPYTJJZFD-PEFMBERDSA-N 0.000 claims 29
- NWAHPBGBDIFUFD-KKUMJFAQSA-N Asp-Tyr-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O NWAHPBGBDIFUFD-KKUMJFAQSA-N 0.000 claims 28
- LESXFEZIFXFIQR-LURJTMIESA-N Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)NCC(O)=O LESXFEZIFXFIQR-LURJTMIESA-N 0.000 claims 28
- GPAHWYRSHCKICP-GUBZILKMSA-N Met-Glu-Glu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O GPAHWYRSHCKICP-GUBZILKMSA-N 0.000 claims 28
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 claims 28
- QWTLUPDHBKBULE-UHFFFAOYSA-N 2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]acetyl]amino]acetyl]amino]acetyl]amino]acetyl]amino]acetyl]amino]acetic acid Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(O)=O QWTLUPDHBKBULE-UHFFFAOYSA-N 0.000 claims 27
- XTQFHTHIAKKCTM-YFKPBYRVSA-N Gly-Glu-Gly Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O XTQFHTHIAKKCTM-YFKPBYRVSA-N 0.000 claims 27
- YMDNFPNTIPQMJP-NAKRPEOUSA-N Ser-Ile-Met Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(O)=O YMDNFPNTIPQMJP-NAKRPEOUSA-N 0.000 claims 27
- 108010069205 aspartyl-phenylalanine Proteins 0.000 claims 27
- 108010038633 aspartylglutamate Proteins 0.000 claims 27
- 108010025306 histidylleucine Proteins 0.000 claims 27
- 108010048818 seryl-histidine Proteins 0.000 claims 27
- 108010057821 leucylproline Proteins 0.000 claims 26
- FLMYSKVSDVHLEW-SVSWQMSJSA-N Ser-Thr-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FLMYSKVSDVHLEW-SVSWQMSJSA-N 0.000 claims 25
- BTWMICVCQLKKNR-DCAQKATOSA-N Val-Leu-Ser Chemical compound CC(C)[C@H]([NH3+])C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C([O-])=O BTWMICVCQLKKNR-DCAQKATOSA-N 0.000 claims 25
- ADSGHMXEAZJJNF-DCAQKATOSA-N Ala-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N ADSGHMXEAZJJNF-DCAQKATOSA-N 0.000 claims 24
- WQWSMEOYXJTFRU-GUBZILKMSA-N Leu-Glu-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O WQWSMEOYXJTFRU-GUBZILKMSA-N 0.000 claims 24
- 108010085325 histidylproline Proteins 0.000 claims 24
- XABFFGOGKOORCG-CIUDSAMLSA-N Cys-Asp-Leu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O XABFFGOGKOORCG-CIUDSAMLSA-N 0.000 claims 23
- 108010006664 gamma-glutamyl-glycyl-glycine Proteins 0.000 claims 23
- 102000004196 processed proteins & peptides Human genes 0.000 claims 23
- 108090000765 processed proteins & peptides Proteins 0.000 claims 23
- OGNJZUXUTPQVBR-BQBZGAKWSA-N Glu-Gly-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O OGNJZUXUTPQVBR-BQBZGAKWSA-N 0.000 claims 22
- YWAQATDNEKZFFK-BYPYZUCNSA-N Gly-Gly-Ser Chemical compound NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O YWAQATDNEKZFFK-BYPYZUCNSA-N 0.000 claims 22
- SBVPYBFMIGDIDX-SRVKXCTJSA-N Pro-Pro-Pro Chemical compound OC(=O)[C@@H]1CCCN1C(=O)[C@H]1N(C(=O)[C@H]2NCCC2)CCC1 SBVPYBFMIGDIDX-SRVKXCTJSA-N 0.000 claims 22
- 108010016686 methionyl-alanyl-serine Proteins 0.000 claims 22
- 229920001184 polypeptide Polymers 0.000 claims 22
- 108010048397 seryl-lysyl-leucine Proteins 0.000 claims 22
- VILLWIDTHYPSLC-PEFMBERDSA-N Asp-Glu-Ile Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VILLWIDTHYPSLC-PEFMBERDSA-N 0.000 claims 21
- MBRWOKXNHTUJMB-CIUDSAMLSA-N Cys-Pro-Glu Chemical compound [H]N[C@@H](CS)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O MBRWOKXNHTUJMB-CIUDSAMLSA-N 0.000 claims 21
- ILWHFUZZCFYSKT-AVGNSLFASA-N Glu-Lys-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O ILWHFUZZCFYSKT-AVGNSLFASA-N 0.000 claims 21
- MSASLZGZQAXVFP-PEDHHIEDSA-N Ile-Met-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N MSASLZGZQAXVFP-PEDHHIEDSA-N 0.000 claims 21
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 claims 21
- 108010013835 arginine glutamate Proteins 0.000 claims 21
- JLWZLIQRYCTYBD-IHRRRGAJSA-N Leu-Lys-Arg Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O JLWZLIQRYCTYBD-IHRRRGAJSA-N 0.000 claims 20
- PWPBLZXWFXJFHE-RHYQMDGZSA-N Leu-Pro-Thr Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O PWPBLZXWFXJFHE-RHYQMDGZSA-N 0.000 claims 20
- 108010077112 prolyl-proline Proteins 0.000 claims 20
- NMRHDSAOIURTNT-RWMBFGLXSA-N Arg-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N NMRHDSAOIURTNT-RWMBFGLXSA-N 0.000 claims 19
- HUWYGQOISIJNMK-SIGLWIIPSA-N Ile-Ile-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N HUWYGQOISIJNMK-SIGLWIIPSA-N 0.000 claims 19
- FCWFBHMAJZGWRY-XUXIUFHCSA-N Ile-Leu-Met Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)O)N FCWFBHMAJZGWRY-XUXIUFHCSA-N 0.000 claims 19
- HBJZFCIVFIBNSV-DCAQKATOSA-N Leu-Arg-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(O)=O HBJZFCIVFIBNSV-DCAQKATOSA-N 0.000 claims 19
- HYIFFZAQXPUEAU-QWRGUYRKSA-N Leu-Gly-Leu Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(C)C HYIFFZAQXPUEAU-QWRGUYRKSA-N 0.000 claims 19
- BVLPIIBTWIYOML-ZKWXMUAHSA-N Ala-Val-Asp Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O BVLPIIBTWIYOML-ZKWXMUAHSA-N 0.000 claims 18
- HOBNTSHITVVNBN-ZPFDUUQYSA-N Asp-Ile-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC(=O)O)N HOBNTSHITVVNBN-ZPFDUUQYSA-N 0.000 claims 18
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 claims 18
- 125000002987 valine group Chemical compound [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 18
- XWFWAXPOLRTDFZ-FXQIFTODSA-N Ala-Pro-Ser Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O XWFWAXPOLRTDFZ-FXQIFTODSA-N 0.000 claims 17
- WATXSTJXNBOHKD-LAEOZQHASA-N Glu-Asp-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O WATXSTJXNBOHKD-LAEOZQHASA-N 0.000 claims 17
- MUSGDMDGNGXULI-DCAQKATOSA-N Glu-Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O MUSGDMDGNGXULI-DCAQKATOSA-N 0.000 claims 17
- KJBGAZSLZAQDPV-KKUMJFAQSA-N Glu-Phe-Arg Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)N KJBGAZSLZAQDPV-KKUMJFAQSA-N 0.000 claims 17
- DSFYPIUSAMSERP-IHRRRGAJSA-N Leu-Leu-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N DSFYPIUSAMSERP-IHRRRGAJSA-N 0.000 claims 17
- QNBVTHNJGCOVFA-AVGNSLFASA-N Leu-Leu-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCC(O)=O QNBVTHNJGCOVFA-AVGNSLFASA-N 0.000 claims 17
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 claims 17
- 108010086434 alanyl-seryl-glycine Proteins 0.000 claims 17
- 210000004027 cell Anatomy 0.000 claims 17
- 108010031719 prolyl-serine Proteins 0.000 claims 17
- 108010090894 prolylleucine Proteins 0.000 claims 17
- 108010011667 Ala-Phe-Ala Proteins 0.000 claims 16
- QDXQWFBLUVTOFL-FXQIFTODSA-N Asn-Met-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(=O)N)N QDXQWFBLUVTOFL-FXQIFTODSA-N 0.000 claims 16
- NXTYATMDWQYLGJ-BQBZGAKWSA-N Cys-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CS NXTYATMDWQYLGJ-BQBZGAKWSA-N 0.000 claims 16
- DTPOVRRYXPJJAZ-FJXKBIBVSA-N Gly-Arg-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N DTPOVRRYXPJJAZ-FJXKBIBVSA-N 0.000 claims 16
- GDOZQTNZPCUARW-YFKPBYRVSA-N Gly-Gly-Glu Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CCC(O)=O GDOZQTNZPCUARW-YFKPBYRVSA-N 0.000 claims 16
- YAALVYQFVJNXIV-KKUMJFAQSA-N His-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CN=CN1 YAALVYQFVJNXIV-KKUMJFAQSA-N 0.000 claims 16
- UNBFGVQVQGXXCK-KKUMJFAQSA-N Phe-Ser-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O UNBFGVQVQGXXCK-KKUMJFAQSA-N 0.000 claims 16
- RWCOTTLHDJWHRS-YUMQZZPRSA-N Pro-Pro Chemical compound OC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 RWCOTTLHDJWHRS-YUMQZZPRSA-N 0.000 claims 16
- KDBHVPXBQADZKY-GUBZILKMSA-N Pro-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 KDBHVPXBQADZKY-GUBZILKMSA-N 0.000 claims 16
- WBAXJMCUFIXCNI-WDSKDSINSA-N Ser-Pro Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O WBAXJMCUFIXCNI-WDSKDSINSA-N 0.000 claims 16
- 239000003795 chemical substances by application Substances 0.000 claims 16
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 claims 16
- 108010034529 leucyl-lysine Proteins 0.000 claims 16
- KMSGYZQRXPUKGI-BYPYZUCNSA-N Gly-Gly-Asn Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CC(N)=O KMSGYZQRXPUKGI-BYPYZUCNSA-N 0.000 claims 15
- RNMNYMDTESKEAJ-KKUMJFAQSA-N His-Leu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CN=CN1 RNMNYMDTESKEAJ-KKUMJFAQSA-N 0.000 claims 15
- CMNMPCTVCWWYHY-MXAVVETBSA-N Ile-His-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC(C)C)C(=O)O)N CMNMPCTVCWWYHY-MXAVVETBSA-N 0.000 claims 15
- VCSBGUACOYUIGD-CIUDSAMLSA-N Leu-Asn-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O VCSBGUACOYUIGD-CIUDSAMLSA-N 0.000 claims 15
- QCSFMCFHVGTLFF-NHCYSSNCSA-N Leu-Asp-Val Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O QCSFMCFHVGTLFF-NHCYSSNCSA-N 0.000 claims 15
- FUKDBQGFSJUXGX-RWMBFGLXSA-N Lys-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)N)C(=O)O FUKDBQGFSJUXGX-RWMBFGLXSA-N 0.000 claims 15
- WZVSHTFTCYOFPL-GARJFASQSA-N Lys-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CCCCN)N)C(=O)O WZVSHTFTCYOFPL-GARJFASQSA-N 0.000 claims 15
- FSXRLASFHBWESK-UHFFFAOYSA-N dipeptide phenylalanyl-tyrosine Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FSXRLASFHBWESK-UHFFFAOYSA-N 0.000 claims 15
- 108010083708 leucyl-aspartyl-valine Proteins 0.000 claims 15
- MKZCBYZBCINNJN-DLOVCJGASA-N Ala-Asp-Phe Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MKZCBYZBCINNJN-DLOVCJGASA-N 0.000 claims 14
- HKRXJBBCQBAGIM-FXQIFTODSA-N Arg-Asp-Ser Chemical compound C(C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)O)N)CN=C(N)N HKRXJBBCQBAGIM-FXQIFTODSA-N 0.000 claims 14
- YFXFOZPXVFPBDH-VZFHVOOUSA-N Cys-Ala-Thr Chemical compound C[C@@H](O)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](N)CS)C(O)=O YFXFOZPXVFPBDH-VZFHVOOUSA-N 0.000 claims 14
- ZALGPUWUVHOGAE-GVXVVHGQSA-N Glu-Val-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CCC(=O)O)N ZALGPUWUVHOGAE-GVXVVHGQSA-N 0.000 claims 14
- PHONXOACARQMPM-BQBZGAKWSA-N Gly-Ala-Met Chemical compound [H]NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(O)=O PHONXOACARQMPM-BQBZGAKWSA-N 0.000 claims 14
- JNGJGFMFXREJNF-KBPBESRZSA-N Gly-Glu-Trp Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O JNGJGFMFXREJNF-KBPBESRZSA-N 0.000 claims 14
- FFYYUUWROYYKFY-IHRRRGAJSA-N His-Val-Leu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O FFYYUUWROYYKFY-IHRRRGAJSA-N 0.000 claims 14
- XLXPYSDGMXTTNQ-UHFFFAOYSA-N Ile-Phe-Leu Natural products CCC(C)C(N)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=CC=C1 XLXPYSDGMXTTNQ-UHFFFAOYSA-N 0.000 claims 14
- NEEOBPIXKWSBRF-IUCAKERBSA-N Leu-Glu-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O NEEOBPIXKWSBRF-IUCAKERBSA-N 0.000 claims 14
- ODRREERHVHMIPT-OEAJRASXSA-N Leu-Thr-Phe Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ODRREERHVHMIPT-OEAJRASXSA-N 0.000 claims 14
- PINHPJWGVBKQII-SRVKXCTJSA-N Lys-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCCCN)N PINHPJWGVBKQII-SRVKXCTJSA-N 0.000 claims 14
- XJFPXLWGZWAWRQ-UHFFFAOYSA-N 2-[[2-[[2-[[2-[[2-[(2-azaniumylacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]acetyl]amino]acetate Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(O)=O XJFPXLWGZWAWRQ-UHFFFAOYSA-N 0.000 claims 13
- OAGVHWYIBZMWLA-YFKPBYRVSA-N Glu-Gly-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)NCC(O)=O OAGVHWYIBZMWLA-YFKPBYRVSA-N 0.000 claims 13
- QPXBPQUGXHURGP-UWVGGRQHSA-N Leu-Gly-Met Chemical compound CC(C)C[C@@H](C(=O)NCC(=O)N[C@@H](CCSC)C(=O)O)N QPXBPQUGXHURGP-UWVGGRQHSA-N 0.000 claims 13
- XVZCXCTYGHPNEM-UHFFFAOYSA-N Leu-Leu-Pro Natural products CC(C)CC(N)C(=O)NC(CC(C)C)C(=O)N1CCCC1C(O)=O XVZCXCTYGHPNEM-UHFFFAOYSA-N 0.000 claims 13
- GVUVRRPYYDHHGK-VQVTYTSYSA-N Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 GVUVRRPYYDHHGK-VQVTYTSYSA-N 0.000 claims 13
- PPQRSMGDOHLTBE-UWVGGRQHSA-N Ser-Phe Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PPQRSMGDOHLTBE-UWVGGRQHSA-N 0.000 claims 13
- ODXKUIGEPAGKKV-KATARQTJSA-N Thr-Leu-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)O)N)O ODXKUIGEPAGKKV-KATARQTJSA-N 0.000 claims 13
- VTVVYQOXJCZVEB-WDCWCFNPSA-N Thr-Leu-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O VTVVYQOXJCZVEB-WDCWCFNPSA-N 0.000 claims 13
- CDKZJGMPZHPAJC-ULQDDVLXSA-N Tyr-Leu-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 CDKZJGMPZHPAJC-ULQDDVLXSA-N 0.000 claims 13
- AZSHAZJLOZQYAY-FXQIFTODSA-N Val-Ala-Ser Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O AZSHAZJLOZQYAY-FXQIFTODSA-N 0.000 claims 13
- CCDFBRZVTDDJNM-GUBZILKMSA-N Ala-Leu-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O CCDFBRZVTDDJNM-GUBZILKMSA-N 0.000 claims 12
- BVBKBQRPOJFCQM-DCAQKATOSA-N Arg-Asn-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O BVBKBQRPOJFCQM-DCAQKATOSA-N 0.000 claims 12
- GMUOCGCDOYYWPD-FXQIFTODSA-N Asn-Pro-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O GMUOCGCDOYYWPD-FXQIFTODSA-N 0.000 claims 12
- PMWSGVRIMIFXQH-KKUMJFAQSA-N His-His-Leu Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](N)CC=1NC=NC=1)C1=CN=CN1 PMWSGVRIMIFXQH-KKUMJFAQSA-N 0.000 claims 12
- 108010002386 Interleukin-3 Proteins 0.000 claims 12
- WIDZHJTYKYBLSR-DCAQKATOSA-N Leu-Glu-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O WIDZHJTYKYBLSR-DCAQKATOSA-N 0.000 claims 12
- QVFGXCVIXXBFHO-AVGNSLFASA-N Leu-Glu-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O QVFGXCVIXXBFHO-AVGNSLFASA-N 0.000 claims 12
- XFIHDSBIPWEYJJ-YUMQZZPRSA-N Lys-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN XFIHDSBIPWEYJJ-YUMQZZPRSA-N 0.000 claims 12
- AIRZWUMAHCDDHR-KKUMJFAQSA-N Lys-Leu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O AIRZWUMAHCDDHR-KKUMJFAQSA-N 0.000 claims 12
- VYWNORHENYEQDW-YUMQZZPRSA-N Pro-Gly-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 VYWNORHENYEQDW-YUMQZZPRSA-N 0.000 claims 12
- WDXYVIIVDIDOSX-DCAQKATOSA-N Ser-Arg-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CCCN=C(N)N WDXYVIIVDIDOSX-DCAQKATOSA-N 0.000 claims 12
- FMXFHNSFABRVFZ-BZSNNMDCSA-N Tyr-Lys-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O FMXFHNSFABRVFZ-BZSNNMDCSA-N 0.000 claims 12
- YTUABZMPYKCWCQ-XQQFMLRXSA-N Val-His-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@@H]2C(=O)O)N YTUABZMPYKCWCQ-XQQFMLRXSA-N 0.000 claims 12
- 108010011559 alanylphenylalanine Proteins 0.000 claims 12
- 108010018006 histidylserine Proteins 0.000 claims 12
- 108010070409 phenylalanyl-glycyl-glycine Proteins 0.000 claims 12
- PHHRSPBBQUFULD-UWVGGRQHSA-N Arg-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)N PHHRSPBBQUFULD-UWVGGRQHSA-N 0.000 claims 11
- FMVLWTYYODVFRG-BQBZGAKWSA-N Gly-Asn-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)CN FMVLWTYYODVFRG-BQBZGAKWSA-N 0.000 claims 11
- SOEATRRYCIPEHA-BQBZGAKWSA-N Gly-Glu-Glu Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O SOEATRRYCIPEHA-BQBZGAKWSA-N 0.000 claims 11
- WCHONUZTYDQMBY-PYJNHQTQSA-N His-Pro-Ile Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WCHONUZTYDQMBY-PYJNHQTQSA-N 0.000 claims 11
- FHKZHRMERJUXRJ-DCAQKATOSA-N His-Ser-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CN=CN1 FHKZHRMERJUXRJ-DCAQKATOSA-N 0.000 claims 11
- 101001033279 Homo sapiens Interleukin-3 Proteins 0.000 claims 11
- XGDCYUQSFDQISZ-BQBZGAKWSA-N Leu-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(O)=O XGDCYUQSFDQISZ-BQBZGAKWSA-N 0.000 claims 11
- BRTVHXHCUSXYRI-CIUDSAMLSA-N Leu-Ser-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O BRTVHXHCUSXYRI-CIUDSAMLSA-N 0.000 claims 11
- NOXSEHJOXCWRHK-DCAQKATOSA-N Pro-Cys-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@@H]1CCCN1 NOXSEHJOXCWRHK-DCAQKATOSA-N 0.000 claims 11
- KDGARKCAKHBEDB-NKWVEPMBSA-N Ser-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CO)N)C(=O)O KDGARKCAKHBEDB-NKWVEPMBSA-N 0.000 claims 11
- ADJDNJCSPNFFPI-FXQIFTODSA-N Ser-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO ADJDNJCSPNFFPI-FXQIFTODSA-N 0.000 claims 11
- NADLKBTYNKUJEP-KATARQTJSA-N Ser-Thr-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O NADLKBTYNKUJEP-KATARQTJSA-N 0.000 claims 11
- 108010047495 alanylglycine Proteins 0.000 claims 11
- 108010029539 arginyl-prolyl-proline Proteins 0.000 claims 11
- BUQICHWNXBIBOG-LMVFSUKVSA-N Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)N BUQICHWNXBIBOG-LMVFSUKVSA-N 0.000 claims 10
- UPKMBGAAEZGHOC-RWMBFGLXSA-N Arg-His-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O UPKMBGAAEZGHOC-RWMBFGLXSA-N 0.000 claims 10
- NLRJGXZWTKXRHP-DCAQKATOSA-N Asn-Leu-Arg Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O NLRJGXZWTKXRHP-DCAQKATOSA-N 0.000 claims 10
- QHAJMRDEWNAIBQ-FXQIFTODSA-N Asp-Arg-Asn Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O QHAJMRDEWNAIBQ-FXQIFTODSA-N 0.000 claims 10
- RLZBLVSJDFHDBL-KBIXCLLPSA-N Glu-Ala-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O RLZBLVSJDFHDBL-KBIXCLLPSA-N 0.000 claims 10
- ATVYZJGOZLVXDK-IUCAKERBSA-N Glu-Leu-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O ATVYZJGOZLVXDK-IUCAKERBSA-N 0.000 claims 10
- JRDYDYXZKFNNRQ-XPUUQOCRSA-N Gly-Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN JRDYDYXZKFNNRQ-XPUUQOCRSA-N 0.000 claims 10
- OQQKUTVULYLCDG-ONGXEEELSA-N Gly-Lys-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)CN)C(O)=O OQQKUTVULYLCDG-ONGXEEELSA-N 0.000 claims 10
- BAYQNCWLXIDLHX-ONGXEEELSA-N Gly-Val-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)CN BAYQNCWLXIDLHX-ONGXEEELSA-N 0.000 claims 10
- WNGVUZWBXZKQES-YUMQZZPRSA-N Leu-Ala-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O WNGVUZWBXZKQES-YUMQZZPRSA-N 0.000 claims 10
- ZURHXHNAEJJRNU-CIUDSAMLSA-N Leu-Asp-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O ZURHXHNAEJJRNU-CIUDSAMLSA-N 0.000 claims 10
- VCHVSKNMTXWIIP-SRVKXCTJSA-N Leu-Lys-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O VCHVSKNMTXWIIP-SRVKXCTJSA-N 0.000 claims 10
- OIQSIMFSVLLWBX-VOAKCMCISA-N Lys-Leu-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OIQSIMFSVLLWBX-VOAKCMCISA-N 0.000 claims 10
- WXHHTBVYQOSYSL-FXQIFTODSA-N Met-Ala-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O WXHHTBVYQOSYSL-FXQIFTODSA-N 0.000 claims 10
- GVMUJUPXFQFBBZ-GUBZILKMSA-N Ser-Lys-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O GVMUJUPXFQFBBZ-GUBZILKMSA-N 0.000 claims 10
- RRRRCRYTLZVCEN-HJGDQZAQSA-N Thr-Leu-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O RRRRCRYTLZVCEN-HJGDQZAQSA-N 0.000 claims 10
- IVXJODPZRWHCCR-JYJNAYRXSA-N Val-Arg-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N IVXJODPZRWHCCR-JYJNAYRXSA-N 0.000 claims 10
- PIFJAFRUVWZRKR-QMMMGPOBSA-N Val-Gly-Gly Chemical compound CC(C)[C@H]([NH3+])C(=O)NCC(=O)NCC([O-])=O PIFJAFRUVWZRKR-QMMMGPOBSA-N 0.000 claims 10
- DAEFQZCYZKRTLR-ZLUOBGJFSA-N Ala-Cys-Asp Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(O)=O)C(O)=O DAEFQZCYZKRTLR-ZLUOBGJFSA-N 0.000 claims 9
- MPLOSMWGDNJSEV-WHFBIAKZSA-N Ala-Gly-Asp Chemical compound [H]N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O MPLOSMWGDNJSEV-WHFBIAKZSA-N 0.000 claims 9
- OLVCTPPSXNRGKV-GUBZILKMSA-N Ala-Pro-Pro Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 OLVCTPPSXNRGKV-GUBZILKMSA-N 0.000 claims 9
- NZGRHTKZFSVPAN-BIIVOSGPSA-N Ala-Ser-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N NZGRHTKZFSVPAN-BIIVOSGPSA-N 0.000 claims 9
- UGZUVYDKAYNCII-ULQDDVLXSA-N Arg-Phe-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O UGZUVYDKAYNCII-ULQDDVLXSA-N 0.000 claims 9
- DAPLJWATMAXPPZ-CIUDSAMLSA-N Asn-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC(N)=O DAPLJWATMAXPPZ-CIUDSAMLSA-N 0.000 claims 9
- NBKLEMWHDLAUEM-CIUDSAMLSA-N Asp-Ser-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)N NBKLEMWHDLAUEM-CIUDSAMLSA-N 0.000 claims 9
- SJPMNHCEWPTRBR-BQBZGAKWSA-N Glu-Glu-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O SJPMNHCEWPTRBR-BQBZGAKWSA-N 0.000 claims 9
- ZCOJVESMNGBGLF-GRLWGSQLSA-N Glu-Ile-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O ZCOJVESMNGBGLF-GRLWGSQLSA-N 0.000 claims 9
- YRMZCZIRHYCNHX-RYUDHWBXSA-N Glu-Phe-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(O)=O YRMZCZIRHYCNHX-RYUDHWBXSA-N 0.000 claims 9
- DTLLNDVORUEOTM-WDCWCFNPSA-N Glu-Thr-Lys Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(O)=O DTLLNDVORUEOTM-WDCWCFNPSA-N 0.000 claims 9
- QXUPRMQJDWJDFR-NRPADANISA-N Glu-Val-Ser Chemical compound CC(C)[C@H](NC(=O)[C@@H](N)CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O QXUPRMQJDWJDFR-NRPADANISA-N 0.000 claims 9
- PYTZFYUXZZHOAD-WHFBIAKZSA-N Gly-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)CN PYTZFYUXZZHOAD-WHFBIAKZSA-N 0.000 claims 9
- BEQGFMIBZFNROK-JGVFFNPUSA-N Gly-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)CN)C(=O)O BEQGFMIBZFNROK-JGVFFNPUSA-N 0.000 claims 9
- UHPAZODVFFYEEL-QWRGUYRKSA-N Gly-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)CN UHPAZODVFFYEEL-QWRGUYRKSA-N 0.000 claims 9
- GLACUWHUYFBSPJ-FJXKBIBVSA-N Gly-Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)CN GLACUWHUYFBSPJ-FJXKBIBVSA-N 0.000 claims 9
- MUGLKCQHTUFLGF-WPRPVWTQSA-N Gly-Val-Met Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)CN MUGLKCQHTUFLGF-WPRPVWTQSA-N 0.000 claims 9
- 102000000646 Interleukin-3 Human genes 0.000 claims 9
- WCTCIIAGNMFYAO-DCAQKATOSA-N Leu-Cys-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(O)=O WCTCIIAGNMFYAO-DCAQKATOSA-N 0.000 claims 9
- NFNVDJGXRFEYTK-YUMQZZPRSA-N Leu-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O NFNVDJGXRFEYTK-YUMQZZPRSA-N 0.000 claims 9
- YFBBUHJJUXXZOF-UWVGGRQHSA-N Leu-Gly-Pro Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O YFBBUHJJUXXZOF-UWVGGRQHSA-N 0.000 claims 9
- VTJUNIYRYIAIHF-IUCAKERBSA-N Leu-Pro Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O VTJUNIYRYIAIHF-IUCAKERBSA-N 0.000 claims 9
- DPURXCQCHSQPAN-AVGNSLFASA-N Leu-Pro-Pro Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 DPURXCQCHSQPAN-AVGNSLFASA-N 0.000 claims 9
- CQZNGNCAIXMAIQ-UBHSHLNASA-N Pro-Ala-Phe Chemical compound C[C@H](NC(=O)[C@@H]1CCCN1)C(=O)N[C@@H](Cc1ccccc1)C(O)=O CQZNGNCAIXMAIQ-UBHSHLNASA-N 0.000 claims 9
- MCWHYUWXVNRXFV-RWMBFGLXSA-N Pro-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2 MCWHYUWXVNRXFV-RWMBFGLXSA-N 0.000 claims 9
- JPIDMRXXNMIVKY-VZFHVOOUSA-N Ser-Ala-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JPIDMRXXNMIVKY-VZFHVOOUSA-N 0.000 claims 9
- KRDSCBLRHORMRK-JXUBOQSCSA-N Thr-Lys-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O KRDSCBLRHORMRK-JXUBOQSCSA-N 0.000 claims 9
- XTDDIVQWDXMRJL-IHRRRGAJSA-N Val-Leu-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](C(C)C)N XTDDIVQWDXMRJL-IHRRRGAJSA-N 0.000 claims 9
- XXWBHOWRARMUOC-NHCYSSNCSA-N Val-Lys-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)O)N XXWBHOWRARMUOC-NHCYSSNCSA-N 0.000 claims 9
- 108010060199 cysteinylproline Proteins 0.000 claims 9
- 108010072405 glycyl-aspartyl-glycine Proteins 0.000 claims 9
- 108010073472 leucyl-prolyl-proline Proteins 0.000 claims 9
- 108010051110 tyrosyl-lysine Proteins 0.000 claims 9
- XVZCXCTYGHPNEM-IHRRRGAJSA-N (2s)-1-[(2s)-2-[[(2s)-2-amino-4-methylpentanoyl]amino]-4-methylpentanoyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(O)=O XVZCXCTYGHPNEM-IHRRRGAJSA-N 0.000 claims 8
- HKZAAJSTFUZYTO-LURJTMIESA-N (2s)-2-[[2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoic acid Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O HKZAAJSTFUZYTO-LURJTMIESA-N 0.000 claims 8
- QCTFKEJEIMPOLW-JURCDPSOSA-N Ala-Ile-Phe Chemical compound C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 QCTFKEJEIMPOLW-JURCDPSOSA-N 0.000 claims 8
- CREYEAPXISDKSB-FQPOAREZSA-N Ala-Thr-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O CREYEAPXISDKSB-FQPOAREZSA-N 0.000 claims 8
- JSNWZMFSLIWAHS-HJGDQZAQSA-N Asp-Thr-Leu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC(=O)O)N)O JSNWZMFSLIWAHS-HJGDQZAQSA-N 0.000 claims 8
- WTNLLMQAFPOCTJ-GARJFASQSA-N Cys-His-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CS)N)C(=O)O WTNLLMQAFPOCTJ-GARJFASQSA-N 0.000 claims 8
- SRIRHERUAMYIOQ-CIUDSAMLSA-N Cys-Leu-Ser Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O SRIRHERUAMYIOQ-CIUDSAMLSA-N 0.000 claims 8
- SRZZZTMJARUVPI-JBDRJPRFSA-N Cys-Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CS)N SRZZZTMJARUVPI-JBDRJPRFSA-N 0.000 claims 8
- MHYHLWUGWUBUHF-GUBZILKMSA-N Cys-Val-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CS)N MHYHLWUGWUBUHF-GUBZILKMSA-N 0.000 claims 8
- AKJRHDMTEJXTPV-ACZMJKKPSA-N Glu-Asn-Ala Chemical compound C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CCC(O)=O)C(O)=O AKJRHDMTEJXTPV-ACZMJKKPSA-N 0.000 claims 8
- SNFUTDLOCQQRQD-ZKWXMUAHSA-N Glu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(O)=O SNFUTDLOCQQRQD-ZKWXMUAHSA-N 0.000 claims 8
- YOTHMZZSJKKEHZ-SZMVWBNQSA-N Glu-Trp-Lys Chemical compound C1=CC=C2C(C[C@@H](C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@@H](N)CCC(O)=O)=CNC2=C1 YOTHMZZSJKKEHZ-SZMVWBNQSA-N 0.000 claims 8
- LPCKHUXOGVNZRS-YUMQZZPRSA-N Gly-His-Ser Chemical compound [H]NCC(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(O)=O LPCKHUXOGVNZRS-YUMQZZPRSA-N 0.000 claims 8
- CCBIBMKQNXHNIN-ZETCQYMHSA-N Gly-Leu-Gly Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O CCBIBMKQNXHNIN-ZETCQYMHSA-N 0.000 claims 8
- CKRJBQJIGOEKMC-SRVKXCTJSA-N His-Lys-Ser Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O CKRJBQJIGOEKMC-SRVKXCTJSA-N 0.000 claims 8
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 8
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 8
- QUAAUWNLWMLERT-IHRRRGAJSA-N Leu-Arg-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(O)=O QUAAUWNLWMLERT-IHRRRGAJSA-N 0.000 claims 8
- CLVUXCBGKUECIT-HJGDQZAQSA-N Leu-Asp-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CLVUXCBGKUECIT-HJGDQZAQSA-N 0.000 claims 8
- DDVHDMSBLRAKNV-IHRRRGAJSA-N Leu-Met-Leu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O DDVHDMSBLRAKNV-IHRRRGAJSA-N 0.000 claims 8
- QESXLSQLQHHTIX-RHYQMDGZSA-N Leu-Val-Thr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QESXLSQLQHHTIX-RHYQMDGZSA-N 0.000 claims 8
- XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 claims 8
- 101100342977 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-1 gene Proteins 0.000 claims 8
- UIGMAMGZOJVTDN-WHFBIAKZSA-N Ser-Gly-Ser Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O UIGMAMGZOJVTDN-WHFBIAKZSA-N 0.000 claims 8
- XNCUYZKGQOCOQH-YUMQZZPRSA-N Ser-Leu-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O XNCUYZKGQOCOQH-YUMQZZPRSA-N 0.000 claims 8
- MEJHFIOYJHTWMK-VOAKCMCISA-N Thr-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)[C@@H](C)O MEJHFIOYJHTWMK-VOAKCMCISA-N 0.000 claims 8
- MEBDIIKMUUNBSB-RPTUDFQQSA-N Thr-Phe-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O MEBDIIKMUUNBSB-RPTUDFQQSA-N 0.000 claims 8
- CJEHCEOXPLASCK-MEYUZBJRSA-N Thr-Tyr-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)[C@H](O)C)CC1=CC=C(O)C=C1 CJEHCEOXPLASCK-MEYUZBJRSA-N 0.000 claims 8
- PAPWZOJOLKZEFR-AVGNSLFASA-N Val-Arg-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)O)N PAPWZOJOLKZEFR-AVGNSLFASA-N 0.000 claims 8
- PGQUDQYHWICSAB-NAKRPEOUSA-N Val-Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N PGQUDQYHWICSAB-NAKRPEOUSA-N 0.000 claims 8
- 108010077245 asparaginyl-proline Proteins 0.000 claims 8
- 108010077515 glycylproline Proteins 0.000 claims 8
- 108010009298 lysylglutamic acid Proteins 0.000 claims 8
- 229930182817 methionine Natural products 0.000 claims 8
- 108010093296 prolyl-prolyl-alanine Proteins 0.000 claims 8
- 210000000130 stem cell Anatomy 0.000 claims 8
- XRUJOVRWNMBAAA-NHCYSSNCSA-N Ala-Phe-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=CC=C1 XRUJOVRWNMBAAA-NHCYSSNCSA-N 0.000 claims 7
- RTZCUEHYUQZIDE-WHFBIAKZSA-N Ala-Ser-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O RTZCUEHYUQZIDE-WHFBIAKZSA-N 0.000 claims 7
- NCQMBSJGJMYKCK-ZLUOBGJFSA-N Ala-Ser-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O NCQMBSJGJMYKCK-ZLUOBGJFSA-N 0.000 claims 7
- KUFVXLQLDHJVOG-SHGPDSBTSA-N Ala-Thr-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](C)N)O KUFVXLQLDHJVOG-SHGPDSBTSA-N 0.000 claims 7
- UHFUZWSZQKMDSX-DCAQKATOSA-N Arg-Leu-Asn Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N UHFUZWSZQKMDSX-DCAQKATOSA-N 0.000 claims 7
- COXMUHNBYCVVRG-DCAQKATOSA-N Arg-Leu-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O COXMUHNBYCVVRG-DCAQKATOSA-N 0.000 claims 7
- CMLGVVWQQHUXOZ-GHCJXIJMSA-N Asn-Ala-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O CMLGVVWQQHUXOZ-GHCJXIJMSA-N 0.000 claims 7
- SCQIQCWLOMOEFP-DCAQKATOSA-N Asp-Leu-Arg Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O SCQIQCWLOMOEFP-DCAQKATOSA-N 0.000 claims 7
- BWJZSLQJNBSUPM-FXQIFTODSA-N Asp-Pro-Asn Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O BWJZSLQJNBSUPM-FXQIFTODSA-N 0.000 claims 7
- SWJYSDXMTPMBHO-FXQIFTODSA-N Cys-Pro-Ser Chemical compound [H]N[C@@H](CS)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O SWJYSDXMTPMBHO-FXQIFTODSA-N 0.000 claims 7
- IRXNJYPKBVERCW-DCAQKATOSA-N Glu-Leu-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O IRXNJYPKBVERCW-DCAQKATOSA-N 0.000 claims 7
- MWMJCGBSIORNCD-AVGNSLFASA-N Glu-Leu-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O MWMJCGBSIORNCD-AVGNSLFASA-N 0.000 claims 7
- QOXDAWODGSIDDI-GUBZILKMSA-N Glu-Ser-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)O)N QOXDAWODGSIDDI-GUBZILKMSA-N 0.000 claims 7
- JPWIMMUNWUKOAD-STQMWFEESA-N Gly-Asp-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CN JPWIMMUNWUKOAD-STQMWFEESA-N 0.000 claims 7
- QEYUCKCWTMIERU-SRVKXCTJSA-N His-Lys-Asp Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)O)N QEYUCKCWTMIERU-SRVKXCTJSA-N 0.000 claims 7
- PYNPBMCLAKTHJL-SRVKXCTJSA-N His-Pro-Glu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O PYNPBMCLAKTHJL-SRVKXCTJSA-N 0.000 claims 7
- PZAJPILZRFPYJJ-SRVKXCTJSA-N His-Ser-Leu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O PZAJPILZRFPYJJ-SRVKXCTJSA-N 0.000 claims 7
- UIEZQYNXCYHMQS-BJDJZHNGSA-N Ile-Lys-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)O)N UIEZQYNXCYHMQS-BJDJZHNGSA-N 0.000 claims 7
- PXKACEXYLPBMAD-JBDRJPRFSA-N Ile-Ser-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PXKACEXYLPBMAD-JBDRJPRFSA-N 0.000 claims 7
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 7
- LHSGPCFBGJHPCY-UHFFFAOYSA-N L-leucine-L-tyrosine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 LHSGPCFBGJHPCY-UHFFFAOYSA-N 0.000 claims 7
- IIKJNQWOQIWWMR-CIUDSAMLSA-N Leu-Cys-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)N IIKJNQWOQIWWMR-CIUDSAMLSA-N 0.000 claims 7
- DZQMXBALGUHGJT-GUBZILKMSA-N Leu-Glu-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O DZQMXBALGUHGJT-GUBZILKMSA-N 0.000 claims 7
- HVJVUYQWFYMGJS-GVXVVHGQSA-N Leu-Glu-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O HVJVUYQWFYMGJS-GVXVVHGQSA-N 0.000 claims 7
- OYQUOLRTJHWVSQ-SRVKXCTJSA-N Leu-His-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(O)=O OYQUOLRTJHWVSQ-SRVKXCTJSA-N 0.000 claims 7
- RGUXWMDNCPMQFB-YUMQZZPRSA-N Leu-Ser-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O RGUXWMDNCPMQFB-YUMQZZPRSA-N 0.000 claims 7
- IWMJFLJQHIDZQW-KKUMJFAQSA-N Leu-Ser-Phe Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 IWMJFLJQHIDZQW-KKUMJFAQSA-N 0.000 claims 7
- JHDNAOVJJQSMMM-GMOBBJLQSA-N Met-Ile-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CCSC)N JHDNAOVJJQSMMM-GMOBBJLQSA-N 0.000 claims 7
- USBFEVBHEQBWDD-AVGNSLFASA-N Met-Leu-Val Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O USBFEVBHEQBWDD-AVGNSLFASA-N 0.000 claims 7
- BKWJQWJPZMUWEG-LFSVMHDDSA-N Phe-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 BKWJQWJPZMUWEG-LFSVMHDDSA-N 0.000 claims 7
- FRKBNXCFJBPJOL-GUBZILKMSA-N Pro-Glu-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O FRKBNXCFJBPJOL-GUBZILKMSA-N 0.000 claims 7
- XYSXOCIWCPFOCG-IHRRRGAJSA-N Pro-Leu-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O XYSXOCIWCPFOCG-IHRRRGAJSA-N 0.000 claims 7
- FDMKYQQYJKYCLV-GUBZILKMSA-N Pro-Pro-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 FDMKYQQYJKYCLV-GUBZILKMSA-N 0.000 claims 7
- SXJOPONICMGFCR-DCAQKATOSA-N Pro-Ser-Lys Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O SXJOPONICMGFCR-DCAQKATOSA-N 0.000 claims 7
- VMLONWHIORGALA-SRVKXCTJSA-N Ser-Leu-Leu Chemical compound CC(C)C[C@@H](C([O-])=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]([NH3+])CO VMLONWHIORGALA-SRVKXCTJSA-N 0.000 claims 7
- PAXANSWUSVPFNK-IUKAMOBKSA-N Thr-Ile-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N PAXANSWUSVPFNK-IUKAMOBKSA-N 0.000 claims 7
- XUGYQLFEJYZOKQ-NGTWOADLSA-N Thr-Ile-Trp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N XUGYQLFEJYZOKQ-NGTWOADLSA-N 0.000 claims 7
- KKHRWGYHBZORMQ-NHCYSSNCSA-N Val-Arg-Glu Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N KKHRWGYHBZORMQ-NHCYSSNCSA-N 0.000 claims 7
- 239000000556 agonist Substances 0.000 claims 7
- 235000004279 alanine Nutrition 0.000 claims 7
- 108010078326 glycyl-glycyl-valine Proteins 0.000 claims 7
- 108010089804 glycyl-threonine Proteins 0.000 claims 7
- 108010012058 leucyltyrosine Proteins 0.000 claims 7
- 230000008707 rearrangement Effects 0.000 claims 7
- 210000000952 spleen Anatomy 0.000 claims 7
- QVVDVENEPNODSI-BTNSXGMBSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylidene Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O QVVDVENEPNODSI-BTNSXGMBSA-N 0.000 claims 6
- AWZKCUCQJNTBAD-SRVKXCTJSA-N Ala-Leu-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCCN AWZKCUCQJNTBAD-SRVKXCTJSA-N 0.000 claims 6
- WPWUFUBLGADILS-WDSKDSINSA-N Ala-Pro Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O WPWUFUBLGADILS-WDSKDSINSA-N 0.000 claims 6
- KWKQGHSSNHPGOW-BQBZGAKWSA-N Arg-Ala-Gly Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)NCC(O)=O KWKQGHSSNHPGOW-BQBZGAKWSA-N 0.000 claims 6
- YCYXHLZRUSJITQ-SRVKXCTJSA-N Arg-Pro-Pro Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 YCYXHLZRUSJITQ-SRVKXCTJSA-N 0.000 claims 6
- XWGJDUSDTRPQRK-ZLUOBGJFSA-N Asn-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O XWGJDUSDTRPQRK-ZLUOBGJFSA-N 0.000 claims 6
- BHQQRVARKXWXPP-ACZMJKKPSA-N Asn-Asp-Glu Chemical compound C(CC(=O)O)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)N)N BHQQRVARKXWXPP-ACZMJKKPSA-N 0.000 claims 6
- MYVBTYXSWILFCG-BQBZGAKWSA-N Asn-Met-Gly Chemical compound CSCC[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC(=O)N)N MYVBTYXSWILFCG-BQBZGAKWSA-N 0.000 claims 6
- YXVAESUIQFDBHN-SRVKXCTJSA-N Asn-Phe-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(O)=O YXVAESUIQFDBHN-SRVKXCTJSA-N 0.000 claims 6
- NURJSGZGBVJFAD-ZLUOBGJFSA-N Asp-Cys-Ser Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)O)N)C(=O)O NURJSGZGBVJFAD-ZLUOBGJFSA-N 0.000 claims 6
- 102000003951 Erythropoietin Human genes 0.000 claims 6
- 108090000394 Erythropoietin Proteins 0.000 claims 6
- LGYZYFFDELZWRS-DCAQKATOSA-N Glu-Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O LGYZYFFDELZWRS-DCAQKATOSA-N 0.000 claims 6
- RFTVTKBHDXCEEX-WDSKDSINSA-N Glu-Ser-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)NCC(O)=O RFTVTKBHDXCEEX-WDSKDSINSA-N 0.000 claims 6
- ZAPFAWQHBOHWLL-GUBZILKMSA-N Glu-Ser-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)O)N ZAPFAWQHBOHWLL-GUBZILKMSA-N 0.000 claims 6
- XPJBQTCXPJNIFE-ZETCQYMHSA-N Gly-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)CN XPJBQTCXPJNIFE-ZETCQYMHSA-N 0.000 claims 6
- SSFWXSNOKDZNHY-QXEWZRGKSA-N Gly-Pro-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)CN SSFWXSNOKDZNHY-QXEWZRGKSA-N 0.000 claims 6
- BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 claims 6
- ABPRMMYHROQBLY-NKWVEPMBSA-N Gly-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)CN)C(=O)O ABPRMMYHROQBLY-NKWVEPMBSA-N 0.000 claims 6
- OLIFSFOFKGKIRH-WUJLRWPWSA-N Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CN OLIFSFOFKGKIRH-WUJLRWPWSA-N 0.000 claims 6
- VPZXBVLAVMBEQI-VKHMYHEASA-N Glycyl-alanine Chemical compound OC(=O)[C@H](C)NC(=O)CN VPZXBVLAVMBEQI-VKHMYHEASA-N 0.000 claims 6
- GIRSNERMXCMDBO-GARJFASQSA-N His-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CC2=CN=CN2)N)C(=O)O GIRSNERMXCMDBO-GARJFASQSA-N 0.000 claims 6
- BBQABUDWDUKJMB-LZXPERKUSA-N Ile-Ile-Ile Chemical compound CC[C@H](C)[C@H]([NH3+])C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C([O-])=O BBQABUDWDUKJMB-LZXPERKUSA-N 0.000 claims 6
- CSQNHSGHAPRGPQ-YTFOTSKYSA-N Ile-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)O)N CSQNHSGHAPRGPQ-YTFOTSKYSA-N 0.000 claims 6
- HUORUFRRJHELPD-MNXVOIDGSA-N Ile-Leu-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N HUORUFRRJHELPD-MNXVOIDGSA-N 0.000 claims 6
- XLXPYSDGMXTTNQ-DKIMLUQUSA-N Ile-Phe-Leu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(O)=O XLXPYSDGMXTTNQ-DKIMLUQUSA-N 0.000 claims 6
- LJKJVTCIRDCITR-SRVKXCTJSA-N Leu-Cys-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N LJKJVTCIRDCITR-SRVKXCTJSA-N 0.000 claims 6
- RXGLHDWAZQECBI-SRVKXCTJSA-N Leu-Leu-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O RXGLHDWAZQECBI-SRVKXCTJSA-N 0.000 claims 6
- XOWMDXHFSBCAKQ-SRVKXCTJSA-N Leu-Ser-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC(C)C XOWMDXHFSBCAKQ-SRVKXCTJSA-N 0.000 claims 6
- VEGLGAOVLFODGC-GUBZILKMSA-N Lys-Glu-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O VEGLGAOVLFODGC-GUBZILKMSA-N 0.000 claims 6
- LMKSBGIUPVRHEH-FXQIFTODSA-N Met-Ala-Asn Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(N)=O LMKSBGIUPVRHEH-FXQIFTODSA-N 0.000 claims 6
- UHRNIXJAGGLKHP-DLOVCJGASA-N Phe-Ala-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O UHRNIXJAGGLKHP-DLOVCJGASA-N 0.000 claims 6
- CGBYDGAJHSOGFQ-LPEHRKFASA-N Pro-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2 CGBYDGAJHSOGFQ-LPEHRKFASA-N 0.000 claims 6
- CGSOWZUPLOKYOR-AVGNSLFASA-N Pro-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 CGSOWZUPLOKYOR-AVGNSLFASA-N 0.000 claims 6
- AFWBWPCXSWUCLB-WDSKDSINSA-N Pro-Ser Chemical compound OC[C@@H](C([O-])=O)NC(=O)[C@@H]1CCC[NH2+]1 AFWBWPCXSWUCLB-WDSKDSINSA-N 0.000 claims 6
- SNGZLPOXVRTNMB-LPEHRKFASA-N Pro-Ser-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CO)C(=O)N2CCC[C@@H]2C(=O)O SNGZLPOXVRTNMB-LPEHRKFASA-N 0.000 claims 6
- AIOWVDNPESPXRB-YTWAJWBKSA-N Pro-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2)O AIOWVDNPESPXRB-YTWAJWBKSA-N 0.000 claims 6
- VVEQUISRWJDGMX-VKOGCVSHSA-N Pro-Trp-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@@H]3CCCN3 VVEQUISRWJDGMX-VKOGCVSHSA-N 0.000 claims 6
- IDQFQFVEWMWRQQ-DLOVCJGASA-N Ser-Ala-Phe Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O IDQFQFVEWMWRQQ-DLOVCJGASA-N 0.000 claims 6
- VQBLHWSPVYYZTB-DCAQKATOSA-N Ser-Arg-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)N VQBLHWSPVYYZTB-DCAQKATOSA-N 0.000 claims 6
- RFBKULCUBJAQFT-BIIVOSGPSA-N Ser-Cys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CS)NC(=O)[C@H](CO)N)C(=O)O RFBKULCUBJAQFT-BIIVOSGPSA-N 0.000 claims 6
- IOVHBRCQOGWAQH-ZKWXMUAHSA-N Ser-Gly-Ile Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(O)=O IOVHBRCQOGWAQH-ZKWXMUAHSA-N 0.000 claims 6
- CICQXRWZNVXFCU-SRVKXCTJSA-N Ser-His-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(O)=O CICQXRWZNVXFCU-SRVKXCTJSA-N 0.000 claims 6
- ZIFYDQAFEMIZII-GUBZILKMSA-N Ser-Leu-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZIFYDQAFEMIZII-GUBZILKMSA-N 0.000 claims 6
- DINQYZRMXGWWTG-GUBZILKMSA-N Ser-Pro-Pro Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 DINQYZRMXGWWTG-GUBZILKMSA-N 0.000 claims 6
- HHSILIQTHXABKM-YDHLFZDLSA-N Val-Asp-Phe Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(O)=O HHSILIQTHXABKM-YDHLFZDLSA-N 0.000 claims 6
- 108010076324 alanyl-glycyl-glycine Proteins 0.000 claims 6
- 108010060035 arginylproline Proteins 0.000 claims 6
- 229940105423 erythropoietin Drugs 0.000 claims 6
- 108010004609 gamma-carboxyglutamyl-gamma-carboxyglutamic acid Proteins 0.000 claims 6
- 108010049041 glutamylalanine Proteins 0.000 claims 6
- 108010027668 glycyl-alanyl-valine Proteins 0.000 claims 6
- 108010028188 glycyl-histidyl-serine Proteins 0.000 claims 6
- 108010037850 glycylvaline Proteins 0.000 claims 6
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 6
- 102000055276 human IL3 Human genes 0.000 claims 6
- 108010090333 leucyl-lysyl-proline Proteins 0.000 claims 6
- 239000003446 ligand Substances 0.000 claims 6
- 108010056582 methionylglutamic acid Proteins 0.000 claims 6
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 6
- 108010015796 prolylisoleucine Proteins 0.000 claims 6
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 5
- HHGYNJRJIINWAK-FXQIFTODSA-N Ala-Ala-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N HHGYNJRJIINWAK-FXQIFTODSA-N 0.000 claims 5
- OMNVYXHOSHNURL-WPRPVWTQSA-N Ala-Phe Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 OMNVYXHOSHNURL-WPRPVWTQSA-N 0.000 claims 5
- DCVYRWFAMZFSDA-ZLUOBGJFSA-N Ala-Ser-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O DCVYRWFAMZFSDA-ZLUOBGJFSA-N 0.000 claims 5
- OMSKGWFGWCQFBD-KZVJFYERSA-N Ala-Val-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OMSKGWFGWCQFBD-KZVJFYERSA-N 0.000 claims 5
- SKTGPBFTMNLIHQ-KKUMJFAQSA-N Arg-Glu-Phe Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O SKTGPBFTMNLIHQ-KKUMJFAQSA-N 0.000 claims 5
- GHODABZPVZMWCE-FXQIFTODSA-N Asp-Glu-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O GHODABZPVZMWCE-FXQIFTODSA-N 0.000 claims 5
- RPUYTJJZXQBWDT-SRVKXCTJSA-N Asp-Phe-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC(=O)O)N RPUYTJJZXQBWDT-SRVKXCTJSA-N 0.000 claims 5
- 102000007644 Colony-Stimulating Factors Human genes 0.000 claims 5
- 108010071942 Colony-Stimulating Factors Proteins 0.000 claims 5
- ZOXBSICWUDAOHX-GUBZILKMSA-N Glu-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CCC(O)=O ZOXBSICWUDAOHX-GUBZILKMSA-N 0.000 claims 5
- GJBUAAAIZSRCDC-GVXVVHGQSA-N Glu-Leu-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O GJBUAAAIZSRCDC-GVXVVHGQSA-N 0.000 claims 5
- BXSZPACYCMNKLS-AVGNSLFASA-N Glu-Ser-Phe Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O BXSZPACYCMNKLS-AVGNSLFASA-N 0.000 claims 5
- GGEJHJIXRBTJPD-BYPYZUCNSA-N Gly-Asn-Gly Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O GGEJHJIXRBTJPD-BYPYZUCNSA-N 0.000 claims 5
- HKSNHPVETYYJBK-LAEOZQHASA-N Gly-Ile-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)CN HKSNHPVETYYJBK-LAEOZQHASA-N 0.000 claims 5
- HAXARWKYFIIHKD-ZKWXMUAHSA-N Gly-Ile-Ser Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O HAXARWKYFIIHKD-ZKWXMUAHSA-N 0.000 claims 5
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 5
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 5
- MMFKFJORZBJVNF-UWVGGRQHSA-N His-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CN=CN1 MMFKFJORZBJVNF-UWVGGRQHSA-N 0.000 claims 5
- VDHOMPFVSABJKU-ULQDDVLXSA-N His-Phe-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC2=CN=CN2)N VDHOMPFVSABJKU-ULQDDVLXSA-N 0.000 claims 5
- AMSYMDIIIRJRKZ-HJPIBITLSA-N Ile-His-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N AMSYMDIIIRJRKZ-HJPIBITLSA-N 0.000 claims 5
- JNLSTRPWUXOORL-MMWGEVLESA-N Ile-Ser-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N JNLSTRPWUXOORL-MMWGEVLESA-N 0.000 claims 5
- KGCLIYGPQXUNLO-IUCAKERBSA-N Leu-Gly-Glu Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(O)=O KGCLIYGPQXUNLO-IUCAKERBSA-N 0.000 claims 5
- CCQLQKZTXZBXTN-NHCYSSNCSA-N Leu-Gly-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(O)=O CCQLQKZTXZBXTN-NHCYSSNCSA-N 0.000 claims 5
- CHJKEDSZNSONPS-DCAQKATOSA-N Leu-Pro-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O CHJKEDSZNSONPS-DCAQKATOSA-N 0.000 claims 5
- LHSGPCFBGJHPCY-STQMWFEESA-N Leu-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 LHSGPCFBGJHPCY-STQMWFEESA-N 0.000 claims 5
- 108010079364 N-glycylalanine Proteins 0.000 claims 5
- KPEIBEPEUAZWNS-ULQDDVLXSA-N Phe-Leu-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 KPEIBEPEUAZWNS-ULQDDVLXSA-N 0.000 claims 5
- ZYNBEWGJFXTBDU-ACRUOGEOSA-N Phe-Tyr-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC2=CC=CC=C2)N ZYNBEWGJFXTBDU-ACRUOGEOSA-N 0.000 claims 5
- KQCCDMFIALWGTL-GUBZILKMSA-N Pro-Asn-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]1CCCN1 KQCCDMFIALWGTL-GUBZILKMSA-N 0.000 claims 5
- FKYKZHOKDOPHSA-DCAQKATOSA-N Pro-Leu-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O FKYKZHOKDOPHSA-DCAQKATOSA-N 0.000 claims 5
- FDMCIBSQRKFSTJ-RHYQMDGZSA-N Pro-Thr-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O FDMCIBSQRKFSTJ-RHYQMDGZSA-N 0.000 claims 5
- NBDHWLZEMKSVHH-UVBJJODRSA-N Pro-Trp-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@@H]3CCCN3 NBDHWLZEMKSVHH-UVBJJODRSA-N 0.000 claims 5
- SSJMZMUVNKEENT-IMJSIDKUSA-N Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CO SSJMZMUVNKEENT-IMJSIDKUSA-N 0.000 claims 5
- RZEQTVHJZCIUBT-WDSKDSINSA-N Ser-Arg Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N RZEQTVHJZCIUBT-WDSKDSINSA-N 0.000 claims 5
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 claims 5
- VFWQQZMRKFOGLE-ZLUOBGJFSA-N Ser-Ser-Cys Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N)O VFWQQZMRKFOGLE-ZLUOBGJFSA-N 0.000 claims 5
- STGXWWBXWXZOER-MBLNEYKQSA-N Thr-Ala-His Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 STGXWWBXWXZOER-MBLNEYKQSA-N 0.000 claims 5
- WKQNLTQSCYXKQK-VFAJRCTISA-N Trp-Lys-Thr Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WKQNLTQSCYXKQK-VFAJRCTISA-N 0.000 claims 5
- 108700014844 flt3 ligand Proteins 0.000 claims 5
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 claims 5
- 108010003700 lysyl aspartic acid Proteins 0.000 claims 5
- 108010053725 prolylvaline Proteins 0.000 claims 5
- 108010078580 tyrosylleucine Proteins 0.000 claims 5
- AUXMWYRZQPIXCC-KNIFDHDWSA-N (2s)-2-amino-4-methylpentanoic acid;(2s)-2-aminopropanoic acid Chemical compound C[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O AUXMWYRZQPIXCC-KNIFDHDWSA-N 0.000 claims 4
- CXLUIRPQSBYREP-WDSKDSINSA-N (3s)-3-[[(2s)-2-amino-4,4-dicarboxybutanoyl]amino]propane-1,1,3-tricarboxylic acid Chemical compound OC(=O)C(C(O)=O)C[C@H](N)C(=O)N[C@@H](CC(C(O)=O)C(O)=O)C(O)=O CXLUIRPQSBYREP-WDSKDSINSA-N 0.000 claims 4
- RLMISHABBKUNFO-WHFBIAKZSA-N Ala-Ala-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O RLMISHABBKUNFO-WHFBIAKZSA-N 0.000 claims 4
- CXRCVCURMBFFOL-FXQIFTODSA-N Ala-Ala-Pro Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O CXRCVCURMBFFOL-FXQIFTODSA-N 0.000 claims 4
- IASNWHAGGYTEKX-IUCAKERBSA-N Arg-Arg-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(O)=O IASNWHAGGYTEKX-IUCAKERBSA-N 0.000 claims 4
- BNYNOWJESJJIOI-XUXIUFHCSA-N Arg-Lys-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)N BNYNOWJESJJIOI-XUXIUFHCSA-N 0.000 claims 4
- HZPSDHRYYIORKR-WHFBIAKZSA-N Asn-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O HZPSDHRYYIORKR-WHFBIAKZSA-N 0.000 claims 4
- GLWFAWNYGWBMOC-SRVKXCTJSA-N Asn-Leu-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O GLWFAWNYGWBMOC-SRVKXCTJSA-N 0.000 claims 4
- 101100512078 Caenorhabditis elegans lys-1 gene Proteins 0.000 claims 4
- 102000004127 Cytokines Human genes 0.000 claims 4
- 108090000695 Cytokines Proteins 0.000 claims 4
- PHONAZGUEGIOEM-GLLZPBPUSA-N Glu-Glu-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PHONAZGUEGIOEM-GLLZPBPUSA-N 0.000 claims 4
- MXJYXYDREQWUMS-XKBZYTNZSA-N Glu-Thr-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O MXJYXYDREQWUMS-XKBZYTNZSA-N 0.000 claims 4
- SCCPDJAQCXWPTF-VKHMYHEASA-N Gly-Asp Chemical compound NCC(=O)N[C@H](C(O)=O)CC(O)=O SCCPDJAQCXWPTF-VKHMYHEASA-N 0.000 claims 4
- IEFJWDNGDZAYNZ-BYPYZUCNSA-N Gly-Glu Chemical compound NCC(=O)N[C@H](C(O)=O)CCC(O)=O IEFJWDNGDZAYNZ-BYPYZUCNSA-N 0.000 claims 4
- BHPQOIPBLYJNAW-NGZCFLSTSA-N Gly-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN BHPQOIPBLYJNAW-NGZCFLSTSA-N 0.000 claims 4
- TVUWMSBGMVAHSJ-KBPBESRZSA-N Gly-Leu-Phe Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 TVUWMSBGMVAHSJ-KBPBESRZSA-N 0.000 claims 4
- DBJYVKDPGIFXFO-BQBZGAKWSA-N Gly-Met-Ala Chemical compound [H]NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(O)=O DBJYVKDPGIFXFO-BQBZGAKWSA-N 0.000 claims 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 4
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 4
- VCBWXASUBZIFLQ-IHRRRGAJSA-N His-Pro-Leu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O VCBWXASUBZIFLQ-IHRRRGAJSA-N 0.000 claims 4
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 claims 4
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 4
- 101000619708 Homo sapiens Peroxiredoxin-6 Proteins 0.000 claims 4
- FZWVCYCYWCLQDH-NHCYSSNCSA-N Ile-Leu-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)O)N FZWVCYCYWCLQDH-NHCYSSNCSA-N 0.000 claims 4
- 108090000978 Interleukin-4 Proteins 0.000 claims 4
- 102000004388 Interleukin-4 Human genes 0.000 claims 4
- SITWEMZOJNKJCH-UHFFFAOYSA-N L-alanine-L-arginine Natural products CC(N)C(=O)NC(C(O)=O)CCCNC(N)=N SITWEMZOJNKJCH-UHFFFAOYSA-N 0.000 claims 4
- PDQDCFBVYXEFSD-SRVKXCTJSA-N Leu-Leu-Asp Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O PDQDCFBVYXEFSD-SRVKXCTJSA-N 0.000 claims 4
- WXZOHBVPVKABQN-DCAQKATOSA-N Leu-Met-Asp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)O)N WXZOHBVPVKABQN-DCAQKATOSA-N 0.000 claims 4
- DRWMRVFCKKXHCH-BZSNNMDCSA-N Leu-Phe-Leu Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C([O-])=O)CC1=CC=CC=C1 DRWMRVFCKKXHCH-BZSNNMDCSA-N 0.000 claims 4
- WMIOEVKKYIMVKI-DCAQKATOSA-N Leu-Pro-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O WMIOEVKKYIMVKI-DCAQKATOSA-N 0.000 claims 4
- IZPVWNSAVUQBGP-CIUDSAMLSA-N Leu-Ser-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O IZPVWNSAVUQBGP-CIUDSAMLSA-N 0.000 claims 4
- AMSSKPUHBUQBOQ-SRVKXCTJSA-N Leu-Ser-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O)N AMSSKPUHBUQBOQ-SRVKXCTJSA-N 0.000 claims 4
- AAKRWBIIGKPOKQ-ONGXEEELSA-N Leu-Val-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O AAKRWBIIGKPOKQ-ONGXEEELSA-N 0.000 claims 4
- 102100022239 Peroxiredoxin-6 Human genes 0.000 claims 4
- NAXPHWZXEXNDIW-JTQLQIEISA-N Phe-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H](N)CC1=CC=CC=C1 NAXPHWZXEXNDIW-JTQLQIEISA-N 0.000 claims 4
- GLUYKHMBGKQBHE-JYJNAYRXSA-N Phe-Val-Arg Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 GLUYKHMBGKQBHE-JYJNAYRXSA-N 0.000 claims 4
- ALJGSKMBIUEJOB-FXQIFTODSA-N Pro-Ala-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@@H]1CCCN1 ALJGSKMBIUEJOB-FXQIFTODSA-N 0.000 claims 4
- LNOWDSPAYBWJOR-PEDHHIEDSA-N Pro-Ile-Ile Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O LNOWDSPAYBWJOR-PEDHHIEDSA-N 0.000 claims 4
- BGWKULMLUIUPKY-BQBZGAKWSA-N Pro-Ser-Gly Chemical compound OC(=O)CNC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1 BGWKULMLUIUPKY-BQBZGAKWSA-N 0.000 claims 4
- QMCDMHWAKMUGJE-IHRRRGAJSA-N Ser-Phe-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O QMCDMHWAKMUGJE-IHRRRGAJSA-N 0.000 claims 4
- JLKWJWPDXPKKHI-FXQIFTODSA-N Ser-Pro-Asn Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CO)N)C(=O)N[C@@H](CC(=O)N)C(=O)O JLKWJWPDXPKKHI-FXQIFTODSA-N 0.000 claims 4
- YGCDFAJJCRVQKU-RCWTZXSCSA-N Thr-Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)[C@@H](C)O YGCDFAJJCRVQKU-RCWTZXSCSA-N 0.000 claims 4
- DSGIVWSDDRDJIO-ZXXMMSQZSA-N Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DSGIVWSDDRDJIO-ZXXMMSQZSA-N 0.000 claims 4
- COYHRQWNJDJCNA-NUJDXYNKSA-N Thr-Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O COYHRQWNJDJCNA-NUJDXYNKSA-N 0.000 claims 4
- PXYJUECTGMGIDT-WDSOQIARSA-N Trp-Arg-Leu Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(O)=O)=CNC2=C1 PXYJUECTGMGIDT-WDSOQIARSA-N 0.000 claims 4
- PQPWEALFTLKSEB-DZKIICNBSA-N Tyr-Val-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O PQPWEALFTLKSEB-DZKIICNBSA-N 0.000 claims 4
- FZSPNKUFROZBSG-ZKWXMUAHSA-N Val-Ala-Asp Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(O)=O FZSPNKUFROZBSG-ZKWXMUAHSA-N 0.000 claims 4
- JYVKKBDANPZIAW-AVGNSLFASA-N Val-Arg-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C(C)C)N JYVKKBDANPZIAW-AVGNSLFASA-N 0.000 claims 4
- LCHZBEUVGAVMKS-RHYQMDGZSA-N Val-Thr-Leu Chemical compound CC(C)C[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(O)=O LCHZBEUVGAVMKS-RHYQMDGZSA-N 0.000 claims 4
- FKNHDDTXBWMZIR-GEMLJDPKSA-N acetic acid;(2s)-1-[(2r)-2-amino-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid Chemical compound CC(O)=O.SC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O FKNHDDTXBWMZIR-GEMLJDPKSA-N 0.000 claims 4
- 108010050025 alpha-glutamyltryptophan Proteins 0.000 claims 4
- 108010066198 glycyl-leucyl-phenylalanine Proteins 0.000 claims 4
- 108010015792 glycyllysine Proteins 0.000 claims 4
- 108010044311 leucyl-glycyl-glycine Proteins 0.000 claims 4
- 108010073093 leucyl-glycyl-glycyl-glycine Proteins 0.000 claims 4
- 108010084572 phenylalanyl-valine Proteins 0.000 claims 4
- 108010004914 prolylarginine Proteins 0.000 claims 4
- 108010070643 prolylglutamic acid Proteins 0.000 claims 4
- 108020003175 receptors Proteins 0.000 claims 4
- 102000005962 receptors Human genes 0.000 claims 4
- PQFMROVJTOPVDF-JBDRJPRFSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-carboxypropanoyl]amino]-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]butanedioic acid Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O PQFMROVJTOPVDF-JBDRJPRFSA-N 0.000 claims 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 3
- ZODMADSIQZZBSQ-FXQIFTODSA-N Ala-Gln-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZODMADSIQZZBSQ-FXQIFTODSA-N 0.000 claims 3
- BHTBAVZSZCQZPT-GUBZILKMSA-N Ala-Pro-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N BHTBAVZSZCQZPT-GUBZILKMSA-N 0.000 claims 3
- NHWYNIZWLJYZAG-XVYDVKMFSA-N Ala-Ser-His Chemical compound C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N NHWYNIZWLJYZAG-XVYDVKMFSA-N 0.000 claims 3
- OGUPCHKBOKJFMA-SRVKXCTJSA-N Arg-Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N OGUPCHKBOKJFMA-SRVKXCTJSA-N 0.000 claims 3
- OTZMRMHZCMZOJZ-SRVKXCTJSA-N Arg-Leu-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O OTZMRMHZCMZOJZ-SRVKXCTJSA-N 0.000 claims 3
- ZPWMEWYQBWSGAO-ZJDVBMNYSA-N Arg-Thr-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ZPWMEWYQBWSGAO-ZJDVBMNYSA-N 0.000 claims 3
- HXWUJJADFMXNKA-BQBZGAKWSA-N Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(N)=O HXWUJJADFMXNKA-BQBZGAKWSA-N 0.000 claims 3
- FYYSIASRLDJUNP-WHFBIAKZSA-N Glu-Asp Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(O)=O FYYSIASRLDJUNP-WHFBIAKZSA-N 0.000 claims 3
- KOSRFJWDECSPRO-WDSKDSINSA-N Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(O)=O KOSRFJWDECSPRO-WDSKDSINSA-N 0.000 claims 3
- CUXJIASLBRJOFV-LAEOZQHASA-N Glu-Gly-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(O)=O CUXJIASLBRJOFV-LAEOZQHASA-N 0.000 claims 3
- HILMIYALTUQTRC-XVKPBYJWSA-N Glu-Gly-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O HILMIYALTUQTRC-XVKPBYJWSA-N 0.000 claims 3
- YBAFDPFAUTYYRW-YUMQZZPRSA-N Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(O)=O YBAFDPFAUTYYRW-YUMQZZPRSA-N 0.000 claims 3
- BBBXWRGITSUJPB-YUMQZZPRSA-N Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(O)=O BBBXWRGITSUJPB-YUMQZZPRSA-N 0.000 claims 3
- BIYNPVYAZOUVFQ-CIUDSAMLSA-N Glu-Pro-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O BIYNPVYAZOUVFQ-CIUDSAMLSA-N 0.000 claims 3
- SITLTJHOQZFJGG-XPUUQOCRSA-N Glu-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(O)=O SITLTJHOQZFJGG-XPUUQOCRSA-N 0.000 claims 3
- IXKRSKPKSLXIHN-YUMQZZPRSA-N Gly-Cys-Leu Chemical compound [H]NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(O)=O IXKRSKPKSLXIHN-YUMQZZPRSA-N 0.000 claims 3
- XMPXVJIDADUOQB-RCOVLWMOSA-N Gly-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C([O-])=O)NC(=O)CNC(=O)C[NH3+] XMPXVJIDADUOQB-RCOVLWMOSA-N 0.000 claims 3
- OLPPXYMMIARYAL-QMMMGPOBSA-N Gly-Gly-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CNC(=O)CN OLPPXYMMIARYAL-QMMMGPOBSA-N 0.000 claims 3
- LCRDMSSAKLTKBU-ZDLURKLDSA-N Gly-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN LCRDMSSAKLTKBU-ZDLURKLDSA-N 0.000 claims 3
- FVEWRQXNISSYFO-ZPFDUUQYSA-N Ile-Arg-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N FVEWRQXNISSYFO-ZPFDUUQYSA-N 0.000 claims 3
- UKTUOMWSJPXODT-GUDRVLHUSA-N Ile-Asn-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N1CCC[C@@H]1C(=O)O)N UKTUOMWSJPXODT-GUDRVLHUSA-N 0.000 claims 3
- ZNOBVZFCHNHKHA-KBIXCLLPSA-N Ile-Ser-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N ZNOBVZFCHNHKHA-KBIXCLLPSA-N 0.000 claims 3
- 102100039064 Interleukin-3 Human genes 0.000 claims 3
- 102000015696 Interleukins Human genes 0.000 claims 3
- 108010063738 Interleukins Proteins 0.000 claims 3
- QLROSWPKSBORFJ-BQBZGAKWSA-N L-Prolyl-L-glutamic acid Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 QLROSWPKSBORFJ-BQBZGAKWSA-N 0.000 claims 3
- XIRYQRLFHWWWTC-QEJZJMRPSA-N Leu-Ala-Phe Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 XIRYQRLFHWWWTC-QEJZJMRPSA-N 0.000 claims 3
- KSZCCRIGNVSHFH-UWVGGRQHSA-N Leu-Arg-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O KSZCCRIGNVSHFH-UWVGGRQHSA-N 0.000 claims 3
- OIARJGNVARWKFP-YUMQZZPRSA-N Leu-Asn-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O OIARJGNVARWKFP-YUMQZZPRSA-N 0.000 claims 3
- JKGHDYGZRDWHGA-SRVKXCTJSA-N Leu-Asn-Leu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O JKGHDYGZRDWHGA-SRVKXCTJSA-N 0.000 claims 3
- IASQBRJGRVXNJI-YUMQZZPRSA-N Leu-Cys-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)NCC(O)=O IASQBRJGRVXNJI-YUMQZZPRSA-N 0.000 claims 3
- KVMULWOHPPMHHE-DCAQKATOSA-N Leu-Glu-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O KVMULWOHPPMHHE-DCAQKATOSA-N 0.000 claims 3
- OXRLYTYUXAQTHP-YUMQZZPRSA-N Leu-Gly-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(O)=O OXRLYTYUXAQTHP-YUMQZZPRSA-N 0.000 claims 3
- BJWKOATWNQJPSK-SRVKXCTJSA-N Leu-Met-Glu Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N BJWKOATWNQJPSK-SRVKXCTJSA-N 0.000 claims 3
- OVAOHZIOUBEQCJ-IHRRRGAJSA-N Lys-Leu-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O OVAOHZIOUBEQCJ-IHRRRGAJSA-N 0.000 claims 3
- IOQWIOPSKJOEKI-SRVKXCTJSA-N Lys-Ser-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O IOQWIOPSKJOEKI-SRVKXCTJSA-N 0.000 claims 3
- YRAWWKUTNBILNT-FXQIFTODSA-N Met-Ala-Ala Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O YRAWWKUTNBILNT-FXQIFTODSA-N 0.000 claims 3
- HUKLXYYPZWPXCC-KZVJFYERSA-N Met-Ala-Thr Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O HUKLXYYPZWPXCC-KZVJFYERSA-N 0.000 claims 3
- MPGJIHFJCXTVEX-KKUMJFAQSA-N Phe-Arg-Glu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O MPGJIHFJCXTVEX-KKUMJFAQSA-N 0.000 claims 3
- HXSUFWQYLPKEHF-IHRRRGAJSA-N Phe-Asn-Arg Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N HXSUFWQYLPKEHF-IHRRRGAJSA-N 0.000 claims 3
- YCCUXNNKXDGMAM-KKUMJFAQSA-N Phe-Leu-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YCCUXNNKXDGMAM-KKUMJFAQSA-N 0.000 claims 3
- IEHDJWSAXBGJIP-RYUDHWBXSA-N Phe-Val Chemical compound CC(C)[C@@H](C([O-])=O)NC(=O)[C@@H]([NH3+])CC1=CC=CC=C1 IEHDJWSAXBGJIP-RYUDHWBXSA-N 0.000 claims 3
- HMNSRTLZAJHSIK-YUMQZZPRSA-N Pro-Arg Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 HMNSRTLZAJHSIK-YUMQZZPRSA-N 0.000 claims 3
- UVKNEILZSJMKSR-FXQIFTODSA-N Pro-Asn-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]1CCCN1 UVKNEILZSJMKSR-FXQIFTODSA-N 0.000 claims 3
- AMBLXEMWFARNNQ-DCAQKATOSA-N Pro-Asn-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@@H]1CCCN1 AMBLXEMWFARNNQ-DCAQKATOSA-N 0.000 claims 3
- HXNYBZQLBWIADP-WDSKDSINSA-N Pro-Cys Chemical compound OC(=O)[C@H](CS)NC(=O)[C@@H]1CCCN1 HXNYBZQLBWIADP-WDSKDSINSA-N 0.000 claims 3
- UREQLMJCKFLLHM-NAKRPEOUSA-N Pro-Ile-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O UREQLMJCKFLLHM-NAKRPEOUSA-N 0.000 claims 3
- POQFNPILEQEODH-FXQIFTODSA-N Pro-Ser-Ala Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O POQFNPILEQEODH-FXQIFTODSA-N 0.000 claims 3
- MDAWMJUZHBQTBO-XGEHTFHBSA-N Pro-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@@H]1CCCN1)O MDAWMJUZHBQTBO-XGEHTFHBSA-N 0.000 claims 3
- KHRLUIPIMIQFGT-AVGNSLFASA-N Pro-Val-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O KHRLUIPIMIQFGT-AVGNSLFASA-N 0.000 claims 3
- HEQPKICPPDOSIN-SRVKXCTJSA-N Ser-Asp-Tyr Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HEQPKICPPDOSIN-SRVKXCTJSA-N 0.000 claims 3
- MIJWOJAXARLEHA-WDSKDSINSA-N Ser-Gly-Glu Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(O)=O MIJWOJAXARLEHA-WDSKDSINSA-N 0.000 claims 3
- XUDRHBPSPAPDJP-SRVKXCTJSA-N Ser-Lys-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CO XUDRHBPSPAPDJP-SRVKXCTJSA-N 0.000 claims 3
- OCWWJBZQXGYQCA-DCAQKATOSA-N Ser-Lys-Met Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(O)=O OCWWJBZQXGYQCA-DCAQKATOSA-N 0.000 claims 3
- FPCGZYMRFFIYIH-CIUDSAMLSA-N Ser-Lys-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O FPCGZYMRFFIYIH-CIUDSAMLSA-N 0.000 claims 3
- BMKNXTJLHFIAAH-CIUDSAMLSA-N Ser-Ser-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O BMKNXTJLHFIAAH-CIUDSAMLSA-N 0.000 claims 3
- CTONFVDJYCAMQM-IUKAMOBKSA-N Thr-Asn-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H]([C@@H](C)O)N CTONFVDJYCAMQM-IUKAMOBKSA-N 0.000 claims 3
- ASJDFGOPDCVXTG-KATARQTJSA-N Thr-Cys-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(O)=O ASJDFGOPDCVXTG-KATARQTJSA-N 0.000 claims 3
- JMGJDTNUMAZNLX-RWRJDSDZSA-N Thr-Glu-Ile Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JMGJDTNUMAZNLX-RWRJDSDZSA-N 0.000 claims 3
- XSTGOZBBXFKGHA-YJRXYDGGSA-N Thr-His-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N)O XSTGOZBBXFKGHA-YJRXYDGGSA-N 0.000 claims 3
- HPQHHRLWSAMMKG-KATARQTJSA-N Thr-Lys-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)O)N)O HPQHHRLWSAMMKG-KATARQTJSA-N 0.000 claims 3
- VZBWRZGNEPBRDE-HZUKXOBISA-N Trp-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)N VZBWRZGNEPBRDE-HZUKXOBISA-N 0.000 claims 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 3
- PMDOQZFYGWZSTK-LSJOCFKGSA-N Val-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)C(C)C PMDOQZFYGWZSTK-LSJOCFKGSA-N 0.000 claims 3
- MBGFDZDWMDLXHQ-GUBZILKMSA-N Val-Met-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](C(C)C)N MBGFDZDWMDLXHQ-GUBZILKMSA-N 0.000 claims 3
- HWNYVQMOLCYHEA-IHRRRGAJSA-N Val-Ser-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N HWNYVQMOLCYHEA-IHRRRGAJSA-N 0.000 claims 3
- 108010044940 alanylglutamine Proteins 0.000 claims 3
- 108010070944 alanylhistidine Proteins 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 108010068380 arginylarginine Proteins 0.000 claims 3
- 108010021908 aspartyl-aspartyl-glutamyl-aspartic acid Proteins 0.000 claims 3
- 108010068265 aspartyltyrosine Proteins 0.000 claims 3
- 108020001507 fusion proteins Proteins 0.000 claims 3
- 102000037865 fusion proteins Human genes 0.000 claims 3
- 108010019832 glycyl-asparaginyl-glycine Proteins 0.000 claims 3
- 239000001963 growth medium Substances 0.000 claims 3
- 108010053037 kyotorphin Proteins 0.000 claims 3
- 108010076756 leucyl-alanyl-phenylalanine Proteins 0.000 claims 3
- 210000000265 leukocyte Anatomy 0.000 claims 3
- KXKVLQRXCPHEJC-UHFFFAOYSA-N methyl acetate Chemical compound COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims 3
- 108010020755 prolyl-glycyl-glycine Proteins 0.000 claims 3
- 108010061238 threonyl-glycine Proteins 0.000 claims 3
- PCDUALPXEOKZPE-DXCABUDRSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoic acid Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O PCDUALPXEOKZPE-DXCABUDRSA-N 0.000 claims 2
- SCAKQYSGEIHPLV-IUCAKERBSA-N (4S)-4-[(2-aminoacetyl)amino]-5-[(2S)-2-(carboxymethylcarbamoyl)pyrrolidin-1-yl]-5-oxopentanoic acid Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O SCAKQYSGEIHPLV-IUCAKERBSA-N 0.000 claims 2
- XWTNPSHCJMZAHQ-QMMMGPOBSA-N 2-[[2-[[2-[[(2s)-2-amino-4-methylpentanoyl]amino]acetyl]amino]acetyl]amino]acetic acid Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)NCC(=O)NCC(O)=O XWTNPSHCJMZAHQ-QMMMGPOBSA-N 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- SITWEMZOJNKJCH-WDSKDSINSA-N Ala-Arg Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N SITWEMZOJNKJCH-WDSKDSINSA-N 0.000 claims 2
- WKOBSJOZRJJVRZ-FXQIFTODSA-N Ala-Glu-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O WKOBSJOZRJJVRZ-FXQIFTODSA-N 0.000 claims 2
- CXISPYVYMQWFLE-VKHMYHEASA-N Ala-Gly Chemical compound C[C@H]([NH3+])C(=O)NCC([O-])=O CXISPYVYMQWFLE-VKHMYHEASA-N 0.000 claims 2
- VWEWCZSUWOEEFM-WDSKDSINSA-N Ala-Gly-Ala-Gly Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(O)=O VWEWCZSUWOEEFM-WDSKDSINSA-N 0.000 claims 2
- VGPWRRFOPXVGOH-BYPYZUCNSA-N Ala-Gly-Gly Chemical compound C[C@H](N)C(=O)NCC(=O)NCC(O)=O VGPWRRFOPXVGOH-BYPYZUCNSA-N 0.000 claims 2
- LMFXXZPPZDCPTA-ZKWXMUAHSA-N Ala-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N LMFXXZPPZDCPTA-ZKWXMUAHSA-N 0.000 claims 2
- 108010076441 Ala-His-His Proteins 0.000 claims 2
- CKLDHDOIYBVUNP-KBIXCLLPSA-N Ala-Ile-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(O)=O CKLDHDOIYBVUNP-KBIXCLLPSA-N 0.000 claims 2
- OEVCHROQUIVQFZ-YTLHQDLWSA-N Ala-Thr-Ala Chemical compound C[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](C)C(O)=O OEVCHROQUIVQFZ-YTLHQDLWSA-N 0.000 claims 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims 2
- XPSGESXVBSQZPL-SRVKXCTJSA-N Arg-Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O XPSGESXVBSQZPL-SRVKXCTJSA-N 0.000 claims 2
- IGULQRCJLQQPSM-DCAQKATOSA-N Arg-Cys-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(O)=O IGULQRCJLQQPSM-DCAQKATOSA-N 0.000 claims 2
- NKBQZKVMKJJDLX-SRVKXCTJSA-N Arg-Glu-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O NKBQZKVMKJJDLX-SRVKXCTJSA-N 0.000 claims 2
- AUFHLLPVPSMEOG-YUMQZZPRSA-N Arg-Gly-Glu Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O AUFHLLPVPSMEOG-YUMQZZPRSA-N 0.000 claims 2
- CYXCAHZVPFREJD-LURJTMIESA-N Arg-Gly-Gly Chemical compound NC(=N)NCCC[C@H](N)C(=O)NCC(=O)NCC(O)=O CYXCAHZVPFREJD-LURJTMIESA-N 0.000 claims 2
- MSILNNHVVMMTHZ-UWVGGRQHSA-N Arg-His-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CN=CN1 MSILNNHVVMMTHZ-UWVGGRQHSA-N 0.000 claims 2
- WYBVBIHNJWOLCJ-IUCAKERBSA-N Arg-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCNC(N)=N WYBVBIHNJWOLCJ-IUCAKERBSA-N 0.000 claims 2
- UZGFHWIJWPUPOH-IHRRRGAJSA-N Arg-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N UZGFHWIJWPUPOH-IHRRRGAJSA-N 0.000 claims 2
- FRBAHXABMQXSJQ-FXQIFTODSA-N Arg-Ser-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O FRBAHXABMQXSJQ-FXQIFTODSA-N 0.000 claims 2
- XVAPVJNJGLWGCS-ACZMJKKPSA-N Asn-Glu-Asn Chemical compound C(CC(=O)O)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N XVAPVJNJGLWGCS-ACZMJKKPSA-N 0.000 claims 2
- NCFJQJRLQJEECD-NHCYSSNCSA-N Asn-Leu-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O NCFJQJRLQJEECD-NHCYSSNCSA-N 0.000 claims 2
- MDDXKBHIMYYJLW-FXQIFTODSA-N Asn-Met-Asp Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)N)N MDDXKBHIMYYJLW-FXQIFTODSA-N 0.000 claims 2
- HMUKKNAMNSXDBB-CIUDSAMLSA-N Asn-Met-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(O)=O HMUKKNAMNSXDBB-CIUDSAMLSA-N 0.000 claims 2
- OERMIMJQPQUIPK-FXQIFTODSA-N Asp-Arg-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O OERMIMJQPQUIPK-FXQIFTODSA-N 0.000 claims 2
- VPSHHQXIWLGVDD-ZLUOBGJFSA-N Asp-Asp-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O VPSHHQXIWLGVDD-ZLUOBGJFSA-N 0.000 claims 2
- CKAJHWFHHFSCDT-WHFBIAKZSA-N Asp-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O CKAJHWFHHFSCDT-WHFBIAKZSA-N 0.000 claims 2
- DTNUIAJCPRMNBT-WHFBIAKZSA-N Asp-Gly-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(O)=O DTNUIAJCPRMNBT-WHFBIAKZSA-N 0.000 claims 2
- MGSVBZIBCCKGCY-ZLUOBGJFSA-N Asp-Ser-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O MGSVBZIBCCKGCY-ZLUOBGJFSA-N 0.000 claims 2
- VHUKCUHLFMRHOD-MELADBBJSA-N Asp-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC(=O)O)N)C(=O)O VHUKCUHLFMRHOD-MELADBBJSA-N 0.000 claims 2
- QOJJMJKTMKNFEF-ZKWXMUAHSA-N Asp-Val-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC(O)=O QOJJMJKTMKNFEF-ZKWXMUAHSA-N 0.000 claims 2
- ABLJDBFJPUWQQB-DCAQKATOSA-N Cys-Leu-Arg Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CS)N ABLJDBFJPUWQQB-DCAQKATOSA-N 0.000 claims 2
- KVCJEMHFLGVINV-ZLUOBGJFSA-N Cys-Ser-Asn Chemical compound SC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC(N)=O KVCJEMHFLGVINV-ZLUOBGJFSA-N 0.000 claims 2
- 102100040004 Gamma-glutamylcyclotransferase Human genes 0.000 claims 2
- GZWOBWMOMPFPCD-CIUDSAMLSA-N Glu-Asp-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)N GZWOBWMOMPFPCD-CIUDSAMLSA-N 0.000 claims 2
- LSPKYLAFTPBWIL-BYPYZUCNSA-N Glu-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(O)=O LSPKYLAFTPBWIL-BYPYZUCNSA-N 0.000 claims 2
- JHSRJMUJOGLIHK-GUBZILKMSA-N Glu-Met-Glu Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)O)N JHSRJMUJOGLIHK-GUBZILKMSA-N 0.000 claims 2
- YBTCBQBIJKGSJP-BQBZGAKWSA-N Glu-Pro Chemical compound OC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O YBTCBQBIJKGSJP-BQBZGAKWSA-N 0.000 claims 2
- JSIQVRIXMINMTA-ZDLURKLDSA-N Glu-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(O)=O JSIQVRIXMINMTA-ZDLURKLDSA-N 0.000 claims 2
- LWYUQLZOIORFFJ-XKBZYTNZSA-N Glu-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCC(=O)O)N)O LWYUQLZOIORFFJ-XKBZYTNZSA-N 0.000 claims 2
- ZQIMMEYPEXIYBB-IUCAKERBSA-N Gly-Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CN ZQIMMEYPEXIYBB-IUCAKERBSA-N 0.000 claims 2
- QSVCIFZPGLOZGH-WDSKDSINSA-N Gly-Glu-Ser Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O QSVCIFZPGLOZGH-WDSKDSINSA-N 0.000 claims 2
- UFPXDFOYHVEIPI-BYPYZUCNSA-N Gly-Gly-Asp Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CC(O)=O UFPXDFOYHVEIPI-BYPYZUCNSA-N 0.000 claims 2
- QPCVIQJVRGXUSA-LURJTMIESA-N Gly-Gly-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)CNC(=O)CN QPCVIQJVRGXUSA-LURJTMIESA-N 0.000 claims 2
- UUYBFNKHOCJCHT-VHSXEESVSA-N Gly-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN UUYBFNKHOCJCHT-VHSXEESVSA-N 0.000 claims 2
- JJGBXTYGTKWGAT-YUMQZZPRSA-N Gly-Pro-Glu Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O JJGBXTYGTKWGAT-YUMQZZPRSA-N 0.000 claims 2
- WNGHUXFWEWTKAO-YUMQZZPRSA-N Gly-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN WNGHUXFWEWTKAO-YUMQZZPRSA-N 0.000 claims 2
- POJJAZJHBGXEGM-YUMQZZPRSA-N Gly-Ser-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)CN POJJAZJHBGXEGM-YUMQZZPRSA-N 0.000 claims 2
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 claims 2
- 101000886680 Homo sapiens Gamma-glutamylcyclotransferase Proteins 0.000 claims 2
- 101000716729 Homo sapiens Kit ligand Proteins 0.000 claims 2
- BCVIOZZGJNOEQS-XKNYDFJKSA-N Ile-Ile Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(O)=O)[C@@H](C)CC BCVIOZZGJNOEQS-XKNYDFJKSA-N 0.000 claims 2
- TVYWVSJGSHQWMT-AJNGGQMLSA-N Ile-Leu-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N TVYWVSJGSHQWMT-AJNGGQMLSA-N 0.000 claims 2
- AKQFLPNANHNTLP-VKOGCVSHSA-N Ile-Pro-Trp Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)O)N AKQFLPNANHNTLP-VKOGCVSHSA-N 0.000 claims 2
- BVRPESWOSNFUCJ-LKTVYLICSA-N Ile-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)[C@@H](C)CC)C(O)=O)=CNC2=C1 BVRPESWOSNFUCJ-LKTVYLICSA-N 0.000 claims 2
- 108010002616 Interleukin-5 Proteins 0.000 claims 2
- 102000000743 Interleukin-5 Human genes 0.000 claims 2
- 108090001005 Interleukin-6 Proteins 0.000 claims 2
- 102000004889 Interleukin-6 Human genes 0.000 claims 2
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 claims 2
- DEFJQIDDEAULHB-IMJSIDKUSA-N L-alanyl-L-alanine Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(O)=O DEFJQIDDEAULHB-IMJSIDKUSA-N 0.000 claims 2
- HFKJBCPRWWGPEY-BQBZGAKWSA-N L-arginyl-L-glutamic acid Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(O)=O HFKJBCPRWWGPEY-BQBZGAKWSA-N 0.000 claims 2
- QOOWRKBDDXQRHC-BQBZGAKWSA-N L-lysyl-L-alanine Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN QOOWRKBDDXQRHC-BQBZGAKWSA-N 0.000 claims 2
- 241000880493 Leptailurus serval Species 0.000 claims 2
- PBCHMHROGNUXMK-DLOVCJGASA-N Leu-Ala-His Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 PBCHMHROGNUXMK-DLOVCJGASA-N 0.000 claims 2
- XBBKIIGCUMBKCO-JXUBOQSCSA-N Leu-Ala-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XBBKIIGCUMBKCO-JXUBOQSCSA-N 0.000 claims 2
- SENJXOPIZNYLHU-IUCAKERBSA-N Leu-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N SENJXOPIZNYLHU-IUCAKERBSA-N 0.000 claims 2
- FJUKMPUELVROGK-IHRRRGAJSA-N Leu-Arg-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N FJUKMPUELVROGK-IHRRRGAJSA-N 0.000 claims 2
- UCOCBWDBHCUPQP-DCAQKATOSA-N Leu-Arg-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O UCOCBWDBHCUPQP-DCAQKATOSA-N 0.000 claims 2
- STAVRDQLZOTNKJ-RHYQMDGZSA-N Leu-Arg-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O STAVRDQLZOTNKJ-RHYQMDGZSA-N 0.000 claims 2
- OGCQGUIWMSBHRZ-CIUDSAMLSA-N Leu-Asn-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O OGCQGUIWMSBHRZ-CIUDSAMLSA-N 0.000 claims 2
- HPBCTWSUJOGJSH-MNXVOIDGSA-N Leu-Glu-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O HPBCTWSUJOGJSH-MNXVOIDGSA-N 0.000 claims 2
- QJUWBDPGGYVRHY-YUMQZZPRSA-N Leu-Gly-Cys Chemical compound CC(C)C[C@@H](C(=O)NCC(=O)N[C@@H](CS)C(=O)O)N QJUWBDPGGYVRHY-YUMQZZPRSA-N 0.000 claims 2
- XWOBNBRUDDUEEY-UWVGGRQHSA-N Leu-His Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CNC=N1 XWOBNBRUDDUEEY-UWVGGRQHSA-N 0.000 claims 2
- CFZZDVMBRYFFNU-QWRGUYRKSA-N Leu-His-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)NCC(O)=O CFZZDVMBRYFFNU-QWRGUYRKSA-N 0.000 claims 2
- IAJFFZORSWOZPQ-SRVKXCTJSA-N Leu-Leu-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O IAJFFZORSWOZPQ-SRVKXCTJSA-N 0.000 claims 2
- KYIIALJHAOIAHF-KKUMJFAQSA-N Leu-Leu-His Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 KYIIALJHAOIAHF-KKUMJFAQSA-N 0.000 claims 2
- UCNNZELZXFXXJQ-BZSNNMDCSA-N Leu-Leu-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 UCNNZELZXFXXJQ-BZSNNMDCSA-N 0.000 claims 2
- RRVCZCNFXIFGRA-DCAQKATOSA-N Leu-Pro-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O RRVCZCNFXIFGRA-DCAQKATOSA-N 0.000 claims 2
- GZRABTMNWJXFMH-UVOCVTCTSA-N Leu-Thr-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GZRABTMNWJXFMH-UVOCVTCTSA-N 0.000 claims 2
- FACUGMGEFUEBTI-SRVKXCTJSA-N Lys-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CCCCN FACUGMGEFUEBTI-SRVKXCTJSA-N 0.000 claims 2
- YEIYAQQKADPIBJ-GARJFASQSA-N Lys-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCCN)N)C(=O)O YEIYAQQKADPIBJ-GARJFASQSA-N 0.000 claims 2
- ZAWOJFFMBANLGE-CIUDSAMLSA-N Lys-Cys-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CCCCN)N ZAWOJFFMBANLGE-CIUDSAMLSA-N 0.000 claims 2
- GJJQCBVRWDGLMQ-GUBZILKMSA-N Lys-Glu-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O GJJQCBVRWDGLMQ-GUBZILKMSA-N 0.000 claims 2
- FMIIKPHLJKUXGE-GUBZILKMSA-N Lys-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCCN FMIIKPHLJKUXGE-GUBZILKMSA-N 0.000 claims 2
- ATIPDCIQTUXABX-UWVGGRQHSA-N Lys-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCCN ATIPDCIQTUXABX-UWVGGRQHSA-N 0.000 claims 2
- ZMYHJISLFYTQGK-FXQIFTODSA-N Met-Asp-Asn Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O ZMYHJISLFYTQGK-FXQIFTODSA-N 0.000 claims 2
- ADHNYKZHPOEULM-BQBZGAKWSA-N Met-Glu Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O ADHNYKZHPOEULM-BQBZGAKWSA-N 0.000 claims 2
- HZVXPUHLTZRQEL-UWVGGRQHSA-N Met-Leu-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O HZVXPUHLTZRQEL-UWVGGRQHSA-N 0.000 claims 2
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 claims 2
- WYBVBIHNJWOLCJ-UHFFFAOYSA-N N-L-arginyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCCN=C(N)N WYBVBIHNJWOLCJ-UHFFFAOYSA-N 0.000 claims 2
- AUEJLPRZGVVDNU-UHFFFAOYSA-N N-L-tyrosyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CC1=CC=C(O)C=C1 AUEJLPRZGVVDNU-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- WPTYDQPGBMDUBI-QWRGUYRKSA-N Phe-Gly-Asn Chemical compound N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O WPTYDQPGBMDUBI-QWRGUYRKSA-N 0.000 claims 2
- YTILBRIUASDGBL-BZSNNMDCSA-N Phe-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 YTILBRIUASDGBL-BZSNNMDCSA-N 0.000 claims 2
- KNYPNEYICHHLQL-ACRUOGEOSA-N Phe-Leu-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 KNYPNEYICHHLQL-ACRUOGEOSA-N 0.000 claims 2
- IFMDQWDAJUMMJC-DCAQKATOSA-N Pro-Ala-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O IFMDQWDAJUMMJC-DCAQKATOSA-N 0.000 claims 2
- ZCXQTRXYZOSGJR-FXQIFTODSA-N Pro-Asp-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O ZCXQTRXYZOSGJR-FXQIFTODSA-N 0.000 claims 2
- NXEYSLRNNPWCRN-SRVKXCTJSA-N Pro-Glu-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O NXEYSLRNNPWCRN-SRVKXCTJSA-N 0.000 claims 2
- VPEVBAUSTBWQHN-NHCYSSNCSA-N Pro-Glu-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O VPEVBAUSTBWQHN-NHCYSSNCSA-N 0.000 claims 2
- HAAQQNHQZBOWFO-LURJTMIESA-N Pro-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1 HAAQQNHQZBOWFO-LURJTMIESA-N 0.000 claims 2
- UCXDHBORXLVBNC-ZLUOBGJFSA-N Ser-Asn-Cys Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(O)=O UCXDHBORXLVBNC-ZLUOBGJFSA-N 0.000 claims 2
- FIDMVVBUOCMMJG-CIUDSAMLSA-N Ser-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CO FIDMVVBUOCMMJG-CIUDSAMLSA-N 0.000 claims 2
- DBIDZNUXSLXVRG-FXQIFTODSA-N Ser-Asp-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)N DBIDZNUXSLXVRG-FXQIFTODSA-N 0.000 claims 2
- WOUIMBGNEUWXQG-VKHMYHEASA-N Ser-Gly Chemical compound OC[C@H](N)C(=O)NCC(O)=O WOUIMBGNEUWXQG-VKHMYHEASA-N 0.000 claims 2
- ZUDXUJSYCCNZQJ-DCAQKATOSA-N Ser-His-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CO)N ZUDXUJSYCCNZQJ-DCAQKATOSA-N 0.000 claims 2
- NFDYGNFETJVMSE-BQBZGAKWSA-N Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CO NFDYGNFETJVMSE-BQBZGAKWSA-N 0.000 claims 2
- SBMNPABNWKXNBJ-BQBZGAKWSA-N Ser-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CO SBMNPABNWKXNBJ-BQBZGAKWSA-N 0.000 claims 2
- RHAPJNVNWDBFQI-BQBZGAKWSA-N Ser-Pro-Gly Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O RHAPJNVNWDBFQI-BQBZGAKWSA-N 0.000 claims 2
- SRSPTFBENMJHMR-WHFBIAKZSA-N Ser-Ser-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SRSPTFBENMJHMR-WHFBIAKZSA-N 0.000 claims 2
- XQJCEKXQUJQNNK-ZLUOBGJFSA-N Ser-Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O XQJCEKXQUJQNNK-ZLUOBGJFSA-N 0.000 claims 2
- VGQVAVQWKJLIRM-FXQIFTODSA-N Ser-Ser-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O VGQVAVQWKJLIRM-FXQIFTODSA-N 0.000 claims 2
- LDEBVRIURYMKQS-WISUUJSJSA-N Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CO LDEBVRIURYMKQS-WISUUJSJSA-N 0.000 claims 2
- GZYNMZQXFRWDFH-YTWAJWBKSA-N Thr-Arg-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(=O)O)N)O GZYNMZQXFRWDFH-YTWAJWBKSA-N 0.000 claims 2
- AYCQVUUPIJHJTA-IXOXFDKPSA-N Thr-His-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(O)=O AYCQVUUPIJHJTA-IXOXFDKPSA-N 0.000 claims 2
- QOLYAJSZHIJCTO-VQVTYTSYSA-N Thr-Pro Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(O)=O QOLYAJSZHIJCTO-VQVTYTSYSA-N 0.000 claims 2
- NDZYTIMDOZMECO-SHGPDSBTSA-N Thr-Thr-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O NDZYTIMDOZMECO-SHGPDSBTSA-N 0.000 claims 2
- NHQVWACSJZJCGJ-FLBSBUHZSA-N Thr-Thr-Ile Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O NHQVWACSJZJCGJ-FLBSBUHZSA-N 0.000 claims 2
- OGOYMQWIWHGTGH-KZVJFYERSA-N Thr-Val-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O OGOYMQWIWHGTGH-KZVJFYERSA-N 0.000 claims 2
- 102000036693 Thrombopoietin Human genes 0.000 claims 2
- 108010041111 Thrombopoietin Proteins 0.000 claims 2
- ADBDQGBDNUTRDB-ULQDDVLXSA-N Tyr-Arg-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O ADBDQGBDNUTRDB-ULQDDVLXSA-N 0.000 claims 2
- QYSBJAUCUKHSLU-JYJNAYRXSA-N Tyr-Arg-Val Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(O)=O QYSBJAUCUKHSLU-JYJNAYRXSA-N 0.000 claims 2
- HVHJYXDXRIWELT-RYUDHWBXSA-N Tyr-Glu-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O HVHJYXDXRIWELT-RYUDHWBXSA-N 0.000 claims 2
- IBIDRSSEHFLGSD-YUMQZZPRSA-N Val-Arg Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IBIDRSSEHFLGSD-YUMQZZPRSA-N 0.000 claims 2
- VVZDBPBZHLQPPB-XVKPBYJWSA-N Val-Glu-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O VVZDBPBZHLQPPB-XVKPBYJWSA-N 0.000 claims 2
- LYERIXUFCYVFFX-GVXVVHGQSA-N Val-Leu-Glu Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N LYERIXUFCYVFFX-GVXVVHGQSA-N 0.000 claims 2
- UMPVMAYCLYMYGA-ONGXEEELSA-N Val-Leu-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O UMPVMAYCLYMYGA-ONGXEEELSA-N 0.000 claims 2
- QRVPEKJBBRYISE-XUXIUFHCSA-N Val-Lys-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)N QRVPEKJBBRYISE-XUXIUFHCSA-N 0.000 claims 2
- STTYIMSDIYISRG-UHFFFAOYSA-N Valyl-Serine Chemical compound CC(C)C(N)C(=O)NC(CO)C(O)=O STTYIMSDIYISRG-UHFFFAOYSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 108010008685 alanyl-glutamyl-aspartic acid Proteins 0.000 claims 2
- 108010056243 alanylalanine Proteins 0.000 claims 2
- 108010009111 arginyl-glycyl-glutamic acid Proteins 0.000 claims 2
- 210000003743 erythrocyte Anatomy 0.000 claims 2
- 238000000684 flow cytometry Methods 0.000 claims 2
- 108010026364 glycyl-glycyl-leucine Proteins 0.000 claims 2
- 108010079413 glycyl-prolyl-glutamic acid Proteins 0.000 claims 2
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 claims 2
- 108010045383 histidyl-glycyl-glutamic acid Proteins 0.000 claims 2
- 108010028295 histidylhistidine Proteins 0.000 claims 2
- 102000044890 human EPO Human genes 0.000 claims 2
- 102000055151 human KITLG Human genes 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 108010064486 phenylalanyl-leucyl-valine Proteins 0.000 claims 2
- 108010073101 phenylalanylleucine Proteins 0.000 claims 2
- IBIDRSSEHFLGSD-UHFFFAOYSA-N valinyl-arginine Natural products CC(C)C(N)C(=O)NC(C(O)=O)CCCN=C(N)N IBIDRSSEHFLGSD-UHFFFAOYSA-N 0.000 claims 2
- QPUQFUKWLQUBQJ-ZQIUZPCESA-N (2s)-2-[[2-[[(2s)-2-[[(2s)-1-(2-aminoacetyl)pyrrolidine-2-carbonyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-methylbutanoic acid Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1C(=O)CN QPUQFUKWLQUBQJ-ZQIUZPCESA-N 0.000 claims 1
- VOUUHEHYSHWUHG-UWVGGRQHSA-N (2s)-2-[[2-[[2-[[2-[[(2s)-2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoic acid Chemical compound NCC(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O VOUUHEHYSHWUHG-UWVGGRQHSA-N 0.000 claims 1
- PIDRBUDUWHBYSR-UHFFFAOYSA-N 1-[2-[[2-[(2-amino-4-methylpentanoyl)amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)CC(N)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)N1CCCC1C(O)=O PIDRBUDUWHBYSR-UHFFFAOYSA-N 0.000 claims 1
- OZRFYUJEXYKQDV-UHFFFAOYSA-N 2-[[2-[[2-[(2-amino-3-carboxypropanoyl)amino]-3-carboxypropanoyl]amino]-3-carboxypropanoyl]amino]butanedioic acid Chemical compound OC(=O)CC(N)C(=O)NC(CC(O)=O)C(=O)NC(CC(O)=O)C(=O)NC(CC(O)=O)C(O)=O OZRFYUJEXYKQDV-UHFFFAOYSA-N 0.000 claims 1
- QMOQBVOBWVNSNO-UHFFFAOYSA-N 2-[[2-[[2-[(2-azaniumylacetyl)amino]acetyl]amino]acetyl]amino]acetate Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(O)=O QMOQBVOBWVNSNO-UHFFFAOYSA-N 0.000 claims 1
- VQUVCIYMYJAJIZ-UHFFFAOYSA-N 2-[n-ethyl-4-[2-(1-methylpyridin-1-ium-4-yl)ethenyl]anilino]ethanol;tetraphenylboranuide Chemical compound C1=CC(N(CCO)CC)=CC=C1\C=C\C1=CC=[N+](C)C=C1.C1=CC=CC=C1[B-](C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 VQUVCIYMYJAJIZ-UHFFFAOYSA-N 0.000 claims 1
- IMIZPWSVYADSCN-UHFFFAOYSA-N 4-methyl-2-[[4-methyl-2-[[4-methyl-2-(pyrrolidine-2-carbonylamino)pentanoyl]amino]pentanoyl]amino]pentanoic acid Chemical compound CC(C)CC(C(O)=O)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C1CCCN1 IMIZPWSVYADSCN-UHFFFAOYSA-N 0.000 claims 1
- BYXHQQCXAJARLQ-ZLUOBGJFSA-N Ala-Ala-Ala Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O BYXHQQCXAJARLQ-ZLUOBGJFSA-N 0.000 claims 1
- JBGSZRYCXBPWGX-BQBZGAKWSA-N Ala-Arg-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)C)CCCN=C(N)N JBGSZRYCXBPWGX-BQBZGAKWSA-N 0.000 claims 1
- CCUAQNUWXLYFRA-IMJSIDKUSA-N Ala-Asn Chemical compound C[C@H]([NH3+])C(=O)N[C@H](C([O-])=O)CC(N)=O CCUAQNUWXLYFRA-IMJSIDKUSA-N 0.000 claims 1
- NXSFUECZFORGOG-CIUDSAMLSA-N Ala-Asn-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O NXSFUECZFORGOG-CIUDSAMLSA-N 0.000 claims 1
- CXZFXHGJJPVUJE-CIUDSAMLSA-N Ala-Cys-Leu Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)O)N CXZFXHGJJPVUJE-CIUDSAMLSA-N 0.000 claims 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 claims 1
- FUSPCLTUKXQREV-ACZMJKKPSA-N Ala-Glu-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O FUSPCLTUKXQREV-ACZMJKKPSA-N 0.000 claims 1
- KXEVYGKATAMXJJ-ACZMJKKPSA-N Ala-Glu-Asp Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O KXEVYGKATAMXJJ-ACZMJKKPSA-N 0.000 claims 1
- LJFNNUBZSZCZFN-WHFBIAKZSA-N Ala-Gly-Cys Chemical compound N[C@@H](C)C(=O)NCC(=O)N[C@@H](CS)C(=O)O LJFNNUBZSZCZFN-WHFBIAKZSA-N 0.000 claims 1
- BEMGNWZECGIJOI-WDSKDSINSA-N Ala-Gly-Glu Chemical compound [H]N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O BEMGNWZECGIJOI-WDSKDSINSA-N 0.000 claims 1
- NBTGEURICRTMGL-WHFBIAKZSA-N Ala-Gly-Ser Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O NBTGEURICRTMGL-WHFBIAKZSA-N 0.000 claims 1
- SMCGQGDVTPFXKB-XPUUQOCRSA-N Ala-Gly-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N SMCGQGDVTPFXKB-XPUUQOCRSA-N 0.000 claims 1
- CFPQUJZTLUQUTJ-HTFCKZLJSA-N Ala-Ile-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](C)N CFPQUJZTLUQUTJ-HTFCKZLJSA-N 0.000 claims 1
- SUMYEVXWCAYLLJ-GUBZILKMSA-N Ala-Leu-Gln Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O SUMYEVXWCAYLLJ-GUBZILKMSA-N 0.000 claims 1
- DEWWPUNXRNGMQN-LPEHRKFASA-N Ala-Met-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N1CCC[C@@H]1C(=O)O)N DEWWPUNXRNGMQN-LPEHRKFASA-N 0.000 claims 1
- IORKCNUBHNIMKY-CIUDSAMLSA-N Ala-Pro-Glu Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O IORKCNUBHNIMKY-CIUDSAMLSA-N 0.000 claims 1
- IPWKGIFRRBGCJO-IMJSIDKUSA-N Ala-Ser Chemical compound C[C@H]([NH3+])C(=O)N[C@@H](CO)C([O-])=O IPWKGIFRRBGCJO-IMJSIDKUSA-N 0.000 claims 1
- KLALXKYLOMZDQT-ZLUOBGJFSA-N Ala-Ser-Asn Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC(N)=O KLALXKYLOMZDQT-ZLUOBGJFSA-N 0.000 claims 1
- HOVPGJUNRLMIOZ-CIUDSAMLSA-N Ala-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)N HOVPGJUNRLMIOZ-CIUDSAMLSA-N 0.000 claims 1
- WNHNMKOFKCHKKD-BFHQHQDPSA-N Ala-Thr-Gly Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O WNHNMKOFKCHKKD-BFHQHQDPSA-N 0.000 claims 1
- 241001136792 Alle Species 0.000 claims 1
- 108010039224 Amidophosphoribosyltransferase Proteins 0.000 claims 1
- 241000024188 Andala Species 0.000 claims 1
- SGYSTDWPNPKJPP-GUBZILKMSA-N Arg-Ala-Arg Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SGYSTDWPNPKJPP-GUBZILKMSA-N 0.000 claims 1
- DPXDVGDLWJYZBH-GUBZILKMSA-N Arg-Asn-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O DPXDVGDLWJYZBH-GUBZILKMSA-N 0.000 claims 1
- PBSOQGZLPFVXPU-YUMQZZPRSA-N Arg-Glu-Gly Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O PBSOQGZLPFVXPU-YUMQZZPRSA-N 0.000 claims 1
- GOWZVQXTHUCNSQ-NHCYSSNCSA-N Arg-Glu-Val Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O GOWZVQXTHUCNSQ-NHCYSSNCSA-N 0.000 claims 1
- BNODVYXZAAXSHW-IUCAKERBSA-N Arg-His Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CNC=N1 BNODVYXZAAXSHW-IUCAKERBSA-N 0.000 claims 1
- LVMUGODRNHFGRA-AVGNSLFASA-N Arg-Leu-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O LVMUGODRNHFGRA-AVGNSLFASA-N 0.000 claims 1
- NIUDXSFNLBIWOB-DCAQKATOSA-N Arg-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N NIUDXSFNLBIWOB-DCAQKATOSA-N 0.000 claims 1
- NOZYDJOPOGKUSR-AVGNSLFASA-N Arg-Leu-Met Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(O)=O NOZYDJOPOGKUSR-AVGNSLFASA-N 0.000 claims 1
- CLICCYPMVFGUOF-IHRRRGAJSA-N Arg-Lys-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O CLICCYPMVFGUOF-IHRRRGAJSA-N 0.000 claims 1
- AUZAXCPWMDBWEE-HJGDQZAQSA-N Arg-Thr-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O AUZAXCPWMDBWEE-HJGDQZAQSA-N 0.000 claims 1
- BXLDDWZOTGGNOJ-SZMVWBNQSA-N Arg-Trp-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CCCN=C(N)N)N BXLDDWZOTGGNOJ-SZMVWBNQSA-N 0.000 claims 1
- PSUXEQYPYZLNER-QXEWZRGKSA-N Arg-Val-Asn Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O PSUXEQYPYZLNER-QXEWZRGKSA-N 0.000 claims 1
- ULBHWNVWSCJLCO-NHCYSSNCSA-N Arg-Val-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCN=C(N)N ULBHWNVWSCJLCO-NHCYSSNCSA-N 0.000 claims 1
- VYZBPPBKFCHCIS-WPRPVWTQSA-N Arg-Val-Gly Chemical compound OC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCN=C(N)N VYZBPPBKFCHCIS-WPRPVWTQSA-N 0.000 claims 1
- QLSRIZIDQXDQHK-RCWTZXSCSA-N Arg-Val-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QLSRIZIDQXDQHK-RCWTZXSCSA-N 0.000 claims 1
- LEFKSBYHUGUWLP-ACZMJKKPSA-N Asn-Ala-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O LEFKSBYHUGUWLP-ACZMJKKPSA-N 0.000 claims 1
- MFFOYNGMOYFPBD-DCAQKATOSA-N Asn-Arg-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O MFFOYNGMOYFPBD-DCAQKATOSA-N 0.000 claims 1
- NKTLGLBAGUJEGA-BIIVOSGPSA-N Asn-Cys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CS)NC(=O)[C@H](CC(=O)N)N)C(=O)O NKTLGLBAGUJEGA-BIIVOSGPSA-N 0.000 claims 1
- SPCONPVIDFMDJI-QSFUFRPTSA-N Asn-Ile-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O SPCONPVIDFMDJI-QSFUFRPTSA-N 0.000 claims 1
- IQTUDDBANZYMAR-WDSKDSINSA-N Asn-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(N)=O IQTUDDBANZYMAR-WDSKDSINSA-N 0.000 claims 1
- KSGAFDTYQPKUAP-GMOBBJLQSA-N Asn-Met-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KSGAFDTYQPKUAP-GMOBBJLQSA-N 0.000 claims 1
- AEZCCDMZZJOGII-DCAQKATOSA-N Asn-Met-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O AEZCCDMZZJOGII-DCAQKATOSA-N 0.000 claims 1
- QGABLMITFKUQDF-DCAQKATOSA-N Asn-Met-Lys Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N QGABLMITFKUQDF-DCAQKATOSA-N 0.000 claims 1
- PBFXCUOEGVJTMV-QXEWZRGKSA-N Asn-Met-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(O)=O PBFXCUOEGVJTMV-QXEWZRGKSA-N 0.000 claims 1
- OSZBYGVKAFZWKC-FXQIFTODSA-N Asn-Pro-Cys Chemical compound NC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(O)=O OSZBYGVKAFZWKC-FXQIFTODSA-N 0.000 claims 1
- BYLSYQASFJJBCL-DCAQKATOSA-N Asn-Pro-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O BYLSYQASFJJBCL-DCAQKATOSA-N 0.000 claims 1
- UWFOMGUWGPRVBW-GUBZILKMSA-N Asn-Pro-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(=O)N)N UWFOMGUWGPRVBW-GUBZILKMSA-N 0.000 claims 1
- GZXOUBTUAUAVHD-ACZMJKKPSA-N Asn-Ser-Glu Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O GZXOUBTUAUAVHD-ACZMJKKPSA-N 0.000 claims 1
- HPBNLFLSSQDFQW-WHFBIAKZSA-N Asn-Ser-Gly Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O HPBNLFLSSQDFQW-WHFBIAKZSA-N 0.000 claims 1
- ZUFPUBYQYWCMDB-NUMRIWBASA-N Asn-Thr-Glu Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZUFPUBYQYWCMDB-NUMRIWBASA-N 0.000 claims 1
- XLDMSQYOYXINSZ-QXEWZRGKSA-N Asn-Val-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N XLDMSQYOYXINSZ-QXEWZRGKSA-N 0.000 claims 1
- LMIWYCWRJVMAIQ-NHCYSSNCSA-N Asn-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N LMIWYCWRJVMAIQ-NHCYSSNCSA-N 0.000 claims 1
- KRXIWXCXOARFNT-ZLUOBGJFSA-N Asp-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O KRXIWXCXOARFNT-ZLUOBGJFSA-N 0.000 claims 1
- NECWUSYTYSIFNC-DLOVCJGASA-N Asp-Ala-Phe Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 NECWUSYTYSIFNC-DLOVCJGASA-N 0.000 claims 1
- IXIWEFWRKIUMQX-DCAQKATOSA-N Asp-Arg-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O IXIWEFWRKIUMQX-DCAQKATOSA-N 0.000 claims 1
- UQBGYPFHWFZMCD-ZLUOBGJFSA-N Asp-Asn-Asn Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O UQBGYPFHWFZMCD-ZLUOBGJFSA-N 0.000 claims 1
- SBHUBSDEZQFJHJ-CIUDSAMLSA-N Asp-Asp-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC(O)=O SBHUBSDEZQFJHJ-CIUDSAMLSA-N 0.000 claims 1
- WBDWQKRLTVCDSY-WHFBIAKZSA-N Asp-Gly-Asp Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O WBDWQKRLTVCDSY-WHFBIAKZSA-N 0.000 claims 1
- RQYMKRMRZWJGHC-BQBZGAKWSA-N Asp-Gly-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)O)N RQYMKRMRZWJGHC-BQBZGAKWSA-N 0.000 claims 1
- UJGRZQYSNYTCAX-SRVKXCTJSA-N Asp-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(O)=O UJGRZQYSNYTCAX-SRVKXCTJSA-N 0.000 claims 1
- CJUKAWUWBZCTDQ-SRVKXCTJSA-N Asp-Leu-Lys Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O CJUKAWUWBZCTDQ-SRVKXCTJSA-N 0.000 claims 1
- UMHUHHJMEXNSIV-CIUDSAMLSA-N Asp-Leu-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(O)=O UMHUHHJMEXNSIV-CIUDSAMLSA-N 0.000 claims 1
- QNMKWNONJGKJJC-NHCYSSNCSA-N Asp-Leu-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O QNMKWNONJGKJJC-NHCYSSNCSA-N 0.000 claims 1
- YWLDTBBUHZJQHW-KKUMJFAQSA-N Asp-Lys-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)N YWLDTBBUHZJQHW-KKUMJFAQSA-N 0.000 claims 1
- LIQNMKIBMPEOOP-IHRRRGAJSA-N Asp-Phe-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(=O)O)N LIQNMKIBMPEOOP-IHRRRGAJSA-N 0.000 claims 1
- AHWRSSLYSGLBGD-CIUDSAMLSA-N Asp-Pro-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O AHWRSSLYSGLBGD-CIUDSAMLSA-N 0.000 claims 1
- ZBYLEBZCVKLPCY-FXQIFTODSA-N Asp-Ser-Arg Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O ZBYLEBZCVKLPCY-FXQIFTODSA-N 0.000 claims 1
- HRVQDZOWMLFAOD-BIIVOSGPSA-N Asp-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)N)C(=O)O HRVQDZOWMLFAOD-BIIVOSGPSA-N 0.000 claims 1
- GXHDGYOXPNQCKM-XVSYOHENSA-N Asp-Thr-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CC(=O)O)N)O GXHDGYOXPNQCKM-XVSYOHENSA-N 0.000 claims 1
- LLRJPYJQNBMOOO-QEJZJMRPSA-N Asp-Trp-Gln Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)O)N LLRJPYJQNBMOOO-QEJZJMRPSA-N 0.000 claims 1
- MRYDJCIIVRXVGG-QEJZJMRPSA-N Asp-Trp-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O MRYDJCIIVRXVGG-QEJZJMRPSA-N 0.000 claims 1
- XWKBWZXGNXTDKY-ZKWXMUAHSA-N Asp-Val-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC(O)=O XWKBWZXGNXTDKY-ZKWXMUAHSA-N 0.000 claims 1
- WAEDSQFVZJUHLI-BYULHYEWSA-N Asp-Val-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O WAEDSQFVZJUHLI-BYULHYEWSA-N 0.000 claims 1
- GIKOVDMXBAFXDF-NHCYSSNCSA-N Asp-Val-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O GIKOVDMXBAFXDF-NHCYSSNCSA-N 0.000 claims 1
- RKXVTTIQNKPCHU-KKHAAJSZSA-N Asp-Val-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC(O)=O RKXVTTIQNKPCHU-KKHAAJSZSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 1
- 101100228196 Caenorhabditis elegans gly-4 gene Proteins 0.000 claims 1
- 101100285688 Caenorhabditis elegans hrg-7 gene Proteins 0.000 claims 1
- 241000251204 Chimaeridae Species 0.000 claims 1
- 229920000742 Cotton Polymers 0.000 claims 1
- GRNOCLDFUNCIDW-ACZMJKKPSA-N Cys-Ala-Glu Chemical compound C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CS)N GRNOCLDFUNCIDW-ACZMJKKPSA-N 0.000 claims 1
- PRVVCRZLTJNPCS-FXQIFTODSA-N Cys-Arg-Asn Chemical compound C(C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CS)N)CN=C(N)N PRVVCRZLTJNPCS-FXQIFTODSA-N 0.000 claims 1
- BYALSSDCQYHKMY-XGEHTFHBSA-N Cys-Arg-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CS)N)O BYALSSDCQYHKMY-XGEHTFHBSA-N 0.000 claims 1
- DZLQXIFVQFTFJY-BYPYZUCNSA-N Cys-Gly-Gly Chemical compound SC[C@H](N)C(=O)NCC(=O)NCC(O)=O DZLQXIFVQFTFJY-BYPYZUCNSA-N 0.000 claims 1
- KPENUVBHAKRDQR-GUBZILKMSA-N Cys-His-Glu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(O)=O KPENUVBHAKRDQR-GUBZILKMSA-N 0.000 claims 1
- VBIIZCXWOZDIHS-ACZMJKKPSA-N Cys-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CS VBIIZCXWOZDIHS-ACZMJKKPSA-N 0.000 claims 1
- WVLZTXGTNGHPBO-SRVKXCTJSA-N Cys-Leu-Leu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O WVLZTXGTNGHPBO-SRVKXCTJSA-N 0.000 claims 1
- HBHMVBGGHDMPBF-GARJFASQSA-N Cys-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CS)N HBHMVBGGHDMPBF-GARJFASQSA-N 0.000 claims 1
- GGRDJANMZPGMNS-CIUDSAMLSA-N Cys-Ser-Leu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O GGRDJANMZPGMNS-CIUDSAMLSA-N 0.000 claims 1
- OELDIVRKHTYFNG-WDSKDSINSA-N Cys-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CS OELDIVRKHTYFNG-WDSKDSINSA-N 0.000 claims 1
- ALTQTAKGRFLRLR-GUBZILKMSA-N Cys-Val-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CS)N ALTQTAKGRFLRLR-GUBZILKMSA-N 0.000 claims 1
- 102000009109 Fc receptors Human genes 0.000 claims 1
- 108010087819 Fc receptors Proteins 0.000 claims 1
- 238000007096 Glaser coupling reaction Methods 0.000 claims 1
- CRRFJBGUGNNOCS-PEFMBERDSA-N Gln-Asp-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O CRRFJBGUGNNOCS-PEFMBERDSA-N 0.000 claims 1
- ZQPOVSJFBBETHQ-CIUDSAMLSA-N Gln-Glu-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O ZQPOVSJFBBETHQ-CIUDSAMLSA-N 0.000 claims 1
- DOQUICBEISTQHE-CIUDSAMLSA-N Gln-Pro-Asp Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O DOQUICBEISTQHE-CIUDSAMLSA-N 0.000 claims 1
- CVPXINNKRTZBMO-CIUDSAMLSA-N Glu-Arg-Asn Chemical compound C(C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)N)CN=C(N)N CVPXINNKRTZBMO-CIUDSAMLSA-N 0.000 claims 1
- NLKVNZUFDPWPNL-YUMQZZPRSA-N Glu-Arg-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O NLKVNZUFDPWPNL-YUMQZZPRSA-N 0.000 claims 1
- DYFJZDDQPNIPAB-NHCYSSNCSA-N Glu-Arg-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(O)=O DYFJZDDQPNIPAB-NHCYSSNCSA-N 0.000 claims 1
- TUTIHHSZKFBMHM-WHFBIAKZSA-N Glu-Asn Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(O)=O TUTIHHSZKFBMHM-WHFBIAKZSA-N 0.000 claims 1
- AFODTOLGSZQDSL-PEFMBERDSA-N Glu-Asn-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)O)N AFODTOLGSZQDSL-PEFMBERDSA-N 0.000 claims 1
- LJLPOZGRPLORTF-CIUDSAMLSA-N Glu-Asn-Met Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(O)=O LJLPOZGRPLORTF-CIUDSAMLSA-N 0.000 claims 1
- NTBDVNJIWCKURJ-ACZMJKKPSA-N Glu-Asp-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NTBDVNJIWCKURJ-ACZMJKKPSA-N 0.000 claims 1
- OXEMJGCAJFFREE-FXQIFTODSA-N Glu-Gln-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O OXEMJGCAJFFREE-FXQIFTODSA-N 0.000 claims 1
- GYCPQVFKCPPRQB-GUBZILKMSA-N Glu-Gln-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)N GYCPQVFKCPPRQB-GUBZILKMSA-N 0.000 claims 1
- NKLRYVLERDYDBI-FXQIFTODSA-N Glu-Glu-Asp Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O NKLRYVLERDYDBI-FXQIFTODSA-N 0.000 claims 1
- YLJHCWNDBKKOEB-IHRRRGAJSA-N Glu-Glu-Phe Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O YLJHCWNDBKKOEB-IHRRRGAJSA-N 0.000 claims 1
- IQACOVZVOMVILH-FXQIFTODSA-N Glu-Glu-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O IQACOVZVOMVILH-FXQIFTODSA-N 0.000 claims 1
- QYPKJXSMLMREKF-BPUTZDHNSA-N Glu-Glu-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)N QYPKJXSMLMREKF-BPUTZDHNSA-N 0.000 claims 1
- QJCKNLPMTPXXEM-AUTRQRHGSA-N Glu-Glu-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O QJCKNLPMTPXXEM-AUTRQRHGSA-N 0.000 claims 1
- KRGZZKWSBGPLKL-IUCAKERBSA-N Glu-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)N KRGZZKWSBGPLKL-IUCAKERBSA-N 0.000 claims 1
- OPAINBJQDQTGJY-JGVFFNPUSA-N Glu-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CCC(=O)O)N)C(=O)O OPAINBJQDQTGJY-JGVFFNPUSA-N 0.000 claims 1
- VGUYMZGLJUJRBV-YVNDNENWSA-N Glu-Ile-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(O)=O VGUYMZGLJUJRBV-YVNDNENWSA-N 0.000 claims 1
- ZSWGJYOZWBHROQ-RWRJDSDZSA-N Glu-Ile-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ZSWGJYOZWBHROQ-RWRJDSDZSA-N 0.000 claims 1
- BCYGDJXHAGZNPQ-DCAQKATOSA-N Glu-Lys-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O BCYGDJXHAGZNPQ-DCAQKATOSA-N 0.000 claims 1
- ZQYZDDXTNQXUJH-CIUDSAMLSA-N Glu-Met-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)O)N ZQYZDDXTNQXUJH-CIUDSAMLSA-N 0.000 claims 1
- TWYFJOHWGCCRIR-DCAQKATOSA-N Glu-Pro-Arg Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O TWYFJOHWGCCRIR-DCAQKATOSA-N 0.000 claims 1
- WIKMTDVSCUJIPJ-CIUDSAMLSA-N Glu-Ser-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCN=C(N)N WIKMTDVSCUJIPJ-CIUDSAMLSA-N 0.000 claims 1
- VNCNWQPIQYAMAK-ACZMJKKPSA-N Glu-Ser-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O VNCNWQPIQYAMAK-ACZMJKKPSA-N 0.000 claims 1
- QCMVGXDELYMZET-GLLZPBPUSA-N Glu-Thr-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O QCMVGXDELYMZET-GLLZPBPUSA-N 0.000 claims 1
- YQAQQKPWFOBSMU-WDCWCFNPSA-N Glu-Thr-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O YQAQQKPWFOBSMU-WDCWCFNPSA-N 0.000 claims 1
- ZQNCUVODKOBSSO-XEGUGMAKSA-N Glu-Trp-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](C)C(O)=O ZQNCUVODKOBSSO-XEGUGMAKSA-N 0.000 claims 1
- VXEFAWJTFAUDJK-AVGNSLFASA-N Glu-Tyr-Ser Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCC(=O)O)N)O VXEFAWJTFAUDJK-AVGNSLFASA-N 0.000 claims 1
- UGVQELHRNUDMAA-BYPYZUCNSA-N Gly-Ala-Gly Chemical compound [NH3+]CC(=O)N[C@@H](C)C(=O)NCC([O-])=O UGVQELHRNUDMAA-BYPYZUCNSA-N 0.000 claims 1
- VSVZIEVNUYDAFR-YUMQZZPRSA-N Gly-Ala-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN VSVZIEVNUYDAFR-YUMQZZPRSA-N 0.000 claims 1
- IWAXHBCACVWNHT-BQBZGAKWSA-N Gly-Asp-Arg Chemical compound NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IWAXHBCACVWNHT-BQBZGAKWSA-N 0.000 claims 1
- MOJKRXIRAZPZLW-WDSKDSINSA-N Gly-Glu-Ala Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O MOJKRXIRAZPZLW-WDSKDSINSA-N 0.000 claims 1
- YYPFZVIXAVDHIK-IUCAKERBSA-N Gly-Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CN YYPFZVIXAVDHIK-IUCAKERBSA-N 0.000 claims 1
- CCQOOWAONKGYKQ-BYPYZUCNSA-N Gly-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)CN CCQOOWAONKGYKQ-BYPYZUCNSA-N 0.000 claims 1
- LHYJCVCQPWRMKZ-WEDXCCLWSA-N Gly-Leu-Thr Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LHYJCVCQPWRMKZ-WEDXCCLWSA-N 0.000 claims 1
- PFMUCCYYAAFKTH-YFKPBYRVSA-N Gly-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)CN PFMUCCYYAAFKTH-YFKPBYRVSA-N 0.000 claims 1
- OJNZVYSGVYLQIN-BQBZGAKWSA-N Gly-Met-Asp Chemical compound [H]NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(O)=O OJNZVYSGVYLQIN-BQBZGAKWSA-N 0.000 claims 1
- GGLIDLCEPDHEJO-BQBZGAKWSA-N Gly-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)CN GGLIDLCEPDHEJO-BQBZGAKWSA-N 0.000 claims 1
- OHUKZZYSJBKFRR-WHFBIAKZSA-N Gly-Ser-Asp Chemical compound [H]NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O OHUKZZYSJBKFRR-WHFBIAKZSA-N 0.000 claims 1
- JQFILXICXLDTRR-FBCQKBJTSA-N Gly-Thr-Gly Chemical compound NCC(=O)N[C@@H]([C@H](O)C)C(=O)NCC(O)=O JQFILXICXLDTRR-FBCQKBJTSA-N 0.000 claims 1
- HUFUVTYGPOUCBN-MBLNEYKQSA-N Gly-Thr-Ile Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O HUFUVTYGPOUCBN-MBLNEYKQSA-N 0.000 claims 1
- MYXNLWDWWOTERK-BHNWBGBOSA-N Gly-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN)O MYXNLWDWWOTERK-BHNWBGBOSA-N 0.000 claims 1
- VHOLZZKNEBBHTH-YUMQZZPRSA-N His-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CNC=N1 VHOLZZKNEBBHTH-YUMQZZPRSA-N 0.000 claims 1
- STOOMQFEJUVAKR-KKUMJFAQSA-N His-His-His Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)C1=CNC=N1 STOOMQFEJUVAKR-KKUMJFAQSA-N 0.000 claims 1
- VYUXYMRNGALHEA-DLOVCJGASA-N His-Leu-Ala Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O VYUXYMRNGALHEA-DLOVCJGASA-N 0.000 claims 1
- OQDLKDUVMTUPPG-AVGNSLFASA-N His-Leu-Glu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O OQDLKDUVMTUPPG-AVGNSLFASA-N 0.000 claims 1
- AIPUZFXMXAHZKY-QWRGUYRKSA-N His-Leu-Gly Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O AIPUZFXMXAHZKY-QWRGUYRKSA-N 0.000 claims 1
- CZVQSYNVUHAILZ-UWVGGRQHSA-N His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CN=CN1 CZVQSYNVUHAILZ-UWVGGRQHSA-N 0.000 claims 1
- 101001055157 Homo sapiens Interleukin-15 Proteins 0.000 claims 1
- 101000799461 Homo sapiens Thrombopoietin Proteins 0.000 claims 1
- 102000002265 Human Growth Hormone Human genes 0.000 claims 1
- 108010000521 Human Growth Hormone Proteins 0.000 claims 1
- 239000000854 Human Growth Hormone Substances 0.000 claims 1
- NKVZTQVGUNLLQW-JBDRJPRFSA-N Ile-Ala-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)O)N NKVZTQVGUNLLQW-JBDRJPRFSA-N 0.000 claims 1
- HZYHBDVRCBDJJV-HAFWLYHUSA-N Ile-Asn Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(O)=O)CC(N)=O HZYHBDVRCBDJJV-HAFWLYHUSA-N 0.000 claims 1
- KTGFOCFYOZQVRJ-ZKWXMUAHSA-N Ile-Glu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O KTGFOCFYOZQVRJ-ZKWXMUAHSA-N 0.000 claims 1
- UBHUJPVCJHPSEU-GRLWGSQLSA-N Ile-Glu-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N UBHUJPVCJHPSEU-GRLWGSQLSA-N 0.000 claims 1
- CDGLBYSAZFIIJO-RCOVLWMOSA-N Ile-Gly-Gly Chemical compound CC[C@H](C)[C@H]([NH3+])C(=O)NCC(=O)NCC([O-])=O CDGLBYSAZFIIJO-RCOVLWMOSA-N 0.000 claims 1
- SJLVSMMIFYTSGY-GRLWGSQLSA-N Ile-Ile-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N SJLVSMMIFYTSGY-GRLWGSQLSA-N 0.000 claims 1
- TWPSALMCEHCIOY-YTFOTSKYSA-N Ile-Ile-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)O)N TWPSALMCEHCIOY-YTFOTSKYSA-N 0.000 claims 1
- JWBXCSQZLLIOCI-GUBZILKMSA-N Ile-Leu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(O)=O)CC(C)C JWBXCSQZLLIOCI-GUBZILKMSA-N 0.000 claims 1
- PKGGWLOLRLOPGK-XUXIUFHCSA-N Ile-Leu-Arg Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N PKGGWLOLRLOPGK-XUXIUFHCSA-N 0.000 claims 1
- TWYOYAKMLHWMOJ-ZPFDUUQYSA-N Ile-Leu-Asn Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O TWYOYAKMLHWMOJ-ZPFDUUQYSA-N 0.000 claims 1
- UWBDLNOCIDGPQE-GUBZILKMSA-N Ile-Lys Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN UWBDLNOCIDGPQE-GUBZILKMSA-N 0.000 claims 1
- GVNNAHIRSDRIII-AJNGGQMLSA-N Ile-Lys-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O)N GVNNAHIRSDRIII-AJNGGQMLSA-N 0.000 claims 1
- IDMNOFVUXYYZPF-DKIMLUQUSA-N Ile-Lys-Phe Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N IDMNOFVUXYYZPF-DKIMLUQUSA-N 0.000 claims 1
- TWVKGYNQQAUNRN-ACZMJKKPSA-N Ile-Ser Chemical compound CC[C@H](C)[C@H]([NH3+])C(=O)N[C@@H](CO)C([O-])=O TWVKGYNQQAUNRN-ACZMJKKPSA-N 0.000 claims 1
- RQJUKVXWAKJDBW-SVSWQMSJSA-N Ile-Ser-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N RQJUKVXWAKJDBW-SVSWQMSJSA-N 0.000 claims 1
- QHUREMVLLMNUAX-OSUNSFLBSA-N Ile-Thr-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)O)N QHUREMVLLMNUAX-OSUNSFLBSA-N 0.000 claims 1
- JTBFQNHKNRZJDS-SYWGBEHUSA-N Ile-Trp-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](C)C(=O)O)N JTBFQNHKNRZJDS-SYWGBEHUSA-N 0.000 claims 1
- 102100022297 Integrin alpha-X Human genes 0.000 claims 1
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 108090000174 Interleukin-10 Proteins 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 108090000176 Interleukin-13 Proteins 0.000 claims 1
- 108090000172 Interleukin-15 Proteins 0.000 claims 1
- 102000003812 Interleukin-15 Human genes 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 108010002586 Interleukin-7 Proteins 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 108010002335 Interleukin-9 Proteins 0.000 claims 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- MJOZZTKJZQFKDK-GUBZILKMSA-N Leu-Ala-Gln Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCC(N)=O MJOZZTKJZQFKDK-GUBZILKMSA-N 0.000 claims 1
- WSGXUIQTEZDVHJ-GARJFASQSA-N Leu-Ala-Pro Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@@H]1C(O)=O WSGXUIQTEZDVHJ-GARJFASQSA-N 0.000 claims 1
- NTRAGDHVSGKUSF-AVGNSLFASA-N Leu-Arg-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O NTRAGDHVSGKUSF-AVGNSLFASA-N 0.000 claims 1
- HASRFYOMVPJRPU-SRVKXCTJSA-N Leu-Arg-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(O)=O)C(O)=O HASRFYOMVPJRPU-SRVKXCTJSA-N 0.000 claims 1
- ILJREDZFPHTUIE-GUBZILKMSA-N Leu-Asp-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O ILJREDZFPHTUIE-GUBZILKMSA-N 0.000 claims 1
- JQSXWJXBASFONF-KKUMJFAQSA-N Leu-Asp-Phe Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O JQSXWJXBASFONF-KKUMJFAQSA-N 0.000 claims 1
- HQUXQAMSWFIRET-AVGNSLFASA-N Leu-Glu-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN HQUXQAMSWFIRET-AVGNSLFASA-N 0.000 claims 1
- PRZVBIAOPFGAQF-SRVKXCTJSA-N Leu-Glu-Met Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(O)=O PRZVBIAOPFGAQF-SRVKXCTJSA-N 0.000 claims 1
- ZFNLIDNJUWNIJL-WDCWCFNPSA-N Leu-Glu-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ZFNLIDNJUWNIJL-WDCWCFNPSA-N 0.000 claims 1
- BABSVXFGKFLIGW-UWVGGRQHSA-N Leu-Gly-Arg Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCNC(N)=N BABSVXFGKFLIGW-UWVGGRQHSA-N 0.000 claims 1
- FMEICTQWUKNAGC-YUMQZZPRSA-N Leu-Gly-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O FMEICTQWUKNAGC-YUMQZZPRSA-N 0.000 claims 1
- VBZOAGIPCULURB-QWRGUYRKSA-N Leu-Gly-His Chemical compound CC(C)C[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N VBZOAGIPCULURB-QWRGUYRKSA-N 0.000 claims 1
- HYMLKESRWLZDBR-WEDXCCLWSA-N Leu-Gly-Thr Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O HYMLKESRWLZDBR-WEDXCCLWSA-N 0.000 claims 1
- KXODZBLFVFSLAI-AVGNSLFASA-N Leu-His-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(C)C)CC1=CN=CN1 KXODZBLFVFSLAI-AVGNSLFASA-N 0.000 claims 1
- CSFVADKICPDRRF-KKUMJFAQSA-N Leu-His-Leu Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C([O-])=O)CC1=CN=CN1 CSFVADKICPDRRF-KKUMJFAQSA-N 0.000 claims 1
- ORWTWZXGDBYVCP-BJDJZHNGSA-N Leu-Ile-Cys Chemical compound SC[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CC(C)C ORWTWZXGDBYVCP-BJDJZHNGSA-N 0.000 claims 1
- LXKNSJLSGPNHSK-KKUMJFAQSA-N Leu-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N LXKNSJLSGPNHSK-KKUMJFAQSA-N 0.000 claims 1
- IEWBEPKLKUXQBU-VOAKCMCISA-N Leu-Leu-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IEWBEPKLKUXQBU-VOAKCMCISA-N 0.000 claims 1
- ONPJGOIVICHWBW-BZSNNMDCSA-N Leu-Lys-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 ONPJGOIVICHWBW-BZSNNMDCSA-N 0.000 claims 1
- GNRPTBRHRRZCMA-RWMBFGLXSA-N Leu-Met-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N1CCC[C@@H]1C(=O)O)N GNRPTBRHRRZCMA-RWMBFGLXSA-N 0.000 claims 1
- GCXGCIYIHXSKAY-ULQDDVLXSA-N Leu-Phe-Arg Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O GCXGCIYIHXSKAY-ULQDDVLXSA-N 0.000 claims 1
- WXDRGWBQZIMJDE-ULQDDVLXSA-N Leu-Phe-Met Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCSC)C(O)=O WXDRGWBQZIMJDE-ULQDDVLXSA-N 0.000 claims 1
- FYPWFNKQVVEELI-ULQDDVLXSA-N Leu-Phe-Val Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C(C)C)C(O)=O)CC1=CC=CC=C1 FYPWFNKQVVEELI-ULQDDVLXSA-N 0.000 claims 1
- YUTNOGOMBNYPFH-XUXIUFHCSA-N Leu-Pro-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(O)=O YUTNOGOMBNYPFH-XUXIUFHCSA-N 0.000 claims 1
- LRKCBIUDWAXNEG-CSMHCCOUSA-N Leu-Thr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LRKCBIUDWAXNEG-CSMHCCOUSA-N 0.000 claims 1
- KLSUAWUZBMAZCL-RHYQMDGZSA-N Leu-Thr-Pro Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(O)=O KLSUAWUZBMAZCL-RHYQMDGZSA-N 0.000 claims 1
- CNWDWAMPKVYJJB-NUTKFTJISA-N Leu-Trp-Ala Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)CC(C)C)C(=O)N[C@@H](C)C(O)=O)=CNC2=C1 CNWDWAMPKVYJJB-NUTKFTJISA-N 0.000 claims 1
- WFCKERTZVCQXKH-KBPBESRZSA-N Leu-Tyr-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(O)=O WFCKERTZVCQXKH-KBPBESRZSA-N 0.000 claims 1
- BGGTYDNTOYRTTR-MEYUZBJRSA-N Leu-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC(C)C)N)O BGGTYDNTOYRTTR-MEYUZBJRSA-N 0.000 claims 1
- FBNPMTNBFFAMMH-UHFFFAOYSA-N Leu-Val-Arg Natural products CC(C)CC(N)C(=O)NC(C(C)C)C(=O)NC(C(O)=O)CCCN=C(N)N FBNPMTNBFFAMMH-UHFFFAOYSA-N 0.000 claims 1
- XOEDPXDZJHBQIX-ULQDDVLXSA-N Leu-Val-Phe Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 XOEDPXDZJHBQIX-ULQDDVLXSA-N 0.000 claims 1
- 108090000581 Leukemia inhibitory factor Proteins 0.000 claims 1
- KCXUCYYZNZFGLL-SRVKXCTJSA-N Lys-Ala-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O KCXUCYYZNZFGLL-SRVKXCTJSA-N 0.000 claims 1
- 108010062166 Lys-Asn-Asp Proteins 0.000 claims 1
- BYPMOIFBQPEWOH-CIUDSAMLSA-N Lys-Asn-Asp Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N BYPMOIFBQPEWOH-CIUDSAMLSA-N 0.000 claims 1
- SSJBMGCZZXCGJJ-DCAQKATOSA-N Lys-Asp-Met Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(O)=O SSJBMGCZZXCGJJ-DCAQKATOSA-N 0.000 claims 1
- UGTZHPSKYRIGRJ-YUMQZZPRSA-N Lys-Glu Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O UGTZHPSKYRIGRJ-YUMQZZPRSA-N 0.000 claims 1
- RBEATVHTWHTHTJ-KKUMJFAQSA-N Lys-Leu-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O RBEATVHTWHTHTJ-KKUMJFAQSA-N 0.000 claims 1
- WRODMZBHNNPRLN-SRVKXCTJSA-N Lys-Leu-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O WRODMZBHNNPRLN-SRVKXCTJSA-N 0.000 claims 1
- LJADEBULDNKJNK-IHRRRGAJSA-N Lys-Leu-Val Chemical compound CC(C)C[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O LJADEBULDNKJNK-IHRRRGAJSA-N 0.000 claims 1
- LECIJRIRMVOFMH-ULQDDVLXSA-N Lys-Pro-Phe Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 LECIJRIRMVOFMH-ULQDDVLXSA-N 0.000 claims 1
- YSZNURNVYFUEHC-BQBZGAKWSA-N Lys-Ser Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CO)C(O)=O YSZNURNVYFUEHC-BQBZGAKWSA-N 0.000 claims 1
- JMNRXRPBHFGXQX-GUBZILKMSA-N Lys-Ser-Glu Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O JMNRXRPBHFGXQX-GUBZILKMSA-N 0.000 claims 1
- SQXZLVXQXWILKW-KKUMJFAQSA-N Lys-Ser-Phe Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O SQXZLVXQXWILKW-KKUMJFAQSA-N 0.000 claims 1
- ZOKVLMBYDSIDKG-CSMHCCOUSA-N Lys-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCCN ZOKVLMBYDSIDKG-CSMHCCOUSA-N 0.000 claims 1
- VHTOGMKQXXJOHG-RHYQMDGZSA-N Lys-Thr-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O VHTOGMKQXXJOHG-RHYQMDGZSA-N 0.000 claims 1
- OHXUUQDOBQKSNB-AVGNSLFASA-N Lys-Val-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OHXUUQDOBQKSNB-AVGNSLFASA-N 0.000 claims 1
- MDDUIRLQCYVRDO-NHCYSSNCSA-N Lys-Val-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN MDDUIRLQCYVRDO-NHCYSSNCSA-N 0.000 claims 1
- VKCPHIOZDWUFSW-ONGXEEELSA-N Lys-Val-Gly Chemical compound OC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN VKCPHIOZDWUFSW-ONGXEEELSA-N 0.000 claims 1
- OZVXDDFYCQOPFD-XQQFMLRXSA-N Lys-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCCN)N OZVXDDFYCQOPFD-XQQFMLRXSA-N 0.000 claims 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- JHKXZYLNVJRAAJ-WDSKDSINSA-N Met-Ala Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(O)=O JHKXZYLNVJRAAJ-WDSKDSINSA-N 0.000 claims 1
- MUYQDMBLDFEVRJ-LSJOCFKGSA-N Met-Ala-His Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CNC=N1 MUYQDMBLDFEVRJ-LSJOCFKGSA-N 0.000 claims 1
- ULNXMMYXQKGNPG-LPEHRKFASA-N Met-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCSC)N ULNXMMYXQKGNPG-LPEHRKFASA-N 0.000 claims 1
- BVXXDMUMHMXFER-BPNCWPANSA-N Met-Ala-Tyr Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O BVXXDMUMHMXFER-BPNCWPANSA-N 0.000 claims 1
- XOMXAVJBLRROMC-IHRRRGAJSA-N Met-Asp-Phe Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 XOMXAVJBLRROMC-IHRRRGAJSA-N 0.000 claims 1
- KQBJYJXPZBNEIK-DCAQKATOSA-N Met-Glu-Arg Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCNC(N)=N KQBJYJXPZBNEIK-DCAQKATOSA-N 0.000 claims 1
- AETNZPKUUYYYEK-CIUDSAMLSA-N Met-Glu-Asn Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O AETNZPKUUYYYEK-CIUDSAMLSA-N 0.000 claims 1
- JPCHYAUKOUGOIB-HJGDQZAQSA-N Met-Glu-Thr Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JPCHYAUKOUGOIB-HJGDQZAQSA-N 0.000 claims 1
- FYRUJIJAUPHUNB-IUCAKERBSA-N Met-Gly-Arg Chemical compound CSCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCNC(N)=N FYRUJIJAUPHUNB-IUCAKERBSA-N 0.000 claims 1
- UZWMJZSOXGOVIN-LURJTMIESA-N Met-Gly-Gly Chemical compound CSCC[C@H](N)C(=O)NCC(=O)NCC(O)=O UZWMJZSOXGOVIN-LURJTMIESA-N 0.000 claims 1
- SXWQMBGNFXAGAT-FJXKBIBVSA-N Met-Gly-Thr Chemical compound CSCC[C@H](N)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O SXWQMBGNFXAGAT-FJXKBIBVSA-N 0.000 claims 1
- HZLSUXCMSIBCRV-RVMXOQNASA-N Met-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCSC)N HZLSUXCMSIBCRV-RVMXOQNASA-N 0.000 claims 1
- HWROAFGWPQUPTE-OSUNSFLBSA-N Met-Ile-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CCSC)N HWROAFGWPQUPTE-OSUNSFLBSA-N 0.000 claims 1
- KMSMNUFBNCHMII-IHRRRGAJSA-N Met-Leu-Lys Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCCN KMSMNUFBNCHMII-IHRRRGAJSA-N 0.000 claims 1
- VQILILSLEFDECU-GUBZILKMSA-N Met-Pro-Ala Chemical compound [H]N[C@@H](CCSC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O VQILILSLEFDECU-GUBZILKMSA-N 0.000 claims 1
- MIXPUVSPPOWTCR-FXQIFTODSA-N Met-Ser-Ser Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O MIXPUVSPPOWTCR-FXQIFTODSA-N 0.000 claims 1
- KAKJTZWHIUWTTD-VQVTYTSYSA-N Met-Thr Chemical compound CSCC[C@H]([NH3+])C(=O)N[C@@H]([C@@H](C)O)C([O-])=O KAKJTZWHIUWTTD-VQVTYTSYSA-N 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- PKFBJSDMCRJYDC-GEZSXCAASA-N N-acetyl-s-geranylgeranyl-l-cysteine Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CSC[C@@H](C(O)=O)NC(C)=O PKFBJSDMCRJYDC-GEZSXCAASA-N 0.000 claims 1
- HTTYNOXBBOWZTB-SRVKXCTJSA-N Phe-Asn-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N HTTYNOXBBOWZTB-SRVKXCTJSA-N 0.000 claims 1
- JEBWZLWTRPZQRX-QWRGUYRKSA-N Phe-Gly-Asp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O JEBWZLWTRPZQRX-QWRGUYRKSA-N 0.000 claims 1
- NAOVYENZCWFBDG-BZSNNMDCSA-N Phe-His-His Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CC=CC=C1 NAOVYENZCWFBDG-BZSNNMDCSA-N 0.000 claims 1
- JWBLQDDHSDGEGR-DRZSPHRISA-N Phe-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 JWBLQDDHSDGEGR-DRZSPHRISA-N 0.000 claims 1
- RFCVXVPWSPOMFJ-STQMWFEESA-N Phe-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 RFCVXVPWSPOMFJ-STQMWFEESA-N 0.000 claims 1
- INHMISZWLJZQGH-ULQDDVLXSA-N Phe-Leu-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 INHMISZWLJZQGH-ULQDDVLXSA-N 0.000 claims 1
- MWQXFDIQXIXPMS-UNQGMJICSA-N Phe-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC1=CC=CC=C1)N)O MWQXFDIQXIXPMS-UNQGMJICSA-N 0.000 claims 1
- APZNYJFGVAGFCF-JYJNAYRXSA-N Phe-Val-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccccc1)C(C)C)C(O)=O APZNYJFGVAGFCF-JYJNAYRXSA-N 0.000 claims 1
- 108010004729 Phycoerythrin Proteins 0.000 claims 1
- DZZCICYRSZASNF-FXQIFTODSA-N Pro-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 DZZCICYRSZASNF-FXQIFTODSA-N 0.000 claims 1
- DRVIASBABBMZTF-GUBZILKMSA-N Pro-Ala-Met Chemical compound C[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@@H]1CCCN1 DRVIASBABBMZTF-GUBZILKMSA-N 0.000 claims 1
- XQLBWXHVZVBNJM-FXQIFTODSA-N Pro-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 XQLBWXHVZVBNJM-FXQIFTODSA-N 0.000 claims 1
- HFZNNDWPHBRNPV-KZVJFYERSA-N Pro-Ala-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O HFZNNDWPHBRNPV-KZVJFYERSA-N 0.000 claims 1
- OOLOTUZJUBOMAX-GUBZILKMSA-N Pro-Ala-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O OOLOTUZJUBOMAX-GUBZILKMSA-N 0.000 claims 1
- OBVCYFIHIIYIQF-CIUDSAMLSA-N Pro-Asn-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O OBVCYFIHIIYIQF-CIUDSAMLSA-N 0.000 claims 1
- SFECXGVELZFBFJ-VEVYYDQMSA-N Pro-Asp-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SFECXGVELZFBFJ-VEVYYDQMSA-N 0.000 claims 1
- QXNSKJLSLYCTMT-FXQIFTODSA-N Pro-Cys-Asp Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)O)C(=O)O QXNSKJLSLYCTMT-FXQIFTODSA-N 0.000 claims 1
- MGDFPGCFVJFITQ-CIUDSAMLSA-N Pro-Glu-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O MGDFPGCFVJFITQ-CIUDSAMLSA-N 0.000 claims 1
- LGSANCBHSMDFDY-GARJFASQSA-N Pro-Glu-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCC(=O)O)C(=O)N2CCC[C@@H]2C(=O)O LGSANCBHSMDFDY-GARJFASQSA-N 0.000 claims 1
- ZKQOUHVVXABNDG-IUCAKERBSA-N Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 ZKQOUHVVXABNDG-IUCAKERBSA-N 0.000 claims 1
- FMLRRBDLBJLJIK-DCAQKATOSA-N Pro-Leu-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1 FMLRRBDLBJLJIK-DCAQKATOSA-N 0.000 claims 1
- RUDOLGWDSKQQFF-DCAQKATOSA-N Pro-Leu-Asn Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O RUDOLGWDSKQQFF-DCAQKATOSA-N 0.000 claims 1
- XQPHBAKJJJZOBX-SRVKXCTJSA-N Pro-Lys-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O XQPHBAKJJJZOBX-SRVKXCTJSA-N 0.000 claims 1
- RMODQFBNDDENCP-IHRRRGAJSA-N Pro-Lys-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O RMODQFBNDDENCP-IHRRRGAJSA-N 0.000 claims 1
- PCWLNNZTBJTZRN-AVGNSLFASA-N Pro-Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 PCWLNNZTBJTZRN-AVGNSLFASA-N 0.000 claims 1
- KBUAPZAZPWNYSW-SRVKXCTJSA-N Pro-Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 KBUAPZAZPWNYSW-SRVKXCTJSA-N 0.000 claims 1
- MKGIILKDUGDRRO-FXQIFTODSA-N Pro-Ser-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1 MKGIILKDUGDRRO-FXQIFTODSA-N 0.000 claims 1
- XDKKMRPRRCOELJ-GUBZILKMSA-N Pro-Val-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1 XDKKMRPRRCOELJ-GUBZILKMSA-N 0.000 claims 1
- 102100029812 Protein S100-A12 Human genes 0.000 claims 1
- 101710110949 Protein S100-A12 Proteins 0.000 claims 1
- 239000012979 RPMI medium Substances 0.000 claims 1
- QFBNNYNWKYKVJO-DCAQKATOSA-N Ser-Arg-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CCCN=C(N)N QFBNNYNWKYKVJO-DCAQKATOSA-N 0.000 claims 1
- NRCJWSGXMAPYQX-LPEHRKFASA-N Ser-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)N)C(=O)O NRCJWSGXMAPYQX-LPEHRKFASA-N 0.000 claims 1
- FFOKMZOAVHEWET-IMJSIDKUSA-N Ser-Cys Chemical compound OC[C@H](N)C(=O)N[C@@H](CS)C(O)=O FFOKMZOAVHEWET-IMJSIDKUSA-N 0.000 claims 1
- DSSOYPJWSWFOLK-CIUDSAMLSA-N Ser-Cys-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(O)=O DSSOYPJWSWFOLK-CIUDSAMLSA-N 0.000 claims 1
- LAFKUZYWNCHOHT-WHFBIAKZSA-N Ser-Glu Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O LAFKUZYWNCHOHT-WHFBIAKZSA-N 0.000 claims 1
- HJEBZBMOTCQYDN-ACZMJKKPSA-N Ser-Glu-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O HJEBZBMOTCQYDN-ACZMJKKPSA-N 0.000 claims 1
- LALNXSXEYFUUDD-GUBZILKMSA-N Ser-Glu-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O LALNXSXEYFUUDD-GUBZILKMSA-N 0.000 claims 1
- VQBCMLMPEWPUTB-ACZMJKKPSA-N Ser-Glu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O VQBCMLMPEWPUTB-ACZMJKKPSA-N 0.000 claims 1
- GZFAWAQTEYDKII-YUMQZZPRSA-N Ser-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO GZFAWAQTEYDKII-YUMQZZPRSA-N 0.000 claims 1
- LOKXAXAESFYFAX-CIUDSAMLSA-N Ser-His-Cys Chemical compound OC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CS)C(O)=O)CC1=CN=CN1 LOKXAXAESFYFAX-CIUDSAMLSA-N 0.000 claims 1
- CLKKNZQUQMZDGD-SRVKXCTJSA-N Ser-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CC1=CN=CN1 CLKKNZQUQMZDGD-SRVKXCTJSA-N 0.000 claims 1
- DJACUBDEDBZKLQ-KBIXCLLPSA-N Ser-Ile-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(O)=O DJACUBDEDBZKLQ-KBIXCLLPSA-N 0.000 claims 1
- IAORETPTUDBBGV-CIUDSAMLSA-N Ser-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CO)N IAORETPTUDBBGV-CIUDSAMLSA-N 0.000 claims 1
- KCGIREHVWRXNDH-GARJFASQSA-N Ser-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N KCGIREHVWRXNDH-GARJFASQSA-N 0.000 claims 1
- YUJLIIRMIAGMCQ-CIUDSAMLSA-N Ser-Leu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YUJLIIRMIAGMCQ-CIUDSAMLSA-N 0.000 claims 1
- MUJQWSAWLLRJCE-KATARQTJSA-N Ser-Leu-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MUJQWSAWLLRJCE-KATARQTJSA-N 0.000 claims 1
- XKFJENWJGHMDLI-QWRGUYRKSA-N Ser-Phe-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(O)=O XKFJENWJGHMDLI-QWRGUYRKSA-N 0.000 claims 1
- BSXKBOUZDAZXHE-CIUDSAMLSA-N Ser-Pro-Glu Chemical compound [H]N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O BSXKBOUZDAZXHE-CIUDSAMLSA-N 0.000 claims 1
- GZGFSPWOMUKKCV-NAKRPEOUSA-N Ser-Pro-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO GZGFSPWOMUKKCV-NAKRPEOUSA-N 0.000 claims 1
- FKYWFUYPVKLJLP-DCAQKATOSA-N Ser-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO FKYWFUYPVKLJLP-DCAQKATOSA-N 0.000 claims 1
- XZKQVQKUZMAADP-IMJSIDKUSA-N Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(O)=O XZKQVQKUZMAADP-IMJSIDKUSA-N 0.000 claims 1
- GYDFRTRSSXOZCR-ACZMJKKPSA-N Ser-Ser-Glu Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O GYDFRTRSSXOZCR-ACZMJKKPSA-N 0.000 claims 1
- JCLAFVNDBJMLBC-JBDRJPRFSA-N Ser-Ser-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JCLAFVNDBJMLBC-JBDRJPRFSA-N 0.000 claims 1
- OZPDGESCTGGNAD-CIUDSAMLSA-N Ser-Ser-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CO OZPDGESCTGGNAD-CIUDSAMLSA-N 0.000 claims 1
- JURQXQBJKUHGJS-UHFFFAOYSA-N Ser-Ser-Ser-Ser Chemical compound OCC(N)C(=O)NC(CO)C(=O)NC(CO)C(=O)NC(CO)C(O)=O JURQXQBJKUHGJS-UHFFFAOYSA-N 0.000 claims 1
- PYTKULIABVRXSC-BWBBJGPYSA-N Ser-Ser-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PYTKULIABVRXSC-BWBBJGPYSA-N 0.000 claims 1
- FGBLCMLXHRPVOF-IHRRRGAJSA-N Ser-Tyr-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O FGBLCMLXHRPVOF-IHRRRGAJSA-N 0.000 claims 1
- HSWXBJCBYSWBPT-GUBZILKMSA-N Ser-Val-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(O)=O HSWXBJCBYSWBPT-GUBZILKMSA-N 0.000 claims 1
- 241001351225 Sergey Species 0.000 claims 1
- IGROJMCBGRFRGI-YTLHQDLWSA-N Thr-Ala-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O IGROJMCBGRFRGI-YTLHQDLWSA-N 0.000 claims 1
- ZUXQFMVPAYGPFJ-JXUBOQSCSA-N Thr-Ala-Lys Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCCN ZUXQFMVPAYGPFJ-JXUBOQSCSA-N 0.000 claims 1
- XSLXHSYIVPGEER-KZVJFYERSA-N Thr-Ala-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O XSLXHSYIVPGEER-KZVJFYERSA-N 0.000 claims 1
- PKXHGEXFMIZSER-QTKMDUPCSA-N Thr-Arg-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N)O PKXHGEXFMIZSER-QTKMDUPCSA-N 0.000 claims 1
- BECPPKYKPSRKCP-ZDLURKLDSA-N Thr-Glu Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O BECPPKYKPSRKCP-ZDLURKLDSA-N 0.000 claims 1
- OQCXTUQTKQFDCX-HTUGSXCWSA-N Thr-Glu-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N)O OQCXTUQTKQFDCX-HTUGSXCWSA-N 0.000 claims 1
- ADPHPKGWVDHWML-PPCPHDFISA-N Thr-Ile-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N ADPHPKGWVDHWML-PPCPHDFISA-N 0.000 claims 1
- AHOLTQCAVBSUDP-PPCPHDFISA-N Thr-Ile-Lys Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](N)[C@@H](C)O)C(=O)N[C@@H](CCCCN)C(O)=O AHOLTQCAVBSUDP-PPCPHDFISA-N 0.000 claims 1
- YJCVECXVYHZOBK-KNZXXDILSA-N Thr-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H]([C@@H](C)O)N YJCVECXVYHZOBK-KNZXXDILSA-N 0.000 claims 1
- BQBCIBCLXBKYHW-CSMHCCOUSA-N Thr-Leu Chemical compound CC(C)C[C@@H](C([O-])=O)NC(=O)[C@@H]([NH3+])[C@@H](C)O BQBCIBCLXBKYHW-CSMHCCOUSA-N 0.000 claims 1
- MECLEFZMPPOEAC-VOAKCMCISA-N Thr-Leu-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N)O MECLEFZMPPOEAC-VOAKCMCISA-N 0.000 claims 1
- ABWNZPOIUJMNKT-IXOXFDKPSA-N Thr-Phe-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(O)=O ABWNZPOIUJMNKT-IXOXFDKPSA-N 0.000 claims 1
- NYQIZWROIMIQSL-VEVYYDQMSA-N Thr-Pro-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O NYQIZWROIMIQSL-VEVYYDQMSA-N 0.000 claims 1
- IVDFVBVIVLJJHR-LKXGYXEUSA-N Thr-Ser-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O IVDFVBVIVLJJHR-LKXGYXEUSA-N 0.000 claims 1
- NBIIPOKZPUGATB-BWBBJGPYSA-N Thr-Ser-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N)O NBIIPOKZPUGATB-BWBBJGPYSA-N 0.000 claims 1
- XHWCDRUPDNSDAZ-XKBZYTNZSA-N Thr-Ser-Glu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N)O XHWCDRUPDNSDAZ-XKBZYTNZSA-N 0.000 claims 1
- UQCNIMDPYICBTR-KYNKHSRBSA-N Thr-Thr-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O UQCNIMDPYICBTR-KYNKHSRBSA-N 0.000 claims 1
- ABCLYRRGTZNIFU-BWAGICSOSA-N Thr-Tyr-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N)O ABCLYRRGTZNIFU-BWAGICSOSA-N 0.000 claims 1
- OHGNSVACHBZKSS-KWQFWETISA-N Trp-Ala Chemical compound C1=CC=C2C(C[C@H]([NH3+])C(=O)N[C@@H](C)C([O-])=O)=CNC2=C1 OHGNSVACHBZKSS-KWQFWETISA-N 0.000 claims 1
- IXEGQBJZDIRRIV-QEJZJMRPSA-N Trp-Asn-Glu Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O IXEGQBJZDIRRIV-QEJZJMRPSA-N 0.000 claims 1
- PWIQCLSQVQBOQV-AAEUAGOBSA-N Trp-Glu Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CNC2=C1 PWIQCLSQVQBOQV-AAEUAGOBSA-N 0.000 claims 1
- CZWIHKFGHICAJX-BPUTZDHNSA-N Trp-Glu-Glu Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CNC2=C1 CZWIHKFGHICAJX-BPUTZDHNSA-N 0.000 claims 1
- SAKLWFSRZTZQAJ-GQGQLFGLSA-N Trp-Ile-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N SAKLWFSRZTZQAJ-GQGQLFGLSA-N 0.000 claims 1
- YDTKYBHPRULROG-LTHWPDAASA-N Trp-Ile-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N YDTKYBHPRULROG-LTHWPDAASA-N 0.000 claims 1
- JXNRXNCCROJZFB-RYUDHWBXSA-N Tyr-Arg Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 JXNRXNCCROJZFB-RYUDHWBXSA-N 0.000 claims 1
- HPYDSVWYXXKHRD-VIFPVBQESA-N Tyr-Gly Chemical compound [O-]C(=O)CNC(=O)[C@@H]([NH3+])CC1=CC=C(O)C=C1 HPYDSVWYXXKHRD-VIFPVBQESA-N 0.000 claims 1
- HIINQLBHPIQYHN-JTQLQIEISA-N Tyr-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 HIINQLBHPIQYHN-JTQLQIEISA-N 0.000 claims 1
- KHCSOLAHNLOXJR-BZSNNMDCSA-N Tyr-Leu-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O KHCSOLAHNLOXJR-BZSNNMDCSA-N 0.000 claims 1
- SOAUMCDLIUGXJJ-SRVKXCTJSA-N Tyr-Ser-Asn Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O SOAUMCDLIUGXJJ-SRVKXCTJSA-N 0.000 claims 1
- ZLFHAAGHGQBQQN-GUBZILKMSA-N Val-Ala-Pro Natural products CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O ZLFHAAGHGQBQQN-GUBZILKMSA-N 0.000 claims 1
- AHHJARQXFFGOKF-NRPADANISA-N Val-Glu-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N AHHJARQXFFGOKF-NRPADANISA-N 0.000 claims 1
- AEMPCGRFEZTWIF-IHRRRGAJSA-N Val-Leu-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O AEMPCGRFEZTWIF-IHRRRGAJSA-N 0.000 claims 1
- JKHXYJKMNSSFFL-IUCAKERBSA-N Val-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN JKHXYJKMNSSFFL-IUCAKERBSA-N 0.000 claims 1
- GVJUTBOZZBTBIG-AVGNSLFASA-N Val-Lys-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N GVJUTBOZZBTBIG-AVGNSLFASA-N 0.000 claims 1
- IJGPOONOTBNTFS-GVXVVHGQSA-N Val-Lys-Glu Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O IJGPOONOTBNTFS-GVXVVHGQSA-N 0.000 claims 1
- XPKCFQZDQGVJCX-RHYQMDGZSA-N Val-Lys-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)N)O XPKCFQZDQGVJCX-RHYQMDGZSA-N 0.000 claims 1
- DOFAQXCYFQKSHT-SRVKXCTJSA-N Val-Pro-Pro Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 DOFAQXCYFQKSHT-SRVKXCTJSA-N 0.000 claims 1
- VIKZGAUAKQZDOF-NRPADANISA-N Val-Ser-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O VIKZGAUAKQZDOF-NRPADANISA-N 0.000 claims 1
- HTONZBWRYUKUKC-RCWTZXSCSA-N Val-Thr-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O HTONZBWRYUKUKC-RCWTZXSCSA-N 0.000 claims 1
- NLNCNKIVJPEFBC-DLOVCJGASA-N Val-Val-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCC(O)=O NLNCNKIVJPEFBC-DLOVCJGASA-N 0.000 claims 1
- 108010017893 alanyl-alanyl-alanine Proteins 0.000 claims 1
- 108010024078 alanyl-glycyl-serine Proteins 0.000 claims 1
- 108010041407 alanylaspartic acid Proteins 0.000 claims 1
- 108010005233 alanylglutamic acid Proteins 0.000 claims 1
- INJRKJPEYSAMPD-UHFFFAOYSA-N aluminum;silicic acid;hydrate Chemical compound O.[Al].[Al].O[Si](O)(O)O INJRKJPEYSAMPD-UHFFFAOYSA-N 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 108010025592 aminoadipoyl-cysteinyl-allylglycine Proteins 0.000 claims 1
- 235000019270 ammonium chloride Nutrition 0.000 claims 1
- 108010040443 aspartyl-aspartic acid Proteins 0.000 claims 1
- 108010093581 aspartyl-proline Proteins 0.000 claims 1
- 238000013475 authorization Methods 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 238000004166 bioassay Methods 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 208000035269 cancer or benign tumor Diseases 0.000 claims 1
- 239000006285 cell suspension Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000009089 cytolysis Effects 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 108010009297 diglycyl-histidine Proteins 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000005516 engineering process Methods 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 108010064177 glutamine synthetase I Proteins 0.000 claims 1
- 108010079547 glutamylmethionine Proteins 0.000 claims 1
- KZNQNBZMBZJQJO-YFKPBYRVSA-N glyclproline Chemical compound NCC(=O)N1CCC[C@H]1C(O)=O KZNQNBZMBZJQJO-YFKPBYRVSA-N 0.000 claims 1
- 108010000434 glycyl-alanyl-leucine Proteins 0.000 claims 1
- 108010033706 glycylserine Proteins 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 210000004209 hair Anatomy 0.000 claims 1
- 208000018706 hematopoietic system disease Diseases 0.000 claims 1
- 102000056003 human IL15 Human genes 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000010354 integration Effects 0.000 claims 1
- 108010027338 isoleucylcysteine Proteins 0.000 claims 1
- 238000002372 labelling Methods 0.000 claims 1
- 108010047926 leucyl-lysyl-tyrosine Proteins 0.000 claims 1
- 108010030617 leucyl-phenylalanyl-valine Proteins 0.000 claims 1
- MVCNPXUMKZNDRO-OAHLLOKOSA-N lysergene Chemical compound C1=CC(C2=CC(=C)CN([C@@H]2C2)C)=C3C2=CNC3=C1 MVCNPXUMKZNDRO-OAHLLOKOSA-N 0.000 claims 1
- 108010064235 lysylglycine Proteins 0.000 claims 1
- 108010017391 lysylvaline Proteins 0.000 claims 1
- 108010085203 methionylmethionine Proteins 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 238000001823 molecular biology technique Methods 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 claims 1
- MXHCPCSDRGLRER-UHFFFAOYSA-N pentaglycine Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(O)=O MXHCPCSDRGLRER-UHFFFAOYSA-N 0.000 claims 1
- 210000005259 peripheral blood Anatomy 0.000 claims 1
- 239000011886 peripheral blood Substances 0.000 claims 1
- 210000004976 peripheral blood cell Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 108010051242 phenylalanylserine Proteins 0.000 claims 1
- 108700042769 prolyl-leucyl-glycine Proteins 0.000 claims 1
- 238000001742 protein purification Methods 0.000 claims 1
- 210000004989 spleen cell Anatomy 0.000 claims 1
- 108010071097 threonyl-lysyl-proline Proteins 0.000 claims 1
- 108010017949 tyrosyl-glycyl-glycine Proteins 0.000 claims 1
- 108010073969 valyllysine Proteins 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5403—IL-3
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Jsou popsány nové proteiny multi-funkčních chimérních agonistů hematopoietických receptorů, sekvence DNA, které kódují proteiny multi-funkčních chimérních agonistů hematopoietických receptorů, způsoby výroby multi-funkčních chimérních agonistů hematopoietických receptorů a způsoby použití multi-funkčních chimérních agonistů hematopoietických receptorů.
Description
CZ 295843 B6
Malti-fankční chimérní agonisté hematopoietických receptorů
Oblast techniky 5
Tento vynález se týká multi-funkčních chimérních agonistů hematopoietických receptorů. Tyto multi-funkční chimérní agonisté hematopoietických receptorů si zachovávají jednu nebo více aktivit individuálních komponent chimérní molekuly a také mohou vykazovat zlepšenou stimulující aktivitu na hematopoietických buněk a nebo zlepšený aktivitní profil, který může 10 zahrnovat snížení nežádoucích biologických aktivit spojených s individuálními hematopoietic-kými růstovými faktory a nebo mít zlepšené fyzikální vlastnosti, které mohou zahrnovat zvýšenou rozpustnost, stabilitu a účinnost renaturace. 15 Dosavadní stav techniky
Kolonie stimulující faktory (CSF), které stimulují diferenciaci anebo proliferaci buněk kostní dřeně, vyvolaly velký zájem, pro jejich terapeutický potenciál při obnovení snížených hladin buněk odvozených od hematopoietických kmenových buněk. 20 CSF jak v lidském, tak v myším systému identifikovány a rozlišeny podle svých aktivit. Například granulocytová CSF (G-CSF) a makrofágová CSF (M-CSF) stimulují in vitro tvorby neutrofílních granulocytových a makrofágových kolonií, zatímco GM-CSF a interleukin-3 (IL—3) mají širší aktivity a stimulují tvorbu jak makrofágových, tak neutrofílních a eosinofilních 25 granulocytových kolonií. IL-3 také stimuluje tvorbu kolonií žímých buněk, megakaryocytů a čistých i směsných kolonií erytrocytů. US 4 877 729 a US 4 959 454 ukazují sekvenci cDNA gribona pro IL-3 a odvozenou sekvenci lidské DNA kódující IL-3 a proteinové sekvence, které kódují. Popsaná hIL-3 má spíše serin než 30 prolin v poloze 8 řetězce proteinu.
Mezinárodní patentová přihláška (PCT) WO 88/00598 popisuje IL-3 podobnou gibonní a lidské IL-3. hIL-3 obsahuje změnu Ser8 na Pro8. Jsou dány návrhy nahradit Cys serinem a tím rozbít disulfidický můstek a nahradit jednu či více aminokyselin v glykosylační místě. 35 US 4 810 643 popisuje DNA sekvenci kódující lidský G-CSF. WO 91/02754 popisuje fúzní protein složený z GM-CSF a IL-3, který má zvýšenou biologickou aktivitu ve srovnání se samotnými GM-CSF a IL-3. Také jsou popsané neglykosylované analogy 40 IL-3 a GM-CSF proteinů jako komponent pro multi-funkční chimérní agonisty hematopoietických receptorů. WO 92/04455 popisuje fuzní proteiny složené z IL-3 připojené k lymfokinu vybraného ze skupiny tvořené IL-3, IL-6, IL-7, IL-9, IL—11, EPO a G-CSF. 45 WO 95/21197 a WO 95/21254 popisují fuzní proteiny schopné širokých multi-funkčních hematopoietických vlastností. GB 2 285 446 se týká c-mpl ligandu (trombopoietin) a různých forem trombopoietinu, o kterých 50 se ukázalo, že ovlivňují replikaci, diferenciaci a maturaci megakaryocytů a progenitorových buněk megakaryocytů, které se mohou použít pro léčení trombocytopenie. EP 675 201 AI se týká c-mpl ligandu (růstový a rozvojový faktor megakaryocytů (MGDF)), alelických variací c-mpl ligandu a c-mpl ligandu spojených k polymerům rozpustným ve vodě, 55 jako je polyethylenglykol. -1 - 5 CZ 295843 B6 WO 95/21920 zajišťuje c-mpl ligand řádu myšovitých a lidský c-mpl ligand a jeho poly-peptidické fragmenty. Proteiny jsou užitečné při in vivo a ex vivo terapii pro stimulaci produkce trombocytů.
Patent US 4 703 008 Lin, F-K. popisuje cDNA sekvenci kódující erythropoetin, způsoby produkce a použití erythropoetinu. WO 91/05867 popisuje analogy lidského erythropoetinu mající větší počet pro připojení ío karbohydrátu než lidský erythropoetin, jako EPO (Asn69), EPO (Asn125, Ser127), EPO (Thr125), a EPO (Pro124, Thr125). WO 94/24160 popisuje muteiny erythropoetinu, které mají zvýšenou aktivitu, specificky substituce aminokyselin v polohách 20, 49, 73, 140, 143, 146, 147 a 154. 15 WO 94/28391 popisuje proteinovou sekvenci nativního flt3 ligandu a cDNA sekvenci kódující flt3 ligand, metody exprese flt3 ligandu v hostitelských buňkách transfekovaných s cDNA a metody léčení pacientů s hematopoietickou poruchou pomocí flt3 ligandu. 20 Patent US 5 554 512 je zaměřen na lidský flt3 ligand jako izolovaný protein, DNA kódující flt3 ligand, hostitelské buňky transfekované s cDNA kódující flt3 ligand a metody léčení pacientů flt3 ligandem. WO 94/26891 připravuje savčí flt3 ligandy včetně izolátu, který má inzerci 29 aminokyselin, a 25 jeho fragmenty. Přesmyky proteinových sekvencí V evoluci hrají změny DNA sekvencí důležitou úlohu při vytváření rozmanitých proteinových 30 struktur a funkcí. Genová duplikace a přesouvá exonů poskytují důležitý mechanismus pro rychlé vytvoření rozmanitosti a tak zajišťuje organismy s výhodou v soutěži, zejména proto, že základní četnost mutací je nízká (Doolittle, Protein Science 1: 191-200 (1992)).
Rozvoj metod rekombinantní DNA umožnil studium účinků transpozice sekvencí na skládání, 35 struktuiy a funkce proteinů. Přístup použitý k vytváření nových sekvencí se podobá přirozeně se vyskytujícím pánům proteinů, které jsou příbuzné lineární reorganizací svých sekvencí aminokyselin (Gunningham a kol., Proč. Nati. Acad. Sci. U.S.A. 76: 3218-3222 (1979), Teather a Erfle, J. Bacteriol. 172: 3837-3841 (1990), Schimming a kol., Eur. J. Biochem. 204: 13-19 (1992), Yamiuchi a Minamikawa, FEBSLett. 260:127-130, 1991; MacGregor a kol., FEBS Lett. 40 378: 263-266). První aplikace in vitro tohoto typu reorganizace proteinů byl popsán
Goldenbergem a Creinghtonem (J. Mol. Biol. 165: 407-413 (1983). Nový N-konec se vybere na vnitřním místě (místo zlomu) původní sekvence, nová sekvence má stejné pořadí aminokyselin jako originál od místa zlomu dokud nedosáhne aminokyselinu, která je na místě originálního C-konce nebo blízko něj. V tomto místě se připojí nová sekvence, buď přímo nebo přes další část 45 sekvence (spojovník) k aminokyselině, která je na místě originálního N-konce nebo blízko něj a nová sekvence pokračuje se stejnou sekvencí jako originální, dosud nedosáhne bod, které je na místě aminokyseliny, která byla na místě N-konce k místu zlomu originální sekvence. Tento zbytek tvoří nový C-konec řetězce. 50 Tento přístup se použil na proteiny s rozsahem velikosti od 58 do 462 aminokyselin (Goldenberg a Creighton J. Mol. Biol., 165: 407-413 (1983), Li a Coffino, Mol. Cell. Biol.13: 2377-2383 (1983)). Přezkoušené proteiny představovaly široký rozsah strukturních tříd, včetně proteinů, které obsahují převážně α-šroubovnici (interleukin-4, Kreitman a kol., Cytokine 7: 311-318 (1995), β—listy (interleukin-1, Horlick a kol., Protein Eng. 5: 427-431 (1992) nebo směsi těchto 55 dvou (izomeráza fosforibosyl anthranilátu z kvasinek, Luger a kol., Science 243: 206-210 -2- CZ 295843 B6 (1989)). Široké kategorie funkce proteinů jsou představeny v těchto studiích reorganizací sekvencí:
Reduktáza dihydrofolátu: Buchwalder a kol., Biochemistry 31: 1621-1630 (1994), Protasova a 5 kol., Protein Eng. 7: 1373-1377, (1995).
Ribonukleáza TI: Mullins a kol., J. Am. Chem. Soc. 116: 5529-5533 (1994), Garrett a kol., Protein Science 5: 204-211 (1996). ío Bacillus β-glukanas: Hahn a kol., Proč. Nati. Acad. Sci. U.S.A. 91: 10417-10421 (1994).
Transkarbamoyláza aspartátu: Yang a Schachman, Proč. Nati. Acad. Sci. U.S.A. 90: 11980— 11984 (1993). Izomeráza fosforibosyl anthranilátu: Luger a kol., Science 243: 206-210 (1989), Luger a kol., Protein Eng. 3: 249-258 (1990). 15
Pepsin/pepsinogen Lin a kol., Protein Science 4: 159-166 (1995).
Dehydrogenáza glyceraldehyd-3-fosfátu: Vignais a kol., Protein Science 4: 994-1000 (1995). 20 Dekarboxyláza ornithinu: Li a Coffíno, Mol. Cell. Biol. 13: 2377-2383 (1983).
Dehydrogenáza fosfoglycerátu z kvasinek: Ritco-Vonsovici a kol., Biochemistry 34: 16543-16551 (1995). 25 Inhibitor enzymů
Inhibitor bazického trypsinu z pankreatu: Goldenberg a Creighton J. Mol. Biol., 165: 407-413 (1983). 30 Cytokiny
Interleukin-lb: Horlick a kol., Protein Eng. 5: 427—431 (1992).
Interleukin-4: Kreitman a kol., Cytokine 7: 311-318 (1995). 35
Doména rozpoznávání kinázy tyrosinu
Doména α-spektrinu SH3: Viguera a kol. J. Mol. Biol., 247: 670-681 (1995). 40 T ran smembránový protein
Omp A: Koebnik a Kraemer J. Mol. Biol., 250: 617-626 (1995).
Chimémí protein 45
Interleukin-4-exotoxin Pseudomonas: Kreitman a kol., Proč. Nati. Acad. Sci. U.S.A. 91: 6889-6893 (1994). Výsledky těchto studií byly velmi rozdílné. V mnoha případech se pozorovala významně nižší 50 aktivita, rozpustnost nebo termodynamická stabilita (reduktáza dihydrofolátu E. coli, transkarbamoyláza aspartátu, izomeráza fosforibosyl anthranilátu, dehydrogenáza glyceraldehyd-3-fosfátu, dekarboxyláza ornithinu, omp A, dehydrogenáza fosfoglycerátu z kvasinek). V jiných případech se zdálo, že reorganizované sekvence proteinů mají mnohé téměř shodné vlastnosti jako jejich přirozené protějšky (inhibitor bazického tiypsinu z pankreatu, 4 lysozym, ribo-55 nukleáza TI, Bacillus b-glukanasa, interleukin-lb, doména SH3 a-spektrinu, pepsinogen, -3- CZ 295843 B6 interleukin-4). Ve výjimečných případech se pozorovalo neočekávané zlepšení některých vlastností oproti přirozené sekvenci, například rozpustnost a rychlost skládání u reorganizovaných sekvencí domény a-spektrinu SH3 a afinity receptorová afinita a antitumorov aktivita transponované fúzní molekuly interleukin-4-Pseudomonas exotoxin (Kreitman a kol., Proč. 5 Nati. Acad. Sci. U.S.A. 91: 6889-6893 (1994), Kreitman a kol., Cancer Res. 55: 3357-3363 (1995)). Základní motivací těchto typů studií byla studie úlohy interakcí na krátkou a dlouhou vzdálenost při skládání a stabilitě proteinů. Reorganizace sekvencí tohoto typu mění podmnožinu interakcí, 10 které jsou na dlouhou vzdálenost v původní sekvenci na interakci na krátkou vzdálenost v nové sekvenci a obráceně. Skutečnost, že mnohé z těchto reorganizací sekvencí jsou schopné získat konformaci s alespoň nějakou aktivitou, je přesvědčujícím důkazem, že skládání proteinů probíhá mnoha cestami skládání (Viguera a kol. J. Mol. Biol., 247: 670-681 (1995). V případě domény a-spektrinu SH3 výběr nových konců v polohách, které odpovídají zlomům b-vlásenky vedlo 15 k proteinům s mírně menší stabilitou, které jsou však přesto schopné se skládat.
Polohy vnitřních míst zlomu použité ve zde citovaných studiích se nalézají pouze na povrchu proteinů a jsou rozděleny podél lineární sekvence bez jakéhokoliv zřejmého sklonu směrem ke koncům nebo středu (variace relativní vzdálenosti od originálního Ň-konce k místu zlomu je asi 20 10 až 80% celkové délky sekvence). Spojovníky spojující originální N- a C-konce v těchto studiích se měnily od 0 od 9 zbytků. V jednom případě (Yang a Schachman, Proč. Nati. Acad. Sci. U.S.A. 90: 11980-11984 (1993)) část sekvence se odstranila od originálního C-koncového segmentu a spojení se dosáhlo od okleštěného C-konce k originálnímu segmentu N-konce. Ve spojovnících se často používají ohebné hydrofílní zbytky jako Gly a Ser. Viguera a kol. J. Mol. 25 Biol. 247: 670-681 (1995) porovnali spojení originálních N— a C-konců se spojovníkem s 3— nebo 4- zbytky, spojovník s 3-zbytky byl termodynamicky méně stabilní. Protasova a kol. (Protein Eng. 7: 1373-1377 (1994)) použili spojovníky s 3— nebo 5-zbytky ke spojení originálních N-konců reduktázy dihydrofolátu E. coli, pouze spojovník s 3- zbytky produkoval protein v dobrém výtěžku. 30
Podstata vynálezu
Hematopoietický protein obsahující sekvenci aminokyselin obecného vzorce: 35
Ri-Li-R2, R2—Lj—R], Ri-R2 nebo R2—Ri kde Ri je 40 (ΙΠ) polypeptidický agonista lidského fit—3 receptoru obsahující modifikovanou aminokyselinovou sekvenci fit—3 ligandu s následujícím vzorcem: CZ 295843 B6
ThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeu 10 20 30 40 50 60 70
HisPhcValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGln 80 90 100
GluThrSerGluGlnLeuValAlaLeuLysProTrpneThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCys 110 120 130
GlnProAspSerSerThrLeu (SEQ ID NO:466), kde 1 až 7 aminokyselin z C-konce může být případně odstraněno z tohoto polypeptidického agonisty flt3 receptoru a dojde k lineárnímu přeskupení sekvence, 5 kde N-konec je připojen k C-konci přímo nebo pomocí spojovníku (L2) schopného připojit N-konec k C-konci a po otevření takto vzniklé cirkulámí molekuly jsou vytvořeny nové C- a N-konce lineární molekuly mezi zbytky aminokyselinových párů: 28-29 42-43 93-94 29-30 64-65 94-95 30-31 65-66 95-96 31-32 66-67 96-97 32-33 86-87 97-98 34-35 87-88 98-99 36-37 88-89 99-100 37-38 89-90 100-101 38-39 90-91 101-102 39-40 91-92 102-103 40- 41 41- 42 92-93 v uvedeném pořadí; a R2 jsou nezávisle vybrané ze skupiny sestávající z: 25 (I) polypeptidického agonisty lidského EPO receptoru obsahujícím modifikovanou EPO sekvenci aminokyselin s následujícím vzorcem: -5 - CZ 295843 B6 10 20 30 40 50 60 70 80 90 100
140 150
GluAlaCysArgThrGIyAspArg 160 (SEQ ID NO:464), kde 1 až 6 aminokyselin z N-konce a/nebo 1 až 5 z C-konce může být případně odstraněno z tohoto polypeptidického agonisty EPO receptoru a dojde k lineárnímu přeskupení sekvence, kde N-konec je připojen k C-konci nebo pomocí spojovníku (L2) schopného připojit N-konec k C-konci a po otevření takto vzniklé cirkulámí molekuly jsou vytvořeny nové C- a N-konce lineární molekuly mezi zbytky aminokyselinových párů: 10 15 20 25 23-24 47-48 109-110 24-25 48-49 110-111 25-26 49-50 111-112 26-27 50-51 112-113 27-28 51-52 113-114 28-29 52-53 114-115 29-30 53-54 115-116 30-31 54-55 116-117 31-32 55-56 117-118 32-33 56-57 118-119 33-34 57-58 119-120 34-35 77-78 120-121 35-36 78-79 121-122 36-37 79-80 122-123 37-38 80-81 123-124 38-39 81-82 124-125 39-40 82-83 125-126 40-41 84-85 126-127 41-42 85-86 127-128 42-43 86-87 128-129 43-44 87-88 129-130 44—45 88-89 130-131 45-46 108-109 131-132 46-47 v uvedeném pořadí; 6- 30 CZ 295843 B6 (II) polypeptidického agonisty lidského receptoru faktoru kmenových buněk obsahujícím modifikovanou aminokyselinovou sekvenci faktoru kmenových buněk s následujícím vzorcem: 10 20 30 40 50 60 70 80
AsnlleValAspAspIxuValGluCysValLysGluAsnSerSerLysAspLeuLysLysSerPheLysSerProGluPro 90 100 110 120 130
ThrSerAspCysValValSerSerThrLeuSerProGluLysAspSerArgValSerValThrLysProPheMetLeu 140 150 160
ProProValAlaAla 165 (SEQ BD NO:465>, 5 kde 1 až 23 aminokyselin může být případně odstraněno z C-konce tohoto agonisty receptoru faktoru kmenových buněk a dojde k lineárnímu přeskupení sekvence, kde Lj je spojovníkem schopným spojit Ri k R2; a 10 kde N-konec je spojen k C-konci přímo nebo pomocí spojovníku (L2) schopného spojit N-konec k C-konci a po otevření takto vzniklé cirkulámí molekuly jsou vytvořeny nové C- a N-konce lineární molekuly mezi zbytky aminokyselinových párů: 23-24 39-40 96-97 24-25 40-41 97-98 25-26 64-65 98-99 26-27 65-66 99-100 27-28 66-67 100-101 28-29 67-68 101-102 29-30 68-69 102-103 30-31 69-70 103-104 31-32 70-71 104-105 32-33 89-90 105-106 33-34 90-91 106-107 34-35 91-92 107-108 35-36 92-93 108-109 36-37 93-94 109-110 37-38 94-95 110-111 38-39 95-96 v uvedeném pořadí; k tomuto hematopoietickému proteinu může bezprostředně předcházet (methionin-1), (alanin-1) nebo (methionin , alanin-1). -7- CZ 295843 B6 (III) polypeptidického agonisty lidského fit—3 receptoru obsahujícím modifikovanou aminokyselinovou sekvenci fit—3 ligandu s následujícím vzorcem: 10 20 30 40 50
GlnArgTrpMetGluArgLeuLysThrValAlaGIySerLysMetGlnGlyLeuLeuGluArgValAsnThK31une 60 70 80 90 100
GluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrAigGInAsnPheSerArgCysLeuGluLeuGlnCys 110 120 130
GlnProAspSerSer ThrLeu (SEQ ID NO:466), 5 kde 1 až 7 aminokyselin z C-konce může být případně odstraněno z tohoto polypeptidického agonisty flt3 receptoru a dojde k lineárnímu přeskupení sekvence, kde Lije spojovníkem schopným spojit Ri k R2; a 10 kde N-konec je připojen k C-konci přímo nebo pomocí spojovníku (L2) schopného připojit N-konec k C-konci a po otevření takto vzniklé cirkulámí molekuly jsou vytvořeny nové C- a N-konce lineární molekuly mezi zbytky aminokyselinových párů: 28-29 42-43 93-94 29-30 64-65 94-95 30-31 65-66 95-96 31-32 66-67 96-97 32-33 86-87 97-98 34-35 87-88 98-99 36-37 88-89 99-100 37-38 89-90 100-101 38-39 90-91 101-102 39-40 91-92 102-103 40- 41 41- 42 92-93 v uvedeném pořadí; tomuto hematopoietickému proteinu může případně bezprostředně předcházet (methionin'1), (alanin'1) nebo (methionin'2, alanin'1). (IV) polypeptidu obsahujícím modifikovanou sekvenci aminokyselin lidského G-CSF s následujícím vzorcem: -8- CZ 295843 B6
Xaa Xaa Xaa Gly Pro Ala Ser Ser Lea Pro Gin Ser Xaa Leu Leu Xaa Xaa Xaa Glu Gin Val Xaa 10 20
Lys Xaa Gin Gly Xaa Gly Ala Xaa Leu Gin Glu Xaa Leu Xaa Ala Thr Tyr Lys Leu Xaa Xaa Xaa 30 40
Glu Xaa Xaa Val Xaa Xaa Gly His Ser Xaa Gly Ile Pro Trp Ala Pro Leu Ser Ser Xaa Pro Ser Xaa 50 60
Ala Leu Xaa Leu Ala Gly Xaa Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu 70 80
Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Xaa Thr Leu Gin Xaa Asp Val Ala 90 100 110
Asp Phe Ala Xaa Thr Ile Trp Gin Gin Met Glu Xaa Xaa Gly Met Ala Pro Ala Leu Gin Pro Thr 120 130
Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Xaa Gin Xaa Xaa Ala Gly Gly Val Leu Val Ala Ser 140 150
5
Xaa v poloze 1 je Thr, Ser, Arg, Tyr nebo Gly;
Xaa v poloze 2 je Pro nebo Leu; 10 Xaa v poloze 3 je Leu, Arg, Tyr nebo Ser;
Xaa v poloze 13 je Phe, Ser, His, Thr nebo Pro;
Xaa v poloze 16 je Lys, Pro, Ser, Thr nebo His; 15
Xaa v poloze 17 je Cys, Ser, Gly, Ala, Ile, Tyr nebo Arg;
Xaa v poloze 18 je Leu, Thr, Pro, His, Ile nebo Cys; 20 Xaa v poloze 22 je Arg, Tyr, Ser, Thr nebo Ala;
Xaa v poloze 24 je Ile, Pro, Tyr nebo Leu;
Xaa v poloze 27 je Asp nebo Gly; 25
Xaa v poloze 30 je Ala, Ile, Leu nebo Gly;
Xaa v poloze 34 je Lys nebo Ser; 30 Xaa v poloze 36 je Cys nebo Ser; -9- CZ 295843 B6
Xaa v poloze 42 je Cys nebo Ser;
Xaa v poloze 43 je His, Thr, Gly, Val, Lys, Trp, Ala, Arg, Cys nebo Leu; 5
Xaa v poloze 44 je Pro, Gly, Arg, Asp, Val, Ala, His, Trp, Gin nebo Thr;
Xaa v poloze 46 je Glu, Arg, Phe, Arg, Ile nebo Ala; ío Xaa v poloze 47 je Leu nebo Thr;
Xaa v poloze 49 je Leu, Phe, Arg nebo Ser;
Xaa v poloze 50 je Leu, Ile, His, Pro nebo Tyr; 15
Xaa v poloze 54 je Leu nebo His;
Xaa v poloze 64 je Cys nebo Ser; 20 Xaa v poloze 67 je Gin, Lys, Leu nebo Cys;
Xaa v poloze 70 je Gin, Pro, Leu, Arg nebo Ser;
Xaa v poloze 74 je Cys nebo Ser; 25
Xaa v poloze 104 je Asp, Gly nebo Val;
Xaa v poloze 108 je Leu, Ala, Val, Arg, Trp, Gin nebo Gly; 30 Xaa v poloze 115 je Thr, His, Leu nebo Ala;
Xaa v poloze 120 je Gin, Gly, Arg, Lys nebo His;
Xaa v poloze 123 je Glu, Arg, Phe nebo Thr; 35
Xaa v poloze 144 je Phe, His, Arg, Pro, Leu, Gin nebo Glu;
Xaa v poloze 146 je Arg nebo Gin; 40 Xaa v poloze 147 je Arg nebo Gin;
Xaa v poloze 156 je His, Gly nebo Ser;
Xaa v poloze 159 je Ser, Arg, Thr, Tyr, Val nebo Gly; 45
Xaa v poloze 162 je Glu, Leu, Gly nebo Trp;
Xaa v poloze 163 je Val, Gly, Arg nebo Ala; 50 Xaa v poloze 169 je Arg, Ser, Leu, Arg nebo Cys;
Xaa v poloze 170 je His, Arg nebo Ser; kde 1 až 11 aminokyselin zN-konce a/nebo 1 až 5 aminokyselin z C-konce může být případně 55 odstraněno z této modifikované aminokyselinové sekvence lidského G-CSF a dojde k lineárnímu -10- CZ 295843 B6 přeskupení sekvence, kde N-konec je připojen k C-konci přímo nebo pomocí spojovníku (L2) schopného připojit N-konec k C-konci a po otevření takto vzniklé cirkulární molekuly jsou vytvořeny nové C- a N-konce lineární molekuly mezi zbytky aminokyselinových párů: 38-39 62-63 123-124 39-40 63-64 124-125 40-41 64-65 125-126 41-42 65-66 126-127 42-43 66-67 128-129 43-44 67-68 128-129 45-46 68-69 129-130 48-49 69-70 130-131 49-50 70-71 131-132 52-53 71-72 132-133 53-54 91-92 133-134 54-55 92-93 134-135 55-56 93-94 135-136 56-57 94-95 136-137 57-58 95-96 137-138 58-59 96-97 138-139 59-60 97-98 139-140 60-61 98-99 140-141 61-62 99-100 141-142 nebo 142-143 v uvedeném pořadí. (V) polypeptidu obsahujícím modifikovanou sekvenci aminokyselin lidského IL-3 s následujícím vzorcem:
Ala Pro Met Thr Gin Thr Thr Ser Leu Lys Thr Ser Trp Val Asn Cys Xaa Xaa Xaa Xaa Xaa Xaa 10 20
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa 30 40
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 50 60
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 70 80
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 90 100
Xaa Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gin Gin Thr 110 120 Thr Leu Ser Leu Ala Ite Phe (SEQ ID NO:859), 130 kde Xaa v poloze 17 je Ser, Lys, Gly, Asp, Met, Gin nebo Arg;
Xaa v poloze 18 je Asn, His, Leu, Ile, Phe, Arg nebo Gin; -11 - CZ 295843 B6
Xaa v poloze 19 je Met, Phe, Ile, Arg, Gly, Ala nebo Cys;
Xaa v poloze 20 je Ile, Cys, Gin, Glu, Arg, Pro nebo Ala; 5
Xaa v poloze 21 je Asp, Phe, Lys, Arg, Ala, Gly, Glu, Gin, Asn, Thr, Ser nebo Val;
Xaa v poloze 22 je Glu, Trp, Pro, Ser, Ala, His, Asp, Asn, Gin, Leu, Val nebo Gly; ία Xaa v poloze 23 je Ile, Val, Ala, Gly, Trp, Lys, Phe, Leu, Ser nebo Arg;
Xaa v poloze 24 je Ile, Gly, Val, Arg, Ser, Phe nebo Leu;
Xaa v poloze 25 je Thr, His, Gly, Gin, Arg, Pro nebo Ala; 15
Xaa v poloze 26 je His, Thr, Phe, Gly, Arg, Ala nebo Trp;
Xaa v poloze 27 je Leu, Gly, Arg, Thr, Ser nebo Ala; 20 Xaa v poloze 28 je Lys, Arg, Leu, Gin, Gly, Pro, Val nebo Trp;
Xaa v poloze 29 je Gin, Asn, Leu, Pro, Arg nebo Val;
Xaa v poloze 30 je Pro, His, Thr, Gly, Asp, Gin, Ser, Leu nebo Lys; 25
Xaa v poloze 31 je Pro, Asp, Gly, Ala, Arg, Leu nebo Gin;
Xaa v poloze 32 je Leu, Val, Arg, Gin, Asn, Gly, Ala nebo Glu; 30 Xaa v poloze 33 je Pro, Leu, Gin, Ala, Thr nebo Glu;
Xaa v poloze 34 je Leu, Val, Gly, Ser, Lys, Glu, Gin, Thr, Arg, Ala, Phe, Ile nebo Met;
Xaa v poloze 35 je Leu, Ala, Gly, Asn, Pro, Gin nebo Val; 35
Xaa v poloze 36 je Asp, Leu nebo Val;
Xaa v poloze 37 je Phe, Ser, Pro, Trp nebo Ile; 40 Xaa v poloze 38 je Asn nebo Ala;
Xaa v poloze 40 je Leu, Trp nebo Arg;
Xaa v poloze 41 je Asn, Cys, Arg, Leu, His, Met nebo Pro; 45
Xaa v poloze 42 je Gly, Asp, Ser, Cys, Asn, Lys, Thr, Leu, Val, Glu, Phe, Tyr, Ile, Met nebo Ala;
Xaa v poloze 43 je Glu, Asn, Tyr, Leu, Phe, Asp, Ala, Cys, Gin, Arg, Thr, Gly nebo Ser; 50 Xaa v poloze 44 je Asp, Ser, Leu, Arg, Lys, Thr, Met, Trp, Glu, Asn, Gin, Ala nebo Pro;
Xaa v poloze 45 je Gin, Pro, Phe, Val, Met, Leu, Thr, Lys, Trp, Asp, Asn, Arg, Ser, Ala, Ile, Glu nebo His; 55 Xaa v poloze 46 je Asp, Phe, Ser, Thr, Cys, Glu, Asn, Gin, Lys, His, Ala, Tyr, Ile, Val nebo Gly; -12- CZ 295843 B6
Xaa v poloze 47 je Ile, Gly, Val, Ser, Arg, Pro nebo His;
Xaa v poloze 48 je Leu, Ser, Cys, Arg, Ile, His, Phe, Glu, Lys, Thr, Ala, Met, Val nebo Asn; 5
Xaa v poloze 49 je Met, Arg, Ala, Gly, Pro, Asn, His nebo Asp;
Xaa v poloze 50 je Glu, Leu, Thr, Asp, Tyr, Lys, Asn, Ser, Ala, Ile, Val, His, Phe, Met nebo Gin; 10 Xaa v poloze 51 je Asn, Arg, Met, Pro, Ser, Thr nebo His;
Xaa v poloze 52 je Asn, His, Arg, Leu, Gly, Ser nebo Thr;
Xaa v poloze 53 je Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser nebo Met; 15
Xaa v poloze 54 je Arg, Asp, Ile, Ser, Val, Thr, Gin, Asn, Lys, His, Ala nebo Leu;
Xaa v poloze 55 je Arg, Thr, Val, Ser, Leu nebo Gly; 20 Xaa v poloze 56 je Pro, Gly, Cys, Ser, Gin, Glu, Arg, His, Thr, Ala, Tyr, Phe, Leu, Val nebo Lys;
Xaa v poloze 57 je Asn nebo Gly;
Xaa v poloze 58 je Leu, Ser, Asp, Arg, Gin, Val nebo Cys; 25
Xaa v poloze 59 je Glu, Tyr, His, Leu, Pro nebo Arg;
Xaa v poloze 60 je Ala, Ser, Pro, Tyr, Asn nebo Thr; 30 Xaa v poloze 61 je Phe, Asn, Glu, Pro, Lys, Arg nebo Ser;
Xaa v poloze 62 je Asn, His, Val, Arg, Pro, Thr, Asp nebo Ile;
Xaa v poloze 63 je Arg, Tyr, Trp, Lys, Ser, His, Pro nebo Val; 35
Xaa v poloze 64 je Ala, Asn, Pro, Ser nebo Lys;
Xaa v poloze 65 je Val, Thr, Pro, His, Leu, Phe nebo Ser; 40 Xaa v poloze 66 je Lys, Ile, Arg, Val, Asn, Glu nebo Ser;
Xaa v poloze 67 je Ser, Ala, Phe, Val, Gly, Asn, Ile, Pro nebo His;
Xaa v poloze 68 je Leu, Val, Trp, Ser, Ile, Phe, Thr nebo His; 45
Xaa v poloze 69 je Gin, Ala, Pro, Thr, Glu, Arg, Trp, Gly nebo Leu;
Xaa v poloze 70 je Asn, Leu, Val, Trp, Pro nebo Ala; 50 Xaa v poloze 71 je Ala, Met, Leu, Pro, Arg, Glu, Thr, Gin, Trp nebo Asn;
Xaa v poloze 72 je Ser, Glu, Met, Ala, His, Asn, Arg nebo Asp;
Xaa v poloze 73 je Ala, Glu, Asp, Leu, Ser, Gly, Thr nebo Arg; -13- 55 CZ 295843 B6
Xaa v poloze 74 je Ile, Met, Thr, Pro, Arg, Gly, Ala;
Xaa v poloze 75 je Glu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gin nebo Leu; 5 Xaa v poloze 76 je Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly nebo Asp;
Xaa v poloze 77 je Ile, Ser, Arg, Thr nebo Leu;
Xaa v poloze 78 je Leu, Ala, Ser, Glu, Phe, Gly nebo Arg; 10
Xaa v poloze 79 je Lys, Thr, Asn, Met, Arg, Ile, Gly nebo Asp;
Xaa v poloze 80 je Asn, Trp, Val, Gly, Thr, Leu, Glu nebo Arg; 15 Xaa v poloze 81 je Leu, Gin, Gly, Ala, Trp, Arg, Val nebo Lys;
Xaa v poloze 82 je Leu, Gin, Lys, Trp, Arg, Asp, Glu, Asn, His, Thr, Ser, Ala, Tyr, Phe Ile, Met nebo Val; 20 Xaa v poloze 83 je Pro, Ala, Thr, Trp, Arg nebo Met;
Xaa v poloze 84 je Cys, Glu, Gly, Arg, Met nebo Val;
Xaa v poloze 85 je Leu, Asn, Val nebo Gin; 25
Xaa v poloze 86 je Pro, Cys, Arg, Ala nebo Lys;
Xaa v poloze 87 je Leu, Ser, Trp nebo Gly; 30 Xaa v poloze 88 je Ala, Lys, Arg, Val nebo Trp;
Xaa v poloze 89 je Thr, Asp, Cys, Leu, Val, Glu, His, Asn nebo Ser;
Xaa v poloze 90 je Ala, Pro, Ser, Thr, Gly, Asp, Ile nebo Met; 35
Xaa v poloze 91 je Ala, Pro, Ser, Thr, Phe, Leu, Asp nebo His;
Xaa v poloze 92 je Pro, Phe, Arg, Ser, Lys, His, Ala, Gly, Ile nebo Leu; 40 Xaa v poloze 93 je Thr, Asp, Ser, Asn, Pro, Ala, Leu nebo Arg;
Xaa v poloze 94 je Arg, Ile, Ser, Glu, Leu, Val, Gin, Lys, His, Ala nebo Pro;
Xaa v poloze 95 je His, Gin, Pro, Arg, Val, Leu, Gly, Thr, Asn, Lys, Ser, Ala, Trp, Phe, Ile nebo 45 Tyr;
Xaa v poloze 96 je Pro, Lys, Tyr, Gly, Ile nebo Thr;
Xaa v poloze 97 je Ile, Val, Lys, Ala nebo Asn; 50
Xaa v poloze 98 je His, Ile, Asn, Leu, Asp, Ala, Thr, Glu, Gin, Gin, Ser, Phe, Met, Val, Lys, Arg, Tyr nebo Pro;
Xaa v poloze 99 je Ile, Leu, Arg, Asp, Val, Pro, Gin, Gly, Ser, Phe nebo His; - 14- 55 CZ 295843 B6
Xaa v poloze 100 je Lys, Tyr, Leu, His, Arg, Ile, Ser, Gin nebo Pro;
Xaa v poloze 101 je Asp, Pro, Met, Lys, His, Thr, Val, Tyr, Glu, Asn, Ser, Ala, Gly, Ile, Leu nebo Gin; 5
Xaa v poloze 102 je Gly, Leu, Glu, Lys, Ser, Tyr nebo Pro;
Xaa v poloze 103 je Asp nebo Ser; 10 Xaa v poloze 104 je Trp, Val, Cys, Tyr, Thr, Met, Pro, Leu, Gin, Lys, Ala, Phe nebo Gly;
Xaa v poloze 105 je Asn, Pro, Ala, Phe, Ser, Trp, Gin, Tyr, Leu, Lys, Ile, Asp nebo His;
Xaa v poloze 106 je Glu, Ser, Ala, Lys, Thr, Ile, Gly nebo Pro; 15
Xaa v poloze 108 je Arg, Lys, Asp, Leu, Thr, Ile, Gin, His, Ser, Ala nebo Pro;
Xaa v poloze 109 je Arg, Thr, Pro, Glu, Tyr, Leu, Ser nebo Gly; 20 Xaa v poloze 110 je Lys, Ala, Asn, Thr, Leu, Arg, Gin, His, Glu, Ser nebo Trp;
Xaa v poloze 111 je Leu, Ile, Arg, Asp nebo Met;
Xaa v poloze 112 je Thr, Val, Gin, Tyr, Glu, His, Ser nebo Phe; 25
Xaa v poloze 113 je Phe, Ser, Cys, His, Gly, Trp, Tyr, Asp, Lys, Leu, Ile, Val nebo Asn;
Xaa v poloze 114 je Tyr, Cys, His, Ser, Trp, Arg nebo Leu; 30 Xaa v poloze 115 je Leu, Asn, Val, Pro, Arg, Ala, His, Thr, Trp nebo Met;
Xaa v poloze 116 je Lys, Leu, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp, Ser, Asn, His, Ala, Tyr, Phe, Gin nebo Ile; 35 Xaa v poloze 117 je Thr, Ser, Asn, Ile, Trp, Lys nebo Pro;
Xaa v poloze 118 je Leu, Ser, Pro, Ala, Glu, Cys, Asp nebo Tyr;
Xaa v poloze 119 je Glu, Ser, Lys, Pro, Leu, Thr, Tyr nebo Arg; 40
Xaa v poloze 120 je Asn, Ala, Pro, Leu, His, Val nebo Gin;
Xaa v poloze 121 je Ala, Ser, Ile, Asn, Pro, Lys, Asp nebo Gly; 45 Xaa v poloze 122 je Gin, Ser, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr nebo Cys;
Xaa v poloze 123 je Ala, Met, Glu, His, Ser, Pro, Tyr nebo Leu; kde Li je spojovníkem schopným spojit Ri k R2; a 50 kde 1 až 14 aminokyselin je případně odstraněno zN-konce a/nebo 1 až 15 aminokyselin je případně odstraněno zC-konce této modifikované sekvence aminokyselin lidského IL-3; a kde od 0 do 44 aminokyselin označených Xaa je různých od odpovídajících aminokyselin nativního (1-133) lidského interleukinu-3 a dojde k lineárnímu přeskupení sekvence, kde N-konec je 55 připojen k C-konci přímo nebo pomocí spojovníku (L2) schopného připojit N-konec k C-konci a -15- 5 CZ 295843 B6 po otevření takto vzniklé cirkulámí molekuly jsou vytvořeny nové C- a N-konce lineární molekuly mezi zbytky aminokyselinových párů: 10 15 26-27 49-50 27-28 50-51 28-29 51-52 29-30 52-53 30-31 53-54 31-32 54-55 32-33 64-65 33-34 65-66 34-35 66-67 35-36 67-68 36-37 68-69 37-38 69-70 38-39 70-71 39-40 71-72 40-41 72-73 41-42 82-83 20 83- 84 84- 85 85- 86 86- 87 87- 88 88- 89 89- 90 90- 91 91- 92 92- 93 97- 98 98- 99 99- 100 100- 101 101-102 102-103 nebo 103-104 v uvedeném pořadí; polypeptid může být též vybrán ze skupiny sestávající z:
Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ue His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Ala Glu Asp Val Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin (SEQ ID NO:803);
Ala Asn Cys Ser Ile Met Ile Asp Glu Ue Ue His His Leu Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu
Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ue Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ue Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr LeuGlu Gin Ala Gin Glu Gin Gin (SEQ ED NO:804);
Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ue His His Leu Lys Val Pro Pro Ala Pro Leu Leu Asp Ser Asn Asn Leu Asn Ser Glu Asp Met Asp Ue Leu Met Glu Arg Asn Leu Arg Leu Pro Asn Leu
Leu Ala Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ue Lys Ala Gly Asp Tip Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin (SEQ ID NO:805);a -16- CZ 295843 B6
Asn Cys Ser Ile Met Ile Asp GIu Ile De His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu
Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin (SEQ ID NO:806) tomuto hematopoietickému proteinu může případně bezprostředně předcházet (methionin'1), (alanin"1) nebo (methionin 2, alanin'1); (VI) polypeptidu obsahujícím modifikovanou sekvenci aminokyselin lidského c-mpl ligandu s následujícím vzorcem:
SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeu 10 20
SerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThr 30 40 50
GlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAIaAlaArgGly 60 70
GlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGln 80 90 100
SerLeuLeuGlyThrGtnXaaXaaXaaXaaGlyArgThrThrAlaHisLysAspProAsnAlallePheLeuSerPhe 110 120 130
GlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArg 140 150 (SEQ ID NO:86Q), 10 kde
Xaa v poloze 112 je odstraněn neboje to Leu, Ala, Val, Ile, Pro, Phe, Trp nebo Met; 15
Xaa v poloze 113 je odstraněn neboje to Pro, Phe, Ala, Val, Leu, Ile, Trp nebo Met;
Xaa v poloze 114 je odstraněn neboje to Pro, Phe, Ala, Val, Leu, Ile, Trp nebo Met; 20 Xaa v poloze 115 je odstraněn nebo je to Gin, Gly, Ser, Thr, Tyr nebo Asn a dojde k lineárnímu přeskupení sekvence, kde N-konec je spojen k C-konci přímo nebo pomocí spojovníku (L2) schopného spojit N-konec k C-konci a po otevření takto vzniklé cirkulámí molekuly jsou vytvořeny nové C- a N-konce lineární molekuly mezi zbytky aminokyselinových párů: 25 26-27 51-52 108-109 27-28 52-53 109-110 28-29 53-54 110-111 29-30 54-55 111-112 -17- CZ 295843 B6 30-31 55-56 112-113 32-33 56-57 113-114 33-34 57-58 114-115 34-35 58-59 115-116 36-37 59-60 116-117 37-38 78-79 117-118 38-39 79-80 118-119 40-41 80-81 119-120 41—42 81-82 120-121 42-43 82-83 121-122 43-44 83-84 122-123 44-45 84-85 123-124 46-47 85-86 124-125 47-48 86-87 125-126 48-49 87-88 126-127 50-51 88-89 nebo 127-128 v uvedeném pořadí; (VII) polypeptidu obsahujícím modifikovanou sekvenci aminokyselin lidského IL-3 s následují-20 cím vzorcem:
Ala Pro Met Thr Gin Thr Thr Ser Leu Lys Thr Ser Tip Val Asn Cys Xaa Xaa Xaa Xaa Xaa Xaa 10 20
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa 30 40
Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 50 60
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 70 80
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 90 100
Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gin Gin Thr Thr 110 120
Leu Ser Leu Ala Ile Phe (SEQ ID NO:859), 130 kde Xaa v poloze 17 je Ser, Lys, Gly, Asp, Met, Gin nebo Arg; 25
Xaa v poloze 18 je Asn, His, Leu, Ile, Phe, Arg nebo Gin;
Xaa v poloze 19 je Met, Phe, Ile, Arg, Gly, Ala nebo Cys; 30 Xaa v poloze 20 je Ile, Cys, Gin, Glu, Arg, Pro nebo Ala;
Xaa v poloze 21 je Asp, Phe, Lys, Arg, Ala, Gly, Glu, Gin, Asn, Thr, Ser nebo Val;
Xaa v poloze 22 je Glu, Trp, Pro, Ser, Ala, His, Asp, Asn, Gin, Leu, Val nebo Gly; 35
Xaa v poloze 23 je Ile, Val, Ala, Gly, Trp, Lys, Phe, Leu, Ser nebo Arg; - 18- CZ 295843 B6
Xaa v poloze 24 je lle, Gly, Val, Arg, Ser, Phe nebo Leu;
Xaa v poloze 25 je Thr, His, Gly, Gin, Arg, Pro nebo Ala; 5
Xaa v poloze 26 je His, Thr, Phe, Gly, Arg, Ala nebo Trp;
Xaa v poloze 27 je Leu, Gly, Arg, Thr, Ser nebo Ala; io Xaa v poloze 28 je Lys, Arg, Leu, Gin Gly, Pro, Val nebo Trp;
Xaa v poloze 29 je Gin, Asn, Leu, Pro, Arg nebo Val;
Xaa v poloze 30 je Pro, His, Thr, Gly, Asp, Gin, Ser, Leu nebo Lys; 15
Xaa v poloze 31 je Pro, Asp, Gly, Ala, Arg, Leu nebo Gin;
Xaa v poloze 32 je Leu, Val, Arg, Gin, Asn, Gly, Ala nebo Glu; 20 Xaa v poloze 33 je Pro, Leu, Gin, Ala, Thr nebo Glu;
Xaa v poloze 34 je Leu, Val, Gly, Ser, Lys, Glu, Gin, Thr, Arg, Ala, Phe, lle nebo Met;
Xaa v poloze 35 je Leu, Ala, Gly, Asn, Pro, Gin nebo Val; 25
Xaa v poloze 36 je Asp, Leu nebo Val;
Xaa v poloze 37 je Phe, Ser, Pro, Trp nebo lle; 30 Xaa v poloze 38 je Asn nebo Ala;
Xaa v poloze 40 je Leu, Trp nebo Arg;
Xaa v poloze 41 je Asn, Cys, Arg, Leu, His, Met nebo Pro; 35
Xaa v poloze 42 je Gly, Asp, Ser, Cys, Asn, Lys, Thr, Leu, Val, Glu, Phe, Tyr, lle, Met nebo Ala;
Xaa v poloze 43 je Glu, Asn, Tyr, Leu, Phe, Asp, Ala, Cys, Gin, Arg, Thr, Gly nebo Ser; 40 Xaa v poloze 44 je Asp, Ser, Leu, Arg, Lys, Thr, Met, Trp, Glu, Asn, Gin, Ala nebo Pro;
Xaa v poloze 45 je Gin, Pro, Phe, Val, Met, Leu, Thr, Lys, Trp, Asp, Asn, Arg, Ser, Ala, lle, Glu nebo His; 45 Xaa v poloze 46 je Asp, Phe, Ser, Thr, Cys, Glu, Asn, Gin, Lys, His, Ala, Tyr, lle, Val nebo Gly; Xaa v poloze 47 je lle, Gly, Val, Ser, Arg, Pro nebo His;
Xaa v poloze 48 je Leu, Ser, Cys, Arg, lle, His, Phe, Glu, Lys, Thr, Ala, Met, Val nebo Asn; 50
Xaa v poloze 49 je Met, Arg, Ala, Gly, Pro, Asn, His nebo Asp;
Xaa v poloze 50 je Glu, Leu, Thr, Asp, Tyr, Lys, Asn, Ser, Ala, lle, Val, His, Phe, Met nebo Gin; 55 Xaa v poloze 51 je Asn, Arg, Met, Pro, Ser, Thr nebo His; - 19- CZ 295843 B6
Xaa v poloze 52 je Asn, His, Arg, Leu, Gly, Ser nebo Thr;
Xaa v poloze 53 je Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser nebo Met; 5
Xaa v poloze 54 je Arg, Asp, Ile, Ser, Val, Thr, Gin, Asn, Lys, His, Ala nebo Leu;
Xaa v poloze 55 je Arg, Thr, Val, Ser, Leu nebo Gly; io Xaa v poloze 56 je Pro, Gly, Cys, Ser, Gin, Glu, Arg, His, Thr, Ala, Tyr, Phe, Leu, Val nebo Lys;
Xaa v poloze 57 je Asn nebo Gly;
Xaa v poloze 58 je Leu, Ser, Asp, Arg, Gin, Val nebo Cys; 15
Xaa v poloze 59 je Glu, Tyr, His, Leu, Pro nebo Arg;
Xaa v poloze 60 je Ala, Ser, Pro, Tyr, Asn nebo Thr; 20 Xaa v poloze 61 je Phe, Asn, Glu, Pro, Lys, Arg nebo Ser;
Xaa v poloze 62 je Asn, His, Val, Arg, Pro, Thr, Asp nebo Ile;
Xaa v poloze 63 je Arg, Tyr, Trp, Lys, Ser, His, Pro nebo Val; 25
Xaa v poloze 64 je Ala, Asn, Pro, Ser nebo Lys;
Xaa v poloze 65 je Val, Thr, Pro, His, Leu, Phe nebo Ser; 30 Xaa v poloze 66 je Lys, Ile, Arg, Val, Asn, Glu nebo Ser;
Xaa v poloze 67 je Ser, Ala, Phe, Val, Gly, Asn, Ile, Pro nebo His;
Xaa v poloze 68 je Leu, Val, Trp, Ser, Ile, Phe, Thr nebo His; 35
Xaa v poloze 69 je Gin, Ala, Pro, Thr, Glu, Arg, Trp, Gly nebo Leu;
Xaa v poloze 70 je Asn, Leu, Val, Trp, Pro nebo Ala; 40 Xaa v poloze 71 je Ala, Met, Leu, Pro, Arg, Glu, Thr, Gin, Trp nebo Asn;
Xaa v poloze 72 je Ser, Glu, Met, Ala, His, Asn, Arg nebo Asp;
Xaa v poloze 73 je Ala, Glu, Asp, Leu, Ser, Gly, Thr nebo Arg; 45
Xaa v poloze 74 je Ile, Met, Thr, Pro, Arg, Gly, Ala;
Xaa v poloze 75 je Glu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gin nebo Leu; 50 Xaa v poloze 76 je Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly nebo Asp;
Xaa v poloze 77 je Ile, Ser, Arg, Thr nebo Leu;
Xaa v poloze 78 je Leu, Ala, Ser, Glu, Phe, Glu nebo Arg; -20- 55 CZ 295843 B6
Xaa v poloze 79 je Lys, Thr, Asn, Met, Arg, Ile, Gly nebo Asp;
Xaa v poloze 80 je Asn, Trp, Val, Gly, Thr, Leu, Glu nebo Arg; 5 Xaa v poloze 81 je Leu, Gin, Gly, Ala, Trp, Arg, Val nebo Lys;
Xaa v poloze 82 je Leu, Gin, Lys, Trp, Arg, Asp, Glu, Asn, His, Thr, Ser, Ala, Tyr, Phe Ile, Met nebo Val; ío Xaa v poloze 83 je Pro, Ala, Thr, Trp, Arg nebo Met;
Xaa v poloze 84 je Cys, Glu, Gly, Arg, Met nebo Val;
Xaa v poloze 85 je Leu, Asn, Val nebo Gin; 15
Xaa v poloze 86 je Pro, Cys, Arg, Ala nebo Lys;
Xaa v poloze 87 je Leu, Ser, Trp nebo Gly; 20 Xaa v poloze 88 je Ala, Lys, Arg, Val nebo Trp;
Xaa v poloze 89 je Thr, Asp, Cys, Leu, Val, Glu, His, Asn nebo Ser;
Xaa v poloze 90 je Ala, Pro, Ser, Thr, Gly, Asp, Ile nebo Met; 25
Xaa v poloze 91 je Ala, Pro, Ser, Thr, Phe, Leu, Asp nebo His;
Xaa v poloze 92 je Pro, Phe, Arg, Ser, Lys, His, Ala, Gly, Ile nebo Leu; 30 Xaa v poloze 93 je Thr, Asp, Ser, Asn, Pro, Ala, Leu nebo Arg;
Xaa v poloze 94 je Arg, Ile, Ser, Glu, Leu, Val, Gin, Lys, His, Ala nebo Pro;
Xaa v poloze 95 je His, Gin, Pro, Arg, Val, Leu, Gly, Thr, Asn, Lys, Ser, Ala, Trp, Phe, Ile nebo 35 Tyr;
Xaa v poloze 96 je Pro, Lys, Tyr, Gly, Ile nebo Thr;
Xaa v poloze 97 je Ile, Val, Lys, Ala nebo Asn; 40
Xaa v poloze 98 je His, Ile, Asn, Leu, Asp, Ala, Thr, Glu, Gin, Ser, Phe, Met, Val, Lys, Arg, Tyr nebo Pro;
Xaa v poloze 99 je Ile, Leu, Arg, Asp, Val, Pro, Gin, Gly, Ser, Phe nebo His; 45
Xaa v poloze 100 je Lys, Tyr, Leu, His, Arg, Ile, Ser, Gin nebo Pro;
Xaa v poloze 101 je Asp, Pro, Met, Lys, His, Thr, Val, Tyr, Glu, Asn, Ser, Ala, Gly, Ile, Leu nebo Gin; 50
Xaa v poloze 102 je Gly, Leu, Glu, Lys, Ser, Tyr nebo Pro;
Xaa v poloze 103 je Asp nebo Ser; 55 Xaa v poloze 104 je Trp, Val, Cys, Tyr, Thr, Met, Pro, Leu, Gin, Lys, Ala, Phe nebo Gly; -21 - CZ 295843 B6
Xaa v poloze 105 je Asn, Pro, Ala, Phe, Ser, Trp, Gin, Tyr, Leu, Lys, Ile, Asp nebo His;
Xaa v poloze 106 je Glu, Ser, Ala, Lys, Thr, Ile, Glu nebo Pro; 5
Xaa v poloze 108 je Arg, Lys, Asp, Leu, Thr, Ile, Gin, His, Ser, Ala nebo Pro;
Xaa v poloze 109 je Arg, Thr, Pro, Glu, Tyr, Leu, Ser nebo Gly; io Xaa v poloze 110 je Lys, Ala, Asn, Thr, Leu, Arg, Gin, His, Glu, Ser nebo Trp;
Xaa v poloze 111 je Leu, Ile, Arg, Asp nebo Met;
Xaa v poloze 112 je Thr, Val, Gin, Tyr, Glu, His, Ser nebo Phe; 15
Xaa v poloze 113 je Phe, Ser, Cys, His, Gly, Trp, Tyr, Asp, Lys, Leu, Ile, Val nebo Asn;
Xaa v poloze 114 je Tyr, Cys, His, Ser, Trp, Arg nebo Leu; 20 Xaa v poloze 115 je Leu, Asn, Val, Pro, Arg, Ala, His, Thr, Trp nebo Met;
Xaa v poloze 116 je Lys, Leu, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp, Ser, Asn, His, Ala, Tyr, Phe, Gin nebo Ile; 25 Xaa v poloze 117 je Thr, Ser, Asn, Ile, Trp, Lys nebo Pro;
Xaa v poloze 118 je Leu, Ser, Pro, Ala, Glu, Cys, Asp nebo Tyr;
Xaa v poloze 119 je Glu, Ser, Lys, Pro, Leu, Thr, Tyr nebo Arg; 30
Xaa v poloze 120 je Asn, Ala, Pro, Leu, His, Val nebo Gin;
Xaa v poloze 121 je Ala, Ser, Ile, Asn, Pro, Lys, Asp nebo Gly; 35 Xaa v poloze 122 je Gin, Ser, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr nebo Cys;
Xaa v poloze 123 je Ala, Met, Glu, His, Ser, Pro, Tyr nebo Leu; kde 1 až 14 aminokyselin je případně odstraněno zN-konce a/nebo 1 až 15 aminokyselin je 40 případně odstraněno z C-konce této modifikované sekvence aminokyselin lidského IL-3; a kde od 1 do 44 aminokyselin označených Xaa je různých od odpovídajících aminokyselin nativního (1-133) lidského interleukinu-3; (VIII) faktoru vybraného ze skupiny sestávající z faktoru stimulujícího kolonie, cytokinu, 45 lymfokinu, interleukinu, a hematopoietického růstového faktoru a kde Li je spojovníkem schopným spojit Ri k R2; L2 je spojovníkem schopným připojit N-konec k C-konci za lineárního přeskupení sekvence; 50 tomuto hematopoietickému proteinu může případně bezprostředně předcházet (methionin'1), (alanin'1) nebo (methionin'2, alanin'1); R2 může být též polypeptidem obsahujícím modifikovanou sekvenci aminokyselin lidského G-CSF s následujícím vzorcem: -22- 55 CZ 295843 B6
Xaa Xaa Xaa Gly Pro Ala Ser Ser Leu Pro Gin Ser Xaa Leu Leu Xaa Xaa Xaa Glu Gin Val Xaa 10 20
Lys Xaa Gin Gly Xaa Gly Ala Xaa Leu Gin Glu Xaa Leu Xaa Ala Thr Tyr Lys Leu Xaa Xaa Xaa 30 40
Glu Xaa Xaa Val Xaa Xaa Gly His Ser Xaa Gly Ue Pro Trp Ala Pro Leu Ser Ser Xaa Pro Ser Xaa 50 60
Ala Leu Xaa Leu Ala Gly Xaa Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu 70 80
Gin Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Xaa Thr Leu Gin Xaa Asp Val Ala 90 100 110
Asp Phe Ala Xaa Thr Ile Trp Gin Gin Met Glu Xaa Xaa Gly Met Ala Pro Ala Leu Gin Pro Thr 120 130
Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Xaa Gin Xaa Xaa Ala Gly Gly Val Leu Val Ala Ser 140 150
Xaa Leu Gin Xaa Phe Leu Xaa Xaa Ser Tyr Arg Val Leu Xaa Xaa Leu Ala Gin Pro 160 170 (SEQIDNO:858>, kde 5
Xaa v poloze 1 je Thr, Ser, Arg, Tyr nebo Gly;
Xaa v poloze 2 je Pro nebo Leu; 10 Xaa v poloze 3 je Leu, Arg, Tyr nebo Ser;
Xaa v poloze 13 je Phe, Ser, His, Thr nebo Pro;
Xaa v poloze 16 je Lys, Pro, Ser, Thr nebo His; 15
Xaa v poloze 17 je Cys, Ser, Gly, Ala, Ile, Tyr nebo Arg; Xaa v poloze 18 je Leu, Thr, Pro, His, Ile nebo Cys; 20 Xaa v poloze 22 je Arg, Tyr, Ser, Thr nebo Ala;
Xaa v poloze 24 je Ile, Pro, Tyr nebo Leu;
Xaa v poloze 27 je Asp nebo Gly; 25
Xaa v poloze 30 je Ala, Ile, Leu nebo Gly;
Xaa v poloze 34 je Lys nebo Ser; 30 Xaa v poloze 36 je Cys nebo Ser;
Xaa v poloze 42 je Cys nebo Ser; -23- CZ 295843 B6
Xaa v poloze 43 je His, Thr, Gly, Val, Lys, Trp, Ala, Arg, Cys nebo Leu;
Xaa v poloze 44 je Pro, Gly, Arg, Asp, Val, Ala, His, Trp, Gin nebo Thr; 5
Xaa v poloze 46 je Glu, Arg, Phe, Arg, Ile nebo Ala;
Xaa v poloze 47 je Leu nebo Thr; io Xaa v poloze 49 je Leu, Phe, Arg nebo Ser;
Xaa v poloze 50 je Leu, Ile, His, Pro nebo Tyr;
Xaa v poloze 54 je Leu nebo His; 15
Xaa v poloze 64 je Cys nebo Ser;
Xaa v poloze 67 je Gin, Lys, Leu nebo Cys; 20 Xaa v poloze 70 je Gin, Pro, Leu, Arg nebo Ser;
Xaa v poloze 74 je Cys nebo Ser;
Xaa v poloze 104 je Asp, Gly nebo Val; 25
Xaa v poloze 108 je Leu, Ala, Val, Arg, Trp, Gin nebo Gly;
Xaa v poloze 115 je Thr, His, Leu nebo Ala; 30 Xaa v poloze 120 je Gin, Gly, Arg, Lys nebo His;
Xaa v poloze 123 je Glu, Arg, Phe nebo Thr;
Xaa v poloze 144 je Phe, His, Arg, Pro, Leu, Gin nebo Glu; 35
Xaa v poloze 146 je Arg nebo Gin;
Xaa v poloze 147 je Arg nebo Gin; 40 Xaa v poloze 156 je His, Gly nebo Ser;
Xaa v poloze 159 je Ser, Arg, Thr, Tyr, Val nebo Gly;
Xaa v poloze 162 je Glu, Leu, Gly nebo Trp; 45
Xaa v poloze 163 je Val, Gly, Arg nebo Ala;
Xaa v poloze 169 je Arg, Ser, Leu, Arg nebo Cys; 50 Xaa v poloze 170 je His, Arg nebo Ser; kde 1-11 aminokyselin zN-konce a/nebo 1-5 aminokyselin zC-konce může být případně odstraněno z této modifikované sekvence aminokyselin lidského G-CSF a dojde k lineárnímu přeskupení sekvence, kde N-konec je spojen k C-konci přímo nebo pomocí spojovníku (L2) -24- CZ 295843 B6 schopného spojit N-konec k C-konci a po otevření takto vzniklé cirkulární molekuly jsou vytvořeny nové C- a N-konce lineární molekuly mezi zbytky aminokyselinových párů: 38-39 62-63 123-124 5 39-40 63-64 124-125 40-41 64-65 125-126 41-42 65-66 126-127 42-43 66-67 128-129 43-44 67-68 128-129 ío 45-46 68-69 129-130 48-49 69-70 130-131 49-50 70-71 131-132 52-53 71-72 132-133 53-54 91-92 133-134 15 54-55 92-93 134-135 55-56 93-94 135-136 56-57 94-95 136-137 57-58 95-96 137-138 58-59 96-97 138-139 20 59-60 97-98 139-140 60-61 98-99 140-141 61-62 99-100 141-142 nebo 142-143 25 v uvedeném pořadí; kde Li je spojovníkem schopným spojit Ri k R2; tomuto hematopoietickému proteinu může případně bezprostředně předcházet (methionin'1), 30 (alanin'1) nebo (methionin'2, alanin'1).
Hematopoietický protein může být vybrán též ze skupiny, kterou tvoří:
AlaAsnCysSerllcMeťlleAspGluílelleHisHisLeuLysArgProProAlaProLeuLeuAspProAsnAsnLeuAsn
AspGiuAspValSerlleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsn
LeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArg
HisProIleHeUeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAIaGln
GluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrileAsnProSerProProSer
LysGluSerHisLysSerProAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAJaGlnArgTrp
MetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThr
LysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGlu
GlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSer
ThrLcuSerGlyGlyAsnGlySerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPhe
AlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProVaiThrValAlaSerAsnLeuGln (SEQ ID NO:58l) -25- CZ 295843 B6
AlaAsnCysSerlIeMetlleAspGluIIelteHisHisLeuLysArgProProAlaProLeuLeuAspProAsnAsnLeuAsn
AspGluAspValSerlleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaVaJLysAsn
LeuGluAsnAlaSerGIyJIeGluAlalleLeuArgAsnLeuGInProCysLeuProSerAlaThrAlaAlaProSerArg
HisProIleílelleLysAlaGlyAspTipGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGInAlaGln GIuGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlIeAsnProSerProProSer
LysGluSerHisLysSerProAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrp
MetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheVaJThr
LysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGIuThrSerGlu
GlnLeuValAlaLeuLysProTrpUeThrArgGlnAsnPheSerArgCysLeuGluLeuGInCysGlnProAspSerSer
ThrLeuSerGJyGlyAsnGlySerGlyGlyAsnGlyThrGInAspCysSerPheGInHisSerProlleSerSerAspPhe
AlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGIn (SEQ ID NO:582)
AlaAsnCysSeríleMetlleAspGIuIlelleHisHisLeuLysArgProProAIaProLeuLeuAspProAsnAsnLeuAsn
AspGluAspValSerlleLeuMetAspArgAsnLeuArgLeuProAsnJLeuGluSerPheValArgAlaValLysAsn
LeuGluAsnAIaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAiaThrAlaAIaProSerArg
HisProllelleHeLysAlaGlyAspTipGlnGluPheArgGIuLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGln
GluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsttProSerProProSer
LysGluSerHisLysSerProAsnMetAlaSerLysMetGInGlyLeuLeuGluArgValAsnThrGluIleHisPheVal
ThrLysCysAlaPheGlnProProProSetCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGinGluThrSer
GluGluLeuValAlaLeuLysProTrpIJeThrArgGlnAsnPheSerArgCysLeuGluLeuGkiCysGInProAspSer
SerThrLeuSerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHisSerProlleSerSerAspPheAlaValLysIleArg
GluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGLnAspGluGluLeuCysGlyGly
LeuTrp ArgLeuValLeu AlaGlnArgT rpMetGluArgLeuLysThrV al AlaGly (SEQ ID NO:583); -26- CZ 295843 B6
AlaAsnCysSerlleMetlleAspGiuIlelleHisHÍsLeuLysArgProProAlaProLeuLeuAspProAsnAsnLeuAsn
AspGluAspValSerlleLeuMetAspArgAsnLeuArgLeuProAsnLeuGIuSerPheValArgAlaValLysAsn
LeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArg
HisProllellelleLysAlaGlyAspTrpGlnGluPheArgGhiLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGIn
GluGlnGbnTyrValGluGlyGlyGlyGIySerProGlyGluProSerGlyProIleSerThrHeAsnProSerProProSer
LysGluSerHisLysSerProAsnMetAlaSerLysMetGinGlyLeuLeuGhiArgValAsnThrGluIleHisPheVa]
ThrLysCysAlaPheGlnProProProSerCysl^uArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSer
GluGlnLeuValAiaLeuLysProTTpneThrArgGínAsnPheSerArgCysLeuGíuLeuGInCysGlnProAspSer
SerThrLeuSerGlyGlyAsnGlySerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHisSerProI]eSerSerAsp
PheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVaJAlaSerAsnLeuGlnAspGlu
GluLeuCysGlyGLyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGly (SEQ ID NO:584);
AlaAsnCysSerlleMetlleAspGMlelieHisHisLeuLysArgProProAlaProLeuLeuAspProAsnAsnLeu
AsnAspGluAspValSerlleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPbeValArgAlaValLys
AsjíLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAíaProSer
ArgHisProIlellelleLysAlaGlyAspTiipGlnGluPheArgGluLysLeuThrPheTyrLeuValTlirLeuGluGlnAla G InGluGlnGlnT yrV alGIuGlyGlyGlyGlySerProGlyGluProScrGlyProIleSerThrll eAsnProSerProPro
SerLysGluSerHisLysSerProAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeiiAlaGtnArg
TrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheVal
ThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSer
GluGlnLeuValAlaLeuLysProTrpI!eThrArgGlaA.snPheSerArgCysLeuGluLeuGlnCysGlnProAspSer
SerThrLeuSerGlyGlyAsnGíySerGlyGlyAsnGlySerGIyGlyAsnGlyThrGlnAspCysSerPheGlnHisSer
ProlleSerSerAspPheAlaValLysIleArgGIuLeuSerAspTyrlxuLeuGlnAspTyrProValThrValAlaSerAsn
LeuGln (SEQ ID NO:585); -27- CZ 295843 B6
AiaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaProLeuLeuAspProAsnAsnLeuAsn
AspGluAspValSerlleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsn
LeuGluAsnAlaSerGiylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArg
HisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGln
GluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSer
LysGluSerHisLysSerProAsnMetAlaProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGln
GluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGIn
ProAspSerSerThrLeuSerGlyGlyAsnGlyThrGlnAspCysSerPlieGlnHisSerProIleSerSerAspPheAla
ValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeu
CysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGln
GlyLeuLeuGluArgValAsnThrGIuIleHisPheValThrLysCysAlaPheGlnPro (SEQ ID NO:586);
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaProLeuLeuAspProAsnAsnLeu
AsuAspGiuAspValSerlleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLys
AsnLeuGluAsnAlaSerGlyneGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer
ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThfLeuGluGln
AlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsnProSerPro
ProSerLysGluSerHisLysSerProAsnMetAlaProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeu
LeuGlnGluThrSerGluGlnLeuValAIaLeuLysProTrpDeThrArgGlnAsnPheSerArgCysLeuGiuLeu
GlnCysGlnProAspSerSerThrLeuSerGIyGlyAsnGlySerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHis
SerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAia
SerAsnLeuGlnAspGluGIuLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLys
ThrValAlaGlySerLysMetGlnGlyLeuLeuGIuArgValAsnThrGIuOeHisPheValThrLysCysAlaPheGln
Pro (SEQEDNO:587); -28- CZ 295843 B6
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaProLeuLeuAspProAsnAsnLeu
AsnAspGluAspValSerlleLeuMetAspArgAsnLeaArgLeuProAsnLeuGluSerPheValArgAlaValLys
AsnLeuGluAsnAlaSerGlylleGluAlalIeLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer
ArgHisProIlellelleLysAlaGlyAspTrpGlnGIuPheArgGluLysLeuThrPheTyrLeuValTtirLeuGluGln
AlaGlnGfuGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsnProSerPro
ProSerLysGluSerHisLysSerProAsnMetAlaProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeu
LeuGlnGluThrSerG!uGIrLLeuValAlaLeuLysProTrpIleThrArgGInAsnPheSerArgCysLeuGluLeu
GlnCysGlnProAspSerSerThrLeuSerGlyGlyAsnGIySerGlyGIyAsnGIySerGlyGIyAsnGlyThrGlnAsp
CysSerPheGInHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSeaAspTyrLeuLeuGlnAspTyr
ProValThrValAlaSerAsnLeiiGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrp
MetGluArgLeuLysThrValAIaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThiGluIleHisPheVal
ThrLysCysAlaPheGlnPro (SEQIDNO:588);
AlaAspGluGluLeuCysGlyGtyLeuTrpArgLeuValLeuAlaGinArgTrpMetGluArgLeuLysThrValAla
GlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGIuIleHisPheVaiThrLysC^AIaPheGlnProProPro
SerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp
IleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSeTThrLeuGlyGlyGlySerGlyGiy
GlySerGlyGlyGlySerGlyGlyGlySerGiyGlyGlySerGIyThrGlnAspCysSerPheGlnHisSerProIleSerSer
AspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGInAspTyrProValThrValAlaSerAsnLeuGlnTyr
ValGIuGlyGlyGlyGlySerProGlyGlyGlySerGlyGlyGlySerAsnMetAlaThrProLeuGlyProAlaSerSer
LeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeaGlnGluLysLeu
CysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuScr
SerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeu
GlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeaAspThrLeuGlnLeuAspValAlaAspPheAlaThrThr
IleTrpGInGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAla
PheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGinSerPheLeuGluValSerTyrArgValLeuArgHÍs
LeuAlaGinPro (SEQ ID NO:743); -29- CZ 295843 B6
AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeu
GlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAla
GlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu[[eHis
PheValThrLysCysAlaPheGinProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGlu
ThrSerGluGlnLeuValAíaLeuLysProTipIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGInPro
AspSerSerThrLeuTyrValGluGIyGlyGlyGlySerProGlyGlyGlySerGlyGlyGIySerAsnMetAlaThrPro
LeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLcuGíuGinValArgLysIleGlnGlyAspGlyAla
AlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylle
ProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPhe
LeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProTlirLeuAspThrLeuGlnLeuAspVal
AlaAspPheAIaThrThrlleTrpGlnGInMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGInGlyAlaMet
ProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGJyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSer
TyrArgV alLeuArgHisLeuAlaGlnPro (SEQIDNO:659);
AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGly
AspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisPtoGluGIuLeuValLeuLeuGlyHis
SerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGinLeuAlaGlyCysLeuSerGlnLeuHis
SerGIyLeuPheLeuTyrGlnGiyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThLeu
GlnLeuAspValAlaAspPheAlaThrThrlIeTrpGinGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnPro
ThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGInSer
PheLeuGluValSerTyrArgValLeuATgHisLeuAlaGlnProTyrValGiuGlyGlyGlyGlySerProGlyGluPro
SerGlyProIleSerThrlleAsnProSerProProSerLysGIuSerHisLysSerProAsnMetAlaAspGluGluLeuCys GlyGlyLeuT rpArgLeu V alLeuAlaGlnArgTrpMetGlu ArgLeuLysThrV al A laGl ySerLysMetGlnGly
LeuLeuGluArgVaLAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheVal
GlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGinLeuValAlaLeuLysProTrpIleThrArgGlnAsnPhe
SerArgCysLeuGluLeuGlnCysGInProAspSerSerThrLeuGIyGlyGlySerGlyGlyGlySerGlyGlyGIySer
GlyGlyGlySerGlyGlyGlySetGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIle
ArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln (SEQ ID NO:705); -30- CZ 295843 B6
AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAJaGlnArgTrpMetGluArgLeuLysThrValAla
GlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProPR)
SerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp
IleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThiLeuGlyGlyGlySerGlyGly
GlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSer AspPheAlaValLysIleArgGluLeuSerAspT yrLeuLeuGlnAspTyrPro V aIThrV ai AI aS erAsnLeuGlnT yr ValGluGlyGlyGlyGlySerProGlyGlyGlySerGlyGlyGlySerAsnMetAlaThrProLeuGlyProAlaSerSer
LeuProGlnSerPheLeuLeuLysSerLeuGluGlnVaLArgLysIleGlnGlyAspGlyAlaAiaLeuGlnGluLysLeu
CysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSer
SerCysProSerGlnAIaLeuGlnLeuAlaGlyCysLeuSerGInLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeu
GlnAlaLeuGluGlyneSerProGluLeuGlyProThrLeuAspThrLeiiGlnLeuAspValAlaAspPheAIaThrThr
IleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGInGlyAlaMetProAlaPheAlaSerAla
PheGlnArgArgAIaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHÍs
LeuAlaGlnPro (SEQ ID NO:743) spojovník Lije polypeptid schopný připojení Ri k R2 v délce 4 až 500 aminokyselin vybraný ze skupiny sestávající z: (Gl/Ser)0 (SEQ ID NO:861); (GIy4Ser)n (SEQ ID N0:8Ó2); (Gl/Serf (SEQ ID NO:863); (Gl/Ser)" (SEQ ID NO:864); (AlaGlySer)" (SEQ ID NO:865);
GlyGlyGlySerGlyGlySerGlyGlyGlySerGIuGlyGlyGlySerGluGlyGlyGlySer GIuGlyGlyGlySerGIuGlyGlyGlyScrGlyGlyGlySer (SEQ ID NO:800); IleSeiGliiProSerGlyProSerGIyProIleSerThrlIeAsiiProSerProProProSerLysGluSerHis LysSerPro (SEQ ID NO:801);
IleGluGIyArglleSerGIuProSerGlyProIIeSerThrlleAsnProSerProProSerLysGluSerHis LysSerPro (SEQ ID NO:802); kde n je nezávisle celé číslo takové, aby celkový počet aminokyselin spojovníku L] byl 4 až 500 a -31 - 5 10 15 20 25 30 35 40 45 50 CZ 295843 B6 spojovník L2 je polypeptid vybraný ze skupiny sestávající z: Ser; Asn; Gly; Thr; GlySer; AlaAla; GlySerGly; GlyGlyGly; GlyAsnGly; GlyAlaGly; GlyThrGly; AlaSerAla; AlaAlaAla; GlyGlyGlySer GlyGlyGlySerGlyGlyGlySer GlyGlyGlySerGlyGlyGlySerGlyGlyGlySer SerGlyGlySerGlyGlySer GluPheGlyAsnMet GluPheGlyGlyAsnMet GluPheGlyGlyAsnGlyGlyAsnMet GlyGlySerAspMetAlaGly SerGlyGlyAsnGly SerGlyGlyAsnGlySerGlyGlyAsnGly SerGlyGlyAsnGlySerGlyGlyAsnGlySerGlyGlyAsnGly SerGlyGlySerGlySerGlyGlySerGly SerGlyGlySerGlySerGlyGlySerGlySerGlyGlySerGly (SEQ ID NO:778); (SEQ ID NO:779); (SEQ ID NO:780); (SEQIDNO:781); (SEQ ID NO:782); (SEQ IDNO:783); (SEQ ID NO:784); (SEQ ID NO:785); (SEQ ID NO:786); (SEQ ID NO:787); (SEQ ID NO:788); (SEQ ID NO:789); (SEQ ID NO:790); -32- 55 5 CZ 295843 B6
GlyGlyGlySerGlyGly
GlyGlyGlySerGlyGlyGly
GlyGlyGlySerGlyGlyGlySerGlyGly
GlyGlyGlySerGIyGlyGJySerGlyGlyGlySerGly
GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGly (SEQ ID NO:791); (SEQ ID NO:792); (SEQ ID NO:793); (SEQIDN0.794); (SEQ ID NO:795); 10
GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGIyGIyGlySerGlyGlyGlySerGIy (SEQ ID NO:796);
ProProProTrpSerProArgProLeuGlyAlaThrAlaProThrAIaGlyGlnProProLeu 15 (SEQ ID NO:797);
ProProProTrpSerProArgProLeuGlyAlaThrAlaProThr (SEQ ID NO:798); a
ValGluThrValPheHisArgValSerGlnAspGlyLeuLeuThrSer (SEQ IDNO:799); 20
Hematopoietický protein se připraví kultivací hostitelské buňky transformované nebo transfekto-vané replikovatelným vektorem obsahujícím molekulu nukleové kyseliny za vhodných nutričních podmínek způsobem dovolujícím expresi tohoto hematopoietického proteinu a izolaci tohoto hematopoietického proteinu. Dále se provede impulzová modulace těchto hematopoietických 25 progenitorových buněk nebo buněk CD34+ antigenem.
Molekula nukleové kyseliny kódující hematopoietický protein je vybraná ze skupiny stávající z:
GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACC
TTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAAC
CTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCAT
CAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCA
CCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAAC
TG ACGTTCT ATCTGGTT ACCCTTGAGC AAGCGC AGGAAC A AC AGT ACGT AGAGGGCGG
TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGT
CTAAAGAATCTCATAAATCTCCAAACATGGCCGACGAGGAGCTCTGCGGGGGCCTCTG
GCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAG
ATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGGCT
TTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAG
GAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC
GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCAGGCGGTAACGGCAG
TGGAGGTAATGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCGGACTTCG
CTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCC
TCCAACCTGCAG (SEQEDNO:12l); -33 - CZ 295843 B6
GCT AACTGCTCT AT AATGATCGATGAAATTAT AC ATCACTTAAAGAGACC ACCTGC ACC
TTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAAC
CTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCAT
CAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCA
CCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAAC
TGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG
TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAAGCCGTCTCCTCCGT
CTAAAGAATCTCATAAATCTCCAAACATGGCCGACGAGGAGCTCTGCGGGGGCCTCTG
GCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAG
ATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCT
TTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAG
GAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC
GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCTGGAGGTAACGGATC
CGGTGGCAATGGGAGCGGCGGAAATGGAACCCAGGACTGCTCCTTCCAACACAGCCCC
ATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTA
CCCAGTCACCGTGGCCTCCAACCTGCAG (SEQ ID NO: 122);
GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACC
TTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAAC
CTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCAT
CAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCA
CCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAAC
TGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG
TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGT
CTAAAGAATCTCATAAATCTCCAAACATGGCCTCCAAGATGCAAGGCTTGCTGGAGCG
CGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTC
TTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTG
GCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCA
GCCCGACTCCTCAACCCTGTCTGGCGGCAACGGCACGCAGGACTGCTCCTTCCAACAC
AGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCA
AGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTC
TGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGG (SEQ ID NO: 123); -34- CZ 295843 B6
GCT AACTGCTCT ATAATG ATCGATGAAATT AT AC ATC ACTT AAAG AGACC ACCTGCACC
TTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAAC
CTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCAT
CAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCA
CCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAAC
TGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG
TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGT
CTAAAGAATCTCATAAATCTCCAAACATGGCCTCCAAGATGCAAGGCTTGCTGGAGCG
CGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTC
TTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTG
GCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCA
GCCCGACTCCTCAACCCTGTCTGGAGGTAACGGATCCGGAGGTAATGGCACCCAGGAC
TGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTC
TGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAG
CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGA
CTGTCGCTGGG (SEQ ID NO: 124);
GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACC
TTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAAC
CTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCAT
CAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCA
CCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAAC
TGACGTT CT ATCTGGTTACCCTT G AGCAAGCGC AGG AAC A AC AGTACGT AG AGGGCGG
TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGT
CTAAAGAATCTCATAAATCTCCAAACATGGCCTCCAAGATGCAAGGCTTGCTGGAGCG
CGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTC
TTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTG
GCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCA
GCCCGACTCCTCAACCCTGTCTGGAGGTAACGGATCCGGTGGCAATGGGAGCGGCGGA
AATGGAACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAA
AATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACC
TGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGAT
GGAGCGGCTCAAGACTGTCGCTGGG (SEQIDNO:125); -35- CZ 295843 B6
GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACC
TTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAAC
CTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCAT
CAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCA
CCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAAC
TG ACGTTCTATCTGGTTACCCTTGAGCAAGCGC AGGAACAACAGT ACGT AG AGGGCGG
TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGT
CTAAAGAATCTCATAAATCTCCAAACATGGCCCCCCCCAGCTGTCTTCGCTTCGTCCAG
ACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCT
GGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCA
ACCCTGTCTGGCGGCAACGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTC
CGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCA
CCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCT
GGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTG
CTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCC (SEQIDNO:126);
GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACC
TTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAAC
CTTCGACTTCCAAACCTGGAGAGCTTCGT AAGGGCTGTCAAGAACTT AGAAAATGC AT
CAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCA
CCCTCTCGACAT CC AAT C ATC AT C AAGGC AGGTG ACT GGCA AGAATTCCGGGAAAAAC
TGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG
TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGT
CTAAAGAATCTCATAAATCTCCAAACATGGCCCCCCCCAGCTGTCTTCGCTTCGTCCAG
ACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCT
GGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCA
ACCCTGTCAGGCGGTAACGGCAGTGGAGGTAATGGCACCCAGGACTGCTCCTTCCAAC
ACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTT
CAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGAGCTCTGCGGGGGCCT
CTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCC
AAGATGCAAGGCTrGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTG
CCTTTCAGCCC (SEQ ID NO: 127); -36- CZ 295843 B6
GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACC
TTTGCTGGACCCG A ACAACCTCAATGACG AAGACGTCT CT ATCCTG AT GGACCGAAAC
CTTCGACTTCC AAACCT GG AGAGCTTCGT AAGGGCTGTCA AG AACTT AG AAAATGC AT
CAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCA
CCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAAC
TGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG
TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGT
CTAAAGAATCTCATAAATCTCCAAACATGGCCCCCCCCAGCTGTCTTCGCTTCGTCCAG
ACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCT
GGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCA
ACCCTGTCTGGAGGTAACGGCAGTGGTGGTAATGGGAGCGGCGGAAATGGAACCCAG
GACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCT
GTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGG
AGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAA
GACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACAC
TTTGTCACCAAATGTGCCTTTCAGCCC (SEQIDNO:128);
GCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGG
AGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACAC
GGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCG
TCCAGACCAACATCTCCCGCCTCCTGCAGGAGAeCTCCGAGCAGCTGGTGGCGTGAAG
CCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTC
CTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGGGTGGCICAG
GGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTC
GCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGC
CTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGGTGGTTCTGGCGGC
GGCTCCAACATGGCTACACCATTGGGCCCTGCCAGCTCCCTGCCCAGAGCTTCCTGCTC
AAGTCTTTAGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAG
CTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCT
GGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGC
TGCTTGAGCCAACTCCATAGCGGCCmTCCTCTACCAGGGGCTCCTGCAGGCCCTGGA
AGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGAC
TTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGC
CCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGT -37- CZ 295843 B6
CCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACC
TTGCGCAGCCG (SEQIDNO:282);
GGCCACTCAGGACTGCTCTTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAA
TCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTG
CAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGATGGA
GCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGACACGG
AGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCC
AGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCC
CTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCT
CAACCCTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGGTGGTTCTGGCGGCGGCTC
CAACATGGCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGT
CTTTAGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGT
GTGCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGC
ATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCTGGCAGGCTGCTTGAG
CCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCGCAGGCCCTGGAAGGGATATC
CCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCA
CCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGG
TGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTA
GCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCG (SEQIDNO:198);
GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAGA
GCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCACC
TACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTG
GGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAA
CTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCC
CGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTGCCACCACCA
TCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGC
CATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCC
ATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCCTAC
GTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACC
CGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGATGAAGAACTGTGT
GGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCG
CTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCAC
CAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCC -38- CZ 295843 B6
GCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCA
GAACTTCTCCCGGTGCCTGGAGGTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTG
GGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTA
CCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGT
GAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG (SEQ ID NO:244);
GCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGG
AGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACAC
GGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCG
TCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAA
GCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACT
CCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGGGTGGCTCA
GGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTT
CGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGG
CCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGGTGGTTCTGGCGG
CGGCTCCAACATGGCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGC tcaagtctttagagcaagtgagaaagatccagggcgatggcgcagcgctccaggaga
AGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCT
CTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAG
GCTGCITGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTG
GAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCG
ACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCA
GCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGG
GTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCA
CCTTGCGC AGCCG (SEQ Π> NO:282)
Hematopoietický protein se u pacienta použije s antigenem a/nebo s jedním nebo více faktory 5 vybranými ze skupiny sestávající z GM-CSF, IL-4, TNF-α, faktoru kmenových buněk (SCF), fit—3 ligandu, IL-3, IL-3 varianty, fúzního proteinu IL-3 varianty a multifunkčního receptoro-vého agonisty.
Hematopoietický protein je možné využít pro zvýšení tvorby krvetvorných buněk, kde krvetvorné 10 buňky jsou CD34+ buňky, buňky periferní krve, pro selektivní ex vivo expanzi krvetvorných buněk, pro léčení pacienta majícího krvetvornou poruchu, pro použití při lidské genové terapii, pro léčení člověka s tumorem, infekcí nebo auto-imunitní onemocnění.
Farmaceutická kompozice obsahuje hematopoietický protein a farmaceuticky přijatelný nosič. Výhodná místa zlomu, u kterých lze připravit nový N-konec a N-konec v polypeptidu (I) shora, jsou: 23-24, 24-25, 25-26, 27-28, 28-29, 29-30, 30-32, 31-32, 32-33, 33-34, 34-35, 35-36, -39- 15 CZ 295843 B6 36-37, 37-38, 38-39, 40-41, 4W2, 42-43, 52-53, 53-54, 54-55, 55-56, 77-78, 78-79, 79-80, 80-81, 81-82, 82-83, 83-84, 84-85, 85-86, 86-87, 109-110, 110-111, 110-111,111-112,112-113, 113-114, 114-115, 115-116, 116-117, 117-118, 118-119, 119-120, 120-121, 121-122, 122-123, 123-124, 124-125, 125-126, 126-127, 127-128, 128-129, 129-130, 130-131 a 131— 5 132.
Nej lepší místa zlomu, u kterých lze připravit nový N-konec a N-konec v polypeptidu (I) shora, jsou: 23-24, 24-25, 31-32, 32-33, 37-38, 38-39, 82-83, 83-84, 85-86, 86-87, 87-88, 125-126, 126-127 a 131-132. 10 15
Agonisté receptoru EPO podle tohoto vynálezu mohou obsahovat substituce amino kyselin, jak je popisuje WO 94/24160, nebo jedno či více míst glykosylace u Asn24, Asn83 a Asn12 jsou zaměněna na jiné amino kyseliny, jako jsou, nikoliv však omezeně, Asp nebo Glu, delece a inzerce. Také se zamýšlí, aby agonisty receptoru EPO tohoto vynálezu mohly mít delece amino kyselin buď u jednoho nebo obou N- a C-konců originálního proteinu a nebo delece od nových N- a C-konců sekvence reorganizovaných proteinů ve vzorcích ukázaných shora. Výhodnější místa zlomu, u kterých lze připravit nový N-konec a N-konec v polypeptidu (II) shora, jsou: 23-24, 24-25, 25-26, 33-34, 34-35, 35-36, 36-37, 38-39, 39-40, 40-41, 64-65, 20 65-66, 66-67, 67-68, 68-69, 69-70, 70-71, 89-90, 90-91, 91-92, 92-93, 93-94, 94-95, 95-96, 96-97, 97-98, 98-99, 99-100, 100-101, 101-102, 102-103, 103-104, 104-105 a 105-106.
Nej lepší místa zlomu, u kterých lze připravit nový N-konec a N-konec v polypeptidu (II) shora, jsou: 64-65, 65-66,92-93 a 93-94. Výhodná místa zlomu, u kterých lze připravit nový N-konec a N-konec v polypeptidu (III) shora, jsou: 36-37, 37-38, 39-40, 41-42, 42-43, 64-65, 65-66, 66-67, 86-87, 87-88, 88-89, 89-90, 90-91, 91-92, 92-93, 93-94, 94-95, 95-96, 96-97, 97-98, 98-99,99-100 a 100-101. 30 Nejlepší místa zlomu, u kterých lze připravit nový N-konec a N-konec v polypeptidu (III) shora, jsou: 39-40, 65-66,89-90,99-100 a 100-101. Výhodná místa zlomu, u kterých lze připravit nový N-konec a N-konec v polypeptidu (IV) shora, jsou: 38-39, 39-40, 40-41, 41^12, 48^19, 53-54, 54-55, 55-56, 56-57, 57-58, 58-59, 35 59-60, 60-61, 61-62, 62-63, 64-65, 65-66, 66-67, 67-68, 68-69, 69-70, 96-97, 125-126, 126-127, 127-128, 128-129, 129-130, 130-131, 131-132, 132-133, 133-134, 134-135, 135-136, 136-137, 137-138, 138-139, 139-140, 140-141 a 141-142.
Nejlepší místa zlomu, u kterých lze připravit nový N-konec a N-konec v polypeptidu (IV) shora, 40 jsou: 38-39, 48^19, 96-97, 125-126, 132-133 a 141-142. Výhodná místa zlomu, u kterých lze připravit nový N-konec a N-konec v polypeptidu (V) shora, jsou: 28-29, 29-30, 30-31, 31-32, 32-33, 33-34, 34-35, 35-36, 36-37, 37-38, 38-39, 39-40, 66-67, 67-68, 68-69, 69-70, 70-71, 84-85, 85-86, 86-87, 87-88, 88-89, 89-90, 90-91, 98-99, 45 99-100, 100-101 a 101-102.
Nej lepší místa zlomu, u kterých lze připravit nový N-konec a N-konec v polypeptidu (V) shora, jsou: 34-35, 69-70 a 90-91. 50 Výhodná místa zlomu, u kterých lze připravit nový N-konec a N-konec v polypeptidu (VI) shora, jsou: 80-81, 81-82, 82-83, 83-84, 84-85, 85-86, 86-87, 108-109, 109-110, 110-111, 111-112, 112-113, 113-114, 114-115, 115-116, 116-117, 117-118, 118-119, 119-120, 120-121, 121-122, 122-123, 123-124, 124-125, 125-126 a 126-127. -40- CZ 295843 B6
Nejlepší místa zlomu, u kterých lze připravit nový N-konec a N-konec v polypeptidu (V) shora, jsou: 81-82,108-109,115-116, 119-120,122-123 a 125-126.
Multi-funkční agonisty receptoru tohoto vynálezu mohou být představeny následujícími vzorci: 5 (T,)a-(L,)b-X1-(L)c-X2-{L2)d-(T2)e nebo io X]-(L)c-X2-(L)-Y |-(L)c-Y2, kde X! je peptid, který obsahuje sekvenci amino kyselin odpovídající sekvenci zbytků n+1 až J 15 originálního proteinu, mající zbytky amino kyselin až J s amino koncem u zbytku 1, L je případný spojovník, X2 je peptid, který obsahuje sekvenci amino kyselin zbytku 1 až n originálního proteinu; 20 Y] je peptid, který obsahuje sekvenci amino kyselin odpovídající sekvenci zbytků n=l až K originálního proteinu, mající zbytky amino kyselin číslované postupně 1 až K s amino koncem u zbytku 1; 25 Y2 je peptid, který obsahuje sekvenci amino kyselin odpovídající sekvenci zbytků 1 až n originálního proteinu;
Li a L2 jsou případné peptidové mezerníky: 30 n je celé číslo v rozmezí od 1 do J—1; b, c, a d jsou každé nezávisle 0 nebo 1; a a e jsou buď 0 nebo 1 s výhradou, že a a e nemohou být oba 0; a 35 T] aT2 jsou proteiny.
Multi-funkční chimérní agonisty hematopoietických receptorů tohoto vynálezu mohou obsahovat substituce, delece a/nebo inzerce amino kyselin v individuálních proteinových komponentách 40 chimérní molekuly. Také se zamýšlí, aby multi-funkční chimérní agonisty hematopoietických receptorů tohoto vynálezu mohly mít delece amino kyselin buď u jednoho nebo obou N- a C-konců originálního proteinu a nebo delece od nových N- a C-konců sekvence reorganizovaných proteinů ve vzorcích ukázaných shora. 45 Mimo to se tento vynález týká rekombinantních vektorů exprese obsahujících nukleotidové sekvence kódující multi-funkční chimérní agonisty hematopoietických receptorů, příbuzné mikrobiální systémy exprese a procesů přípravy multi-funkčních chimémích agonistů hematopoietických receptorů. Vynález se také týká farmaceutických kompozic obsahujících multi-funkční chimérní agonisty hematopoietických receptorů a metod použití multi-funkčních 50 chimérních agonistů hematopoietických receptorů.
Vedle použití multi-funkčních chimémích agonistů hematopoietických receptorů tohoto vynálezu in vivo se předpokládá, že použití in vitro by zahrnovaly schopnost stimulovat kostní dřeň a aktivaci a růst buněk krve před infuzí pacientům. Jiným zamýšleným použitím je produkce 55 dendritických buněk jak in vivo tak ex vivo. -41 - CZ 295843 B6
Dendritické buňky se připraví oddělením hematopoietických progenitorových buněk nebo buněk CD34+ od ostatních buněk, načež se provede kultivace těchto hematopoietických progenitorových buněk nebo buněk CD34+ v kultivačním médiu obsahujícím hematopoietický protein, 5 jeden či více faktorů vybraných ze skupiny sestávající z GM-CSF, IL-4, TNF-α, faktoru kmenových buněk (SCF), fit—3 ligandu, IL-3, IL-3 varianty, fúzního proteinu IL-3 varianty a multifunkčního receptorového agonisty. Předpokládá se, že snížená afinita spojených proteinů je působena, alespoň z části, neschopností ío individuálních skupin dosáhnout svou nativní konformaci, když jsou zapojeny do chimémí molekuly nebo do stérické zábrany mezi aktivním místem individuálních skupin spojeného proteinu. Vynález překonává tato omezení zabezpečením nových multi-funkčních chimérních agonistů hematopoietických receptorů, které mají vazebnou afinitu srovnatelnou nebo větší než individuální složky chimémí molekuly. 15
Tento vynález zahrnuje multi-funkční agonisty hematopoietického receptorů tvořené z kovalentně spojených polypeptidů, z nichž každý může působit přes různý a specifický buněčný receptor, aby inicioval komplementární biologické aktivity. Hematopoezie vyžaduje složitou sérii buněčných příhod, při kterých kmenové buňky přecházejí kontinuálně do velkých populací 20 zrajících buněk ve všech hlavních liniích. Dosud je známo alespoň 20 regulátorů s hemato-poietickou o proliferační aktivitou. Většina z těchto proliferačních regulátorů může stimulovat jeden či jiný typ tvorby kolonií in vitro, přesný vzor tvorby kolonií stimulovaný každým regulátorem je zcela odlišný. Žádné dva regulátory nestimulují přesně stejným vzorem tvorby kolonie, jak se vyhodnocuje podle počtu kolonií, nebo důležitěji podle vzoru linií a dozrávání 25 buněk tvořících vyvíjející se kolonie. Proliferační odpovědi lze nejsnáze analyzovat ve zjednodušených in vitro kultivačních soustavách. Lze rozlišit tři zcela různé parametry, změny velikosti kolonie, změny počtu kolonií a linií buněk. Na rodičovské buňky mohou působit dva či více faktorů, což indukuje tvorbu většího počtu rodičovských buněk, což zvětšuje velikost kolonie. Dva či více faktorů může dovolit proliferaci většího počtu rodičovských buněk, protože 30 existují buď odlišné podmnožiny rodičovských buněk, které odpovídají pouze jednomu faktoru, nebo protože rodičovské buňky vyžadují stimulaci dvěma či více faktory před tím, než jsou schopny odpovědi. Kolonie stimulující faktory zahrnují GM-CSF, G-CSF, G-CSF Ser17, G-CSF Ala17, c-mpl ligandu (TPO), M-CSF, erythropoietinu (EPO), IL-1, IL-4, IL-2, IL-3, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, LIF, flt3/flk2 ligandu, lidského 35 růstového hormonu, růstového faktoru B-buněk, faktoru diferenciace B-buněk, faktoru diferenciace eosinofilů a faktoru kmenových buněk (SCF). Aktivita dalších receptorů v buňce použitím dvou či více faktorů může zvýšit mitotický signál, protože dojde ke koalescenci z počátku se lišících signálních cest do společné konečné cesty dostihujících jádro (Metcalf, Nátuře 339-27, 1989). Synergii by mohly vysvětlit jiné mechanismy. Například pokud jedna 40 signální cesta je omezena meziaktivací další signální cesty způsobenou druhým faktorem, může to vést k superaditivní odpovědi. V některých případech aktivace jednoho receptomího typu může vést k zvýšené expresi jiných receptorů (Metcalf, Blood 82:3515-3523, 1993). Dva či více faktorů mohou vést kjiným vzorům linií buněk než jeden faktor. Použití multi-funkčních chimérních agonistů hematopoietického receptorů může mít potenciální klinickou výhodu 45 vyplývající z proliferační odpovědi, která není možná u jediného faktoru.
Receptory hematopoietických a jiných růstových faktorů lze seskupit do dvou odlišných rodin příbuzných proteinů: 1) receptory tyrosin kinázy včetně těch pro růstový faktor epidermu, M-CSF (Sherr, Blood 75:1, 1990), a SCF (Yarden a kol., EMBO J. 6:3341, 1987) a 2) krvetvorné 50 receptory neobsahující doménu tyrosin kinázy, ale vykazující zřejmou podobu vjejich mimo-buněčné doméně (Bazan, PNAS USA 87:6934-6938, 1990). Do této skupiny jsou zahrnuty erythropoietin (EPO, D°Andrea a kol., Cell 57.277, 1989), GM-CSF (Gearing a kol., EMBO J. 8:3667, 1989), IL-3 (Kitamura a kol., Cell 66:1165, 1991), G-CSF (Fukunaga a kol. J. Bio. Chem. 265-14008-15, 1990), IL-4 (Harada a kol., PNAS USA 87:857, 1990, IL-5 (Takaki a kol., 55 EMBO J. 9:4367, 1990), IL-6 (Yamasaki a kol., Science 241:825, 1988), IL-7 (Goodwin a kol. -42- CZ 295843 B6
Cell 60:941-51, 1990), UF (Gearing a kol., EMBO J. 10:2839, 1991), a IL-2 (Cosman a kol., AíoZ-Immunol. 23: 935-94, 1986). Většina z poslední skupiny receptorů existuje ve vysoce afmitní formě jako heterodimery. Po vazbě ligandů specifické alfa-řetězce se asociují alespoň s jedním jiným receptorovým řetězcem (beta-řetězec, gama-řetězec). Mnoho z těchto receptorů 5 má společnou receptorovou podjednotku. Alfa-řetězce pro GM-CSF, IL-3 a IL-5 mají společný stejný beta-řetězec (Kitamura a kol., Cell 66:1165, 1991), Takaki a kol., EMBO J. 10:2833-8, 1991) a receptorové komplexy pro IL-6, LIF a IL-11 mají společný beta-řetězec (Taga a kol., Cell 58:573-81, 1989, Gearing a kol., Science 255:1434-7, 1992). Receptorové komplexy pro IL-2, IL-4 a IL-7, IL-9 a IL-15 mají společný beta-řetězec (Kondo aj., Science 262:1874, 1993, 10 Russel a kol., Science 266: 1042-1045, 1993, Noguchi a j., Science 262:1877, 1993; Giri a kol., EMBOJ. 13:2822-2830, 1994).
Použití vícenásobně působícího hematopoietického faktoru může mít také potenciální výhodu ve snížení požadavků na buňky produkující faktory a jejich indukční soustavy. Pokud existují ome-15 zení ve schopnosti buňky produkovat faktor, potom snížení požadovaných koncentrací každého faktoru při jejich použití v kombinaci může užitečně snížit požadavky na buňky produkující faktory. Použití vícenásobně působícího hematopoietického faktoru může snížit množství faktorů, které by byly potřeba, a pravděpodobně snížit možnost nepříznivých vedlejších účinků. 20 Nové sloučeniny tohoto vynálezu jsou představeny vzorci vybranými ze skupiny tvořené:
Ri—L]—R2, R2—Li—Ri, R]—R2, a R2—Ri kde R) a R2 jsou jak byly definovány shora. 25 R2 je preferovaně faktor stimulující kolonie s jinou, ale komplementární aktivitou k Ri. Komplementární aktivitou se rozumí aktivita, která zvyšuje nebo mění odpověď na jiný buněčný modulátor. Rt polypeptid je spojený k R2 polypeptidu buď přímo nebo přes spojovník. Výraz „přímo“ definuje multi-funkční chimémí agonisty hematopoietického receptorů, ve kterých 30 polypeptidy jsou spojené bez peptidického spojovacího členu. Tedy Lj představuje chemickou vazbu nebo segment polypeptidu, ke kterému jsou jak R] tak R2 spojeny v rámci. Neobvykleji Li je lineární peptid, ke kterému jsou jak Rj tak R2 spojeny amidovými vazbami spojujícími karboxylový konec Ri na aminový konec Li a karboxylový konec Li na aminový konec R2. „Spojeny v rámci“ znamená že nedochází k translační terminaci nebo zlomu mezí čtecími rámci 35 R| a R2.
Neúplný seznam jiných růstových faktorů, například kolonie stimulujících faktorů (CSF), jako jsou cytokiny, lymfokiny, interleukiny, krvetvorné růstové faktory, které lze spojit k (I), (II), nebo (III), zahrnují GM-CSF, G-CSF, c-mpl ligand (také známé jako TPO nebo MCSF), M-40 CSF, erythropoietin (EPO), IL-1, IL-4, IL-2, IL-3, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL—13, IL-15, LIF, flt3/flk2 ligand, lidský růstový hormon, faktor diferenciace B-buněk, faktor diferenciace eosinofilů a faktor kmenových buněk (SCF), také známý jako ocelový faktor nebo c-kit ligand. Mimo to vynález zahrnuje použití modifikovaných molekul R] nebo R2 nebo mutovaných či modifikovaných DNA řetězců kódujících tyto molekuly Ri nebo R2. Tento 45 vynález také zahrnuje multi-funkční chimémí agonisty hematopoietického receptorů, ve kterých Ri nebo R2 je hIL-3 variant, variant c-mpl ligandu nebo variant G-CSF. „hIL-3 varianť1 je definován jako hIL-3 molekula, ve kterém jsou substituce amino kyselin anebo vypuštěné části hIL-3, jak popisuje WO 94/12638, WO 94/12639 a WO 95/00646, jakož i jiné varianty známé v oboru. „Variant c-mpl Iigandu“ je definován jako molekula c-mpl ligandu, ve které jsou 50 substituce amino kyselin anebo vypuštěné části c-mpl ligandu, jak popisuje US přihláška 08/383,035, jakož i jiné varianty známé v oboru. „Variant G-CSF“ je definován jako molekula G-CSF, ve které jsou substituce amino kyselin anebo vypuštěné části G-CSF, jak se zde popisuje, jakož i jiné varianty známé v oboru. -43- CZ 295843 B6
Vedle seznamu multi-funkčních chimérních agonistů hematopoietických receptorů shora, IL—3 varianty popsané v WO 94/12639 a WO 94/12638, agonisty G-CSF receptorů popsané v WO 97/12977, agonisty c-mpl receptorů popsané v WO 97/12978, agonisty IL-3 receptorů popsané v WO 97/12979 mohou být R1 nebo R2 tohoto vynálezu. Jak se zde používá, „IL-3 varianty'4 se 5 týká variant IL-3, které se uvádějí v WO 94/12639 a WO 94/12638. Jak se zde používá, „spojené proteiny" se týká spojených proteinů, které se uvádějí v WO 95/21197 a 95/21254. Jak se zde používá, „G-CSF agonisty receptorů" se týká G-CSF agonistů receptorů, které se popisují v WO 97/12978. Jak se zde používá, „c-mpl agonisty receptorů" se týká c-mpl agonistů receptorů, které se popisují v WO 97/12978. Jak se zde používá", IL-3 agonisty receptorů" se týká IL-3 10 agonistů receptorů, které se popisují v WO 97/12979. Jak se zde používá, „multifunkční agonisty receptorů" se týká multifunkčních agonistů receptorů, které se popisují v WO 97/12985.
Spojovník (Li) je obecně polypeptid s délkou 1 až 500 aminokyselin. Spojovníky spojující dvě molekuly jsou s výhodou navrženy tak, aby (1) dovolily dvěma molekulám se složit a působit na 15 sobě nezávisle, (2) neměly tendenci tvořit uspořádanou sekundární strukturu, která by mohla reagovat s funkčními doménami dvou proteinů, (3) měly minimální hydrofobní charakteristiku, která by mohla reagovat s funkčními doménami proteinů a (4) zajistily stérické oddělení R| a R2 tak, aby Rj a R2 mohly reagovat současně se svými odpovídajícími receptory v jedné buňce. Typicky povrchové aminokyseliny v ohebných oblastech proteinů zahrnují Gly, Asn a Ser. Lze 20 očekávat, že podstatě jakákoliv permutace řetězce aminokyselin obsahující Gly, Asn a Ser by měly vyhovět shora daným kritériím pro řetězce spojovníků. Jiné neutrální aminokyseliny, jako je Thr a Ala, lze rovněž použít v řetězci spojovníku. Další aminokyseliny lze rovněž zařadit do spojovníků k dodání jednotlivých míst restrikce v řetězci spojovníku, aby se usnadnila konstrukce multi-funkčních chimérních agonistů hematopoietických receptorů. 25 Výhodné spojovníky Li tohoto vynálezu zahrnují řetězce vybrané ze skupiny vzorců: (Gly3Ser)n (SEQ ID NO:861), (Gly4Ser)n (SEQ ID NO:862), (Gly5Ser)n (SEQ ID NO:863), (GlynSer)n (SEQ ID NO:864), (GlySer)n nebo (AlaGlySer)n (SEQ ID NO:865). 30 Jedním příkladem vysoce ohebného spojovníku je oblast bohatá na glycin a serin přítomná v plil proteinu vláknitých bakteriofágů, například bakteriofágů Ml3 nebo fd (Schaller a kol., PNAS USA 72: 737-741, 1975). Tato oblast dává dlouhou ohebnou spojovací oblast mezi dvěma doménami plil povrchového proteinu. Spojovací oblasti se skládají z řetězce aminokyselin:
GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGluGlyGlyGlySerGlu
GlyGlyGlySerGluGlyGlyGlySerGIuGlyGlyGIySerGlyGlyGlySer (SEQ ID NO:800). 35
Tento vynález také zahrnuje spojovací členy, ve kterých jsou začleněny řetězce rozpoznávání endopeptidázy. Taková místa štěpení mohou mít cenu při dělení jednotlivých složek multi-funkčních chimérních agonistů hematopoietických receptorů, aby se zjistilo, zda jsou dobře 40 složeny a jsou aktivní in vitro. Příklady různých endopeptidáz zahrnují, ale ne omezeně, plazmin, enterokinázu, kallikrein, urokinázu, aktivátor tkáňového plazminogenu, clostripain, chymosin, collagenázu, Russelovu zmijí proteázu, enzym štěpení postprolinu, V8 proteázu, trombin a faktor Xa. 45 Segmenty peptidového spojovníku z kloubové oblasti těžkých řetězových imunoglobulinů IgG, IgA, IgM, IdG nebo IgE dávají úhlový vztah mezi spojenými polypeptidy. Zvlášť užitečné jsou ty kloubové oblasti, ve kterých jsou cysteiny nahrazeny šeřiny. Preferované spojovníky tohoto -44- CZ 295843 B6 vynálezu zahrnují řetězce odvozené z myší IgG gama 2b kloubové oblasti, ve které jsou cysteiny nahrazeny šeřiny. Tyto spojovací členy také mohou zahrnovat místa štěpení endopeptidázou. Příklady takových spojovníků zahrnují následující řetězce:
IleSerGluProSerGlyProIleSerThrlieAsnProSerProProSerLys GluSerHisLysSerPro (SEQ ID NO:801) a
IleGluGlyArglleSerGluProSerGlyProIleSerThrlIeAsnProSer ProProSerLysGluSerHisLysSerPro (SEQ ID NO:802). 5
Tento vynález však není omezen formou, velikostí nebo počtem použitých řetězců spojovníků a jediným požadavkem na spojovník je, aby funkčnost nevadila skládání a s funkcí jednotlivých molekul multi-funkčního chimérního agonistu hematopoietických receptorů. 10
Stanovení spojovníku L2 Délka sekvence amino kyselin spojovníku se může vybrat empiricky nebo s ohledem na strukturní informaci nebo s použitím kombinace obou přístupů. 15
Když není dostupná žádná strukturní informace, může se připravit malá série spojovníků pro testování s použitím designu jehož délka se mění, aby přesáhl rozpětí od 0 do 50 cm'8 a jejichž sekvence se vybere, aby byla konsistentní s povrchovou expozicí (hydrofilnost, Hopp a Woods, Mol, Immunol, 20: 483-489 (1993), Kyte a Doolittle, J. Mol. Biol., 157: 105-132 (1982)), povrch 20 exponovaný rozpouštědlu (Lee a Richards, J. Mol. Biol., 55: 379-400 (1971)) a schopnost zaujmout potřebnou konformaci bez rozbití konfigurace agonistu receptorů EPO (konformačně ohebný Karplus a Schulz, Neurwissenschaften 72: 212-213 (1985). Předpokládaje průměrnou translaci 2,0 až 3,8 10'8 na zbytek by to znamenalo, že délka ke zkoušení by byla mezi 0 až 30 zbytky s preferovaným rozmezím mezi 0 až 15 zbytky. Příkladem pro takovou empirickou sérii 25 by byla konstrukce spojovníků s pomocí kazetové sekvence Gly-Gly-Gly-Ser opakované n krát, kde n je 1, 2, 3 nebo 4. Odborníci poznají, že existuje mnoho takových sekvencí, které se liší délkou nebo sloužením, které mohou sloužit jako spojovníky s prvotním ohledem, aby nebyly příliš dlouhé nebo krátké (srovnej Sandhu, Critical Rev. Biotech. 12: 437-452 (1992)). Pokud jsou příliš dlouhé, entropické účinky by asi destabilizovaly troj-rozměmé složení a také by 30 mohly učinit skládání kineticky nepraktické, a pokud jsou příliš krátké, budou asi destabilizovat molekulu pro torsní a stérické pnutí.
Odborníci na analýzu strukturní informace proteinů poznají, že s využitím vzdálenosti mezi konci řetězce, definované jako vzdálenost mezi c-alfa uhlíky, se může definovat délka řetězce, který se 35 má použít, nebo alespoň omezit počet možností, které se musí testovat při empirickém výběru spojovníků. Také poznají, že v některých případech jsou polohy konců polypeptidu špatně definované ve strukturních modelech odvozených zdifrakce X-paprsků nebo ze spektroskopických údajů nukleární magnetické rezonance. Pokud je to pravda, musí se brát zřetel na tuto situaci, aby se správně určila délka potřebného spojovníku. Z těch zbytků, jejichž polohy jsou 40 dobře definované, se vyberou dva zbytky, které jsou v sekvenci blízko ke koncům řetězce a vzdálenost mezi jejich c-alfa uhlíky se využije k výpočtu přibližné délky spojovníku mezi nimi. S využitím vypočtené délky se pak vyberou spojovníky s rozmezím počtu zbytků (vypočtené s využitím 2,0 až 3,8 10"8 na zbytek). Tyto spojovníky se mohou komponovat s původní sekvencí, podle potřeby zkrátit nebo prodloužit. Když se prodlužují, další zbytky se mohou vybrat, aby 45 byly ohebné nebo hydrofilní, jak se popisuje shora, nebo případně se původní sekvence může substituovat s použitím série spojovníků, jeden například je kazetový přístup „Gly-Gly-Gly-Ser“ -45- CZ 295843 B6 zmíněný shora nebo se případně může použít kombinace původní sekvence a nové sekvence mající přibližnou celkovou délku.
Stanovení aminových a karboxylových konců Ri a R2 5
Sekvence R| a R2 schopná se skládat do biologicky aktivních stavů se může připravit vhodným výběrem poloh počátku (aminový konec) a konce (karboxylový konec) z původního řetězce polypeptidu s použitím sekvence spojovníku L2, jak se popisuje shora. Aminové a karboxylové konce se vyberou v rozmezí obecného rozpětí sekvence uváděného jako oblast místa zlomu 10 s použitím směrnic, jak se popisují níže. Nová sekvence amino kyselin se tak vytvoří výběrem aminových a karboxylových konců v rozmezí stejné oblasti místa zlomu. V mnoha případech výběr nových konců bude takový, aby původní poloha karboxylového konce bezprostředně předcházela aminovému konci. Avšak odborníci poznají, že výběry konců kdekoliv uvnitř oblasti mohou fungovat a že povedou efektivně bud’ k delecím nebo adicím aminových nebo karboxy-15 lových částí nové sekvence. Ústředním dogmatem molekulární biologie je to, že primární sekvence amino kyselin proteinu diktuje skládání do troj-rozměmé struktury potřebné pro expresi jeho biologické funkce. Odborníkům jsou známé způsoby, jak získat roj-rozměmou strukturní informaci s využitím difrakce X— 20 paprsků jednotlivých krystalů proteinu nebo nukleární magnetické resonanční spektroskopie roztoků proteinu. Příklady strukturní informace, která je relevantní k identifikaci oblastí míst zlomu zahrnují lokaci a typ sekundární struktury proteinu (alfa a 3-10 šroubovnice, paralelní anti-paralelní beta vrstvy, zvraty a obraty a smyčky (Kabsch a Sander, Biopolymers, 22: 2577-2637 (1983)), stupeň vystavení zbytků amino kyselin rozpouštědlu, rozsah a typ interakcí zbytků 25 mezi sebou (Choyhia, Ann. Rev. Biochem. 53: 537-572 (1984)) a statické a dynamické rozdělení konformací podél řetězce polypeptidu (Alber a Methews, Methods Enzymol. 154: 511-533 (1987)). V některých případech je známá další informace o vystavení zbytků rozpouštědlu, jedním případem je místo potranslačního spojení uhlovodíku, které je nutně na povrchu proteinu. Když není dostupná experimentální strukturní informace, nebo se nemůže získat, jsou též 30 dostupné způsoby, jak analyzovat primární sekvenci amino kyselin, aby se mohly předpovědět terciární a sekundární struktury proteinu, přístupnost rozpouštědlu a výskyt obratů a smyček. Někdy lze aplikovat pro empirické stanovení vystavení povrchu biochemické metody, když nejsou uskutečnitelné přímé strukturní metody, například s využitím identifikace míst štěpení řetězce po omezené proteolýze, aby se zjistilo vystavení povrchu (Gentile a Salvátore, Eur. J. 35 Biochem. 218: 603-621 (1993)).
Tak s použitím buď experimentálně odvozené strukturní informace nebo způsobů predikce (například Srisnivisan a Rose, Proteins: Struct. Funct. and Genetics: 22 81-99 (1995)) se pohlédne původní sekvence amino kyselin, aby se klasifikovaly oblasti podle toho, jsou nebo 40 nejsou integrální pro udržení sekundární a terciární struktury. Výskyt sekvencí s oblastmi, o nichž je známo, že se účastní periodické sekundární struktury (alfa a 3-10 šroubovice, paralelní a antiparalelní beta vrstvy) jsou oblasti, které je nutné se vyhnout. Podobně oblasti sekvence amino kyselin, u nichž se pozorovalo nebo předpovědělo, že mají nízký stupeň vystavení rozpouštědlu, jsou pravděpodobněji částí tak zvaného hydrofobního jádra proteinu a mělo by se 45 jim také vyhnout při výběru. Naproti tomu oblasti, o kterých je známo nebo předpověděno, že jsou na povrchu obratů nebo smyček a zvláště ty oblasti, o kterých je známo, že nejsou potřebné pro biologickou aktivitu, jsou preferovaná místa pro umístění extrémů řetězce polypeptidu. Kontinuální kusy sekvence amino kyselin, kterým se dává přednost na základě kritérií shora se uvádějí jako oblasti míst zlomu. 50
Aby se usnadnilo čistění nebo identifikace multi-funkčního chimérního agonistu hemato-poietických receptorů proteinů, lze též přidat další peptidové sekvence (například poly-His). Lze též přidat vysoce antigenní peptid, který by umožnil rychlý test a snadné čistění proteinu multi-funkčního chimérního agonistu hematopoietických receptorů specifickou monoklonální antičásti- 55 cí. -46- CZ 295843 B6 „Mutantní řetězec aminokyselin", „mutantní protein", „variantní protein", „mutein" nebo „mutantní polypeptid" se týká polypeptidu majícího řetězec aminokyselin, který se liší od nativního řetězce v důsledku delecí aminokyselin, substitucí nebo obojího, nebo je kódován 5 řetězcem nukleotidů úmyslně odlišným od nativního řetězce. „Nativní řetězec" se týká řetězce aminokyselin nebo nukleových kyselin, který je identický s divokým typem nebo s nativní formou genu či proteinu.
Hematopoietické růstové faktory lze charakterizovat jeho schopností stimulovat tvorbu kolonií 10 progenitorů lidských krvetvorných buněk. Vytvořené kolonie zahrnují erythroidy, granulocyty, megakaryocyty, granulocytické makrofágy a jejich směsi. Rada hematopoietických růstových faktorů demonstrovala schopnost obnovit funkci kostní dřevě a populací periferních krevních buněk na terapeuticky blahodárné hladiny ve studiích provedených nejprve na primátech a potom na lidech. Mnohé z těchto biologických aktivit hematopoietických růstových faktorů vyžadují 15 přenos signálu a vysokou afinitu vazby na receptor. Multi-fimkční chimémí agonisty hematopoietických receptorů tohoto vynálezu mohou vykazovat užitečné vlastnosti, jako mít podobnou či vyšší biologickou aktivitu ve srovnání s jediným faktorem, nebo mít zlepšený poločas nebo snížené nežádoucí postranní účinky, nebo kombinaci těchto vlastností. 20 Multi-funkční chimémí agonisté hematopoietických receptorů, které mají malou čí žádnou agonistickou aktivitu, by mohly být užiteční jako agonisté, jako antigeny pro produkci protilátek užitečných v imunologii nebo imunoterapii, jako genetické vzorky nebo meziprodukty použité konstrukci jiných užitečných hIL-3 muteinů. 25 Biologickou aktivitu proteinů multi-funkčního chimémího agonisty hematopoietických receptorů tohoto vynálezu lze určit syntézou DNA liniemi buněk závislými na faktoru nebo počítáním jednotek tvořících kolonie v testu kostní dřeně in vitro.
Multi-funkční chimérní agonisté hematopoietických receptorů tohoto vynálezu mohou rovněž 30 vykazovat zlepšený terapeutický profil ve srovnání s jednotlivě působícími hematopoietickými agonisty. Například některé multi-funkční chimémí agonisty hematopoietických receptorů tohoto vynálezu mohou mít podobnou nebo silnější aktivitu růstu faktoru, aniž by měly podobné nebo zvýšené postranní účinky. 35 Tento vynález také zahrnuje DNA řetězce, které kódují proteiny multi-funkčního chimérního agonisty hematopoietických receptorů, DNA řetězce, které jsou podstatně podobné a vykonávají podstatně stejnou funkci a DNA řetězce, které se liší od DNA řetězců kódujících multi-funkční chimérní agonisty hematopoietických receptorů tohoto vynálezu pouze pro degeneraci genetického kódu. Také jsou zahrnuty do tohoto vynálezu ologonukleidové meziprodukty použité pro 40 konstrukci mutantních DNA, a polypeptidy kódované těmito ologonukleidy.
Ke konstrukci DNA sekvencí tohoto vynálezu lze použít techniky genetického inženýrství, které jsou nyní v oboru standardní (US patent 4,935,233 a Sambrook a kol., „Molecular Cloning, A ALaboratory Manual", Cold Spring Harbor Laboratory (1989)). Jedním takovým způsobem je 45 kazetová mutageneze (Wells a kol., Gene 34:315-323, (1985)), při které se část kódujícího řetězce hIL-3 v plazmidu nahradí syntetickým ologonukleidem, který kóduje žádané substituce aminokyselin v části mezi dvěma místy restrikce. Páry komplementárních syntetických ologonukleidů, které kódují žádaný gen, lze připravit a 50 vzájemně spojit. DNA řetězec ologonukleidu by kódoval řetězec amino kyselin žádaného genu s výjimkou substituovaných a nebo vypuštěných z řetězce. DNA plazmidu může reagovat s vybranými restriktivními endonukleázami a pak být připojována ke spojeným ologonukleidům. Připojené směsi lze použít k transformaci soutěžících JM101 55 buněk na resistenci k vhodnému antibiotiku. Jednotlivé kolonie lze vybrat a DNA plazmidu -47- CZ 295843 B6 testovat restriktivní analýzou a nebo sekvencováním DNA, aby se identifikovaly plazmidy s žádanými geny.
Klonování sekvencí DNA nových multi-funkčních chimérních agonistů hematopoietických 5 receptorů s alespoň jednou sekvencí DNA jiného kolonie stimulujícího faktoru lze dosáhnout použitím mezivektorů. Alternativně lze klonovat jeden gen do vektoru obsahujícího jiný gen. Pro spojení sekvencí DNA lze použít spojovníky a adaptéry, jakož i pro náhradu ztracených sekvencí, kdy místo restrikce je uvnitř oblasti zájmu. Tedy genetický materiál (DNA) kódující jeden polypeptid, peptidický spojovník a jiný polypeptid se vloží do vhodného vektoru exprese, který 10 se použije k transformaci baktérie, kvasinky, hmyzí buňky nebo savčích buněk. Transformovaný organismus se pěstuje a protein se izoluje standardními technikami. Vzniklý produkt je tedy novým proteinem, který má kolonie stimulující faktor připojený spojovníkem k druhé kolonie stimulujícímu faktoru. 15 Jiný aspekt tohoto vynálezu dává DNA plazmidové vektory pro použití při expresi těchto nových multi-funkčních chimérních agonistů hematopoietických receptorů.
Tyto vektory obsahují nové DNA řetězce popsané shora, které kódují nové polypeptidy tohoto vynálezu. Vhodné vektory, které mohou transformovat mikroorganismy schopné exprese multi-20 funkčních chimérních agonistů hematopoietických receptorů, zahrnují vektory exprese obsahující řetězce nukleidů kódující multi-ťunkční chimémí agonisty hematopoietických receptorů připojené k transkripčním a translačním regulačním řetězcům, které jsou vybrány podle použité hostitelské buňky. 25 Vektory zahrnující modifikované řetězce, jak jsou popsané shora, jsou zahrnuty do tohoto vynálezu a jsou užitečné při výrobě multi-funkčních chimérních agonistů hematopoietických receptorů. Vektor použitý při tomto způsobu také obsahuje vybrané regulační řetězce v operativním spojení s kódujícími DNA řetězci tohoto vynálezu a je schopný usměrnit jejich replikaci a expresi ve vybraných hostitelských buňkách. 30
Jako jiný aspekt tohoto vynálezu je dán způsob výroby nových multi-funkčních chimérních agonistů hematopoietických receptorů. Způsob tohoto vynálezu vyžaduje kultivaci vhodných buněk nebo linií buněk, které se transformovaly vektorem obsahujícím DNA řetězce kódující expresi nových multi-funkčních chimérních agonistů hematopoietických receptorů. Vhodné 35 buňky nebo linie buněk mohou být bakteriální buňky. Například různé kmeny E. coli jsou dobře známými hostitelskými buňkami v oboru biotechnologie. Příklady takových kmenů zahrnují kmeny E. coli JM101 (Yanish-Perron a kol., Gene 33: 103-119, (1985)) a MON105 (Obukowitz a kol., Applied Environmental Microbiology 58: 1511-1523, (1992)). Do tohoto vynálezu je též zahrnuta exprese proteinu multi-funkčního chimérního agonisty hematopoietických receptorů 40 pomocí chromozomálního vektoru exprese pro E. coli založeném na bakteriofágu Mu (Weinberg a kol., Gene 126: 25-33, (1993)). Různé kmeny B. subtilis lze též použít při tomto způsobu. Mnoho kmenů kvasinek známých odborníkům je též dostupných jako hostitelské buňky pro expresi polypeptidů tohoto vynálezu. Když se vyjádří v cytoplazmě E. coli gen kódující multi-funkční chimérní agonisty hematopoietických receptorů tohoto vynálezu, lze je též konstruovat 45 tak, že se přidají na 5' konec kodonu genu, aby kódoval Met-2-Al-l- nebo Met-1 na N-konci proteinu. N-konce proteinů připravené v cytoplazmě E. coli jsou postiženy posttranslační úpravou methionin aminopeptidázou (Ben Bassat a kol., J. Bac. 169:751-757 (1987)) a možná jinými peptidázami, takže po expresi se odštěpí methionin od N-konce. Multi-funkční chimémí agonista hematopoietických receptorů podle tohoto vynálezu může zahrnovat polypeptidy multi-50 funkčního chimérního agonisty hematopoietických receptorů mající Met-1, Ala-1 nebo Met-2-Ala-1 na N-jinými peptidázami, takže po expresi se odštěpí methionin od N-konce. Multi-funkční chimémí agonista hematopoietických receptorů podle tohoto vynálezu může zahrnovat polypeptidy multi-funkčního chimérního agonisty hematopoietických receptorů mající Met-1, Ala-1 nebo Met-2-Ala-l a N-konci. Tito mutantní multi-funkční chimémí agonisté hemato-55 poietických receptorů se také mohou vyjádřit v E. coli spojením signálního peptidu sekrece k N- -48- CZ 295843 B6 konci. Tento signální peptid se odštěpí od polypeptidu jako část vylučovacího procesu. Další strategie pro dosažení vysoké úrovně exprese genů v E. coli lze nalézt v Savvas, C.M. {Microbiological Reviews 60; 512-538, 1996). 5 Vhodné pro použití podle tohoto vynálezu jsou také savčí buňky, jako jsou buňky vaječníku čínského křečka (CHO). Obecné způsoby vyjádření cizích genů v savčích buňkách jsou shrnuty v Kaufman, R. J. Genetic Engineering, Principles and Methods, Vol. 9, J. K. Setlow, editor, Plenům Press, New York (1987). 10 Konstruuje se takový vektor exprese, ve kterém silný promotor schopný funkce v savčích buňkách, vede transkripci kódující oblasti signálního peptidu eukaryotické sekrece, která je translačně spojena ke kódující oblasti pro multi-funkční chimémí agonist hematopoietických receptorů. Například lze použít plazmidy jako pcDNA, I/Neo, pRc/RSV a pRc/CMV (získané od Invitrogen Corp., San Diego, Kalifornie). Kódující oblast signálního peptidu eukaryotické sekre-15 ce může být ze samotného genu nebo může být z jiného vylučovaného savčího proteinu (Bayne M.L. a kol., Proč. Nati. Acad. Sci USA 84, 2638-2642, 1987). Pro konstrukci vektoru obsahujícího gen, se vektor DNA transfektuje do savčích buněk. Těmito buňkami mohou být například COS7, HeLa, BHK, CHO nebo myší L linie. Buňky lze pěstovat například v DMEM mediu (JRH Scientifíc). Polypeptid vylučovaný do média lze získat standardními biochemickými 20 postupy po přechodné expresi na 24 až 72 hodin po transfekci buněk nebo po ustavení stálých linií buněk po selekci na resistenci na antibiotickou resistenci. Selekce vhodných savčích hostitelských buněk a způsoby pro transformaci, kultivaci, amplifíkaci, testování a produkci produktu a čistění jsou známé odborníkům. Viz například Gething a Sambrook, Nátuře, 293:620-625 (1981) nebo alternativně Kaufman a kol., Mol. Cell. Biol., 5(7):1750-1759 (1985) nebo 25 Howley a kol., US patent číslo 4,419,446. Jinou vhodnou savčí buněčnou linií je opičí buněčná linie COS-1. Podobně užitečnou savčí buněčnou linií je buněčná linie CV-1.
Pokud je to žádoucí, lze použít při způsobu podle tohoto vynálezu jako hostitelské buňky hmyzí buňky. Viz například Miller a kol., Genetic Engeneering 8: 277-298 (Plenům Press, 1986) a tam 30 citované odkazy. Vedle obecných způsobů pro expresi cizích genů v hmyzích buňkách se popisuje použití vektorů Baculovirus vM.D., Summers a G.E. Smith (1987), A Manual of Methods for Baculovirus Vektors and Insect Cell Culture Procedures, Texas Agricultural Experiment Station Bulletin, číslo 1555. Konstruuje se vektor pro expresi obsahující transferový vektor Baculorivu, ve kterém se silný promotor Baculoviru (jako je polyhedronový promotor) 35 žene transkripci kódující oblasti signálního peptidu eukaryotické sekrece, která je translačně spojena ke kódující oblasti pro polypeptid multi-funkčního chimémího agonistu hematopoietických receptorů. Například lze použít plazmid pVL1392 (získaný od Invitrogen Corp., San Diego, Kalifornie). Po konstrukci vektoru nesoucího gen kódující polypeptid multi-funkčního chimémího agonistu hematopoietických receptorů, dva mikrogramy této DNA se kotransfekují 40 s jedním mikrogramem DNA Baculoviru (viz Summers a Smith (1987)) do hmyzích buněk, kmen SF9. Čistý rekombinantní Baculovirus nesoucí multi-funkční chimérní agonist hematopoietických receptorů se použije k infekci kultivovaných buněk, například v médiu Excell 401 bez séra (JRH Biosciences, Lenexa, Kansas). Multi-funkční chimémí agonist hematopoietických receptorů vylučovaný do média se může získat standardními biochemickými postupy. Kalové 45 vody ze savčích nebo hmyzích buněk po expresi proteinu multi-funkčního chimémího agonistu hematopoietických receptorů se mohou nejprve koncentrovat s použitím kteréhokoliv z řady komerčních koncentračních jednotek.
Multi-funkční chimérní agonisté hematopoietických receptorů podle tohoto vynálezu mohou být 50 užiteční při léčení nemocí charakteristických sníženými hladinami bud’ myeloidních, erythroid-ních, lymfoidních nebo megakaryocytových buněk krvetvorné soustavy nebo jejich kombinacemi. Mimo to se mohou použít k aktivaci zralých myeloidních a nebo lymfoidních buněk. Mezi stavy citlivými k léčení spojenými polypeptidy podle tohoto vynálezu patří leukopenie, snížení počtu cirkulujících leukocytů (bílé krvinky) v periferní krvi. Leukopenie může být způsobena 55 vystavení jistým virům nebo radiací. Je často vedlejším účinkem různých forem terapie proti -49- CZ 295843 B6 rakovině, například vystavení chemoterapeutickým lékům, radiaci a infekci nebo krvácení. Terapeutické léčení leukopenie těmito multi-funkčními chimérními agonisty hematopoietických receptorů podle tohoto vynálezu může zabránit nežádoucím vedlejším účinkům působeným současnými léky. 5
Multi-funkční chimérní agonisté hematopoietických receptorů podle tohoto vynálezu mohou být užiteční při léčení neutropenie a například při léčení takových podmínek, jako je aplastická anemie, cyklická neutropenie, idiopatická neutropenie, syndrom Chediak-Higashi, systemický lupus erythematosus (SLE), leukémie, myelodysplastický syndrom a myelofibróza. 10
Multi-funkční chimérní agonisté hematopoietických receptorů podle tohoto vynálezu mohou být užiteční při léčení nebo prevenci trombocytopenie. Nyní je jedinou terapií pro trombocytopenii transfuze krevních destiček, která je nákladná a přináší významné riziko infekce (HIV, HBV) a alloimunizace. Multi-funkční chimérní agonisté hematopoietických receptorů mohou zamezit 15 nebo snížit potřebu transfuzí krevních destiček. Těžká trombocytopenie může být způsobena genetickými defekty, jako je Fanconiho anemie, syndromy Wiscott-Aldrich nebo Mya-Hegglin. Získaná trombocytopenie může být způsobena auto- nebo allo-protilátkami, jako při imunitní trombocytopenii purpura, systemickém lupus erythematosus, hemolytické anemii nebo fetální mateřské nesnášenlivosti. Mimo to k trombocytopenii vedou splenomegalie, roztroušená intra-20 vaskulární koagulace, trombotická trombocytopenie purpura, infekce nebo prosthetické srdeční chlopně. Těžká trombocytopenie může být také způsobena chemoterapií a nebo radiační terapií nebo rakovinou. Trombocytopenie může být také způsobena invazí do kostní dřeně karcinomem, lymfomem, leukémií nebo fibrózou. 25 Multi-funkční chimérní agonisté hematopoietických receptorů podle tohoto vynálezu mohou být užiteční při mobilizaci krvetvorných rodičovských a kmenových buněk do periferní krve. Rodičovské buňky v periferní krvi se ukázaly být účinnými při regeneraci pacientů při vyrovnání autotransplantací kostní dřeně. Krvetvorné růstové faktory včetně G-CSF a GM-CSF prokázaly schopnost zvyšovat počet cirkulujících krvetvorných rodičovských a kmenových buněk kperi-30 ferní krvi. To zjednodušilo postup pro sbírání periferních kmenových buněk a dramaticky snížilo cenu procedury snížením počtu potřebných pheresí. Multi-funkční chimérní agonisté hematopoietických receptorů mohou být užiteční při mobilizaci kmenových buněk a dále zvyšovat účinek transplantací periferních kmenových buněk. 35
Tabulka 1
OLIGONUKLEOTIDY 40 C-mplNcoI ACGTCCATGGCNTCNCCNGCNCCNCCTGCTTGTGCACTCCGAGTC (SEQ ID NO:317)
N=A,C,G or T
Ecompl ATGCACGAATTCCCTGACGCAGAGGGTGGA (SEQ ID NO:318) 45 50 c-mplHindlII TGACAAGCTTACCTGACGCAGAGGGTGGACCCT (SEQ ID NO:319) 4L-5' AATTCGGCAA (SEQ ID NO:320) 4L-3' CATGTTGCCG (SEQ ID NO:321) 5L-5' AATTCGGCGGCAA (SEQ ID NO:322) 5L-3' CATGTTGCCGCCG (SEQ ID NO:323) -50- 55 CZ 295843 B6 8L-5' AATTCGGCGGCAACGGCGGCAA (SEQ ID NO:324) 81,-3' CATGTTGCCGCCGTTGCCGCCG (SEQ ID NO:325) 31-5' CGATCCATGGAGGTTCACCCTTTGCCT (SEQ ID NO:326) 31-3' GATCAAGCTTATGGGCACTGGCTCAGTCT (SEQ ID NO:327) 35-5' CGATACATGTTGCCTACACCTGTCCTG (SEQ ID NO:328) 35-3' GATCAAGCTTAAGGGTGAACCTCTGGGCA (SEQ ID NO:329) 39-5' CGATCCATGGTCCTGCTGCCTGCTGTG (SEQ ID NO:330) 39-3' GATCAAGCTTAAGGTGTAGGCAAAGGGTG (SEQ ID NO:331) 43-5' CGATCCATGGCTGTGGACTTTAGCTTGGGA (SEQ ID NO:332) 43-3' GATCAAGCTTAAGGCAGCAGGACAGGTGT (SEQ ID NO:333) 45-5' CGATCCATGGACTTTAGCTTGGGAGAA (SEQ ID NO:334) 45-3' GATCAAGCTTACACAGCAGGCAGCAGGAC (SEQ ID NO:335) 49-5' CGATCCATGGGAGAATGGAAAACCCAG (SEQ ID NO:336) 49-3' GATCAAGCTTACAAGCTAAAGTCCACAGC (SEQ ID NO:337) 82-5' CGATCCATGGGACCCACTTGCCTCTCA (SEQ ID NO:338) 82-3' GATCAAGCTTACAGTTGTCCCCGTGCTGC (SEQ ID NO:339) 109-5' CAGTCCATGGGAACCCAGCTTCCTCCA (SEQ ID NO:340) 109-3' GATCAAGCTTAAAGGAGGCTCTGCAGGGC (SEQ ID NO:341) 116-5' CGATCCATGGGCAGGACCACAGCTCAC (SEQ ID NO:342) 116-3' GATCAAGCTTACTGTGGAGGAAGCTGGGTT (SEQ ID NO:343) 120-5' CGATCCATGGCTCACAAGGATCCCAATGCC (SEQ ID NO:344) 120-3' GATCAAGCTTATGTGGTCCTGCCCTGTGG (SEQ ID NO:345) 123-5' CGATCCATGGATCCCAATGCCATCTTCCTG (SEQ ID NO:346) 123-3' GATCAAGCTTACTTGTGAGCTGTGGTCCT (SEQ ID NO:347) 126-5' CGATCCATGGCCATCTTCCTGAGCTTCCAA (SEQ ID NO:348) 126-3' GATCAAGCTTAATTGGGATCCTTGTGAGCTGT (SEQ ID NO:349)
SYNNOXAl.REQ AATTCCGTCG TAAACTGACC TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAGT ACGTAGAGGG CGGTGGAGGC TCC (SEQ ID NO:350) CZ 295843 B6
SYNN0XA2.REQ CCGGGGAGCC TCCACCGCCC TCTACGTACT GTTGAGCCTG CGCGTTCTCC AAGGTTTTCA GATAGAAGGT CAGTTTACGA CGG (SEQ ID NO:351) 5 Llsyn.for GTTACCCTTG CTAACTGCTC Llsyn.rev CGATCATTAT CTGCGCTTGC 10 L3syn.for GTTACCCTTG CTGGCGGTGG (SEQ ID NO 15 L3syn.rev CGATCATTAT GCCAGAGCCA (SEQ ID NO 35start.seq GATCGACCAT 20 NO:356) 34rev.seq CTCGATTACG 70start.seq GATCGACCAT 25 NO:358) 69rev.seq CTCGATTACG 91start.seq GATCGACCAT 30 NO:360) 90rev.seq CTCGATTACG lOlstart.seq GATCGACCAT GG 35 lOOrev.seq CTCGATTACG L-llstart.seq GCTCTGAGAG CTGCGCAAGG 40 L-llstop.seq CAGCCCTCTG AGCTTCCTGC P-blstart.seq GGGCTGCGCA 45 P-blstop.seq ACACCATTGG 39start.seq GATCGACCAT NO:368) 50 38stop.Seq CGATCGAAGC NO:369) 97start.seq GATCGACCAT 55 NO:370)
GATCGACCAT GGCTCTGGAC CCGAACAACC TC (SEQ ID -52- 10 96stop.Seq 126start.seq 125stop.Seq 133start.seq 132stop.seq 15 CZ 295843 B6 CGATCGAAGC TTATTAGGAT ATCCCTTCCA GGGCCT (SEQ ID NO:371)
GATCGACCAT GGCTATGGCC CCTGCCCTGC AG (SEQ ID NO:372) CGATCGAAGC TTATTATCCC AGTTCTTCCA TCTGCT (SEQ ID NO:373)
GATCGACCAT GGCTACCCAG GGTGCCATGC CG (SEQ ID NO:374) CGATCGAAGC TTATTAGGGC TGCAGGGCAG GGGCCA (SEQ ID NO:375) 142start.seq GATCGACCAT GGCTTCTGCT TTCCAGCGCC GG (SEQ ID NO:376) 141stop.Seq 20 GLYXA1 GLYXA2 CGATCGAAGC TTATTAGGCG AAGGCCGGCA TGGCAC (SEQ ID NO:377) GTAGAGGGCG GTGGAGGCTC C (SEQ ID NO:378) CCGGGGAGCC TCCACCGCCC TCTAC (SEQ ID NO:379) 25 lGGGSfor TTCTACGCCA CCTTGCGCAG CCCGGCGGCG GCTCTGACAT GTCTACACCA TTG (SEQ ID NO:380) lGGGSrev CAATGGTGTA GACATGTCAG AGCCGCCGCC GGGCTGCGCA AGGTGGCGTA GAA (SEQ ID NO:381) 30 35 NCOFLT HIND160 HIND165 FL23For
40 FH3AFor SCF.REV 45 3 9FOR 39REV 65FOR 50 6 5 RE V 89FOR 55 8 9REV CTGACCATGGCNACCCAGGACTGCTCCTTCCAA (SEQ ID NO:807) ACTGAAGCTTAGGGCTGACACTGCAGCTCCAG (SEQ ID NO:808) ACTGAAGCTTACAGGGTTGAGGAGTCGGGCTG (SEQ ID NO:809) GACTGCCATGGCNACYCAGGAYTGYTCYTTYCAACACAGCCCCATC (SEQ ID NO:810) GACTGCCATGGCNACYCAGGAYTGYTCYTTYCAACACAGCCCCATC (SEQ ID NO:811) TGTCCAAACTCATCAATGTATC (SEQ ID NO:812) CATGGCCATGGCCGACGAGGAGCTCTGCGGGGGCCTCT (SEQ ID NO:813) GCTAGAAGCTTACTGCAGGTTGGAGGCCACGGTGAC (SEQ ID NO:814) CATGGCCATGGCCTCCAAGATGCAAGGCTTGCTGGAGC (SEQ ID NO:815) GCTAGAAGCTTACCCAGCGACAGTCTTGAGCCGCTC (SEQ ID NO:816) CATGGCCATGGCCCCCCCCAGCTGTCTTCGCTTCGT (SEQ ID NO:817) GCTAGAAGCTTAGGGCTGAAAGGCACATTTGGTGACA (SEQ ID NO:818) -53 - CZ 295843 B6 L5A CCCTGTCTGGCGGGAACGGCACCCAGGACTGCTCCTTCCAAC (SEQ ID NO:819) L10A 5 GCGGTAACGGCAGTGGAGGTAATGGCACCCAGGACTGCTCCTTCCAAC (SEQ ID NO:820) L15A ACGGCAGTGGTGGCAATGGGAGCGGCGGAAATGGAACCCAGGACT GCTCCTTCCAAC (SEQ ID NO:821) 10 L5B GTGCCGTTGCCGCCAGACAGGGTTGAGGAGTCGGGCTG (SEQ ID NO:822) L10B ATTACCTCCACTGCCGTTACCGCCTGACAGGGTTGAGGAGTCGGG CTG (SEQ ID NO:823) 15 L15B GCTCCCATTGCCACCACTGCCGTTACCTCCAGACAGGGTTGAGGA GTCGGGCTG (SEQ ID NO:824) L15C GATGAGGATCCGGTGGCAATGGGAGCGGCGGAAATGGAACCCAGG ACTGCTCCTTCCACC (SEQ ID NO:825) 20 L15D GATGACGGATCCGTTACCTCCAGACAGGGTTGAGGAGTCGGGCTG (SEQ ID NO:826) L15E 25 GATGACGGATCCGGAGGTAATGGCACCCAGGACTGCTCCTTCCAAC (SEQ ID NO:827) 339FOR2 GACTGCCATGGCCGACGAGGAGCTCTGCG (SEQ ID NO:828) 339REV2 GACTCAAGCTTACTGCAGGTTGGAGGCC (SEQ ID NO:829) 30
339-10FOR3 GACTCGGGATCCGGAGGTTCTGGCACCCAGGACTGCTCC (SEQ ID NO:830)
339-15FOR2 GACTGGGATCCGGTGGCAGTGGGAGCGGCGGATCTGGAACC (SEQ ID
35 NO: 831) 339REV3 NO:832) GACTTGGGATCCACTACCTCCAGACAGGGTTGAGGA GTC (SEQ ID 40 FLN3 NO:833) ACTGACGGATCCACCGCCCAGGGTTGAGGAGTCGGGCTG (SEQ ID FLN7 ACTGACGGATCCACCTCCTGACCCACCGCCCAGGGTTGAGGAGTCGGGCTG 45 (SEQ ID NO: 834)
FLN11 ACTGACGGATCCACCTCCTGACCCACCTCCTGACCCACCGCCCAG GGTTGAGGAGTCGGGCTG (SEQ ID NO:835) 50 C-term ACGTAAAGCTTACAGGGTTGAGGAGTCG (SEQ ID NO:836) FLC3 GTCAGTGGATCCGGAGGTACCCAGGACTGCTCCTTCCAA C (SEQ ID NO:837)
55 FLC4 GTCAGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAAC (SEQ ID NO:838) -54- CZ 295843 B6 FLC10 TCAGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAG 5 N-term GACTGCTCCTTCCAAC (SEQ ID NO:839) TAGTCCATGGCCACCCAGGACTGCTCC (SEQ ID NO:840) 134.rev GCATTACGTAGGGCTGACACTGCAGCTCGAG (SEQ ID NO:841) 10 139.rev GCATTACGTACAGGGTTGAGGAGTCGGGCTG (SEQ ID NO:842) F129for GTCAGACCATGGCCGATTACCCAGTCACCGTGGCCTC (SEQ ID NO:843); 15 FL29rev TC T GACAAGCT TAT T GAAGCAGGTAGT CAGACAGCTCAC (SEQ ID NO:844); FL35for GTCAGCCCATGGCCGCCTCCAACCTGCAGGACGAGGA (SEQ ID NO:845); 20 FL35rev TCTGACAAGCTTACACGGTGACTGGGTAACTTGAAGC (SEQ ID NO:846); FL63for 25 GTCAGACCATGGCCGTCGCTGGGTCCAAGATGCAAGGC (SEQ ID NO:847); FL63rev TCTGACAAGCTTAAGTCTTGAGCCGCTCCATCCAGCG (SEQ ID NO:848); 30 FL95for GTCAGACCATGGCCCGCTTCGTCCAGACCAACATCTCC (SEQ ID NO:849); FL95rev TCTGACAAGCTTAAAGACAGCTGGGGGGGGGCTGAA (SEQ ID NO:850); 35 FL99for GTCAGACCATGGCCACCAACATCTCCCGCCTCCTGCAG (SEQ ID NO:851); FL99rev CTCGACAAGCTTACTGGACGAAGCGAAGACAGCTGGG 40 (SEQ ID NO:852); FLTAFLS1 GATCACATGTCTACAAATCAAGATCTGCCTGTG (SEQ ID NO:853) FLTR1N 45 HGCFOR GATCGAATTCGTTGTCTTGGATGAAAGGGA (SEQ ID NO:854) ACTTGAATTCATCATCCTGGGCCTGTTCGGGC (SEQ ID NO:855) HGCREV ACTCAAGCTTAGAAGCTCCCCAGCGCCTCC (SEQ ID NO:856) 50 FL29FOR GTCAGACCATGGCCGATTACCCAGTCACCGTGGCCTC (SEQ ID NO:382) FL35FOR GTCAGCCCATGGCCGCCTCCAACCTGCAGGACGAGGA (SEQ ID NO:383) -55- 55 CZ 295843 B6 FL63FOR GTCAGACCATGGCCGTCGCTGGGTCCAAGATGCAAGGC (SEQ ID NO:384) FL95FOR 5 GTCAGACCATGGCCCGCTTCGTCCAGACCAACATCTCC (SEQ ID NO:385) FL99FOR GTCAGACCATGGCCACCAACATCTCCCGCCTCCTGCAG (SEQ ID NO:386) 10 FL29REV TCTGACAAGCTTATTGAAGCAGGTAGTCAGACAGCTCAC (SEQ ID NO:387) FL35REV 15 TCTGACAAGCTTACACGGTGACTGGGTAATCTTGAAGC (SEQ ID NO:388) FL63REV TCTGACAAGCTTAAGTCTTGAGCCGCTCCATCCAGCG (SEQ ID NO:389) 89 REVSTOP GTCAAGAAGCTTACGGCTGAAAGGCACATTTG 20 (EQ ID NO: 390) FL95REV TCTGACAAGCTTAAAGACAGCTGGGGGGGGGCTGAA (SEQ ID NO:391) 25 FL99REV CTCGACAAGCTTACTGGACGAAGCGAAGACAGCTGGG (SEQ ID NO:392) Flt36 30 GTTGCCATGGCNTCNAAYCTGCARGAYGARGARCTGT GCGGGGGCCTCTGGCGGCTG (SEQ ID NO:393) Flt37 GTTGCCATGGCNAAYCTGCARGAYGARGARCTGTGYG GGGGCCTCTGGCGGCTGGTC (SEQ ID NO:394) Flt38 35 GTTGCCATGGCNCTGCARGAYGARGARCTGTGYGGYG GCCTCTGGCGGCTGGTCCTG (SEQ ID NO:395) Flt39 GTTGCCATGGCNCARGAYGARGARCTGTGYGGYGGYC TCTGGCGGCTGGTCCTGGCA (SEQ ID NO:396) 40 Flt40 GTTGCCATGGCNGAYGARGARCTGTGYGGYGGYCTCT GGCGGCTGGTCCTGGCACAG (SEQ ID NO:397) Flt41 45 GTTGCCATGGCNGARGARCTGTGYGGYGGYCTCTGGC GGCTGGTCCTGGCACAGCGC (SEQ ID NO:398) Flt42 GTTGCCATGGCNGARCTGTGYGGYGGYCTGTGGCGYC TGGTCCTGGCACAGCGCTGG (SEQ ID NO:399) Flt43 50 GTTGCCATGGCNCTGTGYGGYGGYCTGTGGCGYCTGG TCCTGGCACAGCGCTGGATG (SEQ ID NO:400) 40 COLI GTTGCCATGGCWGATGAAGAACTGTGTGGNGGNCTGTGGCGG (SEQ ID NO:401) 55 3 6 RE V TATGCAAGCTTAGGCCACGGTGACTGGGTA (SEQ ID NO:402) -56- CZ 295843 B6 3 7 RE V TATGCAAGCTTAGGAGGCCACGGTGACTGG (SEQ ID NO:403) 5 38REV TATGCAAGCTTAGTTGGAGGCCACGGTGAC (SEQ ID NO:404) 39REV 10 TATGCAAGCTTACAGGTTGGAGGCCACGGT (SEQ ID NO:405) 4 IRE V TATGCAAGCTTAGTCCAGGTTGGAGGCCAC (EQ ID NO:406) 4 2 RE V 15 TATGCAAGCTTACTCGTCCAGGTTGGAGGC (SEQ ID NO:407) 43REV TATGCAAGCTTACTCCTCGTCCAGGTTGGA (SEQ ID NO:408) 20 3 9N TERM-2 GACTAGCCATGGCNGAYGARGARCTGTGYGGTGGCCTCTGGCGG (SEQ ID NO:409)
SNA BlCTERM GACTAGTACGTACTGCAGGTTGGAGGCCACGG 25 (SEQ ID NO: 410)
29SMB1 GCAGGTTACGTATTGAAGCAGGTAGTCAGACAGCTC (SEQ ID NO:411) 30 34SNAB1 GCAGGTTACGTACACGGTGACTGGGTAATCTTGAAG (SEQ ID NO:412) 63SNAB1 35 GCAGGTTACGTAAGTCTTGAGCCGCTCCATCCAGC (SEQ ID NO:413) 66SNAB1 GCAGGTTACGTAGCCAGCGACAGTCTTGAGCCGCTC (SEQ ID NO:414) 89N-TERMCSLI GTCAAGCCATGGCNCCRCCRAGCTGTCTRCGCT 40 TCGTTCAGACCAACTC (SEQ ID NO:415) 89SNAB1 GCAGGTTACGTACGGCTGAAAGGCACATTTGGTGACAA (SEQ ID NO:416) 45 9 4 5 SMB1 GCAGGTTACGTAAAGACAGCTGGGGGGGGG (SEQ ID NO:417) 98SUAB1 GCAGGTTACGTACTGGACGAAGCGAAGACAGCTG (SEQ ID NO:418) 50 BAM FOR 1 TCAGTTGGATCCGGCGGCGGAAGCGGAGGTGGCTCTGGGGGAGGTA (SEQ ID NO:426) -57- 55 CZ 295843 B6 BAM REV 1 TCAGTTGGATCCTCCGCCAGAACCACCGCCTGACCCACCTCCTGACCC (SEQ ID NO:427)
NAVŘEV L GTCTGAGGCGCCACCGCACCGACCGCTGGACAACCGCCTCTGACCC AGGACTGCTCCTTC (SEQ ID NO:428)
NAVŘEV S GTCTGAGGCGCCACCGCACCGACCACCCAGGACTGCTCCTTCCAAC (SEQ ID NO:429)
NAVFOR GTCTGAGGCGCCGAGTGGACGCGGGCTCCACGGTGGCGGCAGGGT TGAGGAGTCGGGCTG (SEQ ID NO:430) XBAFORl GCTACGTCTAGATCTCCTGACCTCGACCCAGGACTGCTCCTTCCAAC (SEQ ID NO:447) XBAREV1 GCTAGTTCTAGACCATCCTGGCTGACACGGTGAAACACCGTCTCTACG GGCTGACACTGCAGCTCCAG (SEQ ID NO:448)
LNK1FOR GTCAGTACTAGTATGGGTGTCCGGGCTCTTCGGCTCCTGCAGG TTGGAGGCCACGG (SEQ ID NO:449)
LNK1REV GTCAGTACTAGTCCGCCATCTCCGACACCATTAGGCCCTGCCAGC (SEQ ID NO:450)
LNK2FOR GTCAGTTCCGGAGATTTCGGTTCTGCAGAGGGCTGCGCAAGG TGGCGTA (SEQ ID NO:451)
LNK2REV GTCAGTTCCGGATACTCATACCAGCCCGCCATCCCCGGGTTCTA ATCTGCAAGATGAAGAGCTG (SEQ ID NO:452)
LNK7FOR GTCAGTACTAGTATGGGTGTCCGGGCTCTTCGGAAAGGCACATTT GGTGACAAAGTGTATC (SEQ ID NO:453)
LNK7REV GTCAGTACTAGTCCGCCATCTCCGGGTACACCATTAGGCCCTG CCAGC (SEQ ID NO:454)
LNK8REV GTCAGTTCCGGATACTCATACCAGCCCGCCATCCCCGGGTAAGGCC TTTCAGCCCCCCCCCAG (SEQ ID NO:455)
ClFOR GTCAGACCATGGCCACTCAGGACTCCTCTTTTC (SEQ ID NO:456) C3FOR CACTTTGTCACCAAATCTGCCTTTCAG (SEQ ID NO:457) C3REV CTGAAAGGCAGATTTGGTGACAAAGTG (SEQ ID NO:458) CZ 295843 B6 C5F0R C5REV 5 C6REV GPF0R1 10 GPREV2 GCCCCCCCCCAGCTCTCTTCG (SEQ ID NO:459) CGAAGAGAGCTGGGGGGGGGC (SEQ ID NO:460) GTCAGTTACGTACAGGGTTGAAGGAGTCGGGCTGAGACTGC (SEQ ID NO:461) GTCAGTCCATGGCTACTCAAGGTGCTATGC (SEQ ID NO:462) GTAGCATACGTAGGGCTGCAGGGCAGGGGCC (SEQ ID NO:463) 15 Tabulka 2 GENOVÉ SEKVENCE pMON30304 20 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCT GGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAA ACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAA 25 GGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGC AGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACT ATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGT (SEQ ID NO:l) pMON26458 30 TCCCCAGCTCCACCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCT TCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTG TGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGA GCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTC 35 ATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTG GAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGC TTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGT CAGGGAATTC (SEQ ID NO:2) 40 pMON28548 TCCCCAGCTCCACCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCT TCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTG TGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGA 45 GCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTC ATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTG GAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGC TTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGT CAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTA 50 AACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTG CCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGA GACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGG GACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTC CTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGGGCAGGACCACAGCTCACAAGGATCCCAATGC 55 CATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGT CCACCCTCTGCGTCAGG (SEQ ID NO:3) -59- CZ 295843 B6 pMON28500 TCCCCAGCTCCACCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCT 5 TCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTG TGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGA GCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTC ATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTG GAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGC 10 TTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGT CAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAAC TGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCT ACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGAC CAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGAC 15 AACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTT GGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGA TCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTG TAGGAGGGTCCACCCTCTGCGTCAGG (SEQ ID NO:4) 20 pMON28501 TCCCCAGCTCCACCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCT TCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTG TGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGA 25 GCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTC ATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTG GAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGC TTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGT CAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTA 30 AACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTG CCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGA GACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGG GACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTC CTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAA 35 GGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGC TTGTAGGAGGGTCCACCCTCTGCGTCAGG (SEQ ID NO:5) pMON28502 40 TCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCT TCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTG TGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGA GCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTC ATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTG 45 GAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGC TTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGT CAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAG TCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTT CACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCA 50 GATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGG CAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTC CGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCAC AGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTT TCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGG 55 (SEQ ID NO: 6) -60- CZ 295843 B6
Syntanl
1 CATGGCTAAC 5 51 GACCACCTGC 101 TCTATCCTGA 151 AAGGGCTGTC 201 GTAATCTCCA 251 CCAATCATCA 10 301 GTTCTATCTG 351 CTAACTGCTC 401 CCTGCACCTT 451 CCTGATGGAC 501 CTGTCAAGAA 15 551 CTCCAACCAT 601 CATCATCAAG 651 ATCTGGTTAC (SEQ ID NO: 20 Syntan3 1 CATGGCTAAC 51 GACCACCTGC 101 TCTATCCTGA 25 151 AAGGGCTGTC 201 GTAATCTCCA 251 CCAATCATCA 301 GTTCTATCTG 351 CTGGCGGTGG 30 401 ATTATACATC 451 CCTCAATGAC 501 CAAACCTGGA 551 GGTATTGAGG 601 GGCCGCACCC 35 651 AATTCCGGGA 701 GAACAACAGT pMON31104 40 1 ATGGCTCTGG 51 GGACCGAAAC 101 AGAACTTAGA 151 CCATGTCTGC 201 CAAGGCAGGT 45 251 TTACCCTTGA 301 ATAATGATCG 351 GTACGTAGAG 401 CTACTATCAA 451 ATGGCTACCC 50 501 GGCAGGAGGG 551 CGTACCGCGT 601 TCTCAGAGCT 651 CGATGGCGCA 701 ACCCCGAGGA 55 751 CCCCTGAGCT 801 CCAACTCCAT TGCTCTATAA TGATCGATGA ACCTTTGCTG GACCCGAACA TGGACCGAAA CCTTCGACTT AAGAACTTAG AAAATGCATC ACCATGTCTG CCCTCTGCCA TCAAGGCAGG TGACTGGCAA GTTACCCTTG AGCAAGCGCA TATAATGATC GATGAAATTA TGCTGGACCC GAACAACCTC CGAAACCTTC GACTTCCAAA CTTAGAAAAT GCATCAGGTA GTCTGCCCTC TGCCACGGCC GCAGGTGACT GGCAAGAATT CCTTGAGCAA GCGCAGGAAC 7) TGCTCTATAA TGATCGATGA ACCTTTGCTG GACCCGAACA TGGACCGAAA CCTTCGACTT AAGAACTTAG AAAATGCATC ACCATGTCTG CCCTCTGCCA TCAAGGCAGG TGACTGGCAA GTTACCCTTG AGCAAGCGCA CAGCGGCGGC GGTTCTAACT ACTTAAAGAG ACCACCTGCA GAAGACGTCT CTATCCTGAT GAGCTTCGTA AGGGCTGTCA CAATTCTTCG TAATCTCCAA TCTCGACATC CAATCATCAT AAAACTGACG TTCTATCTGG AC (SEQ ID NO:8)
ACCCGAACAA CCTCAATGAC CTTCGACTTC CAAACCTGGA AAATGCATCA GGTATTGAGG CCTCTGCCAC GGCCGCACCC GACTGGCAAG AATTCCGGGA GCAAGCGCAG GAACAACAGG ATGAAATTAT ACATCACTTA GGCGGTGGAG GCTCCCCGGG CCCGTCTCCT CCGTCTAAAG AGGGTGCCAT GCCGGCCTTC GTCCTGGTTG CTAGCCATCT TCTACGCCAC CTTGCGCAGC TCCTGCTCAA GTCTTTAGAG GCGCTCCAGG AGAAGCTGTG GCTGGTGCTG CTCGGACACT CCTGCCCCAG CCAGGCCCTG AGCGGCCTTT TCCTCTACCA
AATTATACAT CACTTAAAGA ACCTCAATGA CGAAGACGTC CCAAACCTGG AGAGCTTCGT AGGTATTGAG GCAATTCTTC CGGCCGCACC CTCTCGACAT GAATTCCGGG AAAAACTGAC GGAACAACAG GGTGGTGGCT TACATCACTT AAAGAGACCA AATGACGAAG ACGTCTCTAT CCTGGAGAGC TTCGTAAGGG TTGAGGCAAT TCTTCGTAAT GCACCCTCTC GACATCCAAT CCGGGAAAAA CTGACGTTCT AACAGTAC
AATTATACAT CACTTAAAGA ACCTCAATGA CGAAGACGTC CCAAACCTGG AGAGCTTCGT AGGTATTGAG GCAATTCTTC CGGCCGCACC CTCTCGACAT GAATTCCGGG AAAAACTGAC GGAACAACAG GGTGGTGGCT GCTCTATAAT GATCGATGAA CCTTTGCTGG ACCCGAACAA GGACCGAAAC CTTCGACTTC AGAACTTAGA AAATGCATCA CCATGTCTGC CCTCTGCCAC CAAGGCAGGT GACTGGCAAG TTACCCTTGA GCAAGCGCAG
GAAGACGTCT CTATCCTGAT GAGCTTCGTA AGGGCTGTCA CAATTCTTCG TAATCTCCAA TCTCGACATC CAATCATCAT AAAACTGACG TTCTATCTGG GTGGTGGCTC TAACTGCTCT AAGAGACCAC CTGCACCTTT TGAACCGTCT GGTCCAATCT AATCTCATAA ATCTCCAAAC GCCTCTGCTT TCCAGCGCCG GCAGAGCTTC CTGGAGGTGT CCTCTGGCGG CTCTGGCGGC CAAGTGAGAA AGATCCAGGG TGCCACCTAC AAGCTGTGCC CTCTGGGCAT CCCCTGGGCT CAGCTGGCAG GCTGCTTGAG GGGGCTCCTG CAGGCCCTGG -61 - CZ 295843 B6 851 AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GCAGCTGGAC 901 GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT 951 GGCCCCTGCC CTGCAGCCCT AATAA (SEQ ID NO:9) 5 pMON31105
1 ATGGCTAATG 51 TCTGCCCTCT 101 CAGGTGACTG 10 151 CTTGAGCAAG 201 GATCGATGAA 251 ACCCGAACAA 301 CTTCGACTTC 351 ATACGTAGAG 15 401 CTACTATCAA 451 ATGGCTACCC 501 GGCAGGAGGG 551 CGTACCGCGT 601 TCTCAGAGCT 20 651 CGATGGCGCA 701 ACCCCGAGGA 751 CCCCTGAGCT 801 CCAACTCCAT 851 AAGGGATATC 25 901 GTCGCCGACT 951 GGCCCCTGCC
CATCAGGTAT TGAGGCAATT GCCACGGCCG CACCCTCTCG GCAAGAATTC CGGGAAAAAC CGCAGGAACA ACAGGGTGGT ATTATACATC ACTTAAAGAG CCTCAATGAC GAAGACGTCT CAAACCTGGA GAGCTTCGTA GGCGGTGGAG GCTCCCCGGG CCCGTCTCCT CCGTCTAAAG AGGGTGCCAT GCCGGCCTTC GTCCTGGTTG CTAGCCATCT TCTACGCCAC CTTGCGCAGC TCCTGCTCAA GTCTTTAGAG GCGCTCCAGG AGAAGCTGTG GCTGGTGCTG CTCGGACACT CCTGCCCCAG CCAGGCCCTG AGCGGCCTTT TCCTCTACCA CCCCGAGTTG GGTCCCACCT TTGCCACCAC CATCTGGCAG CTGCAGCCCT AATAA (SEQ CTTCGTAATC TCCAACCATG ACATCCAATC ATCATCAAGG TGACGTTCTA TCTGGTTACC GGCTCTAACT GCTCTATAAT ACCACCTGCA CCTTTGCTGG CTATCCTGAT GGACCGAAAC AGGGCTGTCA AGAACTTAGA TGAACCGTCT GGTCCAATCT AATCTCATAA ATCTCCAAAC GCCTCTGCTT TCCAGCGCCG GCAGAGCTTC CTGGAGGTGT CCTCTGGCGG CTCTGGCGGC CAAGTGAGAA AGATCCAGGG TGCCACCTAC AAGCTGTGCC CTCTGGGCAT CCCCTGGGCT CAGCTGGCAG GCTGCTTGAG GGGGCTCCTG CAGGCCCTGG TGGACACACT GCAGCTGGAC CAGATGGAAG AACTGGGAAT ID NO:10) pMON31106
30 1 ATGGCTGCAC 51 AGAATTCCGG 101 AGGAACAACA 151 ATACATCACT 201 CAATGACGAA 35 251 ACCTGGAGAG 301 ATTGAGGCAA 351 CTACGTAGAG 401 CTACTATCAA 451 ATGGCTACCC 40 501 GGCAGGAGGG 551 CGTACCGCGT 601 TCTCAGAGCT 651 CGATGGCGCA 701 ACCCCGAGGA 45 751 CCCCTGAGCT 801 CCAACTCCAT 851 AAGGGATATC 901 GTCGCCGACT 951 GGCCCCTGCC 50
CCTCTCGACA TCCAATCATC GAAAAACTGA CGTTCTATCT GGGTGGTGGC TCTAACTGCT TAAAGAGACC ACCTGCACCT GACGTCTCTA TCCTGATGGA CTTCGTAAGG GCTGTCAAGA TTCTTCGTAA TCTCCAACCA GGCGGTGGAG GCTCCCCGGG CCCGTCTCCT CCGTCTAAAG AGGGTGCCAT GCCGGCCTTC GTCCTGGTTG CTAGCCATCT TCTACGCCAC CTTGCGCAGC TCCTGCTCAA GTCTTTAGAG GCGCTCCAGG AGAAGCTGTG GCTGGTGCTG CTCGGACACT CCTGCCCCAG CCAGGCCCTG AGCGGCCTTT TCCTCTACCA CCCCGAGTTG GGTCCCACCT TTGCCACCAC CATCTGGCAG CTGCAGCCCT AATAA (SEQ ATCAAGGCAG GTGACTGGCA GGTTACCCTT GAGCAAGCGC CTATAATGAT CGATGAAATT TTGCTGGACC CGAACAACCT CCGAAACCTT CGACTTCCAA ACTTAGAAAA TGCATCAGGT TGTCTGCCCT CTGCCACGGC TGAACCGTCT GGTCCAATCT AATCTCATAA ATCTCCAAAC GCCTCTGCTT TCCAGCGCCG GCAGAGCTTC CTGGAGGTGT CCTCTGGCGG CTCTGGCGGC CAAGTGAGAA AGATCCAGGG TGCCACCTAC AAGCTGTGCC CTCTGGGCAT CCCCTGGGCT CAGCTGGCAG GCTGCTTGAG GGGGCTCCTG CAGGCCCTGG TGGACACACT GCAGCTGGAC CAGATGGAAG AACTGGGAAT ID NO:11) pMON31107
1 ATGGCTGCAG 51 GGTTACCCTT 55 101 CTATAATGAT 151 TTGCTGGACC GTGACTGGCA AGAATTCCGG GAGCAAGCGC AGGAACAACA CGATGAAATT ATACATCACT CGAACAACCT CAATGACGAA
GAAAAACTGA CGTTCTATCT GGGTGGTGGC TCTAACTGCT TAAAGAGACC ACCTGCACCT GACGTCTCTA TCCTGATGGA -62- CZ 295843 B6
201 CCGAAACCTT 251 ACTTAGAAAA 301 TGTCTGCCCT 351 GTACGTAGAG 5 401 CTACTATCAA 451 ATGGCTACCC 501 GGCAGGAGGG 551 CGTACCGCGT 601 TCTCAGAGCT 10 651 CGATGGCGCA 701 ACCCCGAGGA 751 CCCCTGAGCT 801 CCAACTCCAT 851 AAGGGATATC 15 901 GTCGCCGACT 951 GGCCCCTGCC pMON31108 20 . 1 ATGGCTCTGG 51 GGACCGAAAC 101 AGAACTTAGA 151 CCATGTCTGC 201 CAAGGCAGGT 25 251 TTACCCTTGA 301 AGCGGCGGCG 351 CTTAAAGAGA 401 CGGGTGAACC 451 AAAGAATCTC 30 501 CTTCGCCTCT 551 ATCTGCAGAG 601 CAGCCCTCTG 651 AGAGCAAGTG 701 TGTGTGCCAC 35 751 CACTCTCTGG 801 CCTGCAGCTG 851 ACCAGGGGCT 901 ACCTTGGACA 951 GCAGCAGATG 40 (SEQ ID NO
CGACTTCCAA ACCTGGAGAG TGCATCAGGT ATTGAGGCAA CTGCCACGGC CGCACCCTCT GGCGGTGGAG GCTCCCCGGG CCCGTCTCCT CCGTCTAAAG AGGGTGCCAT GCCGGCCTTC GTCCTGGTTG CTAGCCATCT TCTACGCCAC CTTGCGCAGC TCCTGCTCAA GTCTTTAGAG GCGCTCCAGG AGAAGCTGTG GCTGGTGCTG CTCGGACACT CCTGCCCCAG CCAGGCCCTG AGCGGCCTTT TCCTCTACCA CCCCGAGTTG GGTCCCACCT TTGCCACCAC CATCTGGCAG CTGCAGCCCT AATAA (SEQ ACCCGAACAA CCTCAATGAC CTTCGACTTC CAAACCTGGA AAATGCATCA GGTATTGAGG CCTCTGCCAC GGCCGCACCC GACTGGCAAG AATTCCGGGA GCAAGCGCAG GAACAACAGG GTTCTAACTG CTCTATAATG CCACCTGCAC CTTTGTACGT GTCTGGTCCA ATCTCTACTA ATAAATCTCC AAACATGGCT GCTTTCCAGC GCCGGGCAGG CTTCCTGGAG GTGTCGTACC GCGGCTCTGG CGGCTCTCAG AGAAAGATCC AGGGCGATGG CTACAAGCTG TGCCACCCCG GCATCCCCTG GGCTCCCCTG GCAGGCTGCT TGAGCCAACT CCTGCAGGCC CTGGAAGGGA CACTGCAGCT GGACGTCGCC GAAGAACTGG GAATGGCCCC : 13) CTTCGTAAGG GCTGTCAAGA TTCTTCGTAA TCTCCAACCA CGACATCCAA TCATCATCAA TGAACCGTCT GGTCCAATCT AATCTCATAA ATCTCCAAAC GCCTCTGCTT TCCAGCGCCG GCAGAGCTTC CTGGAGGTGT CCTCTGGCGG CTCTGGCGGC CAAGTGAGAA AGATCCAGGG TGCCACCTAC AAGCTGTGCC CTCTGGGCAT CCCCTGGGCT CAGCTGGCAG GCTGCTTGAG GGGGCTCCTG CAGGCCCTGG TGGACACACT GCAGCTGGAC CAGATGGAAG AACTGGGAAT ID NO:12)
GAAGACGTCT CTATCCTGAT GAGCTTCGTA AGGGCTGTCA CAATTCTTCG TAATCTCCAA TCTCGACATC CAATCATCAT AAAACTGACG TTCTATCTGG GTGGTGGCTC TGGCGGTGGC ATCGATGAAA TTATACATCA AGAGGGCGGT GGAGGCTCCC TCAACCCGTC TCCTCCGTCT ACCCAGGGTG CCATGCCGGC AGGGGTCCTG GTTGCTAGCC GCGTTCTACG CCACCTTGCG AGCTTCCTGC TCAAGTCTTT CGCAGCGCTC CAGGAGAAGC AGGAGCTGGT GCTGCTCGGA AGCTCCTGCC CCAGCCAGGC CCATAGCGGC CTTTTCCTCT TATCCCCCGA GTTGGGTCCC GACTTTGCCA CCACCATCTG TGCCCTGCAG CCCTAATAA pMON31109
1 ATGGCTAATG 45 51 TCTGCCCTCT 101 CAGGTGACTG 151 CTTGAGCAAG 201 CGGCGGTTCT 251 AGAGACCACC 50 301 GTCTCTATCC 351 CGTAAGGGCT 401 CGGGTGAACC 451 AAAGAATCTC 501 CTTCGCCTCT 55 551 ATCTGCAGAG 601 CAGCCCTCTG
CATCAGGTAT TGAGGCAATT GCCACGGCCG CACCCTCTCG GCAAGAATTC CGGGAAAAAC CGCAGGAACA ACAGGGTGGT AACTGCTCTA TAATGATCGA TGCACCTTTG CTGGACCCGA TGATGGACCG AAACCTTCGA GTCAAGAACT TAGAATACGT GTCTGGTCCA ATCTCTACTA ATAAATCTCC AAACATGGCT GCTTTCCAGC GCCGGGCAGG CTTCCTGGAG GTGTCGTACC GCGGCTCTGG CGGCTCTCAG
CTTCGTAATC TCCAACCATG ACATCCAATC ATCATCAAGG TGACGTTCTA TCTGGTTACC GGCTCTGGCG GTGGCAGCGG TGAAATTATA CATCACTTAA ACAACCTCAA TGACGAAGAC CTTCCAAACC TGGAGAGCTT AGAGGGCGGT GGAGGCTCCC TCAACCCGTC TCCTCCGTCT ACCCAGGGTG CCATGCCGGC AGGGGTCCTG GTTGCTAGCC GCGTTCTACG CCACCTTGCG AGCTTCCTGC TCAAGTCTTT -63- CZ 295843 B6 651 AGAGCAAGTG 701 TGTGTGCCAC 751 CACTCTCTGG 801 CCTGCAGCTG 5 851 ACCAGGGGCT 901 ACCTTGGACA 951 GCAGCAGATG (SEQ ID NO 10 pMON31110 1 ATGGCTGCAC 51 AGAATTCCGG 101 AGGAACAACA 15 151 TGCTCTATAA 201 ACCTTTGCTG 251 TGGACCGAAA 301 AAGAACTTAG 351 ACCATGTCTG 20 401 CGGGTGAACC 451 AAAGAATCTC 501 CTTCGCCTCT 551 ATCTGCAGAG 601 CAGCCCTCTG 25 651 AGAGCAAGTG 701 TGTGTGCCAC 751 CACTCTCTGG 801 CCTGCAGCTG 851 ACCAGGGGCT 30 901 ACCTTGGACA 951 GCAGCAGATG (SEQ ID NO 35 pMON31111 1 ATGGCTGCAG 51 GGTTACCCTT 101 GCAGCGGCGG 151 CACTTAAAGA 40 201 CGAAGACGTC 251 AGAGCTTCGT 301 GCAATTCTTC 351 CTCTCGACAT 401 CGGGTGAACC 45 451 AAAGAATCTC 501 CTTCGCCTCT 551 ATCTGCAGAG 601 CAGCCCTCTG 651 AGAGCAAGTG 50 701 TGTGTGCCAC 751 CACTCTCTGG 801 CCTGCAGCTG 851 ACCAGGGGCT 901 ACCTTGGACA 55 951 GCAGCAGATG (SEQ ID NO: AGAAAGATCC AGGGCGATGG CTACAAGCTG TGCCACCCCG GCATCCCCTG GGCTCCCCTG GCAGGCTGCT TGAGCCAACT CCTGCAGGCC CTGGAAGGGA CACTGCAGCT GGACGTCGCC GAAGAACTGG GAATGGCCCC :14) CCTCTCGACA TCCAATCATC GAAAAACTGA CGTTCTATCT GGGTGGTGGC TCTGGCGGTG TGATCGATGA AATTATACAT GACCCGAACA ACCTCAATGA CCTTCGACTT CCAAACCTGG AAAATGCATC AGGTATTGAG CCCTCTGCCA CGGCCTACGT GTCTGGTCCA ATCTCTACTA ATAAATCTCC AAACATGGCT GCTTTCCAGC GCCGGGCAGG CTTCCTGGAG GTGTCGTACC GCGGCTCTGG CGGCTCTCAG AGAAAGATCC AGGGCGATGG CTACAAGCTG TGCCACCCCG GCATCCCCTG GGCTCCCCTG GCAGGCTGCT TGAGCCAACT CCTGCAGGCC CTGGAAGGGA CACTGCAGCT GGACGTCGCC GAAGAACTGG GAATGGCCCC : 15) GTGACTGGCA AGAATTCCGG GAGCAAGCGC AGGAACAACA CGGTTCTAAC TGCTCTATAA GACCACCTGC ACCTTTGCTG TCTATCCTGA TGGACCGAAA AAGGGCTGTC AAGAACTTAG GTAATCTCCA ACCATGTCTG CCAATCATCA TCAAGTACGT GTCTGGTCCA ATCTCTACTA ATAAATCTCC AAACATGGCT GCTTTCCAGC GCCGGGCAGG CTTCCTGGAG GTGTCGTACC GCGGCTCTGG CGGCTCTCAG AGAAAGATCC AGGGCGATGG CTACAAGCTG TGCCACCCCG GCATCCCCTG GGCTCCCCTG GCAGGCTGCT TGAGCCAACT CCTGCAGGCC CTGGAAGGGA CACTGCAGCT GGACGTCGCC GAAGAACTGG GAATGGCCCC : 16)
CGCAGCGCTC CAGGAGAAGC AGGAGCTGGT GCTGCTCGGA AGCTCCTGCC CCAGCCAGGC CCATAGCGGC CTTTTCCTCT TATCCCCCGA GTTGGGTCCC GACTTTGCCA CCACCATCTG TGCCCTGCAG CCCTAATAA
ATCAAGGCAG GTGACTGGCA GGTTACCCTT GAGCAAGCGC GCAGCGGCGG CGGTTCTAAC CACTTAAAGA GACCACCTGC CGAAGACGTC TCTATCCTGA AGAGCTTCGT AAGGGCTGTC GCAATTCTTC GTAATCTCCA AGAGGGCGGT GGAGGCTCCC TCAACCCGTC TCCTCCGTCT ACCCAGGGTG CCATGCCGGC AGGGGTCCTG GTTGCTAGCC GCGTTCTACG CCACCTTGCG AGCTTCCTGC TCAAGTCTTT CGCAGCGCTC CAGGAGAAGC AGGAGCTGGT GCTGCTCGGA AGCTCCTGCC CCAGCCAGGC CCATAGCGGC CTTTTCCTCT TATCCCCCGA GTTGGGTCCC GACTTTGCCA CCACCATCTG TGCCCTGCAG CCCTAATAA
GAAAAACTGA CGTTCTATCT GGGTGGTGGC TCTGGCGGTG TGATCGATGA AATTATACAT GACCCGAACA ACCTCAATGA CCTTCGACTT CCAAACCTGG AAAATGCATC AGGTATTGAG CCCTCTGCCA CGGCCGCACC AGAGGGCGGT GGAGGCTCCC TCAACCCGTC TCCTCCGTCT ACCCAGGGTG CCATGCCGGC AGGGGTCCTG GTTGCTAGCC GCGTTCTACG CCACCTTGCG AGCTTCCTGC TCAAGTCTTT CGCAGCGCTC CAGGAGAAGC AGGAGCTGGT GCTGCTCGGA AGCTCCTGCC CCAGCCAGGC CCATAGCGGC CTTTTCCTCT TATCCCCCGA GTTGGGTCCC GACTTTGCCA CCACCATCTG TGCCCTGCAG CCCTAATAA -64- CZ 295843 B6 PMON13182
1 ATGGCTAACT 5 51 ACCACCTGCA 101 CTATCCTGAT 151 AGGGCTGTCA 201 TAATCTCCAA 251 CAATCATCAT 10 301 TTCTATCTGG 351 CGGTGGAGGC 401 ACAAGCTGTG 451 ATCCCCTGGG 501 AGGCTGCTTG 15 551 TGCAGGCCCT 601 CTGCAGCTGG 651 AGAACTGGGA 701 CCTTCGCCTC 751 CATCTGCAGA 20 801 GCAGCCCTCT 851 TAGAGCAAGT 901 CTGTGTGCCA GCTCTATAAT GATCGATGAA CCTTTGCTGG ACCCGAACAA GGACCGAAAC CTTCGACTTC AGAACTTAGA AAATGCATCA CCATGTCTGC CCTCTGCCAC CAAGGCAGGT GACTGGCAAG TTACCCTTGA GCAAGCGCAG TCCCCGGGTG GTGGTTCTGG CCACCCCGAG GAGCTGGTGC CTCCCCTGAG CTCCTGCCCC AGCCAACTCC ATAGCGGCCT GGAAGGGATA TCCCCCGAGT ACGTCGCCGA CTTTGCCACC ATGGCCCCTG CCCTGCAGCC TGCTTTCCAG CGCCGGGCAG GCTTCCTGGA GGTGTCGTAC GGCGGCTCTG GGGGCTCTCA GAGAAAGATC CAGGGCGATG CCTAATAA (SEQ ID N0:1' ATTATACATC ACTTAAAGAG CCTCAATGAC GAAGACGTCT CAAACCTGGA GAGCTTCGTA GGTATTGAGG CAATTCTTCG GGCCGCACCC TCTCGACATC AATTCCGGGA AAAACTGACG GAACAACAGT ACGTAGAGGG CGGCGGCTCC AACATGGCTT TGCTCGGACA CTCTCTGGGC AGCCAGGCCC TGCAGCTGGC TTTCCTCTAC CAGGGGCTCC TGGGTCCCAC CTTGGACACA ACCATCTGGC AGCAGATGGA CACCCAGGGT GCCATGCCGG GAGGGGTCCT GGTTGCTAGC CGCGTTCTAC GCCACCTTGC GAGCTTCCTG CTCAAGTCTT GCGCAGCGCT CCAGGAGAAG ) pMON13183 25
1 ATGGCTAACT 51 ACCACCTGCA 101 CTATCCTGAT 151 AGGGCTGTCA 30 201 TAATCTCCAA 251 CAATCATCAT 301 TTCTATCTGG 351 CGGTGGAGGC 401 CGTCTCCTCC 35 451 CTGTGCCACC 501 CTGGGCTCCC 551 GCTTGAGCCA 601 GCCCTGGAAG 651 GCTGGACGTC 40 701 TGGGAATGGC 751 GCCTCTGCTT 801 GCAGAGCTTC 851 CCTCTGGCGG 901 CAAGTGAGAA 45 951 TGCCACCTAA GCTCTATAAT GATCGATGAA CCTTTGCTGG ACCCGAACAA GGACCGAAAC CTTCGACTTC AGAACTTAGA AAATGCATCA CCATGTCTGC CCTCTGCCAC CAAGGCAGGT GACTGGCAAG TTACCCTTGA GCAAGCGCAG TCCCCGGGTG AACCGTCTGG GTCTAAAGAA TCTCATAAAT CCGAGGAGCT GGTGCTGCTC CTGAGCTCCT GCCCCAGCCA ACTCCATAGC GGCCTTTTCC GGATATCCCC CGAGTTGGGT GCCGACTTTG CCACCACCAT CCCTGCCCTG CAGCCCACCC TCCAGCGCCG GGCAGGAGGG CTGGAGGTGT CGTACCGCGT CTCTGGCGGC TCTCAGAGCT AGATCCAGGG CGATGGCGCA TAA (SEQ ID NO:18)
ATTATACATC ACTTAAAGAG CCTCAATGAC GAAGACGTCT CAAACCTGGA GAGCTTCGTA GGTATTGAGG CAATTCTTCG GGCCGCACCC TCTCGACATC AATTCCGGGA AAAACTGACG GAACAACAGT ACGTAGAGGG TCCAATCTCT ACTATCAACC CTCCAAACAT GGCTTACAAG GGACACTCTC TGGGCATCCC GGCCCTGCAG CTGGCAGGCT TCTACCAGGG GCTCCTGCAG CCCACCTTGG ACACACTGCA CTGGCAGCAG ATGGAAGAAC AGGGTGCCAT GCCGGCCTTC GTCCTGGTTG CTAGCCATCT TCTACGCCAC CTTGCGCAGC TCCTGCTCAA GTCTTTAGAG GCGCTCCAGG AGAAGCTGTG pMON13184
1 ATGGCTAACT 50 51 ACCACCTGCA 101 CTATCCTGAT 151 AGGGCTGTCA 201 TAATCTCCAA 251 CAATCATCAT 55 301 TTCTATCTGG 351 CGGTGGAGGC
GCTCTATAAT GATCGATGAA CCTTTGCTGG ACCCGAACAA GGACCGAAAC CTTCGACTTC AGAACTTAGA AAATGCATCA CCATGTCTGC CCTCTGCCAC CAAGGCAGGT GACTGGCAAG TTACCCTTGA GCAAGCGCAG TCCCCGGGTG GTGGTTCTGG
ATTATACATC ACTTAAAGAG CCTCAATGAC GAAGACGTCT CAAACCTGGA GAGCTTCGTA GGTATTGAGG CAATTCTTCG GGCCGCACCC TCTCGACATC AATTCCGGGA AAAACTGACG GAACAACAGT ACGTAGAGGG CGGCGGCTCC AACATGGCTC -65 - 5 5 10 CZ 295843 B6 401 CCGAGTTGGG TCCCACCTTG GACACACTGC AGCTGGACGT 451 GCCACCACCA TCTGGCAGCA GATGGAAGAA CTGGGAATGG 501 GCAGCCCACC CAGGGTGCCA TGCCGGCCTT CGCCTCTGCT 551 GGGCAGGAGG GGTCCTGGTT GCTAGCCATC TGCAGAGCTT 601 TCGTACCGCG TTCTACGCCA CCTTGCGCAG CCCTCTGGCG 651 CTCTCAGAGC TTCCTGCTCA AGTCTTTAGA GCAAGTGAGA 701 GCGATGGCGC AGCGCTCCAG GAGAAGCTGT GTGCCACCTA 751 CACCCCGAGG AGCTGGTGCT GCTCGGACAC TCTCTGGGCA 801 TCCCCTGAGC TCCTGCCCCA GCCAGGCCCT GCAGCTGGCA 851 GCCAACTCCA TAGCGGCCTT TTCCTCTACC AGGGGCTCCT 901 GAAGGGATAT CCTAATAA (SEQ ID NO:19) pMON13185
CGCCGACTTT CCCCTGCCCT TTCCAGCGCC CCTGGAGGTG GCTCTGGCGG AAGATCCAGG CAAGCTGTGC TCCCCTGGGC GGCTGCTTGA GCAGGCCCTG 15 20 25 30 35 1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC 51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC 101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA 301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT 351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT 401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT 451 TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG 501 CACCATCTGG CAGCAGATGG AAGAACTGGG AATGGCCCCT 551 CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA 601 GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG 651 CCGCGTTCTA CGCCACCTTG CGCAGCCCTC TGGCGGCTCT 701 AGAGCTTCCT GCTCAAGTCT TTAGAGCAAG TGAGAAAGAT 751 GGCGCAGCGC TCCAGGAGAA GCTGTGTGCC ACCTACAAGC 801 CGAGGAGCTG GTGCTGCTCG GACACTCTCT GGGCATCCCC 851 TGAGCTCCTG CCCCAGCCAG GCCCTGCAGC TGGCAGGCTG 901 CTCCATAGCG GCCTTTTCCT CTACCAGGGG CTCCTGCAGG 951 GATATCCTAA TAA (SEQ ID NO:20) PMON13186
ACTTAAAGAG GAAGACGTCT GAGCTTCGTA CAATTCTTCG TCTCGACATC AAAACTGACG ACGTAGAGGG ACTATCAACC GGCTCCCGAG ACTTTGCCAC GCCCTGCAGC GCGCCGGGCA AGGTGTCGTA GGCGGCTCTC CCAGGGCGAT TGTGCCACCC TGGGCTCCCC CTTGAGCCAA CCCTGGAAGG 40 45 50
1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC
51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC
101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA
151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG
201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC
251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA
301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT
351 CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC
401 TGGCCCCTGC CCTGCAGCCC ACCCAGGGTG CCATGCCGGC
451 GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG GTTGCTAGCC
501 CTTCCTGGAG GTGTCGTACC GCGTTCTACG CCACCTTGCG
551 GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT
601 AGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC
651 CTACAAGCTG TGCCACCCCG AGGAGCTGGT GCTGCTCGGA
701 GCATCCCCTG GGCTCCCCTG AGCTCCTGCC CCAGCCAGGC
751 GCAGGCTGCT TGAGCCAACT CCATAGCGGC CTTTTCCTCT
801 CCTGCAGGCC CTGGAAGGGA TATCCCCCGA GTTGGGTCCC
851 CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG 901 GAAGAACTGG GATAATAA (SEQ ID NO:21)
ACTTAAAGAG GAAGACGTCT GAGCTTCGTA CAATTCTTCG TCTCGACATC AAAACTGACG ACGTAGAGGG AACATGGCTA CTTCGCCTCT ATCTGCAGAG CAGCCCTCTG AGAGCAAGTG TGTGTGCCAC CACTCTCTGG CCTGCAGCTG ACCAGGGGCT ACCTTGGACA GCAGCAGATG -66- 55 CZ 295843 B6 PMON13187
1 ATGGCTAACT 5 51 ACCACCTGCA 101 CTATCCTGAT 151 AGGGCTGTCA 201 TAATCTCCAA 251 CAATCATCAT 10 301 TTCTATCTGG 351 CGGTGGAGGC 401 CGTCTCCTCC 451 CCTGCCCTGC 501 CCAGCGCCGG 15 551 TGGAGGTGTC 601 TCTGGCGGCT 651 GATCCAGGGC 701 AGCTGTGCCA 751 CCCTGGGCTC 20 801 CTGCTTGAGC 851 AGGCCCTGGA 901 CAGCTGGACG 951 ACTGGGATAA 25 PMON13188 1 ATGGCTAACT 51 ACCACCTGCA 101 CTATCCTGAT 30 151 AGGGCTGTCA 201 TAATCTCCAA 251 CAATCATCAT 301 TTCTATCTGG 351 CGGTGGAGGC 35 401 CCCAGGGTGC 451 GGGGTCCTGG 501 CGTTCTACGC 551 GCTTCCTGCT 601 GCAGCGCTCC 40 651 GGAGCTGGTG 701 GCTCCTGCCC 751 CATAGCGGCC 801 ATCCCCCGAG 851 ACTTTGCCAC 45 901 GCCCTGCAGC GCTCTATAAT GATCGATGAA CCTTTGCTGG ACCCGAACAA GGACCGAAAC CTTCGACTTC AGAACTTAGA AAATGCATCA CCATGTCTGC CCTCTGCCAC CAAGGCAGGT GACTGGCAAG TTACCCTTGA GCAAGCGCAG TCCCCGGGTG AACCGTCTGG GTCTAAAGAA TCTCATAAAT AGCCCACCCA GGGTGCCATG GCAGGAGGGG TCCTGGTTGC GTACCGCGTT CTACGCCACC CTCAGAGCTT CCTGCTCAAG GATGGCGCAG CGCTCCAGGA CCCCGAGGAG CTGGTGCTGC CCCTGAGCTC CTGCCCCAGC CAACTCCATA GCGGCCTTTT AGGGATATCC CCCGAGTTGG TCGCCGACTT TGCCACCACC TAA (SEQ ID NO:22) GCTCTATAAT GATCGATGAA CCTTTGCTGG ACCCGAACAA GGACCGAAAC CTTCGACTTC AGAACTTAGA AAATGCATCA CCATGTCTGC CCTCTGCCAC CAAGGCAGGT GACTGGCAAG TTACCCTTGA GCAAGCGCAG TCCCCGGGTG GTGGTTCTGG CATGCCGGCC TTCGCCTCTG TTGCTAGCCA TCTGCAGAGC CACCTTGCGC AGCCCTCTGG CAAGTCTTTA GAGCAAGTGA AGGAGAAGCT GTGTGCCACC CTGCTCGGAC ACTCTCTGGG CAGCCAGGCC CTGCAGCTGG TTTTCCTCTA CCAGGGGCTC TTGGGTCCCA CCTTGGACAC CACCATCTGG CAGCAGATGG CCTAATAA (SEQ ID NO:2!
ATTATACATC ACTTAAAGAG CCTCAATGAC GAAGACGTCT CAAACCTGGA GAGCTTCGTA GGTATTGAGG CAATTCTTCG GGCCGCACCC TCTCGACATC AATTCCGGGA AAAACTGACG GAACAACAGT ACGTAGAGGG TCCAATCTCT ACTATCAACC CTCCAAACAT GGCTATGGCC CCGGCCTTCG CCTCTGCTTT TAGCCATCTG CAGAGCTTCC TTGCGCAGCC CTCTGGCGGC TCTTTAGAGC AAGTGAGAAA GAAGCTGTGT GCCACCTACA TCGGACACTC TCTGGGCATC CAGGCCCTGC AGCTGGCAGG CCTCTACCAG GGGCTCCTGC GTCCCACCTT GGACACACTG ATCTGGCAGC AGATGGAAGA ATTATACATC ACTTAAAGAG CCTCAATGAC GAAGACGTCT CAAACCTGGA GAGCTTCGTA GGTATTGAGG CAATTCTTCG GGCCGCACCC TCTCGACATC AATTCCGGGA AAAACTGACG GAACAACAGT ACGTAGAGGG CGGCGGCTCC AACATGGCTA CTTTCCAGCG CCGGGCAGGA TTCCTGGAGG TGTCGTACCG CGGCTCTGGC GGCTCTCAGA GAAAGATCCA GGGCGATGGC TACAAGCTGT GCCACCCCGA CATCCCCTGG GCTCCCCTGA CAGGCTGCTT GAGCCAACTC CTGCAGGCCC TGGAAGGGAT ACTGCAGCTG GACGTCGCCG AAGAACTGGG AATGGCCCCT ') PMON13189
1 ATGGCTAACT 50 51 ACCACCTGCA 101 CTATCCTGAT 151 AGGGCTGTCA 201 TAATCTCCAA 251 CAATCATCAT 55 301 TTCTATCTGG 351 CGGTGGAGGC
GCTCTATAAT GATCGATGAA CCTTTGCTGG ACCCGAACAA GGACCGAAAC CTTCGACTTC AGAACTTAGA AAATGCATCA CCATGTCTGC CCTCTGCCAC CAAGGCAGGT GACTGGCAAG TTACCCTTGA GCAAGCGCAG TCCCCGGGTG AACCGTCTGG
ATTATACATC ACTTAAAGAG CCTCAATGAC GAAGACGTCT CAAACCTGGA GAGCTTCGTA GGTATTGAGG CAATTCTTCG GGCCGCACCC TCTCGACATC AATTCCGGGA AAAACTGACG GAACAACAGT ACGTAGAGGG TCCAATCTCT ACTATCAACC -67- CZ 295843 B6 401 CGTCTCCTCC GTCTAAAGAA 451 GGTGCCATGC CGGCCTTCGC 501 CCTGGTTGCT AGCCATCTGC 551 TACGCCACCT TGCGCAGCCC 601 CTGCTCAAGT CTTTAGAGCA 651 GCTCCAGGAG AAGCTGTGTG 701 TGGTGCTGCT CGGACACTCT 751 TGCCCCAGCC AGGCCCTGCA 801 CGGCCTTTTC CTCTACCAGG 851 CCGAGTTGGG TCCCACCTTG 901 GCCACCACCA TCTGGCAGCA 951 GCAGCCCTAA TAA (SEQ I] TCTCATAAAT CTCCAAACAT GGCTACCCAG CTCTGCTTTC CAGCGCCGGG CAGGAGGGGT AGAGCTTCCT GGAGGTGTCG TACCGCGTTC TCTGGCGGCT CTGGCGGCTC TCAGAGCTTC AGTGAGAAAG ATCCAGGGCG ATGGCGCAGC CCACCTACAA GCTGTGCCAC CCCGAGGAGC CTGGGCATCC CCTGGGCTCC CCTGAGCTCC GCTGGCAGGC TGCTTGAGCC AACTCCATAG GGCTCCTGCA GGCCCTGGAA GGGATATCCC GACACACTGC AGCTGGACGT CGCCGACTTT GATGGAAGAA CTGGGAATGG CCCCTGCCCT i NO:24) 15 20 25 30 35 PMON13190 1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG 51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTT 401 CTGCTTTCCA GCGCCGGGCA GGAGGGGTCC TGGTTGCTAG CCATCTGCAG 451 AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA CGCCACCTTG CGCAGCCCTC 501 TGGCGGCTCT GGCGGCTCTC AGAGCTTCCT GCTCAAGTCT TTAGAGCAAG 551 TGAGAAAGAT CCAGGGCGAT GGCGCAGCGC TCCAGGAGAA GCTGTGTGCC 601 ACCTACAAGC TGTGCCACCC CGAGGAGCTG GTGCTGCTCG GACACTCTCT 651 GGGCATCCCC TGGGCTCCCC TGAGCTCCTG CCCCAGCCAG GCCCTGCAGC 701 TGGCAGGCTG CTTGAGCCAA CTCCATAGCG GCCTTTTCCT CTACCAGGGG 751 CTCCTGCAGG CCCTGGAAGG GATATCCCCC GAGTTGGGTC CCACCTTGGA 801 CACACTGCAG CTGGACGTCG CCGACTTTGC CACCACCATC TGGCAGCAGA 851 TGGAAGAACT GGGAATGGCC CCTGCCCTGC AGCCCACCCA GGGTGCCATG 901 CCGGCCTTCG CCTAATAA (SEQ ID NO:25) pMON13191
1 ATGGCTAACT 51 ACCACCTGCA 40 101 CTATCCTGAT 151 AGGGCTGTCA 201 TAATCTCCAA 251 CAATCATCAT 301 TTCTATCTGG 45 351 CGGTGGAGGC 401 CGTCTCCTCC 451 TTCCAGCGCC 501 CCTGGAGGTG 551 GCTCTGGCGG 50 601 AAGATCCAGG 651 CAAGCTGTGC 701 TCCCCTGGGC 751 GGCTGCTTGA 801 GCAGGCCCTG 55 851 TGCAGCTGGA
GCTCTATAAT GATCGATGAA CCTTTGCTGG ACCCGAACAA GGACCGAAAC CTTCGACTTC AGAACTTAGA AAATGCATCA CCATGTCTGC CCTCTGCCAC CAAGGCAGGT GACTGGCAAG TTACCCTTGA GCAAGCGCAG TCCCCGGGTG AACCGTCTGG GTCTAAAGAA TCTCATAAAT GGGCAGGAGG GGTCCTGGTT TCGTACCGCG TTCTACGCCA CTCTCAGAGC TTCCTGCTCA GCGATGGCGC AGCGCTCCAG CACCCCGAGG AGCTGGTGCT TCCCCTGAGC TCCTGCCCCA GCCAACTCCA TAGCGGCCTT GAAGGGATAT CCCCCGAGTT CGTCGCCGAC TTTGCCACCA
ATTATACATC ACTTAAAGAG CCTCAATGAC GAAGACGTCT CAAACCTGGA GAGCTTCGTA GGTATTGAGG CAATTCTTCG GGCCGCACCC TCTCGACATC AATTCCGGGA AAAACTGACG GAACAACAGT ACGTAGAGGG TCCAATCTCT ACTATCAACC CTCCAAACAT GGCTTCTGCT GCTAGCCATC TGCAGAGCTT CCTTGCGCAG CCCTCTGGCG AGTCTTTAGA GCAAGTGAGA GAGAAGCTGT GTGCCACCTA GCTCGGACAC TCTCTGGGCA GCCAGGCCCT GCAGCTGGCA TTCCTCTACC AGGGGCTCCT GGGTCCCACC TTGGACACAC CCATCTGGCA GCAGATGGAA -68- CZ 295843 B6
901 GAACTGGGAA TGGCCCCTGC 951 CTTCGCCTAA TAA (SEQ I 5 pMON13192 1 ATGGCTAACT GCTCTATAAT 51 ACCACCTGCA CCTTTGCTGG 101 CTATCCTGAT GGACCGAAAC 151 AGGGCTGTCA AGAACTTAGA 10 201 TAATCTCCAA CCATGTCTGC 251 CAATCATCAT CAAGGCAGGT 301 TTCTATCTGG TTACCCTTGA 351 CGGTGGAGGC TCCCCGGGTG 401 ACAAGCTGTG CCACCCCGAG 15 451 ATCCCCTGGG CTCCCCTGAG 501 AGGCTGCTTG AGCCAACTCC 551 TGCAGGCCCT GGAAGGGATA 601 CTGCAGCTGG ACGTCGCCGA 651 AGAACTGGGA ATGGCCCCTG 20 701 CCTTCGCCTC TGCTTTCCAG 751 CATCTGCAGA GCTTCCTGGA 801 GCAGCCCACA CCATTGGGCC 851 TCAAGTCTTT AGAGCAAGTG 25 901 CAGGAGAAGC TGTGTGCCAC pMON13193 1 ATGGCTAACT GCTCTATAAT 51 ACCACCTGCA CCTTTGCTGG 30 101 CTATCCTGAT GGACCGAAAC 151 AGGGCTGTCA AGAACTTAGA 201 TAATCTCCAA CCATGTCTGC 251 CAATCATCAT CAAGGCAGGT 301 TTCTATCTGG TTACCCTTGA 35 351 CGGTGGAGGC TCCCCGGGTG 401 CGTCTCCTCC GTCTAAAGAA 451 CTGTGCCACC CCGAGGAGCT 501 CTGGGCTCCC CTGAGCTCCT 551 GCTTGAGCCA ACTCCATAGC 40 601 GCCCTGGAAG GGATATCCCC 651 GCTGGACGTC GCCGACTTTG 701 TGGGAATGGC CCCTGCCCTG 751 GCCTCTGCTT TCCAGCGCCG 801 GCAGAGCTTC CTGGAGGTGT 45 851 CCACACCATT GGGCCCTGCC 901 TCTTTAGAGC AAGTGAGAAA 951 GAAGCTGTGT GCCACCTAAT pMON25190 50 1 ATGGCTAACT GCTCTATAAT 51 ACCACCTGCA CCTTTGCTGG 101 CTATCCTGAT GGACCGAAAC 151 AGGGCTGTCA AGAACTTAGA 55 201 TAATCTCCAA CCATGTCTGC 251 CAATCATCAT CAAGGCAGGT CCTGCAGCCC ACCCAGGGTG CCATGCCGGC NO: 2 6) GATCGATGAA ATTATACATC ACTTAAAGAG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTTCGACTTC CAAACCTGGA GAGCTTCGTA AAATGCATCA GGTATTGAGG CAATTCTTCG CCTCTGCCAC GGCCGCACCC TCTCGACATC GACTGGCAAG AATTCCGGGA AAAACTGACG GCAAGCGCAG GAACAACAGT ACGTAGAGGG GTGGTTCTGG CGGCGGCTCC AACATGGCTT GAGCTGGTGC TGCTCGGACA CTCTCTGGGC CTCCTGCCCC AGCCAGGCCC TGCAGCTGGC ATAGCGGCCT TTTCCTCTAC CAGGGGCTCC TCCCCCGAGT TGGGTCCCAC CTTGGACACA CTTTGCCACC ACCATCTGGC AGCAGATGGA CCCTGCAGCC CACCCAGGGT GCCATGCCGG CGCCGGGCAG GAGGGGTCCT GGTTGCTAGC GGTGTCGTAC CGCGTTCTAC GCCACCTTGC CTGCCAGCTC CCTGCCCCAG AGCTTCCTGC AGAAAGATCC AGGGCGATGG CGCAGCGCTC CTAATAA (SEQ ID NO:27) GATCGATGAA ATTATACATC ACTTAAAGAG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTTCGACTTC CAAACCTGGA GAGCTTCGTA AAATGCATCA GGTATTGAGG CAATTCTTCG CCTCTGCCAC GGCCGCACCC TCTCGACATC GACTGGCAAG AATTCCGGGA AAAACTGACG GCAAGCGCAG GAACAACAGT ACGTAGAGGG AACCGTCTGG TCCAATCTCT ACTATCAACC TCTCATAAAT CTCCAAACAT GGCTTACAAG GGTGCTGCTC GGACACTCTC TGGGCATCCC GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT GGCCTTTTCC TCTACCAGGG GCTCCTGCAG CGAGTTGGGT CCCACCTTGG ACACACTGCA CCACCACCAT CTGGCAGCAG ATGGAAGAAC CAGCCCACCC AGGGTGCCAT GCCGGCCTTC GGCAGGAGGG GTCCTGGTTG CTAGCCATCT CGTACCGCGT TCTACGCCAC CTTGCGCAGC AGCTCCCTGC CCCAGAGCTT CCTGCTCAAG GATCCAGGGC GATGGCGCAG CGCTCCAGGA AA (SEQ ID NO:28)
GATCGATGAA ATTATACATC ACTTAAAGAG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTTCGACTTC CAAACCTGGA GAGCTTCGTA AAATGCATCA GGTATTGAGG CAATTCTTCG CCTCTGCCAC GGCCGCACCC TCTCGACATC GACTGGCAAG AATTCCGGGA AAAACTGACG -69- CZ 295843 B6
301 TTCTATCTGG TTACCCTTGA 351 CGGTGGAGGC TCCCCGGGTG 401 CCGAGTTGGG TCCCACCTTG 451 GCCACCACCA TCTGGCAGCA 5 501 GCAGCCCACC CAGGGTGCCA 551 GGGCAGGAGG GGTCCTGGTT 601 TCGTACCGCG TTCTACGCCA 651 CAGCTCCCTG CCCCAGAGCT 701 AGATCCAGGG CGATGGCGCA 10 751 AAGCTGTGCC ACCCCGAGGA 801 CCCCTGGGCT CCCCTGAGCT 851 GCTGCTTGAG CCAACTCCAT 901 CAGGCCCTGG AAGGGATATC 15 pMON25191 1 ATGGCTAACT GCTCTATAAT 51 ACCACCTGCA CCTTTGCTGG 101 CTATCCTGAT GGACCGAAAC 20 151 AGGGCTGTCA AGAACTTAGA 201 TAATCTCCAA CCATGTCTGC 251 CAATCATCAT CAAGGCAGGT 301 TTCTATCTGG TTACCCTTGA 351 CGGTGGAGGC TCCCCGGGTG 25 401 CGTCTCCTCC GTCTAAAGAA 451 TTGGGTCCCA CCTTGGACAC 501 CACCATCTGG CAGCAGATGG 551 CCACCCAGGG TGCCATGCCG 601 GGAGGGGTCC TGGTTGCTAG 30 651 CCGCGTTCTA CGCCACCTTG 701 CCCTGCCCCA GAGCTTCCTG 751 CAGGGCGATG GCGCAGCGCT 801 GTGCCACCCC GAGGAGCTGG 851 GGGCTCCCCT GAGCTCCTGC 35 901 TTGAGCCAAC TCCATAGCGG 951 CCTGGAAGGG ATATCCTAAT GCAAGCGCAG GAACAACAGT ACGTAGAGGG GTGGTTCTGG CGGCGGCTCC AACATGGCTC GACACACTGC AGCTGGACGT CGCCGACTTT GATGGAAGAA CTGGGAATGG CCCCTGCCCT TGCCGGCCTT CGCCTCTGCT TTCCAGCGCC GCTAGCCATC TGCAGAGCTT CCTGGAGGTG CCTTGCGCAG CCCACACCAT TGGGCCCTGC TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CTAATAA (SEQ ID NO:29) GATCGATGAA ATTATACATC ACTTAAAGAG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTTCGACTTC CAAACCTGGA GAGCTTCGTA AAATGCATCA GGTATTGAGG CAATTCTTCG CCTCTGCCAC GGCCGCACCC TCTCGACATC GACTGGCAAG AATTCCGGGA AAAACTGACG GCAAGCGCAG GAACAACAGT ACGTAGAGGG AACCGTCTGG TCCAATCTCT ACTATCAACC TCTCATAAAT CTCCAAACAT GGCTCCCGAG ACTGCAGCTG GACGTCGCCG ACTTTGCCAC AAGAACTGGG AATGGCCCCT GCCCTGCAGC GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA CCATCTGCAG AGCTTCCTGG AGGTGTCGTA CGCAGCCCAC ACCATTGGGC CCTGCCAGCT CTCAAGTCTT TAGAGCAAGT GAGAAAGATC CCAGGAGAAG CTGTGTGCCA CCTACAAGCT TGCTGCTCGG ACACTCTCTG GGCATCCCCT CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC CCTTTTCCTC TACCAGGGGC TCCTGCAGGC AA (SEQ ID NO:30) pMON13194
40 1 ATGGCTAACT GCTCTATAAT 51 ACCACCTGCA CCTTTGCTGG 101 CTATCCTGAT GGACCGAAAC 151 AGGGCTGTCA AGAACTTAGA 201 TAATCTCCAA CCATGTCTGC 45 251 CAATCATCAT CAAGGCAGGT 301 TTCTATCTGG TTACCCTTGA 351 CGGTGGAGGC TCCCCGGGTG 401 TGGCCCCTGC CCTGCAGCCC 451 GCTTTCCAGC GCCGGGCAGG 50 501 CTTCCTGGAG GTGTCGTACC 551 CATTGGGCCC TGCCAGCTCC 601 GAGCAAGTGA GAAAGATCCA 651 GTGTGCCACC TACAAGCTGT 701 ACTCTCTGGG CATCCCCTGG 55 751 CTGCAGCTGG CAGGCTGCTT 801 CCAGGGGCTC CTGCAGGCCC
GATCGATGAA ATTATACATC ACTTAAAGAG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTTCGACTTC CAAACCTGGA GAGCTTCGTA AAATGCATCA GGTATTGAGG CAATTCTTCG CCTCTGCCAC GGCCGCACCC TCTCGACATC GACTGGCAAG AATTCCGGGA AAAACTGACG GCAAGCGCAG GAACAACAGT ACGTAGAGGG GTGGTTCTGG CGGCGGCTCC AACATGGCTA ACCCAGGGTG CCATGCCGGC CTTCGCCTCT AGGGGTCCTG GTTGCTAGCC ATCTGCAGAG GCGTTCTACG CCACCTTGCG CAGCCCACAC CTGCCCCAGA GCTTCCTGCT CAAGTCTTTA GGGCGATGGC GCAGCGCTCC AGGAGAAGCT GCCACCCCGA GGAGCTGGTG CTGCTCGGAC GCTCCCCTGA GCTCCTGCCC CAGCCAGGCC GAGCCAACTC CATAGCGGCC TTTTCCTCTA TGGAAGGGAT ATCCCCCGAG TTGGGTCCCA -70- CZ 295843 B6
851 CCTTGGACAC ACTGCAGCTG 901 CAGCAGATGG AAGAACTGGG c pMON13195 1 ATGGCTAACT GCTCTATAAT 51 ACCACCTGCA CCTTTGCTGG 101 CTATCCTGAT GGACCGAAAC 151 AGGGCTGTCA AGAACTTAGA 10 201 TAATCTCCAA CCATGTCTGC 251 CAATCATCAT CAAGGCAGGT 301 TTCTATCTGG TTACCCTTGA 351 CGGTGGAGGC TCCCCGGGTG 401 CGTCTCCTCC GTCTAAAGAA 15 451 CCTGCCCTGC AGCCCACCCA 501 CCAGCGCCGG GCAGGAGGGG 551 TGGAGGTGTC GTACCGCGTT 601 GGCCCTGCCA GCTCCCTGCC 651 AGTGAGAAAG ATCCAGGGCG 20 701 CCACCTACAA GCTGTGCCAC 751 CTGGGCATCC CCTGGGCTCC 801 GCTGGCAGGC TGCTTGAGCC 851 GGCTCCTGCA GGCCCTGGAA 901 GACACACTGC AGCTGGACGT 25 951 GATGGAAGAA CTGGGATAAT GACGTCGCCG ACTTTGCCAC CACCATCTGG ΑΤΑΔΤΑΑ (SEQ ID NO:31) GATCGATGAA ATTATACATC ACTTAAAGAG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTTCGACTTC CAAACCTGGA GAGCTTCGTA AAATGCATCA GGTATTGAGG CAATTCTTCG CCTCTGCCAC GGCCGCACCC TCTCGACATC GACTGGCAAG AATTCCGGGA AAAACTGACG GCAAGCGCAG GAACAACAGT ACGTAGAGGG AACCGTCTGG TCCAATCTCT ACTATCAACC TCTCATAAAT CTCCAAACAT GGCTATGGCC GGGTGCCATG CCGGCCTTCG CCTCTGCTTT TCCTGGTTGC TAGCCATCTG CAGAGCTTCC CTACGCCACC TTGCGCAGCC CACACCATTG CCAGAGCTTC CTGCTCAAGT CTTTAGAGCA ATGGCGCAGC GCTCCAGGAG AAGCTGTGTG CCCGAGGAGC TGGTGCTGCT CGGACACTCT CCTGAGCTCC TGCCCCAGCC AGGCCCTGCA AACTCCATAG CGGCCTTTTC CTCTACCAGG GGGATATCCC CCGAGTTGGG TCCCACCTTG CGCCGACTTT GCCACCACCA TCTGGCAGCA ΑΆ (SEQ ID NO:32) pMON13196
1 ATGGCTAACT GCTCTATAAT 30 51 ACCACCTGCA CCTTTGCTGG 101 CTATCCTGAT GGACCGAAAC 151 AGGGCTGTCA AGAACTTAGA 201 TAATCTCCAA CCATGTCTGC 251 CAATCATCAT CAAGGCAGGT 35 301 TTCTATCTGG TTACCCTTGA 351 CGGTGGAGGC TCCCCGGGTG 401 CCCAGGGTGC CATGCCGGCC 451 GGGGTCCTGG TTGCTAGCCA 501 CGTTCTACGC CACCTTGCGC 40 551 TGCCCCAGAG CTTCCTGCTC 601 GGCGATGGCG CAGCGCTCCA 651 CCACCCCGAG GAGCTGGTGC 701 CTCCCCTGAG CTCCTGCCCC 751 AGCCAACTCC ATAGCGGCCT 45 801 GGAAGGGATA TCCCCCGAGT 851 ACGTCGCCGA CTTTGCCACC 50 901 ATGGCCCCTG pMON13197 CCCTGCAGCC 1 ATGGCTAACT GCTCTATAAT 51 ACCACCTGCA CCTTTGCTGG 101 CTATCCTGAT GGACCGAAAC 151 AGGGCTGTCA AGAACTTAGA 55 201 TAATCTCCAA CCATGTCTGC 251 CAATCATCAT CAAGGCAGGT GATCGATGAA ATTATACATC ACTTAAAGAG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTTCGACTTC CAAACCTGGA GAGCTTCGTA AAATGCATCA GGTATTGAGG CAATTCTTCG CCTCTGCCAC GGCCGCACCC TCTCGACATC GACTGGCAAG AATTCCGGGA AAAACTGACG GCAAGCGCAG GAACAACAGT ACGTAGAGGG GTGGTTCTGG CGGCGGCTCC AACATGGCTA TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA TCTGCAGAGC TTCCTGGAGG TGTCGTACCG AGCCCACACC ATTGGGCCCT GCCAGCTCCC AAGTCTTTAG AGCAAGTGAG AAAGATCCAG GGAGAAGCTG TGTGCCACCT ACAAGCTGTG TGCTCGGACA CTCTCTGGGC ATCCCCTGGG AGCCAGGCCC TGCAGCTGGC AGGCTGCTTG TTTCCTCTAC CAGGGGCTCC TGCAGGCCCT TGGGTCCCAC CTTGGACACA CTGCAGCTGG ACCATCTGGC AGCAGATGGA AGAACTGGGA CTAATAA (SEQ ID NO:33)
GATCGATGAA ATTATACATC ACTTAAAGAG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTTCGACTTC CAAACCTGGA GAGCTTCGTA AAATGCATCA GGTATTGAGG CAATTCTTCG CCTCTGCCAC GGCCGCACCC TCTCGACATC GACTGGCAAG AATTCCGGGA AAAACTGACG -71 - CZ 295843 B6
301 TTCTATCTGG TTACCCTTGA 351 CGGTGGAGGC TCCCCGGGTG 401 CGTCTCCTCC GTCTAAAGAA 451 GGTGCCATGC CGGCCTTCGC 5 501 CCTGGTTGCT AGCCATCTGC 551 TACGCCACCT TGCGCAGCCC 601 CAGAGCTTCC TGCTCAAGTC 651 TGGCGCAGCG CTCCAGGAGA 701 CCGAGGAGCT GGTGCTGCTC 10 751 CTGAGCTCCT GCCCCAGCCA 801 ACTCCATAGC GGCCTTTTCC 851 GGATATCCCC CGAGTTGGGT 901 GCCGACTTTG CCACCACCAT 15 951 CCCTGCCCTG CAGCCCTAAT pMON13198 1 ATGGCTAACT GCTCTATAAT 51 ACCACCTGCA CCTTTGCTGG 20 101 CTATCCTGAT GGACCGAAAC 151 AGGGCTGTCA AGAACTTAGA 201 TAATCTCCAA CCATGTCTGC 251 CAATCATCAT CAAGGCAGGT 301 TTCTATCTGG TTACCCTTGA 25 351 CGGTGGAGGC TCCCCGGGTG 401 CTGCTTTCCA GCGCCGGGCA 451 AGCTTCCTGG AGGTGTCGTA 501 ACCATTGGGC CCTGCCAGCT 551 TAGAGCAAGT GAGAAAGATC 30 601 CTGTGTGCCA CCTACAAGCT 651 ACACTCTCTG GGCATCCCCT 701 CCCTGCAGCT GGCAGGCTGC 751 TACCAGGGGC TCCTGCAGGC 801 CACCTTGGAC ACACTGCAGC 35 851 GGCAGCAGAT GGAAGAACTG 901 GGTGCCATGC CGGCCTTCGC GCAAGCGCAG GAACAACAGT ACGTAGAGGG AACCGTCTGG TCCAATCTCT ACTATCAACC TCTCATAAAT CTCCAAACAT GGCTACCCAG CTCTGCTTTC CAGCGCCGGG CAGGAGGGGT AGAGCTTCCT GGAGGTGTCG TACCGCGTTC ACACCATTGG GCCCTGCCAG CTCCCTGCCC TTTAGAGCAA GTGAGAAAGA TCCAGGGCGA AGCTGTGTGC CACCTACAAG CTGTGCCACC GGACACTCTC TGGGCATCCC CTGGGCTCCC GGCCCTGCAG CTGGCAGGCT GCTTGAGCCA TCTACCAGGG GCTCCTGCAG GCCCTGGAAG CCCACCTTGG ACACACTGCA GCTGGACGTC CTGGCAGCAG ATGGAAGAAC TGGGAATGGC AA (SEQ ID NO:34) GATCGATGAA ATTATACATC ACTTAAAGAG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTTCGACTTC CAAACCTGGA GAGCTTCGTA AAATGCATCA GGTATTGAGG CAATTCTTCG CCTCTGCCAC GGCCGCACCC TCTCGACATC GACTGGCAAG AATTCCGGGA AAAACTGACG GCAAGCGCAG GAACAACAGT ACGTAGAGGG GTGGTTCTGG CGGCGGCTCC AACATGGCTT GGAGGGGTCC TGGTTGCTAG CCATCTGCAG CCGCGTTCTA CGCCACCTTG CGCAGCCCAC CCCTGCCCCA GAGCTTCCTG CTCAAGTCTT CAGGGCGATG GCGCAGCGCT CCAGGAGAAG GTGCCACCCC GAGGAGCTGG TGCTGCTCGG GGGCTCCCCT GAGCTCCTGC CCCAGCCAGG TTGAGCCAAC TCCATAGCGG CCTTTTCCTC CCTGGAAGGG ATATCCCCCG AGTTGGGTCC TGGACGTCGC CGACTTTGCC ACCACCATCT GGAATGGCCC CTGCCCTGCA GCCCACCCAG CTAATAA (SEQ ID NO:35) pMON13199
40 1 ATGGCTAACT GCTCTATAAT 51 ACCACCTGCA CCTTTGCTGG 101 CTATCCTGAT GGACCGAAAC 151 AGGGCTGTCA AGAACTTAGA 201 TAATCTCCAA CCATGTCTGC 45 251 CAATCATCAT CAAGGCAGGT 301 TTCTATCTGG TTACCCTTGA 351 CGGTGGAGGC TCCCCGGGTG 401 CGTCTCCTCC GTCTAAAGAA 451 TTCCAGCGCC GGGCAGGAGG 50 501 CCTGGAGGTG TCGTACCGCG 551 TGGGCCCTGC CAGCTCCCTG 601 CAAGTGAGAA AGATCCAGGG 651 TGCCACCTAC AAGCTGTGCC 701 CTCTGGGCAT CCCCTGGGCT 55 751 CAGCTGGCAG GCTGCTTGAG 801 GGGGCTCCTG CAGGCCCTGG
GATCGATGAA ATTATACATC ACTTAAAGAG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTTCGACTTC CAAACCTGGA GAGCTTCGTA AAATGCATCA GGTATTGAGG CAATTCTTCG CCTCTGCCAC GGCCGCACCC TCTCGACATC GACTGGCAAG AATTCCGGGA AAAACTGACG GCAAGCGCAG GAACAACAGT ACGTAGAGGG AACCGTCTGG TCCAATCTCT ACTATCAACC TCTCATAAAT CTCCAAACAT GGCTTCTGCT GGTCCTGGTT GCTAGCCATC TGCAGAGCTT TTCTACGCCA CCTTGCGCAG CCCACACCAT CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG ACCCCGAGGA GCTGGTGCTG CTCGGACACT CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CCAACTCCAT AGCGGCCTTT TCCTCTACCA AAGGGATATC CCCCGAGTTG GGTCCCACCT -72- CZ 295843 B6 851 TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG 901 CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC 951 CATGCCGGCC TTCGCCTAAT AA (SEQ ID NO:36)
5 pMON31112 1 ATGGCTAACT 51 GCCACCGCTG 101 ATATCCTAAT 10 151 CGTGCTGTCA 201 AAATCTCCTG 251 CAATCCATAT 301 TTCTATCTGA 351 CGGTGGAGGC 15 401 CGTCTCCTCC 451 GGTGCCATGC 501 CCTGGTTGCT 551 TACGCCACCT 601 CTGCTCAAGT 20 651 GCTCCAGGAG 701 TGGTGCTGCT 751 TGCCCCAGCC 801 CGGCCTTTTC 851 CCGAGTTGGG 25 901 GCCACCACCA 951 GCAGCCCTAA pMON31113 30 1 ATGGCTAACT 51 GCCACCGCTG 101 ATATCCTGAT 151 CGTGCTGTCA 201 AAATCTCCTG 35 251 CAATCATCAT 301 TTCTATCTGA 351 CGGTGGAGGC 401 CGTCTCCTCC 451 GGTGCCATGC 40 501 CCTGGTTGCT 551 TACGCCACCT 601 CAGAGCTTCC 651 TGGCGCAGCG 701 CCGAGGAGCT 45 751 CTGAGCTCCT 801 ACTCCATAGC 851 GGATATCCCC 901 GCCGACTTTG 50 951 CCCTGCCCTG pMON31114 1 ATGGCTAACT 51 GCCACCGCTG 55 101 ATATCCTGAT 151 CGTGCTGTCA GCTCTAACAT GATCGATGAA CCGCTGCTGG ACTTCAACAA GGAAAATAAC CTTCGTCGTC AGTCTCTGCA GAATGCATCA GCTCTAACAT GATCGATGAA CCGCTGCTGG ACTTCAACAA GGACAATAAC CTTCGTCGTC AGTCTCTGCA GAATGCATCA CCATGTCTGC CGCTAGCCAC CAAGGACGGT GACTGGAATG AAACCTTGGA GAACGCGCAG TCCCCGGGTG AACCGTCTGG GTCTAAAGAA TCTCATAAAT CGGCCTTCGC CTCTGCTTTC AGCCATCTGC AGAGCTTCCT TGCGCAGCCC TCTGGCGGCT CTTTAGAGCA AGTGAGAAAG AAGCTGTGTG CCACCTACAA CGGACACTCT CTGGGCATCC AGGCCCTGCA GCTGGCAGGC CTCTACCAGG GGCTCCTGCA TCCCACCTTG GACACACTGC TCTGGCAGCA GATGGAAGAA TAA (SEQ ID NO:37)
GCTCTAACAT GATCGATGAA CCGCTGCTGG ACTTCAACAA GGAAAATAAC CTTCGTCGTC AGTCTCTGCA GAATGCATCA CCATGTCTGC CCCTGGCCAC CCGTGACGGT GACTGGAATG AAACCTTGGA GAACGCGCAG TCCCCGGGTG AACCGTCTGG GTCTAAAGAA TCTCATAAAT CGGCCTTCGC CTCTGCTTTC AGCCATCTGC AGAGCTTCCT TGCGCAGCCC ACACCATTGG TGCTCAAGTC TTTAGAGCAA CTCCAGGAGA AGCTGTGTGC GGTGCTGCTC GGACACTCTC GCCCCAGCCA GGCCCTGCAG GGCCTTTTCC TCTACCAGGG CGAGTTGGGT CCCACCTTGG CCACCACCAT CTGGCAGCAG CAGCCCTAAT AA (SEQ ID
ATCATCACCC ACCTGAAGCA CCTCAATGGT GAAGACCAAG CAAACCTCGA GGCATTCAAC GCAATTGAGA GCATTCTTAA GGCCGCACCC ACGCGACATC AATTCCGTCG TAAACTGACC GCTCAACAGT ACGTAGAGGG TCCAATCTCT ACTATCAACC CTCCAAACAT GGCTACCCAG CAGCGCCGGG CAGGAGGGGT GGAGGTGTCG TACCGCGTTC CTGGCGGCTC TCAGAGCTTC ATCCAGGGCG ATGGCGCAGC GCTGTGCCAC CCCGAGGAGC CCTGGGCTCC CCTGAGCTCC TGCTTGAGCC AACTCCATAG GGCCCTGGAA GGGATATCCC AGCTGGACGT CGCCGACTTT CTGGGAATGG CCCCTGCCCT ATCATCACCC ACCTGAAGCA CCTCAATGGT GAAGACCAAG CAAACCTCGA GGCATTCAAC GCAATTGAGA GCATTCTTAA GGCCGCACCC ACGCGACATC AATTCCGTCG TAAACTGACC GCTCAACAGT ACGTAGAGGG TCCAATCTCT ACTATCAACC CTCCAAACAT GGCTACCCAG CAGCGCCGGG CAGGAGGGGT GGAGGTGTCG TACCGCGTTC GCCCTGCCAG CTCCCTGCCC GTGAGAAAGA TCCAGGGCGA CACCTACAAG CTGTGCCACC TGGGCATCCC CTGGGCTCCC CTGGCAGGCT GCTTGAGCCA GCTCCTGCAG GCCCTGGAAG ACACACTGCA GCTGGACGTC ATGGAAGAAC TGGGAATGGC NO:38)
ATCATCACCC ACCTGAAGCA CCTCAATGGT GAAGACCAAG CAAACCTCGA GGCATTCAAC GCAATTGAGA GCATTCTTAA -73 - CZ 295843 B6
201 AAATCTCCTG 251 CAATCATCAT 301 TTCTATCTGA 351 CGGTGGAGGC 5 401 CGTCTCCTCC 451 GGTGCCATGC 501 CCTGGTTGCT 551 TACGCCACCT 601 CTGCTCAAGT 10 651 GCTCCAGGAG 701 TGGTGCTGCT 751 TGCCCCAGCC 801 CGGCCTTTTC 851 CCGAGTTGGG 15 901 GCCACCACCA 951 GCAGCCCTAA CCATGTCTGC CCCTGGCCAC CCGTGACGGT GACTGGAATG AAACCTTGGA GAACGCGCAG TCCCCGGGTG AACCGTCTGG GTCTAAAGAA TCTCATAAAT CGGCCTTCGC CTCTGCTTTC AGCCATCTGC AGAGCTTCCT TGCGCAGCCC TCTGGCGGCT CTTTAGAGCA AGTGAGAAAG AAGCTGTGTG CCACCTACAA CGGACACTCT CTGGGCATCC AGGCCCTGCA GCTGGCAGGC CTCTACCAGG GGCTCCTGCA TCCCACCTTG GACACACTGC TCTGGCAGCA GATGGAAGAA TAA (SEQ ID NO:39)
GGCCGCACCC ACGCGACATC AATTCCGTCG TAAACTGACC GCTCAACAGT ACGTAGAGGG TCCAATCTCT ACTATCAACC CTCCAAACAT GGCTACCCAG CAGCGCCGGG CAGGAGGGGT GGAGGTGTCG TACCGCGTTC CTGGCGGCTC TCAGAGCTTC ATCCAGGGCG ATGGCGCAGC GCTGTGCCAC CCCGAGGAGC CCTGGGCTCC CCTGAGCTCC TGCTTGAGCC AACTCCATAG GGCCCTGGAA GGGATATCCC AGCTGGACGT CGCCGACTTT CTGGGAATGG CCCCTGCCCT pMON31115
20 1 ATGGCTAACT 51 GCCACCGCTG 101 ATATCCTAAT 151 CGTGCTGTCA 201 AAATCTCCTG 25 251 CAATCCATAT 301 TTCTATCTGA 351 CGGTGGAGGC 401 CGTCTCCTCC 451 GGTGCCATGC 30 501 CCTGGTTGCT 551 TACGCCACCT 601 CAGAGCTTCC 651 TGGCGCAGCG 701 CCGAGGAGCT 35 751 CTGAGCTCCT 801 ACTCCATAGC 851 GGATATCCCC 901 GCCGACTTTG 951 CCCTGCCCTG
GCTCTAACAT GATCGATGAA CCGCTGCTGG ACTTCAACAA GGACAATAAC CTTCGTCGTC AGTCTCTGCA GAATGCATCA CCATGTCTGC CGCTAGCCAC CAAGGACGGT GACTGGAATG AAACCTTGGA GAACGCGCAG TCCCCGGGTG AACCGTCTGG GTCTAAAGAA TCTCATAAAT CGGCCTTCGC CTCTGCTTTC AGCCATCTGC AGAGCTTCCT TGCGCAGCCC ACACCATTGG TGCTCAAGTC TTTAGAGCAA CTCCAGGAGA AGCTGTGTGC GGTGCTGCTC GGACACTCTC GCCCCAGCCA GGCCCTGCAG GGCCTTTTCC TCTACCAGGG CGAGTTGGGT CCCACCTTGG CCACCACCAT CTGGCAGCAG CAGCCCTAAT AA (SEQ ID ATCATCACCC ACCTGAAGCA CCTCAATGGT GAAGACCAAG CAAACCTCGA GGCATTCAAC GCAATTGAGA GCATTCTTAA GGCCGCACCC ACGCGACATC AATTCCGTCG TAAACTGACC GCTCAACAGT ACGTAGAGGG TCCAATCTCT ACTATCAACC CTCCAAACAT GGCTACCCAG CAGCGCCGGG CAGGAGGGGT GGAGGTGTCG TACCGCGTTC GCCCTGCCAG CTCCCTGCCC GTGAGAAAGA TCCAGGGCGA CACCTACAAG CTGTGCCACC TGGGCATCCC CTGGGCTCCC CTGGCAGGCT GCTTGAGCCA GCTCCTGCAG GCCCTGGAAG ACACACTGCA GCTGGACGTC ATGGAAGAAC TGGGAATGGC NO:40) 40 pMON28505
GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCT GGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAA 45 ACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAA GGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGC AGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACT ATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGAGGTTCACCCTTTGCC 50 TACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGA CCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGA CAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCT TGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGG ATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTT 55 GTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGC -74- CZ 295843 B6 TTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCC AGTGCCCA (SEQ ID NO:41) PMON28506 5 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCT GGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAA ACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAA 10 GGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGC AGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACT ATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGTTGCCTACACCTGTCCT GCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGG ACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCC 15 ACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCA GAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCA TCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCC ACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCG AGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGG 20 TTCACCCT (SEQ ID NO: 42) pMON28507 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCT 25 GGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAA ACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAA GGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGC AGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACT 30 ATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGTCCTGCTGCCTGCTGT GGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAG CAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCA TCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGG AACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCT 35 TCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTC AGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAA ACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGC CTACACCT (SEQ ID NO:43) 40 pMON28508 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCT GGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAA ACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT 45 CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAA GGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGC AGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACT ATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGTGGACTTTAGCTT GGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTC 50 TGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGG CAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCC TCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGC TCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGC GGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGA 55 CTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCC TGCTGCCT (SEQ ID NO:44) -75- CZ 295843 B6 pMON28509 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCT 5 GGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAA ACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAA GGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGC AGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACT 10 ATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGACTTTAGCTTGGGAGA ATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGG AGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTT TCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACA GGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAG 15 GAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAAC ATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCA TGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGC CTGCTGTG (SEQ ID NO:45) 20 pMON28510 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCT GGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAA ACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT 25 CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAA GGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCGGTTACCCTTGAGCAAGCGCA GGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGGAACCGTCTGGTCCAATCTCTACTAT CAACCCGTCTCCTCCGTCTAAAGAATCTCATAAACTCCAAACATGGGAGAATGGAAAACCCAGAT GGAGGAGACCAAGGCACAGGACATTCTGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGC 30 ACGGGGACAACTGGGACCCACTTGCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCT CCTCCTTGGGGCCCTGCAGGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCA CAAGGATCCCAATGCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGAT GCTTGTAGGGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCC TGCTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAC 35 CAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGTTG (SEQ ID NO:46) pMON28511 40 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCT GGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAA ACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAA GGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGC 45 AGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACT ATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGACCCACTTGCCTCTC ATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTG GAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGC TTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGT 50 CAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTA AACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTG CCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGA GACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGG GACAACTG (SEQ ID NO:47) -76- 55 CZ 295843 B6 PMON28512 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCT GGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAA 5 ACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAA GGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGC AGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACT ATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGAACCCAGCTTCCTCC 10 ACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCC GAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGC AACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTC CCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGC TGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGAC 15 ATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCAC TTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGA GCCTCCTT (SEQ ID NO:48) pMON28513 20 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCT GGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAA ACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAA 25 GGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGC AGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACT ATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGCAGGACCACAGCTCA CAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGA TGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCG 30 CCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACT GAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCT TGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTT CTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGG GCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTC 35 CTCCACAG (SEQ ID NO: 4 9) pMON28514 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCT 40 GGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAA ACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAA GGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGC AGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACT 45 ATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTCACAAGGATCCCAA TGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAG GGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGAC CTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCC AGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGA 50 AAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGA GTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGG ACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCA GGACCACA (SEQ ID NO:50) -77- 55 CZ 295843 B6 pMON28515 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCT GGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAA 5 ACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAA GGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGC AGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACT ATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGATCCCAATGCCATCTT 10 CCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCC TCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTC CTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCA CCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGA TGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCA 15 GCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCG TCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAG CTCACAAG (SEQ ID NO:51) pMON28516 20 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCT GGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAA ACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAA 25 GGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGC AGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACT ATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCATCTTCCTGAGCTT CCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCA GGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAA 30 CTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCC TACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGA CCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGA CAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCT TGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGG 35 ATCCCAAT (SEQ ID NO: 52) PMON28519 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCT 40 GGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAA ACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAA GGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGC AGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACT 45 ATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGAGGTTCACCCTTTGCC TACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGA CCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGA CAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCT TGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGG 50 ATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTT GTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTG TGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGT GCCCA (SEQ ID NO:53) -78- 55 CZ 295843 B6 PMON28520 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCT GGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAA 5 ACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAA GGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGC AGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACT ATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGTTGCCTACACCTGTCCT 10 GCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGG ACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCC ACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCA GAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCA TCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCC 15 ACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGT CCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTC ACCCT (SEQ ID NO:54) pMON28521 20 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCT GGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAA ACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAA 25 GGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGC AGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACT ATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGTCCTGCTGCCTGCTGT GGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAG CAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCA 30 TCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGG AACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCT TCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTC AGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACT GCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTA 35 CACCT (SEQ ID NO: 55) PMON28522 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCT 40 GGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAA ACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAA GGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGC AGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACT 45 ATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGTGGACTTTAGCTT GGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTC TGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGG CAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCC TCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGC 50 TCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGC AACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTC CCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGC TGCCT (SEQ ID NO:56) -79- 55 CZ 295843 B6 pMON28523 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCT GGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAA 5 ACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAA GGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGC AGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACT ATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGACTTTAGCTTGGGAGA 10 ATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGG AGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTT TCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACA GGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAG GAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATG 15 GCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGT CCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTG CTGTG (SEQ ID NO:57) pMON28524 20 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCT GGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAA ACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAA 25 GGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGC AGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACT ATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGAGAATGGAAAACCCA GATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGG CAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTC 30 CGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCAC AGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTT TCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCT CCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAG ACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTA 35 GCTTG (SEQ ID NO: 58) pMON28525 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCT 40 GGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAA ACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAA GGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGC AGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACT 45 ATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGACCCACTTGCCTCTC ATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTG GAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGC TTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGT CAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAAC 50 TGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCT ACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGAC CAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGAC AACTG (SEQ ID NO:59) -80- 55 CZ 295843 B6 pMON2852 6 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCT GGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAA 5 ACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAA GGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGC AGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACT ATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGAACCCAGCTTCCTCC 10 ACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCC GAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAAC ATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCA TGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGC CTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATT 15 CTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTG CCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCC TCCTT (SEQ ID NO:60) pMON28527 20 G C T AAC T G C T C T AT AAT G AT C G AT GAAAT T AT AC AT C AC T T AAAG AG AC C AC C T G C AC C T T T G C T GGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAA ACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAA 25 GGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGC AGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACT ATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGCAGGACCACAGCTCA CAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGA TGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCT 30 GCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAG CCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGG GAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTG CTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCA GCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTC 35 CACAG (SEQ ID NO: 61) pMON28528 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCT 40 GGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAA ACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAA GGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGC AGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACT 45 ATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTCACAAGGATCCCAA TGCCATCTTCCTGAGCTTGCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAG GGTCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTC CGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGA GGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAA 50 CCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTG ATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACA GGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGA CCACA (SEQ ID NO:62) -81 - 55 CZ 295843 B6 pMON28529 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCT GGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAA 5 ACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAA GGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGC AGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACT ATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGATCCCAATGCCATCTT 10 CCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCC TCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTC AGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCC TTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGG AGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCA 15 CGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCT CCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTC ACAAG (SEQ ID NO:63) pMON28530 20 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCT GGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAA ACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAA 25 GGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGC AGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACT ATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCATCTTCCTGAGCTT CCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCA GGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTG 30 CTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTAC ACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCA AGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAA CTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGG GGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATC 35 CCAAT (SEQ ID NO: 64) pMON28533 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCT 40 GGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTGACTTCCAAA CCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATGAGGCAATTCTTCG TAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGCATCCAATCATCATCAAGGC AGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATTGGTTACCCTTGAGCAAGCGCAGGA ACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGTAACCGTCTGGTCCAATCTCTACTATCAAC 45 CCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGAGGTTCACCCTTTGCCTACACC TGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGG CACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTG GGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGC CCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCA 50 ATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGA GGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCC TGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGA GCCAGTGCCCA (SEQ ID NO:65) -82- 55 CZ 295843 B6 pMON28534 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCT GGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAA 5 ACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAA GGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGC AGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACT ATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGTTGCCTACACCTGTCCT 10 GCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGG ACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCC ACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCA GAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCA TCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCC 15 ACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTG TGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGT GCCCAGAGGTTCACCCT (SEQ ID NO:66) pMON28535 20 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCT GGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAA ACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAA 25 GGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGC AGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACT ATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGTCCTGCTGCCTGCTGT GGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAG CAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCA 30 TCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGG AACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCT TCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTC AGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGT CCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTC 35 ACCCTTTGCCTACACCT (SEQ ID NO:67) pMON28536 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCT 40 GGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAA ACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAA GGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGC AGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACT 45 ATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGTGGACTTTAGCTT GGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTC TGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGG CAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCC TCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGC 50 TCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGC GGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACT GCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTA CACCTGTCCTGCTGCCT (SEQ ID NO:68) -83- 55 CZ 295843 B6 pMON28537 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCT GGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAA 5 ACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAA GGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGC AGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACT ATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGACTTTAGCTTGGGAGA 10 ATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGG AGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTT TCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACA GGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAG GAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAAC 15 GGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCG TGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTG TCCTGCTGCCTGCTGTG (SEQ ID NO:69) pMON28538 20 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCT GGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAA ACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAA 25 GGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGC AGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACT ATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGAGAATGGAAAACCCA GATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGG CAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTC 30 CGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCAC AGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTT TCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATG GCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGT CCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTG 35 CTGTGGACTTTAGCTTG (SEQ ID NO:70) pMON28539 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCT 40 GGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAA ACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAA GGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGC AGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACT 45 ATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGACCCACTTGCCTCTC ATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTG GAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGC TTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGT CAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAG 50 TCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTT CACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCA GATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGG CAGCACGGGGACAACTG (SEQ ID NO:71) -84- 55 CZ 295843 B6 PMON28540 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCT GGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAA 5 ACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAA GGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGC AGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACT ATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGAACCCAGCTTCCTCC 10 ACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCC GAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGC AACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCT TCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACAC CTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAG 15 GCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACT GGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGG CCCTGCAGAGCCTCCTT (SEQ ID NO:72) pMON28541 20 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCT GGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAA ACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAA 25 GGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGC AGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACT ATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGCAGGACCACAGCTCA CAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGA TGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCC 30 CCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCA CAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGG ACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCA GTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATC CCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAA 35 CCCAGCTTCCTCCACAG (SEQ ID NO:73) PMON28542 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCT 40 GGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAA ACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAA GGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGC AGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACT 45 ATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTCACAAGGATCCCAA TGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAG GGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCT GCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAG CCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGG 50 GAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTG CTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCA GCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTC CACAGGGCAGGACCACA (SEQ ID NO:74) 55 CZ 295843 B6 pMON28543 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCT GGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAA 5 ACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAA GGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGC AGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACT ATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGATCCCAATGCCATCTT 10 CCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCC TCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGAC CTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCC AGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGA AAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGA 15 GTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGG ACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCA GGACCACAGCTCACAAG (SEQ ID NO:75) pMON28544 20 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCT GGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAA ACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAA 25 GGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGC AGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACT ATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCATCTTCCTGAGCTT CCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCA GGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGAGCTCCGAGTC 30 CTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCA CCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGA TGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCA GCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCG TCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAG 35 CTCACAAGGATCCCAAT (SEQ ID NO:76) PMON28545 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCT 40 GGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAA ACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAA GGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGC AGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACT 45 ATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGATCCCAATGCCATCTT CCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCC TCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTC CTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCA CCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGA 50 TGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCA GCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCG TCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGGGCAGGACCACAGCTCACAAG (SEQ ID NO:77) -86- 55 CL 295843 B6 PMON15981
1 ATGGCTAACT 51 ACCACCTGCA 5 101 CTATCCTGAT 151 AGGGCTGTCA 201 TAATCTCCAA 251 CAATCATCAT 301 TTCTATCTGG 10 351 CGGTGGAGGC 401 CGTCTCCTCC 451 CTGTGCCACC 501 CTGGGCTCCC 551 GCTTGAGCCA 15 601 GCCCTGGAAG 651 GCTGGACGTC 701 TGGGAATGGC 751 GCCTCTGCTT 801 GCAGAGCTTC 20 851 CCGGCGGCGG 901 CCCCAGAGCT 951 CGATGGCGCA (SEQ ID NO:78) 25 pMON15982 1 ATGGCTAACT 51 ACCACCTGCA 101 CTATCCTGAT 30 151 AGGGCTGTCA 201 TAATCTCCAA 251 CAATCATCAT 301 TTCTATCTGG 351 CGGTGGAGGC 35 401 CGTCTCCTCC 451 TTGGGTCCCA 501 CACCATCTGG 551 CCACCCAGGG 601 GGAGGGGTCC 40 651 CCGCGTTCTA 701 CACCATTAGG 751 TTAGAGCAAG 801 GCTGTGTGCC 851 GACACTCTCT 45 901 GCCCTGCAGC 951 CTACCAGGGG (SEQ ID NO:79) pMON15965 50 1 ATGGCTAACT 51 ACCACCTGCA 101 CTATCCTGAT 151 AGGGCTGTCA 55 201 TAATCTCCAA 251 CAATCATCAT
GCTCTATAAT GATCGATGAA CCTTTGCTGG ACCCGAACAA GGATCGAAAC CTTCGACTTC AGAACTTAGA AAATGCATCA CCATGTCTGC CCTCTGCCAC CAAGGCAGGT GACTGGCAAG TTACCCTTGA GCAAGCGCAG TCCCCGGGTG AACCGTCTGG GTCTAAAGAA TCTCATAAAT CCGAGGAGCT GGTGCTGCTC CTGAGCTCCT GCCCCAGCCA ACTCCATAGC GGCCTTTTCC GGATATCCCC CGAGTTGGGT GCCGACTTTG CCACCACCAT CCCTGCCCTG CAGCCCACCC TCCAGCGCCG GGCAGGAGGG CTGGAGGTGT CGTACCGCGT CTCTGACATG GCTACACCAT TCCTGCTCAA GTCTTTAGAG GCGCTCCAGG AGAAGCTGTG
GCTCTATAAT GATCGATGAA CCTTTGCTGG ACCCGAACAA GGATCGAAAC CTTCGACTTC AGAACTTAGA AAATGCATCA CCATGTCTGC CCTCTGCCAC CAAGGCAGGT GACTGGCAAG TTACCCTTGA GCAAGCGCAG TCCCCGGGTG AACCGTCTGG GTCTAAAGAA TCTCATAAAT CCTTGGACAC ACTGCAGCTG CAGCAGATGG AAGAACTGGG TGCCATGCCG GCCTTCGCCT TGGTTGCTAG CCATCTGCAG CGCCACCTTG CGCAGCCCGG CCCTGCCAGC TCCCTGCCCC TGAGGAAGAT CCAGGGCGAT ACCTACAAGC TGTGCCACCC GGGCATCCCC TGGGCTCCCC TGGCAGGCTG CTTGAGCCAA CTCCTGCAGG CCCTGGAAGG
GCTCTATAAT GATCGATGAA CCTTTGCTGG ACCCGAACAA GGATCGAAAC CTTCGACTTC AGAACTTAGA AAATGCATCA CCATGTCTGC CCTCTGCCAC CAAGGCAGGT GACTGGCAAG
ATTATACATC ACTTAAAGAG CCTCAATGAC GAAGACGTCT CAAACCTGGA GAGCTTCGTA GGTATTGAGG CAATTCTTCG GGCCGCACCC TCTCGACATC AATTCCGGGA AAAACTGACG GAACAACAGT ACGTAGAGGG TCCAATCTCT ACTATCAACC CTCCAAACAT GTCTTACAAG GGACACTCTC TGGGCATCCC GGCCCTGCAG CTGGCAGGCT TCTACCAGGG GCTCCTGCAG CCCACCTTGG ACACACTGCA CTGGCAGCAG ATGGAAGAAC AGGGTGCCAT GCCGGCCTTC GTCCTGGTTG CTAGCCATCT TCTACGCCAC CTTGCGCAGC TAGGCCCTGC CAGCTCCCTG CAAGTGAGGA AGATCCAGGG TGCCACCTAA TAA
ATTATACATC ACTTAAAGAG CCTCAATGAC GAAGACGTCT CAAACCTGGA GAGCTTCGTA GGTATTGAGG CAATTCTTCG GGCCGCACCC TCTCGACATC AATTCCGGGA AAAACTGACG GAACAACAGT ACGTAGAGGG TCCAATCTCT ACTATCAACC CTCCAAACAT GTCTCCCGAG GACGTCGCCG ACTTTGCCAC AATGGCCCCT GCCCTGCAGC CTGCTTTCCA GCGCCGGGCA AGCTTCCTGG AGGTGTCGTA CGGCGGCTCT GACATGGCTA AGAGCTTCCT GCTCAAGTCT GGCGCAGCGC TCCAGGAGAA CGAGGAGCTG GTGCTGCTCG TGAGCTCCTG CCCCAGCCAG CTCCATAGCG GCCTTTTCCT GATATCCTAA TAA
ATTATACATC ACTTAAAGAG CCTCAATGAC GAAGACGTCT CAAACCTGGA GAGCTTCGTA GGTATTGAGG CAATTCTTCG GGCCGCACCC TCTCGACATC AATTCCGGGA AAAACTGACG -87- CZ 295843 B6
301 TTCTATCTGG 351 CGGTGGAGGC 401 CGTCTCCTCC 451 TTCCAGCGCC 5 501 CCTGGAGGTG 551 GCTCTGACAT 601 TTCCTGCTCA 651 AGCGCTCCAG 701 AGCTGGTGCT 10 751 TCCTGCCCCA 801 TAGCGGCCTT 851 CCCCCGAGTT 901 TTTGCCACCA 951 CCTGCAGCCC 15 (SEQ ID NO:80) pMON15966 1 ATGGCTAACT 20 51 ACCACCTGCA 101 CTATCCTGAT 151 AGGGCTGTCA 201 TAATCTCCAA 251 CAATCATCAT 25 301 TTCTATCTGG 351 CGGTGGAGGC 401 CGTCTCCTCC 451 CCTGCCCTGC 501 CCAGCGCCGG 30 551 TGGAGGTGTC 601 TCTGACATGG 651 CCTGCTCAAG 701 CGCTCCAGGA 751 CTGGTGCTGC 35 801 CTGCCCCAGC 851 GCGGCCTTTT 901 CCCGAGTTGG 951 TGCCACCACC (SEQ ID NO:81) 40 PMON15967 1 ATGGCTAACT 51 ACCACCTGCA 45 101 CTATCCTGAT 151 AGGGCTGTCA 201 TAATCTCCAA 251 CAATCATCAT 301 TTCTATCTGG 50 351 CGGTGGAGGC 401 CGTCTCCTCC 451 GGTGCCATGC 501 CCTGGTTGCT 551 TACGCCACCT 55 601 GGCCCTGCCA 651 AGTGAGGAAG
TTACCCTTGA GCAAGCGCAG TCCCCGGGTG AACCGTCTGG GTCTAAAGAA TCTCATAAAT GGGCAGGAGG GGTCCTGGTT TCGTACCGCG TTCTACGCCA GGCTACACCA TTAGGCCCTG AGTCTTTAGA GCAAGTGAGG GAGAAGCTGT GTGCCACCTA GCTCGGACAC TCTCTGGGCA GCCAGGCCCT GCAGCTGGCA TTCCTCTACC AGGGGCTCCT GGGTCCCACC TTGGACACAC CCATCTGGCA GCAGATGGAA ACCCAGGGTG CCATGCCGGC
GCTCTATAAT GATCGATGAA CCTTTGCTGG ACCCGAACAA GGATCGAAAC CTTCGACTTC AGAACTTAGA AAATGCATCA CCATGTCTGC CCTCTGCCAC CAAGGCAGGT GACTGGCAAG TTACCCTTGA GCAAGCGCAG TCCCCGGGTG AACCGTCTGG GTCTAAAGAA TCTCATAAAT AGCCCACCCA GGGTGCCATG GCAGGAGGGG TCCTGGTTGC GTACCGCGTT CTACGCCACC CTACACCATT AGGCCCTGCC TCTTTAGAGC AAGTGAGGAA GAAGCTGTGT GCCACCTACA TCGGACACTC TCTGGGCATC CAGGCCCTGC AGCTGGCAGG CCTCTACCAG GGGCTCCTGC GTCCCACCTT GGACACACTG ATCTGGCAGC AGATGGAAGA
GCTCTATAAT GATCGATGAA CCTTTGCTGG ACCCGAACAA GGATCGAAAC CTTCGACTTC AGAACTTAGA AAATGCATCA CCATGTCTGC CCTCTGCCAC CAAGGCAGGT GACTGGCAAG TTACCCTTGA GCAAGCGCAG TCCCCGGGTG AACCGTCTGG GTCTAAAGAA TCTCATAAAT CGGCCTTCGC CTCTGCTTTC AGCCATCTGC AGAGCTTCCT TGCGCAGCCC GGCGGCGGCT GCTCCCTGCC CCAGAGCTTC ATCCAGGGCG ATGGCGCAGC
GAACAACAGT ACGTAGAGGG TCCAATCTCT ACTATCAACC CTCCAAACAT GTCTTCTGCT GCTAGCCATC TGCAGAGCTT CCTTGCGCAG CCCGGCGGCG CCAGCTCCCT GCCCCAGAGC AAGATCCAGG GCGATGGCGC CAAGCTGTGC CACCCCGAGG TCCCCTGGGC TCCCCTGAGC GGCTGCTTGA GCCAACTCCA GCAGGCCCTG GAAGGGATAT TGCAGCTGGA CGTCGCCGAC GAACTGGGAA TGGCCCCTGC CTTCGCCTAA TAA
ATTATACATC ACTTAAAGAG CCTCAATGAC GAAGACGTCT CAAACCTGGA GAGCTTCGTA GGTATTGAGG CAATTCTTCG GGCCGCACCC TCTCGACATC AATTCCGGGA AAAACTGACG GAACAACAGT ACGTAGAGGG TCCAATCTCT ACTATCAACC CTCCAAACAT GTCTATGGCC CCGGCCTTCG CCTCTGCTTT TAGCCATCTG CAGAGCTTCC TTGCGCAGCC CGGCGGCGGC AGCTCCCTGC CCCAGAGCTT GATCCAGGGC GATGGCGCAG AGCTGTGCCA CCCCGAGGAG CCCTGGGCTC CCCTGAGCTC CTGCTTGAGC CAACTCCATA AGGCCCTGGA AGGGATATCC CAGCTGGACG TCGCCGACTT ACTGGGATAA TAA
ATTATACATC ACTTAAAGAG CCTCAATGAC GAAGACGTCT CAAACCTGGA GAGCTTCGTA GGTATTGAGG CAATTCTTCG GGCCGCACCC TCTCGACATC AATTCCGGGA AAAACTGACG GAACAACAGT ACGTAGAGGG TCCAATCTCT ACTATCAACC CTCCAAACAT GTCTACCCAG CAGCGCCGGG CAGGAGGGGT GGAGGTGTCG TACCGCGTTC CTGACATGGC TACACCATTA CTGCTCAAGT CTTTAGAGCA GCTCCAGGAG AAGCTGTGTG -88- CZ 295843 B6
701 CCACCTACAA 751 CTGGGCATCC 801 GCTGGCAGGC 851 GGCTCCTGCA 5 901 GACACACTGC 951 GATGGAAGAA (SEQ ID NO:82) pMONl5960 10 1 ATGGCTACAC 51 CAAGTCTTTA 101 AGGAGAAGCT 151 CTGCTCGGAC 15 201 CAGCCAGGCC 251 TTTTCCTCTA 301 TTGGGTCCCA 351 CACCATCTGG 401 CCACCCAGGG 20 451 GGAGGGGTCC 501 CCGCGTTCTA 551 CACCATTGGG 601 TTAGAGCAAG 651 GCTGTGTGCC 25 701 GACACTCTCT 751 GCCCTGCAGC 801 CTACCAGGGG 851 CCACCTTGGA 901 TGGCAGCAGA 30 1001 TCCTGGTTGC 1051 CTACGCCACC PMON32132
GCTGTGCCAC CCCGAGGAGC CCTGGGCTCC CCTGAGCTCC TGCTTGAGCC AACTCCATAG GGCCCTGGAA GGGATATCCC AGCTGGACGT CGCCGACTTT CTGGGAATGG CCCCTGCCCT CATTGGGCCC TGCCAGCTCC GAGCAAGTGA GGAAGATCCA GTGTGCCACC TACAAGCTGT ACTCTCTGGG CATCCCCTGG CTGCAGCTGG CAGGCTGCTT CCAGGGGCTC CTGCAGGCCC CCTTGGACAC ACTGCAGCTG CAGCAGATGG AAGAACTGGG TGCCATGCCG GCCTTCGCCT TGGTTGCTAG CCATCTGCAG CGCCACCTTG CGCAGCCCGG CCCTGCCAGC TCCCTGCCCC TGAGGAAGAT CCAGGGCGAT ACCTACAAGC TGTGCCACCC GGGCATCCCC TGGGCTCCCC TGGCAGGCTG CTTGAGCCAA CTCCTGCAGG CCCTGGAAGG CACACTGCAG CTGGACGTCG TGGAAGAACT GGGAATGGCC TAGCCATCTG CAGAGCTTCC TTGCGCAGCC CTGATAA (S1
TGGTGCTGCT CGGACACTCT TGCCCCAGCC AGGCCCTGCA CGGCCTTTTC CTCTACCAGG CCGAGTTGGG TCCCACCTTG GCCACCACCA TCTGGCAGCA GCAGCCCTAA TAA CTGCCCCAGA GCTTCCTGCT GGGCGATGGC GCAGCGCTCC GCCACCCCGA GGAGCTGGTG GCTCCCCTGA GCTCCTGCCC GAGCCAACTC CATAGCGGCC TGGAAGGGAT ATCCCCCGAG GACGTCGCCG ACTTTGCCAC AATGGCCCCT GCCCTGCAGC CTGCTTTCCA GCGCCGGGCA AGCTTCCTGG AGGTGTCGTA CGGCGGCTCT GACATGGCTA AGAGCTTCCT GCTCAAGTCT GGCGCAGCGC TCCAGGAGAA CGAGGAGCTG GTGCTGCTCG TGAGCTCCTG CCCCAGCCAG CTCCATAGCG GCCTTTTCCT GATATCCCCC GAGTTGGGTC CCGACTTTGC CACCACCATC CCTGCCCTGC AGCCCACCCA TGGAGGTGTC GTACCGCGTT :Q ID NO: 83) 35 TCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCT TCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTG TGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGA GCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTC ATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTG 40 GAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGC TTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGT CAGG (SEQ ID NO:84) PMON32133 45 TCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCT TCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTG TGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGA GCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTC 50 ATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTG GAACCCAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTG CTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGG (SEQ ID NO:85) 55 CZ 295843 B6 pMON32134 TCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCT TCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTG 5 TGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGA GCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTC ATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTG GAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGC TTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGT 10 CAGG (SEQ ID NO: 86)
Pmonl3181 1 CCATGGCTAA 15 51 AGACCACCTG 101 CTCTATCCTG 151 TAAGGGCTGT 201 CGTAATCTCC 251 TCCAATCATC 20 301 CGTTCTATCT 351 ggcggtggag 401 CCCGTCTCCT 451 CCGCATGCAA 25 Pmonl3180.Seg 1 CCATGGCTAA 51 AGACCACCTG 101 CTCTATCCTG 30 151 TAAGGGCTGT 201 CGTAATCTCC 251 TCCAATCATC 301 CGTTCTATCT 351 ggcggtggag 35 401 AGGTACCGCA pMON30237.seq
TCACTTAAAG ACGAAGACGT GAGAGCTTCG GGCAATTCTT CCTCTCGACA GAAAAACTGA GTACGTAgag CTACTATCAA ATGTAAGGTA
TCACTTAAAG ACGAAGACGT GAGAGCTTCG GGCAATTCTT CCTCTCGACA GAAAAACTGA GTACGTAgag CCAACATGTA CTGCTCTATA ATGATCGATG AAATTATACA CACCTTTGCT GGACCCGAAC AACCTCAATG ATGGATCGAA ACCTTCGACT TCCAAACCTG CAAGAACTTA GAAAATGCAT CAGGTATTGA AACCATGTCT GCCCTCTGCC ACGGCCGCAC ATCAAGGCAG GTGACTGGCA AGAATTCCGG GGTTACCCTT GAGCAAGCGC AGGAACAACA gctcCCCGGG TGAACCGTCT GGTCCAATCT CCGTCTAAAG AATCTCATAA ATCTCCAAAC GCTT (SEQ ID NO:87) CTGCTCTATA ATGATCGATG AAATTATACA CACCTTTGCT GGACCCGAAC AACCTCAATG ATGGATCGAA ACCTTCGACT TCCAAACCTG CAAGAACTTA GAAAATGCAT CAGGTATTGA AACCATGTCT GCCCTCTGCC ACGGCCGCAC ATCAAGGCAG GTGACTGGCA AGAATTCCGG GGTTACCCTT GAGCAAGCGC AGGAACAACA gctcCCCGGG TGGTGGTTCT GGCGGCGGCT TGCAAGCTT (SEQ ID NO:88) GCCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGC 40 TGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCA CCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGCGCTCTGGCGG CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTC CAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCA CCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACC 45 AACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAA GCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTC AGCCC (SEQ ID NO:89) pMON30238.seq 50
GCCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGC TGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCA CCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGG CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTC 55 CAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCA CCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACC -90- CZ 295843 B6 AACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAA GCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTC AGCCCGACTCCTCAACCCTG (SEQ ID NO:90) 5 pMON30239.seq GCCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGC TGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCA CCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGG 10 CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTC CAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCA CCAAATGTGCCTTTCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAA GCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTC AGCCCGACTCCTCAACCCTG (SEQ ID NO:91) 15 pMON32329.seq GGAACTCAGGATTGTTCTTTCCAACACAGCCCCATCTCCTCCGACTTCGC TGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCA 20 CCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGG CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTC CAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCA CCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACC AACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAA 25 GCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTC AGCCC (SEQ ID NO:92) pMON32330.seq 30 GGTACCCAGGATTGTTCTTTCCAACACAGCCCCATCTCCTCCGACTTCGC TGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCA CCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGG CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTC CAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCA 35 CCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACC AACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAA GCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTC AGCCCGACTCCTCAACCCTG (SEQ ID NO:93) 40 pMON32341. seq GCCACTCAGGACTGTTCTTTCCAACACAGCCCCATCTCCTCCGACTTCGC TGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCA CCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGG 45 CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTC CAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCA CCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACC AACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAA GCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTC 50 AGCCC (SEQ ID NO: 94) pMON32342.seq
GCCACTCAGGACTGCTCTTTTCAACACAGCCCCATCTCCTCCGACTTCGC 55 TGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCA CCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGG -91 - CZ 295843 B6 CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTC CAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCA CCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACC AACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAA 5 GCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTC AGCCCGACTCCTCAACCCTG (SEQ ID NO:95) pMON32320.seq 10 GCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG CCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC 15 AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC CTGTCTGGAGGTAACGGATCCGGTGGCAATGGGAGCGGCGGAAATGGAAC CCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCA AAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTG GCCTCCAACCTGCAG (SEQ ID NO:96) 20 pMON32321.seq GCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC 25 TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG CCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC CTGTCAGGCGGTAACGGCAGTGGAGGTAATGGCACCCAGGACTGCTCCTT 30 CCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGT CTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG (SEQ ID NO:97) pMON32322.seq 35 GCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG CCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT 40 GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC CTGTCTGGCGGCAACGGCACCCAGGACTGCTCCTTCCAACACAGCCCCAT CTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTC AAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG (SEQ ID NO:98) 45 pMON32323.seq
GCCTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTT TGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCC 50 AGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCG CTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCA GTGTCAGCCCGACTCCTCAACCCTGTCTGGAGGTAACGGATCCGGTGGCA ATGGGAGCGGCGGAAATGGAACCCAGGACTGCTCCTTCCAACACAGCCCC ATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCT 55 TCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCT -92- CZ 295843 B6 GCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC AAGACTGTCGCTGGG (SEQ ID NO:99) pMON32324.seq 5 GCCTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTT TGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCC AGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCG CTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCA 10 GTGTCAGCCCGACTCCTCAACCCTGTCTGGAGGTAACGGATCCGGAGGTA ATGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTC GCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGT CACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGC GGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGG 15 (SEQ ID NO: 100) pMON32325.seq GCCTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTT 20 TGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCC AGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCG CTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCA GTGTCAGCCCGACTCCTCAACCCTGTCTGGCGGCAACGGCACGCAGGACT GCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGT 25 GAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAA CCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCAC AGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGG (SEQ ID NO:101) pMON32326.seq 30 GCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC CTGTCTGGAGGTAACGGCAGTGGTGGCAATGGGAGCGGTGGAAATGGAAC 35 CCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCA AAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTG GCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGT CCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGA TGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAA 40 TGTGCCTTTCAGCCC (SEQ ID NO:102) pMON32327.seq GCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT 45 GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC CTGTCAGGCGGTAACGGCAGTGGAGGTAATGGCACCCAGGACTGCTCCTT CCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGT CTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG 50 GACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTG GATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGG AGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCC (SEQ ID NO:103) -93 - 55 CZ 295843 B6 pMON32328.seq GCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC 5 AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC CTGTCTGGCGGCAACGGCACGCAGGACTGCTCCTTCCAACACAGCCCCAT CTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTC AAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGC GGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAA 10 GACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGG AGATACACTTTGTCACCAAATGTGCCTTTCAGCCC (SEQ ID NO:104) pMON32348.seq 15 GCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG CCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC 20 AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC CTGTCTGGAGGTAGTGGATCCGGAGGTTCTGGCAACCCAGGACTGCTCCT TCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTG TCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG (SEQ ID NO:105) 25 pMON32350.seq GCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC 30 TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG CCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC CTGTCTGGAGGTAGTGGATCCGGTGGCAGTGGGAGCGGCGGATCTGGAAC 35 CCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCA AAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTG GCCTCCAACCTGCAG (SEQ ID NO:106) FLT3N.seq 40 CCATGGCCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGAC TTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCC AGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCT GGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCT 45 GGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTT TGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCC AGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCG CTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCA GTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGATCC (SEQ ID NO:107) 50 FLT3C.seq
GGATCCGGAGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTC CGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATT 55 ACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGC CTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGT -94- CZ 295843 B6 CGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATAC ACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTC GTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGT GGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGC 5 TGCAGTGTCAGCCCGACTCCTCAACCCTGTAAGCTT (SEQ ID NO:108) FLT7N.seq CCATGGCCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGAC 10 TTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCC AGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCT GGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCT GGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTT TGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCC 15 AGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCG CTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCA GTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGATCC (SEQ ID NO:109) 20 FLT4C. seq GGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTC CTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAG ATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGG 25 GGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGAC TGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGA TACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGC TTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCT GGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGG 30 AGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTAAGCTT (SEQ ID NO:110) FLT11N.seq 35 CCATGGCCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGAC TTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCC AGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCT GGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCT GGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTT 40 TGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCC AGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCG CTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCA GTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAG GAGGTGGATCC (SEQ ID NO:111) 45 FLT10C.seq
GGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTT CCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGT 50 CTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG GACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTG GATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGG AGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCC CCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCA 55 GGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGA -95- CZ 295843 B6 ACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTG TAAGCTT (SEQ ID NO:112) pMON32365.seq 5 GCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG CCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT 10 GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC CTGGGCGGTGGATCCGGAGGTACCCAGGACTGCTCCTTCCAACACAGCCC CATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGC TTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG (SEQ ID NO:113) 15 pMON32366.seq
GCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC 20 TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG CCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC CTGGGCGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAG 25 CCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACC TGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG (SEQ ID NO:114) pMON32367.seq 30 GCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG CCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC 35 AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC CTGGGCGGTGGGTCAGGAGGTGGATCCGGAGGTACCCAGGACTGCTCCTT CCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGT CTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG (SEQ ID NO:115) 40 pMON32368.seq GCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC 45 TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG CCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC CTGGGCGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGA 50 CTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCC GTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCC AACCTGCAG (SEQ ID NO:116) -96- CZ 295843 B6 pMON32369.seq GCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC 5 TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG CCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC CTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCAC 10 CCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCA AAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTG GCCTCCAACCTGCAG (SEQ ID NO:117) pMON32370.seq 15 GCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG CCCCCCCCCAGCTGCCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT 20 GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC CTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTC AGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCT CCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAA 25 GATTACCCAGTCACCGTGGCCTCCAACCTGCAG (SEQ ID NO:118) pMON30247.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC 30 ACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTA TCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC 35 TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCACCCAGGAC TGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCG TGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCA 40 ACCTGCAGGACGAGGAGCTCTGCGGGGCGCTCTGGCGGCTGGTCCTGGCA CAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGG CTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCT TTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGC CTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCAC 45 TCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCC (SEQ ID NO:119) pMON30248.seq
GC TAACT GCTCTATAATGAT CGAT GAAAT TATACAT CACT TAAAGAGACC 50 ACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTA TCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC 55 TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT -97- CZ 295843 B6 CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCACCCAGGAC TGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCG TGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCA ACCTGCAGGACGAGGAGCTCTGCGGGGCGCTCTGGCGGCTGGTCCTGGCA 5 CAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGG CTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCT TTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGC CTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCAC TCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCT 10 CAACCCTG (SEQ ID NO: 120) pMON32332.seq
GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC 15 ACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTA TCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC 20 TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGACGAGGAG CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCG GCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA 25 ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCAGGCGGT AACGGCAGTGGAGGTAATGGCACCCAGGACTGCTCCTTCCAACACAGCCC 30 CATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGC TTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG (SEQ ID NO:121) pMON32333.seq 35 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTA TCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA 40 TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGACGAGGAG CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCG 45 GCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCTGGAGGT 50 AACGGATCCGGTGGCAATGGGAGCGGCGGAAATGGAACCCAGGACTGCTC CTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGC TGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTG CAG (SEQ ID NO:122) -98- 55 CZ 295843 B6 pMON32334 . seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTA 5 TCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG 10 TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCTCCAAGATG CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATG TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG 15 ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA CTCCTCAACCCTGTCTGGCGGCAACGGCACGCAGGACTGCTCCTTCCAAC ACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGAC TACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGA GGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGG 20 AGCGGCTCAAGACTGTCGCTGGG (SEQ ID NO:123) pMON32335.seq
GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC 25 ACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTA TCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC 30 TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCTCCAAGATG CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATG TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT 35 CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA CTCCTCAACCCTGTCTGGAGGTAACGGATCCGGAGGTAATGGCACCCAGG ACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATC CGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTC 40 CAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGG CACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGG (SEQ ID NO:124) pMON32336.seq
45 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTA TCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA 50 TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCTCCAAGATG CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATG 55 TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG -99- CZ 295843 B6 ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA CTCCTCAACCCTGTCTGGAGGTAACGGATCCGGTGGCAATGGGAGCGGCG GAAATGGAACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGAC TTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCC 5 AGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCT GGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCT GGG (SEQ ID NO:125) pMON32337.seq 10 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTA TCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA 15 TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCCCCCCAGC 20 TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCTGGCGGC AACGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTT CGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAG 25 TCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGG CGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGG GTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTG TCACCAAATGTGCCTTTCAGCCC (SEQ ID NO:126) 30 pMON32338 . seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTA TCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG 35 GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT 40 CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCAGGCGGT AACGGCAGTGGAGGTAATGGCACCCAGGACTGCTCCTTCCAACACAGCCC 45 CATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGC TTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTC TGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCT CAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACA CGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCC (SEQ ID NO:127) 50 pMON32339.seq
GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTA 55 TCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA - 100- CZ 295843 B6 TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT 5 CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCTGGAGGT AACGGCAGTGGTGGTAATGGGAGCGGCGGAAATGGAACCCAGGACTGCTC 10 CTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGC TGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTG CAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG 15 CCC (SEQ ID NO: 128) pMON32364.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC 20 ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC 25 TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCGACTCAGGAC TGTTCTTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCG TGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCA 30 ACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCA CAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGG CTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCT TTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGC CTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCAC 35 TCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCC (SEQ ID NO:129) pMON32377.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC 40 ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC 45 TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCAACCCAGGAC TGCTCTTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCG TGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCA 50 ACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCA CAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGG CTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCT TTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGC CTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCAC 55 TCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCT CAACCCTG (SEQ ID NO:130) - 101 - CZ 295843 B6 pMON32392.seq GCCACTCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGC 5 TGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCA CCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGG CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTC CAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCA CCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACC 10 AACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAA GCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTC AGCCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCA ATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCC AAACATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAA 15 AGAGACCACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGAC ATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATT CGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTC TTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGA CATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACT 20 GACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG (SEQ ID NO:131) pMON32352.seq
GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC 25 ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC 30 TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCCAACATGGCCGACGAGGAG CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCG GCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA 35 ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCAGGCGGT AACGGCAGTGGAGGTAATGGCACCCAGGACTGCTCCTTCCAACACAGCCC 40 CATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGC TTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG (SEQ ID NO:132) pMON32353.seq
45 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA 50 TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGACGAGGAG CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCG 55 GCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC - 102- CZ 295843 B6 TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCTGGAGGT AACGGATCCGGTGGCAATGGGAGCGGCGGAAATGGAACCCAGGACTGCTC 5 CTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGC TGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTG CAG (SEQ ID NO:133) pMON32354.seq 10 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA 15 TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCTCCAAGATG 20 CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATG TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA CTCCTCAACCCTGTCTGGCGGCAACGGCACGCAGGACTGCTCCTTCCAAC 25 ACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGAC TACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGA GGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGG AGCGGCTCAAGACTGTCGCTGGG (SEQ ID NO:134) 30 pMON32355. seq G C TAAC T G C T C TATAAT GAT C GAT GAAAT TATACAT CAC T TAAAGAGAC C ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG 35 GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT 40 CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCTCCAAGATG CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATG TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA 45 CTCCTCAACCCTGTCTGGAGGTAACGGATCCGGAGGTAATGGCACCCAGG ACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATC CGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTC CAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGG CACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGG (SEQ ID NO:135) 50 pMON32356.seq
GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA 55 TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA -103 - CZ 295843 B6 TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT 5 CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCTCCAAGATG CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATG TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA 10 CTCCTCAACCCTGTCTGGAGGTAACGGATCCGGTGGCAATGGGAGCGGCG GAAATGGAACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGAC TTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCC AGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCT GGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCT 15 GGG (SEQ ID NO: 136) pMON32357.seq G C T AAC T G C T C T ATAAT GAT C GAT GAAAT TATACAT CAC T TAAAGAGAC C 20 ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC 25 TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC 30 GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCTGGCGGC AACGGCACGCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTT CGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAG TCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGG CGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGG 35 GTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTG TCACCAAATGTGCCTTTCAGCCC (SEQ ID NO:137) pMON32358.seq
40 GC TAAC T G C T C TATAAT GAT C GAT GAAAT TATACAT CAC T TAAAGAGAC C
ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA 45 TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC 50 CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCAGGCGGT AACGGCAGTGGAGGTAATGGCACCCAGGACTGCTCCTTCCAACACAGCCC CATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGC TTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTC 55 TGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCT - 104- CZ 295843 B6 CAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACA CGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCC (SEQ ID NO:138) pMON32359.seq 5 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA 10 TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCCCCCCAGC 15 TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCTGGAGGT AACGGCAGTGGTGGCAATGGGAGCGGCGGAAATGGAACCCAGGACTGCTC CTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGC 20 TGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTG CAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG CCC (SEQ ID NO:139) 25 pMON32360.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA 30 TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG 35 TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCCAACATGGCCGACGAGGAG CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCG GCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC 40 TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCTGGAGGT AGTGGATCCGGAGGTTCTGGCACCCAGGACTGCTCCTTCCAACACAGCCC CATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGC 45 TTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG (SEQ ID NO:140) pMON32362.seq
G C TAAC T GC T C TATAAT GAT C GAT GAAAT TATACAT CAC T TAAAGAGAC C 50 ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC 55 TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT - 105- CZ 295843 B6 CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGACGAGGAG CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCG GCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC 5 TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCTGGAGGT AGTGGATCCGGTGGCAGTGGGAGCGGCGGATCTGGAACCCAGGACTGCTC CTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGC 10 TGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTG CAG (SEQ ID NO:141) pMON32393.seq
15 GCCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGC TGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCA CCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGG CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTC CAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCA 20 CCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACC AACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAA GCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTC AGCCCGACTCCTCAACCCTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGT GAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGA 25 ATCTCATAAATCTCCAAACATGGCTAACTGCTCTATAATGATCGATGAAA TTATACATCACTTAAAGAGACCACCTAACCCTTTGCTGGACCCGAACAAC CTCAATTCTGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCC AAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAG GTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACG 30 G C C GCAC C C T C T C GACAT C CAAT CAT CAT CAAGG CAGG T GAC T GG CAAGA ATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGG AACAACAG (SEQ ID NO:142) pMON32371.seq 35 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA 40 TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGACGAGGAG 45 CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCG GCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC 50 GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGA TCCGGAGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGA CTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACC CAGTCACCGTGGCCTCCAACCTGCAG (SEQ ID NO:143) - 106- 55 CZ 295843 B6 pMON32372.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA 5 TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG 10 TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGACGAGGAG CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCG GCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC 15 TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGA TCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTC CGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATT 20 ACCCAGTCACCGTGGCCTCCAACCTGCAG (SEQ ID NO:144) pMON32373.seq
GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC 25 ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC 30 TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGACGAGGAG CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCG GCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA 35 ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGG TCAGGAGGTGGATCCGGAGGTACCCAGGACTGCTCCTTCCAACACAGCCC 40 CATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGC TTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG (SEQ ID NO:145) pMON32374.seq
45 GC TAAC T G C T C TATAAT GAT C GAT GAAAT TATACAT CAC T TAAAGAGAC C
ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA 50 TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTČTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGACGAGGAG CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCG 55 GCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC - 107- CZ 295843 B6
TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGA TCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCA 5 ACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTG ACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG (SEQ ID NO:146) pMON32375.seq 10 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA 15 TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGACGAGGAG CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCG 20 GCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGG 25 TCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTC CTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGC TGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTG CAG (SEQ ID NO:147) 30 pMON3237 6. seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG 35 GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT 40 CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGACGAGGAG CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCG GCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC 45 CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGG TCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAG TGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCG CTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTC 50 ACCGTGGCCTCCAACCTGCAG (SEQ ID NO:148) pMON32378.seq
GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC 55 ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG - 108- CZ 295843 B6 GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG 5 TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCTCCAAGATG CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATG TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG 10 ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA CTCCTCAACCCTGGGCGGTGGATCCGGAGGTACCCAGGACTGCTCCTTCC AACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCT GACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGA CGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGA 15 TGGAGCGGCTCAAGACTGTCGCTGGG (SEQ ID NO:149) pMON32379.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC 20 ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC 25 TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCTCCAAGATG CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATG TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT 30 CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA CTCCTCAACCCTGGGCGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCT TCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTG TCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCA 35 GGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCT GGATGGAGCGGCTCAAGACTGTCGCTGGG (SEQ ID NO:150) pMON32380.seq
40 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA 45 TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCTCCAAGATG CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATG 50 TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA CTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGATCCGGAGGTACCCAGG ACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATC 55 CGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTC - 109- CZ 295843 B6 CAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGG CACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGG (SEQ ID NO: 151) pMON32381.seq 5 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA 10 TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCTCCAAGATG 15 CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATG TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA CTCCTCAACCCTGGGCGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTG 20 GTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCT GTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCAC CGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGC TGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGG (SEQ ID NO:152) 25 pMON32382 . seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG 30 GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT 35 CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCTCCAAGATG CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATG TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA 40 CTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCG GAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGAC TTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCC AGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCT GGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCT 45 GGG (SEQ ID NO: 153) pMON32383.seq
GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC 50 ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC 55 TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT -110- CZ 295843 B6 CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCTCCAAGATG CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATG TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG 5 ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA CTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCG GAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACAC AGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTA CCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGG 10 AGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAG CGGCTCAAGACTGTCGCTGGG (SEQ ID NO:154) pMON32384.seq 15 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA 20 TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC 25 CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGA TCCGGAGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGA CTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACC CAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTC 30 TGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGC TGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACT TTGTCACCAAATGTGCCTTTCAGCCC (SEQ ID NO:155) pMON32385.seq 35 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA 40 TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCCCCCCAGC 45 TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGA TCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTC CGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATT 50 ACCCAGTCACCGTGGCCTCCAACCTGCAGGATGAGGAGCTCTGCGGGGGC CTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGT CGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATAC ACTTTGTCACCAAATGTGCCTTTCAGCCC (SEQ ID NO:156) - 111 - 55 CZ 295843 B6 pMON3238 6.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA 5 TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG 10 TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGG 15 TCAGGAGGTGGATCCGGAGGTACCCAGGACTGCTCCTTCCAACACAGCCC CATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGC TTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTC TGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCT CAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACA 20 CGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCC (SEQ ID NO:157) pMON32387.seq
GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC 25 ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC 30 TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC 35 GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGA TCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCA ACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTG ACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGAC GAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGAT 40 GGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGC GCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCC (SEQ ID NO:158) pMON32388.seq
45 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA 50 TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC 55 CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGG -112- CZ 295843 B6 TCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTC CTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGC TGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTG CAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG 5 CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG CCC (SEQ ID NO:159) pMON3238 9.seq 10 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA 15 TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCCCCCCAGC 20 TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGG TCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAG TGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCG 25 CTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTC ACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCG GCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGT CCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTC ACCAAATGTGCCTTTCAGCCC (SEQ ID NO:160) 30 hflt3-28291inkl0.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA 35 TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG 40 TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGATTACCCA GTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTG GCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTG GGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTT 45 GTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCA GACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGC TGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAG TGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGATCCGG AGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCG 50 CTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAA (SEQ ID NO:161) hflt3-28291inkl5.seq
GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC 55 ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG - 113 - CZ 295843 B6 GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG 5 TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGATTACCCA GTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTG GCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTG GGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTT 10 GTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCA GACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGC TGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAG TGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGG AGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCA 15 TCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTT CAA (SEQ ID NO:162) hflt3-34351inklO.seq 20 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA . TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA 25 TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGCCTCCAAC CTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACA 30 GCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCT TGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTT CAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCT CCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTC GCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCA 35 ACCCTGGGCGGTGGGTCAGGAGGTGGATCCGGAGGTACCCAGGACTGCTC CTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGC TGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTG (SEQ ID NO:163) hflt3-34351inkl5.seq 40
GC TAAC T GC T C TATAAT GAT C GAT GAAAT TATACAT CAC T TAAAGAGAC C ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA 45 TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA T CAT CAT CAAGG CAG G T GAC T GGCAAGAAT T C C GGGAAAAAC T G AC GT T C TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAAGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGCCTCCAAC 50 CTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACA GCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCT TGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTT CAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCT CCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTC 55 GCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCA ACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGG -114- CZ 295843 B6 CACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTG TCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACC GTG (SEQ ID NO:164) 5 hflt3-62631inkl0.seq GC TAACT GC T C TATAAT GAT CGAT GAAAT TATACAT CACT TAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG 10 GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT 15 CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGTCGCTGGG TCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGT CACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGA CCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTG 20 TCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGATCCGGAG GTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCT GTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCAC CGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGC TGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACT (SEQ ID NO:165) 25 hflt3-62631inkl5.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA 30 TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG 35 TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGTCGCTGGG TCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGT CACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGA CCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG 40 AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTG TCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAG GTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATC TCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCA AGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCG 45 GGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAG ACT (SEQ ID NO:166) hflt3-94951inkl0.seq
50 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA 55 TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG - 115- CZ 295843 B6
TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCGCTTCGTC CAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGC GCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGC 5 AGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGATCC GGAGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTT CGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAG TCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGG CGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGG 10 GTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTG TCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTT (SEQ ID NO:167) hfIt3-94951inkl5.seq 15 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA 20 TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCGCTTCGTC CAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGC 25 GCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGC AGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTGAGGAGGTGGGTCA GGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCC CATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGC TTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTC 30 TGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCT CAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACA CGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGT CTT (SEQ ID NO:168) 35 hf It3-98991inkl0 . seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG 40 GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAAGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT 45 CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCACCAACATC TCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTG GATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCG ACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGATCCGGAGGTACCCAG GACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAAT 50 CCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCT CCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTG GCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCA AGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTG CCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAG (SEQ ID NO:169) 55 -116- CZ 295843 B6 hfIt3-98991inkl5.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA 5 TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG 10 TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCACCAACATC TCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTG GATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCG ACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCC 15 GGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGA CTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACC CAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTC TGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGC TGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACT 20 TTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTC CAG (SEQ ID NO:170) hflt3-28291ink6.seq 25 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA 30 TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGATTACCCA GTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTG 35 GCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTG GGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTT GTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCA GACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGC TGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAG 40 TGTCAGCCCGACTCCTCAACCCTGGGCGGTGGATCCGGAGGTACCCAGGA CTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCC GTGAGCTGTCTGACTACCTGCTTCAA (SEQ ID NO:171) hflt3-28291ink7.seq 45
GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA 50 TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGATTACCCA 55 GTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTG GCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTG -117- CZ 295843 B6 GGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTT GTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCA GACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGC TGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAG 5 TGTCAGCCCGACTCCTCAACCCTGGGCGGTGGATCCGGAGGTGGCACCCA GGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAA TCCGTGAGCTGTCTGACTACCTGCTTCAA (SEQ ID NO:172) hfIt3-28291inkl3.seq 10 GCTAACT GC T C TATAAT GAT CGAT GAAAT TATACAT CAC T TAAAGAGAC C ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA 15 TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGATTACCCA 20 GTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTG GCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTG GGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTT GTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCA GACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGC 25 TGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAG TGTCAGCCCGACTCCTCAACCCTGGGCGGTGGATCCGGAGGTGGCTCAGG GGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCT CCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAA (SEQ ID NO:173) 30 hfIt3-28291ink21.seq G C TAAC T GC T C TATAAT GAT C GAT GAAAT TATACATCAC T TAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG 35 GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT 40 CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGATTACCCA GTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTG GCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTG GGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTT GTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCA 45 GACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGC TGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAG TGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGG AGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCT CCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAG 50 CTGTCTGACTACCTGCTTCAA (SEQ ID NO:174) hflt3-34351ink6.seq
GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC 55 ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG - 118- CZ 295843 B6 GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG 5 TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGCCTCCAAC CTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACA GCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCT TGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTT 10 CAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCT CCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTC GCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCA ACCCTGGGCGGTGGATCCGGAGGTACTGCTCCTTCCAACACAGCCCCATC TCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCA 15 AGATTACCCAGTCACCGTG (SEQ ID NO:175) hflt3-34351ink7.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC 20 ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC 25 TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGCCTCCAAC CTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACA GCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCT 30 TGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTT CAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCT CCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTC GCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCA ACCCTGGGCGGTGGATCCGGAGGTGGCACTGCTCCTTCCAACACAGCCCC 35 ATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCT TCAAGATTACCCAGTCACCGTG (SEQ ID NO:176) hfIt3-34351inkl3.seq
40 GC TAACTGCTC TATAATGAT CGATGAAAT TATACATCAC T TAAAGAGACC
ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA 45 TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGCCTCCAAC CTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACA 50 GCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCT TGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTT CAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCT CCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTC GCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCA 55 ACCCTGGGCGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACTGC - 119- CZ 295843 B6 TCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGA GCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTG (SEQ ID NO:177) hfIt3-34351ink21.seq 5 GC TAAC T G C T C TATAAT GAT C GAT GAAAT TATACATCACT TAAAGAGAC C ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA 10 TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGCCTCCAAC 15 CTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACA GCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCT TGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTT CAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCT CCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTC 20 GCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCA ACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGG CTCAGGGGGAGGTAGTGGTAGGACTGCTCCTTCCAACACAGCCCCATCTC CTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAG ATTACCCAGTCACCGTG (SEQ ID NO:178) 25 hfIt3-62631ink6.seq GC TAAC T G C T C TATAAT GAT CGAT GAAAT TATACAT CAC T TAAAGAGAC C ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA 30 TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG 35 TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGTCGCTGGG TCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGT CACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGA CCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG 40 AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTG TCAGCCCGACTCCTCAACCCTGGGCGGTGGATCCGGAGGTACCCAGGACT GCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGT GAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAA CCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCAC 45 AGCGCTGGATGGAGCGGCTCAAGACT (SEQ ID NO:179) hfIt3-62631ink7.seq
GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC 50 ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC 55 TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT - 120- CZ 295843 B6 CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGTCGCTGGG TCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGT CACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGA CCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG 5 AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTG TCAGCCCGACTCCTCAACCCTGGGCGGTGGATCCGGAGGTGGCACCCAGG ACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATC CGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTC CAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGG 10 CACAGCGCTGGATGGAGCGGCTCAAGACT (SEQ ID NO:180) hflt3-62631inkl3.seq
GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC 15 ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC 20 TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGTCGCTGGG TCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGT CACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGA 25 CCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTG TCAGCCCGACTCCTCAACCCTGGGCGGTGGATCCGGAGGTGGCTCAGGGG GAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCC GACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTA 30 CCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCC TCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACT (SEQ ID NO:181) hflt3-62631ink21.seq 35 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA 40 TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGTCGCTGGG TCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGT 45 CACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGA CCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTG TCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAG GTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCC 50 TTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCT GTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGC AGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGC TGGATGGAGCGGCTCAAGACT (SEQ ID NO:182) -121 - 55 CZ 295843 B6 hflt3-94951ink6. seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA 5 TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG 10 TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCGCTTCGTC CAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGC GCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGC AGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGATCCGGAGGTACCCAG 15 GACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAAT CCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCT CCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTG GCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCA AGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTG 20 CCTTTCAGCCCCCCCCCAGCTGTCTT (SEQ ID NO:183) hflt3-94951ink7.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC 25 ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC 30 TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCGCTTCGTC CAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGC GCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGC 35 AGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGATCCGGAGGTGGCACC CAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAA AATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGG CCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTC CTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGAT 40 GCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAAT GTGCCTTTCAGCCCCCCCCCAGCTGTCTT (SEQ ID NO:184) hflt3-94951inkl3.seq
45 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA 50 TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCGCTTCGTC CAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGC 55 GCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGC AGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGATCCGGAGGTGGCTCA -122- CZ 295843 B6
GGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTC CTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAG ATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGG GGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGAC 5 TGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGA TACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTT (SEQ ID NO:185) hflt3-94951ink21.seq 10 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA 15 TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCGCTTCGTC CAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGC 20 GCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGC AGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCA GGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTG CTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTG AGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAAC 25 CTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACA GCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCT TGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTT CAGCCCCCCCCCAGCTGTCTT (SEQ ID NO:186) 30 hflt3-98991ink6.seq G C TAAC T G C T C TATAAT GAT C GAT GAAAT TATACAT CAC T TAAAGAGAC C ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG 35 GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAAGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT 40 CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCACCAACATC TCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTG GATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCG ACTCCTCAACCCTGGGCGGTGGATCCGGAGGTACCCAGGACTGCTCCTTC CAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTC 45 TGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGG ACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGG ATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGA GCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCC CCCCCAGCTGTCTTCGCTTCGTCCAG (SEQ ID NO:187) 50 hfIt3-98991ink7.seq
GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA 55 TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA - 123 - CZ 295843 B6 TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAAGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT 5 CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCACCAACATC TCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTG GATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCG ACTCCTCAACCCTGGGCGGTGGATCCGGAGGTGGCACCCAGGACTGCTCC TTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCT 10 GTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGC AGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGC TGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCT GGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGC CCCCCCCCAGCTGTCTTCGCTTCGTCCAG (SEQ ID NO:188) 15 hfIt3-98991inkl3.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA 20 TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG 25 TGGAAGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCACCAACATC TCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTG GATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCG ACTCCTCAACCCTGGGCGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGT 30 GGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGC TGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCA CCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGG CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTC CAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCA 35 CCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAG (SEQ ID NO:189) hflt3-98991ink21.seq
GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC 40 ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC 45 TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCACCAACATC TCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTG GATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCG 50 ACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCC GGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACA CAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACT ACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAG GAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGA 55 GCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCG - 124- CZ 295843 B6 TGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCC AGCTGTCTTCGCTTCGTCCAG (SEQ ID NO:190) pMON32390 5 GGATCCACCATGAGCCGCCTGCCCGTCCTGCTCCTGCTCCAACTCCTGGT CCGCCCCGCCATGTCTACAAATCAAGATCTGCCTGTGATCAAGTGTGTTT TAAT CAAT CATAAGAACAAT GAT T CAT CAGT GGGGAAGT CAT CAT CATAT CCCATGGTATCAGAATCCCCGGAAGACCTCGGGTGTGCGTTGAGACCCCA 10 GAGCTCAGGGACAGTGTACGAAGCTGCCGCTGTGGAAGTGGATGTATCTG CTTCCATCACACTGCAAGTGCTGGTCGATGCCCCAGGGAACATTTCCTGT CTCTGGGTCTTTAAGCACAGCTCCCTGAATTGCCAGCCACATTTTGATTT ACAAAACAGAGGAGTTGTTTCCATGGTCATTTTGAAAATGACAGAAACCC AAG C T G GAGAATAC CTACTTTTTATT CAGAG T GAAGCTAC CAAT TACACA 15 ATATTGTTTACAGTGAGTATAAGAAATACCCTGCTTTACACATTAAGAAG ACCTTACTTTAGAAAAATGGAAAACCAGGACGCCCTGGTCTGCATATCTG AGAGCGTTCCAGAGCCGATCGTGGAATGGGTGCTTTGCGATTCACAGGGG GAAAGCTGTAAAGAAGAAAGTCCAGCTGTTGTTAAAAAGGAGGAAAAAGT GCTTCATGAATTATTTGGGATGGACATAAGGTGCTGTGCCAGAAATGAAC 20 TGGGCAGGGAATGCACCAGGCTGTTCACAATAGATCTAAATCAAACTCCT CAGAC CACAT T GC CACAAT TAT T TCT TAAAGTAGGGGAAC CC T TAT GGAT AAGGTGCAAAGCTGTTCATGTGAACCATGGATTCGGGCTCACCTGGGAAT TAGAAAACAAAGCACTCGAGGAGGGCAACTACTTTGAGATGAGTACCTAT TCAACAAACAGAACTATGATACGGATTCTGTTTGCTTTTGTATCATCAGT 25 GGCAAGAAACGACACCGGATACTACACTTGTTCCTCTTCAAAGCATCCCA GTCAATCAGCTTTGGTTACCATCGTAGAAAAGGGATTTATAAATGCTACC AATTCAAGTGAAGATTATGAAATTGACCAATATGAAGAGTTTTGTTTTTC TGTCAGGTTTAAAGCCTACCCACAAATCAGATGTACGTGGACCTTCTCTC GAAAATCATTTCCTTGTGAGCAAAAGGGTCTTGATAACGGATACAGCATA 30 TCCAAGTTTTGCAATCATAAGCACCAGCCAGGAGAATATATATTCCATGC AGAAAAT GAT GAT GC C CAAT T TAC CAAAAT GT T CAC G CT GAATATAAGAA GGAAACCTCAAGTGCTCGCAGAAGCATCGGCAAGTCAGGCGTCCTGTTTC TCGGATGGATACCCATTACCATCTTGGACCTGGAAGAAGTGTTCAGACAA GTCTCCCAACTGCACAGAAGAGATCACAGAAGGAGTCTGGAATAGAAAGG 35 CTAACAGAAAAGTGTTTGGACAGTGGGTGTCGAGCAGTACTCTAAACATG AGTGAAGCCATAAAAGGGTTCCTGGTCAAGTGCTGTGCATACAATTCCCT TGGCACATCTTGTGAGACGATCCTTTTAAACTCTCCAGGCCCCTTCCCTT TCATCCAAGACAACGAATTCATCATCCTGGGCCTGTTCGGCCTCCTGCTG TTGCTCACCTGCCTCTGTGGAACTGCCTGGCTCTGTTGCAGCCCCAACAG 40 GAAGAATCCCCTCTGGCCAAGTGTCCCAGACCCAGCTCACAGCAGCCTGG GCTCCTGGGTGCCCACAATCATGGAGGAGGATGCCTTCCAGCTGCCCGGC CTTGGCACGCCACCCATCACCAAGCTCACAGTGCTGGAGGAGGATGAAAA GAAGCCGGTGCCCTGGGAGTCCCATAACAGCTCAGAGACCTGTGGCCTCC CCACTCTGGTCCAGACCTATGTGCTCCAGGGGGACCCAAGAGCAGTTTCC 45 ACCCAGCCCCAATCCCAGTCTGGCACCAGCGATCAGGTCCTTTATGGGCA GCTGCTGGGCAGCCCCACAAGCCCAGGGCCAGGGCACTATCTCCGCTGTG ACTCCACTCAGCCCCTCTTGGCGGGCCTCACCCCCAGCCCCAAGTCCTAT GAGAACCTCTGGTTCCAGGCCAGCCCCTTGGGGACCCTGGTAACCCCAGC CCCAAGCCAGGAGGACGACTGTGTCTTTGGGCCACTGCTCAACTTCCCCC 50 TCCTGCAGGGGATCCGGGTCCATGGGATGGAGGCGCTGGGGAGCTTC (SEQ ID NO:I9I) pMON30329.seq
GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAG 55 AGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCAC CTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCC - 125 - CZ 295843 B6 TGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCC AACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATC CCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACC ACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGG 5 GTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGC TAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAG CCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTA TCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCACCCAGGA CTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTG 10 TCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGG AGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAA GACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACAC TTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCA ACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGAT 15 CACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC CTG (SEQ ID NO:192) pMON32173.seq 20 GCCACTCAGGACTGCTCTTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAA TCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCT GCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATG GAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACA CGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTT 25 CGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCG ACTCCTCAACCCTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCC AATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATG GCTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAA 30 TCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCT GCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATG GAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACA CGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTT CGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG 35 AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCG ACTCCTCAACCCTG (SEQ ID NO:193) pMON32175.seq
40 GCCACCCAGGACTGCTCCTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAA TCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCT GCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATG GAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACA CGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTT 45 CGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG AAGCCATGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCG ACTCCTCAACCCTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCC AATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATG GCTACACCATTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTGCTTAG 50 AGCAAGTGAGGAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCAC CTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCC TGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCC AACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATC CCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACC 55 ACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGG GTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGC - 126- CZ 295843 B6 TAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTTTACGCCACCTTGCGCAG CCC (SEQ ID NO:194) pMON32204.seq 5 GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAG AGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCAC CTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCC TGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCC 10 AACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATC CCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACC ACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGG GTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGC TAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAG 15 CCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTA TCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCACTCAGGA CTGCTCTTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTG TCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGG AGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAA 20 GACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACAC TTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCA ACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGAT CACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC CTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTA 25 TCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTACCCAGGA CTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTG TCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGG AGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAA GACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACAC 30 TTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCA ACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGAT CACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC CTG (SEQ ID NO:195) 35 pMON32205. seq
GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCAC CTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAA CCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCA 40 TCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCG CACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAA ACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGC GGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTC CGTCTAAAGAATCTCATAAATCTCCAAACATGGCCACTCAGGACTGCTCTTTTCAACA 45 CAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTT CAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCC TCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTC CAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGT GCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCC 50 TGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTT CTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTACGTAGAGGGC GGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTC CGTCTAAAGAATCTCATAAATCTCCAAACATGGCTACCCAGGACTGCTCCTTCCAACA CAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTT 55 CAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCC TCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTC -127- CZ 295843 B6 CAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGT GCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCC TGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTT CTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTG 5 (SEQ ID NO:196) pMON32208.seq GCCACTCAGGACTGCTCTTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAA 10 TCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCT GCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATG GAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACA CGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTT CGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG 15 AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCG ACTCCTCAACCCTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCC AATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATG GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAG AGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCAC 20 CTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCC TGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCC AACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATC CCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACC ACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGG 25 GTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGC TAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAG CCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTA TCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTACCCAGGA CTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTG 30 TCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGG AGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAA GACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACAC TTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCA ACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGAT 35 CACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC CTG (SEQ ID NO:197) pMON35767.seq/pMON32191.seq
40 GGCCACTCAGGACTGCTCTTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAA ATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACC TGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGAT GGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAAC ACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCT 45 TCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCT GAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCC GACTCCTCAACCCTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGGTGGTTCTGGCG GCGGCTCCAACATGGCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCT GCTCAAGTCTTTAGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAG 50 AAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACT CTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGC AGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCC CTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCG CCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCT 55 GCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGA - 128- CZ 295843 B6 GGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTAC GCCACCTTGCGCAGCCG (SEQ ID NO:198) pMON32397.seq 5 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACC CTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAA CCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCA TCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCG 10 CACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAA ACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGC GGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTC CGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGATTACCCAGTCACCGTGGCCTC CAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGC 15 TGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCG TGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCT TCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTG GCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTC AGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGATCCGGAGGTACCCAGGA 20 CTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTG TCTGACTACCTGCTTCAA (SEQ ID NO:199) pMON32398.seq 25 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACC CTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAA CCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCA TCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCG CACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAA 30 ACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGC GGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTC CGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGATTACCCAGTCACCGTGGCCTC CAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGC TGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCG 35 TGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCT TCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTG GCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTC AGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGG AGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTC 40 AAAATCCGTGAGCTGTCTGACTACCTGCTTCAA (SEQ ID NO:200) pMON32399.seq
GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACC 45 CTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAA CCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCA TCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCG CACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAA ACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGC 50 GGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTC CGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGCCTCCAACCTGCAGGACGAGGA GCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAG ACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACT TTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAA 55 CATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATC ACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCC - 129- CZ 295843 B6 TGGGCGGTGGGTCAGGAGGTGGATCCGGAGGTACCCAGGACTGCTCCTTCCAACACAG CCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAA GATTACCCAGTCACCGTG (SEQ ID NO:201) 5 pMON35700.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACC CTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAA CCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCA 10 TCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCG CACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAA ACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAAGGC GGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTC CGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGCCTCCAACCTGCAGGACGAGGA 15 GCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAG ACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACT TTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAA CATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATC ACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCC 20 TGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTG CTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCT GACTACCTGCTTCAAGATTACCCAGTCACCGTG (SEQ ID NO:202) pMON35701.seq 25 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACC CTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAA CCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCA TCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCG 30 CACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAA ACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGC GGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTC CGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGTCGCTGGGTCCAAGATGCAAGG CTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCC 35 CCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCT CCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCT GGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGATCC GGAGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCA AAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAA 40 CCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGG ATGGAGCGGCTCAAGACT (SEQ ID NO:203) pMON35702.seq
45 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACC CTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAA CCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCA TCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCG CACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAA 50 ACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGC GGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTC CGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGTCGCTGGGTCCAAGATGCAAGG CTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCC CCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCT 55 CCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCT GGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCA -130- CZ 295843 B6 GGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCT CCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGT CACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTC CTGGCACAGCGCTGGATGGAGCGGCTCAAGACT (SEQ ID NO:204) 5 pMON35703.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACC CTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAA 10 CCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCA TCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCG CACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAA ACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGC GGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTC 15 CGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCGCTTCGTCCAGACCAACATCTC CCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGC CAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCG GTGGGTCAGGAGGTGGATCCGGAGGTACCCAGGACTGCTCCTTCCAACACAGCCCCAT CTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTAC 20 CCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGC TGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCA AGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG CCCCCCCCCAGCTGTCTT (SEQ ID NO:205) 25 pMON35704. seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACC CTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAA CCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCA 30 TCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCG CACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAA ACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGC GGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTC CGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCGCTTCGTCCAGACCAACATCTC 35 CCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGC CAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCG GTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTT CCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTAC CTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCG 40 GGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGC TGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACC AAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTT (SEQ ID NO:206) pMON35705.seq 45
GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACC CTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAA CCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCA TCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCG 50 CACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAA ACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGC GGTGGAAGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTC CGTCTAAAGAATCTCATAAATCTCCAAACATGGCCACCAACATCTCCCGCCTCCTGCA GGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCC 55 CGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAG GTGGATCCGGAGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTT -131 - CZ 295843 B6 CGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTG GCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCAC AGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGA GCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC 5 TGTCTTCGCTTCGTCCAG (SEQ ID NO:207) pMON35706.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACC 10 CTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAA CCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCA TCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCG CACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAA ACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGC 15 GGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTC CGTCTAAAGAATCTCATAAATCTCCAAACATGGCCACCAACATCTCCCGCCTCCTGCA GGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCC CGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAG GTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCC 20 CATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGAT TACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGC GGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGAT GCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTT CAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAG (SEQ ID NO:208) 25 pMON35733.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACC CTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAA 30 CCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCA TCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCG CACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAA ACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGC GGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTC 35 CGTCTAAAGAATCTCATAAATCTCCAAACATGGCTTCTAATCTGCAAGATGAAGAGCT GTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACT GTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTG TCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACAT CTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACT 40 CGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGG GCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAG TGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAA ATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCC (SEQ ID NO:209) 45 pMON35734.seq
GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACC CTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAA 50 CCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCA TCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCG CACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAA ACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGC GGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTC 55 CGTCTAAAGAATCTCATAAATCTCCAAACATGGCCAACCTGCAAGATGAAGAGCTGTG TGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTC - 132- CZ 295843 B6 GCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCA CCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTC CCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGC CAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCG 5 GTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGG TACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATC CGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCC (SEQ ID NO:210) 10 pMON35735. seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACC CTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAA CCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCA 15 TCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCG CACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAA ACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGC GGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTC CGTCTAAAGAATCTCATAAATCTCCAAACATGGCTCTGCAGGATGAGGAACTGTGCGG 20 CGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCT GGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCA AATGTGCTTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCG CCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAG AACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTG 25 GGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTAC CCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGT GAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAAC (SEQ ID NO:211) 30 pMON35736. seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACC CTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAA CCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCA 35 TCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCG CACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAA ACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGC GGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTC CGTCTAAAGAATCTCATAAATCTCCAAACATGGCTCAAGATGAAGAGCTGTGTGGTGG 40 TCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGG TCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAAT GTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCT CCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAAC TTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGT 45 CAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCA GGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAG CTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTG (SEQ ID NO:212) 50 pMON35738 . seq
GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACC CTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAA CCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCA 55 TCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCG CACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAA - 133 - CZ 295843 B6 ACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGC GGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTC CGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGAAGAACTGTGTGGTGGTCTGTG GCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAG 5 ATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCT TTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCA GGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCC CGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAG GTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTG 10 CTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCT GACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGAC (SEQ ID NO:213) pMON35739.seq 15 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACC CTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAA CCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCA TCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCG 20 CACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAA ACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGC GGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTC CGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGAGCTGTGTGGTGGCCTGTGGCG TCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATG 25 CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTC AGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGA GACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAAAACTTCTCCCGG TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTG GGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTC 30 CTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGAC TACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAG (SEQ ID NO:214) pMON35740.seq 35 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACC CTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAA CCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCA TCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCG 40 CACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAA ACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGC GGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTC CGTCTAAAGAATCTCATAAATCTCCAAACATGGCTCTGTGCGGTGGTCTGTGGCGTCT GGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAA 45 GGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGC CCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGAC CTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGC CTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGT CAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTT 50 CCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTAC CTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAG (SEQ ID NO:215) - 134- CZ 295843 B6 pMON35741.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACC CTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAA 5 CCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCA TCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCG CACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAA ACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGC GGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTC 10 CGTCTAAAGAATCTCATAAATCTCCAAACATGGCTTCTAATCTGCAAGATGAAGAGCT GTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACT GTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTG TCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACAT CTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACT 15 CGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGG GCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAG TGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTCCGCTGTCAAA ATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCC (SEQ ID NO:216) 20 pMON35742.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACC CTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAA 25 CCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCA TCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCG CACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAA ACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGC GGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTC 30 CGTCTAAAGAATCTCATAAATCTCCAAACATGGCTCAAGATGAAGAACTGTGCGGTGG TCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGG TCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAAT GTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCT CCTGCGGGAGACCTCCGAGCAGCCGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAAC 35 TTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGT CAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCA GGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAG CTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTG (SEQ ID NO:217) 40 pMON35743.seq
GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACC CTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAA 45 CCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCA TCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCG CACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAA ACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGC GGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTC 50 CGTCTAAAGAATCTCATAAATCTCCAAACATGGCTCTGTGCGGTGGTCTGTGGCGTCT GGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAA GGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGC CCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGAC CTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGC 55 CTGGAGCTGCAGTGTCGGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGT CAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTT - 135 - CZ 295843 B6
CCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAGATCCGTGAGCTGTCTGACTAC
CTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAG (SEQ ID NO:218) 5 pMON32179.seq GCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGG AGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACAC GGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTC 10 GTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGA AGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA CTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGC TCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCG ACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCAC 15 CGTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACT ATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTAACTGCT CTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTGGA CCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACT CCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTG 20 AGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCG ACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG (SEQ ID NO:219) pMON35707.seq 25 GCGGATGAGGAGCTGTGCGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGG AGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACAC GGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCGCCCAGCTGTCTTCGCTTC GTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGA 30 GGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA CTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGATCCGGAGGTACCCAGGACTGCTCC TTCCAACACAGCCCCATCTCCTCCGACTTCGGTGTCAAAATCCGTGAGCTGTCTGACT ACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCG 35 TCTAAAGAATCTCATAAATCTCCAAACATGGCTAACTGCTCTATAATGATCGATGAAA TTATACATCACTTAAAGAGACCACCTAACCCTTTGCTGGACCCGAACAACCTCAATTC TGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTC GTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATC TCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAA 40 GGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAG CAAGCGCAGGAACAACAG (SEQ ID NO:220) pMON35708.seq
45 GCCGACGAGGAGCTGTGCGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGG AGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACAC GGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTC GTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGA AGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA 50 CTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGA ACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCC GTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCA GTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATC AACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTAACTGCTCTA 55 TAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTGGACCC GAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCA - 136- CZ 295843 B6 AACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGG CAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACA TCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTAT CTGGTTACCCTTGAGCAAGCGCAGGAACAACAG (SEQ ID NO:221) 5 pMON35709.seq GCAGACGAGGAGCTGTGCGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGG AGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACAC 10 GGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTC GTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGA AGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA CTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGC TCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCG 15 ACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCAC CGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAA ACATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACC TAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAA 20 CGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAA ATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCAC GGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGG GAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG (SEQ ID NO:222) 25 pMON35710.seq GCGGACGAGGAGCTGTGCGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGG AGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCCTGCTGGAGCGCGTGAACAC 30 GGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCCTC GTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGA AGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA CTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGA ACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCC 35 GTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCA GTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATC AACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTAACTGCTCTA TAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTGGACCC GAACAAC C T CAAT T C T GAAGACAT GGATAT C C T GAT G GAAC GAAAC C T T C GAAC T CCA 40 AACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGG CAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACA TCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTAT CTGGTTACCCTTGAGCAAGCGCAGGAACAACAG (SEQ ID NO:223) 45 pMON35711. seq
GCGGATGAGGAGCTGTGTGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGG GGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACAC GGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTC 50 GTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGA AGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA CTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGC TCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCG ACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCAC 55 CGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAA - 137- CZ 295843 B6 ACATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACC TAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAA CGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAA ATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCAC 5 GGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGG GAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG (SEQ ID NO:224) pMON35719.seq 10 GGCCGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGC CTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGT CCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATG TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC 15 CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACT TCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTC AGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACAC AGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTC AATACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTAT 20 CAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTAACTGCTCT ATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTGGACC CGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCC AAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAG GCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGAC 25 ATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTA TCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG (SEQ ID NO:225) pMON35720.seq 30 GCCGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGG CACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCT GGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCC AGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGC AGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCT 35 GCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGT GGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACT TCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGT GTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATC AACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTAACTGCTCTA 40 TAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTGGACCC GAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCA AACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGG CAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACA TCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTAT 45 CTGGTTACCCTTGAGCAAGCGCAGGAACAACAG (SEQ ID NO:226) pMON35721.seq
GCCGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACT 50 TTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAA CATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATC ACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCC TGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTG CTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCT 55 GACTACCTGCTTCAGGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGC TCTGCGGGGGCCTCTGGCGGČTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGAC - 138- CZ 295843 B6 TTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATC AACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTAACTGCTCTA TAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTGGACCC GAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCA 5 AACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGG CAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACA TCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTAT CTGGTTACCCTTGAGCAAGCGCAGGAACAACAG (SEQ ID NO:227) 10 pMON35722 . seq GCCTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCA AATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCG CCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAG 15 AACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTG GGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCA ACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTG CTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGG GCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGG 20 CTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATC AACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTAACTGCTCTA TAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTGGACCC GAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCA AACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGG 25 CAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACA TCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTAT CTGGTTACCCTTGAGCAAGCGCAGGAACAACAG (SEQ ID NO:228) pMON35723.seq 30 GCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGA CCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTG CCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGG TCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCT 35 CCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCC AGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTG GTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAG GCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCC GTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATC 40 AACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTAACTGCTCTA TAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTGGACCC GAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCA AACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGG CAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACA 45 TCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTAT CTGGTTACCCTTGAGCAAGCGCAGGAACAACAG (SEQ ID NO:229) pMON35725.seq
50 GCCACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGC CCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTC CTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACC CAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTYGCTGTCAAAATCCGTG AGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGA 55 CGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGG CTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGA - 139- CZ 295843 B6 TACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCA GTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATC AACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTAACTGCTCTA TAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTGGACCC 5 GAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCA AACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGG CAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACA TCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTAT CTGGTTACCCTTGAGCAAGCGCAGGAACAACAG (SEQ ID NO:230) 10 pMON35726.seq GCCCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGG TGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTG 15 TCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCC GGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTG TCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTC CAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGC TGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAACGCG 20 TGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTTT TTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATC AACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTAACTGCTCTA TAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTGGACCC GAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCA 25 AACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGG CAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACA TCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTAT CTGGTTACCCTTGAGCAAGCGCAGGAACAACAG (SEQ ID NO:231) 30 pMON3574 4 . seq GCTTCAAATCTGCAGGATGAAGAGCTGTGCGGGGGCCTCTGGCGGCTGGTCCTGGCAC AGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGA GCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC 35 TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGC TGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCA GTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGA TCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCC CCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGA 40 TTACCCAGTCACCGTGGCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAA ACATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACC TAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAA CGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAA 45 ATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCAC GGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGG GAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG (SEQ ID NO:232) 50 pMON35745. seq
GCTAATCTGCAAGATGAGGAGCTGTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGC GCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCG CGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGT 55 CTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGG TGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTG - 140- CZ 295843 B6 TCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCC GGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCA TCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTA CCCAGTCACCGTGGCCTCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT 5 GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAA ACATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACC TAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAA CGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAA ATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCAC 10 GGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGG GAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG (SEQ ID NO:233) pMON35746.seq 15 GCGCTGCAGGATGAAGAGCTGTGTGGCGGCCTCTGGCGGCTGGTCCTGGCACAGCGCT TGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGT GAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTT CGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGG 20 CGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCA GCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGA GGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCT CCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCC AGTCACCGTGGCCTCCAACTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT 25 GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAA ACATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACC TAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAA CGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAA ATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCAC 30 GGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGG GAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG (SEQ ID NO:234) pMON35747.seq 35 GCGCAAGATGAGGAACTGTGTGGTGGTCTCTGGCGGCTGGTCCTGGCACAGCGCTGGA TGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAA CACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGC TTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGC 40 TGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCC CGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGT GGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCT CCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGT CACCGTGGCCTCCAACCTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT 45 GGTCCAATCTCTACTATCAACCCGTCTCCCCCGTCTAAAGAATCTCATAAATCTCCAA ACATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACC TAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAA CGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAA ATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCAC 50 GGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGG GAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG (SEQ ID NO:235) - 141 - CZ 295843 B6 pMON35748.seq GCTGAAGAACTGTGTGGTGGCCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGC GGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGA 5 GATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTC CAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGC CCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTC CTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCA GGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACT 10 TCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGT GGCCTCCAACCTGCAGGACTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAA ACATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACC TAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAA 15 CGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAA ATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCAC GGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGG GAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG (SEQ ID NO:236) 20 pMON35749.seq GCTCTGTGCGGTGGCCTGTGGCGTCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCA AGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACA 25 CTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACC AACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGA TCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAAC CCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGA GGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTG 30 TCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTC CAACCTGCAGGACGAGGAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAA ACATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACC TAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAA 35 CGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAA ATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCAC GGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGG GAAAAACT GAC GTTCTATCTGGTTACCCTT GAGCAAGC GCAGGAACAACAG (SEQ ID NO:237) 40 pMON35750.seq
GCACTGTGTGGTGGTCTGTGGCGTCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCA AGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACA 45 CTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACC AACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGA TCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAAC CCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGA GGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTG 50 TCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTC CAACCTGCAGGACGAGGAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAA ACATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACC TAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAA 55 CGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAA ATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCAC - 142- CZ 295843 B6
GGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGG
GAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG (SEQ ID NO:238) 5 pMON35769.seq GCTCTGTGTGGCGGTCTGTGGCGTCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCA AGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACA CTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACC 10 AACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGA TCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCGGCCCGACTCCTCAAC CCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGA GGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTG TCAAGATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTC 15 CAACCTGCAGGACGAGGAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAA ACATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACC TAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAA CGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAA 20 ATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCAC GGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGG GAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG (SEQ ID NO:239) 25 pMON35771. seq GCCTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCA AATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCG CCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAG 30 AACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTG GGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCA ACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTG CTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGG GCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGG 35 CTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATC AACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTAACTGCTCTA TAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTGGACCC GAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCA AACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGG 40 CAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACA TCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTAT CTGGTTACCCTTGAGCAAGCGCAGGAACAACAG (SEQ ID NO:240) pMON35774.seq 45
GCTCAAGATGATGAGCTGTGTGGTGGTCTCTGGCGGCTGGTCCTGGCACAGCGCTGGA TGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAA CACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGC TTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGC 50 TGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCC CGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGCGGTGGTTCTGGCGGA GGATCCGGCGGCGGAAGCGGAGGTGGCTCTGGGGGAGGTAGTGGTACCCAGGACTGCT CCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGA CTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGTACGTAGAGGGCGGT 55 GGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGT CTAAAGAATCTCATAAATCTCCAAACATGGCTAACTGCTCTATAATGATCGATGAAAT - 143 - CZ 295843 B6 TATACATCACTTAAAGAGACCACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCT GAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCG TAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCT CCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG 5 GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGC AAGCGCAGGAACAACAG (SEQ ID NO:241) pMON35775.seq 10 GCCCAAGATGAAGAACTGTGTGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGA TGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAA CACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGC TTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGC TGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCC 15 CGACTCCTCAACCCTGCCGCCACCGTGGAGCCCGCGTCCACTCGGCGCCACCGCACCG ACCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAA TCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCT GTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATC AACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTAACTGCTCTA 20 TAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTGGACCC GAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCA AACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGG CAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACA TCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTAT 25 CTGGTTACCCTTGAGCAAGCGCAGGAACAACAG (SEQ ID NO:242) pMON35776.seq GCCCAAGATGAAGAACTGTGTGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGA 30 TGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAA CACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGC TTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGC TGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCC CGACTCCTCAACCCTGCCGCCACCGTGGAGCCCGCGTCCACTCGGCGCCACCGCACCG 35 ACCGCTGGACAACCGCCTCTGACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCT CCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGT CACCGTGGCCTCCAACCTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAA ACATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACC 40 TAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAA CGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAA ATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCAC GGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGG GAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG 45 (SEQ ID NO: 243) pMON32169.seq/pMON40000.seq
GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAG 50 AGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCAC CTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCC TGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCC AACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATC CCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACC 55 ACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGG GTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGC -144- CZ 295843 B6 TAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAG CCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTA TCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGATGAAGA ACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAG 5 ACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACT TTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAA CATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATC ACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCC TGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGG 10 TAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTC AAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCA ACCTGCAG (SEQ ID NO:244) pMON32188.seq 15 GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAG AGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCAC CTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCC TGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCC 20 AACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATC CCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACC ACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGG GTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGC TAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAG 25 CCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTA TCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCAAATCTGCA AGACGAGGAGCTGTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAG CGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGG AGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGT 30 CCAGATCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAG CCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACT CCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTC AGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGAC TTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCG 35 TGGCCTCC (SEQ ID NO: 245) pMON32273.seq
GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAG 40 AGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCAC CTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCC TGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCC AACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATC CCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACC 45 ACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGG GTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGC TAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAG CCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTA TCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCCCCCCAG 50 CTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAG CTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGC AGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGG ATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGC CCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAG 55 ATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTG GCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAG - 145 - CZ 295843 B6 ATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCT TTCAGCCC (SEQ ID NO:246) pMON35795.seq 5 GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAG AGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCAC CTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCC TGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCC 10 AACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATC CCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACC ACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGG GTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGC TAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAG 15 CCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTA TCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTCTGCAGGA TGAGGAACTGTGCGGCGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGG CTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGA TACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCA 20 GACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCC TGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCT CAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGG GGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTC GCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGG 25 CCTCCAAC (SEQ ID NO: 247) pMON35796.seq GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAG 30 AGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCAC CTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCC TGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCC AACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATC CCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACC 35 ACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGG GTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGC TAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAG CCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTA TCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTCAAGATGA 40 AGAGCTGTGTGGTGGTCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATAC ACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGAC CAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAA 45 CCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGG AGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCT GTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCT CCAACCTG (SEQ ID NO:248) 50 pMON35797. seq
GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAG AGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCAC CTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCC 55 TGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCC AACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATC - 146- CZ 295843 B6 CCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACC ACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGG GTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGC TAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAG 5 CCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTA TCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGAAGAACT GTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACT GTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTG TCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACAT 10 CTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACT CGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGG GCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAG TGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAA ATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACC 15 TGCAGGAC (SEQ ID NO: 249) pMON35798.seq GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAG 20 AGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCAC CTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCC TGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCC AACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATC CCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACC 25 ACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGG GTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGC TAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAG CCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTA TCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGAGCTGTG 30 TGGTGGCCTGTGGCGTCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTC GCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCA CCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTC CCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGC CAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCG 35 GTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGG TACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATC CGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGC AGGACGAG (SEQ ID NO:250) 40 pMON35799. seq
GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAG AGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCAC CTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCC 45 TGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCC AACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATC CCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACC ACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGG GTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGC 50 TAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAG CCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTA TCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTCTGTGCGG TGGTCTGTGGCGTCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCT GGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCA 55 AATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCG CCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAG -147- CZ 295843 B6 AACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTG GGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTAC CCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGT GAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGG 5 ACGAGGAG (SEQ ID NO:251) pMON39914.seq GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAG 10 AGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCAC CTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCC TGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCC AACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATC CCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACC 15 ACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGG GTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGC TAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAG CCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTA TCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGATGAAGA 20 ACTGTGTGGTGGGCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAG ACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACT TTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAA CATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATC ACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCC 25 TGCCGCCACCGTGGAGCCCGCGTCCACTCGGCGCCACCGCACCGACCACCCAGGACTG CTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCT GACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG (SEQ ID NO:252) 30 pMON39915. seq GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAG AGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCAC CTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCC 35 TGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCC AACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATC CCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACC ACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGG GTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGC 40 TAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAG CCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTA TCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGATGAAGA ACTGTGTGGTGGGCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAG ACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACT 45 TTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAA CATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATC ACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCC TGGGCGGTGGGTCAGGAGGTGGGTCAGGCGGTGGTTCTGGCGGAGGATCCGGCGGCGG AAGCGGAGGTGGCTCTGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGC 50 CCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAG ATTACCCAGTCACCGTGGCCTCCAACCTGCAG (SEQ ID NO:253) pMON39916.seq
55 GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAG AGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCAC -148- CZ 295843 B6 CTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCC TGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCC AACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATC CCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACC 5 ACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGG GTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGC TAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAG CCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTA TCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGATGAAGA 10 ACTGTGTGGTGGGCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAG ACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACT TTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAA CATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATC ACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCC 15 TGCCGCCACCGTGGAGCCCGCGTCCACTCGGCGCCACCGCACCGACCGCTGGACAACC GCCTCTGACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTC AAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCA ACCTGCAG (SEQ ID NO:254) 20 pMON35712. seq GCCGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCC TCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTC CAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGT 25 GCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCC TGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTT CTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCA GGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACA GCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCA 30 A (SEQ ID NO: 255) pMON35713.seq GCCGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGG 35 CACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCT GGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCC AGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGC AGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCT GCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGT 40 GGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACT TCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGT G (SEQ ID NO:256) pMON35714.seq 45 GCCGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACT TTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAA CATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATC ACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCC 50 TGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTG CTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCT GACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGC TCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGAC T (SEQ ID NO:257) - 149- 55 CZ 295843 B6 pMON35715.seq GCCTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCA AATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCG 5 CCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAG AACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTG GGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCA ACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTG CTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGG 10 GCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGG G (SEQ ID NO:258) pMON35716.seq 15 GCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGA CCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTG CCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGG TCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCT CCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCC 20 AGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTG GTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAG GCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCC C (SEQ ID NO:259) 25 pMON35717. seq GCCCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGG TGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTG TCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCC 30 GGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTG TCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTC CAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGC TGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCG TGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCT 35 T (SEQ ID NO: 260) pMON35718.seq GCCACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGC 40 CCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTC CTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACC CAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTG AGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGA CGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGG 45 CTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGA TACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCA G (SEQ ID NO:261) pMON32170.seq 50
GCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGG AGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACAC GGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTC GTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGA 55 AGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA CTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGC - 150- CZ 295843 B6 TCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCG ACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCAC CGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAA 5 ACATGGCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTC TTTAGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGT GCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCA TCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTT GAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGG 10 ATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTG CCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCAC CCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTG GTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTG CGCAGCCC (SEQ ID NO:262) 15 pMON32187.seq GCAGATGAAGAACTGTGTGGGGGACTGTGGCGTCTGGTCCTGGCACAGCGCTGGATGG AGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACAC 20 GGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTC GTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGA AGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA CTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGC TCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCG 25 ACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCAC CGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAA ACATGGCTACACCATTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTG CTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGT 30 GCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCA TCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTT GAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGG ATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTG CCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCAC 35 CCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTG GTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTG CGCAGCCC (SEQ ID NO:263) PMON32271.seq 40
GCTGATGAAGAACTGTGTGGTGGGCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGG AGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACAC GGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTC GTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGA 45 AGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA CTCCTCAACCCTGCCGCCACCGTGGAGCCCGCGTCCACTCGGCGCCACCGCACCGACC GCTGGACAACCGCCTCTGACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCG ACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCAC CGTGGCCTCCAACCTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGGTGGTTCTGGC 50 GGCGGCTCCAACATGGCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCC TGCTCAAGTCTTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGCGCAGCGCTCCAGGA GAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACAC TCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGG CAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGC 55 CCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTC GCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCC - 151 - CZ 295843 B6 TGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGG AGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTA CGCCACCTTGCGCAGCCG (SEQ ID NO:264) 5 pMON32272.seq GCTGATGAAGAACTGTGTGGTGGGCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGG AGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACAC GGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTC 10 GTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGA AGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA CTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGCGGTGGTTCTGGCGGAGGA TCCGGCGGCGGAAGCGGAGGTGGCTCTGGGGGAGGTAGTGGTACCCAGGACTGCTCCT TCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTA 15 CCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGT GGAGGCTCCCCGGGTGGTGGTTCTGGCGGCGGCTCCAACATGGCTACACCATTGGGCC CTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAGAGCAAGTGAGGAAGAT CCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCAC CCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCT 20 CCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCT TTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCC ACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGA TGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTT CGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGC 25 TTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCG (SEQ ID NO:265) pMON32274.seq 30 GCTGATGAAGAACTGTGTGGTGGGCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGG AGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACAC GGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTC GTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGA AGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA 35 CTCCTCAACCCTGCCGCCACCGTGGAGCCCGCGTCCACTCGGCGCCACCGCACCGACC ACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCC GTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGTA CGTAGAGGGCGGTGGAGGCTCCCCGGGTGGTGGTTCTGGCGGCGGCTCCAACATGGCT ACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAGAGC 40 AAGTGAGRAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTA CAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGG GCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAAC TCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCC CGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACC 45 ATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTG CCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAG CCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCG (SEQ ID NO:266) 50 pMON35751. seq
GCGGATGAGGAGCTGTGCGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGG AGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACAC GGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTC 55 GTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGA GGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA - 152- CZ 295843 B6 CTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGATCCGGAGGTACCCAGGACTGCTCC TTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACT ACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCG 5 TCTAAAGAATCTCATAAATCTCCAAACATGGCTACACCATTAGGCCCTGCCAGCTCCC TGCCCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAAGTGAGGAAGATCCAGGGCGATGG CGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCTG GTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCC AGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCA 10 GGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACA CTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGG GAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTT CCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTG TCGTACCGCGTTCTACGCCACCTTGCGCAGCCC (SEQ ID NO:267) 15 pMON35752.seq GCCGACGAGGAGCTGTGCGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGG AGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACAC 20 GGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTC GTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGA AGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA CTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGC ACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCC 25 GTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCA GTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATC AACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTACACCATTAG GCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAAGTGAGGAA GATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGC 30 CACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGA GCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGG CCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGT CCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGC AGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGC 35 CTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAG AGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC (SEQ ID NO:268) pMON35753.seq 40
GCAGACGAGGAGCTGTGCGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGG AGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACAC GGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTC GTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGA 45 AGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA CTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGC TCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCG ACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCAC CGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT 50 GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAA ACATGGCTACACCATTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTG CTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGT GCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCA TCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTT 55 GAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGG ATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTG -153- CZ 295843 B6 CCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCAC CCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTG GTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTGTACGCCACCTTG CGCAGCCC (SEQ ID NO:269) 5 pMON35754.seq GCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGA CCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTG 10 CCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGG TCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCT CCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCC AGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTG GTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAG 15 GCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCC GTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATC AACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTACACCATTAG GCCCTGCCAGCTCCGTGCCCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAAGTGAGGAA GATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGC 20 CACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGA GCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGG CCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGT CCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGC AGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGC 25 CTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAG AGCTTCCTGGAGGTGTCGTACCGCGTTATACGCCACCTTGCGCAGCCC (SEQ ID NO:270) pMON35755.seq 30 GCTTCAAATCTGCAGGATGAAGAGCTGTGCGGGGGCCTCTGGCGGCTGGTCCTGGCAC AGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGA GCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGC 35 TGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCA GTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGA TCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCC CCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGA TTACCCAGTCACCGTGGCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT 40 GGTCCAATCTCTACTATCAACCCGTCTCATCCGTCTAAAGAATCTCATAAATCTCCAA ACATGGCTACACCATTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTG CTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGT GCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCA TCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTT 45 GAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGG ATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTG CCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCAC CCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTG GTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTG 50 CGCAGCCC (SEQ ID NO: 271) pMON35756.seq
GCTAATCTGCAAGATGAGGAGCTGTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGC 55 GCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCG CGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGT - 154- CZ 295843 B6 CTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGG TGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTG TCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCC GGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCA 5 TCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTA CCCAGTCACCGTGGCCTCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAA ACATGGCTACACCATTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTG CTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGT 10 GCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCA TCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTT GAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGG ATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTG CCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCAC 15 CCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTG GTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTATACGCCACCTTG CGCAGCCC (SEQ ID NO:272) pMON35757.seq 20 GCGCTGCAGGATGAAGAGCTGTGTGGCGGCCTCTGGCGGCTGGTCCTGGCACAGCGCT TGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGT GAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTT CGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGG 25 CGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCA GCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGA GGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCT CCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCC AGTCACCGTGGCCTCCAACTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT 30 GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAA ACATGGCTACACCATTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTG CTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGT GCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCA TCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTT 35 GAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGG ATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTG CCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCAC CCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTG GTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTG 40 CGCAGCCC (SEQ ID NO: 273) pMON35758.seq
GCACTGTGCGGTGGTCTGTGGCGTCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCA 45 AGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACA CTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACC AACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGA TCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTACAGTGTCAGCCCGACTCCTCAAC CCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGA 50 GGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTG TCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTC CAACCTGCAGGACGAGGAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAA ACATGGCTACACCATTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTG 55 CTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGT GCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCA - 155 - CZ 295843 B6 TCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTT GAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGG ATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTG CCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCAC 5 CCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTG GTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTG CGCAGCCC (SEQ ID NO:274) pMON35759.seq 10 GCCTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCA AATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCG CCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAG AACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTG 15 GGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCA ACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTG CTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGG GCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGG CTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATC 20 AACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTACACCATTAG GCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAAGTGAGGAA GATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGC CACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGA GCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGG 25 CCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGT CCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGC AGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGC CTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAG AGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC 30 (SEQ ID NO: 275) pMON35760.seq GCCTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCA 35 AATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCG CCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAG AACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTG GGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCA ACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTG 40 CTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGG GCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGG CTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATC AACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTACACCATTAG GCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAAGTGAGGAA 45 GATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGC CACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGA GCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGG CCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGT CCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGC 50 AGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGC CTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAG AGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC (SEQ ID NO:276) - 156- 55 CZ 295843 B6 pMON35761.seq GCGCTGTGTGGTGGTCTGTGGCGTCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCA AGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACA 5 CTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACC AACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGA TCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCGGCCCGACTCCTCAAC CCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGA GGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCAACTTCGCTG 10 TCAAGATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTC CAACCTGCAGGACGAGGAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATTTTTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAA ACATGGCTACACCATTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTG CTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGT 15 GCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCA TCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTT GAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGG ATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTG CCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCAC 20 CCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTG GTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTG CGCAGCCC (SEQ ID NO:277) pMON35762.seq 25 GCTGAACTGTGTGGTGGTCTGTGGCGTCTGGTCCTGGCACAGCGCTGGATGGAGCGGC TCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGAT ACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAG ACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCT 30 GGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTC AACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGG GGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCG CTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGC CTCCAACCTGCAGGACGAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT 35 GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAA ACATGGCTACACCATTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTG CTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGT GCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCA TCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTT 40 GAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGG ATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTG CCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCAC CCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTG GTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTG 45 CGCAGCCC (SEQ ID NO:278) pMON35763.seq
GCTGAAGAACTGTGTGGTGGCCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGC 50 GGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGA GATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTC CAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGC CCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTC CTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCA 55 GGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACT TCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGT - 157- CZ 295843 B6 GGCCTCCAACCTGCAGGACTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAA ACATGGCTACACCATTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTG CTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGT 5 GCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCA TCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTT GAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGG ATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTG CCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCAC 10 CCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTG GTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTG CGCAGCCC (SEQ ID NO:279) pMON35764.seq 15 GCTCAGGACGAGGAACTGTGTGGTGGTCTCTGGCGGCTGGTCCTGGCACAGCGCTGGA TGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAA CACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGC TTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGC 20 TGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCC CGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGT GGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCT CCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGT CACCGTGGCCTCCAACCTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT 25 GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAA ACATGGCTACACCATTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTG CTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGT GCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCA TCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTT 30 GAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGG ATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTG CCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCAC CCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTG GTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTG 35 CGCAGCCC (SEQ ID NO:280) pMON357 65.seq
GCCACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGC 40 CCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTC CTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACC CAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTTGCTGTCAAAATCCGTG AGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGA CGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGG 45 CTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGA TACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCA GTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATC AACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTACACCATTAG GCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAAGTGAGGAA 50 GATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGC CACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGA GCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGG CCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGT CCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGC 55 AGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGC - 158- CZ 295843 B6 CTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAG AGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC (SEQ ID NO:281) 5 pMON35766.seq/pMON32190.seq/pMON40001.seq GCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGG AGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACAC GGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTC 10 GTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGA AGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA CTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGC TCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCG ACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCAC 15 CGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGGTGGTTCT GGCGGCGGCTCCAACATGGCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCT TCCTGCTCAAGTCTTTAGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCA GGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGA CACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGC 20 TGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCA GGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGAC GTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTG CCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGC AGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTT 25 CTACGCCACCTTGCGCAGCCG (SEQ ID NO:282} pMON357 68.seq GCTCAAGATGAAGAACTGTGCGGTGGTCTCTGGCGGCTGGTCCTGGCACAGCGCTGGA 30 TGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAA CACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGC TTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGC TGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCC CGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGCGGATCCGGAGGT 35 GGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCT CCGACTCCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGT CACCGTGGCCTCCAACCTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAA ACATGGCTACACCATTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTG 40 CTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGT GCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCA TCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTT GAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGG ATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTG 45 CCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCAC CCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTG GTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTG CGCAGCCC (SEQ ID NO:283) 50 pMON35770. seq
GCGCTGTGTGGTGGCCTGTGGCGTCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCA AGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACA CTTTGTCACCAAATATGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACC 55 AACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGA TCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCGGCCCGACTCCTCAAC - 159- CZ 295843 B6 CCTGGGCGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACC CAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAGATCCGTG AGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGA CGAGGAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCT 5 ACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTACAC CATTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAAGT GAGGAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAG CTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTC CCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCA 10 TAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAG TTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCT GGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCAT GCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCAT CTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC 15 (SEQ ID NO: 284 ) pMON35772.seq GCCTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCA 20 AATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCG CCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAG AACTTCTTCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTG GGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCA ACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTG 25 CTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGG GCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGG CTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATC AACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTACACCATTAG GCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAAGTGAGGAA 30 GATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGC CACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGA GCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGG CCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGT CCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGC 35 AGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGC CTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAG AGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC (SEQ ID NO:285) 40 pMON35773. seq
GCTCAAGACGAAGAACTGTGTGGTGGTCTCTGGCGGCTGGTCCTGGCACAGCGCTGGA TGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAA CACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGC 45 TTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGC TGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCC CGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGCGGTGGTTCTGGCGGA GGATCCGGCGGCGGAAGCGGAGGTGGCTCTGGGGGAGGTAGTGGTACCCAGGACTGCT CCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGA 50 CTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGTACGTAGAGGGCGGT GGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGT CTAAAGAATCTCATAAATCTCCAAACATGGCTACACCATTAGGCCCTGCCAGCTCCCT GCCCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGC GCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCTGG 55 TGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCA GGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAG - 160- CZ 295843 B6 GGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACAC TGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGG AATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTC CAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGT 5 CGTACCGCGTTCTACGCCACCTTGCGCAGCCC (SEQ ID NO:286) pMON35777.seq GCCCAAGATGAAGAACTGTGTGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGA 10 TGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAA CACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGC TTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGC TGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCC CGACTCCTCAACCCTGCCGCCACCGTGGAGCCCGCGTCCACTCGGCGCCACCGCACCG 15 ACCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAA TCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCT GTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATC AACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTACACCATTAG GCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAAGTGAGGAA 20 GATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGC CACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGA GCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGG CCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGT CCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGC 25 AGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGC CTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAG AGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC (SEQ ID NO:287) 30 pMON35778 . seq GCCCAAGATGAAGAACTGTGTGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGA TGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAA CACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGC 35 TTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGC TGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCC CGACTCCTCAACCCTGCCGCCACCGTGGAGCCCGCGTCCACTCGGCGCCACCGCACCG ACCGCTGGACAACCGCCTCTGACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCT CCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGT 40 CACCGTGGCCTCCAACCTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAA ACATGGCTACACCATTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTG CTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGT GCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCA 45 TCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTT GAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGG ATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTG CCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCAC CCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTG 50 GTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTG CGCAGCCC (SEQ ID NO:288) pMON35779.seq
55 GCTGATGAAGAACTGTGTGGTGGGCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGG AGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACAC -161 - CZ 295843 B6 GGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTC GTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGA AGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA CTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGCGGTGGTTCTGGCGGAGGA 5 TCCGGCGGCGGAAGCGGAGGTGGCTCTGGGGGAGGTAGTGGTACCCAGGACTGCTCCT TCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTA CCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGT GGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGT CTAAAGAATCTCATAAATCTCCAAACATGGCTACACCATTAGGCCCTGCCAGCTCCCT 10 GCCCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGC GCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCTGG TGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCA GGCCCTGCAGCTGGGAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAG GGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACAC 15 TGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGG AATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTC CAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGT CGTACCGCGTTCTACGCCACCTTGCGCAGCCC (SEQ ID NO:289) 20 pMON35780. seq GCTGATGAAGAACTGTGTGGTGGGCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGG AGCGGCCCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACAC GGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTC 25 GTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGA AGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA CTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGCGGTGGTTCTGGCGGAGGA TCCGGCGGCGGAAGCGGAGGTGGCTCTGGGGGAGGTAGTGGTACCCAGGACTGCTCCT TCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTA 30 CCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGT GGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGT CTAAAGAATCTCATAAATCTCCAAACATGGCTACACCATTAGGCCCTGCCAGCTCCCT GCCCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGC GCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCTGG 35 TGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCA GGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAG GGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACAC TGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGG AATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTC 40 CAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGT CGTACCGCGTTCTACGCCACCTTGCGCAGCCC (SEQ ID NO:290) pMON35782.seq
45 GCGGACGAGGAGCTGTGCGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGG AGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACAC GGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTC GTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGA AGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA 50 CTCCTCAACCCTGCCGCCACCGTGGAGCCCGCGTCCACTCGGCGCCACCGCACCGACC GCTGGACAACCGCCTCTGACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCG ACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCAC CGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGCACCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAA 55 ACATGGCTACACCATTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTG CTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGT - 162- CZ 295843 B6 GCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCA TCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTT GAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGG ATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTG 5 CCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCAC CCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTG GTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTG CGCAGCCC (SEQ ID NO:291) 10 pMON39908 . seq GCTGATGAGGAGCTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGG AGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACAC GGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTC 15 GTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGA AGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGT AGAGACGGTGTTTCACCGTGTCAGCCAGGATGGTCTAGATCTCCTGACCTCGACCCAG GACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGC TGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGTACGT 20 AGAGGGCGGTGGAGGCTCCCCGGGTGGTGGTTCTGGCGGCGGCTCCAACATGGCTACA CCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAGAGCAAG TGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACTAACAA GCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCT CCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCC 25 ATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGA GTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATC TGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCA TGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCA TCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCG 30 (SEQ ID NO: 292) pMON32275.seq GCTGATGAAGAACTGTGTGGTGGGCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGG 35 AGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACAC GGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTC GTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGA AGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA CTCCTCAACCCTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCA 40 ATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGG CTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAGA GCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACC TACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCT GGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCA 45 ACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCC CCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCA CCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGG TGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCT AGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGC 50 CCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTAT CAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCAACCCAGGAC TGCTCTTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGT CTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG (SEQ ID NO:293) - 163 - 55 CZ 295843 B6 pMON35781.seq GCCACCCAGGACTGCTCCTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAA TCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCT 5 GCAGGAGCCGAAGAGCCCGGACACCCATACTAGTCCGCCATCTCCGACACCATTAGGC CCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAGAGCAAGTGAGAAAGA TCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCA CCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGC TCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCC 10 TTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGCCC CACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAG ATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCT TCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAG CTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCCTCTGCAGAACCG 15 AAATCTCCGGATACTCATACCAGCCCGCCATCCCCGGGTTCTAATCTGCAAGATGAAG AGCTGTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAA GACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACAC TTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGCCTTCGCTTCGTCCAGACCA ACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGAT 20 CACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC CTG (SEQ ID NO:294) pMON35783.seq 25 GCCACCCAGGACTGCTCCTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAA TCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCT GCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATG GAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTGGCAGGGGCGCGTGAACA CGGAGATACACTTTGTCACCAAATGTGCCTTTCCGAAGAGCCCGGACACCCATACTAG 30 TCCGCCATCTCCGGGTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTG CTCAAGTCTTTAGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGA AGCTGTGTGCCACTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCT CTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAG GCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCT 35 GGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCC GACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGC AGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGG GGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGC CACCTTGCGCAGCCCTCTGCAGAACCGAAATCTCCGGATACTCATACCAGCCCGCCAT 40 CCCCGGGTAAGGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACAT CTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACT CGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTG (SEQ ID NO:295) 45 pMON32276. seq
GCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGG AGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACAC GGAGATACACTTTGTCACCAAATCTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTC 50 GTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGA AGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA CTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGC TCAGGGGGAGGTAGTGGTACCCAGGACTCCTCCTTCCAACACAGCCCCATCTCCTCCG ACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCAC 55 CGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGGTGGTTCT GGCGGCGGCTCCAACATGGCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCT - 164- CZ 295843 B6 TCCTGCTCAAGTCTTTAGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCA GGAGAAGCTGTGTGCCACTAACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGA CACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGC TGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCA 5 GGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGAC GTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTG CCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGC AGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTT CTACGCCACCTTGCGCAGCCG (SEQ ID NO:296) 10 pMON32277.seq GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAG AGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCAC 15 CTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCC TGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCC AACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATC CCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACC ACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGG 20 GTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGC TAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAG CCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTA TCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGATGAAGA ACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAG 25 ACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACT TTGTCACCAAATCTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAA CATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATC ACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCC TGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGG 30 TAGTGGTACCCAGGACTCCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTC AAAATCCGCGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCA ACCTGCAG (SEQ ID NO:297) pMON32278.seq 35 GCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGG AGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACAC GGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTCTCTTCGCTTC GTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGA 40 AGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTAGAGCTGCAGTCTCAGCCCGA CTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGC TCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCG ACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCAC CGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGGTGGTTCT 45 GGCGGCGGCTCCAACATGGCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCT TCCTGCTCAAGTCTTTAGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCA GGAGAAGCTGTGTGCCACTAACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGA CACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGC TGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCA 50 GGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGAC GTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTG CCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGC AGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTT CTACGCCACCTTGCGCAGCCG (SEQ ID NO:298) -165 - 55 CZ 295843 B6 pMON32279.seq GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAG AGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCAC 5 CTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCC TGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCC AACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATC CCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACC ACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGG 10 GTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGC TAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAG CCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTA TCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCAGATGAAGA ACTGTGTGGGGGCCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAG 15 ACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACT TTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTCTCTTCGCTTCGTCCAGACCAA CATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATC ACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTCTCAGCCCGACTCCTCAACCC TGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGG 20 TAGTGGTACTCAGGACTGTTCTTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTC AAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCA ACCTGCAG (SEQ ID NO:299) pMON35790.seq 25 GCCACTCAGGACTCCTCTTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAA TCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCT GCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATG GAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACA 30 CGGAGATACACTTTGTCACCAAATCTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTT CGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCG ACTCCTCAACCCTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGGTGGTTCTGGCGG CGGCTCCAACATGGCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTG 35 CTCAAGTCTTTAGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGA AGCTGTGTGCCACTAACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTC TCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCA GGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCC TGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGC 40 CGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTG CAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAG GGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACG CCACCTTGCGCAGCCG (SEQ ID NO:300) 45 pMON35791. seq
GCCACTCAGGACTGTTCTTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAA TCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCT GCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATG 50 GAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACA CGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTCTCTTCGCTT CGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTCTCAGCCCG ACTCCTCAACCCTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGGTGGTTCTGGCGG 55 CGGCTCCAACATGGCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTG CTCAAGTCTTTAGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGA - 166- CZ 295843 B6 AGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTC TCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCA GGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCC TGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGC 5 CGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTG CAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAG GGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACG CCACCTTGCGCAGCCG (SEQ ID NO:301) 10 pMON35792 . seq GCCACTCAGGACTGTTCTTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAA TCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCT GCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATG 15 GAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACA CGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTT CGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTACGTAGAGG GCGGTGGAGGCTCCCCGGGTGGTGGTTCTGGCGGCGGCTCCAACATGGCTACACCATT 20 GGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAGAGCAAGTGAGA AAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACTAACAAGCTGT GCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCT GAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGC GGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGG 25 GTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCA GCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCG GCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGC AGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCG (SEQ ID NO:302) 30 pMON39905.seq GCCACTCAGGACTGTTCTTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAA TCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCT 35 GCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATG GAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACA CGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTT CGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTCTCAGCCCG 40 ACTCCTCAACCCTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGGTGGTTCTGGCGG CGGCTCCAACATGGCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTG CTCAAGTCTTTAGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGA AGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTC TCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCA 45 GGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCC TGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGC CGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTG CAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAG GGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACG 50 CCACCTTGCGCAGCCG (SEQ ID NO:303) pMON39906.seq
GCCACTCAGGACTGTTCTTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAA 55 TCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCT GCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATG - 167- CZ 295843 B6 GAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACA CGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTT CGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGCGCCTGGAGCTGCAGTCTCAGCCCG 5 ACTCCTCAACCCTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGGTGGTTCTGGCGG CGGCTCCAACATGGCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTG CTCAAGTCTTTAGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGA AGCTGTGTGCCACTAACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTC TCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCA 10 GGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCC TGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGC CGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTG CAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAG GGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACG 15 CCACCTTGCGCAGCCG (SEQ ID NO:304) pMON39909.seq GCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGG 20 AGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACAC GGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTC GTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGA AGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA CTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGC 25 TCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCG ACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCAC CGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGGTGGTTCT GGCGGCGGCTCCAACATGGCTACTCAAGGTGCTATGCCAGCTTTTGCTTCTGCTTTTC AACGTCGTGCAGGTGGTGTTCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTC 30 GTACCGCGTTCTACGCCACCTTGCGCAGCCCTCTGGCGGCTCTGGCGGCTCTCAGAGC TTCCTGCTCAAGTCTTTAGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCC AGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGG ACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAG CTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGC 35 AGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGA CGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCT GCCCTGCAGCCC (SEQ ID NO:305) pMON39910.seq 40
GCTACTCAAGGTGCTATGCCAGCTTTTGCTTCTGCTTTTCAACGTCGTGCAGGTGGTG TTCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCA CCTTGCGCAGCCCTCTGGCGGCTCTGGCGGCTCTCAGAGCTTCCTGCTCAAGTCTTTA GAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCA 45 CCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCC CTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGC CAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATAT CCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCAC CACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCTACGTA 50 GAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGACGAGGAGCTCTGCGG GGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCT GGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCA AATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCG 55 CCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAG AACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTG - 168- CZ 295843 B6 GGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTAC CCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGT GAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG (SEQ ID NO:306) 5 pMON35727.seq GCCGACGAGGAGCTGTGCGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGG AGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACAC 10 GGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTC GTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGA AGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA CTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGA ACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCC 15 GTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCA GTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATC AACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGACGAGGAGC TCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGAC TGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTT 20 GTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACA TCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCAC TCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTG GGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTGCT CCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGA 25 CTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG (SEQ ID NO:307) PMON32168.seq 30 GCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGG AGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACAC GGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTC GTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGA AGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA 35 CTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGC TCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCG ACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCAC CGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAA 40 ACATGGCTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGT CAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAAATTACCCAGTCACCGTGGCCTCC AACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCT GGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGT GAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTT 45 CGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGG CGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCA GCCCGACTCCTCAACCCTG (SEQ ID NO:308) pMON32195.seq 50
GCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGG AGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACAC GGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTC GTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGA 55 AGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA CTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGC - 169- CZ 295843 B6 TCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCG ACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCAC CGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGGTGGTTCT GGCGGCGGCTCCAACATGGCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCT 5 TCCTGCTCAAGTCTTTAGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCA GGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGA CACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGC TGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCA GGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGAC 10 GTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTG CCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGC AGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTT CTACGCCACCTTGCGCAGCCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGT CTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCC 15 AAACATGGCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGC TGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCG TGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCT TCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTG GCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTC 20 AGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGG AGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATC TCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACC CAGTCACCGTGGCCTCCAACCTGCAG (SEQ ID NO:309) 25 pMON32196. seq GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAG AGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCAC CTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCC 30 TGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCC AACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATC CCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACC ACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGG GTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGC 35 TAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAG CCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTA TCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGATGAAGA ACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAG ACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACT 40 TTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAA CATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATC ACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCC TGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGG TAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTC 45 AAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCA ACCTGCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTC TACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTACC CAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTG AGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGA 50 CGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGG CTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGA TACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCA GACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCC TGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCT 55 CAACCCTG (SEQ ID NO: 310) - 170- CZ 295843 B6 pMON32197.seq GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAG AGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCAC 5 CTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCC TGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCC AACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATC CCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACC ACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGG 10 GTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGC TAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAG CCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTA TCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGATGAAGA ACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAG 15 ACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACT TTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAA CATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATC ACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCC TGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGG 20 TAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTC AAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCA ACCTGCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTC TACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGAT GAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGC 25 TCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGAT ACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAG ACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCT GGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTC AACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGG 30 GGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCG CTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGC CTCCAACCTGCAG (SEQ ID NO:311) pMON32206.seq 35
GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCAC CTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAA CCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCA TCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCG 40 CACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAA ACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGC GGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTC CGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGATGAAGAACTGTGTGGTGGTCT GTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCC 45 AAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTG CCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTC TCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAG GAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGA 50 CTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTG TCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGTACGTAG AGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTC TCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGATGAAGAACTGTGTGGT GGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTG 55 GGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAA ATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGC - 171 - CZ 295843 B6 CTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGA ACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGG GTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACC CAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTG 5 AGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG (SEQ ID NO:312) pMON32207.seq 10 GCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGG AGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACAC GGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTC GTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGA AGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA 15 CTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGC TCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCG ACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCAC CGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGGTGGTTCT GGCGGCGGCTCCAACATGGCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCC 20 TGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTT GCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCC CCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCG AGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGA GCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGA 25 GGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAAC ACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCT TCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGC TCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAG AATCTCATAAATCTCCAAACATGGCTACACCATTAGGCCCTGCCAGCTCCCTGCCCCA 30 GAGCTTCCTGCTCAAGTGCTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGCGCAGCG CTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGC TCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCT GCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTC CTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGC 35 TGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGC CCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGC CGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACC GCGTTCTACGCCACCTTGCGCAGCCCTGATAAGGATCCGAATTCGGCAGC (SEQ ID NO:313) 40 pMON35728.seq
GCCGACGAGGAGCTGTGCGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGG AGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACAC 45 GGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTC GTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGA AGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA CTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGA ACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCC 50 GTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCA GTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATC AACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTAACTGCTCTA TAAT GAT CGAT GAAAT TATACAT CAC T TAAAGAGAC CACC TAAC CCTTTGCTGGACCC GAACAACCTCAATTCT GAAGACAT GGATAT CCTGATGGAACGAAACCTT CGAACT CCA 55 AACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGG CAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACA - 172- CZ 295843 B6 TCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTAT CTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCC CGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATC TCATAAATCTCCAAACATGGCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTC 5 CTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCT TGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCC CCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCC GAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGG AGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGG 10 AGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCC GACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCA CCGTGGCCTCCAACCTGCAG (SEQ ID NO:314) pMON32183.seq 15 GCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGG AGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACAC GGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTC GTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGA 20 AGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA CTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGC TCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCG ACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCAC CGTGGCCTCCAACCTGCAGGAATTCAAGCTTGAGCCCAGAGGGCCCACAATCAAGCCC 25 TGTCCTCCATGCAAATGCCCAGCACCTAACCTCTTGGGTGGACCATCCGTCTTCATCT TCCCTCCAAAGATCAAGGATGTACTCATGATCTCCCTGAGCCCCATAGTCACATGTGT GGT GGT GGATGT GAGCGAGGAT GACCCAGATGTCCAGAT CAGCTGGT TT GT GAACAAC GTGGAAGTACACACAGCTCAGACACAAACCCATAGAGAGGATTACAACAGTACTCTCC GGGCGGTCAGTGCCCTCCCCATCCAGCACCAGGACTGGATGAGTGGCAAGGAGTTCAA 30 ATGCAAGGTCAACAACAAAGACCTCCCAGCGCCCATCGAGAGAACCATCTCAAAACCC AAAGGGTCAGTAAGAGCTCCACAGGTATATGTCTTGCCTCCACCAGAAGAAGAGATGA CTAAGAAACAGGTCACTCTGACCTGCATGGTCACAGACTTCATGCCTGAAGACATTTA CGTGGAGTGGACCAACAACGGGAAAACAGAGCTAAACTACAAGAACACTGAACCAGTC CTGGACTCTGATGGTTCTTACTTCATGTACAGCAAGCTGAGAGTGGAAAAGAAGAACT 35 GGGTGGAAAGAAATAGCTACTCCTGTTCAGTGGTCCACGAGGGTCTGCACAATCACCA CACGACTAAGAGCTTCTCCCGGACTCCGGGTAAA (SEQ ID NO:315) pMON32184.seq
40 GCCACCCAGGACTGCTCCTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAA TCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCT GCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATG GAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACA CGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTT 45 CGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCG ACTCCTCAACCCTGGAATTCAAGCTTGAGCCCAGAGGGCCCACAATCAAGCCCTGTCC TCCATGCAAATGCCCAGCACCTAACCTCTTGGGTGGACCATCCGTCTTCATCTTCCCT CCAAAGATCAAGGATGTACTCATGATCTCCCTGAGCCCCATAGTCACATGTGTGGTGG 50 TGGATGTGAGCGAGGATGACCCAGATGTCCAGATCAGCTGGTTTGTGAACAACGTGGA AGTACACACAGCTCAGACACAAACCCATAGAGAGGATTACAACAGTACTCTCCGGGCG GTCAGTGCCCTCCCCATCCAGCACCAGGACTGGATGAGTGGCAAGGAGTTCAAATGCA AGGTCAACAACAAAGACCTCCCAGCGCCCATCGAGAGAACCATCTCAAAACCCAAAGG GTCAGTAAGAGCTCCACAGGTATATGTCTTGCCTCCACCAGAAGAAGAGATGACTAAG 55 AAACAGGTCACTCTGACCTGCATGGTCACAGACTTCATGCCTGAAGACATTTACGTGG AGTGGACCAACAACGGGAAAACAGAGCTAAACTACAAGAACACTGAACCAGTCCTGGA - 173 - CZ 295843 B6 CTCTGATGGTTCTTACTTCATGTACAGCAAGCTGAGAGTGGAAAAGAAGAACTGGGTG GAAAGAAATAGCTACTCCTGTTCAGTGGTCCACGAGGGTCTGCACAATCACCACACGA CTAAGAGCTTCTCCCGGACTCCGGGTAAA (SEQ ID NO:316) 5
Tabulka 3 PROTEINOVÉ SEKVENCE 10 pMON26458pep
SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHis ValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeu LeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAla 15 GlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGln LeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeu LeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAla HisLysAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArg PheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPhe (SEQ ID NO:467) 20 pMON28548pep
SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHis ValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeu 25 LeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAla GlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGln LeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeu LeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAla HisLysAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArg 30 PheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnMetAla SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHis ValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeu LeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAla GlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGln 35 LeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeu LeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnGlyArgThrThrAlaHisLysAspPro AsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeu ValGlyGlySerThrLeuCysValArg (SEQ ID NO:468) 40 pMON28500
SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgA spSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLe uProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLys 45 ThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuL euLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSe rSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeu GlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisL ysAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysVa 50 lArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGly AsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysL euLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluVa lHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGly GluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaV 55 alThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProTh rCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeu - 174- CZ 295843 B6
GlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrT hrAlaHisLysAspProAsnAlallePheLeuSerPheGlnHisLeuLeuAr gGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArg (SEQ ID NO:469) 5 pMON28501
SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHis ValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeu 10 LeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAla GlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGln LeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeu LeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAla HisLysAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArg 15 PheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnMetAla SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHis ValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeu LeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAla GlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGln 20 LeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeu LeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAla HisLysAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArg PheLeuMetLeuValGlyGlySerThrLeuCysValArg (SEQ ID NO:470) 25 pMON28502
SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHis ValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeu LeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAla 30 GlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGln LeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeu LeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAla HisLysAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArg PheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnGlyGly 35 AsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArg AspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThr ProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGlu ThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAla ArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnVal 40 ArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArg ThrThrAlaHisLysAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArgGly LysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArg (SEQ ID NO:471) 13182.Pept 45
Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala - 175- CZ 295843 B6
Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro 5 Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg ío Ala Lys Thr Ile Gin (SEQ ID Gly NO: - Asp 472) Gly Ala Ala Leu Gin Glu Lys Leu Cys 13183.Pept
Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp 20 Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro 25 Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro 30 Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val 35 Arg Ala Lys Thr Ile Gin (SEQ ID Gly Asp NO:473) Gly Ala Ala Leu Gin Glu Lys Leu Cys 13184.Pept
Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 40 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp 45 Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu 50 Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys 55 Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys -176- CZ 295843 B6
Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser (SEQ ID NO: 474) 5 13185.Pept Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu 10 Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly . Gly Gly Gly Ser Pro 15 Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin 20 Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Alci Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu 25 Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser (SEQ ID NO:475) 30 13186.Pept Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu 35 Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro 40 Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu 45 Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu 50 Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly (SEQ ID NO:476) -177- CZ 295843 B6 13187.Pept
Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp 5 Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu 10 Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser 15 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser 20 Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu 25 Leu Gly (SEQ ID NO:477) 13188.Pept Asn Cys Ser Ile Met Ile Asp Glu Ile ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp 30 Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu 35 Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser 40 Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr 45 Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro (SEQ ID NO:478) 50 13189.Pept Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu 55 Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr -178- CZ 295843 B6
Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro 5 Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin 10 Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly 15 Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro (SEQ ID NO:479) 13190.Pept 20
Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile 25 Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Ser Ala Phe Gin 30 Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu 35 Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu 40 Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala (SEQ ID NO:480) 13191.Pept 45 Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr 50 Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Ser Ala Phe Gin 55 Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser - 179- CZ 295843 B6
Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys 5 Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu 10 Gly Phe Met Ala Ala Pro (SEQ ID Ala Leu NO:481) Gin Pro Thr Gin Gly Ala Met Pro Ala 13192.Pept
Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp 20 Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala 25 Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg 30 Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu 35 Lys Leu Cys Ala Thr (SEQ ID NO:482) 13193.Pept Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp 40 Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu 45 Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala 50 Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg 55 Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Thr Pro Leu - 180- CZ 295843 B6
Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr (SEQ ID NO: 483) 5 25190.Pept Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu 10 Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro 15 Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe 20 Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu 25 Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser (SEQ ID NO:484) "ÍO pMON25191.Pep Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile 35 Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro 40 Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe 45 Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu 50 Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser (SEQ ID NO:485) - 181 - CZ 295843 B6 13194.Pept
Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp 5 Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu 10 Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro 15 Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu 20 Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly (SEQ ID NO:486) 25 13195. Pept
Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu 30 Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro 35 Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro 40 Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu 45 Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly (SEQ ID NO:487) 50 13196.Pept Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu 55 Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr -182- CZ 295843 B6
Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Thr Gin Gly Ala 5 Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala 10 Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp 15 Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro (SEQ ID NO:488) 13197.Pept 20 Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr 25 Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gin Gly Ala 30 Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala 35 Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Al a Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp 40 Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro (SEQ ID NO:489) 13198.Pept 45 Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr 50 Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe 55 Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys -183 - CZ 295843 B6
Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser 5 Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala 10 Met Pro Ala Phe Ala (SEQ ID NO: 490) 13199.Pept Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp 15 Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu 20 Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Thr 25 Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser 30 Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala 35 Met Pro Ala Phe Ala (SEQ ID NO:491) 31104.Pep Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala 40 Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Gly Gly Gly Ser Asn Cys Ser Ile Met Ile Asp Glu Ile Ile 45 His His Leu Lys Arg Pro Pro Ala Pro Leu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu 50 Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser 55 Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser - 184- CZ 295843 B6
Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro (SEQ ID NO: 492) 5 31105.Pep Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr 10 Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Gly Gly Gly Ser Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Tyr Val Glu Gly Gly 15 Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly 20 Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly Hip Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly 25 Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe AI a Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro (SEQ ID NO:493) 30 31106.Pep Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Gly Gly Gly Ser Asn Cys Ser Ile Met Ile 35 Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Tyr Val Glu Gly Gly 40 Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly 45 Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly 50 Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro (SEQ ID NO:494) - 185- 55 CZ 295843 B6 31107.Pep
Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Gly Gly Gly Ser Asn 5 Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala 10 Ala Pro Ser Arg His Pro Ile Ile Ile Lys Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu 15 Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser 20 Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met 25 Ala Pro Ala Leu Gin Pro (SEQ ID NO:495) 31108.Pep Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala 30 Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Asn Cys 35 Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala 40 Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp 45 Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro 50 (SEQ ID NO:496) 31109.Pep Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys 55 Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr - 186- CZ 295843 B6
Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin (SEQ ID Met Glu NO:497) Glu Leu Gly Met Ala Pro Ala Leu Gin Pro 31110.Pep
Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin 25 Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn 30 Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala 35 Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His 40 Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp 45 Gin Gin (SEQ ID Met Glu NO:498) Glu Leu Gly Met Ala Pro Ala Leu Gin Pro 31111.Pep 50 Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn 55 Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin - 187- CZ 295843 B6
Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin (SEQ ID Met Glu NO:499) Glu Leu Gly Met Ala Pro Ala Leu Gin Pro PMON15981 20 MetAlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAla ProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsn LeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSer GlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaPro SerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThr 25 PheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGlu SerHisLysSerProAsnMetAlaTyrLysLeuCysHisProGluGluLeuValLeuLeu GlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGln LeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGln 30 AlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspVal AlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeu GlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGly ValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHis LeuAlaGlnProGlyGlyGlySerAspMetAlaThrProLeuGlyProAlaSerSerLeu 35 ProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAla AlaLeuGlnGluLysLeuCysAlaThr (SEQ ID NO:500) PMON15982 40 MetAlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAla ProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsn LeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSer GlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaPro SerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThr 45 PheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGlu SerHisLysSerProAsnMetAlaProGluLeuGlyProThrLeuAspThrLeuGlnLeu AspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaPro AlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAla 50 GlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeu ArgHisLeuAlaGlnProGlyGlyGlySerAspMetAlaThrProLeuGlyProAlaSer SerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAsp GlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeu ValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGln 55 AlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGly LeuLeuGlnAlaLeuGluGlylleSer (SEQ ID NO:501) - 188- CZ 295843 B6 pMON15965
MetAlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAla 5 ProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsn LeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSer GlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaPro SerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThr PheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly 10 SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGlu SerHisLysSerProAsnMetAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuVal AlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGln ProGlyGlyGlySerAspMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSer PheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGln 15 GluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHis SerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAla GlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeu GluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAsp PheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnPro 20 ThrGlnGlyAlaMetProAlaPheAla (SEQ ID NO:502) pMON15966
MetAlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAla 25 ProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsn LeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSer GlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaPro SerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThr PheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly 30 SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGlu SerHisLysSerProAsnMetAlaMetAlaProAlaLeuGlnProThrGlnGlyAlaMet ProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeu GlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProGlyGlyGly SerAspMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLys 35 SerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCys AlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylle ProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSer GlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSer ProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThr 40 IleTrpGlnGlnMetGluGluLeuGly (SEQ ID NO:503) pMON15967
MetAlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAla 45 ProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsn LeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSer GlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaPro SerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThr PheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly 50 SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGlu SerHisLysSerProAsnMetAlaThrGlnGlyAlaMetProAlaPheAlaSerAlaPhe GlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSer TyrArgValLeuArgHisLeuAlaGlnProGlyGlyGlySerAspMetAlaThrProLeu GlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLys 55 IleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHis ProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSer -189- CZ 295843 B6
CysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPhe LeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeu AspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGlu LeuGlyMetAlaProAlaLeuGlnPro (SEQ ID NO:504) 5 pMON31112.pep
MetAlaAsnCysSerAsnMetlleAspGluIlelleThrHisLeuLysGlnProProLeu ProLeuLeuAspPheAsnAsnLeuAsnGlyGluAspGlnAspIleLeuMetAspAsnAsn 10 LeuArgArgProAsnLeuGluAlaPheAsnArgAlaValLysSerLeuGlnAsnAlaSer AlalleGluSerlleLeuLysAsnLeuLeuProCysLeuProLeuAlaThrAlaAlaPro ThrArgHisProIleHisIleLysAspGlyAspTrpAsnGluPheArgArgLysLeuThr PheTyrLeuLysThrLeuGluAsnAlaGlnAlaGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGlu 15 SerHisLysSerProAsnMetAlaThrGlnGlyAlaMetProAlaPheAlaSerAlaPhe GlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSer TyrArgValLeuArgHisLeuAlaGlnProSerGlyGlySerGlyGlySerGlnSerPhe LeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGlu LysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSer 20 LeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGly CysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGlu GlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPhe AlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnPro (SEQ ID NO:505) 25 pMON31113.pep
MetAlaAsnCysSerAsnMetlleAspGluIlelleThrHisLeuLysGlnProProLeu ProLeuLeuAspPheAsnAsnLeuAsnGlyGluAspGlnAspIleLeuMetGluAsnAsn 30 LeuArgArgProAsnLeuGluAlaPheAsnArgAlaValLysSerLeuGlnAsnAlaSer AlalleGluSerlleLeuLysAsnLeuLeuProCysLeuProLeuAlaThrAlaAlaPro ThrArgHisProIlellelleArgAspGlyAspTrpAsnGluPheArgArgLysLeuThr PheTyrLeuLysThrLeuGluAsnAlaGlnAlaGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGlu 35 SerHisLysSerProAsnMetAlaThrGlnGlyAlaMetProAlaPheAlaSerAlaPhe GlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSer TyrArgValLeuArgHisLeuAlaGlnProThrProLeuGlyProAlaSerSerLeuPro GlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAla LeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeu 40 GlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGln LeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGln AlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspVal AlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeu GlnPro (SEQ ID NO:506) 45 pMON31114.pep
MetAlaAsnCysSerAsnMetlleAspGluIlelleThrHisLeuLysGlnProProLeu ProLeuLeuAspPheAsnAsnLeuAsnGlyGluAspGlnAspIleLeuMetGluAsnAsn 50 LeuArgArgProAsnLeuGluAlaPheAsnArgAlaValLysSerLeuGlnAsnAlaSer AlalleGluSerlleLeuLysAsnLeuLeuProCysLeuProLeuAlaThrAlaAlaPro ThrArgHisProIlellelleArgAspGlyAspTrpAsnGluPheArgArgLysLeuThr PheTyrLeuLysThrLeuGluAsnAlaGlnAlaGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGlu 55 SerHisLysSerProAsnMetAlaThrGlnGlyAlaMetProAlaPheAlaSerAlaPhe GlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSer - 190- CZ 295843 B6
TyrArgValLeuArgHisLeuAlaGlnProSerGlyGlySerGlyGlySerGlnSerPhe LeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGlu LysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSer LeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGly 5 CysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGlu GlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPhe AlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnPro (SEQ ID NO:507) 10 pMON31115 .pep
MetAlaAsnCysSerAsnMetlleAspGluIlelleThrHisLeuLysGlnProProLeu ProLeuLeuAspPheAsnAsnLeuAsnGlyGluAspGlnAspIleLeuMetAspAsnAsn LeuArgArgProAsnLeuGluAlaPheAsnArgAlaValLysSerLeuGlnAsnAlaSer 15 AlalleGluSerlleLeuLysAsnLeuLeuProCysLeuProLeuAlaThrAlaAlaPro ThrArgHisProIleHisIleLysAspGlyAspTrpAsnGluPheArgArgLysLeuThr PheTyrLeuLysThrLeuGluAsnAlaGlnAlaGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGlu SerHisLysSerProAsnMetAlaThrGlnGlyAlaMetProAlaPheAlaSerAlaPhe 20 GlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSer TyrArgValLeuArgHisLeuAlaGlnProThrProLeuGlyProAlaSerSerLeuPro GlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAla LeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeu GlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGln 25 LeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGln AlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspVal AlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeu GlnPro (SEQ ID NO:508) 30 pMON28505
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly 35 IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetGluValHisProLeuProThrProValLeuLeuProAlaVal 40 AspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeu GlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThr CysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeu GlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspPro AsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeu 45 ValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnMetAlaSerProAlaPro ProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSer ArgLeuSerGlnCysPro (SEQ ID NO:509) pMON28506 50
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer 55 ArgHi s ProlleIleIleLysAláGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer - 191 - CZ 295843 B6
ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetLeuProThrProValLeuLeuProAlaValAspPheSerLeu GlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThr LeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSer 5 LeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeu GlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlallePhe LeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySer ThrLeuCysValArgGluPheGlyGlyAsnMetAlaSerProAlaProProAlaCysAsp LeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGln 10 CysProGluValHisPro (SEQ ID NO:510) pMON28507
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro 15 LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer 20 ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLys ThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGlu GlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGln LeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeu 25 ProProGlnGlyArgThrThrAlaHisLysAspProAsnAlallePheLeuSerPheGln HisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysVal ArgGluPheGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeu SerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluVal HisProLeuProThrPro (SEQ ID NO:511) 30 pMON28508
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu 35 ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer 40 HisLysSerProAsnMetAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGlu GluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAla AlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGln ValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGly ArgThrThrAlaHisLysAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArg 45 GlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGly GlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeu ArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuPro ThrProValLeuLeuPro (SEQ ID NO:512) 50 pMON28509
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly 55 IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe - 192- CZ 295843 B6
TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThr LysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArg 5 GlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArg LeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThr ThrAlaHisLysAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLys ValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsn MetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAsp 10 SerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrPro ValLeuLeuProAlaVal (SEQ ID NO:513) PMON28510 15 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe 20 TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAsp IleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGly ProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGly 25 AlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLys AspProAsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeu MetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnMetAlaSerPro AlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeu HisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuPro 30 AlaValAspPheSerLeu (SEQ ID NO:514) pMON28511
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro 35 LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer 40 ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGly GlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGln GlyArgThrThrAlaHisLysAspProAsnAlallePheLeuSerPheGlnHisLeuLeu ArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPhe 45 GlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeu LeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeu ProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMet GluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMet AlaAlaArgGlyGlnLeu (SEQ ID NO:515) 50 pMON28512
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu 55 ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer -193 - CZ 295843 B6
ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLys 5 AspProAsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeu MetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnMetAlaSerPro AlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeu HisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuPro AlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAsp 10 IleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGly ProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGly AlaLeuGlnSerLeuLeu (SEQ ID NO:516) pMON28513 15
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer 20 ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetGlyArgThrThrAlaHisLysAspProAsnAlallePheLeu SerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThr 25 LeuCysValArgGluPheGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeu ArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCys ProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGly GluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeu LeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeu 30 LeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGly ThrGlnLeuProProGln (SEQ ID NO:517) pMON28514 35 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe 40 TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaHisLysAspProAsnAlallePheLeuSerPheGlnHis LeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArg GluPheGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSer 45 LysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHis ProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThr GlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGly ValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeu SerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuPro 50 ProGlnGlyArgThrThr (SEQ ID NO:518) pMON28515
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro 55 LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly - 194- CZ 295843 B6
IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer 5 HisLysSerProAsnMetAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArg GlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGly GlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeu ArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuPro ThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGlu 10 GluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAla AlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGln ValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGly ArgThrThrAlaHisLys (SEQ ID NO:519) 15 pMON28516
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly 20 IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysVal 25 ArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnMet AlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSer HisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProVal LeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLys AlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGly 30 GlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeu LeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThr AlaHisLysAspProAsn (SEQ ID NO:520) pMON28519 35
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer 40 ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetGluValHisProLeuProThrProValLeuLeuProAlaVal AspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeu 45 GlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThr CysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeu GlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspPro AsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeu ValGlyGlySerThrLeuCysValArgGluPheGlyAsnMetAlaSerProAlaProPro 50 AlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArg LeuSerGlnCysPro (SEQ ID NO:521) pMON28520 55 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu -195- CZ 295843 B6
ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer 5 ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetLeuProThrProValLeuLeuProAlaValAspPheSerLeu GlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThr LeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSer LeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeu 10 GlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlallePhe LeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySer ThrLeuCysValArgGluPheGlyAsnMetAlaSerProAlaProProAlaCysAspLeu ArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCys ProGluValHisPro (SEQ ID NO:522) 15 pMON28521
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu 20 ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer 25 HisLysSerProAsnMetValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLys ThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGlu GlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGln LeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeu ProProGlnGlyArgThrThrAlaHisLysAspProAsnAlallePheLeuSerPheGln 30 HisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysVal ArgGluPheGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSer LysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHis ProLeuProThrPro (SEQ ID NO:523) 35 pMON28522
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGl-uAsnAlaSerGly 40 IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGlu 45 GluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAla AlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGln ValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGly ArgThrThrAlaHisLysAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArg GlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGly 50 AsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArg AspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThr ProValLeuLeuPro (SEQ ID NO:524) - 196- CZ 295843 B6 PMON28523
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu 5 ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer 10 HisLysSerProAsnMetAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThr LysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArg GlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArg LeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThr ThrAlaHisLysAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLys 15 ValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyAsnMet AlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSer HisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProVal LeuLeuProAlaVal (SEQ ID NO:525) 20 pMON28524
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly 25 IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAsp 30 IleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGly ProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGly AlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLys AspProAsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeu MetLeuValGlyGlySerThrLeuCysValArgGluPheGlyAsnMetAlaSerProAla 35 ProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHis SerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAla ValAspPheSerLeu (SEQ ID NO:526) pMON28525 40
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer 45 ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGly GlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGln 50 GlyArgThrThrAlaHisLysAspProAsnAlallePheLeuSerPheGlnHisLeuLeu ArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPhe GlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeu ArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuPro ThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGlu 55 GluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAla AlaArgGlyGlnLeu (SEQ ID NO:527) - 197- CZ 295843 B6 PMON28526
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro 5 LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer io ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLys AspProAsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeu MetLeuValGlyGlySerThrLeuCysValArgGluPheGlyAsnMetAlaSerProAla ProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHis 15 SerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAla ValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIle LeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyPro ThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAla LeuGlnSerLeuLeu (SEQ ID NO:528) 20 pMON28527
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu 25 ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer 30 HisLysSerProAsnMetGlyArgThrThrAlaHisLysAspProAsnAlallePheLeu SerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThr LeuCysValArgGluPheGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArg ValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysPro GluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGlu 35 TrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeu LeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeu GlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThr GlnLeuProProGln (SEQ ID NO:529) 40 pMON28528
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly 45 IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaHisLysAspProAsnAlallePheLeuSerPheGlnHis 50 LeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArg GluPheGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLys LeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisPro LeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGln MetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyVal 55 - 198- CZ 295843 B6
MetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSer GlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProPro GlnGlyArgThrThr (SEQ ID NO:530) 5 pMON28529
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly 10 IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHísProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArg 15 GlyLysVaXArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGly AsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArg AspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThr ProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGlu ThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAla 20 ArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnVal ArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArg ThrThrAlaHisLys (SEQ ID NO:531) PMON28530 25
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer 30 ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysVal ArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyAsnMetAla 35 SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHis ValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeu LeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAla GlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGln LeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeu 40 LeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAla HisLysAspProAsn (SEQ ID NO:532) PMON28533 45 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe 50 TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSer HisLysSerProAsnMetGluValHisProLeuProThrProValLeuLeuProAlaVal AspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeu GlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThr 55 CysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeu GlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspPro - 199- CZ 295843 B6
AsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeu ValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnGlyGlyAsnMetAlaSer ProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisVal LeuHisSerArgLeuSerGlnCysPro (SEQ ID NO:533) 5 pMON28534
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu 10 ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer 15 HisLysSerProAsnMetLeuProThrProValLeuLeuProAlaValAspPheSerLeu GlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThr LeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSer LeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeu GlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlallePhe 20 LeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySer ThrLeuCysValArgGluPheGlyGlyAsnGlyGlyAsnMetAlaSerProAlaProPro AlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArg LeuSerGlnCysProGluValHisPro (SEQ ID NO:534) 25 pMON28535
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly 30 IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLys 35 ThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGlu GlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGln LeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeu ProProGlnGlyArgThrThrAlaHisLysAspProAsnAlallePheLeuSerPheGln HisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysVal 40 ArgGluPheGlyGlyAsnGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeu ArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCys ProGluValHisProLeuProThrPro (SEQ ID NO:535) pMON28536 45
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer 50 ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGlu GluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAla 55 AlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGln ValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGly -200- CZ 295843 B6
ArgThrThrAlaHisLysAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArg GlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGly GlyAsnGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSer LysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHis 5 ProLeuProThrProValLeuLeuPro (SEQ ID NO:536) pMON28537
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro 10 LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer 15 ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThr LysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArg GlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArg LeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThr 20 ThrAlaHisLysAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLys ValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsn GlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeu LeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeu ProThrProValLeuLeuProAlaVal (SEQ ID NO:537) 25 pMON28538
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu 30 ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer 35 HisLysSerProAsnMetGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAsp IleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGly ProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGly AlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLys AspProAsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeu 40 MetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnGlyGlyAsnMet AlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSer HisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProVal LeuLeuProAlaValAspPheSerLeu (SEQ ID NO:538) 45 pMON28539
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly 50 IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGly 55 GlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGln GlyArgThrThrAlaHisLysAspProAsnAlallePheLeuSerPheGlnHisLeuLeu -201 - CZ 295843 B6
ArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPhe GlyGlyAsnGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeu SerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluVal HisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLys 5 ThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGlu GlyValMetAlaAlaArgGlyGlnLeu (SEQ ID NO:539) pMON28540 10 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe 15 TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLys AspProAsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeu MetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnGlyGlyAsnMet 20 AlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSer HisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProVal LeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLys AlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGly GlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeu 25 LeuLeuGlyAlaLeuGlnSerLeuLeu (SEQ ID NO:540) pMON28541
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro 30 LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer 35 ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetGlyArgThrThrAlaHisLysAspProAsnAlallePheLeu SerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThr LeuCysValArgGluPheGlyGlyAsnGlyGlyAsnMetAlaSerProAlaProProAla CysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeu 40 SerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPhe SerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAla ValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeu SerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSer LeuLeuGlyThrGlnLeuProProGln (SEQ ID NO:541) 45 pMON28542
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu 50 ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer 55 HisLysSerProAsnMetAlaHisLysAspProAsnAlallePheLeuSerPheGlnHis LeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArg -202- CZ 295843 B6 . GluPheGlyGlyAsnGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArg ValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysPro GluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGlu TrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeu 5 LeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeu GlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThr GlnLeuProProGlnGlyArgThrThr (SEQ ID NO:542) pMON28543 10
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer 15 ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArg GlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGly 20 GlyAsnGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSer LysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHis ProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThr GlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGly ValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeu 25 SerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuPro ProGlnGlyArgThrThrAlaHisLys (SEQ ID NO:543) pMON28544 30 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe 35 TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysVal ArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnGly GlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeu 40 ArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuPro ThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGlu GluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAla AlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGln ValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGly 45 ArgThrThrAlaHisLysAspProAsn (SEQ ID NO:544) pMON28545
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro 50 LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer 55 ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArg -203- CZ 295843 B6
GlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGly GlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeu ArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuPro ThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGlu 5 GluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAla AlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGln ValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnGlyArgThrThrAla HisLys (SEQ ID NO:545) 10 pMON32132
SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHis ValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeu LeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAla 15 GlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGln LeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeu LeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAla HisLysAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArg PheLeuMetLeuValGlyGlySerThrLeuCysValArg (SEQ ID NO:546) 20 PMON32133
SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHis ValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeu 25 LeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAla GlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGln LeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeu LeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnGlyArgThrThrAlaHisLysAspPro AsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeu 30 ValGlyGlySerThrLeuCysValArg (SEQ ID NO:547) PMON32134
SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHis 35 ValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeu LeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAla GlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGln LeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeu LeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAla 40 HisLysAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArg PheLeuMetLeuValGlyGlySerThrLeuCysValArg (SEQ ID NO:548) pMON30237.pep 45 AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaV alLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVa lAlaSerAsnLeuGlnAspGluGluLeuCysGlyAlaLeuTrpArgLeuVal LeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetG InGlyLeuLeuGluArgValAsnThrGIulleHisPheValThrLysCysAl 50 aPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArg LeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrA rgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnPro (SEQ ID NO:549) -204- 55 CZ 295843 B6 pMON30238.pep
AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaV alLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVa 5 lAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuVal LeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetG InGlyLeuLeuGluArgValAsnThrGIulleHisPheValThrLysCysAl aPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArg LeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrA 10 rgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerTh rLeu (SEQ ID NO:550) pMON30239.pep 15 AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaV alLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVa lAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuVal LeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetG InGlyLeuLeuGluArgValAsnThrGIulleHisPheValThrLysCysAl 20 aPheGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArg GlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrL eu (SEQ ID NO:551) pMON32329.pep 25
GlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaV alLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVa lAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuVal LeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetG 30 InGlyLeuLeuGluArgValAsnThrGIulleHisPheValThrLysCysAl aPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArg LeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrA rgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnPro (SEQ ID NO:552) 35 pMON32330.pep
GlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaV alLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVa 40 lAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuVal LeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetG InGlyLeuLeuGluArgValAsnThrGIulleHisPheValThrLysCysAl aPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArg LeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrA 45 rgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerTh rLeu (SEQ ID NO:553) pMON32341.pep 50 AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaV alLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVa lAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuVal LeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetG lnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAl 55 aPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArg -205 - CZ 295843 B6
LeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrA rgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnPro (SEQ ID NO:554) 5 pMON32342.pep
AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaV alLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVa lAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuVal 10 LeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetG InGlyLeuLeuGluArgValAsnThrGIulleHisPheValThrLysCysAl aPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArg LeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrA rgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerTh 15 rLeu (SEQ ID NO:555) pMON32320.pep
AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgT 20 rpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGl uArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProPro ProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluT hrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSe rArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuSerGlyGly 25 AsnGlySerGlyGlyAsnGlySerGlyGlyAsnGlyThrGlnAspCysSerP heGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSe rAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln (SEQ ID NO:556) 30 pMON32321 .pep
AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgT rpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGl uArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProPro 35 ProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluT hrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSe rArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuSerGlyGly AsnGlySerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHisSerProI leSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGl 40 nAspTyrProValThrValAlaSerAsnLeuGln (SEQ ID NO:557) pMON32322.pep
AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgT 45 rpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGl uArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProPro ProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluT hrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSe rArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuSerGlyGly 50 AsnGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheA laValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValTh rValAlaSerAsnLeuGln (SEQ ID NO:558) -206- CZ 295843 B6 pMON32323.pep
AlaSerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheV alThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnTh 5 rAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLys ProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnP roAspSerSerThrLeuSerGlyGlyAsnGlySerGlyGlyAsnGlySerGl yGlyAsnGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAsp PheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProV 10 alThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpAr gLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGly (SEQ ID NO:559) pMON32324.pep 15
AlaSerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheV alThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnTh rAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLys ProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnP 20 roAspSerSerThrLeuSerGlyGlyAsnGlySerGlyGlyAsnGlyThrGl nAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIle ArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerA snLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGl nArgTrpMetGluArgLeuLysThrValAlaGly (SEQ ID NO:560) 25 pMON32325.pep
AlaSerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheV alThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnTh 30 rAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLys ProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnP roAspSerSerThrLeuSerGlyGlyAsnGlyThrGlnAspCysSerPheGl nHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluG 35 luLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluAr gLeuLysThrValAlaGly (SEQ ID NO:561) pMON32326.pep 40 AlaProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuG InGluThrSerGIuGInLeuValAlaLeuLysProTrpIleThrArgGInAs nPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuSer GlyGlyAsnGlySerGlyGlyAsnGlySerGlyGlyAsnGlyThrGlnAspC ysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGl 45 uLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeu GlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgT rpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGl uArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnPro (SEQ ID NO:562) 50 pMON32327.pep
AlaProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuG lnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAs 55 nPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuSer GlyGlyAsnGlySerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHisS -207- CZ 295843 B6 erProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLe uLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeu CysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuL ysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGl 5 ulleHisPheValThrLysCysAlaPheGInPro (SEQ ID NO:563) pMON32328.pep
AlaProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuG 10 InGluThrSerGIuGInLeuValAlaLeuLysProTrpIleThrArgGInAs nPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuSer GlyGlyAsnGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerA spPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrPr oValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrp 15 ArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlyS erLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValTh rLysCysAlaPheGlnPro (SEQ ID NO:564) pMON32348.pep 20
AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgT rpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGl uArgValAsnThrGIulleHisPheValThrLysCysAlaPheGInProPro ProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluT 25 hrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSe rArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuSerGlyGly SerGlySerGlyGlySerGlySerGlyGlySerGlyThrGlnAspCysSerP heGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSe rAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln 30 (SEQ ID NO: 565) pMON32350.pep
AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgT 35 rpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGl uArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProPro ProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluT hrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSe rArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuSerGlyGly 40 SerGlySerGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProI leSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGl nAspTyrProValThrValAlaSerAsnLeuGln (SEQ ID NO:566) FLT3N.pep 45
MetAlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheA laValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValTh rValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeu ValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysM 50 etGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCy sAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleT hrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSe rThrLeuGlyGlyGlySer (SEQ ID NO:567) -208- 55 CZ 295843 B6 FLT3C.pep
GlySerGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerA spPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrPr 5 oValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrp ArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlyS erLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValTh rLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsn IleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProT 10 rpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAs pSerSerThrLeu (SEQ ID NO:568) FLT7N.pep 15 MetAlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheA laValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValTh rValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeu ValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysM etGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCy 20 sAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleT hrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSe rThrLeuGlyGlyGlySerGlyGlyGlySer (SEQ ID NO:569) 25 FLT4C.pep
GlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerS erAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTy rProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeu 30 TrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaG lySerLysMetGInGlyLeuLeuGluArgValAsnThrGIulleHisPheVa IThrLysCysAlaPheGInProProProSerCysLeuArgPheValGInThr AsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysP roTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnPr 35 oAspSerSerThrLeu (SEQ ID NO:570) FLTllN.pep
MetAlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheA 40 laValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValTh rValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeu ValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysM etGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCy sAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSer 45 ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleT hrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSe rThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySer (SEQ ID NO:571) 50 FLTlOC.pep
GlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheG lnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAs pTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGlu 55 GluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluA rgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAs -209- CZ 295843 B6 nThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCys LeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluG lnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLe uGluLeuGlnCysGlnProAspSerSerThrLeu (SEQ ID NO:572) 5 pMON32365.pep
AlaAspGluGluLeuCysGIyGlyLeuTrpArgLeuValLeuAlaGlnArgT rpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGl 10 uArgValAsnThrGIulleHisPheValThrLysCysAlaPheGInProPro ProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluT hrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSe rArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGly SerGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspP 15 heAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProVa lThrValAlaSerAsnLeuGln (SEQ ID NO:573) pMON32366.pep 20 AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgT rpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGl uArgValAsnThrGIulleHisPheValThrLysCysAlaPheGInProPro ProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluT hrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSe 25 rArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGly SerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerA spPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrPr oValThrValAlaSerAsnLeuGln (SEQ ID NO:574) 30 pMON32367 .pep
AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgT rpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGl uArgValAsnThrGIulleHisPheValThrLysCysAlaPheGInProPro 35 ProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluT hrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSe rArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGly SerGlyGlyGlySerGlyGlyThrGlnAspCysSerPheGlnHisSerProI leSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGl 40 nAspTyrProValThrValAlaSerAsnLeuGln (SEQ ID NO:575) pMON32368.pep
AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgT 45 rpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGl uArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProPro ProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluT hrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSe rArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGly 50 SerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnH isSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTy rLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln (SEQ ID NO:576) -210- CZ 295843 B6 pMON32369.pep
AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgT rpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGl 5 uArgValAsnThrGIulleHisPheValThrLysCysAlaPheGInProPro ProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluT hrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSe rArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGly SerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerP 10 heGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSe rAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln (SEQ ID NO:577) pMON32370.pep 15
AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgT rpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGl uArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProPro ProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluT 20 hrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSe rArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGly SerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerG lyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaVa lLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVal 25 AlaSerAsnLeuGln (SEQ ID NO:578) pMON30247.pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP 30 roAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLe uMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaVal LysAsnLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr 35 LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaThrGlnAspCysSerPheGlnHisSer ProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuL euGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCy 40 sGlyAlaLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLys ThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluI leHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPh eValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuG 45 InCysGInPro (SEQ ID NO: 579) pMON30248.pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP 50 roAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLe uMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaVal LysAsnLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr 55 LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl -211 - CZ 295843 B6 uSerHisLysSerProAsnMetAlaThrGlnAspCysSerPheGlnHisSer ProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuL euGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCy sGlyAlaLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLys 5 ThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluI leHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPh eValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuG InCysGInProAspSerSerThrLeu (SEQ ID NO:580) 10 pMON32332.pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP roAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLe 15 uMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaVal LysAsnLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG 20 lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrp ArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlyS erLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValTh rLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsn 25 IleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProT rpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAs pSerSerThrLeuSerGlyGlyAsnGlySerGlyGlyAsnGlyThrGlnAsp CysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgG luLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLe 30 uGln (SEQ ID NO: 581) pMON32333.pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP 35 roAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLe uMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaVal LysAsnLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr 40 LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrp ArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlyS erLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValTh 45 rLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsn IleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProT rpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAs pSerSerThrLeuSerGlyGlyAsnGlySerGlyGlyAsnGlyThrGlnAsp CysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgG 50 luLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLe uGln (SEQ ID NO:582) pMON32334.pep 55 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP roAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLe -212- CZ 295843 B6 uMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaVal LysAsnLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr 5 LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaSerLysMetGlnGlyLeuLeuGluArg ValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProS erCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSe 10 rGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArg CysLeuGluLeuGlnCysGlnProAspSerSerThrLeuSerGlyGlyAsnG lyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaVa lLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVal AlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValL 15 euAlaGlnArgTrpMetGluArgLeuLysThrValAlaGly (SEQ ID NO:583) pMON32335.pep 20 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP roAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLe uMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaVal LysAsnLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy 25 sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaSerLysMetGlnGlyLeuLeuGluArg ValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProS 30 erCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSe rGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArg CysLeuGluLeuGlnCysGlnProAspSerSerThrLeuSerGlyGlyAsnG lySerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHisSerProIleSe rSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAsp 35 TyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyL euTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAl aGly (SEQ ID NO:584) pMON32336.pep 40
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP roAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLe uMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaVal LysAsnLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP 45 roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrp 50 ArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlyS erLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValTh rLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsn IleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProT rpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAs 55 pSerSerThrLeuSerGlyGlyAsnGlySerGlyGlyAsnGlySerGlyGly AsnGlyThrGlnAspGysSerPheGlnHisSerProIleSerSerAspPheA -213- CZ 295843 B6 laValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValTh rValAlaSerAsnLeuGln (SEQ ID NO:585) pMON32337.pep 5
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP roAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLe uMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaVal LysAsnLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP ío roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaProProSerCysLeuArgPheValGln 15 ThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuL ysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGl nProAspSerSerThrLeuSerGlyGlyAsnGlyThrGlnAspCysSerPhe GlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerA spTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGl 20 uGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValA snThrGIulleHísPheValThrLysCysAlaPheGlnPro (SEQ ID NO:586) 25 pMON32338 . pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP roAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLe uMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaVal 30 LysAsnLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl 35 uSerHisLysSerProAsnMetAlaProProSerCysLeuArgPheValGln ThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuL ysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGl nProAspSerSerThrLeuSerGlyGlyAsnGlySerGlyGlyAsnGlyThr GlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysI 40 leArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSe rAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAla GlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyL euLeuGluArgValAsnThrGIulleHisPheValThrLysCysAlaPheGl nPro (SEQ ID NO:587) 45 pMON32339.pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP roAlaProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLe 50 uMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaVal LysAsnLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG 55 lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaProProSerCysLeuArgPheValGln -214- CZ 295843 B6
ThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuL YsProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGl nProAspSerSerThrLeuSerGlyGlyAsnGlySerGlyGlyAsnGlySer GlyGlyAsnGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerA 5 spPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrPr oValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrp ArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlyS erLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValTh rLysCysAlaPheGlnPro (SEQ ID NO:588) 10 pMON32364.pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe 15 uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG 20 lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaThrGlnAspCysSerPheGlnHisSer ProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuL euGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCy sGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLys 25 ThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluI leHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPh eValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuG InCysGinPro (SEQ ID NO:589) 30 pMON32377.pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe 35 uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG 40 lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaThrGlnAspCysSerPheGlnHisSer ProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuL euGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCy sGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLys 45 ThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluI leHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPh eValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuG InCysGInProAspSerSerThrLeu (SEQ ID NO:590) 50 pMON32352.pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe 55 uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP -215- CZ 295843 B6 roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl 5 uSerHisLysSerProAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrp ArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlyS erLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValTh rLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsn IleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProT 10 rpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAs pSerSerThrLeuSerGlyGlyAsnGlySerGlyGlyAsnGlyThrGlnAsp CysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgG luLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLe uGln (SEQ ID NO:591) 15 pMON32353.pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe 20 uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG 25 lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrp ArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlyS erLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValTh rLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsn 30 IleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProT rpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAs pSerSerThrLeuSerGlyGlyAsnGlySerGlyGlyAsnGlySerGlyGly AsnGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheA laValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValTh 35 rValAlaSerAsnLeuGln (SEQ ID NO:592) pMON32354.pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP 40 roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr 45 LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaSerLysMetGlnGlyLeuLeuGluArg ValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProS erCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSe 50 rGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArg CysLeuGluLeuGlnCysGlnProAspSerSerThrLeuSerGlyGlyAsnG lyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaVa lLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVal AlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValL 55 euAlaGlnArgTrpMetGluArgLeuLysThrValAlaGly (SEQ ID NO:593) -216- CZ 295843 B6 pMON32355.pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP 5 roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr 10 LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaSerLysMetGlnGlyLeuLeuGluArg ValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProS erCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSe 15 rGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArg CysLeuGluLeuGlnCysGlnProAspSerSerThrLeuSerGlyGlyAsnG lySerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHisSerProIleSe rSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAsp TyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyL 20 euTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAl aGly (SEQ ID NO:594) pMON32356.pep 25 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy 30 sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaSerLysMetGlnGlyLeuLeuGluArg ValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProS 35 erCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSe rGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArg CysLeuGluLeuGlnCysGlnProAspSerSerThrLeuSerGlyGlyAsnG lySerGlyGlyAsnGlySerGlyGlyAsnGlyThrGlnAspCysSerPheGl nHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAsp 40 TyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluG luLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluAr gLeuLysThrValAlaGly (SEQ ID NO:595) pMON32357.pep 45
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP 50 roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaProProSerCysLeuArgPheValGln 55 ThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuL ysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGl -217- CZ 295843 B6 nProAspSerSerThrLeuSerGlyGlyAsnGlyThrGlnAspCysSerPhe GlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerA spTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGl uGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu 5 ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValA snThrGIulleHisPheValThrLysCysAlaPheGInPro (SEQ ID NO:596) pMON32358.pep 10
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP 15 roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaProProSerCysLeuArgPheValGln 20 ThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuL ysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGl nProAspSerSerThrLeuSerGlyGlyAsnGlySerGlyGlyAsnGlyThr GlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysI leArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSe 25 rAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAla GlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyL euLeuGluArgValAsnThrGIulleHisPheValThrLysCysAlaPheGl nPro (SEQ ID NO:597) 30 pMON32359 .pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal 35 LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl 40 uSerHisLysSerProAsnMetAlaProProSerCysLeuArgPheValGln ThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuL ysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGl nProAspSerSerThrLeuSerGlyGlyAsnGlySerGlyGlyAsnGlySer GlyGlyAsnGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerA 45 spPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrPr oValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrp ArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlyS erLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValTh rLysCysAlaPheGlnPro (SEQ ID NO:598) 50 pMON32360.pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe 55 uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP -218- CZ 295843 B6 roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl 5 uSerHisLysSerProAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrp ArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlyS erLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValTh rLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsn IleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProT 10 rpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAs pSerSerThrLeuSerGlyGlySerGlySerGlyGlySerGlyThrGlnAsp CysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgG luLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLe uGln (SEQ ID NO:599) 15 pMON32362.pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe 20 uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG 25 lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrp ArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlyS erLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValTh rLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsn 30 IleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProT rpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAs pSerSerThrLeuSerGlyGlySerGlySerGlyGlySerGlySerGlyGly SerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheA laValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValTh 35 rValAlaSerAsnLeuGln (SEQ ID NO:600) PMON32392.pep
AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaV 40 alLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVa lAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuVal LeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetG lnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAl aPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArg 45 LeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrA rgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProTyrValGluGl yGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsnPro SerProProSerLysGluSerHisLysSerProAsnMetAlaAsnCysSerI leMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLe 50 uAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsn LeuArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluA snAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSe rAlaThrAlaAlaProSerArgHisProIlellelleLysAlaGlyAspTrp GlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaG 55 InGluGInGIn (SEQ ID NO:601) -219- CZ 295843 B6 pMON32393.pep
AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaV alLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVa 5 lAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuVal LeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetG InGlyLeuLeuGluArgValAsnThrGIulleHisPheValThrLysCysAl aPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArg LeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrA 10 rgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerTh rLeuTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIle SerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnM etAlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgPr oProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIle 15 LeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaV alLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGl nProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelle LysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValT hrLeuGluGlnAlaGlnGluGlnGln (SEQ ID NO:602) 20 pMON32396.pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe 25 uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerProHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG 30 lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaThrGlnAspCysSerPheGlnHisSer ProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuL euGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCy sGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLys 35 ThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluI leHisPheValThrLysCysAlaPheGlnGluThrSerGluGlnLeuValAl aLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGln CysGlnProAspSerSerThrLeu (SEQ ID NO:603) 40 pMON32371 .pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal 45 LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl 50 uSerHisLysSerProAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrp ArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlyS erLysMetGInGlyLeuLeuGluArgValAsnThrGIulleHisPheValTh rLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsn IleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProT 55 rpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAs pSerSerThrLeuGlyGlyGlySerGlyGlyThrGlnAspCysSerPheGln -220- CZ 295843 B6
HisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspT yrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln (SEQ ID NO:604) 5 pMON 3 2 3 7 2.pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal 10 LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl 15 uSerHisLysSerProAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrp ArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlyS erLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValTh rLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsn IleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProT 20 rpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAs pSerSerThrLeuGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPhe GlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerA spTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln (SEQ ID NO:605) 25 pMON32373.pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe 30 uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG 35 lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrp ArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlyS erLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValTh rLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsn 40 IleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProT rpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAs pSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyThrGlnAsp CysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgG luLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLe 45 uGln (SEQ ID NO: 606) pMON32374.pep
AlaAsnCysSerlleMetlleAspGluIlelleHísHisLeuLysArgProP 50 roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr 55 LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl -221 - CZ 295843 B6 uSerHisLysSerProAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrp ArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlyS erLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValTh rLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsn 5 IleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProT rpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAs pSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGly ThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValL ysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAl 10 aSerAsnLeuGln (SEQ ID NO:607) pMON32375.pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP 15 roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr 20 LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrp ArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlyS erLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValTh 25 rLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsn IleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProT rpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAs pSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGly GlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheA 30 laValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValTh rValAlaSerAsnLeuGln (SEQ ID NO:608) pMON32376.pep 35 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy 40 sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrp ArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlyS 45 erLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValTh rLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsn IleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProT rpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAs pSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGly 50 GlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerP rolleSerSerAspPheAlaValLysIleArgGiuLeuSerAspTyrLeuLe uGlnAspTyrProValThrValAlaSerAsnLeuGln (SEQ ID NO:609) -222- 55 CZ 295843 B6 pMON32378.pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe 5 uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG 10 lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaSerLysMetGlnGlyLeuLeuGluArg ValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProS erCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSe rGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArg 15 CysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerG lyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAl aValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThr ValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuV alLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGly (SEQ ID 20 NO: 610) pMON32379.pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP 25 roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr 30 LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaSerLysMetGlnGlyLeuLeuGluArg ValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProS erCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSe 35 rGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArg CysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerG lyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPh eAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProVal ThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgL 40 euValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGly (SEQ ID NO:611) pMON32380.pep 45 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy 50 sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaSerLysMetGlnGlyLeuLeuGluArg ValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProS 55 erCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSe rGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArg -223 - CZ 295843 B6
CysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerG lyGlyGlySerGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSe rSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAsp TyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyL 5 euTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAl aGly (SEQ ID NO:612) pMON32 3 81.pep 10 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy 15 sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaSerLysMetGlnGlyLeuLeuGluArg ValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProS 20 erCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSe rGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArg CysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerG lyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSe rProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeu 25 LeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuC ysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLy sThrValAlaGly (SEQ ID NO:613) pMON32382.pep 30
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP 35 roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaSerLysMetGlnGlyLeuLeuGluArg 40 ValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProS erCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSe rGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArg CysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerG lyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGl 45 nHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluG luLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluAr gLeuLysThrValAlaGly (SEQ ID NO:614) 50 pMON32383 .pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal 55 LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy -224- CZ 295843 B6 sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaSerLysMetGlnGlyLeuLeuGluArg 5 ValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProS erCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSe rGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArg CysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerG lyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyTh 10 rGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLys IleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaS erAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAl aGlnArgTrpMetGluArgLeuLysThrValAlaGly (SEQ ID NO:615) 15 pMON32384.pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe 20 uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG 25 lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaProProSerCysLeuArgPheValGln ThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuL ysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGl nProAspSerSerThrLeuGlyGlyGlySerGlyGlyThrGlnAspCysSer 30 PheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuS erAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAs pGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMet GluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgV alAsnThrGluIleHisPheValThrLysCysAlaPheGlnPro (SEQ ID 35 NO: 616) pMON32385.pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP 40 roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr 45 LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaProProSerCysLeuArgPheValGln ThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuL ysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGl 50 nProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlyThrGlnAspCys SerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluL euSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGl nAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrp MetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluA 55 rgValAsnThrGIulleHisPheValThrLysCysAlaPheGInPro (SEQ ID NO:617) -225 - CZ 295843 B6 pMON32386.pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP 5 roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr 10 LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaProProSerCysLeuArgPheValGln ThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuL ysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGl 15 nProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyThr GlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysI leArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSe rAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAla GlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyL 20 euLeuGluArgValAsnThrGIulleHisPheValThrLysCysAlaPheGl nPro (SEQ ID NO:618) pMON32387.pep 25 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy 30 sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaProProSerCysLeuArgPheValGln ThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuL 35 ysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGl nProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGly SerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheA laValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValTh rValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeu 40 ValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysM etGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCy sAlaPheGlnPro (SEQ ID NO:619) pMON32388.pep 45
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP 50 roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaProProSerCysLeuArgPheValGln 55 ThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuL ysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGl -226- CZ 295843 B6 nProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGly SerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerA spPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrPr oValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrp 5 ArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlyS erLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValTh rLysCysAlaPheGlnPro (SEQ ID NO:620) pMON32389.pep 10
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP 15 roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaProProSerCysLeuArgPheValGln 20 ThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuL ysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGl nProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGly SerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnH isSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTy 25 rLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGlu
LeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgL euLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnTh rGlulleHisPheValThrLysCysAlaPheGInPro (SEQ ID NO:621) 30 hflt3-28291inkl0.pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe 35 uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG 40 lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaAspTyrProValThrValAlaSerAsn LeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnA rgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLe uGluArgValAsnThrGIulleHisPheValThrLysCysAlaPheGInPro 45 ProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnG luThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPh eSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGly GlySerGlyGlyGlySerGlyGlyThrGlnAspCysSerPheGlnHisSerP rolleSerSerAspPheAlaValLysIleArgGIuLeuSerAspTyrLeuLe 50 uGln (SEQ ID NO: 622) hfIt3-28291inkl5.pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP 55 roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal -227- CZ 295843 B6
LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG 5 lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaAspTyrProValThrValAlaSerAsn LeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnA rgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLe uGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnPro 10 ProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnG luThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPh eSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGly GlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysS erPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLe 15 uSerAspTyrLeuLeuGln (SEQ ID NO:623) hfIt3-34351inkl0.pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP 20 roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr 25 LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaAlaSerAsnLeuGlnAspGluGluLeu CysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuL ysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGl 30 ulleHisPheValThrLysCysAlaPheGInProProProSerCysLeuArg PheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuV alAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLe uGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySer GlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheA 35 laValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValTh rVal (SEQ ID NO:624) hfIt3-34351inkl5.pep
40 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy 45 sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaAlaSerAsnLeuGlnAspGluGluLeu CysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuL 50 ysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGl ulleHisPheValThrLysCysAlaPheGInProProProSerCysLeuArg PheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuV alAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLe uGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySer 55 GlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProI -228- CZ 295843 B6 leSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGl nAspTyrProValThrVal (SEQ ID NO:625) hflt3-62631inkl0.pep 5
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP 10 roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaValAlaGlySerLysMetGlnGlyLeu 15 LeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnP roProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGl nGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsn PheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyG lyGlySerGlyGlyGlySerGlyGlyThrGlnAspCysSerPheGlnHisSe 20 rProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeu LeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuC ysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLy sThr (SEQ ID NO:626) 25 hflt3-62631inkl5.pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal 30 LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl 35 uSerHisLysSerProAsnMetAlaValAlaGlySerLysMetGlnGlyLeu LeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnP roProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGl nGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsn PheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyG 40 lyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCy sSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGlu LeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuG lnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTr pMetGluArgLeuLysThr (SEQ ID NO:627) 45 hflt3-94951inkl0.pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe 50 uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG 55 lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaArgPheValGlnThrAsnlleSerArg -229- CZ 295843 B6
LeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrA rgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerTh rLeuGlyGlyGlySerGlyGlyGlySerGlyGlyThrGlnAspCysSerPhe GlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerA 5 spTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGl uGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValA snThrGIulleHisPheValThrLysCysAlaPheGInProProProSerCy sLeu (SEQ ID NO:628) 10 hflt3-94951inkl5.pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe 15 uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG 20 lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaArgPheValGlnThrAsnlleSerArg LeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrA rgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerTh rLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThr 25 GlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysI leArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSe rAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAla GlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyL euLeuGluArgValAsnThrGIulleHisPheValThrLysCysAlaPheGl 30 nProProProSerCysLeu (SEQ ID NO:629) hflt3-98991inkl0.pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP 35 roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr 40 LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlySerSerProG lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaThrAsnlleSerArgLeuLeuGlnGlu ThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheS erArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGl 45 ySerGlyGlyGlySerGlyGlyThrGlnAspCysSerPheGlnHisSerPro IleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuG lnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGl yGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleH 50 isPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheVa lGln (SEQ ID NO:630) hflt3-98991inkl5.pep 55 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe -230- CZ 295843 B6 uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr 5 LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaThrAsnlleSerArgLeuLeuGlnGlu ThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheS erArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGl 10 ySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSer PheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuS erAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAs pGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMet GluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgV 15 alAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSe rCysLeuArgPheValGln (SEQ ID NO:631) hfIt3-28291ink6.pep 20 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy 25 sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaAspTyrProValThrValAlaSerAsn LeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnA 30 rgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLe uGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnPro ProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnG luThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPh eSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGly 35 GlySerGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerA spPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGln (SEQ ID NO:632) hflt3-28291ink7.pep 40
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP 45 roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaAspTyrProValThrValAlaSerAsn 50 LeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnA rgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLe uGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnPro ProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnG luThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPh 55 eSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGly -231 - CZ 295843 B6
GlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerS erAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGln (SEQ ID NO:633) 5 hfIt3-28291inkl3.pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal 10 LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl 15 uSerHisLysSerProAsnMetAlaAspTyrProValThrValAlaSerAsn LeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnA rgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLe uGluArgValAsnThrGIulleHisPheValThrLysCysAlaPheGInPro ProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnG 20 luThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPh eSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGly GlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheG InHisSerProIleSerSerAspPheAlaValLysIleArgGIuLeuSerAs pTyrLeuLeuGln (SEQ ID NO:634) 25 hflt3-28291ink21.pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe 30 uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG 35 lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaValAlaGlySerLysMetGlnGlyLeu LeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnP roProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGl nGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsn 40 PheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyG lyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGl ySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPhe AlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValT hrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLe 45 uValLeuAlaGlnArgTrpMetGluArgLeuLysThr (SEQ ID NO:635) hflt3-34351ink6.pep
50 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy 55 sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG -232 - CZ 295843 B6 lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaAlaSerAsnLeuGlnAspGluGluLeu CysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuL ysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGl 5 ulleHisPheValThrLysCysAlaPheGInProProProSerCysLeuArg PheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuV alAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLe uGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyThrGln AspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleA 10 rgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVal (SEQ ID NO:636) hflt3-34351ink7.pep 15 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy 20 sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaAlaSerAsnLeuGlnAspGluGluLeu CysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuL 25 ysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGl ulleHísPheValThrLysCysAlaPheGInProProProSerCysLeuArg PheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuV alAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLe uGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlyThr 30 GlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysI leArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVal (SEQ ID NO:637) hflt3-34351ink!3.pep 35
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP 40 roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaAlaSerAsnLeuGlnAspGluGluLeu 45 CysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuL ysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGl ulleHisPheValThrLysCysAlaPheGInProProProSerCysLeuArg PheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuV alAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLe 50 uGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySer GlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerS erAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTy rProValThrVal (SEQ ID NO:638) -233- 55 CZ 295843 B6 hflt3-34351ink21.pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe 5 uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG 10 lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaAlaSerAsnLeuGlnAspGluGluLeu CysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuL ysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGl ulleHisPheValThrLysCysAlaPheGInProProProSerCysLeuArg 15 PheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuV alAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLe uGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySer GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysS erPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLe 20 uSerAspTyrLeuLeuGlnAspTyrProValThrVal (SEQ ID NO:639) hfIt3-62631ink6.pep 25 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy 30 sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaValAlaGlySerLysMetGlnGlyLeu LeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnP 35 roProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGl nGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsn PheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyG lyGlySerGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSe rAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyr 40 ProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuT rpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr (SEQ ID NO:640) hflt3-62631ink7.pep 45
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP 50 roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaValAlaGlySerLysMetGlnGlyLeu 55 LeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnP roProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGl -234- CZ 295843 B6 nGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsn PheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyG lyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSe rSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAsp 5 TyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyL euTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr (SEQ ID NO:641) hflt3-62631inkl3.pep 10
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlňP 15 roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaValAlaGlySerLysMetGlnGlyLeu 20 LeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnP roProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGl nGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsn PheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyG lyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPh 25 eGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSer AspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspG luGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGl uArgLeuLysThr (SEQ ID NO:642) 30 hf It3-62631ink21 .pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal 35 LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl 40 uSerHisLysSerProAsnMetAlaValAlaGlySerLysMetGlnGlyLeu LeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnP roProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGl nGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsn PheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyG 45 lyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGl ySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPhe AlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValT hrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLe uValLeuAlaGlnArgTrpMetGluArgLeuLysThr 50 (SEQ ID NO: 643) hflt3-94951ink6.pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP 55 roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal - 235 - CZ 295843 B6
LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG 5 lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaArgPheValGlnThrAsnlleSerArg LeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrA rgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerTh rLeuGlyGlyGlySerGlyGlyThrGlnAspCysSerPheGlnHisSerPro 10 IleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuG lnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGl YGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleH isPheValThrLysCysAlaPheGlnProProProSerCysLeu (SEQ ID 15 NO: 64 4 ) hfIt3-94951ink7.pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP 20 roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr 25 LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaArgPheValGlnThrAsnlleSerArg LeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrA rgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerTh 30 rLeuGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSer ProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuL euGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCy sGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLys ThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluI 35 leHisPheValThrLysCysAlaPheGlnProProProSerCysLeu (SEQ ID NO:645) hfIt3-94951inkl3.pep
40 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy 45 sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaArgPheValGlnThrAsnlleSerArg LeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrA 50 rgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerTh rLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAsp CysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgG luLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLe uGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArg 55 TrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuG -236- CZ 295843 B6 luArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProPr oProSerCysLeu (SEQ ID NO:646) hflt3-94951ink21.pep 5
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP 10 roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaArgPheValGlnThrAsnlleSerArg 15 LeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrA rgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerTh rLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySer GlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerS erAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTy 20 rProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeu TrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaG lySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheVa lThrLysCysAlaPheGlnProProProSerCysLeu (SEQ ID NO:647) 25 hflt3-98991ink6.pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe 30 uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlySerSerProG 35 lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaThrAsnlleSerArgLeuLeuGlnGlu ThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheS erArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGl ySerGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAsp 40 PheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProV alThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpAr gLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySer LysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrL ysCysAlaPheGlnProProProSerCysLeuArgPheValGln (SEQ ID 45 NO: 648) hfIt3-98991ink7.pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP 50 roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr 55 LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlySerSerProG lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl -237- CZ 295843 B6 uSerHisLysSerProAsnMetAlaThrAsnlleSerArgLeuLeuGlnGlu ThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheS erArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGl ySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSer 5 AspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrP roValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTr pArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGly SerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValT hrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln (SEQ 10 ID NO: 649) hflt3-98991inkl3.pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP 15 roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr 20 LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlySerSerProG lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaThrAsnlleSerArgLeuLeuGlnGlu ThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheS erArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGl 25 ySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGln HisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspT yrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGl uLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnT 30 hrGIulleHisPheValThrLysCysAlaPheGInProProProSerCysLe uArgPheValGln (SEQ ID NO:650) hflt3-98991ink21.pep 35 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProP roAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLe uMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaVal LysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnP roCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy 40 sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThr LeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProG lyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGl uSerHisLysSerProAsnMetAlaThrAsnlleSerArgLeuLeuGlnGlu ThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheS 45 erArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGl ySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySer GlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaV alLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVa lAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuVal 50 LeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetG InGlyLeuLeuGluArgValAsnThrGIulleHisPheValThrLysCysAl aPheGlnProProProSerCysLeuArgPheValGln (SEQ ID NO:651)
55 GlySerThrMetSerArgLeuProValLeuLeuLeuLeuGlnLeuLeuValArgProAlaMetSe rThrAsnGInAspLeuProVallleLysCysValLeulleAsnHisLysAsnAsnAspSerSerV -238 - CZ 295843 B6 alGlyLysSerSerSerTyrProMetValSerGluSerProGluAspLeuGlyCysAlaLeuArg ProGlnSerSerGlyThrValTyrGluAlaAlaAlaValGluValAspValSerAlaSerlleTh rLeuGlnValLeuValAspAlaProGlyAsnlleSerCysLeuTrpValPheLysHisSerSerL euAsnCysGlnProHisPheAspLeuGlnAsnArgGlyValValSerMetValIleLeuLysMet 5 ThrGluThrGlnAlaGlyGluTyrLeuLeuPhelleGlnSerGluAlaThrAsnTyrThrlleLe uPheThrValSerlleArgAsnThrLeuLeuTyrThrLeuArgArgProTyrPheArgLysMetG luAsnGlnAspAlaLeuValCysIleSerGluSerValProGluProIleValGluTrpValLeu CysAspSerGlnGlyGluSerCysLysGluGluSerProAlaValValLysLysGluGluLysVa ILeuHisGluLeuPheGlyMetAspIleArgCysCysAlaArgAsnGluLeuGlyArgGIuCysT io hrArgLeuPheThrlleAspLeuAsnGlnThrProGlnThrThrLeuProGlnLeuPheLeuLys ValGlyGluProLeuTrpIleArgCysLysAlaValHisValAsnHisGlyPheGlyLeuThrTr pGluLeuGluAsnLysAlaLeuGluGluGlyAsnTyrPheGluMetSerThrTyrSerThrAsnA rgThrMetlleArglleLeuPheAlaPheValSerSerValAlaArgAsnAspThrGlyTyrTyr ThrCysSerSerSerLysHisProSerGlnSerAlaLeuValThrlleValGluLysGlyPhell 15 eAsnAlaThrAsnSerSerGluAspTyrGluIleAspGlnTyrGluGluPheCysPheSerValA rgPheLysAlaTyrProGlnlleArgCysThrTrpThrPheSerArgLysSerPheProCysGlu GlnLysGlyLeuAspAsnGlyTyrSerlleSerLysPheCysAsnHisLysHisGlnProGlyGl uTyrllePheHisAlaGluAsnAspAspAlaGlnPheThrLysMetPheThrLeuAsnlleArgA rgLysProGlnValLeuAlaGluAlaSerAlaSerGlnAlaSerCysPheSerAspGlyTyrPro 20 LeuProSerTrpThrTrpLysLysCysSerAspLysSerProAsnCysThrGluGluIleThrGl uGlyValTrpAsnArgLysAlaAsnArgLysValPheGlyGlnTrpValSerSerSerThrLeuA snMetSerGluAlalleLysGlyPheLeuValLysCysCysAlaTyrAsnSerLeuGlyThrSer CysGluThrlleLeuLeuAsnSerProGlyProPheProPhelleGlnAspAsnGluPhellell eLeuGlyLeuPheGlyLeuLeuLeuLeuLeuThrCysLeuCysGlyThrAlaTrpLeuCysCysS 25 erProAsnArgLysAsnProLeuTrpProSerValProAspProAlaHisSerSerLeuGlySer TrpValProThrlleMetGluGluAspAlaPheGlnLeuProGlyLeuGlyThrProProIleTh rLysLeuThrValLeuGluGluAspGluLysLysProValProTrpGluSerHisAsnSerSerG luThrCysGlyLeuProThrLeuValGlnThrTyrValLeuGlnGlyAspProArgAlaValSer ThrGlnProGlnSerGlnSerGlyThrSerAspGlnValLeuTyrGlyGlnLeuLeuGlySerPr 30 oThrSerProGlyProGlyHisTyrLeuArgCysAspSerThrGlnProLeuLeuAlaGlyLeuT hrProSerProLysSerTyrGluAsnLeuTrpPheGlnAlaSerProLeuGlyThrLeuValThr ProAlaProSerGlnGluAspAspCysValPheGlyProLeuLeuAsnPheProLeuLeuGlnGl ylleArgValHisGlyMetGluAlaLeuGlySerPhe (SEQ ID NO:652) 35 pMON30329.pep
AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnVa lArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysH isProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCys 40 ProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGl nGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnL euAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAla LeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyVa lLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaG 45 lnProTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsn ProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrGlnAspCysSerPheGl nHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnA spTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeu ValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLe 50 uGluArgValAsnThrGIulleHisPheValThrLysCysAlaPheGInProProProSerCysL euArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeu LysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSe rThrLeu (SEQ ID NO:653) -239- 55 CZ 295843 B6 pMON32173.pep
AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGl uLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluL 5 euCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAla GlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAl aPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluT hrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGlu LeuGlnCysGlnProAspSerSerThrLeuTyrValGluGlyGlyGlyGlySerProGlyGluPr 10 oSerGlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnM etAlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArg GluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGl uLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValA laGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCys 15 AlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGl uThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuG luLeuGlnCysGlnProAspSerSerThrLeu (SEQ ID NO:654) pMON32175.pep 20
AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGl uLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluL euCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAla GlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAl 25 aPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluT hrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGlu LeuGlnCysGlnProAspSerSerThrLeuTyrValGluGlyGlyGlyGlySerProGlyGluPr oSerGlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnM etAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGln 30 ValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCy sHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerC ysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyr GlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGl nLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProA 35 laLeuGlnProThrGlnGlyAlaMetPřoAlaPheAlaSerAlaPheGlnArgArgAlaGlyGly ValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAl aGlnPro (SEQ ID NO:655) pMON32204.pep 40
AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnVa lArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysH isProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCys ProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGl 45 nGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnL euAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAla LeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyVa ILeuValAlaSerHisLeuGInSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaG lnProTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsn 50 ProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrGlnAspCysSerPheGl nHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnA spTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeu ValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLe uGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCysL 55 euArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeu LysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSe -240- CZ 295843 B6 rThrLeuTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleA snProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrGlnAspCysSerPhe GlnHisSerProIléSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGl nAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgL 5 euValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeu LeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCy sLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaL euLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSer SerThrLeu (SEQ ID NO:656) 10 pMON32205.pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaProLeuLe uAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeuArgLeuProA 15 snLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlylleGluAlalleLeu ArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaG lnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThr IleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrGlnAspCysSe 20 rPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuL euGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrp ArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGl yLeuLeuGluArgValAsnThrGIulleHisPheValThrLysCysAlaPheGInProProProS erCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal 25 AlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAs pSerSerThrLeuTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerT hrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrGlnAspCys SerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLe uLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuT 30 rpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGln GlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProPr 0SerCysLeuArgPheValGlnThrAsnIleSerArgLeuLeuGlnGluThrSerGluGlnLeuV alAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnPro AspSerSerThrLeu (SEQ ID NO:657) 35 pMON32208.pep
AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGl uLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluL 40 euCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAla GlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAl aPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluT hrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGlu LeuGlnCysGlnProAspSerSerThrLeuTyrValGluGlyGlyGlyGlySerProGlyGluPr 45 oSerGlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnM etAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGln ValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCy sHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerC ysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyr 50 GlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGl nLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProA laLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGly ValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAl aGlnProTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleA 55 snProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrGlnAspCysSerPhe GlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGl -241 - CZ 295843 B6 nAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgL euValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeu LeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCy sLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaL 5 euLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSer SerThrLeu (SEQ ID NO:658) pMON35767.pep/pMON32191.pep 10 AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGl uLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluL euCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAla GlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAl aPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluT 15 hrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGlu LeuGlnCysGlnProAspSerSerThrLeuTyrValGluGlyGlyGlyGlySerProGlyGlyGl ySerGlyGlyGlySerAsnMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheL euLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeu CysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlyllePr 20 oTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuH isSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGly ProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGl uGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaP heGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyr 25 ArgValLeuArgHisLeuAlaGlnPro (SEQ ID NO:659) pMON32397.pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLe 30 uAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThrProA snLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeu ArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaG lnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThr 35 IleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaAspTyrProValTh rValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnA rgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsn ThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGl nThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleT 40 hrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGly GlySerGlyGlyGlySerGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAs pPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGln (SEQ ID NO:660) pMON32398.pep 45
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLe uAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThrProA snLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeu ArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy 50 sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaG InGluGInGInTyrValGIuGlyGlyGlyGlySerProGlyGluProSerGIyProIleSerThr IleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaAspTyrProValTh rValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnA rgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsn 55 ThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGl nThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleT -242 - CZ 295843 B6 hrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGly GlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSe rProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGln (SEQ ID NO:661) 5 pMON32399.pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLe uAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThrProA 10 snLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeu ArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaG InGluGInGInTyrValGIuGlyGlyGlyGlySerProGlyGluProSerGIyProIleSerThr IleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaAlaSerAsnLeuGl 15 nAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuL ysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheVal ThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLe uLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerA rgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySer 20 GlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleAr gGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVal (SEQ ID NO:662) pMON35700.pep 25 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLe uAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThrProA snLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeu ArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaG 30 InGluGInGInTyrValGIuGlyGlyGlyGlySerProGlyGluProSerGIyProIleSerThr IleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaAlaSerAsnLeuGl nAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuL ysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheVal ThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLe 35 uLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerA rgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySer GlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPh eAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVal (SEQ ID NO:663) 40 pMON35701.pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLe uAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThrProA 45 snLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeu ArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaG InGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThr IleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaValAlaGlySerLy 50 sMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnP roProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGlu GlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCy sGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyThrGlnAspCysS erPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeu 55 LeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTr pArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr (SEQ ID NO:664) -243- CZ 295843 B6 pMON35702.pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLe 5 uAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThrProA snLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeu ArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaG InGluGInGInTyrValGIuGlyGlyGlyGlySerProGlyGluProSerGIyProIleSerThr 10 IleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaValAlaGlySerLy sMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnP roProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGlu GlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCy sGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyG 15 lyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGlu LeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLe uCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr (SEQ ID NO:665) 20 pMON35703 .pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLe uAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThrProA snLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeu 25 ArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaG InGluGInGInTyrValGIuGlyGlyGlyGlySerProGlyGluProSerGIyProIleSerThr IleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaArgPheValGlnTh rAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrA 30 rgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGiyGly SerGlyGlyGlySerGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPh eAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerA snLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHi 35 sPheValThrLysCysAlaPheGlnProProProSerCysLeu (SEQ ID NO:666) pMON35704.pep
AlaAsnCysSerlleMetlleAspGlullelleHisHisLeuLysArgProProAsnProLeuLe 40 uAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThrProA snLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeu ArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaG InGluGInGInTyrValGIuGlyGlyGlyGlySerProGlyGluProSerGIyProIleSerThr 45 IleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaArgPheValGlnTh rAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrA rgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGly SerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerPr oIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProV 50 alThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAla GlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgVa lAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeu (SEQ ID NO:667) -244- 55 CZ 295843 B6 pMON35705.pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLe uAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThrProA 5 snLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeu ArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaG InGluGinGInTyrValGIuGlyGlyGlySerSerProGlyGluProSerGIyProIleSerThr IleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrAsnlleSerAr 10 gLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheS erArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGly SerGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIl eArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspG luGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr 15 ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLy sCysAlaPheGlnProProProSerCysLeuArgPheValGln (SEQ ID NO:668) pMON35706.pep 20 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLe uAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThrProA snLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeu ArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaG 25 InGluGinGInTyrValGIuGlyGlyGlyGlySerProGlyGluProSerGIyProIleSerThr IleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrAsnlleSerAr gLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheS erArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGly SerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAs 30 pPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaS erAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMet GluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIl eHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln (SEQ ID NO:669) 35 pMON35733.pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLe uAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThrProA 40 snLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeu ArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaG InGluGInGInTyrValGIuGlyGlyGlyGlySerProGlyGluProSerGIyProIleSerThr IleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaSerAsnLeuGlnAs 45 pGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysT hrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThr LysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLe uGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgC ysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGly 50 GlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerPr oIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProV alThrValAla (SEQ ID NO:670) -245 - CZ 295843 B6 pMON35734.pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLe uAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThrProA 5 snLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeu ArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaG InGluGInGInTyrValGIuGlyGlyGlyGlySerProGlyGluProSerGIyProIleSerThr IleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaAsnLeuGlnAspGl 10 uGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrV alAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLys CysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGl nGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysL euGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGly 15 GlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIl eSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValT hrValAlaSer (SEQ ID NO:671) pMON35735.pep 20
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLe uAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThrProA snLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeu ArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy 25 sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaG lnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThr IleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaLeuGlnAspGluGl uLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValA laGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCys 30 AlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGl uThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuG luLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGly SerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSe rSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrV 35 alAlaSerAsn (SEQ ID NO:672) pMON35736.pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLe 40 uAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThrProA snLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeu ArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaG InGluGInGInTyrValGIuGlyGlyGlyGlySerProGlyGluProSerGIyProIleSerThr 45 IleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaGlnAspGluGluLe uCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaG lySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAla PheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluTh rSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluL 50 euGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySer GlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSe rAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValA laSerAsnLeu (SEQ ID NO:673) -246- 55 CZ 295843 B6 pMON35738.pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLe uAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThrProA 5 snLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeu ArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaG lnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThr IleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaGluGluLeuCysGl 10 yGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerL YsMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGln ProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGl uGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnC ysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGly 15 GlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPh eAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerA snLeuGlnAsp (SEQ ID NO:674) pMON35739.pep 20
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLe uAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThrProA snLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeu ArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy 25 sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaG lnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThr IleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaGluLeuCysGlyGl yLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysM etGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnPro 30 ProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGl nLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysG lnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGly SerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAl aValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnL 35 euGlnAspGlu (SEQ ID NO:675) pMON35740.pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLe 40 uAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThrProA snLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeu ArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaG lnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThr 45 IleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaLeuCysGlyGlyLe uTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetG lnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProPro ProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLe uValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnP 50 roAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySer GlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaVa lLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuG lnAspGluGlu (SEQ ID NO:676) -247- 55 CZ 295843 B6 pMON35741.pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLe uAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThrProA 5 snLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeu ArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaG InGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThr IleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaSerAsnLeuGlnAs 10 pGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysT hrValAlaGlySerLysMetGInGlyLeuLeuGluArgValAsnThrGIulleHisPheValThr LysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLe uGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgC ysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGly 15 GlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerPr oIleSerSerAspSerAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProV alThrValAla (SEQ ID NO:677) pMON35742.pep 20
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLe uAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThrProA snLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeu ArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy 25 sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaG InGluGInGInTyrValGIuGlyGlyGlyGlySerProGlyGluProSerGIyProIleSerThr IleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaGlnAspGluGluLe uCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaG lySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAla 30 PheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLěuArgGluTh rSerGluGlnProValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluL euGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySer GlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSe rAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValA 35 laSerAsnLeu (SEQ ID NO:678) pMON35743.pep
AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLe 40 uAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThrProA snLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeu ArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaG InGluGInGInTyrValGIuGlyGlyGlyGlySerProGlyGluProSerGIyProIleSerThr 45 IleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaLeuCysGlyGlyLe uTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetG lnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProPro ProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLe uValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysArgP 50 roAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySer GlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaVa lLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuG lnAspGluGlu (SEQ ID NO:679) -248- 55 CZ 295843 B6 pMON32179.pep
AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLe uLysThrValAlaGlySerLysMetGInGlyLeuLeuGluArgValAsnThrGIulleHisPheV 5 alThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArg LeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSe rArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlyS erGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHis SerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTy 10 rProValThrValTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerT hrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaAsnCysSerlle MetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLeuAspProAsnAsnLe uAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheV alArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnPro 15 CysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLysAlaGlyAspTrpGl nGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGln (SEQ ID NO:680) pMON35707.pep 20
AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLe uLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheV alThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArg LeuLeuGlnGluThrSerGluGlnLeuValAlaLeuArgProTrpIleThrArgGlnAsnPheSe 25 rArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlyS erGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIle ArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnTyrVa lGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsnProSerProP roSerLysGluSerHisLysSerProAsnMetAlaAsnCysSerlleMetlleAspGluIlelle 30 HisHisLeuLysArgProProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAs pIleLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisL euGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThr AlaAlaProSerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLe uThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGln (SEQ ID NO:681) 35 pMON35708.pep
AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLe uLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheV 40 alThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArg LeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSe rArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlyS erGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAsp PheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSe 45 rAsnLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrl leAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaAsnCysSerlleMet IleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLeuAspProAsnAsnLeuAs nSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValA rgAlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCys 50 LeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLysAlaGlyAspTrpGlnGl uPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGln (SEQ ID NO:682) -249- CZ 295843 B6 pMON35709.pep
AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLe uLysThrValAlaGlySerLysMetGInGlyLeuLeuGluArgValAsnThrGIulleHisPheV 5 alThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArg LeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSe rArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlyS erGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHis SerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTy 10 rProValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGluProS erGlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMet AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLe uAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThrProA snLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeu 15 ArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaG InGluGInGIn (SEQ ID NO:683) pMON35710.pep 20
AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLe uLysThrValAlaGlySerLysMetGInGlyLeuLeuGluArgValAsnThrGIulleHisPheV alThrLysCysAlaPheGlnProProProSerCysLeuArgLeuValGlnThrAsnlleSerArg LeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSe 25 rArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlyS erGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAsp PheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSe rAsnLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrl leAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaAsnCysSerlleMet 30 IleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLeuAspProAsnAsnLeuAs nSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValA rgAlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCys LeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLysAlaGlyAspTrpGlnGl uPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGln 35 (SEQ ID NO: 684) pMON35711-pep
AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlyArgLe 40 uLysThrValAlaGlySerLysMetGInGlyLeuLeuGluArgValAsnThrGIulleHisPheV alThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGInThrAsnlleSerArg LeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSe rArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlyS erGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHis 45 SerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTy rProValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGluProS erGlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMet AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLe uAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThrProA 50 snLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeu ArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaG InGluGInGIn (SEQ ID NO:685) -250- 55 CZ 295843 B6 pMON35719.pep
MetAlaAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTr pArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnG 5 lyLeuLeuGluArgValAsnThrGIulleHisPheValThrLysCysAlaPheGInProProPro SerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVa lAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProA spSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGln AspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAs 10 pTyrLeuLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerT hrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaAsnCysSerlle MetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLeuAspProAsnAsnLe uAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheV alArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnPro 15 CysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLysAlaGlyAspTrpGl nGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGln (SEQ ID NO:686) pMON35720.pep 20
AlaAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnAr gTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnT hrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln ThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleTh 25 rArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyG lySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSer ProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrPr oValThrValTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrl leAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaAsnCysSerlleMet 30 IleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLeuAspProAsnAsnLeuAs nSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValA rgAlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCys LeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLysAlaGlyAspTrpGlnGl uPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGln 35 (SEQ ID NO: 687) pMON35721.pep
AlaValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValTh 40 rLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuL euGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArg CysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGl yGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheA laValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsn 45 LeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluAr gLeuLysThrTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrl leAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaAsnCysSerlleMet IleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLeuAspProAsnAsnLeuAs nSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValA 50 rgAlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCys LeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLysAlaGlyAspTrpGlnGl uPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGln (SEQ ID NO:688) -251 - 55 CZ 295843 B6 PMON35722.pep
AlaSerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAl aPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluT hrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGlu LeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySe rGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysI leArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAsp GluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysTh rValAlaGlyTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrl leAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaAsnCysSerlleMet IleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLeuAspProAsnAsnLeuAs nSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValA rgAlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCys LeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLysAlaGlyAspTrpGlnGl uPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGln (SEQ ID NO:689) pMON35723.pep
AlaProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGl
uGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnC ysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGly
GlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGl
uLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluL euCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAla
GlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAl aPheGlnProTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrl leAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaAsnCysSerlleMet
IleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLeuAspProAsnAsnLeuAs
nSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValA rgAlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCys
LeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLysAlaGlyAspTrpGlnGl uPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGln (SEQ ID NO:690) pMON35725.pep
AlaThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIl eThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyG lyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHis SerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTy rProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValL euAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGlu ArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuAr gPheValGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrl leAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaAsnCysSerlleMet IleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLeuAspProAsnAsnLeuAs nSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValA rgAlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCys LeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLysAlaGlyAspTrpGlnGl uPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGln (SEQ ID NO:691) -252- CZ 295843 B6 pMON35726.pep
AlaArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLe uLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerS 5 erThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCys SerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLe uLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuT rpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGln GlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProPr 10 oSerCysPheTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrl leAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaAsnCysSerlleMet IleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLeuAspProAsnAsnLeuAs nSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValA rgAlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCys 15 LeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLysAlaGlyAspTrpGlnGl uPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGln (SEQ ID NO:692) pMON35744.pep 20
AlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTr pMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrG lulleHisPheValThrLysCysAlaPheGInProProProSerCysLeuArgPheValGInThr AsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrAr 25 gGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlyS erGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCys SerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLe uLeuGlnAspTyrProValThrValAlaTyrValGluGlyGlyGlyGlySerProGlyGluProS erGlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMet 30 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLe uAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThrProA snLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeu ArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaG 35 InGluGInGIn (SEQ ID NO: 693) pMON35745.pep
AlaAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMe 40 tGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluI leHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsn IleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGl nAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerG lyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSer 45 PheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLe uGlnAspTyrProValThrValAlaSerTyrValGluGlyGlyGlyGlySerProGlyGluProS erGlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMet AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLe uAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThrProA 50 snLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeu ArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGIuPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaG InGluGInGIn (SEQ ID NO:694) -253 - 55 CZ 295843 B6 pMON35746.pep
AlaLeuGlnÁspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgLeuMetGl uArgLeuLysThrValAlaGlySerLysMetGInGlyLeuLeuGluArgValAsnThrGIulleH 5 isPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlle SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAs nPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyG lyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPhe GlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGl 10 nAspTyrProValThrValAlaSerAsnTyrValGluGlyGlyGlyGlySerProGlyGluProS erGlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMet AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLe uAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThrProA snLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeu 15 ArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaG InGluGInGIn (SEQ ID NO:695) pMON35747.pep 20
AlaGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluAr gLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisP heValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPh 25 eSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyG lySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGln HisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAs pTyrProValThrValAlaSerAsnLeuTyrValGluGlyGlyGlyGlySerProGlyGluProS erGlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMet 30 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLe uAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThrProA snLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeu ArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaG 35 InGluGInGIn (SEQ ID NO: 696) pMON35748.pep
AlaGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLy 40 sThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValT hrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeu LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerAr gCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerG lyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSer 45 ProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrPr oValThrValAlaSerAsnLeuGlnAspTyrValGluGlyGlyGlyGlySerProGlyGluProS erGlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMet AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLe uAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThrProA 50 snLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeu ArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaG InGluGInGIn (SEQ ID NO:697) -254- 55 CZ 295843 B6 pMON35749.pep
AlaLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVa lAlaGlySerLysMetGInGlyLeuLeuGluArgValAsnThrGIulleHisPheValThrLysC 5 ysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGln GluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLe uGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyG lySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIle SerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValTh 10 rValAlaSerAsnLeuGlnAspGluGluTyrValGluGlyGlyGlyGlySerProGl.yGluProS erGlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMet AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLe uAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThrProA snLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeu 15 ArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaG InGluGInGIn (SEQ ID NO:698) pMON35750.pep 20
AlaLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVa lAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysC ysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGln GluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLe 25 uGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyG lySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIle SerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValTh rValAlaSerAsnLeuGlnAspGluGluTyrValGluGlyGlyGlyGlySerProGlyGluProS erGlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMet 30 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLe uAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThrProA snLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeu ArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaG 35 InGluGInGIn (SEQ ID NO:699) pMON35769.pep
AlaLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVa 40 lAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysC ysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGln GluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLe uGluLeuGlnCysArgProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyG lySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIle 45 SerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValTh rValAlaSerAsnLeuGlnAspGluGluTyrValGluGlyGlyGlyGlySerProGlyGluProS erGlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMet AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLe uAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThrProA 50 snLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeu ArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaG InGluGInGIn (SEQ ID NO:700) 55 CZ 295843 B6 pMON35771.pep
AlaSerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAl aPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluT 5 hrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGlu LeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySe rGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysI leArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAsp GluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysTh 10 rValAlaGlyTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrl leAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaAsnCysSerlleMet IleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLeuAspProAsnAsnLeuAs nSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValA rgAlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCys 15 LeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLysAlaGlyAspTrpGlnGl uPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGln (SEQ ID NO:701) pMON35774.pep 20
AlaGlnAspAspGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluAr gLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisP heValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPh 25 eSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyG lySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySer GlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGl uLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuTyrValGluGlyG lyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLys 30 GluSerHisLysSerProAsnMetAlaAsnCysSerlleMetlleAspGluIlelleHisHisLe uLysArgProProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuM etGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsn AlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaPr oSerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheT 35 yrLeuValThrLeuGluGlnAlaGlnGluGlnGln (SEQ ID NO:702) pMON35775.pep
AlaGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluAr 40 gLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisP heValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPh eSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuProProProTrpSerProA rgProLeuGlyAlaThrAlaProThrThrGlnAspCysSerPheGlnHisSerProIleSerSer 45 AspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAl aSerAsnLeuTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrl leAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaAsnCysSerlleMet IleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLeuAspProAsnAsnLeuAs nSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValA 50 rgAlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCys LeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLysAlaGlyAspTrpGlnGl uPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGln (SEQ ID NO:703) -256- 55 CZ 295843 B6 pMON35776.pep
AlaGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluAr gLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisP 5 heValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPh eSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuProProProTrpSerProA rgProLeuGlyAlaThrAlaProThrAlaGlyGlnProProLeuThrGlnAspCysSerPheGln HisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAs 10 pTyrProValThrValAlaSerAsnLeuTyrValGluGlyGlyGlyGlySerProGlyGluProS erGlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMet AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLe uAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThrProA snLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeu 15 ArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaG InGluGInGIn (SEQ ID NO:704) pMON32169.pep/pMON40000.pep 20
AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnVa lArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysH isProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCys ProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGl 25 nGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnL euAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAla LeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyVa ILeuValAlaSerHisLeuGInSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaG lnProTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsn 30 ProSerProProSerLysGluSerHisLysSerProAsnMetAlaAspGluGluLeuCysGlyGl yLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysM etGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnPro ProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGl nLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysG 35 lnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGly SerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAl aValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnL euGln (SEQ ID NO:705) 40 pMON32188 .pep
AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnVa lArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysH isProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCys 45 ProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGl nGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnL euAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAla LeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyVa ILeuValAlaSerHisLeuGInSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaG 50 lnProTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsn ProSerProProSerLysGluSerHisLysSerProAsnMetAlaAsnLeuGlnAspGluGluLe uCysGlyGlyLeuTrpArgLeuValLeuAlaGInArgTrpMetGluArgLeuLysThrValAlaG lySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAla PheGlnProProProSerCysLeuArgPheValGlnlleAsnlleSerArgLeuLeuGlnGluTh 55 rSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluL euGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySer -257- CZ 295843 B6
GlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSe rAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValA laSer (SEQ ID NO:706) 5 pMON32273.pep
AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnVa lArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysH isProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCys 10 ProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGl nGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnL euAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAla LeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyVa ILeuValAlaSerHisLeuGInSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaG 15 lnProTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsn ProSerProProSerLysGluSerHisLysSerProAsnMetAlaProProSerCysLeuArgPh eValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProT rpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyTh 20 rGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuS erAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCys GlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySe rLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheG lnPro (SEQ ID NO:707) 25 pMON35795.pep
AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnVa lArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysH 30 isProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCys ProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGl nGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnL euAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAla LeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyVa 35 lLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaG lnProTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsn ProSerProProSerLysGluSerHisLysSerProAsnMetAlaLeuGlnAspGluGluLeuCy sGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlyS erLysMetGInGlyLeuLeuGluArgValAsnThrGIulleHisPheValThrLysCysAlaPhe 40 GlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSe rGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuG InCysGInProAspSerSerThrLeuGlyGlyGlySerGIyGlyGlySerGIyGlyGlySerGIy GlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAs pPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaS 45 erAsn (SEQ ID NO: 708) pMON35796.pep
AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnVa 50 lArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysH isProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCys ProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGl nGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnL euAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAla 55 LeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyVa ILeuValAlaSerHisLeuGInSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaG -258- CZ 295843 B6 lriProTyrVaiGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsn ProSerProProSerLysGluSerHisLysSerProAsnMetAlaGlnAspGluGluLeuCysGl yGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerL ysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGln 5 ProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGl uGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnC ysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGly GlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPh eAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerA 10 snLeu (SEQ ID NO:709) pMON35797.pep
AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnVa 15 lArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysH isProGluGlu.LeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCys ProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGl nGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnL euAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAla 20 LeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyVa ILeuValAlaSerHisLeuGInSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaG lnProTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsn ProSerProProSerLysGluSerHisLysSerProAsnMetAlaGluGluLeuCysGlyGlyLe uTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetG 25 InGlyLeuLeuGluArgValAsnThrGIulleHisPheValThrLysCysAlaPheGInProPro ProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLe uValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnP roAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySer GlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaVa 30 lLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuG lnAsp (SEQ ID NO:710) pMON35798.pep 35 AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnVa lArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysH isProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCys ProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGl nGlyLeuLeuGlnAlaLeuGluGlylieSerProGluLeuGlyProThrLeuAspThrLeuGlnL 40 euAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAla LeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyVa ILeuValAlaSerHisLeuGInSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaG lnProTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsn ProSerProProSerLysGluSerHisLysSerProAsnMetAlaGluLeuCysGlyGlyLeuTr 45 pArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnG lyLeuLeuGluArgValAsnThrGIulleHisPheValThrLysCysAlaPheGInProProPro SerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVa lAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProA spSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGly 50 GlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLy sIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnA spGlu (SEQ ID NO:711) -259- CZ 295843 B6 pMON35799.pep
AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnVa lArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysH 5 isProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCys ProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGl nGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnL euAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAla LeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyVa 10 ILeuValAlaSerHisLeuGInSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaG lnProTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsn ProSerProProSerLysGluSerHisLysSerProAsnMetAlaLeuCysGlyGlyLeuTrpAr gLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyL euLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSer 15 CysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAl aLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspS erSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGly GlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIl eArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspG 20 luGlu (SEQ ID NO: 712) pMON39914.pep
AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnVa 25 lArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysH isProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCys ProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGl nGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnL euAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAla 30 LeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyVa lLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaG lnProTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsn ProSerProProSerLysGluSerHisLysSerProAsnMetAlaAspGluGluLeuCysGlyGl yLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysM 35 etGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnPro ProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGl nLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysG lnProAspSerSerThrLeuProProProTrpSerProArgProLeuGlyAlaThrAlaProThr ThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLe 40 uSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln (SEQ ID NO:713) pMON39915.pep 45 AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnVa lArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysH isProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCys ProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGl nGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnL 50 euAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAla LeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyVa ILeuValAlaSerHisLeuGInSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaG lnProTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsn ProSerProProSerLysGluSerHisLysSerProAsnMetAlaAspGluGluLeuCysGlyGl 55 yLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysM etGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnPro -260- CZ 295843 B6
ProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGl nLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysG lnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGly SerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHi 5 sSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspT yrProValThrValAlaSerAsnLeuGln (SEQ ID NO:714) pMON39916.pep 10 AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnVa lArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysH isProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCys ProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGl nGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnL 15 euAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAla LeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyVa ILeuValAlaSerHisLeuGInSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaG lnProTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsn ProSerProProSerLysGluSerHisLysSerProAsnMetAlaAspGluGluLeuCysGlyGl 20 yLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysM etGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnPro ProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGl nLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysG lnProAspSerSerThrLeuProProProTrpSerProArgProLeuGlyAlaThrAlaProThr 25 AlaGlyGlnProProLeuThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAl aValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnL euGln (SEQ ID NO:715) pMON35712.pep 30
AlaAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpAr gLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyL euLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSer CysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAl 35 aLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspS erSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAsp CysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTy rLeuLeuGln (SEQ ID NO:716) 40 pMON35713 .pep
AlaAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnAr gTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnT hrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln 45 ThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleTh rArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyG lySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSer ProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrPr oValThrVal (SEQ ID NO:717) 50 pMON35714.pep
AlaValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValTh rLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuL 55 euGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArg CysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGl -261 - CZ 295843 B6 yGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheA laValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsn LeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluAr gLeuLysThr (SEQ ID NO:718) 5 pMON35715.pep
AlaSerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAl aPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluT 10 hrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGlu LeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySe rGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysI leArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAsp GluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysTh 15 rValAlaGly (SEQ ID NO:719) pMON35716.pep
AlaProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGl 20 uGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnC ysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGly GlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGl uLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluL euCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAla 25 GlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAl aPheGlnPro (SEQ ID NO:720) pMON35717.pep 30 AlaArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLe uLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerS erThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCys SerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLe uLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuT 35 rpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGln GlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProPr oSerCysLeu (SEQ ID NO:721) PMON35718.pep 40
AlaThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIl eThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyG lyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHis SerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTy 45 rProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValL euAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGlu ArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuAr gPheValGln (SEQ ID NO:722) 50 pMON32170 .pep
AlaAspGluGluLeuCysGlyGIyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLe uLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheV alThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArg 55 LeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSe rArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlyS -262- CZ 295843 B6 erGlyGlyGlySerGlyGlyGlyŠerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHis SerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTy rProValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGluProS erGlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMet 5 AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnVa lArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysH isProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCys ProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGl nGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnL 10 euAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAla LeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyVa ILeuValAlaSerHisLeuGInSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaG lnPro (SEQ ID NO:723) 15 pMON32187 .pep
AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLe uLysThrValAlaGlySerLysMetGInGlyLeuLeuGluArgValAsnThrGIulleHisPheV alThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArg 20 LeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSe rArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlyS erGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHis SerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTy rProValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGluProS 25 erGlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMet AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGlnVa lArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysH isProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCys ProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGl 30 nGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnL euAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAla LeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyVa ILeuValAlaSerHisLeuGInSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaG lnPro (SEQ ID NO:724) 35 pMON32271.pep
AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLe uLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheV 40 alThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArg LeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSe rArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuProProProTrpSerProArgP roLeuGlyAlaThrAlaProThrAlaGlyGlnProProLeuThrGlnAspCysSerPheGlnHis SerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTy 45 rProValThrValAlaSerAsnLeuTyrValGluGlyGlyGlyGlySerProGlyGlyGlySerG lyGlyGlySerAsnMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeu LysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAl aThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpA laProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSer 50 GlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProTh rLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluL euGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGln ArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgVa ILeuArgHisLeuAlaGInPro (SEQ ID NO:725) -263 - 55 CZ 295843 B6 pMON32272.pep
AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLe uLysThrValAlaGlySerLysMetGInGlyLeuLeuGluArgValAsnThrGIulleHisPheV 5 alThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArg LeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSe rArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlyS erGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGly ThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLe 10 uSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnTyrValGluGlyG lyGlyGlySerProGlyGlyGlySerGlyGlyGlySerAsnMetAlaThrProLeuGlyProAla SerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGl yAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuL euGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeu 15 AlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGl uGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaT hrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAla MetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGl nSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro (SEQ ID NO:726) 20 pMON32274.pep
AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLe uLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheV 25 alThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArg LeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSe rArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuProProProTrpSerProArgP roLeuGlyAlaThrAlaProThrThrGlnAspCysSerPheGlnHisSerProIleSerSerAsp PheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSe 30 rAsnLeuTyrValGluGlyGlyGlyGlySerProGlyGlyGlySerGlyGlyGlySerAsnMetA laThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnVal ArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHi sProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysP roSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGln 35 GlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLe uAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaL euGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyVal LeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGl nPro (SEQ ID NO:727) 40 pMON35751.pep
AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLe uLysThrValAlaGlySerLysMetGInGlyLeuLeuGluArgValAsnThrGIulleHisPheV 45 alThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArg LeuLeuGlnGluThrSerGluGlnLeuValAlaLeuArgProTrpIleThrArgGlnAsnPheSe rArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlyS erGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIle ArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnTyrVa 50 lGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsnProSerProP roSerLysGluSerHisLysSerProAsnMetAlaThrProLeuGlyProAlaSerSerLeuPro GlnSerPheLeuLeuLysCysLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGl nGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerL euGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeu 55 SerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerPr oGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpG -264- CZ 295843 B6 lnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMeťProAlaPhe AlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGl uValSerTyrArgValLeuArgHisLeuAlaGlnPro (SEQ ID NO:728) 5 pMON35752.pep
AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLe uLysThrValAlaGlySerLysMetGInGlyLeuLeuGluArgValAsnThrGIulleHisPheV alThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArg 10 LeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSe rArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlyS erGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAsp PheAlaValLysIleArgGluLeuSerAapTyrLeuLeuGlnAspTyrProValThrValAlaSe rAsnLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrl 15 leAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrProLeuGlyPro AlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGlnValArgLysIleGlnGlyAs pGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValL euLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGln LeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLe 20 uGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheA laThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGly AlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLe uGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro (SEQ ID NO:729) 25 pMON35753.pep
AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLe uLysThrValAlaGlySerLysMetGInGlyLeuLeuGluArgValAsnThrGIulleHisPheV 30 alThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArg LeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSe rArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlyS erGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHis SerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTy 35 rProValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGluProS erGlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMet AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGlnVa lArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysH isProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCys 40 ProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGl nGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnL euAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAla LeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyVa ILeuValAlaSerHisLeuGinSerPheLeuGluValSerTyrArgValValArgHisLeuAlaG 45 lnPro (SEQ ID NO: 730) pMON35754.pep
AlaProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGl 50 uGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnC ysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGly GlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGl uLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluL euCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAla 55 GlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAl aPheGlnProTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrl -265 - CZ 295843 B6 leAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrProLeuGlyPro AlaSerSerValProGlnSerPheLeuLeuLysCysLeuGluGlnValArgLysIleGlnGlyAs pGlyAlaAlaleuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValL euLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGln 5 LeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLe uGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheA laThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGly AlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLe uGlnSerPheLeuGluValSerTyrArgValIleArgHisLeuAlaGlnPro 10 (SEQ ID NO: 731) pMON35755.pep
AlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTr 15 pMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrG lulleHisPheValThrLysCysAlaPheGInProProProSerCysLeuArgPheValGInThr AsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrAr gGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlyS erGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCys 20 SerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLe uLeuGlnAspTyrProValThrValAlaTyrValGluGlyGlyGlyGlySerProGlyGluProS erGlyProIleSerThrlleAsnProSerHisProSerLysGluSerHisLysSerProAsnMet AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGlnVa lArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysH 25 isProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCys ProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGl nGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnL euAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAla LeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyVa 30 ILeuValAlaSerHisLeuGInSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaG lnPro (SEQ ID NO:732) pMON35756.pep 35 AlaAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMe tGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluI leHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsn IleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGl nAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerG 40 lyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSer PheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLe uGlnAspTyrProValThrValAlaSerTyrValGluGlyGlyGlyGlySerProGlyGluProS erGlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMet AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGlnVa 45 lArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysH isProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCys ProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGl nGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnL euAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAla 50 LeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyVa lLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValIleArgHisLeuAlaG lnPro (SEQ ID NO:733) -266- CZ 295843 B6 pMON35757.pep
AlaLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgLeuMetGl uArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleH 5 isPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlle SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAs nPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyG lyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPhe GlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGl 10 nAspTyrProValThrValAlaSerAsnTyrValGluGlyGlyGlyGlySerProGlyGluProS erGlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMet AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGlnVa lArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysH isProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCys 15 ProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGl nGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnL euAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAla LeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyVa lLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaG 20 lnPro (SEQ ID NO: 734) pMON35758.pep
AlaLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVa 25 lAlaGlySerLysMetGInGlyLeuLeuGluArgValAsnThrGIulleHisPheValThrLysC ysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGln GluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLe uGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyG lySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIle 30 SerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValTh rValAlaSerAsnLeuGlnAspGluGluTyrValGluGlyGlyGlyGlySerProGlyGluProS erGlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMet AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGlnVa lArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysH 35 isProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCys ProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGl nGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnL euAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAla LeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyVa 40 ILeuValAlaSerHisLeuGInSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaG lnPro (SEQ ID NO:735) pMON35759.pep 45 AlaSerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAl aPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluT hrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGlu LeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySe rGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysI 50 leArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAsp GluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysTh rValAlaGlyTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrl leAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrProLeuGlyPro AlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGlnValArgLysIleGlnGlyAs 55 pGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValL euLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGln -267- CZ 295843 B6
LeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLe uGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheA laThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGly AlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLe 5 uGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro (SEQ ID NO:736) pMON35760.pep 10 AlaSerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAl aPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluT hrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGlu LeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySe rGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysI 15 leArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAsp GluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysTh rValAlaGlyTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrl leAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrProLeuGlyPro AlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGlnValArgLysIleGlnGlyAs 20 pGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValL euLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGln LeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLe uGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheA laThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGly 25 AlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLe uGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro (SEQ ID NO:737) pMON35761.pep 30
AlaLeuCysGlyGlyLeuTrpArgLeuValLeuAIaGlnArgTrpMetGluArgLeuLysThrVa lAlaGlySerLysMetGInGlyLeuLeuGluArgValAsnThrGIulleHisPheValThrLysC ysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGln GluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLe 35 uGluLeuGlnCysArgProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyG lySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIle SerSerAsnPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValTh rValAlaSerAsnLeuGlnAspGluGluTyrValGluGlyGlyGlyGlySerProGlyGluProS erGlyProIlePheThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMet 40 AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGlnVa lArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysH isProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCys ProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGl nGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnL 45 euAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAla LeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyVa lLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaG lnPro (SEQ ID NO:738) 50 pMON357 62 .pep
AlaGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysTh rValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrL ysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeu 55 GlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCy sLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyG -268 - CZ 295843 B6 lyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerPro IleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProVa IThrValAlaSerAsnLeuGInAspGluTyrValGIuGlyGlyGlyGlySerProGlyGluProS erGlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMet 5 AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGlnVa lArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysH isProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCys ProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGl nGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnL io euAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAla LeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyVa ILeuValAlaSerHisLeuGInSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaG lnPro (SEQ ID NO:739) 15 pMON357 63 .pep
AlaGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLy sThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValT hrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeu 20 LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerAr gCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerG lyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSer ProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrPr oValThrValAlaSerAsnLeuGlnAspTyrValGluGlyGlyGlyGlySerProGlyGluProS 25 erGlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMet AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGlnVa lArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysH isProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCys ProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGl 30 nGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnL euAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAla LeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyVa ILeuValAlaSerHisLeuGInSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaG lnPro (SEQ ID NO:740) 35 pMON35764.pep
AlaGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluAr gLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisP 40 heValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPh eSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyG lySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGln HisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAs 45 pTyrProValThrValAlaSerAsnLeuTyrValGluGlyGlyGlyGlySerProGlyGluProS erGlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMet AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGlnVa lArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysH isProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCys 50 ProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGl nGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnL euAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAla LeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyVa lLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaG 55 lnPro (SEQ ID NO:741) -269- CZ 295843 B6 pMON35765.pep
AlaThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIl eThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyG 5 lyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHis SerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTy rProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValL euAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGlu ArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuAr 10 gPheValGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrl leAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrProLeuGlyPro AlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGlnValArgLysIleGlnGlyAs pGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValL euLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGln 15 LeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLe uGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheA laThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGly AlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLe uGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro 20 (SEQ ID NO: 742) pMON35766.pep/pMON32190.pep/pMON40001.pep
AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLe 25 uLysThrValAlaGlySerLysMetGInGlyLeuLeuGluArgValAsnThrGIulleHisPheV alThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArg LeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSe rArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlyS erGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHis 30 SerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTy rProValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGlyGlyS erGlyGlyGlySerAsnMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeu LeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCy sAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProT 35 rpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHis SerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyPr oThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluG luLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPhe GlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrAr 40 gValLeuArgHisLeuAlaGlnPro (SEQ ID NO:743) pMON35768.pep
AlaGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluAr 45 gLeuLysThrValAlaGlySerLysMetGInGlyLeuLeuGluArgValAsnThrGIulleHisP heValTh*rLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnIleSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPh eSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyG lySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGln 50 HisSerProIleSerSerAspSerAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAs pTyrProValThrValAlaSerAsnLeuTyrValGluGlyGlyGlyGlySerProGlyGluProS erGlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMet AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGlnVa lArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysH 55 isProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCys ProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGl -270- CZ 295843 B6 nGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnL euAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAla LeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyVa ILeuValAlaSerHisLeuGInSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaG 5 lnPro (SEQ ID NO:744) pMON35770.pep
AlaLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVa 10 lAlaGlySerLysMetGInGlyLeuLeuGluArgValAsnThrGIulleHisPheValThrLysT yrAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGln GluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLe uGluLeuGlnCysArgProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyG lySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPhe 15 AlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAs nLeuGlnAspGluGluTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleS erThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrProLeu GlyProAlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGlnValArgLysIleGl nGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluL 20 euValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAla LeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGl nAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaA spPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThr GlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSe 25 rHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro (SEQ ID NO:745) pMON35772.pep 30 AlaSerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAl aPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluT hrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPhePheArgCysLeuGlu LeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySe rGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysI 35 leArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAsp GluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysTh rValAlaGlyTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrl leAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrProLeuGlyPro AlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGlnValArgLysIleGlnGlyAs 40 pGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValL euLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGln LeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLe uGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheA laThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGly 45 AlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLe uGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro (SEQ ID NO:746) pMON35773.pep 50
AlaGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluAr gLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisP heValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPh 55 eSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyG lySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySer -271 - CZ 295843 B6
GlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGl uLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuTyrValGluGlyG lyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLys GluSerHisLysSerProAsnMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPh 5 eLeuLeuLysCysLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysL euCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylle ProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLe uHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuG lyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMet 10 GluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAl aPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerT yrArgValLeuArgHisLeuAlaGlnPro (SEQ ID NO:747) pMON35777.pep 15
AlaGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluAr gLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisP heValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPh 20 eSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuProProProTrpSerProA rgProLeuGlyAlaThrAlaProThrThrGlnAspCysSerPheGlnHisSerProIleSerSer AspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAl aSerAsnLeuTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrl leAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrProLeuGlyPro 25 AlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGlnValArgLysIleGlnGlyAs pGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValL euLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGln LeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLe uGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheA 30 laThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGly AlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLe uGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro (SEQ ID NO:748) 35 pMON35778 .pep
AlaGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluAr gLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisP heValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSer 40 ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPh eSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuProProProTrpSerProA rgProLeuGlyAlaThrAlaProThrAlaGlyGlnProProLeuThrGlnAspCysSerPheGln HisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAs pTyrProValThrValAlaSerAsnLeuTyrValGluGlyGlyGlyGlySerProGlyGluProS 45 erGlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMet AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGlnVa lArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysH isProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCys ProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGl 50 nGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnL euAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAla LeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyVa ILeuValAlaSerHisLeuGInSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaG lnPro (SEQ ID NO:749) -272- 55 CZ 295843 B6 pMON35779.pep
AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLe uLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheV 5 alThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArg LeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSe rArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlyS erGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGly ThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLe 10 uSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnTyrValGluGlyG lyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLys GluSerHisLysSerProAsnMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPh eLeuLeuLysCysLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysL euCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylle 15 ProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLe uHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuG lyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMet GluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAl aPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerT 20 yrArgValLeuArgHisLeuAlaGlnPro (SEQ ID NO:750) pMON35780.pep
AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgPr 25 oLysThrValAlaGlySerLysMetGInGlyLeuLeuGluArgValAsnThrGIulleHisPheV alThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArg LeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSe rArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlyS erGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGly 30 ThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLe uSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnTyrValGluGlyG lyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLys GluSerHisLysSerProAsnMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPh eLeuLeuLysCysLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysL 35 euCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylle ProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLe uHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuG lyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMet GluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAl 40 aPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerT yrArgValLeuArgHisLeuAlaGlnPro (SEQ ID NO:751) pMON35782.pep 45 AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLe uLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheV alThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArg LeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSe rArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuProProProTrpSerProArgP 50 roLeuGlyAlaThrAlaProThrAlaGlyGlnProProLeuThrGlnAspCysSerPheGlnHis SerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTy rProValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGlyThrProGlyGluProS erGlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMet AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGlnVa 55 lArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysH isProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCys -273- CZ 295843 B6
ProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGl nGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnL euAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAla LeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyVa 5 lLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaG lnPro (SEQ ID NO:752) pMON39908.pep 10 AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLe uLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheV alThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArg LeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSe rArgCysLeuGluLeuGlnCysGlnProValGluThrValPheHisArgValSerGlnAspGlyL 15 euAspLeuLeuThrSerThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAla ValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLe uGlnTyrValGluGlyGlyGlyGlySerProGlyGlyGlySerGlyGlyGlySerAsnMetAlaT hrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArg LysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrAsnLysLeuCysHisPr 20 oGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProS erGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGly LeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAs pValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuG lnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeu 25 ValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPr o (SEQ ID NO:753) pMON32275.pep 30 AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLe uLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheV alThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArg LeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSe rArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuTyrValGluGlyGlyGlyGlyS 35 erProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSerHis LysSerProAsnMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLy sSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaT hrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAla ProLeuSerSerCysProSerGInAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGl 40 yLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrL euAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeu GlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnAr gArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValL euArgHisLeuAlaGlnProTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyPro 45 IleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrGl nAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerA spTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln (SEQ ID NO:754) pMON35781.pep 50
AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGl uLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnGluProLysS erProAspThrHisThrSerProProSerProThrProLeuGlyProAlaSerSerLeuProGln SerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGl 55 uLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuG lylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSer -274- CZ 295843 B6
GlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGl uLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnG lnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAla SerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluVa 5 lSerTyrArgValLeuArgHisLeuAlaGlnProSerAlaGluProLysSerProAspThrHisT hrSerProProSerProGlySerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeu ValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLe uGluArgValAsnThrGIulleHisPheValThrLysCysAlaPheGInProProProSerCysL euArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeu 10 LysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSe rThrLeu (SEQ ID NO:755) pMON35783.pep 15 AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGl uLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluL euCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAla GlySerLysMetGlnGlyTrpGlnGlyArgValAsnThrGluIleHisPheValThrLysCysAl aPheProLysSerProAspThrHisThrSerProProSerProGlyThrProLeuGlyProAlaS 20 erSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGly AlaAlaLeuGlnGluLysLeuCysAlaTyrLysLeuCysHisProGluGluLeuValLeuLeuGl yHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaG lyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGly IleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrTh 25 rlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetP roAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSer PheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProSerAlaGluProLysSerPr oAspThrHisThrSerProProSerProGlyLysAlaPheGlnProProProSerCysLeuArgP heValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysPro 30 TrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLe u (SEQ ID NO:756) pMON32276.pep 35 AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLe uLysThrValAlaGlySerLysMetGInGlyLeuLeuGluArgValAsnThrGIulleHisPheV alThrLysSerAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArg LeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSe rArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlyS 40 erGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspSerSerPheGlnHis SerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTy rProValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGlyGlyS erGlyGlyGlySerAsnMetAIaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeu LeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCy 45 sAlaThrAsnLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProT rpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHis SerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyPr oThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluG luLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPhe 50 GlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrAr gValLeuArgHisLeuAlaGlnPro (SEQ ID NO:757) pMON32277.pep
55 AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnVa lArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysH -275- CZ 295843 B6 isProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCys ProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGl nGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnL euAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAla 5 LeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyVa ILeuValAlaSerHisLeuGInSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaG lnProTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsn ProSerProProSerLysGluSerHisLysSerProAsnMetAlaAspGluGluLeuCysGlyGl yLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysM 10 etGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysSerAlaPheGlnPro ProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGl nLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysG lnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGly SerGlyGlyGlySerGlyThrGlnAspSerSerPheGlnHisSerProIleSerSerAspPheAl 15 aValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnL euGln (SEQ ID NO:758) pMON32278-pep 20 AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLe uLysThrValAlaGlySerLysMetGInGlyLeuLeuGluArgValAsnThrGIulleHisPheV alThrLysCysAlaPheGlnProProProSerSerLeuArgPheValGlnThrAsnlleSerArg LeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSe rArgCysLeuGluLeuGlnSerGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlyS 25 erGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHis SerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTy rProValThrValAlaSerAsnLeuGlnTyřValGluGlyGlyGlyGlySerProGlyGlyGlyS erGlyGlyGlySerAsnMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeu LeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCy 30 sAlaThrAsnLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProT rpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHis SerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyPr 0ThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrIleTrpGlnGlnMetGluG luLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPhe 35 GlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrAr gValLeuArgHisLeuAlaGlnPro (SEQ ID NO:759) pMON32279.pep 40 AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnVa lArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysH isProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCys ProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGl nGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnL 45 euAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAla LeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyVa ILeuValAlaSerHisLeuGInSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaG lnProTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsn ProSerProProSerLysGluSerHisLysSerProAsnMetAlaAspGluGluLeuCysGlyGl 50 yLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysM etGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnPro ProProSerSerLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGl nLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnSerG lnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGly 55 SerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAl -276- CZ 295843 B6 aValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnL euGln (SEQ ID NO:760) pMON35790.pep 5
AlaThrGlnAspSerSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGl uLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluL euCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAla GlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysSerAl 10 aPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluT hrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGlu LeuGlnCysGlnProAspSerSerThrLeuTyrValGluGlyGlyGlyGlySerProGlyGlyGl ySerGlyGlyGlySerAsnMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheL euLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeu 15 CysAlaThrAsnLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlyllePr oTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuH isSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGly ProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGl uGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaP 20 heGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyr ArgValLeuArgHisLeuAlaGlnPro (SEQ ID NO:761) pMON35791.pep 25 AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGl uLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluL euCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAla GlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAl aPheGlnProProProSerSerLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluT 30 hrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGlu LeuGlnSerGlnProAspSerSerThrLeuTyrValGluGlyGlyGlyGlySerProGlyGlyGl ySerGlyGlyGlySerAsnMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheL euLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeu CysAlaThrAsnLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlyllePr 35 oTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuH isSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGly ProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGl uGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaP heGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyr 40 ArgValLeuArgHisLeuAlaGlnPro (SEQ ID NO:762) pMON35792.pep
AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGl 45 uLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluL euCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAla GlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAl aPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluT hrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGlu 50 LeuGlnTyrValGluGlyGlyGlyGlySerProGlyGlyGlySerGlyGlyGlySerAsnMetAl aThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValA rgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrAsnLysLeuCysHis ProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysPr 0SerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnG 55 lyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeu AspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLe -277- CZ 295843 B6
uGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValL euValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGln
Pro (SEQ ID NO:763) 5 pMON39905.pep
AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGl uLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluL euCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAla 10 GlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAl aPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluT hrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGlu LeuGlnSerGlnProAspSerSerThrLeuTyrValGluGlyGlyGlyGlySerProGlyGlyGl ySerGlyGlyGlySerAsnMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheL 15 euLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeu CysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlyllePr oTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuH isSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGly ProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGl 20 uGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaP heGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyr ArgValLeuArgHisLeuAlaGlnPro (SEQ ID NO:764) pMON39906.pep 25 ;AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGl uLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluL euCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAla GlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAl 30 aPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluT hrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgArgLeuGlu LeuGlnSerGlnProAspSerSerThrLeuTyrValGluGlyGlyGlyGlySerProGlyGlyGl ySerGlyGlyGlySerAsnMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheL euLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeu 35 CysAlaThrAsnLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlyllePr oTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuH isSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGly ProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGl uGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaP 40 heGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyr ArgValLeuArgHisLeuAlaGlnPr (SEQ ID NO:765) pMON39909.pep 45 AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLe uLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheV alThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArg LeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSe rArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlyS 50 erGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHis SerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTy rProValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGlyGlyS erGlyGlyGlySerAsnMetAlaThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArg ArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLe 55 uArgHisLeuAlaGlnProSerGlyGlySerGlyGlySerGlnSerPheLeuLeuLysSerLeuG luGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLys -278- CZ 295843 B6
LeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSe rSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheL euTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThr LeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAl 5 aProAlaLeuGlnPro (SEQ ID NO:766) pMON39910.pep
AlaThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuVa 10 lAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProS erGlyGlySerGlyGlySerGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGln GlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLe uValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaL euGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGln 15 AlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAs pPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProTyrV alGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsnProSerPro ProSerLysGluSerHisLysSerProAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrpAr gLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyL 20 euLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSer CysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAl aLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspS erSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGly GlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIl 25 eArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln (SEQ ID NO:767) pMON35727.pep 30 AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLe uLysThrValAlaGlySerLysMetGInGlyLeuLeuGluArgValAsnThrGIulleHisPheV alThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArg LeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSe rArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlyS 35 erGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAsp PheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSe rAsnLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrl leAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaAspGluGluLeuCys GlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySe 40 rLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheG lnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSer GluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGl nCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyG lyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArg 45 GluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln (SEQ ID NO:768) pMON32168.pep 50 AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLe uLysThrValAlaGlySerLysMetGInGlyLeuLeuGluArgValAsnThrGIulleHisPheV alThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArg LeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSe rArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlyS 55 erGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHis SerProIIeSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTy -279- CZ 295843 B6 rProValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGluProS erGlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMet AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGl uLeuSerAspTyrLeuLeuGlnAsnTyrProValThrValAlaSerAsnLeuGlnAspGluGluL 5 euCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAla GlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAl aPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluT hrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGlu LeuGlnCysGlnProAspSerSerThrLeu (SEQ ID NO:769) 10 pMON32195.pep
AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLe uLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheV 15 alThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArg LeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSe rArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlyS erGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHis SerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTy 20 rProValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGlyGlyS erGlyGlyGlySerAsnMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeu LeuLysSerLeuGluGlnValArgLysIleGInGlyAspGlyAlaAlaLeuGlnGluLysLeuCy sAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProT rpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHis 25 SerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyPr 0ThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrIleTrpGlnGlnMetGluG luLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPhe GlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrAr gValLeuArgHisLeuAlaGlnProTyrValGluGlyGlyGlyGlySerProGlyGluProSerG 30 lyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAla AspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLy sThrValAlaGlySerLysMetGInGlyLeuLeuGluArgValAsnThrGIulleHisPheValT hrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeu LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerAr 35 gCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerG lyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSer ProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrPr oValThrValAlaSerAsnLeuGln (SEQ ID NO:770) 40 pMON32196. pep
AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnVa lArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysH isProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCys 45 ProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGl nGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnL euAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAla LeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyVa lLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaG 50 lnProTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsn ProSerProProSerLysGluSerHisLysSerProAsnMetAlaAspGluGluLeuCysGlyGl yLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysM etGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnPro ProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGl 55 nLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysG lnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGly -280- CZ 295843 B6
SerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAl aValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnL euGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsn ProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrGlnAspCysSerPheGl 5 nHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnA spTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeu ValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLe uGluArgValAsnThrGIulleHisPheValThrLysCysAlaPheGInProProProSerCysL euArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeu 10 LysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSe rThrLeu (SEQ ID NO:771) pMON32197.pep 15 AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnVa lArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysH isProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCys ProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGl nGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnL 20 euAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAla LeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyVa ILeuValAlaSerHisLeuGInSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaG lnProTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsn ProSerProProSerLysGluSerHisLysSerProAsnMetAlaAspGluGluLeuCysGlyGl 25 yLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysM etGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnPro ProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGl nLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysG lnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGly 30 SerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAl aValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnL euGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsn ProSerProProSerLysGluSerHisLysSerProAsnMetAlaAspGluGluLeuCysGlyGl yLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysM 35 etGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnPro ProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGl nLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysG lnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGly SerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAl 40 aValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnL euGln (SEQ ID NO:772) pMON32206.pep 45 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaProLeuLe uAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeuArgLeuProA snLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlylleGluAlalleLeu ArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLy sAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaG 50 InGluGInGInTyrValGIuGlyGlyGlyGlySerProGlyGluProSerGIyProIleSerThr IleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaAspGluGluLeuCy sGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlyS erLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPhe GlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSe 55 rGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuG InCysGInProAspSerSerThrLeuGlyGlyGlySerGIyGlyGlySerGIyGlyGlySerGiy -281 - CZ 295843 B6
GlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAs pPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaS erAsnLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThr IleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaAspGluGluLeuCy 5 sGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlyS erLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPhe GlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSe rGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuG InCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGly 10 GlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAs pPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaS erAsnLeuGln (SEQ ID NO:773) pMON32207.pep 15
AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLe uLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheV alThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArg LeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSe 20 rArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlyS erGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHis SerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTy rProValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGlyGlyS erGlyGlyGlySerAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAla 25 GlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgVa lAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheV alGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp IleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGl yGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrG 30 lnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSer AspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGl yGlySerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluS erHisLysSerProAsnMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeu LeuLysCysLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCy 35 sAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProT rpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHis SerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyPr oThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluG luLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPhe 40 GlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrAr gValLeuArgHisLeuAlaGlnProSTPSTPGlySerGluPheGlySer (SEQ ID NO:774) pMON35728.pep 45 AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLe uLysThrValAlaGlySerLysMetGInGlyLeuLeuGluArgValAsnThrGIulleHisPheV alThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArg LeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSe rArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlyS 50 erGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAsp PheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSe rAsnLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrl leAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaAsnCysSerlleMet IleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLeuAspProAsnAsnLeuAs 55 nSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValA rgAlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCys -282- CZ 295843 B6
LeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLysAlaGlyAspTrpGlnGl uPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValG luGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrpArgLe 5 uValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuL euGluArgValAsnThrGIulleHisPheValThrLysCysAlaPheGInProProProSerCys LeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLe uLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerS erThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCys 10 SerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLe uLeuGlnAspTyrProValThrValAlaSerAsnLeuGln (SEQ ID NO:775) pMON32183.pep 15 AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLe uLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnlhrGluIleHisPheV alThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArg LeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSe rArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlyS 20 erGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHis SerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTy rProValThrValAIaSerAsnLeuGlnGluPheLysLeuGluProArgGlyProThrlleLysP roCysProProCysLysCysProAlaProAsnLeuLeuGlyGlyProSerValPhellePhePro ProLysIleLysAspValLeuMetlleSerLeuSerProIleValThrCysValValValAspVa 25 lSerGluAspAspProAspValGlnlleSerTrpPheValAsnAsnValGluValHisThrAlaG lnThrGlnThrHisArgGluAspTyrAsnSerThrLeuArgAlaValSerAlaLeuProIleGln HisGlnAspTrpMetSerGlyLysGluPheLysCysLysValAsnAsnLysAspLeuProAlaPr olleGluArgThrlleSerLysProLysGlySerValArgAlaProGInValTyrValLeuProP roProGluGluGluMetThrLysLysGlnValThrLeuThrCysMetValThrAspPheMetPro 30 GluAspIleTyrValGluTrpThrAsnAsnGlyLysThrGluLeuAsnTyrLysAsnThrGluPr oValLeuAspSerAspGlySerTyrPheMetTyrSerLysLeuArgValGluLysLysAsnTrpV alGluArgAsnSerTyrSerCysSerValValHisGluGlyLeuHisAsnHisHisThrThrLys SerPheSerArgThrProGlyLys (SEQ ID NO:776) 35 pMON32184 .pep
AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGl uLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluL euCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAla 40 GlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAl aPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluT hrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGlu LeuGlnCysGlnProAspSerSerThrLeuGluPheLysLeuGluProArgGlyProThrlleLy sProCysProProCysLysCysProAlaProAsnLeuLeuGlyGlyProSerValPhellePheP 45 roProLysIleLysAspValLeuMetlleSerLeuSerProIleValThrCysValValValAsp ValSerGluAspAspProAspValGlnlleSerTrpPheValAsnAsnValGluValHisThrAl aGlnThrGlnThrHisArgGluAspTyrAsnSerThrLeuArgAlaValSerAlaLeuProIleG InHisGInAspTrpMetSerGIyLysGluPheLysCysLysValAsnAsnLysAspLeuProAla ProIleGluArgThrlleSerLysProLysGlySerValArgAlaProGlnValTyrValLeuPr 50 oProProGluGluGluMetThrLysLysGlnValThrLeuThrCysMetValThrAspPheMetP roGluAspIleTyrValGluTrpThrAsnAsnGlyLysThrGluLeuAsnTyrLysAsnThrGlu ProValLeuAspSerAspGlySerTyrPheMetTyrSerLysLeuArgValGluLysLysAsnTr pValGluArgAsnSerTyrSerCysSerValValHisGluGlyLeuHisAsnHisHisThrThrL ysSerPheSerArgThrProGlyLys (SEQ ID NO:777) -283 - 55 CZ 295843 B6
Stručný popis obrázků
Obrázek 1 schematicky ukazuje reorganizaci sekvence proteinu. N-konec (N) a C-konec (C) nativního proteinu jsou spojeny pomocí spojovníku nebo jsou spojeny přímo. Protein je otevřen 5 vmiste zlomu, což vytvoří nový N-konec (nový N) a nový C-konec (nový C), což vede k proteinu s novou lineární sekvencí aminokyselin. Reorganizovanou molekulu ze syntetizovat de novo jako lineární molekulu a nemusí se procházet kroky spojování původního N-konce a C-konce a otvírání proteinu v místě zlomu. io Obrázek 2 ukazuje schematicky metodu I pro vytvoření nových proteinů, ve kterých původní N-konec a C-konec nativního proteinu jsou spojeny pomocí spojovníku a vytvoří se odlišný N-konec a C-konec proteinu. V ukázaném příkladu reorganizace sekvence vede k novému genu kódujícího protein s novým N—koncem vytvořeným u aminokyseliny 97 původního proteinu. Původní C-konec (aminokyselina 174) je spojen k aminokyselině 11 (aminokyseliny 1-10 jsou 15 odstraněny) spojovací oblastí a nový C-konec se vytvoří u aminokyseliny 96 původní sekvence.
Obrázek 3 ukazuje schematicky metodu II pro vytvoření nových proteinů, ve kterých původní N-konec a C-konec nativního proteinu jsou spojeny bez spojovníku, a vytvoří se odlišný N-konec a C-konec proteinu. V ukázaném příkladu reorganizace sekvence vede k novému genu kódujícímu 20 protein s novým N-koncem vytvořeným u aminokyseliny 97 původního proteinu. Původní C-konec (aminokyselina 174) je spojen k aminokyselině 96 původní sekvence.
Obrázek 4 ukazuje schematicky metodu III pro vytvoření nových proteinů, ve kteiých původní N-konec a C-konec nativního proteinu jsou spojeny pomocí spojovníku a vytvoří se odlišný N-25 konec a C-konec proteinu. V ukázaném příkladu reorganizace sekvence vede k novému genu kódujícímu proteinu novým N-koncem vytvořeným u aminokyseliny 97 původního proteinu. Původní C-konec (aminokyselina 174) je spojen k aminokyselině 1 spojovací oblastí a nový C-konec se vytvoří u aminokyseliny 96 původní sekvence. 30 Obrázek 5 ukazuje bioaktivitu multi-funkčních agonistů receptorů obsahujících flt3 receptorové agonisty pMON32332, pMON32333, pMON32334 a pMON32335 ve srovnání s rekombinantní nativní flt3 (Genzyme) v testu proliferace MUTZ-2 buněk. MT = klamavá transfekce.
Obrázek 6 ukazuje DNA sekvenci kódující lidský zralý EPO založenou na sekvenci Lin a kol. 35 (PNAS 82: 7580-7584 (1985)).
Obrázky 7a a 7b ukazují DNA sekvenci kódující lidský nativní faktor kmenových buněk založenou na sekvenci Martin a kol. (Cell 63: 203-211, 1990). 40 Obrázek 8 ukazuje DNA sekvenci kódující rozpustný faktor kmenových buněk založenou na sekvenci Langley a kol. (Archives of Bichemistry and Biophysica 311:55-61, 1994).
Obrázky 9a a 9b ukazují DNA sekvenci kódující 209 amino kyseliny zralé formy flt3 ligandu z Lyman a kol. (Oncogene 11:1165-1172, 1995). 45
Obrázek 10 ukazuje DNA sekvenci kódující 134 amino kyselin rozpustné formy flt3 ligandu z Lyman a kol. (Oncogene 11:1165-1172, 1995). Následující příklady osvětlí vynález podrobněji. Rozumí se však, že vynález není omezen těmito 50 specifickými příklady. -284- CZ 295843 B6 Příklady provedení vynálezu 5 Příklad 1
Konstrukce parentálního BHK vektoru exprese ío A. Odstranění AflIII místa ze savčího expresního plazmidu.
Zkonstruoval se nový savčí expresní vektor, aby přijímal NcoI-HindlII nebo AflIII-HindlII genové fragmenty do čtecího rámci a zároveň 3' na hIL-3 receptorového agonistu genu pMON13146 (WO 94/12638) a myšího IgG2b spojovacího fragmentu. Nejprve se odstranilo 15 jediné AflIII místo z pMON3934, což je derivát pMON3359. pMON3359 je vektor založený na pUC18 obsahující savčí rámec exprese. Rámec obsahuje herpes simplex virový promotor IE110 (-800 to +120) následovaný modifikovanou lidskou IL-3 signální peptidovou sekvencí a pozdní SV40 poly-adenylačním (poly-A) signálem, který se subklonoval do pUC18 polyspojovníku (viz Hippenmeyer aj., Bio/Technology, 1993, strany 1037-1041). Modifikovaná lidská IL-3 signální 20 sekvence, která usnadňuje sekreci genových produktů ven z buňky, je rámovaná BamHI místem na 5' konci a jediným Ncol místem na 3' konci. Jediné HindlII místo je 3' vzhledem k Ncol místu a 5' k poly-A sekvenci. DNA sekvence kódující signál peptid je uvedena níže (místa restrikčního enzymu jsou ukázána shora). ATG (methionin) kodon uvnitř Ncol místa je ve čtecím rámci s iniciačním ATG kodonem signálního peptidu (podtrženo); 25
BamHI
5’GGATCCACCATGAGCCGCCTGCCCGTCCTGCTCCTGCTCCAACTCCTGGTCCGCCC CGCCATGG
Ncol (SEQ Π> NO:857)
Jediné AflIII místo se odstranilo z pMON3934 štěpením s AflIII, potom následovalo doplnění přesahů přidáním DNA polymerázy a nukleotidů. Odštěpený DNA fragment se čistil soupravou 30 Magie PCR Clean up (Promega) a ligoval se s T4 DNA ligázou. Ligační reakce se transformovala do DH5ta™ a buňky se daly na misky s LB-agarem a ampicillinem. Individuální kolonie se testovaly na ztrátu AflIII místa restrikční analýzou s AflIII a HindlII což vede k jedinému fragmentu, pokud se odstraní AflIII místo. Vzniklý plazmid se označil pMON30275. 35 B. Transfer rámce agonisty hIL-3 receptoru pMON13416/IgG2b do pMON30275.
NcoI-HindlII fragment (asi 425 bp) zpMON30245 se připojil k NcoI-HindlII fragmentu (asi 3800 bp) zpMON30275. pMON30245 (WO 94/12638) obsahuje gen kódující hIL-3 agonistu receptoru pMON13416 spojený k myšímu IgG2b kloubovému fragmentu. Hned vedle 3' IgG2b 40 kloubu a 5' k HindlII místu je AflIII místo. Geny se mohou klonovat do AfHH-HindlH míst jako NcoI-HindlII nebo AflIIT-Hindlfl fragmenty v rámci shIL-3 variantou pMON13416/IgG2b kloubu, aby se vytvořily nové chiméry. Ncol místo a AflIII místo mají kompatibilní přesahy a ligují se, avšak obě místa rozlišení se ztratí. Plazmid pMON30304 obsahující DNA sekvenci (SEQ ID NO:l), kódující hIL-3 variantu pMON13416 spojený smyší IgG2b pantovou oblastí 45 byl výsledkem tohoto klonování. -285- CZ 295843 B6 Příklad 2 5 Konstrukce meziplazmidu obsahujícího jednu kopii c-mpl ligandu genu (1-153) dimemí matrice
Aby se generoval plazmid DNA s kódující sekvencí c-mpl (1-153) ligandu následovaný jediným EcoRI restrikčním místem, gen se izoluje reverzní transkriptáza/polymerázovou řetězovou reakcí (RT/PCR). Lidská fetální (šarže číslo 38130) a dospělá játra (šarže číslo 46018) A+ RNA se ío získají od Clontech (Palo Alto, CA) jako zdroj c-mpl ligandu mediátorové RNA (mRNA). Prvý běh cDNA reakcí se provede pomocí cDNA Cycle™ Kit získaný od Invitrogen (San Diego, CA). V RT reakci se použijí náhodné primery a oligo dT primer, aby se vytvořila cDNA z kombinace lidské a fetální jatemí mRNA. Pro amplifikaci c-mpl ligandu fragmentu genu kódujícího aminokyseliny 1-153, slouží RT produkt jako matrice pro PCR s kombinací primerů původního 15 primeru: c~mpolNcoI (SEQ ID NO:317) a reverzního primeru: Ecompl. Primer c-mplNcoI se připojuje k c-mpl ligandovému genu (báze č. 279-311 založená na sekvenci c-mpl ligandu z Genové bank přístupové číslo L33410nebo de Sauvage aj. Nátuře 369: 533-538 (1994)) a kóduje Ncol restrikční místo enzymu bezprostředně 5' k prvému kodonu (Ser+1) c-mpl ligandu. Ncol restrikční místo enzymu kóduje kodony methioninu a alaninu před Ser+1 a zahrnuje 20 degeneraci kodonu pro Ala kodon a prvé čtyři kodony (Ser, Pro, Ala, & Pro) c-mpl ligandu Ecompl primer se připojuje k bázím #720-737 c-mpl ligandu a kóduje EcoRI místo (GAATTC) ve čtecím rámci s c-mpl ligandovým genem bezprostředně následující Arg-153. EcoRI místo tvoří Glu a Phe kodony následující Arg-153. 480 bp PCR produkt se čistil, štěpil se sNeol a EcoRI a připojil se k NcoI-EcoRI fragmentu vektoru pMON3993 (asi 4550 bp). pMON3993 byl 25 derivátem pMON3359 (popsaný v příkladu 1). Sekvence lidského IL-3 signálního peptidu, která byla subklonovaná jako BamHI fragment do jediného BamHI místa mezi IE110 promotorem a poly-A signálem, obsahuje Ncol místo ve svém 3' konci a je následovaná jediným EcoRI místem. Plazmid pMON26458 obsahující DNA sekvenci (SEQ ID NO:2) kódující aminokyseliny 1-153 c-mpl ligandu (SEQ ID NO:467) byl výsledkem tohoto klonování. 30 Příklad 3
Konstrukce parentálních plazmidů obsahujících druhé geny s dimemí matricí 35
Pro amplifikaci c-mpl ligandu fragmentů genu startujícího u aminokyseliny 1 (Ser) s terminálním kodonem následujícím aminokyselinu 153 (Arg), slouží RT reakce z příkladu 2 jako matrice pro PCR s kombinací následujících primerů; c-mplNcoI (SEQ ID NO:317) (původní primer) a c-mplHindlII (SEQ Π) NO:319) (reverzní primer). Primer c-mplNcoI (SEQ ID NO:317) je 40 popsaný v příkladu 2. Primer c-mplHindlII (SEQ ID NO:319), který se připojuje kbázím č. 716-737 c-mpl ligandu, přidává jak terminační kodon, tak HindlII místo restrikčního enzymu bezprostředně následující konečný kodon, Arg153. Z RT cDNA vzorků se vytvoří dva typy PCR produktů, jeden z delecí kodonů pro aminokyseliny 45 112-115 a jeden bez delece těchto kodonů. PCR produkty c-mpl ligandu (asi 480 bp) se naštěpí s Ncol a HindlII restrikčními enzymy pro transfer do savčího expresního vektoru pMON3934. pMON3934 se štěpí s Ncol a HindlII (asi 3800 bp) a přijme PCR produkty. Výsledkem klonování byl plazmid pMON32132 (SEQ ID NO:84), kódující aminokyseliny 1-153 50 pro c-mpl ligand (SEQ ID NO:546), plazmid pMON32134 (SEQ ID NO:86), kódující aminokyseliny 1-153 pro c-mpl ligand (SEQ ID NO:548) a plazmid, pMON32133 (SEQ ID NO:85), kódující aminokyseliny 1-153 pro c-mpl ligand s delecí kodonů 112-115 (112-115) (SEQ ID NO:547). -286- CZ 295843 B6 Příklad 4 5 Generace PCR dimemí matrice 5L s 112-115 delecemi v druhém c-mpl ligandu genu PCR matrice pro generování nových forem c-mpl ligandu se konstruuje ligací 3,7 Kbp BstXI/EcoRI fragmentu pMON26458 k 1 Kbp NcoI/BstXI fragmentu z pMON32133 (obsahující delece aminokyselin 112-115) spolu s EcoRI/AflHI 5L syntetickým oligonukleotidovým spojov-ío níkem 5L5' (SEQ ID NO:322) a 5L-3' (SEQ Π) NO:323).
EcoRI konec spojovníku se liguje s EcoRI koncem pMON26458. Aflin konec spojovníku se liguje sNeol místem pMON32133 a po ligaci se nezachová žádné restrikční místo. BstXI místa pMON26458 a pMON32133 se také ligují. Výsledkem tohoto klonování je plazmid pMON28548 15 obsahující sekvenci DNA (SEQ ID NO:3), která kóduje aminokyseliny 1-153 c-mpl ligandy připojené prostřednictvím GluPheGlyGlyAsnMet (SEQ ID NO:783) spojovníku k aminokyselinám 1-153 c-mpl ligandu, který obsahuje deleci amino-kyselin 112-115 (SEQ ED NO:468). 20 Příklad 5
Generace PCR dimémí matrice 4L 25 PCR matrice pro generování nových forem c-mpl ligandu se konstruuje ligací 3,7 Kbp BstXI/EcoRI fragmentu pMON26458 k 1 Kbp NcoI/BstXI fragmentu zpMON32132 spolu s EcoRI/AflIII 4L syntetickým oligonukleotidovým spojovníkem 4L-5' (SEQ ID NO:320) a 4L-3' (SEQ ID NO:321). 30 EcoRI konec spojovníku se liguje s EcoRI koncem pMON26458. AflIII konec spojovníku se liguje sNeol místem pMON32132 a žádné restrikční místo se po ligaci nezachová. BstXI míst pMON26458 a pMON32132 se také ligují. Výsledkem tohoto klonování je plazmid pMON28500a obsahující sekvenci DNA (SEQ Π) NO:4), která kóduje aminokyseliny 1-153 c-mpl ligandu spojené prostřednictvím GluPheGlyAsnMetAla (SEQ ID NO:223) spojovníku (4L) 35 k aminokyselinám 1-153 c-mpl ligandu (SEQ ID NO:469). Příklad 6
40 Generace PCR dimémí matrice 5L PCR matrice pro generování nových forem c-mpl ligandu se konstruuje ligací 3.7 Kbp BstXI/EcoRI fragmentu zpMON26458 k 1 Kbp NcoI/BstXI fragmentu zpMON32132 spolu s EcoRI/AflIII 5L syntetickým oligonukleotidovým spojovníkem 5L-5' (SEQ ID NO:322) a 5L-45 3' (SEQ ID NO:323).
EcoRI konec spojovníku se liguje s EcoRI koncem pMON26458. AflIII konec spojovníku se liguje sNeol místem pMON32132 a žádné restrikční místo se po ligaci nezachová. BstXI místa pMON26458 a pMON32132 se také ligují. Plazmid pMON28501 je výsledkem klonování a 50 obsahuje sekvenci DNA (SEQ Π) NO:4), která kóduje aminokyseliny 1-153 c-mpl ligandu spojené prostřednictvím GluPheGlyGlyAsnMet (SEQ ID NO:783) spojovníku (5L) k aminokyselinám 1-153 c-mpl ligandu (SEQ ID NO:470). -287- CZ 295843 B6 Příklad 7
5 Generace PCR dimémích matric 8L PCR matrice pro generování nových forem c-mpl ligandu se konstruuje ligací 3.7 Kbp BstXI/EcoRI fragmentu zpMON26458 k 1 Kbp NcoI/BstXI fragmentu zpMON32134 spolu s EcoRI/AflIII 8L syntetickým oligonukleotidovým spojovníkem 8L-5' (SEQ DD NO:324) a 8L-ío 3' (SEQ DD NO:325).
EcoRI konec spojovníku se liguje s EcoRI koncem pMON26458. AflIII konec spojovníku se liguje sNeol místem pMON32134 a žádné restrikční místo se po ligací nezachová. BstXI místa pMIN26458 a pMON32134 se také ligují. Výsledkem tohoto klonování je plazmid pMON28502 15 obsahující sekvenci DNA (SEQ ID NO:6), která kóduje aminokyseliny 1-153 c-mpl ligandu připojené prostřednictvím GluPheGlyGlyAsnGlyGIyAsnMetAla (SEQ ID NO:224) spojovníku (8L) k aminokyselinám 1-153 c-mpl ligandu (SEQ Π) NO:471). 20 Příklady 8-44
Generace nových c-mpl ligand genů s novým N-koncem a C-koncem A. PCR generace genů kódujících nové c-mpl ligandy receptorových agonistů. 25
Geny kódující nové c-mpl ligandy receptorových agonistů se generovaly pomocí metody III (Horlick aj., Prot. Eng. 5: 427-433, 1992). PCR reakce se prováděly pomocí dimémích matric pMON28500, 28501, 28502 nebo 28548 a jednoho z nastavení syntetických primerů níže. (Prvé číslo se týká polohy prvé aminokyseliny v originální sekvenci. Například 31-5' a 31-3' se 30 odvolává na 5' a 3' oligo primery pro sekvence začínající u kodonu odpovídající zbytku 31 originální sekvence). 31-5’ (SEQ ID NO:326) a 31-3’ (SEQ ID NO:327), 35-5’ (SEQ ID NO:328) a 35-3’ (SEQ ID NO:329), 39-5’ (SEQ ID NO:330) a 39-3’ (SEQ ID NO:331), 43-5’ (SEQ ID NO:332) a 43-3’ (SEQ ID NO:333), 45-5’ (SEQ ID NO:334) a 45-3* (SEQ ID NO:335), 49-5’ (SEQ ID NO:336) a 49-3’ (SEQ ID NO:337), 82-5’ (SEQ ID NO:338) and 82-3’ (SEQ ID NO:339), 109-5’ (SEQ ID NO:340) a 109-3’ (SEQ ID NO:341), 115-5’ (SEQ ID NO:342) a 115-3’ (SEQ ID NO:343), 120-5’ (SEQ ID NO:344) a 120-3’ (SEQ ID NO:345), 123-5’ (SEQ ID NO:346) a 123-3’ (SEQ ID NO:347), 126-5’ (SEQ ID NO;348) a 126-3’ (SEQ ID NO:349). 35 Matrice a oligonukleotidové sekvence užívané v PCR reakcích jsou uvedeny v tabulce 4. Produkty, které se vytvořily, byly dlouhé asi 480 bp a čistily se pomocí Magie PCR Clean up kits (Pr omega). B. Subklonování nových genových produktů c-mpl receptorových agonistů do savčího vektoru 40 exprese pro generaci chimér.
PCR produkty c-mpl receptorových agonistů genu se štěpí Ncol a HindlII nebo AflIII a HindlII restrikčními enzymy (asi 470 bp) pro transfer do savčího vektoru exprese. Vektor exprese pMON30304 se štěpí Ncol a HindlII (asi 4200 bp) a přijímá PCR produkty jako NcoI-HindlII -288- CZ 295843 B6 nebo AflIII-HindlII fragmenty. Restrikční štěpy PCR produktu a vzniklé plazmidy jsou uvedeny v tabulce 4. 5 Tabulka 4 PCR PCR ! Spojovník Vzniklý Místo zlomu Přiklad L PCR templář Produkt Primer Produkt Restrikční štěpení plazmid pMON v c-mpl ligandu Přiklad 8 pMON28501 31 Ncol/Hindlíl 5L 28505 30-31 Příklad 9 PMON28501 35 AflDI/HindlJI 5L 28506 34-35 Příklad 10 pMON28501 39 Ncol/Hindlíl 5L 28507 38-39 Přikladli pMON28501 43 Ncol/Hindlíl 5L 28508 42-43 Příklad 12 pMON28501 45 NcoI/HíndlU 5L 28509 44-45 Přiklad 13 pMON28501 49 Ncol/Hindlíl 5L 28510 48-49 Přiklad 14 PMON28501 82 Ncol/Hindffl 5L 28511 81-82 Příklad 15 pMON28501 109 Ncol/Hindlíl 5L 28512 108-109 Příklad 16 pMON28501 116 Ncol/Hindm 5L 28513 115-116 Příklad 17 pMON28501 120 Ncol/HindUI 5L 28514 119-120 Příklad 18 pMON2850l 123 Ncol/Hindlíl 5L 28515 122-123 Příklad 19 pMON28501 126 Ncol/Hindlíl 5L 28516 125-126 Příklad 20 pMON28500 31 Ncol/Hindlíl 4L 28519 30-31 Příklad 21 pMON28500 35 AflíII/HindlII 4L 28520 34-35 Příklad 22 pMON28500 39 NcoI/HindTII 4L 28521 38-39 Příklad 23 pMON28500 43 Ncol/Hindlíl 4L 28522 42-43 Příklad 24 pMON28500 45 Ncol/Hindm 4L 28523 44-45 Příklad 25 pMON28500 49 Ncol/HindUI 4L 28524 48-49 Příklad 26 pMON28500 82 Ncol/H indlll 4L 28525 81-82 Příklad 27 ΡΜΟΝ28500 109 NcoI/HindlU 4L 28526 108-109 Příklad 28 pMON28500 116 Ncol/Hindffl 4L 28527 115-116 Příklad 29 pMON28500 120 Ncol/Hindlíl 4L 28528 119-120 Příklad 30 pMON28500 123 Ncol/Hindlíl 4L 28529 122-123 Příklad 31 pMON28500 126 Ncol/Hindffl 4L 28530 125-126 -289- CZ 295843 B6
Tabulka 4 (pokračování) PCR PCR Spojovník Vzniklý (Místo zlomu Příklad č. PCR templát Produkt Produkt plazmid v c-mpl lígandu Primer Restrikční pMON štěpení Příklad 32 pMON28502 31 NcoI/HindíII 8L 28533 30-31 Příklad 33 pMON28502 35 Aíím/Hindlll 8L 28534 34-35 Příklad 34 pMON28502 39 NcoI/HindíII 8L 28535 38-39 Příklad 35 pMON28502 43 Ncol/HindlII 8L 28536 42-43 Příklad 3 6 pMON28502 45 NcoI/HindíII 8L 28537 44-45 Příklad 37 pMON28502 49 Ncoí/Hindffl 8L 28538 48-49 Příklad 38 pMON28502 82 NcoI/HindíII 8L 28539 81-82 Příklad 39 pMON28502 109 Ncol/Hindm 8L 28540 108-109 Příklad 40 pMOH28502 116 NcoI/HindíII 8L 28541 115-116 Příklad 41 pMON28502 120 Ncol/Hindin 8L 28542 119-120 Příklad 42 pMON28502 123 NcoI/HindíII 8L 28543 122-123 Příklad 43 pMON28502 126 NcoI/HindíII 8L 28544 125-126 Příklad 44 pMON28548 123 NcoFHindlII 5L 28545 122-123 Příklad 45 io Konstrukce pMON 15960
Konstrukce pMON15960 meziplazmidu použitého pro konstruování plazmidů obsahujících sekvence DNA kódující G-CSF Ser17 snovým N-koncem a C-koncem. Plazmid pACAC177 (Chang, A.C.Y. a Cohen, S.N. J. Bacteriol. 134: 1141-1156, 1978) DNA se štěpí restrikčními 15 enzymy HindlII a BamHI, což vede kHindlII, BamHI fragmentu o velikosti 3092 páru bází. Plazmidová pMON13037 (WO 95/21254) DNA se štěpí BglII a FspI, což vede kBglII, FspI fragmentu s 616 páry bází. Druhý vzorek plazmidů pMON13037 DNA se štěpí s Ncol a HindlII, což vedlo kNeol, HidlII fragmentu s 556 páry bází. Syntetické DNA oligonukleotidy lGGGS“for“ (SEQ ID NO:380) a lGGGS“rev“ (SEQ ID NO:381) vzájemně hybridizují a pak se 20 štěpí AflIII a FspI, což vede kAflIII, FspI fragmentu s 21 páry bází. Restrikční fragmenty se ligují a ligační reakční směs se použije k transformování E. coli K-12 kmen JM101. Transformované baktérie se selektují na ampicillin-obsahujících miskách. Plazmid DNA se vyizoluje a analyzuje restrikční analýzou, aby se potvrdil správný inzert. -290- CZ 295843 B6 Příklad 46
Konstrukce pMON 15981 5 Konstrukce pMON15981 plazmidu obsahující sekvence DNA kódující multi-funkční hemato-poietické receptorové agonisty. Plazmidová pMON 15960 DNA se štěpí restrikčním enzymem Smál a použije se jako matrice v PCR reakci pomocí syntetických DNA oligonukleotidů 38 stop (SEQ ID NO:369) a 39 start (SEQ ID NO:368) jako primem, což vede k amplifikaci DNA fragmentu o délce 576 párů bází. Amplifikovaný fragment se štěpí restrikčními enzymy HindlII a io Ncol, což vede k HindlII, Ncol fragmentu o délce 558 párů bází. Plazmidová pMON13181 DNA se štěpí HindlII a AflIII, což vede k HindlII, AflIII fragmentu s 4068 páry bází. Restrikční fragmenty se ligují a ligační reakční směs se použije k transformaci E. coli K-12 kmen JM101. Transformované baktérie se selektují na ampicillin-obsahujících miskách. Plazmid DNA se vyizoluje, analyzuje restrikční analýzou a sekvenuje, aby se potvrdilo správné vložení. Plazmid, 15 pMON15981, obsahuje sekvenci DNA (SEQ ID NO:78), která kóduje následující sekvence aminokyselin:
MetAlaAsnCysScrlleMetlIeAspGlullelleHisHÍsLeuLysArgProProAla
ProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsn
LeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAJaSer
GlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaPro
SerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGIuLysLeuThr
PheT yrLeu V alThrLeuGluGlnAlaGlnGIuGlnGlnT yrValGl uGlyGlyGlyGly
SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGlu
SerHisLysSerProAsnMetAlaTyrLysLeuCysHisProGluGluLeuValLeuLeu
GlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGln
LeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGln
AlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGJnLeuAspVal
AlaAspPheAIaThrThrUeTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeu
GlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGly
ValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHis
LeuAlaGlnProGlyGlyGlySerAspMetAlaThrProLeuGlyProAlaSerSerLeu
ProGlnSerPheLeuLeuLysSerLeuGluGlttValArgLysIleGlnGlyAspGlyAla
AlaLeuGlnGluLysLeuCysAlaThr (SEQ ID NO:500) -291 - 20 CZ 295843 B6 Příklad 47 5 Konstrukce pMON 15982
Konstrukce pMON15982, plazmidu obsahující sekvence DNA kódující multi-funkční hemato-poietické receptorové agonisty. Plazmidová pMON15960 DNA se štěpí restrikěním enzymem Smál a použije se jako matrice v PCR reakci pomocí syntetických DNA oligonukleotidů 96 stop 10 (SEQ ID NO:371) a 97 start (SEQ ID NO:370) jako primerů, což vede kamplifíkaci DNA fragmentu s 576 páry bází. Amplifikovaný fragment se štěpí restrikčními enzymy HindlII a Ncol, což vede kHindlII, Ncol fragmentu s 558 páry bází. Plazmid, pMON13181, DNA se štěpí HindlII a AflIII, což vede k HindlII, AflIII fragmentu s 4068 páry bází. Restrikční fragmenty se ligují a ligační reakční směs se použije pro transformaci E. coli K-12 kmenu JM101. Transfor-15 mované baktérie se selektují na ampicillin-obsahujících miskách. Plazmid DNA se vyizoluje, analyzuje se restrikční analýzou a sekvenuje, aby se potvrdilo správné vložení. Plazmid pMON 15982 obsahuje sekvenci DNA (SEQ ID NO:79), která kóduje následující sekvence aminokyselin:
MetAlaAsnCysSerlleMetlleAspGhillelleHísHisLeuLysArgProProAla
ProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsn
LeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSer
GlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaPro
SerArgHIsProílellelleLysAIaGlyAspTrpGlnGluPheArgGluLysLeuThr
PheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGty
SerProGlyGIuProSerGlyProIleSerThrlleAsnProSerProProSerLysGlu
SerHisLysSerProAsnMetAlaProGluLeuGlyProThrLeuAspThrLeuGlnLeu
AspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMctAiaPro
AlaLeuGlnProThrGInGlyAlaMetProAIaPheAlaSerAlaPheGlnArgArgAIa
GlyGlyValLeuValAlaSerHisLeuGlnSerPlieLeuGIuValSerTyrArgValLeu
ArgHisLeuAlaGInProGlyGlyGlySerAspMetAlaThrProLeuGlyProAlaSer
SerLeuProGlnSerPheLeuLeuLysSerLeuGluGJnValArgLysIleGlnGlyAsp
GlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGiuGluLeu
ValLeuLeuGlyHisSerLeuGlylIeProTrpAlaProLeuSerSerCysProSerGln
AlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGly
LeuLeuGlnAlaLeuGluGlyfleSer (SEQ ID NO:50l) -292- CZ 295843 B6 Příklad 48
Konstrukce pMON 15965 5 Konstrukce pMON15965 plazmidu obsahujícího sekvence DNA kódující multi-funkční hemato-poietické receptorové agonisty. Plazmidová pMON 15960 DNA se štěpí restrikčním enzymem Smál a použije se jako matrice v PCR reakci pomocí syntetických DNA oligonukleotidů 142 stop (SEQ ID NO:377) a 141 start (SEQ ID NO:376) jako primem, což vede kamplifřkaci DNA fragmentu s 576 páry bází. Amplifikovaný fragment se štěpí restrikčními enzymy HindlII a Ncol, 10 což vede k HindlII, Ncol fragmentu s 558 páry bází. Plazmid, pMON13181 se štěpí HindlII a AflIII, což vede k HindlII, AflIII fragmentu s 4068 páry bází. Restrikční fragmenty se ligují a ligační reakční směs se použije pro transformaci E. coli K-12 kmenu JM101. Transformované baktérie se selektují na ampicillin-obsahujících miskách. Plazmidová DNA se vyizoluje, analyzuje se restrikční analýzou a sekvenuje se, aby se potvrdilo správné vložení. Plazmid 15 pMON15965 obsahuje sekvenci DNA (SEQ ID NO:80), která kóduje následující sekvence aminokyselin:
MetAlaAsnCysSerlleMetIleAspGluIIelleHisHisLeuLysArgProProAla
ProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlIeLeuMetAspArgAsn
LeuArgLeuProAsnLeuGluSerPheValArgAIaValLysAsnLeuGIuAsnAlaSer
GlylleGluAlalIeLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaPro
SerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThr
Ph eT yrLeuV al ThrLeuGluGlnAlaGl nG 1 uGlnGlnT yrV alGluGlyGlyGl yG ly
SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGIu
SerHisLysSerProAsnMetAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuVal
AlaSerH isLeuGlnSerPheLeuGIuV alSerT yrArgV alLeu ArgH isLeuAlaGln
ProGlyGlyGlySerAspMetAlaThrProLeuGiyProAlaSerSerLeuProGlnSer
PheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGln
GluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHis
SerLeuGlylleProTrpAIaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAla
GlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeu
GluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAsp
PheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnPro
ThrGlnGlyAlaMetProAlaPheAla (SEQ ID NO:502) -293 - CZ 295843 B6 Příklad 49
Konstrukce pMON 15966 5 Konstrukce pMON 15966, plazmidu obsahujícího sekvence DNA kódující multi-funkční hemato-poietické receptorové agonisty. DNA plazmidu pMON 15960 se štěpila restrikčním enzymem Smál a použije se jako matrice v PCR reakci pomocí syntetických DNA oligonukleotidů 126 stop (SEQ ID NO:372) a 125 start (SEQ ID NO:373) jako primerů, což vede kamplifíkaci DNA fragmentu s 576 páry bází. Amplifikovaný fragment se štěpí restrikčními enzymy HindlII a Ncol, ío což vede k HindlII, Ncol fragmentu s 558 páry bází. DNA plazmidu pMON13181 se štěpí HindlII a AflIII, což vede k HindlII, AflIII fragmentu s 4068 páry bází. Restrikční fragmenty se ligují a ligační reakční směs se použije pro transformaci E. coli K-12 kmenu JM101. Transformované baktérie se selektují na ampicillin-obsahujících miskách. Plazmid DNA se vyizoluje, analyzuje restrikční analýzou a sekvenuje, aby se potvrdilo správné vložení. Plazmid 15 pMON15966 obsahuje sekvenci DNA (SEQ ID NO:81), která kóduje následující sekvence aminokyselin:
MetAlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAla
ProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsn
LeuArgLeuProAsnLeuGIuSerPheValArgAIaValLysAsnLeuGluAsnAlaSer
GlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaPro
SerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGIuLysLeuThr
PheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly
SerProGlyGluProSerGIyProIleSerThrlleAsnProSerProProSerLysGlu
SerHisLysSerProAsnMetAlaMetAlaProAlaLeuGlnProThrGlnGlyAlaMet
ProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeu
GlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProGlyGlyGIy
SerAspMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeiiLys
SerLeuGluGlnValArgLysHeGlnGlyAspGlyAlaAlaLeuGlnGIuLysLeuCys
AlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGIyHisSerLeuGlylle
ProTrpAlaProLeuSerSerCysProSerGinAlaLeuGlnLeuAlaGlyCysLeuSer
GlnLeuHisSerGlyLeuPheLeuTyrGInGlyLeuLeuGlnAlaLeuGluGlylIeSer
ProGluLeuGlyProThrlLeuAspThrLeuGlnLeuAspValAlaAspPheAJaThrThr
IleTrpGlnGlnMetGluGluLeuGly (SEQ ID NO:503) -294- 5 CZ 295843 B6 Příklad 50
Konstrukce pMON 15967
Konstrukce pMON 15967 plazmidu obsahujícího DNA sekvence kódující multi-funkční hemato-poietické receptorové agonisty. Plazmidová DNA pMON 15960 se štěpí restrikčním enzymem Smál a použije se jako matrice v PCR reakci pomocí syntetických DNA oligonukleotidů 132 stop (SEQ ID NO:375) a 133 start (SEQ ID NO:374) jako primerů, což vede kamplifikaci DNA ío fragmentu s 576 páry bází. Amplifikovaný fragment se štěpí restrikčními enzymy HindlII a Ncol, což vede k HindlII, Ncol fragmentu s 558 páry bází. DNA plazmidu pMON13181 se štěpí HindlII a AflIII, což vede k HindlII, AflIII fragmentu s 4068 páry bází. Restrikční fragmenty se ligují a ligační reakční směs se použije k transformaci E. coli K-12 kmenu JM101. Transformované baktérie se selektovaly na ampicillin-obsahujících miskách. Plazmid DNA se vyizoluje, 15 analyzuje restrikční analýzou a sekvenuje, aby se potvrdilo správné vložení. Plazmid pMON15967 obsahuje sekvenci DNA (SEQ ID NO:82), která kóduje následující sekvenci aminokyselin:
MetAlaAsnCysSeríleMetíleAspGluIlelleHisHisl^euLysArgProProAla
ProLeuLeuAspProAsnAsrtLeuAsnAspGluAspValSerlleLeuMetAspArgAsn
LeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSer
GlylleGluAIalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaPro
SerArgHisProIlellelleLysAIaGIyAspTrpGlnGluPheArgGluLysLeuThr
PheTyrLeuValThrLeuGluGlnAlaGlnGIuGlnGlnTyrValGluGIyGlyGlyGly
SerProGlyGluProSerGlyProIleSerTTtrlleAsnProSerProProSerLysGlu
SerHisLysSerProAsnMetAIaThrGlnGlyAlaMetProAlaPheAlaSerAlaPhe
GlnArgArgAlaGlyGlyValLeuValAlaSefHisLeuGlnSerPheLeuGluValSer
TyrArgValLeuArgHisLeuAlaGInProGlyGlyGlySerAspMetAlaThrProLeu
GlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLys
IleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHis
ProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSer
CysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPhe
AspThrLeuGlnLeuAspValAlaAspPheAlaThtThrlleTrpGlnGInMetGluGlu LeuGlyMetAlaProAlaLeuGlnPro SEQ ID NO:504 -295- CZ 295843 B6 Příklad 51
Konstrukce pMON13180 meziplazmidu použitého pro konstruování plazmidů, které obsahují 5 sekvence DNA kódující multi-funkční hematopoietické receptorové agonisty DNA plazmidů pMON13046 (WO 95/21254) se štěpí restrikčními endonukleázami Xmal a SnaBI, což vede ke vzniku vektorového fragmentu s 4018 páry bází. Xmal-SnaBI fragment s 4018 páry bází se čistí pomocí Magie DNA Clean-up System kit (Promega, Madison, WI), ve ío kterém se Xmal-SnaBI vložený fragment i s 25 páry bází nezachová. Z komplementárního páru syntetických oligonukleotidů, glyxal (SEQ ID NO:378) a glyxa2 (SEQ ID NO:379), se záměrně odstraní sekvence kódující štěpné místo faktoru Xa. Když jsou správně sestaveny, tyto oligo-nukleotidy také vedou kXmal a SnaBI koncům. Primery, Glyxal a glyxa2, se připojují ve spouštěcím pufru (20 mmol Tris-HCl pH 7,5, 10 mmol mgC12, 50 mmol NaCl) zahříváním při 15 70 °C po deset minut a nechají se pomalu ochladit. Xmal-SnaBI fragment s 4018 páry bází zpMON13046 se liguje se sestavenými oligonukleotidy pomocí T4 DNA ligázy (Boehringe Mannheim, Indianopolis, IN). Část ligační reakční směsi se použije k transformování E. coli kmene DH5a buněk (Life Technologies, Gaithersburg, MD). Transformované baktérie se selektují na ampicillin-obsahujících miskách. Plazmidová DNA izolovaná z transformantů se 20 analyzuje pomocí testu založeného na PCR. Plazmidová DNA ze selektovaných transformantů se sekvenuje, aby se potvrdilo správné vložení oligonukleotidů. Vzniklý plazmid se označí pMON13180 (SEQ ID NO:88). 25 Příklad 52
Konstrukce pMON13181 meziplazmidu použitého pro konstruování plazmidů, které obsahují sekvence DNA kódující multi-funkční hematopoietické receptorové agonisty 30 DNA plazmidů pMON13047 (WO 95/21254) se štěpí restrikčními endonukleázami Xmal a SnaBI, což vede ke vzniku vektorového fragmentu s 4063 páry bází. Xmal-SnaBI fragment s 4063 páry bází se čistí pomocí Magie DNA Clean-up System kit (Promega, Madison, WI), ve kterém se Xmal-SnaBI vsunutý fragment s 25 páry bází nezachová. Z komplementárního páru syntetických oligonukleotidů, glyxal (SEQ ID NO:378) a glyxa2 (SEQ ID NO:379) se záměrně 35 odstraní sekvence kódující štěpné místo faktoru Xa. Když jsou správně sestaveny, tyto oligonukleotidy také vedou ke Xmal a SnaBI koncům. Glyxal a glyxa2 se rekombinují v rekombi-načním pufru zahříváním při 70 °C po deset minut a nechají se pomalu ochladit. Xmal-SnaBI fragment s 4063 páry bází zpMON13046 se liguje se sestavenými oligonukleotidy pomocí T4 DNA ligázy (Boehringer Mannheim, Indianapolis, IN). Část ligační reakční směsi se použije 40 k transformování E. coli kmene DH5a buněk (Life Technologied, Gaithersburg, MD). Transformované baktérie se selektovaly na ampicillin-obsahujících miskách. Plazmid DNA vyizolovaný z transformantů se analyzuje pomocí testu založeného na PCR. Plazmidová DNA ze selektovaných transformantů se sekvenuje, aby se potvrdilo správné vložení oligonukleotidů. Vzniklý plazmid se označí pMON13181 (SEQ ID NO:87). 45 Příklad 53
Konstrukce pMON 13182 50
Nový N-konec/C-konec genu vpMON13182 se vytvoří pomocí metody I jak se popisuje v kapitole Materiály a metody. Fragment Start se vytvoří a amplifíkuje se z G-CSF Ser17 sekvence vpMON13037 pomocí nastavení primerů, 39 start (SEQ ID NO:368) a L—11 start (SEQ ID NO:364). Fragment Stop se vytvoří a amplifíkuje se z G-CSF Ser17 sekvence 55 vpMON13037 pomocí nastavení primerů 38 stop (SEQ ID NO:369) a L—11 stop (SEQ ID -296- CZ 295843 B6 NO:365). Plná délka nového N-konec/C-konec G-CSF Ser17 genu se vytvoří a amplifikuje se z připojených fragmentů Start a Stop pomocí primerů 39 start a 38 stop. Výsledný DNA fragment, který obsahuje nový gen, se štěpí restrikčními endonukleázami Ncol a 5 HindlII a čistí se pomocí Magie DNA Clean-up System kit (Promega, Madison, WI). Meziplazmid, pMON13180, se štěpí restrikčními endonukleázami HindlII a AflIII, což vede ke vzniku vektorového fragmentu s 4023 páry bází, a čistí se pomocí Magie DNA Clean-up System kit (Promega, Madison, WI). Vyčištěné restrikční fragmenty se kombinují a ligují pomocí T4 DNA ligázy (Boehringer Mannheim, Indianapolis, IN). Část ligační reakční směsi se použije ío k transformování buněk E. coli kmene DH5a (Life Technologies, Gaithersburg, MD). Transformované baktérie se selektují na ampicillin-obsahujících miskách. Plazmidová DNA se vyizoluje a sekvenuje, aby se potvrdilo správné vložení. Výsledný plazmid se označí pMON13182. E. coli kmen JMI01 se transformuje spMON13182 k expresi proteinu a izolaci proteinu 15 z inkluzních částic.
Plazmid pMON13182 obsahuje sekvenci DNA (SEQ ID NO: 17), která kóduje následující sekvence aminokyselin:
Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Vat Ala Asp Phe Ala Thr Thr Ile >n Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro -297- CZ 295843 B6
Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys lle Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr (SEQ ID NO:472) Příklad 54 5
Konstrukce pMON 13183
Nový N-konec/C-konec genu vpMON13183 se vytvořil pomocí metody I, jak je popsáno v kapitole Materiály a metody. „Fragment Start“ se vytvoří a amplifikuje se z G-CSF Ser17 ío sekvence vpMON13037 pomocí nastavení primerů, 39 start (SEQ ID NO:368) a L—11 start (SED ID NO:364). Fragment Stop se vytvoří a amplifikuje se z G-CSF Ser17 sekvence vpMON13037 pomocí nastavení primerů 38 stop (SEQ ID NO:369) a L-ll stop (SEQ ID NO:365). Plná délka nového N-konec/C-konec G-CSF Ser17 genu se vytvoří a amplifikuje z připojených fragmentů Start a Stop pomocí 39 start a 38 stop. 15 Výsledný DNA fragment, který obsahuje nový gen, se štěpí restrikčními endonukleázami Ncol a HindlII a čistí se pomocí Magie DNA Clean-up System Kit (Promega, Madison, WI). Meziplazmid pMON13181 se štěpí restrikčními endonukleázami HindlII a AflIII, což vede ke vzniku vektorového fragmentu s 4068 páry bází. Ten se čistí pomocí Magie DNA Clean-up 20 System kit (Promega, Madison, WI). Vyčištěné restrikční fragmenty se smíchají a ligují pomocí T4 DNA ligázy (Boehringer Mannheim, Indianapolis, IN). Část ligační reakční směsi se použije k transformování buněk E. coli kmene DH5a (Life Technologies, Gaithersburg, MD). Transformované baktérie se selektují na ampicillin-obsahujících miskách. Plazmidová DNA se vyizoluje a sekvenuje, aby se potvrdilo správné vložení. Výsledný plazmid se označí pMON13183. 25 E. coli kmen JM101 se transformuje spMON13183 k expresi proteinu a izolaci proteinu z inkluzních částic.
Plazmid pMON13183 obsahuje sekvenci DNA (SEQ ID NO: 18), která kóduje následující 30 sekvenci aminokyselin:
Asm Cys Ser lle Met lle Asp Glu lle lle His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser lle Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly lle Glu Ala lle Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr -298 - CZ 295843 B6
Ala Ala Pro Ser Arg His Pro Ile Ile Ue Lys Ala Gly Asp Trp
Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro
Gly Glu Pro Ser Gly Pro ile Ser Thr Ile Asn Pro Ser Pro Pro
Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Tyr Lys Leu Cys
His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro
Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala
Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly
Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr
Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile
Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro
Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg
Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu
Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly
Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val
Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys
Ala Thr (SEQ ID NO:473) 5 Příklad 55
Konstrukce pMON 13184
Nový N-konec/C-konec genu vpMON13184 se vytvoří pomocí metody I, jak se popisuje 10 v kapitole Materiály a metody. Fragment Start se vytvoří a amplifíkuje se z G-CSF Ser17 sekvence pMON13037 pomocí nastavení primerů, 97 start (SEQ ID NO:370) a L-l 1 start (SEQ ID NO:364). Fragment Stop se vytvoří a amplifíkuje se z G-CSF Ser17 sekvence v pMON13037 pomocí nastavení primerů 96 stop (SEQ ID NO:371) a L-l 1 stop (SEQ ID NO:365). Vytvořila se plná délka nového N-konec/C-konec G-CSF Ser17 genu a amplifíkovala se z připojených ís fragmentů Start a Stop pomocí 97 start a 96 stop. Výsledný DNA fragment, obsahující nový gen, se štěpí restrikčními endonukleázami Ncol a HindlII a vyčistí se pomocí Magie DNA Clean-up System kit (Promega, Madison WI). Meziplazmid pMON 13180 se štěpí restrikčními endonukleázami HindlII a AflIII, což vedlo ke 20 vzniku vektorového fragmentu s 4023 páry bází. Ten se vyčistí pomocí Magie DNA Clean-up System kit (Promega, Madison, WI). Vyčištěné restrikční fragmenty se smíchají a ligují pomocí -299- CZ 295843 B6 T4 DNA ligázy (Boehringer Mannheim, Indianapolis, IN). Část ligační reakční směsi se použije k transformování buněk E. coli kmene DH5a (Life Technologies, Gaithersburg, MD). Transformované baktérie se selektují na ampicillin-obsahujících miskách. Plazmid DNA se vyizoluje a sekvenuje, aby se potvrdilo správné vložení. Výsledný plazmid se označí pMON13184. 5 E. coli kmen JMI01 se transformuje spMON13184 k expresi proteinu a izolaci proteinu z inkluzních částic.
Plazmid, pMON13184, obsahuje sekvenci DNA (SEQ ID NO: 19), která kóduje následující 10 sekvenci aminokyselin:
Asn Cys Ser Ile Met tle Asp Glu tle Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tip Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys
Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Tip Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser (SEQ 1D NO:474) -300- CZ 295843 B6 Příklad 56 5 Konstrukce pMON 13185
Nový N-konec/C-konec genu vpMON13185 se vytvoří pomocí metody I, jak se popisuje v kapitole Materiály a metody. Fragment Start se vytvoří a amplifíkuje se z G-CSF Ser17 sekvence v pMON13037 pomocí nastavení primerů 97 start (SEQ ID NO:370) a L-l 1 start (SEQ 10 ID NO:364). Fragment Stop se vytvoří a amplifíkuje se z G-CSF Ser17 sekvence v pMON13037 pomocí nastavení primerů 96 stop (SEQ ID NO.371) a L-l 1 stop (SEQ ID NO:365). Plná délka nového N-konec/C-konec G-CSF Ser 17 genu se vytvoří a amplifíkuje se z připojených fragmentů Start a Stop pomocí 97 start a 96 stop. 15 Výsledný DNA fragment, který obsahuje nový gen, se štěpí restrikčními endonukleázami Ncol a HindlII a vyčistí se pomocí Magie DNA Clean-up System kit (Promega, Madison, WI). Meziplazmid, pMON13181, se štěpí restrikčními endonukleázami HindlII a AflIII, což vedle ke vzniku vektorového fragmentu s 4068 páry bází. Ten se čistí pomocí Magie DNA Clean-up System kit (Promega, Madison, WI). Vyčištěné restrikční fragmenty se smíchají a ligují pomocí 20 T4 DNÁ ligázy (Boehringer, Mannheim, Indianapolis, In). Část ligační reakční směsi se použije k transformování buněk E. coli kmene DH5ot (Life Technologie, Gaithersburg, MD). Transformované baktérie se selektují na ampicillin-obsahujících miskách. Plazmid DNA se vyizoluje a sekvenuje, aby se potvrdilo správné vložení. Výsledný plazmid se označí pMON13185. 25 E. coli kmen JMI01 se transformuje spMON13185 k expresi proteinu a izolaci proteinu z inkluzních částic.
Plazmid, pMON13185, obsahuje sekvenci DNA (SEQ ID NO:20), která kóduje následující sekvenci aminokyselin: 30
Asn Cys Ser Ile Met Ile Asp Glu Ile IJe His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Pro Glu Leu Gly -301 - CZ 295843 B6
Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser (SEQ ID NO:475) Příklad 57 5
Konstrukce pMON 13186
Nový N-konec/C-konec genu vpMON13186 se vytvoří pomocí metody 1, jak se popisuje v kapitole Materiály a metody. Fragment Start se vytvoří a amplifíkuje se z G-CSF Ser17 io sekvence vpMON13037 pomocí nastavení primerů 126 start (SEQ ID NO:372) a L—11 start (SEQ ID NO:364). Fragment Stop se vytvoří a amplifíkuje se z G-CSF Ser17 sekvence vpMON13037 pomocí nastavení primerů 125 stop (SEQ ID NO:373) a L-ll stop (SEQ ID NO:365). Plná délka nového N-konec/C-konec G-CSF Ser17 genu se vytvoří a amplifíkuje se z připojených fragmentů Start a Stop pomocí 126 start a 125 stop. 15 Výsledný DNA fragment, který obsahuje nový gen, se štěpí restrikčními endonukleázami Ncol a HindlII a vyčistí se pomocí Magie DNA Clean-up System kit (Promega, Madison, WI). Meziplazmid, pMON13180, se štěpí restrikčními endonukleázami HindlII a AflIII, což vede ke vzniku vektorového fragmentu s 4023 páry bází. Ten se čistí pomocí Magie DNA Clean-up 20 System kitu (Promega, Madikson, WI). Vyčištěné restrikční fragmenty se smíchají a ligují pomocí T4 DNA ligázy (Boehringer Mannheim, Indianapolis, IN). Část ligační reakční směsi se použije k transformování buněk E. coli kmene DH5a (Life Technologies, Gaithersburg, MD). Transformované baktérie se selektují na ampicillin-obsahujících miskách. Plazmid DNA se vyizoluje a sekvenuje, aby se potvrdilo správné vložení. Výsledný plazmid se označí 25 pMON13186. E. coli kmen JM101 se transformuje spMON13186 k expresi proteinu a izolaci proteinu z inkluzních částic. -302- CZ 295843 B6
Plazmid, pMON13186, obsahuje sekvenci DNA (SEQ ID NO:21), která kóduje následující sekvence aminokyselin:
Asn Cys Ser Ile Met Ue Asp Glu Ile Tle His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Vat Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser
Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu
Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly (SEQ ID NO:47ó) Příklad 58 10 Konstrukce pMON13187
Nový N-konec/C-konec genu vpMON13187 se vytvoří pomocí metody I, jak se popisuje v kapitole Materiály a metody. Fragment Start se vytvoří a amplifikuje se z G-CSF Ser17 -303 - CZ 295843 B6 sekvence vpMON13037 pomocí nastavení primerů 126 start (SEQ ID NO:372) a L-ll start (SEQ ID NO:364). Fragment Stop se vytvoří a amplifíkuje se z G-CSF Ser17 sekvence vpMON13037 pomocí nastavení primerů 125 stop (SEQ ID NO:373) a L-ll stop (SEQ ID NO:365). Plná délka nového N-konec/C-konec G-CSF Ser17 genu se vytvoří a amplifíkuje se 5 z připojených fragmentů Start a Stop pomocí 126 start a 125 stop. Výsledný DNA fragment, který obsahuje nový gen, se štěpí restrikčními endonukleázami Ncol a HindlII a čistí se pomocí Magie DNA Clean-up System kit (Promega, Madison, WI). Mezi-plazmid, pMON 13181, se štěpí restrikčními endonukleázami HindlII a AflIII, což vede ke vzniku ío vektorového fragmentu s 4068 páry bází. Ten se čistí pomocí Magie DNA Clean-up System kitu (Promega, Madison, WI). Vyčištěné restrikční fragmenty se kombinují a ligují pomocí T4 DNA ligázy (Boehringer Mannheim, Indianapolis, IN). Část ligační reakční směsi se použije k transformování buněk E. coli kmene DH5a (Life Technologies, Gaithersburg, MD). Transformované baktérie se selektují na ampicillin-obsahujících miskách. Plazmid DNA se vyizoluje a sekvenuje, 15 aby se potvrdilo správné vložení. Výsledný plazmid se označí pMON13187. E. coli kmen JMI01 se transformuje spMON13187 k expresi proteinu a izolaci proteinu z inkluzních částic. 20 Plazmid, pMON13187, obsahuje sekvenci DNA (SEQ ID NO:22), která kóduje následující sekvenci aminokyselin:
Asn Cys Ser íle Met Ile Asp Ghi Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser
Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu
Glu Gin Va! Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu -304- CZ 295843 B6
Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Gíu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Tip Gin Gin Met Glu Glu Leu Gly (SEQ ID NO:477) Příklad 59 5
Konstrukce pMON 13188
Nový N-konec/C-konec genu vpMON13188 se vytvoří pomocí metody I, jak se popisuje v kapitole Materiály a metody. Fragment Start se vytvoří a amplifikuje se z G-CSF Ser17 io sekvence vpMON13037 pomocí nastavení primerů 133 start (SEQ ID NO:374) a L—11 start (SEQ ID NO:364). Fragment Stop se vytvoří a amplifikuje se z G-CSF Ser17 sekvence vpMON13037 pomocí nastavení primerů 132 stop (SEQ ID NO:375) a L—11 stop (SEQ ID NO:365). Plná délka nového N-konec/C-konec G-CSF Ser17 genu se vytvoří a amplifikuje se z připojených fragmentů Start a Stop pomocí 133 start a 132 stop. 15 Výsledný DNA fragment, který obsahuje nový gen, se štěpí restrikčními endonukleázami Ncol a HindlII a čistí se pomocí Magie DNA Clean-up System kitu (Promega, Madison, WI). Meziplazmid, pMON13180, se štěpí restrikčními endonukleázami HindlII a Afllll, což vede ke vzniku vektorového fragmentu s 4023 páry bází. Ten se čistí pomocí Magie DNA Clean-up 20 System kitu (Promega, Madison, WI). Vyčištěné restrikční fragmenty se smíchají a ligují pomocí T4 DNA ligázy (Boehringer Mannheim, Indianapolis, IN). Část ligační reakční směsi se použije k transformování buněk E. coli kmene DH5a (Life Technologies, Gaithersburg, MD). Transformované baktérie se selektují na ampicillin-obsahujících miskách. Plazmid DNA se vyizoluje a sekvenuje, aby se potvrdilo správné vložení. Výsledný plazmid se označí pMON13188. 25 E. coli kmen JM101 se transformuje spMON13188 k expresi proteinu a izolaci proteinu z inkluzních částic.
Plazmid pMON13188 obsahuje sekvenci DNA (SEQ ID NO:23), která kóduje následující 30 sekvenci aminokyselin:
Asn Cys Ser Ile Met De Asp Glu Jtte Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile -305 - CZ 295843 B6
Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr
Ala Ala Pro Ser Arg His Pro Ile De Ile Lys Ala Gly Asp Trp
Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu
Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Thr Gin Gly Ala
Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val
Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg
Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser
Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin
Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys
Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly
Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin
Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr
Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly
Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr
Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu
Gin Pro (SEQ ID NO:478) 5 Příklad 60
Konstrukce pMON 13189
Nový N-konec/C-konec genu vpMON13189 se vytvoří pomocí metody I, jak se popisuje 10 v kapitole Materiály a metody. Fragment Start se vytvoří a amplifíkuje se z G-CSF Ser17 sekvence vpMON13037 pomocí nastavení primerů 133 start (SEQ ID NO:374) a L-ll start (SEQ ID NO:364). Fragment Stop se vytvoří a amplifíkuje se z G-CSF Ser17 sekvence vpMNO13037 pomocí nastavení primerů 132 stop (SEQ ID NO:375) a L-ll stop (SEQ IN NO:365). Plná délka nového N-konec/C-konec G-CSF Ser17 gene se vytvoří a amplifíkuje se 15 z připojených fragmentů Start a Stop pomocí 133 start a 132 stop. Výsledný DNA fragment, který obsahuje nový gen, se štěpí restrikčními endonukleázami Ncol a HindlII a čistí se pomocí Magie DNA Clean-up System kitu (Promega, Madison, WI). Meziplazmid pMON13181 se štěpí restrikčními endonukleázami HindlII a AflIII, což vede ke 20 vzniku vektorového fragmentu s 4068 páry bází. Ten se čistí pomoci Magie DNA Clean-up System kitu (Promega, Madison, WI). Čištěné restrikční fragmenty se smíchají a ligují pomocí -306- CZ 295843 B6 T4 DNA ligázy (Boehringer Mannheim, Indianapolis, IN). Část ligační reakční směsi se použije k transformování buněk E. coli kmene DH5a (Life Technologies, Gaithersburg, MD). Transformované baktérie se selektují na ampicillin-obsahujících miskách. Plazmid DNA se vyizoluje a sekvenuje, aby se potvrdilo správné vložení. Výsledný plazmid se označí pMON13189. 5 E. coli kmen JMI01 se transformuje spMON13189 k expresi proteinu a izolaci proteinu z inkluzních částic.
Plazmid pMON13189 obsahuje sekvenci DNA (SEQ ID NO:24), která kóduje následující io sekvenci aminokyselin:
Asn Cys Ser Ile Met Ile Asp Ghi Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro De Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly -307- CZ 295843 B6
Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Aa Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro (SEQ ID NO:479) Příklad 61 5
Konstrukce pMON 13190
Nový N-konec/C-konec genu vpMON13190 se vytvoří pomocí metody I, jak se popisuje v kapitole Materiály a metody. Fragment Start se vytvoří a amplifikuje se zG-CSF Ser17 10 sekvence vpMON13037 pomocí nastavení primerů 142 start (SEQ ID NO:376) a L—11 start (SEQ ID NO:364). Fragment Stop se vytvoří a amplifikuje se zG-CS Ser17 sekvence v pMON13037 pomocí nastavení primeru, 141 stop (SEQ ID NO: 377) a L-l stop (SEQ ID NO: 365). Plná délka nového N-konec/C-konec genu G-CSF Ser17 se vytvoří a amplifikuje se z připojených fragmentů Start a Stop pomocí 142 start a 141 stop. 15 Výsledný DNA fragment, který obsahuje nový gen, se štěpí restrikčními endonukleázami Ncol a HindlII a čistí se pomocí magie DNA Clean-up System kitu (Promega, Madison WI). Mezi-plazmid pMON13180 se štěpí restrikčními endonukleázami HindlII a AflIII, což vede ke vzniku vektorového fragmentu s 4023 páiy bází. Ten se čistí pomocí Magie DNA Clean-up System kitu 20 (Promega, Madison, WI). Vyčištěné restrikční fragmenty se smíchají a ligují pomocí T4 DNA ligázy (Boehringer Mannheim, Indianapolis, IN). Část ligační reakční směsi se použije k transformování buněk E. coli kmene DH5a (Life Technologies, Caithersburg, MD). Transformované baktérie se selektují na ampicillin-obsahujících miskách. Plazmid DNA se vyizoluje a sekvenuje, aby se potvrdilo správné vložení. Výsledný plazmid se označí pMON13190. 25 E. coli kmen JMI01 se transformuje spMON13190 k expresi proteinu a izolaci proteinu z inkluzních částic.
Plazmid, pMON13190, obsahuje sekvenci DNA (SEQ ID NO:25), která kóduje následující 30 sekvenci aminokyselin:
Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg
Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp
Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu
Ser Phe Val Arg Aa Val Lys Asn Leu Glu Asn Aa Ser Gly Ile Glu Aa Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Aa Thr
Ala Aa Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp
Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Aa Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro
Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Aa Ser Aa Phe Gin -308- CZ 295843 B6
Arg Arg Ala Gly (My Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys De Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr De Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala (SEQ ID NO:480) Příklad 62 5
Konstrukce pMON 13191
Nový N-konec/C-konec genu vpMON13191 se vytvoří pomocí metody I, jak se popisuje v kapitole Materiály a metody. Fragment Start se vytvoří a amplifikuje se zG-CSF Ser17 io Sekvence vpMON13037 pomocí nastavení primerů, 142 start (SEQ ID NO:376) a L—11 start (SEQ ID NO:364). Fragment Stop se vytvoří a amplifikuje se zG-CSF Ser17 sekvence vpMON13037 pomocí nastavení primeru 141 stop (SEQ ID NO:377) a L—11 stop (SEQ ID NO:365). Plná délka nového N-konec/C-konec genu G-CSF Ser17 se vytvoří a amplifikuje se z připojených Fragmentů Start a Stop pomocí 142 start a 141 stop. 15 Výsledný DNA fragment, který obsahuje nový gen, se štěpí restrikčními endonukleázami Ncol a HindlII a čistí se pomocí Magie DNA Clean-up System kitu (Promega, Madison, WI). Meziplazmid, pMON13181, se štěpí restrikčními endonukleázami HindlII a AflIII, což vede ke vzniku vektorového fragmentu s 4068 páry bází. Ten se čistí pomocí Magie DNA Clean-up 20 System kitu (Promega, Madison, WI). Vyčištěné restrikční fragmenty se smíchají a ligují pomocí T4 DNA ligázy (Boehringer Mannheim, Indianapolis, IN). Část ligační reakení směsi se použije k transformování buněk E. coli kmene DH5a (Life Technologies, Gaithersburg, MD). Transformované baktérie se selektují na ampicillin-obsahujících miskách. Plazmid DNA se vyizoluje a sekvenuje, aby se potvrdilo správné vložení. Výsledný plazmid se označí pMON13191. 25 E. coli kmen JM101 se transformuje spMON13191 k expresi proteinu a izolaci proteinu z inkluzních částic.
Plazmid, pMON13191, obsahuje sekvenci DNA (SEQ ID NO:26), která kóduje následující 30 sekvenci aminokyselin: -309- CZ 295843 B6
Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg
Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp
Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu
Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile
Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr
Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp
Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu
Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro
Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro
Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Ser Ala Phe Gin
Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe
Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser
Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu
Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys
Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys
Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His
Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly
Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp
Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu
Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala
Phe Ala (SEQ ID NO: 481) -310- CZ 295843 B6 Příklad 63
Konstrukce pMON 13192 5 Nový N-konec/C-konec genu vpMON13192 se vytvoří pomocí metody II, jak se popisuje v kapitole Materiály a metody. Fragment Start se vytvoří a amplifíkuje se z G-CSF sekvence vpMON13037 pomocí nastavení primerů, 39 start (SEQ ID NO:368) a P-bl start (SEQ ID NO:366). Fragment Stop se vytvoří a amplifíkuje se z G-CSF Ser17 sekvence vpMON13037 pomocí nastavení primerů, 38 stop (SEQ ID NO:369) a P-bl stop (SEQ ID NO:367). Fragment 10 Start se štěpí restrikční endonukleázou Ncol a Fragment Stop se štěpí restrikční endonukleázou HindlII. Po čištění se štěpené fragmenty Start a Stop smíchají a ligují se k NcoI-HindlII fragmentu vektoru pMON3934 s přibližně 3800 páry bází.
Meziplazmid popsaný shora obsahuje plnou délku nového N-konec/C-konec G-CSF Ser17 genu 15 a štěpí se restrikčními endonukleázami Ncol a HindlII. Štěpená DNA se rozdělí na 1% TEA gelu, obarveném ethidium bromidem a plné délka nového N-konec/C-konec G-CSF Ser17 genu se vyizoluje pomocí Geneclean (BiolOl, Vista CA). Meziplazmid, pMON13180, se štěpí restrikčními endonukleázami HindlII a AflIII, což vede ke vzniku vektorového fragmentu s 4023 páry bází. Ten se čistil pomocí Magie DNA Clean-up System kit (Promega, Madison, WI). 20 Vyčištěné restrikční fragmenty se smíchají a ligují pomocí T4 DNA ligázy (Boehringer Mannheim, Indianapolis, IN). Část ligační reakční směsi se použije k transformování buněk E. coli kmene DH5a (Life Technoligies, Gaithersburg, MD). Transformované baktérie se selektují na ampicilin-obsahujících miskách. Plazmid DNA se vyizoluje a sekvenuje, aby se potvrdilo správné vložení nového genu. Výsledný plazmid se označí pMON13192. 25 E. coli kmen JM101 se transformuje spMON13192 k expresi proteinu a izolaci proteinu z inkluzních částic.
Plazmid, pMON13192, obsahuje sekvenci DNA (SEQ ID NO:27), která kóduje následující 30 sekvenci aminokyselin: 13I92,Pept
Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Gíu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Gíu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro -311 - CZ 295843 B6
Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly íle Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr (SEQ ID NO:482) Příklad 64 5
Konstrukce pMON 13193
Nový N-konec/C-konec genu vpMON13193 se vytvořil pomocí metody II, jak se popisuje v Materiály a metody. Fragment Start se vytvořil a amplifikoval se z G-CSF Ser17 sekvence io vpMON13037 pomocí nastavení primem, 39 start (SEQ ID NO:368) a P-bl start (SEQ ID NO:366). Fragment Stop se vytvořil a amplifikoval se z G-CSF Ser17 sekvence v pMON13037 pomocí nastavení primem 38 stop (SEQ ID NO:369) a P-bl stop (SEQ ID NO:367). Fragment Start se štěpil restrikční endonukleázou Ncol a Fragment Stop se štěpil restrikční endonukleázou HindlII. Po čištění se štěpené fragmenty Start a Stop zkombinovaly a ligovaly do NcoI-HindlII 15 vektorového fragmentu s přibližně 3800 páry bází z pMON3934.
Meziplazmid popsaný shora obsahoval plnou délku nového N-konec/C-konec G-CSF Ser17 genu a štěpil se restrikčními endonukleázami Ncol a HindlII. Štěpená DNA se rozdělila na 1% TAE gelu, barvila se ethidium bromidem a plná délka nového N-konec/C-konec G-CSF Ser17 genu se 20 izolovala pomocí Geneclean (BiolOl, Vista, CA). Meziplazmid, pMON13181, se štěpil restrikčními endonukleázami HindlII a AflIII, což vedlo ke vzniku vektorového fragmentu s 4068 páry bází. Ten se čistil pomocí Magie DNA Clean-up System kit (Promega, Madison, WI). Vyčištěné restrikční fragmenty se kombinovaly a ligovaly pomocí T4 DNA ligázy (Boehringer Mannheim, Indianapolis, IN). Část ligační reakční směsi se použila k transformování 25 buněk E. coli kmene DH5a (Life Technologies, Gaithersburt, MD). Transformované baktérie se selektovaly na ampicillin-obsahujících miskách. Plazmid DNA se izoloval a sekvenoval, aby se potvrdilo správné vložení nového genu. Výsledný plazmid se označil pMON13193. E. coli kmen JMI01 se transformoval spMON13193 k expresi proteinu a izolaci proteinu 30 z inkluzních částic. -312- CZ 295843 B6
Plazmid, pMON13193, obsahuje sekvenci DNA (SEQ ID NO:28), která kóduje následující sekvenci aminokyselin:
Asn Cys Ser Ile Met Tle Asp Gtu Ile Iíe His His Leu Lys Arg
Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp
Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu
Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile
Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp
Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu
Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Giy Ser Pro
Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro
Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Tyr Lys Leu Cys
His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro
Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala
Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly
Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr
Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile
Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro
Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg
Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu
Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Thr Pro Leu
Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu
Glu Gin Val Arg Lys lie Gin Gly Asp Gly Ala Ala Leu Gin Glu
Lys Leu Cys Ala Thr (SEQ ID NO:483) -313- CZ 295843 B6 Příklad 65
Konstrukce pMON25190 5 Nový N-konec/C-konec genu vpMON25190 se vytvořil pomocí metody II, jak se popisuje v Materiálu a metody. Fragment Start se vytvořila a amplifíkoval se zG-CSF sekvence vpMON13037 pomocí nastavení primerů, 97 start (SEQ ID NO.370) a P-bl start (SEQ ID NO:366) Fragment Stop se vytvořil a amplifíkoval se zG-CSF Ser17 sekvence vpMON13037 pomocí nastavení primerů, 96 stop (SEQ ID NO:371) a P-bl stop (SEQ ID NO:367). Fragment ío Start se štěpit restrikční endonukleázou Ncol a fragment Stop se štěpil restrikční endonukleázou HindlII. Po čištění se štěpené fragmenty Start a Stop zkombinovaly a ligovaly se k NcoI-HindlII vektorovému fragmentu pMON3934 s přibližně 3800 páry bází.
Meziplazmid popsaný shora obsahuje plnou délku nového N-konec/C-konec G-CSF Ser17 genu 15 a štěpí se restrikčními endonukleázami Ncol a HindlII. Štěpená DNA se rozdělí na 1% TAE gelu, obarveném ethidium bromidem a plná délka nového N-konce/C-konec G-CSF Ser17 genu se vyizoluje pomocí Geneclean (Bio 101, Vista, CA). Meziplazmid, pMON13180, se štěpí restrikčními endonukleázami HindlII a AflIII, což vede ke vzniku vektorového fragmentu s 4023 páry bází. Ten se čistí pomocí Magie DNA Celan-up System kit (Promega, Madison, 20 WI). Vyčištěné restrikční fragmenty se smíchaní a ligují pomocí T4 DNA ligázy (Boehringer Mannheim, Indianapolis, IN). Část ligační reakční směsi se použije k transformování buněk E. coli kmene DH5a (Life Technologies, Gaithersburg, MD). Transformované baktérie se selektují na ampicillin-obsahujících miskách. Plazmid DNA se vyizoluje a sekvenuje, aby se potvrdilo správné vložení nového genu. Výsledný plazmid se označí pMON25190. 25 E. coli kmen JM101 se transformuje spMON25190 k expresi proteinu a izolaci proteinu z inkluzních částic.
Plazmid, pMON25190, obsahuje sekvenci DNA (SEQ ID NO:29), která kóduje následující 30 sekvenci aminokyselin:
Asn Cys Ser He Met Ile Asp Glu Ile Dle His His Leu Lys Arg
Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp
Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu
Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He
Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr
Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp
Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu
Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro
Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr
Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu -314- CZ 295843 B6
Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin
Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe
Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Thr
Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu
Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu
Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu
Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser
Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala
Leu Glu Gly Ile Ser (SEQ ID NO:484) s Příklad 66
Konstrukce pMON25191
Nový N-konec/C-konec genu vpMON25191 se vytvoří pomocí metody II, jak se popisuje ío v kapitole Materiály a metody. Fragment Start se vytvoří a amplifikuje se z G-CSF Ser17 sekvence v pMON13037 pomocí nastavení primerů, 97 start (SEQ ID NO:370) a P-bl start (SEQ ID NO:366). Fragment Stop se vytvoří a amplifikuje se z G-CSF Ser17 sekvence v pMON13037 pomocí nastavení primeru 96 stop (SEQ ID NO:371) a P-bl stop (SEQ ID NO:367). Fragment Start se štěpí restrikční endonukleázou Ncol a Fragment Stop se štěpí restrikční endonukleázou 15 HindlII. Po čištění se štěpené fragmenty Start a Stop smíchají a ligují se do Ncol-Hindin vektorového fragmentu s přibližně 3800 páry bází pMON3934.
Meziplazmid popsaný shora obsahuje plnou délku nového N-konec/C-konec G-CSF Ser17 genu a štěpí se restrikčními endonukleázami Ncol a HindlII. Štěpená DNA se rozdělí na 1% TEA gelu, 20 obarveném ethidium bromidem a plná délka nového N-konec/C-konec G-CSF Ser17 genu se vyizoluje pomocí Geneclean (BiolOl, Vista, CA). Meziplazmid, pMON13181, se štěpí restrikčními endonukleázami HindlII a AflIII, což vede ke vzniku vektorového fragmentu s 4068 pár bází. Ten se čistí pomocí Magie DNA Clean-up System kit (Promega, Madison WI). Vyčištěné restrikční fragmenty se smíchají a ligují pomocí T4 DNA ligázy (Boehringer 25 Mannheim, Indianapolis, IN). Část ligační reakční směs se použije k transformování buněk E. coli kmene DH5oc (Life Technologie, Gaithersburg, MD). Transformované baktérie se selektují na ampicillin-obsahujících miskách. Plazmid DNA se vyizoluje a sekvenuje, aby se potvrdilo správné vložní nového genu. Výsledný plazmid se označí pMON25191. 30 E. coli kmen JMI01 se transformuje spMON25191 k expresi proteinu a izolaci proteinu z inkluzních částic.
Plazmid, pMON25191, obsahuje sekvenci DNA (SEQ ID NO:30), která kóduje následující sekvenci aminokyselin: -315- CZ 295843 B6
Asn Cys Ser Ile Met Ile Asp GIu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile De Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Olu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser (SEQ ID NO:485) Příklad 67
Konstrukce pMON 13194
Nový N-konec/C-konec genu vpMON13194 se vytvoří pomocí metody II, jak se popisuje v kapitole Materiály a metody. Fragment Start se vytvoří a amplifikuje se zG-CSF Ser17 -316- CZ 295843 B6 sekvence vpMON13037 pomocí nastavení primerů, 126 start (SEQ ID NO:372) a P-bl start (SEQ ID NO:366). Fragment Stop se vytvoří a amplifíkuje se zG-CSF Ser17 sekvence vpMON13037 pomocí nastavení primeru 125 stop (SEQ ID NO:371) a P-bl stop (SEQ ID NO:367). Fragment Start se štěpí restrikční endonukleázou Ncol a Fragment Stop se štěpí 5 restrikční endonukleázou HindlII. Po čištění se štěpené fragmenty Start a Stop smíchají a ligují se do NcoI-HindlII vektorového fragmentu s přibližně 3800 pár bází pMON3934.
Meziplazmid popsaný shora obsahuje plnou délku nového N-konec/C-konec G-CSF Ser17 genu a štěpí se restrikčními endonukleázami Ncol a HindlII. Štěpená DNA se rozdělí na 1% TEA gelu, ío obarveném ethidium bromidem a plná délka nového N-konec/C-konec G-CSF Ser17 genu se vyizoluje pomocí Geneclean (BiolOl, Vista, CA). Meziplazmid, pMON13180, se štěpí restrikčními endonukleázami HindlII a AflIII, což vede ke vzniku vektorového fragmentu s 4023 pár bází. Ten se čistí pomocí Magie DNA Clean-up System kit (Promega, Madison, WI). Vyčištěné restrikční fragmenty se smíchají a ligují pomocí T4 DNA ligázy (Boehringer 15 Mannheim, Indianapolis, IN). Část ligační reakční směsi se použije k transformování buněk E. coli kmene DH5a (Life Technologies, Gaithersburg, MD). Transformované baktérie se selektují na ampicíllin-obsahujících miskách. Plazmid DNA se vyizoluje a sekvenuje, aby se potvrdilo správné vložení nového genu. Výsledný plazmid se označí pMON13194. 20 E. coli kmen JMI01 se transformuje spMON13194 k expresi proteinu a izolaci proteinu z inkluzních částic.
Plazmid, pMON13194, obsahuje sekvenci DNA (SEQ ID NO:31), která kóduje následující sekvenci aminokyselin: 25
Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg
Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp
Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu
Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile
Glu Ala De Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile De Ile Lys Ala Gly Asp Trp
Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu
Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro
Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Met Ala Pro Ala
Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe
Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro
Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu -317- CZ 295843 B6
Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly (SEQ ID N0.486) Příklad 68 5
Konstrukce pMON 13195
Nový N-konec/C-konec genu vpMON13195 se vytvoří pomocí metody II, jak se popisuje v kapitole Materiály a metody. Fragment Start se vytvoří a amplifikuje se z G-CSF Ser17 ío sekvence vpMON13037 pomocí nastavení primerů 126 start (SEQ ID NO:372) a P-bl start (SEQ ID NO:366). Fragment Stop se vytvoří a amplifikuje se z G-CSF Ser17 sekvence vpMON13037 pomocí nastavení primeru 125 stop (SEQ ID NO:373) a P-bl stop (SEQ ID NO:367). Fragment Start se štěpí restrikční endonukleázou Ncol a Fragment Stop se štěpí restrikční endonukleázou HindlII. Po čištění se štěpené fragmenty Start a Stop smíchají a ligují se 15 do NcoI-HindlII vektorového fragmentu s přibližně 3800 pár bází pMON3934.
Meziplazmid popsaný shora obsahuje plnou délku nového N-konec/C-konec G-CSF Ser17 genu a štěpí se restrikčními endonukleázami Ncol a HindlII. Štěpená DNA se rozdělí na 1% TAE gelu, obarveném se ethidium bromidem a plná délka nového N-konec/C-konec G-CSF Ser17 genu se 20 vyizoluje pomocí Geneclean (BiolOl, Vista, CA). Meziplazmid, pMON13181, se štěpí restrikčními endonukleázami HindlII a AflIII, což vede ke vzniku vektorového fragmentu s 4068 páry bází. Ten se čistí pomocí Magie DNA Clean-up System Kit (Promega, Madison, WI). Vyčištěné restrikční fragmenty se smíchají a ligují se pomocí T4 DNA ligázy (Boehringer Mannheim, Indianapolis, IN). Část ligační reakční směsi se použije k transformování buněk E. 25 coli kmene DH5a (Life Technologies, Gaithersburg, MD). Transformované baktérie se selektují na ampicillin-obsahujících miskách. Plazmid DNA se vyizoluje a sekvenuje, aby se potvrdilo správné vložení nového genu. Výsledný plazmid se označí pMON13195. E. coli kmen JMI 01 se transformuje spMON13195 k expresi proteinu a izolaci proteinu 30 z inkluzních částic.
Plazmid, pMON13195, obsahuje sekvenci DNA (SEQ ID NO:32), která kóduje následující sekvenci aminokyselin: -318- CZ 295843 B6
Asn Cys Ser De Met De Asp Glu He lle His His Leu Lys Arg
Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp
Val Ser lle Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu
Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly lle
Glu Ala lle Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr
Ala Ala Pro Ser Arg His Pro lle lle lle Lys Ala Gly Asp Trp
Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu
Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro
Gly Glu Pro Ser Gly Pro lle Ser Thr lle Asn Pro Ser Pro Pro
Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Met Ala Pro Ala
Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe
Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser
Phe Leu Glu Val Ser Tyr Arg Val Lea Arg His Leu Ala Gin Pro
Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys De Gin Gly Asp Gly Ala Ala
Leu Gin Glu Lys Leu Cys Ala Tin Tyr Lys Leu Cys Hts Pro Glu
Glu Leu Val Leu Leu Gly His Ser Leu Gly De Pro Trp Ala Pro
Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu
Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin
Ala Leu Glu Gly De Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr
Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr De Trp Gin Gin
Met au Ghi Leu Gly (SEQ ID NO:487) 5 Příklad 69
Konstrukce pMON 13196
Nový N-konec/C-konec genu vpMON13196 se vytvoří pomocí metody II, jak se popisuje 10 v kapitole materiály a metody. Fragment Start se vytvoří a amplifikuje se z G-CSF sekvence -319- CZ 295843 B6 vpMON13037 pomocí nastavení primerů 133 start (SEQ ID NO:374) a P-bl start (SEQ ID NO:366). Fragment Stop se vytvoří a amplifikuje se zG-CSFSer17 sekvence vpMON13037 pomocí nastavení primerů 132 stop (SEQ ID NO:375) a P-bl stop (SEQ ID NO:367). Fragment Start se štěpí restrikční endonukleázou Ncol a Fragment Stop se štěpí restrikční endonukleázou 5 HindlII. Po čištění se štěpené fragmenty Start a Stop smíchají a ligují se kNcoI-HindlII fragmentu vektoru s přibližně 3800 páry bází pMON3934.
Meziplazmid popsaný shora obsahuje plnou délku nového N-konec/C-konec G-CSF Ser17 genu a štěpí se restrikčními endonukleázami Ncol a HindlII. Štěpená DNA se rozdělí na 1 % TAE gelu, ío obarveném ethidium bromidem a plná délka nového N-konec/C-konec G-CSF Ser17 genu se vyizoluje pomocí Geneclean (BiolOl, Vista, CA). Meziplazmid, pMON13180, se štěpí restrikčními endonukleázami HindlII a AflIII, což vede ke vzniku vektorového fragmentu s 4023 páry bází. Ten se čistí pomocí Magie DNA Clean-up System Kit (Promega, Madison, WI). Vyčištěné restrikční fragmenty se smíchají a ligují pomocí T4 DNA ligázy (Boehringer 15 Mannheim, Indianapolis, IN). Část ligační reakční směsi se použije k transformování buněk E. coli kmene DH5a (Life Technologies, Gaithersburg, MD). Transformované baktérie se selektují na ampicillin-obsahujících miskách. Plazmid DNA se vyizoluje a sekvenuje, aby se potvrdilo správné vložení nového genu. Výsledný plazmid se označí pMON13196. 20 E. coli kmen JMI01 se transformuje spMON13196 k expresi proteinu a izolaci proteinu z inkluzních částic.
Plazmid, pMON13196, obsahuje sekvenci DNA (SEQ ID NO:33), která kóduje následující sekvenci aminokyselin: 25
Asn Cys Ser Ile Met Ile Asp Glu Ile Re His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Giy Re Glu Ala Re Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Re Ile Re Lys Ala (My Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Oly Giy Gly Ser Gly Gly Gly Ser Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Thr Pro Leu (My Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Aig -320 - CZ 295843 B6
Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Iie Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Iie Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Iie Trp Gin Glu Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro (SEQ ID NO:488) Příklad 70 5
Konstrukce pMON 13197
Nový N-konec/C-konec genu vpMON13197 se vytvoří pomocí metody II, jak se popisuje v kapitole Materiály a metody. Fragment Start se vytvoří a amplifikuje se z G-CSF Ser17 10 sekvence vpMON13037 pomocí nastavení primerů 133 start (SEQ ID NO:374) a P-bl start (SEQ ID NO:366). Fragment Stop se vytvoří a amplifikuje se z G-CSF Ser17 sekvence vpMON13037 pomocí nastavení primeru 132 stop (SEQ ID NO:375) a P-bl stop (SEQ ID NO:367). Fragment Start se štěpí restrikční endonukleázou Ncol a Fragment Stop se štěpí restrikční endonukleázou HindlII. Po čištění se štěpené fragmenty Start a Stop smíchají a ligují se 15 do NcoI-HindlII vektorového fragmentu s přibližně 3800 pár bází pMON3934.
Meziplazmid popsaný shora obsahuje plnou délku nového N-konec/C-konec G-CSF Ser17 genu a štěpí se restrikčními endonukleázami Ncol a HindlII. Štěpená DNA se rozdělí na 1% TAE gelu, obarveném ethidium bromidem a plná délka nového N-konec/C-konec G-CSF Ser17 genu se 20 vyizoluje pomocí Geneclean (BiolOl, Vista CA). Meziplazmid, pMON13181, se štěpí restrikčními endonukleázami HindlII a AflIII, což vede ke vzniku vektorového fragmentu s 4068 pár bází. Ten se čistí pomocí Magie DNA Clean-up System kit (Promega, Madison, WI). Vyčištěné restrikční fragmenty se smíchají a ligují pomocí T4 DNA ligázy (Boehringer Mannheim, Indianapolis, IN). Část ligační reakční směsi se použije k transformování buněk 25 E. coli kmen DH5a (Fife Technologies, Gaithersburg, MD). Transformované baktérie se selektují na ampicillin-obsahujících miskách. Plazmid DNA se vyizoluje a sekvenuje, aby se potvrdilo správné vložení nového genu. Výsledný plazmid se označí pMON13197. E. coli kmen JMI01 se transformuje spMON13197 k expresi proteinu a izolaci proteinu 30 z inkluzních částic.
Plazmid, pMON13197, obsahuje sekvenci DNA (SEQ ID NO:34), která kóduje následující sekvenci aminokyselin: -321 - CZ 295843 B6
Asn Cys Ser Ile Met Ile Asp Olu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Oly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr (SEQ ID N0.489) 5 Příklad 71
Konstrukce pMON 13198
Nový N-konec/C-konec genu vpMON13198 se vytvoří pomocí metody II, jak se popisuje 10 v kapitole Materiály a metody. Fragment Start se vytvoří a amplifikuje se zG-CSF sekvence vpMON13037 pomocí nastavení primerů 142 start (SEQ ID NO:376) a P-bl start (SEQ ID NO:366). Fragment Stop se vytvoří a amplifikuje se zG-CSF Ser17 sekvence vpMON13037 -322 - CZ 295843 B6 pomocí nastavení primerů 141 stop (SEQ ID NO:377) a P-bl stop (SEQ ID NO:367). Fragment Start se štěpí restrikční endonukleázou Ncol a fragment Stop se štěpí restrikční endonukleázou HindlII. Po čištění se štěpené fragmenty Start a Stop smíchají a ligují se k NcoI-HindlII vektorovému fragmentu s přibližně 3800 páry bází pMON3934, 5
Meziplazmid popsaný shora obsahuje plnou délku nového N-konec/C-konec G-CSF Ser17 genu a štěpí se restrikčními endonukleázami Ncol a HindlII. Štěpená DNA se rozdělí na 1 % TAE gelu, obarveném ethidium bromidem a plná délka nového N-konec/C-konec G-CSF Ser17 genu se vyizoluje pomocí Geneclean (BiolOl, Vista, CA). Meziplazmid, pMON13180, se štěpí 10 restrikčními endonukleázami HindlII a AflIII, což vede ke vzniku 4023 páru bází vektorového fragmentu. Ten se čistí pomocí Magie DNA Clean-up System kit (Promega, Madison, WI). Vyčištěné restrikční fragmenty se smíchají a ligují pomocí T4 DNA ligázy (Boehringer Mannheim, Indianapolis, In). Část ligační reakční směsi se použije k transformování buněk E. coli kmene DH5a (Life Technologies, Gaitersburg, MD). Transformované baktérie se 15 selektují na ampicillin-obsahujících miskách. Plazmid DNA se vyizoluje a sekvenuje, aby se potvrdilo správné vložení nového genu. Výsledný plazmid se označí pMON13198. E. coli kmen JM101 se transformuje spMON13198 k expresi proteinu a izolaci proteinu z inkluzních částic. 20
Plazmid, pMON13198, obsahuje sekvenci DNA (SEQ ID NO:35), která kóduje následující sekvenci aminokyselin:
Asn Cys Ser Ile Met Ue Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ue Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ue Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin On Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ue Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu -323 - CZ 295843 B6
Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala (SEQ ID NO:490) Příklad 72 5
Konstrukce pMON 13199
Nový N-konec/C-konec genu vpMON13199 se vytvoří pomocí metody II, jak se popisuje v kapitole Materiály a metody. Fragment Start se vytvoří a amplifikuje se zG-CSF Ser17 10 Sekvence vpMON13037 pomocí nastavení primerů 142 start (SEQ ID NO:376) a P-bl start (SEQ ID NO: 366). Fragment Stop se vytvoří a amplifikuje se zG-CSF Ser17 sekvence vpMON13037 pomocí nastavení primeru 141 stop (SEQ ID NO:377) a P-bl stop (SEQ ID NO:367). Fragment Start se štěpí restrikční endonukleázou Ncol a Fragment Stop se štěpí restrikční endonukleázou HindlII. Po čištění se štěpené fragmenty Start a Stop smíchají a ligují se 15 do NcoI-HindlII vektorového fragmentu s přibližně 3800 páry bází pMON3934.
Meziplazmid popsaný shora obsahuje plnou délku nového N-konec/C-konec G-CSF Ser17 genu a štěpí se restrikěními endonukleázami Ncol a HindlII. Štěpená DNA se rozdělí na 1 % TAE gelu, obarveném ethidium bromidem a plné délka nového N-konec/C-konec G-CSF Ser17 genu 20 se vyizoluje pomocí Geneclean (Bio 101, Vista, CA). Meziplazmid, pMON13181, se štěpí restrikěními endonukleázami HindlII a AflIII, což vede ke vzniku vektorového fragmentu s 4068 páry bází. Ten se čistí pomocí Magie DNA Clean-up System kit (Promega, Madison, WI). Vyčištěné restrikční fragmenty se smíchají a ligují pomocí T4 DNA ligázy (Boehringer Mannheim, Indianapolis, IN). Část ligační reakční směsi se použije k transformování buněk 25 E. coli kmene DH5a (Life Technologies, Gaithersburg, MD). Transformované baktérie se selektují na ampicillin-obsahujících miskách. Plazmid DNA se vyizoluje a sekvenuje, aby se potvrdilo správné vložení nového genu. Výsledný plazmid se označí pMON13199. E. coli kmen JM101 se transformuje spMON13199 k expresi proteinu a izolaci proteinu 30 z inkluzních částic.
Plazmid, pMON13199, obsahuje sekvenci DNA (SEQ ID NO:36), která kóduje následující sekvenci aminokyselin:
Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu -324 - CZ 295843 B6
Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ue Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Ghi Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr De Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Tip Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala (SEQ ID NO:491) Příklad 73 5
Konstrukce tandemově duplikované matrice plazmidu, Syntanl
Aby se vytvořila tandemově duplikovaná matrice hIL-3 receptorového agonisty pMON13416, Syntanl, tři DNA se spojí prostředky ligace pomocí T4 DNA ligázy (Boehringe Mannhein). Tři 10 DNA jsou: 1) pMON13046, obsahující hIL-3 receptorového agonistu pMON13416, kteiý se štěpí s BstEII a SnaBI; 2) připojený komplementární pár syntetických oligonukleotidů, LI syn. „fof‘ (SEQ ID NO:352) a Llsyn. „rev“ (SEQ ID NO:353), která obsahují sekvence kódující spojovník, který spojuje C-terminální a N-terminální konce originálního proteinu a malé množství okolní pMON13416 sekvence a který, když se správně složí, vede k BstEII a Clal 15 koncům; a 3) část hIL-3 receptorového agonisty pMON13416 štěpeného z pMON13046 s Clal -325 - CZ 295843 B6 (DNA se pěstovala v samičích-buňkách DMI (Life Technologies)) a SnaBI. Štěpené DNA se rozlišily na 0,9% TAE gelu, barveném ethidium bromidem a vyizolují pomocí Geneclean (BiolOl). 5 Část ligační reakční směsi se použije k transformování buněk E. coli kmene DH5a (Life Technologies, Gaithersburg, MD). Mini připravená DNA se vyizoluje z transformantů a transformanty se otestují pomocí PCR. Plazmid DNA z vybraných transformantů se sekvenuje, aby se získala správná matrice. Výsledný plazmid se označí syntanl a obsahuje sekvenci DNA (SEQ ID NO:7). io Příklad 74
Konstrukce tandemově duplikované matrice, syntan3 15
Aby se vytvořila tandemově duplikovaná matrice hIL-3 receptorového agonisty pMON13416, syntan3, tři DNA se spojily prostředky ligace pomocí T4 DNA ligázy (Boehringer Mannheim). Tři DNA jsou: 1) pMON13046, obsahující hIL-3 receptorového agonistu pMON13416, který se štěpí s BstEII a SnaBI; 2) žíhaný komplementární pár syntetických oligonukleotidů, L3syn.for 20 (SEQ ID NO:354) a L3syn.rev. (SEQ ID NO:355), které obsahují sekvence kódující spojovník, který spojuje C-terminální a N-terminální konce originálního proteinu a malé množství okolní pMON13416 sekvence a který, když se správně složí, vede k BstEII a SnaBI koncům; a 3) část hIL-3 receptorového agonisty pMON13416 štěpeného z pMON13046 s Clal (DNA se pěstovala v samičích buňkách, DMI (Life Technologies)) a SnaBI. Štěpené DNA se rozliší na 0,9% TAE 25 gelu obarveném ethidium bromidem a vyizolují pomocí Geneclean (BiolOl). Část ligační reakční směsi se použije k transformování buněk E. coli kmene DH5a (Life Technologies, Gaithersburg, MD). Mini připravená DNA se vyizoluje z transformantů a transformanty se otestují pomocí PCR. Plazmid DNA z vybraných transformantů se sekvenuje, 30 aby se získala správná matrice. Výsledný plazmid se označí syntan3 a obsahuje sekvenci DNA (SEQ ID NO:8). Příklad 75 35
Konstrukce pMON31104
Nový N-konec/C-konec genu vpMON31104 se vytvoří pomocí metody III, jak se popisuje v kapitole Materiály a metody. Plná délka nového N-konec/C-konec genu hIL-3 receptorového 40 agonisty pMON13416 se vytvoří a amplifíkuje se zmeziplazmidu, Syntanl, pomocí nastavení primerů 35 start (SEQ ID NO:356) a 34 rev (SEQ ID NO:357). Výsledný DNA fragment, který obsahuje nový gen, se štěpí restrikčními endonukleázami Ncol a SnaBI. Štěpený fragment DNA se rozdělí na 1% TAE gelu, obarveném ethidium bromidem a 45 vyizoluje se pomocí Geneclean (BiolOl, Vista, CA). Vyčištěný štěpený fragment DNA se liguje do expresního vektoru pMON13189, pomocí T4 DNA ligázy (Boehringer Mannheim, Indianapolis, IN). pMON13189 DNA se předem štěpí NCOI a SnaBI, aby se odstranila kódující sekvence hIL3 receptorového agonisty pMON13416 a vyizoluje se vektorový fragment s 4254 páry bází pomocí Geneclean (BiolOl, Vista, CA) po rozlišení na 0,8% TAE gelu a 50 barvení ethidium bromidem. Část ligační reakční směsi se použije k transformaci E. coli kmenu DH5a (Life Technologied, Gaithersburg, MD). Transformované baktérie se selektují na ampicillin-obsahujících miskách. Plazmid DNA se vyizoluje a sekvenuje se, aby se potvrdilo správné vložení. Výsledný plazmid se označí pMON31104. -326- CZ 295843 B6 E. coli kmen JMI01 se transformuje spMON31104 k expresi proteinu a izolaci proteinu z inkluzních částic.
Plazmid, pMON31104, obsahuje sekvenci DNA (SEQ ID NO:9), která kóduje následující 5 sekvenci aminokyselin:
Leu Asp Pro Asn Asm Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile De He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Gly Gly Gly Ser Asn Cys Ser Ile Met Ile Asp Glu De De His His Leu Lys Arg Pro Pro Ala Pro Leu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr De Asn Pro Ser Pro Pro Ser Lys Glu Ser Hts Lys Ser Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys De Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly De Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly De Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro (SEQ ID NO:492) -327- CZ 295843 B6 Příklad 76
Konstrukce pMON31105 5 Nový N-konec/C-konec genu vpMON31105 se vytvoří pomocí metody III, jak se popisuje v kapitole Materiály a metody. Plná délka nového N-konec/C-konec genu hIL-3 receptorového agonisty pMON13416 se vytvoří a amplifíkuje se z meziplazmidu, Syntanl, pomocí nastavení primerů 70 start (SEQ ID NO:358) a 69 rev (SEQ ID NO:359). 10 Výsledný fragment DNA, který obsahuje nový gen, se štěpí restrikčními endonukleázami Ncol a SnaBI. Štěpený fragment DNA se rozdělí na 1% TAE genu, obarví se ethidium bromidem a vyizoluje se pomocí Geneclean (BiolOl, Vista, CA). Vyčištěný štěpený fragment DNA se liguje do expresního vektoru pMON13189 pomocí T4 DNA ligázy (Boehringer Mannheim, Indianapolis, IN). pMON13189 DNA se předem štěpí sNeol a SnaBI, aby se odstranila kódující 15 sekvence hIL3 receptorového agonisty pMON13416 a vektorový fragment s 4254 páry bází se vyizoluje pomocí Geneclean (BiolOl, Vista, CA) po rozlišení na 0,8% TAE gelu obarveném ethidium bromidem. Část ligační reakční směsi se použije k transformaci E. coli kmene DH5a (Life Technologies, Gaithersburg, MD). Transformované baktérie se selektují na ampicillin-obsahujících miskách. Plazmidová DNA se vyizoluje a sekvenuje se, aby se potvrdilo správné 20 vložení. Výsledný plazmid se označí pMON31105. E. coli kmen JMI01 se transformuje spMON31105 k expresi proteinu a izolaci proteinu z inkluzních částic. 25 Plazmid, pMON31105, obsahuje sekvenci DNA (SEQ ID NO: 10), která kóduje protein s následující sekvencí aminokyselin:
Asn Ala Ser Gly De Glu Ala íle Leu Arg Asn Leu Gin Pro Cys
Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile He
Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr
Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Gly Gly Gly Ser
Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg
Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp
Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu
Ser Phe Val Arg Ala Val Lys Asn Leu Glu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn
Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala
Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg
Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu -328- CZ 295843 B6
Val Star Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr De Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro (SEQ ID NO:493) Příklad 77 5
Konstrukce pMON31106
Nový N-konec/C-konec genu vpMON31106 se vytvoří pomocí metody III, jak se popisuje v kapitole Materiály a metody. Plná délka nového N-konec/C-konec genu hIL-3 receptorového 10 agonisty pMON13416 se vytvoří a amplifikuje z meziplazmidu, Syntanl, pomocí nastavení primerů 91 start (SEQ ID NO.360) a 90 rev (SEQ ID NO:361). Výsledný fragment DNA, který obsahuje nový gen, se štěpí restrikčními endonukleázami Ncol a SnaBI. Štěpený fragment DNA se rozdělí na 1% TAE genu obarvením ethidium bromidem a 15 vyizoluje se pomocí Geneclean (BiolOl, Vista, CA). Vyčištěný štěpený fragment DNA se ligoval do expresního vektoru pMON13189, pomocí T4 DNA ligázy (Boehringer Mannheim, Indianapolis, IN).pMON13189 DNA se předem štěpí sNeol a SnaBI, aby se odstranila kódující sekvence hIL3 receptorového agonisty pMON13416 a vektorový fragment s 4254 páry bází se vyizoluje pomocí Geneclean (BiolOl, Vista, CA) po rozlišení na 0,8% TAE gelu a barvení 20 ethidium bromidem. Část ligační reakční směsi se použije k transformaci E. coli kmene DH5a (Life Technologies, Gaithersburg, MD). Transformované baktérie se selektují na ampicillin-obsahujících miskách. Plazmid DNA se vyizoluje a sekvenuje se, aby se potvrdil správný inzert. Výsledný plazmid se označí pMON31106. 25 E. coli kmen JM101 se transformuje spMON31106 k expresi proteinu a izolaci proteinu z inkluzních částic.
Plazmid, pMON31106, obsahuje sekvenci DNA (SEQ ID NO:ll), která kóduje protein s následující sekvencí aminokyselin: -329- CZ 295843 B6
Ala Pro Ser Arg Hiš Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin
Ghi Phe Arg GJu Lys Leu Thr Phe Tyr Leu Val Thr Leu Olu Gin
Ala Gin Glu Gin Gin Gly Gly Gly Ser Asn Cys Ser Ile Met Ile
Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu
Asp Pro Asn Asn Leu Asn Asp Olu Asp Val Ser Ile Leu Met Asp
Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val
Lys Asn Leu Glu Asn Ala Ser Gly fle Glu Ala Ile Leu Arg Asn
Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Tyr Val Glu Gly Gly
Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn
Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala
Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg
Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu
Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly
Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val
Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys
Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly
His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser
Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly
Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala
Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met
Ala Pro Ala Leu Gin Pro (SEQ ID N0.494) 5 Příklad 78
Konstrukce pMON31107
Nový N-konec/C-konec genu vpMON31107 se vytvoří pomocí metody III, jak se popisuje 10 v kapitole Materiály a metody. Plná délka nového N-konec/C-konec genu hIL-3 receptorového -330- CZ 295843 B6 agonisty pMON13416 se vytvoří a amplifikuje z meziplazmidu, Syntanl, pomocí nastavení primerů 101 start (SEQ ID NO:362) a 100 rev (SEQ ID NO:363). Výsledný fragment DNA, který obsahuje nový gen, se štěpí restrikčními endonukleázami Ncol a 5 SnaBI. Štěpený fragment DNA se rozdělil na 1% TAE gelu obarveném ethidium bromidem a vyizoluje se pomocí Geneclean (BiolOl, Vista, CA). Vyčištěný štěpený fragment DNA se ligoval do expresního vektoru pMON13189 pomocí T4 DNA ligázy (Boehringer Mannheim, Indianapolis, IN). pMON13189 DNA se předem štěpí sNeol a SnaBI, aby se odstranila kódující sekvence hIL3 receptorového agonisty pMON13416 a vektorový fragment s 4254 páry bází se io vyizoluje pomocí Geneclean (BiolOl, Vista, CA) po rozlišení na 0,8% TAE gelu a barvení ethidium bromidem. Část ligační reakční směsi se použije k transformaci E. coli kmene DH5a (Life Technologies, Gaithersburg, MD). Transformované baktérie se selektují na ampicillin-obsahujících miskách. Plazmid DNA se vyizoluje a sekvenuje se, aby se potvrdilo správné vložení. Výsledný plazmid se označí pMON31107. 15 E. coli kmen JMI01 se transformuje spMON31107 k expresi proteinu a izolaci proteinu z inkluzních částic.
Plazmid, pMON31107, obsahuje sekvenci DNA (SEQ ID NO:12), která kóduje následující 20 sekvenci aminokyselin:
Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu
Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Gly Gly Gly Ser Asn
Cys Ser He Met Ile Asp Glu Ile Be His His Leu Lys Arg Pro
Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser
Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu
Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala
Ala Pro Ser Arg His Pro Be Ile Ile Lys Tyr Val Glu Gly Gly
Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Be Asn
Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala
Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg
Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu
Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly
Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys
Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly -331 - CZ 295843 B6
Ks Ser Leu Gly lle Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly lle Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr lle Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro (SEQ ID NO:495) Příklad 79 5
Konstrukce pMON31108
Nový N-konec/C-konec genu vpMON31108 se vytvoří pomocí metody III, jak se popisuje v kapitole Materiály a metody. Plná délka nového N-konec/C-konec genu hIL-3 receptorového 10 agonisty pMON13416 se vytvoří a amplifíkuje se z meziplazmidu, Syntan3, pomocí nastavení primerů 35 start (SEQ ID NO:356) a 34 rev (SEQ ID NO:357). Výsledný DNA fragment, který obsahuje nový gen, se štěpí restrikčními endonukleázami Ncol a SnaBI. Štěpený fragment DNA se rozdělí na 1% TAE gelu obarveném ethidium bromidem 15 avyizoluje se pomocí Geneclean (BiolOl, Vista, CA), Vyčištěný štěpený fragment DNA se ligoval do expresního vektoru pMON13189 pomocí T4 DNA ligázy (Boehringer Mannheim, Indianapolis, IN). pMON13189 DNA byla předem štěpená sNCOI a SnaBI, aby se odstranila kódující sekvence hIL3 receptorového agonisty pMON13416 a vektorový fragment s 4254 páry bází se vyizoluje pomocí Geneclean (BiolOl, Vista, CA) po rozlišení na 0,8% TAE gelu 20 obarveném ethidium bromidem. Část ligační reakční směsi se použije k transformaci E. coli kmene DH5a ,Life Technologies, Gaithersburg, MD). Transformované baktérie se selektují na ampicillin-obsahujících miskách. Plazmid DNA se vyizoluje a sekvenuje se, aby se potvrdilo správné vložení. Výsledný plazmid se označí pMON31108. 25 E. coli kmen JMI01 se transformuje spMON31108 k expresi proteinu a izolaci proteinu z inkluzních částic.
Plazmid, pMON31108, obsahuje sekvenci DNA (SEQ ID NO:13), která kóduje následující sekvenci aminokyselin: 30
Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser De Leu Met
Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala De Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro De De De Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin -332 - CZ 295843 B6
Gin Gly Gly Gly Ser Gly Oly Gly Ser Gly dy Gly Ser Asn Cys
Ser De Met Ile Asp Glu Ile De His His Leu Lys Arg Pro Pro
Ala Pro Leu Tyr Val Glu Gly Gly dy dy Ser Pro dy du Pro
Ser dy Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu
Ser His Lys Ser Pro Asn Met Ala Thr Gin dy Ala Met Pro Ala
Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly dy Val Leu Val Ala
Ser His Leu dn Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg
His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser dn Ser Phe
Leu Leu Lys Ser Leu du dn Val Arg Lys Ile dn dy Asp Gly Ala Ala Leu Gin du Lys Leu Cys Ala Thr Tyr Lys Leu Cys His
Pro Glu Glu Leu Val Leu Leu dy His Ser Leu Gly Ile Pro Trp
Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala dy
Cys Leu Ser Gin Leu His Ser dy Leu Phe Laj Tyr Gin dy Leu
Leu dn Ala Leu du dy De Ser Pro du Leu Gly Pro Thr Leu
Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp
Gin dn Met Glu du Leu Gly Met Ala Pro Ala Leu Gin Pro (SEQ ID NO:496) 5 Příklad 80
Konstrukce pMON31109
Nový N-konec/C-konec genu vpMON31109 se vytvoří pomocí metody III, jak se popisuje 10 v kapitole Materiály a metody. Plná délka nového N-konec/C-konec genu hIL-3 receptorového agonisty pMON13416 se vytvoří a amplifikuje se z mezíplazmidu, Syntan3, pomocí nastavení primerů 70 start (SEQ ID NO:358) a 69 rev (SEQ ID NO:359). Výsledný fragment DNA, který obsahuje nový gen, se štěpí restrikčními endonukleázami Ncol a 15 SnaBI. Štěpený fragment DNA se rozdělil na 1% TAE gelu obarveném ethidium bromidem a vyizoluje se pomocí Geneclean (BiolOl, Vista, CA). Vyčištěný štěpený fragment DNA se ligoval do expresního vektoru pMON13189, pomocí T4 DNA ligázy (Boehringer Mannheim, Indianapolis, IN). pMON13189 DNA byla předem štěpená sNeol a SnaBI, aby se odstranila kódující sekvence hIL3 receptorového agonisty pMON13416 a vektorový fragment s 4254 páry 20 bází se vyizoluje pomocí Geneclean (BiolOl, Vista, CA) po rozlišení na 0,8% TAE gelu a barvení ethidium bromidem. Část ligační reakční směsi se použije k transformaci E. coli kmene DH5a (Life technologies, Gaithersburg, MD). Transformované baktérie se selektují na ampicillin-obsahujících miskách. Plazmid DNA se vyizoluje a sekvenuje se, aby se potvrdilo správné vložení. Výsledný plazmid se označí pMON31109. - 333 - CZ 295843 B6 E. coli kmen JM101 se transformuje spMON31109 k expresi proteinu a izolaci proteinu z inkluzních částic. 5 Plazmid, pMON31109, obsahuje sekvenci DNA (SEQ ID NO: 14), která kóduje následující sekvenci aminokyselin:
Asn Ala Ser Gly He Glu Ala lle Leu Arg Asn Leu Gin Pro Cys
Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro lle lle lle
Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr
Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Gly Gly Gly Ser
Gly Gly Gly Ser Gly Gly Gly Ser Asn Cys Ser lle Met lle Asp
Glu lle lle His His Leu Lys Aig Pro Pro Ala Pro Leu Leu Asp
Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Re Leu Met Asp Arg
Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys
Asn Leu Glu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro
Ser Gly Pro lle Ser Thr lle Asn Pro Ser Pro Pro Ser Lys Glu
Ser His Lys Ser Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala
Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala
Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg
His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Glu Ser Phe
Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Re Gin Gly Asp Gly
Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His
Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Re Pro Trp
Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly
Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu
Leu Gin Ala Leu Glu Gly Re Ser Pro Glu Leu Gly Pro Thr Leu
Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Re Trp
Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro (SEQ ID NO:497) -334- 5 CZ 295843 B6 Příklad 81
Konstrukce pMON31110
Nový N-konec/C-konec genu vpMON31110 se vytvoří pomocí metody ΙΠ, jak se popisuje v kapitole Materiály a metody. Plná délka nového N-konec/C-konec genu hIL-3 receptorového agonisty pMON13416 se vytvoří a amplifikuje se z meziplazmidu, Syntan3, pomocí nastavení primem 91 start (SEQ ID NO:360) a 90 rev (SEQ ID NO:361). 10 Výsledný fragment DNA, který obsahuje nový gen, se štěpí restrikčními endonukleázami Ncol a SnaBI. Štěpený fragment DNA se rozdělí na 1% TAE gelu obarveném ethidium bromidem a vyizoluje se pomocí Geneclean (BiolOl, Vista, CA). Vyčištěný štěpený fragment DNA se liguje do expresního vektoru pMON13189 pomocí T4 DNA ligázy (Boehringer Mannheim, 15 Indianapolis, IN). pMON1319 DNA byla předem štěpená sNeol a SnaBI, aby se odstranila kódující sekvence hIL3 receptorového agonisty pMON13416 a vektorový fragment s 4254 páry bází se vyizoluje pomocí Geneclean (BiolOl, Vista, CA) po rozlišení na 0,8% TAE gelu obarveném ethidium bromidem. Část ligační reakční směsi se použije k transformaci E. coli kmene DH5a (Life Technologies, Gaithersburg, MD). Transformované baktérie se selektují na 20 ampicillin-obsahujících miskách. Plazmid DNA se vyizoluje a sekvenuje se, aby se potvrdilo správné vložení. Výsledný plazmid se označí pMON31110. E. coli kmen JMI01 se transformuje spMON31110 k expresi proteinu a izolaci proteinu z inkluzních částic. 25
Plazmid, pMON31110, obsahuje sekvenci DNA (SEQ ID NO:15), která kóduje následující sekvenci aminokyselin:
Ala Pro Ser Arg His Pro Iíe Ile De Lys Ala Gly Asp Trp Gin
Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Ghi Gin
Ala Gin au Gín Gin Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly
Gly Ser Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp
Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn
Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro
Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu
Ser His Lys Ser Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala „ Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala - 335 - CZ 295843 B6
Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg
His Leu Ala Gin Pro Ser Oly Gly Ser Gly Giy Ser Gin Ser Phe
Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly
Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His
Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly De Pro Tip
Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly
Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu
Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu
Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr De Trp
Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro (SEQ ED NO:498) Příklad 82 5
Konstrukce pMON31111
Nový N-konec/C-konec genu v pMON31111 se vytvoří pomocí metody III, jak se popisuje v kapitole Materiály a metody. Plná délka nového N-konec/C-konec genu hIL-3 receptorového 10 agonisty pMON13416 se vytvoří a amplifíkuje se z meziplazmidu, Syntan3, pomocí nastavení příměrů 101 start (SEQ ID NO:362) a 100 rev (SEQ ID NO:363). Výsledný fragment DNA, který obsahuje nový gen, se štěpí restrikčními endonukleázami Ncol a SnaBI. Štěpený fragment DNA se rozdělí na 1% TAE gelu obarveném ethidium bromidem a 15 vyizoluje se pomocí Geneclean (Biol-01, Vista, CA). Vyčištěný štěpený fragment DNA se liguje do expresního vektoru pMON13189, pomocí T4 DNA lígázy (Boehringer Mannheim, Indianapolis, In). pMON13189 DNA byla předem štěpena sNeol a SnaBI, aby se odstranila kódující sekvence hIL3 receptorového agonisty pMON13416 a fragment vektoru s 4254 páry bází se vyizoluje pomocí Geneclean (BiolOl, Vista, CA) po rozlišení na 0,8% TAE gelu 20 obarveném ethidium bromidem. Část ligační reakční směsi se použije k transformaci E. coli kmene DH5a (Life Technologies, Gaithersburg, MD). Transformované baktérie se selektují na ampicillin-obsahujících miskách. Plazmid DNA se vyizoluje a sekvenuje se, aby se potvrdilo správné vložení. Výsledný plazmid se označí pMON31111. 25 E. coli kmen JMI01 se transformuje spMON31111 k expresi proteinu a izolaci proteinu z inkluzních částic.
Plazmid, pMON31111, obsahuje sekvenci DNA (SEQ ID NO: 16), která kóduje následující sekvenci aminokyselin: -336- CZ 295843 B6
Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Asn Cys Ser Ile Met He Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly
Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu
Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp
Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro (SEQ ID NO:499) 5 Příklad 83
Konstrukce pMON31112
Konstrukce pMON31112 plazmidu obsahujícího sekvenci DNA kódující multi-funkčního ίο hematopoietického receptorového agonistu, který aktivuje hIL-3 receptor a G-CSF receptor. -337- CZ 295843 B6
Plazmid pMON13189 DNA se štěpí s restrikčními enzymy Ncol a Xmal, což vede ke vzniku Ncol, Xmal vektorového fragmentu, který se vyizoluje a čistí z 0,8% agarózového gelu. DNA z druhého plazmidu, pMON13222 (WO 94/12639, US sériové číslo 08/411,796) se štěpí s Ncol a EcoRI, což vede ke vzniku Ncol, EcoRI fragmentu s 281 páry bází. Tento fragment se vyizoluje 5 a čistí z 1,0% agarózového gelu. Dva oligonukleotidy SYNNOXA1.REX (SEQ ID NO:350) a SYNNOXA2.REQ (SEQ ID NO:351) se denaturovaly teplem a ligují se kDNA fragmentu s 281 páry bází zpMON13222 do vektorového fragmentu DNA zpMON13189. Část ligační směsi se pak transformuje do E. coli K-12 kmene JM101. Transformované baktérie se selektují na ampicillin—obsahujících miskách. Plazmidová DNA se vyizoluje, analyzovala se restrikční 10 analýzou, aby se ukázala přítomnost EcoRV fragmentu, a ten se sekvenuje, aby se potvrdila správná vložení.
Plazmid, pMON31112, obsahuje sekvenci DNA (SEQ ID NO:37), která kóduje následující sekvenci aminokyselin: 15
MetAlaAsnCysSerAsnMetlleAspGluIleDeThrHisLeuLysGInProProLeuPro
LeuLeuAspPheAsnAsnLeuAsnGlyGluAspGlnAspIleLeuMetAspAsnAsnLeuArgArg
ProAstiLeuGluAlaPheAsnArgAlaValLysSerLeuGlnAsnAJaSerAlallsGhiSerlle
LeuLysAsnLeuLeuProCysLeuProLeuAlaThrAlaAJaProThrArgHisProlleHis
IleLysAspGlyAspTípAsnGluPheArgArgLysLeuThrPheTyrLeuLysThrLeuGluAsn AIaGlnAlaCHnGlnTyTVal0uGlyGlyGlyGlySerProGlyGIuProSerGIyProIleSer
ThrlleAsnProSerProProSerLysGluSerHidLysSerProAsnMetAlaThrGlnGly
AlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyVaiLeuValAJaSerHÍsLeu
GlnSerPheLeuGluVaIS©rTyrArgValLeuArgHisLeuAlaGtoProSerGÍyG9yS«rGly
GlySerGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGIyAspGlyAla
AlaLeuGinGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGly
HisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGly
CysLeuSerGlnLeuTTisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGly
DeSerProGlwL^0yProThrL®uLAspThrLeuGlnLeuAspValAlaAspPheAlaThrThr
DeTrpGlnGínMetGluGluLaiGlyMetAlaProAlaLeuGlnPro (SEQ ID NO:505)
Konstrukce pMON31113 20
Konstrukce pMON31113, plazmidu obsahujícího DNA sekvenci kódující multi-funkčního hematopoietického receptorového agonistu, který aktivuje hIL-3 receptor a G-CSF receptor. Plazmid pMON13197 DNA se štěpí s restrikčními enzymy Ncol a Xmal, což vede ke vzniku Ncol, Xmal vektorového fragmentu, který se vyizoluje a čistí z 0,8% agarózového gelu. DNA 25 druhého plazmidu, pMON13239 (WO 94/12639, US sériové číslo 08/411,796) se štěpí Ncol a EcoRI, což vede ke vzniku Ncol, EcoRI fragmentu s 281 páry bází. Tento fragment se vyizoluje a čistí z 1,0% agarózového gelu. Dva oligonukleotidy SYNNOXA1.REQ (SEQ ID NO:350) a SYNNOYA2.REQ (SEQ ID NO:351) se denaturuje teplem a ligují se kDNA fragmentu -338- CZ 295843 B6 s281 páry bází zpMON13239 do DNA vektorového fragmentu zpMON13197. Část ligační směsi se pak transformuje do E. coli K-12 kmene JM101. Transformované baktérie se selektují na ampicillin-obsahujících miskách. Plazmid DNA se vyizoluje, analyzuje restrikční analýzou, aby se ukázala přítomnost EcoRV fragmentu, a ten se sekvenuje, aby se potvrdila správná 5 vložení.
Plazmid, pMON31113, obsahuje sekvenci DNA (SEQ ID NO:38), která kóduje následující sekvenci aminokyselin:
MetAiaAsnCysSerAsnMeíIleAspGluIlelleThrHisLeuLysGlnProProLeuPro
LeuLeuAspPheAsnAsíiLeuAsnGlyGluAspGlnAspIleLeuMetGluAsnAsnLeuArgArg 10
ProAsnLeuGluAlaPheAsnArgAiaValLysSerLeuGlnAsnAlaSerAlalleGluSerne
LeuLysAsnLeuLeuProCysLaiProLeuAlaThrAlaAlaProThrArgHlsProIlellelle
ArgAspGIyAspTrpAsnGliiPheArgArgLysLeuThrPheTyrLeuLysThrLeuGIuAsn
AlaGlnAiaGlnGlnTyrValGiuGlyGlyGIyGiySerProGlyGluProSerGlyProIleSer
ThrlleAsnProSerProProSerLysGIuSerHisLysSerProAsnMetAlaThrGlnGlyAla
MetProAlaPheAlaSerAlaPheGInArgAigAlaGlyGlyValLeuValAIaSerHisLeuG
InSerPheLeuGiuValSerTyrArgValLeuArgHisLeuAlaGlnProThrProLeuGlyPro
AlaSerSerL^uProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAsp
GlyAiaAlaLeuGlnGluLysLajCysAlaThrTyrLysL^iCysHtsProGluGIuLeuVal
LeuLeuGlyHÍsSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaí.^uGln
LeuAlaGlyCysL^SerGínLeuHisSerGlyl^Phel^uTyrGlttGlyLeuLeuGlnAla
Le uGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAJaAspPhe
AlaThrThrUeTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnPro (SEQ ID NO:506) Příklad 85 15
Konstrukce pMON31114
Konstrukce pMON31114, plazmidu obsahujícího DNA sekvenci kódující multi-funkcního hematopoietického antagonistu receptoru, který aktivuje hIL-3 receptor a G-CSF receptor. -339- 20 CZ 295843 B6
Plazmid pMON13189 DNA se rozštěpí restrikčními enzymy Ncol a Xmal což vede kNeol, Xmal fragmentu vektoru, který se izoluje a čistí se z 0,8% agarózového gelu. DNA z druhého plazmidu, pMON13239 (WI94/12639, US 08/411,796), se štěpí Ncol a EcoRI, což vede k Ncol, EcoRI fragmentu s 281 páry bází. Tento fragment se izoluje a čistí se z 1,0% agarózového gelu. 5 Dva oligonukleotidy SYNNOXA1.REQ (SEQ ID NO:350) a SYNNOXA2.REQ (SEQ ID NO:351) se připojí k DNA fragmentu s 281 páry bází z pMON13239 do DNA fragmentu vektoru zpMON13189. Část ligační směsi se pak transformuje do E. coli K-12 kmen JM101. Transformované baktérie se selektují na ampicillin-obsahujících deskách. Plazmid DNA se vyizoluje, analyzuje restrikční analýzou, aby se potvrdila EcoRV fragmentu, a ten se sekvenuje, aby se 10 potvrdily správné inzerty.
Plazmid, pMON31114, obsahuje DNA sekvenci (SEQ ID NO:39), která kóduje následující sekvenci amino kyselin:
MetAlaAsnCysSerAsnMetlleAspGluIleDeThrHísLeuLysGlnProProLeuProLeu
LeuAspPheAsnAsnLeuAsnGlyGluAspGlnAspIleLeuMetGluAsnAsnLeuArgArg
ProAsnLeuGluAlaPheAsnArgAlaValLysSerLeuGlnAsnAIaSerAlalIeGluSerlle
LeuLysAsnLaiLeuProCysLeuProLeuAlaThrAlaAlaProThrArgHisProIlellelle
ArgAspGlyAspTrpAsnGiuPheArgArgLysLeuThrPhoTyrLeuLysThrLeuGluAsn
AlaGlnAlaGlnGlnTyrValGluGlyGlyGlyGIySerProdyGlMProSerGlyProIleSer
ThrlleAsáProSerProProSerLysGluSerHi&LysSerProAsnMetAlaThrGhiGlyAla
MetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGln
SerPheLéuGluValSerTyrArgValLeuArgHisLeuAIaGlnProSerGlyGlySeiGlyGly
SerGlnSerPheLeuLeuLysSerLeuGluGlnVaLArgLysneGlnGlyAspGíyAlaAlaLeu
GlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGiuLeuValLeuLeuGlyHis
SerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCys
LeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylle
SerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlle 5 TrpGlriGlnMetGluGluLeuGlyMetAlaProAlaLeuGInPro (SEQ ID NO: 507) Příklad 86 20 Konstrukce pMON31115
Konstrukce pMON31115, plazmidu obsahujícího DNA sekvenci kódující multi-funkční hemato-poietický antagonist receptoru, který aktivuje hIL-3 receptor a G-CSF receptor. -340- CZ 295843 B6
Plazmid pMON13197 DNA se rozštěpí restrikčními enzymy Ncol a Xmal, což vede kNeol, Xmal fragmentu vektoru, který se vyizoluje a čistí se z 0,8% agarózového gelu. DNA z druhého plazmidu, pMON 13222, se rozštěpí Ncol a EcoRI, což vede k Ncol, EcoRI fragmentu s 281 páry bází. Tento fragment se vyizoluje a čistí se z 1,0% agarózového gelu. Dva oligonukleotidy 5 SYNNOXA1 .REQ (SEQ ID NO:350) a SYNNOXA2.REQ (SEQ ID NO:351) se připojí k DNA fragmentu zpMON13222 s 281 páry bází do DNA fragmentu vektoru zpMON13197. Část ligační směsi se pak transformuje do E. coli K-12 kmenu JMI01. Transformované baktérie se selektují na ampicillin-obsahujících deskách. Plazmid DNA se vyizoluje, analyzuje se restrikční analýzou, aby se ukázala přítomnost EcoRV fragmentu a ten se sekvenuje, aby se potvrdily 10 správné inzerty.
Plazmid, pMON31115, obsahuje DNA sekvenci (SEQ ID NO:40), která kóduje následující sekvenci amino kyselin:
MetAlaAsnCysSerAsnMetlleAspGluIleBeThrHisLeuLysGlnProProLewProLaiLeu
AspPheAsnAsnLeuAsnGIyGluAspGlnAspIleLeuMetAspAsnAsnLeuArgArgPro
AsnLeuGluAlaPheAsnArgAlaValLysSerLeuGlnAsnAlaSerAlaDeGtuSerlleLeu
LysAsnLeuLeuProCysLeuProLeuAlaThrAlaAlaProThrArgHisProlleHisIleLysAsp
GlyAspTrpAsnGluPheArgArgLysLeuThrPheTyrLeuLysThrLeiiGluAsnAlaGlnAla
GlnGlnTyrVáGluGlyGJyGlyGlySerProGlyGluProSeKjlyProIleSerTMeAsnProSer
ProProSerLysGluSerHisLysSerProAsnMetAlaThrGlnGlyAlaMetProAlaPheAlaSer
AlaPheGlnArgArgAlaGlyGlyValLeuValAíaSerHisLeitGlnSerPheLeuGluValSerTyr
ArgValLeuArgHisLeuAlaGlnProThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeu
UsuLysSerLeuGluGlnValArgLysneCHnGiyAspGlyAJaAlaLeuGlnGhiLysLóuCysAla
ThrTyrLysLeuCysHisProGíuGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaPfO
LeuSerSerCysProSerGlnAIaLeuGíttLeuAJaGlyCysLeuSerGlnLeuHisSerGIyLajPhe
LeuTyrGhiGlyLeuLeuGinAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeu
GlrtLeuAspValAJaAspPheAlaThrThrleTrpGlnGlnMetGluGluLeuGlyMetAlaPro
AlaLeuGlnPro (SEQ ID NO: 508) Příklad 87 20 Stanovení in vitro aktivity proteinů multi-funkčního agonisty hematopoietického receptoru
Koncentraci multi-funkčního agonisty hematopoietického receptoru lze stanovit pomocí sendvičové ELISA založené na afmitně čištěných polyklonálních protilátkách. Alternativně se koncentrace proteinu může stanovit analýzou kompozice amino kyselin. Biaktivita multi-funkčního 25 agonisty hematopoietického receptoru se může stanovit řadou testů in vitro. Například multi- -341 - CZ 295843 B6 funkční agonista hematopoietického receptoru, který váže hIL-3 receptor a G-CSF receptor se mže testovat testy proliferace buněk pomocí buněčných linií vyjadřujících hIL-3 anebo G-CSF receptory. Jeden takový test je test proliferace buněk AML-193. AML-193 buňky obsahující na IL-3 a G-CSF, což dovoluje, aby se stanovila kombinovaná bioaktivita IL-3/G-CSF multi-5 funkčního agonisty hematopoietického receptoru. Jiným takovým testem je test proliferace TF1 buněk. Mimo to se mohou použít jiné buněčné linie závislé na faktoru, jako M-NFS-60(ATCC, CRL 1838) nebo 32D, což jsou myší buněčné linie závislé na IL-3. Aktivita IL-3 je druhově specifická, zatím co G-CSF není, tedy bioaktivita G-CSF komponenty IL-3/G-CSF multi-funkčního agonisty hematopoietického receptoru se může určit nezávisle. Buněčné linie, jako ίο BHK nebo myší Baf/3, která nevyjadřuje receptor pro daný ligand se může transfektovat plazmidem obsahujícím gen kódující žádaný receptor. Příkladem takové buněčné linie je BaF3 transfektovaný shG-CSF receptorem (BaF3/hG-CSF). Aktivitu multi-funkčního agonisty hematopoietického receptoru v těchto buněčných liniích lze srovnat s hIL-3 nebo G-CSF samotnými nebo společnými. Bioaktivita příkladů multi-funkčních agonistů hematopoietického 15 receptoru podle tohoto vynálezu, která se testovala testy proliferace buněk BaF3/hG-CSF a proliferace buněk TF1, je ukázána v tabulce 5 a v tabulce 6. Bioaktivita multi-funkčního agonisty hematopoietického receptoru je vyjádřena jako relativní aktivita srovnaná se standardním proteinem pMON13056 (WO 95/21254), který má aktivitu vázající IL-3 a G-CSF receptor. Bioaktivita příkladů multi-funkčních agonistů hematopoietického receptoru podle tohoto 20 vynálezu, která se testovala testy proliferace buněk BaF3/c-mpl proliferace buněk TF1, je ukázána v tabulce 7 a v tabulce 8. -342- CZ 295843 B6
Tabulka 5
Proliferační aktivita buněk duálních agonistů IL-3/G-CSF receptoru
BaF3/hG-CSF relativní aktivita TF1 pMON v testu prolíferace recepturové relativní aktivita v testu buňky* prolíferace buňky* 13182 0.015 1.1 13183 0.02 nd 13184 0.01 0.3 13185 0.023 0,36 13186 0.36 0,45 13187 0.07 0.26 13188 0.64 1.3 13189 0.58 1,37 13190 0.045 1.2 13191 0.14 2.7 13192 0.09 2.2 13193 0.06 3.0 25190 nd nd 25191 0.43 1.2 13194 ad nd 13195 1.3 4.3 13196 0.66 0.5 13197 0.6 0.77 13198 0.6 0.5 13199 nd nd 15982 0.7 1.9 15981 0.068 1.2 15965 0.7 0.82 15966 0.36 1.48 15967 0.62 1.37 nd = nestanoveno * Bioaktivita multi-funkčního agonisty hematopoietického receptoru se vyjadřuje jako relativní 10 aktivita srovnaná se standardním proteinem pMON13056. n=3 nebo větší -343 - CZ 295843 B6
Tabulka 6
Proliferační aktivita buněk duálních agonistů IL-3/G-CSF receptoru
BaF3/hG-CSF relativní TF1 pMON aktivita v testu proliferace relativní aktivita receptorové buňky v testu pmliferaee buňky 31104 + + 31105 4· + 31106 + + 31107 nd nd 31108 + + 31109 + + 31110 nd nd 31111 nd' nd 31112 + + 31113 Hh + 31114 + 31115 + + 31116 nd nd 31117 nd nd nd = nestanoveno + Bioaktivita (n=l nebo 2) multi-funkčního agonisty hematopoietického receptorového agonisty io se vyjadřuje jako relativní aktivita srovnaná se standardním proteinem pMON13056. n=3 nebo větší „+“ znamená, že molekula byla srovnatelná s pMON13056. -344- CZ 295843 B6
Tabulka 7
Proliferační aktivita buňky pMON BaO/c-mpl relativní aktivita v testu proliferace receptorove buňky* TFl test proliferační aktivity buňky 28505 - + 28506 - 4* 28507 - 4" 28508 - + 28509 - + 28510 - + 28511 + 4- 28512 4· 4- 28513 4· + 28514 4" + 28519 - 28520 - + 28521 - + 28522 - + 28523 - + 28524 - + 28525 + + 28526 + + 28533 - + 28534 - + 28535 - + 28536 - + 28537 - + 28538 - 4* 28539 4“ + 28540 + + 28541 + 4" 28542 + + 28543 + + -345 - CZ 295843 B6
Tabulka 7 (pokračování) 28544 + + 28545 + -f. * Aktivita naměřená v BaO buněčné linii transfektované c-mpl receptorem, relativně k c-mpl 5 ligandu (1-153). T Aktivita naměřená relativně k pMON13056.
Podobným způsobem se mohou použít k měření bioaktivity žádaného multi-funkčního agonisty 10 hematopoietického receptoru jiné buněčné linie závislé na faktoru, známé odborníkům v tomto oboru. Methylcelulózový test se může použít ke stanovení účinků multifunkčních agonistů hematopoietického receptoru na expresi hematopoietických progenitorních buněk a vzoru různých typů hematopoietických kolonií in vitro. Methylcelulózový test může poskytnout odhad frekvence prekurzů, protože se měří frekvence rodičovských buněk na 100 000 vložených buněk. 15 Aby se vymezily primerní linie krvetvorných rodičovských a kmenových buněk, použily se dlouhodobé kultury vazivové tkáně. Tento test se může použít k stanovení, zda multi-funkční agonist hematopoietického receptoru stimuluje expanzi velmi primitivních krvetvorných a/nebo kmenových buněk. Mimo to lze provést omezující ředění kultur, což poskytne odhad frekvence primitivních rodičovských buněk stimulovaných multi-funkčním agonistou hematopoietického 20 receptoru.
Tabulka 8 PMON# Aktivita IL-3 agonisty (AML test proliferace buněk) Aktivita agonisty c-mpl receptoru (Baf/3-c-mpl testpreliferace buněk) 28505 + - 28506 + - 28507 + - 28508 + - 28509 + - 28510 + - 28511 + + 28512 + + 28513 + + 28514 + + 28515 + + 28519 4* - 28520 + - -346- CZ 295843 B6
Tabulka 8 (pokračování) 28521 4· - 28522 + • 28523 + - 28524 + - 28525 + + 28526 + + 28527 + + 28528 + + 28529 + 4 28535 + - 28539 + + 28540 4 + 28541 + + 28542 4 4 28545 + + 28551 + + 28571 4 5 Příklad 88 G-CSF varianty, které obsahují substituce jednotlivých nebo mnoha aminokyselin, se připravily pomocí technik PCR mutageneze, jak je popsáno v WO 94/12639 a WO 94/12638. Tyto a jiné varianty (například substituce aminokyselin, inzerce nebo delece a N-terminální nebo C-io terminální extenze) by také mohl odborník v oboru získat pomocí řady jiných metod včetně sestavení syntetického genu nebo mutageneze zaměřené na místo (viz Taylor aj., Nucl. Acids Res., 13: 7864-8785 [1985]; Kunkel aj., Proč. Nati. Acad. Sci. USA, 82: 488-492 [1985]; Sambrook aj., Molecular Cloning: A Laboratory Manual, 2. vydání, Cold Spring, Harbor Laboratory Press, Cold Spring Harbor, NY, [1989], (WO 94/12639) a (WO 94/12638)). 15 Substituce je možné provést jednotlivě nebo v kombinaci s jinými substitucemi a/nebo delecemi a/nebo inzercemi anebo extenzí aminokyselin. Po sekvenčním ověření změn se plazmidová DNA se může transfektovat do vhodné savčí buňky, hmyzí buňky nebo bakteriálního kmenu jako E. coli pro produkci. Známé varianty G-CSF, které jsou aktivní, zahrnují substituce v polohách 1 (Thr na Ser, Arg nebo Gly), 2 (Pro na Leu), 3 (Leu na Arg nebo Ser) a 17 (Cys na Ser) a delece 20 aminokyselin 1-11 (Kuga aj. Biochemical and Biophysical Research Comm. 159: 103-111 (1989)). Tyto substituční varianty G-CSF aminokyselin se mohou použít jako matrice k vytvoření G-CSF agonistů receptorů, ve kterých se vytvoří nový N-konec a nový C-konec. Příklady substitučních variant G-CSF aminokyselin jsou uvedeny v tabulce 9. Příklad 89
Stanovení bioaktivity substitučních variant G-CSF aminokyselin 30 Substituční varianty G-CSF aminokyselin se mohou testovat na proliferační aktivitu buněk pomocí Baf/3 buněčné linie transfektované s lidským G-CSF receptorem. Bioaktivita -347- CZ 295843 B6 příkladných substitučních variantů G-CSF amino kyselin je uvedena v tabulce 9 relativně k nativnímu lidskému G-CSF. „+“ představuje srovnatelnou aktivitu k nativní a představuje významně sníženou nebo žádnou měřitelnou aktivitu.
Tabulka 9
Proliferační aktivita G-CSF variant v BAF3 buněčné linii transfektované s lidským G-CSF receptorem pozice nativní amino- mutantní amino· aktivita * aminokyseliny -kyselina •kyselina 13 Phe Ser + 13 Phe His + 13 Phe Thr + 13 Phe Pro + 16 Lys Pro "f· 16 Lys Šer + 16 Lys Thr +· 16 Lys His 18 Leu Pro + 18 Leu Thr + 18 Leu His + 18 Leu Cys + 18 Leu lle + 19 Glu Ala - 19 Glu Thr - 19 Glu Arg - 19 Glu Pro * 19 Glu Leu - 19 Glu Ser - 22 Arg Tyr + 22 Arg Ser + 22 Arg Ala + 22 Arg Thr +* 24 lle Pro + 24 llc Leu 24 De Tyr + 27 Asp Gly + 30 Ala Be + 30 Ala Leu + 34 Lys Ser + -348- CZ 295843 B6
Tabulka 9 (pokračování) 43 IBs Gly + 43 His Thr + 43 ms Val 4 43 His Lys 4· 43 His Trp 4* 43 His Ala + 43 His Arg 4* 43 His Cys + 43 His Leu + 44 Pro Arg + 44 Pro Asp + 44 Pro Val + 44 Pro Ala + 44 Pro His + 44 Pro Gin + 44 Pro Trp + 44 Pro Gly 4 44 Pro Thr + 46 Pro Ala 4 46 Glw Arg 4 47 Glu Thr + 49 Lea Phe 4 49 Leu Arg 4 49 Leu Ser 4 50 Leu His 4 54 Leu His + 67 Gin Lys + 67 Gis Leu + 67 Gla Cys + 70 Gin Pro 4 70 Gin Leu + 70 Gin Arg + 70 Gin Ser + 104 Asp Gly + 104 Asp Val + 108 Leu Ala + 108 Leu Val + 108 Leu Arg 4 108 Leu Gly + -349- CZ 295843 B6
Tabulka 9 (pokračování) 108 Leu Tip + 108 Leu Gin 115 Thr His + 115 Thr Leu 4- 115 Thr Ala 4“ 144 Phe His + 144 Phe Arg + 144 Phe Pro + 144 Phe Leu + 144 Phe Glu + 146 Arg Gin + 147 Arg Gin 4- 156 His Asp - 156 His Ser + 156 His Gly + 159 Ser Arg + 159 Ser Thr + 159 Ser Tyr + 159 Ser Val + 159 Ser Gly 162 Glu Gly - 162 Glu Trp + 162 Glu Leu + 163 Val Arg + 163 Val Ala + 163 Val Gly + 165 TVr Cys nd 169 Ser Leu + 169 Ser Cys + 169 Ser Arg + 170 His Arg Hh 170 His Ser + * aktivita relativně k nativnímu hG-CSF 5 nd = nestanoveno -350- CZ 295843 B6 Příklad 90
Izolace cDNA kódující flt3 ligand 5 Tři klony flt3 ligandu se amplifikují z lidské kostní dřeně póly A+ RNA (Clontech) pomocí NCOFLT, HINDI60 a HINDI65 PCR primerů (podle podmínek navrhovaných výrobcem). Tyto ampliflkované PCR produkty se přečistí na gelu a klonují se do BHK vektoru exprese pMON5723 za tvorby pMON30237 (NCOFLT + HIND 160), pMON30238 (NCOFLT + HIND 165) a klonu delece pMON30239 (NCOFLT + HIND165). Delece vpMON30239 ío představuje aminokyselinový zbytek 89 až 106. Příklad 91 15 flt3 agonisty receptoru s přeskládanou sekvencí se konstruují pomocí řady metod a typů spojovníku. Prvá množina konstruktů obsahujících spojovníkový peptid (SerGlyGlyAsnGly)X (kde X = 1,2, nebo 3) s místy zlomu 39/40, 65/66 a 89/90 se připraví pomocí dvojkrokového PCR procesu popsaného Mullins a kol., ve kterých čelní polovina a zadní polovina každé konečné sekvence přeskupené molekuly se připraví odděleně v prvém kroku PCR, potom 20 párované produkty prvého reakčního kroku se smíchají v druhém kroku PCR a rozšiřují se při absenci exogenních primerů. Například aby se připravily tři prekurzorní molekuly s místem zlomu 89/90 s SerGlyGlyAsnGly SEQ ID NO:786, SerGlyGlyAsnGlySerGlyGlyAsnGly SEQ ID NO:787 a SerGlyGIyAsnGlySerGlyGlyAsnGlySerGlyGlySsnGly SEQ ID NO:788, se spojovníky aminokyselin (pMON32326, pMON32327 a pMON32328), vytvoří se šest počátečních PCR 25 produktů. Následující páry primerů se použijí v prvém kroku PCR reakce: a) 89For/L5B; b) 89For/L10B; c) 89For/L15B; d) 89Rev/L5A; e) 89Rev/L10A; a f) 89Rev/L15A. Stejný přístup se použije k přípravě pMON32321 (39/40 místo zlomu páry primerů 39For/L10B a 39Rev/L10A) a pMON32325 (65/66 místo zlomu, páry primerů 65For/L5B a 65Rev/L5A) prekurzory. S výjimkou poznámky níže, všechny postupné PCR reakce užívají složky PCR Optrimizer Kit 30 (Invitrogen) a amplifíkační podmínky podle protokolu navrhovaného výrobcem. Reakce se nastaví následovně: 50 pmol každého primerů, 10 ul 5X pufru B [300 mmol Tris-HCl (pH 8.5), 10 mmol mgCl2, 75 mmol (NH4)2S04], 5 U Taq polymery a 100 ng teplem denaturované DNA (v tomto příkladě pMON30238) matrice se smíchají a vodou se doplní na konečný objem 45 μΐ. Reakce se předem inkubuje 1-5 minut při 80 °C, potom se přidá 5 μΐ 10 mmol dNTP ke každé 35 reakci a proběhne denaturace 2 minuty při 94 °C přes amplifíkací v Perkin Elmer model 480 DNA v amplifíkátoru. Provede se sedm cyklů DNA amplifíkace za následujících podmínek: denaturace teplem jednu minutu při 94 °C, dvě minuty dalších cyklů skládajících se z jedné minuty denaturace teplem při 94 °C následovně čtyři minuty annealing/extenze při 72 °C, a konečného 7 minutového cyklu extenze při 72 °C. S výjimkou pMON32328, produkty PCR 40 amplifíkace proběhnou elektroforézou na 1,2% TAE agarózovém gelu a proužky určité délky (hlavní produkt amplifíkace) se vyříznou a čistí se pomocí Geneclean II (Bio 101). Vzorky se resuspendují v 10 μΐ dH20. Produkty amplifíkace na pMON32328 se čistí přímo pomocí Wizard PCR Clean UP kit (Promega) a DNA se eluuje v 50 μΐ dH20. Metoda konstrukce prekurzorů pMON32322 (39/40 místo zlomu, pár primerů 39For/L5B a 39Rev/L5A) se modifikuje zvyšo-45 váním množství matrice na 1 pg a měněním podmínek PCR amplifíkace následovně: šest cyklů 94 °C, 1 minutu, 65 °C po 2 minuty a 72 °C po 2 1/2 minuty, následně 15 cyklů 94 °C po 1 minutu, 70 °C po 2 minuty a 72 °C po 2 minuty a jediný cyklus extenze při 72 °C sedm minut. Druhý PCR krok využívá gelem čištěné prekurzory z prvého PCR kroku jako kombinaci primer/matrice následovně: 5 μΐ každé prekurzorní molekuly (například pro pMON32328 PCR 50 produkty z páru primerů 89For/L5B a 89Rev/L5A), 10 μΐ 5X pufru B, 5 U Taq polymerázy a 24 μΐ dH20. Reakční směsi se zahřívají pět minut při 80 °C, přidá se 5 μΐ 10 mmol dNTP a reakční směsi se teplem denaturují při 94 °C po dvě minuty. Podmínky DNA amplifíkace jsou následující. 15 cyklů 94 °C jedna minuta, 69 °C dvě minuty, pak následně tři minuty extenze při 72 °C. Aby se umožnilo ukončení extenze, poslední cyklus byl následovaný jedním krokem -351 - CZ 295843 B6 extenze při 72 °C sedm minut. Inkubační doba při 80 °C se snížila na dvě minuty a počet cyklů se snížil na deset cyklů pro pMON32325 (PCR produkty 65For/L5B a 65Rev/L5A). PCR reakční produkty vhodné velikosti se čistily gelem na a 1,2 % TAE agarózovém gelu pomocí Geneclean II. Pro anneagling pMON32322 (39For/L5B a 39Rev/L5A) se teplota sníží na 68 °C a doba 5 annealing se sníží na dvě minuty. Mimo to PCR produkt se čistí pomocí Wizard PCR Clean Up kit (Promega) podle dodavatelem navrhovaného protokolu. Druhý PCR krok se modifikuje pro pMON32326 (PCR produkty z 89For/L15B a 89Rev/L15A) následovně. Tři nastavení PCR reakční směsi se provedou stejně jako shora, s výjimkou pro typ vzorku pufru (buď 5X pufř B, D, nebo J - PCR Optimizer Kit). Složení pufru D a J se liší od pufru B jen o pH nebo [MgCl2]. ío [MgCl2], v pufru D je 3,5 mmol, zatímco pH pufru J je 9,5. Protokol se modifikuje zvyšováním počtu PCR cyklů na 20, a 15 μΐ alikvoty se odebírají na konci cyklů 10, 15 a 20. Pět μΐ alikvotu v každém čase se analyzuje na přítomnost amplifikovaného produktu na 1,2% TBE agarózovém gelu. Zbytek pufru B, D, a J PCR reakční směsi se spojí a postupně se čistí pomocí Wizard PCR Clean Up Kit protokolu. DNA se eluuje v 50 μΐ dH20. 15
Vyčištěné vzorky z druhého kroku PCR reakce se rozštěpí s NcoI/HindlII pomocí jedné ze dvou standardizovaných podmínek štěpení. Pro Geneclean II čištěné vzorky se 10 μΐ DNA štěpí v 20 μΐ reakční směsi s 7,5 U každé NcoI/HindlII po dvě hodiny při 37 °C a čistí se na 1,1% TAE agarózovém gelu opět s Geneclean II. Vzorky připravené pro ligaci se resuspendují v 10 μΐ 20 0Η2Ο. Pro pMON32322, se 20 μΐ vzorek štěpí v 50 μΐ reakčního objemu s 20 U každé Ncol a
HindlII po 3 hodiny při 37 °C. Přidá se 0,1 objem 3 mol NaOAc (pH 5,5) a 2,5 objem EtOH, smíchá a skladuje se při -20 °C přes noc. DNA se získá centrifugám 20 minut při 13,000 otáčkách za minutu a 4 °C v mikroodstředivce Sigma Mk 202. Získaná DNA se promyje zchlazeným 70% EtOH, lyofilizuje se a resuspenduje se v 10 μΐ dH20. 25 Příklad 92
Jiný přístup se použije ke konstrukci pMON32320 (39/40 místo zlomu, spojovník s patnácti 30 amino kyselinami), pMON32323 (65/66 místo zlomu, spojovník s patnácti amino kyselinami) a pMON32324 (65/66 místo zlomu, spojovník s deseti amino kyselinami). Navrhly se nové primery (L15C, L15D, L15E), aby zahrnuly BamHI restrikční místo do primem, které bylo v rámci, aby se umožnilo klonování do BamHI místa a udržel se vhodný čtecí rámec. PCR reakční podmínky pro prvý krok se provede identicky k těm, které se popisují pro pMON32322 35 s výjimkou, že se použije následující skupina párů primerů: 65For/L15D a 65Rev/L15E (pMON32324); 39For/L15D a 39Rev/L15C (pMON32320); a 65For/L15D a 65Rev/L15C (pMON32323). PCR reakční produkty se čistí pomocí Wizard PCR Clean Up kit, jak se popisuje, a eluují se v 50 μΐ dH20. Vzorky se rozštěpí buď NcoI/BamHI (39For/L15D a 65For/L15D) nebo BamHI/HindlII (39Rev/L15C, 65Rev/L15C a 65Rev/L15E). Restrikční štěpení se provede 40 následovně: 10 μΐ čištěných produktů PCR reakce, 3 μΐ 10X univerzálního restrikčního pufru, 15 U buď Ncol nebo HindlII, 15 U BamHI v konečném reakčním objemu 30 μΐ. Reakce se inkubuje po 90 minut při 37 °C, a PCR produkty se přečistí na 1,1 % TAE agarózovém gelu pomocí Geneclean II. Ligačně-připravená DNA se resuspendovala v 10 μΐ dH20. Inzerty se připojí k NcoI/HindlII štěpenému pMON3977 (BHK savčího vektom exprese), který se ošetří 45 krabí alkalickou fosfatázou (SAP) buď třemi cestami (pMON32320, pMON32323, nebo pMON32324) nebo dvěma cestami (pMON32321, pMON32322, pMON32325, pMON32326, pMON32327 a pMON32328) ligační reakcí následovně: 2,5 μΐ inzertu (2 μΐ každého páru primerů amplikonu pro pMON32320, pMON32323 a pMON32324) se přidá k 50 ng vektoru v deseti μ reakční směsi pomocí standardních ligačních podmínek. Dva μΐ každé reakční směsi se 50 transformují s 100 μΐ chemicky kompetentních DH5 buněk (Gibco/BRL) podle protokolu navrhovaného výrobcem. Dvacet pět μΐ a 200 μΐ alikvoty se dají na desky LB obsahující 50 pg/ml ampicillinu a inkubují se přes noc. Izolované kolonie se seberou a DNA se připraví z 50 ml kultur přes noc pomocí souprav Qiagen DNA midiprep. DNA se kvantifikuje absorbancí při A260/A280 a ověří se na správnou velikost inzertu elektroforéz na agarózovém gelu -352- CZ 295843 B6 s následujícím štěpením 1 μg matrice NcoI/HindlII restrikčními endonukleázami. Vzorky obsahující inzerty předpokládané velikosti se sekvenují v obou orientacích pomocí vektor-specifických primerů pomocí automatizovaného fluorescenčního DNA sekvencovače model 373A (Perkin Elmer ABi). Sekvenovací reakce se provede v 20 μΐ reakčního objemu pomocí 5 amplifikátoru Perkin Elmer model 480 DNA následovně: jeden pg matrice, 3,2 pmol primeru, 1 μΐ DMSO, 9.5 μΐ Taq terminatorového dideoxy primeru (Perkin Elmer ABI) se smíchá a podrobí se 25 cyklům sekvenující amplifíkace následovně: 30 sekund při 94 °C, 15 sekund anaeling při 50 °C, následovně čtyřminutový cyklus annealingu při 60 °C. Vzorky se čistí pomocí Centri-Sep spin kolon (Princeton Separatins) podle protokolu navrhovaného výrobcem, ío lyofilizují a podrobí se sekvenční analýze. Vzorky obsahující předpokládané sekvence aminokyselin se vyberou pro analýzu a přidělí se jim pMON čísla. Příklad 93 15
Podobný přístup užitý ke konstrukci pMON32320, pMON32323 a pMON32324 se použil k zavedení druhého typu spojovníku (SerGlyGlySerGly)X, kde x = 2 nebo 3, do dvou sekvenčně přeskupených sekvencí obsahujících 39/40 místo zlomu (pMON32348 a 32350). Páry primerů jsou následující: pro pMON32348 kombinace 339For2/339Rev3 a 339Rev2/339-10For3 a pro 20 pMON32350 kombinace 339For2/339Rev3 a 339Rev2/339-15For3 se použijí, aby se vytvořily tři produkty PCR amplifíkace. Každá PCR amplifíkace se provede následovně: k 100 ng teplem denaturované pMON32320, 50 pmol každého páru primerů, 10 μΐ 5X pufru B, 5 U Taq poly-merázy, přidá se dH20 na konečný objem 45 μΐ. Reakce se předem inkubují, jak se popisuje shora. Provede se patnáct cyklů amplifíkace následujících podmínek: denaturace teplem při 94 °C 25 jedna minuta, následovně dvojminutový krok annealingu při 70 °C a tři minuty anaeling při 72 °C. Po posledním cyklu se provede jediný krok extenze při 72 °C po 7 minut. Produkty PCR amplifíkace, páry primerů 339For2/339Rev3, 339Rev2/339-10For3, a 339Rev2/339-15For2 se čistí pomocí Wizard PCR Clean Up kit (Promega) a eluují se v 50 μΐ dH20. NcoI/BamHI štěpení pro 339For2/339Rev3 pár primerů se provede následovně: 8 μΐ DNA matrice se smíchá s 2 μΐ 30 universálního restrikčního pufru a 10 U každé Ncol a BamHI v 20 μΐ reakčního objemu a inkubuje 90 minut při 37 °C. Produkt štěpení se čistí pomocí Geneclean II protokolu pro přímé čištění, a ligačně připravená DNA se resuspenduje v 10 μΐ dH20. Restrikční produkty a postupné čištění pro 339Rev2/339-10For3 a 339Rev2/339-15For2 produkty amplifíkace se provede stejně, jak se popisovalo při 339For2/339Rev3 amplikony s výjimkou, že 10 U HindlII se nahradila za 35 Ncol. Standardní ligace se provádí přidáním k 50 ng NcoI/HindlII/SAP-ošetřené, na gelu přečištěné pMON3977, 0,5 μΐ 339For2/Rev3 amplikonu, 1 μΐ buď 339Rev2/339-10For3 (pMON32348) nebo 339Rev2/339-15For3 (pMON32350) amplikonů, 5U T4 DNA ligázy a 1 μΐ 10 X pufru ligázy v 10 μΐ reakčního objemu po 60 minut při teplotě okolí. Následující kroky vedoucí ke konečnému prověření DNA sekvence se provedou podle popisu shora. 40 Příklad 94 Třetí typ spojovníku s proměnným motivem opakování (GlyGlyGlySer)X se zavede do jiné 45 skupiny sekvencí přeskupeného flt3 antagonisty receptoru z modulárně konstruovaných matric. Tyto délky spojovníku jsou: 6 AA spojovník (GlyGlyGlySerGlyGly SEQ ID NO:792), 7 AA spojovník (GlyGlyGlySerGlyGlyGly SEQ ID NO:793), 10 AA spojovník (GlyGlyGlySerGlyGlyGlySerGlyGly SEQ ID NO:794), 13 AA spojovník (GlyGlyGlySer GlyGlyGlySerGlyGlyGlySerGly SEQ IN NO:795), 15 AA spojovník 50 (GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGly SEQ ID NO:796); a 21 AA spojovník (GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGly SEQ ID NO:797) se zbytky amino kyselin. Tyto modulární matrice, každá obsahující dimér htfl3 ligandu oddělný BamHI-obsahující spojovníkem jednotné délky, se konstruují následovně. Šest PLAZMID mezimatric, FL3N, FL7N, FL11N, FL3C, FL4C a FL10C, se konstruuje PCR pomocí -353 - CZ 295843 B6 párovaných primerů a PMON30238 jako matrice podle amplifikačních podmínek podobných použitým pro pMON32322. Na reakci se přidá 50pmol každému primeru k lOOng teplem-denaturované matrice a reakce se upraví, jak se popisuje pro pMON32322. Amplifíkační podmínky jsou následující: sedm cyklů 94 °C jednu minutu; dvě minuty při 65 °C a 2,5 minut při 5 72 °C; následovně deset cyklů jednu minutu při 94 °C, dvě minuty při 70 °C a 2,5 minuty při 72 °C. Jediná sedmiminutová extenze při 72 °C ukončila amplifíkační reakce. Páry primerů použité ke konstrukci každého meziproduktu jsou; N-term/FLN3 (FL3N); N-term/FLN7 (FL7N); N-term/FLNl 1 (FL11N); C term/FLC3 (FL3C); C-term/FLC4 (FL4C); a C-term/FLClO (FL10C). Produkty PCR amplifikace se čistí Wizard PCR Clean Up kits (Promega) io a eluují se v 50 μΐ dH20. Čištěná DNA pro prvou podmnožinu FL3N, FL7N a FL11N, se rozštěpí NcoI/BamHI čištěnými gelem, jak se popisovalo dříve, a připojí se k NcoI/BamHI/Sap-ošetřenému pSE420 vektoru DNA (Invitrogen).
Mezimatrice druhé podskupiny, FL3C, FL4C a FL10C, se konstruují identickým způsobem 15 s výjimkou, že HindlII se použije místo Ncol. Následující kroky vedoucí ke konečnému potvrzení DNA sekvence se použijí podle výše uvedeného popisu. Příklad 95 20 K přípravě konečných šest matric se rozštěpí dvě podskupiny meziproduktů v pSE420 buď sNcoI/Bamffl (FL3N, FL7N, FLllN-subset 1) nebo BamHI/HindlII (FL3C, FL4C, FL10C-subset 2) a přečistí se na gelu pomocí Geneclean Π, jak je popsáno výše. Jeden amplikovaný meziprodukt z každé podskupiny se připojí k NcoI/HindlII/SAP-ošetřenému pMON3977 na 25 reakci a transformuje se do DH5a buněk, jak je popsáno výše, pomocí následující kombinace, aby se vytvořily specifické délky spojovníku: šest AA spojovník (FL3N a FL3C), sedm AA spojovník (FL3N a FL4C), deset AA spojovník (FL7N a FL3C), třináct AA spojovník (FL3N a FL10C), patnáct AA spojovník (FL11N a FL4C) a 21 AA spojovník (FL1 ln a F110C). DNA se připravila z 50 ml kultury přes noc z jediné kolonii z každé šesti kombinací, jak je popsáno výše, 30 analyzovala se na správnou velikost inzertu NcoI/HindlII restrikční analýzou, a použila se jako matrice. Páry primerů 39For/39Rev (39/40 místo zlomu); 65For/65Rev (65/66 místo zlomu) a 89For/89Rev (89/90 místo zlomu) se použily k PCR amplifikace každé matrice, jak se popisuje pro pMON32322 s výjimkou, že se použilo 75 pmol každého primeru. Amplifíkační podmínky se modifikovaly následovně: šest cyklů při 94 °C jednu minutu, 2 minuty při 70 °C, 2,5 minuty při 35 72 °C; následně devět cyklů při 94 °C jednu minutu a tři minuty při 72 °C. Po posledním cyklu následuje konečná extenze šest minut při 72 °C, která poskytuje dost času pro plnou extenzi produktů. Vzorky se čistí pomocí Wizard PCR Clean UP kit, jak je uvedeno výše, a dvojitě se rozštěpí NcoI/HindlII. Tyto produkty amplifikace se čistí opět pomocí Wizard PCR Clean Up kit. Mimo to všech šest molekul spojovníku s různou délkou pro 39/40 místo zlomu se klonuje do 40 NcoI/HindlII/SAP-ošetřeného pMON3977 jako jednotlivé proteiny (pMON32365, pMON32366, pMON32367, pMON32368, pMON32369 a 32370). Následující kroky vedoucí ke konečnému potvrzení DNA sekvence se provedou jak je popsáno výše. 45 Příklad 96
Zkonstruovaly se geny kódující molekuly multi-funkčního chimémího agonisty receptoru skládající se zIL-3 agonisty receptoru, zpMON13416 (WO 94/12638) spojeného přes IgG2b spojovníku buď k nativnímu flt3 ligandu nebo k sekvenci přeskupeného flt3 agonisty receptoru, 50 příklad 91-93. Inzerty obsahující žádanou molekulu sekvenčně přeskupeného flt3 agonisty receptoru se izolují z parenterálního plazmidu jako NcoI/HindlII restrikční fragment a připojí se k pMON30304 štěpeného AflIII/Hind III/SAP. Postupné kroky vedoucí ke konečnému potvrzení DNA sekvence se provedou jak je popsáno výše. Výsledné plazmidy obsahující DNA sekvenci kódující multi-funkční chimérní molekuly obsahující agonistu IL-3 receptoru (z pMON13416) a 55 sekvenčně přeskupeného agonistu flt3 receptoru jsou uvedeny v tabulce 9. -354- CZ 295843 B6
Tabulka 9 Výsledný plazmid prekurzory permuteinů flt3 ligandu pMON30247 pMON30237 pMON30248 pMON30238 pMON32332 pMON32321 PMON32333 pMON32320 pMON32334 pMON32325 pMON32335 pMON32324 pMON32336 pMON32323 pMON32337 pMON32328 pMON32338 pMON32327 pMON32339 pMON32326 Příklad 97 Zkonstruovaly se geny kódující molekuly multi-funkčního chimémího agonistu receptoru skládající se zIL-3 agonisty receptoru, zpMON13288 (WO 94/12638) spojeného přes IgG2b spojovník buď k nativnímu flt3 ligandu nebo k sekvenci přeskupeného flt3 agonisty receptoru, příklady 91-93. Inzerty obsahující žádanou molekulu sekvenčně přeskupeného flt3 antagonisty receptoru se izolují z parentálního plazmidu jako NcoI/HindlII restrikční fragment a připojí se k pMON30311 štěpenému AflIII/Hind III/SAP. Postupné kroky vedoucí ke konečnému prověření DNA sekvence se provedou jak je popsáno výše. Výsledné plazmidy obsahující DNA sekvenci kódující multi-funkční chimérní molekuly obsahující agonistu IL-3 receptoru (z pMON13416) a sekvenčně přeskupeného agonistu flt3 receptoru jsou uvedeny v tabulce 10.
Tabulka 10 20
Vzniklý plazmid Prekurzory Flt3 ligandu pMON32364 ΡΜΟΝ30237 pMON32377 pMON30238 pMON32352 pMON32321 pMON32353 PMON32320 pMON32354 pMON32325 pMON32355 pMON32324 pMON32356 pMON32323 pMON32357 PMON32328 pMON32358 pMON32327 pMON32359 pMON32326 pMON32360 PMON32348 pMON32362 pMON32350 pMON32396 pMON30239 -355- CZ 295843 B6 Příklad 98 5 Dvě chimémí molekuly se sekvenčně přeskupeným komponentem hflt3 antagonisty receptoru uN-konce chimémí molekuly se zkonstruují pomocí PCR, pMON32360 a pMON32362 plazmidové DNA jako matrice a párů primerů N-term/134rev a N-term/139 rev, aby se nahradil stop kodon u C-konce molekuly nativního flt3 ligandu s inframe SnaBI restrikčním místem. Reakční směsi se připraví jak je popsáno výše pro pMON32322. Amplifikační podmínky jsou ío následovně: sedm cyklů při 94 °C jednu minutu, 65 °C dvě minuty a 72 °C 2 1/2 minut a provede se dalších 10 cyklů amplifikace, ve kterých se teplota annealingu zvýší z 65 °C na 70 °C. Vzorky se čistí pomocí Wizard PCR Purification kitu a protokolu a eluují se v 50 μΐ dH20, 20 μΐ každého vzorku se rozštěpí Ncol a SnaBI. Plazmíd, pMON26431, DNA se rozštěpí Ncol a SnaBI a spojí se s produkty PCR reakce štěpenými Nco/SnaBI. Transformace kompetentních DH5 buněk a 15 postupné kroky vedoucí ke konečnému potvrzení DNA sekvence se provedou jak je popsáno výše. Příklad 99 20 Pět dalších míst zlomu hflt3 ligandu se připraví pomocí primerů 28/29 (28For/28Rev), 34/35 (34For/34/Rev), 62/63 (62For/62Rev), 94/95 (94For/94Rev) a 98/99 (98For/98Rev) pro amplifíkaci spojovníku s deseti a patnácti amino kyselinami (GlyGlyGlySer)x, jak je popsáno výše. Výsledné PCR produkty se rozštěpí NcoI/HindlII a smíchají se s pMON30311, rozštěpí se 25 AflIII/HindlII/SAP, jak je popsáno výše. Transformace kompetentních DH5 buněk a postupné kroky vedoucí ke konečnému potvrzení DNA sekvence se provedou jak je popsáno výše. Příklad 100 30
Pro zvýšenou expresi sekvenčně přeskupených agonistů hflt3 receptorů v E. coli se použijí N— terminální specifické primery kódující degenerované kodony k re-engineeringu forem 1-134 a 1-139 nativního hflt3 ligandu vE. coli vektoru exprese pMON5723. Páry primerů FH3AFor/SCF.rev (Ala2) a Flt23For/SCF (Gly2) se použijí kPCR amplifíkaci N-terminální 35 degenerované směsi sekvence kódující nativní flt3 ligand pomocí reakčních podmínek, jak je popsáno pro pMON23222, s tou výjimkou, že počet cyklů amplifikace se sníží na patnáct cyklů 1 minuta při 95 °C, 2 minuty při 55 °C a 2 1/2 minut při 72 °C. Amplikony se čistí pomocí Wizard PCR Clean up kit (Promega) a eluují se v 50 μΐ dH20. Restrikční štěpení NcoI/HindlII a následné gelové čištění pomocí Geneclean II se provede podle popisu výše. Inzerty se připojí 40 k NcoI/HindlII/SAP-ošetřené, na gelu přečištěné plazmidové DNA pMON5723 a transformují se do kompetentních DH5oc buněk, jak je popsáno výše. Alikvoty transformovaných buněk se dají na desky sLB agarózovým médiem obsahujícím 75 pg/ml spectinomycinu, inkubující se 14-16 hodin při 37 °C a kolonie se spočítají. Po prověření kolonií se zbytek každé transformační směsi inkubuje přes noc (14-16 hodin) při 37 °C v 2 x 5 ml LB media obsahujícího 75 pg/ml 45 spectinomycinu, inkubují se 14-16 hodin při 37 °C a kolonie se spočítají. Po prověření kolonií se zbytek každé transformační směsi inkubuje přes noc (14-16 hodin) při 37 °C v 2 x 5 ml LB media obsahujícího 75 pg/ml spectinomycinu. Miniprep DNA se připraví pomocí Wizard DNA 373A Miniprep kit (Promega) podle doporučeného protokolu. Čištěná miniprep DNA se eluuje v 50 μΐ dH20 a 1-2 μΐ se použijí k transformaci chemicky kompetentních MON207 buněk. 25 a 50 200 μΐ alikvoty se dají na desky LB média obsahující 75 pg/ml spectinomycinu a inkubují se 12- 15 hodin při 37 °C. Kolonie izolované z 40-50 jamek, každá reprezentující originální pár primerů se selektují a rozprostřou se na LB/spectinomycin master deskách a inkubují se dalších 4-6 hodin při 37 °C. -356- CZ 295843 B6
Individuální sekvenčně přeskupené klony hflt3 agonisty receptoru se prověří na E. coli expresi v mikrotitračním formátu s 96 jamkami k selekci na zlepšenou úroveň exprese. Na jamku se naočkuje 100 μΐ minimálního M9 média (včetně 1% kasaminové kyseliny) s jedinou kolonií (40-50 izolátů se analyzuje na každý hflt3 PCR pár primem), inkubuje se při 37 °C a 200 otáčkách za 5 minutu po 3-4 hodiny (1=0) a indukuje se přidáním 5 μΐ/jamku 1 mg/ml čerstvě připravené nalidixové kyseliny (v 0,1 N NaOH). Po dalších čtyřech hodinách inkubace při 37 °C (1=4) se odeberou asi 5-10 μΐ alikvoty z každé jamky a analyzují se světelnou mikroskopií na přítomnost refraktivních částic a výsledky se vyjádří jako přibližná procenta buněk obsahujících refraktilní částice k celkovému počtu buněk. Klony mající nejvyšší úroveň exprese se selektují na násle-ío dovné studie exprese v 10 ml. Pět ml kultury inkubované přes noc se pěstuje vLB médiu v přítomnosti 75 pg/ml spectinomycinu při 37 °C. V 10 ml čerstvě připraveném minimálním M9 (s 1% kasaminovou kyselinou) v 125 ml třepacích baňkách se provede inokulace s dostatkem buněk inkubovaných přes noc, aby se dosáhl počáteční odečet 20 Klettových jednotek a potom se inkubuje asi 3-4 hodiny při 37 °C za třepání dokud se nedosáhne hustoty asi 110-150 Klettových 15 jednotek (1=0) a indukce 50 μΐ čerstvě připravené nalidixové kyseliny (10 mg/ml v 0,1 N NaOH). Jeden ml alikvotu se odstraní a buňky se peletují po jednu minutu v mikroodstředivce. Super-natanty se odstraní odsátím a pelety se skladují při -20 °C, dokud nejsou připravené pro SDS-PAGE analýzu. Zbytek indukovaných buněk se inkubuje po další čtyři hodiny při 37 °C za třepání, po této době (1=4) se změří hustota buněk (v Klettových jednotkách). Jedno ml alikvoty 20 se odstraní z každého vzorku, peletují se a skladují, jak je popsáno výše. Jiný 5-10 μΐ alikvot se odstraní z každé baňky a analyzuje světelnou mikroskopií na přítomnost refraktivních částic. Peletované vzorky se resuspendují v objemu (v μΐ) 2X pufru pro elektroforézu (včetně 1% B-merkaptoethanolu) rovného hodnotě 1=4 Klettových jednotek, vaří se 5 minut a 6-7 μΐ se elektroforézuje na 12% nebo 14% Tris-Glycin SDS polyakiylamidovém gelu (Novex) 90 minut 25 při 90 voltech. Gely se fixují, barví se a připraví se pro sušení podle doporučeného protokolu (Novex). Klony se selektují pro zvýšenou expresi založenou na vytvoření jediného indukovaného proužku proteinu (1=4) odpovídajícího předpokládané velikosti ve srovnání s 1=0 vzorky.
Midiprep DNA se také připraví ze selektovaných klonů vykazujících vysokou úroveň induko-30 váného proteinu, jak je popsáno výše, a kroky vedoucí ke konečnému potvrzení DNA sekvence se provedou též přesně podle výše uvedeného popisu. Tyto klony se označí pMON32329, pMON32330, pMON32341 a pMON32342. 35 Příklad 101
Také se konstruovala skupina chimémích molekul multi-funkčních agonistů receptoru obsahujících IL-3 agonistů receptoru (z pMON13288) a nativní flt3 ligand pro expresi v E. coli. Geny kódující chimérní molekuly multi-funkčního agonisty receptoru zpMON32364 a pMON32377 40 se uvolní z parenterálního vektoru štěpením Ncol/Hind III a připojí se kpMON5677 vektoru, transformují se do MON207 buněk a jednotlivé izoláty se odeberou, jak je popsáno výše. Tyto konstrukty se označí pMON32394 (inzert z pMON32364) a pMON32395 (inzert z pMON32377). 45 Příklad 102
Zkrácený Flt3 receptor se izoluje jako 1,4 Kb PCR produkt pomocí 50 pmol primerů FLTAFLS1 a FLTR1N s přibližně 10 ng plazmidové pMON27184 jako matrice. Primery se navrhnou 50 k produkci AflIII restrikčního místa ve směru 5' k prvému Asn kodonu vznikající kódující sekvence a také jak EcoRI restrikční místo ve směru 5' k předpokládané transmembránové oblasti. Reakční směs se rozštěpí s AflIII a EcoRI pomocí standardních reakčních podmínek a spojí se sNcoI/EcoRI štěpeným plazmidem pMON26458. Tento plazmid obsahuje následující DNA sekvenci: -357- CZ 295843 B6 5-GGATCCACCATGAGCCGCCTGCCCGTCCTGCTCCTGCTCCAACTCCTGGTCCGCCC CGCCATGGCTAAAGCTT - 3' SEQ ID NO:857, kódující IL-3 signální sekvenci. Tato sekvence obsahuje BamHI restrikční místo na 5' konci a zahrnuje ATG methionin jako prvou aminokyselinu signální sekvence 3' k BamHI místu. Tato signální sekvence se štěpí buňkou, za vzniku 5' Met/Ala spojením Ncol místa signální sekvence s AflIII místem receptoru vzniklého PCR reakcí. Celá zkrácená forma receptoru spolu s IL-3 signální sekvencí by se mohla vyříznout z vektoru jako štěp BamHI/EcoRI (hIL3L/hFflt3R).
Znovu se vytvořila katalytická doména pMON30298 (hG-CSFR), aby vzniklo in frame EcoRI restrikční místo u transmembránové/cytoplazmické vazby pomoci PCR - následovně: k 0,5 pg teplem denaturované pMON30298 se přidala 100 pmol každého primeru HGCFfor a HGCFrev, 10 μΐ 5X pufru J, 5U Taq polymerázy a dH20 na konečný objem 45 μΐ, jak je popsáno výše. PCR amplifíkace se provede následovně: šest cyklů (jedna minuta při 94 °C, dvě minuty při 64 °C a tři minuty při 70 °C), následované devíti cykly (jedna minuta při 94 °C, čtyři minuty při 70 °C). Konečná jednominutová extenze se provede sedm minut při 70 °C. Deset μΐ každé PCR reakční směsi se přečistí na gelu pomocí Geneclean II, jak je popsáno výše, a eluuje se v 10 μΐ dH20. Vzorky se rozštěpí 10 U každé EcoRI a HindlII v 20 μΐ reakční směsi během 90 minut při 37 °C. Vzorky se opět přečistí na gelu (Geneclean II), jak je uvedeno výše, a eluují se v 10 pg dH20. Dva μΐ inzertu se spojí s 50 ng NcoI/HindlII/fosfatázovaného pSE420 vektoru v 10 μΐ reakční směsi popsané výše. Transformace kompetentních DH5a buněk a následné kroky vedoucí ke konečnému potvrzení DNA sekvence se provedou přesně, jak je popsáno výše. Selektované klony se potom sekvenují k ověření přítomnosti in frame EcoRI místa a také k potvrzení správné G-CSFR katalytické domény DNA sekvence. Klony obsahující předpokládané sekvence se rozštěpí s EcoRI/HindlII, jak je popsáno výše, a přečistí se na gelu. Vyčištěné inzerty hG-SCFR (EcoRI/HindlII) a hIL3L/hFlt3R (BamHI/EcoRI) fragmentů se připojí k BamHI/HindlII/fosfatá-zovanému pcDNA 3.1 (-) vektoru (Invitrogen). Transformace kompetentních DH5a buněk a následné kroky vedoucí ke konečnému potvrzení DNA sekvence se provedou, jak je popsáno výše. Příklad 103
Další geny kódující sekvence přeskupených Flt3 ligandů se konstruují pomocí dimémích meziproduktů matrice dříve popsaných. Pro flt3 agonistu receptoru s přeskupenou sekvencí flt3 agonisty receptoru mající spojovník s patnácti amino kyselinami (GlyGlyGlySerjjGlyGlyGly SEQ I NO:795 se použijí jako matrice dimémí meziprodukty Flt4C.seq a FltlN.seq. Místa zlomu odpovídající aminokyselinovým zbytkům 28/29, 34/35, 62/63, 94/95 a 98/99 Flt3 ligandu, se zkonstruují pomocí PCR za použití PCR Optimizer kit (Invitrogen) a následujících párů primerů, FL29For/F129rev, FL35For/FL35rev, FL63For/FL63rev, FL95For/FL95rev, FL99For/FL99rev, jak je popsáno v příkladu 94. Podmínky amplifíkace byly následující: sedm cyklů při 94 °C 1 minutu, 62 °C 2 minuty a 2,5 minut při 70 °C; dvanáct cyklů při 94 °C 1 minutu, při 68 °C po 2 minuty a při 70 °C 2,5 minuty; následovaný konečným cyklem 7 minut při 72 °C. PCR produkty odpovídající předpokládané velikosti inzertu se rozštěpí Ncol a HindlII a přečistí se na gelu, jak je popsáno dříve, pomocí Gene Clean II (Bio 101) podle výrobcem navrhovaného protokolu. Vzorky se rozsuspendují v 10 μΐ konečného objemu v dH20. Inzerty se klonují jako jednotlivé geny do savčího vektoru exprese pMON3934 (NcoI/HindlII/SAP ošetřené) a označí se pMON35712, pMON35713, pMON35714, pMON35715, pMON35716, pMON35717 a pMON35718.
Geny kódující chimérní proteiny obsahující agonistu IL-3 receptoru kódované pMON13288 (WO 94/12638), zde označované jako „IL-3 agonista receptoru I“, a sekvenčně přeskupený Ftl3 ligand se připraví klonováním PCR produktů s páry primerů místa zlomu 28/29, 34/35, 62/63, 94/95 a 98/99 místy zlomu do AflIII/HindlII/SAP-ošetřeného pMON30311 po přečištění - 358 - CZ 295843 B6 restrikčních štěpů. Výsledné plazmidy se označí jako pMON32398, pMON35700, pMON35702, pMON35704 a pMON35706. Mimo to se použijí stejné páry primerů ve spojení s meziprodukty dimémí matrice Flt7N.seq a Flt3C.seq ke konstrukci spojovníku s deseti amino kyselinami (GlyGlyGlySer)2GlyGly SEQ ID NO:793, forem těchto chimérních proteinů IL-3 agonisty receptoru I/Flt3L; pMON32397, pMON32399, pMON35701, pMON35703 a pMON35705. Příklad 104
Geny kódující chimémí proteiny IL-3 agonisty receptoru I/FU3L obsahující zbytek spojovníku s 21 amino kyselinami (GlyGlyGlySer)5Gly SEQ ID NO:796 se zkonstruují pomocí podobného PCR přístupu pomocí meziproduktů chimérní matrice Fltl 1N. seqa FltlOC.seq a následující párů primerů; Flt36/36rev, Flt37/37rev, Flt38/38rev, Flt39/39Rev, Flt41/41rev, Flt42/42rev a Flt43/43rev. Tyto páry primerů odpovídají následujícím místům zlomu Flt3 ligandu 35/36; 36/37; 37/38; 38/39; 40/41; 41/42; a 42/43 (39/40 místo zlomu se dříve konstruovalo jako pMON32376) a použijí se pro PCR amplifikaci pomocí následující amplifíkačních podmínek: sedm cyklů při 94 °C -1 minutu, 66 °C - 2 minuty a 2,5 minuty při 70 °C; patnáct cyklů při 94 °C - 1 minutu a 70 °C po 4 minuty; následované konečným cyklem 7 minut při 72 °C pomocí Invitrogen PCR Optimizer kit (pufr B). Po dokončeném potvrzení DNA sekvence se konstrukty označí jako pMON35733, pMON35734, pMON35735, pMON35736, pMON35738, pMON35739, pMON35740, pMON35741, pMON35742 a pMON35743. Chyby PCR inkorporace vedou ke dvěma jednotlivým substitucím aminokyselin sekvenčně přeskupeného Flt3 chimérního patrna (pMON35741, 35/36 místo zlomu; pMON35743, 42/43 místo zlomu) a jednoho konstruktu (pMON35742, 38/39 místo zlomu) obsahujícího dvě substituce aminokyselin Q133 až R133 a Q100 až R100 a L112 až P112 v Flt3L skupině, které se konstruují a testují jako část těchto sérií.
Další chimémí proteiny Flt3L/IL-3 antagonisty receptoru I, ve kterých alternativní Flt3L místa zlomu odpovídají zbytkům aminokyselin Flt3 ligandu 28/29, 34/35, 62/63, 65/66, 89/90, 94/95 a 98/99, dříve popsaným, se také konstruují se spojovníkem s patnácti amino kyselinami (GlyGlyGlySer)3GlyGlyGly matrice FLt4C a FLtllN. PCR reakční směsi jsou podobné popsaným v příkladu 103 s výjimkou, že reverzní primery kódující C-konec sekvenčně přeskupených Flt3 skupin se modifikují záměnou HindlII restrikčníhomísta SnaBI rozlišovací sekvencí. Parametry cyklu PCR amplifikace jsou následovně: sedm cyklů při 94 °C - 1 minutu 66 °C -2 minuty, a 2,5 minuty při 70 °C; čtrnáct cyklů při 94 °C po 1 minutu a 70 °C po 4 minuty; následované konečným cyklem 7 minut při 72 °C. PCR čištění, restrikční štěpení a čištění se provedou, jak je popsáno výše. Inzerty se připojí k NcoI/SnaBI/SAP-ošetřenému pMON26431 (BHK vektoru exprese obsahujícímu skupinu IgG2b spojovník/IL-3 agonista receptoru skupiny I), následně: 50 ng ošetřeného vektoru, inzert (10:1 inzerťvektor), I jednotka T4 DNA ligázy (Gibco BRL) a 1 μΐ 10X pufr ligázy v 10 μΐ reakčního objemu. Ligace se inkubují jednu hodinu při okolní teplotě, potom se odeberou 2 μΐ každé ligační směsi a použijí se k transformaci 100 μΐ chemicky kompetentních DH10B (alternativně DH5a) buněk (Gibco BRL) podle protokolu navrhovaného výrobcem. Jedno pětinové a 1/25 objemy každé transformační směsi se dají na agarové desky obohacené vhodnými antibiotickými značkovači a inkubují se přes noc (14-lójiodin) při 37 °C. Izolované kolonie se sklidí a DNA se připraví podle Qiagen midiprep protokolu, jak je popsáno výše.
Sekvenční analýzou selektované klony se prověří na 28/29 místo zlomu (pMON35719), 34/35 místo zlomu (pMON35720), 62/63 místo zlomu (pMON35721), 65/66 místo zlomu (pMON35722), 89/90 místo zlomu (pMON35723) a 98/99 místo zlomu (pMON35725). pMON35726 obsahuje jednotlivé substituce aminokyselin (Leu94 až Phe94) pro 94/95 místo zlomu. Flt3L/IL-3 chimémí konstrukty antagonistu receptoru I s Flt3L místem zlomu 39/40 a proměnným počtem aminokyselin spojovníku 10, 15 a 21 AA jsou reprezentovány pMON35707, pMON35708, pMON35709, pMON35710 a pMON35711. Tyto konstrukty se vytvoří PCR amplifikaci jedné z následujících matric; pMON32373, pMON32375, nebo pMON32376 a Flt3L-specifického páru primerů 39N TERM-1/SNAB1C TERM. Standardní PCR reakční směsi -359- CZ 295843 B6 se připraví podle popisu výše a DNA produkt se amplifíkuje pomocí následujících parametrů: sedm cyklů při 94 °C - 1 minutu, 62 °C - 2 minuty a 2,5 minut při 70 °C; dvanáct cyklů při 94 °C 1 minutu, 68 °C - 2 minuty a 70 °C - 2,5 minuty; s následovaným konečným cyklem 7 minut při 72 °C. PCR produkty odpovídající předpokládané velikosti inzertu se úplně rozštěpí 5 Ncol a SnaBI, přečistí se na gelu a klonují se, jak je popsáno výše, do savčího vektoru exprese pMON26431 (NcoI/SnaBI/SAP ošetřené) jako Flt3L/IgG2b/IL-3 chimérní proteiny agonisty receptoru I. Dva tyto konstrukty obsahují chyby PCR inkorporace v sekvenčně přeskupeném Flt3 chimérním partneru, což vede k jednotlivým substitucím aminokyselin F96 až L96 a E58 až G58 (pMON35710apMON35711). 10 Příklad 105
Jiné série chimérních proteinů, sekvenčně přeskupené Flt3/IL-3 agonisty receptoru I s místy 15 zlomu odpovídajícími zbytkům aminokyselin Flt3 ligandu 35/6, 36/37, 38/39, 40/41, 41/42, 42/43 a 65/66 dříve popsaný, a spojovníku s 21 aminokyselinami, se také konstruují pomocí selektovaného antagonistu IL-3 receptor I/sekvenčně přeskupené Flt3L konstrukty jako matrice (viz tabulka 11 níže). Jednou výjimkou je, že matrice spojovníku s patnácti amino kyselinami (pMON35715) se použila ke konstrukci 65/66 místa zlomu, pMON35771. 20
Tabulka 11
Flt3L/IL-3 agonista receptoru IIL-3 agonista receptoru I/Flt3L 25
Konstruktmatrice Flt3L místo zlomu Pár primerů pMON35744 pMON35733 35/36 Flt36/36Rev’ pMON35745 pMON35734 36/37 Fk37/37Rev' pMON35746 pMON35735 37/38 Flt38/38Rev* pMON35747 pMON35736 38/39 Flt39/39Rev* pMON35748 pMON35738 40/41 Flt41/41 Rev’ pMON35749 pMON35739 41/42 Fh42/42Rev’ pMON35750 pMON35740 42/43 Flt43/43ReV pMON35769 pMON35743 42/43 Flt43/43Rev· pMON35771 pMON35715 65/66 65For/66SnaBI
Použijí se páry primerů kódující stejná restrikční místa jako ty, co se použily ke konstrukci pMON35719-35725. Reverzní primery 36Rev', 37 Rev', 38 Rev', 39 Rev', 41 Rev', 42 Rev' a 30 43 Rev' se použijí k vytvoření in frame SnaBI místa. Použily se stejné forward primery Flt36,
Flt37, Flt38, Flt39, Flt41, Flt42 a Flt43. PCR reakční směsi jsou identické s popsanými dříve, avšak s výjimkou pMON35771, podmínky amplifikace se modifikují následovně: 18 cyklů při 94 °C - 1 minutu, 68 °C - 2 minuty a 70 °C - 2,5 minuty a následně jeden cyklus extenze při 70 °C - 7 minut. Pro pMON35771 amplifíkační podmínky jsou následovně: šest cyklů při 35 94 °C - 1 minutu, 66 °C - 2 minuty a 2,5 minuty při 70 °C; patnáct cyklů při 94 °C - 1 minutu a 70 °C - 4 minuty a následně konečný cyklus 7 min při 72 °C. Flt3-specifické PCR produkty amplifikace se restrikčně rozštěpí, přečistí se a klonují se do pMON26431 (BHK vektoru exprese obsahující skupinu IgG2b spojovník/IL-3 agonista receptoru I), jak je popsáno v příkladu 104. -360- 5 CZ 295843 B6
Jedna varianta, pMON32179, se konstruuje jako 34/40 místo zlomu pomocí PCR páru primerů Flt40/34Rev a dimérní matrice meziproduktů FltlN.seq a FltlOC.seq. Podmínky PCR ampli-fikace a následné klonování jsou identické s použitými ke klonování pMON35771. Tři další chimérní Flt3L/IL-3 agonisté receptoru I (38/39 místo zlomu) se navrhnou a konstruují se pro testování účinků proměnlivé délky a složení spojovníku. Pomocí pMON35709 jako matrice, se délka GlySer spojovníku expanduje k dosažení 29 zbytků aminokyselin s motivem (GlyGlyGlySer)7Gly pomocí páru primerů BamForl/38Rev (reakční produkt uváděný jako PCR 10 A) a Flt38/BamRevl (reakční produkt uváděný jako PCR B). Podmínky amplifikace jsou následující: šest cyklů při 94 °C - 1 minutu, 66 °C - 2 minuty a 2,5 minuty při 70 °C; patnáct cyklů při 94 °C - 1 minutu a 70 °C - 4 minuty; následované konečným cyklem 7 minut při 72 °C. Výsledné PCR produkty se čistí pomocí a Promega PCR clean up kit a rozštěpí se bud’ s NcoI/BanHI (PCR A) nebo BamHI/SnaBI (PCR B), čistí se gelem a připojí se k pMON26431 15 (BHK vektor exprese obsahující skupinu IgG2b spojovník/IL-3 antagonist receptoru I skupina), jak je popsáno výše. Výsledný konstrukt se sekvenčně ověří a označí pMON35774. Při srovnání se pMON35775 a 35776 liší tím, že GlySer spojovník se nahradí nativními Flt3L zbytky amino kyselin 140-154 (pMON35775) nebo 140-160 (pMON35776) obsahujícími jedinou substituci aminokyseliny. PCR reakční podmínky jsou identické, jak se popisuje pro pMON35774 20 s výjimkou, že se použijí následující páry primerů: 38For/Navfor a 38Rev/NavRevS (pMON35775); a 38For/Navfor a 38Rev/NavRevL (pMON35776). Kaši se substituuje za BamHI, jinak kroky klonování těchto produktů PCR amplifikace jsou identické s použitými pro pMON3574. Sekvenční analýza ukázala chyby indukované PCR v mnohanásobných izolátech pro oba pMON35775 a 35776. Aby se získala konečná správná sekvence, je potřeba znovu 25 rozštěpit selektované subklony s Narl/SnaBI a Ncol/Narl a použít tyto fragmenty přečištěné na gelu, aby se reklonovaly žádané konstrukty.
Konstruovala se také řada Flt3L dimémích chimémích molekul pro testování jako BHK transienty. pMON32173, sestávající ze dvou nativních Flt3 molekul spojených IgG2b spojov-30 níkem se sestaví ze dvou předem existujících molekul následovně: NcoI/SnaBi Flt3L-obsahující inzert zpMON32393 se připojí kNcoI/SnaBI výřezu přečištěném na gelu, pMON32377, ve kterém se uvolní chimérní partner IL-3 agonisty receptoru I. Podobně pMON35727 (39/40 místo zlomu, spojovník s patnácti amino kyselinami) se sestaví pomocí Flt3L inzertu z pMON35708 (jako NcoI/SnaBI inzert) přečištěného na gelu pMON32375, ve kterém se vyřízne IL-3 chimérní 35 partner agonisty receptoru. Třetí Flt3L dimér, pMON32168, (39/40 místo zlomu, spojovník s 21 aminokyselinami) se sestaví následovně: NcoI/SnaBi inzert zpMON32165 (E. coli ekvivalentní pMON35709, sestavený subklonováním NcoI/BamHI fragmentu zpMON32163 a BamHI/HindlII fragmentu pMON35709 do NcoI/HindlII-rozštěpeného pMON5723). NcoI/SnaBi inzert z pMON32165 (Flt3L 1-139 (39/40)L21) a SnaBI/Hindffl inzert (IgG2/Flt3L 40 1-139 (39/40)L21) zpMON32376 se subklonují do E. coli vektoru produkce pMON5723, což vytvoří pMON32167. NcoI/HindlII inzert z pMON32167 se potom subklonuje do pMON30304 a označí se jako pMON32168. 45 Příklad 106 Série trimérních molekul, každá skládající se ze dvou Flt3L skupin a jediné kopie IL-3 agonisty receptoru I nebo IL-3 agonisty receptoru II (IL-3 agonista receptoru kódovaný pMON13416 (WO 94/12638), zde označovaný jako „agonista IL-3 receptoru II“), se také konstruuje z předem 50 existující molekuly pomocí restrikčně štěpených fragmentů přečištěných na gelu. pMON35728 se sestaví pomocí NcoI/EcoRI (Flt3L/IgG2b/IL-3 receptorový agonista I) inzertů zpMON32375 a EcoRI/HindlII (IL-3 antagonista receptoru I/IgG2b/F113L) inzertu zpMON35708. Dva fragmenty se potom znovu připojí k NcoI/HindlII/SAP-ošetřenému savčímu vektoru exprese pMON3934 a subklonují se, jak je popsáno výše. pMON32205 (IL-3 agonista receptoru 55 II/IgG2B/Flt3 1—139/IgG2B/Flt3 1-139) se vytvoří připojením NcoI/HindlII fragmentu -361 - CZ 295843 B6 zpMON32173 k AflIII/HindlII místu pMON30304. Podobný přístup se použije ke konstrukci pMON32206 (IL-3 agonista receptoru MgG2b/Flt3L (39/40)L21/IgG2b/Flt3L (39/40)L21). NcoI/HindlII fragment zpMON32167 se přečistí na gelu a subklonuje se do AflIII/Hind III— štěpeného pMON30304 (který obsahuje IL-3 antagonist receptoru II/IgG2b-skupinu). Plazmid 5 pMON32207 (Flt3L (39/40)L21/IgG2b/Flt3L (39/40)L21)/G-CSF) se získá subklonováním inzertu NcoI/HindlII čištěného na gelu zpMON32170 do meziproduktu pMON32198 (AflIII/HindlII). pMON32208 (Flt3L l-139/IgG2b/G-CSF/IgG2b/Flt3Ll-139) se vytvoří subklonováním inzertu SnaBI čištěného na gelu z pMON30320 (jako IgG2b/G-CSF) do SnaBI-štěpeného/SAP-ošetřeného pMON32173. pMON32204 se vytvoří subklonováním NcoI/HindlII 10 inzertu zpMON32173 do AflIII/HindlII-štěpeného pMON30309 (který obsahuje G-CSF/IgG2b). pMON32195 (Flt3L l-139(39/40)L21/IgG2b/G-CSF/Flt3L 1—139(39/40)L21) se zkonstruuje subklonováním NcoI/SacI inzertu zpMON32190 a SacI/HIndlII fragmentu zpMON32171 do NcoI/HindlII-štěpeného pMON30304. pMON32196 (G-CSF/IgG2b/Flt3L 1-139(39/40)L21/IgG2b/Flt3L 1-139) se vytvoří subklonováním NcoI/AflIII fragmentu 15 zpMON30309 (jako G-CSF/IgG2b) do NcoI/SAP-ošetřeného pMON32168 (Flt3L 1-139(39/40)L21/IgG2b/Flt3L 1-139) a ověřením orientace DNA sekvenční a restrikční analýzou. pMON32197 (G-CSF/IgG2b/Flt3L l-139(39/40)L21/IgG2b/Flt3L 1-139 (39/40)L21) se konstruuje subklonováním NcoI/HindlII inzertu zpMON32167 (Flt3 1-139(39/40)L21/IgG2b/Flt3L 1-139 (39/40)L21) do AflIII/HindlII místa vpMON30309 (βίο CSF/IgG2b). Příklad 108 25 Série molekul obsahujících Flt3L se konstruuje jako BHK transienty náhradou IL-3 agonisty receptoru I nebo IL-3 agonisty receptoru II s G-CSF jako chimémím partnerem. Pro chimémí proteiny exprimované přechodně a připravené pomocí BHK vektoru pMON3934, může G-CSF skupina kódovat v poloze 17 Ser nebo Cys. Pro molekuly použité buď k expresi E. coli nebo nepřechodnou expresi v savčích systémech exprese, je v poloze 17 G-CSF partnera kódovaný 30 výhradně Ser. Chiméry nativního Flt3L a G-CSF se připraví jako BHK konstrukty exprese v obou orientacích: G-CSF/IgG2b/Flt3L (pMON30329) a Flt3L/IgG2b/G-CSF (pMON32175). pMON30329 se sestaví subklonováním Flt3L 1-139 inzertu zpMON30238 (jako Ncol/Hind III digest) do pMON30309 (který obsahuje G-CSF/IgG2b), štěpí se AflIII/HindlII, zatím co pMON32175 se konstruuje pomocí NcoI/SnaBI inzertu, čištěného na gelu, zpMON32393 do 35 NcoI/SnaBI štěpené pMON262420 (který obsahuje IgG2b/G-CSf gen). Třetí nativní chimérní molekula G-CSF/Flt3L, pMON32191, se liší od pMON32175 v tom, že má GlySer spojovník na místě IgG2b chimérního spojovníku, jak se navrhl pro expresi v E. coli. pMON321912 se sestaví pomocí stejného NcoI/SnaBI inzertu, přečištěného na gelu, zpMON32393 do NcoI/SnaBI štěpeného pMON31123 (který obsahuje GlySer/G-CSF gen). BHK ekvivalent, pMON35767, se 40 sestaví subklonováním NcoI/HindlII chimérního genu, přečištěného na gelu, zpMON32191 do BHK vektoru pMON3934. Příklad 109 45
Dvě série sekvenčně přeskupených Flt3L chimér se konstruují náhradou složky IL-3 agonisty receptoru I v G-CSF. Prvá množina s orientací G-CSF/IgG2B/ sekvence přeskupené Flt3L, se sestaví následovně: pMON30329 (G-CSF/IgG2b/Flt3L 1-139) se štěpí SnaBI/HindlII a vektorem obsahujícím G-CSF skupinu čištěnou na gelu, jak je popsáno výše. SnaBI/HindlII-50 štěpené inzerty z vhodných konstruktů IL-3 agonistů receptorů I/Flt3L jsou uvedeny dále v tabulce 12. Ty se potom subklonují do pMON30329 (SnaBI/HindlII). -362- CZ 295843 B6
Tabulka 12 G-CSF/IgG2b/Flt3L konstrukty a jejich analogy IL-3 agonisty receptoru I Flt3L místo zlomu pMON(G-CSF) pMON (IL-3 receptoru aeonista I) 35/36L21 pMON32188 pMON35733 89/90L21 pMON32273 pMON32389 37/38L21 pMON35795 pMON35735 38/39L21 pMON35796 pMON35?36 40/41L21 pMON35797 pMON35738 41/42L21 pMON35798 pMON35739 42/43L21 pMON35799 pMON35740 5 pMON32169 (G-CSF/IgG2b/Flt3L 1-139 (39/40)L21) se sestaví pomocí NcoI/BamHI inzertu zpMON32163 a BamHI/HindlII inzertu zpMON32370 subklonovaných do AflIII/HIndlII-štěpené pMON30309. Tři molekuly v těchto sériích nemají žádné přímé přímočásti IL-3 agonisty 10 receptoru I. Prvý, pMON39914, se sestaví pomocí BHK vektoru exprese pMON30309 (který obsahuje G-CSF/IgG2b), rozštěpí se AfllII/HindlII a Flt3 1-139 (39/40)L29 inzertem z pMON32243 (jako NcoI/HindlII). Pro pMON39915, Flt3L 1-154 (39/40) gen z pMON32242 (jako NcoI/HindlII inzert) se subklonuje do parentálního vektoru pMON30309. pMON39916 se sestaví přesně jako pMON39915 s tím rozdílem, že se použije inzert Flt3L 1—160 (39/40) 15 z pMON32252. pMON32242, 32243 a 32252 jsou konstrukty E. coli exprese obsahující nechimérní sekvenčně přeskupený Flt3L gen (jako NcoI/HindlII). Konečně inzert z pMON35799 se subklonuje do pMON5723 (jako NcoI/HindlII fragment) pro expresi v E. coli. Tento E. coli produkční plazmid se označí jako pMON39904. 20 Příklad 110
Zkonstruovalo se též mnoho chimér z druhé série G-CSF s orientací Flt3L/IgG2b/G-CSF ze svých analogů IL-3 antagonisty receptoru I, jak je uvedeno dále v tabulce 13. -363 - CZ 295843 B6
Tabulka 13
Flt3L/IgG2b/G-CSF konstrukty a jejich analogy IL-3 agonisty receptoru I místo zlomu pMON(G-CSF) pMON(IL-3 receotoru aaonistv I) 39/40L1G pMON35751 pMON35707 39/40L15 pMON35752 pMON35708 39/40L21 pMON35753 pMON35709 89/90L15 pMON35754 pMON35723 35/36L21 pMON35755 pMON35744 36/37L21 pMON35756 ΡΜΟΝ35745 37/38L21 pMON35757 pMON35746 34/35L15 pMON35759 pMON35720 65/66L15 pMON35760 pMON35722 98/99Π5 pMON35765 pMON35725 5
Tyto konstrukty se sestaví pomocí NcoI/SnaBI-štěpeného pMON36113 (BHK vektor obsahující IgG2b/G-CSF gen) a specifických NcoI/SnaBI-štěpených sekvenčně přeskupených Flt3L inzertů chimérních proteinů z Flt3L/IL-3 agonisty receptoru I v tabulce výše. Výsledné plazmidy se ío označí jako pMON32170, pMON32871, pMON32271, pMON32172, pMON32174, pMON35751, pMON35752, pMON35753, pMON35754, pMON35755, pMON35756, pMON35757, pMON335758, pMON35759, pMON35760, pMON35761, pMON35762, pMON35763, pMON35764, pMON35765, pMON35766, pMON35767, pMON35768, pMON35770, pMON35772, pMON35773, pMON35777, pMON35778, pMON35779, 15 pMON35780, pMON35782 a pMON39908. pMON35777 a pMON35778 se zkonstruují pomocí PCR a sestaví se ze stejných Ncol/Narl a Narl/SnaBI inzertů, jak se popisuje pro pMON35775 a pMON35776, stím rozdílem, že NcoI/SnaBI-štěpený pMON35751 se použije jako parentální vektor obsahující IgG2b/G-CSF 20 gen. Ke konstrukci ekvivalentu pMON35778 s 39/40 místem zlomu, se použije pár primerů Flt40/SnaBI C-konec k reamplifikaci pMON35778 matrice. Podmínky amplifikace se použijí stejné, jako pro pMON35771 s tím rozdílem, že počáteční Tanneai se sníží z 66 na 55 °C. Výsledný konstrukt se označí jako pMON35782 (Flt3 1-160 (39/40)/IgG2b/G-CSF). 25 pMON32170 (Flt3L l-139(39/40)L21/IgG2B/G-CSF) se sestaví pomocí NcoI/SnaBI inzertu zpMON32165, připojí se k NcoI/SnaBI-štěpenému pMON26430 (který obsahuje IgG2B/G-CSF). pMON35764 (Flt3L (38/39)L21/IgG2b/G-CSF) se klonuje následovně: sekvenčně přeskupený Flt3 inzert se amplifíkuje pomocí matrice pMON35736 a páru primerů Flt39/39Rev. Podmínky amplifikace jsou identické s použitými pro pMON35771, s tím rozdílem, že počáteční 30 Tanneai se sníží z 66 to 56 °C. NcoI/SnaBI štěpená PCR amplifikace se subklonuje do NcoI/SnaBI-štěpeného pMON35754 obsahující IgG2b/G-CSF gen. pMON35768 (Flt3L (38/39)L21/IgG2b/G-CSF) má mutaci u zbytku 15 (Ser na Phe) Flt3 chimémího partner. pMON35762 (Flt3 matrice pMON35739), pMON35763 (Flt3 matrice 35738), pMON35758 (Flt3 matrice 35740), pMON35770 (pMON35743 jako Flt3L matrice se zkonstruují přesně, jak se 35 popisuje pro pMON35764. pMON35772, a S125 až F125 mutant sekvenčně přeskupeného Flt3 genu v pMON35760, se klonuje PCR pomocí pMON35715 jako Flt3 matrice a páru primerů -364- CZ 295843 B6 65For/655SnaBI. PCR amplifíkačrií podmínky jsou identické s použitými k amplifikaci Flt3 genů zpMON35733, pMON35734, pMON35735 a pMON35736 popsaných dříve. pMON35761 je Q133 až R33 mutant sekvenčně přeskupeného Flt3L genu v pMON35758. pMON35773 (Flt3L 1-139 (38/39)L29/IgG2B/G-CSF) se klonuje, jak se popisuje pro pMON35774, s tím rozdílem, že 5 se použije pMON26430 (NcoI/SnaBI/SAP-ošetřené) obsahující IgG2b/G-CSF gen jako parentální vektor.
Ke konstrukci ekvivalentu s 39/40 místem zlomu, se použije pMON35773 jako matrice v PCR amplifíkační reakci s párem primerů Flt40/SnaBI C-term. Amplifikace se provede přesně, jak se io popisuje pro pMON35771. NcoI/SnaBI-štěpený produkt amplifikace se subklonuje do pMON26430 (NcoI/SnaBI/SAP-ošetřeného), což vede kpMON35779 (Flt3L 1-139 (39/40)L29/IgG2B/G-CSF). pMON35780 je varianta pMON35779 a kóduje jedinou mutaci aminokyseliny (L60 na P60) sekvenčně přeskupeného Flt3 chimérního partnera. pMON32190 (Flt3L 1-139 (39/40)L21/GS/G-CSF) obsahuje alternativní GlySer chimérní spojovník, který 15 nahrazuje IgG2b spojovník pMON32170. NcoI/SnaBI fragment Flt3L genu zpMON32165 (Flt3L 1-139 (39/40)L212/IgG2b/IL-3 receptorový agonista I vE. coli vektoru exprese pMON5723) se subklonuje do NcoI/SnaBI-štěpeného pMON31123. BHK expresní ekvivalent, pMON35766, se zkonstruuje subklonováním celého Flt3L/GlySer/G-CSF chimérního inzertu jako NcoI/HindlII fragmentu do pMON3934. 20 pMON39908 je podobný pMON35779 s tím rozdílem, že zbytky 133-160 Flt3L aminokyselin se nahradí sekvencí aminokyselin VETVFHRVSQDGLDLLTS SEQ ID NO:798, která je homologní k alternativními spojené variantě Flt3L (Genbank přístupové číslo HSU29874). pMON32190 se použije jako PCR matrice s následujícím nastavením páru primerů Flt40/XbaRev 25 a SnaBICterm/XbaFor. Podmínky amplifikace se použijí stejně jako pro pMON35771 stím rozdílem, že počáteční Taniiac] se sníží z 66 na 64 °C. Oba PCR produkty přečištěné na gelu se rozštěpí buď Ncol/Xbal (Flt40/XbaRev PCR produkt) nebo Xbal/SnaBI (SnaBICterm/XbaFor PCR produkt) a subklonují se do pMON26430 (zreagovaného s NcoI/SnaBI/SAP). pMON32273 (Flt3L 1-139 (39/40)L21/IgG2b/G-CSF) se zkonstruuje PCR zpMON35777 spárem primerů 30 FltConNco/Grev k reamplifikaci 38/39 Flt3L skupiny jako 39/40. Přečištěný amplikon se rozštěpí sNcoI/SnaBI a subklonuje se do NcoI/SnaBI-štěpeného pMON32191 a označí se pMON32259 (pro E. coli produkci). Pro BHK expresi se NcoI/HindlII inzert z pMON32259 subklonuje do pMON3934 (NcoI/HindlII). 35 Příklad 103
Zkonstruují se jiné série chimérních proteinů, ve kterých Flt3L partner obsahuje jednu nebo dvě Cys mutace (Tabulky XIA a XIB). pMON35790 (Flt3L 1-139 (C4^S4, C85->S85)/GS/G-CSF 40 (Serl7)), se zkonstruuje PCR pomocí pMON32191 jako matrice u páru primerů ClFor/C3Rev a C3For/139Rev ve dvou reakcích. pMON35791 (Flt3L 1-139 (C93^S93, C132->S132)/GS/G-CSF (Serl7)), se také zkonstruuje PCR pomocí pMON32191 jako matrice a páru primerů C5For/C6Rev a C5Rev/N-term. Podmínky amplifikace použijí jako pro pMON35771 stím rozdílem, že počáteční Tannaei se sníží z 66 na 64 °C. Druhé kolo PCR se provede pomocí 45 amplikonů (10 μΐ každého) z prvého kola a PCR produkty se potom přečistí, rozštěpí se sNcoI/SnaBI a subklonují se do NcoI/SnaBI-štěpeného pMON32191. Podmínky PCR amplifikace pro druhé kolo se modifikují následovně: počáteční Tanneai se zvýší na 68 °C a počet cyklů se zvýšil z 6 na 15. Žádná další amplifikace není nutná. Tyto konstrukty PMON35787 (C4 -► S4, C85-S85), a pMON35788 (C93-+S93, CI23->S132) se použijí pro expresi E. coli. BHK 50 expresní ekvivalenty, pMON35790 a 35791, se zkonstruují subklonováním správně mutovaných Flt3L/GlySer/G-CSF chimérních inzertů jako NcoI/HindlII fragmenty do pMON3934. pMON35792 (Flt3L l-132(C,32->Sl32)/GlySer/G-CSF (Serl7)) se zkonstruuje PCR pomocí pMON32191 jako matrice a páru primerů FLDlRev/FltNTerm. -365- CZ 295843 B6 PMON39905 (Flt3L 1-139 (C132^S,32)/GlySer/G-CSF (Ser 17)) se zkonstruuje PCR pomocí pMON32191 jako matrice a páru primerů FLMlRev/FltNTerm. pMON39906 (Flt3L 1-139(C127—>S127/C32—>S132)/GlySer/G-CSF (Serl 7)) obsahuje jednu substituci aminokyseliny ve zbytku 127 sekvenčně přeskupeného Flt3L partnera, výsledek chyb během PCR amplifikace 5 pMON39905. pMON32276 (Flt3L 1-139 (39/40)L21(C4-»S4/C85->S85)GlySer/G-CSF (Serl 7» se zkonstruuje dvěma koly PCR. Vytvoří se tři počáteční amplikony: PCR1 (pMON32190 matrice a pár primerů G10L/85N); PCR 7 (pMON32190 matrice a pár primerů 4N/85S); a PCR 4 (pMON32198 10 matrice a pár primerů 4S/3605Rev.). Pro druhé kolo se PCR1, 4 a 7 re-amplifikují ve smíchané směsi, což vede k PCR A. PCR A se přečistí, rozštěpí se NcoI/SnaBI a subklonuje do pMON30277 (GlySer/G-CSF). Příští tři konstrukty se generují podobným způsobem. pMON32277 (G-CSF (Serl7)/IgG2B/Flt3L 1-139 (39/40)L21(C4-+S4/C85^S85)) prvým kolem PCR generuje tři počáteční amplikony: PCR1 (pMON32190 matrice a pár primerů G10L/85N); 15 PCR 7 (pMON3219 matrice a pár primerů 4N/85S); a PCR 6 (pMON32169 matrice a pár primerů 4S/360RRev). Pro druhé kolo se PCR1, 6 a 7 re-amplifikují ve smíchané směsi vedoucí k PCR B. PCR B se přečistí, rozštěpí se NcoI/HindlII a subklonuje se do NcoI/HindlII-štěpeného pMON30309 (G-CSF(Serl7)/IgG2B). pMON32278 (Flt3L 1-139 (39/40)L21(C93^S93/C132-*S132)/GlySer/G-CSF (Serl7)) v prvém kole PCR se generují tři 20 počáteční amplikony: PCR2 (pMON32190 matrice a pár primerů G10L/93N); PCR 8 (pMON32190 matrice a pár primerů 132N/93S); a PCR 3 (pMON32198 matrice a pár primerů 132S/3605Rev). Pro druhé kolo se PCR2, 3 a 8 re-amplifikuje ve smíchané směsi, což vede k PCR C. PCR C se přečistí, rozštěpí se NcoI/SnaBI a subklonuje do pMON30277 (GlySer/G-CSF). pMON32279 G-CSF (Serl7)/ígG2B/Flt3L 1-139 (39/40)L21 (C93->S93/C 132^S132)) 25 prvým kolem PCR generuje tři počáteční amolikony. PCR2 (pMON32190 matrice a pár primerů G10L/93N); PCR8 (pMON32190 matrice a pár primerů 132N/93S); a PCR 5 (pMON32169 matrice a pár primerů 132S/3605Rev). Pro druhé kolo se PCR2, 5 a 8 re-amplifikuje ve smíchané směsi, což vede k PCR D. PCR D se přečistí, rozštěpí se NcoI/HindlII a subklonuje se do N col/HindlII-štěpeného pMON30309 (G-CSF(Ser 17)/IgG2b). 30 Příklad 112 pMON39909 (Flt3L l-139(39/40)L21/GS/G-CSF(Serl7)(133/132)) je jedním ze dvou Flt3/G-35 CSF chimérních proteinů, ve kterých jsou oba proteiny sekvenčně přeskupené. NcoI/AflIII fragment zMON32198 obsahující Flt3L l-139(39/40)L21/GlySer gen se subklonuje do NcoI/SAP-ošetřeného pMON25187 (E. coli produkční plazmid obsahující jedinou kopii G-CSF(Serl 7)(133/132)). Po ověření DNA sekvence se chimémí inzert subklonuje do pMON3934 jako NcoI/HindlII fragment a označí se pMON39909. pMON39910 (G- 40 CSF(Serl7)(133/132/IgG2B/Flt3L 1—139(39/40)L21) se zkonstruuje PCR pomocí PMON25l87 jako matrice a páru primerů GPForl/GPRev2. Podmínky amplifikace jsou identické s použitými pro pMON39908. NcoI/SnaBI-štěpený G-CSF(Serl7)(133/132) se subklonuje do NcoI/SnaBI místa pMON32376 obsahujícího IgG2B/Flt3L 1-139 (39/40)L21 gen. 45 Příklad 113 pMON40000 je produkční plazmid modifikovaný zpClneo (Promega) obsahující G-CSF(Ser 17)/GlySer/Flt3L 1-139 (39/40)L21 po expresi vNSO buňkách (pMON32169 je BHK 50 ekvivalent). pMON40000 obsahuje element CMV IE promotor/zesilovač, IL-3 vedoucí sekvenci bezprostředně proti směru CSF(Serl7)/GlySer/Flt3L 1-139 (39/40)L21, zkrácený promotor thymidin kinázy, SV40 pozdní póly A signální sekvenci a několik hypersenzitivních oblastí (část IgH 3 min LCR) DNAsy 1. -366- 55 CZ 295843 B6 Příklad 114
Bioaktivita multi-funkčních chimémích hematopoietických agonistů receptorů 5
Tabulka 14
Test in vitro multi-funkčních chimérních hematopoietických agonistů receptorů
Klon BAF3/FLT3L ProIifer*ee‘ BAF3/FLT3L ProKferoce a CFU-GM Kolonie 5 pMON30247 +4 + + pMON32l69 +++ Ή-4 pMON32175 pMON32190 +++ pMON32191 -M4 Λ * » WT* pMON32333 + pMON32342 ++ pMON32352 + + PMON32360 + 4* PMON35766 + PMON40000 1 t > TTT ΡΜΟΝ400024 +4 •HHh 10
Legenda: +: Snížená aktivita ve srovnání s kontrolou 15 ++: Ekvivalentní aktivita ve srovnání s kontrolou +++: Zvýšená aktivita ve srovnání s kontrolou -367- CZ 295843 B6 1 Srovnáno s kontrolou: pMON30247 2 Srovnáno s kontrolou: pMON32352 3 Srovnáno s vhodnou společně přidávanou kontrolou 4 Analyzováno ve skupině klonů pMON40000 a pMON40002 Příklad 115 Stanovení bioaktivity 10
Tabulka 15
Ex vivo biotest multi-funkčních chimérních agonistů hematopoietických receptorů 15
Kion(y)) Hematopoietícká expanze ex vivo1 Expanze dendritických buněk ex vivo2 Celková expanze Neutrofilní prekursory Mega- karyocytové prekursory Celková expanze Funkce pMON32175 + + + PMON32191 + + +4* 4-4- 44 pMON32360 4* + + +4 H-3 reccptorový agonista 1, MFR agonista I, MFR agonista Π ++ . 1 » TT ++ D-3 reccptorový agonista I, MFR agonista!, MFR agonista Π, pMON30247 +++ ++ 1 1 1 FIT 11-3 reccptorový agonista I, MFR agonista I, MFR agonista II, pMON323ÓO 4-H* ++ +4* -368 - CZ 295843 B6
Tabulka 15 (pokračování) 11-3 receptorový agonista I, MFR agonista I, MFR agonista II, pMON32333 -H- 4-f *H" H-3 receptorový agonista I, MFR agonista 1, MFR agonista H, pMON3219J +++ +++ +++ B-3 receptorový agonista 1, MFR agonista I, MFR agonista Q, pMON32175 ++ +-H* +4+ MFR agonista Π, pMON32!91 + +++ pMON30247 +++ PMON32352 ++ 5 'Legenda: +: Snížená aktivita ve srovnání s IL-3, IL-6, SCF, G-CSF (kontrola s literaturou) ++: Ekvivalentní aktivita s IL-3, IL-6, SCF, G-CSF ((kontrola s literaturou) (mezi 20%)) -H-+: Zvýšená aktivita ve srovnání s IL-3, IL-6, SCF, G-CSF (kontrola s literaturou) 10
Kultivační podmínky: X-Vivo 10 Média, 37 °C, 5% C02, 11 dnů inkubace 2Legenda: 15 +: Snížená aktivita ve srovnání s GM-CSF, TNFa, SCF (kontrola s literaturou) ++: Ekvivalentní aktivita ve srovnání s GM-CSF, TNFa, SCF ((kontrola s literaturou)(mezi 20%)) +++: Zvýšená aktivita ve srovnání s GM-CSF, TNFa, SCF (kontrola s literaturou) 20 Kultivační podmínky: IMDM-20 média obohacená lOOng/ml GM-CSF, 100 ng/ml TNFa 20 ng/ml SCF, při 37 °C/5% C02 po 18-22 dnů MFR agonista I = pMON31140 (WO 95/21197) MFR agonista II = pMON28571 (WO 97/12985) -369- CZ 295843 B6
Test hematopoietické ex vivo expanze CD34+ obohacené progenitorní buňky z lidské kostní dřeně se vyizolují a kultivují se v koncentraci 5xl04 buněk/ml v X-Vivo 10 + 1% HSA s testovanými cytokiny a kontrolami, aby se zjistil expanzní potenciál cytokinů. Buňky expandují a znovu se dají na desky v koncentraci 5x104 buněk/ml s novým médiem a cytokiny kolem 5 dne podle růstu buněk. 10. den se buňky sklidí a charakterizují se. Buňky se z desek odeberou a zředí se na koncentraci lxlO6 buněk/ml. Stanoví se celková expanze buněk a buňky se charakterizují na hematopoietické progenitorní buňky CFU Pre- a Post expanzí v methylcelulóze (Stem Cell Technologies, MethocultHCC3534). Expandované buňky se také charakterizují průtokovou cytometrií na liniově specifické fenotypy: CD1 lb(PE)/CD15(FITC), CD34 (FITC), CD41a (FITC).
Text ex vivo expanze dendritických buněk CD34+ obohacené progenitorní buňky z lidské kostní dřeně se vyizolují a kultivují se v koncentraci 2x104 buněk/ml v IMDM/20% FCS s testovanými cytokiny a kontrolami, aby se zjistil expanzní potenciál. Buňky expandují a znovu se dají na desky v koncentraci 5xl04 buněk/ml snovým médiem a cytokiny kolem 5. dne podle růstu buněk. 18.-22. den se buňky sklidí a charakterizují se. Stanoví se celková expanze průtokovou cytometrií na liniově specifické fenotypy: HLA-DR;(PE)/CDla+(FITC), CD86+(PE)/CDla+(FITC), CD19-(FITC). Stanoví se expanze dendritických buněk jako celková expanze buněk x % HLA-DR+/CDla+. Funkční aktivita buněk se stanoví pomocí 1-cestné reakce smíchaných lymfocytů. Promyté ozářené kultivované dendritické buňky se přidají ve stupňovaných dávkách k alogenně odpovídajícím mononukleárním buňkám se přidají ve stupňovaných dávkách k alogenně odpovídajícím mononukleárním buňkám periferní krve na mikrotitračních deskách s 96-jamkami. Schopnost dendritických buněk sloužit jako buňky prezentující antigen se stanoví podle stupně proliferace stimulované v odpovídajících připravených buňkách, měřená zabudováním 3H thymidinu. Příklad 116 Vazba receptoru
Tabulka 16
Analýzy vazby receptoru
Sloučenina Flt3-Fc G-CSFR IL-3R" Kj (nM) ICJ0(nM) IC» (nM) pMON32342 26" 7 >1000 pMON30247 36*7 ** 6.6" 0.5 pMON32360 45*17 26(2) pMON32352 56*5 13 *4 pMON32191 37*14 0.33 * 0.01 -370- CZ 295843 B6
Tabulka 16 (pokračování) 11-3 receptur agonisty 11 ‘ >1000 1.3H0.2 11-3 receptur agonisty! > 1000 3.7 " 0.6 G-CSF 0.69 * 0.08 >100 5 Data jsou vyjádřena jako průměr „ SEM z alespoň tří pokusů stanovených v triplikátech s výjimkou pMON 32360, kde jen (2) experimenty se dokončily.
Afinita Fit—3 agonisty obsahujícího chimérní molekuly se hodnotila v testech vazby receptoru. BIACORE analýza se provede přímou imobilizací Flt3-Fc a Kd hodnoty se vypočítají ze io stanovení konstant rychlosti asociace a disociace. Testy kompetitivních vazeb se používají pro hodnocení interakcí chimérní molekuly buď s G-CSF receptorem transfektovaným do BamF3 buněk nebo s „ podjednotkami IL-3 receptoru exprimovaného v BHK buňkách. Kompetitivní testy pomocí těchto buněk používají radioligand specifický pro agonistu a IC50 hodnoty se stanoví pro kompetitivní chiméry pomocí logit-log analýzy křivek reakce na dávku. 15 Příklad 117 Bioaktivita in vivo
Tabulka 17 Údaje o in vivo testech myších multi-funkčních chimémích hematopoietických agonistů 25 receptoru
Klon Periferní krev Slezina I-A^/CDl \c I-A°7CD8+ l-A*7CDllc* I-Afr7CD8+ CFU-GM/Slezina DC buňky/μΐ krve DC buňky/slezina (x 10®) Celkové zvýšeni 'tMXBBirr ND ND 33.5 23.8 78 pMON32342 m5 -HJ5- S.O 4.5 2 pMON32360 ND ND 64.5 37,5 183 pMÓtami 17,089 ŽJ76 ÍTO ^5 53 C57BL/6 myši se injikují s.c. pMON30247, pMON32342 nebo pMON32360 (150 pg/den) nebo 30 pMON32191 (200 pg/den) nebo Mouše Sérum Albumin (MSA, 200 pg/den) po 10 dní. 11. den se provede terminální krvácení srdeční punkcí. Počty leukocytů se získají z celé krve. Leukocyty z periferní krve se získají centrifugací v gradientu (Histopaque) s následnou lyží amonium -371 -
Claims (40)
- CZ 295843 B6 chloridem, aby se dále odstranily erytrocyty. Buňky se označí pro průtokovou cytometrii pomocí přímých monoklonálních protilátek konjugovaných s fluoresceinem nebo fykoerythrinem (Pharmingen). Před označením se zablokují ne-specifické vazby Fc receptoru pomocí FcBlock (Pharmingen). Buňky se analyzují na FacScan průtokovém cytometru (Becton/Dickinson). Procenta pozitivních buněk, stanovená počítáním integrace a íytotypů, se vypočítají podle počtu WBC. Kleiny z ošetřených zvířat se odstraní asepticky a rozmělní se v RPMI médiu jehlami. Buněčná suspenze se získá pomocí tupého konce pístu 5 cm3 stříkačky. Následuje filtrace přes bavlnu, aby se odstranily klky. Erytrocyty se odstraní lyží amonium chloridem, buňky se promyjí, resuspendují se a spočítají pomocí Coulter čítače (Coulter Electronics). Buňky se připraví pro průtokovou cytometrii, jak je popsáno výše. Fenotyp se vyjádří jak počet buněk/slezinu na základě procent buněk s pozitivním fenotypem a celkového počtu WBC slezin. CFU kultury se získají rozestřením na desky - 1,5 x 106 buněk sleziny/1 ml v trojím provedení do jamek s methylcelulózou s myšími cytokiny w/o erythropoietinu (Stem Call Technologies). Kultury se inkubují 10 dní při 37 °C a počítají se na inversním mikroskopu. CFU se definuje jako kolonie buněk svíce než 50buňkami. Stanoví se zvýšení CFU/slezinu (celkový počet CFU/slezinu testované sloučeniny/celkový počet CFU/slezinu MSA kontroly). MSA kontrolní hodnoty periferní krve byly 15 a 347 buněk/μΐ pro I-Ab+/CDllc+ a I-Ab+/CD8+. MSA kontrolní hodnoty pro leukocyty ze sleziny byly 2 a 1 x 106 buněk/slezinu pro I-Ab7CDllc+ a I-Ab+/CD8+. Předpokládá se, že odborník v oboru může využít popisu vynálezu v širokém rozsahu. Výhodná provedení jsou proto uvedena jako ilustrativní a neomezující vynález v žádném směru. Dodatečné podrobnosti týkající se technik molekulární biologie, čištění proteinů a biotestů lze nalézt v WO 94/12639, WO 94/12638, WO 95/20976, WO 95/21197, WO 95/20977, WO 95/21254 a WO 96/23888, které jsou uvedeny v odkazech. Všechny reference, patenty nebo přihlášky zde citované jsou sem zařazeny odkazem. Různé další příklady budou zřejmé odborníkovi po přečtení tohoto popisu bez toho, že by se odchýlil od rozsahu vynálezu. Všechny takové příklady jsou v rozsahu připojených nároků. PATENTOVÉ NÁROKY 1. Hematopoietický protein obsahující sekvenci aminokyselin obecného vzorce: Ri-Li-R2, R2~Έ]—R], R,-R2 nebo R2—Ri kde R]je (III) polypeptidický agonista lidského fit—3 receptoru obsahující modifikovanou aminokyselinovou sekvenci fit—3 ligandu s následujícím vzorcem: ThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeu 10 20 GlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAla 30 40 50 -372- CZ 295843 B6 GlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle 60 70 HisPheValThrLysCysAlaPheGlnProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGln 80 90 100 GluThrSerGluGlnLeuV a! AlaLeuLysProTrpfleThrArgGInAsnPheS erArgCysLeuGluLeuGInCys 110 120 130 GlnProAspSerSerThrLeu (SEQ ID NO:466), kde 1 až 7 aminokyselin z C-konce může být případně odstraněno z tohoto polypeptidického agonisty fit—3 receptoru a dojde k lineárnímu přeskupení sekvence, kde N-konec je spojen k C-konci přímo nebo pomocí spojovníku (L2) schopného spojit N-konec k C-konci a po otevření takto vzniklé cirkulámí molekuly jsou vytvořeny nové C- a N-konce lineární molekuly mezi zbytky aminokyselinových párů: 28-29 42-43 93-94 29-30 64-65 94-95 30-31 65-66 95-96 31-32 66-67 96-97 32-33 86-87 97-98 34-35 87-88 98-99 36-37 88-89 99-100 37-38 89-90 100-101 38-39 90-91 101-102 39-40 91-92 102-103 40- 41 41- 42 92-93 v uvedeném pořadí; a R2 je nezávisle vybrán ze skupiny sestávající z: 25 (I) polypeptidického agonisty lidského EPO receptoru obsahujícím modifikovanou EPO sekvenci aminokyselin s následujícím vzorcem: AlaProProArgLeuIleCysAspSerArgValLeuGluArgTyrLeuLeuGluAlaLysGluAlaGluAsnlleThr 10 20 ThrGlyCysAlaGIuHisCysSerLeuAsnGluAsnlleThrValProAspThrLysValAsnPheTyrAlaTrpLys 30 40 50 ArgMetGluValGlyGlnGlnAlaValGluValTrpGlnGlyLeuAlaLeuLeuSerGluAlaValLeuArgGlyGln 60 70 AlaLeuLeuValAsnSerSerGlnProTrpGluProLeuGlnLeuHisValAspLysAlaValSerGlyLeuArgSer 80 90 100 LeuThrThrLeuLeuArgAlaLeuGlyAlaGlnLysGluAlafleSerProProAspAlaAlaSerAlaAlaProLeu 110 120 130 -373- CZ 295843 B6 ArgThrlleThrAlaAspThrPheArgLysLeuPheArgValTyrSerAsnPheLeuArgGlyLysLeuLysLeuTyr 140 150 ThrGlyGluAlaCysArgThrGlyAspArg 160 (SEQ ID NO:464), kde 1 až 6 aminokyselin z N-konce a/nebo 1 až 5 z C-konce může být případně odstraněno z tohoto polypeptidového agonisty EPO receptoru a dojde k lineárnímu přeskupení sekvence, kde N-konec je spojen k C-konci přímo nebo pomocí spojovníku (L2) schopného spojit N-konec k C-konci a po otevření takto vzniklé cirkulámí molekuly jsou vytvořeny nové C- a N-konce lineární molekuly mezi zbytky aminokyselinových párů: 23-24 47-48 109-110 24-25 48-49 110-111 25-26 49-50 111-112 26-27 50-51 112-113 27-28 51-52 113-114 28-29 52-53 114-115 29-30 53-54 115-116 30-31 54-55 116-117 31-32 55-56 117-118 32-33 56-57 118-119 33-34 57-58 119-120 34-35 77-78 120-121 35-36 78-79 121-122 36-37 79-80 122-123 37-38 80-81 123-124 38-39 81-82 124-125 39-40 82-83 125-126 40-41 84-85 126-127 41-42 85-86 127-128 42-43 86-87 128-129 43-44 87-88 129-130 44-45 88-89 130-131 45-46 108-109 131-132 46-47 v uvedeném pořadí; (II) polypeptidického agonisty lidského receptoru faktoru kmenových buněk obsahujícím modifikovanou aminokyselinovou sekvenci faktoru kmenových buněk s následujícím vzorcem: GluGHylleCysArgAsnArgValThrAsnAsnValLysAspValThrLysLeuValAlaAsnLeuProLysAspTyr 10 20 MetlleThrLeuLysTyrValProGIyMetAspValLeuProSerHisCysTrpUeSerGluMetValValGInLeu 30 40 50 SerAspSerLeuThrAspLeuLeuAspLysPheSerAsníleSerGluGlyLeuSerAsnTyrSerllelleAspLys 60 70 LeuValAsnlleValAspAspLeuValGluCysValLysGluAsnSerSerLysAspLeuLysLysSerPheLysSer 80 90 100 -374- CZ 295843 B6 ProGluProArgLeuPheThrProGIuGIuPhePheArgllePheAsnArgSerlleAspAlaPheLysAspPheVal 110 120 130 ValAlaSerGluThrSerAspCysValValSerSerThrLeuSerProGluLysAspSerArgValSerValThrLys 140 150 ProPheMetLeuProProValAlaAla (SEQ ID NO:465), 160 kde 1 až 23 aminokyselin může být případně odstraněno z C-konce tohoto agonisty receptoru faktoru kmenových buněk a dojde k lineárnímu přeskupení sekvence, kde N-konec je spojen k C-konci přímo nebo pomocí spojovníku (L2) schopného spojit N-konec k C-konci a po otevření takto vzniklé cirkulární molekuly jsou vytvořeny nové C- a N-konce lineární molekuly mezi zbytky aminokyselinových párů: 23-24 39-40 96-97 24-25 40-41 97-98 25-26 64-65 98-99 26-27 65-66 99-100 27-28 66-67 100-101 28-29 67-68 101-102 29-30 68-69 102-103 30-31 69-70 103-104 31-32 70-71 104-105 32-33 89-90 105-106 33-34 90-91 106-107 34-35 91-92 107-108 35-36 92-93 108-109 36-37 93-94 109-110 37-38 94-95 110-111 38-39 95-96 v uvedeném pořadí; (III) polypeptidického agonisty lidského fit—3 receptoru obsahujícím modifikovanou aminokyselinovou sekvenci fit—3 ligandu s následujícím vzorcem: ThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeu 10 20 GlnAspTyrProValThrValAlaSerAsnLeuGlnAspCUuGluLeuCysGlyGlyLeuTrpArgLeuValLeuAla 30 40 50 GlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle 60 70 80 90 100 GluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCys 110 120 130 GlnProAsp SerSerThrLeu (SEQ ID NO:466), -375- CZ 295843 B6 kde 1 až 7 aminokyselin z C-konce může být případně odstraněno z tohoto polypeptidického agonisty fit—3 receptoru a dojde k lineárnímu přeskupení sekvence, kde N-konec je spojen k C-konci přímo nebo pomocí spojovníku (L2) schopného spojit N-5 konec k C-konci a po otevření takto vzniklé cirkulární molekuly jsou vytvořeny nové C- a N-konce lineární molekuly mezi zbytky aminokyselinových párů: 28-29 42-43 93-94 29-30 64-65 94-95 30-31 65-66 95-96 31-32 66-67 96-97 32-33 86-87 97-98 34-35 87-88 98-99 36-37 88-89 99-100 37-38 89-90 100-101 38-39 90-91 101-102 39-40 91-92 102-103 40- 41 41- 42 92-93 v uvedeném pořadí; (IV) polypeptidu obsahujícím modifikovanou sekvenci aminokyselin lidského G-CSF s následujícím vzorcem Xaa Xaa Xaa Gly Pro Ala Ser Ser Leu Pro Gin Ser XaaLeu Leu Xaa Xaa Xaa Glu Gin Val Xaa 10 20 Lys Xaa Gin Gly Xaa GlyAla Xaa Leu Gin Glu Xaa Leu Xaa Ala Thr Tyr Lys Leu Xaa Xaa 30 40 Xaa Glu Xaa Xaa Val Xaa Xaa Gly His Ser Xaa Gly IleProTrpAla Pro Leu Ser Ser Xaa Pro Ser 50 60 XaaLeuAlaGtyXaaLeuSerGlnLeuHisSerGIyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylle 70 80 90 SerProGluLeuGlyProThrLeuXaaThrLeuGlnXaaAspValAlaAspPheAlaXaaThrlleTrpGln 100 110 GJnMet Glu Xaa Xaa Gly Met Ala Pro Ala Leu Gin Pro ThrGln Gly Ala Met Pro Ala Phe Ala 120 130 140 SerAla Xaa Gin Xaa Xaa AlaGly Gly Val Leu Val Ala Ser Xaa Leu Gin Xaa Phe Leu Xaa 150 160 XaaSerTyr Arg Val Leu Xaa Xaa Leu Ala Gin Pro 170 (SEQ ED NO: 858), 25 kde Xaa v poloze 1 je Thr, Ser, Arg, Tyr nebo Gly; Xaa v poloze 2 je Pro nebo Leu; Xaa v poloze 3 je Leu, Arg, Tyr nebo Ser; -376- 30 CZ 295843 B6 Xaa v poloze 13 je Phe, Ser, His, Thr nebo Pro; Xaa v poloze 16 je Lys, Pro, Ser, Thr nebo His; Xaa v poloze 17 je Cys, Ser, Gly, Ala, Ile, Tyr nebo Arg; Xaa v poloze 18 je Leu, Thr, Pro, His, Ile nebo Cys; Xaa v poloze 22 je Arg, Tyr, Ser, Thr nebo Ala; Xaa v poloze 24 je Ile, Pro, Tyr nebo Leu; Xaa v poloze 27 je Asp nebo Gly; Xaa v poloze 30 je Ala, Ile, Leu nebo Gly; Xaa v poloze 34 je Lys nebo Ser; Xaa v poloze 36 je Cys nebo Ser; Xaa v poloze 42 je Cys nebo Ser; Xaa v poloze 43 je His, Thr, Gly, Val, Lys, Trp, Ala, Arg, Cys nebo Leu; Xaa v poloze 44 je Pro, Gly, Arg, Asp, Val, Ala, His, Trp, Gin nebo Thr; Xaa v poloze 46 je Glu, Arg, Phe, Arg, Ile nebo Ala; Xaa v poloze 47 je Leu nebo Thr; Xaa v poloze 49 je Leu, Phe, Arg nebo Ser; Xaa v poloze 50 je Leu, Ile, His, Pro nebo Tyr; Xaa v poloze 54 je Leu nebo His; Xaa v poloze 64 je Cys nebo Ser; Xaa v poloze 67 je Gin, Lys, Leu nebo Cys; Xaa v poloze 70 je Gin, Pro, Leu, Arg nebo Ser; Xaa v poloze 74 je Cys nebo Ser; Xaa v poloze 104 je Asp, Gly nebo Val; Xaa v poloze 108 je Leu, Ala, Val, Arg, Trp, Gin nebo Gly; Xaa v poloze 115 je Thr, His, Leu nebo Ala; Xaa v poloze 120 je Gin, Gly, Arg, Lys nebo His; Xaa v poloze 123 je Glu, Arg, Phe nebo Thr; Xaa v poloze 144 je Phe, His, Arg, Pro, Leu, Gin nebo Glu; -377 - CZ 295843 B6 Xaa v poloze 146 je Arg nebo Gin; Xaa v poloze 147 je Arg nebo Gin; 5 Xaa v poloze 156 je His, Gly nebo Ser; Xaa v poloze 159 je Ser, Arg, Thr, Tyr, Val nebo Gly; ío Xaa v poloze 162 je Glu, Leu, Gly nebo Trp; Xaa v poloze 163 je Val, Gly, Arg nebo Ala; Xaa v poloze 169 je Arg, Ser, Leu, Arg nebo Cys; 15 Xaa v poloze 170 je His, Arg nebo Ser; kde 1 až 11 aminokyselin z N-konce a/nebo 1 až 5 aminokyselin z C-konce může být případně odstraněno z této modifikované aminokyselinové sekvence lidského G-CSF a dojde k lineárnímu 20 přeskupení sekvence, kde N-konec je spojen k C-konci přímo nebo pomocí spojovníku (L2) schopného spojit N-konec k C-konci a po otevření takto vzniklé cirkulámí molekuly jsou vytvořeny nové C- a N-konce lineární molekuly mezi zbytky aminokyselinových párů: 38-39 62-63 123-124 25 39-40 63-64 124-125 40-41 64-65 125-126 41-42 65-66 126-127 42-43 66-67 128-129 43-44 67-68 128-129 30 45-46 68-69 129-130 48-49 69-70 130-131 49-50 70-71 131-132 52-53 71-72 132-133 53-54 91-92 133-134 35 54-55 92-93 134-135 55-56 93-94 135-136 56-57 94-95 136-137 57-58 95-96 137-138 58-59 96-97 138-139 40 59-60 97-98 139-140 60-61 98-99 140-141 61-62 99-100 141-142 nebo 142-143 v uvedeném pořadí; 45 (V) polypeptidu obsahujícím modifikovanou sekvenci aminokyselin lidského IL-3 s následujícím vzorcem: Ala Pro Met Thr Gin Thr Thr Ser Leu Lys Thr Ser Trp Val AsnCys Xaa Xaa Xaa Xaa Xaa Xaa 10 20 Xaa Xaa Xaa Xaa Xaa Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa 30 40 CZ 295843 B6 Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa XaaXaa Xaa Xaa Xaa 50 60 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 70 80 Xaa Xaa Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa XaaXaa 90 100 Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa XaaXaa Xaa Xaa Gin Gin Thr Thr 110 120 Leu Ser Leu Ala De Phe 130 (SEQ ID NO:859), kde Xaa v poloze 17 je Ser, Lys, Gly, Asp, Met, Gin nebo Arg; Xaa v poloze 18 je Asn, His, Leu, Ile, Phe, Arg nebo Gin; Xaa v poloze 19 je Met, Phe, Ile, Arg, Gly, Ala nebo Cys; Xaa v poloze 20 je Ile, Cys, Gin, Glu, Arg, Pro nebo Ala; Xaa v poloze 21 je Asp, Phe, Lys, Arg, Ala, Gly, Glu, Gin, Asn, Thr, Ser nebo Val; Xaa v poloze 22 je Glu, Trp, Pro, Ser, Ala, His, Asp, Asn, Gin, Leu, Val nebo Gly; Xaa v poloze 23 je Ile, Val, Ala, Gly, Trp, Lys, Phe, Leu, Ser nebo Arg; Xaa v poloze 24 je Ile, Gly, Val, Arg, Ser, Phe nebo Leu; Xaa v poloze 25 je Thr, His, Gly, Gin, Arg, Pro nebo Ala; Xaa v poloze 26 je His, Thr, Phe, Gly, Arg, Ala nebo Trp; Xaa v poloze 27 je Leu, Gly, Arg, Thr, Ser nebo Ala; Xaa v poloze 28 je Lys, Arg, Leu, Gin, Gly, Pro, Val nebo Trp; Xaa v poloze 29 je Gin, Asn, Leu, Pro, Arg nebo Val; Xaa v poloze 30 je Pro, His, Thr, Gly, Asp, Gin, Ser, Leu nebo Lys; Xaa v poloze 31 je Pro, Asp, Gly, Ala, Arg, Leu nebo Gin; Xaa v poloze 32 je Leu, Val, Arg, Gin, Asn, Gly, Ala nebo Glu; Xaa v poloze 33 je Pro, Leu, Gin, Ala, Thr nebo Glu; Xaa v poloze 34 je Leu, Val, Gly, Ser, Lys, Glu, Gin, Thr, Arg, Ala, Phe, Ile nebo Met; Xaa v poloze 35 je Leu, Ala, Gly, Asn, Pro, Gin nebo Val; Xaa v poloze 36 je Asp, Leu nebo Val; -379- CZ 295843 B6 Xaa v poloze 37 je Phe, Ser, Pro, Trp nebo Ile; Xaa v poloze 38 je Asn nebo Ala; 5 Xaa v poloze 40 je Leu, Trp nebo Arg; Xaa v poloze 41 je Asn, Cys, Arg, Leu, His, Met nebo Pro; Xaa v poloze 42 je Gly, Asp, Ser, Cys, Asn, Lys, Thr, Leu, Val, Glu, Phe, Tyr, Ile, Met nebo Ala; 10 Xaa v poloze 43 je Glu, Asn, Tyr, Leu, Phe, Asp, Ala, Cys, Gin, Arg, Thr, Gly nebo Ser; Xaa v poloze 44 je Asp, Ser, Leu, Arg, Lys, Thr, Met, Trp, Glu, Asn, Gin, Ala nebo Pro; 15 Xaa v poloze 45 je Gin, Pro, Phe, Val, Met, Leu, Thr, Lys, Trp, Asp, Asn, Arg, Ser, Ala, Ile, Glu nebo His; Xaa v poloze 46 je Asp, Phe, Ser, Thr, Cys, Glu, Asn, Gin, Lys, His, Ala, Tyr, Ile, Val nebo Gly; 20 Xaa v poloze 47 je Ile, Gly, Val, Ser, Arg, Pro nebo His; Xaa v poloze 48 je Leu, Ser, Cys, Arg, Ile, His, Phe, Glu, Lys, Thr, Ala, Met, Val nebo Asn; Xaa v poloze 49 je Met, Arg, Ala, Gly, Pro, Asn, His nebo Asp; 25 Xaa v poloze 50 je Glu, Leu, Thr, Asp, Tyr, Lys, Asn, Ser, Ala, Ile, Val, His, Phe, Met nebo Gin; Xaa v poloze 51 je Asn, Arg, Met, Pro, Ser, Thr nebo His; 30 Xaa v poloze 52 je Asn, His, Arg, Leu, Gly, Ser nebo Thr; Xaa v poloze 53 je Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser nebo Met; Xaa v poloze 54 je Arg, Asp, Ile, Ser, Val, Thr, Gin, Asn, Lys, His, Ala nebo Leu; 35 Xaa v poloze 55 je Arg, Thr, Val, Ser, Leu nebo Gly; Xaa v poloze 56 je Pro, Gly, Cys, Ser, Gin, Glu, Arg, His, Thr, Ala, Tyr, Phe, Leu, Val nebo Lys; 40 Xaa v poloze 57 je Asn nebo Gly; Xaa v poloze 58 je Leu, Ser, Asp, Arg, Gin, Val nebo Cys; Xaa v poloze 59 je Glu, Tyr, His, Leu, Pro nebo Arg; 45 Xaa v poloze 60 je Ala, Ser, Pro, Tyr, Asn nebo Thr; Xaa v poloze 61 je Phe, Asn, Glu, Pro, Lys, Arg nebo Ser; 50 Xaa v poloze 62 je Asn, His, Val, Arg, Pro, Thr, Asp nebo Ile; Xaa v poloze 63 je Arg, Tyr, Trp, Lys, Ser, His, Pro nebo Val; Xaa v poloze 64 je Ala, Asn, Pro, Ser nebo Lys; -380- 55 CZ 295843 B6 Xaa v poloze 65 je Val, Thr, Pro, His, Leu, Phe nebo Ser; Xaa v poloze 66 je Lys, Ile, Arg, Val, Asn, Glu nebo Ser; Xaa v poloze 67 je Ser, Ala, Phe, Val, Gly, Asn, Ile, Pro nebo His; Xaa v poloze 68 je Leu, Val, Trp, Ser, Ile, Phe, Thr nebo His; Xaa v poloze 69 je Gin, Ala, Pro, Thr, Glu, Arg, Trp, Gly nebo Leu; Xaa v poloze 70 je Asn, Leu, Val, Trp, Pro nebo Ala; Xaa v poloze 71 je Ala, Met, Leu, Pro, Arg, Glu, Thr, Gin, Trp nebo Asn; Xaa v poloze 72 je Ser, Glu, Met, Ala, His, Asn, Arg nebo Asp; Xaa v poloze 73 je Ala, Glu, Asp, Leu, Ser, Gly, Thr nebo Arg; Xaa v poloze 74 je Ile, Met, Thr, Pro, Arg, Gly, Ala; Xaa v poloze 75 je Glu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gin nebo Leu; Xaa v poloze 76 je Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly nebo Asp; Xaa v poloze 77 je Ile, Ser, Arg, Thr nebo Leu; Xaa v poloze 78 je Leu, Ala, Ser, Glu, Phe, Gly nebo Arg; Xaa v poloze 79 je Lys, Thr, Asn, Met, Arg, Ile, Gly nebo Asp; Xaa v poloze 80 je Asn, Trp, Val, Gly, Thr, Leu, Glu nebo Arg; Xaa v poloze 81 je Leu, Gin, Gly, Ala, Trp, Arg, Val nebo Lys; Xaa v poloze 82 je Leu, Gin, Lys, Trp, Arg, Asp, Glu, Asn, His, Thr, Ser, Ala, Tyr, Phe, Ile, Met nebo Val; Xaa v poloze 83 je Pro, Ala, Thr, Trp, Arg nebo Met; Xaa v poloze 84 je Cys, Glu, Gly, Arg, Met nebo Val; Xaa v poloze 85 je Leu, Asn, Val nebo Gin; Xaa v poloze 86 je Pro, Cys, Arg, Ala nebo Lys; Xaa v poloze 87 je Leu, Ser, Trp nebo Gly; Xaa v poloze 88 je Ala, Lys, Arg, Val nebo Trp; Xaa v poloze 89 je Thr, Asp, Cys, Leu, Val, Glu, His, Asn nebo Ser; Xaa v poloze 90 je Ala, Pro, Ser, Thr, Gly, Asp, Ile nebo Met; Xaa v poloze 91 je Ala, Pro, Ser, Thr, Phe, Leu, Asp nebo His; -381 - CZ 295843 B6 Xaa v poloze 92 je Pro, Phe, Arg, Ser, Lys, His, Ala, Gly, Ile nebo Leu; Xaa v poloze 93 je Thr, Asp, Ser, Asn, Pro, Ala, Leu nebo Arg; 5 Xaa v poloze 94 je Arg, Ile, Ser, Glu, Leu, Val, Gin, Lys, His, Ala nebo Pro; Xaa v poloze 95 je His, Gin, Pro, Arg, Val, Leu, Gly, Thr, Asn, Lys, Ser, Ala, Trp, Phe, Ile nebo Tyr; ío Xaa v poloze 96 je Pro, Lys, Tyr, Gly, Ile nebo Thr; Xaa v poloze 97 je Ile, Val, Lys, Ala nebo Asn; Xaa v poloze 98 je His, Ile, Asn, Leu, Asp, Ala, Thr, Glu, Gin, Ser, Phe, Met, Val, Lys, Arg, Tyr 15 nebo Pro; Xaa v poloze 99 je Ile, Leu, Arg, Asp, Val, Pro, Gin, Gly, Ser, Phe nebo His; Xaa v poloze 100 je Lys, Tyr, Leu, His, Arg, Ile, Ser, Gin nebo Pro; 20 Xaa v poloze 101 je Asp, Pro, Met, Lys, His, Thr, Val, Tyr, Glu, Asn, Ser, Ala, Gly, Ile, Leu nebo Gin; Xaa v poloze 102 je Gly, Leu, Glu, Lys, Ser, Tyr nebo Pro; 25 Xaa v poloze 103 je Asp nebo Ser; Xaa v poloze 104 je Trp, Val, Cys, Tyr, Thr, Met, Pro, Leu, Gin, Lys, Ala, Phe nebo Gly; 30 Xaa v poloze 105 je Asn, Pro, Ala, Phe, Ser, Trp, Gin, Tyr, Leu, Lys, Ile, Asp nebo His; Xaa v poloze 106 je Glu, Ser, Ala, Lys, Thr, Ile, Gly nebo Pro; Xaa v poloze 108 je Arg, Lys, Asp, Leu, Thr, Ile, Gin, His, Ser, Ala nebo Pro; 35 Xaa v poloze 109 je Arg, Thr, Pro, Glu, Tyr, Leu, Ser nebo Gly; Xaa v poloze 110 je Lys, Ala, Asn, Thr, Leu, Arg, Gin, His, Glu, Ser nebo Trp; 40 Xaa v poloze 111 je Leu, Ile, Arg, Asp nebo Met; Xaa v poloze 112 je Thr, Val, Gin, Tyr, Glu, His, Ser nebo Phe; Xaa v poloze 113 je Phe, Ser, Cys, His, Gly, Trp, Tyr, Asp, Lys, Leu, Ile, Val nebo Asn; 45 Xaa v poloze 114 je Tyr, Cys, His, Ser, Trp, Arg nebo Leu; Xaa v poloze 115 je Leu, Asn, Val, Pro, Arg, Ala, His, Thr, Trp nebo Met; 50 Xaa v poloze 116 je Lys, Leu, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp, Ser, Asn, His, Ala, Tyr, Phe, Gin nebo Ile; Xaa v poloze 117 je Thr, Ser, Asn, Ile, Trp, Lys nebo Pro; 55 Xaa v poloze 118 je Leu, Ser, Pro, Ala, Glu, Cys, Asp nebo Tyr; -382- CZ 295843 B6 Xaa v poloze 119 je Glu, Ser, Lys, Pro, Leu, Thr, Tyr nebo Arg; Xaa v poloze 120 je Asn, Ala, Pro, Leu, His, Val nebo Gin; Xaa v poloze 121 je Ala, Ser, Ile, Asn, Pro, Lys, Asp nebo Gly; Xaa v poloze 122 je Gin, Ser, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr nebo Cys; Xaa v poloze 123 je Ala, Met, Glu, His, Ser, Pro, Tyr nebo Leu; kde 1 až 14 aminokyselin je případně odstraněno zN-konce a/nebo 1 až 15 aminokyselin je případně odstraněno z C-konce této modifikované sekvence aminokyselin lidského IL-3; a kde od 0 do 44 aminokyselin označených Xaa je různých od odpovídajících aminokyselin nativního (1-133) lidského interleukinu-3 a dojde k lineárnímu přeskupení sekvence, kde N-konec je spojen k C-konci přímo nebo pomocí spojovníku (L2) schopného spojit N-konec k C-konci a po otevření takto vzniklé cirkulární molekuly jsou vytvořeny nové C- a N-konce lineární molekuly mezi zbytky aminokyselinových párů: 26-27 49-50 27-28 50-51 28-29 51-52 29-30 52-53 30-31 53-54 31-32 54-55 32-33 64-65 33-34 65-66 34-35 66-67 35-36 67-68 36-37 68-69 37-38 69-70 38-39 70-71 39-40 71-72 40-41 72-73 41-42 82-83 83- 84 84- 85 85- 86 86- 87 87- 88 88- 89 89- 90 90- 91 91- 92 92- 93 97- 98 98- 99 99- 100 100- 101 101-102 102-103 nebo 103-104 v uvedeném pořadí; (VI) polypeptidu obsahujícím modifikovanou sekvenci aminokyselin lidského c-mpl ligandu s následujícím vzorcem: SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisVatLeuHisSerArgLeu 10 20 SerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLys 30 40 50 ThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAIaArg 60 70 GlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeai 80 90 100 -383 - CZ 295843 B6 GlnSerLeuLeuGlyThrGInXaaXaaXaaXaaGlyArgThrThrAlaHisLysAspProAsnAlaDePheLeu 110 120 130 SerPheGlnlIisLeuLeu ArgGiyLy sV al ArgPheLeuMetLeu ValGlyGly SerThrLeuCysVal Arg 140 150 (SEQ ID NO:860), kde Xaa v poloze 112 je odstraněn neboje to Leu, Ala, Val, Ile, Pro, Phe, Trp nebo Met; Xaa v poloze 113 je odstraněn neboje to Pro, Phe, Ala, Val, Leu, Ile, Trp nebo Met; Xaa v poloze 114 je odstraněn neboje to Pro, Phe, Ala, Val, Leu, Ile, Trp nebo Met; Xaa v poloze 115 je odstraněn neboje to Gin, Gly, Ser, Thr, Tyr nebo Asn a dojde k lineárnímu přeskupení sekvence, kde N-konec je spojen k C-konci přímo nebo pomocí spojovníku (L2) schopného spojit N-konec k C-konci a po otevření takto vzniklé cirkulámí molekuly jsou vytvořeny nové C- a N-konce lineární molekuly mezi zbytky aminokyselinových párů: 26-27 51-52 108-109 27-28 52-53 109-110 28-29 53-54 110-111 29-30 54-55 111-112 30-31 55-56 112-113 32-33 56-57 113-114 33-34 57-58 114-115 34-35 58-59 115-116 36-37 59-60 116-117 37-38 78-79 117-118 38-39 79-80 118-119 40-41 80-81 119-120 41-42 81-82 120-121 42-43 82-83 121-122 43-44 83-84 122-123 44-45 84-85 123-124 46-47 85-86 124-125 47-48 86-87 125-126 48-49 87-88 126-127 50-51 88-89 nebo 127-128 v uvedeném pořadí; (VII) polypeptidu obsahujícím modifikovanou sekvenci aminokyselin lidského IL-3 s následujícím vzorcem: Ala Pro Met Thr Gin Thr Thr Ser Leu Lys Thr Ser Trp Val AsnCys Xaa Xaa Xaa Xaa Xaa Xaa 10 20 Xaa Xaa Xaa Xaa Xaa Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa 30 40 Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa XaaXaa Xaa Xaa Xaa 50 60 -384- CZ 295843 B6 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 70 80 Xaa Xaa Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa XaaXaa 90 100 Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa XaaXaa Xaa Xaa Gin Gin Thr Thr 110 120 Leu Ser Leu Ala Ile Phe (SEQ ID NO:859), 130 kde Xaa v poloze 17 je Ser, Lys, Gly, Asp, Met, Gin nebo Arg; 5 Xaa v poloze 18 je Asn, His, Leu, Ile, Phe, Arg nebo Gin; Xaa v poloze 19 je Met, Phe, Ile, Arg, Gly, Ala nebo Cys; Xaa v poloze 20 je Ile, Cys, Gin, Glu, Arg, Pro nebo Ala; 10 Xaa v poloze 21 je Asp, Phe, Lys, Arg, Ala, Gly, Glu, Gin, Asn, Thr, Ser nebo Val; Xaa v poloze 22 je Glu, Trp, Pro, Ser, Ala, His, Asp, Asn, Gin, Leu, Val nebo Gly; 15 Xaa v poloze 23 je Ile, Val, Ala, Gly, Trp, Lys, Phe, Leu, Ser nebo Arg; Xaa v poloze 24 je Ile, Gly, Val, Arg, Ser, Phe nebo Leu; Xaa v poloze 25 je Thr, His, Gly, Gin, Arg, Pro nebo Ala; 20 Xaa v poloze 26 je His, Thr, Phe, Gly, Arg, Ala nebo Trp; Xaa v poloze 27 je Leu, Gly, Arg, Thr, Ser nebo Ala; 25 Xaa v poloze 28 je Lys, Arg, Leu, Gin, Gly, Pro, Val nebo Trp; Xaa v poloze 29 je Gin, Asn, Leu, Pro, Arg nebo Val; Xaa v poloze 30 je Pro, His, Thr, Gly, Asp, Gin, Ser, Leu nebo Lys; 30 Xaa v poloze 31 je Pro, Asp, Gly, Ala, Arg, Leu nebo Gin; Xaa v poloze 32 je Leu, Val, Arg, Gin, Asn, Gly, Ala nebo Glu; 35 Xaa v poloze 33 je Pro, Leu, Gin, Ala, Thr nebo Glu; Xaa v poloze 34 je Leu, Val, Gly, Ser, Lys, Glu, Gin, Thr, Arg, Ala, Phe, Ile nebo Met; Xaa v poloze 35 je Leu, Ala, Gly, Asn, Pro, Gin nebo Val; 40 Xaa v poloze 36 je Asp, Leu nebo Val; Xaa v poloze 37 je Phe, Ser, Pro, Trp nebo Ile; 45 Xaa v poloze 38 je Asn nebo Ala; -385- CZ 295843 B6 Xaa v poloze 40 je Leu, Trp nebo Arg; Xaa v poloze 41 je Asn, Cys, Arg, Leu, His, Met nebo Pro; s Xaa v poloze 42 je Gly, Asp, Ser, Cys, Asn, Lys, Thr, Leu, Val, Glu, Phe, Tyr, Ile, Met nebo Ala; Xaa v poloze 43 je Glu, Asn, Tyr, Leu, Phe, Asp, Ala, Cys, Gin, Arg, Thr, Gly nebo Ser; Xaa v poloze 44 je Asp, Ser, Leu, Arg, Lys, Thr, Met, Trp, Glu, Asn, Gin, Ala nebo Pro; 10 Xaa v poloze 45 je Gin, Pro, Phe, Val, Met, Leu, Thr, Lys, Trp, Asp, Asn, Arg, Ser, Ala, Ile, Glu nebo His; Xaa v poloze 46 je Asp, Phe, Ser, Thr, Cys, Glu, Asn, Gin, Lys, His, Ala, Tyr, Ile, Val nebo Gly; 15 Xaa v poloze 47 je Ile, Gly, Val, Ser, Arg, Pro nebo His; Xaa v poloze 48 je Leu, Ser, Cys, Arg, Ile, His, Phe, Glu, Lys, Thr, Ala, Met, Val nebo Asn; 20 Xaa v poloze 49 je Met, Arg, Ala, Gly, Pro, Asn, His nebo Asp; Xaa v poloze 50 je Glu, Leu, Thr, Asp, Tyr, Lys, Asn, Ser, Ala, Ile, Val, His, Phe, Met nebo Gin; Xaa v poloze 51 je Asn, Arg, Met, Pro, Ser, Thr nebo His; 25 Xaa v poloze 52 je Asn, His, Arg, Leu, Gly, Ser nebo Thr; Xaa v poloze 53 je Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser nebo Met; 30 Xaa v poloze 54 je Arg, Asp, Ile, Ser, Val, Thr, Gin, Asn, Lys, His, Ala nebo Leu; Xaa v poloze 55 je Arg, Thr, Val, Ser, Leu nebo Gly; Xaa v poloze 56 je Pro, Gly, Cys, Ser, Gin, Glu, Arg, His, Thr, Ala, Tyr, Phe, Leu, Val nebo Lys; 35 Xaa v poloze 57 je Asn nebo Gly; Xaa v poloze 58 je Leu, Ser, Asp, Arg, Gin, Val nebo Cys; 40 Xaa v poloze 59 je Glu, Tyr, His, Leu, Pro nebo Arg; Xaa v poloze 60 je Ala, Ser, Pro, Tyr, Asn nebo Thr; Xaa v poloze 61 je Phe, Asn, Glu, Pro, Lys, Arg nebo Ser; 45 Xaa v poloze 62 je Asn, His, Val, Arg, Pro, Thr, Asp nebo Ile; Xaa v poloze 63 je Arg, Tyr, Trp, Lys, Ser, His, Pro nebo Val; 50 Xaa v poloze 64 je Ala, Asn, Pro, Ser nebo Lys; Xaa v poloze 65 je Val, Thr, Pro, His, Leu, Phe nebo Ser; Xaa v poloze 66 je Lys, Ile, Arg, Val, Asn, Glu nebo Ser; -386- 55 CZ 295843 B6 Xaa v poJoze 67 je Ser, Ala, Phe, Val, Gly, Asn, Ile, Pro nebo His; Xaa v poloze 68 je Leu, Val, Trp, Ser, Ile, Phe, Thr nebo His; 5 Xaa v poloze 69 je Gin, Ala, Pro, Thr, Glu, Arg, Trp, Gly nebo Leu; Xaa v poloze 70 je Asn, Leu, Val, Trp, Pro nebo Ala; Xaa v poloze 71 je Ala, Met, Leu, Pro, Arg, Glu, Thr, Gin, Trp nebo Asn; 10 Xaa v poloze 72 je Ser, Glu, Met, Ala, His, Asn, Arg nebo Asp; Xaa v poloze 73 je Ala, Glu, Asp, Leu, Ser, Gly, Thr nebo Arg; 15 Xaa v poloze 74 je Ile, Met, Thr, Pro, Arg, Gly, Ala; Xaa v poloze 75 je Glu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gin nebo Leu; Xaa v poloze 76 je Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly nebo Asp; 20 Xaa v poloze 77 je Ile, Ser, Arg, Thr nebo Leu; Xaa v poloze 78 je Leu, Ala, Ser, Glu, Phe, Gly nebo Arg; 25 Xaa v poloze 79 je Lys, Thr, Asn, Met, Arg, Ile, Gly nebo Asp; Xaa v poloze 80 je Asn, Trp, Val, Gly, Thr, Leu, Glu nebo Arg; Xaa v poloze 81 je Leu, Gin, Gly, Ala, Trp, Arg, Val nebo Lys; 30 Xaa v poloze 82 je Leu, Gin, Lys, Trp, Arg, Asp, Glu, Asn, His, Thr, Ser, Ala, Tyr, Phe Ile, Met nebo Val; Xaa v poloze 83 je Pro, Ala, Thr, Trp, Arg nebo Met; 35 Xaa v poloze 84 je Cys, Glu, Gly, Arg, Met nebo Val; Xaa v poloze 85 je Leu, Asn, Val nebo Gin; 40 Xaa v poloze 86 je Pro, Cys, Arg, Ala nebo Lys; Xaa v poloze 87 je Leu, Ser, Trp nebo Gly; Xaa v poloze 88 je Ala, Lys, Arg, Val nebo Trp; 45 Xaa v poloze 89 je Thr, Asp, Cys, Leu, Val, Glu, His, Asn nebo Ser; Xaa v poloze 90 je Ala, Pro, Ser, Thr, Gly, Asp, Ile nebo Met; 50 Xaa v poloze 91 je Ala, Pro, Ser, Thr, Phe, Leu, Asp nebo His; Xaa v poloze 92 je Pro, Phe, Arg, Ser, Lys, His, Ala, Gly, Ile nebo Leu; Xaa v poloze 93 je Thr, Asp, Ser, Asn, Pro, Ala, Leu nebo Arg; -387- 55 CZ 295843 B6 Xaa v poloze 94 je Arg, Ile, Ser, Glu, Leu, Val, Gin, Lys, His, Ala nebo Pro; Xaa v poloze 95 je His, Gin, Pro, Arg, Val, Leu, Gly, Thr, Asn, Lys, Ser, Ala, Trp, Phe, Ile nebo Tyr; 5 Xaa v poloze 96 je Pro, Lys, Tyr, Gly, Ile nebo Thr; Xaa v poloze 97 je Ile, Val, Lys, Ala nebo Asn; ío Xaa v poloze 98 je His, Ile, Asn, Leu, Asp, Ala, Thr, Glu, Gin, Ser, Phe, Met, Val, Lys, Arg, Tyr nebo Pro; Xaa v poloze 99 je Ile, Leu, Arg, Asp, Val, Pro, Gin, Gly, Ser, Phe nebo His; 15 Xaa v poloze 100 je Lys, Tyr, Leu, His, Arg, Ile, Ser, Gin nebo Pro; Xaa v poloze 101 je Asp, Pro, Met, Lys, His, Thr, Val, Tyr, Glu, Asn, Ser, Ala, Gly, Ile, Leu nebo Gin; 20 Xaa v poloze 102 je Gly, Leu, Glu, Lys, Ser, Tyr nebo Pro; Xaa v poloze 103 je Asp nebo Ser; Xaa v poloze 104 je Trp, Val, Cys, Tyr, Thr, Met, Pro, Leu, Gin, Lys, Ala, Phe nebo Gly; 25 Xaa v poloze 105 je Asn, Pro, Ala, Phe, Ser, Trp, Gin, Tyr, Leu, Lys, Ile, Asp nebo His; Xaa v poloze 106 je Glu, Ser, Ala, Lys, Thr, Ile, Gly nebo Pro; 30 Xaa v poloze 108 je Arg, Lys, Asp, Leu, Thr, Ile, Gin, His, Ser, Ala nebo Pro; Xaa v poloze 109 je Arg, Thr, Pro, Glu, Tyr, Leu, Ser nebo Gly; Xaa v poloze 110 je Lys, Ala, Asn, Thr, Leu, Arg, Gin, His, Glu, Ser nebo Trp; 35 Xaa v poloze 111 je Leu, Ile, Arg, Asp nebo Met; Xaa v poloze 112 je Thr, Val, Gin, Tyr, Glu, His, Ser nebo Phe; 40 Xaa v poloze 113 je Phe, Ser, Cys, His, Gly, Trp, Tyr, Asp, Lys, Leu, Ile, Val nebo Asn; Xaa v poloze 114 je Tyr, Cys, His, Ser, Trp, Arg nebo Leu; Xaa v poloze 115 je Leu, Asn, Val, Pro, Arg, Ala, His, Thr, Trp nebo Met; 45 Xaa v poloze 116 je Lys, Leu, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp, Ser, Asn, His, Ala, Tyr, Phe, Gin nebo Ile; Xaa v poloze 117 je Thr, Ser, Asn, Ile, Trp, Lys nebo Pro; 50 Xaa v poloze 118 je Leu, Ser, Pro, Ala, Glu, Cys, Asp nebo Tyr; Xaa v poloze 119 je Glu, Ser, Lys, Pro, Leu, Thr, Tyr nebo Arg; 55 Xaa v poloze 120 je Asn, Ala, Pro, Leu, His, Val nebo Gin; -388- CZ 295843 B6 Xaa v poloze 121 je Ala, Ser, Ile, Asn, Pro, Lys, Asp nebo Gly; Xaa v poloze 122 je Gin, Ser, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr nebo Cys; 5 Xaa v poloze 123 je Ala, Met, Glu, His, Ser, Pro, Tyr nebo Leu; kde 1 až 14 aminokyselin je případně odstraněno zN-konce a/nebo 1 až 15 aminokyselin je případně odstraněno zC-konce této modifikované sekvence aminokyselin lidského IL-3; a kde od 1 do 44 aminokyselin označených Xaa je různých od odpovídajících aminokyselin nativního 10 (1-133) lidského interleukinu-3; a (Vlil) faktoru vybraného ze skupiny sestávající z faktoru stimulujícího kolonie, cytokinu, lymfokinu, interleukinu, a hematopoietického růstového faktoru 15 a kde L, je spojovníkem schopným spojit R.J k R2; L2 je spojovníkem schopným připojit N-konec k C-konci za lineárního přeskupení sekvence; tomuto hematopoietickému proteinu může případně bezprostředně předcházet (methionin1), (alanin1) nebo (methionin2, alanin'); 20 spojovník Lj je polypeptid schopný připojení R1 k R2 v délce 4 až 500 aminokyselin vybraný ze skupiny sestávající z: (Gl/Serf (SE Q ID NO:8ót); (Gly4Ser)n (SEQ ID NO:862); (Gly3Ser)n (SEQ ID NO:863); (Gly"Ser)n (SEQ ID NO:864); (AlaGlySeif (SEQ ID NO:865); GlyGlyGlySerGlyGlySerGlyGlyGIySerGluGíyGlyGlySerGluGlyGlyGlySer GluGlyGlyGlySerGluGlyGlyGlySerGlyGlyGlySer (SEQ ID NO:800); lleSerGluProSerGlyProSerGlyProIleSerThrlleAstiProSerProProProSerLysGluSerH isLysSerPro (SEQ ID NO:801); UeGluGlyArglleSerGluPraSerGIyProneSerThrlleAsinProSerProProSerLysGluSerH isLysSerPro (SEQ ID NO: 802); 25 kde n je nezávisle celé číslo takové, aby celkový počet aminokyselin spojovníku L, byl 4 až 500 a spojovník L2 je polypeptid vybraný ze skupiny sestávající z: 30 Ser; Asn; 35 Gly; -389- CZ 295843 B6 Thr; GlySer; AlaAla; GlySerGly; GlyGlyGly; GlyAsnGly; GlyAlaGly; GlyThrGly; AlaSerAla; AlaAlaAla; GlyGlyGlySer GlyGlyGlySerGlyGlyGlySer GlyGlyGlySerGlyGlyGlySerGlyGlyGlySer SerGlyGlySerGlyGlySer GluPheGlyAsnMet GluPheGlyGlyAsnMet GluPheGlyGlyAsnGlyGlyAsnMet GlyGlySerAspMetAlaGly SerGlyGlyAsnGly SerGlyGlyAsnGlySerGlyGlyAsnGly SerGlyGlyAsnGlySerGlyGlyAsnGlySerGlyGlyAsnGly SerGlyGlySerGlySerGlyGlySerGly SerGlyGlySerGlySerGlyGlySerGlySerGlyGlySerGly GlyGlyGlySerGlyGly GlyGlyGlySerGlyGlyGly GlyGlyGIySerGlyGIyGlySerGlyGly GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGly GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGly (SEQ ID NO:778); (SEQ ID NO:779); (SEQ ID NO:780); (SEQIDNO:781); (SEQ ID NO:782); (SEQ ID NO:783); (SEQ ID NO:784); (SEQ ID NO:785); (SEQ IDNO:786); (SEQ ID NO:787); (SEQ ID NO:788); (SEQ ID NO:789); (SEQ ID NO: 790); (SEQIDNO:791); (SEQ ID NO:792); (SEQ ID NO:793); (SEQ ID NO:794); (SEQ ID NO:795); -390- CZ 295843 B6 GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGly (SEQ ID NO:796); 5 ProProProTrpSerProArgProLeuGlyAlaThrAlaProThrAlaGlyGlnProProLeu (SEQ IDNO:797); ProProProTrpSerProArgProLeuGlyAlaThrAlaProThr (SEQ ID NO:798); a 10 ValGluThrValPheHisArgValSerGlnAspGlyLeuLeuThrSer (SEQ IDNO:799).
- 2. Hematopoietický protein podle nároku 1 obsahující sekvenci aminokyselin s následujícím vzorcem: 15 Ri—Li—R2, R2—Li—Ri, Rj—R2 nebo R2—Ri kde Ri je, jak definováno v nároku 1 a R2 je nezávisle vybrané ze skupiny sestávající z 20 (I) polypeptidického agonisty lidského EPO receptoru obsahujícím modifikovanou sekvenci aminokyselin EPO s následujícím vzorcem: AlaProProArgLeuIleCysAspSerArgValLeuGluArgTyrLeuLeuGluAIaLysGluAiaGluAsnlleThr 10 20 30 40 50 ArgMetGluValGlyGlnGlnAlaValGluValTrpGlnGlyLeuAlaLeuLeuSerGluAlaValLeuArgGlyGln 60 70 AlaLeuLeuValAsnSerSerGlnProTrpGluProLeuGlnLeuHisValAspLysAlaValSerGlyLeuArgSer 80 90 100 LeuThrThrLeuLeuArgAlaLeuGlyAlaGlnLysGluAlalleSerProProAspAlaAlaSerAlaAlaProLeu 110 120 130 ArgThrlleThrAlaAspThrPheArgLysLeuPheArgValTyrSerAsnPhel^uArgGlyLysLeuLysLajiTyr 140 150 ThrGlyGluAlaCysArgThrGlyAspArg 160 (SEQ ID NO:464), 25 kde 1-6 aminokyselin zN-konce a/nebo 1-5 aminokyselin zC-konce může být případně odstraněno z tohoto polypeptidického agonisty receptoru EPO a kde N-konec je spojen k C-konci přímo nebo pomocí spojovníku (L2) schopného spojit N-konec k C-konci a majícího nové C- a N-konce u aminokyselin: 23-24 47-48 109-110 24-25 48-49 110-111 25-26 49-50 111-112 26-27 50-51 112-113 27-28 51-52 113-114 28-29 52-53 114-115 29-30 53-54 115-116 391 - CZ 295843 B6 30-31 54-55 116-117 31-32 55-56 117-118 32-33 56-57 118-119 33-34 57-58 119-120 34-35 77-78 120-121 35-36 78-79 121-122 36-37 79-80 122-123 37-38 80-81 123-124 38-39 81-82 124-125 39-40 82-83 125-126 40-41 84-85 126-127 41-42 85-86 127-128 42—43 86-87 128-129 43—44 87-88 129-130 44-45 88-89 130-131 45—46 108-109 131-132 46-47 v uvedeném pořadí; (II) polypeptidického agonisty receptoru lidského faktoru kmenových buněk obsahujícím modifi-20 kovanou sekvenci aminokyselin faktoru kmenových buněk s následujícím vzorcem: GluGlylleCysArgAsnArgValThrAsnAsnValLysAspValThrLysLeuValAlaAsnLeuProLysAspTyr 10 20 MetlleThrLeuLysTyrValProGlyMetAspValLeuProSerHisCysTrpUeSerGluMetValValGlnLeu 30 40 50 SerAspSerLeuThrAspLeuLeuAspLysPheSerAsnlIeSerGluGlyLeuSerAsnTyrSerllelIeAspLys 60 70 LeuValAsnlleValAspAspLeuValGluCysValLysGluAsnSerSerLysAspLeuLysLysSerPheLysSer 80 90 100 ProGluProArgLeuPheThrProGluGluPhePheArgllePheAsnArgSerlleAspAlaPheLysAspPheVal 110 120 130 ValAlaSerGluThrSerAspCysValValSerSerThrLeuSerProGluLysAspSerArgValSerValThrLys 140 150 ProPheMetLeuProPro V al AlaAla 160 (SEQ ID NO:465), 25 kde 1 až 23 aminokyselin může být případně odstraněno od C-konce tohoto agonisty receptoru faktoru kmenových buněk a kde N-konec je spojen k C-konci přímo nebo pomocí spojovníku (L2) schopného spojit N-konec k C-konci a majícího nové C- a N-konce u aminokyselin: 23-24 39-40 96-97 24-25 40^41 97-98 25-26 64-65 98-99 26-27 65-66 99-100 27-28 66-67 100-101 28-29 67-68 101-102 29-30 68-69 102-103 30-31 69-70 103-104 31-32 70-71 104-105 392 - CZ 295843 B6 32-33 89-90 105-106 33-34 90-91 106-107 34-35 91-92 107-108 35-36 92-93 108-109 36-37 93-94 109-110 37-38 94-95 110-111 38-39 95-96 v uvedeném pořadí; (III) polypeptidického agonisty lidského fit—3 receptoru obsahujícím modifikovanou sekvenci 10 aminokyselin fit—3 ligandu s následujícím vzorcem: ThrGlnAspCysSerPheGInHisSerProIIeSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeu 10 20 GlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAla 30 40 50 GlnArgTrpMetGluArgLeuLysThrValAIaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle 60 70 HisPheValThrLysCysAlaPheGlnProProSerCysLeuArgPheValGlnThrAsníleSerArgLeuLeuGIn 80 90 100 GluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCys 110 120 130 GlnProAspSerSerThrLeu (SEQ ID NO:466), kde 1 až 7 aminokyselin zC-konce může být případně odstraněno z tohoto polypeptidového 15 agonisty receptoru fit—3 a kde N-konec je spojen k C-konci přímo nebo pomocí spojovníku (L2) schopného spojit N-konec k C-konci a majícího nové C- a N-konce u aminokyselin: 28-29 42-43 93-94 29-30 64-65 94-95 30-31 65-66 95-96 31-32 66-67 96-97 32-33 86-87 97-98 34-35 87-88 98-99 36-37 88-89 99-100 37-38 89-90 100-101 38-39 90-91 101-102 39-40 91-92 102-103 40- 41 41- 42 92-93 v uvedeném pořadí; 30 (V) polypeptidu obsahujícím modifikovanou sekvenci aminokyselin lidského IL-3 s následujícím vzorcem: Ala Pro Met Thr Gin Thr Thr Ser Leu Lys Thr Ser Tip Val AsnCys Xaa Xaa Xaa Xaa Xaa Xaa 10 20 Xaa Xaa Xaa Xaa Xaa Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa 30 40 -393 - CZ 295843 B6 Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa XaaXaa Xaa Xaa Xaa 50 60 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 70 80 Xaa Xaa Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa XaaXaa Xaa Xaa Xaa XaaXaa 90 100 Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa XaaXaa Xaa Xaa CHn On Thr Thr 110 120 Leu Ser Leu Ala Ile Phe 130 (SEQIDN0.859), kde Xaa v poloze 17 je Ser, Lys, Gly, Asp, Met, Gin nebo Arg; 5 Xaa v poloze 18 je Asn, His, Leu, Ile, Phe, Arg nebo Gin; Xaa v poloze 19 je Met, Phe, Ile, Arg, Gly, Ala nebo Cys; Xaa v poloze 20 je Ile, Cys, Gin, Glu, Arg, Pro nebo Ala; 10 Xaa v poloze 21 je Asp, Phe, Lys, Arg, Ala, Gly, Glu, Gin, Asn, Thr, Ser nebo Val; Xaa v poloze 22 je Glu, Trp, Pro, Ser, Ala, His, Asp, Asn, Gin, Leu, Val nebo Gly; 15 Xaa v poloze 23 je Ile, Val, Ala, Gly, Trp, Lys, Phe, Leu, Ser nebo Arg; Xaa v poloze 24 je Ile, Gly, Val, Arg, Ser, Phe nebo Leu; Xaa v poloze 25 je Thr, His, Gly, Gin, Arg, Pro nebo Ala; 20 Xaa v poloze 26 je His, Thr, Phe, Gly, Arg, Ala nebo Trp; Xaa v poloze 27 je Leu, Gly, Arg, Thr, Ser nebo Ala; 25 Xaa v poloze 28 je Lys, Arg, Leu, Gin, Gly, Pro, Val nebo Trp; Xaa v poloze 29 je Gin, Asn, Leu, Pro, Arg nebo Val; Xaa v poloze 30 je Pro, His, Thr, Gly, Asp, Gin, Ser, Leu nebo Lys; 30 Xaa v poloze 31 je Pro, Asp, Gly, Ala, Arg, Leu nebo Gin; Xaa v poloze 32 je Leu, Val, Arg, Gin, Asn, Gly, Ala nebo Glu; 35 Xaa v poloze 33 je Pro, Leu, Gin, Ala, Thr nebo Glu; Xaa v poloze 34 je Leu, Val, Gly, Ser, Lys, Glu, Gin, Thr, Arg, Ala, Phe, Ile nebo Met; Xaa v poloze 35 je Leu, Ala, Gly, Asn, Pro, Gin nebo Val; Xaa v poloze 36 je Asp, Leu nebo Val; -394- 40 CZ 295843 B6 Xaa v poloze 37 je Phe, Ser, Pro, Trp nebo Ile; Xaa v poloze 38 je Asn nebo Ala; 5 Xaa v poloze 40 je Leu, Trp nebo Arg; Xaa v poloze 41 je Asn, Cys, Arg, Leu, His, Met nebo Pro; Xaa v poloze 42 je Gly, Asp, Ser, Cys, Asn, Lys, Thr, Leu, Val, Glu, Phe, Tyr, Ile, Met nebo Ala; 10 Xaa v poloze 43 je Glu, Asn, Tyr, Leu, Phe, Asp, Ala, Cys, Gin, Arg, Thr, Gly nebo Ser; Xaa v poloze 44 je Asp, Ser, Leu, Arg, Lys, Thr, Met, Trp, Glu, Asn, Gin, Ala nebo Pro; 15 Xaa v poloze 45 je Gin, Pro, Phe, Val, Met, Leu, Thr, Lys, Trp, Asp, Asn, Arg, Ser, Ala, Ile, Glu nebo His; Xaa v poloze 46 je Asp, Phe, Ser, Thr, Cys, Glu, Asn, Gin, Lys, His, Ala, Tyr, Ile, Val nebo Gly; 20 Xaa v poloze 47 je Ile, Gly, Val, Ser, Arg, Pro nebo His; Xaa v poloze 48 je Leu, Ser, Cys, Arg, Ile, His, Phe, Glu, Lys, Thr, Ala, Met, Val nebo Asn; Xaa v poloze 49 je Met, Arg, Ala, Gly, Pro, Asn, His nebo Asp; 25 Xaa v poloze 50 je Glu, Leu, Thr, Asp, Tyr, Lys, Asn, Ser, Ala, Ile, Val, His, Phe, Met nebo Gin; Xaa v poloze 51 je Asn, Arg, Met, Pro, Ser, Thr nebo His; 30 Xaa v poloze 52 je Asn, His, Arg, Leu, Gly, Ser nebo Thr; Xaa v poloze 53 je Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser nebo Met; Xaa v poloze 54 je Arg, Asp, Ile, Ser, Val, Thr, Gin, Asn, Lys, His, Ala nebo Leu; 35 Xaa v poloze 55 je Arg, Thr, Val, Ser, Leu nebo Gly; Xaa v poloze 56 je Pro, Gly, Cys, Ser, Gin, Glu, Arg, His, Thr, Ala, Tyr, Phe, Leu, Val nebo Lys; 40 Xaa v poloze 57 je Asn nebo Gly; Xaa v poloze 58 je Leu, Ser, Asp, Arg, Gin, Val nebo Cys; Xaa v poloze 59 je Glu, Tyr, His, Leu, Pro nebo Arg; 45 Xaa v poloze 60 je Ala, Ser, Pro, Tyr, Asn nebo Thr; Xaa v poloze 61 je Phe, Asn, Glu, Pro, Lys, Arg nebo Ser; 50 Xaa v poloze 62 je Asn, His, Val, Arg, Pro, Thr, Asp nebo Ile; Xaa v poloze 63 je Arg, Tyr, Trp, Lys, Ser, His, Pro nebo Val; Xaa v poloze 64 je Ala, Asn, Pro, Ser nebo Lys; -395- 55 CZ 295843 B6 Xaa v poloze 65 je Val, Thr, Pro, His, Leu, Phe nebo Ser; Xaa v poloze 66 je Lys, Ile, Arg, Val, Asn, Glu nebo Ser; 5 Xaa v poloze 67 je Ser, Ala, Phe, Val, Gly, Asn, Ile, Pro nebo His; Xaa v poloze 68 je Leu, Val, Trp, Ser, Ile, Phe, Thr nebo His; Xaa v poloze 69 je Gin, Ala, Pro, Thr, Glu, Arg, Trp, Gly nebo Leu; 10 Xaa v poloze 70 je Asn, Leu, Val, Trp, Pro nebo Ala; Xaa v poloze 71 je Ala, Met, Leu, Pro, Arg, Glu, Thr, Gin, Trp nebo Asn; 15 Xaa v poloze 72 je Ser, Glu, Met, Ala, His, Asn, Arg nebo Asp; Xaa v poloze 73 je Ala, Glu, Asp, Leu, Ser, Gly, Thr nebo Arg; Xaa v poloze 74 je Ile, Met, Thr, Pro, Arg, Gly, Ala; 20 Xaa v poloze 75 je Glu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gin nebo Leu; Xaa v poloze 76 je Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly nebo Asp; 25 Xaa v poloze 77 je Ile, Ser, Arg, Thr nebo Leu; Xaa v poloze 78 je Leu, Ala, Ser, Glu, Phe, Gly nebo Arg; Xaa v poloze 79 je Lys, Thr, Asn, Met, Arg, Ile, Gly nebo Asp; 30 Xaa v poloze 80 je Asn, Trp, Val, Gly, Thr, Leu, Glu nebo Arg; Xaa v poloze 81 je Leu, Gin, Gly, Ala, Trp, Arg, Val nebo Lys; 35 Xaa v poloze 82 je Leu, Gin, Lys, Trp, Arg, Asp, Glu, Asn, His, Thr, Ser, Ala, Tyr, Phe, Ile, Met nebo Val; Xaa v poloze 83 je Pro, Ala, Thr, Trp, Arg nebo Met; 40 Xaa v poloze 84 je Cys, Glu, Gly, Arg, Met nebo Val; Xaa v poloze 85 je Leu, Asn, Val nebo Gin; Xaa v poloze 86 je Pro, Cys, Arg, Ala nebo Lys; 45 Xaa v poloze 87 je Leu, Ser, Trp nebo Gly; Xaa v poloze 88 je Ala, Lys, Arg, Val nebo Trp; 50 Xaa v poloze 89 je Thr, Asp, Cys, Leu, Val, Glu, His, Asn nebo Ser; Xaa v poloze 90 je Ala, Pro, Ser, Thr, Gly, Asp, Ile nebo Met; Xaa v poloze 91 je Ala, Pro, Ser, Thr, Phe, Leu, Asp nebo His; -396- 55 CZ 295843 B6 Xaa v poloze 92 je Pro, Phe, Arg, Ser, Lys, His, Ala, Gly, Ue nebo Leu; Xaa v poloze 93 je Thr, Asp, Ser, Asn, Pro, Ala, Leu nebo Arg; 5 Xaa v poloze 94 je Arg, Ile, Ser, Glu, Leu, Val, Gin, Lys, His, Ala nebo Pro; Xaa v poloze 95 je His, Gin, Pro, Arg, Val, Leu, Gly, Thr, Asn, Lys, Ser, Ala, Trp, Phe, Ile nebo Tyr; io Xaa v poloze 96 je Pro, Lys, Tyr, Gly, Ile nebo Thr; Xaa v poloze 97 je Ile, Val, Lys, Ala nebo Asn; Xaa v poloze 98 je His, Ile, Asn, Leu, Asp, Ala, Thr, Glu, Gin, Ser, Phe, Met, Val, Lys, Arg, Tyr 15 nebo Pro; Xaa v poloze 99 je Ile, Leu, Arg, Asp, Val, Pro, Gin, Gly, Ser, Phe nebo His; Xaa v poloze 100 je Lys, Tyr, Leu, His, Arg, Ile, Ser, Gin nebo Pro; 20 Xaa v poloze 101 je Asp, Pro, Met, Lys, His, Thr, Val, Tyr, Glu, Asn, Ser, Ala, Gly, Ile, Leu nebo Gin; Xaa v poloze 102 je Gly, Leu, Glu, Lys, Ser, Tyr nebo Pro; 25 Xaa v poloze 103 je Asp nebo Ser; Xaa v poloze 104 je Trp, Val, Cys, Tyr, Thr, Met, Pro, Leu, Gin, Lys, Ala, Phe nebo Gly; 30 Xaa v poloze 105 je Asn, Pro, Ala, Phe, Ser, Trp, Gin, Tyr, Leu, Lys, Ile, Asp nebo His; Xaa v poloze 106 je Glu, Ser, Ala, Lys, Thr, Ile, Gly nebo Pro; Xaa v poloze 108 je Arg, Lys, Asp, Leu, Thr, Ile, Gin, His, Ser, Ala nebo Pro; 35 Xaa v poloze 109 je Arg, Thr, Pro, Glu, Tyr, Leu, Ser nebo Gly; Xaa v poloze 110 je Lys, Ala, Asn, Thr, Leu, Arg, Gin, His, Glu, Ser nebo Trp; 40 Xaa v poloze 111 je Leu, Ile, Arg, Asp nebo Met; Xaa v poloze 112 je Thr, Val, Gin, Tyr, Glu, His, Ser nebo Phe; Xaa v poloze 113 je Phe, Ser, Cys, His, Gly, Trp, Tyr, Asp, Lys, Leu, Ile, Val nebo Asn; 45 Xaa v poloze 114 je Tyr, Cys, His, Ser, Trp, Arg nebo Leu; Xaa v poloze 115 je Leu, Asn, Val, Pro, Arg, Ala, His, Thr, Trp nebo Met; 50 Xaa v poloze 116 je Lys, Leu, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp, Ser, Asn, His, Ala, Tyr, Phe, Gin nebo Ile; Xaa v poloze 117 je Thr, Ser, Asn, Ile, Trp, Lys nebo Pro; 55 Xaa v poloze 118 je Leu, Ser, Pro, Ala, Glu, Cys, Asp nebo Tyr; -397- CZ 295843 B6 Xaa v poloze 119 je Glu, Ser, Lys, Pro, Leu, Thr, Tyr nebo Arg; Xaa v poloze 120 je Asn, Ala, Pro, Leu, His, Val nebo Gin; 5 Xaa v poloze 121 je Ala, Ser, Ile, Asn, Pro, Lys, Asp nebo Gly; Xaa v poloze 122 je Gin, Ser, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr nebo Cys; ío Xaa v poloze 123 je Ala, Met, Glu, His, Ser, Pro, Tyr nebo Leu; kde 1 až 14 aminokyselin zN-konce a/nebo 1-15 aminokyselin zC-konce může být případně odstraněno z této modifikované sekvence aminokyselin lidského IL-3, a 15 kde od 1 do 44 aminokyselin označených Xaa je různých od odpovídajících aminokyselin nativního (1-133) lidského interleukinu-3; (VII) faktoru vybraného ze skupiny sestávající z faktoru stimulujícího kolonie, cytokinu, lymfo-kinu, interleukinu, a hematopoietického růstového faktoru a 20 kde Li je spojovníkem schopným spojit 1¾ k R2; a tomuto hematopoietickému proteinu může případně bezprostředně přecházet (methionin1), (alanin'1) nebo (methionin-2, alanin'1); s výhradou, že alespoň R] nebo R2 je vybraný z poly-25 peptidů vzorců (I), (II) nebo (III).
- 3. Hematopoietický protein podle nároku 2, kde polypeptid (V) je vybraný ze skupiny sestávající z: 30 Ala Asn Cys Ser Ile Met Ile Asp Glu Ue Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Ala Glu Asp Val Asp Ue Leu Met Glu Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ue Leu Arg Asn Leu Gin Pro Cys Lesu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ue Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin (SEQ ID NO: 803); -398- CZ 295843 B6 Ala Asn Cys Ser Xle Met íle Asp Glu Ile Ife His His Leu Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ue Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg GJu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin (SEQ ID NO:804); Ala Asn Cys Ser Ile Met Ile Asp Glu Ue Ue His His Leu Lys Val Pro Pro Ala Pro Leu Leu Asp Ser Asn Asn Leu Asn Ser Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn Leu Leu Ala Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala De Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile De De Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin (SEQ ID NO:80$;a Asn Cys Ser De Met De Asp Glu De De His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser De Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly De Glu Ala De Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro De De De Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin (SEQ ID N0:806). -399- CZ 295843 B6
- 4. Hematopoietický protein podle nároku 1 obsahující sekvenci aminokyselin s následujícím vzorcem: R]-Li—R.2, R-2-L]—Rj, R]—R2 nebo R2—R] kde Ri je polypeptid obsahující modifikovanou sekvenci aminokyselin fit—3 ligandu s následujícím vzorcem: ThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeu 10 20 GlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAla 30 40 50 GlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle 60 70 HisPheValThrLysCysAlaPheGlnProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGln 80 90 100 130 (SEQ ID NO:466), 110 120 GlnProAspSerSerThrLeu 10 kde N-konec je spojen k C-konci přímo nebo pomocí spojovníku (L2) schopného spojit N— konec k C-konci a majícího nové C- a N-konce u aminokyselin: 28-29 42^43 93-94 29-30 64-65 94-95 30-31 65-66 95-96 31-32 66-67 96-97 32-33 86-87 97-98 34-35 87-88 98-99 36-37 88-89 99-100 37-38 89-90 100-101 38-39 90-91 101-102 39-40 91-92 102-103 40- 41 41- 42 92-93 v uvedeném pořadí; kde R2 je polypeptidem obsahujícím modifikovanou sekvenci aminokyselin lidského IL-3 s následujícím vzorcem: Ala Pro Met Thr Gin Thr Thr Ser Leu Lys Thr Ser Trp Val AsnCys Xaa Xaa Xaa Xaa Xaa Xaa 10 20 Xaa Xaa Xaa Xaa Xaa Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa 30 40 Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa XaaXaa Xaa Xaa Xaa 50 60 -400- CZ 295843 B6 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 70 80 Xaa Xaa Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa XaaXaa 90 100 Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa XaaXaa Xaa Xaa Gin Gin Thr Thr 110 120 Leu Ser Leu Ala Ile Phe 130 (SEQIDN0.859), kde Xaa v poloze 17 je Ser, Lys, Gly, Asp, Met, Gin nebo Arg; 5 Xaa v poloze 18 je Asn, His, Leu, Ile, Phe, Arg nebo Gin; Xaa v poloze 19 je Met, Phe, Ile, Arg, Gly, Ala nebo Cys; Xaa v poloze 20 je Ile, Cys, Gin, Glu, Arg, Pro nebo Ala; 10 Xaa v poloze 21 je Asp, Phe, Lys, Arg, Ala, Gly, Glu, Gin, Asn, Thr, Ser nebo Val; Xaa v poloze 22 je Glu, Trp, Pro, Ser, Ala, His, Asp, Asn, Gin, Leu, Val nebo Gly; 15 Xaa v poloze 23 je Ile, Val, Ala, Gly, Trp, Lys, Phe, Leu, Ser nebo Arg; Xaa v poloze 24 je Ile, Gly, Val, Arg, Ser, Phe nebo Leu; Xaa v poloze 25 je Thr, His, Gly, Gin, Arg, Pro nebo Ala; 20 Xaa v poloze 26 je His, Thr, Phe, Gly, Arg, Ala nebo Trp; Xaa v poloze 27 je Leu, Gly, Arg, Thr, Ser nebo Ala; 25 Xaa v poloze 28 je Lys, Arg, Leu, Gin, Gly, Pro, Val nebo Trp; Xaa v poloze 29 je Gin, Asn, Leu, Pro, Arg nebo Val; Xaa v poloze 30 je Pro, His, Thr, Gly, Asp, Gin, Ser, Leu nebo Lys; 30 Xaa v poloze 31 je Pro, Asp, Gly, Ala, Arg, Leu nebo Gin; Xaa v poloze 32 je Leu, Val, Arg, Gin, Asn, Gly, Ala nebo Glu; 35 Xaa v poloze 33 je Pro, Leu, Gin, Ala, Thr nebo Glu; Xaa v poloze 34 je Leu, Val, Gly, Ser, Lys, Glu, Gin, Thr, Arg, Ala, Phe, Ile nebo Met; Xaa v poloze 35 je Leu, Ala, Gly, Asn, Pro, Gin nebo Val; 40 Xaa v poloze 36 je Asp, Leu nebo Val; Xaa v poloze 37 je Phe, Ser, Pro, Trp nebo Ile; 45 Xaa v poloze 38 je Asn nebo Ala; -401 - CZ 295843 B6 Xaa v poloze 40 je Leu, Trp nebo Arg; Xaa v poloze 41 je Asn, Cys, Arg, Leu, His, Met nebo Pro; 5 Xaa v poloze 42 je Gly, Asp, Ser, Cys, Asn, Lys, Thr, Leu, Val, Glu, Phe, Tyr, Ile, Met nebo Ala; Xaa v poloze 43 je Glu, Asn, Tyr, Leu, Phe, Asp, Ala, Cys, Gin, Arg, Thr, Gly nebo Ser; 10 Xaa v poloze 44 je Asp, Ser, Leu, Arg, Lys, Thr, Met, Trp, Glu, Asn, Gin, Ala nebo Pro; Xaa v poloze 45 je Gin, Pro, Phe, Val, Met, Leu, Thr, Lys, Trp, Asp, Asn, Arg, Ser, Ala, Ile, Glu nebo His; 15 Xaa v poloze 46 je Asp, Phe, Ser, Thr, Cys, Glu, Asn, Gin, Lys, His, Ala, Tyr, Ile, Val nebo Gly; Xaa v poloze 47 je Ile, Gly, Val, Ser, Arg, Pro nebo His; Xaa v poloze 48 je Leu, Ser, Cys, Arg, Ile, His, Phe, Glu, Lys, Thr, Ala, Met, Val nebo Asn; 20 Xaa v poloze 49 je Met, Arg, Ala, Gly, Pro, Asn, His nebo Asp; Xaa v poloze 50 je Glu, Leu, Thr, Asp, Tyr, Lys, Asn, Ser, Ala, Ile, Val, His, Phe, Met nebo Gin; 25 Xaa v poloze 51 je Asn, Arg, Met, Pro, Ser, Thr nebo His; Xaa v poloze 52 je Asn, His, Arg, Leu, Gly, Ser nebo Thr; Xaa v poloze 53 je Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser nebo Met; 30 Xaa v poloze 54 je Arg, Asp, Ile, Ser, Val, Thr, Gin, Asn, Lys, His, Ala nebo Leu; Xaa v poloze 55 je Arg, Thr, Val, Ser, Leu nebo Gly; 35 Xaa v poloze 56 je Pro, Gly, Cys, Ser, Gin, Glu, Arg, His, Thr, Ala, Tyr, Phe, Leu, Val nebo Lys; Xaa v poloze 57 je Asn nebo Gly; Xaa v poloze 58 je Leu, Ser, Asp, Arg, Gin, Val nebo Cys; 40 Xaa v poloze 59 je Glu, Tyr, His, Leu, Pro nebo Arg; Xaa v poloze 60 je Ala, Ser, Pro, Tyr, Asn nebo Thr; 45 Xaa v poloze 61 je Phe, Asn, Glu, Pro, Lys, Arg nebo Ser; Xaa v poloze 62 je Asn, His, Val, Arg, Pro, Thr, Asp nebo Ile; Xaa v poloze 63 je Arg, Tyr, Trp, Lys, Ser, His, Pro nebo Val; 50 Xaa v poloze 64 je Ala, Asn, Pro, Ser nebo Lys; Xaa v poloze 65 je Val, Thr, Pro, His, Leu, Phe nebo Ser; 55 Xaa v poloze 66 je Lys, Ile, Arg, Val, Asn, Glu nebo Ser; -402- CZ 295843 B6 Xaa v poloze 67 je Ser, Ala, Phe, Val, Gly, Asn, Ile, Pro nebo His; Xaa v poloze 68 je Leu, Val, Trp, Ser, Ile, Phe, Thr nebo His; 5 Xaa v poloze 69 je Gin, Ala, Pro, Thr, Glu, Arg, Trp, Gly nebo Leu; Xaa v poloze 70 je Asn, Leu, Val, Trp, Pro nebo Ala; ío Xaa v poloze 71 je Ala, Met, Leu, Pro, Arg, Glu, Thr, Gin, Trp nebo Asn; Xaa v poloze 72 je Ser, Glu, Met, Ala, His, Asn, Arg nebo Asp; Xaa v poloze 73 je Ala, Glu, Asp, Leu, Ser, Gly, Thr nebo Arg; 15 Xaa v poloze 74 je Ile, Met, Thr, Pro, Arg, Gly, Ala; Xaa v poloze 75 je Glu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gin nebo Leu; 20 Xaa v poloze 76 je Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly nebo Asp; Xaa v poloze 77 je Ile, Ser, Arg, Thr nebo Leu; Xaa v poloze 78 je Leu, Ala, Ser, Glu, Phe, Gly nebo Arg; 25 Xaa v poloze 79 je Lys, Thr, Asn, Met, Arg, Ile, Gly nebo Asp; Xaa v poloze 80 je Asn, Trp, Val, Gly, Thr, Leu, Glu nebo Arg; 30 Xaa v poloze 81 je Leu, Gin, Gly, Ala, Trp, Arg, Val nebo Lys; Xaa v poloze 82 je Leu, Gin, Lys, Trp, Arg, Asp, Glu, Asn, His, Thr, Ser, Ala, Tyr, Phe, Ile, Met nebo Val; 35 Xaa v poloze 83 je Pro, Ala, Thr, Trp, Arg nebo Met; Xaa v poloze 84 je Cys, Glu, Gly, Arg, Met nebo Val; Xaa v poloze 85 je Leu, Asn, Val nebo Gin; 40 Xaa v poloze 86 je Pro, Cys, Arg, Ala nebo Lys; Xaa v poloze 87 je Leu, Ser, Trp nebo Gly; 45 Xaa v poloze 88 je Ala, Lys, Arg, Val nebo Trp; Xaa v poloze 89 je Thr, Asp, Cys, Leu, Val, Glu, His, Asn nebo Ser; Xaa v poloze 90 je Ala, Pro, Ser, Thr, Gly, Asp, Ile nebo Met; 50 Xaa v poloze 91 je Ala, Pro, Ser, Thr, Phe, Leu, Asp nebo His; Xaa v poloze 92 je Pro, Phe, Arg, Ser, Lys, His, Ala, Gly, Ile nebo Leu; 55 Xaa v poloze 93 je Thr, Asp, Ser, Asn, Pro, Ala, Leu nebo Arg; -403- CZ 295843 B6 Xaa v poloze 94 je Arg, Ile, Ser, GIu, Leu, Val, Gin, Lys, His, Ala nebo Pro; Xaa v poloze 95 je His, Gin, Pro, Arg, Val, Leu, Gly, Thr, Asn, Lys, Ser, Ala, Trp, Phe, Ile nebo 5 Tyr; Xaa v poloze 96 je Pro, Lys, Tyr, Gly, Ile nebo Thr; Xaa v poloze 97 je Ile, Val, Lys, Ala nebo Asn; 10 Xaa v poloze 98 je His, Ile, Asn, Leu, Asp, Ala, Thr, Glu, Gin, Ser, Phe, Met, Val, Lys, Arg, Tyr nebo Pro; Xaa v poloze 99 je Ile, Leu, Arg, Asp, Val, Pro, Gin, Gly, Ser, Phe nebo His; 15 Xaa v poloze 100 je Lys, Tyr, Leu, His, Arg, Ile, Ser, Gin nebo Pro; Xaa v poloze 101 je Asp, Pro, Met, Lys, His, Thr, Val, Tyr, Glu, Asn, Ser, Ala, Gly, Ile, Leu nebo Gin; 20 Xaa v poloze 102 je Gly, Leu, Glu, Lys, Ser, Tyr nebo Pro; Xaa v poloze 103 je Asp nebo Ser; 25 Xaa v poloze 104 je Trp, Val, Cys, Tyr, Thr, Met, Pro, Leu, Gin, Lys, Ala, Phe nebo Gly; Xaa v poloze 105 je Asn, Pro, Ala, Phe, Ser, Trp, Gin, Tyr, Leu, Lys, Ile, Asp nebo His; Xaa v poloze 106 je Glu, Ser, Ala, Lys, Thr, Ile, Gly nebo Pro; 30 Xaa v poloze 108 je Arg, Lys, Asp, Leu, Thr, Ile, Gin, His, Ser, Ala nebo Pro; Xaa v poloze 109 je Arg, Thr, Pro, Glu, Tyr, Leu, Ser nebo Gly; 35 Xaa v poloze 110 je Lys, Ala, Asn, Thr, Leu, Arg, Gin, His, Glu, Ser nebo Trp; Xaa v poloze 111 je Leu, Ile, Arg, Asp nebo Met; Xaa v poloze 112 je Thr, Val, Gin, Tyr, Glu, His, Ser nebo Phe; 40 Xaa v poloze 113 je Phe, Ser, Cys, His, Gly, Trp, Tyr, Asp, Lys, Leu, Ile, Val nebo Asn; Xaa v poloze 114 je Tyr, Cys, His, Ser, Trp, Arg nebo Leu; 45 Xaa v poloze 115 je Leu, Asn, Val, Pro, Arg, Ala, His, Thr, Trp nebo Met; Xaa v poloze 116 je Lys, Leu, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp, Ser, Asn, His, Ala, Tyr, Phe, Gin nebo Ile; 50 Xaa v poloze 117 je Thr, Ser, Asn, Ile, Trp, Lys nebo Pro; Xaa v poloze 118 je Leu, Ser, Pro, Ala, Glu, Cys, Asp nebo Tyr; Xaa v poloze 119 je Glu, Ser, Lys, Pro, Leu, Thr, Tyr nebo Arg; -404- 55 CZ 295843 B6 Xaa v poloze 120 je Asn, Ala, Pro, Leu, His, Val nebo Gin; Xaa v poloze 121 je Ala, Ser, Ile, Asn, Pro, Lys, Asp nebo Gly; 5 Xaa v poloze 122 je Gin, Ser, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr nebo Cys; Xaa v poloze 123 je Ala, Met, Glu, His, Ser, Pro, Tyr nebo Leu; kde 1 až 14 aminokyselin je případně odstraněno zN-konce a/nebo 1 až 15 aminokyselin je io případně odstraněno z C-konce této modifikované sekvence aminokyselin lidského interleukinu-3; a kde od 1 do 44 aminokyselin označených Xaa je různých od odpovídajících aminokyselin nativního (1-133) lidského interleukinu-3; a kde Li je spojovníkem schopným spojit Rj k R2; a 15 tomuto hematopoietickému proteinu může případně bezprostředně předcházet (methionin’), (alanin'1) nebo (methionin-2, alanin1).
- 5. Hematopoietický protein podle nároku 4, kde R2 je vybraný ze skupiny sestávající z Ala Asn Cys Ser Ile Met De Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Ala Glu Asp Val Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Aig Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tip Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin (SEQ ID NO: 803); Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met Asp De Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ue Leu Arg Asn Lot Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro De De De Lys Ala Gly Asp -405- CZ 295843 B6 Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin (SEQ ID NO:804); Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Val Pro Pro Ala Pro Leu Leu Asp Ser Asn Asn Leu Asn Ser Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn Leu Leu Ala Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin (SEQ ID NO:80$*,a Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ue Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile De Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin (SEQ IDNO:806). -406- CZ 295843 B6
- 6. Hematopoietický protein podle nároku 1 obsahující sekvenci aminokyselin s následujícím vzorcem: R1-L1-R2, R2 Li Ris R1-R2 nebo R2—Ri kde R] je polypeptid obsahující modifikovanou sekvenci aminokyselin fit—3 ligandu s následujícím vzorcem: ThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeu 10 20 GlnA^pTyrProValThrValAlaSerAsnLeuCSInAspGluGluLeuCysGSyGlyLeuTfpArgLeuVal 30 40 50 GlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle 60 70 HisPheValThrLysCysAlaPheGlnProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGln 80 90 100 GluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluL«jGlnCys 110 120 130 GlnProAspSerSerThrLeu (SEQ ID NO:466) vzniklou lineárním přeskupením sekvence, kde N-konec je spojen k C-konci přímo nebo pomocí spojovníku (L2) schopného spojit N-15 konec k C-konci a po otevření takto vzniklé cirkulámí molekuly jsou vytvořeny nové C- a N-konce lineární molekuly mezi zbytky aminokyselinových párů: 28-29 42-43 93-94 29-30 64-65 94-95 30-31 65-66 95-96 31-32 66-67 96-97 32-33 86-87 97-98 34-35 87-88 98-99 36-37 88-89 99-100 37-38 89-90 100-101 38-39 90-91 101-102 39-40 91-92 102-103 40- 41 41- 42 92-93 v uvedeném pořadí ; 30 kde R2 je faktorem vybraným ze skupiny sestávající z faktoru stimulujícím kolonie, cytokinu, lymfokinu, interleukinu, a hematopoietického růstového faktoru a kde L] je spojovníkem schopným spojit Ri k R2; a tomuto hematopoietickému proteinu může případně bezprostředně předcházet (methionin'1), (alanin'1) nebo (methionin"2, alanin"1). - 407 - 35 CZ 295843 B6
- 7. Hematopoietický protein podle nároku 1 obsahující sekvenci aminokyselin s následujícím vzorcem: R]—L]—R-2, R2-·Lj—Ri, R]—R2 nebo R2—Ri kde Rj je polypeptid obsahující modifikovanou sekvenci aminokyselin flt-3 ligandu s následujícím vzorcem: ThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeul.eu 10 20 GlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAla 30 40 50 GlnArgTrpMetGluArgLoiLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlune 60 70 HisPheValThrLysCysAlaPheGínProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGln 80 90 100 GluThrSerGiuGInLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCys 110 120 130 GlnProAspSerSerThrLeu (SEQ ID NO:466) vzniklou lineárním přeskupením sekvence, kde N-konec je spojen k C-konci přímo nebo pomocí spojovníku (L2) schopného spojit N-konec k C-konci a po otevření takto vzniklé cirkulámí molekuly jsou vytvořeny nové C- a N-15 konce lineární molekuly mezi zbytky aminokyselinových párů: 1 28-29 42-43 93-94 29-30 64-65 94-95 30-31 65-66 95-96 31-32 66-67 96-97 32-33 86-87 97-98 34-35 87-88 98-99 36-37 88-89 99-100 37-38 89-90 100-101 38-39 90-91 101-102 39-40 91-92 102-103 40- 41 41- 42 92-93 v uvedeném pořadí; 30 kde R2 je polypeptidem obsahujícím modifikovanou sekvenci aminokyselin lidského G-CSF s následujícím vzorcem: Xaa Xaa Xaa Gly Pro Ala Ser Ser Leu Pro Gin Ser XaaLeu Leu Xaa Xaa Xaa Glu Gin Val Xaa 10 20 Lys Xaa Gin Gly Xaa GlyAla Xaa Leu Gin au Xaa Leu Xaa Ala Thr Tyr Lys Leu Xaa Xaa 30 40 -408- CZ 295843 B6 Xaa Glu Xaa Xaa Val Xaa Xaa Gly His Ser Xaa Gly Tle ProTrpAla Pro Leu Ser Ser Xaa Pro Ser 50 60 XaaLeuAlaGlyXaaLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylIe 70 80 90 SerProGluLeuGlyProThrLeuXaaThrLeuGlnXaaAspValAlaAspPheAlaXaaThrlleTrpGln 100 110 GlnMet Glu Xaa Xaa Gly Met Ala Pro Ala Leu Gin Pro ThrGln Gly Ala Met Pro Ala Phe Ala 120 130 140 Ser Ala Xaa Gin Xaa Xaa AlaGly Gy Val Leu Val Ala Ser Xaa Leu Gin Xaa Phe Leu Xaa 150 160 XaaSerTyr Arg Val Leu Xaa Xaa Leu Ala Gin Pro 170 $EQIDNO:858), kde 5 Xaa v poloze 1 je Thr, Ser, Arg, Tyr nebo Gly; Xaa v poloze 2 je Pro nebo Leu; Xaa v poloze 3 je Leu, Arg, Tyr nebo Ser; 10 Xaa v poloze 13 je Phe, Ser, His, Thr nebo Pro; Xaa v poloze 16 je Lys, Pro, Ser, Thr nebo His; 15 Xaa v poloze 17 je Cys, Ser, Gly, Ala, Ile, Tyr nebo Arg; Xaa v poloze 18 je Leu, Thr, Pro, His, Ile nebo Cys; Xaa v poloze 22 je Arg, Tyr, Ser, Thr nebo Ala; 20 Xaa v poloze 24 je Ile, Pro, Tyr nebo Leu; Xaa v poloze 27 je Asp nebo Gly; 25 Xaa v poloze 30 je Ala, Ile, Leu nebo Gly; Xaa v poloze 34 je Lys nebo Ser; Xaa v poloze 36 je Cys nebo Ser; 30 Xaa v poloze 42 je Cys nebo Ser; Xaa v poloze 43 je His, Thr, Gly, Val, Lys, Trp, Ala, Arg, Cys nebo Leu; 35 Xaa v poloze 44 je Pro, Gly, Arg, Asp, Val, Ala, His, Trp, Gin nebo Thr; Xaa v poloze 46 je Glu, Arg, Phe, Arg, Ile nebo Ala; -409- CZ 295843 B6 Xaa v poloze 47 je Leu nebo Thr; Xaa v poloze 49 je Leu, Phe, Arg nebo Ser; 5 Xaa v poloze 50 je Leu, Ile, His, Pro nebo Tyr; Xaa v poloze 54 je Leu nebo His; Xaa v poloze 64 je Cys nebo Ser; 10 Xaa v poloze 67 je Gin, Lys, Leu nebo Cys; Xaa v poloze 70 je Gin, Pro, Leu, Arg nebo Ser; 15 Xaa v poloze 74 je Cys nebo Ser; Xaa v poloze 104 je Asp, Gly nebo Val; Xaa v poloze 108 je Leu, Ala, Val, Arg, Trp, Gin nebo Gly; 20 Xaa v poloze 115 je Thr, His, Leu nebo Ala; Xaa v poloze 120 je Gin, Gly, Arg, Lys nebo His; 25 Xaa v poloze 123 je Glu, Arg, Phe nebo Thr; Xaa v poloze 144 je Phe, His, Arg, Pro, Leu, Gin nebo Glu; Xaa v poloze 146 je Arg nebo Gin; 30 Xaa v poloze 147 je Arg nebo Gin; Xaa v poloze 156 je His, Gly nebo Ser; 35 Xaa v poloze 159 je Ser, Arg, Thr, Tyr, Val nebo Gly; Xaa v poloze 162 je Glu, Leu, Gly nebo Trp; Xaa v poloze 163 je Val, Gly, Arg nebo Ala; 40 Xaa v poloze 169 je Arg, Ser, Leu, Arg nebo Cys; Xaa v poloze 170 je His, Arg nebo Ser; 45 kde 1-11 aminokyselin zN-konce a/nebo 1-5 aminokyselin zC-konce může být případně odstraněno z této modifikované sekvence aminokyselin lidského G-CSF a dojde k lineárnímu přeskupení sekvence, kde N-konec je spojen k C-konci přímo nebo pomocí spojovníku (L2) schopného spojit N-konec k C-konci a po otevření takto vzniklé cirkulámí molekuly jsou vytvořeny nové C- a N-konce lineární molekuly mezi zbytky aminokyselinových párů: 50 38-39 62-63 123-124 39-40 63-64 124-125 40-41 64-65 125-126 41—42 65-66 126-127 42-43 66-67 128-129 410- CZ 295843 B6 43-44 67-68 128-129 45-46 68-69 129-130 48-49 69-70 130-131 49-50 70-71 131-132 5 52-53 71-72 132-133 53-54 91-92 133-134 54-55 92-93 134-135 55-56 93-94 135-136 56-57 94-95 136-137 io 57-58 95-96 137-138 58-59 96-97 138-139 59-60 97-98 139-140 60-61 98-99 140-141 61-62 99-100 141-142 15 nebo 142-143 v uvedeném pořadí; kde L] je spojovníkem schopným spojit Ri k R2; 20 tomuto hematopoietickému proteinu může případně bezprostředně předcházet (methionin'1), (alanin'1) nebo (methionin'2, alanin-1).
- 8. Hematopoietický protein podle nároků 1, 2, 3, 4, 5, 6 nebo 7 kde spojovník L2 je vybraný ze 25 skupiny sestávající z: Ser; Asn; 30 Gly; Thr; 35 GlySer; AlaAla; GlySerGly; 40 GlyGlyGly; GlyAsnGly; 45 GlyAlaGly; GlyThrGly; AlaSerAla; 50 AlaAlaAla; GlyGlyGlySer (SEQ ID NO:778); 55 GlyGlyGlySerGlyGlyGlySer (SEQ ID NO:779); -411 - CZ 295843 B6 10 15 20 25 30 GlyGlyGlySerGlyGlyGlySerGlyGlyGlySer SerGIyG lySerG lyGly Ser GIuPheGlyAsnMet GluPheGlyGlyAsnMet GluPheGlyGlyAsnGlyGlyAsnMet GlyGlySerAspMetAlaGly SerGlyGlyAsnGly SerGlyGlyAsnGlySerGlyGlyAsnGly SerGlyGlyAsnGlySerGlyGlyAsnGlySerGlyGlyAsnGly SerGlyGlySerGlySerGlyGlySerGly SerGlyGlySerGlySerGlyGlySerGlySerGlyGlySerGly GlyGlyGlySerGlyGly GlyGlyGlySerGlyGlyGly GlyGlyGlySerGlyGlyGlySerGlyGly GlyGlyGlySerGlyGlyGIySerGlyGlyGlySerGly GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGly (SEQ IDNO:780); (SEQIDNO:781); (SEQ ID NO:782); (SEQ ID NO:783); (SEQ ID NO:784); (SEQ ID NO:785); (SEQ IDNO:786); (SEQ ID NO:787); (SEQ ID NO:788); (SEQ ID NO:789); (SEQ IDNO:790); (SEQ ID NO:791); (SEQ IDNO:792); (SEQ ID NO:793); (SEQ ID NO:794); (SEQ ID NO:795); GlyGIyGlySerGlyGIyGlySerGlyGlyGIySerGlyGlyGlySerGlyGlyGlySerGly 35 40 (SEQ ID NO:796); ProProProTrpSerProArgProLeuGlyAlaThrAlaProThrAlaGlyGlnProProLeu (SEQ IDNO:797); ProProProTrpSerProArgProLeuGlyAlaThrAlaProThr (SEQ ID NO:798); a ValGluThrValPheHisArgValSerGlnAspGlyLeuLeuThrSer (SEQ ID NO:799);
- 9. Hematopoietický protein podle nároku 1, kde tento protein je vybraný ze skupiny, kterou tvoří: AlaAsnCysSerUeMetlleAspGluIlelleHisHisLeuLysArgProProAlaProLeuLeuAspProAsn AsnLeuAsnAspGIuAspValSeríleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPhe ValArgAlaValLysAsnLeuGluAsnAlaSerGlylleGluAlaUeLeuArgAsnLeuGlnProCysLeu ProSerAlaThrAlaAlaProSerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLys -412- CZ 295843 B6 LeuThrPheTyrLeuValThrLeuGluGInAlaGInGIuGInGInTyrValGluGlyGlyGlyGlySerPro GlyGIuProSerGlyProIleSerThrUeAsnProSerProProSerLysGluSerHisLysSerProAsnMet AlaAspGluGluLeuCysGlyGlyLeuT rp ArgLeu ValLeuAIaGlnArgT rpMetGlu ArgLeuLys ThrValAlaGlySerLysMetGInGlyLeuLeuGluArgValAsnThrGIuIJeHisPheValThrLysCys AlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnUeSerArgLeuLeuGlnGluThrSer GIuGlnLeuValAlal^euLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGIn ProAspSerSerThrLeuSerGlyGlyAsnGlySerGIyGíyAsnGiyThrGlnAspCysSerPheGlnHts SerProIleSerSerAspPheAIaValLysIIeArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThr ValAiaSerAsaLeuGln (SEQIDNO:58l); AlaAsnCysSerlleMetlleAspGluUelleHisHisLeuLysArgProProAlaProLeuLeuAspProAsn AsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPhe ValArgAlaValLysAsnLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeu ProSerAJaThrAlaAlaProSerArgHisProllellelleLysAlaGlyAspTrpGInGIuPheArgGluLys LeuThrPheTyrLeuValThrLajGluGInAlaGtoGluGlnGtoTyrValGluGIyGlyGlyGlySerPro GlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMet AlaAspGluGIuLeuCysGlyGlyLeuTrpArgLeuValLeuAJaGlnArgTrpMetGluArgLeuLys ThrValAIaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCys AlaPheGtaProProProSerCysLeuArgPheVaiGlnThrAsnlleSerArgLeuLeuGlnGluThrSer GiuGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsiiPheSerArgCysLeuGluLeuGlnCysGln ProAspSerSerThrLeuSerGlyGlyAsnGlySerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHis SerProIleSerSerAspPheAiaValLysfleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThr ValAlaSerAsnLeuGln (SEQ ID NO: 582); -413- CZ 295843 B6 AlaAsnCysSerlleMetlleAspGluUelIeHisHisLeuLysArgProProAJaProLeuLeuAspProAsn AsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPhe ValArgAlaValLysAsnl^uGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeu ProSerAlaThrAlaAlaProSerArgHÍsProIlellelleLysAlaGlyAspTrpGlnGíuPheArgGluLys LeuTkPheTyrLeuValThrLeuGluGlnAlaGlnGIuGlnGinTyrValGIuGlyGlyGlyGlySerPro GlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMet AlaSerLysMetGInGlyLeuLeuGluArgVaLAsnThrGluIleHisPheVrfrhrLysCysAlaPheGbj ProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGInLeu ValAlaLeuLysProTrpíleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSer SerThrLeuSerGIyGlyAsnGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAIaVal LysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGlu G1 uLeuCysGlyGlyLeuTrp ArgLeu V alLeu AlaGln ArgTrpMetGlu ArgLeuLysThrVal AI aGly (SEQ ID NO:583); AlaAsnCysSerlleMetlieAspGluIlelleHtsHisLeuLysArgProProAlaProLeuLeuAspProAsn AsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheVal ArgAIaValLysAsnLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeaProSer AlaThrAlaAlaProSerArgHisProIleIIeIleLysA]aGlyAspTrpGlnGluPheArgGluLysl/€uThr PheTyrLeuV alThrLeuGluGln AlaGlnGluGlnGlnTyrValGluGlyGlyGJyGIy SerProGlyGlu ProSerGlyProDeSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaSerLys MetGlnGlyLeuLeuGluArgValAsnThrGluIteHisPheValThrLysCysAIaPheGlnProProProSer CysLeuArgPheValGInThrAsnIleSerArgLeuLeuGInGIuThrSerGluGInLeuValAlaLewLys ProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuSerGly GlyAsnGIySerGlyGlyAsnGIyThrGinAspCysSerPheGlnHísSerProIleSerSerAspPheAiaVal LysIleArgGiuLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGIu GluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGIy (SEQ ID NO: 584); -414- CZ 295843 B6 AlaAsnCysSerOeMetUeAspGluUelleHisHisLeuLysArgProProAlaProLeuLeuAspProAsn AsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheVal ArgAIaValLysAsrtLeuGluAsnAJaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeuPro SerAlaThrAlaAlaProSerArgHisProIleílelleLysAlaGlyAspTrpGInGluPheArgGluLysLeu ThrPheTyrLeuValThrLeuGluGInAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGly GluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAla AspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr VaJAiaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGIuíleHisPheValThrLysCysAla PheGlnProProProSerCysLeuArgPheValGlnThrAsnJJeSerArgLeuLeuGlnGluThrSerGIu GlnLeuValAlaLeuLysProTrpIleThrArgGInAsnPheSerArgCysLeuGluLeuGlnCysGlnPro AspSerSerThrLeuSerGlyGlyAsnGlySerGlyGlyAsnGlySerGlyGlyAsnGlyThrGlnAsCys SerPheGlnHisSerProIleSerSerAspPheAlaVaE.ysIleArgGluLeuSerAspTyrLeuLeuGlnAsp TyrProValThrValAlaSerAsnLeuGln (SEQ ID NO: 585); AaAsnCysSerlIeMetlIeAspGluIlelleHisHisLeuLysArgProProAIaProLeuLeuAspProAsn AsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPhe ValArgAlaValLysAsnLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeu ProSerAiaThrAlaAIaPro SerArgHisProIlelIelleLysAIaGly AspT rpGlnGluPhe ArgGIuLys LeuThrPheTyrLeuValThrLeuGluGlnAlaGInGluGInGlnTyrValGluGlyGIyGlyGIySerPro GlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMet AlaProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeu ValAlaLeuLysProTrpHeThrArgGInAsnPheSerArgCysLeuGluLeuGInCysGlnProAspSer SerThrLeuSerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAla ValLysDeArgGiuLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGInAsp GluGluLeuCysGIyGIyLeuTrpArgLeuVaJLeuAlaGlnArgTrpMetGluArgLeuLysThrValAla GlySerLysMetGlnGlyLeuLeuGluArgVaLAsnThrGluíleHisPheValThrLysCysAlaPheGlnPro (SEQ ID NO:586); -415- CZ 295843 B6 AlaAsnCysSerlIeMeííleAspGluIIeíleHisHisLeuLysArgProProAlaProLeuLeuAspProAsn AsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPhe ValArgAlaValLysAsnLeuGluAsnAíaSerGlylleGluAIalleLeuArgAstiLeuGlnProCysLeu ProSerAlaThrAlaAlaProSerArgHisProIlelIelleLysAlaGlyAspTrpGlnGluPheArgGluLys LeuThrPheTyrLeuValThrLeuGluGInAlaGInGluGlnGlnTyrValGtuGlyGlyGlyGlySerPro GlyGluProSerGlyProfleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMet AlaProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeu ValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAsp SerSerThrLeuSerGlyGlyAsnGlySerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHisSerPro IleSerSerAspPheAlaValLysUeAfgGluLeuSerAspTyrLeuLeuGIoAspTyrProValThrVal AlaSerAsnLeuGínAspGIuGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMet GluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlulleHisPhe ValThrLysCysAlaPheGlnPro (SEQ ID NO:587); AlaAsnCysSerlieMetíleAspGluIlelleHisHÍsLeuLysArgProProAIaProLeuLeuAspProAsn AsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeuArgLeuProAstiLeuGluSerPhe ValArgAlaValLysAsnLeuGluAsnAJaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeu ProSerAlaThrAlaAlaProSerArgHisProIlellelleLysAlaGlyAspTrpGInGluPheArgGIuLys LeuThrPheTyrLeuVdThrLeuGluGlnAlaGinGluGlnGlnTyrValGluGlyGlyGlyGlySerPro GlyGluProSerGiyProIleSerThrHeAsnProSerProProSerLysGluSerHisLysSerProAsnMeí AlaProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeu ValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSer TTirLeuSerGlyGlyAsnGlySerGlyGlyAsnGlySerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHis SerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThr ValAIaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAIaGlnArgTrpMet GluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPhe ValThrLysCysAlaPheGlnPro (SEQ ID NO: 588); -416- CZ 295843 B6 AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLys ThrValAlaGlySerLysMetGlnGIyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCys AlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGInGluThrSer GluGlnLeuValAlaLeuLysProTrplleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGln ProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGIyGlyGlySerGlyGly GlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeu SerAspTyrLeuLeuGlnAspTyrProValThrValAIaSerAsnLeuGlnTyrValGluGIyGlyGlyGIy SerProGlyGlyGlySer GlyGlyGlySerAsnMetAlaThrProLeuGlyProAlaSerSerLeuProGInSer PheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAIaAlaLeuGlnGluLysLeuCys GlyLeuLeuGInAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAla AspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAiaProAlaLeuGInProThrGlnGlyAla MetProAlaPheAlaSerAIaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeu GluValSeiTyrArg ValLeuArgHisLeuAlaGInPro (SEQ ID NO:743); TyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeu TrpArgLeuValLeuAlaGliiArgTrpMetGluArgLexjLysThrValAlaGIySerLysMetGlnGíyLeu LeuGiuArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArg PheValGlnThrAsaíleSerArgLeuLeuGtnGluThrSerGIuGlnLeuValAlaLeuLysProTrplle ThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuTyrValGlu GlyGlyGlyGlySerProOyGlyGIySerGlyGlyGlySerAsnMetAlaThrProLeuGlyProAiaSer SerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGIyAlaAlaLeu GlnGiuLysLeuCysAlaThrTyrLysLeuCysHisPiOGluGluLeuValLeuLeuGlyHisSerLeu -417- CZ 295843 B6 GlylleProTrpAJaProLeuSerSerCysProSerGlnAIaLeuGlnLeuAJaOyCysLeuSerGlnLeuHis SerGlyLeuPheLeuTyrGinGlyLeuLeuGlnAJaLeuGiuGlyneSerProGluLeuGlyProThrLeuAsp ThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGIyMetAlaPro AlaLeuGlnProThrGlnGlyAlaMetProAlaPheAIaSerAIaPheGlnArgArgAlaGlyGlyValLeu ValAlaSerHisLeuGlnSerPheLeuGIuValSerTyr ArgValLeuArgHisLeuAlaGlnPro (SEQIDNO:659); AiaThrProLeuGlyProAíaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIle GlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuVal LeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAIaGly CysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGIyLeuLeuGlnAlaJLeuGluGlylleSerPro GIuLeuGlyProThrLeuAspThrLeuGlnLeuAspValAjaAspPheAlaThrThrlleTrpGlnGin MetGluGluLeuGlyMetAlaProAiaLeuGlnProThrGInGlyAlaMetProAIaPheAlaSerAlaPhe GlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGInSerPheLeuGluValSerTyrArgValLeu ArgHisLeuAlaGlnProTyrValGIuGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlle AsnProSerProProSerLysGluSerlIisLysSerProAsnMetAlaAspGluGluLeuCysGlyGIyLeu TrpArgLeuVaiLeuAlaGlnArgTrpMetGluArglxuLysThrValAlaGlySerLysMetGlnGlyLeu LeuGluArgValAsnThrGIuIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPhe ValGlnThrAsnIleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlal,euLysProTrpíJeThrArg GlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGiySerGIyGly GlySerGlyGlyGlySerGlyGIyGlySerGlyGlyGlySerGlyThrGinAspCysSerPheGlnHisSer ProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGtaAspTyrProValThr ValAlaSerAsnLeuGIn (SEQ ID NO:705); AiaAspGluGIuLeuCysGlyGlyLeuTrpArgLeuValLeuAIaGInArgTrpMetGluArgLeuLys ThrValAlaGlySerLysMetGlnGlyLeuLeuGIuArgValAsnThrGluIieHisPheValThrLys CysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThr SeiGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCys GlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGly -418- CZ 295843 B6 GlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProlleSerSerAspPheAlaValLysIleArgGlu LeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGly GlySerProGlyGlyGlySerGlyGlyGiySerAsnMetAlaThrProLeuGlyProAlaSerSerLeuPro GlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLys LeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrp AlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGIyCysLeuSerGlnLeuHisSerGlyLeuPhe LeuTyrGlnGlyLeuLeuGlnAlaLeuGluGIylleSerProGIuLeuGlyProThrLeuAspThrLeuGln LeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGIuGluLeuGlyMetAlaProAlaLeuGln ProThrGlnGlyAlaMetProAIaPheAlaSerAlaPheGlnArgArgAlaGIyGlyValLeuVaJAlaSer HisLeuGlnSerPheLeuGluValSerTyrArg ValLeuArgHisLeuAlaGlnPro (SEQ ID NO:743).
- 10. Hematopoietický protein podle nároků 1, 2 nebo 6, kde uvedené kolonie stimulující faktor je 5 vybraný ze skupiny sestávající z GM-CSF, G-CSF, G-CSF Ser17, c-mpl ligandu (TPO), M- CSF, erythropoietinu (EPO), IL-1, IL-4, IL-2, IL-3, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-
- 11. Hematopoietický protein podle nároku 10, kde kolonie stimulující faktor je vybraný ze skupiny sestávající z G-CSF, G-CSF Ser17, G-CSF Ala17 a c-mpl ligandu (TPO).11, IL-12, IL-13, IL-15, LIF, flt3/flk2 ligandu, lidského růstového hormonu, růstového faktoru B-buněk, faktoru diferenciace B-buněk, faktoru diferenciace eosinofilů a faktoru kmenových buněk (SCF). 10
- 12. Molekula nukleové kyseliny kódující hematopoietický protein podle nároku 1. 15
- 13. Molekula nukleové kyseliny kódující hematopoietický protein podle nároku 2.
- 14. Molekula nukleové kyseliny kódující hematopoietický protein podle nároku 3.
- 15. Molekula nukleové kyseliny kódující hematopoietický protein podle nároku 4.
- 16. Molekula nukleové kyseliny kódující hematopoietický protein podle nároku 5.
- 17. Molekula nukleové kyseliny kódující hematopoietický protein podle nároku 6. 25
- 18. Molekula nukleové kyseliny kódující hematopoietický protein podle nároku 7.
- 19. Molekula nukleové kyseliny kódující hematopoietický protein podle nároku 8.
- 20. Molekula nukleové kyseliny kódující hematopoietický protein podle nároku 9.
- 21. Molekula nukleové kyseliny kódující hematopoietický protein podle nároku 10.
- 22. Molekula nukleové kyseliny kódující hematopoietický protein podle nároku 11. -419- 35 CZ 295843 B6
- 23. Molekula nukleové kyseliny podle nároku 12 vybraná ze skupiny sestávající z: GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTA TCCTGATGGACCGAAACCTTCGACTTCX2AAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGACGAGGAG CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCG GCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCGCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCAGGCGGT AACGGCAGTGGAGGTAATGGCACCCAGGACTGCTCCTTCCAACACAGCCC CATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGC TTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG (SEQIDNO:12l); GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTA TCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCT GTC AAGAACTT AG AAAATGC ATC AGGT ATT GAGGC AATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC -420- CZ 295843 B6 TATCTGGTTACCCTTGAGCAAGCGeAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGACGAGGAG CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCG GCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCTGGAGGT AACGGATCCGGTGGCAATGGGAGCGGCGGAAATGGAACCCAGGACTGCTC CTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGC TGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTG CAG (SEQIDNO:122); GCTAACTGCTC T AT A ATGAT CG ATGAAATTATAC ATC AC TT AAAGAGAC C ACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTA TCCTGATGG ACCG AAACCTTCGACTTCC AAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCTCCAAGATG CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATG IGCťnTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA CTCCTCAACCCTGTCTGGCGGCAACGGCACGCAGGACTGCTCCTTCCAAC -421 - CZ 295843 B6 ACAGCCCCATCTCCTCCGACITCGCTGTCAAAATCCGTGAGCTGTCTGAC TACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGA GGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGG AGCGGCTCAAGACTGTCGCTGGG (SEQ ID NO: 123); GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTA TCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC T ATCTGGTT ACCCTTG AGCAAGCGCAGGAAC AACAGTACGT AGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCTCCAAGATG CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATG TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA CTCCTCAACCCTGTCTGGAGGTAACGGATCCGGAGGTAATGGCACCCAGG ACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATC CGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTC CAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGG CACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGG (SEQ ID NO: 124); GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTA TCCTG AT GG ACCGAAACCTT C G ACTTCC AAACCTGGAGAGCTT CGT A AGG GCTGTC AAG AACTT AGAAAAT GC ATC AGGT ATTGAGGC AATTCTTCGT AA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA -422- CZ 295843 B6 TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC T ATCTGGTT ACCCTTGAGC AAGCGC AGGAAC AAC AGTACGT AGAGGGCGG TATCTGGTTACCCTTGAGC AAGCGC AGG AAC AAC AGT ACGT AGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CT CCTCCGT CT A A AG AATCT CATAAAT CTCCAAACATGGCCTCC AAGAT G CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATG TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA CTCCTCAACCCTGTCTGGAGGTAACGGATCCGGTGGCAATGGGAGCGGCG GAAATGGAACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGAC TTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCC AGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCT GGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCT GGG (SEQ ID NO: 125) GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTA TCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGT ATTGAGGC AATTCTTCGT AA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC T ATCT GGTTACCCTTGAGC AAGCGC AGGAACAAC AGT ACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCTGGCGGC -423 - CZ 295843 B6 AACGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTT CGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAG TCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGG CGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGG GTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTG TCACCAAATGTGCCTTTCAGCCC (SEQIDNO:126); GCTAACTGCTCTAT AATG ATCGAT GAAATT AT AC ATC ACTTAAAGAGACC ACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTA TCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TC ATC AT C AAGGCAGGT G ACTGGC AAGAATTCCGGGAAAAACTGACGTT C TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCGTGTCAGGCGGT AACGGCAGTGGAGGTAATGGCACCCAGGACTGCTCCTTCCAACACAGCCC CATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGC TTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTC TGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCT CAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACA CGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCC (SEQ ID NO: 127); -424- CZ 295843 B6 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTA TCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCT GTC AAGAACTT AGAAAATGCATC AGGT ATT G AGGC AATTCTTCGT AA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCTGGAGGT AACGGCAGTGGTGGTAATGGGAGCGGCGGAAATGGAACCCAGGACTGCTC CTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGC TGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTG CAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG CCC (SEQIDNO:128); GCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATG GAGCGGCTGAAGACTGTCGCTGGGTCGAAGATGCAAGGCTTGCTGGAGCGCGTGAAC ACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCT TCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCT GAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCC GACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGT GGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCT CCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGT CACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGGTGG TTCTGGCGGCGGCTCCAACATGGCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAG -425- CZ 295843 B6 AGCTTCCTGCTCAAGTCTTTAGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCG CTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTG CTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCC TGCAGCTGGCAGGCTGCTTGAGCCAACTGCATAGCGGCCTTTTCCTCTACCAGGGGCT CCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCA GCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAAT GGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAG cgccgggcaggaggggtcctggttgctagccatctgcagagcttcctggaggtgtcg TACCGCGTTCTACGCCACCTTGCGCAGCCG (SEQ ID NO:282); ggccactcaggactgctcttttcaacacagccccatctcctccgacttcgctgtcaaa atccgtgagctgtctgactacctgcttcaagattacccagtcaccgtggcctccaacc tgcaggacgaggagctctgcgggggcctctggcggctggtcctggcacagcgctgga tggagcggctcaagactgtcgctgggtccaagatgcaaggcttgctggagcgcgtga acacggagatacactttgtcaccaaatgtgcctttcagcccccccccagctgtcttcg cttcgtccagaccaacatctcccgcctcctgcaggagacctgcgagcagctggtggcg ctgaagccctggatcactcgccagaacttctcccggtgcctggagctgcagtgtcagc CCGACTCCTCAACCCTGTACGTAGAGGGCGGtGGAGGCTCCCCGGGTGGTGGTTCTG GCGGCGGCTCCAACATGGCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTT cctgctcaagtctttagagcaagtgagaaagatccagggcgatggcgcagcgctcca ggagaagctgtgtgccacctacaagctgtgccaccccgaggagctggtgctgctcgg acactctctgggcatcccctgggctcccctgagctcctgccccagccaggccctgcag ctggcaggctgcttgagccaactccatagcggccttttcctctaccaggggctcctgc aggccctggaagggatatcccccgagttgggtcccaccttggacacactgcagctgg acgtcgccgactttgccaccaccatctggcagcagatggaagaagtgggaatggccc ctgccctgcagcccacccagggtgccatgccggccttcgcctctgctttccagcgccg ggcaggaggggtcctggttgctagccatctgcagagcttcctggaggtgtcgtaccg cgttctacgccaccttgcgcagccg (SEQ ID NO: 198); GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAG AGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCC ACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCC CCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAG -426- CZ 295843 B6 CCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTCSGAAGGGATA TCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCA CCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCC AGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGT TGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCG CAGCCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCT ACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGATG AAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGC TCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGA TACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAG ACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCC TGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCT CAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAG GGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTT CGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTG GCCTCCAACCTGCAG (SEQ ID NO:244); GCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATG GAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAAC ACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCeCCCCCAGCTGTCTTGGCT TCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCT GAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCC GACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGT GGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCT CCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGT CACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGGTGG TTCTGGCGGCGGCTCCAACATGGCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAG AGCTTCCTGCTCAAGTCTTTAGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCG CTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTG CTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCC TGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCT CCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCA GCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAAT GGCCCCTGCCCTGGAGCCCACCCAGGGTGGCATGCCGGCCTTCGCCTCTGCTTTGCAG CGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCG T ACCGCGTTCT ACGCCACCTT GCGC AGCCG (SEQ ID NO:282). -427- CZ 295843 B6
- 24. Způsob výroby hematopoietického proteinu podle nároku 1, vyznačující se tím, že se provede kultivace za vhodných nutričních podmínek, hostitelské buňky transformované nebo transfektované replikovatelným vektorem obsahujícím molekulu nukleové kyseliny podle 5 kteréhokoliv z nároků 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22 nebo 23 způsobem dovolujícím expresi tohoto hematopoietického protienu a izolaci tohoto hematopoietického proteinu.
- 25. Farmaceutická kompozice, vyznačující se tím, že obsahuje hematopoietický protein podle nároku 1, 2, 3,4, 5, 6, 7, 9 nebo 10 a farmaceuticky přijatelný nosič. 10
- 26. Hematopoietický protein podle nároku 1 pro použití pro zvýšení tvorby krvetvorných buněk u pacienta.
- 27. Hematopoietický protein podle nároku 1 pro použití pro selektivní ex vivo expanzi krve-15 tvorných buněk u pacienta.
- 28. Hematopoietický protein podle nároku 1 pro použití pro léčení pacienta majícího krvetvornou poruchu.
- 29. Hematopoietický protein podle nároku 1 pro použití při lidské genové terapii.
- 30. Hematopoietický protein podle kteréhokoliv z nároků 27,28, kde tyto krvetvorné buňky jsou CD34+ buňky.
- 31. Hematopoietický protein podle kteréhokoliv z nároků 27,28, kde tyto krvetvorné buňky jsou buňky periferní krve.
- 32. Způsob přípravy dendritických buněk, vyznačený tím, že se provede oddělení hematopoietických progenitorových buněk nebo buněk CD34+ od ostatních buněk, načež se 30 provede kultivace těchto hematopoietických progenitorových buněk nebo buněk CD34+ v kultivačním médiu obsahujícím hematopoietický protein podle nároku 1,2, 3 nebo 4.
- 33. Způsob podle nároku 32, vyznačující se tím, že se dále provede impulzová modulace těchto hematopoietických progenitorových buněk nebo buněk CD34+ antigenem. 35
- 34. Způsob podle nároku 32, vyznačující se tím, že kultivační médium dále obsahuje jeden či více faktorů vybraných ze skupiny sestávající zGM-CSF, IL-4, TNF-a, faktoru kmenových buněk (SCF), fit—3 ligandu, IL-3, IL—3 varianty, fúzního proteinu IL-3 varianty a multifunkčního receptorového agonisty. 40
- 35. Způsob podle nároku 33, vyznačující se tím, že kultivační médium dále obsahuje jeden či více faktorů vybraných ze skupiny sestávající z: GM-CSF, IL-4, TNF-a, faktoru kmenových buněk (SCF), fit—3 ligandu, IL-3, IL-3 varianty, fúzního proteinu IL-3 varianty a multifunkčního receptorového agonisty. 45
- 36. Hematopoietický protein podle nároku 1 pro použití pro léčení člověka s tumorem, infekcí nebo auto-imunitním onemocněním. -428- CZ 295843 B6
- 37. Hematopoietický protein podle nároku 36 použitý s jedním nebo více faktory vybranými ze skupiny sestávající z GM-CSF, IL-4, TNF-α, faktoru kmenových buněk (SCF), fit—3 ligandu, IL-3, IL-3 varianty, fúzního proteinu IL-3 varianty a multifunkčního receptorového agonisty.
- 38. Hematopoietický protein podle nároku 36, použitý s antigenem pacientovi.
- 39. Hematopoietický protein podle nároku 37, použitý s antigenem pacientovi. 10 476 stránek sekvencí a 19 výkresů 15 -429- 5 10 15 20 25 30 35 40 45 50 CZ 295843 B6 SEKVENČNÍ PROTOKOL (1) OBECNÉ INFORMACE (i) PŘIHLAŠOVATEL: G. D. Searle (ii) NÁZEV VYNÁLEZU: MULTIFUNKČNÍ CHIMÉRNÍ AGONISTÉ HEMATOPOIETICKÉHO RECEPTORU (iii) POČET SEKVENCÍ: 865 (iv) KONTAKTNTÍ ADRESA: (A) ADRESÁT: G. D. Searle & Co. (B) ULICE: P.O. Box 5110 (C) MĚSTO: Chicago (D) STÁT: IL (E) ZEMĚ: U. S. A. (F) ZIP: 60680 (v) POČÍTAČ (A) TYP MEDIA: Disketa (B) POČÍTAČ: IBM kompatibilní (C) OPERAČNÍ SYSTÉM: DOS (D) SOFTWARE: FastSEQ for Windows Verze 2.0 (vi) STÁVAJÍCÍ DATA O PŘIHLÁŠCE: (A) ČÍSLO PŘIHLÁŠKY: (B) DATUM PODÁNÍ: 22. ŘÍJNA 1997 (C) KLASIFIKACE: (vii) PŘEŠLÁ DATA O PŘIHLÁŠCE: (A) ČÍSLO PŘIHLÁŠKY: 60/029,629 (B) DATUM PODÁNÍ: 22. ŘÍJNA 1996 (viii) ZÁSTUPCE/INFORMACE (A) JMÉNO: Bennett, Dennis A (B) REGISTRAČNÍ ČÍSLO: 34,547 (C) REFERENCE/DOCKET ČÍSLO: C-2994 (ix) TELEFONNÍ INFORMACE: (A) TELEFON: 314-737-6986 (B) TELEFAX: 314-737-6972 (C) TELEX: (2) INFORMACE PRO SEQ ID NO:l: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 439 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:l: 55 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 60 120 180 240 -430- 60 CZ 295843 B6 CGACATCCAA TCATCATCAA GGGAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGT (2) INFORMACE PRO SEQ ID NO:2: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 465 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:2: TCCCCAGCTC CACCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TGACTCCCAT GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC ACCTGTCCTG CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GACCAAGGCA CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC ACGGGGACAA CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CCGTCTCCTC CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGCTTCCTC CACAGGGCAG GACCACAGCT CACAAGGATC CCAATGCCAT CTTCCTGAGC TTCCAACACC TGCTCCGAGG AAAGGTGCGT TTCCTGATGC TTGTAGGAGG GTCCACCCTC TGCGTCAGGG AATTC (2) INFORMACE PRO SEQ ID NO:3: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 927 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:3: TCCCCAGCTC CACCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TGACTCCCAT GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC ACCTGTCCTG CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GACCAAGGCA CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC ACGGGGACAA CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CCGTCTCCTC CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGCTTCCTC CACAGGGCAG GACCACAGCT CACAAGGATC CCAATGCCAT CTTCCTGAGC TTCCAACACC TGCTCCGAGG AAAGGTGCGT TTCCTGATGC TTGTAGGAGG GTCCACCCTC TGCGTCAGGG AATTCGGCGG CAACATGGCG TCTCCCGCTC CGCCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TGACTCCCAT GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC ACCTGTCCTG CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GACCAAGGCA CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC ACGGGGACAA CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CCGTCTCCTC CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGGGCAGGA CCACAGCTCA CAAGGATCCC AATGCCATCT TCCTGAGCTT CCAACACCTG CTCCGAGGAA AGGTGCGTTT CCTGATGCTT GTAGGAGGGT CCACCCTCTG CGTCAGG (2) INFORMACE PRO SEQ ID NO:4: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 936 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:4: 300 360 420 439 60 120 180 240 300 360 420 465 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 927 CZ 295843 B6 TCCCCAGCTC CACCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TGACTCCCAT GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC ACCTGTCCTG CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GACCAAGGCA CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC ACGGGGACAA CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CCGTCTCCTC CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGCTTCCTC CACAGGGCAG GACCACAGCT CACAAGGATC CCAATGCCAT CTTCCTGAGC TTCCAACACC TGCTCCGAGG AAAGGTGCGT TTCCTGATGC TTGTAGGAGG GTCCACCCTC TGCGTCAGGG AATTCGGCAA CATGGCGTCT CCCGCTCCGC CTGCTTGTGA CCTCCGAGTC CTCAGTAAAC TGCTTCGTGA CTCCCATGTC CTTCACAGCA GACTGAGCCA GTGCCCAGAG GTTCACCCTT TGCCTACACC TGTCCTGCTG CCTGCTGTGG ACTTTAGCTT GGGAGAATGG AAAACCCAGA TGGAGGAGAC CAAGGCACAG GACATTCTGG GAGCAGTGAC CCTTCTGCTG GAGGGAGTGA TGGCAGCACG GGGACAACTG GGACCCACTT GCCTCTCATC CCTCCTGGGG CAGCTTTCTG GACAGGTCCG TCTCCTCCTT GGGGCCCTGC AGAGCCTCCT TGGAACCCAG CTTCCTCCAC AGGGCAGGAC CACAGCTCAC AAGGATCCCA ATGCCATCTT CCTGAGCTTC CAACACCTGC TCCGAGGAAA GGTGCGTTTC CTGATGCTTG TAGGAGGGTC CACCCTCTGC GTCAGG (2) INFORMACE PRO SEQ ID NO:5: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 939 párů bázi (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:5: TCCCCAGCTC CACCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TGACTCCCAT GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC ACCTGTCCTG CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GACCAAGGCA CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC ACGGGGACAA CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CCGTCTCCTC CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGCTTCCTC CACAGGGCAG GACCACAGCT CACAAGGATC CCAATGCCAT CTTCCTGAGC TTCCAACACC TGCTCCGAGG AAAGGTGCGT TTCCTGATGC TTGTAGGAGG GTCCACCCTC TGCGTCAGGG AATTCGGCGG CAACATGGCG TCTCCCGCTC CGCCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TGACTCCCAT GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC ACCTGTCCTG CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GACCAAGGCA CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC ACGGGGACAA CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CCGTCTCCTC CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGCTTCCTC CACAGGGCAG GACCACAGCT CACAAGGATC CCAATGCCAT CTTCCTGAGC TTCCAACACC TGCTCCGAGG AAAGGTGCGT TTCCTGATGC TTGTAGGAGG GTCCACCCTC TGCGTCAGG (2) INFORMACE PRO SEQ ID NO:6: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 948 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:6: TCCCCAGCGC CGCCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TGACTCCCAT GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC ACCTGTCCTG CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GACCAAGGCA CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC ACGGGGACAA CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CCGTCTCCTC CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGCTTCCTC CACAGGGCAG GACCACAGCT 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 936 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 939 60 120 180 240 300 360 CZ 295843 B6 CACAAGGATC CCAATGCCAT CTTCCTGAGC TTCCAACACC TGCTCCGAGG AAAGGTGCGT TTCCTGATGC TTGTAGGAGG GTCCACCCTC TGCGTCAGGG AATTCGGCGG CAACGGCGGC AACATGGCGT CCCCAGCGCC GCCTGCTTGT GACCTCCGAG TCCTCAGTAA ACTGCTTCGT GACTCCCATG TCCTTCACAG CAGACTGAGC CAGTGCCCAG AGGTTCACCC TTTGCCTACA 5 CCTGTCCTGC TGCCTGCTGT GGACTTTAGC TTGGGAGAAT GGAAAACCCA GATGGAGGAG ACCAAGGCAC AGGACATTCT GGGAGCAGTG ACCCTTCTGC TGGAGGGAGT GATGGCAGCA CGGGGACAAC TGGGACCCAC TTGCCTCTCA TCCCTCCTGG GGCAGCTTTC TGGACAGGTC CGTCTCCTCC TTGGGGCCCT GCAGAGCCTC CTTGGAACCC AGCTTCCTCC ACAGGGCAGG ACCACAGCTC ACAAGGATCC CAATGCCATC TTCCTGAGCT TCCAACACCT GCTCCGAGGA 10 AAGGTGCGTT TCCTGATGCT TGTAGGAGGG TCCACCCTCT GCGTCAGG (2) INFORMACE PRO SEQ ID NO:7: (i) CHARAKTERISTIKY SEKVENCE: 15 (A) DÉLKA: 688 párů bázi (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 20 (xi) POPIS SEKVENCE: SEQ ID NO:7: CATGGCTAAC TGCTCTATAA TGATCGATGA AATTATACAT CACTTAAAGA GACCACCTGC ACCTTTGCTG GACCCGAACA ACCTCAATGA CGAAGACGTC TCTATCCTGA TGGACCGAAA CCTTCGACTT CCAAACCTGG AGAGCTTCGT AAGGGCTGTC AAGAACTTAG AAAATGCATC 25 AGGTATTGAG GCAATTCTTC GTAATCTCCA ACCATGTCTG CCCTCTGCCA CGGCCGCACC CTCTCGACAT CCAATCATCA TCAAGGCAGG TGACTGGCAA GAATTCCGGG AAAAACTGAC GTTCTATCTG GTTACCCTTG AGCAAGCGCA GGAACAACAG GGTGGTGGCT CTAACTGCTC TATAATGATC GATGAAATTA TACATCACTT AAAGAGACCA CCTGCACCTT TGCTGGACCC GAACAACCTC AATGACGAAG ACGTCTCTAT CCTGATGGAC CGAAACCTTC GACTTCCAAA 30 CCTGGAGAGC TTCGTAAGGG CTGTCAAGAA CTTAGAAAAT GCATCAGGTA TTGAGGCAAT TGTTCGTAAT CTCCAACCAT GTCTGCCCTC TGCCACGGCC GCACCCTCTC GACATCCAAT CATCATCAAG GCAGGTGACT GGCAAGAATT CCGGGAAAAA CTGACGTTCT ATCTGGTTAC CCTTGAGCAA GCGCAGGAAC AACAGTAC 35 (2) INFORMACE PRO SEQ ID NO:8: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 712 párů bází (B) TYP: nukleová kyselina 40 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO: 8: 420 480 540 600 660 720 780 840 900 948 60 120 180 240 300 360 420 480 540 600 660 688 45 50 55 CATGGCTAAC TGCTCTATAA ACCTTTGCTG GACCCGAACA CCTTCGACTT CCAAACCTGG AGGTATTGAG GCAATTCTTC CTCTCGACAT CCAATCATCA GTTCTATCTG GTTACCCTTG CAGCGGCGGC GGTTCTAACT ACCACCTGCA CCTTTGCTGG GGACCGAAAC CTTCGACTTC AAATGCATCA GGTATTGAGG GGCCGCACCC TCTCGACATC AAAACTGACG TTCTATCTGG TGATCGATGA AATTATACAT ACCTCAATGA CGAAGACGTC AGAGCTTCGT AAGGGCTGTC GTAATCTCCA ACCATGTCTG TCAAGGCAGG TGACTGGCAA AGCAAGCGCA GGAACAACAG GCTCTATAAT GATCGATGAA ACCCGAACAA CCTCAATGAC CAAACCTGGA GAGCTTCGTA CAATTCTTCG TAATCTCCAA CAATCATCAT CAAGGCAGGT TTACCCTTGA GCAAGCGCAG CACTTAAAGA GACCACCTGC TCTATCCTGA TGGACCGAAA AAGAACTTAG AAAATGCATC CCCTCTGCCA CGGCCGCACC GAATTCCGGG AAAAACTGAC GGTGGTGGCT CTGGCGGTGG ATTATACATC ACTTAAAGAG GAAGACGTCT CTATCCTGAT AGGGCTGTCA AGAACTTAGA CCATGTCTGC CCTCTGCCAC GACTGGCAAG AATTCCGGGA GAACAACAGT AC 60 120 180 240 300 360 420 480 540 600 660 712 (2) INFORMACE PRO SEQ ID NO:9: 60 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 975 párů bází -433 - CZ 295843 B6 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 5 (xi) POPIS SEKVENCE: SEQ ID NO:9: ATGGCTCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 10 TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGG GTGGTGGCTC TAACTGCTCT ATAATGATCG ATGAAATTAT ACATCACTTA AAGAGACCAC CTGCACCTTT GTACGTAGAG GGCGGTGGAG GCTCCCCGGG TGAACCGTCT GGTCCAATCT CTACTATCAA CCCGTCTCCT CCGTCTAAAG AATCTCATAA ATCTCCAAAC ATGGCTACCC AGGGTGCCAT GCCGGCCTTC 15 GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC CCTCTGGCGG CTCTGGCGGC TCTCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG 20 CAGCTGGCAG GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCT AATAA 25 (2) INFORMACE PRO SEQ ID NO:10: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 975 párů bází (B) TYP: nukleová kyselina 30 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:10: 35 ATGGCTAATG CATCAGGTAT TGAGGCAATT CTTCGTAATC TCCAACCATG TCTGCCCTCT GCCACGGCCG CACCCTCTCG ACATCCAATC ATCATCAAGG CAGGTGACTG GCAAGAATTC CGGGAAAAAC TGACGTTCTA TCTGGTTACC CTTGAGCAAG CGCAGGAACA ACAGGGTGGT GGCTCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC 40 CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA ATACGTAGAG GGCGGTGGAG GCTCCCCGGG TGAACCGTCT GGTCCAATCT CTACTATCAA CCCGTCTCCT CCGTCTAAAG AATCTCATAA ATCTCCAAAC ATGGCTACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC CCTCTGGCGG CTCTGGCGGC 45 TCTCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GCAGCTGGAC 50 GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCT AATAA (2) INFORMACE PRO SEQ ID NO:11: 55 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 975 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 97 5 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 975 -434- 60 50 55 CZ 295843 B6 (xi) POPIS SEKVENCE: SEQ ID NO:11: ATGGCTGCAC CCTCTCGACA TCCAATCATC ATCAAGGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT GAGCAAGCGC AGGAACAACA GGGTGGTGGC 5 TCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CTACGTAGAG GGCGGTGGAG GCTCCCCGGG TGAACCGTCT GGTCCAATCT CTACTATCAA CCCGTCTCCT 10 CCGTCTAAAG AATCTCATAA ATCTCCAAAC ATGGCTACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC CCTCTGGCGG CTCTGGCGGC TCTCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG 15 CTCGGACACT CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCT AATAA 20 (2) INFORMACE PRO SEQ ID NO:12: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 975 párů bází 25 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:12: 30 ATGGCTGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT GAGCAAGCGC AGGAACAACA GGGTGGTGGC TCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG 35 GCTGTCAAGA ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GTACGTAGAG GGCGGTGGAG GCTCCCCGGG TGAACCGTCT GGTCCAATCT CTACTATCAA CCCGTCTCCT CCGTCTAAAG AATCTCATAA ATCTCCAAAC ATGGCTACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTTC 40 CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC CCTCTGGCGG CTCTGGCGGC TCTCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG 45 CAGGCCCTGG AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCT AATAA (2) INFORMACE PRO SEQ ID NO:13: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 999 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:13: ATGGCTCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC 60 CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 975 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 975 60 120 180 -435- 45 50 CZ 295843 B6 TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGG GTGGTGGCTC TGGCGGTGGC AGCGGCGGCG GTTCTAACTG CTCTATAATG ATCGATGAAA TTATACATCA CTTAAAGAGA CCACCTGCAC CTTTGTACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACC GTCTGGTCCA 5 ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AAACATGGCT ACCCAGGGTG CCATGCCGGC CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG GTTGCTAGCC ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CCACCTTGCG CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT AGAGCAAGTG AGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC TGTGTGCCAC CTACAAGCTG 10 TGCCACCCCG AGGAGCTGGT GCTGCTCGGA CACTCTCTGG GCATCCCCTG GGCTCCCCTG AGCTCCTGCC CCAGCCAGGC CCTGCAGCTG GCAGGCTGCT TGAGCCAACT CCATAGCGGC CTTTTCCTCT ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA TATCCCCCGA GTTGGGTCCC ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG GCAGCAGATG GAAGAACTGG GAATGGCCCC TGCCCTGCAG CCCTAATAA 15 (2) INFORMACE PRO SEQ ID NO:14: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 999 párů bází 20 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:14: 25 ATGGCTAATG CATCAGGTAT TGAGGCAATT CTTCGTAATC TCCAACCATG TCTGCCCTCT GCCACGGCCG CACCCTCTCG ACATCCAATC ATCATCAAGG CAGGTGACTG GCAAGAATTC CGGGAAAAAC TGACGTTCTA TCTGGTTACC CTTGAGCAAG CGCAGGAACA ACAGGGTGGT GGCTCTGGCG GTGGCAGCGG CGGCGGTTCT AACTGCTCTA TAATGATCGA TGAAATTATA 30 CATCACTTAA AGAGACCACC TGCACCTTTG CTGGACCCGA ACAACCTCAA TGACGAAGAC GTCTCTATCC TGATGGACCG AAACCTTCGA CTTCCAAACC TGGAGAGCTT CGTAAGGGCT GTCAAGAACT TAGAATACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AAACATGGCT ACCCAGGGTG CCATGCCGGC CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG 35 GTTGCTAGCC ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CCACCTTGCG CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT AGAGCAAGTG AGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC TGTGTGCCAC CTACAAGCTG TGCCACCCCG AGGAGCTGGT GCTGCTCGGA CACTCTCTGG GCATCCCCTG GGCTCCCCTG AGCTCCTGCC CCAGCCAGGC CCTGCAGCTG GCAGGCTGCT TGAGCCAACT CCATAGCGGC 40 CTTTTCCTCT ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA TATCCCCCGA GTTGGGTCCC ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG GCAGCAGATG GAAGAACTGG GAATGGCCCC TGCCCTGCAG CCCTAATAA (2) INFORMACE PRO SEQ ID NO:15: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 999 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:15: ATGGCTGCAC CCTCTCGACA TCCAATCATC ATCAAGGCAG GTGACTGGCA AGAATTCCGG 55 GAAAAACTGA CGTTCTATCT GGTTACCCTT GAGCAAGCGC AGGAACAACA GGGTGGTGGC TCTGGCGGTG GCAGCGGCGG CGGTTCTAAC TGCTCTATAA TGATCGATGA AATTATACAT CACTTAAAGA GACCACCTGC ACCTTTGCTG GACCCGAACA ACCTCAATGA CGAAGACGTC TCTATCCTGA TGGACCGAAA CCTTCGACTT CCAAACCTGG AGAGCTTCGT AAGGGCTGTC AAGAACTTAG AAAATGCATC AGGTATTGAG GCAATTCTTC GTAATCTCCA ACCATGTCTG 60 CCCTCTGCCA CGGCCTACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AAACATGGCT 240 300 360 420 480 540 600 660 720 780 840 900 960 999 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 999 60 120 180 240 300 360 420 480 -436- CZ 295843 B6 ACCCAGGGTG CCATGCCGGC CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG GTTGCTAGCC ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CCACCTTGCG CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT AGAGCAAGTG AGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC TGTGTGCCAC CTACAAGCTG 5 TGCCACCCCG AGGAGCTGGT GCTGCTCGGA CACTCTCTGG GCATCCCCTG GGCTCCCCTG AGCTCCTGCC CCAGCCAGGC CCTGCAGCTG GCAGGCTGCT TGAGCCAACT CCATAGCGGC CTTTTCCTCT ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA TATCCCCCGA GTTGGGTCCC ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG GCAGCAGATG GAAGAACTGG GAATGGCCCC TGCCCTGCAG CCCTAATAA (2) INFORMACE PRO SEQ ID NO:16: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 999 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:16: ATGGCTGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT GAGCAAGCGC AGGAACAACA GGGTGGTGGC TCTGGCGGTG GCAGCGGCGG CGGTTCTAAC TGCTCTATAA TGATCGATGA AATTATACAT CACTTAAAGA GACCACCTGC ACCTTTGCTG GACCCGAACA ACCTCAATGA CGAAGACGTC TCTATCCTGA TGGACCGAAA CCTTCGACTT 25 CCAAACCTGG AGAGCTTCGT AAGGGCTGTC AAGAACTTAG AAAATGCATC AGGTATTGAG GCAATTCTTC GTAATCTCCA ACCATGTCTG CCCTCTGCCA CGGCCGCACC CTCTCGACAT CCAATCATCA TCAAGTACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AAACATGGCT ACCCAGGGTG CCATGCCGGC CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG 30 GTTGCTAGCC ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CCACCTTGCG CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT AGAGCAAGTG AGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC TGTGTGCCAC CTACAAGCTG TGCCACCCCG AGGAGCTGGT GCTGCTCGGA CACTCTCTGG GCATCCCCTG GGCTCCCCTG AGCTCCTGCC CCAGCCAGGC CCTGCAGCTG GCAGGCTGCT TGAGCCAACT CCATAGCGGC 35 CTTTTCCTCT ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA TATCCCCCGA GTTGGGTCCC ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG GCAGCAGATG GAAGAACTGG GAATGGCCCC TGCCCTGCAG CCCTAATAA (2) INFORMACE PRO SEQ ID NO:17: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 918 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:17: ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 50 CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC 55 TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTT ACAAGCTGTG CCACCCCGAG GAGCTGGTGC TGCTCGGACA CTCTCTGGGC ATCCCCTGGG CTCCCCTGAG CTCCTGCCCC AGCCAGGCCC TGCAGCTGGC AGGCTGCTTG AGCCAACTCC ATAGCGGCCT TTTCCTCTAC CAGGGGCTCC TGCAGGCCCT GGAAGGGATA TCCCCCGAGT TGGGTCCCAC CTTGGACACA CTGCAGCTGG ACGTCGCCGA CTTTGCCACC ACCATCTGGC AGCAGATGGA AGAACTGGGA 60 ATGGCCCCTG CCCTGCAGCC CACCCAGGGT GCCATGCCGG CCTTCGCCTC TGCTTTCCAG CGCCGGGCAG GAGGGGTCCT GGTTGCTAGC CATCTGCAGA GCTTCCTGGA GGTGTCGTAC 540 600 660 720 780 840 900 960 999 10 15 20 40 45 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 999 60 120 180 240 300 360 420 480 540 600 660 720 780 -437- 35 40 CZ 295843 B6 CGCGTTCTAC GCCACCTTGC GCAGCCCTCT GGCGGCTCTG GCGGCTCTCA GAGCTTCCTG CTCAAGTCTT TAGAGCAAGT GAGAAAGATC CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTAATAA 5 (2) INFORMACE PRO SEQ ID NO:18: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 963 párů bází (B) TYP: nukleová kyselina 10 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:18: 15 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 20 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTTACAAG CTGTGCCACC CCGAGGAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG 25 GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CCCTGCCCTG CAGCCCACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC CCTCTGGCGG CTCTGGCGGC TCTCAGAGCT TCCTGCTCAA GTCTTTAGAG 30 CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAA TAA (2) INFORMACE PRO SEQ ID NO:19: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 918 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:19: ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC 45 CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTC CCGAGTTGGG TCCCACCTTG 50 GACACACTGC AGCTGGACGT CGCCGACTTT GCCACCACCA TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCT GCAGCCCACC CAGGGTGCCA TGCCGGCCTT CGCCTCTGCT TTCCAGCGCC GGGCAGGAGG GGTCCTGGTT GCTAGCCATC TGCAGAGCTT CCTGGAGGTG TCGTACCGCG TTCTACGCCA CCTTGCGCAG CCCTCTGGCG GCTCTGGCGG CTCTCAGAGC TTCCTGCTCA AGTCTTTAGA GCAAGTGAGA AAGATCCAGG GCGATGGCGC AGCGCTCCAG 55 GAGAAGCTGT GTGCCACCTA CAAGCTGTGC CACCCCGAGG AGCTGGTGCT GCTCGGACAC TCTCTGGGCA TCCCCTGGGC TCCCCTGAGC TCCTGCCCCA GCCAGGCCCT GCAGCTGGCA GGCTGCTTGA GCCAACTCCA TAGCGGCCTT TTCCTCTACC AGGGGCTCCT GCAGGCCCTG GAAGGGATAT CCTAATAA 840 900 918 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 963 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 918 -438- 30 35 CZ 295843 B6 (2) INFORMACE PRO SEQ ID NO:20: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 963 párů bázi 5 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:20: 10 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 15 TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTCCCGAG TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC CACCATCTGG CAGCAGATGG AAGAACTGGG AATGGCCCCT 20 GCCCTGCAGC CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA CGCCACCTTG CGCAGCCCTC TGGCGGCTCT GGCGGCTCTC AGAGCTTCCT GCTCAAGTCT TTAGAGCAAG TGAGAAAGAT CCAGGGCGAT GGCGCAGCGC TCCAGGAGAA GCTGTGTGCC ACCTACÁAGC TGTGCCACCC CGAGGAGCTG GTGCTGCTCG GACACTCTCT GGGCATCCCC 25 TGGGCTCCCC TGAGCTCCTG CCCCAGCCAG GCCCTGCAGC TGGCAGGCTG CTTGAGCCAA CTCCATAGCG GCCTTTTCCT CTACCAGGGG CTCCTGCAGG CCCTGGAAGG GATATCCTAA TAA (2) INFORMACE PRO SEQ ID NO:21: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 918 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:21: ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 40 CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC 45 TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA TGGCCCCTGC CCTGCAGCCC ACCCAGGGTG CCATGCCGGC CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG GTTGCTAGCC ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CCACCTTGCG CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT AGAGCAAGTG AGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC TGTGTGCCAC CTACAAGCTG 50 TGCCACCCCG AGGAGCTGGT GCTGCTCGGA CACTCTCTGG GCATCCCCTG GGCTCCCCTG AGCTCCTGCC CCAGCCAGGC CCTGCAGCTG GCAGGCTGCT TGAGCCAACT CCATAGCGGC CTTTTCCTCT ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA TATCCCCCGA GTTGGGTCCC ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG GCAGCAGATG GAAGAACTGG GATAATAA 55 (2) INFORMACE PRO SEQ ID NO:22: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 963 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 963 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 918 -439- 60 50 CZ 295843 B6 (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:22: 5 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 10 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTATGGCC CCTGCCCTGC AGCCCACCCA GGGTGCCATG CCGGCCTTCG CCTCTGCTTT CCAGCGCCGG GCAGGAGGGG TCCTGGTTGC TAGCCATCTG CAGAGCTTCC TGGAGGTGTC GTACCGCGTT CTACGCCACC TTGCGCAGCC CTCTGGCGGC 15 TCTGGCGGCT CTCAGAGCTT CCTGCTCAAG TCTTTAGAGC AAGTGAGAAA GATCCAGGGC GATGGCGCAG CGCTCCAGGA GAAGCTGTGT GCCACCTACA AGCTGTGCCA CCCCGAGGAG CTGGTGCTGC TCGGACACTC TCTGGGCATC CCCTGGGCTC CCCTGAGCTC CTGCCCCAGC CAGGCCCTGC AGCTGGCAGG CTGCTTGAGC CAACTCCATA GCGGCCTTTT CCTCTACCAG GGGCTCCTGC AGGCCCTGGA AGGGATATCC CCCGAGTTGG GTCCCACCTT GGACACACTG 20 CAGCTGGACG TCGCCGACTT TGCCACCACC ATCTGGCAGC AGATGGAAGA ACTGGGATAA TAA (2) INFORMACE PRO SEQ ID NO:23: 25 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 918 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché ' (D) TOPOLOGIE: lineární 30 (xi) POPIS SEKVENCE: SEQ ID NO:23: ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC 35 CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA CCCAGGGTGC CATGCCGGCC 40 TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCTCTGG CGGCTCTGGC GGCTCTCAGA GCTTCCTGCT CAAGTCTTTA GAGCAAGTGA GAAAGATCCA GGGCGATGGC GCAGCGCTCC AGGAGAAGCT GTGTGCCACC TACAAGCTGT GCCACCCCGA GGAGCTGGTG CTGCTCGGAC ACTCTCTGGG CATCCCCTGG GCTCCCCTGA GCTCCTGCCC CAGCCAGGCC 45 CTGCAGCTGG CAGGCTGCTT GAGCCAACTC CATAGCGGCC TTTTCCTCTA CCAGGGGCTC CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC CACCATCTGG CAGCAGATGG AAGAACTGGG AATGGCCCCT GCCCTGCAGC CCTAATAA (2) INFORMACE PRO SEQ ID NO:24: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 963 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 963 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 918 -440- 55 50 55 CZ 295843 B6 (xi) POPIS SEKVENCE: SEQ ID NO:24: ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC 5 CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGAA 10 TCTCATAAAT CTCCAAACAT GGCTACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG TACCGCGTTC TACGCCACCT TGCGCAGCCC TCTGGCGGCT CTGGCGGCTC TCAGAGCTTC CTGCTCAAGT CTTTAGAGCA AGTGAGAAAG ATCCAGGGCG ATGGCGCAGC GCTCCAGGAG AAGCTGTGTG CCACCTACAA GCTGTGCCAC CCCGAGGAGC TGGTGCTGCT CGGACACTCT 15 CTGGGCATCC CCTGGGCTCC CCTGAGCTCC TGCCCCAGCC AGGCCCTGCA GCTGGCAGGC TGCTTGAGCC AACTCCATAG CGGCCTTTTC CTCTACCAGG GGCTCCTGCA GGCCCTGGAA GGGATATCCC CCGAGTTGGG TCCCACCTTG GACACACTGC AGCTGGACGT CGCCGACTTT GCCACCACCA TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCT GCAGCCCTAA TAA 20 (2) INFORMACE PRO SEQ ID NO:25: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 918 párů bází 25 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:25: 30 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 35 TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTT CTGCTTTCCA GCGCCGGGCA GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA CGCCACCTTG CGCAGCCCTC TGGCGGCTCT GGCGGCTCTC AGAGCTTCCT GCTCAAGTCT 40 TTAGAGCAAG TGAGAAAGAT CCAGGGCGAT GGCGCAGCGC TCCAGGAGAA GCTGTGTGCC ACCTACAAGC TGTGCCACCC CGAGGAGCTG GTGCTGCTCG GACACTCTCT GGGCATCCCC TGGGCTCCCC TGAGCTCCTG CCCCAGCCAG GCCCTGCAGC TGGCAGGCTG CTTGAGCCAA CTCCATAGCG GCCTTTTCCT CTACCAGGGG CTCCTGCAGG CCCTGGAAGG GATATCCCCC GAGTTGGGTC CCACCTTGGA CACACTGCAG CTGGACGTCG CCGACTTTGC CACCACCATC 45 TGGCAGCAGA TGGAAGAACT GGGAATGGCC CCTGCCCTGC AGCCCACCCA GGGTGCCATG CCGGCCTTCG CCTAATAA (2) INFORMACE PRO SEQ ID NO:26: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 963 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:26: ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC 60 CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 963 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 918 60 120 180 240 -441 - CZ 295843 B6 TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTTCTGCT TTCCAGCGCC GGGCAGGAGG GGTCCTGGTT 5 GCTAGCCATC TGCAGAGCTT CCTGGAGGTG TCGTACCGCG TTCTACGCCA CCTTGCGCAG CCCTCTGGCG GCTCTGGCGG CTCTCAGAGC TTCCTGCTCA AGTCTTTAGA GCAAGTGAGA AAGATCCAGG GCGATGGCGC AGCGCTCCAG GAGAAGCTGT GTGCCACCTA CAAGCTGTGC CACCCCGAGG AGCTGGTGCT GCTCGGACAC TCTCTGGGCA TCCCCTGGGC TCCCCTGAGC TCCTGCCCCA GCCAGGCCCT GCAGCTGGCA GGCTGCTTGA GCCAACTCCA TAGCGGCCTT 10 TTCCTCTACC AGGGGCTCCT GCAGGCCCTG GAAGGGATAT CCCCCGAGTT GGGTCCCACC TTGGACACAC TGCAGCTGGA CGTCGCCGAC TTTGCCACCA CCATCTGGCA GCAGATGGAA GAACTGGGAA TGGCCCCTGC CCTGCAGCCC ACCCAGGGTG CCATGCCGGC CTTCGCCTAA TAA 15 (2) INFORMACE PRO SEQ ID NO:27: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 927 párů bází (B) TYP: nukleová kyselina 20 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:27: 25 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 30 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTT ACAAGCTGTG CCACCCCGAG GAGCTGGTGC TGCTCGGACA CTCTCTGGGC ATCCCCTGGG CTCCCCTGAG CTCCTGCCCC AGCCAGGCCC TGCAGCTGGC AGGCTGCTTG AGCCAACTCC ATAGCGGCCT TTTCCTCTAC CAGGGGCTCC TGCAGGCCCT GGAAGGGATA TCCCCCGAGT TGGGTCCCAC CTTGGACACA 35 CTGCAGCTGG ACGTCGCCGA CTTTGCCACC ACCATCTGGC AGCAGATGGA AGAACTGGGA ATGGCCCCTG CCCTGCAGCC CACCCAGGGT GCCATGCCGG CCTTCGCCTC TGCTTTCCAG CGCCGGGCAG GAGGGGTCCT GGTTGCTAGC CATCTGCAGA GCTTCCTGGA GGTGTCGTAC CGCGTTCTAC GCCACCTTGC GCAGCCCACA CCATTGGGCC CTGCCAGCTC CCTGCCCCAG AGCTTCCTGC TCAAGTCTTT AGAGCAAGTG AGAAAGATCC AGGGCGATGG CGCAGCGCTC 40 CAGGAGAAGC TGTGTGCCAC CTAATAA (2) INFORMACE PRO .SEQ ID NO:28: (i) CHARAKTERISTIKY SEKVENCE: 45 (A) DÉLKA: 972 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 50 (xi) POPIS SEKVENCE: SEQ ID NO:28: ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA 55 GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTTACAAG CTGTGCCACC CCGAGGAGCT GGTGCTGCTC 60 GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG 300 360 420 480 540 600 660 720 780 840 900 960 963 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 927 60 120 180 240 300 360 420 480 540 600 -442- 5 CZ 295843 B6 GCCCTGGAAG GGATATCCCC GCCGACTTTG CCACCACCAT CAGCCCACCC AGGGTGCCAT GTCCTGGTTG CTAGCCATCT CTTGCGCAGC CCACACCATT TCTTTAGAGC AAGTGAGAAA GCCACCTAAT AA CGAGTTGGGT CCCACCTTGG CTGGCAGCAG ATGGAAGAAC GCCGGCCTTC GCCTCTGCTT GCAGAGCTTC CTGGAGGTGT GGGCCCTGCC AGCTCCCTGC GATCCAGGGC GATGGCGCAG ACACACTGCA GCTGGACGTC TGGGAATGGC CCCTGCCCTG TCCAGCGCCG GGCAGGAGGG CGTACCGCGT TCTACGCCAC CCCAGAGCTT CCTGCTCAAG CGCTCCAGGA GAAGCTGTGT 660 720 780 840 900 960 972 10 15 (2) INFORMACE PRO SEQ ID NO:29: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 927 párů bázi (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:29: ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 20 CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC 25 TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTC CCGAGTTGGG TCCCACCTTG GACACACTGC AGCTGGACGT CGCCGACTTT GCCACCACCA TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCT GCAGCCCACC CAGGGTGCCA TGCCGGCCTT CGCCTCTGCT TTCCAGCGCC GGGCAGGAGG GGTCCTGGTT GCTAGCCATC TGCAGAGCTT CCTGGAGGTG TCGTACCGCG TTCTACGCCA CCTTGCGCAG CCCACACCAT TGGGCCCTGC CAGCTCCCTG 30 CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CTAATAA 35 (2) INFORMACE PRO SEQ ID NO:30: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 972 párů bází 40 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:30: 45 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 50 TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTCCCGAG TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC CACCATCTGG CAGCAGATGG AAGAACTGGG AATGGCCCCT 55 GCCCTGCAGC CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA CGCCACCTTG CGCAGCCCAC ACCATTGGGC CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTCTT TAGAGCAAGT GAGAAAGATC CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GTGCCACCCC GAGGAGCTGG TGCTGCTCGG ACACTCTCTG 60 GGCATCCCCT GGGCTCCCCT GAGCTCCTGC CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC TCCATAGCGG CCTTTTCCTC TACCAGGGGC TCCTGCAGGC CCTGGAAGGG 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 927 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 -443- 5CZ 295843 B6 972 ATATCCTAAT AA (2) INFORMACE PRO SEQ ID NO:31: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 927 párů bázi (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 10 (xi) POPIS SEKVENCE: SEQ ID NO:31: ATGGCTAACT GCTCTATAAT GATCGATGAA CCTTTGCTGG ACCCGAACAA CCTCAATGAC 15 CTTCGACTTC CAAACCTGGA GAGCTTCGTA GGTATTGAGG CAATTCTTCG TAATCTCCAA TCTCGACATC CAATCATCAT CAAGGCAGGT TTCTATCTGG TTACCCTTGA GCAAGCGCAG TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC 20 ACCCAGGGTG CCATGCCGGC CTTCGCCTCT GTTGCTAGCC ATCTGCAGAG CTTCCTGGAG CAGCCCACAC CATTGGGCCC TGCCAGCTCC GAGCAAGTGA GAAAGATCCA GGGCGATGGC TACAAGCTGT GCCACCCCGA GGAGCTGGTG 25 GCTCCCCTGA GCTCCTGCCC CAGCCAGGCC CATAGCGGCC TTTTCCTCTA CCAGGGGCTC TTGGGTCCCA CCTTGGACAC ACTGCAGCTG CAGCAGATGG AAGAACTGGG ATAATAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60 GAAGACGTCT CTATCCTGAT GGACCGAAAC 120 AGGGCTGTCA AGAACTTAGA AAATGCATCA 180 CCATGTCTGC CCTCTGCCAC GGCCGCACCC 240 GACTGGCAAG AATTCCGGGA AAAACTGACG 300 GAACAACAGT ACGTAGAGGG CGGTGGAGGC 360 AACATGGCTA TGGCCCCTGC CCTGCAGCCC 420 GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG 480 GTGTCGTACC GCGTTCTACG CCACCTTGCG 540 CTGCCCCAGA GCTTCCTGCT CAAGTCTTTA 600 GCAGCGCTCC AGGAGAAGCT GTGTGCCACC 660 CTGCTCGGAC ACTCTCTGGG CATCCCCTGG 720 CTGCAGCTGG CAGGCTGCTT GAGCCAACTC 780 CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG 840 GACGTCGCCG ACTTTGCCAC CACCATCTGG 900 927 30 (2) INFORMACE PRO SEQ ID NO:32: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 972 párů bází (B) TYP: nukleová kyselina 35 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:32: 40 ATGGCTAACT GCTCTATAAT GATCGATGAA CCTTTGCTGG ACCCGAACAA CCTCAATGAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA GGTATTGAGG CAATTCTTCG TAATCTCCAA TCTCGACATC CAATCATCAT CAAGGCAGGT 45 TTCTATCTGG TTACCCTTGA GCAAGCGCAG TCCCCGGGTG AACCGTCTGG TCCAATCTCT TCTCATAAAT CTCCAAACAT GGCTATGGCC CCGGCCTTCG CCTCTGCTTT CCAGCGCCGG CAGAGCTTCC TGGAGGTGTC GTACCGCGTT 50 . GGCCCTGCCA GCTCCCTGCC CCAGAGCTTC ATCCAGGGCG ATGGCGCAGC GCTCCAGGAG CCCGAGGAGC TGGTGCTGCT CGGACACTCT TGCCCCAGCC AGGCCCTGCA GCTGGCAGGC CTCTACCAGG GGCTCCTGCA GGCCCTGGAA 55 GACACACTGC AGCTGGACGT CGCCGACTTT CTGGGATAAT AA ATTATACATC ACTTAAAGAG ACCACCTGCA 60 GAAGACGTCT CTATCCTGAT GGACCGAAAC 120 AGGGCTGTCA AGAACTTAGA AAATGCATCA 180 CCATGTCTGC CCTCTGCCAC GGCCGCACCC 240 GACTGGCAAG AATTCCGGGA AAAACTGACG 300 GAACAACAGT ACGTAGAGGG CGGTGGAGGC 360 ACTATCAACC CGTCTCCTCC GTCTAAAGAA 420 CCTGCCCTGC AGCCCACCCA GGGTGCCATG 480 GCAGGAGGGG TCCTGGTTGC TAGCCATCTG 540 CTACGCCACC TTGCGCAGCC CACACCATTG 600 CTGCTCAAGT CTTTAGAGCA AGTGAGAAAG 660 AAGCTGTGTG CCACCTACAA GCTGTGCCAC 720 CTGGGCATCC CCTGGGCTCC CCTGAGCTCC 780 TGCTTGAGCC AACTCCATAG CGGCCTTTTC 840 GGGATATCCC CCGAGTTGGG TCCCACCTTG 900 GCCACCACCA TCTGGCAGCA GATGGAAGAA 960 972 (2) INFORMACE PRO SEQ ID NO:33: 60 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 927 párů bází -444- 25 30 CZ 295843 B6 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 5 (xi) POPIS SEKVENCE: SEQ ID NO:33: ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA 10 GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA CCCAGGGTGC CATGCCGGCC TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC 15 TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCACACC ATTGGGCCCT GCCAGCTCCC TGCCCCAGAG CTTCCTGCTC AAGTCTTTAG AGCAAGTGAG AAAGATCCAG GGCGATGGCG CAGCGCTCCA GGAGAAGCTG TGTGCCACCT ACAAGCTGTG CCACCCCGAG GAGCTGGTGC TGCTCGGACA CTCTCTGGGC ATCCCCTGGG CTCCCCTGAG CTCCTGCCCC AGCCAGGCCC TGCAGCTGGC AGGCTGCTTG AGCCAACTCC ATAGCGGCCT TTTCCTCTAC 20 CAGGGGCTCC TGCAGGCCCT GGAAGGGATA TCCCCCGAGT TGGGTCCCAC CTTGGACACA CTGCAGCTGG ACGTCGCCGA CTTTGCCACC ACCATCTGGC AGCAGATGGA AGAACTGGGA ATGGCCCCTG CCCTGCAGCC CTAATAA (2) INFORMACE PRO SEQ ID NO:34: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 972 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:34: ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 35 CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC 40 TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG TACCGCGTTC TACGCCACCT TGCGCAGCCC ACACCATTGG GCCCTGCCAG CTCCCTGCCC CAGAGCTTCC TGCTCAAGTC TTTAGAGCAA GTGAGAAAGA TCCAGGGCGA TGGCGCAGCG 45 CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC CCGAGGAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CCCTGCCCTG 50 CAGCCCTAAT AA (2) INFORMACE PRO SEQ ID NO:35: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 927 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 927 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 972 -445- 55 50 55 CZ 295843 B6 (xi) POPIS SEKVENCE: SEQ ID NO:35: ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC 5 CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTT CTGCTTTCCA GCGCCGGGCA 10 GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA CGCCACCTTG CGCAGCCCAC ACCATTGGGC CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTCTT TAGAGCAAGT GAGAAAGATC CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GTGCCACCCC GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT GGGCTCCCCT GAGCTCCTGC CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC 15 TTGAGCCAAC TCCATAGCGG CCTTTTCCTC TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG AGTTGGGTCC CACCTTGGAC ACACTGCAGC TGGACGTCGC CGACTTTGCC ACCACCATCT GGCAGCAGAT GGAAGAACTG GGAATGGCCC CTGCCCTGCA GCCCACCCAG GGTGCCATGC CGGCCTTCGC CTAATAA 20 (2) INFORMACE PRO SEQ ID NO:36: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 972 párů bází (B) TYP: nukleová kyselina 25 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:36: 30 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 35 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTTCTGCT TTCCAGCGCC GGGCAGGAGG GGTCCTGGTT GCTAGCCATC TGCAGAGCTT CCTGGAGGTG TCGTACCGCG TTCTACGCCA CCTTGCGCAG CCCACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG 40 CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG 45 CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC TTCGCCTAAT AA (2) INFORMACE PRO SEQ ID NO:37: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 963 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:37: ATGGCTAACT GCTCTAACAT GATCGATGAA ATCATCACCC ACCTGAAGCA GCCACCGCTG CCGCTGCTGG ACTTCAACAA CCTCAATGGT GAAGACCAAG ATATCCTAAT GGACAATAAC 60 CTTCGTCGTC CAAACCTCGA GGCATTCAAC CGTGCTGTCA AGTCTCTGCA GAATGCATCA GCAATTGAGA GCATTCTTAA AAATCTCCTG CCATGTCTGC CGCTAGCCAC GGCCGCACCC 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 927 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 972 60 120 180 240 -446- 45 50 CZ 295843 B6 ACGCGACATC CAATCCATAT CAAGGACGGT GACTGGAATG AATTCCGTCG TAAACTGACC TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAGT ACGTAGAGGG CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC 5 CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG TACCGCGTTC TACGCCACCT TGCGCAGCCC TCTGGCGGCT CTGGCGGCTC TCAGAGCTTC CTGCTCAAGT CTTTAGAGCA AGTGAGAAAG ATCCAGGGCG ATGGCGCAGC GCTCCAGGAG AAGCTGTGTG CCACCTACAA GCTGTGCCAC CCCGAGGAGC TGGTGCTGCT CGGACACTCT CTGGGCATCC CCTGGGCTCC CCTGAGCTCC TGCCCCAGCC AGGCCCTGCA GCTGGCAGGC 10 TGCTTGAGCC AACTCCATAG CGGCCTTTTC CTCTACCAGG GGCTCCTGCA GGCCCTGGAA GGGATATCCC CCGAGTTGGG TCCCACCTTG GACACACTGC AGCTGGACGT CGCCGACTTT GCCACCACCA TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCT GCAGCCCTAA TAA 15 (2) INFORMACE PRO SEQ ID NO:38: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 972 párů bází (B) TYP: nukleová kyselina 20 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:38: 25 ATGGCTAACT GCTCTAACAT GATCGATGAA ATCATCACCC ACCTGAAGCA GCCACCGCTG CCGCTGCTGG ACTTCAACAA CCTCAATGGT GAAGACCAAG ATATCCTGAT GGAAAATAAC CTTCGTCGTC CAAACCTCGA GGCATTCAAC CGTGCTGTCA AGTCTCTGCA GAATGCATCA GCAATTGAGA GCATTCTTAA AAATCTCCTG CCATGTCTGC CCCTGGCCAC GGCCGCACCC ACGCGACATC CAATCATCAT CCGTGACGGT GACTGGAATG AATTCCGTCG TAAACTGACC 30 TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAGT ACGTAGAGGG CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG TACCGCGTTC TACGCCACCT TGCGCAGCCC ACACCATTGG GCCCTGCCAG CTCCCTGCCC 35 CAGAGCTTCC TGCTCAAGTC TTTAGAGCAA GTGAGAAAGA TCCAGGGCGA TGGCGCAGCG CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC CCGAGGAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC 40 GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CCCTGCCCTG CAGCCCTAAT AA (2) INFORMACE PRO SEQ ID NO:39: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 963 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:39: ATGGCTAACT GCTCTAACAT GATCGATGAA ATCATCACCC ACCTGAAGCA GCCACCGCTG CCGCTGCTGG ACTTCAACAA CCTCAATGGT GAAGACCAAG ATATCCTGAT GGAAAATAAC 55 CTTCGTCGTC CAAACCTCGA GGCATTCAAC CGTGCTGTCA AGTCTCTGCA GAATGCATCA GCAATTGAGA GCATTCTTAA AAATCTCCTG CCATGTCTGC CCCTGGCCAC GGCCGCACCC ACGCGACATC CAATCATCAT CCGTGACGGT GACTGGAATG AATTCCGTCG TAAACTGACC TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAGT ACGTAGAGGG CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGAA 60 TCTCATAAAT CTCCAAACAT GGCTACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG 300 360 420 480 540 600 660 720 780 840 900 960 963 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 972 60 120 180 240 300 360 420 480 540 -447- 40 45 CZ 295843 B6 TACCGCGTTC TACGCCACCT TGCGCAGCCC TCTGGCGGCT CTGGCGGCTC TCAGAGCTTC CTGCTCAAGT CTTTAGAGCA AGTGAGAAAG ATCCAGGGCG ATGGCGCAGC GCTCCAGGAG AAGCTGTGTG CCACCTACAA GCTGTGCCAC CCCGAGGAGC TGGTGCTGCT CGGACACTCT CTGGGCATCC CCTGGGCTCC CCTGAGCTCC TGCCCCAGCC AGGCCCTGCA GCTGGCAGGC 5 TGCTTGAGCC AACTCCATAG CGGCCTTTTC CTCTACCAGG GGCTCCTGCA GGCCCTGGAA GGGATATCCC CCGAGTTGGG TCCCACCTTG GACACACTGC AGCTGGACGT CGCCGACTTT GCCACCACCA TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCT GCAGCCCTAA TAA 10 (2) INFORMACE PRO SEQ ID NO:40: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 970 párů bází (B) TYP: nukleová kyselina 15 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:40: 20 ATGGCTAACT GCTCTAACAT GATCGATGAA ATCATCACCC ACCTGAAGCA GCCACCGCTG CCGCTGCTGG ACTTCAACAA CCTCAATGGT GAAGACCAAG ATATCCTAAT GGACAATAAC CTTCGTCGTC CAAACCTCGA GGCATTCAAC CGTGCTGTCA AGTCTCTGCA GAATGCATCA GCAATTGAGA GCATTCTTAA AAATCTCCTG CCATGTCTGC CGCTAGCCAC GGCCGCACCC GCGACATCCA ATCCATATCA AGGACGGTGA CTGGAATGAA TTCCGTCGTA AACTGACCTT 25 CTATCTGAAA ACCTTGGAGA ACGCGCAGGC TCAACAGTAC GTAGAGGGCG GTGGAGGCTC CCCGGGTGAA CCGTCTGGTC CAATCTCTAC TATCAACCCG TCTCCTCCGT CTAAAGAATC TCATAAATCT CCAAACATGG CTACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA CGCCACCTTG CGCAGCCCAC ACCATTGGGC CCTGCCAGCT CCCTGCCCCA 30 GAGCTTCCTG CTCAAGTCTT TAGAGCAAGT GAGAAAGATC CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GTGCCACCCC GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT GGGCTCCCCT GAGCTCCTGC CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC TCCATAGCGG CCTTTTCCTC TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG AGTTGGGTCC CACCTTGGAC ACACTGCAGC TGGACGTCGC 35 CGACTTTGCC ACCACCATCT GGCAGCAGAT GGAAGAACTG GGAATGGCCC CTGCCCTGCA GCCCTAATAA (2) INFORMACE PRO SEQ ID NO:41: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 918 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:41: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 50 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 55 CATAAATCTC CAAACATGGA GGTTCACCCT TTGCCTACAC CTGTCCTGCT GCCTGCTGTG GACTTTAGCT TGGGAGAATG GAAAACCCAG ATGGAGGAGA CCAAGGCACA GGACATTCTG GGAGCAGTGA CCCTTCTGCT GGAGGGAGTG ATGGCAGCAC GGGGACAACT GGGACCCACT TGCCTCTCAT CCCTCCTGGG GCAGCTTTCT GGACAGGTCC GTCTCCTCCT TGGGGCCCTG CAGAGCCTCC TTGGAACCCA GCTTCCTCCA CAGGGCAGGA CCACAGCTCA CAAGGATCCC 60 AATGCCATCT TCCTGAGCTT CCAACACCTG CTCCGAGGAA AGGTGCGTTT CCTGATGCTT GTAGGAGGGT CCACCCTCTG CGTCAGGGAA TTCGGCGGCA ACATGGCGTC TCCCGCTCCG 600 660 720 780 840 900 960 963 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 970 60 120 180 240 300 360 420 480 540 600 660 720 780 840 -448- CZ 295843 B6 CCTGCTTGTG ACCTCCGAGT CCTCAGTAAA CTGCTTCGTG ACTCCCATGT CCTTCACAGC AGACTGAGCC AGTGCCCA (2) INFORMACE PRO SEQ ID NO:42: 5 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 918 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché 10 (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:42: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 15 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 20 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGTT GCCTACACCT GTCCTGCTGC CTGCTGTGGA CTTTAGCTTG GGAGAATGGA AAACCCAGAT GGAGGAGACC AAGGCACAGG ACATTCTGGG AGCAGTGACC CTTCTGCTGG AGGGAGTGAT GGCAGCACGG GGACAACTGG GACCCACTTG CCTCTCATCC CTCCTGGGGC AGCTTTCTGG ACAGGTCCGT CTCCTCCTTG GGGCCCTGCA GAGCCTCCTT 25 GGAACCCAGC TTCCTCCACA GGGCAGGACC ACAGCTCACA AGGATCCCAA TGCCATCTTC CTGAGCTTCC AACACCTGCT CCGAGGAAAG GTGCGTTTCC TGATGCTTGT AGGAGGGTCC ACCCTCTGCG TCAGGGAATT CGGCGGCAAC ATGGCGTCTC CCGCTCCGCC TGCTTGTGAC CTCCGAGTCC TCAGTAAACT GCTTCGTGAC TCCCATGTCC TTCACAGCAG ACTGAGCCAG TGCCCAGAGG TTCACCCT 30 (2) INFORMACE PRO SEQ ID NO:43: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 918 párů bází 35 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:43: 40 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 45 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGT CCTGCTGCCT GCTGTGGACT TTAGCTTGGG AGAATGGAAA ACCCAGATGG AGGAGACCAA GGCACAGGAC ATTCTGGGAG CAGTGACCCT TCTGCTGGAG 50 GGAGTGATGG CAGCACGGGG ACAACTGGGA CCCACTTGCC TCTCATCCCT CCTGGGGCAG CTTTCTGGAC AGGTCCGTCT CCTCCTTGGG GCCCTGCAGA GCCTCCTTGG AACCCAGCTT CCTCCACAGG GCAGGACCAC AGCTCACAAG GATCCCAATG CCATCTTCCT GAGCTTCCAA CACCTGCTCC GAGGAAAGGT GCGTTTCCTG ATGCTTGTAG GAGGGTCCAC CCTCTGCGTC AGGGAATTCG GCGGCAACAT GGCGTCTCCC GCTCCGCCTG CTTGTGACCT CCGAGTCCTC 55 AGTAAACTGC TTCGTGACTC CCATGTCCTT CACAGCAGAC TGAGCCAGTG CCCAGAGGTT CACCCTTTGC CTACACCT (2) INFORMACE PRO SEQ ID NO:44: 60 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 918 párů bází 900 918 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 918 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 918 -449- 25 30 CZ 295843 B6 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 5 (xi) POPIS SEKVENCE: SEQ ID NO:44: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 10 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC TGTGGACTTT AGCTTGGGAG AATGGAAAAC CCAGATGGAG 15 GAGACCAAGG CACAGGACAT TCTGGGAGCA GTGACCCTTC TGCTGGAGGG AGTGATGGCA GCACGGGGAC AACTGGGACC CACTTGCCTC TCATCCCTCC TGGGGCAGCT TTCTGGACAG GTCCGTCTCC TCCTTGGGGC CCTGCAGAGC CTCCTTGGAA CCCAGCTTCC TCCACAGGGC AGGACCACAG CTCACAAGGA TCCCAATGCC ATCTTCCTGA GCTTCCAACA CCTGCTCCGA GGAAAGGTGC GTTTCCTGAT GCTTGTAGGA GGGTCCACCC TCTGCGTCAG GGAATTCGGC 20 GGCAACATGG CGTCTCCCGC TCCGCCTGCT TGTGACCTCC GAGTCCTCAG TAAACTGCTT CGTGACTCCC ATGTCCTTCA CAGCAGACTG AGCCAGTGCC CAGAGGTTCA CCCTTTGCCT ACACCTGTCC TGCTGCCT (2) INFORMACE PRO SEQ ID NO:45: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 918 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:45: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 35 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 40 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGA CTTTAGCTTG GGAGAATGGA AAACCCAGAT GGAGGAGACC AAGGCACAGG ACATTCTGGG AGCAGTGACC CTTCTGCTGG AGGGAGTGAT GGCAGCACGG GGACAACTGG GACCCACTTG CCTCTCATCC CTCCTGGGGC AGCTTTCTGG ACAGGTCCGT CTCCTCCTTG GGGCCCTGCA GAGCCTCCTT GGAACCCAGC TTCCTCCACA GGGCAGGACC 45 ACAGCTCACA AGGATCCCAA TGCCATCTTC CTGAGCTTCC AACACCTGCT CCGAGGAAAG GTGCGTTTCC TGATGCTTGT AGGAGGGTCC ACCCTCTGCG TCAGGGAATT CGGCGGCAAC ATGGCGTCTC CCGCTCCGCC TGCTTGTGAC CTCCGAGTCC TCAGTAAACT GCTTCGTGAC TCCCATGTCC TTCACAGCAG ACTGAGCCAG TGCCCAGAGG TTCACCCTTT GCCTACACCT GTCCTGCTGC CTGCTGTG 50 (2) INFORMACE PRO SEQ ID NO:46: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 907 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 918 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 918 -450- 55 CZ 295843 B6 (xi) POPIS SEKVENCE: SEQ ID NO:46: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 5 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCGGTTAC CCTTGAGCAA GCGCAGGAAC AACAGTACGT AGAGGGCGGT GGAGGCTCCC CGGGGAACCG TCTGGTCCAA TCTCTACTAT CAACCCGTCT CCTCCGTCTA AAGAATCTCA 10 TAAACTCCAA ACATGGGAGA ATGGAAAACC CAGATGGAGG AGACCAAGGC ACAGGACATT CTGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC ACGGGGACAA CTGGGACCCA CTTGCTCTCA TCCCTCCTGG GGCAGCTTTC TGGACAGGTC CGTCTCCTCC TTGGGGCCCT GCAGGCCTCC TTGGAACCCA GCTTCCTCCA CAGGGCAGGA CCACAGCTCA CAAGGATCCC AATGCATCTT CCTGAGCTTC CAACACCTGC TCCGAGGAAA GGTGCGTTTC CTGATGCTTG 15 TAGGGGGTCC ACCCTCTGCG TCAGGGAATT CGGCGGCAAC ATGGCGTCTC CCGCTCCGCC TGCTGTGACC TCCGAGTCCT CAGTAAACTG CTTCGTGACT CCCATGTCCT TCACAGCAGA CTGACCAGTG CCCAGAGGTT CACCCTTTGC CTACACCTGT CCTGCTGCCT GCTGTGGACT TTAGTTG 20 (2) INFORMACE PRO SEQ ID NO:47: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 917 párů bází (B) TYP: nukleová kyselina 25 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:47: 30 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 35 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGG ACCCACTTGC CTCTCATCCC TCCTGGGGCA GCTTTCTGGA CAGGTCCGTC TCCTCCTTGG GGCCCTGCAG AGCCTCCTTG GAACCCAGCT TCCTCCACAG GGCAGGACCA CAGCTCACAA GGATCCCAAT GCCATCTTCC TGAGCTTCCA ACACCTGCTC 40 CGAGGAAAGG TGCGTTTCCT GATGCTTGTA GGAGGGTCCA CCCTCTGCGT CAGGGAATTC GGCGGCAACA TGGCGTCTCC CGCTCCGCCT GCTTGTGACC TCCGAGTCCT CAGTAAACTG CTTCGTGACT CCCATGTCCT TCACAGCAGA CTGAGCCAGT GCCCAGAGGT TCACCCTTTG CCTACACCTG TCCTGCTGCC TGCTGTGGAC TTTAGCTTGG GAGAATGGAA AACCCAGATG GAGGAGACCA AGGCACAGGA CATTCTGGGA GCAGTGACCC TTCTGCTGGA GGGAGTGATG 45 GCAGCACGGG GACAACT (2) INFORMACE PRO SEQ ID NO:48: (i) CHARAKTERISTIKY SEKVENCE: 50 (A) DÉLKA: 918 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 55 (xi) POPIS SEKVENCE: SEQ ID NO:48: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 60 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 907 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 917 60 120 180 240 300 -451 - CZ 295843 B6 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCČ CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGG AACCCAGCTT CCTCCACAGG GCAGGACCAC AGCTCACAAG GATCCCAATG CCATCTTCCT GAGCTTCCAA CACCTGCTCC GAGGAAAGGT GGGTTTCCTG ATGCTTGTAG GAGGGTCCAC CCTCTGCGTC AGGGAATTCG GCGGCAACAT GGCGTCTCCC GCTCCGCCTG CTTGTGACCT CCGAGTCCTC AGTAAACTGC TTCGTGACTC CCATGTCCTT CACAGCAGAC TGAGCCAGTG CCCAGAGGTT CACCCTTTGC CTACACCTGT CCTGCTGCCT GCTGTGGACT TTAGCTTGGG AGAATGGAAA ACCCAGATGG AGGAGACCAA GGCACAGGAC ATTCTGGGAG CAGTGACCCT TCTGCTGGAG GGAGTGATGG CAGCACGGGG ACAACTGGGA CCCACTTGCC TCTCATCCCT CCTGGGGCAG CTTTCTGGAC AGGTCCGTCT CCTCCTTGGG GCCCTGCAGA GCCTCCTT (2) INFORMACE PRO SEQ ID NO:49: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 918 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:49: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGG CAGGACCACA GCTCACAAGG ATCCCAATGC CATCT-TCCTG AGCTTCCAAC ACCTGCTCCG AGGAAAGGTG CGTTTCCTGA TGCTTGTAGG AGGGTCCACC CTCTGCGTCA GGGAATTCGG CGGCAACATG GCGTCTCCCG CTCCGCCTGC TTGTGACCTC CGAGTCCTCA GTAAACTGCT TCGTGACTCC CATGTCCTTC ACAGCAGACT GAGCCAGTGC CCAGAGGTTC ACCCTTTGCC TACACCTGTC CTGCTGCCTG CTGTGGACTT TAGCTTGGGA GAATGGAAAA CCCAGATGGA GGAGACCAAG GCACAGGACA TTCTGGGAGC AGTGACCCTT CTGCTGGAGG GAGTGATGGC AGCACGGGGA CAACTGGGAC CCACTTGCCT CTCATCCCTC CTGGGGCAGC TTTCTGGACA GGTCCGTCTC CTCCTTGGGG CCCTGCAGAG CCTCCTTGGA ACCCAGCTTC CTCCACAG (2) INFORMACE PRO SEQ ID NO:50: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 918 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:50: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC TCACAAGGAT CCCAATGCCA TCTTCCTGAG CTTCCAACAC CTGCTCCGAG GAAAGGTGCG TTTCCTGATG CTTGTAGGAG GGTCCACCCT CTGCGTCAGG GAATTCGGCG GCAACATGGC GTCTCCCGCT CCGCCTGCTT GTGACCTCCG AGTCCTCAGT AAACTGCTTC GTGACTCCCA TGTCCTTCAC AGCAGACTGA GCCAGTGCCC AGAGGTTCAC CCTTTGCCTA CACCTGTCCT GCTGCCTGCT GTGGACTTTA GCTTGGGAGA ATGGAAAACC 360 420 480 540 600 660 720 780 840 900 918 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 918 60 120 180 240 300 360 420 480 540 600 660 720 CZ 295843 B6 CAGATGGAGG AGACCAAGGC ACAGGACATT CTGGGAGCAG TGACCCTTCT GCTGGAGGGA GTGATGGCAG CACGGGGACA ACTGGGACCC ACTTGCCTCT CATCCCTCCT GGGGCAGCTT TCTGGACAGG TCCGTCTCCT CCTTGGGGCC CTGCAGAGCC TCCTTGGAAC CCAGCTTCCT CCACAGGGCA GGACCACA (2) INFORMACE PRO SEQ ID NO:51: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 918 párů bázi (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineárni (xi) POPIS SEKVENCE: SEQ ID NO:51: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGA TCCCAATGCC ATCTTCCTGA GCTTCCAACA CCTGCTCCGA GGAAAGGTGC GTTTCCTGAT GCTTGTAGGA GGGTCCACCC TCTGCGTCAG GGAATTCGGC GGCAACATGG CGTCTCCCGC TCCGCCTGCT TGTGACCTCC GAGTCCTCAG TAAACTGCTT CGTGACTCCC ATGTCCTTCA CAGCAGACTG AGCCAGTGCC CAGAGGTTCA CCCTTTGCCT ACACCTGTCC TGCTGCCTGC TGTGGACTTT AGCTTGGGAG AATGGAAAAC CCAGATGGAG GAGACCAAGG CACAGGACAT TCTGGGAGCA GTGACCCTTC TGCTGGAGGG AGTGATGGCA GCACGGGGAC AACTGGGACC CACTTGCCTC TCATCCCTCC TGGGGCAGCT TTCTGGACAG GTCCGTCTCC TCCTTGGGGC CCTGCAGAGC CTCCTTGGAA CCCAGCTTCC TCCACAGGGC AGGACCACAG CTCACAAG (2) INFORMACE PRO SEQ ID NO:52: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 918 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:52: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CATCTTCCTG AGCTTCCAAC ACCTGCTCCG AGGAAAGGTG CGTTTCCTGA TGCTTGTAGG AGGGTCCACC CTCTGCGTCA GGGAATTCGG CGGCAACATG GCGTCTCCCG CTCCGCCTGC TTGTGACCTC CGAGTCCTCA GTAAACTGCT TCGTGACTCC CATGTCCTTC ACAGCAGACT GAGCCAGTGC CCAGAGGTTC ACCCTTTGCC TACACCTGTC CTGCTGCCTG CTGTGGACTT TAGCTTGGGA GAATGGAAAA CCCAGATGGA GGAGACCAAG GCACAGGACA TTCTGGGAGC AGTGACCCTT CTGCTGGAGG GAGTGATGGC AGCACGGGGA CAACTGGGAC CCACTTGCCT CTCATCCCTC CTGGGGCAGC TTTCTGGACA GGTCCGTCTC CTCCTTGGGG CCCTGCAGAG CCTCCTTGGA ACCCAGCTTC CTCCACAGGG CAGGACCACA GCTCACAAGG ATCCCAAT 780 840 900 918 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 918 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 918 -453 - CZ 295843 B6 (2) INFORMACE PRO SEQ ID NO:53: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 915 párů bázi (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:53: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGA GGTTCACCCT TTGCCTACAC CTGTCCTGCT GCCTGCTGTG GACTTTAGCT TGGGAGAATG GAAAACCCAG ATGGAGGAGA CCAAGGCACA GGACATTCTG GGAGCAGTGA CCCTTCTGCT GGAGGGAGTG ATGGCAGCAC GGGGACAACT GGGACCCACT TGCCTCTCAT CCCTCCTGGG GCAGCTTTCT GGACAGGTCC GTCTCCTCCT TGGGGCCCTG CAGAGCCTCC TTGGAACCCA GCTTCCTCCA CAGGGCAGGA CCACAGCTCA CAAGGATCCC AATGCCATCT TCCTGAGCTT CCAACACCTG CTCCGAGGAA AGGTGCGTTT CCTGATGCTT GTAGGAGGGT CCACCCTCTG CGTCAGGGAA TTCGGCAACA TGGCGTCTCC CGCTCCGCCT GCTTGTGACC TCCGAGTCCT CAGTAAACTG CTTCGTGACT CCCATGTCCT TCACAGCAGA CTGAGCCAGT GCCCA (2) INFORMACE PRO SEQ ID NO:54: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 915 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:54: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGTT GCCTACACCT GTCCTGCTGC CTGCTGTGGA CTTTAGCTTG GGAGAATGGA AAACCCAGAT GGAGGAGACC AAGGCACAGG ACATTCTGGG AGCAGTGACC CTTCTGCTGG AGGGAGTGAT GGCAGCACGG GGACAACTGG GACCCACTTG CCTCTCATCC CTCCTGGGGC AGCTTTCTGG ACAGGTCCGT CTCCTCCTTG GGGCCCTGCA GAGCCTCCTT GGAACCCAGC TTCCTCCACA GGGCAGGACC ACAGCTCACA AGGATCCCAA TGCCATCTTC CTGAGCTTCC AACACCTGCT CCGAGGAAAG GTGCGTTTCC TGATGCTTGT AGGAGGGTCC ACCCTCTGCG TCAGGGAATT CGGCAACATG GCGTCTCCCG CTCCGCCTGC TTGTGACCTC CGAGTCCTCA GTAAACTGCT TCGTGACTCC CATGTCCTTC ACAGCAGACT GAGCCAGTGC CCAGAGGTTC ACCCT (2) INFORMACE PRO SEQ ID NO:55: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 915 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 915 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 915 CZ 295843 B6 (xi) POPIS SEKVENCE: SEQ ID NO:55: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 5 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 10 CATAAATCTC CAAACATGGT CCTGCTGCCT GCTGTGGACT TTAGCTTGGG AGAATGGAAA ACCCAGATGG AGGAGACCAA GGCACAGGAC ATTCTGGGAG CAGTGACCCT TCTGCTGGAG GGAGTGATGG CAGCACGGGG ACAACTGGGA CCCACTTGCC TCTCATCCCT CCTGGGGCAG CTTTCTGGAC AGGTCCGTCT CCTCCTTGGG GCCCTGCAGA GCCTCCTTGG AACCCAGCTT CCTCCACAGG GCAGGACCAC AGCTCACAAG GATCCCAATG CCATCTTCCT GAGCTTCCAA 15 CACCTGCTCC GAGGAAAGGT GCGTTTCCTG ATGCTTGTAG GAGGGTCCAC CCTCTGCGTC AGGGAATTCG GCAACATGGC GTCTCCCGCT CCGCCTGCTT GTGACCTCCG AGTCCTCAGT AAACTGCTTC GTGACTCCCA TGTCCTTCAC AGCAGACTGA GCCAGTGCCC AGAGGTTCAC CCTTTGCCTA CACCT 20 (2) INFORMACE PRO SEQ ID NO:56: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 915 párů bází (B) TYP: nukleová kyselina 25 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:56: 30 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 35 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC TGTGGACTTT AGCTTGGGAG AATGGAAAAC CCAGATGGAG GAGACCAAGG CACAGGACAT TCTGGGAGCA GTGACCCTTC TGCTGGAGGG AGTGATGGCA GCACGGGGAC AACTGGGACC CACTTGCCTC TCATCCCTCC TGGGGCAGCT TTCTGGACAG 40 GTCCGTCTCC TCCTTGGGGC CCTGCAGAGC CTCCTTGGAA CCCAGCTTCC TCCACAGGGC AGGACCACAG CTCACAAGGA TCCCAATGCC ATCTTCCTGA GCTTCCAACA CCTGCTCCGA GGAAAGGTGC GTTTCCTGAT GCTTGTAGGA GGGTCCACCC TCTGCGTCAG GGAATTCGGC AACATGGCGT CTCCCGCTCC GCCTGCTTGT GACCTCCGAG TCCTCAGTAA ACTGCTTCGT GACTCCCATG TCCTTCACAG CAGACTGAGC CAGTGCCCAG AGGTTCACCC TTTGCCTACA 45 CCTGTCCTGC TGCCT (2) INFORMACE PRO SEQ ID NO:57: (i) CHARAKTERISTIKY SEKVENCE: 50 (A) DÉLKA: 915 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 55 (xi) POPIS SEKVENCE: SEQ ID NO:57: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 915 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 915 60 120 180 -455 - 60 CZ 295843 B6 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 5 CATAAATCTC CAAACATGGA CTTTAGCTTG GGAGAATGGA AAACCCAGAT GGAGGAGACC AAGGCACAGG ACATTCTGGG AGCAGTGACC CTTCTGCTGG AGGGAGTGAT GGCAGCACGG GGACAACTGG GACCCACTTG CCTCTCATCC CTCCTGGGGC AGCTTTCTGG ACAGGTCCGT CTCCTCCTTG GGGCCCTGCA GAGCCTCCTT GGAACCCAGC TTCCTCCACA GGGCAGGACC ACAGCTCACA AGGATCCCAA TGCCATCTTC CTGAGCTTCC AACACCTGCT CCGAGGAAAG 10 GTGCGTTTCC TGATGCTTGT AGGAGGGTCC ACCCTCTGCG TCAGGGAATT CGGCAACATG GCGTCTCCCG CTCCGCCTGC TTGTGACCTC CGAGTCCTCA GTAAACTGCT TCGTGACTCC CATGTCCTTC ACAGCAGACT GAGCCAGTGC CCAGAGGTTC ACCCTTTGCC TACACCTGTC CTGCTGCCTG CTGTG 15 (2) INFORMACE PRO SEQ ID NO:58: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 915 párů bází (B) TYP: nukleová kyselina 20 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:58: 25 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 30 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGG AGAATGGAAA ACCCAGATGG AGGAGACCAA GGCACAGGAC ATTCTGGGAG CAGTGACCCT TCTGCTGGAG GGAGTGATGG CAGCACGGGG ACAACTGGGA CCCACTTGCC TCTCATCCCT CCTGGGGCAG CTTTCTGGAC AGGTCCGTCT CCTCCTTGGG 35 GCCCTGCAGA GCCTCCTTGG AACCCAGCTT CCTCCACAGG GCAGGACCAC AGCTCACAAG GATCCCAATG CCATCTTCCT GAGCTTCCAA CACCTGCTCC GAGGAAAGGT GCGTTTCCTG ATGCTTGTAG GAGGGTCCAC CCTCTGCGTC AGGGAATTCG GCAACATGGC GTCTCCCGCT CCGCCTGCTT GTGACCTCCG AGTCCTCAGT AAACTGCTTC GTGACTCCCA TGTCCTTCAC AGCAGACTGA GCCAGTGCCC AGAGGTTCAC CCTTTGCCTA CACCTGTCCT GCTGCCTGCT 40 GTGGACTTTA GCTTG (2) INFORMACE PRO SEQ ID NO:59: (i) CHARAKTERISTIKY SEKVENCE: 45 (A) DÉLKA: 915 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 50 (xi) POPIS SEKVENCE: SEQ ID NO:59: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 55 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGG ACCCACTTGC CTCTCATCCC TCCTGGGGCA GCTTTCTGGA 60 CAGGTCCGTC TCCTCCTTGG GGCCCTGCAG AGCCTCCTTG GAACCCAGCT TCCTCCACAG GGCAGGACCA CAGCTCACAA GGATCCCAAT GCCATCTTCC TGAGCTTCCA ACACCTGCTC 240 300 360 420 480 540 600 660 720 780 840 900 915 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 915 60 120 180 240 300 360 420 480 540 600 -456- CZ 295843 B6 CGAGGAAAGG TGCGTTTCCT GATGCTTGTA GGAGGGTCCA CCCTCTGCGT CAGGGAATTC GGCAACATGG CGTCTCCCGC TCCGCCTGCT TGTGACCTCC GAGTCCTCAG TAAACTGCTT CGTGACTCCC ATGTCCTTCA CAGCAGACTG AGCCAGTGCC CAGAGGTTCA CCCTTTGCCT ACACCTGTCC TGCTGCCTGC TGTGGACTTT AGCTTGGGAG AATGGAAAAC CCAGATGGAG GAGACCAAGG CACAGGACAT TCTGGGAGCA GTGACCCTTC TGCTGGAGGG AGTGATGGCA GCACGGGGAC AACTG (2) INFORMACE PRO SEQ ID NO:60: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 915 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:60: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGG AACCCAGCTT CCTCCACAGG GCAGGACCAC AGCTCACAAG GATCCCAATG CCATCTTCCT GAGCTTCCAA CACCTGCTCC GAGGAAAGGT GCGTTTCCTG ATGCTTGTAG GAGGGTCCAC CCTCTGCGTC AGGGAATTCG GCAACATGGC GTCTCCCGCT CCGCCTGCTT GTGACCTCCG AGTCCTCAGT AAACTGCTTC GTGACTCCCA TGTCCTTCAC AGCAGACTGA GCCAGTGCCC AGAGGTTCAC CCTTTGCCTA CACCTGTCCT GCTGCCTGCT GTGGACTTTA GCTTGGGAGA ATGGAAAACC CAGATGGAGG AGACCAAGGC ACAGGACATT CTGGGAGCAG TGACCCTTCT GCTGGAGGGA GTGATGGCAG CACGGGGACA ACTGGGACCC ACTTGCCTCT CATCCCTCCT GGGGCAGCTT TCTGGACAGG TCCGTCTCCT CCTTGGGGCC CTGCAGAGCC TCCTT (2) INFORMACE PRO SEQ ID NO:61: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 915 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:61: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGG CAGGACCACA GCTCACAAGG ATCCCAATGC CATCTTCCTG AGCTTCCAAC ACCTGCTCCG AGGAAAGGTG CGTTTCCTGA TGCTTGTAGG AGGGTCCACC CTCTGCGTCA GGGAATTCGG CAACATGGCG TCTCCCGCTC CGCCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TGACTCCCAT GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC ACCTGTCCTG CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GACCAAGGCA CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC ACGGGGACAA CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CCGTCTCCTC CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGCTTCCTC CACAG 660 720 780 840 900 915 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 915 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 915 30 35 55 CZ 295843 B6 (2) INFORMACE PRO SEQ ID NO:62: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 915 párů bázi 5 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:62: 10 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 15 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC TCACAAGGAT CCCAATGCCA TCTTCCTGAG CTTCCAACAC CTGCTCCGAG GAAAGGTGCG TTTCCTGATG CTTGTAGGAG GGTCCACCCT CTGCGTCAGG 20 GAATTCGGCA ACATGGCGTC TCCCGCTCCG CCTGCTTGTG ACCTCCGAGT CCTCAGTAAA CTGCTTCGTG ACTCCCATGT CCTTCACAGC AGACTGAGCC AGTGCCCAGA GGTTCACCCT TTGCCTACAC CTGTCCTGCT GCCTGCTGTG GACTTTAGCT TGGGAGAATG GAAAACCCAG ATGGAGGAGA CCAAGGCACA GGACATTCTG GGAGCAGTGA CCCTTCTGCT GGAGGGAGTG ATGGCAGCAC GGGGACAACT GGGACCCACT TGCCTCTCAT CCCTCCTGGG GCAGCTTTCT 25 GGACAGGTCC GTCTCCTCCT TGGGGCCCTG CAGAGCCTCC TTGGAACCCA GCTTCCTCCA CAGGGCAGGA CCACA (2) INFORMACE PRO SEQ ID NO:63: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 915 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:63: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 40 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 45 CATAAATCTC CAAACATGGA TCCCAATGCC ATCTTCCTGA GCTTCCAACA CCTGCTCCGA GGAAAGGTGC GTTTCCTGAT GCTTGTAGGA GGGTCCACCC TCTGCGTCAG GGAATTCGGC AACATGGCGT CTCCCGCTCC GCCTGCTTGT GACCTCCGAG TCCTCAGTAA ACTGCTTCGT GACTCCCATG TCCTTCACAG CAGACTGAGC CAGTGCCCAG AGGTTCACCC TTTGCCTACA CCTGTCCTGC TGCCTGCTGT GGACTTTAGC TTGGGAGAAT GGAAAACCCA GATGGAGGAG 50 ACCAAGGCAC AGGACATTCT GGGAGCAGTG ACCCTTCTGC TGGAGGGAGT GATGGCAGCA CGGGGACAAC TGGGACCCAC TTGCCTCTCA TCCCTCCTGG GGCAGCTTTC TGGACAGGTC CGTCTCCTCC TTGGGGCCCT GCAGAGCCTC CTTGGAACCC AGCTTCCTCC ACAGGGCAGG ACCACAGCTC ACAAG (2) INFORMACE PRO SEQ ID NO:64: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 915 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 915 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 915 -458- 60 CZ 295843 B6 (xi) POPIS SEKVENCE: SEQ ID NO:64: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 5 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 10 CATAAATCTC CAAACATGGC CATCTTCCTG AGCTTCCAAC ACCTGCTCCG AGGAAAGGTG CGTTTCCTGA TGCTTGTAGG AGGGTCCACC CTCTGCGTCA GGGAATTCGG CAACATGGCG TCTCCCGCTC CGCCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TGACTCCCAT GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC ACCTGTCCTG CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GACCAAGGCA 15 CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC ACGGGGACAA CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CCGTCTCCTC CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGCTTCCTC CACAGGGCAG GACCACAGCT CACAAGGATC CCAAT 20 (2) INFORMACE PRO SEQ ID NO:65: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 921 párů bázi (B) TYP: nukleová kyselina 25 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:65: 30 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT GACTTCCAAA CCTGGAGAGC TTCGTAAGGG CTGTCAAGAA CTTAGAAAAT GCATCAGGTA TGAGGCAATT CTTCGTAATC TCCAACCATG TCTGCCCTCT GCCACGGCCG CACCCTCTCG CATCCAATCA TCATCAAGGC AGGTGACTGG CAAGAATTCC GGGAAAAACT GACGTTCTAT 35 TGGTTACCCT TGAGCAAGCG CAGGAACAAC AGTACGTAGA GGGCGGTGGA GGCTCCCCGG TAACCGTCTG GTCCAATCTC TACTATCAAC CCGTCTCCTC CGTCTAAAGA ATCTCATAAA TCTCCAAACA TGGAGGTTCA CCCTTTGCCT ACACCTGTCC TGCTGCCTGC TGTGGACTTT AGCTTGGGAG AATGGAAAAC CCAGATGGAG GAGACCAAGG CACAGGACAT TCTGGGAGCA GTGACCCTTC TGCTGGAGGG AGTGATGGCA GCACGGGGAC AACTGGGACC CACTTGCCTC 40 TCATCCCTCC TGGGGCAGCT TTCTGGACAG GTCCGTCTCC TCCTTGGGGC CCTGCAGAGC CTCCTTGGAA CCCAGCTTCC TCCACAGGGC AGGACCACAG CTCACAAGGA TCCCAATGCC ATCTTCCTGA GCTTCCAACA CCTGCTCCGA GGAAAGGTGC GTTTCCTGAT GCTTGTAGGA GGGTCCACCC TCTGCGTCAG GGAATTCGGC GGCAACGGCG GCAACATGGC GTCCCCAGCG CCGCCTGCTT GTGACCTCCG AGTCCTCAGT AAACTGCTTC GTGACTCCCA TGTCCTTCAC 45 AGCAGACTGA GCCAGTGCCC A (2) INFORMACE PRO SEQ ID NO:66: (i) CHARAKTERISTIKY SEKVENCE: 50 (A) DÉLKA: 927 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 55 (xi) POPIS SEKVENCE: SEQ ID NO:66: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 915 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 921 60 120 180 -459- 60 CZ 295843 B6 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 5 CATAAATCTC CAAACATGTT GCCTACACCT GTCCTGCTGC CTGCTGTGGA CTTTAGCTTG GGAGAATGGA AAACCCAGAT GGAGGAGACC AAGGCACAGG ACATTCTGGG AGCAGTGACC CTTCTGCTGG AGGGAGTGAT GGCAGCACGG GGACAACTGG GACCCACTTG CCTCTCATCC CTCCTGGGGC AGCTTTCTGG ACAGGTCCGT CTCCTCCTTG GGGCCCTGCA GAGCCTCCTT GGAACCCAGC TTCCTCCACA GGGCAGGACC ACAGCTCACA AGGATCCCAA TGCCATCTTC 10 CTGAGCTTCC AACACCTGCT CCGAGGAAAG GTGCGTTTCC TGATGCTTGT AGGAGGGTCC ACCCTCTGCG TCAGGGAATT CGGCGGCAAC GGCGGCAACA TGGCGTCCCC AGCGCCGCCT GCTTGTGACC TCCGAGTCCT CAGTAAACTG CTTCGTGACT CCCATGTCCT TCACAGCAGA CTGAGCCAGT GCCCAGAGGT TCACCCT 15 (2) INFORMACE PRO SEQ ID NO:67: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 927 párů bází (B) TYP: nukleová kyselina 20 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:67: 25 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 30 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGT CCTGCTGCCT GCTGTGGACT TTAGCTTGGG AGAATGGAAA ACCCAGATGG AGGAGACCAA GGCACAGGAC ATTCTGGGAG CAGTGACCCT TCTGCTGGAG GGAGTGATGG CAGCACGGGG ACAACTGGGA CCCACTTGCC TCTCATCCCT CCTGGGGCAG 35 CTTTCTGGAC AGGTCCGTCT CCTCCTTGGG GCCCTGCAGA GCCTCCTTGG AACCCAGCTT CCTCCACAGG GCAGGACCAC AGCTCACAAG GATCCCAATG CCATCTTCCT GAGCTTCCAA CACCTGCTCC GAGGAAAGGT GCGTTTCCTG ATGCTTGTAG GAGGGTCCAC CCTCTGCGTC AGGGAATTCG GCGGCAACGG CGGCAACATG GCGTCCCCAG CGCCGCCTGC TTGTGACCTC CGAGTCCTCA GTAAACTGCT TCGTGACTCC CATGTCCTTC ACAGCAGACT GAGCCAGTGC 40 CCAGAGGTTC ACCCTTTGCC TACACCT (2) INFORMACE PRO SEQ ID NO:68: (i) CHARAKTERISTIKY SEKVENCE: 45 (A) DÉLKA: 927 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 50 (xi) POPIS SEKVENCE: SEQ ID NO:68: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 55 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC TGTGGACTTT AGCTTGGGAG AATGGAAAAC CCAGATGGAG 60 GAGACCAAGG CACAGGACAT TCTGGGAGCA GTGACCCTTC TGCTGGAGGG AGTGATGGCA GCACGGGGAC AACTGGGACC CACTTGCCTC TCATCCCTCC TGGGGCAGCT TTCTGGACAG 240 300 360 420 480 540 600 660 720 780 840 900 927 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 927 60 120 180 240 300 360 420 480 540 600 -460- 10 15 CZ 295843 B6 GTCCGTCTCC TCCTTGGGGC CCTGCAGAGC CTCCTTGGAA CCCAGCTTCC TCCACAGGGC AGGACCACAG CTCACAAGGA TCCCAATGCC ATCTTCCTGA GCTTCCAACA CCTGCTCCGA GGAAAGGTGC GTTTCCTGAT GCTTGTAGGA GGGTCCACCC TCTGCGTCAG GGAATTCGGC GGCAACGGCG GCAACATGGC GTCCCCAGCG CCGCCTGCTT GTGACCTCCG AGTCCTCAGT 5 AAACTGCTTC GTGACTCCCA TGTCCTTCAC AGCAGACTGA GCCAGTGCCC AGAGGTTCAC CCTTTGCCTA CACCTGTCCT GCTGCCT (2) INFORMACE PRO SEQ ID NO:69: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 927 párů bázi (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:69: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 20 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 25 CATAAATCTC CAAACATGGA CTTTAGCTTG GGAGAATGGA AAACCCAGAT GGAGGAGACC AAGGCACAGG ACATTCTGGG AGCAGTGACC CTTCTGCTGG AGGGAGTGAT GGCAGCACGG GGACAACTGG GACCCACTTG CCTCTCATCC CTCCTGGGGC AGCTTTCTGG ACAGGTCCGT CTCCTCCTTG GGGCCCTGCA GAGCCTCCTT GGAACCCAGC TTCCTCCACA GGGCAGGACC ACAGCTCACA AGGATCGCAA TGCCATCTTC CTGAGCTTCC AACACCTGCT CCGAGGAAAG 30 GTGCGTTTCC TGATGCTTGT AGGAGGGTCC ACCCTCTGCG TCAGGGAATT CGGCGGCAAC GGCGGCAACA TGGCGTCCCC AGCGCCGCCT GCTTGTGACC TCCGAGTCCT CAGTAAACTG CTTCGTGACT CCCATGTCCT TCACAGCAGA CTGAGCCAGT GCCCAGAGGT TCACCCTTTG CCTACACCTG TCCTGCTGCC TGCTGTG 35 (2) INFORMACE PRO SEQ ID NO:70: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 927 párů bází (B) TYP: nukleová kyselina 40 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:70: 45 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 50 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGG AGAATGGAAA ACCCAGATGG AGGAGACCAA GGCACAGGAC ATTCTGGGAG CAGTGACCCT TCTGCTGGAG GGAGTGATGG CAGCACGGGG ACAACTGGGA CCCACTTGCC TCTCATCCCT CCTGGGGCAG CTTTCTGGAC AGGTCCGTCT CCTCCTTGGG 55 GCCCTGCAGA GCCTCCTTGG AACCCAGCTT CCTCCACAGG GCAGGACCAC AGCTCACAAG GATCCCAATG CCATCTTCCT GAGCTTCCAA CACCTGCTCC GAGGAAAGGT GCGTTTCCTG ATGCTTGTAG GAGGGTCCAC CCTCTGCGTC AGGGAATTCG GCGGCAACGG CGGCAACATG GCGTCCCCAG CGCCGCCTGC TTGTGACCTC CGAGTCCTCA GTAAACTGCT TCGTGACTCC CATGTCCTTC ACAGCAGACT GAGCCAGTGC CCAGAGGTTC ACCCTTTGCC TACACCTGTC 60 CTGCTGCCTG CTGTGGACTT TAGCTTG 660 720 780 840 900 927 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 927 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 927 -461 - 30 35 CZ 295843 B6 (2) INFORMACE PRO SEQ ID NO:71: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 927 párů bází 5 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:71: 10 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 15 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGG ACCCACTTGC CTCTCATCCC TCCTGGGGCA GCTTTCTGGA CAGGTCCGTC TCCTCCTTGG GGCCCTGCAG AGCCTCCTTG GAACCCAGCT TCCTCCACAG 20 GGCAGGACCA CAGCTCACAA GGATCCCAAT GCCATCTTCC TGAGCTTCCA ACACCTGCTC CGAGGAAAGG TGCGTTTCCT GATGCTTGTA GGAGGGTCCA CCCTCTGCGT CAGGGAATTC GGCGGCAACG GCGGCAACAT GGCGTCCCCA GCGCCGCCTG CTTGTGACCT CCGAGTCCTC AGTAAACTGC TTCGTGACTC CCATGTCCTT CACAGCAGAC TGAGCCAGTG CCCAGAGGTT CACCCTTTGC CTACACCTGT CCTGCTGCCT GCTGTGGACT TTAGCTTGGG AGAATGGAAA 25 ACCCAGATGG AGGAGACCAA GGCACAGGAC ATTCTGGGAG CAGTGACCCT TCTGCTGGAG GGAGTGATGG CAGCACGGGG ACAACTG (2) INFORMACE PRO SEQ ID NO:72: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 927 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:72: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 40 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 45 CATAAATCTC CAAACATGGG AACCCAGCTT CCTCCACAGG GCAGGACCAC AGCTCACAAG GATCCCAATG CCATCTTCCT GAGCTTCCAA CACCTGCTCC GAGGAAAGGT GCGTTTCCTG ATGCTTGTAG GAGGGTCCAC CCTCTGCGTC AGGGAATTCG GCGGCAACGG CGGCAACATG GCGTCCCCAG CGCCGCCTGC TTGTGACCTC CGAGTCCTCA GTAAACTGCT TCGTGACTCC CATGTCCTTC ACAGCAGACT GAGCCAGTGC CCAGAGGTTC ACCCTTTGCC TACACCTGTC 50 CTGCTGCCTG CTGTGGACTT TAGCTTGGGA GAATGGAAAA CCCAGATGGA GGAGACCAAG GCACAGGACA TTCTGGGAGC AGTGACCCTT CTGCTGGAGG GAGTGATGGC AGCACGGGGA CAACTGGGAC CCACTTGCCT CTCATCCCTC CTGGGGCAGC TTTCTGGACA GGTCCGTCTC CTCCTTGGGG CCCTGCAGAG CCTCCTT 55 (2) INFORMACE PRO SEQ ID NO:73: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 927 párů bází (B) TYP: nukleová kyselina 60 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 927 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 927 -462- CZ 295843 B6 (xi) POPIS SEKVENCE: SEQ ID NO:73: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 5 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 10 CATAAATCTC CAAACATGGG CAGGACCACA GCTCACAAGG ATCCCAATGC CATCTTCCTG AGCTTCCAAC ACCTGCTCCG AGGAAAGGTG CGTTTCCTGA TGCTTGTAGG AGGGTCCACC CTCTGCGTCA GGGAATTCGG CGGCAACGGC GGCAACATGG CGTCCCCAGC GCCGCCTGCT TGTGACCTCC GAGTCCTCAG TAAACTGCTT CGTGACTCCC ATGTCCTTCA CAGCAGACTG AGCCAGTGCC CAGAGGTTCA CCCTTTGCCT ACACCTGTCC TGCTGCCTGC TGTGGACTTT 15 AGCTTGGGAG AATGGAAAAC CCAGATGGAG GAGACCAAGG CACAGGACAT TCTGGGAGCA GTGACCCTTC TGCTGGAGGG AGTGATGGCA GCACGGGGAC AACTGGGACC CACTTGCCTC TCATCCCTCC TGGGGCAGCT TTCTGGACAG GTCCGTCTCC TCCTTGGGGC CCTGCAGAGC CTCCTTGGAA CCCAGCTTCC TCCACAG 20 (2) INFORMACE PRO SEQ ID NO:74: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 927 párů bází (B) TYP: nukleová kyselina 25 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:74: 30 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 35 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC TCACAAGGAT CCCAATGCCA TCTTCCTGAG CTTCCAACAC CTGCTCCGAG GAAAGGTGCG TTTCCTGATG CTTGTAGGAG GGTCCACCCT CTGCGTCAGG GAATTCGGCG GCAACGGCGG CAACATGGCG TCCCCAGCGC CGCCTGCTTG TGACCTCCGA 40 GTCCTCAGTA AACTGCTTCG TGACTCCCAT GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC ACCTGTCCTG CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GACCAAGGCA CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC ACGGGGACAA CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CCGTCTCCTC CTTGGGGCCC TGCAGAGCCT CCTTGGAACC 45 CAGCTTCCTC CACAGGGCAG GACCACA (2) INFORMACE PRO SEQ ID NO:75: (i) CHARAKTERISTIKY SEKVENCE: 50 (A) DÉLKA: 927 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 55 (xi) POPIS SEKVENCE: SEQ ID NO:75: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 927 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 927 60 120 180 -463 - 60 CZ 295843 B6 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 5 CATAAATCTC CAAACATGGA TCCCAATGCC ATCTTCCTGA GCTTCCAACA CCTGCTCCGA GGAAAGGTGC GTTTCCTGAT GCTTGTAGGA GGGTCCACCC TCTGCGTCAG GGAATTCGGC GGCAACGGCG GCAACATGGC GTCCCCAGCG CCGCCTGCTT GTGACCTCCG AGTCCTCAGT AAACTGCTTC GTGACTCCCA TGTCCTTCAC AGCAGACTGA GCCAGTGCCC AGAGGTTCAC CCTTTGCCTA CACCTGTCCT GCTGCCTGCT GTGGACTTTA GCTTGGGAGA ATGGAAAACC 10 CAGATGGAGG AGACCAAGGC ACAGGACATT CTGGGAGCAG TGACCCTTCT GCTGGAGGGA GTGATGGCAG CACGGGGACA ACTGGGACCC ACTTGCCTCT CATCCCTCCT GGGGCAGCTT TCTGGACAGG TCCGTCTCCT CCTTGGGGCC CTGCAGAGCC TCCTTGGAAC CCAGCTTCCT CCACAGGGCA GGACCACAGC TCACAAG 15 (2) INFORMACE PRO SEQ ID NO:76: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 927 párů bází (B) TYP: nukleová kyselina 20 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xí) POPIS SEKVENCE: SEQ ID NO:76: 25 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 30 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CATCTTCCTG AGCTTCCAAC ACCTGCTCCG AGGAAAGGTG CGTTTCCTGA TGCTTGTAGG AGGGTCCACC CTCTGCGTCA GGGAATTCGG CGGCAACGGC GGCAACATGG CGTCCCCAGC GCCGCCTGCT TGTGACCTCC GAGTCCTCAG TAAACTGCTT 35 CGTGACTCCC ATGTCCTTCA CAGCAGACTG AGCCAGTGCC CAGAGGTTCA CCCTTTGCCT ACACCTGTCC TGCTGCCTGC TGTGGACTTT AGCTTGGGAG AATGGAAAAC CCAGATGGAG GAGACCAAGG CACAGGACAT TCTGGGAGCA GTGACCCTTC TGCTGGAGGG AGTGATGGCA GCACGGGGAC AACTGGGACC CACTTGCCTC TCATCCCTCC TGGGGCAGCT TTCTGGACAG GTCCGTCTCC TCCTTGGGGC CCTGCAGAGC CTCCTTGGAA CCCAGCTTCC TCCACAGGGC 40 AGGACCACAG CTCACAAGGA TCCCAAT (2) INFORMACE PRO SEQ ID NO:77: (i) CHARAKTERISTIKY SEKVENCE: 45 (A) DÉLKA: 906 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 50 (xi) POPIS SEKVENCE: SEQ ID NO:77: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 55 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGA TCCCAATGCC ATCTTCCTGA GCTTCCAACA CCTGCTCCGA 60 GGAAAGGTGC GTTTCCTGAT GCTTGTAGGA GGGTCCACCC TCTGCGTCAG GGAATTCGGC GGCAACATGG CGTCTCCCGC TCCGCCTGCT TGTGACCTCC GAGTCCTCAG TAAACTGCTT 240 300 360 420 480 540 600 660 720 780 840 900 927 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 927 60 120 180 240 300 360 420 480 540 600 -464- 10 15 CZ 295843 B6 CGTGACTCCC ATGTCCTTCA CAGCAGACTG AGCCAGTGCC CAGAGGTTCA CCCTTTGCCT ACACCTGTCC TGCTGCCTGC TGTGGACTTT AGCTTGGGAG AATGGAAAAC CCAGATGGAG GAGACCAAGG CACAGGACAT TCTGGGAGCA GTGACCCTTC TGCTGGAGGG AGTGATGGCA GCACGGGGAC AACTGGGACC CACTTGCCTC TCATCCCTCC TGGGGCAGCT TTCTGGACAG 5 GTCCGTCTCC TCCTTGGGGC CCTGCAGAGC CTCCTTGGAA CCCAGGGCAG GACCACAGCT CACAAG (2) INFORMACE PRO SEQ ID NO:78: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 993 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:78: ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGATCGAAAC 20 CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGAA 25 TCTCATAAAT CTCCAAACAT GTCTTACAAG CTGTGCCACC CCGAGGAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CCCTGCCCTG 30 CAGCCCACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC CCGGCGGCGG CTCTGACATG GCTACACCAT TAGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGGA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAA TAA 35 (2) INFORMACE PRO SEQ ID NO:79: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 993 párů bází 40 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:79: 45 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 50 TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GTCTCCCGAG TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC CACCATCTGG CAGCAGATGG AAGAACTGGG AATGGCCCCT 55 GCCCTGCAGC CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA CGCCACCTTG CGCAGCCCGG CGGCGGCTCT GACATGGCTA CACCATTAGG CCCTGCCAGC TCCCTGCCCC AGAGCTTCCT GCTCAAGTCT TTAGAGCAAG TGAGGAAGAT CCAGGGCGAT GGCGCAGCGC TCCAGGAGAA GCTGTGTGCC ACCTACAAGC TGTGCCACCC CGAGGAGCTG 60 GTGCTGCTCG GACACTCTCT GGGCATCCCC TGGGCTCCCC TGAGCTCCTG CCCCAGCCAG GCCCTGCAGC TGGCAGGCTG CTTGAGCCAA CTCCATAGCG GCCTTTTCCT CTACCAGGGG 660 720 780 840 900 906 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 993 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 -465- CZ 295843 B6 CTCCTGCAGG CCCTGGAAGG GATATCCTAA TAA 993 (2) INFORMACE PRO SEQ ID NO:80: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 993 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:80: ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60 CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGATCGAAAC 120 CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA 180 GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 240 TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 300 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC 360 TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGAA 420 TCTCATAAAT CTCCAAACAT GTCTTCTGCT TTCCAGCGCC GGGCAGGAGG GGTCCTGGTT 480 GCTAGCCATC TGCAGAGCTT CCTGGAGGTG TCGTACCGCG TTCTACGCCA CCTTGCGCAG 540 CCCGGCGGCG GCTCTGACAT GGCTACACCA TTAGGCCCTG CCAGCTCCCT GCCCCAGAGC 600 TTCCTGCTCA AGTCTTTAGA GCAAGTGAGG AAGATCCAGG GCGATGGCGC AGCGCTCCAG 660 GAGAAGCTGT GTGCCACCTA CAAGCTGTGC CACCCCGAGG AGCTGGTGCT GCTCGGACAC 720 TCTCTGGGCA TCCCCTGGGC TCCCCTGAGC TCCTGCCCCA GCCAGGCCCT GCAGCTGGCA 780 GGCTGCTTGA GCCAACTCCA TAGCGGCCTT TTCCTCTACC AGGGGCTCCT GCAGGCCCTG 840 GAAGGGATAT CCCCCGAGTT GGGTCCCACC TTGGACACAC TGCAGCTGGA CGTCGCCGAC 900 TTTGCCACCA CCATCTGGCA GCAGATGGAA GAACTGGGAA TGGCCCCTGC CCTGCAGCCC 960 ACCCAGGGTG CCATGCCGGC CTTCGCCTAA TAA 993 (2) INFORMACE PRO SEQ ID NO:81: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 993 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:81: ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60 CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGATCGAAAC 120 CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA 180 GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 240 TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 300 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC 360 TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGAA 420 TCTCATAAAT CTCCAAACAT GTCTATGGCC CCTGCCCTGC AGCCCACCCA GGGTGCCATG 480 CCGGCCTTCG CCTCTGCTTT CCAGCGCCGG GCAGGAGGGG TCCTGGTTGC TAGCCATCTG 540 CAGAGCTTCC TGGAGGTGTC GTACCGCGTT CTACGCCACC TTGCGCAGCC CGGCGGCGGC 600 TCTGACATGG CTACACCATT AGGCCCTGCC AGCTCCCTGC CCCAGAGCTT CCTGCTCAAG 660 TCTTTAGAGC AAGTGAGGAA GATCCAGGGC GATGGCGCAG CGCTCCAGGA GAAGCTGTGT 720 GCCACCTACA AGCTGTGCCA CCCCGAGGAG CTGGTGCTGC TCGGACACTC TCTGGGCATC 780 CCCTGGGCTC CCCTGAGCTC CTGCCCCAGC CAGGCCCTGC AGCTGGCAGG CTGCTTGAGC 840 CAACTCCATA GCGGCCTTTT CCTCTACCAG GGGCTCCTGC AGGCCCTGGA AGGGATATCC 900 CCCGAGTTGG GTCCCACCTT GGACACACTG CAGCTGGACG TCGCCGACTT TGCCACCACC 960 ATCTGGCAGC AGATGGAAGA ACTGGGATAA TAA 993 CZ 295843 B6 (2) INFORMACE PRO SEQ ID NO:82: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 993 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:82: ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GTCTACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG TACCGCGTTC TACGCCACCT TGCGCAGCCC GGCGGCGGCT CTGACATGGC TACACCATTA GGCCCTGCCA GCTCCCTGCC CCAGAGCTTC CTGCTCAAGT CTTTAGAGCA AGTGAGGAAG ATCCAGGGCG ATGGCGCAGC GCTCCAGGAG AAGCTGTGTG CCACCTACAA GCTGTGCCAC CCCGAGGAGC TGGTGCTGCT CGGACACTCT CTGGGCATCC CCTGGGCTCC CCTGAGCTCC TGCCCCAGCC AGGCCCTGCA GCTGGCAGGC TGCTTGAGCC AACTCCATAG CGGCCTTTTC CTCTACCAGG GGCTCCTGCA GGCCCTGGAA GGGATATCCC CCGAGTTGGG TCCCACCTTG GACACACTGC AGCTGGACGT CGCCGACTTT GCCACCACCA TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCT GCAGCCCTAA TAA (2) INFORMACE PRO SEQ ID NO:83: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1027 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:83: ATGGCTACAC CATTGGGCCC TGCCAGCTCC CTGCCCCAGA GCTTCCTGCT CAAGTCTTTA GAGCAAGTGA GGAAGATCCA GGGCGATGGC GCAGCGCTCC AGGAGAAGCT GTGTGCCACC TACAAGCTGT GCCACCCCGA GGAGCTGGTG CTGCTCGGAC ACTCTCTGGG CATCCCCTGG GCTCCCCTGA GCTCCTGCCC CAGCCAGGCC CTGCAGCTGG CAGGCTGCTT GAGCCAACTC CATAGCGGCC TTTTCCTCTA CCAGGGGCTC CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC CACCATCTGG CAGCAGATGG AAGAACTGGG AATGGCCCCT GCCCTGCAGC CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA CGCCACCTTG CGCAGCCCGG CGGCGGCTCT GACATGGCTA CACCATTGGG CCCTGCCAGC TCCCTGCCCC AGAGCTTCCT GCTCAAGTCT TTAGAGCAAG TGAGGAAGAT CCAGGGCGAT GGCGCAGCGC TCCAGGAGAA GCTGTGTGCC ACCTACAAGC TGTGCCACCC CGAGGAGCTG GTGCTGCTCG GACACTCTCT GGGCATCCCC TGGGCTCCCC TGAGCTCCTG CCCCAGCCAG GCCCTGCAGC TGGCAGGCTG CTTGAGCCAA CTCCATAGCG GCCTTTTCCT CTACCAGGGG CTCCTGCAGG CCCTGGAAGG GATATCCCCC GAGTTGGGTC CCACCTTGGA CACACTGCAG CTGGACGTCG CCGACTTTGC CACCACCATC TGGCAGCAGA TGGAAGAACT GGGAATGGCC CCTGCCCTGC AGCCCACCCA TCCTGGTTGC TAGCCATCTG CAGAGCTTCC TGGAGGTGTC GTACCGCGTT CTACGCCACC TTGCGCAGCC CTGATAA (2) INFORMACE PRO SEQ ID NO:84: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 459 párů bází 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 993 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1027 -467- 55 CZ 295843 B6 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 5 (xi) POPIS SEKVENCE: SEQ ID NO:84: TCTCCCGCTC CGCCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TGACTCCCAT GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC ACCTGTCCTG CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GACCAAGGCA 10 CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC ACGGGGACAA CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CCGTCTCCTC CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGCTTCCTC CACAGGGCAG GACCACAGCT CACAAGGATC CCAATGCCAT CTTCCTGAGC TTCCAACACC TGCTCCGAGG AAAGGTGCGT TTCCTGATGC TTGTAGGAGG GTCCACCCTC TGCGTCAGG 15 (2) INFORMACE PRO SEQ ID NO:85: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 447 párů bází 20 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:85: 25 TCTCCCGCTC CGCCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TGACTCCCAT GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC ACCTGTCCTG CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GACCAAGGCA CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC ACGGGGACAA 30 CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CCGTCTCCTC CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGGGCAGGA CCACAGCTCA CAAGGATCCC AATGCCATCT TCCTGAGCTT CCAACACCTG CTCCGAGGAA AGGTGCGTTT CCTGATGCTT GTAGGAGGGT CCACCCTCTG CGTCAGG 35 (2) INFORMACE PRO SEQ ID NO:86: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 459 párů bází (B) TYP: nukleová kyselina 40 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:86: 45 TCCCCAGCGC CGCCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TGACTCCCAT GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC ACCTGTCCTG CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GACCAAGGCA CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC ACGGGGACAA CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CCGTCTCCTC 50 CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGCTTCCTC CACAGGGCAG GACCACAGCT CACAAGGATC CCAATGCCAT CTTCCTGAGC TTCCAACACC TGCTCCGAGG AAAGGTGCGT TTCCTGATGC TTGTAGGAGG GTCCACCCTC TGCGTCAGG (2) INFORMACE PRO SEQ ID NO:87: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 464 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 60 120 180 240 300 360 420 459 60 120 180 240 300 360 420 447 60 120 180 240 300 360 420 459 -468- 60 CZ 295843 B6 (xi) POPIS SEKVENCE: SEQ ID NO:87: CCATGGCTAA CTGCTCTATA ATGATCGATG AAATTATACA TCACTTAAAG AGACCACCTG CACCTTTGCT GGACCCGAAC AACCTCAATG ACGAAGACGT CTCTATCCTG ATGGATCGAA ACCTTCGACT TCCAAACCTG GAGAGCTTCG TAAGGGCTGT CAAGAACTTA GAAAATGCAT CAGGTATTGA GGCAATTCTT CGTAATCTCC AACCATGTCT GCCCTCTGCC ACGGCCGCAC CCTCTCGACA TCCAATCATC ATCAAGGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT GAGCAAGCGC AGGAACAACA GTACGTAGAG GGCGGTGGAG GCTCCCCGGG TGAACCGTCT GGTCCAATCT CTACTATCAA CCCGTCTCCT CCGTCTAAAG AATCTCATAA ATCTCCAAAC ATGTAAGGTA CCGCATGCAA GCTT (2) INFORMACE PRO SEQ ID NO:88: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 419 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:88: CCATGGCTAA CTGCTCTATA ATGATCGATG AAATTATACA TCACTTAAAG AGACCACCTG CACCTTTGCT GGACCCGAAC AACCTCAATG ACGAAGACGT CTCTATCCTG ATGGATCGAA ACCTTCGACT TCCAAACCTG GAGAGCTTCG TAAGGGCTGT CAAGAACTTA GAAAATGCAT CAGGTATTGA GGCAATTCTT CGTAATCTCC AACCATGTCT GCCCTCTGCC ACGGCCGCAC CCTCTCGACA TCCAATCATC ATCAAGGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT GAGCAAGCGC AGGAACAACA GTACGTAGAG GGCGGTGGAG GCTCCCCGGG TGGTGGTTCT GGCGGCGGCT CCAACATGTA AGGTACCGCA TGCAAGCTT (2) INFORMACE PRO SEQ ID NO:89: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 405 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:89: GCCACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG GACGAGGAGC TCTGCGGGGC GCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC AGCCC (2) INFORMACE PRO SEQ ID NO:90: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 420 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:90: GCCACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 60 120 180 240 300 360 420 4 64 60 120 180 240 300 360 419 60 120 180 240 300 360 405 60 120 -469- CZ 295843 B6 GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC 5 ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC AGCCCGACTC CTCAACCCTG (2) INFORMACE PRO SEQ ID NO:91: (i) CHARAKTERISTIKY SEKVENCE: 10 (A) DÉLKA: 366 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 15 (xi) POPIS SEKVENCE: SEQ ID NO:91: GCCACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG 20 CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC CTTTCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTG 180 240 300 360 420 60 120 180 240 300 360 366 25 (2) INFORMACE PRO SEQ ID NO:92: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 405 párů bází (B) TYP: nukleová kyselina 30 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID .NO: 92': 35 GGAACTCAGG ATTGTTCTTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC 40 AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC AGCCC 60 120 180 240 300 360 405 45 50 (2) INFORMACE PRO SEQ ID NO:93: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 420 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:93: 55 GGTACCCAGG ATTGTTCTTT CGTGAGCTGT CTGACTACCT GACGAGGAGC TCTGCGGGGG CTCAAGACTG TCGCTGGGTC CACTTTGTCA CCAAATGTGC AACATCTCCC GCCTCCTGCA ACTCGCCAGA ACTTCTCCCG CCAACACAGC CCCATCTCCT GCTTCAAGAT TACCCAGTCA CCTCTGGCGG CTGGTCCTGG CAAGATGCAA GGCTTGCTGG CTTTCAGCCC CCCCCCAGCT GGAGACCTCC GAGCAGCTGG GTGCCTGGAG CTGCAGTGTC CCGACTTCGC TGTCAAAATC CCGTGGCCTC CAACCTGCAG CACAGCGCTG GATGGAGCGG AGCGCGTGAA CACGGAGATA GTCTTCGCTT CGTCCAGACC TGGCGCTGAA GCCCTGGATC AGCCCGACTC CTCAACCCTG 60 120 180 240 300 360 420 -470- 60 CZ 295843 B6 (2) INFORMACE PRO SEQ ID NO:94: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 405 párů bází 5 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:94: 10 GCCACTCAGG ACTGTTCTTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA 15 CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC AGCCC (2) INFORMACE PRO SEQ ID NO:95: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 420 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:95: GCCACTCAGG ACTGCTCTTT TCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC 30 CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC 35 ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC AGCCCGACTC CTCAACCCTG (2) INFORMACE PRO SEQ ID NO:96: (i) CHARAKTERISTIKY SEKVENCE: 40 (A) DÉLKA: 465 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 45 (xi) POPIS SEKVENCE: SEQ ID NO:96: GCCGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 50 ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGTCTGGAG GTAACGGATC CGGTGGCAAT GGGAGCGGCG GAAATGGAAC CCAGGACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG' GCCTCCAACC TGCAG 55 (2) INFORMACE PRO SEQ ID NO:97: 60 120 180 240 300 360 405 20 25 60 120 180 240 300 360 420 60 120 180 240 300 360 420 465 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 450 párů bází -471 - 60 55 CZ 295843 B6 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 5 (xi) POPIS SEKVENCE: SEQ ID NO:97: GCCGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 10 ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGTCAGGCG GTAACGGCAG TGGAGGTAAT GGCACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 15 (2) INFORMACE PRO SEQ ID NO:98: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 435 párů bází 20 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:98: 25 GCCGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 30 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGTCTGGCG GCAACGGCAC CCAGGACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC TGCAG 35 (2) INFORMACE PRO SEQ ID NO:99: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 465 párů bází (B) TYP: nukleová kyselina 40 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:99: 45 GCCTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG AGATACACTT TGTCACCAAA TGTGCCTTTC AGCCCCCCCC CAGCTGTCTT CGCTTCGTCC AGACCAACAT CTCCCGCCTC CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG CTGAAGCCCT GGATCACTCG CCAGAACTTC TCCCGGTGCC TGGAGCTGCA GTGTCAGCCC GACTCCTCAA CCCTGTCTGG AGGTAACGGA TCCGGTGGCA ATGGGAGCGG CGGAAATGGA ACCCAGGACT GCTCCTTCCA ACACAGCCCC 50 ATCTCCTCCG ACTTCGCTGT CAAAATCCGT GAGCTGTCTG ACTACCTGCT TCAAGATTAC CCAGTCACCG TGGCCTCCAA CCTGCAGGAC GAGGAGCTCT GCGGGGGCCT CTGGCGGCTG GTCCTGGCAC AGCGCTGGAT GGAGCGGCTC AAGACTGTCG CTGGG (2) INFORMACE PRO SEQ ID NO:100: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 450 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 60 120 180 240 300 360 420 450 60 120 180 240 300 360 420 435 60 120 180 240 300 360 420 465 -472- 60 CZ 295843 B6 (xi) POPIS SEKVENCE: SEQ ID NO:100: GCCTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG AGATACACTT TGTCACCAAA TGTGCCTTTC AGCCCCCCCC CAGCTGTCTT CGCTTCGTCC AGACCAACAT CTCCCGCCTC 5 CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG CTGAAGCCCT GGATCACTCG CCAGAACTTC TCCCGGTGCC TGGAGCTGCA GTGTCAGCCC GACTCCTCAA CCCTGTCTGG AGGTAACGGA TCCGGAGGTA ATGGCACCCA GGACTGCTCC TTCCAACACA GCCCCATCTC CTCCGACTTC GCTGTCAAAA TCCGTGAGCT GTCTGACTAC CTGCTTCAAG ATTACCCAGT CACCGTGGCC TCCAACCTGC AGGACGAGGA GCTCTGCGGG GGCCTCTGGC GGCTGGTCCT GGCACAGCGC 10 TGGATGGAGC GGCTCAAGAC TGTCGCTGGG (2) INFORMACE PRO SEQ ID NO:101: (i) CHARAKTERISTIKY SEKVENCE: 15 (A) DÉLKA: 435 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 20 (xi) POPIS SEKVENCE: SEQ ID NO:101: GCCTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG AGATACACTT TGTCACCAAA TGTGCCTTTC AGCCCCCCCC CAGCTGTCTT CGCTTCGTCC AGACCAACAT CTCCCGCCTC CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG CTGAAGCCCT GGATCACTCG CCAGAACTTC 25 TCCCGGTGCC TGGAGCTGCA GTGTCAGCCC GACTCCTCAA CCCTGTCTGG CGGCAACGGC ACGCAGGACT GCTCCTTCCA ACACAGCCCC ATCTCCTCCG ACTTCGCTGT CAAAATCCGT GAGCTGTCTG ACTACCTGCT TCAAGATTAC CCAGTCACCG TGGCCTCCAA CCTGCAGGAC GAGGAGCTCT GCGGGGGCCT CTGGCGGCTG GTCCTGGCAC AGCGCTGGAT GGAGCGGCTC AAGACTGTCG CTGGG 30 (2) INFORMACE PRO SEQ ID NO:102: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 465 párů bází 35 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:102: 40 GCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGTCTGGAG GTAACGGCAG TGGTGGCAAT GGGAGCGGTG GAAATGGAAC CCAGGACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC 45 TTCGCTGTCA AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC TGCAGGACGA GGAGCTCTGC GGGGGCCTCT GGCGGCTGGT CCTGGCACAG CGCTGGATGG AGCGGCTCAA GACTGTCGCT GGGTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG AGATACACTT TGTCACCAAA TGTGCCTTTC AGCCC 50 (2) INFORMACE PRO SEQ ID NO:103: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 450 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 60 120 180 240 300 360 420 450 60 120 180 240 300 360 420 435 60 120 180 240 300 360 420 4 65 -473 - 55 CZ 295843 B6 (xi) POPIS SEKVENCE: SEQ ID NO:103: GCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG 5 GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGTCAGGCG GTAACGGCAG TGGAGGTAAT GGCACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA 10 CACTTTGTCA CCAAATGTGC CTTTCAGCCC (2) INFORMACE PRO SEQ ID NO:104: (i) CHARAKTERISTIKY SEKVENCE: 15 (A) DÉLKA: 435 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 20 (xi) POPIS SEKVENCE: SEQ ID NO:104: GCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGTCTGGCG GCAACGGCAC GCAGGACTGC 25 TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC TGCAGGACGA GGAGCTCTGC GGGGGCCTCT GGCGGCTGGT CCTGGCACAG CGCTGGATGG AGCGGCTCAA GACTGTCGCT GGGTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG AGATACACTT TGTCACCAAA TGTGCCTTTC AGCCC 30 (2) INFORMACE PRO SEQ ID NO:105: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 451 párů bází 35 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:105: 40 GCCGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 45 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGTCTGGAG GTAGTGGATC CGGAGGTTCT GGCAACCCAG GACTGCTCCT TCCAACACAG CCCCATCTCC TCCGACTTCG CTGTCAAAAT CCGTGAGCTG TCTGACTACC TGCTTCAAGA TTACCCAGTC ACCGTGGCCT CCAACCTGCA G 50 (2) INFORMACE PRO SEQ ID NO:106: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 465 párů bází (B) TYP: nukleová kyselina 55 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:106: 60 120 180 240 300 360 420 450 60 120 180 240 300 360 420 435 60 120 180 240 300 360 420 451 -474- 5 CZ 295843 B6 GCCGACGAGG AGCTCTGCGG CGGCTCAAGA CTGTCGCTGG ATACACTTTG TCACCAAATG ACCAACATCT CCCGCCTCCT ATCACTCGCC AGAACTTCTC CTGTCTGGAG GTAGTGGATC TCCTTCCAAC ACAGCCCCAT TACCTGCTTC AAGATTACCC GGGCCTCTGG CGGCTGGTCC GTCCAAGATG CAAGGCTTGC TGCCTTTCAG CCCCCCCCCA GCAGGAGACC TCCGAGCAGC CCGGTGCCTG GAGCTGCAGT CGGTGGCAGT GGGAGCGGCG CTCCTCCGAC TTCGCTGTCA AGTCACCGTG GCCTCCAACC TGGCACAGCG CTGGATGGAG TGGAGCGCGT GAACACGGAG GCTGTCTTCG CTTCGTCCAG TGGTGGCGCT GAAGCCCTGG GTCAGCCCGA CTCCTCAACC GATCTGGAAC CCAGGACTGC AAATCCGTGA GCTGTCTGAC TGCAG 60 120 180 240 300 360 420 4 65 10 (2) INFORMACE PRO SEQ ID NO:107: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 437 párů bází(B) TYP: nukleová kyselina 15 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:107: 20 CCATGGCCAC CCAGGACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC TGCAGGACGA GGAGCTCTGC GGGGGCCTCT GGCGGCTGGT CCTGGCACAG CGCTGGATGG AGCGGCTCAA GACTGTCGCT GGGTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG AGATACACTT TGTCACCAAA TGTGCCTTTC AGCCCCCCCC CAGCTGTCTT CGCTTCGTCC 25 AGACCAACAT CTCCCGCCTC CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG CTGAAGCCCT GGATCACTCG CCAGAACTTC TCCCGGTGCC TGGAGCTGCA GTGTCAGCCC GACTCCTCAA CCCTGGGCGG TGGATCC 60 120 180 240 300 360 420 437 30 35 (2) INFORMACE PRO SEQ ID NO:108: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 436 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:108: GGATCCGGAG GTACCCAGGA CTGCTCCTTC CAACACAGCC CCATCTCCTC CGACTTCGCT 40 GTCAAAATCC GTGAGCTGTC TGACTACCTG CTTCAAGATT ACCCAGTCAC CGTGGCCTCC AACCTGCAGG ACGAGGAGCT CTGCGGGGGC CTCTGGCGGC TGGTCCTGGC ACAGCGCTGG ATGGAGCGGC TCAAGACTGT CGCTGGGTCC AAGATGCAAG GCTTGCTGGA GCGCGTGAAC ACGGAGATAC ACTTTGTCAC CAAATGTGCC TTTCAGCCCC CCCCCAGCTG TCTTCGCTTC GTCCAGACCA ACATCTCCCG CCTCCTGCAG GAGACCTCCG AGCAGCTGGT GGCGCTGAAG 45 CCCTGGATCA CTCGCCAGAA CTTCTCCCGG TGCCTGGAGC TGCAGTGTCA GCCCGACTCC TCAACCCTGT AAGCTT 60 120 180 240 300 360 420 436 50 55 (2) INFORMACE PRO SEQ ID NO:109: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 449 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:109: CCATGGCCAC CCAGGACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC 60 TGCAGGACGA GGAGCTCTGC GGGGGCCTCT GGCGGCTGGT CCTGGCACAG CGCTGGATGG 60 120 180 -475 - CZ 295843 B6 AGCGGCTCAA GACTGTCGCT GGGTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG AGATACACTT TGTCACCAAA TGTGCCTTTC AGCCCCCCCC CAGCTGTCTT CGCTTCGTCC AGACCAACAT CTCCCGCCTC CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG CTGAAGCCCT GGATCACTCG CCAGAACTTC TCCCGGTGCC TGGAGCTGCA GTGTCAGCCC GACTCCTCAA 5 CCCTGGGCGG TGGGTCAGGA GGTGGATCC (2) INFORMACE PRO SEQ ID NO:110: (i) CHARAKTERISTIKY SEKVENCE: 10 (A) DÉLKA: 439 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 15 (xi) POPIS SEKVENCE: SEQ ID NO:110: GGATCCGGAG GTGGCACCCA GGACTGCTCC TTCCAACACA GCCCCATCTC CTCCGACTTC GCTGTCAAAA TCCGTGAGCT GTCTGACTAC CTGCTTCAAG ATTACCCAGT CACCGTGGCC TCCAACCTGC AGGACGAGGA GCTCTGCGGG GGCCTCTGGC GGCTGGTCCT GGCACAGCGC 20 TGGATGGAGC GGCTCAAGAC TGTCGCTGGG TCCAAGATGC AAGGCTTGCT GGAGCGCGTG AACACGGAGA TACACTTTGT CACCAAATGT GCCTTTCAGC CCCCCCCCAG CTGTCTTCGC TTCGTCCAGA CCAACATCTC CCGCCTCCTG CAGGAGACCT CCGAGCAGCT GGTGGCGCTG AAGCCCTGGA TCACTCGCCA GAACTTCTCC CGGTGCCTGG AGCTGCAGTG TCAGCCCGAC TCCTCAACCC TGTAAGCTT 25 (2) INFORMACE PRO SEQ ID NO:111: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 461 párů bází 30 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:111: 35 CCATGGCCAC CCAGGACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC TGCAGGACGA GGAGCTCTGC GGGGGCCTCT GGCGGCTGGT CCTGGCACAG CGCTGGATGG AGCGGCTCAA GACTGTCGCT GGGTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG 40 AGATACACTT TGTCACCAAA TGTGCCTTTC AGCCCCCCCC CAGCTGTCTT CGCTTCGTCC AGACCAACAT CTCCCGCCTC CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG CTGAAGCCCT GGATCACTCG CCAGAACTTC TCCCGGTGCC TGGAGCTGCA GTGTCAGCCC GACTCCTCAA CCCTGGGCGG TGGGTCAGGA GGTGGGTCAG GAGGTGGATC C 45 (2) INFORMACE PRO SEQ ID NO:112: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 457 párů bází (B) TYP: nukleová kyselina 50 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:112: 55 GGATCCGGAG GTGGCTCAGG GGGAGGTAGT GGTACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC CTTTCAGCCC 60 CCCCCCAGCT GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC 240 300 360 420 449 60 120 180 240 300 360 420 439 60 120 180 240 300 360 420 461 60 120 180 240 300 360 -476- 5 10 CZ 295843 B6 GAGCAGCTGG TGGCGCTGAA GCCCTGGATC ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC AGCCCGACTC CTCAACCCTG TAAGCTT 420 457 (2) INFORMACE PRO SEQ ID NO:113: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 438 párů bázi (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:113: GCCGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 15 CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGGGCGGTG GATCCGGAGG TACCCAGGAC TGCTCCTTCC AACACAGCCC CATCTCCTCC 20 GACTTCGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC TTCAAGATTA CCCAGTCACC GTGGCCTCCA ACCTGCAG 60 120 180 240 300 360 420 438 25 30 (2) INFORMACE PRO SEQ ID NO:114: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 441 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:114: GCCGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 35 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGGGCGGTG GATCCGGAGG TGGCACCCAG GACTGCTCCT TCCAACACAG CCCCATCTCC TCCGACTTCG CTGTCAAAAT CCGTGAGCTG TCTGACTACC TGCTTCAAGA TTACCCAGTC 40 ACCGTGGCCT CCAACCTGCA G 60 120 180 240 300 360 420 441 (2) INFORMACE PRO SEQ ID NO:115: (i) CHARAKTERISTIKY SEKVENCE: 45 (A) DÉLKA: 450 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 50 (xi) POPIS SEKVENCE: SEQ ID NO:115: 55 GCCGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG ATACACTTTG TCACCAAATG TGCCTTTCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC ATCACTCGCC AGAACTTCTC CCGGTGCCTG CTGGGCGGTG GGTCAGGAGG TGGATCCGGA CCCATCTCCT CCGACTTCGC TGTCAAAATC TACCCAGTCA CCGTGGCCTC CAACCTGCAG CGGCTGGTCC TGGCACAGCG CTGGATGGAG CAAGGCTTGC TGGAGCGCGT GAACACGGAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC GGTACCCAGG ACTGCTCCTT CCAACACAGC CGTGAGCTGT CTGACTACCT GCTTCAAGAT 60 120 180 240 300 360 420 450 -477- 60 CZ 295843 B6 (2) INFORMACE PRO SEQ ID NO:116: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 459 párů bázi 5 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:116: 10 GCCGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 15 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGGGCGGTG GATCCGGAGG TGGCTCAGGG GGAGGTAGTG GTACCCAGGA CTGCTCCTTC CAACACAGCC CCATCTCCTC CGACTTCGCT GTCAAAATCC GTGAGCTGTC TGACTACCTG CTTCAAGATT ACCCAGTCAC CGTGGCCTCC AACCTGCAG 20 (2) INFORMACE PRO SEQ ID NO:117: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 465 párů bází (B) TYP: nukleová kyselina 25 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:117: 30 GCCGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 35 CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCAC CCAGGACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC TGCAG (2) INFORMACE PRO SEQ ID NO:118: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 483 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:118: GCCGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 50 CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGCCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCTC AGGGGGAGGT 55 AGTGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG CAG 60120 180 240 300 360 420 459 60120 180 240 300 360 420 465 40 45 60120 180 240 300 360 420 480 483 -478- CZ 295843 B6 (2) INFORMACE PRO SEQ ID NO:119: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 843 párů bází 5 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:119: 10 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 15 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CACCCAGGAC TGCTCCTTCC AACACAGCCC CATCTCCTCC GACTTCGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC TTCAAGATTA CCCAGTCACC 20 GTGGCCTCCA ACCTGCAGGA CGAGGAGCTC TGCGGGGCGC TCTGGCGGCT GGTCCTGGCA CAGCGCTGGA TGGAGCGGCT CAAGACTGTC GCTGGGTCCA AGATGCAAGG CTTGCTGGAG CGCGTGAACA CGGAGATACA CTTTGTCACC AAATGTGCCT TTCAGCCCCC CCCCAGCTGT CTTCGCTTCG TCCAGACCAA CATCTCCCGC CTCCTGCAGG AGACCTCCGA GCAGCTGGTG GCGCTGAAGC CCTGGATCAC TCGCCAGAAC TTCTCCCGGT GCCTGGAGCT GCAGTGTCAG 25 CCC (2) INFORMACE PRO SEQ ID NO:120: (i) CHARAKTERISTIKY SEKVENCE: 30 (A) DÉLKA: 858 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 35 (xi) POPIS SEKVENCE: SEQ ID NO:120: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 40 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CACCCAGGAC TGCTCCTTCC AACACAGCCC CATCTCCTCC 45 GACTTCGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC TTCAAGATTA CCCAGTCACC GTGGCCTCCA ACCTGCAGGA CGAGGAGCTC TGCGGGGCGC TCTGGCGGCT GGTCCTGGCA CAGCGCTGGA TGGAGCGGCT CAAGACTGTC GCTGGGTCCA AGATGCAAGG CTTGCTGGAG CGCGTGAACA CGGAGATACA CTTTGTCACC AAATGTGCCT TTCAGCCCCC CCCCAGCTGT CTTCGCTTCG TCCAGACCAA CATCTCCCGC CTCCTGCAGG AGACCTCCGA GCAGCTGGTG 50 GCGCTGAAGC CCTGGATCAC TCGCCAGAAC TTCTCCCGGT GCCTGGAGCT GCAGTGTCAG CCCGACTCCT CAACCCTG (2) INFORMACE PRO SEQ ID NO:121: 55 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 888 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 60 120 180 240 300 360 420 480 540 600 660 720 780 840 843 60 120 180 240 300 360 420 480 540 600 660 720 780 840 858 -479- 60 CZ 295843 B6 (xi) POPIS SEKVENCE: SEQ ID NO:121: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 5 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 10 CATAAATCTC CAAACATGGC CGACGAGGAG CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG GCACAGCGCT GGATGGAGCG GCTCAAGACT GTCGCTGGGT CCAAGATGCA AGGCTTGCTG GAGCGCGTGA ACACGGAGAT ACACTTTGTC ACCAAATGTG CCTTTCAGCC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT 15 CAGCCCGACT CCTCAACCCT GTCAGGCGGT AACGGCAGTG GAGGTAATGG CACCCAGGAC TGCTCCTTCC AACACAGCCC CATCTCCTCC GACTTCGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC TTCAAGATTA CCCAGTCACC GTGGCCTCCA ACCTGCAG (2) INFORMACE PRO SEQ ID NO:122: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 903 párů bázi (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:122: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 30 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 35 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CGACGAGGAG CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG GCACAGCGCT GGATGGAGCG GCTCAAGACT GTCGCTGGGT CCAAGATGCA AGGCTTGCTG GAGCGCGTGA ACACGGAGAT ACACTTTGTC ACCAAATGTG CCTTTCAGCC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG 40 GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT GTCTGGAGGT AACGGATCCG GTGGCAATGG GAGCGGCGGA AATGGAACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG CAG 45 (2) INFORMACE PRO SEQ ID NO:123: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 873 párů bází 50 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:123: 55 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 60 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 60 120 180 240 300 360 420 480 540 600 660 720 780 840 888 20 25 60 20 180 240 300 360 420 480 540 600 660 720 780 840 900 903 60 120 180 240 300 -480- CZ 295843 B6 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGTCTGGCG GCAACGGCAC GCAGGACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC TGCAGGACGA GGAGCTCTGC GGGGGCCTCT GGCGGCTGGT CCTGGCACAG CGCTGGATGG AGCGGCTCAA GACTGTCGCT GGG (2) INFORMACE PRO SEQ ID NO:124: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 888 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:124: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGTCTGGAG GTAACGGATC CGGAGGTAAT GGCACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGG (2) INFORMACE PRO SEQ ID NO:125: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 903 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:125: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGTCTGGAG GTAACGGATC CGGTGGCAAT GGGAGCGGCG GAAATGGAAC CCAGGACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC TGCAGGACGA GGAGCTCTGC 360 420 480 540 600 660 720 780 840 873 60 120 180 240 300 360 420 480 540 600 660 720 780 840 888 60 120 180 240 300 360 420 480 540 600 660 720 780 840 CZ 295843 B6 GGGGGCCTCT GGCGGCTGGT CCTGGCACAG CGCTGGATGG AGCGGCTCAA GACTGTCGCT GGG (2) INFORMACE PRO SEQ ID NO:126: 5 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 873 párů bázi (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché 10 (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:126: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 15 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 20 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT GTCTGGCGGC AACGGCACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 25 ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG CAGGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG CCC 30 (2) INFORMACE PRO SEQ ID NO:127: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 888 párů bázi (B) TYP: nukleová kyselina 35 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:127: 40 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 45 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT GTCAGGCGGT 50 AACGGCAGTG GAGGTAATGG CACCCAGGAC TGCTCCTTCC AACACAGCCC CATCTCCTCC GACTTCGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC TTCAAGATTA CCCAGTCACC GTGGCCTCCA ACCTGCAGGA CGAGGAGCTC TGCGGGGGCC TCTGGCGGCT GGTCCTGGCA CAGCGCTGGA TGGAGCGGCT CAAGACTGTC GCTGGGTCCA AGATGCAAGG CTTGCTGGAG CGCGTGAACA CGGAGATACA CTTTGTCACC AAATGTGCCT TTCAGCCC 55 (2) INFORMACE PRO SEQ ID NO:128: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 903 párů bází 60 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché 900 903 60 120 180 240 300 360 420 480 540 600 660 720 780 840 873 60 120 180 240 300 360 420 480 540 600 660 720 780 840 888 -482- 50 55 CZ 295843 B6 (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:128: 5 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 10 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT GTCTGGAGGT 15 AACGGCAGTG GTGGTAATGG GAGCGGCGGA AATGGAACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG CAGGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG 20 CCC (2) INFORMACE PRO SEQ ID NO:129: (i) CHARAKTERISTIKY SEKVENCE: 25 (A) DÉLKA: 843 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 30 (xi) POPIS SEKVENCE: SEQ ID NO:129: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 35 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC GACTCAGGAC TGTTCTTTCC AACACAGCCC CATCTCCTCC 40 GACTTCGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC TTCAAGATTA CCCAGTCACC GTGGCCTCCA ACCTGCAGGA CGAGGAGCTC TGCGGGGGCC TCTGGCGGCT GGTCCTGGCA CAGCGCTGGA TGGAGCGGCT CAAGACTGTC GCTGGGTCCA AGATGCAAGG CTTGCTGGAG CGCGTGAACA CGGAGATACA CTTTGTCACC AAATGTGCCT TTCAGCCCCC CCCCAGCTGT CTTCGCTTCG TCCAGACCAA CATCTCCCGC CTCCTGCAGG AGACCTCCGA GCAGCTGGTG 45 GCGCTGAAGC CCTGGATCAC TCGCCAGAAC TTCTCCCGGT GCCTGGAGCT GCAGTGTCAG CCC (2) INFORMACE PRO SEQ ID NO:130: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 858 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:130: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 60 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 903 60 120 180 240 300 360 420 480 540 600 660 720 780 840 843 60 120 180 240 -483 - 15 20 40 45 CZ 295843 B6 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC AACCCAGGAC TGCTCTTTTC AACACAGCCC CATCTCCTCC 5 GACTTCGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC TTCAAGATTA CCCAGTCACC GTGGCCTCCA ACCTGCAGGA CGAGGAGCTC TGCGGGGGCC TCTGGCGGCT GGTCCTGGCA CAGCGCTGGA TGGAGCGGCT CAAGACTGTC GCTGGGTCCA AGATGCAAGG CTTGCTGGAG CGCGTGAACA CGGAGATACA CTTTGTCACC AAATGTGCCT TTCAGCCCCC CCCCAGCTGT CTTCGCTTCG TCCAGACCAA CATCTCCCGC CTCCTGCAGG AGACCTCCGA GCAGCTGGTG 10 GCGCTGAAGC CCTGGATCAC TCGCCAGAAC TTCTCCCGGT GCCTGGAGCT GCAGTGTCAG CCCGACTCCT CAACCCTG (2) INFORMACE PRO SEQ ID NO:131: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 843 párů bázi (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:131: GCCACTCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 25 GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC AGCCCTACGT AGAGGGCGGT 30 GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AAACATGGCT AACTGCTCTA TAATGATCGA TGAAATTATA CATCACTTAA AGAGACCACC TAACCCTTTG CTGGACCCGA ACAACCTCAA TTCTGAAGAC ATGGATATCC TGATGGAACG AAACCTTCGA ACTCCAAACC TGCTCGCATT CGTAAGGGCT GTCAAGCACT TAGAAAATGC ATCAGGTATT GAGGCAATTC TTCGTAATCT CCAACCATGT 35 CTGCCCTCTG CCACGGCCGC ACCCTCTCGA CATCCAATCA TCATCAAGGC AGGTGACTGG CAAGAATTCC GGGAAAAACT GACGTTCTAT CTGGTTACCC TTGAGCAAGC GCAGGAACAA CAG (2) INFORMACE PRO SEQ ID NO:132: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 888 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:132: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 50 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 55 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CCAACATGGC CGACGAGGAG CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG GCACAGCGCT GGATGGAGCG GCTCAAGACT GTCGCTGGGT CCAAGATGCA AGGCTTGCTG GAGCGCGTGA ACACGGAGAT ACACTTTGTC ACCAAATGTG CCTTTCAGCC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG 60 GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT GTCAGGCGGT AACGGCAGTG GAGGTAATGG CACCCAGGAC 300 360 420 480 540 600 660 720 780 840 858 60 120 180 240 300 360 420 480 540 600 660 720 780 840 843 60 120 180 240 300 360 420 480 540 600 660 720 780 -484- CZ 295843 B6 TGCTCCTTCC AACACAGCCC CATCTCCTCC GACTTCGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC TTCAAGATTA CCCAGTCACC GTGGCCTCCA ACCTGCAG (2) INFORMACE PRO SEQ ID NO:133: 5 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 903 párů bázi (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché 10 (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:133: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 15 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 20 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CGACGAGGAG CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG GCACAGCGCT GGATGGAGCG GCTCAAGACT GTCGCTGGGT CCAAGATGCA AGGCTTGCTG GAGCGCGTGA ACACGGAGAT ACACTTTGTC ACCAAATGTG CCTTTCAGCC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAÁCATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG 25 GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT GTCTGGAGGT AACGGATCCG GTGGCAATGG GAGCGGCGGA AATGGAACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG CAG 30 (2) INFORMACE PRO SEQ ID NO:134: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 873 párů bází 35 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:134: 40 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 45 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 50 ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGTCTGGCG GCAACGGCAC GCAGGACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC TGCAGGACGA GGAGCTCTGC GGGGGCCTCT GGCGGCTGGT CCTGGCACAG 55 CGCTGGATGG AGCGGCTCAA GACTGTCGCT GGG (2) INFORMACE PRO SEQ ID NO:135: (i) CHARAKTERISTIKY SEKVENCE: 60 (A) DÉLKA: 888 párů bází (B) TYP: nukleová kyselina 840 888 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 903 60 120 180 240 300 360 420 480 540 600 660 720 780 840 873 -485- 50 55 CZ 295843 B6 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:135: 5 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 10 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 15 ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGTCTGGAG GTAACGGATC CGGAGGTAAT GGCACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG GACGAGGAGC TCTGCGGGGG CCTCTGGCGG 20 CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGG (2) INFORMACE PRO SEQ ID NO:136: (i) CHARAKTERISTIKY SEKVENCE: 25 (A) DÉLKA: 903 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE:, lineární 30 (xi) POPIS SEKVENCE: SEQ ID NO:136: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 35 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 40 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGTCTGGAG GTAACGGATC CGGTGGCAAT GGGAGCGGCG GAAATGGAAC CCAGGACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC 45 TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC TGCAGGACGA GGAGCTCTGC GGGGGCCTCT GGCGGCTGGT CCTGGCACAG CGCTGGATGG AGCGGCTCAA GACTGTCGCT GGG (2) INFORMACE PRO SEQ ID NO:137: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 873 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:137: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 60 120 180 240 300 360 420 480 540 600 660 720 780 840 888 60 120 180 24 0 300 360 420 480 540 600 660 720 780 840 900 903 60 120 180 -486- CZ 295843 B6 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT GTCTGGCGGC AACGGCACGC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG CAGGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG CCC (2) INFORMACE PRO SEQ ID NO:138: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 888 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:138: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT GTCAGGCGGT AACGGCAGTG GAGGTAATGG CACCCAGGAC TGCTCCTTCC AACACAGCCC CATCTCCTCC GACTTCGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC TTCAAGATTA CCCAGTCACC GTGGCCTCCA ACCTGCAGGA CGAGGAGCTC TGCGGGGGCC TCTGGCGGCT GGTCCTGGCA CAGCGCTGGA TGGAGCGGCT CAAGACTGTC GCTGGGTCCA AGATGCAAGG CTTGCTGGAG CGCGTGAACA CGGAGATACA CTTTGTCACC AAATGTGCCT TTCAGCCC (2) INFORMACE PRO SEQ ID NO:139: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 903 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:139: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT GTCTGGAGGT AACGGCAGTG GTGGCAATGG GAGCGGCGGA AATGGAACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA ATCCGTGAGC TGTCTGACTA CCTGCTTCAA 240 300 360 420 480 540 600 660 720 780 840 873 60 120 180 240 300 360 420 480 540 600 660 720 780 840 888 60 120 180 240 300 360 420 480 540 600 660 720 CZ 295843 B6 GATTACCCAG TCACCGTGGC CTCCAACCTG CAGGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG CCC (2) INFORMACE PRO SEQ ID NO:140: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 888 párů bázi (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:140: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CCAACATGGC CGACGAGGAG CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG GCACAGCGCT GGATGGAGCG GCTCAAGACT GTCGCTGGGT CCAAGATGCA AGGCTTGCTG GAGCGCGTGA ACACGGAGAT ACACTTTGTC ACCAAATGTG CCTTTCAGCC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT GTCTGGAGGT AGTGGATCCG GAGGTTCTGG CACCCAGGAC TGCTCCTTCC AACACAGCCC CATCTCCTCC GACTTCGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC TTCAAGATTA CCCAGTCACC GTGGCCTCCA ACCTGCAG (2) INFORMACE PRO SEQ ID NO:141: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 903 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:141: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CGACGAGGAG CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG GCACAGCGCT GGATGGAGCG GCTCAAGACT GTCGCTGGGT CCAAGATGCA AGGCTTGCTG GAGCGCGTGA ACACGGAGAT ACACTTTGTC ACCAAATGTG CCTTTCAGCC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT GTCTGGAGGT AGTGGATCCG GTGGCAGTGG GAGCGGCGGA TCTGGAACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG CAG 780 840 900 903 60 120 180 240 300 360 420 480 540 600 660 720 780 840 888 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 903 CZ 295843 B6 (2) INFORMACE PRO SEQ ID NO:142: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 858 párů bázi 5 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:142: 10 GCCACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA 15 CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC AGCCCGACTC CTCAACCCTG TACGTAGAGG GCGGTGGAGG CTCCCCGGGT GAACCGTCTG GTCCAATCTC TACTATCAAC CCGTCTCCTC CGTCTAAAGA ATCTCATAAA TCTCCAAACA TGGCTAACTG CTCTATAATG 20 ATCGATGAAA TTATACATCA CTTAAAGAGA CCACCTAACC CTTTGCTGGA CCCGAACAAC CTCAATTCTG AAGACATGGA TATCCTGATG GAACGAAACC TTCGAACTCC AAACCTGCTC GCATTCGTAA GGGCTGTCAA GCACTTAGAA AATGCATCAG GTATTGAGGC AATTCTTCGT AATCTCCAAC CATGTCTGCC CTCTGCCACG GCCGCACCCT CTCGACATCC AATCATCATC AAGGCAGGTG ACTGGCAAGA ATTCCGGGAA AAACTGACGT TCTATCTGGT TACCCTTGAG 25 CAAGCGCAGG AACAACAG (2) INFORMACE PRO SEQ ID NO:143: (i) CHARAKTERISTIKY SEKVENCE: 30 (A) DÉLKA: 876 párů bázi (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 35 (xi) POPIS SEKVENCE: SEQ ID NO:143: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 40 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CGACGAGGAG CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG 45 GCACAGCGCT GGATGGAGCG GCTCAAGACT GTCGCTGGGT CCAAGATGCA AGGCTTGCTG GAGCGCGTGA ACACGGAGAT ACACTTTGTC ACCAAATGTG CCTTTCAGCC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT GGGCGGTGGA TCCGGAGGTA CCCAGGACTG CTCCTTCCAA 50 CACAGCCCCA TCTCCTCCGA CTTCGCTGTC AAAATCCGTG AGCTGTCTGA CTACCTGCTT CAAGATTACC CAGTCACCGT GGCCTCCAAC CTGCAG (2) INFORMACE PRO SEQ ID NO:144: 55 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 879 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 60 120 180 240 300 360 420 480 540 600 660 720 780 840 858 60 120 180 240 300 360 420 480 540 600 660 720 780 840 876 -489- CZ 295843 B6 (xi) POPIS SEKVENCE: SEQ ID NO:144: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CGACGAGGAG CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG GCACAGCGCT GGATGGAGCG GCTCAAGACT GTCGCTGGGT CCAAGATGCA AGGCTTGCTG GAGCGCGTGA ACACGGAGAT ACACTTTGTC ACCAAATGTG CCTTTCAGCC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT GGGCGGTGGA TCCGGAGGTG GCACCCAGGA CTGCTCCTTC CAACACAGCC CCATCTCCTC CGACTTCGCT GTCAAAATCC GTGAGCTGTC TGACTACCTG CTTCAAGATT ACCCAGTCAC CGTGGCCTCC AACCTGCAG (2) INFORMACE PRO SEQ ID NO:145: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 888 párů bázi (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:145: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CGACGAGGAG CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG GCACAGCGCT GGATGGAGCG GCTCAAGACT GTCGCTGGGT CCAAGATGCA AGGCTTGCTG GAGCGCGTGA ACACGGAGAT ACACTTTGTC ACCAAATGTG CCTTTCAGCC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT GGGCGGTGGG TCAGGAGGTG GATCCGGAGG TACCCAGGAC TGCTCCTTCC AACACAGCCC CATCTCCTCC GACTTCGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC TTCAAGATTA CCCAGTCACC GTGGCCTCCA ACCTGCAG (2) INFORMACE PRO SEQ ID NO:146: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 897 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:146: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 60 120 180 240 300 360 420 480 540 600 660 720 780 840 879 60 120 180 240 300 360 420 480 540 600 660 720 780 840 888 60 120 180 240 300 360 420 CZ 295843 B6 CATAAATCTC CAAACATGGC CGACGAGGAG CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG GCACAGCGCT GGATGGAGCG GCTCAAGACT GTCGCTGGGT CCAAGATGCA AGGCTTGCTG GAGCGCGTGA ACACGGAGAT ACACTTTGTC ACCAAATGTG CCTTTCAGCC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG 5 GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT GGGCGGTGGA TCCGGAGGTG GCTCAGGGGG AGGTAGTGGT ACCCAGGACT GCTCCTTCCA ACACAGCCCC ATCTCCTCCG ACTTCGCTGT CAAAATCCGT GAGCTGTCTG ACTACCTGCT TCAAGATTAC CCAGTCACCG TGGCCTCCAA CCTGCAG 10 (2) INFORMACE PRO SEQ ID NO:147: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 903 párů bází (B) TYP: nukleová kyselina 15 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:147: 20 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 25 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CGACGAGGAG CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG GCACAGCGCT GGATGGAGCG GCTCAAGACT GTCGCTGGGT CCAAGATGCA AGGCTTGCTG GAGCGCGTGA ACACGGAGAT ACACTTTGTC ACCAAATGTG CCTTTCAGCC CCCCCCCAGC 30 TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT GGGCGGTGGG TCAGGAGGTG GGTCAGGAGG TGGATCCGGA GGTGGCACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 35 CAG (2) INFORMACE PRO SEQ ID NO:148: (i) CHARAKTERISTIKY SEKVENCE: 40 (A) DÉLKA: 921 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 45 (xi) POPIS SEKVENCE: SEQ ID NO:148: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 50 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CGACGAGGAG CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG 55 GCACAGCGCT GGATGGAGCG GCTCAAGACT GTCGCTGGGT CCAAGATGCA AGGCTTGCTG GAGCGCGTGA ACACGGAGAT ACACTTTGTC ACCAAATGTG CCTTTCAGCC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT GGGCGGTGGG TCAGGAGGTG GGTCAGGAGG TGGATCCGGA 60 GGTGGCTCAG GGGGAGGTAG TGGTACCCAG GACTGCTCCT TCCAACACAG CCCCATCTCC TCCGACTTCG CTGTCAAAAT CCGTGAGCTG TCTGACTACC TGCTTCAAGA TTACCCAGTC 480 540 600 660 720 780 840 897 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 903 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 -491 - 5CZ 295843 B6 921 ACCGTGGCCT CCAACCTGCA G (2) INFORMACE PRO SEQ ID NO:149: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 876 párů bázi (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 10 (xi) POPIS SEKVENCE: SEQ ID NO:149: GCTAACTGCT CTATAATGAT CGATGAAATT TTGCTGGACC CGAACAACCT CAATTCTGAA 15 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG ATTGAGGCAA TTCTTCGTAA TCTCCAACCA CGACATCCAA TCATCATCAA GGCAGGTGAC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CCGGGTGAAC CGTCTGGTCC AATCTCTACT 20 CATAAATCTC CAAACATGGC CTCCAAGATG ATACACTTTG TCACCAAATG TGCCTTTCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC ATCACTCGCC AGAACTTCTC CCGGTGCCTG CTGGGCGGTG GATCCGGAGG TACCCAGGAC 25 GACTTCGCTG TCAAAATCCG TGAGCTGTCT GTGGCCTCCA ACCTGCAGGA CGAGGAGCTC CAGCGCTGGA TGGAGCGGCT CAAGACTGTC ATACATCACT TAAAGAGACC ACCTAACCCT 60 GACATGGATA TCCTGATGGA ACGAAACCTT 120 GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CAAGGCTTGC TGGAGCGCGT GAACACGGAG 480 CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 540 TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 600 GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 660 TGCTCCTTCC AACACAGCCC CATCTCCTCC 720 GACTACCTGC TTCAAGATTA CCCAGTCACC 780 TGCGGGGGCC TCTGGCGGCT GGTCCTGGCA 840 GCTGGG 876 (2) INFORMACE PRO SEQ ID NO:150: 30 35 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 879 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:150: GCTAACTGCT CTATAATGAT CGATGAAATT 40 TTGCTGGACC CGAACAACCT CAATTCTGAA CGAACTCCAA ACCTGCTCGC ATTCGTAAGG ATTGAGGCAA TTCTTCGTAA TCTCCAACCA CGACATCCAA TCATCATCAA GGCAGGTGAC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA 45 CCGGGTGAAC CGTCTGGTCC AATCTCTACT CATAAATCTC CAAACATGGC CTCCAAGATG ATACACTTTG TCACCAAATG TGCCTTTCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC ATCACTCGCC AGAACTTCTC CCGGTGCCTG 50 CTGGGCGGTG GATCCGGAGG TGGCACCCAG TCCGACTTCG CTGTCAAAAT CCGTGAGCTG ACCGTGGCCT CCAACCTGCA GGACGAGGAG GCACAGCGCT GGATGGAGCG GCTCAAGACT ATACATCACT TAAAGAGACC ACCTAACCCT 60 GACATGGATA TCCTGATGGA ACGAAACCTT 120 GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CAAGGCTTGC TGGAGCGCGT GAACACGGAG 480 CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 540 TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 600 GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 660 GACTGCTCCT TCCAACACAG CCCCATCTCC 720 TCTGACTACC TGCTTCAAGA TTACCCAGTC 780 CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG 840 GTCGCTGGG 879 55 (2) INFORMACE PRO SEQ ID NO:151: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 888 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární -492- 60 CZ 295843 B6 (xi) POPIS SEKVENCE: SEQ ID NO:151: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGGGCGGTG GGTCAGGAGG TGGATCCGGA GGTACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGG (2) INFORMACE PRO SEQ ID NO:152: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 897 párů bázi (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:152: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGGGCGGTG GATCCGGAGG TGGCTCAGGG GGAGGTAGTG GTACCCAGGA CTGCTCCTTC CAACACAGCC CCATCTCCTC CGACTTCGCT GTCAAAATCC GTGAGCTGTC TGACTACCTG CTTCAAGATT ACCCAGTCAC CGTGGCCTCC AACCTGCAGG ACGAGGAGCT CTGCGGGGGC CTCTGGCGGC TGGTCCTGGC ACAGCGCTGG ATGGAGCGGC TCAAGACTGT CGCTGGG (2) INFORMACE PRO SEQ ID NO:153: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 903 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:153: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 60 120 180 240 300 360 420 480 540 600 660 720 780 840 888 60 120 180 240 300 360 420 480 540 600 660 720 780 840 897 60 120 180 240 300 360 40 45 CZ 295843 B6 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 5 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCAC CCAGGACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC TGCAGGACGA GGAGCTCTGC GGGGGCCTCT GGCGGCTGGT CCTGGCACAG CGCTGGATGG AGCGGCTCAA GACTGTCGCT 10 GGG (2) INFORMACE PRO SEQ ID NO:154: (i) CHARAKTERISTIKY SEKVENCE: 15 (A) DÉLKA: 921 párů bázi (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 20 (xi) POPIS SEKVENCE: SEQ ID NO:154: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 25 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 30 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCTC AGGGGGAGGT AGTGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 35 ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG CAGGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG CGGCTCAAGA CTGTCGCTGG G (2) INFORMACE PRO SEQ ID NO:155: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 876 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:155: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 50 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 55 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT GGGCGGTGGA TCCGGAGGTA CCCAGGACTG CTCCTTCCAA CACAGCCCCA TCTCCTCCGA CTTCGCTGTC 60 AAAATCCGTG AGCTGTCTGA CTACCTGCTT CAAGATTACC CAGTCACCGT GGCCTCCAAC CTGCAGGACG AGGAGCTCTG CGGGGGCCTC TGGCGGCTGG TCCTGGCACA GCGCTGGATG 420 480 540 600 660 720 780 840 900 903 60 120 180 240 300 360 420 480 540 600 6 60 720 780 840 900 921 60 120 180 240 300 360 420 480 540 600 660 720 780 -494- CZ 295843 B6 GAGCGGCTCA AGACTGTCGC TGGGTCCAAG ATGCAAGGCT TGCTGGAGCG CGTGAACACG GAGATACACT TTGTCACCAA ATGTGCCTTT CAGCCC (2) INFORMACE PRO SEQ ID NO:156: 5 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 879 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché 10 (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:156: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 15 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 20 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT GGGCGGTGGA TCCGGAGGTG GCACCCAGGA CTGCTCCTTC CAACACAGCC CCATCTCCTC CGACTTCGCT 25 GTCAAAATCC GTGAGCTGTC TGACTACCTG CTTCAAGATT ACCCAGTCAC CGTGGCCTCC AACCTGCAGG ATGAGGAGCT CTGCGGGGGC CTCTGGCGGC TGGTCCTGGC ACAGCGCTGG ATGGAGCGGC TCAAGACTGT CGCTGGGTCC AAGATGCAAG GCTTGCTGGA GCGCGTGAAC ACGGAGATAC ACTTTGTCAC CAAATGTGCC TTTCAGCCC 30 (2) INFORMACE PRO SEQ ID NO:157: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 888 párů bází (B) TYP: nukleová kyselina 35 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:157: 40 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 45 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT GGGCGGTGGG 50 TCAGGAGGTG GATCCGGAGG TACCCAGGAC TGCTCCTTCC AACACAGCCC CATCTCCTCC GACTTCGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC TTCAAGATTA CCCAGTCACC GTGGCCTCCA ACCTGCAGGA CGAGGAGCTC TGCGGGGGCC TCTGGCGGCT GGTCCTGGCA CAGCGCTGGA TGGAGCGGCT CAAGACTGTC GCTGGGTCCA AGATGCAAGG CTTGCTGGAG CGCGTGAACA CGGAGATACA CTTTGTCACC AAATGTGCCT TTCAGCCC 55 (2) INFORMACE PRO SEQ ID NO:158: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 897 párů bází 60 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché 840 876 60 120 180 240 300 360 420 480 540 600 660 720 780 840 879 60 120 180 240 300 360 420 480 540 600 660 720 780 840 888 -495- 50 55 CZ 295843 B6 (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:158: 5 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 10 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT GGGCGGTGGA 15 TCCGGAGGTG GCTCAGGGGG AGGTAGTGGT ACCCAGGACT GCTCCTTCCA ACACAGCCCC ATCTCCTCCG ACTTCGCTGT CAAAATCCGT GAGCTGTCTG ACTACCTGCT TCAAGATTAC CCAGTCACCG TGGCCTCCAA CCTGCAGGAC GAGGAGCTCT GCGGGGGCCT CTGGCGGCTG GTCCTGGCAC AGCGCTGGAT GGAGCGGCTC AAGACTGTCG CTGGGTCCAA GATGCAAGGC TTGCTGGAGC GCGTGAACAC GGAGATACAC TTTGTCACCA AATGTGCCTT TCAGCCC 20 (2) INFORMACE PRO SEQ ID NO:159: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 903 párů bázi 25 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:159: 30 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 35 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG GTGGCGCTGA AGCCCTGGAT CACTCGCCAG 40 AACTTCTCCC GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT GGGCGGTGGG TCAGGAGGTG GGTCAGGAGG TGGATCCGGA GGTGGCACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG CAGGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG 45 CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG CCC (2) INFORMACE PRO SEQ ID NO:160: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 921 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:160: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 60 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 60 120 180 240 300 360 420 480 540 600 660 720 780 840 897 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 903 60 120 180 240 -496- 15 20 40 CZ 295843 B6 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC 5 CGCCTCCTGC AGGAGACCTC CGAGCAGCTG GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT GGGCGGTGGG TCAGGAGGTG GGTCAGGAGG TGGATCCGGA GGTGGCTCAG GGGGAGGTAG TGGTACCCAG GACTGCTCCT TCCAACACAG CCCCATCTCC TCCGACTTCG CTGTCAAAAT CCGTGAGCTG TCTGACTACC TGCTTCAAGA TTACCCAGTC ACCGTGGCCT CCAACCTGCA GGACGAGGAG 10 CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG GCACAGCGCT GGATGGAGCG GCTCAAGACT GTCGCTGGGT CCAAGATGCA AGGCTTGCTG GAGCGCGTGA ACACGGAGAT ACACTTTGTC ACCAAATGTG CCTTTCAGCC C (2) INFORMACE PRO SEQ ID NO:161: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 888 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:161: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 25 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 30 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CGATTACCCA GTCACCGTGG CCTCCAACCT GCAGGACGAG GAGCTCTGCG GGGGCCTCTG GCGGCTGGTC CTGGCACAGC GCTGGATGGA GCGGCTCAAG ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG TGAACACGGA GATACACTTT GTCACCAAAT GTGCCTTTCA GCCCCCCCCC AGCTGTCTTC GCTTCGTCCA GACCAACATC 35 TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC TGAAGCCCTG GATCACTCGC CAGAACTTCT CCCGGTGCCT GGAGCTGCAG TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT GGGTCAGGAG GTGGATCCGG AGGTACCCAG GACTGCTCCT TCCAACACAG CCCCATCTCC TCCGACTTCG CTGTCAAAAT CCGTGAGCTG TCTGACTACC TGCTTCAA (2) INFORMACE PRO SEQ ID NO:162: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 903 párů bází (B) TYP: nukleová kyselina 45 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:162: 50 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 55 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CGATTACCCA GTCACCGTGG CCTCCAACCT GCAGGACGAG GAGCTCTGCG GGGGCCTCTG GCGGCTGGTC CTGGCACAGC GCTGGATGGA GCGGCTCAAG ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG TGAACACGGA GATACACTTT 60 GTCACCAAAT GTGCCTTTCA GCCCCCCCCC AGCTGTCTTC GCTTCGTCCA GACCAACATC TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC TGAAGCCCTG GATCACTCGC 300 360 420 480 540 600 660 720 780 840 900 921 60 120 180 240 300 360 420 480 540 600 660 720 780 840 888 60 120 180 240 300 360 420 480 540 600 660 720 -497- CZ 295843 B6 CAGAACTTCT CCCGGTGCCT GGAGCTGCAG TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT GGGTCAGGAG GTGGGTCAGG AGGTGGATCC GGAGGTGGCA CCCAGGACTG CTCCTTCCAA CACAGCCCCA TCTCCTCCGA CTTCGCTGTC AAAATCCGTG AGCTGTCTGA CTACCTGCTT CAA 5 (2) INFORMACE PRO SEQ ID NO:163: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 888 párů bázi 10 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:163: 15 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 20 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CGCCTCCAAC CTGCAGGACG AGGAGCTCTG CGGGGGCCTC TGGCGGCTGG TCCTGGCACA GCGCTGGATG GAGCGGCTCA AGACTGTCGC TGGGTCCAAG 25 ATGCAAGGCT TGCTGGAGCG CGTGAACACG GAGATACACT TTGTCACCAA ATGTGCCTTT CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG GTGGGTCAGG AGGTGGATCC GGAGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 30 ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTG (2) INFORMACE PRO SEQ ID NO:164: (i) CHARAKTERISTIKY SEKVENCE: 35 (A) DÉLKA: 903 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 40 (xi) POPIS SEKVENCE: SEQ ID NO:164: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 45 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAAGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CGCCTCCAAC CTGCAGGACG AGGAGCTCTG CGGGGGCCTC 50 TGGCGGCTGG TCCTGGCACA GCGCTGGATG GAGCGGCTCA AGACTGTCGC TGGGTCCAAG ATGCAAGGCT TGCTGGAGCG CGTGAACACG GAGATACACT TTGTCACCAA ATGTGCCTTT CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG GTGGGTCAGG AGGTGGGTCA 55 GGAGGTGGAT CCGGAGGTGG CACCCAGGAC TGCTCCTTCC AACACAGCCC CATCTCCTCC GACTTCGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC TTCAAGATTA CCCAGTCACC GTG (2) INFORMACE PRO SEQ ID NO:165: (i) CHARAKTERISTIKY SEKVENCE: 780 840 900 903 60 120 180 240 300 360 420 480 540 600 660 720 780 840 888 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 903 -498- 60 25 30 CZ 295843 B6 (A) DÉLKA: 888 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:165: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 10 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 15 CATAAATCTC CAAACATGGC CGTCGCTGGG TCCAAGATGC AAGGCTTGCT GGAGCGCGTG AACACGGAGA TACACTTTGT CACCAAATGT GCCTTTCAGC CCCCCCCCAG CTGTCTTCGC TTCGTCCAGA CCAACATCTC CCGCCTCCTG CAGGAGACCT CCGAGCAGCT GGTGGCGCTG AAGCCCTGGA TCACTCGCCA GAACTTCTCC CGGTGCCTGG AGCTGCAGTG TCAGCCCGAC TCCTCAACCC TGGGCGGTGG GTCAGGAGGT GGATCCGGAG GTACCCAGGA CTGCTCCTTC 20 CAACACAGCC CCATCTCCTC CGACTTCGCT GTCAAAATCC GTGAGCTGTC TGACTACCTG CTTCAAGATT ACCCAGTCAC CGTGGCCTCC AACCTGCAGG ACGAGGAGCT CTGCGGGGGC CTCTGGCGGC TGGTCCTGGC ACAGCGCTGG ATGGAGCGGC TCAAGACT (2) INFORMACE PRO SEQ ID NO:166: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 903 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:166: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 35 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 40 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CGTCGCTGGG TCCAAGATGC AAGGCTTGCT GGAGCGCGTG AACACGGAGA TACACTTTGT CACCAAATGT GCCTTTCAGC CCCCCCCCAG CTGTCTTCGC TTCGTCCAGA CCAACATCTC CCGCCTCCTG CAGGAGACCT CCGAGCAGCT GGTGGCGCTG AAGCCCTGGA TCACTCGCCA GAACTTCTCC CGGTGCCTGG AGCTGCAGTG TCAGCCCGAC 45 TCCTCAACCC TGGGCGGTGG GTCAGGAGGT GGGTCAGGAG GTGGATCCGG AGGTGGCACC CAGGACTGCT CCTTCCAACA CAGCCCCATC TCCTCCGACT TCGCTGTCAA AATCCGTGAG CTGTCTGACT ACCTGCTTCA AGATTACCCA GTCACCGTGG CCTCCAACCT GCAGGACGAG GAGCTCTGCG GGGGCCTCTG GCGGCTGGTC CTGGCACAGC GCTGGATGGA GCGGCTCAAG ACT 50 (2) INFORMACE PRO SEQ ID NO:167: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 888 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 60 120 180 240 300 360 420 480 540 600 660 720 780 840 888 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 903 -499- 55 20 25 CZ 295843 B6 (xi) POPIS SEKVENCE: SEQ ID NO:167: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 5 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 10 CATAAATCTC CAAACATGGC CCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG GTGGGTCAGG AGGTGGATCC GGAGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 15 CAGGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTT (2) INFORMACE PRO SEQ ID NO:168: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 903 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:168: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 30 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 35 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG GTGGGTCAGG AGGTGGGTCA GGAGGTGGAT CCGGAGGTGG CACCCAGGAC TGCTCCTTCC AACACAGCCC CATCTCCTCC 40 GACTTCGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC TTCAAGATTA CCCAGTCACC GTGGCCTCCA ACCTGCAGGA CGAGGAGCTC TGCGGGGGCC TCTGGCGGCT GGTCCTGGCA CAGCGCTGGA TGGAGCGGCT CAAGACTGTC GCTGGGTCCA AGATGCAAGG CTTGCTGGAG CGCGTGAACA CGGAGATACA CTTTGTCACC AAATGTGCCT TTCAGCCCCC CCCCAGCTGT CTT 45 (2) INFORMACE PRO SEQ ID NO:169: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 888 párů bází 50 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:169: 55 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 60 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAAGCTCC 60 120 180 240 300 360 420 480 540 600 660 720 780 840 888 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 903 60 120 180 240 300 360 -500- CZ 295843 B6 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CACCAACATC TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC TGAAGCCCTG GATCACTCGC CAGAACTTCT CCCGGTGCCT GGAGCTGCAG TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT GGGTCAGGAG GTGGATCCGG AGGTACCCAG 5 GACTGCTCCT TCCAACACAG CCCCATCTCC TCCGACTTCG CTGTCAAAAT CCGTGAGCTG TCTGACTACC TGCTTCAAGA TTACCCAGTC ACCGTGGCCT CCAACCTGCA GGACGAGGAG CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG GCACAGCGCT GGATGGAGCG GCTCAAGACT GTCGCTGGGT CCAAGATGCA AGGCTTGCTG GAGCGCGTGA ACACGGAGAT ACACTTTGTC ACCAAATGTG CCTTTCAGCC CCCCCCCAGC TGTCTTCGCT TCGTCCAG 10 (2) INFORMACE PRO SEQ ID NO:170: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 903 párů bází 15 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:170: 20 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 25 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC ' CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CACCAACATC TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC TGAAGCCCTG GATCACTCGC CAGAACTTCT CCCGGTGCCT GGAGCTGCAG 30 TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT GGGTCAGGAG GTGGGTCAGG AGGTGGATCC GGAGGTGGCA CCCAGGACTG CTCCTTCCAA CACAGCCCCA TCTCCTCCGA CTTCGCTGTC AAAATCCGTG AGCTGTCTGA CTACCTGCTT CAAGATTACC CAGTCACCGT GGCCTCCAAC CTGCAGGACG AGGAGCTCTG CGGGGGCCTC TGGCGGCTGG TCCTGGCACA GCGCTGGATG GAGCGGCTCA AGACTGTCGC TGGGTCCAAG ATGCAAGGCT TGCTGGAGCG CGTGAACACG 35 GAGATACACT TTGTCACCAA ATGTGCCTTT CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC CAG (2) INFORMACE PRO SEQ ID NO:171: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 876 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:171: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 50 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 55 CATAAATCTC CAAACATGGC CGATTACCCA GTCACCGTGG CCTCCAACCT GCAGGACGAG GAGCTCTGCG GGGGCCTCTG GCGGCTGGTC CTGGCACAGC GCTGGATGGA GCGGCTCAAG ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG TGAACACGGA GATACACTTT GTCACCAAAT GTGCCTTTCA GCCCCCCCCC AGCTGTCTTC GCTTCGTCCA GACCAACATC TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC TGAAGCCCTG GATCACTCGC 60 CAGAACTTCT CCCGGTGCCT GGAGCTGCAG TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT GGATCCGGAG GTACCCAGGA CTGCTCCTTC CAACACAGCC CCATCTCCTC CGACTTCGCT 420 480 540 600 660 720 780 840888 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 903 40 45 60 120 180 240 300 360 420 480 540 600 660 720 780 840 -501 - 5 5 10 30 35 55 CZ 295843 B6 GTCAAAATCC GTGAGCTGTC TGACTACCTG CTTCAA (2) INFORMACE PRO SEQ ID NO:172: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 879 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:172: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 15 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 20 CATAAATCTC CAAACATGGC CGATTACCCA GTCACCGTGG CCTCCAACCT GCAGGACGAG GAGCTCTGCG GGGGCCTCTG GCGGCTGGTC CTGGCACAGC GCTGGATGGA GCGGCTCAAG ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG TGAACACGGA GATACACTTT GTCACCAAAT GTGCCTTTCA GCCCCCCCCC AGCTGTCTTC GCTTCGTCCA GACCAACATC TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC TGAAGCCCTG GATCACTCGC 25 CAGAACTTCT CCCGGTGCCT GGAGCTGCAG TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT GGATCCGGAG GTGGCACCCA GGACTGCTCC TTCCAACACA GCCCCATCTC CTCCGACTTC GCTGTCAAAA TCCGTGAGCT GTCTGACTAC CTGCTTCAA (2) INFORMACE PRO SEQ ID NO:173: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 897 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:173: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 40 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 45 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CGATTACCCA GTCACCGTGG CCTCCAACCT GCAGGACGAG GAGCTCTGCG GGGGCCTCTG GCGGCTGGTC CTGGCACAGC GCTGGATGGA GCGGCTCAAG ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG TGAACACGGA GATACACTTT GTCACCAAAT GTGCCTTTCA GCCCCCCCCC AGCTGTCTTC GCTTCGTCCA GACCAACATC 50 TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC TGAAGCCCTG GATCACTCGC CAGAACTTCT CCCGGTGCCT GGAGCTGCAG TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT GGATCCGGAG GTGGCTCAGG GGGAGGTAGT GGTACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAA (2) INFORMACE PRO SEQ ID NO:174: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 921 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 876 60 120 180 240 300 360 420 480 540 600 660 720 780 840 879 60 120 180 240 300 360 420 480 540 600 660 720 780 840 897 -502- 60 CZ 295843 B6 (xi) POPIS SEKVENCE: SEQ ID NO:174: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 5 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 10 CATAAATCTC CAAACATGGC CGATTACCCA GTCACCGTGG CCTCCAACCT GCAGGACGAG GAGCTCTGCG GGGGCCTCTG GCGGCTGGTC CTGGCACAGC GCTGGATGGA GCGGCTCAAG ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG TGAACACGGA GATACACTTT GTCACCAAAT GTGCCTTTCA GCCCCCCCCC AGCTGTCTTC GCTTCGTCCA GACCAACATC TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC TGAAGCCCTG GATCACTCGC 15 CAGAACTTCT CCCGGTGCCT GGAGCTGCAG TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT GGGTCAGGAG GTGGGTCAGG AGGTGGATCC GGAGGTGGCT CAGGGGGAGG TAGTGGTACC CAGGACTGCT CCTTCCAACA CAGCCCCATC TCCTCCGACT TCGCTGTCAA AATCCGTGAG CTGTCTGACT ACCTGCTTCA A 20 (2) INFORMACE PRO SEQ ID NO:175: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 869 párů bází (B) TYP: nukleová kyselina 25 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:175: 30 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 35 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CGCCTCCAAC CTGCAGGACG AGGAGCTCTG CGGGGGCCTC TGGCGGCTGG TCCTGGCACA GCGCTGGATG GAGCGGCTCA AGACTGTCGC TGGGTCCAAG ATGCAAGGCT TGCTGGAGCG CGTGAACACG GAGATACACT TTGTCACCAA ATGTGCCTTT 40 CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG GTGGATCCGG AGGTACTGCT CCTTCCAACA CAGCCCCATC TCCTCCGACT TCGCTGTCAA AATCCGTGAG CTGTCTGACT ACCTGCTTCA AGATTACCCA GTCACCGTG 45 (2) INFORMACE PRO SEQ ID NO:176: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 872 párů bází 50 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:176: 55 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 60 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 921 60 120 180 240 300 360 420 480 540 600 660 720 780 840 869 60 120 180 240 300 -503 - CZ 295843 B6 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CGCCTCCAAC CTGCAGGACG AGGAGCTCTG CGGGGGCCTC TGGCGGCTGG TCCTGGCACA GCGCTGGATG GAGCGGCTCA AGACTGTCGC TGGGTCCAAG ATGCAAGGCT TGCTGGAGCG CGTGAACACG GAGATACACT TTGTCACCAA ATGTGCCTTT CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG GTGGATCCGG AGGTGGCACT GCTCCTTCCA ACACAGCCCC ATCTCCTCCG ACTTCGCTGT CAAAATCCGT GAGCTGTCTG ACTACCTGCT TCAAGATTAC CCAGTCACCG TG (2) INFORMACE PRO SEQ ID NO:177: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 890 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:177: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CGCCTCCAAC CTGCAGGACG AGGAGCTCTG CGGGGGCCTC TGGCGGCTGG TCCTGGCACA GCGCTGGATG GAGCGGCTCA AGACTGTCGC TGGGTCCAAG ATGCAAGGCT TGCTGGAGCG CGTGAACACG GAGATACACT TTGTCACCAA ATGTGCCTTT CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG GTGGATCCGG AGGTGGCTCA GGGGGAGGTA GTGGTACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG (2) INFORMACE PRO SEQ ID NO:178: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 917 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:178: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CGCCTCCAAC CTGCAGGACG AGGAGCTCTG CGGGGGCCTC TGGCGGCTGG TCCTGGCACA GCGCTGGATG GAGCGGCTCA AGACTGTCGC TGGGTCCAAG ATGCAAGGCT TGCTGGAGCG CGTGAACACG GAGATACACT TTGTCACCAA ATGTGCCTTT CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG GTGGGTCAGG AGGTGGGTCA GGAGGTGGAT CCGGAGGTGG CTCAGGGGGA GGTAGTGGTA GGACTGCTCC TTCCAACACA 360 420 480 540 600 660 720 780 840 872 60 120 180 240 300 360 420 480 540 600 660 720 780 840 890 60 120 180 240 300 360 420 480 540 600 660 720 780 840 -504- CZ 295843 B6 GCCCCATCTC CTCCGACTTC GCTGTCAAAA TCCGTGAGCT GTCTGACTAC CTGCTTCAAG ATTACCCAGT CACCGTG (2) INFORMACE PRO SEQ ID NO:179: 5 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 876 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché 10 (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:179: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 15 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 20 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CGTCGCTGGG TCCAAGATGC AAGGCTTGCT GGAGCGCGTG AACACGGAGA TACACTTTGT CACCAAATGT GCCTTTCAGC CCCCCCCCAG CTGTCTTCGC TTCGTCCAGA CCAACATCTC CCGCCTCCTG CAGGAGACCT CCGAGCAGCT GGTGGCGCTG AAGCCCTGGA TCACTCGCCA GAACTTCTCC CGGTGCCTGG AGCTGCAGTG TCAGCCCGAC 25 TCCTCAACCC TGGGCGGTGG ATCCGGAGGT ACCCAGGACT GCTCCTTCCA ACACAGCCCC ATCTCCTCCG ACTTCGCTGT CAAAATCCGT GAGCTGTCTG ACTACCTGCT TCAAGATTAC CCAGTCACCG TGGCCTCCAA CCTGCAGGAC GAGGAGCTCT GCGGGGGCCT CTGGCGGCTG GTCCTGGCAC AGCGCTGGAT GGAGCGGCTC AAGACT 30 (2) INFORMACE PRO SEQ ID NO:180: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 879 párů bází (B) TYP: nukleová kyselina 35 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID N0:180: 40 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 45 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CGTCGCTGGG TCCAAGATGC AAGGCTTGCT GGAGCGCGTG AACACGGAGA TACACTTTGT CACCAAATGT GCCTTTCAGC CCCCCCCCAG CTGTCTTCGC TTCGTCCAGA CCAACATCTC CCGCCTCCTG CAGGAGACCT CCGAGCAGCT GGTGGCGCTG 50 AAGCCCTGGA TCACTCGCCA GAACTTCTCC CGGTGCCTGG AGCTGCAGTG TCAGCCCGAC TCCTCAACCC TGGGCGGTGG ATCCGGAGGT GGCACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACT 55 (2) INFORMACE PRO SEQ ID NO:181: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 897 párů bází 60 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché 900 917 60 120 180 240 300 360 420 480 540 600 660 720 780 840 876 60 120 180 240 300 360 420 480 540 600 660 720 780 840 879 -505 - 50 55 CZ 295843 B6 (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:181: 5 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 10 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CGTCGCTGGG TCCAAGATGC AAGGCTTGCT GGAGCGCGTG AACACGGAGA TACACTTTGT CACCAAATGT GCCTTTCAGC CCCCCCCCAG CTGTCTTCGC TTCGTCCAGA CCAACATCTC CCGCCTCCTG CAGGAGACCT CCGAGCAGCT GGTGGCGCTG 15 AAGCCCTGGA TCACTCGCCA GAACTTCTCC CGGTGCCTGG AGCTGCAGTG TCAGCCCGAC TCCTCAACCC TGGGCGGTGG ATCCGGAGGT GGCTCAGGGG GAGGTAGTGG TACCCAGGAC TGCTCCTTCC AACACAGCCC CATCTCCTCC GACTTCGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC TTCAAGATTA CCCAGTCACC GTGGCCTCCA ACCTGCAGGA CGAGGAGCTC TGCGGGGGCC TCTGGCGGCT GGTCCTGGCA CAGCGCTGGA TGGAGCGGCT CAAGACT 20 (2) INFORMACE PRO SEQ ID NO:182: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 921 párů bází 25 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:182: 30 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 35 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CGTCGCTGGG TCCAAGATGC AAGGCTTGCT GGAGCGCGTG AACACGGAGA TACACTTTGT CACCAAATGT GCCTTTCAGC CCCCCCCCAG CTGTCTTCGC 40 TTCGTCCAGA CCAACATCTC CCGCCTCCTG CAGGAGACCT CCGAGCAGCT GGTGGCGCTG AAGCCCTGGA TCACTCGCCA GAACTTCTCC CGGTGCCTGG AGCTGCAGTG TCAGCCCGAC TCCTCAACCC TGGGCGGTGG GTCAGGAGGT GGGTCAGGAG GTGGATCCGG AGGTGGCTCA GGGGGAGGTA GTGGTACCCA GGACTGCTCC TTCCAACACA GCCCCATCTC CTCCGACTTC GCTGTCAAAA TCCGTGAGCT GTCTGACTAC CTGCTTCAAG ATTACCCAGT CACCGTGGCC 45 TCCAACCTGC AGGACGAGGA GCTCTGCGGG GGCCTCTGGC GGCTGGTCCT GGCACAGCGC TGGATGGAGC GGCTCAAGAC T (2) INFORMACE PRO SEQ ID NO:183: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 876 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:183: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 60 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 60 120 180 240 300 360 420 480 540 600 660 720 780 840 897 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 921 60 120 180 -506- 15 20 CZ 295843 B6 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 5 CATAAATCTC CAAACATGGC CCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT GTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG GTGGATCCGG AGGTACCCAG GACTGCTCCT TCCAACACAG CCCCATCTCC TCCGACTTCG CTGTCAAAAT CCGTGAGCTG TCTGACTACC TGCTTCAAGA TTACCCAGTC ACCGTGGCCT CCAACCTGCA GGACGAGGAG 10 CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG GCACAGCGCT GGATGGAGCG GCTCAAGACT GTCGCTGGGT CCAAGATGCA AGGCTTGCTG GAGCGCGTGA ACACGGAGAT ACACTTTGTC ACCAAATGTG CCTTTCAGCC CCCCCCCAGC TGTCTT (2) INFORMACE PRO SEQ ID NO:184: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 879 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:184: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 25 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA. ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 30 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG GTGGATCCGG AGGTGGCACC CAGGACTGCT CCTTCCAACA CAGCCCCATC TCCTCCGACT TCGCTGTCAA AATCCGTGAG 35 CTGTCTGACT ACCTGCTTCA AGATTACCCA GTCACCGTGG CCTCCAACCT GCAGGACGAG GAGCTCTGCG GGGGCCTCTG GCGGCTGGTC CTGGCACAGC GCTGGATGGA GCGGCTCAAG ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG TGAACACGGA GATACACTTT GTCACCAAAT GTGCCTTTCA GCCCCCCCCC AGCTGTCTT 40 (2) INFORMACE PRO SEQ ID NO:185: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 897 párů bází (B) TYP: nukleová kyselina 45 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:185: 50 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 55 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG GTGGATCCGG AGGTGGCTCA 60 GGGGGAGGTA GTGGTACCCA GGACTGCTCC TTCCAACACA GCCCCATCTC CTCCGACTTC GCTGTCAAAA TCCGTGAGCT GTCTGACTAC CTGCTTCAAG ATTACCCAGT CACCGTGGCC 240 300 360 420 480 540 600 660 720 780 840 876 60 120 180 240 300 360 420 480 540 600 660 720 780 840 879 60 120 180 240 300 360 420 480 540 600 660 720 -507- CZ 295843 B6 TCCAACCTGC AGGACGAGGA GCTCTGCGGG GGCCTCTGGC GGCTGGTCCT GGCACAGCGC TGGATGGAGC GGCTCAAGAC TGTCGCTGGG TCCAAGATGC AAGGCTTGCT GGAGCGCGTG AACACGGAGA TACACTTTGT CACCAAATGT GCCTTTCAGC CCCCCCCCAG CTGTCTT 5 (2) INFORMACE PRO SEQ ID NO:186: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 921 párů bází (B) TYP: nukleová kyselina 10 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:186: 15 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 20 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG GTGGGTCAGG AGGTGGGTCA 25 GGAGGTGGAT CCGGAGGTGG CTCAGGGGGA GGTAGTGGTA CCCAGGACTG CTCCTTCCAA CACAGCCCCA TCTCCTCCGA CTTCGCTGTC AAAATCCGTG AGCTGTCTGA CTACCTGCTT CAAGATTACC CAGTCACCGT GGCCTCCAAC CTGCAGGACG AGGAGCTCTG CGGGGGCCTC TGGCGGCTGG TCCTGGCACA GCGCTGGATG GAGCGGCTCA AGACTGTCGC TGGGTCCAAG ATGCAAGGCT TGCTGGAGCG CGTGAACACG GAGATACACT TTGTCACCAA ATGTGCCTTT 30 CAGCCCCCCC CCAGCTGTCT T (2) INFORMACE PRO SEQ ID NO:187: (i) CHARAKTERISTIKY SEKVENCE: 35 (A) DÉLKA: 876 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 40 (xi) POPIS SEKVENCE: SEQ ID NO:187: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 45 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAAGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CACCAACATC TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG 50 CTGGTGGCGC TGAAGCCCTG GATCACTCGC CAGAACTTCT CCCGGTGCCT GGAGCTGCAG TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT GGATCCGGAG GTACCCAGGA CTGCTCCTTC CAACACAGCC CCATCTCCTC CGACTTCGCT GTCAAAATCC GTGAGCTGTC TGACTACCTG CTTCAAGATT ACCCAGTCAC CGTGGCCTCC AACCTGCAGG ACGAGGAGCT CTGCGGGGGC CTCTGGCGGC TGGTCCTGGC ACAGCGCTGG ATGGAGCGGC TCAAGACTGT CGCTGGGTCC 55 AAGATGCAAG GCTTGCTGGA GCGCGTGAAC ACGGAGATAC ACTTTGTCAC CAAATGTGCC TTTCAGCCCC CCCCCAGCTG TCTTCGCTTC GTCCAG (2) INFORMACE PRO SEQ ID NO:188: 60 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 879 párů bází 780 840 897 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 921 60 120 180 240 300 360 420 480 540 600 660 720 780 840 876 -508 - 50 55 CZ 295843 B6 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 5 (xi) POPIS SEKVENCE: SEQ ID NO:188: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 10 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAAGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CACCAACATC TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG 15 CTGGTGGCGC TGAAGCCCTG GATCACTCGC CAGAACTTCT CCCGGTGCCT GGAGCTGCAG TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT GGATCCGGAG GTGGCACCCA GGACTGCTCC TTCCAACACA GCCCCATCTC CTCCGACTTC GCTGTCAAAA TCCGTGAGCT GTCTGACTAC CTGCTTCAAG ATTACCCAGT CACCGTGGCC TCCAACCTGC AGGACGAGGA GCTCTGCGGG GGCCTCTGGC GGCTGGTCCT GGCACAGCGC TGGATGGAGC GGCTCAAGAC TGTCGCTGGG 20 TCCAAGATGC AAGGCTTGCT GGAGCGCGTG AACACGGAGA TACACTTTGT CACCAAATGT GCCTTTCAGC CCCCCCCCAG CTGTCTTCGC TTCGTCCAG (2) INFORMACE PRO SEQ ID NO:189: 25 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 897 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 30 (xi) POPIS SEKVENCE: SEQ ID NO:189: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 35 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAAGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 40 CATAAATCTC CAAACATGGC CACCAACATC TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC TGAAGCCCTG GATCACTCGC CAGAACTTCT CCCGGTGCCT GGAGCTGCAG TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT GGATCCGGAG GTGGCTCAGG GGGAGGTAGT GGTACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 45 GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAG (2) INFORMACE PRO SEQ ID NO:190: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 921 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:190: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 60 120 180 240 300 360 420 480 540 600 660 720 780 840 879 60 120 180 240 300 360 420 480 540 600 660 720 780 840 897 60 120 -509- 60 CZ 295843 B6 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 5 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CACCAACATC TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG 480 CTGGTGGCGC TGAAGCCCTG GATCACTCGC CAGAACTTCT CCCGGTGCCT GGAGCTGCAG 540 TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT GGGTCAGGAG GTGGGTCAGG AGGTGGATCC 600 GGAGGTGGCT CAGGGGGAGG TAGTGGTACC CAGGACTGCT CCTTCCAACA CAGCCCCATC 660 10 TCCTCCGACT TCGCTGTCAA AATCCGTGAG CTGTCTGACT ACCTGCTTCA AGATTACCCA 720 GTCACCGTGG CCTCCAACCT GCAGGACGAG GAGCTCTGCG GGGGCCTCTG GCGGCTGGTC 780 CTGGCACAGC GCTGGATGGA GCGGCTCAAG ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG 840 CTGGAGCGCG TGAACACGGA GATACACTTT GTCACCAAAT GTGCCTTTCA GCCCCCCCCC 900 AGCTGTCTTC GCTTCGTCCA G 921 15 (2) INFORMACE PRO SEQ ID NO:191: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 2247 párů bází 20 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:191: 25 GGATCCACCA TGAGCCGCCT GCCCGTCCTG CTCCTGCTCC AACTCCTGGT CCGCCCCGCC 60 ATGTCTACAA ATCAAGATCT GCCTGTGATC AAGTGTGTTT TAATCAATCA TAAGAACAAT 120 GATTCATCAG TGGGGAAGTC ATCATCATAT CCCATGGTAT CAGAATCCCC GGAAGACCTC 180 GGGTGTGCGT TGAGACCCCA GAGCTCAGGG ACAGTGTACG AAGCTGCCGC TGTGGAAGTG 240 30 GATGTATCTG CTTCCATCAC ACTGCAAGTG CTGGTCGATG CCCCAGGGAA CATTTCCTGT 300 CTCTGGGTCT TTAAGCACAG CTCCCTGAAT TGCCAGCCAC ATTTTGATTT ACAAAACAGA 360 GGAGTTGTTT CCATGGTCAT TTTGAAAATG ACAGAAACCC AAGCTGGAGA ATACCTACTT 420 TTTATTCAGA GTGAAGCTAC CAATTACACA ATATTGTTTA CAGTGAGTAT AAGAAATACC 480 CTGCTTTACA CATTAAGAAG ACCTTACTTT AGAAAAATGG AAAACCAGGA CGCCCTGGTC 540 35 TGCATATCTG AGAGCGTTCC AGAGCCGATC GTGGAATGGG TGCTTTGCGA TTCACAGGGG 600 GAAAGCTGTA AAGAAGAAAG TCCAGCTGTT GTTAAAAAGG AGGAAAAAGT GCTTCATGAA 660 TTATTTGGGA TGGACATAAG GTGCTGTGCC AGAAATGAAC TGGGCAGGGA ATGCACCAGG 720 CTGTTCACAA TAGATCTAAA TCAAACTCCT CAGACCACAT TGCCACAATT ATTTCTTAAA 780 GTAGGGGAAC CCTTATGGAT AAGGTGCAAA GCTGTTCATG TGAACCATGG ATTCGGGCTC 840 40 ACCTGGGAAT TAGAAAACAA AGCACTCGAG GAGGGCAACT ACTTTGAGAT GAGTACCTAT 900 TCAACAAACA GAACTATGAT ACGGATTCTG TTTGCTTTTG TATCATCAGT GGCAAGAAAC 960 GACACCGGAT ACTACACTTG TTCCTCTTCA AAGCATCCCA GTCAATCAGC TTTGGTTACC 1020 ATCGTAGAAA AGGGATTTAT AAATGCTACC AATTCAAGTG AAGATTATGA AATTGACCAA 1080 TATGAAGAGT TTTGTTTTTC TGTCAGGTTT AAAGCCTACC CACAAATCAG ATGTACGTGG 1140 45 ACCTTCTCTC GAAAATCATT TCCTTGTGAG CAAAAGGGTC TTGATAACGG ATACAGCATA 1200 TCCAAGTTTT GCAATCATAA GCACCAGCCA GGAGAATATA TATTCCATGC AGAAAATGAT 1260 GATGCCCAAT TTACCAAAAT GTTCACGCTG AATATAAGAA GGAAACCTCA AGTGCTCGCA 1320 GAAGCATCGG CAAGTCAGGC GTCCTGTTTC TCGGATGGAT ACCCATTACC ATCTTGGACC 1380 TGGAAGAAGT GTTCAGACAA GTCTCCCAAC TGCACAGAAG AGATCACAGA AGGAGTCTGG 1440 50 AATAGAAAGG CTAACAGAAA AGTGTTTGGA CAGTGGGTGT CGAGCAGTAC TCTAAACATG 1500 AGTGAAGCCA TAAAAGGGTT CCTGGTCAAG TGCTGTGCAT ACAATTCCCT TGGCACATCT 1560 TGTGAGACGA TCCTTTTAAA CTCTCCAGGC CCCTTCCCTT TCATCCAAGA CAACGAATTC 1620 ATCATCCTGG GCCTGTTCGG CCTCCTGCTG TTGCTCACCT GCCTCTGTGG AACTGCCTGG 1680 CTCTGTTGCA GCCCCAACAG GAAGAATCCC CTCTGGCCAA GTGTCCCAGA CCCAGCTCAC 1740 55 AGCAGCCTGG GCTCCTGGGT GCCCACAATC ATGGAGGAGG ATGCCTTCCA GCTGCCCGGC 1800 CTTGGCACGC CACCCATCAC CAAGCTCACA GTGCTGGAGG AGGATGAAAA GAAGCCGGTG 1860 CCCTGGGAGT CCCATAACAG CTCAGAGACC TGTGGCCTCC CCACTCTGGT CCAGACCTAT 1920 GTGCTCCAGG GGGACCCAAG AGCAGTTTCC ACCCAGCCCC AATCCCAGTC TGGCACCAGC 1980 GATCAGGTCC TTTATGGGCA GCTGCTGGGC AGCCCCACAA GCCCAGGGCC AGGGCACTAT 2040 60 CTCCGCTGTG ACTCCACTCA GCCCCTCTTG GCGGGCCTCA CCCCCAGCCC CAAGTCCTAT 2100 GAGAACCTCT GGTTCCAGGC CAGCCCCTTG GGGACCCTGG TAACCCCAGC CCCAAGCCAG 2160 -510- CZ 295843 B6 GAGGACGACT GTGTCTTTGG GCCACTGCTC AACTTCCCCC TCCTGCAGGG GATCCGGGTC CATGGGATGG AGGCGCTGGG GAGCTTC (2) INFORMACE PRO SEQ ID NO:192: 5 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1047 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché 10 (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:192: GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG 15 CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG 20 CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCTACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AAACATGGCC ACCCAGGACT GCTCCTTCCA ACACAGCCCC 25 ATCTCCTCCG ACTTCGCTGT CAAAATCCGT GAGCTGTCTG ACTACCTGCT TCAAGATTAC CCAGTCACCG TGGCCTCCAA CCTGCAGGAC GAGGAGCTCT GCGGGGGCCT CTGGCGGCTG GTCCTGGCAC AGCGCTGGAT GGAGCGGCTC AAGACTGTCG CTGGGTCCAA GATGCAAGGC TTGCTGGAGC GCGTGAACAC GGAGATACAC TTTGTCACCA AATGTGCCTT TCAGCCCCCC CCCAGCTGTC TTCGCTTCGT CCAGACCAAC ATCTCCCGCC TCCTGCAGGA GACCTCCGAG 30 CAGCTGGTGG CGCTGAAGCC CTGGATCACT CGCCAGAACT TCTCCCGGTG CCTGGAGCTG CAGTGTCAGC CCGACTCCTC AACCCTG (2) INFORMACE PRO SEQ ID NO:193: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 942 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:193: GCCACTCAGG ACTGCTCTTT TCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 45 GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC AGCCCGACTC CTCAACCCTG 50 TACGTAGAGG GCGGTGGAGG CTCCCCGGGT GAACCGTCTG GTCCAATCTC TACTATCAAC CCGTCTCCTC CGTCTAAAGA ATCTCATAAA TCTCCAAACA TGGCTACCCA GGACTGCTCC TTCCAACACA GCCCCATCTC CTCCGACTTC GCTGTCAAAA TCCGTGAGCT GTCTGACTAC CTGCTTCAAG ATTACCCAGT CACCGTGGCC TCCAACCTGC AGGACGAGGA GCTCTGCGGG GGCCTCTGGC GGCTGGTCCT GGCACAGCGC TGGATGGAGC GGCTCAAGAC TGTCGCTGGG 55 TCCAAGATGC AAGGCTTGCT GGAGCGCGTG AACACGGAGA TACACTTTGT CACCAAATGT GCCTTTCAGC CCCCCCCCAG CTGTCTTCGC TTCGTCCAGA CCAACATCTC CCGCCTCCTG CAGGAGACCT CCGAGCAGCT GGTGGCGCTG AAGCCCTGGA TCACTCGCCA GAACTTCTCC CGGTGCCTGG AGCTGCAGTG TCAGCCCGAC TCCTCAACCC TG 2220 2247 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1047 35 40 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 942 -511 - CZ 295843 B6 (2) INFORMACE PRO SEQ ID NO:194: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1047 párů bází 5 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:194: 10 GCCACCCAGG ACTGCTCCTT TCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA 15 CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCATGGATC ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC AGCCCGACTC CTCAACCCTG TACGTAGAGG GCGGTGGAGG CTCCCCGGGT GAACCGTCTG GTCCAATCTC TACTATCAAC CCGTCTCCTC CGTCTAAAGA ATCTCATAAA TCTCCAAACA TGGCTACACC ATTAGGCCCT 20 GCCAGCTCCC TGCCCCAGAG CTTCCTGCTC AAGTGCTTAG AGCAAGTGAG GAAGATCCAG GGCGATGGCG CAGCGCTCCA GGAGAAGCTG TGTGCCACCT ACAAGCTGTG CCACCCCGAG GAGCTGGTGC TGCTCGGACA CTCTCTGGGC ATCCCCTGGG CTCCCCTGAG CTCCTGCCCC AGCCAGGCCC TGCAGCTGGC AGGCTGCTTG AGCCAACTCC ATAGCGGCCT TTTCCTCTAC CAGGGGCTCC TGCAGGCCCT GGAAGGGATA TCCCCCGAGT TGGGTCCCAC CTTGGACACA 25 CTGCAGCTGG ACGTCGCCGA CTTTGCCACC ACCATCTGGC AGCAGATGGA AGAACTGGGA ATGGCCCCTG CCCTGCAGCC CACCCAGGGT GCCATGCCGG CCTTCGCCTC TGCTTTCCAG CGCCGGGCAG GAGGGGTCCT GGTTGCTAGC CATCTGCAGA GCTTCCTGGA GGTGTCGTAC CGCGTTTTAC GCCACCTTGC GCAGCCC 30 (2) INFORMACE PRO SEQ ID NO:195: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1569 párů bází (B) TYP: nukleová kyselina 35 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:195: 40 GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG 45 GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCTACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 50 AAAGAATCTC ATAAATCTCC AAACATGGCC ACTCAGGACT GCTCTTTTCA ACACAGCCCC ATCTCCTCCG ACTTCGCTGT CAAAATCCGT GAGCTGTCTG ACTACCTGCT TCAAGATTAC CCAGTCACCG TGGCCTCCAA CCTGCAGGAC GAGGAGCTCT GCGGGGGCCT CTGGCGGCTG GTCCTGGCAC AGCGCTGGAT GGAGCGGCTC AAGACTGTCG CTGGGTCCAA GATGCAAGGC TTGCTGGAGC GCGTGAACAC GGAGATACAC TTTGTCACCA AATGTGCCTT TCAGCCCCCC 55 CCCAGCTGTC TTCGCTTCGT CCAGACCAAC ATCTCCCGCC TCCTGCAGGA GACCTCCGAG CAGCTGGTGG CGCTGAAGCC CTGGATCACT CGCCAGAACT TCTCCCGGTG CCTGGAGCTG CAGTGTCAGC CCGACTCCTC AACCCTGTAC GTAGAGGGCG GTGGAGGCTC CCCGGGTGAA CCGTCTGGTC CAATCTCTAC TATCAACCCG TCTCCTCCGT CTAAAGAATC TCATAAATCT CCAAACATGG CTACCCAGGA CTGCTCCTTC CAACACAGCC CCATCTCCTC CGACTTCGCT 60 GTCAAAATCC GTGAGCTGTC TGACTACCTG CTTCAAGATT ACCCAGTCAC CGTGGCCTCC AACCTGCAGG ACGAGGAGCT CTGCGGGGGC CTCTGGCGGC TGGTCCTGGC ACAGCGCTGG 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1047 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1140 1200 1260 1320 -512- CZ 295843 B6 ATGGAGCGGC TCAAGACTGT CGCTGGGTCC AAGATGCAAG GCTTGCTGGA GCGCGTGAAC ACGGAGATAC ACTTTGTCAC CAAATGTGCC TTTCAGCCCC CCCCCAGCTG TCTTCGCTTC GTCCAGACCA ACATCTCCCG CCTCCTGCAG GAGACCTCCG AGCAGCTGGT GGCGCTGAAG CCCTGGATCA CTCGCCAGAA CTTCTCCCGG TGCCTGGAGC TGCAGTGTCA GCCCGACTCC 5 TCAACCCTG (2) INFORMACE PRO SEQ ID NO:196: (i) CHARAKTERISTIKY SEKVENCE: 10 (A) DÉLKA: 1380 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 15 (xi) POPIS SEKVENCE: SEQ ID NO:196: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 20 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CACTCAGGAC TGCTCTTTTC AACACAGCCC CATCTCCTCC 25 GACTTCGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC TTCAAGATTA CCCAGTCACC GTGGCCTCCA ACCTGCAGGA CGAGGAGCTC TGCGGGGGCC TCTGGCGGCT GGTCCTGGCA CAGCGCTGGA TGGAGCGGCT CAAGACTGTC GCTGGGTCCA AGATGCAAGG CTTGCTGGAG CGCGTGAACA CGGAGATACA CTTTGTCACC AAATGTGCCT TTCAGCCCCC CCCCAGCTGT CTTCGCTTCG TCCAGACCAA CATCTCCCGC CTCCTGCAGG AGACCTCCGA GCAGCTGGTG 30 GCGCTGAAGC CCTGGATCAC TCGCCAGAAC TTCTCCCGGT GCCTGGAGCT GCAGTGTCAG CCCGACTCCT CAACCCTGTA CGTAGAGGGC GGTGGAGGCT CCCCGGGTGA ACCGTCTGGT CCAATCTCTA CTATCAACCC GTCTCCTCCG TCTAAAGAAT CTCATAAATC TCCAAACATG GCTACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 35 GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC AGCCCGACTC CTCAACCCTG 40 (2) INFORMACE PRO SEQ ID NO:197: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1569 párů bází 45 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:197: 50 GCCACTCAGG ACTGCTCTTT. TCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA 55 CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC AGCCCGACTC CTCAACCCTG TACGTAGAGG GCGGTGGAGG CTCCCCGGGT GAACCGTCTG GTCCAATCTC TACTATCAAC CCGTCTCCTC CGTCTAAAGA ATCTCATAAA TCTCCAAACA TGGCTACACC ATTGGGCCCT 60 GCCAGCTCCC TGCCCCAGAG CTTCCTGCTC AAGTCTTTAG AGCAAGTGAG AAAGATCCAG GGCGATGGCG CAGCGCTCCA GGAGAAGCTG TGTGCCACCT ACAAGCTGTG CCACCCCGAG 1380 1440 1500 1560 1569 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1140 1200 1260 1320 1380 60 120 180 240 300 360 420 480 540 600 660 -513- 20 25 CZ 295843 B6 GAGCTGGTGC TGCTCGGACA CTCTCTGGGC ATCCCCTGGG CTCCCCTGAG CTCCTGCCCC AGCCAGGCCC TGCAGCTGGC AGGCTGCTTG AGCCAACTCC ATAGCGGCCT TTTCCTCTAC CAGGGGCTCC TGCAGGCCCT GGAAGGGATA TCCCCCGAGT TGGGTCCCAC CTTGGACACA CTGCAGCTGG ACGTCGCCGA CTTTGCCACC ACCATCTGGC AGCAGATGGA AGAACTGGGA 5 ATGGCCCCTG CCCTGCAGCC CACCCAGGGT GCCATGCCGG CCTTCGCCTC TGCTTTCCAG CGCCGGGCAG GAGGGGTCCT GGTTGCTAGC CATCTGCAGA GCTTCCTGGA GGTGTCGTAC CGCGTTCTAC GCCACCTTGC GCAGCCCTAC GTAGAGGGCG GTGGAGGCTC CCCGGGTGAA CCGTCTGGTC CAATCTCTAC TATCAACCCG TCTCCTCCGT CTAAAGAATC TCATAAATCT CCAAACATGG CTACCCAGGA CTGCTCCTTC CAACACAGCC CCATCTCCTC CGACTTCGCT 10 GTCAAAATCC GTGAGCTGTC TGACTACCTG CTTCAAGATT ACCCAGTCAC CGTGGCCTCC AACCTGCAGG ACGAGGAGCT CTGCGGGGGC CTCTGGCGGC TGGTCCTGGC ACAGCGCTGG ATGGAGCGGC TCAAGACTGT CGCTGGGTCC AAGATGCAAG GCTTGCTGGA GCGCGTGAAC ACGGAGATAC ACTTTGTCAC CAAATGTGCC TTTCAGCCCC CCCCCAGCTG TCTTCGCTTC GTCCAGACCA ACATCTCCCG CCTCCTGCAG GAGACCTCCG AGCAGCTGGT GGCGCTGAAG 15 CCCTGGATCA CTCGCCAGAA CTTCTCCCGG TGCCTGGAGC TGCAGTGTCA GCCCGACTCC TCAACCCTG (2) INFORMACE PRO SEQ ID NO:198: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1003 párů bázi (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:198: GGCCACTCAG GACTGCTCTT TTCAACACAG CCCCATCTCC TCCGACTTCG CTGTCAAAAT CCGTGAGCTG TCTGACTACC TGCTTCAAGA TTACCCAGTC ACCGTGGCCT CCAACCTGCA 30 GGACGAGGAG CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG GCACAGCGCT GGATGGAGCG GCTCAAGACT GTCGCTGGGT CCAAGATGCA AGGCTTGCTG GAGCGCGTGA ACACGGAGAT ACACTTTGTC ACCAAATGTG CCTTTCAGCC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT 35 GTACGTAGAG GGCGGTGGAG GCTCCCCGGG TGGTGGTTCT GGCGGCGGCT CCAACATGGC TACACCATTG GGCCCTGCCA GCTCCCTGCC CCAGAGCTTC CTGCTCAAGT CTTTAGAGCA AGTGAGAAAG ATCCAGGGCG ATGGCGCAGC GCTCCAGGAG AAGCTGTGTG CCACCTACAA GCTGTGCCAC CCCGAGGAGC TGGTGCTGCT CGGACACTCT CTGGGCATCC CCTGGGCTCC CCTGAGCTCC TGCCCCAGCC AGGCCCTGCA GCTGGCAGGC TGCTTGAGCC AACTCCATAG 40 CGGCCTTTTC CTCTACCAGG GGCTCCTGCA GGCCCTGGAA GGGATATCCC CCGAGTTGGG TCCCACCTTG GACACACTGC AGCTGGACGT CGCCGACTTT GCCACCACCA TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCT GCAGCCCACC CAGGGTGCCA TGCCGGCCTT CGCCTCTGCT TTCCAGCGCC GGGCAGGAGG GGTCCTGGTT GCTAGCCATC TGCAGAGCTT CCTGGAGGTG TCGTACCGCG TTCTACGCCA CCTTGCGCAG CCG 45 (2) INFORMACE PRO SEQ ID NO:199: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 888 párů bází 50 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:199: 55 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 60 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 720 780 840 900 960 1020 1080 1140 1200 1260 1320 1380 1440 1500 1560 1569 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1003 60 120 180 240 300 360 -514- 40 45 CZ 295843 B6 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CGATTACCCA GTCACCGTGG CCTCCAACCT GCAGGACGAG GAGCTCTGCG GGGGCCTCTG GCGGCTGGTC CTGGCACAGC GCTGGATGGA GCGGCŤCAAG ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG TGAACACGGA GATACACTTT 5 GTCACCAAAT GTGCCTTTCA GCCCCCCCCC AGCTGTCTTC GCTTCGTCCA GACCAACATC TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC TGAAGCCCTG GATCACTCGC CAGAACTTCT CCCGGTGCCT GGAGCTGCAG TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT GGGTCAGGAG GTGGATCCGG AGGTACCCAG GACTGCTCCT TCCAACACAG CCCCATCTCC TCCGACTTCG CTGTCAAAAT CCGTGAGCTG TCTGACTACC TGCTTCAA 10 (2) INFORMACE PRO SEQ ID NO:200: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 903 párů bází 15 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:200: 20 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 25 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CGATTACCCA GTCACCGTGG CCTCCAACCT GCAGGACGAG GAGCTCTGCG GGGGCCTCTG GCGGCTGGTC CTGGCACAGC GCTGGATGGA GCGGCŤCAAG 30 ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG TGAACACGGA GATACACTTT GTCACCAAAT GTGCCTTTCA GCCCCCCCCC AGCTGTCTTC GCTTCGTCCA GACCAACATC TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC TGAAGCCCTG GATCACTCGC CAGAACTTCT CCCGGTGCCT GGAGCTGCAG TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT GGGTCAGGAG GTGGGTCAGG AGGTGGATCC GGAGGTGGCA CCCAGGACTG CTCCTTCCAA 35 CACAGCCCCA TCTCCTCCGA CTTCGCTGTC AAAATCCGTG AGCTGTCTGA CTACCTGCTT CAA (2) INFORMACE PRO SEQ ID NO:201: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 888 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:201: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 50 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 55 CATAAATCTC CAAACATGGC CGCCTCCAAC CTGCAGGACG AGGAGCTCTG CGGGGGCCTC TGGCGGCTGG TCCTGGCACA GCGCTGGATG GAGCGGCTCA AGACTGTCGC TGGGTCCAAG ATGCAAGGCT TGCTGGAGCG CGTGAACACG GAGATACACT TTGTCACCAA ATGTGCCTTT CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC 60 CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG GTGGGTCAGG AGGTGGATCC GGAGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 420 480 540 600 660 720 780 840 888 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 903 60 120 180 240 300 360 420 480 540 600 660 720 780 840 -515- 888 5 CZ 295843 B6 ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTG (2) INFORMACE PRO SEQ ID NO:202: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 903 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 10 (xi) POPIS SEKVENCE: SEQ ID NO:202: GCTAACTGCT CTATAATGAT CGATGAAATT TTGCTGGACC CGAACAACCT CAATTCTGAA 15 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG ATTGAGGCAA TTCTTCGTAA TCTCCAACCA CGACATCCAA TCATCATCAA GGCAGGTGAC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CCGGGTGAAC CGTCTGGTCC AATCTCTACT 20 CATAAATCTC CAAACATGGC CGCCTCCAAC TGGCGGCTGG TCCTGGCACA GCGCTGGATG ATGCAAGGCT TGCTGGAGCG CGTGAACACG CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC 25 CTGGAGCTGC AGTGTCAGCC CGACTCCTCA GGAGGTGGAT CCGGAGGTGG CACCCAGGAC GACTTCGCTG TCAAAATCCG TGAGCTGTCT GTG ATACATCACT TAAAGAGACC ACCTAACCCT 60 GACATGGATA TCCTGATGGA ACGAAACCTT 120 GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 CAACAGTACG TAGAAGGCGG TGGAGGCTCC 360 ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CTGCAGGACG AGGAGCTCTG CGGGGGCCTC 480 GAGCGGCTCA AGACTGTCGC TGGGTCCAAG 540 GAGATACACT TTGTCACCAA ATGTGCCTTT 600 CAGACCAACA TCTCCCGCCT CCTGCAGGAG 660 TGGATCACTC GCCAGAACTT CTCCCGGTGC 720 ACCCTGGGCG GTGGGTCAGG AGGTGGGTCA 780 TGCTCCTTCC AACACAGCCC CATCTCCTCC 840 GACTACCTGC TTCAAGATTA CCCAGTCACC 900 903 30 (2) INFORMACE PRO SEQ ID NO:203: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 888 párů bází (B) TYP: nukleová kyselina 35 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:203: 40 GCTAACTGCT CTATAATGAT CGATGAAATT TTGCTGGACC CGAACAACCT CAATTCTGAA CGAACTCCAA ACCTGCTCGC ATTCGTAAGG ATTGAGGCAA TTCTTCGTAA TCTCCAACCA CGACATCCAA TCATCATCAA GGCAGGTGAC 45 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CCGGGTGAAC CGTCTGGTCC AATCTCTACT CATAAATCTC CAAACATGGC CGTCGCTGGG AACACGGAGA TACACTTTGT CACCAAATGT TTCGTCCAGA CCAACATCTC CCGCCTCCTG 50 AAGCCCTGGA TCACTCGCCA GAACTTCTCC TCCTCAACCC TGGGCGGTGG GTCAGGAGGT CAACACAGCC CCATCTCCTC CGACTTCGCT CTTCAAGATT ACCCAGTCAC CGTGGCCTCC CTCTGGCGGC TGGTCCTGGC ACAGCGCTGG 55 (2) INFORMACE PRO SEQ II ATACATCACT TAAAGAGACC ACCTAACCCT 60 GACATGGATA TCCTGATGGA ACGAAACCTT 120 GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 TCCAAGATGC AAGGCTTGCT GGAGCGCGTG 480 GCCTTTCAGC CCCCCCCCAG CTGTCTTCGC 540 CAGGAGACCT CCGAGCAGCT GGTGGCGCTG 600 CGGTGCCTGG AGCTGCAGTG TCAGCCCGAC 660 GGATCCGGAG GTACCCAGGA CTGCTCCTTC 720 GTCAAAATCC GTGAGCTGTC TGACTACCTG 780 AACCTGCAGG ACGAGGAGCT CTGCGGGGGC 840 ATGGAGCGGC TCAAGACT 888 ) NO:204: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 903 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché -516- 60 50 55 CZ 295843 B6 (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:204: 5 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 10 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CGTCGCTGGG TCCAAGATGC AAGGCTTGCT GGAGCGCGTG AACACGGAGA TACACTTTGT CACCAAATGT GCCTTTCAGC CCCCCCCCAG CTGTCTTCGC TTCGTCCAGA CCAACATCTC CCGCCTCCTG CAGGAGACCT CCGAGCAGCT GGTGGCGCTG 15 AAGCCCTGGA TCACTCGCCA GAACTTCTCC CGGTGCCTGG AGCTGCAGTG TCAGCCCGAC TCCTCAACCC TGGGCGGTGG GTCAGGAGGT GGGTCAGGAG GTGGATCCGG AGGTGGCACC CAGGACTGCT CCTTCCAACA CAGCCCCATC TCCTCCGACT TCGCTGTCAA AATCCGTGAG CTGTCTGACT ACCTGCTTCA AGATTACCCA GTCACCGTGG CCTCCAACCT GCAGGACGAG GAGCTCTGCG GGGGCCTCTG GCGGCTGGTC CTGGCACAGC GCTGGATGGA GCGGCTCAAG 20 ACT (2) INFORMACE PRO SEQ ID NO:205: (i) CHARAKTERISTIKY SEKVENCE: 25 (A) DÉLKA: 888 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 30 (xi) POPIS SEKVENCE: SEQ ID NO:205: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 35 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG 40 ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG GTGGGTCAGG AGGTGGATCC GGAGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG CAGGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 45 CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTT (2) INFORMACE PRO SEQ ID NO:206: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 903 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:206: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 60 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 903 60 120 180 240 300 360 420 480 540 600 660 720 780 840 888 60 120 180 240 -517- 15 20 CZ 295843 B6 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG 5 ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG GTGGGTCAGG AGGTGGGTCA GGAGGTGGAT CCGGAGGTGG CACCCAGGAC TGCTCCTTCC AACACAGCCC CATCTCCTCC GACTTCGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC TTCAAGATTA CCCAGTCACC GTGGCCTCCA ACCTGCAGGA CGAGGAGCTC TGCGGGGGCC TCTGGCGGCT GGTCCTGGCA 10 CAGCGCTGGA TGGAGCGGCT CAAGACTGTC GCTGGGTCCA AGATGCAAGG CTTGCTGGAG CGCGTGAACA CGGAGATACA CTTTGTCACC AAATGTGCCT TTCAGCCCCC CCCCAGCTGT CTT (2) INFORMACE PRO SEQ ID NO:207: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 888 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:207: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 25 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAAGCTCC 30 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CACCAACATC TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC TGAAGCCCTG GATCACTCGC CAGAACTTCT CCCGGTGCCT GGAGCTGCAG TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT GGGTCAGGAG GTGGATCCGG AGGTACCCAG GACTGCTCCT TCCAACACAG CCCCATCTCC TCCGACTTCG CTGTCAAAAT CCGTGAGCTG 35 TCTGACTACC TGCTTCAAGA TTACCCAGTC ACCGTGGCCT CCAACCTGCA GGACGAGGAG CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG GCACAGCGCT GGATGGAGCG GCTCAAGACT GTCGCTGGGT CCAAGATGCA AGGCTTGCTG GAGCGCGTGA ACACGGAGAT ACACTTTGTC ACCAAATGTG CCTTTCAGCC CCCCCCCAGC TGTCTTCGCT TCGTCCAG 40 (2) INFORMACE PRO SEQ ID NO:208: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 903 párů bází (B) TYP: nukleová kyselina 45 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:208: 50 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 55 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CACCAACATC TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC TGAAGCCCTG GATCACTCGC CAGAACTTCT CCCGGTGCCT GGAGCTGCAG TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT GGGTCAGGAG GTGGGTCAGG AGGTGGATCC 60 GGAGGTGGCA CCCAGGACTG CTCCTTCCAA CACAGCCCCA TCTCCTCCGA CTTCGCTGTC AAAATCCGTG AGCTGTCTGA CTACCTGCTT CAAGATTACC CAGTCACCGT GGCCTCCAAC 300 360 420 480 540 600 660 720 780 840 900 903 60 120 180 240 300 360 420 480 540 600 660 720 780 840 888 60 120 180 240 300 360 420 480 540 600 660 720 -518- 35 40 CZ 295843 B6 CTGCAGGACG AGGAGCTCTG CGGGGGCCTC TGGCGGCTGG TCCTGGCACA GCGCTGGATG GAGCGGCTCA AGACTGTCGC TGGGTCCAAG ATGCAAGGCT TGCTGGAGCG CGTGAACACG GAGATACACT TTGTCACCAA ATGTGCCTTT CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC CAG 5 (2) INFORMACE PRO SEQ ID NO:209: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 921 párů bází 10 (B) TYP: nukleová kyselina (C) ŘETĚZENI: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:209: 15 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 20 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC TTCTAATCTG CAAGATGAAG AGCTGTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG 25 CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCTC AGGGGGAGGT AGTGGTACCC AGGACTGCTC CTTCCAACAC 30 AGCCCCATCT CCTCCGACTT CGCTGTCAAA ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC C (2) INFORMACE PRO SEQ ID NO:210: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 921 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:210: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 45 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 50 CATAAATCTC CAAACATGGC CAACCTGCAA GATGAAGAGC TGTGTGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG 55 CTGCAGTGTC AGCCCGACTC CTCAACCCTG GGCGGTGGGT CAGGAGGTGG GTCAGGAGGT GGATCCGGAG GTGGCTCAGG GGGAGGTAGT GGTACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC C 780 840 900 903 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 921 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 921 -519- CZ 295843 B6 (2) INFORMACE PRO SEQ ID NO:211: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 921 párů bázi 5 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:211: 10 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 15 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC TCTGCAGGAT GAGGAACTGT GCGGCGGCCT CTGGCGGCTG GTCCTGGCAC AGCGCTGGAT GGAGCGGCTC AAGACTGTCG CTGGGTCCAA GATGCAAGGC 20 TTGCTGGAGC GCGTGAACAC GGAGATACAC TTTGTCACCA AATGTGCTTT TCAGCCCCCC CCCAGCTGTC TTCGCTTCGT CCAGACCAAC ATCTCCCGCC TCCTGCAGGA GACCTCCGAG CAGCTGGTGG CGCTGAAGCC CTGGATCACT CGCCAGAACT TCTCCCGGTG CCTGGAGCTG CAGTGTCAGC CCGACTCCTC AACCCTGGGC GGTGGGTCAG GAGGTGGGTC AGGAGGTGGA TCCGGAGGTG GCTCAGGGGG AGGTAGTGGT ACCCAGGACT GCTCCTTCCA ACACAGCCCC 25 ATCTCCTCCG ACTTCGCTGT CAAAATCCGT GAGCTGTCTG ACTACCTGCT TCAAGATTAC CCAGTCACCG TGGCCTCCAA C (2) INFORMACE PRO SEQ ID NO:212: 30 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 921 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 35 (xi) POPIS SEKVENCE: SEQ ID NO:212: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 40 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 45 CATAAATCTC CAAACATGGC TCAAGATGAA GAGCTGTGTG GTGGTCTCTG GCGGCTGGTC CTGGCACAGC GCTGGATGGA GCGGCTCAAG ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG TGAACACGGA GATACACTTT GTCACCAAAT GTGCCTTTCA GCCCCCCCCC AGCTGTCTTC GCTTCGTCCA GACCAACATC TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC TGAAGCCCTG GATCACTCGC CAGAACTTCT CCCGGTGCCT GGAGCTGCAG 50 TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT GGGTCAGGAG GTGGGTCAGG AGGTGGATCC GGAGGTGGCT CAGGGGGAGG TAGTGGTACC CAGGACTGCT CCTTCCAACA CAGCCCCATC TCCTCCGACT TCGCTGTCAA AATCCGTGAG CTGTCTGACT ACCTGCTTCA AGATTACCCA GTCACCGTGG CCTCCAACCT G 55 (2) INFORMACE PRO SEQ ID NO:213: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 921 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 921 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 921 - 520- 60 CZ 295843 B6 (xi) POPIS SEKVENCE: SEQ ID NO:213: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 5 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 10 CATAAATCTC CAAACATGGC TGAAGAACTG TGTGGTGGTC TGTGGCGGCT GGTCCTGGCA CAGCGCTGGA TGGAGCGGCT CAAGACTGTC GCTGGGTCCA AGATGCAAGG CTTGCTGGAG CGCGTGAACA CGGAGATACA CTTTGTCACC AAATGTGCCT TTCAGCCCCC CCCCAGCTGT CTTCGCTTCG TCCAGACCAA CATCTCCCGC CTCCTGCAGG AGACCTCCGA GCAGCTGGTG GCGCTGAAGC CCTGGATCAC TCGCCAGAAC TTCTCCCGGT GCCTGGAGCT GCAGTGTCAG 15 CCCGACTCCT CAACCCTGGG CGGTGGGTCA GGAGGTGGGT CAGGAGGTGG ATCCGGAGGT GGCTCAGGGG GAGGTAGTGG TACCCAGGAC TGCTCCTTCC AACACAGCCC CATCTCCTCC GACTTCGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC TTCAAGATTA CCCAGTCACC GTGGCCTCCA ACCTGCAGGA C 20 (2) INFORMACE PRO SEQ ID NO:214: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 921 párů bází (B) TYP: nukleová kyselina 25 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:214: 30 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 35 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC TGAGCTGTGT GGTGGCCTGT GGCGTCTGGT CCTGGCACAG CGCTGGATGG AGCGGCTCAA GACTGTCGCT GGGTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG AGATACACTT TGTCACCAAA TGTGCCTTTC AGCCCCCCCC CAGCTGTCTT 40 CGCTTCGTCC AGACCAACAT CTCCCGCCTC CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG CTGAAGCCCT GGATCACTCG CCAAAACTTC TCCCGGTGCC TGGAGCTGCA GTGTCAGCCC GACTCCTCAA CCCTGGGCGG TGGGTCAGGA GGTGGGTCAG GAGGTGGATC CGGAGGTGGC TCAGGGGGAG GTAGTGGTAC CCAGGACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG 45 GCCTCCAACC TGCAGGACGA G (2) INFORMACE PRO SEQ ID NO:215: (i) CHARAKTERISTIKY SEKVENCE: 50 (A) DÉLKA: 921 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 55 (xi) POPIS SEKVENCE: SEQ ID NO:215: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 921 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 921 60 120 180 -521 - 60 CZ 295843 B6 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 5 CATAAATCTC CAAACATGGC TCTGTGCGGT GGTCTGTGGC GTCTGGTCCT GGCACAGCGC TGGATGGAGC GGCTCAAGAC TGTCGCTGGG TCCAAGATGC AAGGCTTGCT GGAGCGCGTG AACACGGAGA TACACTTTGT CACCAAATGT GCCTTTCAGC CCCCCCCCAG CTGTCTTCGC TTCGTCCAGA CCAACATCTC CCGCCTCCTG CAGGAGACCT CCGAGCAGCT GGTGGCGCTG AAGCCCTGGA TCACTCGCCA GAACTTCTCC CGGTGCCTGG AGCTGCAGTG TCAGCCCGAC 10 TCCTCAACCC TGGGCGGTGG GTCAGGAGGT GGGTCAGGAG GTGGATCCGG AGGTGGCTCA GGGGGAGGTA GTGGTACCCA GGACTGCTCC TTCCAACACA GCCCCATCTC CTCCGACTTC GCTGTCAAAA TCCGTGAGCT GTCTGACTAC CTGCTTCAAG ATTACCCAGT CACCGTGGCC TCCAACCTGC AGGACGAGGA G 15 (2) INFORMACE PRO SEQ ID NO:216: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 921 párů bázi (B) TYP: nukleová kyselina 20 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:216: 25 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 30 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC TTCTAATCTG CAAGATGAAG AGCTGTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG 35 CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCTC AGGGGGAGGT AGTGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTC CGCTGTCAAA ATCCGTGAGC TGTCTGACTA CCTGCTTCAA 40 GATTACCCAG TCACCGTGGC C (2) INFORMACE PRO SEQ ID NO:217: (i) CHARAKTERISTIKY SEKVENCE: 45 (A) DÉLKA: 921 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 50 (xi) POPIS SEKVENCE: SEQ ID NO:217: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 55 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC TCAAGATGAA GAACTGTGCG GTGGTCTCTG GCGGCTGGTC 60 CTGGCACAGC GCTGGATGGA GCGGCTCAAG ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG TGAACACGGA GATACACTTT GTCACCAAAT GTGCCTTTCA GCCCCCCCCC 240 300 360 420 480 540 600 660 720 780 840 900 921 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 921 60 120 180 240 300 360 420 480 540 600 -522- 5 CZ 295843 B6 AGCTGTCTTC CCGGTGGCGC TGTCAGCCCG GGAGGTGGCT TCCTCCGACT GTCACCGTGG GCTTCGTCCA TGAAGCCCTG ACTCCTCAAC CAGGGGGAGG TCGCTGTCAA CCTCCAACCT GACCAACATC GATCACTCGC CCTGGGCGGT TAGTGGTACC AATCCGTGAG G TCCCGCCTCC CAGAACTTCT GGGTCAGGAG CAGGACTGCT CTGTCTGACT TGCGGGAGAC CCCGGTGCCT GTGGGTCAGG CCTTCCAACA ACCTGCTTCA CTCCGAGCAG GGAGCTGCAG AGGTGGATCC CAGCCCCATC AGATTACCCA 660 720 780 840 900 921 10 15 (2) INFORMACE PRO SEQ ID NO:218: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 921 párů bázi (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:218: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 20 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 25 CATAAATCTC CAAACATGGC TCTGTGCGGT GGTCTGTGGC GTCTGGTCCT GGCACAGCGC TGGATGGAGC GGCTCAAGAC TGTCGCTGGG TCCAAGATGC AAGGCTTGCT GGAGCGCGTG AACACGGAGA TACACTTTGT CACCAAATGT GCCTTTCAGC CCCCCCCCAG CTGTCTTCGC TTCGTCCAGA CCAACATCTC CCGCCTCCTG CAGGAGACCT CCGAGCAGCT GGTGGCGCTG AAGCCCTGGA TCACTCGCCA GAACTTCTCC CGGTGCCTGG AGCTGCAGTG TCGGCCCGAC 30 TCCTCAACCC TGGGCGGTGG GTCAGGAGGT GGGTCAGGAG GTGGATCCGG AGGTGGCTCA GGGGGAGGTA GTGGTACCCA GGACTGCTCC TTCCAACACA GCCCCATCTC CTCCGACTTC GCTGTCAAGA TCCGTGAGCT GTCTGACTAC CTGCTTCAAG ATTACCCAGT CACCGTGGCC TCCAACCTGC AGGACGAGGA G 35 (2) INFORMACE PRO SEQ ID NO:219: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 906 párů bází (B) TYP: nukleová kyselina 40 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:219: 45 GCTGATGAAG AACTGTGTGG TGGTCTGTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 50 CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCTC AGGGGGAGGT AGTGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGTA CGTAGAGGGC GGTGGAGGCT CCCCGGGTGA ACCGTCTGGT CCAATCTCTA CTATCAACCC GTCTCCTCCG TCTAAAGAAT CTCATAAATC TCCAAACATG GCTAACTGCT CTATAATGAT CGATGAAATT 55 ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA 60 CAACAG 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 921 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 906 -523 - 55 CZ 295843 B6 (2) INFORMACE PRO SEQ ID NO:220: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 888 párů bázi 5 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:220: 10 GCGGATGAGG AGCTGTGCGG TGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAGGCCCTGG 15 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGGGCGGTG GGTCAGGAGG TGGATCCGGA GGTACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG TACGTAGAGG GCGGTGGAGG CTCCCCGGGT GAACCGTCTG GTCCAATCTC TACTATCAAC CCGTCTCCTC CGTCTAAAGA ATCTCATAAA 20 TCTCCAAACA TGGCTAACTG CTCTATAATG ATCGATGAAA TTATACATCA CTTAAAGAGA CCACCTAACC CTTTGCTGGA CCCGAACAAC CTCAATTCTG AAGACATGGA TATCCTGATG GAACGAAACC TTCGAACTCC AAACCTGCTC GCATTCGTAA GGGCTGTCAA GCACTTAGAA AATGCATCAG GTATTGAGGC AATTCTTCGT AATCTCCAAC CATGTCTGCC CTCTGCCACG GCCGCACCCT CTCGACATCC AATCATCATC AAGGCAGGTG ACTGGCAAGA ATTCCGGGAA 25 AAACTGACGT TCTATCTGGT TACCCTTGAG CAAGCGCAGG AACAACAG (2) INFORMACE PRO SEQ ID NO:221: (i) CHARAKTERISTIKY SEKVENCE: 30 (A) DÉLKA: 903 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 35 (xi) POPIS SEKVENCE: SEQ ID NO:221: GCCGACGAGG AGCTGTGCGG TGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 40 ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGAAC CCAGGACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC TGCAGTACGT AGAGGGCGGT 45 GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AAACATGGCT AACTGCTCTA TAATGATCGA TGAAATTATA CATCACTTAA AGAGACCACC TAACCCTTTG CTGGACCCGA ACAACCTCAA TTCTGAAGAC ATGGATATCC TGATGGAACG AAACCTTCGA ACTCCAAACC TGCTCGCATT CGTAAGGGCT GTCAAGCACT TAGAAAATGC ATCAGGTATT GAGGCAATTC TTCGTAATCT CCAACCATGT 50 CTGCCCTCTG CCACGGCCGC ACCCTCTCGA CATCCAATCA TCATCAAGGC AGGTGACTGG CAAGAATTCC GGGAAAAACT GACGTTCTAT CTGGTTACCC TTGAGCAAGC GCAGGAACAA CAG (2) INFORMACE PRO SEQ ID NO:222: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 921 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 60 120 180 240 300 360 420 480 540 600 660 720 780 840 888 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 903 -524- 60 CZ 295843 B6 (xi) POPIS SEKVENCE: SEQ ID NO:222: GCAGACGAGG AGCTGTGCGG TGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 5 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCTC AGGGGGAGGT AGTGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 10 ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG CAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAA CTGCTCTATA ATGATCGATG AAATTATACA TCACTTAAAG AGACCACCTA ACCCTTTGCT GGACCCGAAC AACCTCAATT CTGAAGACAT GGATATCCTG ATGGAACGAA ACCTTCGAAC TCCAAACCTG 15 CTCGCATTCG TAAGGGCTGT CAAGCACTTA GAAAATGCAT CAGGTATTGA GGCAATTCTT CGTAATCTCC AACCATGTCT GCCCTCTGCC ACGGCCGCAC CCTCTCGACA TCCAATCATC ATCAAGGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT GAGCAAGCGC AGGAACAACA G 20 (2) INFORMACE PRO SEQ ID NO:223: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 903 párů bázi (B) TYP: nukleová kyselina 25 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:223: 30 GCGGACGAGG AGCTGTGCGG TGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCCTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CCTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 35 CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGAAC CCAGGACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC TGCAGTACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AAACATGGCT AACTGCTCTA TAATGATCGA TGAAATTATA 40 CATCACTTAA AGAGACCACC TAACCCTTTG CTGGACCCGA ACAACCTCAA TTCTGAAGAC ATGGATATCC TGATGGAACG AAACCTTCGA ACTCCAAACC TGCTCGCATT CGTAAGGGCT GTCAAGCACT TAGAAAATGC ATCAGGTATT GAGGCAATTC TTCGTAATCT CCAACCATGT CTGCCCTCTG CCACGGCCGC ACCCTCTCGA CATCCAATCA TCATCAAGGC AGGTGACTGG CAAGAATTCC GGGAAAAACT GACGTTCTAT CTGGTTACCC TTGAGCAAGC GCAGGAACAA 45 CAG (2) INFORMACE PRO SEQ ID NO:224: (i) CHARAKTERISTIKY SEKVENCE: 50 (A) DÉLKA: 921 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 55 (xi) POPIS SEKVENCE: SEQ ID NO:224: GCGGATGAGG AGCTGTGTGG TGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGGG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 60 ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 921 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 903 60 120 180 240 -525 - 15 20 CZ 295843 B6 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCTC AGGGGGAGGT AGTGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 5 CAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAA CTGCTCTATA ATGATCGATG AAATTATACA TCACTTAAAG AGACCACCTA ACCCTTTGCT GGACCCGAAC AACCTCAATT CTGAAGACAT GGATATCCTG ATGGAACGAA ACCTTCGAAC TCCAAACCTG CTCGCATTCG TAAGGGCTGT CAAGCACTTA GAAAATGCAT CAGGTATTGA GGCAATTCTT 10 CGTAATCTCC AACCATGTCT GCCCTCTGCC ACGGCCGCAC CCTCTCGACA TCCAATCATC ATCAAGGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT GAGCAAGCGC AGGAACAACA G (2) INFORMACE PRO SEQ ID NO:225: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 904 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:225: GGCCGATTAC CCAGTCACCG TGGCCTCCAA CCTGCAGGAC GAGGAGCTCT GCGGGGGCCT 25 CTGGCGGCTG GTCCTGGCAC AGCGCTGGAT GGAGCGGCTC AAGACTGTCG CTGGGTCCAA GATGCAAGGC TTGCTGGAGC GCGTGAACAC GGAGATACAC TTTGTCACCA AATGTGCCTT TCAGCCCCCC CCCAGCTGTC TTCGCTTCGT CCAGACCAAC ATCTCCCGCC TCCTGCAGGA GACCTCCGAG CAGCTGGTGG CGCTGAAGCC CTGGATCACT CGCCAGAACT TCTCCCGGTG CCTGGAGCTG CAGTGTCAGC CCGACTCCTC AACCCTGGGC GGTGGGTCAG GAGGTGGGTC 30 AGGAGGTGGA TCCGGAGGTG GCACCCAGGA CTGCTCCTTC CAACACAGCC CCATCTCCTC CGACTTCGCT GTCAAAATCC GTGAGCTGTC TGACTACCTG CTTCAATACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC TAACTGCTCT ATAATGATCG ATGAAATTAT ACATCACTTA AAGAGACCAC CTAACCCTTT GCTGGACCCG AACAACCTCA ATTCTGAAGA 35 CATGGATATC CTGATGGAAC GAAACCTTCG AACTCCAAAC CTGCTCGCAT TCGTAAGGGC TGTCAAGCAC TTAGAAAATG CATCAGGTAT TGAGGCAATT CTTCGTAATC TCCAACCATG TCTGCCCTCT GCCACGGCCG CACCCTCTCG ACATCCAATC ATCATCAAGG CAGGTGACTG GCAAGAATTC CGGGAAAAAC TGACGTTCTA TCTGGTTACC CTTGAGCAAG CGCAGGAACA ACAG 40 (2) INFORMACE PRO SEQ ID NO:226: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 903 párů bází 45 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:226: 50 GCCGCCTCCA ACCTGCAGGA CGAGGAGCTC TGCGGGGGCC TCTGGCGGCT GGTCCTGGCA CAGCGCTGGA TGGAGCGGCT CAAGACTGTC GCTGGGTCCA AGATGCAAGG CTTGCTGGAG CGCGTGAACA CGGAGATACA CTTTGTCACC AAATGTGCCT TTCAGCCCCC CCCCAGCTGT CTTCGCTTCG TCCAGACCAA CATCTCCCGC CTCCTGCAGG AGACCTCCGA GCAGCTGGTG 55 GCGCTGAAGC CCTGGATCAC TCGCCAGAAC TTCTCCCGGT GCCTGGAGCT GCAGTGTCAG CCCGACTCCT CAACCCTGGG CGGTGGGTCA GGAGGTGGGT CAGGAGGTGG ATCCGGAGGT GGCACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGTACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 60 AAAGAATCTC ATAAATCTCC AAACATGGCT AACTGCTCTA TAATGATCGA TGAAATTATA CATCACTTAA AGAGACCACC TAACCCTTTG CTGGACCCGA ACAACCTCAA TTCTGAAGAC 300 360 420 480 540 600 660 720 780 840 900 921 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 904 60 120 180 240 300 360 420 480 540 600 660 -526- CZ 295843 B6 ATGGATATCC TGATGGAACG AAACCTTCGA ACTCCAAACC TGCTCGCATT CGTAAGGGCT GTCAAGCACT TAGAAAATGC ATCAGGTATT GAGGCAATTC TTCGTAATCT CCAACCATGT CTGCCCTCTG CCACGGCCGC ACCCTCTCGA CATCCAATCA TCATCAAGGC AGGTGACTGG CAAGAATTCC GGGAAAAACT GACGTTCTAT CTGGTTACCC TTGAGCAAGC GCAGGAACAA 5 CAG (2) INFORMACE PRO SEQ ID NO:227: (i) CHARAKTERISTIKY SEKVENCE: 10 (A) DÉLKA: 903 párů bázi (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 15 (xi) POPIS SEKVENCE: SEQ ID NO:227: GCCGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG TGAACACGGA GATACACTTT GTCACCAAAT GTGCCTTTCA GCCCCCCCCC AGCTGTCTTC GCTTCGTCCA GACCAACATC TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC TGAAGCCCTG GATCACTCGC 20 CAGAACTTCT CCCGGTGCCT GGAGCTGCAG TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT GGGTCAGGAG GTGGGTCAGG AGGTGGATCC GGAGGTGGCA CCCAGGACTG CTCCTTCCAA CACAGCCCCA TCTCCTCCGA CTTCGCTGTC AAAATCCGTG AGCTGTCTGA CTACCTGCTT CAGGATTACC CAGTCACCGT GGCCTCCAAC CTGCAGGACG AGGAGCTCTG CGGGGGCCTC TGGCGGCTGG TCCTGGCACA GCGCTGGATG GAGCGGCTCA AGACTTACGT AGAGGGCGGT 25 GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AAACATGGCT AACTGCTCTA TAATGATCGA TGAAATTATA CATCACTTAA AGAGACCACC TAACCCTTTG CTGGACCCGA ACAACCTCAA TTCTGAAGAC ATGGATATCC TGATGGAACG AAACCTTCGA ACTCCAAACC TGCTCGCATT CGTAAGGGCT GTCAAGCACT TAGAAAATGC ATCAGGTATT GAGGCAATTC TTCGTAATCT CCAACCATGT 30 CTGCCCTCTG CCACGGCCGC ACCCTCTCGA CATCCAATCA TCATCAAGGC AGGTGACTGG CAAGAATTCC GGGAAAAACT GACGTTCTAT CTGGTTACCC TTGAGCAAGC GCAGGAACAA CAG (2) INFORMACE PRO SEQ ID NO:228: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 903 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:228: GCCTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG AGATACACTT TGTCACCAAA 45 TGTGCCTTTC AGCCCCCCCC CAGCTGTCTT CGCTTCGTCC AGACCAACAT CTCCCGCCTC CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG CTGAAGCCCT GGATCACTCG CCAGAACTTC TCCCGGTGCC TGGAGCTGCA GTGTCAGCCC GACTCCTCAA CCCTGGGCGG TGGGTCAGGA GGTGGGTCAG GAGGTGGATC CGGAGGTGGC ACCCAGGACT GCTCCTTCCA ACACAGCCCC ATCTCCTCCG ACTTCGCTGT CAAAATCCGT GAGCTGTCTG ACTACCTGCT TCAAGATTAC 50 CCAGTCACCG TGGCCTCCAA CCTGCAGGAC GAGGAGCTCT GCGGGGGCCT CTGGCGGCTG GTCCTGGCAC AGCGCTGGAT GGAGCGGCTC AAGACTGTCG CTGGCTACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AAACATGGCT AACTGCTCTA TAATGATCGA TGAAATTATA CATCACTTAA AGAGACCACC TAACCCTTTG CTGGACCCGA ACAACCTCAA TTCTGAAGAC 55 ATGGATATCC TGATGGAACG AAACCTTCGA ACTCCAAACC TGCTCGCATT CGTAAGGGCT GTCAAGCACT TAGAAAATGC ATCAGGTATT GAGGCAATTC TTCGTAATCT CCAACCATGT CTGCCCTCTG CCACGGCCGC ACCCTCTCGA CATCCAATCA TCATCAAGGC AGGTGACTGG CAAGAATTCC GGGAAAAACT GACGTTCTAT CTGGTTACCC TTGAGCAAGC GCAGGAACAA CAG 720 780 840 900 903 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 903 35 40 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 903 -527- 60 30 35 55 CZ 295843 B6 (2) INFORMACE PRO SEQ ID NO:229: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 903 párů bází 5 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:229: 10 GCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCAC CCAGGACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC 15 TTCGCTGTCA AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC TGCAGGACGA GGAGCTCTGC GGGGGCCTCT GGCGGCTGGT CCTGGCACAG CGCTGGATGG AGCGGCTCAA GACTGTCGCT GGGTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG AGATACACTT TGTCACCAAA TGTGCCTTTC AGCCGTACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 20 AAAGAATCTC ATAAATCTCC AAACATGGCT AACTGCTCTA TAATGATCGA TGAAATTATA CATCACTTAA AGAGACCACC TAACCCTTTG CTGGACCCGA ACAACCTCAA TTCTGAAGAC ATGGATATCC TGATGGAACG AAACCTTCGA ACTCCAAACC TGCTCGCATT CGTAAGGGCT GTCAAGCACT TAGAAAATGC ATCAGGTATT GAGGCAATTC TTCGTAATCT CCAACCATGT CTGCCCTCTG CCACGGCCGC ACCCTCTCGA CATCCAATCA TCATCAAGGC AGGTGACTGG 25 CAAGAATTCC GGGAAAAACT GACGTTCTAT CTGGTTACCC TTGAGCAAGC GCAGGAACAA CAG (2) INFORMACE PRO SEQ ID NO:230: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 903 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:230: GCCACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA 40 ACCCTGGGCG GTGGGTCAGG AGGTGGGTCA GGAGGTGGAT CCGGAGGTGG CACCCAGGAC TGCTCCTTCC AACACAGCCC CATCTCCTCC GACTTYGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC TTCAAGATTA CCCAGTCACC GTGGCCTCCA ACCTGCAGGA CGAGGAGCTC TGCGGGGGCC TCTGGCGGCT GGTCCTGGCA CAGCGCTGGA TGGAGCGGCT CAAGACTGTC GCTGGGTCCA AGATGCAAGG CTTGCTGGAG CGCGTGAACA CGGAGATACA CTTTGTCACC 45 AAATGTGCCT TTCAGCCCCC CCCCAGCTGT CTTCGCTTCG TCCAGTACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AAACATGGCT AACTGCTCTA TAATGATCGA TGAAATTATA CATCACTTAA AGAGACCACC TAACCCTTTG CTGGACCCGA ACAACCTCAA TTCTGAAGAC ATGGATATCC TGATGGAACG AAACCTTCGA ACTCCAAACC TGCTCGCATT CGTAAGGGCT 50 GTCAAGCACT TAGAAAATGC ATCAGGTATT GAGGCAATTC TTCGTAATCT CCAACCATGT CTGCCCTCTG CCACGGCCGC ACCCTCTCGA CATCCAATCA TCATCAAGGC AGGTGACTGG CAAGAATTCC GGGAAAAACT GACGTTCTAT CTGGTTACCC TTGAGCAAGC GCAGGAACAA CAG (2) INFORMACE PRO SEQ ID NO:231: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 903 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 903 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 903 -528- 60 CZ 295843 B6 (xi) POPIS SEKVENCE: SEQ ID NO:231: GCCCGCTTCG TCCAGACCAA CATCTCCCGC CTCCTGCAGG AGACCTCCGA GCAGCTGGTG GCGCTGAAGC CCTGGATCAC TCGCCAGAAC TTCTCCCGGT GCCTGGAGCT GCAGTGTCAG 5 CCCGACTCCT CAACCCTGGG CGGTGGGTCA GGAGGTGGGT CAGGAGGTGG ATCCGGAGGT GGCACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AACGCGTGAA CACGGAGATA 10 CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTTTTTACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AAACATGGCT AACTGCTCTA TAATGATCGA TGAAATTATA CATCACTTAA AGAGACCACC TAACCCTTTG CTGGACCCGA ACAACCTCAA TTCTGAAGAC ATGGATATCC TGATGGAACG AAACCTTCGA ACTCCAAACC TGCTCGCATT CGTAAGGGCT 15 GTCAAGCACT TAGAAAATGC ATCAGGTATT GAGGCAATTC TTCGTAATCT CCAACCATGT CTGCCCTCTG CCACGGCCGC ACCCTCTCGA CATCCAATCA TCATCAAGGC AGGTGACTGG CAAGAATTCC GGGAAAAACT GACGTTCTAT CTGGTTACCC TTGAGCAAGC GCAGGAACAA CAG 20 (2) INFORMACE PRO SEQ ID NO:232: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 921 párů bázi (B) TYP: nukleová kyselina 25 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:232: 30 GCTTCAAATC TGCAGGATGA AGAGCTGTGC GGGGGCCTCT GGCGGCTGGT CCTGGCACAG CGCTGGATGG AGCGGCTCAA GACTGTCGCT GGGTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG AGATACACTT TGTCACCAAA TGTGCCTTTC AGCCCCCCCC CAGCTGTCTT CGCTTCGTCC AGACCAACAT CTCCCGCCTC CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG CTGAAGCCCT GGATCACTCG CCAGAACTTC TCCCGGTGCC TGGAGCTGCA GTGTCAGCCC 35 GACTCCTCAA CCCTGGGCGG TGGGTCAGGA GGTGGGTCAG GAGGTGGATC CGGAGGTGGC TCAGGGGGAG GTAGTGGTAC CCAGGACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAA CTGCTCTATA 40 ATGATCGATG AAATTATACA TCACTTAAAG AGACCACCTA ACCCTTTGCT GGACCCGAAC AACCTCAATT CTGAAGACAT GGATATCCTG ATGGAACGAA ACCTTCGAAC TCCAAACCTG CTCGCATTCG TAAGGGCTGT CAAGCACTTA GAAAATGCAT CAGGTATTGA GGCAATTCTT CGTAATCTCC AACCATGTCT GCCCTCTGCC ACGGCCGCAC CCTCTCGACA TCCAATCATC ATCAAGGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT 45 GAGCAAGCGC AGGAACAACA G (2) INFORMACE PRO SEQ ID NO:233: (i) CHARAKTERISTIKY SEKVENCE: 50 (A) DÉLKA: 921 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 55 (xi) POPIS SEKVENCE: SEQ ID NO:233: GCTAATCTGC AAGATGAGGA GCTGTGCGGG GGCCTCTGGC GGCTGGTCCT GGCACAGCGC TGGATGGAGC GGCTCAAGAC TGTCGCTGGG TCCAAGATGC AAGGCTTGCT GGAGCGCGTG AACACGGAGA TACACTTTGT CACCAAATGT GCCTTTCAGC CCCCCCCCAG CTGTCTTCGC 60 TTCGTCCAGA CCAACATCTC CCGCCTCCTG CAGGAGACCT CCGAGCAGCT GGTGGCGCTG AAGCCCTGGA TCACTCGCCA GAACTTCTCC CGGTGCCTGG AGCTGCAGTG TCAGCCCGAC 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 903 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 921 60 120 180 240 300 -529- CZ 295843 B6 TCCTCAACCC TGGGCGGTGG GTCAGGAGGT GGGTCAGGAG GTGGATCCGG AGGTGGCTCA GGGGGAGGTA GTGGTACCCA GGACTGCTCC TTCCAACACA GCCCCATCTC CTCCGACTTC GCTGTCAAAA TCCGTGAGCT GTCTGACTAC CTGCTTCAAG ATTACCCAGT CACCGTGGCC TCCTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAA CTGCTCTATA ATGATCGATG AAATTATACA TCACTTAAAG AGACCACCTA ACCCTTTGCT GGACCCGAAC AACCTCAATT CTGAAGACAT GGATATCCTG ATGGAACGAA ACCTTCGAAC TCCAAACCTG CTCGCATTCG TAAGGGCTGT CAAGCACTTA GAAAATGCAT CAGGTATTGA GGCAATTCTT CGTAATCTCC AACCATGTCT GCCCTCTGCC ACGGCCGCAC CCTCTCGACA TCCAATCATC ATCAAGGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT GAGCAAGCGC AGGAACAACA G (2) INFORMACE PRO SEQ ID NO:234: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 921 párů bázi (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:234: GCGCTGCAGG ATGAAGAGCT GTGTGGCGGC CTCTGGCGGC TGGTCCTGGC ACAGCGCTTG ATGGAGCGGC TCAAGACTGT CGCTGGGTCC AAGATGCAAG GCTTGCTGGA GCGCGTGAAC ACGGAGATAC ACTTTGTCAC CAAATGTGCC TTTCAGCCCC CCCCCAGCTG TCTTCGCTTC GTCCAGACCA ACATCTCCCG CCTCCTGCAG GAGACCTCCG AGCAGCTGGT GGCGCTGAAG CCCTGGATCA CTCGCCAGAA CTTCTCCCGG TGCCTGGAGC TGCAGTGTCA GCCCGACTCC TCAACCCTGG GCGGTGGGTC AGGAGGTGGG TCAGGAGGTG GATCCGGAGG TGGCTCAGGG GGAGGTAGTG GTACCCAGGA CTGCTCCTTC CAACACAGCC CCATCTCCTC CGACTTCGCT GTCAAAATCC GTGAGCTGTC TGACTACCTG CTTCAAGATT ACCCAGTCAC CGTGGCCTCC AACTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAA CTGCTCTATA ATGATCGATG AAATTATACA TCACTTAAAG AGACCACCTA ACCCTTTGCT GGACCCGAAC AACCTCAATT CTGAAGACAT GGATATCCTG ATGGAACGAA ACCTTCGAAC TCCAAACCTG CTCGCATTCG TAAGGGCTGT CAAGCACTTA GAAAATGCAT CAGGTATTGA GGCAATTCTT CGTAATCTCC AACCATGTCT GCCCTCTGCC ACGGCCGCAC CCTCTCGACA TCCAATCATC ATCAAGGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT GAGCAAGCGC AGGAACAACA G (2) INFORMACE PRO SEQ ID NO:235: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 921 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:235: GCGCAAGATG AGGAACTGTG TGGTGGTCTC TGGCGGCTGG TCCTGGCACA GCGCTGGATG GAGCGGCTCA AGACTGTCGC TGGGTCCAAG ATGCAAGGCT TGCTGGAGCG CGTGAACACG GAGATACACT TTGTCACCAA ATGTGCCTTT CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG GTGGGTCAGG AGGTGGGTCA GGAGGTGGAT CCGGAGGTGG CTCAGGGGGA GGTAGTGGTA CCCAGGACTG CTCCTTCCAA CACAGCCCCA TCTCCTCCGA CTTCGCTGTC AAAATCCGTG AGCTGTCTGA CTACCTGCTT CAAGATTACC CAGTCACCGT GGCCTCCAAC CTGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC AACCCGTCTC CCCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAA CTGCTCTATA ATGATCGATG AAATTATACA TCACTTAAAG AGACCACCTA ACCCTTTGCT GGACCCGAAC AACCTCAATT CTGAAGACAT GGATATCCTG ATGGAACGAA ACCTTCGAAC TCCAAACCTG 360 420 480 540 600 660 720 780 840 900 921 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 921 60 120 180 240 300 360 420 480 540 600 660 720 35 40 CZ 295843 B6 CTCGCATTCG TAAGGGCTGT CAAGCACTTA GAAAATGCAT CAGGTATTGA GGCAATTCTT CGTAATCTCC AACCATGTCT GCCCTCTGCC ACGGCCGCAC CCTCTCGACA TCCAATCATC ATCAAGGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT GAGCAAGCGC AGGAACAACA G 5 (2) INFORMACE PRO SEQ ID NO:236: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 921 párů bázi 10 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:236: 15 GCTGAAGAAC TGTGTGGTGG CCTGTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC 20 ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC AGCCCGACTC CTCAACCCTG GGCGGTGGGT CAGGAGGTGG GTCAGGAGGT GGATCCGGAG GTGGCTCAGG GGGAGGTAGT GGTACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG GACTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 25 AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAA CTGCTCTATA ATGATCGATG AAATTATACA TCACTTAAAG AGACCACCTA ACCCTTTGCT GGACCCGAAC AACCTCAATT CTGAAGACAT GGATATCCTG ATGGAACGAA ACCTTCGAAC TCCAAACCTG CTCGCATTCG TAAGGGCTGT CAAGCACTTA GAAAATGCAT CAGGTATTGA GGCAATTCTT CGTAATCTCC AACCATGTCT GCCCTCTGCC ACGGCCGCAC CCTCTCGACA TCCAATCATC 30 ATCAAGGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT GAGCAAGCGC AGGAACAACA G (2) INFORMACE PRO SEQ ID NO:237: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 921 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:237: GCTCTGTGCG GTGGCCTGTG GCGTCTGGTC CTGGCACAGC GCTGGATGGA GCGGCTCAAG ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG TGAACACGGA GATACACTTT 45 GTCACCAAAT GTGCCTTTCA GCCCCCCCCC AGCTGTCTTC GCTTCGTCCA GACCAACATC TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC TGAAGCCCTG GATCACTCGC CAGAACTTCT CCCGGTGCCT GGAGCTGCAG TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT GGGTCAGGAG GTGGGTCAGG AGGTGGATCC GGAGGTGGCT CAGGGGGAGG TAGTGGTACC CAGGACTGCT CCTTCCAACA CAGCCCCATC TCCTCCGACT TCGCTGTCAA AATCCGTGAG 50 CTGTCTGACT ACCTGCTTCA AGATTACCCA GTCACCGTGG CCTCCAACCT GCAGGACGAG GAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAA CTGCTCTATA ATGATCGATG AAATTATACA TCACTTAAAG AGACCACCTA ACCCTTTGCT GGACCCGAAC AACCTCAATT CTGAAGACAT GGATATCCTG ATGGAACGAA ACCTTCGAAC TCCAAACCTG 55 CTCGCATTCG TAAGGGCTGT CAAGCACTTA GAAAATGCAT CAGGTATTGA GGCAATTCTT CGTAATCTCC AACCATGTCT GCCCTCTGCC ACGGCCGCAC CCTCTCGACA TCCAATCATC ATCAAGGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT GAGCAAGCGC AGGAACAACA G 780 840 900 921 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 921 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 921 -531 - CZ 295843 B6 (2) INFORMACE PRO SEQ ID NO:238: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 921 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:238: GCACTGTGTG GTGGTCTGTG GCGTCTGGTC CTGGCACAGC GCTGGATGGA GCGGCTCAAG ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG TGAACACGGA GATACACTTT GTCACCAAAT GTGCCTTTCA GCCCCCCCCC AGCTGTCTTC GCTTCGTCCA GACCAACATC TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC TGAAGCCCTG GATCACTCGC CAGAACTTCT CCCGGTGCCT GGAGCTGCAG TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT GGGTCAGGAG GTGGGTCAGG AGGTGGATCC GGAGGTGGCT CAGGGGGAGG TAGTGGTACC CAGGACTGCT CCTTCCAACA CAGCCCCATC TCCTCCGACT TCGCTGTCAA AATCCGTGAG CTGTCTGACT ACCTGCTTCA AGATTACCCA GTCACCGTGG CCTCCAACCT GCAGGACGAG GAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAA CTGCTCTATA ATGATCGATG AAATTATACA TCACTTAAAG AGACCACCTA ACCCTTTGCT GGACCCGAAC AACCTCAATT CTGAAGACAT GGATATCCTG ATGGAACGAA ACCTTCGAAC TCCAAACCTG CTCGCATTCG TAAGGGCTGT CAAGCACTTA GAAAATGCAT CAGGTATTGA GGCAATTCTT CGTAATCTCC AACCATGTCT GCCCTCTGCC ACGGCCGCAC CCTCTCGACA TCCAATCATC ATCAAGGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT GAGCAAGCGC AGGAACAACA G (2) INFORMACE PRO SEQ ID NO:239: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 921 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:239: GCTCTGTGTG GCGGTCTGTG GCGTCTGGTC CTGGCACAGC GCTGGATGGA GCGGCTCAAG ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG TGAACACGGA GATACACTTT GTCACCAAAT GTGCCTTTCA GCCCCCCCCC AGCTGTCTTC GCTTCGTCCA GACCAACATC TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC TGAAGCCCTG GATCACTCGC CAGAACTTCT CCCGGTGCCT GGAGCTGCAG TGTCGGCCCG ACTCCTCAAC CCTGGGCGGT GGGTCAGGAG GTGGGTCAGG AGGTGGATCC GGAGGTGGCT CAGGGGGAGG TAGTGGTACC CAGGACTGCT CCTTCCAACA CAGCCCCATC TCCTCCGACT TCGCTGTCAA GATCCGTGAG CTGTCTGACT ACCTGCTTCA AGATTACCCA GTCACCGTGG CCTCCAACCT GCAGGACGAG GAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAA CTGCTCTATA ATGATCGATG AAATTATACA TCACTTAAAG AGACCACCTA ACCCTTTGCT GGACCCGAAC AACCTCAATT CTGAAGACAT GGATATCCTG ATGGAACGAA ACCTTCGAAC TCCAAACCTG CTCGCATTCG TAAGGGCTGT CAAGCACTTA GAAAATGCAT CAGGTATTGA GGCAATTCTT CGTAATCTCC AACCATGTCT GCCCTCTGCC ACGGCCGCAC CCTCTCGACA TCCAATCATC ATCAAGGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT GAGCAAGCGC AGGAACAACA G (2) INFORMACE PRO SEQ ID NO:240: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 903 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 921 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 921 CZ 295843 B6 (xi) POPIS SEKVENCE: SEQ ID NO:240: GCCTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG AGATACACTT TGTCACCAAA TGTGCCTTTC AGCCCCCCCC CAGCTGTCTT CGCTTCGTCC AGACCAACAT CTCCCGCCTC 5 CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG CTGAAGCCCT GGATCACTCG CCAGAACTTC TCCCGGTGCC TGGAGCTGCA GTGTCAGCCC GACTCCTCAA CCCTGGGCGG TGGGTCAGGA GGTGGGTCAG GAGGTGGATC CGGAGGTGGC ACCCAGGACT GCTCCTTCCA ACACAGCCCC ATCTCCTCCG ACTTCGCTGT CAAAATCCGT GAGCTGTCTG ACTACCTGCT TCAAGATTAC CCAGTCACCG TGGCCTCCAA CCTGCAGGAC GAGGAGCTCT GCGGGGGCCT CTGGCGGCTG 10 GTCCTGGCAC AGCGCTGGAT GGAGCGGCTC AAGACTGTCG CTGGCTACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AAACATGGCT AACTGCTCTA TAATGATCGA TGAAATTATA CATCACTTAA AGAGACCACC TAACCCTTTG CTGGACCCGA ACAACCTCAA TTCTGAAGAC ATGGATATCC TGATGGAACG AAACCTTCGA ACTCCAAACC TGCTCGCATT CGTAAGGGCT 15 GTCAAGCACT TAGAAAATGC ATCAGGTATT GAGGCAATTC TTCGTAATCT CCAACCATGT CTGCCCTCTG CCACGGCCGC ACCCTCTCGA CATCCAATCA TCATCAAGGC AGGTGACTGG CAAGAATTCC GGGAAAAACT GACGTTCTAT CTGGTTACCC TTGAGCAAGC GCAGGAACAA CAG 20 (2) INFORMACE PRO SEQ ID NO:241: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 945 párů bází (B) TYP: nukleová kyselina 25 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:241: 30 GCTCAAGATG ATGAGCTGTG TGGTGGTCTC TGGCGGCTGG TCCTGGCACA GCGCTGGATG GAGCGGCTCA AGACTGTCGC TGGGTCCAAG ATGCAAGGCT TGCTGGAGCG CGTGAACACG GAGATACACT TTGTCACCAA ATGTGCCTTT CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA 35 ACCCTGGGCG GTGGGTCAGG AGGTGGGTCA GGCGGTGGTT CTGGCGGAGG ATCCGGCGGC GGAAGCGGAG GTGGCTCTGG GGGAGGTAGT GGTACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGTAC GTAGAGGGCG GTGGAGGCTC CCCGGGTGAA CCGTCTGGTC CAATCTCTAC TATCAACCCG TCTCCTCCGT CTAAAGAATC TCATAAATCT 40 CCAAACATGG CTAACTGCTC TATAATGATC GATGAAATTA TACATCACTT AAAGAGACCA CCTAACCCTT TGCTGGACCC GAACAACCTC AATTCTGAAG ACATGGATAT CCTGATGGAA CGAAACCTTC GAACTCCAAA CCTGCTCGCA TTCGTAAGGG CTGTCAAGCA CTTAGAAAAT GCATCAGGTA TTGAGGCAAT TCTTCGTAAT CTCCAACCAT GTCTGCCCTC TGCCACGGCC GCACCCTCTC GACATCCAAT CATCATCAAG GCAGGTGACT GGCAAGAATT CCGGGAAAAA 45 CTGACGTTCT ATCTGGTTAC CCTTGAGCAA GCGCAGGAAC AACAG (2) INFORMACE PRO SEQ ID NO:242: (i) CHARAKTERISTIKY SEKVENCE: 50 (A) DÉLKA: 903 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 55 (xi) POPIS SEKVENCE: SEQ ID NO:242: GCCCAAGATG AAGAACTGTG TGGTGGCCTC TGGCGGCTGG TCCTGGCACA GCGCTGGATG GAGCGGCTCA AGACTGTCGC TGGGTCCAAG ATGCAAGGCT TGCTGGAGCG CGTGAACACG GAGATACACT TTGTCACCAA ATGTGCCTTT CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC 60 CAGACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 903 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 945 60 120 180 240 - 533 - 15 20 CZ 295843 B6 TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGCCGC CACCGTGGAG CCCGCGTCCA CTCGGCGCCA CCGCACCGAC CACCCAGGAC TGCTCCTTCC AACACAGCCC CATCTCCTCC GACTTCGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC TTCAAGATTA CCCAGTCACC GTGGCCTCCA ACCTGTACGT AGAGGGCGGT 5 GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AAACATGGCT AACTGCTCTA TAATGATCGA TGAAATTATA CATCACTTAA AGAGACCACC TAACCCTTTG CTGGACCCGA ACAACCTCAA TTCTGAAGAC ATGGATATCC TGATGGAACG AAACCTTCGA ACTCCAAACC TGCTCGCATT CGTAAGGGCT GTCAAGCACT TAGAAAATGC ATCAGGTATT GAGGCAATTC TTCGTAATCT CCAACCATGT 10 CTGCCCTCTG CCACGGCCGC ACCCTCTCGA CATCCAATCA TCATCAAGGC AGGTGACTGG CAAGAATTCC GGGAAAAACT GACGTTCTAT CTGGTTACCC TTGAGCAAGC GCAGGAACAA CAG (2) INFORMACE PRO SEQ ID NO:243: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 921 párů bázi (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:243: GCCCAAGATG AAGAACTGTG TGGTGGCCTC TGGCGGCTGG TCCTGGCACA GCGCTGGATG 25 GAGCGGCTCA AGACTGTCGC TGGGTCCAAG ATGCAAGGCT TGCTGGAGCG CGTGAACACG GAGATACACT TTGTCACCAA ATGTGCCTTT CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGCCGC CACCGTGGAG CCCGCGTCCA CTCGGCGCCA CCGCACCGAC CGCTGGACAA 30 CCGCCTCTGA CCCAGGACTG CTCCTTCCAA CACAGCCCCA TCTCCTCCGA CTTCGCTGTC AAAATCCGTG AGCTGTCTGA CTACCTGCTT CAAGATTACC CAGTCACCGT GGCCTCCAAC CTGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAA CTGCTCTATA ATGATCGATG AAATTATACA TCACTTAAAG AGACCACCTA ACCCTTTGCT GGACCCGAAC 35 AACCTCAATT CTGAAGACAT GGATATCCTG ATGGAACGAA ACCTTCGAAC TCCAAACCTG CTCGCATTCG TAAGGGCTGT CAAGCACTTA GAAAATGCAT CAGGTATTGA GGCAATTCTT CGTAATCTCC AACCATGTCT GCCCTCTGCC ACGGCCGCAC CCTCTCGACA TCCAATCATC ATCAAGGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT GAGCAAGCGC AGGAACAACA G 40 (2) INFORMACE PRO SEQ ID NO:244: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1110 párů bází 45 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:244: 50 GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT 55 AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCTACGT AGAGGGCGGT 60 GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AAACATGGCT GATGAAGAAC TGTGTGGTGG TCTGTGGCGG 300 360 420 480 540 600 660 720 780 840 900 903 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 921 60 120 180 240 300 360 420 480 540 600 660 -534- CZ 295843 B6 CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG 5 CTGCAGTGTC AGCCCGACTC CTCAACCCTG GGCGGTGGGT CAGGAGGTGG GTCAGGAGGT GGATCCGGAG GTGGCTCAGG GGGAGGTAGT GGTACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 10 (2) INFORMACE PRO SEQ ID NO:245: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1110 párů bázi (B) TYP: nukleová kyselina 15 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:245: 20 GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG 25 GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCTACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 30 AAAGAATCTC ATAAATCTCC AAACATGGCA AATCTGCAAG ACGAGGAGCT GTGCGGGGGC CTCTGGCGGC TGGTCCTGGC ACAGCGCTGG ATGGAGCGGC TCAAGACTGT CGCTGGGTCC AAGATGCAAG GCTTGCTGGA GCGCGTGAAC ACGGAGATAC ACTTTGTCAC CAAATGTGCC TTTCAGCCCC CCCCCAGCTG TCTTCGCTTC GTCCAGATCA ACATCTCCCG CCTCCTGCAG GAGACCTCCG AGCAGCTGGT GGCGCTGAAG CCCTGGATCA CTCGCCAGAA CTTCTCCCGG 35 TGCCTGGAGC TGCAGTGTCA GCCCGACTCC TCAACCCTGG GCGGTGGGTC AGGAGGTGGG TCAGGAGGTG GATCCGGAGG TGGCTCAGGG GGAGGTAGTG GTACCCAGGA CTGCTCCTTC CAACACAGCC CCATCTCCTC CGACTTCGCT GTCAAAATCC GTGAGCTGTC TGACTACCTG CTTCAAGATT ACCCAGTCAC CGTGGCCTCC 40 (2) INFORMACE PRO SEQ ID NO:246: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1110 párů bází (B) TYP: nukleová kyselina 45 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:246: 50 GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG 55 GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCTACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 60 AAAGAATCTC ATAAATCTCC AAACATGGCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC 720 780 840 900 960 1020 1080 1110 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1110 60 120 180 240 300 360 420 480 540 600 660 720 -535- 10 15 40 45 CZ 295843 B6 ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC AGCCCGACTC CTCAACCCTG GGCGGTGGGT CAGGAGGTGG GTCAGGAGGT GGATCCGGAG GTGGCTCAGG GGGAGGTAGT GGTACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACGT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 5 GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC CTTTCAGCCC (2) INFORMACE PRO SEQ ID NO:247: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1110 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:247: GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG 20 CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG 25 CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCTACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AAACATGGCT CTGCAGGATG AGGAACTGTG CGGCGGCCTC 30 TGGCGGCTGG TCCTGGCACA GCGCTGGATG GAGCGGCTCA AGACTGTCGC TGGGTCCAAG ATGCAAGGCT TGCTGGAGCG CGTGAACACG GAGATACACT TTGTCACCAA ATGTGCCTTT CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG GTGGGTCAGG AGGTGGGTCA 35 GGAGGTGGAT C.CGGAGGTGG CTCAGGGGGA GGTAGTGGTA CCCAGGACTG CTCCTTCCAA CACAGCCCCA TCTCCTCCGA CTTCGCTGTC AAAATCCGTG AGCTGTCTGA CTACCTGCTT CAAGATTACC CAGTCACCGT GGCCTCCAAC (2) INFORMACE PRO SEQ ID NO:248: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1110 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:248: GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG 50 CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG 55 CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCTACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AAACATGGCT CAAGATGAAG AGCTGTGTGG TGGTCTCTGG 60 CGGCTGGTCC TGGCACAGCG CTGGATGGAG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG 780 840 900 960 1020 1080 1110 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1110 60 120 180 240 300 360 420 480 540 600 660 720 780 -536- 10 15 40 45 CZ 295843 B6 CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCTC AGGGGGAGGT AGTGGTACCC AGGACTGCTC CTTCCAACAC 5 AGCCCCATCT CCTCCGACTT CGCTGTCAAA ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG (2) INFORMACE PRO SEQ ID NO:249: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1110 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:249: GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC 20 AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC 25 TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCTACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AAACATGGCT GAAGAACTGT GTGGTGGTCT GTGGCGGCTG GTCCTGGCAC AGCGCTGGAT GGAGCGGCTC AAGACTGTCG CTGGGTCCAA GATGCAAGGC 30 TTGCTGGAGC GCGTGAACAC GGAGATACAC TTTGTCACCA AATGTGCCTT TCAGCCCCCC CCCAGCTGTC TTCGCTTCGT CCAGACCAAC ATCTCCCGCC TCCTGCAGGA GACCTCCGAG CAGCTGGTGG CGCTGAAGCC CTGGATCACT CGCCAGAACT TCTCCCGGTG CCTGGAGCTG CAGTGTCAGC CCGACTCCTC AACCCTGGGC GGTGGGTCAG GAGGTGGGTC AGGAGGTGGA TCCGGAGGTG GCTCAGGGGG AGGTAGTGGT ACCCAGGACT GCTCCTTCCA ACACAGCCCC 35 ATCTCCTCCG ACTTCGCTGT CAAAATCCGT GAGCTGTCTG ACTACCTGCT TCAAGATTAC CCAGTCACCG TGGCCTCCAA CCTGCAGGAC (2) INFORMACE PRO SEQ ID NO:250: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1110 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:250: GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC 50 AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC 55 TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCTACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AAACATGGCT GAGCTGTGTG GTGGCCTGTG GCGTCTGGTC CTGGCACAGC GCTGGATGGA GCGGCTCAAG ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG 60 CTGGAGCGCG TGAACACGGA GATACACTTT GTCACCAAAT GTGCCTTTCA GCCCCCCCCC AGCTGTCTTC GCTTCGTCCA GACCAACATC TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG 840 900 960 1020 1080 1110 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1110 60 120 180 240 300 360 420 480 540 600 660 720 780 840 -537- CZ 295843 B6 CTGGTGGCGC TGAAGCCCTG GATCACTCGC CAGAACTTCT CCCGGTGCCT GGAGCTGCAG TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT GGGTCAGGAG GTGGGTCAGG AGGTGGATCC GGAGGTGGCT CAGGGGGAGG TAGTGGTACC CAGGACTGCT CCTTCCAACA CAGCCCCATC TCCTCCGACT TCGCTGTCAA AATCCGTGAG CTGTCTGACT ACCTGCTTCA AGATTACCCA 5 GTCACCGTGG CCTCCAACCT GCAGGACGAG (2) INFORMACE PRO SEQ ID NO:251: (i) CHARAKTERISTIKY SEKVENCE: 10 (A) DÉLKA: 1110 párů bázi (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 15 (xi) POPIS SEKVENCE: SEQ ID NO:251: GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT 20 CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC 25 TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCTACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AAACATGGCT CTGTGCGGTG GTCTGTGGCG TCTGGTCCTG GCACAGCGCT GGATGGAGCG GCTCAAGACT GTCGCTGGGT CCAAGATGCA AGGCTTGCTG GAGCGCGTGA ACACGGAGAT ACACTTTGTC ACCAAATGTG CCTTTCAGCC CCCCCCCAGC 30 TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT GGGCGGTGGG TCAGGAGGTG GGTCAGGAGG TGGATCCGGA GGTGGCTCAG GGGGAGGTAG TGGTACCCAG GACTGCTCCT TCCAACACAG CCCCATCTCC TCCGACTTCG CTGTCAAAAT CCGTGAGCTG TCTGACTACC TGCTTCAAGA TTACCCAGTC 35 ACCGTGGCCT CCAACCTGCA GGACGAGGAG (2) INFORMACE PRO SEQ ID NO:252: (i) CHARAKTERISTIKY SEKVENCE: 40 (A) DÉLKA: 1092 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 45 (xi) POPIS SEKVENCE: SEQ ID NO:252: GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT 50 CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC 55 TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCTACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AAACATGGCT GATGAAGAAC TGTGTGGTGG GCTGTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC CTTTCAGCCC 60 CCCCCCAGCT GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG 900 960 1020 1080 1110 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1110 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 -538 - CZ 295843 B6 CTGCAGTGTC AGCCCGACTC CTCAACCCTG CCGCCACCGT GGAGCCCGCG TCCACTCGGC GCCACCGCAC CGACCACCCA GGACTGCTCC TTCCAACACA GCCCCATCTC CTCCGACTTC GCTGTCAAAA TCCGTGAGCT GTCTGACTAC CTGCTTCAAG ATTACCCAGT CACCGTGGCC TCCAACCTGC AG 5 (2) INFORMACE PRO SEQ ID NO:253: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1134 párů bázi 10 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:253: 15 GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT 20 AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCTACGT AGAGGGCGGT 25 GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AAACATGGCT GATGAAGAAC TGTGTGGTGG gctgtggcgg CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG agcgcgtgaa cacggagata cactttgtca ccaaatgtgc ctttcagccc CCCCCCAGCT GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC 30 GAGCAGCTGG TGGCGCTGAA GCCCTGGATC ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC AGCCCGACTC CTCAACCCTG GGCGGTGGGT CAGGAGGTGG GTCAGGCGGT GGTTCTGGCG GAGGATCCGG CGGCGGAAGC GGAGGTGGCT CTGGGGGAGG TAGTGGTACC CAGGACTGCT CCTTCCAACA CAGCCCCATC TCCTCCGACT TCGCTGTCAA AATCCGTGAG CTGTCTGACT ACCTGCTTCA AGATTACCCA GTCACCGTGG CCTCCAACCT GCAG 35 (2) INFORMACE PRO SEQ ID NO:254: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1110 párů bází 40 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:254: 45 GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT 50 AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCTACGT AGAGGGCGGT 55 GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AAACATGGCT GATGAAGAAC TGTGTGGTGG GCTGTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC 60 GAGCAGCTGG TGGCGCTGAA GCCCTGGATC ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC AGCCCGACTC CTCAACCCTG CCGCCACCGT GGAGCCCGCG TCCACTCGGC 960 1020 1080 1092 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1134 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 -539- CZ 295843 B6 GCCACCGCAC CGACCGCTGG ACAACCGCCT CTGACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG (2) INFORMACE PRO SEQ ID NO:255: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 465 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:255: GCCGATTACC CAGTCACCGT GGCCTCCAAC CTGCAGGACG AGGAGCTCTG CGGGGGCCTC TGGCGGCTGG TCCTGGCACA GCGCTGGATG GAGCGGCTCA AGACTGTCGC TGGGTCCAAG ATGCAAGGCT TGCTGGAGCG CGTGAACACG GAGATACACT TTGTCACCAA ATGTGCCTTT CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG GTGGGTCAGG AGGTGGGTCA GGAGGTGGAT CCGGAGGTGG CACCCAGGAC TGCTCCTTCC AACACAGCCC CATCTCCTCC GACTTCGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC TTCAA (2) INFORMACE PRO SEQ ID NO:256: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 465 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:256: GCCGCCTCCA ACCTGCAGGA GGAGGAGCTC TGCGGGGGCC TCTGGCGGCT GGTCCTGGCA CAGCGCTGGA TGGAGCGGCT CAAGACTGTC GCTGGGTCCA AGATGCAAGG CTTGCTGGAG CGCGTGAACA CGGAGATACA CTTTGTCACC AAATGTGCCT TTCAGCCCCC CCCCAGCTGT CTTCGCTTCG TCCAGACCAA CATCTCCCGC CTCCTGCAGG AGACCTCCGA GCAGCTGGTG GCGCTGAAGC CCTGGATCAC TCGCCAGAAC TTCTCCCGGT GCCTGGAGCT GCAGTGTCAG CCCGACTCCT CAACCCTGGG CGGTGGGTCA GGAGGTGGGT CAGGAGGTGG ATCCGGAGGT GGCACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTG (2) INFORMACE PRO SEQ ID NO:257: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 465 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:257: GCCGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG TGAACACGGA GATACACTTT GTCACCAAAT GTGCCTTTCA GCCCCCCCCC AGCTGTCTTC GCTTCGTCCA GACCAACATC TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC TGAAGCCCTG GATCACTCGC CAGAACTTCT CCCGGTGCCT GGAGCTGCAG TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT GGGTCAGGAG GTGGGTCAGG AGGTGGATCC GGAGGTGGCA CCCAGGACTG CTCCTTCCAA CACAGCCCCA TCTCCTCCGA CTTCGCTGTC AAAATCCGTG AGCTGTCTGA CTACCTGCTT CAAGATTACC CAGTCACCGT GGCCTCCAAC CTGCAGGACG AGGAGCTCTG CGGGGGCCTC TGGCGGCTGG TCCTGGCACA GCGCTGGATG GAGCGGCTCA AGACT 1020 1080 1110 60 120 180 240 300 360 420 465 60 120 180 240 300 360 420 465 60 120 180 240 300 360 420 465 CZ 295843 B6 (2) INFORMACE PRO SEQ ID NO:258: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 465 párů bázi (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:258: GCCTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG TGTGCCTTTC AGCCCCCCCC CAGCTGTCTT CGCTTCGTCC CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG CTGAAGCCCT TCCCGGTGCC TGGAGCTGCA GTGTCAGCCC GACTCCTGAA GGTGGGTCAG GAGGTGGATC CGGAGGTGGC ACCCAGGACT ATCTCCTCCG ACTTCGCTGT CAAAATCCGT GAGCTGTCTG CCAGTCACCG TGGCCTCCAA CCTGCAGGAC GAGGAGCTCT GTCCTGGCAC AGCGCTGGAT GGAGCGGCTC AAGACTGTCG (2) INFORMACE PRO SEQ ID NO:259: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 465 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:259: GCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGGGCGGTG GGTGGATCCG GAGGTGGCAC CCAGGACTGC TCCTTCCAAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC TACCTGCTTC GCCTCCAACC TGCAGGACGA GGAGCTCTGC GGGGGCCTCT CGCTGGATGG AGCGGCTCAA GACTGTCGCT GGGTCCAAGA GTGAACACGG AGATACACTT TGTCACCAAA TGTGCCTTTC (2) INFORMACE PRO SEQ ID NO:260: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 465 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:260: GCCCGCTTCG TCCAGACCAA CATCTCCCGC CTCCTGCAGG GCGCTGAAGC CCTGGATCAC TCGCCAGAAC TTCTCCCGGT CCCGACTCCT CAACCCTGGG CGGTGGGTCA GGAGGTGGGT GGCACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT (2) INFORMACE PRO SEQ ID NO:261: AGATACACTT TGTCACCAAA 60 AGACCAACAT CTCCCGCCTC 120 GGATCACTCG CCAGAACTTC 180 CCCTGGGCGG TGGGTCAGGA 240 GCTCCTTCCA ACACAGCCCC 300 ACTACCTGCT TCAAGATTAC 360 GCGGGGGCCT CTGGCGGCTG 420 CTGGG 465 CCCGCCTCCT GCAGGAGACC 60 AGAACTTCTC CCGGTGCCTG 120 GGTCAGGAGG TGGGTCAGGA 180 ACAGCCCCAT CTCCTCCGAC 240 AAGATTACCC AGTCACCGTG 300 GGCGGCTGGT CCTGGCACAG 360 TGCAAGGCTT GCTGGAGCGC 420 AGCCC 465 AGACCTCCGA GCAGCTGGTG 60 GCCTGGAGCT GCAGTGTCAG 120 CAGGAGGTGG ATCCGGAGGT 180 CCGACTTCGC TGTCAAAATC 240 CCGTGGCCTC CAACCTGCAG 300 CACAGCGCTG GATGGAGCGG 360 AGCGCGTGAA CACGGAGATA 420 GTCTT 4 65 CZ 295843 B6 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 465 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché 5 (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:261: 10 15 GCCACCAACA TCTCCCGCCT TGGATCACTC GCCAGAACTT ACCCTGGGCG GTGGGTCAGG TGCTCCTTCC AACACAGCCC GACTACCTGC TTCAAGATTA TGCGGGGGCC TCTGGCGGCT GCTGGGTCCA AGATGCAAGG AAATGTGCCT TTCAGCCCCC CCTGCAGGAG ACCTCCGAGC CTCCCGGTGC CTGGAGCTGC AGGTGGGTCA GGAGGTGGAT CATCTCCTCC GACTTCGCTG CCCAGTCACC GTGGCCTCCA GGTCCTGGCA CAGCGCTGGA CTTGCTGGAG CGCGTGAACA CCCCAGCTGT CTTCGCTTCG AGCTGGTGGC GCTGAAGCCC AGTGTCAGCC CGACTCCTCA CCGGAGGTGG CACCCAGGAC TCAAAATCCG TGAGCTGTCT ACCTGCAGGA CGAGGAGCTC TGGAGCGGCT CAAGACTGTC CGGAGATACA CTTTGTCACC TCCAG 60 120 180 240 300 360 420 465 20 25 (2) INFORMACE PRO SEQ ID NO:262: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1110 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xí) POPIS SEKVENCE: SEQ ID NO:262: GCTGATGAAG AACTGTGTGG TGGTCTGTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 30 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCTC AGGGGGAGGT AGTGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 35 ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG CAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAC ACCATTGGGC CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTCTT TAGAGCAAGT GAGAAAGATC CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GTGCCACCCC 40 GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT GGGCTCCCCT GAGCTCCTGC CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC TCCATAGCGG CCTTTTCCTC TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG AGTTGGGTCC CACCTTGGAC ACACTGCAGC TGGACGTCGC CGACTTTGCC ACCACCATCT GGCAGCAGAT GGAAGAACTG GGAATGGCCC CTGCCCTGCA GCCCACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC 45 CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG TACCGCGTTC TACGCCACCT TGCGCAGCCC 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1110 50 55 (2) INFORMACE PRO SEQ ID NO:263: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1110 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:263: GCAGATGAAG CGGCTCAAGA ATACACTTTG AACTGTGTGG CTGTCGCTGG TCACCAAATG GGGACTGTGG GTCCAAGATG TGCCTTTCAG CGTCTGGTCC CAAGGCTTGC CCCCCCCCCA TGGCACAGCG TGGAGCGCGT GCTGTCTTCG CTGGATGGAG GAACACGGAG CTTCGTCCAG 60 120 180 60 -542- CZ 295843 B6 ACCAACATCT CCCGCCTCCT GCAGGAGACC ATCACTCGCC AGAACTTCTC CCGGTGCCTG CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA AGTGGTACCC AGGACTGCTC CTTCCAACAC 5 ATCCGTGAGC TGTCTGACTA CCTGCTTCAA CAGTACGTAG AGGGCGGTGG AGGCTCCCCG AACCCGTCTC CTCCGTCTAA AGAATCTCAT CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CAGGGCGATG GCGCAGCGCT CCAGGAGAAG 10 GAGGAGCTGG TGCTGCTCGG ACACTCTCTG CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ACACTGCAGC TGGACGTCGC CGACTTTGCC GGAATGGCCC CTGCCCTGCA GCCCACCCAG 15 CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT TACCGCGTTC TACGCCACCT TGCGCAGCCC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240 GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300 GGTGGATCCG GAGGTGGCTC AGGGGGAGGT 360 AGCCCCATCT CCTCCGACTT CGCTGTCAAA 420 GATTACCCAG TCACCGTGGC CTCCAACCTG 480 GGTGAACCGT CTGGTCCAAT CTCTACTATC 540 AAATCTCCAA ACATGGCTAC ACCATTAGGC 600 CTCAAGTGCT TAGAGCAAGT GAGGAAGATC 660 CTGTGTGCCA CCTACAAGCT GTGCCACCCC 720 GGCATCCCCT GGGCTCCCCT GAGCTCCTGC 780 TTGAGCCAAC TCCATAGCGG CCTTTTCCTC 840 ATATCCCCCG AGTTGGGTCC CACCTTGGAC 900 ACCACCATCT GGCAGCAGAT GGAAGAACTG 960 GGTGCCATGC CGGCCTTCGC CTCTGCTTTC 1020 AGCCATCTGC AGAGCTTCCT GGAGGTGTCG 1080 1110 (2) INFORMACE PRO SEQ ID NO:264: 20 25 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1062 párů bázi (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:264: GCTGATGAAG AACTGTGTGG TGGGCTGTGG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG 30 ATACACTTTG TCACCAAATG TGCCTTTCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC ATCACTCGCC AGAACTTCTC CCGGTGCCTG CTGCCGCCAC CGTGGAGCCC GCGTCCACTC CCTCTGACCC AGGACTGCTC CTTCCAACAC 35 ATCCGTGAGC TGTCTGACTA CCTGCTTCAA TACGTAGAGG GCGGTGGAGG CTCCCCGGGT ACACCATTGG GCCCTGCCAG CTCCCTGCCC GTGAGGAAGA TCCAGGGCGA TGGCGCAGCG CTGTGCCACC CCGAGGAGCT GGTGCTGCTC 40 CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG GGCCTTTTCC TCTACCAGGG GCTCCTGCAG CCCACCTTGG ACACACTGCA GCTGGACGTC ATGGAAGAAC TGGGAATGGC CCCTGCCCTG GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG 45 CTGGAGGTGT CGTACCGCGT TCTACGCCAC CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60 CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120 CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180 TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240 GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300 GGCGCCACCG CACCGACCGC TGGACAACCG 360 AGCCCCATCT CCTCCGACTT CGCTGTCAAA 420 GATTACCCAG TCACCGTGGC CTCCAACCTG 480 GGTGGTTCTG GCGGCGGCTC CAACATGGCT 540 CAGAGCTTCC TGCTCAAGTC TTTAGAGCAA 600 CTCCAGGAGA AGCTGTGTGC CACCTACAAG 660 GGACACTCTC TGGGCATCCC CTGGGCTCCC 720 CTGGCAGGCT GCTTGAGCCA ACTCCATAGC 780 GCCCTGGAAG GGATATCCCC CGAGTTGGGT 840 GCCGACTTTG CCACCACCAT CTGGCAGCAG 900 CAGCCCACCC AGGGTGCCAT GCCGGCCTTC 960 GTCCTGGTTG CTAGCCATCT GCAGAGCTTC 1020 CTTGCGCAGC CG 1062 (2) INFORMACE PRO SEQ ID NO:265: (i) CHARAKTERISTIKY SEKVENCE: 50 (A) DÉLKA: 1089 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 55 (xi) POPIS SEKVENCE: SEQ ID NO:265: TGGGCTGTGG CGGCTGGTCC GTCCAAGATG CAAGGCTTGC TGCCTTTCAG CCCCCCCCCA GCAGGAGACC TCCGAGCAGC CCGGTGCCTG GAGCTGCAGT TGGCACAGCG CTGGATGGAG 60 TGGAGCGCGT GAACACGGAG 120 GCTGTCTTCG CTTCGTCCAG 180 TGGTGGCGCT GAAGCCCTGG 240 GTCAGCCCGA CTCCTCAACC 300 GCTGATGAAG AACTGTGTGG CGGCTCAAGA CTGTCGCTGG ATACACTTTG TCACCAAATG 60 ACCAACATCT CCCGCCTCCT ATCACTCGCC AGAACTTCTC -543 - CZ 295843 B6 CTGGGCGGTG GGTCAGGAGG TGGGTCAGGC GGTGGTTCTG GCGGAGGATC CGGCGGCGGA AGCGGAGGTG GCTCTGGGGG AGGTAGTGGT ACCCAGGACT GCTCCTTCCA ACACAGCCCC ATCTCCTCCG ACTTCGCTGT CAAAATCCGT GAGCTGTCTG ACTACCTGCT TCAAGATTAC CCAGTCACCG TGGCCTCCAA CCTGCAGTAC GTAGAGGGCG GTGGAGGCTC CCCGGGTGGT 5 GGTTCTGGCG GCGGCTCCAA CATGGCTACA CCATTGGGCC CTGCCAGCTC CCTGCCCCAG AGCTTCCTGC TCAAGTCTTT AGAGCAAGTG AGGAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC TGTGTGCCAC CTACAAGCTG TGCCACCCCG AGGAGCTGGT GCTGCTCGGA CACTCTCTGG GCATCCCCTG GGCTCCCCTG AGCTCCTGCC CCAGCCAGGC CCTGCAGCTG GCAGGCTGCT TGAGCCAACT CCATAGCGGC CTTTTCCTCT ACCAGGGGCT CCTGCAGGCC 10 CTGGAAGGGA TATCCCCCGA GTTGGGTCCC ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG GCAGCAGATG GAAGAACTGG GAATGGCCCC TGCCCTGCAG CCCACCCAGG GTGCCATGCC GGCCTTCGCC TCTGCTTTCC AGCGCCGGGC AGGAGGGGTC CTGGTTGCTA GCCATCTGCA GAGCTTCCTG GAGGTGTCGT ACCGCGTTCT ACGCCACCTT GCGCAGCCG 15 (2) INFORMACE PRO SEQ ID NO:266: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1044 párů bázi 20 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:266: 25 GCTGATGAAG AACTGTGTGG TGGGCTGTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 30 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGCCGCCAC CGTGGAGCCC GCGTCCACTC GGCGCCACCG CACCGACCAC CCAGGACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC TGTACGTAGA GGGCGGTGGA GGCTCCCCGG GTGGTGGTTC TGGCGGCGGC TCCAACATGG CTACACCATT GGGCCCTGCC 35 AGCTCCCTGC CCCAGAGCTT CCTGCTCAAG TCTTTAGAGC AAGTGAGRAA GATCCAGGGC GATGGCGCAG CGCTCCAGGA GAAGCTGTGT GCCACCTACA AGCTGTGCCA CCCCGAGGAG CTGGTGCTGC TCGGACACTC TCTGGGCATC CCCTGGGCTC CCCTGAGCTC CTGCCCCAGC CAGGCCCTGC AGCTGGCAGG CTGCTTGAGC CAACTCCATA GCGGCCTTTT CCTCTACCAG GGGCTCCTGC AGGCCCTGGA AGGGATATCC CCCGAGTTGG GTCCCACCTT GGACACACTG 40 CAGCTGGACG TCGCCGACTT TGCCACCACC ATCTGGCAGC AGATGGAAGA ACTGGGAATG GCCCCTGCCC TGCAGCCCAC CCAGGGTGCC ATGCCGGCCT TCGCCTCTGC TTTCCAGCGC CGGGCAGGAG GGGTCCTGGT TGCTAGCCAT CTGCAGAGCT TCCTGGAGGT GTCGTACCGC GTTCTACGCC ACCTTGCGCA GCCG 45 (2) INFORMACE PRO SEQ ID NO:267: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1077 párů bází (B) TYP: nukleová kyselina 50 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:267: 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1089 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1044 55 GCGGATGAGG AGCTGTGCGG CGGCTCAAGA CTGTCGCTGG ATACACTTTG TCACCAAATG ACCAACATCT CCCGCCTCCT ATCACTCGCC AGAACTTCTC CTGGGCGGTG GGTCAGGAGG CCCATCTCCT CCGACTTCGC TGGCCTCTGG CGGCTGGTCC GTCCAAGATG CAAGGCTTGC TGCCTTTCAG CCCCCCCCCA GCAGGAGACC TCCGAGCAGC CCGGTGCCTG GAGCTGCAGT TGGATCCGGA GGTACCCAGG TGTCAAAATC CGTGAGCTGT TGGCACAGCG CTGGATGGAG TGGAGCGCGT GAACACGGAG GCTGTCTTCG CTTCGTCCAG TGGTGGCGCT GAGGCCCTGG GTCAGCCCGA CTCCTCAACC ACTGCTCCTT CCAACACAGC CTGACTACCT GCTTCAAGAT 60 120 180 240 300 360 420 -544- 60 15 20 45 50 CZ 295843 B6 TACCCAGTCA CCGTGGCCTC CAACCTGCAG TACGTAGAGG GCGGTGGAGG CTCCCCGGGT GAACCGTCTG GTCCAATCTC TACTATCAAC CCGTCTCCTC CGTCTAAAGA ATCTCATAAA TCTCCAAACA TGGCTACACC ATTAGGCCCT GCCAGCTCCC TGCCCCAGAG CTTCCTGCTC AAGTGCTTAG AGCAAGTGAG GAAGATCCAG GGCGATGGCG CAGCGCTCCA GGAGAAGCTG 5 TGTGCCACCT ACAAGCTGTG CCACCCCGAG GAGCTGGTGC TGCTCGGACA CTCTCTGGGC ATCCCCTGGG CTCCCCTGAG CTCCTGCCCC AGCCAGGCCC TGCAGCTGGC AGGCTGCTTG AGCCAACTCC ATAGCGGCCT TTTCCTCTAC CAGGGGCTCC TGCAGGCCCT GGAAGGGATA TCCCCCGAGT TGGGTCCCAC CTTGGACACA CTGCAGCTGG ACGTCGCCGA CTTTGCCACC ACCATCTGGC AGCAGATGGA AGAACTGGGA ATGGCCCCTG CCCTGCAGCC CACCCAGGGT 10 GCCATGCCGG CCTTCGCCTC TGCTTTCCAG CGCCGGGCAG GAGGGGTCCT GGTTGCTAGC CATCTGCAGA GCTTCCTGGA GGTGTCGTAC CGCGTTCTAC GCCACCTTGC GCAGCCC (2) INFORMACE PRO SEQ ID NO:268: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1092 párů bázi (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:268: GCCGACGAGG AGCTGTGCGG TGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 25 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCAC CCAGGACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC 30 TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC TGCAGTACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AAACATGGCT ACACCATTAG GCCCTGCCAG CTCCCTGCCC CAGAGCTTCC TGCTCAAGTG CTTAGAGCAA GTGAGGAAGA TCCAGGGCGA TGGCGCAGCG CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC CCGAGGAGCT GGTGCTGCTC 35 GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CCCTGCCCTG CAGCCCACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG 40 GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC CC (2) INFORMACE PRO SEQ ID NO:269: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1110 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:269: GCAGACGAGG AGCTGTGCGG TGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 55 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCTC AGGGGGAGGT AGTGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 60 ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG CAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 480 540 600 660 720 780 840 900 960 1020 1077 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1092 60 120 180 240 300 360 420 480 540 - 545 - CZ 295843 B6 AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAC ACCATTAGGC CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTGCT TAGAGCAAGT GAGGAAGATC CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GTGCCACCCC GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT GGGCTCCCCT GAGCTCCTGC 5 CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC TCCATAGCGG CCTTTTCCTC TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG AGTTGGGTCC CACCTTGGAC ACACTGCAGC TGGACGTCGC CGACTTTGCC ACCACCATCT GGCAGCAGAT GGAAGAACTG GGAATGGCCC CTGCCCTGCA GCCCACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG 10 TACCGCGTTG TACGCCACCT TGCGCAGCCC (2) INFORMACE PRO SEQ ID NO:270: (i) CHARAKTERISTIKY SEKVENCE: 15 (A) DÉLKA: 1092 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 20 (xi) POPIS SEKVENCE: SEQ ID NO:270: GCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA 25 GGTGGATCCG GAGGTGGCAC CCAGGACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC TGCAGGACGA GGAGCTCTGC GGGGGCCTCT GGCGGCTGGT CCTGGCACAG CGCTGGATGG AGCGGCTCAA GACTGTCGCT GGGTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG AGATACACTT TGTCACCAAA TGTGCCTTTC AGCCGTACGT AGAGGGCGGT 30 GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AAACATGGCT ACACCATTAG GCCCTGCCAG CTCCGTGCCC CAGAGCTTCC TGCTCAAGTG CTTAGAGCAA GTGAGGAAGA TCCAGGGCGA TGGCGCAGCG CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC CCGAGGAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG 35 CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CCCTGCCCTG CAGCCCACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TATACGCCAC 40 CTTGCGCAGC CC (2) INFORMACE PRO SEQ ID NO:271: (i) CHARAKTERISTIKY SEKVENCE: 45 (A) DÉLKA: 1110 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 50 (xi) POPIS SEKVENCE: SEQ ID NO:271: GCTTCAAATC TGCAGGATGA AGAGCTGTGC GGGGGCCTCT GGCGGCTGGT CCTGGCACAG CGCTGGATGG AGCGGCTCAA GACTGTCGCT GGGTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG AGATACACTT TGTCACCAAA TGTGCCTTTC AGCCCCCCCC CAGCTGTCTT 55 CGCTTCGTCC AGACCAACAT CTCCCGCCTC CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG CTGAAGCCCT GGATCACTCG CCAGAACTTC TCCCGGTGCC TGGAGCTGCA GTGTCAGCCC GACTCCTCAA CCCTGGGCGG TGGGTCAGGA GGTGGGTCAG GAGGTGGATC CGGAGGTGGC TCAGGGGGAG GTAGTGGTAC CCAGGACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG 60 GCCTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC AACCCGTCTC ATCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAC ACCATTAGGC 600 660 720 780 840 900 960 1020 1080 1110 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1092 60 120 180 240 300 360 420 480 540 600 -546- 5 CZ 295843 B6 CCTGCCAGCT CAGGGCGATG GAGGAGCTGG CCCAGCCAGG TACCAGGGGC ACACTGCAGC GGAATGGCCC CAGCGCCGGG TACCGCGTTC CCCTGCCCCA GCGCAGCGCT TGCTGCTCGG CCCTGCAGCT TCCTGCAGGC TGGACGTCGC CTGCCCTGCA CAGGAGGGGT TACGCCACCT GAGCTTCCTG CCAGGAGAAG ACACTCTCTG GGCAGGCTGC CCTGGAAGGG CGACTTTGCC GCCCACCCAG CCTGGTTGCT TGCGCAGCCC CTCAAGTGCT CTGTGTGCCA GGCATCCCCT TTGAGCCAAC ATATCCCCCG ACCACCATCT GGTGCCATGC AGCCATCTGC TAGAGCAAGT CCTACAAGCT GGGCTCCCCT TCCATAGCGG AGTTGGGTCC GGCAGCAGAT CGGCCTTCGC AGAGCTTCCT GAGGAAGATC GTGCCACCCC GAGCTCCTGC CCTTTTCCTC CACCTTGGAC GGAAGAACTG CTCTGCTTTC GGAGGTGTCG 660 720 780 840 900 960 1020 1080 1110 10 (2) INFORMACE PRO SEQ ID NO:272: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1110 párů bází 15 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:272: 20 GCTAATCTGC AAGATGAGGA GCTGTGCGGG GGCCTCTGGC GGCTGGTCCT GGCACAGCGC TGGATGGAGC GGCTCAAGAC TGTCGCTGGG TCCAAGATGC AAGGCTTGCT GGAGCGCGTG AACACGGAGA TACACTTTGT CACCAAATGT GCCTTTCAGC CCCCCCCCAG CTGTCTTCGC TTCGTCCAGA CCAACATCTC CCGCCTCCTG CAGGAGACCT CCGAGCAGCT GGTGGCGCTG 25 AAGCCCTGGA TCACTCGCCA GAACTTCTCC CGGTGCCTGG AGCTGCAGTG TCAGCCCGAC TCCTCAACCC TGGGCGGTGG GTCAGGAGGT GGGTCAGGAG GTGGATCCGG AGGTGGCTCA GGGGGAGGTA GTGGTACCCA GGACTGCTCC TTCCAACACA GCCCCATCTC CTCCGACTTC GCTGTCAAAA TCCGTGAGCT GTCTGACTAC CTGCTTCAAG ATTACCCAGT CACCGTGGCC TCCTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 30 AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAC ACCATTAGGC CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTGCT TAGAGCAAGT GAGGAAGATC CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GTGCCACCCC GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT GGGCTCCCCT GAGCTCCTGC CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC TCCATAGCGG CCTTTTCCTC 35 TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG AGTTGGGTCC CACCTTGGAC ACACTGCAGC TGGACGTCGC CGACTTTGCC ACCACCATCT GGCAGCAGAT GGAAGAACTG GGAATGGCCC CTGCCCTGCA GCCCACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG TACCGCGTTA TACGCCACCT TGCGCAGCCC 40 (2) INFORMACE PRO SEQ ID NO:273: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1110 párů bází 45 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:273: 50 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1110 55 GCGCTGCAGG ATGAAGAGCT GTGTGGCGGC ATGGAGCGGC TCAAGACTGT CGCTGGGTCC ACGGAGATAC ACTTTGTCAC CAAATGTGCC GTCCAGACCA ACATCTCCCG CCTCCTGCAG CCCTGGATCA CTCGCCAGAA CTTCTCCCGG TCAACCCTGG GCGGTGGGTC AGGAGGTGGG GGAGGTAGTG GTACCCAGGA CTGCTCCTTC GTCAAAATCC GTGAGCTGTC TGACTACCTG AACTACGTAG AGGGCGGTGG AGGCTCCCCG AACCCGTCTC CTCCGTCTAA AGAATCTCAT CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCTGGCGGC TGGTCCTGGC ACAGCGCTTG AAGATGCAAG GCTTGCTGGA GCGCGTGAAC TTTCAGCCCC CCCCCAGCTG TCTTCGCTTC GAGACCTCCG AGCAGCTGGT GGCGCTGAAG TGCCTGGAGC TGCAGTGTCA GCCCGACTCC TCAGGAGGTG GATCCGGAGG TGGCTCAGGG CAACACAGCC CCATCTCCTC CGACTTCGCT CTTCAAGATT ACCCAGTCAC CGTGGCCTCC GGTGAACCGT CTGGTCCAAT CTCTACTATC AAATCTCCAA ACATGGCTAC ACCATTAGGC CTCAAGTGCT TAGAGCAAGT GAGGAAGATC 60 120 180 240 300 360 420 480 540 600 660 -547- 60 CZ 295843 B6 CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GTGCCACCCC GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT GGGCTCCCCT GAGCTCCTGC CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC TCCATAGCGG CCTTTTCCTC TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG AGTTGGGTCC CACCTTGGAC 5 ACACTGCAGC TGGACGTCGC CGACTTTGCC ACCACCATCT GGCAGCAGAT GGAAGAACTG GGAATGGCCC CTGCCCTGCA GCCCACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG TACCGCGTTC TACGCCACCT TGCGCAGCCC 10 (2) INFORMACE PRO SEQ ID NO:274: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1110 párů bází (B) TYP: nukleová kyselina 15 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:274: 20 GCACTGTGCG GTGGTCTGTG GCGTCTGGTC CTGGCACAGC GCTGGATGGA GCGGCTCAAG ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG TGAACACGGA GATACACTTT GTCACCAAAT GTGCCTTTCA GCCCCCCCCC AGCTGTCTTC GCTTCGTCCA GACCAACATC TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC TGAAGCCCTG GATCACTCGC CAGAACTTCT CCCGGTGCCT GGAGCTACAG TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT 25 GGGTCAGGAG GTGGGTCAGG AGGTGGATCC GGAGGTGGCT CAGGGGGAGG TAGTGGTACC CAGGACTGCT CCTTCCAACA CAGCCCCATC TCCTCCGACT TCGCTGTCAA AATCCGTGAG CTGTCTGACT ACCTGCTTCA AGATTACCCA GTCACCGTGG CCTCCAACCT GCAGGACGAG GAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAC ACCATTAGGC 30 CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTGCT TAGAGCAAGT GAGGAAGATC CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GTGCCACCCC GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT GGGCTCCCCT GAGCTCCTGC CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC TCCATAGCGG CCTTTTCCTC TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG AGTTGGGTCC CACCTTGGAC 35 ACACTGCAGC TGGACGTCGC CGACTTTGCC ACCACCATCT GGCAGCAGAT GGAAGAACTG GGAATGGCCC CTGCCCTGCA GCCCACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG TACCGCGTTC TACGCCACCT TGCGCAGCCC 40 (2) INFORMACE PRO SEQ ID NO:275: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1092 párů bází (B) TYP: nukleová kyselina 45 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:275: 50 GCCTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG AGATACACTT TGTCACCAAA TGTGCCTTTC AGCCCCCCCC CAGCTGTCTT CGCTTCGTCC AGACCAACAT CTCCCGCCTC CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG CTGAAGCCCT GGATCACTCG CCAGAACTTC TCCCGGTGCC TGGAGCTGCA GTGTCAGCCC GACTCCTCAA CCCTGGGCGG TGGGTCAGGA GGTGGGTCAG GAGGTGGATC CGGAGGTGGC ACCCAGGACT GCTCCTTCCA ACACAGCCCC 55 ATCTCCTCCG ACTTCGCTGT CAAAATCCGT GAGCTGTCTG ACTACCTGCT TCAAGATTAC CCAGTCACCG TGGCCTCCAA CCTGCAGGAC GAGGAGCTCT GCGGGGGCCT CTGGCGGCTG GTCCTGGCAC AGCGCTGGAT GGAGCGGCTC AAGACTGTCG CTGGCTACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AAACATGGCT ACACCATTAG GCCCTGCCAG CTCCCTGCCC 60 CAGAGCTTCC TGCTCAAGTG CTTAGAGCAA GTGAGGAAGA TCCAGGGCGA TGGCGCAGCG CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC CCGAGGAGCT GGTGCTGCTC 720 780 840 900 960 1020 1080 1110 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1110 60 120 180 240 300 360 420 480 540 600 660 720 -548- 10 15 40 45 CZ 295843 B6 GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CCCTGCCCTG 5 CAGCCCACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC CC (2) INFORMACE PRO SEQ ID NO:276: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1092 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:276: GCCTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG AGATACACTT TGTCACCAAA 20 TGTGCCTTTC AGCCCCCCCC CAGCTGTCTT CGCTTCGTCC AGACCAACAT CTCCCGCCTC CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG CTGAAGCCCT GGATCACTCG CCAGAACTTC TCCCGGTGCC TGGAGCTGCA GTGTCAGCCC GACTCCTCAA CCCTGGGCGG TGGGTCAGGA GGTGGGTCAG GAGGTGGATC CGGAGGTGGC ACCCAGGACT GCTCCTTCCA ACACAGCCCC ATCTCCTCCG ACTTCGCTGT CAAAATCCGT GAGCTGTCTG ACTACCTGCT TCAAGATTAC 25 CCAGTCACCG TGGCCTCCAA CCTGCAGGAC GAGGAGCTCT GCGGGGGCCT CTGGCGGCTG GTCCTGGCAC AGCGCTGGAT GGAGCGGCTC AAGACTGTCG CTGGCTACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AAACATGGCT ACACCATTAG GCCCTGCCAG CTCCCTGCCC CAGAGCTTCC TGCTCAAGTG CTTAGAGCAA GTGAGGAAGA TCCAGGGCGA TGGCGCAGCG 30 CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC CCGAGGAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CCCTGCCCTG 35 CAGCCCACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC CC (2) INFORMACE PRO SEQ ID NO:277: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1110 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:277: GCGCTGTGTG GTGGTCTGTG GCGTCTGGTC CTGGCACAGC GCTGGATGGA GCGGCTCAAG 50 ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG TGAACACGGA GATACACTTT GTCACCAAAT GTGCCTTTCA GCCCCCCCCC AGCTGTCTTC GCTTCGTCCA GACCAACATC TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC TGAAGCCCTG GATCACTCGC CAGAACTTCT CCCGGTGCCT GGAGCTGCAG TGTCGGCCCG ACTCCTCAAC CCTGGGCGGT GGGTCAGGAG GTGGGTCAGG AGGTGGATCC GGAGGTGGCT CAGGGGGAGG TAGTGGTACC 55 CAGGACTGCT CCTTCCAACA CAGCCCCATC TCCTCCAACT TCGCTGTCAA GATCCGTGAG CTGTCTGACT ACCTGCTTCA AGATTACCCA GTCACCGTGG CCTCCAACCT GCAGGACGAG GAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT TTTTACTATC AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAC ACCATTAGGC CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTGCT TAGAGCAAGT GAGGAAGATC 60 CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GTGCCACCCC GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT GGGCTCCCCT GAGCTCCTGC 780 840 900 960 1020 1080 1092 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1092 60 120 180 240 300 360 420 480 540 600 660 720 780 -549- 5 CZ 295843 B6 CCCAGCCAGG CCCTGCAGCT TACCAGGGGC TCCTGCAGGC ACACTGCAGC TGGACGTCGC GGAATGGCCC CTGCCCTGCA CAGCGCCGGG CAGGAGGGGT TACCGCGTTC TACGCCACCT GGCAGGCTGC TTGAGCCAAC CCTGGAAGGG ATATCCCCCG CGACTTTGCC ACCACCATCT GCCCACCCAG GGTGCCATGC CCTGGTTGCT AGCCATCTGC TGCGCAGCCC TCCATAGCGG CCTTTTCCTC AGTTGGGTCC CACCTTGGAC GGCAGCAGAT GGAAGAACTG CGGCCTTCGC CTCTGCTTTC AGAGCTTCCT GGAGGTGTCG 840 900 960 1020 1080 1110 10 15 (2) INFORMACE PRO SEQ ID NO:278: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1110 párů bázi (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:278: GCTGAACTGT GTGGTGGTCT GTGGCGTCTG GTCCTGGCAC AGCGCTGGAT GGAGCGGCTC AAGACTGTCG CTGGGTCCAA GATGCAAGGC TTGCTGGAGC GCGTGAACAC GGAGATACAC 20 TTTGTCACCA AATGTGCCTT TCAGCCCCCC CCCAGCTGTC TTCGCTTCGT CCAGACCAAC ATCTCCCGCC TCCTGCAGGA GACCTCCGAG CAGCTGGTGG CGCTGAAGCC CTGGATCACT CGCCAGAACT TCTCCCGGTG CCTGGAGCTG CAGTGTCAGC CCGACTCCTC AACCCTGGGC GGTGGGTCAG GAGGTGGGTC AGGAGGTGGA TCCGGAGGTG GCTCAGGGGG AGGTAGTGGT ACCCAGGACT GCTCCTTCCA ACACAGCCCC ATCTCCTCCG ACTTCGCTGT CAAAATCCGT 25 GAGCTGTCTG ACTACCTGCT TCAAGATTAC CCAGTCACCG TGGCCTCCAA CCTGCAGGAC GAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAC ACCATTAGGC CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTGCT TAGAGCAAGT GAGGAAGATC CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GTGCCACCCC 30 GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT GGGCTCCCCT GAGCTCCTGC CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC TCCATAGCGG CCTTTTCCTC TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG AGTTGGGTCC CACCTTGGAC ACACTGCAGC TGGACGTCGC CGACTTTGCC ACCACCATCT GGCAGCAGAT GGAAGAACTG GGAATGGCCC CTGCCCTGCA GCCCACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC 35 CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG TACCGCGTTC TACGCCACCT TGCGCAGCCC 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1110 40 45 (2) INFORMACE PRO SEQ ID NO:279: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1110 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:279: GCTGAAGAAC TGTGTGGTGG CCTGTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA 50 CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC AGCCCGACTC CTCAACCCTG GGCGGTGGGT CAGGAGGTGG GTCAGGAGGT GGATCCGGAG GTGGCTCAGG GGGAGGTAGT GGTACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC 55 CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG GACTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAC ACCATTAGGC CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTGCT TAGAGCAAGT GAGGAAGATC CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GTGCCACCCC 60 GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT GGGCTCCCCT GAGCTCCTGC CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC TCCATAGCGG CCTTTTCCTC 60 120 180 240 300 360 420 480 540 600 660 720 780 840 -550 - 5 CZ 295843 B6 TACCAGGGGC TCCTGCAGGC ACACTGCAGC TGGACGTCGC GGAATGGCCC CTGCCCTGCA CAGCGCCGGG CAGGAGGGGT TACCGCGTTC TACGCCACCT CCTGGAAGGG ATATCCCCCG CGACTTTGCC ACCACCATCT GCCCACCCAG GGTGCCATGC CCTGGTTGCT AGCCATCTGC TGCGCAGCCC AGTTGGGTCC CACCTTGGAC GGCAGCAGAT GGAAGAACTG CGGCCTTCGC CTCTGCTTTC AGAGCTTCCT GGAGGTGTCG 900 960 1020 1080 1110 (2) INFORMACE PRO SEQ ID NO:280: (i) CHARAKTERISTIKY SEKVENCE: 10 (A) DÉLKA: 1110 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 15 (xi) POPIS SEKVENCE: SEQ ID NO:280: GCTCAGGACG AGGAACTGTG TGGTGGTCTC TGGCGGCTGG TCCTGGCACA GCGCTGGATG GAGCGGCTCA AGACTGTCGC TGGGTCCAAG ATGCAAGGCT TGCTGGAGCG CGTGAACACG GAGATACACT TTGTCACCAA ATGTGCCTTT CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC 20 CAGACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG GTGGGTCAGG AGGTGGGTCA GGAGGTGGAT CCGGAGGTGG CTCAGGGGGA GGTAGTGGTA CCCAGGACTG CTCCTTCCAA CACAGCCCCA TCTCCTCCGA CTTCGCTGTC AAAATCCGTG AGCTGTCTGA CTACCTGCTT CAAGATTACC CAGTCACCGT GGCCTCCAAC 25 CTGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAC ACCATTAGGC CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTGCT TAGAGCAAGT GAGGAAGATC CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GTGCCACCCC GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT GGGCTCCCCT GAGCTCCTGC 30 CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC TCCATAGCGG CCTTTTCCTC TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG AGTTGGGTCC CACCTTGGAC ACACTGCAGC TGGACGTCGC CGACTTTGCC ACCACCATCT GGCAGCAGAT GGAAGAACTG GGAATGGCCC CTGCCCTGCA GCCCACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG 35 TACCGCGTTC TACGCCACCT TGCGCAGCCC (2) INFORMACE PRO SEQ ID NO:281: (i) CHARAKTERISTIKY SEKVENCE: 40 (A) DÉLKA: 1092 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 45 (xi) POPIS SEKVENCE: SEQ ID NO:281: GCCACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG GTGGGTCAGG AGGTGGGTCA GGAGGTGGAT CCGGAGGTGG CACCCAGGAC 50 TGCTCCTTCC AACACAGCCC CATCTCCTCC GACTTTGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC TTCAAGATTA CCCAGTCACC GTGGCCTCCA ACCTGCAGGA CGAGGAGCTC TGCGGGGGCC TCTGGCGGCT GGTCCTGGCA CAGCGCTGGA TGGAGCGGCT CAAGACTGTC GCTGGGTCCA AGATGCAAGG CTTGCTGGAG CGCGTGAACA CGGAGATACA CTTTGTCACC AAATGTGCCT TTCAGCCCCC CCCCAGCTGT CTTCGCTTCG TCCAGTACGT AGAGGGCGGT 55 GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AAACATGGCT ACACCATTAG GCCCTGCCAG CTCCCTGCCC CAGAGCTTCC TGCTCAAGTG CTTAGAGCAA GTGAGGAAGA TCCAGGGCGA TGGCGCAGCG CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC CCGAGGAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG 60 CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1110 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 -551 - CZ 295843 B6 GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CCCTGCCCTG CAGCCCACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGGCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC CC 5 (2) INFORMACE PRO SEQ ID NO:282: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1065 párů bázi 10 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:282: 15 GCTGATGAAG AACTGTGTGG TGGTCTGTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 20 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCTC AGGGGGAGGT AGTGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG CAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGGTGGTT CTGGCGGCGG CTCCAACATG 25 GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG 30 GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCG 35 (2) INFORMACE PRO SEQ ID NO:283: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1110 párů bází (B) TYP: nukleová kyselina 40 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:283: 45 GCTCAAGATG AAGAACTGTG CGGTGGTCTC TGGCGGCTGG TCCTGGCACA GCGCTGGATG GAGCGGCTCA AGACTGTCGC TGGGTCCAAG ATGCAAGGCT TGCTGGAGCG CGTGAACACG GAGATACACT TTGTCACCAA ATGTGCCTTT CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA 50 ACCCTGGGCG GTGGGTCAGG AGGTGGGTCA GGAGGCGGAT CCGGAGGTGG CTCAGGGGGA GGTAGTGGTA CCCAGGACTG CTCCTTCCAA CACAGCCCCA TCTCCTCCGA CTCCGCTGTC AAAATCCGTG AGCTGTCTGA CTACCTGCTT CAAGATTACC CAGTCACCGT GGCCTCCAAC CTGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAC ACCATTAGGC 55 CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTGCT TAGAGCAAGT GAGGAAGATC CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GTGCCACCCC GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT GGGCTCCCCT GAGCTCCTGC CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC TCCATAGCGG CCTTTTCCTC TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG AGTTGGGTCC CACCTTGGAC 60 ACACTGCAGC TGGACGTCGC CGACTTTGCC ACCACCATCT GGCAGCAGAT GGAAGAACTG GGAATGGCCC CTGCCCTGCA GCCCACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC 960 1020 1080 1092 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1065 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 - 552 - 35 40 CZ 295843 B6 CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG TACCGCGTTC TACGCCACCT TGCGCAGCCC (2) INFORMACE PRO SEQ ID NO:284: 5 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1098 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché 10 (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:284: GCGCTGTGTG GTGGCCTGTG GCGTCTGGTC CTGGCACAGC GCTGGATGGA GCGGCTCAAG 15 ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG TGAACACGGA GATACACTTT GTCACCAAAT ATGCCTTTCA GCCCCCCCCC AGCTGTCTTC GCTTCGTCCA GACCAACATC TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC TGAAGCCCTG GATCACTCGC CAGAACTTCT CCCGGTGCCT GGAGCTGCAG TGTCGGCCCG ACTCCTCAAC CCTGGGCGGT GGGTCAGGAG GTGGATCCGG AGGTGGCTCA GGGGGAGGTA GTGGTACCCA GGACTGCTCC 20 TTCCAACACA GCCCCATCTC CTCCGACTTC GCTGTCAAGA TCCGTGAGCT GTCTGACTAC CTGCTTCAAG ATTACCCAGT CACCGTGGCC TCCAACCTGC AGGACGAGGA GTACGTAGAG GGCGGTGGAG GCTCCCCGGG TGAACCGTCT GGTCCAATCT CTACTATCAA CCCGTCTCCT CCGTCTAAAG AATCTCATAA ATCTCCAAAC ATGGCTACAC CATTAGGCCC TGCCAGCTCC CTGCCCCAGA GCTTCCTGCT CAAGTGCTTA GAGCAAGTGA GGAAGATCCA GGGCGATGGC 25 GCAGCGCTCC AGGAGAAGCT GTGTGCCACC TACAAGCTGT GCCACCCCGA GGAGCTGGTG CTGCTCGGAC ACTCTCTGGG CATCCCCTGG GCTCCCCTGA GCTCCTGCCC CAGCCAGGCC CTGCAGCTGG CAGGCTGCTT GAGCCAACTC CATAGCGGCC TTTTCCTCTA CCAGGGGCTC CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC CACCATCTGG CAGCAGATGG AAGAACTGGG AATGGCCCCT 30 GCCCTGCAGC CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA CGCCACCTTG CGCAGCCC (2) INFORMACE PRO SEQ ID NO:285: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1092 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:285: GCCTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG AGATACACTT TGTCACCAAA 45 TGTGCCTTTC AGCCCCCCCC CAGCTGTCTT CGCTTCGTCC AGACCAACAT CTCCCGCCTC CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG CTGAAGCCCT GGATCACTCG CCAGAACTTC TTCCGGTGCC TGGAGCTGCA GTGTCAGCCC GACTCCTCAA CCCTGGGCGG TGGGTCAGGA GGTGGGTCAG GAGGTGGATC CGGAGGTGGC ACCCAGGACT GCTCCTTCCA ACACAGCCCC ATCTCCTCCG ACTTCGCTGT CAAAATCCGT GAGCTGTCTG ACTACCTGCT TCAAGATTAC 50 CCAGTCACCG TGGCCTCCAA CCTGCAGGAC GAGGAGCTCT GCGGGGGCCT CTGGCGGCTG GTCCTGGCAC AGCGCTGGAT GGAGCGGCTC AAGACTGTCG CTGGCTACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AAACATGGCT ACACCATTAG GCCCTGCCAG CTCCCTGCCC CAGAGCTTCC TGCTCAAGTG CTTAGAGCAA GTGAGGAAGA TCCAGGGCGA TGGCGCAGCG 55 CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC CCGAGGAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CCCTGCCCTG 60 CAGCCCACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCAC 1080 1110 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1098 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 - 553 - CZ 295843 B6 CTTGCGCAGC CC 1092 (2) INFORMACE PRO SEQ ID NO:286: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1134 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:286: GCTCAAGACG AAGAACTGTG TGGTGGTCTC TGGCGGCTGG TCCTGGCACA GCGCTGGATG 60 GAGCGGCTCA AGACTGTCGC TGGGTCCAAG ATGCAAGGCT TGCTGGAGCG CGTGAACACG 120 GAGATACACT TTGTCACCAA ATGTGCCTTT CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC 180 CAGACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC 240 TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA 300 ACCCTGGGCG GTGGGTCAGG AGGTGGGTCA GGCGGTGGTT CTGGCGGAGG ATCCGGCGGC 360 GGAAGCGGAG GTGGCTCTGG GGGAGGTAGT GGTACCCAGG ACTGCTCCTT CCAACACAGC 420 CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT 480 TACCCAGTCA CCGTGGCCTC CAACCTGTAC GTAGAGGGCG GTGGAGGCTC CCCGGGTGAA 540 CCGTCTGGTC CAATCTCTAC TATCAACCCG TCTCCTCCGT CTAAAGAATC TCATAAATCT 600 CCAAACATGG CTACACCATT AGGCCCTGCC AGCTCCCTGC CCCAGAGCTT CCTGCTCAAG 660 TGCTTAGAGC AAGTGAGGAA GATCCAGGGC GATGGCGCAG CGCTCCAGGA GAAGCTGTGT 720 GCCACCTACA AGCTGTGCCA CCCCGAGGAG CTGGTGCTGC TCGGACACTC TCTGGGCATC 780 CCCTGGGCTC CCCTGAGCTC CTGCCCCAGC CAGGCCCTGC AGCTGGCAGG CTGCTTGAGC 840 CAACTCCATA GCGGCCTTTT CCTCTACCAG GGGCTCCTGC AGGCCCTGGA AGGGATATCC 900 CCCGAGTTGG GTCCCACCTT GGACACACTG CAGCTGGACG TCGCCGACTT TGCCACCACC 960 ATCTGGCAGC AGATGGAAGA ACTGGGAATG GCCCCTGCCC TGCAGCCCAC CCAGGGTGCC 1020 ATGCCGGCCT TCGCCTCTGC TTTCCAGCGC CGGGCAGGAG GGGTCCTGGT TGCTAGCCAT 1080 CTGCAGAGCT TCCTGGAGGT GTCGTACCGC GTTCTACGCC ACCTTGCGCA GCCC 1134 (2) INFORMACE PRO SEQ ID NO:287: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1092 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:287: GCCCAAGATG AAGAACTGTG TGGTGGCCTC TGGCGGCTGG TCCTGGCACA GCGCTGGATG 60 GAGCGGCTCA AGACTGTCGC TGGGTCCAAG ATGCAAGGCT TGCTGGAGCG CGTGAACACG 120 GAGATACACT TTGTCACCAA ATGTGCCTTT CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC 180 CAGACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC 240 TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA 300 ACCCTGCCGC CACCGTGGAG CCCGCGTCCA CTCGGCGCCA CCGCACCGAC CACCCAGGAC 360 TGCTCCTTCC AACACAGCCC CATCTCCTCC GACTTCGCTG TCAAAATCCG TGAGCTGTCT 420 GACTACCTGC TTCAAGATTA CCCAGTCACC GTGGCCTCCA ACCTGTACGT AGAGGGCGGT 480 GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 540 AAAGAATCTC ATAAATCTCC AAACATGGCT ACACCATTAG GCCCTGCCAG CTCCCTGCCC 600 CAGAGCTTCC TGCTCAAGTG CTTAGAGCAA GTGAGGAAGA TCCAGGGCGA TGGCGCAGCG 660 CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC CCGAGGAGCT GGTGCTGCTC 720 GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG 780 CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG 840 GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC 900 GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CCCTGCCCTG 960 CAGCCCACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG 1020 GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCAC 1080 CTTGCGCAGC CC 1092 CZ 295843 B6 (2) INFORMACE PRO SEQ ID NO:288: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1110 párů bází 5 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:288: 10 GCCCAAGATG AAGAACTGTG TGGTGGCCTC TGGCGGCTGG TCCTGGCACA GCGCTGGATG 60 GAGCGGCTCA AGACTGTCGC TGGGTCCAAG ATGCAAGGCT TGCTGGAGCG CGTGAACACG 120 GAGATACACT TTGTCACCAA ATGTGCCTTT CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC 180 CAGACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC 240 15 TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA 300 ACCCTGCCGC CACCGTGGAG CCCGCGTCCA CTCGGCGCCA CCGCACCGAC CGCTGGACAA 360 CCGCCTCTGA CCCAGGACTG CTCCTTCCAA CACAGCCCCA TCTCCTCCGA CTTCGCTGTC 420 AAAATCCGTG AGCTGTCTGA CTACCTGCTT CAAGATTACC CAGTCACCGT GGCCTCCAAC 480 CTGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 540 20 AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAC ACCATTAGGC 600 CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTGCT TAGAGCAAGT GAGGAAGATC 660 CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GTGCCACCCC 720 GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT GGGCTCCCCT GAGCTCCTGC 780 CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC TCCATAGCGG CCTTTTCCTC 840 25 TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG AGTTGGGTCC CACCTTGGAC 900 ACACTGCAGC TGGACGTCGC CGACTTTGCC ACCACCATCT GGCAGCAGAT GGAAGAACTG 960 GGAATGGCCC CTGCCCTGCA GCCCACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC 1020 CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG 1080 TACCGCGTTC TACGCCACCT TGCGCAGCCC 1110 30 (2) INFORMACE PRO SEQ ID NO:289: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1134 párů bází 35 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:289: 40 GCTGATGAAG AACTGTGTGG TGGGCTGTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60 CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180 ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240 45 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300 CTGGGCGGTG GGTCAGGAGG TGGGTCAGGC GGTGGTTCTG GCGGAGGATC CGGCGGCGGA 360 AGCGGAGGTG GCTCTGGGGG AGGTAGTGGT ACCCAGGACT GCTCCTTCCA ACACAGCCCC 420 ATCTCCTCCG ACTTCGCTGT CAAAATCCGT GAGCTGTCTG ACTACCTGCT TCAAGATTAC 480 CCAGTCACCG TGGCCTCCAA CCTGCAGTAC GTAGAGGGCG GTGGAGGCTC CCCGGGTGAA 540 50 CCGTCTGGTC CAATCTCTAC TATCAACCCG TCTCCTCCGT CTAAAGAATC TCATAAATCT 600 CCAAACATGG CTACACCATT AGGCCCTGCC AGCTCCCTGC CCCAGAGCTT CCTGCTCAAG 660 TGCTTAGAGC AAGTGAGGAA GATCCAGGGC GATGGCGCAG CGCTCCAGGA GAAGCTGTGT 720 GCCACCTACA AGCTGTGCCA CCCCGAGGAG CTGGTGCTGC TCGGACACTC TCTGGGCATC 780 CCCTGGGCTC CCCTGAGCTC CTGCCCCAGC CAGGCCCTGC AGCTGGCAGG CTGCTTGAGC 840 55 CAACTCCATA GCGGCCTTTT CCTCTACCAG GGGCTCCTGC AGGCCCTGGA AGGGATATCC 900 CCCGAGTTGG GTCCCACCTT GGACACACTG CAGCTGGACG TCGCCGACTT TGCCACCACC 960 ATCTGGCAGC AGATGGAAGA ACTGGGAATG GCCCCTGCCC TGCAGCCCAC CCAGGGTGCC 1020 ATGCCGGCCT TCGCCTCTGC TTTCCAGCGC CGGGCAGGAG GGGTCCTGGT TGCTAGCCAT 1080 CTGCAGAGCT TCCTGGAGGT GTCGTACCGC GTTCTACGCC ACCTTGCGCA GCCC 1134 - 555 - 60 CZ 295843 B6 (2) INFORMACE PRO SEQ ID NO:290: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1134 párů bázi 5 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:290: 10 GCTGATGAAG AACTGTGTGG TGGGCTGTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60 CGGCCCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180 ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240 15 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300 CTGGGCGGTG GGTCAGGAGG TGGGTCAGGC GGTGGTTCTG GCGGAGGATC CGGCGGCGGA 360 AGCGGAGGTG GCTCTGGGGG AGGTAGTGGT ACCCAGGACT GCTCCTTCCA ACACAGCCCC 420 ATCTCCTCCG ACTTCGCTGT CAAAATCCGT GAGCTGTCTG ACTACCTGCT TCAAGATTAC 480 CCAGTCACCG TGGCCTCCAA CCTGCAGTAC GTAGAGGGCG GTGGAGGCTC CCCGGGTGAA 540 20 CCGTCTGGTC CAATCTCTAC TATCAACCCG TCTCCTCCGT CTAAAGAATC TCATAAATCT 600 CCAAACATGG CTACACCATT AGGCCCTGCC AGCTCCCTGC CCCAGAGCTT CCTGCTCAAG 660 TGCTTAGAGC AAGTGAGGAA GATCCAGGGC GATGGCGCAG CGCTCCAGGA GAAGCTGTGT 720 GCCACCTACA AGCTGTGCCA CCCCGAGGAG CTGGTGCTGC TCGGACACTC TCTGGGCATC 780 CCCTGGGCTC CCCTGAGCTC CTGCCCCAGC CAGGCCCTGC AGCTGGCAGG CTGCTTGAGC 840 25 CAACTCCATA GCGGCCTTTT CCTCTACCAG GGGCTCCTGC AGGCCCTGGA AGGGATATCC 900 CCCGAGTTGG GTCCCACCTT GGACACACTG CAGCTGGACG TCGCCGACTT TGCCACCACC 960 ATCTGGCAGC AGATGGAAGA ACTGGGAATG GCCCCTGCCC TGCAGCCCAC CCAGGGTGCC 1020 ATGCCGGCCT TCGCCTCTGC TTTCCAGCGC CGGGCAGGAG GGGTCCTGGT TGCTAGCCAT 1080 CTGCAGAGCT TCCTGGAGGT GTCGTACCGC GTTCTACGCC ACCTTGCGCA GCCC 1134 30 (2) INFORMACE PRO SEQ ID NO:291: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1110 párů bází 35 (B),TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:291: 40 GCGGACGAGG AGCTGTGCGG TGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60 CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180 ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240 45 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300 CTGCCGCCAC CGTGGAGCCC GCGTCCACTC GGCGCCACCG CACCGACCGC TGGACAACCG 360 CCTCTGACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 420 ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 480 CAGTACGTAG AGGGCGGTGG AGGCACCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 540 50 AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAC ACCATTAGGC 600 CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTGCT TAGAGCAAGT GAGGAAGATC 660 CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GTGCCACCCC 720 GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT GGGCTCCCCT GAGCTCCTGC 780 CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC TCCATAGCGG CCTTTTCCTC 840 55 TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG AGTTGGGTCC CACCTTGGAC 900 ACACTGCAGC TGGACGTCGC CGACTTTGCC ACCACCATCT GGCAGCAGAT GGAAGAACTG 960 GGAATGGCCC CTGCCCTGCA GCCCACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC 1020 CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG 1080 TACCGCGTTC TACGCCACCT TGCGCAGCCC 1110 -556- 60 CZ 295843 B6 (2) INFORMACE PRO SEQ ID NO:292: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1041 párů bází 5 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:292: 10 GCTGATGAGG AGCTGTGTGG TGGTCTGTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 15 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGT AGAGACGGTG TTTCACCGTG TCAGCCAGGA TGGTCTAGAT CTCCTGACCT CGACCCAGGA CTGCTCCTTC CAACACAGCC CCATCTCCTC CGACTTCGCT GTCAAAATCC GTGAGCTGTC TGACTACCTG CTTCAAGATT ACCCAGTCAC CGTGGCCTCC AACCTGCAGT ACGTAGAGGG CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA CACCATTGGG CCCTGCCAGC 20 TCCCTGCCCC AGAGCTTCCT GCTCAAGTCT TTAGAGCAAG TGAGAAAGAT CCAGGGCGAT GGCGCAGCGC TCCAGGAGAA GCTGTGTGCC ACTAACAAGC TGTGCCACCC CGAGGAGCTG GTGCTGCTCG GACACTCTCT GGGCATCCCC TGGGCTCCCC TGAGCTCCTG CCCCAGCCAG GCCCTGCAGC TGGCAGGCTG CTTGAGCCAA CTCCATAGCG GCCTTTTCCT CTACCAGGGG CTCCTGCAGG CCCTGGAAGG GATATCCCCC GAGTTGGGTC CCACCTTGGA CACACTGCAG 25 CTGGACGTCG CCGACTTTGC CACCACCATC TGGCAGCAGA TGGAAGAACT GGGAATGGCC CCTGCCCTGC AGCCCACCCA GGGTGCCATG CCGGCCTTCG CCTCTGCTTT CCAGCGCCGG GCAGGAGGGG TCCTGGTTGC TAGCCATCTG CAGAGCTTCC TGGAGGTGTC GTACCGCGTT CTACGCCACC TTGCGCAGCC G 30 (2) INFORMACE PRO SEQ ID NO:293: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1152 párů bází (B) TYP: nukleová kyselina 35 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:293: 40 GCTGATGAAG AACTGTGTGG TGGGCTGTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 45 CTGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAC ACCATTGGGC CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTCTT TAGAGCAAGT GAGAAAGATC CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GTGCCACCCC GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT GGGCTCCCCT GAGCTCCTGC 50 CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC TCCATAGCGG CCTTTTCCTC TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG AGTTGGGTCC CACCTTGGAC ACACTGCAGC TGGACGTCGC CGACTTTGCC ACCACCATCT GGCAGCAGAT GGAAGAACTG GGAATGGCCC CTGCCCTGCA GCCCACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG 55 TACCGCGTTC TACGCCACCT TGCGCAGCCC TACGTAGAGG GCGGTGGAGG CTCCCCGGGT GAACCGTCTG GTCCAATCTC TACTATCAAC CCGTCTCCTC CGTCTAAAGA ATCTCATAAA TCTCCAAACA TGGCAACCCA GGACTGCTCT TTTCAACACA GCCCCATCTC CTCCGACTTC GCTGTCAAAA TCCGTGAGCT GTCTGACTAC CTGCTTCAAG ATTACCCAGT CACCGTGGCC TCCAACCTGC AG 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1041 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1140 1152 -557- 60 CZ 295843 B6 (2) INFORMACE PRO SEQ ID NO:294: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1047 párů bází 5 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:294: 10 GCCACCCAGG ACTGCTCCTT TCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG GAGCCGAAGA GCCCGGACAC CCATACTAGT CCGCCATCTC CGACACCATT AGGCCCTGCC AGCTCCCTGC CCCAGAGCTT CCTGCTCAAG TCTTTAGAGC AAGTGAGAAA GATCCAGGGC 15 GATGGCGCAG CGCTCCAGGA GAAGCTGTGT GCCACCTACA AGCTGTGCCA CCCCGAGGAG CTGGTGCTGC TCGGACACTC TCTGGGCATC CCCTGGGCTC CCCTGAGCTC CTGCCCCAGC CAGGCCCTGC AGCTGGCAGG CTGCTTGAGC CAACTCCATA GCGGCCTTTT CCTCTACCAG GGGCTCCTGC AGGCCCTGGA AGGGATATCC CCCGAGTTGG GCCCCACCTT GGACACACTG CAGCTGGACG TCGCCGACTT TGCCACCACC ATCTGGCAGC AGATGGAAGA ACTGGGAATG 20 GCCCCTGCCC TGCAGCCCAC CCAGGGTGCC ATGCCGGCCT TCGCCTCTGC TTTCCAGCGC CGGGCAGGAG GGGTCCTGGT TGCTAGCCAT CTGCAGAGCT TCCTGGAGGT GTCGTACCGC GTTCTACGCC ACCTTGCGCA GCCCTCTGCA GAACCGAAAT CTCCGGATAC TCATACCAGC CCGCCATCCC CGGGTTCTAA TCTGCAAGAT GAAGAGCTGT GCGGGGGCCT CTGGCGGCTG GTCCTGGCAC AGCGCTGGAT GGAGCGGCTC AAGACTGTCG CTGGGTCCAA GATGCAAGGC 25 TTGCTGGAGC GCGTGAACAC GGAGATACAC TTTGTCACCA AATGTGCCTT TCAGCCCCCC CCCAGCTGCC TTCGCTTCGT CCAGACCAAC ATCTCCCGCC TCCTGCAGGA GACCTCCGAG CAGCTGGTGG CGCTGAAGCC CTGGATCACT CGCCAGAACT TCTCCCGGTG CCTGGAGCTG CAGTGTCAGC CCGACTCCTC AACCCTG 30 (2) INFORMACE PRO SEQ ID NO:295: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1043 párů bází (B) TYP: nukleová kyselina 35 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:295: 40 GCCACCCAGG ACTGCTCCTT TCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTGGCAGG GGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC CTTTCCGAAG AGCCCGGACA CCCATACTAG TCCGCCATCT 45 CCGGGTACAC CATTGGGCCC TGCCAGCTCC CTGCCCCAGA GCTTCCTGCT CAAGTCTTTA GAGCAAGTGA GAAAGATCCA GGGCGATGGC GCAGCGCTCC AGGAGAAGCT GTGTGCCACT ACAAGCTGTG CCACCCCGAG GAGCTGGTGC TGCTCGGACA CTCTCTGGGC ATCCCCTGGG CTCCCCTGAG CTCCTGCCCC AGCCAGGCCC TGCAGCTGGC AGGCTGCTTG AGCCAACTCC ATAGCGGCCT TTTCCTCTAC CAGGGGCTCC TGCAGGCCCT GGAAGGGATA TCCCCCGAGT 50 TGGGTCCCAC CTTGGACACA CTGCAGCTGG ACGTCGCCGA CTTTGCCACC ACCATCTGGC AGCAGATGGA AGAACTGGGA ATGGCCCCTG CCCTGCAGCC CACCCAGGGT GCCATGCCGG CCTTCGCCTC TGCTTTCCAG CGCCGGGCAG GAGGGGTCCT GGTTGCTAGC CATCTGCAGA GCTTCCTGGA GGTGTCGTAC CGCGTTCTAC GCCACCTTGC GCAGCCCTCT GCAGAACCGA AATCTCCGGA TACTCATACC AGCCCGCCAT CCCCGGGTAA GGCCTTTCAG CCCCCCCCCA 55 GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTG 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1047 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1043 -558- CZ 295843 B6 (2) INFORMACE PRO SEQ ID NO:296: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1065 párů bází 5 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:296: 10 GCTGATGAAG AACTGTGTGG TGGTCTGTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATC TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 15 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCTC AGGGGGAGGT AGTGGTACCC AGGACTCCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG CAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGGTGGTT CTGGCGGCGG CTCCAACATG 20 GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACTAAC AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG 25 GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCG 30 (2) INFORMACE PRO SEQ ID NO:297: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1110 párů bází (B) TYP: nukleová kyselina 35 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:297: 40 GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG 45 GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCTACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 50 AAAGAATCTC ATAAATCTCC AAACATGGCT GATGAAGAAC TGTGTGGTGG TCTGTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATCTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG 55 CTGCAGTGTC AGCCCGACTC CTCAACCCTG GGCGGTGGGT CAGGAGGTGG GTCAGGAGGT GGATCCGGAG GTGGCTCAGG GGGAGGTAGT GGTACCCAGG ACTCCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC CGCGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 60 120 180 240 300 360 420 480 540 600 660 720 - 780 840 900 960 1020 1065 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1110 -559 - CZ 295843 B6 (2) INFORMACE PRO SEQ ID NO:298: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1065 párů bází 5 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:298: 10 GCTGATGAAG AACTGTGTGG TGGTCTGTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTCTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 15 ATCACTCGCC AGAACTTCTC CCGGTGCCTA GAGCTGCAGT CTCAGCCCGA CTCCTCAACC CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCTC AGGGGGAGGT AGTGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG CAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGGTGGTT CTGGCGGCGG CTCCAACATG 20 GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACTAAC AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG 25 GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCG 30 (2) INFORMACE PRO SEQ ID NO:299: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1110 párů bází (B) TYP: nukleová kyselina 35 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:299: 40 GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG 45 GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCTACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 50 AAAGAATCTC ATAAATCTCC AAACATGGCA GATGAAGAAC TGTGTGGGGG CCTGTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT CTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG 55 CTGCAGTCTC AGCCCGACTC CTCAACCCTG GGCGGTGGGT CAGGAGGTGG GTCAGGAGGT GGATCCGGAG GTGGCTCAGG GGGAGGTAGT GGTACTCAGG ACTGTTCTTT TCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1065 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1110 -560- 30 35 CZ 295843 B6 (2) INFORMACE PRO SEQ ID NO:300: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1002 párů bází 5 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:300: 10 GCCACTCAGG ACTCCTCTTT TCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA 15 CACTTTGTCA CCAAATCTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC AGCCCGACTC CTCAACCCTG TACGTAGAGG GCGGTGGAGG CTCCCCGGGT GGTGGTTCTG GCGGCGGCTC CAACATGGCT ACACCATTGG GCCCTGCCAG CTCCCTGCCC CAGAGCTTCC TGCTCAAGTC TTTAGAGCAA 20 GTGAGAAAGA TCCAGGGCGA TGGCGCAGCG CTCCAGGAGA AGCTGTGTGC CACTAACAAG CTGTGCCACC CCGAGGAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC GCCGACTTTG CCACCACCAT CTGGCAGCAG 25 ATGGAAGAAC TGGGAATGGC CCCTGCCCTG CAGCCCACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC CG (2) INFORMACE PRO SEQ ID NO:301: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1002 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:301: GCCACTCAGG ACTGTTCTTT TCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC 40 CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT CTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC 45 ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTCTC AGCCCGACTC CTCAACCCTG TACGTAGAGG GCGGTGGAGG CTCCCCGGGT GGTGGTTCTG GCGGCGGCTC CAACATGGCT ACACCATTGG GCCCTGCCAG CTCCCTGCCC CAGAGCTTCC TGCTCAAGTC TTTAGAGCAA GTGAGAAAGA TCCAGGGCGA TGGCGCAGCG CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC CCGAGGAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC CTGGGCTCCC 50 CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CCCTGCCCTG CAGCCCACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTTC 55 CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC CG (2) INFORMACE PRO SEQ ID NO:302: (i) CHARAKTERISTIKY SEKVENCE: 60 (A) DÉLKA: 978 párů bází (B) TYP: nukleová kyselina 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1002 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1002 -561 - 25 30 CZ 295843 B6 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:302: 5 GCCACTCAGG ACTGTTCTTT TCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA 10 CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGGTG GTTCTGGCGG CGGCTCCAAC ATGGCTACAC CATTGGGCCC TGCCAGCTCC CTGCCCCAGA GCTTCCTGCT CAAGTCTTTA GAGCAAGTGA GAAAGATCCA GGGCGATGGC 15 GCAGCGCTCC AGGAGAAGCT GTGTGCCACT AACAAGCTGT GCCACCCCGA GGAGCTGGTG CTGCTCGGAC ACTCTCTGGG CATCCCCTGG GCTCCCCTGA GCTCCTGCCC CAGCCAGGCC CTGCAGCTGG CAGGCTGCTT GAGCCAACTC CATAGCGGCC TTTTCCTCTA CCAGGGGCTC CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC CACCATCTGG CAGCAGATGG AAGAACTGGG AATGGCCCCT 20 GCCCTGCAGC CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA CGCCACCTTG CGCAGCCG (2) INFORMACE PRO SEQ ID NO:303: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1002 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:303: GCCACTCAGG ACTGTTCTTT TCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC 35 CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC 40 ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTCTC AGCCCGACTC CTCAACCCTG TACGTAGAGG GCGGTGGAGG CTCCCCGGGT GGTGGTTCTG GCGGCGGCTC CAACATGGCT ACACCATTGG GCCCTGCCAG CTCCCTGCCC CAGAGCTTCC TGCTCAAGTC TTTAGAGCAA GTGAGAAAGA TCCAGGGCGA TGGCGCAGCG CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC CCGAGGAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC CTGGGCTCCC 45 CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CCCTGCCCTG CAGCCCACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTTC 50 CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC CG (2) INFORMACE PRO SEQ ID NO:304: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1001 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 978 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1002 -562- 55 CZ 295843 B6 (xi) POPIS SEKVENCE: SEQ ID NO:304: GCCACTCAGG ACTGTTCTTT TCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 5 GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC ACTCGCCAGA ACTTCTCCCG GCGCCTGGAG CTGCAGTCTC AGCCCGACTC CTCAACCCTG 10 TACGTAGAGG GCGGTGGAGG CTCCCCGGGT GGTGGTTCTG GCGGCGGCTC CAACATGGCT ACACCATTGG GCCCTGCCAG CTCCCTGCCC CAGAGCTTCC TGCTCAAGTC TTTAGAGCAA GTGAGAAAGA TCCAGGGCGA TGGCGCAGCG CTCCAGGAGA AGCTGTGTGC CACTAACAAG CTGTGCCACC CCGAGGAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT GCTTGAGCCA ACTCCATAGC 15 GGCCTTTTCC TCTACCAGGG GCTCCTGCAG GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CCCTGCCCTG CAGCCCACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC C 20 (2) INFORMACE PRO SEQ ID NO:305: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1056 párů bázi 25 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineárni (xi) POPIS SEKVENCE: SEQ ID NO:305: 30 GCTGATGAAG AACTGTGTGG TGGTCTGTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 35 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCTC AGGGGGAGGT AGTGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG CAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGGTGGTT CTGGCGGCGG CTCCAACATG 40 GCTACTCAAG GTGCTATGCC AGCTTTTGCT TCTGCTTTTC AACGTCGTGC AGGTGGTGTT CTGGTTGCTA GCCATCTGCA GAGCTTCCTG GAGGTGTCGT ACCGCGTTCT ACGCCACCTT GCGCAGCCCT CTGGCGGCTC TGGCGGCTCT CAGAGCTTCC TGCTCAAGTC TTTAGAGCAA GTGAGAAAGA TCCAGGGCGA TGGCGCAGCG CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC CCGAGGAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC CTGGGCTCCC 45 CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CCCTGCCCTG CAGCCC 50 (2) INFORMACE PRO SEQ ID NO:306: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1101 párů bázi (B) TYP: nukleová kyselina 55 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineárni (xi) POPIS SEKVENCE: SEQ ID NO:306: 60 GCTACTCAAG GTGCTATGCC AGCTTTTGCT TCTGCTTTTC AACGTCGTGC AGGTGGTGTT CTGGTTGCTA GCCATCTGCA GAGCTTCCTG GAGGTGTCGT ACCGCGTTCT ACGCCACCTT 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1001 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1056 60 120 -563 - 20 25 50 55 CZ 295843 B6 GCGCAGCCCT CTGGCGGCTC TGGCGGCTCT CAGAGCTTCC TGCTCAAGTC TTTAGAGCAA GTGAGAAAGA TCCAGGGCGA TGGCGCAGCG CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC CCGAGGAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT GCTTGAGCCA ACTCCATAGC 5 GGCCTTTTCC TCTACCAGGG GCTCCTGCAG GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CCCTGCCCTG CAGCCCTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC CGACGAGGAG CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG 10 GCACAGCGCT GGATGGAGCG GCTCAAGACT GTCGCTGGGT CCAAGATGCA AGGCTTGCTG GAGCGCGTGA ACACGGAGAT ACACTTTGTC ACCAAATGTG CCTTTCAGCC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT GGGCGGTGGG TCAGGAGGTG GGTCAGGAGG TGGATCCGGA 15 GGTGGCTCAG GGGGAGGTAG TGGTACCCAG GACTGCTCCT TCCAACACAG CCCCATCTCC TCCGACTTCG CTGTCAAAAT CCGTGAGCTG TCTGACTACC TGCTTCAAGA TTACCCAGTC ACCGTGGCCT CCAACCTGCA G (2) INFORMACE PRO SEQ ID NO:307: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1032 párů bázi (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:307: GCCGACGAGG AGCTGTGCGG TGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 30 CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGAAC CCAGGACTGC 35 TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC TGCAGTACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AAACATGGCC GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA 40 GGCTTGCTGG AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC AGCCCGACTC CTCAACCCTG GGCGGTGGGT CAGGAGGTGG GTCAGGAGGT GGATCCGGAG GTGGCACCCA GGACTGCTCC TTCCAACACA GCCCCATCTC CTCCGACTTC 45 GCTGTCAAAA TCCGTGAGCT GTCTGACTAC CTGCTTCAAG ATTACCCAGT CACCGTGGCC TCCAACCTGC AG (2) INFORMACE PRO SEQ ID NO:308: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1005 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:308: GCTGATGAAG AACTGTGTGG TGGTCTGTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 60 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1101 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1032 60 120 180 240 -564- 55 CZ 295843 B6 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCTC AGGGGGAGGT AGTGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 5 CAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAC CCAGGACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAAATTACCC AGTCACCGTG GCCTCCAACC TGCAGGACGA GGAGCTCTGC GGGGGCCTCT GGCGGCTGGT CCTGGCACAG CGCTGGATGG AGCGGCTCAA GACTGTCGCT 10 GGGTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG AGATACACTT TGTCACCAAA TGTGCCTTTC AGCCCCCCCC CAGCTGTCTT CGCTTCGTCC AGACCAACAT CTCCCGCCTC CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG CTGAAGCCCT GGATCACTCG CCAGAACTTC TCCCGGTGCC TGGAGCTGCA GTGTCAGCCC GACTCCTCAA CCCTG 15 (2) INFORMACE PRO SEQ ID NO:309: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1650 párů bází (B) TYP: nukleová kyselina 20 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:309: 25 GCTGATGAAG AACTGTGTGG TGGTCTGTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 30 CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCTC AGGGGGAGGT AGTGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG CAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGGTGGTT CTGGCGGCGG CTCCAACATG GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG 35 CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG 40 CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCTACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AAACATGGCT GATGAAGAAC TGTGTGGTGG TCTGTGGCGG 45 CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC AGCCCGACTC CTCAACCCTG GGCGGTGGGT CAGGAGGTGG GTCAGGAGGT 50 GGATCCGGAG GTGGCTCAGG GGGAGGTAGT GGTACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG (2) INFORMACE PRO SEQ ID NO:310: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1632 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 300 360 420 480 540 600 660 720 780 840 900 960 1005 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1140 1200 1260 1320 1380 1440 1500 1560 1620 1650 -565 - 60 CZ 295843 B6 (xi) POPIS SEKVENCE: SEQ ID NO:310: GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCTACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AAACATGGCT GATGAAGAAC TGTGTGGTGG TCTGTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC AGCCCGACTC CTCAACCCTG GGCGGTGGGT CAGGAGGTGG GTCAGGAGGT GGATCCGGAG GTGGCTCAGG GGGAGGTAGT GGTACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG TACGTAGAGG GCGGTGGAGG CTCCCCGGGT GAACCGTCTG GTCCAATCTC TACTATCAAC CCGTCTCCTC CGTCTAAAGA ATCTCATAAA TCTCCAAACA TGGCTACCCA GGACTGCTCC TTCCAACACA GCCCCATCTC CTCCGACTTC GCTGTCAAAA TCCGTGAGCT GTCTGACTAC CTGCTTCAAG ATTACCCAGT CACCGTGGCC TCCAACCTGC AGGACGAGGA GCTCTGCGGG GGCCTCTGGC GGCTGGTCCT GGCACAGCGC TGGATGGAGC GGCTCAAGAC TGTCGCTGGG TCCAAGATGC AAGGCTTGCT GGAGCGCGTG AACACGGAGA TACACTTTGT CACCAAATGT GCCTTTCAGC CCCCCCCCAG CTGTCTTCGC TTCGTCCAGA CCAACATCTC CCGCCTCCTG CAGGAGACCT CCGAGCAGCT GGTGGCGCTG AAGCCCTGGA TCACTCGCCA GAACTTCTCC CGGTGCCTGG AGCTGCAGTG TCAGCCCGAC TCCTCAACCC TG (2) INFORMACE PRO SEQ ID NO:311: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1695 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:311: GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCTACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AAACATGGCT GATGAAGAAC TGTGTGGTGG TCTGTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC AGCCCGACTC CTCAACCCTG GGCGGTGGGT CAGGAGGTGG GTCAGGAGGT GGATCCGGAG GTGGCTCAGG GGGAGGTAGT GGTACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG TACGTAGAGG GCGGTGGAGG CTCCCCGGGT GAACCGTCTG GTCCAATCTC TACTATCAAC CCGTCTCCTC CGTCTAAAGA ATCTCATAAA 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1140 1200 1260 1320 1380 1440 1500 1560 1620 1632 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1140 1200 50 55 CZ 295843 B6 TCTCCAAACA TGGCTGATGA AGAACTGTGT GGTGGTCTGT GGCGGCTGGT CCTGGCACAG CGCTGGATGG AGCGGCTCAA GACTGTCGCT GGGTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG AGATACACTT TGTCACCAAA TGTGCCTTTC AGCCCCCCCC CAGCTGTCTT CGCTTCGTCC AGACCAACAT CTCCCGCCTC CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG 5 CTGAAGCCCT GGATCACTCG CCAGAACTTC TCCCGGTGCC TGGAGCTGCA GTGTCAGCCC GACTCCTCAA CCCTGGGCGG TGGGTCAGGA GGTGGGTCAG GAGGTGGATC CGGAGGTGGC TCAGGGGGAG GTAGTGGTAC CCAGGACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC TGCAG 10 (2) INFORMACE PRO SEQ ID NO:312: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1506 párů bází 15 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:312: 20 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 25 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT CATAAATCTC CAAACATGGC TGATGAAGAA CTGTGTGGTG GTCTGTGGCG GCTGGTCCTG GCACAGCGCT GGATGGAGCG GCTCAAGACT GTCGCTGGGT CCAAGATGCA AGGCTTGCTG 30 GAGCGCGTGA ACACGGAGAT ACACTTTGTC ACCAAATGTG CCTTTCAGCC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT GGGCGGTGGG TCAGGAGGTG GGTCAGGAGG TGGATCCGGA GGTGGCTCAG GGGGAGGTAG TGGTACCCAG GACTGCTCCT TCCAACACAG CCCCATCTCC 35 TCCGACTTCG CTGTCAAAAT CCGTGAGCTG TCTGACTACC TGCTTCAAGA TTACCCAGTC ACCGTGGCCT CCAACCTGCA GTACGTAGAG GGCGGTGGAG GCTCCCCGGG TGAACCGTCT GGTCCAATCT CTACTATCAA CCCGTCTCCT CCGTCTAAAG AATCTCATAA ATCTCCAAAC ATGGCTGATG AAGAACTGTG TGGTGGTCTG TGGCGGCTGG TCCTGGCACA GCGCTGGATG GAGCGGCTCA AGACTGTCGC TGGGTCCAAG ATGCAAGGCT TGCTGGAGCG CGTGAACACG 40 GAGATACACT TTGTCACCAA ATGTGCCTTT CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG GTGGGTCAGG AGGTGGGTCA GGAGGTGGAT CCGGAGGTGG CTCAGGGGGA GGTAGTGGTA CCCAGGACTG CTCCTTCCAA CACAGCCCCA TCTCCTCCGA CTTCGCTGTC 45 AAAATCCGTG AGCTGTCTGA CTACCTGCTT CAAGATTACC CAGTCACCGT GGCCTCCAAC CTGCAG (2) INFORMACE PRO SEQ ID NO:313: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1674 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:313: 1260 1320 1380 1440 1500 1560 1620 1680 1695 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1140 1200 1260 1320 1380 1440 1500 1506 GCTGATGAAG CGGCTCAAGA ATACACTTTG ACCAACATCT AACTGTGTGG CTGTCGCTGG TCACCAAATG CCCGCCTCCT TGGTCTGTGG GTCCAAGATG TGCCTTTCAG GCAGGAGACC CGGCTGGTCC CAAGGCTTGC CCCCCCCCCA TCCGAGCAGC TGGCACAGCG TGGAGCGCGT GCTGTCTTCG TGGTGGCGCT CTGGATGGAG GAACACGGAG CTTCGTCCAG GAAGCCCTGG 600 660 720 780 -567- 60 CZ 295843 B6 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 840 CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCTC AGGGGGAGGT 900 AGTGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 960 ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 1020 S CAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGGTGGTT CTGGCGGCGG CTCCAACATG 540 GCTGATGAAG AACTGTGTGG TGGTCTGTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 600 CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 660 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 720 ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 780 10 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 840 CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCTC AGGGGGAGGT 900 AGTGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 960 ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 1020 CAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 1080 15 AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAC ACCATTAGGC 1140 CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTGCT TAGAGCAAGT GAGGAAGATC 1200 CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GTGCCACCCC 1260 GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT GGGCTCCCCT GAGCTCCTGC 1320 CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC TCCATAGCGG CCTTTTCCTC 1380 20 TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG AGTTGGGTCC CACCTTGGAC 1440 ACACTGCAGC TGGACGTCGC CGACTTTGCC ACCACCATCT GGCAGCAGAT GGAAGAACTG 1500 GGAATGGCCC CTGCCCTGCA GCCCACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC 1560 CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG 1620 TACCGCGTTC TACGCCACCT TGCGCAGCCC TGATAAGGAT CCGAATTCGG CAGC 1674 25 (2) INFORMACE PRO SEQ ID NO:314: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1470 párů bází 30 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:314: 35 GCCGACGAGG AGCTGTGCGG TGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60 CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180 ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240 40 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300 CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGAAC CCAGGACTGC 360 TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC 420 TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC TGCAGTACGT AGAGGGCGGT 480 GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 540 45 AAAGAATCTC ATAAATCTCC AAACATGGCT AACTGCTCTA TAATGATCGA TGAAATTATA 600 CATCACTTAA AGAGACCACC TAACCCTTTG CTGGACCCGA ACAACCTCAA TTCTGAAGAC 660 ATGGATATCC TGATGGAACG AAACCTTCGA ACTCCAAACC TGCTCGCATT CGTAAGGGCT 720 GTCAAGCACT TAGAAAATGC ATCAGGTATT GAGGCAATTC TTCGTAATCT CCAACCATGT 780 CTGCCCTCTG CCACGGCCGC ACCCTCTCGA CATCCAATCA TCATCAAGGC AGGTGACTGG 840 50 CAAGAATTCC GGGAAAAACT GACGTTCTAT CTGGTTACCC TTGAGCAAGC GCAGGAACAA 900 CAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 960 AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCCGA CGAGGAGCTC 1020 TGCGGGGGCC TCTGGCGGCT GGTCCTGGCA CAGCGCTGGA TGGAGCGGCT CAAGACTGTC 1080 GCTGGGTCCA AGATGCAAGG CTTGCTGGAG CGCGTGAACA CGGAGATACA CTTTGTCACC 1140 55 AAATGTGCCT TTCAGCCCCC CCCCAGCTGT CTTCGCTTCG TCCAGACCAA CATCTCCCGC 1200 CTCCTGCAGG AGACCTCCGA GCAGCTGGTG GCGCTGAAGC CCTGGATCAC TCGCCAGAAC 1260 TTCTCCCGGT GCCTGGAGCT GCAGTGTCAG CCCGACTCCT CAACCCTGGG CGGTGGGTCA 1320 GGAGGTGGGT CAGGAGGTGG ATCCGGAGGT GGCACCCAGG ACTGCTCCTT CCAACACAGC 1380 CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT 1440 60 TACCCAGTCA CCGTGGCCTC CAACCTGCAG 1470 -568- CZ 295843 B6 (2) INFORMACE PRO SEQ ID NO:315: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1194 párů bází 5 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:315: 10 GCTGATGAAG AACTGTGTGG TGGTCTGTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60 CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180 ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240 15 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300 CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCTC AGGGGGAGGT 360 AGTGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 420 ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 480 CAGGAATTCA AGCTTGAGCC CAGAGGGCCC ACAATCAAGC CCTGTCCTCC ATGCAAATGC 540 20 CCAGCACCTA ACCTCTTGGG TGGACCATCC GTCTTCATCT TCCCTCCAAA GATCAAGGAT 600 GTACTCATGA TCTCCCTGAG CCCCATAGTC ACATGTGTGG TGGTGGATGT GAGCGAGGAT 660 GACCCAGATG TCCAGATCAG CTGGTTTGTG AACAACGTGG AAGTACACAC AGCTCAGACA 720 CAAACCCATA GAGAGGATTA CAACAGTACT CTCCGGGCGG TCAGTGCCCT CCCCATCCAG 780 CACCAGGACT GGATGAGTGG CAAGGAGTTC AAATGCAAGG TCAACAACAA AGACCTCCCA 840 25 GCGCCCATCG AGAGAACCAT CTCAAAACCC AAAGGGTCAG TAAGAGCTCC ACAGGTATAT 900 GTCTTGCCTC CACCAGAAGA AGAGATGACT AAGAAACAGG TCACTCTGAC CTGCATGGTC 960 ACAGACTTCA TGCCTGAAGA CATTTACGTG GAGTGGACCA ACAACGGGAA AACAGAGCTA 1020 AACTACAAGA ACACTGAACC AGTCCTGGAC TCTGATGGTT CTTACTTCAT GTACAGCAAG 1080 CTGAGAGTGG AAAAGAAGAA CTGGGTGGAA AGAAATAGCT ACTCCTGTTC AGTGGTCCAC 1140 30 GAGGGTCTGC ACAATCACCA CACGACTAAG AGCTTCTCCC GGACTCCGGG TAAA 1194 (2) INFORMACE PRO SEQ ID NO:316: (i) CHARAKTERISTIKY SEKVENCE: 35 (A) DÉLKA: 1131 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 40 (xi) POPIS SEKVENCE: SEQ ID NO:316: GCCACCCAGG ACTGCTCCTT TCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC 60 CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 120 GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG 180 45 CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA 240 CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC 300 AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC 360 ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC AGCCCGACTC CTCAACCCTG 420 GAATTCAAGC TTGAGCCCAG AGGGCCCACA ATCAAGCCCT GTCCTCCATG CAAATGCCCA 480 50 GCACCTAACC TCTTGGGTGG ACCATCCGTC TTCATCTTCC CTCCAAAGAT CAAGGATGTA 540 CTCATGATCT CCCTGAGCCC CATAGTCACA TGTGTGGTGG TGGATGTGAG CGAGGATGAC 600 CCAGATGTCC AGATCAGCTG GTTTGTGAAC AACGTGGAAG TACACACAGC TCAGACACAA 660 ACCCATAGAG AGGATTACAA CAGTACTCTC CGGGCGGTCA GTGCCCTCCC CATCCAGCAC 720 CAGGACTGGA TGAGTGGCAA GGAGTTCAAA TGCAAGGTCA ACAACAAAGA CCTCCCAGCG 780 55 CCCATCGAGA GAACCATCTC AAAACCCAAA GGGTCAGTAA GAGCTCCACA GGTATATGTC 840 TTGCCTCCAC CAGAAGAAGA GATGACTAAG AAACAGGTCA CTCTGACCTG CATGGTCACA 900 GACTTCATGC CTGAAGACAT TTACGTGGAG TGGACCAACA ACGGGAAAAC AGAGCTAAAC 960 TACAAGAACA CTGAACCAGT CCTGGACTCT GATGGTTCTT ACTTCATGTA CAGCAAGCTG 1020 AGAGTGGAAA AGAAGAACTG GGTGGAAAGA AATAGCTACT CCTGTTCAGT GGTCCACGAG 1080 60 GGTCTGCACA ATCACCACAC GACTAAGAGC TTCTCCCGGA CTCCGGGTAA A 1131 -569- CZ 295843 B6 (2) INFORMACE PRO SEQ ID NO:317: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 45 párů bází 5 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 10 (xi) POPIS SEKVENCE: SEQ ID NO:317: ACGTCCATGG CNTCNCCNGC NCCNCCTGCT TGTGCACTCC GAGTC 15 20 (2) INFORMACE PRO SEQ ID NO:318: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 30 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:318: ATGCACGAAT TCCCTGACGC AGAGGGTGGA 25 (2) INFORMACE PRO SEQ ID NO:319: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 33 párů bází (B) TYP: nukleová kyselina 30 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:319: 35 TGACAAGCTT ACCTGACGCA GAGGGTGGAC CCT (2) INFORMACE PRO SEQ ID NO:320: (i) CHARAKTERISTIKY SEKVENCE: 40 (A) DÉLKA: 10 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 45 (xi) POPIS SEKVENCE: SEQ ID NO:320: AATTCGGCAA 50 (2) INFORMACE PRO SEQ ID NO:321: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 10 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární -570- 55 CZ 295843 B6 (xi) POPIS SEKVENCE: SEQ ID NO:321: CATGTTGCCG (2) INFORMACE PRO SEQ ID NO:322: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 13 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:322: AATTCGGCGG CAA (2) INFORMACE PRO SEQ ID NO:323: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 13 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:323: CATGTTGCCG CCG (2) INFORMACE PRO SEQ ID NO:324: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 22 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:324: AATTCGGCGG CAACGGCGGC AA (2) INFORMACE PRO SEQ ID NO:325: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 22 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:325: CATGTTGCCG CCGTTGCCGC CG (2) INFORMACE PRO SEQ ID NO:326: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 27 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární CZ 295843 B6 (xi) POPIS SEKVENCE: SEQ ID NO:326: CGATCCATGG AGGTTCACCC TTTGCCT (2) INFORMACE PRO SEQ ID NO:327: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 29 párů bázi (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:327: GATCAAGCTT ATGGGCACTG GCTCAGTCT (2) INFORMACE PRO SEQ ID NO:328: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 27 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:328: CGATACATGT TGCCTACACC TGTCCTG (2) INFORMACE PRO SEQ ID NO:329: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 29 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:329: GATCAAGCTT AAGGGTGAAC CTCTGGGCA (2) INFORMACE PRO SEQ ID NO:330: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 27 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:330: CGATCCATGG TCCTGCTGCC TGCTGTG (2) INFORMACE PRO SEQ ID NO:331: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 29 párů bází (B) TYP: nukleová kyselina CZ 295843 B6 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:331: 5 GATCAAGCTT AAGGTGTAGG CAAAGGGTG (2) INFORMACE PRO SEQ ID NO:332: 10 15 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 30 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:332: CGATCCATGG CTGTGGACTT TAGCTTGGGA 20 (2) INFORMACE PRO SEQ ID NO:333: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 29 párů bází (B) TYP: nukleová kyselina 25 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:333: 30 GATCAAGCTT AAGGCAGCAG GACAGGTGT (2) INFORMACE PRO SEQ ID NO:334: (i) CHARAKTERISTIKY SEKVENCE: 35 (A) DÉLKA: 27 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 40 (xi) POPIS SEKVENCE: SEQ ID NO:334: CGATCCATGG ACTTTAGCTT GGGAGAA (2) INFORMACE PRO SEQ ID NO:335: 45 50 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 29 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:335: GATCAAGCTT ACACAGCAGG CAGCAGGAC 55 -573 - CZ 295843 B6 (2) INFORMACE PRO SEQ ID NO:336: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 27 párů bází 5 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 10 15 20 (xi) POPIS SEKVENCE: SEQ ID NO:336: CGATCCATGG GAGAATGGAA AACCCAG (2) INFORMACE PRO SEQ ID NO:337: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 29 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:337: GATCAAGCTT ACAAGCTAAA GTCCACAGC 25 (2) INFORMACE PRO SEQ ID NO:338: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 27 párů bází (B) TYP: nukleová kyselina 30 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:338: 35 CGATCCATGG GACCCACTTG CCTCTCA (2) INFORMACE PRO SEQ ID NO:339: (i) CHARAKTERISTIKY SEKVENCE: 40 (A) DÉLKA: 29 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 45 (xi) POPIS SEKVENCE: SEQ ID NO:339: GATCAAGCTT ACAGTTGTCC CCGTGCTGC (2) INFORMACE PRO SEQ ID NO:340: 50 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 27 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární -574- 55 CZ 295843 B6 (xi) POPIS SEKVENCE: SEQ ID NO:340: CAGTCCATGG GAACCCAGCT TCCTCCA 5 (2) INFORMACE PRO SEQ ID NO:341: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 29 párů bází (B) TYP: nukleová kyselina 10 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:341: 15 GATCAAGCTT AAAGGAGGCT CTGCAGGGC (2) INFORMACE PRO SEQ ID NO:342: (i) CHARAKTERISTIKY SEKVENCE: 20 (A) DÉLKA: 27 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 25 (xi) POPIS SEKVENCE: SEQ ID NO:342: CGATCCATGG GCAGGACCAC AGCTCAC (2) INFORMACE PRO SEQ ID NO:343: 30 35 40 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 30 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:343: GATCAAGCTT ACTGTGGAGG AAGCTGGGTT (2) INFORMACE PRO SEQ ID NO:344: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 30 párů bází 45 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 50 (xi) POPIS SEKVENCE: SEQ ID NO:344: CGATCCATGG CTCACAAGGA TCCCAATGCC (2) INFORMACE PRO SEQ ID NO:345: 55 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 29 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární - 575 - 60 CZ 295843 B6 (xi) POPIS SEKVENCE: SEQ ID NO:345: GATCAAGCTT ATGTGGTCCT GCCCTGTGG (2) INFORMACE PRO SEQ ID NO:346: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 30 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:346: CGATCCATGG ATCCCAATGC CATCTTCCTG (2) INFORMACE PRO SEQ ID NO:347: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 29 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:347: GATCAAGCTT ACTTGTGAGC TGTGGTCCT (2) INFORMACE PRO SEQ ID NO:348: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 30 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:348: CGATCCATGG CCATCTTCCT GAGCTTCCAA (2) INFORMACE PRO SEQ ID NO:349: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 32 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:349: GATCAAGCTT AATTGGGATC CTTGTGAGCT GT (2) INFORMACE PRO SEQ ID NO:350: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 83 párů bází (B) TYP: nukleová kyselina 10 CZ 295843 B6 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:350: AATTCCGTCG TAAACTGACC TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAGT ACGTAGAGGG CGGTGGAGGC TCC (2) INFORMACE PRO SEQ ID NO:351: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 83 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché 15 (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:351: CCGGGGAGCC TCCACCGCCC TCTACGTACT GTTGAGCCTG CGCGTTCTCC AAGGTTTTCA 20 GATAGAAGGT CAGTTTACGA CGG (2) INFORMACE PRO SEQ ID NO:352: (i) CHARAKTERISTIKY SEKVENCE: 25 (A) DÉLKA: 59 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 30 (xi) POPIS SEKVENCE: SEQ ID NO:352: GTTACCCTTG AGCAAGCGCA GGAACAACAG. GGTGGTGGCT CTAACTGCTC TATAATGAT (2) INFORMACE PRO SEQ ID NO:353: 35 40 45 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 56 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:353: CGATCATTAT AGAGCAGTTA GAGCCACCAC CCTGTTGTTC CTGCGCTTGC TCAAGG (2) INFORMACE PRO SEQ ID NO:354: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 83 párů bází 50 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:354: GTTACCCTTG AGCAAGCGCA GGAACAACAG GGTGGTGGCT CTGGCGGTGG CAGCGGCGGC GGTTCTAACT GCTCTATAAT GAT -577- CZ 295843 B6 (2) INFORMACE PRO SEQ ID NO:355: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 80 párů bází 5 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:355: 10 CGATCATTAT AGAGCAGTTA GAACCGCCGC CGCTGCCACC GCCAGAGCCA CCACCCTGTT GTTCCTGCGC TTGCTCAAGG 15 20 (2) INFORMACE PRO SEQ ID NO:356: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 32 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:356: 25 GATCGACCAT GGCTCTGGAC CCGAACAACC TC (2) INFORMACE PRO SEQ ID NO:357: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 28 párů bází 30 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 35 (xi) POPIS SEKVENCE: SEQ ID NO:357: CTCGATTACG TACAAAGGTG CAGGTGGT 40 45 (2) INFORMACE PRO SEQ ID NO:358: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 32 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:358: GATCGACCAT GGCTAATGCA TCAGGTATTG AG 50 (2) INFORMACE PRO SEQ ID NO:359: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 28 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární -578- 55 CZ 295843 B6 (xi) POPIS SEKVENCE: SEQ ID NO:359: CTCGATTACG TATTCTAAGT TCTTGACA 5 (2) INFORMACE PRO SEQ ID NO:360: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 32 párů bázi (B) TYP: nukleová kyselina 10 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:360: 15 GATCGACCAT GGCTGCACCC TCTCGACATC CA (2) INFORMACE PRO SEQ ID NO:361: (i) CHARAKTERISTIKY SEKVENCE: 20 (A) DÉLKA: 28 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 25 (xi) POPIS SEKVENCE: SEQ ID NO:361: CTCGATTACG TAGGCCGTGG CAGAGGGC (2) INFORMACE PRO SEQ ID NO:362: 30 35 40 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 32 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:362: GATCGACCAT GGCTGCAGGT GACTGGCAAG AA (2) INFORMACE PRO SEQ ID NO:363: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 28 párů bází 45 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 50 (xi) POPIS SEKVENCE: SEQ ID NO:363: CTCGATTACG TACTTGATGA TGATTGGA (2) INFORMACE PRO SEQ ID NO:364: 55 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 54 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární -579- 60 CZ 295843 B6 (xi) POPIS SEKVENCE: SEQ ID NO:364: GCTCTGAGAG CCGCCAGAGC CGCCAGAGGG CTGCGCAAGG TGGCGTAGAA CGCG 5 (2) INFORMACE PRO SEQ ID NO:365: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 54 párů bází (B) TYP: nukleová kyselina 10 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:365: 15 CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT AGAG (2) INFORMACE PRO SEQ ID NO:366: (i) CHARAKTERISTIKY SEKVENCE: 20 (A) DÉLKA: 18 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 25 (xi) POPIS SEKVENCE: SEQ ID NO:366: GGGCTGCGCA AGGTGGCG (2) INFORMACE PRO SEQ ID NO:367: 30 35 40 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 21 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:367: ACACCATTGG GCCCTGCCAG C (2) INFORMACE PRO SEQ ID NO:368: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 32 párů bází 45 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 50 (xi) POPIS SEKVENCE: SEQ ID NO:368: GATCGACCAT GGCTTACAAG CTGTGCCACC CC (2) INFORMACE PRO SEQ ID NO:369: 55 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 36 párů bází (B) TYP: nukleová kyselina - 580- CZ 295843 B6 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:369: 5 CGATCGAAGC TTATTAGGTG GCACACAGCT TCTCCT (2) INFORMACE PRO SEQ ID NO:370: 10 15 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 32 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:370: GATCGACCAT GGCTCCCGAG TTGGGTCCCA CC 20 (2) INFORMACE PRO SEQ ID NO:371: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 36 párů bází (B) TYP: nukleová kyselina 25 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:371: 30 CGATCGAAGC TTATTAGGAT ATCCCTTCCA GGGCCT (2) INFORMACE PRO SEQ ID NO:372: (i) CHARAKTERISTIKY SEKVENCE: 35 (A) DÉLKA: 32 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 40 (xi) POPIS SEKVENCE: SEQ ID NO:372: GATCGACCAT GGCTATGGCC CCTGCCCTGC AG (2) INFORMACE PRO SEQ ID NO:373: 45 50 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 36 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:373: CGATCGAAGC TTATTATCCC AGTTCTTCCA TCTGCT (2) INFORMACE PRO SEQ ID NO:374: (i) CHARAKTERISTIKY SEKVENCE: -581 - 55 CZ 295843 B6 (A) DÉLKA: 32 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 5 (xi) POPIS SEKVENCE: SEQ ID NO:374: GAT.CGACCAT GGCTACCCAG GGTGCCATGC CG 10 (2) INFORMACE PRO SEQ ID NO:375: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 36 párů bází (B) TYP: nukleová kyselina 15 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:375: 20 CGATCGAAGC TTATTAGGGC TGCAGGGCAG GGGCCA (2) INFORMACE PRO SEQ ID NO:376: (i) CHARAKTERISTIKY SEKVENCE: 25 (A) DÉLKA: 32 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 30 (xi) POPIS SEKVENCE: SEQ ID NO:376: GATCGACCAT GGCTTCTGCT TTCCAGCGCC GG (2) INFORMACE PRO SEQ ID NO:377: 35 40 45 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 36 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:377: CGATCGAAGC TTATTAGGCG AAGGCCGGCA TGGCAC (2) INFORMACE PRO SEQ ID NO:378: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 21 párů bází 50 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:378: GTAGAGGGCG GTGGAGGCTC C -582 - 55 CZ 295843 B6 (2) INFORMACE PRO SEQ ID NO:379: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 25 párů bázi 5 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 10 (xi) POPIS SEKVENCE: SEQ ID NO:379: CCGGGGAGCC TCCACCGCCC TCTAC 15 20 (2) INFORMACE PRO SEQ ID NO:380: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 53 párů bázi (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:380: TTCTACGCCA CCTTGCGCAG CCCGGCGGCG GCTCTGACAT GTCTACACCA TTG 25 (2) INFORMACE PRO SEQ ID NO:381: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 53 párů bází (B) TYP: nukleová kyselina 30 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:381: 35 CAATGGTGTA GACATGTCAG AGCCGCCGCC GGGCTGCGCA AGGTGGCGTA GAA (2) INFORMACE PRO SEQ ID NO:382: (i) CHARAKTERISTIKY SEKVENCE: 40 (A) DÉLKA: 37 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 45 (xi) POPIS SEKVENCE: SEQ ID NO:382: GTCAGACCAT GGCCGATTAC CCAGTCACCG TGGCCTC 50 (2) INFORMACE PRO SEQ ID NO:383: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 37 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární - 583 - 55 CZ 295843 B6 (xi) POPIS SEKVENCE: SEQ ID NO:383: GTCAGCCCAT GGCCGCCTCC AACCTGCAGG ACGAGGA 5 (2) INFORMACE PRO SEQ ID NO:384: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 38 párů bází (B) TYP: nukleová kyselina 10 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:384: 15 GTCAGACCAT GGCCGTCGCT GGGTCCAAGA TGCAAGGC (2) INFORMACE PRO SEQ ID NO:385: (i) CHARAKTERISTIKY SEKVENCE: 20 (A) DÉLKA: 38 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 25 (xi) POPIS SEKVENCE: SEQ ID NO:385: GTCAGACCAT GGCCCGCTTC GTCCAGACCA ACATCTCC (2) INFORMACE PRO SEQ ID NO:386: 30 35 40 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 38 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:386: GTCAGACCAT GGCCACCAAC ATCTCCCGCC TCCTGCAG (2) INFORMACE PRO SEQ ID NO:387: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 39 párů bází 45 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 50 (xi) POPIS SEKVENCE: SEQ ID NO:387: TCTGACAAGC TTATTGAAGC AGGTAGTCAG ACAGCTCAC (2) INFORMACE PRO SEQ ID NO:388: 55 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 38 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární -584- 60 CZ 295843 B6 (xi) POPIS SEKVENCE: SEQ ID NO:388: TCTGACAAGC TTACACGGTG ACTGGGTAAT CTTGAAGC 5 (2) INFORMACE PRO SEQ ID NO:389: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 37 párů bázi (B) TYP: nukleová kyselina 10 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:389: 15 TCTGACAAGC TTAAGTCTTG AGCCGCTCCA TCCAGCG (2) INFORMACE PRO SEQ ID NO:390: (i) CHARAKTERISTIKY SEKVENCE: 20 (A) DÉLKA: 32 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 25 (xi) POPIS SEKVENCE: SEQ ID NO:390: GTCAAGAAGC TTACGGCTGA AAGGCACATT TG (2) INFORMACE PRO SEQ ID NO:391: 30 35 40 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 36 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:391: TCTGACAAGC TTAAAGACAG CTGGGGGGGG GCTGAA (2) INFORMACE PRO SEQ ID NO:392: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 37 párů bází 45 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 50 (xi) POPIS SEKVENCE: SEQ ID NO:392: CTCGACAAGC TTACTGGACG AAGCGAAGAC AGCTGGG (2) INFORMACE PRO SEQ ID NO:393: 55 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 57 párů bází (B) TYP: nukleová kyselina - 585 - 5 CZ 295843 B6 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:393: GTTGCCATGG CNTCNAAYCT GCARGAYGAR GARCTGTGCG GGGGCCTCTG GCGGCTG (2) INFORMACE PRO SEQ ID NO:394: 10 15 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 57 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:394: GTTGCCATGG CNAAYCTGCA RGAYGARGAR CTGTGYGGGG GCCTCTGGCG GCTGGTC 20 (2) INFORMACE PRO SEQ ID NO:395: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 57 párů bází (B) TYP: nukleová kyselina 25 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:395: 30 GTTGCCATGG CNCTGCARGA YGARGARCTG TGYGGYGGCC TCTGGCGGCT GGTCCTG (2) INFORMACE PRO SEQ ID NO:396: (i) CHARAKTERISTIKY SEKVENCE: 35 (A) DÉLKA: 57 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 40 (xi) POPIS SEKVENCE: SEQ ID NO:396: GTTGCCATGG CNCARGAYGA RGARCTGTGY GGYGGYCTCT GGCGGCTGGT CCTGGCA (2) INFORMACE PRO SEQ ID NO:397: 45 50 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 57 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:397: GTTGCCATGG CNGAYGARGA RCTGTGYGGY GGYCTCTGGC GGCTGGTCCT GGCACAG -586- 55 CZ 295843 B6 (2) INFORMACE PRO SEQ ID NO:398: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 57 párů bází 5 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:398: 10 GTTGCCATGG CNGARGARCT GTGYGGYGGY CTCTGGCGGC TGGTCCTGGC ACAGCGC (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 57 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:399: (2) INFORMACE PRO SEQ ID NO:399: 15 20 GTTGCCATGG CNGARCTGTG YGGYGGYCTG TGGCGYCTGG TCCTGGCACA GCGCTGG 25 (2) INFORMACE PRO SEQ ID NO:400: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 57 párů bází (B) TYP: nukleová kyselina 30 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:400: 35 GTTGCCATGG CNCTGTGYGG YGGYCTGTGG CGYCTGGTCC TGGCACAGCG CTGGATG (2) INFORMACE PRO SEQ ID NO:401: (i) CHARAKTERISTIKY SEKVENCE: 40 (A) DÉLKA: 42 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 45 (xi) POPIS SEKVENCE: SEQ ID NO:401: GTTGCCATGG CWGATGAAGA ACTGTGTGGN GGNCTGTGGC GG (2) INFORMACE PRO SEQ ID NO:402: 50 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 30 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární -587- 55 CZ 295843 B6 (xi) POPIS SEKVENCE; SEQ ID NO:402: TATGCAAGCT TAGGCCACGG TGACTGGGTA 5 (2) INFORMACE PRO SEQ ID NO:403: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 30 párů bází (B) TYP: nukleová kyselina 10 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:403: 15 TATGCAAGCT TAGGAGGCCA CGGTGACTGG (2) INFORMACE PRO SEQ ID NO:404: (i) CHARAKTERISTIKY SEKVENCE: 20 (A) DÉLKA: 30 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 25 (xi) POPIS SEKVENCE: SEQ ID NO:404: TATGCAAGCT TAGTTGGAGG CCACGGTGAC (2) INFORMACE PRO SEQ ID NO:405: 30 35 40 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 30 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:405: TATGCAAGCT TACAGGTTGG AGGCCACGGT (2) INFORMACE PRO SEQ ID NO:406: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 30 párů bází 45 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 50 (xi) POPIS SEKVENCE: SEQ ID NO:406: TATGCAAGCT TAGTCCAGGT TGGAGGCCAC (2) INFORMACE PRO SEQ ID NO:407: 55 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 30 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární -588 - 60 CZ 295843 B6 (xi) POPIS SEKVENCE: SEQ ID NO:407: TATGCAAGCT TACTCGTCCA GGTTGGAGGC (2) INFORMACE PRO SEQ ID NO:408: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 30 párů bázi (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:408: TATGCAAGCT TACTCCTCGT CCAGGTTGGA (2) INFORMACE PRO SEQ ID NO:409: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 44 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:409: GACTAGCCAT GGCNGAYGAR GARCTGTGYG GTGGCCTCTG GCGG (2) INFORMACE PRO SEQ ID NO:410: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 32 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:410: GACTAGTACG TACTGCAGGT TGGAGGCCAC GG (2) INFORMACE PRO SEQ ID NO:411: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 36 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:411: GCAGGTTACG TATTGAAGCA GGTAGTCAGA CAGCTC (2) INFORMACE PRO SEQ ID NO:412: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 36 párů bází (B) TYP: nukleová kyselina 5 10 15 CZ 295843 B6 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:412: GCAGGTTACG TACACGGTGA CTGGGTAATC TTGAAG (2) INFORMACE PRO SEQ ID NO:413: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 35 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:413: GCAGGTTACG TAAGTCTTGA GCCGCTCCAT CCAGC 20 (2) INFORMACE PRO SEQ ID NO:414: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 36 párů bází (B) TYP: nukleová kyselina 25 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:414: 30 GCAGGTTACG TAGCCAGCGA CAGTCTTGAG CCGCTC (2) INFORMACE PRO SEQ ID NO:415: (i) CHARAKTERISTIKY SEKVENCE: 35 (A) DÉLKA: 49 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 40 (xi) POPIS SEKVENCE: SEQ ID NO:415: GTCAAGCCAT GGCNCCRCCR AGCTGTCTRC GCTTCGTTCA GACCAACTC 45 50 (2) INFORMACE PRO SEQ ID NO:416: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 38 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:416: GCAGGTTACG TACGGCTGAA AGGCACATTT GGTGACAA - 590- 55 CZ 295843 B6 (2) INFORMACE PRO SEQ ID NO:417: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 30 párů bází 5 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 10 15 20 (xi) POPIS SEKVENCE: SEQ ID NO:417: GCAGGTTACG TAAAGACAGC TGGGGGGGGG (2) INFORMACE PRO SEQ ID NO:418: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 34 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:418: GCAGGTTACG TACTGGACGA AGCGAAGACA GCTG 25 (2) INFORMACE PRO SEQ ID NO:419: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 29 párů bází (B) TYP: nukleová kyselina 30 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:419: 35 TATGCTACGT AGGCCACGGT GACTGGGTA (2) INFORMACE PRO SEQ ID NO:420: (i) CHARAKTERISTIKY SEKVENCE: 40 (A) DÉLKA: 29 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 45 (xi) POPIS SEKVENCE: SEQ ID NO:420: TATGCTACGT AGGAGGCCAC GGTGACTGG (2) INFORMACE PRO SEQ ID NO:421: 50 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 29 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární -591 - 55 CZ 295843 B6 (xi) POPIS SEKVENCE: SEQ ID NO:421: TATGCTACGT AGTTGGAGGC CACGGTGAC (2) INFORMACE PRO SEQ ID NO:422: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 29 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:422: TATGCTACGT ACAGGTTGGA GGCCACGGT (2) INFORMACE PRO SEQ ID NO:423: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 29 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:423: TATGCTACGT AGTCCAGGTT GGAGGCCAC (2) INFORMACE PRO SEQ ID NO:424: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 29 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:424: TATGCTACGT ACTCGTCCAG GTTGGAGGC (2) INFORMACE PRO SEQ ID NO:425: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 29 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:425: TATGCTACGT ACTCCTCGTC CAGGTTGGA (2) INFORMACE PRO SEQ ID NO:426: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 46 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární CZ 295843 B6 (xi) POPIS SEKVENCE: SEQ ID NO:426: TCAGTTGGAT CCGGCGGCGG AAGCGGAGGT GGCTCTGGGG GAGGTA 5 (2) INFORMACE PRO SEQ ID NO:427: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 48 párů bázi (B) TYP: nukleová kyselina 10 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:427: 15 TCAGTTGGAT CCTCCGCCAG AACCACCGCC TGACCCACCT CCTGACCC (2) INFORMACE PRO SEQ ID NO:428: (i) CHARAKTERISTIKY SEKVENCE: 20 (A) DÉLKA: 60 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 25 (xi) POPIS SEKVENCE: SEQ ID NO:428: GTCTGAGGCG CCACCGCACC GACCGCTGGA CAACCGCCTC TGACCCAGGA CTGCTCCTTC (2) INFORMACE PRO SEQ ID NO:429: 30 35 40 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 46 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:429: GTCTGAGGCG CCACCGCACC GACCACCCAG GACTGCTCCT TCCAAC (2) INFORMACE PRO SEQ ID NO:430: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 60 párů bází 45 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:430: 50 GTCTGAGGCG CCGAGTGGAC GCGGGCTCCA CGGTGGCGGC AGGGTTGAGG AGTCGGGCTG (2) INFORMACE PRO SEQ ID NO:431: 55 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 57 párů bází (B) TYP: nukleová kyselina -593 - CZ 295843 B6 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:431: 5 GTTGCCATGG CNTCNAAYCT GCARGAYGAR GARCTGTGCG GGGGCCTCTG GCGGCTG (2) INFORMACE PRO SEQ ID NO:432: 10 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 57 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 15 (xi) POPIS SEKVENCE: SEQ ID NO:432: GTTGCCATGG CNAAYCTGCA RGAYGARGAR CTGTGYGGGG GCCTCTGGCG GCTGGTC 20 (2) INFORMACE PRO SEQ ID NO:433: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 57 párů bází (B) TYP: nukleová kyselina 25 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:433: 30 GTTGCCATGG CNCTGCARGA YGARGARCTG TGYGGYGGCC TCTGGCGGCT GGTCCTG (2) INFORMACE PRO SEQ ID NO:434: (i) CHARAKTERISTIKY SEKVENCE: 35 (A) DÉLKA: 57 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 40 (xi) POPIS SEKVENCE: SEQ ID NO:434: GTTGCCATGG CNCARGAYGA RGARCTGTGY GGYGGYCTCT GGCGGCTGGT CCTGGCA (2) INFORMACE PRO SEQ ID NO:435: 45 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 57 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché 50 (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:435: GTTGCCATGG CNGAYGARGA RCTGTGYGGY GGYCTCTGGC GGCTGGTCCT GGCACAG 55 -594- CZ 295843 B6 (2) INFORMACE PRO SEQ ID NO:436: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 57 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:436: GTTGCCATGG CNGARGARCT GTGYGGYGGY CTCTGGCGGC TGGTCCTGGC ACAGCGC (2) INFORMACE PRO SEQ ID NO:437: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 57 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:437: GTTGCCATGG CNGARCTGTG YGGYGGYCTG TGGCGYCTGG TCCTGGCACA GCGCTGG (2) INFORMACE PRO SEQ ID NO:438: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 57 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:438: GTTGCCATGG CNCTGTGYGG YGGYCTGTGG CGYCTGGTCC TGGCACAGCG CTGGATG (2) INFORMACE PRO SEQ ID NO:439: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 30 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:439: TATGCAAGCT TAGGCCACGG TGACTGGGTA (2) INFORMACE PRO SEQ ID NO:440: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 30 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární CZ 295843 B6 (xi) POPIS SEKVENCE: SEQ ID NO:440: TATGCAAGCT TAGGAGGCCA CGGTGACTGG 5 (2) INFORMACE PRO SEQ ID NO:441: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 30 párů bázi (B) TYP: nukleová kyselina 10 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:441: 15 TATGCAAGCT TAGTTGGAGG CCACGGTGAC (2) INFORMACE PRO SEQ ID NO:442: (i) CHARAKTERISTIKY SEKVENCE: 20 (A) DÉLKA: 30 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 25 (xi) POPIS SEKVENCE: SEQ ID NO:442: TATGCAAGCT TACAGGTTGG AGGCCACGGT (2) INFORMACE PRO SEQ ID NO:443: 30 35 40 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 30 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:443: TATGCAAGCT TACTGCAGGT TGGAGGCCAC (2) INFORMACE PRO SEQ ID NO:444: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 30 párů bází 45 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 50 (xi) POPIS SEKVENCE: SEQ ID NO:444: TATGCAAGCT TAGTCCTGCA GGTTGGAGGC (2) INFORMACE PRO SEQ ID NO:445: 55 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 30 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární -596 - 60 CZ 295843 B6 (xi) POPIS SEKVENCE: SEQ ID NO:445: TATGCAAGCT TACTCGTCCT GCAGGTTGGA 5 (2) INFORMACE PRO SEQ ID NO:446: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 30 párů bází (B) TYP: nukleová kyselina 10 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:446: 15 TATGCAAGCT TACTCCTCGT CCTGCAGGTT (2) INFORMACE PRO SEQ ID NO:447: (i) CHARAKTERISTIKY SEKVENCE: 20 (A) DÉLKA: 47 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 25 (xi) POPIS SEKVENCE: SEQ ID NO:447: GCTACGTCTA GATCTCCTGA CCTCGACCCA GGACTGCTCC TTCCAAC (2) INFORMACE PRO SEQ ID NO:448: 30 35 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 68 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:448: GCTAGTTCTA GACCATCCTG GCTGACACGG TGAAACACCG TCTCTACGGG CTGACACTGC 40 AGCTCCAG (2) INFORMACE PRO SEQ ID NO:449: (i) CHARAKTERISTIKY SEKVENCE: 45 (A) DÉLKA: 56 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 50 (xi) POPIS SEKVENCE: SEQ ID NO:449: GTCAGTACTA GTATGGGTGT CCGGGCTCTT CGGCTCCTGC AGGTTGGAGG CCACGG (2) INFORMACE PRO SEQ ID NO:450: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 45 párů bází -597- 55 CZ 295843 B6 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 5 (xi) POPIS SEKVENCE: SEQ ID NO:450: GTCAGTACTA GTCCGCCATC TCCGACACCA TTAGGCCCTG CCAGC (2) INFORMACE PRO SEQ ID NO:451: 10 15 20 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 49 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:451: GTCAGTTCCG GAGATTTCGG TTCTGCAGAG GGCTGCGCAA GGTGGCGTA (2) INFORMACE PRO SEQ ID NO:452: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 64 párů bází 25 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:452: 30 GTCAGTTCCG GATACTCATA CCAGCCCGCC ATCCCCGGGT TCTAATCTGC AAGATGAAGA GCTG (2) INFORMACE PRO SEQ ID NO:453: 35 40 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 61 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:453: GTCAGTACTA GTATGGGTGT CCGGGCTCTT CGGAAAGGCA CATTTGGTGA CAAAGTGTAT 45 C (2) INFORMACE PRO SEQ ID NO:454: (i) CHARAKTERISTIKY SEKVENCE: 50 (A) DÉLKA: 48 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 55 (xi) POPIS SEKVENCE: SEQ ID NO:454: GTCAGTACTA GTCCGCCATC TCCGGGTACA CCATTAGGCC CTGCCAGC -598 - CZ 295843 B6 (2) INFORMACE PRO SEQ ID NO:455: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 63 párů bází 5 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:455: 10 GTCAGTTCCG GATACTCATA CCAGCCCGCC ATCCCCGGGT AAGGCCTTTC AGCCCCCCCC CAG 15 20 (2) INFORMACE PRO SEQ ID NO:456: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 33 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:456: 25 GTCAGACCAT GGCCACTCAG GACTCCTCTT TTC (2) INFORMACE PRO SEQ ID NO:457: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 27 párů bází 30 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 35 (xi) POPIS SEKVENCE: SEQ ID NO:457: CACTTTGTCA CCAAATCTGC CTTTCAG (2) INFORMACE PRO SEQ ID NO:458: 40 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 27 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:458: 45 CTGAAAGGCA GATTTGGTGA CAAAGTG 50 (2) INFORMACE PRO SEQ ID NO:459: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 21 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární -599- 55 CZ 295843 B6 (xi) POPIS SEKVENCE: SEQ ID NO:459: GCCCCCCCCC AGCTCTCTTC G 5 (2) INFORMACE PRO SEQ ID NO:460: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 21 párů bází (B) TYP: nukleová kyselina 10 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:460: 15 CGAAGAGAGC TGGGGGGGGG C (2) INFORMACE PRO SEQ ID NO:461: (i) CHARAKTERISTIKY SEKVENCE: 20 (A) DÉLKA: 41 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 25 (xi) POPIS SEKVENCE: SEQ ID NO:461: GTCAGTTACG TACAGGGTTG AAGGAGTCGG GCTGAGACTG C (2) INFORMACE PRO SEQ ID NO:462: 30 35 40 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 30 párů bázi (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:462: GTCAGTCCAT GGCTACTCAA GGTGCTATGC (2) INFORMACE PRO SEQ ID NO:463: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 31 párů bází 45 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 50 (xi) POPIS SEKVENCE: SEQ ID NO:463: GTAGCATACG TAGGGCTGCA GGGCAGGGGC C (2) INFORMACE PRO SEQ ID NO:464: 55 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 166 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární -600- 60 5 5 10 15 20 25 CZ 295843 B6 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:464: Ala Pro Pro Arg Leu Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu 1 5 10 15 Leu Glu Ala Lys Glu Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His 20 25 30 Cys Ser Leu Asn Glu Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe 35 40 45 Tyr Ala Trp Lys Arg Met Glu Val Gly Gin Gin Ala Val Glu Val Trp 50 55 60 Gin Gly Leu Ala Leu Leu Ser Glu Ala Val Leu Arg Gly Gin Ala Leu 65 70 75 80 Leu Val Asn Ser Ser Gin Pro Trp Glu Pro Leu Gin Leu His Val Asp 85 90 95 Lys Ala Val Ser Gly Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu 100 105 110 Gly Ala Gin Lys Glu Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala 115 120 125 Pro Leu Arg Thr Ile Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val 130 135 140 Tyr Ser Asn Phe Leu Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala 145 150 155 160 Cys Arg Thr Gly Asp Arg 165 (2) INFORMACE PRO SEQ ID NO:465: 30 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 165 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 35 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:465: 40 45 50 55 Glu Gly Ile Cys Arg Asn Arg Val Thr Asn Asn Val Lys Asp Val Thr 1 5 10 15 Lys Leu Val Ala Asn Leu Pro Lys Asp Tyr Met Ile Thr Leu Lys Tyr 20 25 30 Val Pro Gly Met Asp Val Leu Pro Ser His Cys Trp Ile Ser Glu Met 35 40 45 Val Val Gin Leu Ser Asp Ser Leu Thr Asp Leu Leu Asp Lys Phe Ser 50 55 60 Asn Ile Ser Glu Gly Leu Ser Asn Tyr Ser Ile Ile Asp Lys Leu Val 65 70 75 80 Asn Ile Val Asp Asp Leu Val Glu Cys Val Lys Glu Asn Ser Ser Lys 85 90 95 Asp Leu Lys Lys Ser Phe Lys Ser Pro Glu Pro Arg Leu Phe Thr Pro 100 105 110 Glu Glu Phe Phe Arg Ile Phe Asn Arg Ser Ile Asp Ala Phe Lys Asp 115 120 125 Phe Val Val Ala Ser Glu Thr Ser Asp Cys Val Val Ser Ser Thr Leu 130 135 140 Ser Pro Glu Lys Asp Ser Arg Val Ser Val Thr Lys Pro Phe Met Leu 145 150 155 160 Pro Pro Val Ala Ala 165 -601 - 60 5 CZ 295843 B6 (2) INFORMACE PRO SEQ ID NO:466: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 139 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 10 (xi) POPIS SEKVENCE: SEQ ID NO:466: 15 20 25 30 Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala 1 5 10 15 Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val 20 25 30 Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp 35 40 45 Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala 50 55 60 Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His 65 70 75 80 Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe 85 90 95 Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu 100 105 110 Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu 115 120 125 Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 130 135 (2) INFORMACE PRO SEQ ID NO:467: (i) CHARAKTERISTIKY SEKVENCE: 35 (A) DÉLKA: 155 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 40 (ii) TYP MOLEKULY: žádný 45 50 55 (xi) POPIS SEKVENCE: SEQ ID NO:467: Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu 1 5 10 15 Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gin Cys Pro Glu Val 20 25 30 His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu 35 40 45 Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala Gin Asp Ile Leu 50 55 60 Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gin 65 70 75 80 Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser Gly Gin 85 90 95 Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr Gin Leu 100 105 110 Pro Pro Gin Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala Ile Phe 115 120 125 Leu Ser Phe Gin His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu 130 135 140 -602- 60 5 CZ 295843 B6 Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe 145 150 155 (2) INFORMACE PRO SEQ ID NO:468: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 309 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché 10 (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:468: 15 20 25 30 35 40 45 50 55 Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu 1 5 10 15 Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gin Cys Pro Glu Val 20 25 30 His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu 35 40 45 Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala Gin Asp Ile Leu 50 55 60 Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gin 65 70 75 80 Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser Gly Gin 85 90 95 Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr Gin Leu 100 105 110 Pro Pro Gin Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala Ile Phe 115 120 125 Leu Ser Phe Gin His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu 130 135 140 Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly Gly Asn Met Ala 145 150 155 160 Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu 165 170 175 Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gin Cys Pro Glu Val 180 185 190 His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu 195 200 205 Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala Gin Asp Ile Leu 210 215 220 Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gin 225 230 235 240 Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser Gly Gin 245 250 255 Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr Gin Gly 260 265 270 Arg Thr Thr Ala His Lys Asp Pro Asn Ala Ile Phe Leu Ser Phe Gin 275 280 285 His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu Val Gly Gly Ser 290 295 300 Thr Leu Cys Val Arg 305 (2) INFORMACE PRO SEQ ID NO:469: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 312 aminokyselin (B) TYP: aminokyselina -603 - 60 5 CZ 295843 B6 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:469: Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu 1 5 10 15 10 Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gin Cys Pro Glu Val 20 25 30 His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu 35 40 45 Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala Gin Asp Ile Leu 15 50 55 60 Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gin 65 70 75 80 Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser Gly Gin 85 90 95 20 Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr Gin Leu 100 105 110 Pro Pro Gin Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala Ile Phe 115 120 125 Leu Ser Phe Gin His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu 25 130 135 140 Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly Asn Met Ala Ser 145 150 155 160 Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu Arg 165 170 175 30 Asp Ser His Val Leu His Ser Arg Leu Ser Gin Cys Pro Glu Val His 180 185 190 Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu Gly 195 200 205 Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala Gin Asp Ile Leu Gly 35 210 215 220 Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gin Leu 225 230 235 240 Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser Gly Gin Val 245 250 255 40 Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr Gin Leu Pro 260 265 270 Pro Gin Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala Ile Phe Leu 275 280 285 Ser Phe Gin His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu Val 45 290 295 300 Gly Gly Ser Thr Leu Cys Val Arg 305 310 (2) INFORMACE PRO SEQ ID NO:470: 50 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 313 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché 55 (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID -604- 60 5 10 15 20 25 30 35 40 45 50 55 CZ 295843 B6 Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu 1 5 10 15 Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gin Cys Pro Glu Val 20 25 30 His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu 35 40 45 Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala Gin Asp Ile Leu 50 55 60 Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gin 65 70 75 80 Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser Gly Gin 85 90 95 Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr Gin Leu 100 105 110 Pro Pro Gin Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala Ile Phe 115 120 125 Leu Ser Phe Gin His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu 130 135 140 Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly Gly Asn Met Ala 145 150 155 160 Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu 165 170 175 Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gin Cys Pro Glu Val 180 185 190 His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu 195 200 205 Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala Gin Asp Ile Leu 210 215 220 Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gin 225 230 235 240 Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser Gly Gin 245 250 255 Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr Gin Leu 260 265 270 Pro Pro Gin Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala Ile Phe 275 280 285 Leu Ser Phe Gin His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu 290 295 300 Val Gly Gly Ser Thr Leu Cys Val Arg 305 310 (2) INFORMACE PRO SEQ ID NO:471: (i .) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 316 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ !: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS 1 SEKVENCE: SEQ ID NO:471: Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu 1 5 10 15 Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gin Cys Pro Glu Val 20 25 30 His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu 35 40 45 Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala Gin Asp Ile Leu 50 55 60 -605 - 60 5 10 15 20 25 30 35 40 45 50 55 CZ 295843 B6 Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gin 65 70 75 80 Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser Gly Gin 85 90 95 Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr Gin Leu 100 105 110 Pro Pro Gin Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala Ile Phe 115 120 125 Leu Ser Phe Gin His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu 130 135 140 Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly Gly Asn Gly Gly 145 150 155 160 Asn Met Ala Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser 165 170 175 Lys Leu Leu Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gin Cys 180 185 190 Pro Glu Val His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp 195 200 205 Phe Ser Leu Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala Gin 210 215 220 Asp Ile Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala 225 230 235 240 Arg Gly Gin Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin Leu 245 250 255 Ser Gly Gin Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu Gly 260 265 270 Thr Gin Leu Pro Pro Gin Gly Arg Thr Thr Ala His Lys Asp Pro Asn 275 280 285 Ala Ile Phe Leu Ser Phe Gin His Leu Leu Arg Gly Lys Val Arg Phe 290 295 300 Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg 305 310 315 (2) INFORMACE PRO SEQ ID NO:472: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 302 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:472: Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro 1 5 10 15 Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser 20 25 30 Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val 35 40 45 Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu 50 55 60 Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg 65 70 75 80 His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys 85 90 95 Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr 100 105 110 Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser 115 120 125 -606- 60 5 10 15 20 CZ 295843 B6 Asn Met Ala Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly 130 135 140 His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin 145 150 155 160 Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe 165 170 175 Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu 180 185 190 Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr 195 200 205 Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin 210 215 220 Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg 225 230 235 240 Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val 245 250 255 Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly 260 265 270 Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile 275 280 285 Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr 290 295 300 (2) INFORMACE PRO SEQ ID NO:473: 25 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 317 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché 30 (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:473: 35 40 45 50 55 Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro 1 5 10 15 Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser 20 25 30 Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val 35 40 45 Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu 50 55 60 Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg 65 70 75 80 His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys 85 90 95 Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr 100 105 110 Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser 115 120 125 Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn 130 135 140 Met Ala Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His 145 150 155 160 Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala 165 170 175 Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu 180 185 190 Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly 195 200 205 -607 - 60 5 10 15 CZ 295843 B6 Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr 210 215 220 Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro 225 230 235 240 Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala 245 250 255 Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser 260 265 270 Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly 275 280 285 Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin 290 295 300 Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr 305 310 315 (2) INFORMACE PRO SEQ ID NO:474: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 302 aminokyselin 20 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 25 (xi) POPIS SEKVENCE: SEQ ID NO:474: 30 35 40 45 50 55 Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro 1 5 10 15 Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser 20 25 30 Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val 35 40 45 Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu 50 55 60 Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg 65 70 75 80 His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys 85 90 95 Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr 100 105 110 Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser 115 120 125 Asn Met Ala Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp 130 135 140 Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly 145 150 155 160 Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala 165 170 175 Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu 180 185 190 Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin 195 200 205 Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu 210 215 220 Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys 225 230 235 240 Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu 245 250 255 Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser 260 265 270 -608- 60 CZ 295843 B6 Leu His Ser Gly Leu 285 Gly Ile Ser 300 Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin 275 280 Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu 290 295 (2) INFORMACE PRO SEQ ID NO:475: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 317 aminokyselin 10 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:475: Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro 1 5 10 15 20 Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser 20 25 30 Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val 35 40 45 Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu 25 50 55 60 Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg 65 70 75 80 His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys 85 90 95 30 Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr 100 105 110 Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser 115 120 125 Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn 35 130 135 140 Met Ala Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val 145 150 155 160 Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met 165 170 175 40 Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser 180 185 190 Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin 195 200 205 Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro 45 210 215 220 Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu 225 230 235 240 Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu 245 250 255 50 Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly 260 265 270 His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin 275 280 285 Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe 55 290 295 300 Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser 305 310 315 15 (2) INFORMACE PRO SEQ ID NO:476: 60 (i) CHARAKTERISTIKY SEKVENCE: -609- 5 CZ 295843 B6 (A) DÉLKA: 302 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:476: 10 15 20 25 30 35 40 45 Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro 1 5 10 15 Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser 20 25 30 Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val 35 40 45 Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu 50 55 60 Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg 65 70 75 80 His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys 85 90 95 Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr 100 105 110 Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser 115 120 125 Asn Met Ala Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro 130 135 140 Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala 145 150 155 160 Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His 165 170 175 Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu 180 185 190 Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu 195 200 205 Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu 210 215 220 Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser 225 230 235 240 Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His 245 250 255 Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile 260 265 270 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala 275 280 285 Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly 290 295 300 (2) INFORMACE PRO SEQ ID NO:477: 50 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 317 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché 55 (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:477: -610- 60 5 10 15 20 25 30 35 40 CZ 295843 B6 Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro 1 5 10 15 Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser 20 25 30 Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val 35 40 45 Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu 50 55 60 Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg 65 70 75 80 His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys 85 90 95 Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr 100 105 110 Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser 115 120 125 Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn 130 135 140 Met Ala Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala 145 150 155 160 Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser 165 170 175 His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu 180 185 190 Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys 195 200 205 Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin 210 215 220 Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val 225 230 235 240 Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys 245 250 255 Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser 260 265 270 Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser 275 280 285 Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp 290 295 300 Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly 305 310 315 (2) INFORMACE PRO SEQ ID NO:478: (i) CHARAKTERISTIKY SEKVENCE: 45 (A) DÉLKA: 302 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 50 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:478: 55 Asn 1 Cys Ser Ile Met 5 Ile Asp Glu Ile Ile 10 His His Leu Lys Arg 15 Pro Pro Ala Pro Leu 20 Leu Asp Pro Asn Asn 25 Leu Asn Asp Glu Asp 30 Val Ser Ile Leu Met 35 Asp Arg Asn Leu Arg 40 Leu Pro Asn Leu Glu 45 Ser Phe Val Arg Ala 50 Val Lys Asn Leu Glu 55 Asn Ala Ser Gly Ile 60 Glu Ala Ile Leu -611 - 60 5 10 15 20 25 30 CZ 295843 B6 Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg 65 70 75 80 His· Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys 85 90 95 Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr 100 105 110 Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser 115 120 125 Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin 130 135 140 Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu 145 150 155 160 Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly 165 170 175 Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg 180 185 190 Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr 195 200 205 Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu 210 215 220 Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin 225 230 235 240 Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin 245 250 255 Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr 260 265 270 Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp 275 280 285 Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro 290 295 300 (2) INFORMACE PRO SEQ ID NO:479: (i) CHARAKTERISTIKY SEKVENCE: 35 (A) DÉLKA: 317 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENI: jednoduché (D) TOPOLOGIE: lineární 40 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:479: 45 50 55 Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro 1 5 10 15 Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser 20 25 30 Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val 35 40 45 Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu 50 55 60 Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg 65 70 75 80 His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys 85 90 95 Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr 100 105 110 Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser 115 120 125 Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn 130 135 140 -612- 60 5 10 15 20 CZ 295843 B6 Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg 145 150 155 160 Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu 165 170 175 Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser 180 185 190 Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys 195 200 205 Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr 210 215 220 Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly 225 230 235 240 Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu 245 250 255 Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly 260 265 270 Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu 275 280 285 Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin 290 295 300 Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro 305 310 315 (2) INFORMACE PRO SEQ ID NO:480: 25 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 302 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché 30 (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:480: 35 40 45 50 55 Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro 1 5 10 15 Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser 20 25 30 Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val 35 40 45 Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu 50 55 60 Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg 65 70 75 80 His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys 85 90 95 Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr 100 105 110 Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser 115 120 125 Asn Met Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala 130 135 140 Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His 145 150 155 160 Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu 165 170 175 Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu 180 185 190 Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu 195 200 205 -613 - 60 5 10 15 20 25 30 35 40 45 50 55 CZ 295843 B6 Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser 210 215 220 Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His 225 230 235 240 Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile 245 250 255 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala 260 265 270 Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala 275 280 285 Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala 290 295 300 (2 ) INFORMACE PRO : SEQ : ID NO:481: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 317 , aminokyselin (B) TYP: : aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: : lineární (ii) TYP MOLEKULY : žádný (xi) i POPIS SEKVENCE: SEQ : ID NO:481: Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro 1 5 10 15 Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser 20 25 30 Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val 35 40 45 Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu 50 55 60 Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg 65 70 75 80 His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys 85 90 95 Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr 100 105 110 Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser 115 120 125 Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn 130 135 140 Met Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser 145 150 155 160 His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu 165 170 175 Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys 180 185 190 Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin 195 200 205 Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val 210 215 220 Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys 225 230 235 240 Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser 245 250 255 Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser 260 265 270 Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp 275 280 285 -614- 60 5 GZ 295843 B6 Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro 290 295 300 Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala 305 310 315 (2) INFORMACE PRO SEQ ID NO:482: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 305 aminokyselin 10 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 15 (xi) POPIS SEKVENCE: SEQ ID NO:482: 20 25 30 35 40 45 50 55 Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro 1 5 10 15 Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser 20 25 30 Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val 35 40 45 Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu 50 55 60 Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg 65 70 75 80 His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys 85 90 95 Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr 100 105 110 Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser 115 120 125 Asn Met Ala Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly 130 135 140 His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin 145 150 155 160 Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe 165 170 175 Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu 180 185 190 Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr 195 200 205 Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin 210 215 220 Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg 225 230 235 240 Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val 245 250 255 Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Thr Pro Leu Gly Pro 260 265 270 Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val 275 280 285 Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala 290 295 300 Thr 305 (2) INFORMACE PRO SEQ ID NO:483: (i) CHARAKTERISTIKY SEKVENCE: -615- 60 5 CZ 295843 B6 (A) DÉLKA: 320 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:483: 10 15 20 25 30 35 40 45 Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro 1 5 10 15 Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser 20 25 30 Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val 35 40 45 Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu 50 55 60 Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg 65 70 75 80 His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys 85 90 95 Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr 100 105 110 Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser 115 120 125 Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn 130 135 140 Met Ala Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His 145 150 155 160 Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala 165 170 175 Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu 180 185 190 Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly 195 200 205 Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr 210 215 220 Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro 225 230 235 240 Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala 245 250 255 Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser 260 265 270 Tyr Arg Val Leu Arg His Leu Ala Gin Pro Thr Pro Leu Gly Pro Ala 275 280 285 Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg 290 295 300 Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr 305 310 315 320 50 (2) INFORMACE PRO SEQ ID NO:484: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 305 aminokyselin 55 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:484: -616- 60 CZ 295843 B6 Asn 1 Cys Ser Ile 5 Pro Ala Pro Leu 20 Ile Leu Met 35 Asp Arg Ala 50 Val Lys 10 Arg 65 Asn Leu Gin His Pro Ile Ile 15 Leu Thr Phe Tyr 100 Val Glu Gly 115 Gly Asn Met 130 Ala Pro 20 Val 145 Ala Asp Phe Met Ala Pro Ala 25 Ser Ala Phe Gin 180 Gin Ser Phe 195 Leu Pro Thr 210 Pro Leu 30 Lys 225 Ser Leu Glu Gin Glu Lys Leu 35 Val Leu Leu Gly 260 Cys Pro Ser 275 Gin 40 Ser Ser 305 Gly 290 Leu Phe Met 5 Ile Asp Glu Ile Ile 10 Leu Asp Pro Asn Asn 25 Leu Arg Asn Leu Arg 40 Leu Pro Asn Leu Glu 55 Asn Ala Ser Pro Cys 70 Leu Pro Ser Ala Ile 85 Lys Ala Gly Asp Trp 90 Leu Val Thr Leu Glu 105 Gin Gly Gly Ser Pro 120 Gly Gly Glu Leu Gly 135 Pro Thr Leu Ala Thr 150 Thr Ile Trp Gin Leu 165 Gin Pro Thr Gin Gly 170 Arg Arg Ala Gly Gly 185 Val Glu Val Ser Tyr 200 Arg Val Gly Pro Ala 215 Ser Ser Leu Gin Val 230 Arg Lys Ile Gin Cys 245 Ala Thr Tyr Lys Leu 250 His Ser Leu Gly Ile 265 Pro Ala Leu Gin Leu 280 Ala Gly Leu Tyr Gin 295 Gly Leu Leu His His Leu Lys Arg 15 Pro Asn Asp Glu Asp 30 Val Ser Asn Leu Glu 45 Ser Phe Val Gly Ile 60 Glu Ala Ile Leu Thr 75 Ala Ala Pro Ser Arg 80 Gin Glu Phe Arg Glu 95 Lys Ala Gin Glu Gin 110 Gin Tyr Gly Ser Gly 125 Gly Gly Ser Asp Thr 140 Leu Gin Leu Asp Gin 155 Met Glu Glu Leu Gly 160 Ala Met Pro Ala Phe 175 Ala Leu Val Ala Ser 190 His Leu Leu Arg His 205 Leu Ala Gin Pro Gin 220 Ser Phe Leu Leu Gly Asp 235 Gly Ala Ala Leu 240 Cys His Pro Glu Glu 255 Leu Trp Ala Pro Leu 270 Ser Ser Cys Leu Ser 285 Gin Leu His Gin Ala 300 Leu Glu Gly Ile (2) INFORMACE PRO SEQ ID NO:485: 45 50 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 320 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:485: Asn 1 Cys Ser Ile Met 5 Ile Asp Glu Ile Ile 10 His His Leu Lys Arg 15 Pro Pro Ala Pro Leu 20 Leu Asp Pro Asn Asn 25 Leu Asn Asp Glu Asp 30 Val Ser Ile Leu Met 35 Asp Arg Asn Leu Arg 40 Leu Pro Asn Leu Glu 45 Ser Phe Val 55 -617- 60 5 10 15 20 25 30 35 40 45 50 55 CZ 295843 B6 Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu 50 55 60 Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg 65 70 75 80 His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys 85 90 95 Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr 100 105 110 Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser 115 120 125 Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn 130 135 140 Met Ala Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val 145 150 155 160 Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met 165 170 175 Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser 180 185 190 Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin 195 200 205 Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro 210 215 220 Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys 225 230 235 240 Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin 245 250 255 Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val 260 265 270 Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys 275 280 285 Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser 290 295 300 Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser 305 310 315 320 (2: ) INFORMACE ] PRO SEQ ID NO:486: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 305 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY : žádný (xi) POPIS SEKVENCE: SEQ ID NO:486: Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro 1 5 10 15 Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser 20 25 30 Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val 35 40 45 Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu 50 55 60 Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg 65 70 75 80 His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys 85 90 95 Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr 100 105 110 -618- 60 CZ 295843 B6 Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser 115 120 125 Asn Met Ala Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro 130 135 140 5 Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala 145 150 155 160 Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His 165 170 175 Leu Ala Gin Pro Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser 10 180 185 190 Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly 195 200 205 Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro 210 215 220 15 Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro 225 230 235 240 Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser 245 250 255 Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu 20 260 265 270 Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu 275 280 285 Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu 290 295 300 25 Gly 305 (2; ) INFORMACE ] PRO SEQ ID NO:487: 30 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 320 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché Ί C (D) TOPOLOGIE: lineární Jj (ii) TYP MOLEKULY : žádný (xi) POPIS SEKVENCE: SEQ ID NO:481 ř .
- 40 Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro 1 5 10 15 Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser 20 25 30 Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val 45 35 40 45 Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu 50 55 60 Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg 65 70 75 80 50 His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys 85 90 95 Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr 100 105 110 Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser 55 115 120 125 Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn 130 135 140 Met Ala Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala 145 150 155 160 60 Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser 165 170 175 -619- CZ 295843 B6 His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu 180 185 190 Ala Gin Pro Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe 195 200 205 5 Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala 210 215 220 Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu 225 230 235 240 Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu 10 245 250 255 Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin 260 265 270 Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu 275 280 285 15 Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp 290 295 300 Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly 305 310 315 320 20 (2) INFORMACE : PRO SEQ : ID NO:488: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 305 i aminokyselin (B) TYP: : aminokyselina 25 (C) ŘETĚZENÍ: j< ednoduché (D) TOPOLOGIE: : lineární (ii) TYP MOLEKULY : žádný 30 (xi) POPIS SEKVENCE: SEQ ID NO:488: Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro 1 5 10 15 Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser 35 20 25 30 Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val 35 40 45 Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu 50 55 60 40 Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg 65 70 75 80 His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys 85 90 95 Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr 45 100 105 110 Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser 115 120 125 Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin 130 135 140 50 Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu 145 150 155 160 Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Thr Pro Leu 165 170 175 Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu 55 180 185 190 Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu 195 200 205 Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly 210 215 220 60 His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin 225 230 235 240 -620- CZ 295843 B6 Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe 245 250 255 Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu 260 265 270 5 Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr 275 280 285 Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin 290 295 300 Pro 10 305 (2 ) INFORMACE PRO : SEQ ID NO:4 8 9 : (i) CHARAKTERISTIKY SEKVENCE: 15 (A) DÉLKA: 320 , aminokyselin (B) TYP : aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: . lineární 20 (ii) ' TYP MOLEKULY : žádný (xi) : POPIS SEKVENCE: i SEQ : ID NO: 489: Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro 25 1 5 10 15 Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser 20 25 30 Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val 35 40 45 30 Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu 50 55 60 Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg 65 70 75 80 His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys 35 85 90 95 Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr 100 105 110 Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser 115 120 125 40 Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn 130 135 140 Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg 145 150 155 160 Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu 45 165 170 175 Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Thr Pro Leu Gly 180 185 190 Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin 195 200 205 50 Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys 210 215 220 Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His 225 230 235 240 Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala 55 245 250 255 Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu 260 265 270 Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly 275 280 285 60 Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr 290 295 300 -621 - 5 CZ 295843 B6 Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro 305 310 315 320 (2) INFORMACE PRO SEQ ID NO:490: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 305 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché 10 (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:490: 15 Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro 1 5 10 15 Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser 20 25 30 Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val 35 40 45 Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu 50 55 60 Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg 65 70 75 80 His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys 85 90 95 Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr 100 105 110 Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser 115 120 125 Asn Met Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala 130 135 140 Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His 145 150 155 160 Leu Ala Gin Pro Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser 165 170 175 Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly 180 185 190 Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro 195 200 205 Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro 210 215 220 Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser 225 230 235 240 Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu 245 250 255 Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu 260 265 270 Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu 275 280 285 Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe 290 295 300 Ala 305 20 25 30 35 40 45 50 55 (2) INFORMACE PRO SEQ ID NO:491: (i) CHARAKTERISTIKY SEKVENCE: 60 (A) DÉLKA: 320 aminokyselin (B) TYP: aminokyselina -622- 5 CZ 295843 B6 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:491: 10 15 20 25 30 35 40 45 Asn 1 Cys Ser Ile Pro Ala Pro Leu 20 Ile Leu Met 35 Asp Arg Ala 50 Val Lys Arg 65 Asn Leu Gin His Pro Ile Ile Leu Thr Phe Tyr 100 Val Glu Gly 115 Gly Thr Ile 130 Asn Pro Met 145 Ala Ser Ala His Leu Gin Ser Ala Gin Pro Thr 180 Leu Leu Lys 195 Ser Ala Leu 210 Gin Glu Glu 225 Leu Val Leu Ser Ser Cys Pro Leu His Ser Gly 260 Gly Ile Ser 275 Pro Val Ala 290 Asp Phe Met 305 Ala Pro Ala Met 5 Ile Asp Glu Leu Asp Pro Asn Arg Asn Leu Arg 40 Asn Leu Glu 55 Asn Pro Cys 70 Leu Pro Ile 85 Lys Ala Gly Leu Val Thr Leu Gly Gly Ser Pro 120 Ser Pro Pro 135 Ser Phe Gin 150 Arg Arg Phe 165 Leu Glu Val Pro Leu Gly Pro Leu Glu Gin Val 200 Lys Leu Cys 215 Ala Leu Gly 230 His Ser Ser 245 Gin Ala Leu Leu Phe Leu Tyr Glu Leu Gly Pro 280 Ala Thr Thr 295 Ile Leu Gin 310 Pro Thr Ile Ile 10 His His Asn 25 Leu Asn Asp Leu Pro Asn Leu Ala Ser Gly Ile 60 Ser Ala Thr 75 Ala Asp Trp 90 Gin Glu Glu 105 Gin Ala Gin Gly Glu Pro Ser Lys Glu Ser His 140 Ala Gly Gly 155 Val Ser Tyr 170 Arg Val Ala 185 Ser Ser Leu Arg Lys Ile Gin Thr Tyr Lys Leu 220 Leu Gly Ile 235 Pro Gin Leu 250 Ala Gly Gin 265 Gly Leu Leu Thr Leu Asp Thr Trp Gin Gin Met 300 Gin Gly Ala 315 Met Leu Lys Arg 15 Pro Glu Asp 30 Val Ser Glu 45 Ser Phe Val Glu Ala Ile Leu Ala Pro Ser Arg 80 Phe Arg Glu 95 Lys Glu Gin 110 Gin Tyr Gly 125 Pro Ile Ser Lys Ser Pro Asn Leu Val Ala Ser 160 Leu Arg His 175 Leu Pro Gin 190 Ser Phe Gly 205 Asp Gly Ala Cys His Pro Glu Trp Ala Pro Leu 240 Cys Leu Ser 255 Gin Gin Ala 270 Leu Glu Leu 285 Gin Leu Asp Glu Glu Leu Gly Pro Ala Phe Ala 320 (2) INFORMACE PRO SEQ ID NO:492: 50 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 321 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché 55 (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:492: -623 - 60 5 10 15 20 25 30 35 40 CZ 295843 B6 Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp 1 5 10 15 Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys 20 25 30 Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin 35 40 45 Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile 50 55 60 Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr 65 70 75 80 Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Gly Gly Gly Ser Asn 85 90 95 Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro 100 105 110 Ala Pro Leu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser 115 120 125 Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His 130 135 140 Lys Ser Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser 145 150 155 160 Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin 165 170 175 Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro 180 185 190 Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu 195 200 205 Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu 210 215 220 Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly 225 230 235 240 His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin 245 250 255 Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe 260 265 270 Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu 275 280 285 Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr 290 295 300 Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin 305 310 315 320 Pro (2) INFORMACE PRO SEQ ID NO:493: 45 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 321 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 50 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:493: 55 Asn 1 Ala Ser Gly Ile 5 Glu Ala Ile Leu Arg 10 Asn Leu Gin Pro Cys 15 Leu Pro Ser Ala Thr 20 Ala Ala Pro Ser Arg 25 His Pro Ile Ile Ile 30 Lys Ala Gly Asp Trp 35 Gin Glu Phe Arg Glu 40 Lys Leu Thr Phe Tyr 45 Leu Val Thr -624- 60 CZ 295843 B6 Leu Glu Gin Ala Gin Glu Gin Gin Gly Gly Gly Ser Asn Cys Ser Ile 50 55 60 Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu 65 70 75 80 5 Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp 85 90 95 Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys 100 105 110 Asn Leu Glu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser 10 115 120 125 Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His 130 135 140 Lys Ser Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser 145 150 155 160 15 Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin 165 170 175 Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro 180 185 190 Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu 20 195 200 205 Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu 210 215 220 Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly 225 230 235 240 25 His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin 245 250 255 Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe 260 265 270 Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu 30 275 280 285 Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr 290 295 300 Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin 305 310 315 320 35 Pro (2) INFORMACE : PRO SEQ : ID NO:494 l: (i) CHARAKTERISTIKY SEKVENCE: 40 (A) DÉLKA: 321 i aminokyselin (B) TYP: : aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: ! lineární 45 (ii) TYP MOLEKULY : žádný (xi) POPIS SEKVENCE: SEQ : ID NO:4 94 i: Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu 50 1 5 10 15 Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin 20 25 30 Glu Gin Gin Gly Gly Gly Ser Asn Cys Ser Ile Met Ile Asp Glu Ile 35 40 45 55 Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn 50 55 60 Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu 65 70 75 80 Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala 60 85 90 95 -625 - CZ 295843 B6 Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser 100 105 110 Ala Thr Ala Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser 115 120 125 Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His 130 135 140 Lys Ser Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser 145 150 155 160 Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin 165 170 175 Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro 180 185 190 Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu 195 200 205 Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu 210 215 220 Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly 225 230 235 240 His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin 245 250 255 Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe 260 265 270 Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu 275 280 285 Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr 290 295 300 Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin 305 310 315 320 Pro (2i 1 INFORMACE 1 PRO SEQ ID NO:495: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 321 aminokyselin (B) TYP: : aminokyselina (C) ŘETĚZENÍ jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY : žádný (xi) POPIS SEKVENCE: SEQ ID NO:495: Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val 1 5 10 15 Thr Leu Glu Gin Ala Gin Glu Gin Gin Gly Gly Gly Ser Asn Cys Ser 20 25 30 Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro 35 40 45 Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met 50 55 60 Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val 65 70 75 80 Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu 85 90 95 Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile 100 105 110 Ile Ile Lys Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser 115 120 125 Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His 130 135 140 -626- CZ 295843 B6 Lys Ser Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser 145 150 155 160 Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin 165 170 175 Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro 180 185 190 Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu 195 200 205 Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu 210 215 220 Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly 225 230 235 240 His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin 245 250 255 Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe 260 265 270 Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu 275 280 285 Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr 290 295 300 Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin 305 310 315 320 Pro (2) INFORMACE 1 PRO SEQ ID NO:496: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 329 aminokyselin (B) TYP: : aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY : žádný (xi) POPIS SEKVENCE: SEQ ID NO:496: Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp 1 5 10 15 Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys 20 25 30 Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin 35 40 45 Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile 50 55 60 Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr 65 70 75 80 Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Gly Gly Gly Ser Gly 85 90 95 Gly Gly Ser Gly Gly Gly Ser Asn Cys Ser Ile Met Ile Asp Glu Ile 100 105 110 Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Tyr Val Glu Gly Gly 115 120 125 Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro 130 135 140 Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gin 145 150 155 160 Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly 165 170 175 Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg 180 185 190 -627- CZ 295843 B6 Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin 195 200 205 Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp 210 215 220 5 Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His 225 230 235 240 Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala 245 250 255 Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu 10 260 265 270 Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala 275 280 285 Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin 290 295 300 15 Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu 305 310 315 320 Leu Gly Met Ala Pro Ala Leu Gin Pro 325 20 (2 ) INFORMACE 1 PRO SEQ : ID NO:497: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 329 aminokyselin (B) TYP: aminokyselina 25 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY : žádný 30 (xi) 1 POPIS SEKVENCE: SEQ : ID NO:497 ř . Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu 1 5 10 15 Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala 35 20 25 30 Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr 35 40 45 Leu Glu Gin Ala Gin Glu Gin Gin Gly Gly Gly Ser Gly Gly Gly Ser 50 55 60 40 Gly Gly Gly Ser Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His 65 70 75 80 Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp 85 90 95 Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu 45 100 105 110 Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Tyr Val Glu Gly Gly 115 120 125 Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro 130 135 140 50 Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gin 145 150 155 160 Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly 165 170 175 Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg 55 180 185 190 Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin 195 200 205 Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp 210 215 220 60 Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His 225 230 235 240 -628- 5 10 15 20 25 30 35 40 45 50 55 CZ 295843 B6 Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala 245 250 255 Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu 260 265 270 Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala 275 280 285 Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin 290 295 300 Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu 305 310 315 320 Leu Gly Met Ala Pro Ala Leu Gin Pro 325 (2) INFORMACE : PRO SEQ : ID NO:498: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 329 ; aminokyselin (B) TYP: : aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: . Lineární (ii) TYP MOLEKULY : žádný (xi) POPIS SEKVENCE: SEQ ID NO:498: Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu 1 5 10 15 Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin 20 25 30 Glu Gin Gin Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Asn 35 40 45 Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro 50 55 60 Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile 65 70 75 80 Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg 85 90 95 Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg 100 105 110 Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Tyr Val Glu Gly Gly 115 120 125 Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro 130 135 140 Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gin 145 150 155 160 Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly 165 170 175 Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg 180 185 190 Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin 195 200 205 Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp 210 215 220 Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His 225 230 235 240 Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala 245 250 255 Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu 260 265 270 Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala 275 280 285 -629- 60 5 CZ 295843 B6 Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin 290 295 300 Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu 305 310 315 320 Leu Gly Met Ala Pro Ala Leu Gin Pro 325 (2) INFORMACE PRO SEQ ID NO:499: 10 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 329 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 15 (li) TYP MOLEKULY: žádný 20 25 30 35 40 45 50 55 (xi) POPIS SEKVENCE: SEQ ID NO:499: Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val 1 5 10 15 Thr Leu Glu Gin Ala Gin Glu Gin Gin Gly Gly Gly Ser Gly Gly Gly 20 25 30 Ser Gly Gly Gly Ser Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His 35 40 45 His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn 50 55 60 Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn 65 70 75 80 Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly 85 90 95 Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr 100 105 110 Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Tyr Val Glu Gly Gly 115 120 125 Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro 130 135 140 Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gin 145 150 155 160 Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly 165 170 175 Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg 180 185 190 Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin 195 200 205 Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp 210 215 220 Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His 225 230 235 240 Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala 245 250 255 Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu 260 265 270 Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala 275 280 285 Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin 290 295 300 Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu 305 310 315 320 Leu Gly Met Ala Pro Ala Leu Gin Pro 325 -630- 60 CZ 295843 B6 (2) INFORMACE PRO SEQ ID NO:500: (i) CHARAKTERISTIKY SEKVENCE: 5 (A) DÉLKA: 329 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 10 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:500: Met Ala Asn Cys Ser Ile Met CD i—1 1—1 Asp Glu Ile Ile His His Leu Lys 15 1 5 10 15 Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp 20 25 30 Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser 35 40 45 20 Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala 50 55 60 Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro 65 70 75 80 Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg 25 85 90 95 Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin 100 105 110 Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 115 120 125 30 Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 130 135 140 Pro Asn Met Ala Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu 145 150 155 160 Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser 35 165 170 175 Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu 180 185 190 Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu 195 200 205 40 Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala 210 215 220 Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu 225 230 235 240 Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg 45 245 250 255 Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu 260 265 270 Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Gly Gly Gly Ser 275 280 285 50 Asp Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe 290 295 300 Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala 305 310 315 320 Ala Leu Gin Glu Lys Leu Cys Ala Thr 55 325 (2) INFORMACE PRO SEQ ID NO:501: (i) CHARAKTERISTIKY SEKVENCE: 60 (A) DÉLKA: 329 aminokyselin (B) TYP: aminokyselina -631 - 5 CZ 295843 B6 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:501: 10 15 20 25 30 35 40 45 50 Met 1 Ala Asn Cys Arg Pro Pro Ala 20 Val Ser Ile 35 Leu Phe Val 50 Arg Ala Ile 65 Leu Arg Asn Ser Arg His Pro Glu Lys Leu Thr 100 Gin Tyr Val 115 Glu Ile Ser 130 Thr Ile Pro 145 Asn Met Ala Asp Val Ala Asp Gly Met Ala Pro 180 Ala Ser Ala 195 Phe Leu Gin 210 Ser Phe Gin 225 Pro Gly Gly Ser Leu Pro Gin Ile Gin Gly Asp 260 Lys Leu Cys 275 His Ile Pro 290 Trp Ala Ala 305 Gly Cys Leu Leu Leu Gin Ala Ser 5 Ile Met Ile Pro Leu Leu Asp Met Asp Arg Asn 40 Val Lys Asn 55 Leu Leu Gin 70 Pro Cys Ile 85 Ile Ile Lys Phe Tyr Leu Val Gly Gly Gly Gly 120 Asn Pro Ser 135 Pro Pro Glu 150 Leu Gly Phe 165 Ala Thr Thr Ala Leu Gin Pro Gin Arg Arg Ala 200 Leu Glu Val 215 Ser Gly Ser 230 Asp Met Ser 245 Phe Leu Leu Gly Ala Ala Leu Pro Glu Glu Leu 280 Pro Leu Ser 295 Ser Ser Gin 310 Leu His Leu 325 Glu Gly Ile Asp Glu 10 Ile Ile Pro 25 Asn Asn Leu Leu Arg Leu Pro Glu Asn Ala Ser 60 Leu Pro Ser 75 Ala Ala Gly 90 Asp Trp Thr 105 Leu Glu Gin Ser Pro Gly Glu Pro Ser Lys Glu 140 Pro Thr Leu 155 Asp Ile Trp 170 Gin Gin Thr 185 Gin Gly Ala Gly Gly Val Leu Tyr Arg Val Leu 220 Ala Thr Pro 235 Leu Lys Ser 250 Leu Glu Gin 265 Glu Lys Leu Val Leu Leu Gly Cys Pro Ser Gin 300 Ser Ser Gly Leu 315 Phe His His Leu 15 Lys Asn Asp 30 Glu Asp Asn 45 Leu Glu Ser Gly Ile Glu Ala Thr Ala Ala Pro 80 Gin Glu Phe 95 Arg Ala Gin 110 Glu Gin Pro 125 Ser Gly Pro Ser His Lys Ser Thr Leu Gin Leu 160 Met Glu Glu 175 Leu Met Pro 190 Ala Phe Val 205 Ala Ser His Arg His Leu Ala Gly Pro Ala Ser 240 Gin Val Arg 255 Lys Cys Ala 270 Thr Tyr His 285 Ser Leu Gly Ala Leu Gin Leu Leu Tyr Gin Gly 320 (2) INFORMACE PRO SEQ ID NO:502: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 329 aminokyselin 55 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:502: -632- 60 5 10 15 20 25 30 35 40 45 50 55 CZ 295843 B6 Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys 1 5 10 15 Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp 20 25 30 Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser 35 40 45 Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala 50 55 60 Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro 65 70 75 80 Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg 85 90 95 Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin 100 105 110 Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 115 120 125 Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 130 135 140 Pro Asn Met Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val 145 150 155 160 Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg 165 170 175 His Leu Ala Gin Pro Gly Gly Gly Ser Asp Met Ala Thr Pro Leu Gly 180 185 190 Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin 195 200 205 Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys 210 215 220 Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His 225 230 235 240 Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala 245 250 255 Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu 260 265 270 Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly 275 280 285 Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr 290 295 300 Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro 305 310 315 320 Thr Gin Gly Ala Met Pro Ala Phe Ala 325 (2) INFORMACE PRO SEQ ID NO:503: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 329 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:503: Met 1 Ala Asn Cys Ser 5 Ile Met Ile Asp Glu 10 Ile Ile His His Leu 15 Lys Arg Pro Pro Ala 20 Pro Leu Leu Asp Pro 25 Asn Asn Leu Asn Asp 30 Glu Asp -633- 60 5 10 15 20 25 30 35 40 45 50 55 CZ 295843 B6 Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser 35 40 45 Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala 50 55 60 Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro 65 70 75 80 Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg 85 90 95 Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin 100 105 110 Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 115 120 125 Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 130 135 140 Pro Asn Met Ala Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met 145 150 155 160 Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val 165 170 175 Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg 180 185 190 His Leu Ala Gin Pro Gly Gly Gly Ser Asp Met Ala Thr Pro Leu Gly 195 200 205 Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin 210 215 220 Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys 225 230 235 240 Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His 245 250 255 Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala 260 265 270 Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu 275 280 285 Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly 290 295 300 Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr 305 310 315 320 Ile Trp Gin Gin Met Glu Glu Leu Gly 325 (2) INFORMACE PRO SEQ ID NO:504: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 329 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:504: Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys 1 5 10 15 Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp 20 25 30 Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser 35 40 45 Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala 50 55 60 Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro 65 70 75 80 -634- 60 5 ΙΟ 15 20 25 30 CZ 295843 B6 Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg 85 90 95 Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin 100 105 110 Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 115 120 125 Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 130 135 140 Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe 145 150 155 160 Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe 165 170 175 Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Gly Gly 180 185 190 Gly Ser Asp Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin 195 200 205 Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp 210 215 220 Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His 225 230 235 240 Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala 245 250 255 Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu 260 265 270 Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala 275 280 285 Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin 290 295 300 Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu 305 310 315 320 Leu Gly Met Ala Pro Ala Leu Gin Pro 325 (2) INFORMACE PRO SEQ ID NO:505: 35 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 319 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché 40 (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:505: 45 50 55 Met Ala Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu Lys 1 5 10 15 Gin Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly Glu Asp 20 25 30 Gin Asp Ile Leu Met Asp Asn Asn Leu Arg Arg Pro Asn Leu Glu Ala 35 40 45 Phe Asn Arg Ala Val Lys Ser Leu Gin Asn Ala Ser Ala Ile Glu Ser 50 55 60 Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu Ala Thr Ala Ala Pro 65 70 75 80 Thr Arg His Pro Ile His Ile Lys Asp Gly Asp Trp Asn Glu Phe Arg 85 90 95 Arg Lys Leu Thr Phe Tyr Leu Lys Thr Leu Glu Asn Ala Gin Ala Gin 100 105 110 Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 115 120 125 -635- 60 5 10 15 20 25 CZ 295843 B6 Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 130 135 140 Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe 145 150 155 160 Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe 165 170 175 Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly 180 185 190 Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val 195 200 205 Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala 210 215 220 Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser 225 230 235 240 Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu 245 250 255 Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr 260 265 270 Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro 275 280 285 Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile 290 295 300 Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro 305 310 315 (2) INFORMACE PRO SEQ ID NO:506: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 322 aminokyselin 30 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 35 (xi) POPIS SEKVENCE: SEQ ID NO:506: 40 45 50 55 Met Ala Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu Lys 1 5 10 15 Gin Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly Glu Asp 20 25 30 Gin Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn Leu Glu Ala 35 40 45 Phe Asn Arg Ala Val Lys Ser Leu Gin Asn Ala Ser Ala Ile Glu Ser 50 55 60 Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu Ala Thr Ala Ala Pro 65 70 75 80 Thr Arg His Pro Ile Ile Ile Arg Asp Gly Asp Trp Asn Glu Phe Arg 85 90 95 Arg Lys Leu Thr Phe Tyr Leu Lys Thr Leu Glu Asn Ala Gin Ala Gin 100 105 110 Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 115 120 125 Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 130 135 140 Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe 145 150 155 160 Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe 165 170 175 Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Thr Pro 180 185 190 -636- 60 CZ 295843 B6 Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu 195 200 205 Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys 210 215 220 Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu 225 230 235 240 Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser 245 250 255 Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu 260 265 270 Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu 275 280 285 Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala 290 295 300 Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu 305 310 315 320 Gin Pro (2) INFORMACE PRO SEQ ID NO:507: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 319 aminokyselin (B) TYP: : aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY : žádný (xi) POPIS SEKVENCE: SEQ ID NO:507: Met Ala Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu Lys 1 5 10 15 Gin Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly Glu Asp 20 25 30 Gin Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn Leu Glu Ala 35 40 45 Phe Asn Arg Ala Val Lys Ser Leu Gin Asn Ala Ser Ala Ile Glu Ser 50 55 60 Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu Ala Thr Ala Ala Pro 65 70 75 80 Thr Arg His Pro Ile Ile Ile Arg Asp Gly Asp Trp Asn Glu Phe Arg 85 90 95 Arg Lys Leu Thr Phe Tyr Leu Lys Thr Leu Glu Asn Ala Gin Ala Gin 100 105 110 Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 115 120 125 Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 130 135 140 Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe 145 150 155 160 Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe 165 170 175 Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly 180 185 190 Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val 195 200 205 Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala 210 215 220 Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser 225 230 235 240 -637- 5 10 CZ 295843 B6 Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu 245 250 255 Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr 260 265 270 Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro 275 280 285 Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile 290 295 300 Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro 305 310 315 (2) INFORMACE PRO SEQ ID NO:508: (i) CHARAKTERISTIKY SEKVENCE: 15 (A) DÉLKA: 322 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 20 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:508: 25 30 35 40 45 50 55 Met Ala Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu Lys 1 5 10 15 Gin Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly Glu Asp 20 25 30 Gin Asp Ile Leu Met Asp Asn Asn Leu Arg Arg Pro Asn Leu Glu Ala 35 40 45 Phe Asn Arg Ala Val Lys Ser Leu Gin Asn Ala Ser Ala Ile Glu Ser 50 55 60 Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu Ala Thr Ala Ala Pro 65 70 75 80 Thr Arg His Pro Ile His Ile Lys Asp Gly Asp Trp Asn Glu Phe Arg 85 90 95 Arg Lys Leu Thr Phe Tyr Leu Lys Thr Leu Glu Asn Ala Gin Ala Gin 100 105 110 Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 115 120 125 Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 130 135 140 Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe 145 150 155 160 Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe 165 170 175 Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Thr Pro 180 185 190 Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu 195 200 205 Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys 210 215 220 Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu 225 230 235 240 Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser 245 250 255 Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu 260 265 270 Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu 275 280 285 Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala 290 295 300 -638- 60 5 CZ 295843 B6 Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu 305 310 315 320 Gin Pro (2) INFORMACE PRO SEQ ID NO:509: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 306 aminokyselin (B) TYP: aminokyselina 10 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 15 (xi) POPIS SEKVENCE: SEQ ID NO:509: 20 25 30 35 40 45 50 55 Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Glu Val His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val 145 150 155 160 Asp Phe Ser Leu Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala 165 170 175 Gin Asp Ile Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala 180 185 190 Ala Arg Gly Gin Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin 195 200 205 Leu Ser Gly Gin Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu 210 215 220 Gly Thr Gin Leu Pro Pro Gin Gly Arg Thr Thr Ala His Lys Asp Pro 225 230 235 240 Asn Ala Ile Phe Leu Ser Phe Gin His Leu Leu Arg Gly Lys Val Arg 245 250 255 Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly 260 265 270 Gly Asn Met Ala Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu 275 280 285 Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gin 290 295 300 Cys Pro 305 (2) INFORMACE PRO SEQ ID NO:510: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 306 aminokyselin -639- 60 CZ 295843 B6 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 5 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:510: 10 Ala 1 Asn Cys Pro Pro Ala Ser Ile Leu 35 15 Val Arg 50 Ala Leu 65 Arg Asn Arg His Pro 20 Lys Leu Thr Tyr Val Glu 115 25 Ser Thr 130 Ile Asn 145 Met Leu Gly Glu Trp 30 Gly Ala Val Leu Gly Pro 195 35 Val Arg 210 Leu Pro 225 Pro Gin Leu Ser Phe 40 Val Gly Gly Ser Pro Ala 275 45 Arg His 305 Asp 290 Pro Ser Ser Ile 5 Met Ile Pro 20 Leu Leu Asp Met Asp Arg Asn Val Lys Asn Leu 55 Leu Gin Pro 70 Cys Ile Ile 85 Ile Lys Phe 100 Tyr Leu Val Gly Gly Gly Gly Asn Pro Ser Pro 135 Pro Thr Pro 150 Val Lys Thr 165 Gin Met Thr 180 Leu Leu Leu Thr Cys Leu Ser Leu Leu Gly Ala 215 Gly Arg Thr 230 Thr Gin His 245 Leu Leu Ser 260 Thr Leu Cys Pro Pro Ala Cys His Val Leu His 295 Asp Glu Ile 10 Ile His Pro Asn 25 Asn Leu Asn Leu 40 Arg Leu Pro Asn Glu Asn Ala Ser Gly 60 Leu Pro Ser Ala 75 Thr Ala Gly Asp 90 Trp Gin Thr Leu 105 Glu Gin Ala Ser 120 Pro Gly Glu Pro Pro Ser Lys Glu Ser 140 Leu Leu Pro Ala 155 Val Glu Glu Thr 170 Lys Ala Glu Gly 185 Val Met Ala Ser 200 Leu Leu Gly Gin Leu Gin Ser Leu Leu 220 Ala His Lys Asp 235 Pro Arg Gly Lys 250 Val Arg Val Arg 265 Glu Phe Gly Asp 280 Leu Arg Val Leu Ser Arg Leu Ser Gin 300 His Leu Lys 15 Arg Asp Glu 30 Asp Val Leu 45 Glu Ser Phe Ile Glu Ala Ile Ala Ala Pro Ser 80 Glu Phe Arg 95 Glu Gin Glu 110 Gin Gin Ser 125 Gly Pro Ile His Lys Ser Pro Asp Phe Ser Leu 160 Gin Asp Ile 175 Leu Ala Arg 190 Gly Gin Leu 205 Ser Gly Gin Gly Thr Gin Leu Asn Ala Ile Phe 240 Phe Leu Met 255 Leu Gly Asn 270 Met Ala Ser 285 Lys Leu Leu Cys Pro Glu Val 50 (2) INFORMACE PRO SEQ ID NO:511: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 306 aminokyselin (B) TYP: aminokyselina 55 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 60 (xi) POPIS SEKVENCE: SEQ ID NO:511: -640- CZ 295843 B6 Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 5 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 10 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 15 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Val Leu Leu Pro Ala Val Asp Phe Ser Leu Gly Glu Trp Lys 20 145 150 155 160 Thr Gin Met Glu Glu Thr Lys Ala Gin Asp Ile Leu Gly Ala Val Thr 165 170 175 Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gin Leu Gly Pro Thr 180 185 190 25 Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser Gly Gin Val Arg Leu Leu 195 200 205 Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr Gin Leu Pro Pro Gin Gly 210 215 220 Arg Thr Thr Ala His Lys Asp Pro Asn Ala Ile Phe Leu Ser Phe Gin 30 225 230 235 240 His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu Val Gly Gly Ser 245 250 255 Thr Leu Cys Val Arg Glu Phe Gly Gly Asn Met Ala Ser Pro Ala Pro 260 265 270 35 Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu Arg Asp Ser His 275 280 285 Val Leu His Ser Arg Leu Ser Gin Cys Pro Glu Val His Pro Leu Pro 290 295 300 Thr Pro 40 305 (2) INFORMACE PRO SEQ ID NO:512 > . (i) CHARAKTERISTIKY SEKVENCE: 45 (A) DÉLKA: 306 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ jednoduché (D) TOPOLOGIE: lineární 50 (ii) TYP MOLEKULY: : žádný (xi) POPIS SEKVENCE: SEQ ID NO:512 I a Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 55 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe 35 40 45 60 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 -641 - CZ 295843 B6 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 5 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 10 130 135 140 Asn Met Ala Val Asp Phe Ser Leu Gly Glu Trp Lys Thr Gin Met Glu 145 150 155 160 Glu Thr Lys Ala Gin Asp Ile Leu Gly Ala Val Thr Leu Leu Leu Glu 165 170 175 15 Gly Val Met Ala Ala Arg Gly Gin Leu Gly Pro Thr Cys Leu Ser Ser 180 185 190 Leu Leu Gly Gin Leu Ser Gly Gin Val Arg Leu Leu Leu Gly Ala Leu 195 200 205 Gin Ser Leu Leu Gly Thr Gin Leu Pro Pro Gin Gly Arg Thr Thr Ala 20 210 215 220 His Lys Asp Pro Asn Ala Ile Phe Leu Ser Phe Gin His Leu Leu Arg 225 230 235 240 Gly Lys Val Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val 245 250 255 25 Arg Glu Phe Gly Gly Asn Met Ala Ser Pro Ala Pro Pro Ala Cys Asp 260 265 270 Leu Arg Val Leu Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser 275 280 285 Arg Leu Ser Gin Cys Pro Glu Val His Pro Leu Pro Thr Pro Val Leu 30 290 295 300 Leu Pro 305 35 (2) INFORMACE PRO SEQ ID NO:513: (: L) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 306 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché 40 (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY : žádný 45 (xi) POPIS SEKVENCE: SEQ ID NO:513: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 50 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 55 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 60 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 -642- CZ 295843 B6 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Asp Phe Ser Leu Gly Glu Trp Lys Thr Gin Met Glu Glu Thr 145 150 155 160 Lys Ala Gin Asp Ile Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Val 165 170 175 Met Ala Ala Arg Gly Gin Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu 180 185 190 Gly Gin Leu Ser Gly Gin Val Arg Leu Leu Leu Gly Ala Leu Gin Ser 195 200 205 Leu Leu Gly Thr Gin Leu Pro Pro Gin Gly Arg Thr Thr Ala His Lys 210 215 220 Asp Pro Asn Ala Ile Phe Leu Ser Phe Gin His Leu Leu Arg Gly Lys 225 230 235 240 Val Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu 245 250 255 Phe Gly Gly Asn Met Ala Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg 260 265 270 Val Leu Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser Arg Leu 275 280 285 Ser Gin Cys Pro Glu Val His Pro Leu Pro Thr Pro Val Leu Leu Pro 290 295 300 Ala Val 305 (21 1 INFORMACE PRO SEQ ID NO:514: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 306 aminokyselin (B) TYP: : aminokyselina (C) RETEZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: : žádný (xi) POPIS SEKVENCE: SEQ ID NO:514: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala Gin Asp 145 150 155 160 Ile Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg 165 170 175 Gly Gin Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser 180 185 190 -643 - CZ 295843 B6 Gly Gin Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr 195 200 205 Gin Leu Pro Pro Gin Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala 210 215 220 Ile Phe Leu Ser Phe Gin His Leu Leu Arg Gly Lys Val Arg Phe Leu 225 230 235 240 Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly Gly Asn 245 250 255 Met Ala Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys 260 265 270 Leu Leu Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gin Cys Pro 275 280 285 Glu Val His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe 290 295 300 Ser Leu 305 (2) INFORMACE PRO SEQ ID NO:515: 20 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 306 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 25 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:515: 30 35 40 45 50 55 Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser Gly 145 150 155 160 Gin Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr Gin 165 170 175 Leu Pro Pro Gin Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala Ile 180 185 190 Phe Leu Ser Phe Gin His Leu Leu Arg Gly Lys Val Arg Phe Leu Met 195 200 205 Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly Gly Asn Met 210 215 220 Ala Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu 225 230 235 240 Leu Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gin Cys Pro Glu 245 250 255 -644- 60 5 10 15 20 25 30 35 40 45 50 55 CZ 295843 B6 Val His Pro Leu 260 Pro Thr Pro Val Leu 265 Leu Pro Ala Val Asp 270 Phe Ser Leu Gly Glu 275 Trp Lys Thr Gin Met 280 Glu Glu Thr Lys Ala 285 Gin Asp Ile Leu Gly 290 Ala Val Thr Leu Leu 295 Leu Glu Gly Val Met 300 Ala Ala Arg Gly Gin Leu 305 (2) INFORMACE PRO SEQ ID NO:516: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 306 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:516: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Gly Thr Gin Leu Pro Pro Gin Gly Arg Thr Thr Ala His Lys 145 150 155 160 Asp Pro Asn Ala Ile Phe Leu Ser Phe Gin His Leu Leu Arg Gly Lys 165 170 175 Val Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu 180 185 190 Phe Gly Gly Asn Met Ala Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg 195 200 205 Val Leu Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser Arg Leu 210 215 220 Ser Gin Cys Pro Glu Val His Pro Leu Pro Thr Pro Val Leu Leu Pro 225 230 235 240 Ala Val Asp Phe Ser Leu Gly Glu Trp Lys Thr Gin Met Glu Glu Thr 245 250 255 Lys Ala Gin Asp Ile Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Val 260 265 270 Met Ala Ala Arg Gly Gin Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu 275 280 285 Gly Gin Leu Ser Gly Gin Val Arg Leu Leu Leu Gly Ala Leu Gin Ser 290 295 300 Leu Leu 305 -645- 60 5 CL 295843 B6 (2) INFORMACE PRO SEQ ID NO:517: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 306 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 10 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:517: 15 20 25 30 35 40 45 50 Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala Ile Phe Leu 145 150 155 160 Ser Phe Gin His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu Val 165 170 175 Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly Gly Asn Met Ala Ser 180 185 190 Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu Arg 195 200 205 Asp Ser His Val Leu His Ser Arg Leu Ser Gin Cys Pro Glu Val His 210 215 220 Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu Gly 225 230 235 240 Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala Gin Asp Ile Leu Gly 245 250 255 Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gin Leu 260 265 270 Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser Gly Gin Val 275 280 285 Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr Gin Leu Pro 290 295 300 Pro Gin 305 55 (2) INFORMACE PRO SEQ ID NO:518: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 306 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární -646- 60 5 CZ 295843 B6 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:518: Ala 1 Asn Cys Ser Ile 5 Met Ile Pro Pro Ala Pro 20 Leu Leu Asp 10 Ser Ile Leu 35 Met Asp Arg Asn Val Arg 50 Ala Val Lys Asn Leu 55 15 Leu 65 Arg Asn Leu Gin Pro 70 Cys Arg His Pro Ile Ile 85 Ile Lys Lys Leu Thr Phe 100 Tyr Leu Val 20 Tyr Val Glu 115 Gly Gly Gly Gly Ser Thr 130 Ile Asn Pro Ser Pro 135 25 Asn 145 Met Ala His Lys Asp 150 Pro Leu Leu Arg Gly Lys 165 Val Arg Leu Cys Val Arg 180 Glu Phe Gly 30 Ala Cys Asp 195 Leu Arg Val Leu Leu His 210 Ser Arg Leu Ser Gin 215 35 Pro 225 Val Leu Leu Pro Ala 230 Val Gin Met Glu Glu Thr 245 Lys Ala Leu Leu Glu Gly 260 Val Met Ala 40 Leu Ser Ser 275 Leu Leu Gly Gin Gly Ala 290 Leu Gin Ser Leu Leu 295 Thr Thr 45 3 0 5 Asp Glu Ile Ile His His Leu Lys Arg 10 15 Pro Asn Asn Leu Asn Asp Glu Asp Val 25 30 Leu Arg Leu Pro Asn Leu Glu Ser Phe 40 45 Glu Asn Ala Ser Gly Ile Glu Ala Ile 60 Leu Pro Ser Ala Thr Ala Ala Pro Ser 75 80 Ala Gly Asp Trp Gin Glu Phe Arg Glu 90 95 Thr Leu Glu Gin Ala Gin Glu Gin Gin 105 110 Ser Pro Gly Glu Pro Ser Gly Pro Ile 120 125 Pro Ser Lys Glu Ser His Lys Ser Pro 140 Asn Ala Ile Phe Leu Ser Phe Gin His 155 160 Phe Leu Met Leu Val Gly Gly Ser Thr 170 175 Gly Asn Met Ala Ser Pro Ala Pro Pro 185 190 Ser Lys Leu Leu Arg Asp Ser His Val 200 205 Cys Pro Glu Val His Pro Leu Pro Thr 220 Asp Phe Ser Leu Gly Glu Trp Lys Thr 235 240 Gin Asp Ile Leu Gly Ala Val Thr Leu 250 255 Ala Arg Gly Gin Leu dy Pro Thr Cys 265 270 Leu Ser Gly Gin Val Arg Leu Leu Leu 280 285 Gly Thr Gin Leu Pro Pro Gin Gly Arg 300 (2) INFORMACE PRO SEQ ID NO:519: (i) CHARAKTERISTIKY SEKVENCE: 50 (A) DÉLKA: 306 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 55 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:519: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 60 1 5 10 15 -647- CZ 295843 B6 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Asp Pro Asn Ala Ile Phe Leu Ser Phe Gin His Leu Leu Arg 145 150 155 160 Gly Lys Val Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val 165 170 175 Arg Glu Phe Gly Gly Asn Met Ala Ser Pro Ala Pro Pro Ala Cys Asp 180 185 190 Leu Arg Val Leu Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser 195 200 205 Arg Leu Ser Gin Cys Pro Glu Val His Pro Leu Pro Thr Pro Val Leu 210 215 220 Leu Pro Ala Val Asp Phe Ser Leu Gly Glu Trp Lys Thr Gin Met Glu 225 230 235 240 Glu Thr Lys Ala Gin Asp Ile Leu Gly Ala Val Thr Leu Leu Leu Glu 245 250 255 Gly Val Met Ala Ala Arg Gly Gin Leu Gly Pro Thr Cys Leu Ser Ser 260 265 270 Leu Leu Gly Gin Leu Ser Gly Gin Val Arg Leu Leu Leu Gly Ala Leu 275 280 285 Gin Ser Leu Leu Gly Thr Gin Leu Pro Pro Gin Gly Arg Thr Thr Ala 290 295 300 His Lys 305 (2) INFORMACE PRO SEQ ID NO:520: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 306 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ A jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: : žádný (xi) POPIS SEKVENCE: SEQ ID NO:520: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 -648 - CZ 295843 B6 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Ile Phe Leu Ser Phe Gin His Leu Leu Arg Gly Lys Val 145 150 155 160 Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe 165 170 175 Gly Gly Asn Met Ala Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val 180 185 190 Leu Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser Arg Leu Ser 195 200 205 Gin Cys Pro Glu Val His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala 210 215 220 Val Asp Phe Ser Leu Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys 225 230 235 240 Ala Gin Asp Ile Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met 245 250 255 Ala Ala Arg Gly Gin Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly 260 265 270 Gin Leu Ser Gly Gin Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu 275 280 285 Leu Gly Thr Gin Leu Pro Pro Gin Gly Arg Thr Thr Ala His Lys Asp 290 295 300 Pro Asn 305 (2) INFORMACE PRO SEQ ID NO:521: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 305 aminokyselin (B) TYP: : aminokyselina (C) RETEZENI: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:521: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 -649- CZ 295843 B6 Asn Met Glu Val His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val 145 150 155 160 Asp Phe Ser Leu Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala 165 170 175 5 Gin Asp Ile Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala 180 185 190 Ala Arg Gly Gin Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin 195 200 205 Leu Ser Gly Gin Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu 10 210 215 220 Gly Thr Gin Leu Pro Pro Gin Gly Arg Thr Thr Ala His Lys Asp Pro 225 230 235 240 Asn Ala Ile Phe Leu Ser Phe Gin His Leu Leu Arg Gly Lys Val Arg 245 250 255 15 Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly 260 265 270 Asn Met Ala Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser 275 280 285 Lys Leu Leu Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gin Cys 20 Pro 290 295 300 305 25 (2) INFORMACE PRO SEQ ID NO:522: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 305 aminokyselin (B) TYP: : aminokyselina (C) ŘETEZENI: jednoduché 30 (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: : žádný 35 (xi) POPIS SEKVENCE: SEQ ID NO:522: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg '1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 40 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 45 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 50 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu 55 145 150 155 160 Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala Gin Asp Ile Leu 165 170 175 Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gin 180 185 190 60 Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser Gly Gin 195 200 205 -650- CZ 295843 B6 Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr Gin Leu 210 215 220 Pro Pro Gin Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala Ile Phe 225 230 235 240 Leu Ser Phe Gin His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu 245 250 255 Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly Asn Met Ala Ser 260 265 270 Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu Arg 275 280 285 Asp Ser His Val Leu His Ser Arg Leu Ser Gin Cys Pro Glu Val His 290 295 300 Pro 305 (2: ) INFORMACE PRO SEQ ! ID NO:523: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 305 aminokyselin (B) TYP : aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY : žádný (xi) POPIS SEKVENCE: SEQ ID NO:523: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Val Leu Leu Pro Ala Val Asp Phe Ser Leu Gly Glu Trp Lys 145 150 155 160 Thr Gin Met Glu Glu Thr Lys Ala Gin Asp Ile Leu Gly Ala Val Thr 165 170 175 Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gin Leu Gly Pro Thr 180 185 190 Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser Gly Gin Val Arg Leu Leu 195 200 205 Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr Gin Leu Pro Pro Gin Gly 210 215 220 Arg Thr Thr Ala His Lys Asp Pro Asn Ala Ile Phe Leu Ser Phe Gin 225 230 235 240 His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu Val Gly Gly Ser 245 250 255 Thr Leu Cys Val Arg Glu Phe Gly Asn Met Ala Ser Pro Ala Pro Pro 260 265 270 -651 - CZ 295843 B6 Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu Arg Asp Ser His Val 275 280 285 Leu His Ser Arg Leu Ser Gin Cys Pro Glu Val His Pro Leu Pro Thr 290 295 300 5 Pro 305 (2) INFORMACE PRO SEQ ID NO:524: 10 15 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 305 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:524: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Val Asp Phe Ser Leu Gly Glu Trp Lys Thr Gin Met Glu 145 150 155 160 Glu Thr Lys Ala Gin Asp Ile Leu Gly Ala Val Thr Leu Leu Leu Glu 165 170 175 Gly Val Met Ala Ala Arg Gly Gin Leu Gly Pro Thr Cys Leu Ser Ser 180 185 190 Leu Leu Gly Gin Leu Ser Gly Gin Val Arg Leu Leu Leu Gly Ala Leu 195 200 205 Gin Ser Leu Leu Gly Thr Gin Leu Pro Pro Gin Gly Arg Thr Thr Ala 210 215 220 His Lys Asp Pro Asn Ala Ile Phe Leu Ser Phe Gin His Leu Leu Arg 225 230 235 240 Gly Lys Val Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val 245 250 255 Arg Glu Phe Gly Asn Met Ala Ser Pro Ala Pro Pro Ala Cys Asp Leu 260 265 270 Arg Val Leu Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser Arg 275 280 285 Leu Ser Gin Cys Pro Glu Val His Pro Leu Pro Thr Pro Val Leu Leu 290 295 300 Pro 305 20 25 30 35 40 45 50 55 -652- 60 CZ 295843 B6 (2) INFORMACE PRO SEQ ID NO:525: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 305 aminokyselin 5 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:525: Ala 1 Asn Cys Ser Ile 5 Met Ile 15 Pro Pro Ala Pro 20 Leu Leu Asp Ser Ile Leu 35 Met Asp Arg Asn 20 Val Arg Ala 50 Val Lys Asn Leu 55 Leu 65 Arg Asn Leu Gin Pro 70 Cys Arg His Pro Ile Ile 85 Ile Lys 25 Lys Leu Thr Phe 100 Tyr Leu Val Tyr Val Glu 115 Gly Gly Gly Gly 30 Ser Thr 130 Ile Asn Pro Ser Pro 135 Asn 145 Met Asp Phe Ser Leu 150 Gly Lys Ala Gin Asp Ile 165 Leu Gly 35 Met Ala Ala Arg 180 Gly Gin Leu Gly Gin Leu 195 Ser Gly Gin Val 40 Leu Leu 210 Gly Thr Gin Leu Pro 215 Asp 225 Pro Asn Ala Ile Phe 230 Leu Val Arg Phe Leu Met 245 Leu Val 45 Phe Gly Asn Met 2 60 Ala Ser Pro Leu Ser Lys 275 Leu Leu Arg Asp 50 Gin Cys 290 Pro Glu Val His Pro 295 Val 305 Asp Glu Ile Ile His His Leu Lys Arg 10 15 Pro Asn Asn Leu Asn Asp Glu Asp Val 25 30 Leu Arg Leu Pro Asn Leu Glu Ser Phe 40 45 Glu Asn Ala Ser Gly Ile Glu Ala Ile 60 Leu Pro Ser Ala Thr Ala Ala Pro Ser 75 80 Ala Gly Asp Trp Gin Glu Phe Arg Glu 90 95 Thr Leu Glu Gin Ala Gin Glu Gin Gin 105 110 Ser Pro Gly Glu Pro Ser Gly Pro Ile 120 125 Pro Ser Lys Glu Ser His Lys Ser Pro 140 Glu Trp Lys Thr Gin Met Glu Glu Thr 155 160 Ala Val Thr Leu Leu Leu Glu Gly Val 170 175 Gly Pro Thr Cys Leu Ser Ser Leu Leu 185 190 Arg Leu Leu Leu Gly Ala Leu Gin Ser 200 205 Pro Gin Gly Arg Thr Thr Ala His Lys 220 Ser Phe Gin His Leu Leu Arg Gly Lys 235 240 Gly Gly Ser Thr Leu Cys Val Arg Glu 250 255 Ala Pro Pro Ala Cys Asp Leu Arg Val 265 270 Ser His Val Leu His Ser Arg Leu Ser 280 285 Leu Pro Thr Pro Val Leu Leu Pro Ala 300 (2) INFORMACE PRO SEQ ID NO:526: 55 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 305 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární -653 - 60 5 CZ 295843 B6 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:526: 10 15 20 25 30 35 40 45 Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala Gin Asp 145 150 155 160 Ile Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg 165 170 175 Gly Gin Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser 180 185 190 Gly Gin Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr 195 200 205 Gin Leu Pro Pro Gin Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala 210 215 220 Ile Phe Leu Ser Phe Gin His Leu Leu Arg Gly Lys Val Arg Phe Leu 225 230 235 240 Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly Asn Met 245 250 255 Ala Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu 260 265 270 Leu Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gin Cys Pro Glu 275 280 285 Val His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser 290 295 300 Leu 305 (2) INFORMACE PRO SEQ ID NO:527: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 305 aminokyselin 50 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 55 (xi) POPIS SEKVENCE: SEQ ID NO:527: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 15 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 -654- 60 CZ 295843 B6 Ser Ile Leu Met Asp Arg Asn 35 Val Arg Ala Val Lys Asn Leu 50 55 5 Leu Arg Asn Leu Gin Pro Cys 65 70 Arg His Pro Ile Ile Ile Lys 85 Lys Leu Thr Phe Tyr Leu Val 10 100 Tyr Val Glu Gly Gly Gly Gly 115 Ser Thr Ile Asn Pro Ser Pro 130 135 15 Asn Met Gly Pro Thr Cys Leu 145 150 Gin Val Arg Leu Leu Leu Gly 165 Leu Pro Pro Gin Gly Arg Thr 20 180 Phe Leu Ser Phe Gin His Leu 195 Leu Val Gly Gly Ser Thr Leu 210 215 25 Ser Pro Ala Pro Pro Ala Cys 225 230 Arg Asp Ser His Val Leu His 245 His Pro Leu Pro Thr Pro Val 30 260 Gly Glu Trp Lys Thr Gin Met 275 Gly Ala Val Thr Leu Leu Leu 290 295 35 Leu 305 Leu Arg Leu Pro Asn Leu Glu Ser Phe 40 45 Glu Asn Ala Ser Gly Ile Glu Ala Ile 60 Leu Pro Ser Ala Thr Ala Ala Pro Ser 75 80 Ala Gly Asp Trp Gin Glu Phe Arg Glu 90 95 Thr Leu Glu Gin Ala Gin Glu Gin Gin 105 110 Ser Pro Gly Glu Pro Ser Gly Pro Ile 120 125 Pro Ser Lys Glu Ser His Lys Ser Pro 140 Ser Ser Leu Leu Gly Gin Leu Ser Gly 155 160 Ala Leu Gin Ser Leu Leu Gly Thr Gin 170 175 Thr Ala His Lys Asp Pro Asn Ala Ile 185 190 Leu Arg Gly Lys Val Arg Phe Leu Met 200 205 Cys Val Arg Glu Phe Gly Asn Met Ala 220 Asp Leu Arg Val Leu Ser Lys Leu Leu 235 240 Ser Arg Leu Ser Gin Cys Pro Glu Val 250 255 Leu Leu Pro Ala Val Asp Phe Ser Leu 265 270 Glu Glu Thr Lys Ala Gin Asp Ile Leu 280 285 Glu Gly Val Met Ala Ala Arg Gly Gin 300 (2) INFORMACE PRO SEQ ID NO:528: 40 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 305 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 45 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:528: Ala 1 Asn Cys Ser Ile 5 Met Ile Asp Glu Ile 10 Ile His His Leu Lys 15 Arg Pro Pro Ala Pro 20 Leu Leu Asp Pro Asn 25 Asn Leu Asn Asp Glu Asp 30 Val Ser Ile Leu 35 Met Asp Arg Asn Leu 40 Arg Leu Pro Asn Leu 45 Glu Ser Phe Val Arg 50 Ala Val Lys Asn Leu 55 Glu Asn Ala Ser Gly 60 Ile Glu Ala Ile Leu 65 Arg Asn Leu Gin Pro 70 Cys Leu Pro Ser Ala 75 Thr Ala Ala Pro Ser 80 Arg His Pro Ile Ile 85 Ile Lys Ala Gly Asp 90 Trp Gin Glu Phe Arg 95 Glu 50 55 -655- 60 CZ 295843 B6 Lys Leu Thr Phe 100 Tyr Leu Val Tyr Val Glu 115 Gly Gly Gly Gly 5 Ser Thr 130 Ile Asn Pro Ser Pro 135 Asn 145 Met Gly Thr Gin Leu 150 Pro 10 Asp Pro Asn Ala Ile 165 Phe Leu Val Arg Phe Leu 180 Met Leu Val Phe Gly Asn 195 Met Ala Ser Pro 15 Leu Ser 210 Lys Leu Leu Arg Asp 215 Gin 225 Cys Pro Glu Val His 230 Pro 20 Val Asp Phe Ser Leu 245 Gly Glu Ala Gin Asp Ile 260 Leu Gly Ala Ala Ala Arg 275 Gly Gin Leu Gly 25 Gin Leu 305 Leu 290 Ser Gly Gin Val Arg 295 Thr Leu Glu Gin Ala Gin Glu Gin Gin 105 110 Ser Pro Gly Glu Pro Ser Gly Pro Ile 120 125 Pro Ser Lys Glu Ser His Lys Ser Pro 140 Pro Gin Gly Arg Thr Thr Ala His Lys 155 160 Ser Phe Gin His Leu Leu Arg Gly Lys 170 175 Gly Gly Ser Thr Leu Cys Val Arg Glu 185 190 Ala Pro Pro Ala Cys Asp Leu Arg Val 200 205 Ser His Val Leu His Ser Arg Leu Ser 220 Leu Pro Thr Pro Val Leu Leu Pro Ala 235 240 Trp Lys Thr Gin Met Glu Glu Thr Lys 250 255 Val Thr Leu Leu Leu Glu Gly Val Met 265 270 Pro Thr Cys Leu Ser Ser Leu Leu Gly 280 285 Leu Leu Leu Gly Ala Leu Gin Ser Leu 300 30 (2) INFORMACE PRO SEQ ID NO:529: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 305 aminokyselin (B) TYP: aminokyselina 35 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 40 (xi) POPIS SEKVENCE: SEQ ID NO:529: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala Ile Phe Leu 145 150 155 160 -656- Ser Phe Gin His Leu 165 Leu Arg Gly Gly Ser Thr 180 Leu Cys Val Ala Pro Pro 195 Ala Cys Asp Leu Ser His 210 Val Leu His Ser Arg 215 Leu 225 Pro Thr Pro Val Leu 230 Leu Trp Lys Thr Gin Met 245 Glu Glu Val Thr Leu Leu 260 Leu Glu Gly Pro Thr Cys 275 Leu Ser Ser Leu Leu Leu 290 Leu Gly Ala Leu Gin 295 Gin 20 3 0 5 CZ 295843 B6 Gly Lys Val Arg Phe Leu Met Leu Val 170 175 Arg Glu Phe Gly Asn Met Ala Ser Pro 185 190 Arg Val Leu Ser Lys Leu Leu Arg Asp 200 205 Leu Ser Gin Cys Pro Glu Val His Pro 220 Pro Ala Val Asp Phe Ser Leu Gly Glu 235 240 Thr Lys Ala Gin Asp Ile Leu Gly Ala 250 255 Val Met Ala Ala Arg Gly Gin Leu Gly 265 270 Leu Gly Gin Leu Ser Gly Gin Val Arg 280 285 Ser Leu Leu Gly Thr Gin Leu Pro Pro 300 (2) INFORMACE PRO SEQ ID NO:530: (i) CHARAKTERISTIKY SEKVENCE: 25 (A) DÉLKA: 305 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 30 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:530: 35 40 45 50 55 Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala His Lys Asp Pro Asn Ala Ile Phe Leu Ser Phe Gin His 145 150 155 160 Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu Val Gly Gly Ser Thr 165 170 175 Leu Cys Val Arg Glu Phe Gly Asn Met Ala Ser Pro Ala Pro Pro Ala 180 185 190 Cys Asp Leu Arg Val Leu Ser Lys Leu Leu Arg Asp Ser His Val Leu 195 200 205 His Ser Arg Leu Ser Gin Cys Pro Glu Val His Pro Leu Pro Thr Pro 210 215 220 -657- 60 CZ 295843 B6 Val Leu Leu Pro Ala Val Asp Phe Ser Leu Gly Glu Trp Lys Thr Gin 225 230 235 240 Met Glu Glu Thr Lys Ala Gin Asp Ile Leu Gly Ala Val Thr Leu Leu 245 250 255 Leu Glu Gly Val Met Ala Ala Arg Gly Gin Leu Gly Pro Thr Cys Leu 260 265 270 Ser Ser Leu Leu Gly Gin Leu Ser Gly Gin Val Arg Leu Leu Leu Gly 275 280 285 Ala Leu Gin Ser Leu Leu dy Thr Gin Leu Pro Pro Gin Gly Arg Thr 290 295 300 Thr 305 (2 ) INFORMACE PRO i SEQ : ID NO:531: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: : 305 , aminokyselin (B) TYP : aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: ! lineární (ii) TYP MOLEKULY : žádný (xi) 1 POPIS SEKVENCE: SEQ : ID NO:531: Ala Asn ' Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Asp Pro Asn Ala Ile Phe Leu Ser Phe Gin His Leu Leu Arg 145 150 155 160 Gly Lys Val Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val 165 170 175 Arg Glu Phe Gly Asn Met Ala Ser Pro Ala Pro Pro Ala Cys Asp Leu 180 185 190 Arg Val Leu Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser Arg 195 200 205 Leu Ser Gin Cys Pro Glu Val His Pro Leu Pro Thr Pro Val Leu Leu 210 215 220 Pro Ala Val Asp Phe Ser Leu Gly Glu Trp Lys Thr Gin Met Glu Glu 225 230 235 240 Thr Lys Ala Gin Asp Ile Leu Gly Ala Val Thr Leu Leu Leu Glu Gly 245 250 255 Val Met Ala Ala Arg Gly Gin Leu Gly Pro Thr Cys Leu Ser Ser Leu 260 265 270 Leu Gly Gin Leu Ser Gly Gin Val Arg Leu Leu Leu Gly Ala Leu Gin 275 280 285 -658- CZ 295843 B6 Ser Leu Leu Gly Thr Gin Leu Pro Pro Gin Gly Arg Thr Thr Ala His 290 295 300 Lys 305 5 (2) INFORMACE PRO SEQ ID NO:532: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 305 aminokyselin 10 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 15 (xi) POPIS SEKVENCE: SEQ ID NO:532: Ala 1 Asn Cys Ser Ile 5 Met Ile 20 Pro Pro Ala Pro 20 Leu Leu Asp Ser Ile Leu 35 Met Asp Arg Asn 25 Val Arg 50 Ala Val Lys Asn Leu 55 Leu 65 Arg Asn Leu Gin Pro 70 Cys Arg His Pro Ile Ile 85 Ile Lys 30 Lys Leu Thr Phe 100 Tyr Leu Val Tyr Val Glu 115 Gly Gly Gly Gly 35 Ser Thr 130 Ile Asn Pro Ser Pro 135 Asn 145 Met Ala Ile Phe Leu 150 Ser Arg Phe Leu Met Leu 165 Val Gly 40 Gly Asn Met Ala 180 Ser Pro Ala Ser Lys Leu 195 Leu Arg Asp Ser 45 Cys Pro 210 Glu Val His Pro Leu 215 Asp 225 Phe Ser Leu Gly Glu 230 Trp Gin Asp Ile Leu Gly 245 Ala Val 50 Ala Arg Gly Gin 260 Leu Gly Pro Leu Ser Gly 275 Gin Val Arg Leu 55 Gly Thr 290 Gin Leu Pro Pro Gin 295 Asn 305 Asp Glu Ile Ile His His Leu Lys Arg 10 15 Pro Asn Asn Leu Asn Asp Glu Asp Val 25 30 Leu Arg Leu Pro Asn Leu Glu Ser Phe 40 45 Glu Asn Ala Ser Gly Ile Glu Ala Ile 60 Leu Pro Ser Ala Thr Ala Ala Pro Ser 75 80 Ala Gly Asp Trp Gin Glu Phe Arg Glu 90 95 Thr Leu Glu Gin Ala Gin Glu Gin Gin 105 110 Ser Pro Gly Glu Pro Ser Gly Pro Ile 120 125 Pro Ser Lys Glu Ser His Lys Ser Pro 140 Phe Gin His Leu Leu Arg Gly Lys Val 155 160 Gly Ser Thr Leu Cys Val Arg Glu Phe 170 175 Pro Pro Ala Cys Asp Leu Arg Val Leu 185 190 His Val Leu His Ser Arg Leu Ser Gin 200 205 Pro Thr Pro Val Leu Leu Pro Ala Val 220 Lys Thr Gin Met Glu Glu Thr Lys Ala 235 240 Thr Leu Leu Leu Glu Gly Val Met Ala 250 255 Thr Cys Leu Ser Ser Leu Leu Gly Gin 265 270 Leu Leu Gly Ala Leu Gin Ser Leu Leu 280 285 Gly Arg Thr Thr Ala His Lys Asp Pro (2) INFORMACE PRO SEQ ID NO:533: (i) CHARAKTERISTIKY SEKVENCE: -659- 60 300 5 CZ 295843 B6 (A) DÉLKA: 309 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:533: 10 15 20 25 30 35 40 45 Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Glu Val His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val 145 150 155 160 Asp Phe Ser Leu Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala 165 170 175 Gin Asp Ile Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala 180 185 190 Ala Arg Gly Gin Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin 195 200 205 Leu Ser Gly Gin Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu 210 215 220 Gly Thr Gin Leu Pro Pro Gin Gly Arg Thr Thr Ala His Lys Asp Pro 225 230 235 240 Asn Ala Ile Phe Leu Ser Phe Gin His Leu Leu Arg Gly Lys Val Arg 245 250 255 Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly 260 265 270 Gly Asn Gly Gly Asn Met Ala Ser Pro Ala Pro Pro Ala Cys Asp Leu 275 280 285 Arg Val Leu Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser Arg 290 295 300 Leu Ser Gin Cys Pro 305 50 (2) INFORMACE PRO SEQ ID NO:534: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 309 aminokyselin 55 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:534: -660- 60 CZ 295843 B6 Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 5 20 25 30 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 10 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 15 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 20 Asn Met Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu 145 150 155 160 Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala Gin Asp Ile Leu 165 170 175 Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gin 25 180 185 190 Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser Gly Gin 195 200 205 Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr Gin Leu 210 215 220 30 Pro Pro Gin Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala Ile Phe 225 230 235 240 Leu Ser Phe Gin His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu 245 250 255 Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly Gly Asn Gly Gly 35 260 265 270 Asn Met Ala Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser 275 280 285 Lys Leu Leu Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gin Cys 290 295 300 40 Pro Glu Val His Pro 305 (2) INFORMACE PRO SEQ ID NO:535: 45 50 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 309 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:535: Ala 1 Asn Cys Ser Ile 5 Met Ile Asp Glu Ile 10 Ile His His Leu Lys 15 Arg Pro Pro Ala Pro 20 Leu Leu Asp Pro Asn 25 Asn Leu Asn Asp Glu 30 Asp Val Ser Ile Leu 35 Met Asp Arg Asn Leu 40 Arg Leu Pro Asn Leu 45 Glu Ser Phe i -661 - CZ 295843 B6 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Val Leu Leu Pro Ala Val Asp Phe Ser Leu Gly Glu Trp Lys 145 150 155 160 Thr Gin Met Glu Glu Thr Lys Ala Gin Asp Ile Leu Gly Ala Val Thr 165 170 175 Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gin Leu Gly Pro Thr 180 185 190 Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser Gly Gin Val Arg Leu Leu 195 200 205 Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr Gin Leu Pro Pro Gin Gly 210 215 220 Arg Thr Thr Ala His Lys Asp Pro Asn Ala Ile Phe Leu Ser Phe Gin 225 230 235 240 His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu Val Gly Gly Ser 245 250 255 Thr Leu Cys Val Arg Glu Phe Gly Gly Asn Gly Gly Asn Met Ala Ser 260 265 270 Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu Arg 275 280 285 Asp Ser His Val Leu His Ser Arg Leu Ser Gin Cys Pro Glu Val His 290 295 300 Pro Leu Pro Thr Pro 305 (2) INFORMACE PRO SEQ ID NO:536: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 309 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:536: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 -662- CZ 295843 B6 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Val Asp Phe Ser Leu Gly Glu Trp Lys Thr Gin Met Glu 145 150 155 160 Glu Thr Lys Ala Gin Asp Ile Leu Gly Ala Val Thr Leu Leu Leu Glu 165 170 175 Gly Val Met Ala Ala Arg Gly Gin Leu Gly Pro Thr Cys Leu Ser Ser 180 185 190 Leu Leu Gly Gin Leu Ser Gly Gin Val Arg Leu Leu Leu Gly Ala Leu 195 200 205 Gin Ser Leu Leu Gly Thr Gin Leu Pro Pro Gin Gly Arg Thr Thr Ala 210 215 220 His Lys Asp Pro Asn Ala Ile Phe Leu Ser Phe Gin His Leu Leu Arg 225 230 235 240 Gly Lys Val Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val 245 250 255 Arg Glu Phe Gly Gly Asn Gly Gly Asn Met Ala Ser Pro Ala Pro Pro 260 265 270 Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu Arg Asp Ser His Val 275 280 285 Leu His Ser Arg Leu Ser Gin Cys Pro Glu Val His Pro Leu Pro Thr 290 295 300 Pro Val Leu Leu Pro 305 (2) i INFORMACE PRO SEQ ID NO:537: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 309 aminokyselin (B) TYP: : aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: : žádný (xi) POPIS SEKVENCE: SEQ ID NO:537: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Asp Phe Ser Leu Gly Glu Trp Lys Thr Gin Met Glu Glu Thr 145 150 155 160 Lys Ala Gin Asp Ile Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Val 165 170 175 -663 - 10 15 20 25 30 35 40 45 50 55 CZ 295843 B6 Met Ala Ala Arg Gly Gin Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu 180 185 190 Gly Gin Leu Ser Gly Gin Val Arg Leu Leu Leu Gly Ala Leu Gin Ser 195 200 205 Leu Leu Gly Thr Gin Leu Pro Pro Gin Gly Arg Thr Thr Ala His Lys 210 215 220 Asp Pro Asn Ala Ile Phe Leu Ser Phe Gin His Leu Leu Arg Gly Lys 225 230 235 240 Val Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu 245 250 255 Phe Gly Gly Asn Gly Gly Asn Met Ala Ser Pro Ala Pro Pro Ala Cys 260 265 270 Asp Leu Arg Val Leu Ser Lys Leu Leu Arg Asp Ser His Val Leu His 275 280 285 Ser Arg Leu Ser Gin Cys Pro Glu Val His Pro Leu Pro Thr Pro Val 290 295 300 Leu Leu Pro Ala Val 305 (2) INFORMACE PRO SEQ ID NO:538: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 309 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:538: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala Gin Asp 145 150 155 160 Ile Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg 165 170 175 Gly Gin Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser 180 185 190 Gly Gin Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr 195 200 205 Gin Leu Pro Pro Gin Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala 210 215 220 Ile Phe Leu Ser Phe Gin His Leu Leu Arg Gly Lys Val Arg Phe Leu 225 230 235 240 -664- 60 CZ 295843 B6 Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly Gly Asn 245 250 255 Gly Gly Asn Met Ala Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val 260 265 270 Leu Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser Arg Leu Ser 275 280 285 Gin Cys Pro Glu Val His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala 290 295 300 Val Asp Phe Ser Leu 305 (2) INFORMACE PRO SEQ ID NO:539: (i) CHARAKTERISTIKY SEKVENCE: 15 (A) DÉLKA: 309 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 20 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:539: 25 30 35 40 45 50 55 Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser Gly 145 150 155 160 Gin Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr Gin 165 170 175 Leu Pro Pro Gin Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala Ile 180 185 190 Phe Leu Ser Phe Gin His Leu Leu Arg Gly Lys Val Arg Phe Leu Met 195 200 205 Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly Gly Asn Gly 210 215 220 Gly Asn Met Ala Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu 225 230 235 240 Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gin 245 250 255 Cys Pro Glu Val His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val 260 265 270 Asp Phe Ser Leu Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala 275 280 285 Gin Asp Ile Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala 290 295 300 -665- 60 CZ 295843 B6 Ala Arg Gly Gin Leu 305 (2) INFORMACE PRO SEQ ID NO:540: 5 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 309 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché 10 (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:540: Ala Asn Cys Ser Ile Met Ile 1 5 Pro Pro Ala Pro Leu Leu Asp 20 20 Ser Ile Leu Met Asp Arg Asn 35 Val Arg Ala Val Lys Asn Leu 50 55 Leu Arg Asn Leu Gin Pro Cys 25 65 70 Arg His Pro Ile Ile Ile Lys 85 Lys Leu Thr Phe Tyr Leu Val 100 30 Tyr Val Glu Gly Gly Gly Gly 115 Ser Thr Ile Asn Pro Ser Pro 130 135 Asn Met Gly Thr Gin Leu Pro 35 145 150 Asp Pro Asn Ala Ile Phe Leu 165 Val Arg Phe Leu Met Leu Val 180 40 Phe Gly Gly Asn Gly Gly Asn 195 Asp Leu Arg Val Leu Ser Lys 210 215 Ser Arg Leu Ser Gin Cys Pro 45 225 230 Leu Leu Pro Ala Val Asp Phe 245 Glu Glu Thr Lys Ala Gin Asp 260 50 Glu Gly Val Met Ala Ala Arg 275 Ser Leu Leu Gly Gin Leu Ser 290 295 Leu Gin Ser Leu Leu 55 305 Asp Glu Ile Ile His His Leu Lys Arg 10 15 Pro Asn Asn Leu Asn Asp Glu Asp Val 25 30 Leu Arg Leu Pro Asn Leu Glu Ser Phe 40 45 Glu Asn Ala Ser Gly Ile Glu Ala Ile 60 Leu Pro Ser Ala Thr Ala Ala Pro Ser 75 80 Ala Gly Asp Trp Gin Glu Phe Arg Glu 90 95 Thr Leu Glu Gin Ala Gin Glu Gin Gin 105 110 Ser Pro Gly Glu Pro Ser Gly Pro Ile 120 125 Pro Ser Lys Glu Ser His Lys Ser Pro 140 Pro Gin Gly Arg Thr Thr Ala His Lys 155 160 Ser Phe Gin His Leu Leu Arg Gly Lys 170 175 Gly Gly Ser Thr Leu Cys Val Arg Glu 185 190 Met Ala Ser Pro Ala Pro Pro Ala Cys 200 205 Leu Leu Arg Asp Ser His Val Leu His 220 Glu Val His Pro Leu Pro Thr Pro Val 235 240 Ser Leu Gly Glu Trp Lys Thr Gin Met 250 255 Ile Leu Gly Ala Val Thr Leu Leu Leu 265 270 Gly Gin Leu Gly Pro Thr Cys Leu Ser 280 285 Gly Gin Val Arg Leu Leu Leu Gly Ala 300 (2) INFORMACE PRO SEQ ID NO:541: (i) CHARAKTERISTIKY SEKVENCE: 60 (A) DÉLKA: 309 aminokyselin (B) TYP: aminokyselina -666- CZ 295843 B6 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 5 (xi) POPIS SEKVENCE: SEQ ID NO:541: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 10 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 15 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 20 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 25 130 135 140 Asn Met Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala Ile Phe Leu 145 150 155 160 Ser Phe Gin His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu Val 165 170 175 30 Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly Gly Asn Gly Gly Asn 180 185 190 Met Ala Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys 195 200 205 Leu Leu Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gin Cys Pro 35 210 215 220 Glu Val His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe 225 230 235 240 Ser Leu Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala Gin Asp 245 250 255 40 Ile Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg 260 265 270 Gly Gin Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser 275 280 285 Gly Gin Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr 45 290 295 300 Gin Leu Pro Pro Gin 305 (2) INFORMACE PRO SEQ ID NO:542: 50 55 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 309 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:542: -667- 60 CZ 295843 B6 Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 5 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 10 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 15 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala His Lys Asp Pro Asn Ala Ile Phe Leu Ser Phe Gin His 20 145 150 155 160 Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu Val Gly Gly Ser Thr 165 170 175 Leu Cys Val Arg Glu Phe Gly Gly Asn Gly Gly Asn Met Ala Ser Pro 180 185 190 25 Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu Arg Asp 195 200 205 Ser His Val Leu His Ser Arg Leu Ser Gin Cys Pro Glu Val His Pro 210 215 220 Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu Gly Glu 30 225 230 235 240 Trp Lys Thr Gin Met Glu Glu Thr Lys Ala Gin Asp Ile Leu Gly Ala 245 250 255 Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gin Leu Gly 260 265 270 35 Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser Gly Gin Val Arg 275 280 285 Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr Gin Leu Pro Pro 290 295 300 Gin Gly Arg Thr Thr 40 305 (2) INFORMACE PRO SEQ ID NO:543 (i) CHARAKTERISTIKY SEKVENCE: 45 (A) DÉLKA: 309 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ :: j ednoduché (D) TOPOLOGIE: lineární 50 (ii) TYP MOLEKULY: žádný (xi) POPIS 1 SEKVENCE: SEQ ID NO:543: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 55 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe 35 40 45 60 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 -668- CZ 295843 B6 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 5 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 10 130 135 140 Asn Met Asp Pro Asn Ala Ile Phe Leu Ser Phe Gin His Leu Leu Arg 145 150 155 160 Gly Lys Val Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val 165 170 175 15 Arg Glu Phe Gly Gly Asn Gly Gly Asn Met Ala Ser Pro Ala Pro Pro 180 185 190 Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu Arg Asp Ser His Val 195 200 205 Leu His Ser Arg Leu Ser Gin Cys Pro Glu Val His Pro Leu Pro Thr 20 210 215 220 Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu Gly Glu Trp Lys Thr 225 230 235 240 Gin Met Glu Glu Thr Lys Ala Gin Asp Ile Leu Gly Ala Val Thr Leu 245 250 255 25 Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gin Leu Gly Pro Thr Cys 260 265 270 Leu Ser Ser Leu Leu Gly Gin Leu Ser Gly Gin Val Arg Leu Leu Leu 275 280 285 Gly Ala Leu Gin Ser Leu Leu Gly Thr Gin Leu Pro Pro Gin Gly Arg 30 290 295 300 Thr Thr Ala His Lys 305 (2) INFORMACE PRO SEQ ID NO:544: 35 40 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 309 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:544: 45 Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 50 55 -669- 60 5 10 15 20 25 CZ 295843 B6 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Ile Phe Leu Ser Phe Gin His Leu Leu Arg Gly Lys Val 145 150 155 160 Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe 165 170 175 Gly Gly Asn Gly Gly Asn Met Ala Ser Pro Ala Pro Pro Ala Cys Asp 180 185 190 Leu Arg Val Leu Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser 195 200 205 Arg Leu Ser Gin Cys Pro Glu Val His Pro Leu Pro Thr Pro Val Leu 210 215 220 Leu Pro Ala Val Asp Phe Ser Leu Gly Glu Trp Lys Thr Gin Met Glu 225 230 235 240 Glu Thr Lys Ala Gin Asp Ile Leu Gly Ala Val Thr Leu Leu Leu Glu 245 250 255 Gly Val Met Ala Ala Arg Gly Gin Leu Gly Pro Thr Cys Leu Ser Ser 260 265 270 Leu Leu Gly Gin Leu Ser Gly Gin Val Arg Leu Leu Leu Gly Ala Leu 275 280 285 Gin Ser Leu Leu Gly Thr Gin Leu Pro Pro Gin Gly Arg Thr Thr Ala 290 295 300 His Lys Asp Pro Asn 305 (2) INFORMACE PRO SEQ ID NO:545: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 302 aminokyselin 30 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 35 (xi) POPIS SEKVENCE: SEQ ID NO:545: 40 45 50 55 Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Asp Pro Asn Ala Ile Phe Leu Ser Phe Gin His Leu Leu Arg 145 150 155 160 Gly Lys Val Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val 165 170 175 Arg Glu Phe Gly Gly Asn Met Ala Ser Pro Ala Pro Pro Ala Cys Asp 180 185 190 -670- 60 5 10 15 CZ 295843 B6 Leu Arg Val Leu Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser 195 200 205 Arg Leu Ser Gin Cys Pro Glu Val His Pro Leu Pro Thr Pro Val Leu 210 215 220 Leu Pro Ala Val Asp Phe Ser Leu Gly Glu Trp Lys Thr Gin Met Glu 225 230 235 240 Glu Thr Lys Ala Gin Asp Ile Leu Gly Ala Val Thr Leu Leu Leu Glu 245 250 255 Gly Val Met Ala Ala Arg Gly Gin Leu Gly Pro Thr Cys Leu Ser Ser 260 265 270 Leu Leu Gly Gin Leu Ser Gly Gin Val Arg Leu Leu Leu Gly Ala Leu 275 280 285 Gin Ser Leu Leu Gly Thr Gin Gly Arg Thr Thr Ala His Lys 290 295 300 20 25 30 35 40 45 (2) INFORMACE PRO SEQ ID NO:546: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 153 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:546: Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu 1 5 10 15 Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gin Cys Pro Glu Val 20 25 30 His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu 35 40 45 Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala Gin Asp Ile Leu 50 55 60 Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gin 65 70 75 80 Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser Gly Gin 85 90 95 Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr Gin Leu 100 105 110 Pro Pro Gin Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala Ile Phe 115 120 125 Leu Ser Phe Gin His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu 130 135 140 Val Gly Gly Ser Thr Leu Cys Val Arg 145 150 (2) INFORMACE PRO SEQ ID NO:547: 50 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 149 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché 55 (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:547: -671 - 60 CZ 295843 B6 Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu 1 5 10 15 Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gin Cys Pro Glu Val 20 25 30 His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu 35 40 45 Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala Gin Asp Ile Leu 50 55 60 Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gin 65 70 75 80 Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser Gly Gin 85 90 95 Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr Gin Gly 100 105 110 Arg Thr Thr Ala His Lys Asp Pro Asn Ala Ile Phe Leu Ser Phe Gin 115 120 125 His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu Val Gly Gly Ser 130 135 140 Thr Leu Cys Val Arg 145 (2) INFORMACE PRO SEQ ID NO:548: (i) CHARAKTERISTIKY SEKVENCE: 25 (A) DÉLKA: 153 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 30 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:548: 35 40 45 50 Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu 1 5 10 15 Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gin Cys Pro Glu Val 20 25 30 His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu 35 40 45 Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala Gin Asp Ile Leu 50 55 60 Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gin 65 70 75 80 Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser Gly Gin 85 90 95 Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr Gin Leu 100 105 110 Pro Pro Gin Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala Ile Phe 115 120 125 Leu Ser Phe Gin His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu 130 135 140 Val Gly Gly Ser Thr Leu Cys Val Arg 145 150 (2) INFORMACE PRO SEQ ID NO:549: 55 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 135 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární -672- 60 5 CZ 295843 B6 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:549: 10 15 20 25 30 35 40 45 50 55 Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe 1 5 10 15 Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro 20 25 30 Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Ala Leu 35 40 45 Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val 50 55 60 Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile 65 70 75 80 His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg 85 90 95 Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin 100 105 110 Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys 115 120 125 Leu Glu Leu Gin Cys Gin Pro 130 135 (2) INFORMACE PRO SEQ ID NO:550: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 140 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:550: Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe 1 5 10 15 Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr .Leu Leu Gin Asp Tyr Pro 20 25 30 Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu 35 40 45 Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val 50 55 60 Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile 65 70 75 80 His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg 85 90 95 Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin 100 105 110 Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys 115 120 125 Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 130 135 140 (2) INFORMACE PRO SEQ ID NO:551: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 122 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché -673- 60 5 CZ 295843 B6 (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:551: 10 15 20 25 30 35 40 45 50 Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe 1 5 10 15 Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro 20 25 30 Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu 35 40 45 Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val 50 55 60 Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile 65 70 75 80 His Phe Val Thr Lys Cys Ala Phe Gin Glu Thr Ser Glu Gin Leu Val 85 90 95 Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu 100 105 110 Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 115 120 (2) INFORMACE PRO SEQ ID NO:552: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 135 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:552: Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe 1 5 10 15 Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro 20 25 30 Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu 35 40 45 Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val 50 55 60 Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile 65 70 75 80 His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg 85 90 95 Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin 100 105 110 Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys 115 120 125 Leu Glu Leu Gin Cys Gin Pro 130 135 55 (2) INFORMACE PRO SEQ ID NO:553: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 140 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární -674- 60 5 CZ 295843 B6 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:553: 10 15 20 25 30 35 40 45 50 55 Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe 1 5 10 15 Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro 20 25 30 Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu 35 40 45 Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val 50 55 60 Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile 65 70 75 80 His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg 85 90 95 Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin 100 105 110 Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys 115 120 125 Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 130 135 140 (2) INFORMACE PRO SEQ ID NO:554: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 135 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:554: Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe 1 5 10 15 Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro 20 25 30 Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu 35 40 45 Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val 50 55 60 Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile 65 70 75 80 His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg 85 90 95 Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin 100 105 110 Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys 115 120 125 Leu Glu Leu Gin Cys Gin Pro 130 135 (2) INFORMACE PRO SEQ ID NO:555: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 140 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché -675- 60 5 CZ 295843 B6 (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:555: 10 15 20 25 Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe 1 5 10 15' Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro 20 25 30 Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu 35 40 45 Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val 50 55 60 Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile 65 70 75 80 His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg 85 90 95 Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin 100 105 110 Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys 115 120 125 Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 130 135 140 (2) INFORMACE PRO SEQ ID NO:556: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 155 aminokyselin 30 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 35 (xi) POPIS SEKVENCE: SEQ ID NO:556: 40 45 50 55 Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly 20 25 30 Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser 50 55 60 Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80 Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro 85 90 95 Asp Ser Ser Thr Leu Ser Gly Gly Asn Gly Ser Gly Gly Asn Gly Ser 100 105 110 Gly Gly Asn Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser 115 120 125 Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin 130 135 140 Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin 145 150 155 (2) INFORMACE PRO SEQ ID NO:557: (i) CHARAKTERISTIKY SEKVENCE: -676- 60 5 5 10 15 20 25 CZ 295843 B6 (A) DÉLKA: 150 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:557: Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 1 5 10 15 Arg Trp Meť Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly 20 25 30 Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser 50 55 60 Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80 Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro 85 90 95 Asp Ser Ser Thr Leu Ser Gly Gly Asn Gly Ser Gly Gly Asn Gly Thr 100 105 110 Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val 115 120 125 Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr 130 135 140 Val Ala Ser Asn Leu Gin 145 150 30 (2) INFORMACE PRO SEQ ID NO:558: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 145 aminokyselin 35 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 40 (xi) POPIS SEKVENCE: SEQ ID NO:558: 45 50 Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly 20 25 30 Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser 50 55 60 Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80 Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro 85 90 95 Asp Ser Ser Thr Leu Ser Gly Gly Asn Gly Thr Gin Asp Cys Ser Phe 100 105 110 Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu 115 120 125 -677- 55 5 CZ 295843 B6 Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu 130 135 140 Gin 145 (2) INFORMACE PRO SEQ ID NO:559: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 155 aminokyselin 10 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 15 (xi) POPIS SEKVENCE: SEQ ID NO:559: 20 25 30 35 Ala Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His 1 5 10 15 Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe 20 25 30 Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu 35 40 45 Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu 50 55 60 Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Ser Gly Gly Asn Gly 65 70 75 80 Ser Gly Gly Asn Gly Ser Gly Gly Asn Gly Thr Gin Asp Cys Ser Phe 85 90 95 Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu 100 105 110 Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu 115 120 125 Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 130 135 140 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly 145 150 155 40 45 (2) INFORMACE PRO SEQ ID NO:560: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 150 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:560: 50 55 Ala Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His 1 5 10 15 Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe 20 25 30 Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu 35 40 45 Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu 50 55 60 Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Ser Gly Gly Asn Gly 65 70 75 80 -678 - 60 CZ 295843 B6 Ser Gly Gly Asn Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile 85 90 95 Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu 100 105 110 Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu 115 120 125 Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg 130 135 140 Leu Lys Thr Val Ala Gly 145 150 (2) INFORMACE PRO SEQ ID NO:561: (i) CHARAKTERISTIKY SEKVENCE: 15 (A) DÉLKA: 145 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 20 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:561: . Ala Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His 25 1 5 10 15 Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe 20 25 30 Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu 35 40 45 30 Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu 50 55 60 Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Ser Gly Gly Asn Gly 65 70 75 80 Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala 35 85 90 95 Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val 100 105 110 Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp 115 120 125 40 Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala 130 135 140 Gly 145 45 (2) INFORMACE PRO SEQ ID NO:562: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 155 aminokyselin (B) TYP: aminokyselina 50 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 55 (xi) POPIS SEKVENCE: SEQ ID NO:562: Ala Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser Arg Leu 15 10 15 Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp Ile Thr 60 20 25 30 -679 5 10 15 CZ 295843 B6 Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser 35 40 45 Ser Thr Leu Ser Gly Gly Asn Gly Ser Gly Gly Asn Gly Ser Gly Gly 50 55 60 Asn Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp 65 70 75 80 Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr 85 90 95 Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly 100 105 110 Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr 115 120 125 Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu 130 135 140 Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro 145 150 155 20 25 30 35 40 45 (2) INFORMACE PRO SEQ ID NO:563: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 150 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:563: Ala Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser Arg Leu 1 5 10 15 Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp Ile Thr 20 25 30 Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser 35 40 45 Ser Thr Leu Ser Gly Gly Asn Gly Ser Gly Gly Asn Gly Thr Gin Asp 50 55 60 Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile 65 70 75 80 Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala 85 90 95 Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val 100 105 110 Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys 115 120 125 Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr 130 135 140 Lys Cys Ala Phe Gin Pro 145 150 50 (2) INFORMACE PRO SEQ ID NO:564: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 145 aminokyselin 55 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:564: -680- 60 5 10 15 20 CZ 295843 B6 Ala Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser Arg Leu 1 5 10 15 Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp Ile Thr 20 25 30 Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser 35 40 45 Ser Thr Leu Ser Gly Gly Asn Gly Thr Gin Asp Cys Ser Phe Gin His 50 55 60 Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp 65 70 75 80 Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp 85 90 95 Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp 100 105 110 Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu 115 120 125 Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala Phe Gin 130 135 140 Pro 145 25 30 35 40 45 50 (2) INFORMACE PRO SEQ ID NO:565: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 155 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:565: Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly 20 25 30 Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser 50 55 60 Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80 Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro 85 90 95 Asp Ser Ser Thr Leu Ser Gly Gly Ser Gly Ser Gly Gly Ser Gly Ser 100 105 110 Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser 115 120 125 Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin 130 135 140 Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin 145 150 155 55 (2) INFORMACE PRO SEQ ID NO:566: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 150 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché -681 - 60 CZ 295843 B6 (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:566: Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly 20 25 30 Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser 50 55 60 Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80 Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro 85 90 95 Asp Ser Ser Thr Leu Ser Gly Gly Ser Gly Ser Gly Gly Ser Gly Thr 100 105 110 Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val 115 120 125 Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr 130 135 140 Val Ala Ser Asn Leu Gin 145 150 (2) INFORMACE PRO SEQ ID NO:567: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 145 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:567: Met Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp 1 5 10 15 Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr 20 25 30 Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly 35 40 45 Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr 50 55 60 Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu 65 70 75 80 Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu 85 90 95 Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu 100 105 110 Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg 115 120 125 Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly 130 135 140 Ser 145 -682- 5 CZ 295843 B6 (2) INFORMACE PRO SEQ ID NO:568: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 143 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 10 (xi) POPIS SEKVENCE: SEQ ID NO:568: 15 20 25 30 Gly Ser Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser 1 5 10 15 Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin 20 25 30 Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys 35 40 45 Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu 50 55 60 Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn 65 70 75 80 Thr Glu Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser 85 90 95 Cys Leu Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr 100 105 110 Ser Glu Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe 115 120 125 Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 130 135 140 (2) INFORMACE PRO SEQ ID NO:569: (i) CHARAKTERISTIKY SEKVENCE: 35 (A) DÉLKA: 149 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 40 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:569: 45 50 55 Met Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp 1 5 10 15 Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr 20 25 30 Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly 35 40 45 Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr 50 55 60 Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu 65 70 75 80 Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu 85 90 95 Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu 100 105 110 Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg 115 120 125 Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly 130 135 140 -683 - 60 5CZ 295843 B6 Ser Gly Gly Gly Ser 145 (2) INFORMACE PRO SEQ ID NO:570: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 144 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché 10 (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:570: 15 20 25 30 35 40 45 50 55 Gly Ser Gly Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile 1 5 10 15 Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu 20 25 30 Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu 35 40 45 Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg 50 55 60 Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val 65 70 75 80 Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro 85 90 95 Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu 100 105 110 Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn 115 120 125 Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 130 135 140 (2) INFORMACE PRO SEQ ID NO:571: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 153 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:571: Met Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp 1 5 10 15 Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr 20 25 30 Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly 35 40 45 Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr 50 55 60 Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu 65 70 75 80 Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu 85 90 95 Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu 100 105 110 -684- 60 10 CZ 295843 B6 Gin Leu Val 115 Ala Leu Lys Pro Cys Leu 130 Glu Leu Gin Cys Gin 135 Ser 145 Gly Gly Gly Ser Gly 150 Gly 120 140 Asn Phe Ser Arg 125 Leu Gly Gly Gly (2) INFORMACE PRO SEQ ID NO:572: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 150 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 15 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:572: 20 25 30 35 Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser 1 5 10 15 Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu 20 25 30 Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn 35 40 45 Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala 50 55 60 Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin 65 70 75 80 Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys 85 90 95 Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile 100 105 110 Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro 115 120 125 Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin 130 135 140 Pro Asp Ser Ser Thr Leu 145 150 40 (2) INFORMACE PRO SEQ ID NO:573: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 146 aminokyselin 45 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 50 (xi) POPIS SEKVENCE: SEQ ID NO:573: 55 Ala 1 Asp Glu Glu Leu 5 Cys Gly Gly Leu Trp 10 Arg Leu Val Leu Ala 15 Gin Arg Trp Met Glu 20 Arg Leu Lys Thr Val 25 Ala Gly Ser Lys Met 30 Gin Gly Leu Leu Glu 35 Arg Val Asn Thr Glu 40 Ile His Phe Val Thr 45 Lys Cys Ala Phe Gin 50 Pro Pro Pro Ser Cys 55 Leu Arg Phe Val Gin 60 Thr Asn Ile Ser -685 - 60 CZ 295843 B6 Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80 Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro 85 90 95 Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Thr Gin Asp Cys Ser 100 105 110 Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu 115 120 125 Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn 130 135 140 Leu Gin 145 (2) INFORMACE PRO SEQ ID NO:574: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 147 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 15 20 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:574: 25 Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly 20 25 30 30 Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser 50 55 60 Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 35 65 70 75 80 Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro 85 90 95 Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Thr Gin Asp Cys 100 105 110 40 Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg 115 120 125 Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser 130 135 140 Asn Leu Gin 45 145 (2) INFORMACE PRO SEQ ID NO:575: (i) CHARAKTERISTIKY SEKVENCE: 50 (A) DÉLKA: 150 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 55 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:575: Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 60 1 5 10 15 -686- CZ 295843 B6 Arg Trp Met Glu Arg Leu Lys 20 Leu Leu Glu Arg Val Asn Thr 35 5 Phe Gin Pro Pro Pro Ser Cys 50 55 Arg Leu Leu Gin Glu Thr Ser '65 70 Ile Thr Arg Gin Asn Phe Ser 10 85 Asp Ser Ser Thr Leu Gly Gly 100 Gin Asp Cys Ser Phe Gin His 115 15 Lys Ile Arg Glu Leu Ser Asp 130 135 Val Ala Ser Asn Leu Gin 145 150 Thr Val Ala Gly Ser Lys Met Gin Gly 25 30 Glu Ile His Phe Val Thr Lys Cys Ala 40 45 Leu Arg Phe Val Gin Thr Asn Ile Ser 60 Glu Gin Leu Val Ala Leu Lys Pro Trp 75 80 Arg Cys Leu Glu Leu Gin Cys Gin Pro 90 95 Gly Ser Gly Gly Gly Ser Gly Gly Thr 105 110 Ser Pro Ile Ser Ser Asp Phe Ala Val 120 125 Tyr Leu Leu Gin Asp Tyr Pro Val Thr 140 20 (2) INFORMACE PRO SEQ ID NO:576: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 153 aminokyselin (B) TYP: aminokyselina 25 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 30 (xi) POPIS SEKVENCE: SEQ ID NO:576: Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly 35 20 25 30 Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser 50 55 60 40 Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80 Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro 85 90 95 Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 45 100 105 110 Ser Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp 115 120 125 Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr 130 135 140 50 Pro Val Thr Val Ala Ser Asn Leu Gin 145 150 (2) INFORMACE PRO SEQ ID NO:577: 55 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 155 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 60 5 10 15 20 25 30 35 40 45 50 55 CZ 295843 B6 (xi) POPIS SEKVENCE: SEQ ID NO:577: Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly 20 25 30 Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser 50 55 60 Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80 Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro 85 90 95 Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 100 105 110 Ser Gly Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser 115 120 125 Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin 130 135 140 Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin 145 150 155 (2) INFORMACE PRO SEQ ID NO:578: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 161 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:578: Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly 20 25 30 Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser 50 55 60 Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80 Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro 85 90 95 Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 100 105 110 Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly' Thr Gin Asp Cys Ser Phe 115 120 125 Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu 130 135 140 Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu 145 150 155 160 Gin (2) INFORMACE PRO SEQ ID NO:579: (i) CHARAKTERISTIKY SEKVENCE: -688 - 60 5 CZ 295843 B6 (A) DÉLKA: 281 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:579: 10 15 20 25 30 35 40 45 Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser 145 150 155 160 Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp 165 170 175 Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly 180 185 190 Ala Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys 195 200 205 Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr 210 215 220 Glu Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys 225 230 235 240 Leu Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser 245 250 255 Glu Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser 260 265 270 Arg Cys Leu Glu Leu Gin Cys Gin Pro 275 280 (2) INFORMACE PRO SEQ ID NO:580: (i) CHARAKTERISTIKY SEKVENCE: 50 (A) DÉLKA: 286 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 55 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:580: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 15 10 15 -689- 60 CZ 295843 B6 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser 145 150 155 160 Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp 165 170 175 Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly 180 185 190 Ala Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys 195 200 205 Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr 210 215 220 Glu Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys 225 230 235 240 Leu Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser 245 250 255 Glu Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser 260 265 270 Arg Cys Leu Glu Leu Gin cys Gin Pro Asp Ser Ser Thr Leu 275 280 285 (2) INFORMACE PRO SEQ ID NO:581: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 296 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:581: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 -690- 5 10 15 20 25 CZ 295843 B6 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu 145 150 155 160 Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met 165 170 175 Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys 180 185 190 Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn 195 200 205 Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys 210 215 220 Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys 225 230 235 240 Gin Pro Asp Ser Ser Thr Leu Ser Gly Gly Asn Gly Ser Gly Gly Asn 245 250 255 Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe 260 265 270 Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro 275 280 285 Val Thr Val Ala Ser Asn Leu Gin 290 295 (2) INFORMACE PRO SEQ ID NO:582: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 296 aminokyselin 30 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 35 (xi) POPIS SEKVENCE: SEQ ID NO:582: 40 45 50 55 Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu 145 150 155 160 Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met 165 170 175 Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys 180 185 190 -691 - 60 CZ 295843 B6 Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn 195 200 205 Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys 210 215 220 Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys 225 230 235 240 Gin Pro Asp Ser Ser Thr Leu Ser Gly Gly Asn Gly Ser Gly Gly Asn 245 250 255 Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe 260 265 270 Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro 275 280 285 Val Thr Val Ala Ser Asn Leu Gin 290 295 (2) INFORMACE PRO SEQ ID NO:583: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 291 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:583: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu 145 150 155 160 Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu 165 170 175 Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu 180 185 190 Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg 195 200 205 Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Ser Gly Gly 210 215 220 Asn Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp 225 230 235 240 Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr 245 250 255 Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly 260 265 270 -692- 5 CZ 295843 B6 Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr 275 280 285 Val Ala Gly 290 (2) INFORMACE PRO SEQ ID NO:584: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 296 aminokyselin 10 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 15 (xi) POPIS SEKVENCE: SEQ ID NO:584: 20 25 30 35 40 45 50 55 Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu 145 150 155 160 Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu 165 170 175 Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu 180 185 190 Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg 195 200 205 Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Ser Gly Gly 210 215 220 Asn Gly Ser Gly Gly Asn Gly Thr Gin Asp Cys Ser Phe Gin His Ser 225 230 235 240 Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr 245 250 255 Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu 260 265 270 Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met 275 280 285 Glu Arg Leu Lys Thr Val Ala Gly 290 295 (2) INFORMACE PRO SEQ ID NO:5'85: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 301 aminokyselin (B) TYP: aminokyselina -693 - 60 CZ 295843 B6 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:585: Ala 1 Asn Cys Ser 10 Pro Pro Ala Pro 20 Ser Ile Leu 35 Met 15 Val Arg 50 Ala Val Leu 65 Arg Asn Leu Arg His Pro Ile 20 Lys Leu Thr Phe 100 Tyr Val Glu 115 Gly 25 Ser Thr 130 Ile Asn Asn 145 Met Ala Asp Ala Gin Arg Trp 30 Gin Gly Leu Leu 180 Cys Ala Phe 195 Gin 35 Ile Ser 210 Arg Leu Pro 225 Trp Ile Thr Gin Pro Asp Ser 40 Gly Ser Gly Gly 260 Ile Ser Ser 275 Asp 45 Leu Gin 290 Asp Tyr Ile 5 Met Ile Asp Glu Ile 10 Leu Leu Asp Pro Asn 25 Asn Asp Arg Asn Leu 40 Arg Leu Lys Asn Leu 55 Glu Asn Ala Gin Pro 70 Cys Leu Pro Ser Ile 85 Ile Lys Ala Gly Asp 90 Tyr Leu Val Thr Leu 105 Glu Gly Gly Gly Ser 120 Pro Gly Pro Ser Pro 135 Pro Ser Lys Glu Glu 150 Leu Cys Gly Gly Met 165 Glu Arg Leu Lys Thr 170 Glu Arg Val Asn Thr 185 Glu Pro Pro Pro Ser 200 Cys Leu Leu Gin Glu 215 Thr Ser Glu Arg Gin 230 Asn Phe Ser Arg Ser 245 Thr Leu Ser Gly Gly 250 Asn Gly Thr Gin Asp 265 Cys Phe Ala Val Lys 280 Ile Arg Pro Val Thr 295 Val Ala Ser Ile His His Leu Lys 15 Arg Leu Asn Asp Glu 30 Asp Val Pro Asn Leu 45 Glu Ser Phe Ser Gly 60 Ile Glu Ala Ile Ala 75 Thr Ala Ala Pro Ser 80 Trp Gin Glu Phe Arg 95 Glu Gin Ala Gin Glu 110 Gin Gin Glu Pro Ser 125 Gly Pro Ile Glu Ser 140 His Lys Ser Pro Leu 155 Trp Arg Leu Val Leu 160 Val Ala Gly Ser Lys 175 Met Ile His Phe Val 190 Thr Lys Arg Phe Val 205 Gin Thr Asn Gin Leu 220 Val Ala Leu Lys Cys 235 Leu Glu Leu Gin Cys 240 Asn Gly Ser Gly Gly Asn 255 Ser Phe Gin His 270 Ser Pro Glu Asn Leu Leu 300 Ser 285 Gin Asp Tyr Leu (2) INFORMACE PRO SEQ ID NO:586: (i) CHARAKTERISTIKY SEKVENCE: 50 (A) DÉLKA: 291 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 55 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:586: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 60 1 5 10 15 -694- CZ 295843 B6 Pro Pro Ala Pro 20 Ser Ile Leu 35 Met 5 Val Arg 50 Ala Val Leu 65 Arg Asn Leu Arg His Pro Ile 10 Lys Leu Thr Phe 100 Tyr Val Glu 115 Gly 15 Ser Thr 130 Ile Asn Asn 145 Met Ala Pro Arg Leu Leu Gin 20 Ile Thr Arg Gin 180 Asp Ser Ser 195 Thr 25 Gin His 210 Ser Pro Ser 225 Asp Tyr Leu Gin Asp Glu Glu 30 Arg Trp Met Glu 260 Leu Leu Glu 275 Arg 35 Phe Gin 290 Pro Leu Leu Asp Pro Asn 25 Asn Asp Arg Asn Leu 40 Arg Leu Lys Asn Leu 55 Glu Asn Ala Gin Pro 70 Cys Leu Pro Ser Ile 85 Ile Lys Ala Gly Asp 90 Tyr Leu Val Thr Leu 105 Glu Gly Gly Gly Ser 120 Pro Gly Pro Ser Pro 135 Pro Ser Lys Pro Ser 150 Cys Leu Arg Phe Glu 165 Thr Ser Glu Gin Leu 170 Asn Phe Ser Arg Cys 185 Leu Leu Ser Gly Gly 200 Asn Gly Ile Ser Ser 215 Asp Phe Ala Leu Gin 230 Asp Tyr Pro Val Leu 245 Cys Gly Gly Leu Trp 250 Arg Leu Lys Thr Val 265 Ala Val Asn Thr Glu 280 Ile His Leu Asn Asp Glu 30 Asp Val Pro Asn Leu 45 Glu Ser Phe Ser Gly 60 Ile Glu Ala Ile Ala 75 Thr Ala Ala Pro Ser 80 Trp Gin Glu Phe Arg 95 Glu Gin Ala Gin Glu 110 Gin Gin Glu Pro Ser 125 Gly Pro Ile Glu Ser 140 His Lys Ser Pro Val 155 Gin Thr Asn Ile Ser 160 Val Ala Leu Lys Pro 175 Trp Glu Leu Gin Cys 190 Gin Pro Thr Gin Asp 205 Cys Ser Phe Val Lys 220 Ile Arg Glu Leu Thr 235 Val Ala Ser Asn Leu 240 Arg Leu Val Leu Ala 255 Gin Gly Ser Lys Met 270 Gin Gly Phe Val Thr Lys Cys Ala 285 (2) INFORMACE PRO SEQ ID NO:587: 40 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 296 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 45 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:587: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 50 55 -695- 60 5 10 15 20 25 CZ 295843 B6 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser 145 150 155 160 Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 165 170 175 Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro 180 185 190 Asp Ser Ser Thr Leu Ser Gly Gly Asn Gly Ser Gly Gly Asn Gly Thr 195 200 205 Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val 210 215 220 Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr 225 230 235 240 Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg 245 250 255 Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly 260 265 270 Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe 275 280 285 Val Thr Lys Cys Ala Phe Gin Pro 290 295 (2) INFORMACE PRO SEQ ID NO:588: 30 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 301 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 35 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:588: 40 45 50 55 Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser 145 150 155 160 Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 165 170 175 -696- 60 5 10 15 CZ 295843 B6 Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro 180 185 190 Asp Ser Ser Thr Leu Ser Gly Gly Asn Gly Ser Gly Gly Asn Gly Ser 195 200 205 Gly Gly Asn Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser 210 215 220 Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin 225 230 235 240 Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys 245 250 255 Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu 260 265 270 Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn 275 280 285 Thr Glu Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro 290 295 300 (2) INFORMACE PRO SEQ ID NO:589: 20 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 281 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 25 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:589: 30 35 40 45 50 55 Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser 145 150 155 160 Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp 165 170 175 Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly 180 185 190 Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys 195 200 205 Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr 210 215 220 Glu Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys 225 230 235 240 Leu Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser 245 250 255 -697- 60 5 CZ 295843 B6 Glu Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser 260 265 270 Arg Cys Leu Glu Leu Gin Cys Gin Pro 275 280 (2) INFORMACE PRO SEQ ID NO:590: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 286 aminokyselin 10 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 15 (xi) POPIS SEKVENCE: SEQ ID NO:590: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser 145 150 155 160 Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp 165 170 175 Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly 180 185 190 Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys 195 200 205 Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr 210 215 220 Glu Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys 225 230 235 240 Leu Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser 245 250 255 Glu Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser 260 265 270 Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 275 280 285 20 25 30 35 40 45 50 55 (2) INFORMACE PRO SEQ ID NO:591: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 296 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární -698- 60 5 10 15 20 25 30 35 40 45 50 55 CZ 295843 B6 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:591: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu 145 150 155 160 Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met 165 170 175 Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys 180 185 190 Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn 195 200 205 Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys 210 215 220 Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys 225 230 235 240 Gin Pro Asp Ser Ser Thr Leu Ser Gly Gly Asn Gly Ser Gly Gly Asn 245 250 255 Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe 260 265 270 Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro 275 280 285 Val Thr Val Ala Ser Asn Leu Gin 290 295 (2) INFORMACE PRO SEQ ID NO:592: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 301 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:592: Ala 1 Asn Cys Ser Ile 5 Met Ile Asp Glu Ile 10 Ile His His Leu Lys 15 Arg Pro Pro Asn Pro 20 Leu Leu Asp Pro Asn 25 Asn Leu Asn Ser Glu 30 Asp Met -699- 60 CZ 295843 B6 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu 145 150 155 160 Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met 165 170 175 Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys 180 185 190 Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn 195 200 205 Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys 210 215 220 Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys 225 230 235 240 Gin Pro Asp Ser Ser Thr Leu Ser Gly Gly Asn Gly Ser Gly Gly Asn 245 250 255 Gly Ser Gly Gly Asn Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro 260 265 270 Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu 275 280 285 Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin 290 295 300 (2) INFORMACE PRO SEQ ID NO:593: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 291 aminokyselin (B) TYP: : aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:593: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 -700- CZ 295843 B6 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu 145 150 155 160 Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu 165 170 175 Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu 180 185 190 Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg 195 200 205 Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Ser Gly Gly 210 215 220 Asn Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp 225 230 235 240 Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr 245 250 255 Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly 260 265 270 Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr 275 280 285 Val Ala Gly 290 (2) i INFORMACE PRO SEQ ID NO:594: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 296 aminokyselin (B) TYP: ; aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY; : žádný (xi) POPIS SEKVENCE: SEQ ID NO:594: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu 145 150 155 160 Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu 165 170 175 Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu 180 185 190 -701 - CZ 295843 B6 Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg 195 200 205 Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Ser Gly Gly 210 215 220 Asn Gly Ser Gly Gly Asn Gly Thr Gin Asp Cys Ser Phe Gin His Ser 225 230 235 240 Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr 245 250 255 Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu 260 265 270 Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met 275 280 285 Glu Arg Leu Lys Thr Val Ala Gly 290 295 (2) INFORMACE PRO SEQ ID NO:595: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 301 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:595: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu 145 150 155 160 Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu 165 170 175 Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu 180 185 190 Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg 195 200 205 Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Ser Gly Gly 210 215 220 Asn Gly Ser Gly Gly Asn Gly Ser Gly Gly Asn Gly Thr Gin Asp Cys 225 230 235 240 Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg 245 250 255 Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser 260 265 270 -702- CZ 295843 B6 Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu 275 280 285 Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly 290 295 300 5 (2) INFORMACE PRO SEQ ID NO:596: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 291 aminokyselin 10 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 15 (xi) POPIS SEKVENCE: SEQ ID NO:596: Ala Asn Cys Ser 1 20 Pro Pro Asn Pro 20 Asp Ile Leu Met 35 Val Arg Ala Val 25 50 Leu Arg Asn Leu 65 Arg His Pro Ile 30 Lys Leu Thr Phe 100 Tyr Val Glu Gly 115 Ser Thr Ile Asn 35 130 Asn Met Ala Pro 145 Arg Leu Leu Gin 40 Ile Thr Arg Gin 180 Asp Ser Ser Thr 195 Gin His Ser Pro 45 210 Ser Asp Tyr Leu 225 Gin Asp Glu Glu 50 Arg Trp Met Glu 260 Leu Leu Glu Arg 275 Phe Gin Pro 55 290 Ile 5 Met Ile Asp Glu Ile 10 Leu Leu Asp Pro Asn 25 Asn Glu Arg Asn Leu 40 Arg Thr Lys His Leu 55 Glu Asn Ala Gin Pro 70 Cys Leu Pro Ser Ile 85 Ile Lys Ala Gly Asp 90 Tyr Leu Val Thr Leu 105 Glu Gly Gly Gly Ser 120 Pro Gly Pro Ser Pro 135 Pro Ser Lys Pro Ser 150 Cys Leu Arg Phe Glu 165 Thr Ser Glu Gin Leu 170 Asn Phe Ser Arg Cys 185 Leu Leu Ser Gly Gly 200 Asn Gly Ile Ser Ser 215 Asp Phe Ala Leu Gin 230 Asp Tyr Pro Val Leu 245 Cys Gly Gly Leu Trp 250 Arg Leu Lys Thr Val 265 Ala Val Asn Thr Glu 280 Ile His Ile His His Leu Lys 15 Arg Leu Asn Ser Glu 30 Asp Met Pro Asn Leu 45 Leu Ala Phe Ser Gly 60 Ile Glu Ala Ile Ala 75 Thr Ala Ala Pro Ser 80 Trp Gin Glu Phe Arg 95 Glu Gin Ala Gin Glu 110 Gin Gin Glu Pro Ser 125 Gly Pro Ile Glu Ser 140 His Lys Ser Pro Val 155 Gin Thr Asn Ile Ser 160 Val Ala Leu Lys Pro 175 Trp Glu Leu Gin Cys 190 Gin Pro Thr Gin Asp 205 Cys Ser Phe Val Lys 220 Ile Arg Glu Leu Thr 235 Val Ala Ser Asn Leu 240 Arg Leu Val Leu Ala 255 Gin Gly Ser Lys Met 270 Gin Gly Phe Val Thr 285 Lys Cys Ala (2) INFORMACE PRO SEQ ID NO:597: (i) CHARAKTERISTIKY SEKVENCE: 60 (A) DÉLKA: 296 aminokyselin (B) TYP: aminokyselina -703 - 5 CZ 295843 B6 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ 10 15 20 25 30 35 40 45 Ala Asn Cys Ser 1 Pro Pro Asn Pro Asp Ile Leu 20 Met Val Arg 35 Ala Val Leu 50 Arg Asn Leu 65 Arg His Pro Ile Lys Leu Thr Phe Tyr Val Glu 100 Gly Ser Thr 115 Ile Asn Asn 130 Met Ala Pro 145 Arg Leu Leu Gin Ile Thr Arg Gin Asp Ser Ser 180 Thr Gin Asp 195 Cys Ser Lys 210 Ile Arg Glu 225 Val Ala Ser Asn Leu Val Leu Ala Ser Lys Met 260 Gin Val Thr 275 Lys Cys 290 Ile 5 Met Ile Asp Leu Leu Asp Pro Glu Arg Asn Leu 40 Lys His Leu 55 Glu Gin Pro 70 Cys Leu Ile 85 Ile Lys Ala Tyr Leu Val Thr Gly Gly Gly Ser 120 Pro Ser Pro 135 Pro Pro Ser 150 Cys Leu Glu 165 Thr Ser Glu Asn Phe Ser Arg Leu Ser Gly Gly 200 Phe Gin His 215 Ser Leu Ser 230 Asp Tyr Leu 245 Gin Asp Glu Gin Arg Trp Met Gly Leu Leu Glu 280 Ala Phe Gin 295 Pro ID NO:597: Glu Ile 10 Ile His Asn 25 Asn Leu Asn Arg Thr Pro Asn Asn Ala Ser Gly 60 Pro Ser Ala 75 Thr Gly Asp 90 Trp Gin Leu 105 Glu Gin Ala Pro Gly Glu Pro Ser Lys Glu Ser 140 Arg Phe Val 155 Gin Gin Leu 170 Val Ala Cys 185 Leu Glu Leu Asn Gly Ser Gly Pro Ile Ser Ser 220 Leu Leu Gin 235 Asp Glu Leu 250 Cys Gly Glu 265 Arg Leu Lys Arg Val Asn Thr His Leu Lys 15 Arg Ser Glu 30 Asp Met Leu 45 Leu Ala Phe Ile Glu Ala Ile Ala Ala Pro Ser 80 Glu Phe Arg 95 Glu Gin Glu 110 Gin Gin Ser 125 Gly Pro Ile His Lys Ser Pro Thr Asn Ile Ser 160 Leu Lys Pro 175 Trp Gin Cys 190 Gin Pro Gly 205 Asn Gly Thr Asp Phe Ala Val Tyr Pro Val Thr 240 Gly Leu Trp Arg 255 Thr Val 270 Ala Gly Glu 285 Ile His Phe (2) INFORMACE PRO SEQ ID NO:598: (i) CHARAKTERISTIKY SEKVENCE: 50 (A) DÉLKA: 301 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 55 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:598: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 15 10 15 -704- 60 40 45 CZ 295843 B6 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser 145 150 155 160 Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 165 170 175 Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro 180 185 190 Asp Ser Ser Thr Leu Ser Gly Gly Asn Gly Ser Gly Gly Asn Gly Ser 195 200 205 Gly Gly Asn Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser 210 215 220 Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin 225 230 235 240 Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys 245 250 255 Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu 260 265 270 Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn 275 280 285 Thr Glu Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro 290 295 300 (2) INFORMACE PRO SEQ ID NO:599: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 296 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:599: 50 55 Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 -705- 60 5 10 15 20 25 CZ 295843 B6 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu 145 150 155 160 Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met 165 170 175 Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys 180 185 190 Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn 195 200 205 Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys 210 215 220 Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys 225 230 235 240 Gin Pro Asp Ser Ser Thr Leu Ser Gly Gly Ser Gly Ser Gly Gly Ser 245 250 255 Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe 260 265 270 Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro 275 280 285 Val Thr Val Ala Ser Asn Leu Gin 290 295 (2) INFORMACE PRO SEQ ID NO:600: 30 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 301 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 35 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:600: 40 45 50 55 Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu 145 150 155 160 Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met 165 170 175 -706- 60 CZ 295843 B6 Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys 180 185 190 Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn 195 200 205 Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys 210 215 220 Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys 225 230 235 240 Gin Pro Asp Ser Ser Thr Leu Ser Gly Gly Ser Gly Ser Gly Gly Ser 245 250 255 Gly Ser Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro 260 265 270 Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu 275 280 285 Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin 290 295 300 (2! l INFORMACE PRO SEQ ID NO:601: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 281 aminokyselin (B) TYP : aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: : žádný (xi) POPIS SEKVENCE: SEQ ID NO:601: Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe 1 5 10 15 Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro 20 25 30 Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu 35 40 45 Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val 50 55 60 Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile 65 70 75 80 His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg 85 90 95 Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin 100 105 110 Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys 115 120 125 Leu Glu Leu Gin Cys Gin Pro Tyr Val Glu Gly Gly Gly Gly Ser Pro 130 135 140 Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser 145 150 155 160 Lys Glu Ser His Lys Ser Pro Asn Met Ala Asn Cys Ser Ile Met Ile 165 170 175 Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Asn Pro Leu Leu Asp 180 185 190 Pro Asn Asn Leu Asn Ser Glu Asp Met Asp Ile Leu Met Glu Arg Asn 195 200 205 Leu Arg Thr Pro Asn Leu Leu Ala Phe Val Arg Ala Val Lys His Leu 210 215 220 Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys 225 230 235 240 Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys 245 250 255 -707- 5 CZ 295843 B6 Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val 260 265 270 Thr Leu Glu Gin Ala Gin Glu Gin Gin 275 280 (2) INFORMACE PRO SEQ ID NO:602: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 286 aminokyselin 10 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 15 (xi) POPIS SEKVENCE: SEQ ID NO:602: 20 25 30 35 40 45 50 Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe 1 5 10 15 Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro 20 25 30 Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu 35 40 45 Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val 50 55 60 Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile 65 70 75 80 His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg 85 90 95 Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin 100 105 110 Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys 115 120 125 Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Tyr Val Glu Gly 130 135 140 Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn 145 150 155 160 Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Asn 165 170 175 Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro 180 185 190 Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met Asp Ile 195 200 205 Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe Val Arg 210 215 220 Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg 225 230 235 240 Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His 245 250 255 Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu 260 265 270 Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 275 280 285 55 (2) INFORMACE PRO SEQ ID NO:603: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 268 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární -708 - 60 5 CZ 295843 B6 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:603: 10 15 20 25 30 35 40 Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Pro His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser 145 150 155 160 Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp 165 170 175 Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly 180 185 190 Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys 195 200 205 Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr 210 215 220 Glu Ile His Phe Val Thr Lys Cys Ala Phe Gin Glu Thr Ser Glu Gin 225 230 235 240 Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys 245 250 255 Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 260 265 (2) INFORMACE PRO SEQ ID NO:604: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 292 aminokyselin 45 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 50 (xi) POPIS SEKVENCE: SEQ ID NO:604: 55 Ala 1 Asn Cys Ser Ile 5 Met Ile Asp Glu Ile 10 Ile His His Leu Lys 15 Arg Pro Pro Asn Pro 20 Leu Leu Asp Pro Asn 25 Asn Leu Asn Ser Glu 30 Asp Met Asp Ile Leu 35 Met Glu Arg Asn Leu 40 Arg Thr Pro Asn Leu 45 Leu Ala Phe Val Arg 50 Ala Val Lys His Leu 55 Glu Asn Ala Ser Gly 60 Ile Glu Ala Ile -709- 60 CZ 295843 B6 Leu 65 Arg Asn Leu Gin Pro 70 Cys Arg His Pro Ile Ile 85 Ile Lys 5 Lys Leu Thr Phe 100 Tyr Leu Val Tyr Val Glu 115 Gly Gly Gly Gly 10 Ser Thr 130 Ile Asn Pro Ser Pro 135 Asn 145 Met Ala Asp Glu Glu 150 Leu Ala Gin Arg Trp Met 165 Glu Arg 15 Gin Gly Leu Leu 180 Glu Arg Val Cys Ala Phe 195 Gin Pro Pro Pro 20 Ile Ser 210 Arg Leu Leu Gin Glu 215 Pro 225 Trp Ile Thr Arg Gin 230 Asn Gin Pro Asp Ser Ser 245 Thr Leu 25 Cys Ser Phe Gin 260 His Ser Pro 30 Arg Ser Glu Asn 290 Leu 275 Leu Ser Gin Asp Tyr Leu Leu Pro Ser Ala Thr Ala Ala Pro Ser 75 80 Ala Gly Asp Trp Gin Glu Phe Arg Glu 90 95 Thr Leu Glu Gin Ala Gin Glu Gin Gin 105 110 Ser Pro Gly Glu Pro Ser Gly Pro Ile 120 125 Pro Ser Lys Glu Ser His Lys Ser Pro 140 Cys Gly Gly Leu Trp Arg Leu Val Leu 155 160 Leu Lys Thr Val Ala Gly Ser Lys Met 170 175 Asn Thr Glu Ile His Phe Val Thr Lys 185 190 Ser Cys Leu Arg Phe Val Gin Thr Asn 200 205 Thr Ser Glu Gin Leu Val Ala Leu Lys 220 Phe Ser Arg Cys Leu Glu Leu Gin Cys 235 240 Gly Gly Gly Ser Gly Gly Thr Gin Asp 250 255 Ile Ser Ser Asp Phe Ala Val Lys Ile 265 270 Leu Gin Asp Tyr Pro Val Thr Val Ala 280 285 (2) INFORMACE PRO SEQ ID NO:605: (i) CHARAKTERISTIKY SEKVENCE: 35 (A) DÉLKA: 293 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 40 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:605: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 -710- CZ 295843 B6 As η Met Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu 145 150 155 160 Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met 165 170 175 Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys 180 185 190 Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn 195 200 205 Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys 210 215 220 Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys 225 230 235 240 Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Thr Gin 245 250 255 Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys 260 265 270 Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val 275 280 285 Ala Ser Asn Leu Gin 290 (2) i INFORMACE PRO SEQ ID NO:606: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 296 aminokyselin (B) TYP: : aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: : žádný (xi) POPIS SEKVENCE: SEQ ID NO:606: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu 145 150 155 160 Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met 165 170 175 Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys 180 185 190 Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn 195 200 205 Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys 210 215 220 -711 - 5 10 CZ 295843 B6 Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys 225 230 235 240 Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly 245 250 255 Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe 260 265 270 Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro 275 280 285 Val Thr Val Ala Ser Asn Leu Gin 290 295 (2) INFORMACE PRO SEQ ID NO:607: (i) CHARAKTERISTIKY SEKVENCE: 15 (A) DÉLKA: 299 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 20 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:607: 25 30 35 40 45 50 55 Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu 145 150 155 160 Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met 165 170 175 Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys 180 185 190 Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn 195 200 205 Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys 210 215 220 Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys 225 230 235 240 Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly 245 250 255 Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser 260 265 270 Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin 275 280 285 Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin 290 295 -712- 60 5 CZ 295843 B6 (2) INFORMACE PRO SEQ ID NO:608: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 301 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 10 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:608: 15 20 25 30 35 40 45 50 Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu 145 150 155 160 Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met 165 170 175 Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys 180 185 190 Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn 195 200 205 Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys 210 215 220 Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys 225 230 235 240 Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly 245 250 255 Gly Gly Ser Gly Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro 260 265 270 Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu 275 280 285 Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin 290 295 300 (2) INFORMACE PRO SEQ ID NO:609: 55 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 307 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný -713- 60 5CZ 295843 B6 (xi) POPIS SEKVENCE: SEQ ID NO:609: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu 145 150 155 160 Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met 165 170 175 Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys 180 185 190 Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn 195 200 205 Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys 210 215 220 Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys 225 230 235 240 Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly 245 250 255 Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys 260 265 270 Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg 275 280 285 Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser 290 295 300 Asn Leu Gin 305 10 15 20 25 30 35 40 45 (2) INFORMACE PRO SEQ ID NO:610: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 292 aminokyselin (B) TYP: aminokyselina 50 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 55 (xi) POPIS SEKVENCE: SEQ ID NO:610: Ala 1 Asn Cys Ser Ile 5 Met Ile Asp Glu Ile 10 Ile His His Leu Lys 15 Arg 60 Pro Pro Asn Pro 20 Leu Leu Asp Pro Asn 25 Asn Leu Asn Ser Glu 30 Asp Met -714- CZ 295843 B6 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu 145 150 155 160 Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu 165 170 175 Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu 180 185 190 Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg 195 200 205 Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly 210 215 220 Ser Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser 225 230 235 240 Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp 245 250 255 Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly 260 265 270 Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys 275 280 285 Thr Val Ala Gly 290 (2) INFORMACE PRO SEQ ID NO:611: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 293 aminokyselin (B) TYP: : aminokyselina (C) RETEZENI: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:611: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 -715- CZ 295843 B6 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu 145 150 155 160 Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu 165 170 175 Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu 180 185 190 Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg 195 200 205 Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly 210 215 220 Ser Gly Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser 225 230 235 240 Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin 245 250 255 Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys 260 265 270 Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu 275 280 285 Lys Thr Val Ala Gly 290 (2) INFORMACE PRO SEQ ID NO:612: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 296 aminokyselin (B) TYP: : aminokyselina (C) RETEZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: : žádný (xi) POPIS SEKVENCE: SEQ ID NO:612: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu 145 150 155 160 Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu 165 170 175 Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu 180 185 190 -716- 5 10 15 CZ 295843 B6 Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg 195 200 205 Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly 210 215 220 Ser Gly Gly Gly Ser Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser 225 230 235 240 Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr 245 250 255 Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu 260 265 270 Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met 275 280 285 Glu Arg Leu Lys Thr Val Ala Gly 290 295 (2) INFORMACE PRO SEQ ID NO:613: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 299 aminokyselin 20 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 25 (xi) POPIS SEKVENCE: SEQ ID NO:613: 30 35 40 45 50 55 Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu 145 150 155 160 Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu 165 170 175 Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu 180 185 190 Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg 195 200 205 Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly 210 215 220 Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe 225 230 235 240 Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu 245 250 255 Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu 260 265 270 -717- 60 5 CZ 295843 B6 Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 275 280 285 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly 290 295 (2) INFORMACE PRO SEQ ID NO:614: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 301 aminokyselin 10 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 15 (xi) POPIS SEKVENCE: SEQ ID NO:614: 20 25 30 35 40 45 50 55 Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu 145 150 155 160 Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu 165 170 175 Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu 180 185 190 Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg 195 200 205 Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly 210 215 220 Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gin Asp Cys 225 230 235 240 Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg 245 250 255 Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser 260 265 270 Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu 275 280 285 Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly 290 295 300 (2) INFORMACE PRO SEQ ID NO:615: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 307 aminokyselin (B) TYP: aminokyselina -718- 60 CZ 295843 B6 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 5 (xi) POPIS SEKVENCE: SEQ ID NO:615: Ala Asn Cys Ser 1 10 Pro Pro Asn Pro 20 Asp Ile Leu Met 35 Val Arg Ala Val 15 50 Leu Arg Asn Leu 65 Arg His Pro Ile 20 Lys Leu Thr Phe 100 Tyr Val Glu Gly 115 Ser Thr Ile Asn 25 130 Asn Met Ala Ser 145 Ile His Phe Val 30 Arg Phe Val Gin 180 Gin Leu Val Ala 195 Cys Leu Glu Leu 35 210 Ser Gly Gly Gly 225 Ser Gly Thr Gin 40 Phe Ala Val Lys 260 Pro Val Thr Val 275 Leu Trp Arg Leu 45 290 Val Ala Gly 305 Ile 5 Met Ile Asp Glu Ile 10 Leu Leu Asp Pro Asn 25 Asn Glu Arg Asn Leu 40 Arg Thr Lys His Leu 55 Glu Asn Ala Gin Pro 70 Cys Leu Pro Ser Ile 85 Ile Lys Ala Gly Asp 90 Tyr Leu Val Thr Leu 105 Glu Gly Gly Gly Ser 120 Pro Gly Pro Ser Pro 135 Pro Ser Lys Lys Met 150 Gin Gly Leu Leu Thr 165 Lys Cys Ala Phe Gin 170 Thr Asn Ile Ser Arg 185 Leu Leu Lys Pro Trp 200 Ile Thr Gin Cys Gin 215 Pro Asp Ser Ser Gly 230 Gly Gly Ser Gly Asp 245 Cys Ser Phe Gin His 250 Ile Arg Glu Leu Ser 265 Asp Ala Ser Asn Leu 280 Gin Asp Val Leu Ala 295 Gin Arg Trp Ile His His Leu Lys 15 Arg Leu Asn Ser Glu 30 Asp Met Pro Asn Leu 45 Leu Ala Phe Ser Gly 60 Ile Glu Ala Ile Ala 75 Thr Ala Ala Pro Ser 80 Trp Gin Glu Phe Arg 95 Glu Gin Ala Gin Glu 110 Gin Gin Glu Pro Ser 125 Gly Pro Ile Glu Ser 140 His Lys Ser Pro Glu Arg 155 Val Asn Thr Glu 160 Pro Pro Pro Ser Cys 175 Leu Leu Gin Glu Thr 190 Ser Glu Arg Gin Asn 205 Phe Ser Arg Ser Thr 220 Leu Gly Gly Gly Gly Gly 235 Ser Gly Gly Gly 240 Ser Pro Ile Ser Ser 255 Asp Tyr Leu Leu Gin 270 Asp Tyr Glu Glu Leu 285 Cys Gly Gly Met Glu Arg Leu Lys Thr 300 (2) INFORMACE PRO SEQ ID NO:616: 50 55 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 292 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:616: -719- 60 CZ 295843 B6 Ala Asn Cys 1 Pro Pro Asn 5 Asp Ile Leu 35 Val Arg Ala 50 Leu Arg Asn 10 65 Arg His Pro Lys Leu Thr 15 Tyr Val Glu 115 Ser Thr Ile 130 Asn Met Ala 20 145 Arg Leu Leu Ile Thr Arg 25 Asp Ser Ser 195 Phe Gin His 210 Leu Ser Asp 30 225 Leu Gin Asp Gin Arg Trp 35 Gly Leu Leu 275 Ala Phe Gin 290 Ser Ile 5 Met Ile Pro 20 Leu Leu Asp Met Glu Arg Asn Val Lys His Leu 55 Leu Gin Pro 70 Cys Ile Ile 85 Ile Lys Phe 100 Tyr Leu Val Gly Gly Gly Gly Asn Pro Ser Pro 135 Pro Pro Ser 150 Cys Gin Glu 165 Thr Ser Gin 180 Asn Phe Ser Thr Leu Gly Gly Ser Pro Ile Ser 215 Tyr Leu Leu 230 Gin Glu Glu 245 Leu Cys Met 260 Glu Arg Leu Glu Arg Val Asn Pro Asp Glu Ile 10 Ile His Pro Asn 25 Asn Leu Asn Leu 40 Arg Thr Pro Asn Glu Asn Ala Ser Gly 60 Leu Pro Ser Ala 75 Thr Ala Gly Asp 90 Trp Gin Thr Leu 105 Glu Gin Ala Ser 120 Pro Gly Glu Pro Pro Ser Lys Glu Ser 140 Leu Arg Phe Val 155 Gin Glu Gin Leu 170 Val Ala Arg Cys 185 Leu Glu Leu Gly 200 Ser Gly Gly Thr Ser Asp Phe Ala Val 220 Asp Tyr Pro Val 235 Thr Gly Gly Leu 250 Trp Arg Lys Thr 265 Val Ala Gly Thr 280 Glu Ile His Phe His Leu Lys 15 Arg Ser Glu 30 Asp Met Leu 45 Leu Ala Phe Ile Glu Ala Ile Ala Ala Pro Ser 80 Glu Phe Arg 95 Glu Gin Glu 110 Gin Gin Ser 125 Gly Pro Ile His Lys Ser Pro Thr Asn Ile Ser 160 Leu Lys Pro 175 Trp Gin Cys 190 Gin Pro Gin 205 Asp Cys Ser Lys Ile Arg Glu Val Ala Ser Asn 240 Leu Val Leu 255 Ala Ser Lys 270 Met Gin Val 285 Thr Lys Cys 40 (2) INFORMACE PRO SEQ ID NO:617: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 293 aminokyselin (B) TYP: aminokyselina 45 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 50 (xi) POPIS SEKVENCE: SEQ ID NO:617: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg ,Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 -720- 5 CZ 295843 B6 10 15 20 25 Arg His Pro Ile Lys Leu Thr Phe 100 Tyr Val Glu 115 Gly Ser Thr 130 Ile Asn Asn 145 Met Ala Pro Arg Leu Leu Gin Ile Thr Arg Gin 180 Asp Ser Ser 195 Thr Ser Phe 210 Gin His Glu 225 Leu Ser Asp Asn Leu Gin Asp Ala Gin Arg Trp 260 Gin Gly Leu 275 Leu Cys Ala 290 Phe Gin Ile 85 Ile Lys Ala Tyr Leu Val Thr Gly Gly Gly Ser 120 Pro Ser Pro 135 Pro Pro Ser 150 Cys Leu Glu 165 Thr Ser Glu Asn Phe Ser Arg Leu Gly Gly Gly 200 Ser Pro Ile 215 Ser Tyr Leu 230 Leu Gin Glu 245 Glu Leu Cys Met Glu Arg Leu Glu Pro Arg Val Asn 280 Gly Asp 90 Trp Gin Leu 105 Glu Gin Ala Pro Gly Glu Pro Ser Lys Glu Ser 140 Arg Phe Val 155 Gin Gin Leu 170 Val Ala Cys 185 Leu Glu Leu Ser Gly Gly Gly Ser Asp Phe Ala 220 Asp Tyr Pro 235 Val Gly Gly 250 Leu Trp Lys 265 Thr Val Ala Thr Glu Ile His Glu Phe Arg 95 Glu Gin Glu 110 Gin Gin Ser 125 Gly Pro Ile His Lys Ser Pro Thr Asn Ile Ser 160 Leu Lys Pro 175 Trp Gin Cys 190 Gin Pro Thr 205 Gin Asp Cys Val Lys Ile Arg Thr Val Ala Ser 240 Arg Leu Val 255 Leu Gly Ser 270 Lys Met Phe 285 Val Thr Lys 30 (2) INFORMACE PRO SEQ ID NO:618: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 296 aminokyselin (B) TYP: aminokyselina 35 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 40 (xi) POPIS SEKVENCE: SEQ ID NO:618: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser 145 150 155 160 -721 - 10 15 20 25 30 35 40 45 50 55 CZ 295843 B6 Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 165 170 175 Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro 180 185 190 Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Thr 195 200 205 Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val 210 215 220 Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr 225 230 235 240 Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg 245 250 255 Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly 260 265 270 Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe 275 280 285 Val Thr Lys Cys Ala Phe Gin Pro 290 295 (2) INFORMACE PRO SEQ ID NO:619: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 299 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:619: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser 145 150 155 160 Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 165 170 175 Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro 180 185 190 Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 195 200 205 Ser Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp 210 215 220 Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr 225 230 235 240 -722- 60 5 10 15 20 25 30 35 40 45 50 55 CZ 295843 B6 Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly 245 250 255 Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr 260 265 270 Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu 275 280 285 Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro 290 295 (2) INFORMACE PRO SEQ ID NO:620: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 301 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:620: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn .Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser 145 150 155 160 Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 165 170 175 Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro 180 185 190 Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 195 200 205 Ser Gly Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser 210 215 220 Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin 225 230 235 240 Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys 245 250 255 Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu 260 265 270 Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn 275 280 285 Thr Glu Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro 290 295 300 -723- 60 CZ 295843 B6 (2) INFORMACE PRO SEQ ID NO:621: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 307 aminokyselin 5 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:621: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 20 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 25 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 30 130 135 140 Asn Met Ala Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser 145 150 155 160 Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 165 170 175 35 Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro 180 185 190 Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 195 200 205 Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe 40 210 215 220 Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu 225 230 235 240 Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu 245 250 255 45 Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 260 265 270 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly 275 280 285 Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala 50 290 295 300 Phe Gin Pro 305 (2) INFORMACE PRO SEQ ID NO:622: 55 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 296 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární -724- 60 5 CZ 295843 B6 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:622: 10 15 20 25 30 35 40 Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu 145 150 155 160 Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met 165 170 175 Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu 180 185 190 Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro 195 200 205 Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu 210 215 220 Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg 225 230 235 240 Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser 245 250 255 Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Thr Gin Asp Cys 260 265 270 Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg 275 280 285 Glu Leu Ser Asp Tyr Leu Leu Gin 290 295 (2) INFORMACE PRO SEQ ID NO:623: 45 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 301 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché 50 (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:623: 55 Ala 1 Asn Cys Ser Ile 5 Met Ile Asp Glu Ile 10 Ile His His Leu Lys 15 Arg Pro Pro Asn Pro 20 Leu Leu Asp Pro Asn 25 Asn Leu Asn Ser Glu 30 Asp Met Asp Ile Leu 35 Met Glu Arg Asn Leu 40 Arg Thr Pro Asn Leu 45 Leu Ala Phe -725 - 60 5 10 15 20 25 30 35 40 45 50 55 CZ 295843 B6 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu 145 150 155 160 Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met 165 170 175 Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu 180 185 190 Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro 195 200 205 Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu 210 215 220 Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg 225 230 235 240 Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser 245 250 255 Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly 260 265 270 Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe 275 280 285 Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin 290 295 300 (2) INFORMACE PRO SEQ ID NO:624: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 296 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:624: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn. Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 -726- 60 5 10 15 20 CZ 295843 B6 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu 145 150 155 160 Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val 165 170 175 Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile 180 185 190 His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg 195 200 205 Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin 210 215 220 Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys 225 230 235 240 Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser 245 250 255 Gly Gly Gly Ser Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro 260 265 270 Ile Ser Ser Asp Phe AI a Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu 275 280 285 Leu Gin Asp Tyr Pro Val Thr Val 290 295 (2) INFORMACE PRO SEQ ID NO:625: 25 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 301 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché 30 (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:625: 35 40 45 50 55 Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu 145 150 155 160 Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val 165 170 175 Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile 180 185 190 His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg 195 200 205 -727- 60 5 10 15 20 25 30 35 40 45 50 55 CZ 295843 B6 Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin 210 215 220 Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys 225 230 235 240 Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser 245 250 255 Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gin Asp Cys Ser 260 265 270 Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu 275 280 285 Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val 290 295 300 (2) INFORMACE PRO SEQ ID NO:626: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 296 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:626: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val 145 150 155 160 Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro 165 170 175 Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu 180 185 190 Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn 195 200 205 Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 210 215 220 Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Thr Gin Asp Cys Ser Phe 225 230 235 240 Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu 245 250 255 Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu 260 265 270 Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 275 280 285 -728- 60 5 CZ 295843 B6 Arg Trp Met Glu Arg Leu Lys Thr 290 295 (2) INFORMACE PRO SEQ ID NO:627: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 301 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché 10 (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:627: 15 20 25 30 35 40 45 50 Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val 145 150 155 160 Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro 165 170 175 Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu 180 185 190 Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn 195 200 205 Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 210 215 220 Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr 225 230 235 240 Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val 245 250 255 Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr 260 265 270 Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg 275 280 285 Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr 290 295 300 55 (2) INFORMACE PRO SEQ ID NO:628: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 296 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární -729- 60 CZ 295843 B6 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:628: 5 Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 10 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 15 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 20 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu 25 145 150 155 160 Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn 165 170 175 Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 180 185 190 30 Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Thr Gin Asp Cys Ser Phe 195 200 205 Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu 210 215 220 Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu 35 225 230 235 240 Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 245 250 255 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly 260 265 270 40 Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala 275 280 285 Phe Gin Pro Pro Pro Ser Cys Leu 290 295 45 (2) INFORMACE PRO SEQ ID NO:629: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 301 aminokyselin (B) TYP: aminokyselina 50 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 55 (xi) POPIS SEKVENCE: SEQ ID NO:629: Ala 1 Asn Cys Ser Ile 5 Met Ile Asp Glu Ile 10 Ile His His Leu Lys 15 Arg 60 Pro Pro Asn Pro 20 Leu Leu Asp Pro Asn 25 Asn Leu Asn Ser Glu 30 Asp Met -730- 5 10 15 20 25 30 35 CZ 295843 B6 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu 145 150 155 160 Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn 165 170 175 Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 180 185 190 Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr 195 200 205 Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val 210 215 220 Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr 225 230 235 240 Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg 245 250 255 Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly 260 265 270 Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe 275 280 285 Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu 290 295 300 (2) INFORMACE PRO SEQ ID NO:630: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 296 aminokyselin 40 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 45 (xi) POPIS SEKVENCE: SEQ ID NO:630: 50 55 Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 -731 - 60 5 10 15 20 25 CL 295843 B6 Tyr Val Glu Gly Gly Gly Ser Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin 145 150 155 160 Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys 165 170 175 Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser 180 185 190 Gly Gly Gly Ser Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro 195 200 205 Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu 210 215 220 Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu 225 230 235 240 Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu 245 250 255 Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg 260 265 270 Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro 275 280 285 Pro Ser Cys Leu Arg Phe Val Gin 290 295 (2) INFORMACE PRO SEQ ID NO:631: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 301 aminokyselin 30 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 35 (xi) POPIS SEKVENCE: SEQ ID NO:631: 40 45 50 55 Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin 145 150 155 160 Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys 165 170 175 Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser 180 185 190 - 732 - 60 5 10 15 CZ 295843 B6 Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gin Asp Cys Ser 195 200 205 Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu 210 215 220 Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn 225 230 235 240 Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala 245 250 255 Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin 260 265 270 Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys 275 280 285 Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin 290 295 300 (2) INFORMACE PRO SEQ ID NO:632: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 292 aminokyselin 20 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 25 (xi) POPIS SEKVENCE: SEQ ID NO:632: 30 35 40 45 50 55 Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu 145 150 155 160 Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met 165 170 175 Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu 180 185 190 Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro 195 200 205 Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu 210 215 220 Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg 225 230 235 240 Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser 245 250 255 Thr Leu Gly Gly Gly Ser Gly Gly Thr Gin Asp Cys Ser Phe Gin His 260 265 270 -733 - 60 CZ 295843 B6 Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp 275 280 285 Tyr Leu Leu Gin 290 5 (2) INFORMACE PRO SEQ ID NO:633: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 293 aminokyselin 10 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 15 (xi) POPIS SEKVENCE: SEQ ID NO:633: Ala Asn Cys Ser Ile Met Ile 1 5 20 Pro Pro Asn Pro Leu Leu Asp 20 Asp Ile Leu Met Glu Arg Asn 35 Val Arg Ala Val Lys His Leu 25 50 55 Leu Arg Asn Leu Gin Pro Cys 65 70 Arg His Pro Ile Ile Ile Lys 85 30 Lys Leu Thr Phe Tyr Leu Val 100 Tyr Val Glu Gly Gly Gly Gly 115 Ser Thr Ile Asn Pro Ser Pro 35 130 135 Asn Met Ala Asp Tyr Pro Val 145 150 Glu Leu Cys Gly Gly Leu Trp 165 40 Glu Arg Leu Lys Thr Val Ala 180 Arg Val Asn Thr Glu Ile His 195 Pro Pro Ser Cys Leu Arg Phe 45 210 215 Gin Glu Thr Ser Glu Gin Leu 225 230 Gin Asn Phe Ser Arg Cys Leu 245 50 Thr Leu Gly Gly Gly Ser Gly 260 His Ser Pro Ile Ser Ser Asp 275 Asp Tyr Leu Leu Gin 55 290 Asp Glu Ile Ile His His Leu Lys Arg 10 15 Pro Asn Asn Leu Asn Ser Glu Asp Met 25 30 Leu Arg Thr Pro Asn Leu Leu Ala Phe 40 45 Glu Asn Ala Ser Gly Ile Glu Ala Ile 60 Leu Pro Ser Ala Thr Ala Ala Pro Ser 75 80 Ala Gly Asp Trp Gin Glu Phe Arg Glu 90 95 Thr Leu Glu Gin Ala Gin Glu Gin Gin 105 110 Ser Pro Gly Glu Pro Ser Gly Pro Ile 120 125 Pro Ser Lys Glu Ser His Lys Ser Pro 140 Thr Val Ala Ser Asn Leu Gin Asp Glu 155 160 Arg Leu Val Leu Ala Gin Arg Trp Met 170 175 Gly Ser Lys Met Gin Gly Leu Leu Glu 185 190 Phe Val Thr Lys Cys Ala Phe Gin Pro 200 205 Val Gin Thr Asn Ile Ser Arg Leu Leu 220 Val Ala Leu Lys Pro Trp Ile Thr Arg 235 240 Glu Leu Gin Cys Gin Pro Asp Ser Ser 250 255 Gly Gly Thr Gin Asp Cys Ser Phe Gin 265 270 Phe Ala Val Lys Ile Arg Glu Leu Ser 280 285 (2) INFORMACE PRO SEQ ID NO:634: (i) CHARAKTERISTIKY SEKVENCE: 60 (A) DÉLKA: 299 aminokyselin (B) TYP: aminokyselina -734 - CZ 295843 B6 (C) RETEZENI: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:634: Ala Asn Cys 1 10 Pro Pro Asn Asp Ile Leu 35 Val Arg Ala 15 50 Leu Arg Asn 65 Arg His Pro 20 Lys Leu Thr Tyr Val Glu 115 Ser Thr Ile 25 130 Asn Met Ala 145 Glu Leu Cys 30 Glu Arg Leu Arg Val Asn 195 Pro Pro Ser 35 210 Gin Glu Thr 225 Gin Asn Phe 40 Thr Leu Gly Gin Asp Cys 275 Lys Ile Arg 45 290 Ser Ile 5 Met Ile Pro 20 Leu Leu Asp Met Glu Arg Asn Val Lys His Leu 55 Leu Gin Pro 70 Cys Ile Ile 85 Ile Lys Phe 100 Tyr Leu Val Gly Gly Gly Gly Asn Pro Ser Pro 135 Asp Tyr Pro 150 Val Gly Gly 165 Leu Trp Lys 180 Thr Val Ala Thr Glu Ile His Cys Leu Arg Phe 215 Ser Glu Gin 230 Leu Ser Arg 245 Cys Leu Gly 260 Gly Ser Gly Ser Phe Gin His Glu Leu Ser Asp 295 Asp Glu Ile 10 Ile His Pro Asn 25 Asn Leu Asn Leu 40 Arg Thr Pro Asn Glu Asn Ala Ser Gly 60 Leu Pro Ser Ala 75 Thr Ala Gly Asp 90 Trp Gin Thr Leu 105 Glu Gin Ala Ser 120 Pro Gly Glu Pro Pro Ser Lys Glu Ser 140 Thr Val Ala Ser 155 Asn Arg Leu Val 170 Leu Ala Gly Ser 185 Lys Met Gin Phe 200 Val Thr Lys Cys Val Gin Thr Asn Ile 220 Val Ala Leu Lys 235 Pro Glu Leu Gin 250 Cys Gin Gly Gly 265 Ser Gly Gly Ser 280 Pro Ile Ser Ser Tyr Leu Leu Gin His Leu Lys 15 Arg Ser Glu 30 Asp Met Leu 45 Leu Ala Phe Ile Glu Ala Ile Ala Ala Pro Ser 80 Glu Phe Arg 95 Glu Gin Glu 110 Gin Gin Ser 125 Gly Pro Ile His Lys Ser Pro Leu Gin Asp Glu 160 Gin Arg Trp 175 Met Gly Leu 190 Leu Glu Ala 205 Phe Gin Pro Ser Arg Leu Leu Trp Ile Thr Arg 240 Pro Asp Ser 255 Ser Gly Ser 270 Gly Thr Asp 285 Phe Ala Val (2) INFORMACE PRO SEQ ID NO:635: (i) CHARAKTERISTIKY SEKVENCE: 50 (A) DÉLKA: 307 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 55 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:635: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 60 1 5 10 15 -735- CZ 295843 B6 Pro Pro Asn Pro 20 Leu Leu Asp Asp Ile Leu 35 Met Glu Arg Asn 5 Val Arg 50 Ala Val Lys His Leu 55 Leu 65 Arg Asn Leu Gin Pro 70 Cys 10 Arg His Pro Ile Ile 85 Ile Lys Lys Leu Thr Phe 100 Tyr Leu Val Tyr Val Glu 115 Gly Gly Gly Gly 15 Ser Thr 130 Ile Asn Pro Ser Pro 135 Asn 145 Met Ala Val Ala Gly 150 Ser 20 Asn Thr Glu Ile His 165 Phe Val Ser Cys Leu Arg 180 Phe Val Gin Thr Ser Glu 195 Gin Leu Val Ala 25 Phe Ser 210 Arg Cys Leu Glu Leu 215 Gly 225 Gly Gly Ser Gly Gly 230 Gly 30 Gly Gly Gly Ser Gly 245 Thr Gin Ser Ser Asp Phe 260 Ala Val Lys Gin Asp Tyr 275 Pro Val Thr Val 35 Cys Leu 305 Gly 290 Lys Gly Thr Leu Trp Arg Leu 295 Pro Asn Asn Leu Asn Ser Glu Asp Met 25 30 Leu Arg Thr Pro Asn Leu Leu Ala Phe 40 45 Glu Asn Ala Ser Gly Ile Glu Ala Ile 60 Leu Pro Ser Ala Thr Ala Ala Pro Ser 75 80 Ala Gly Asp Trp Gin Glu Phe Arg Glu 90 95 Thr Leu Glu Gin Ala Gin Glu Gin Gin 105 110 Ser Pro Gly Glu Pro Ser Gly Pro Ile 120 125 Pro Ser Lys Glu Ser His Lys Ser Pro 140 Lys Met Gin Gly Leu Leu Glu Arg Val 155 160 Thr Lys Cys Ala Phe Gin Pro Pro Pro 170 175 Thr Asn Ile Ser Arg Leu Leu Gin Glu 185 190 Leu Lys Pro Trp Ile Thr Arg Gin Asn 200 205 Gin Cys Gin Pro Asp Ser Ser Thr Leu 220 Ser Gly Gly Gly Ser Gly Gly Gly Ser 235 240 Asp Cys Ser Phe Gin His Ser Pro Ile 250 255 Ile Arg Glu Leu Ser Asp Tyr Leu Leu 265 270 Ala Ser Asn Leu Gin Asp Glu Glu Leu 280 285 Val Leu Ala Gin Arg Trp Met Glu Arg 300 40 (2) INFORMACE PRO SEQ ID NO:636: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 292 aminokyselin (B) TYP: aminokyselina 45 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 50 (xi) POPIS SEKVENCE: SEQ ID NO:636: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 -736- 5CZ 295843 B6 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu 145 150 155 160 Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val 165 170 175 Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile 180 185 190 His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg 195 200 205 Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin 210 215 220 Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys 225 230 235 240 Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser 245 250 255 Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp 260 265 270 Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr 275 280 285 Pro Val Thr Val 290 10 15 20 25 30 (2) INFORMACE PRO SEQ ID NO:637: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 293 aminokyselin (B) TYP: aminokyselina 35 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 40 (xi) POPIS SEKVENCE: SEQ ID NO:637: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 ' 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu 145 150 155 160 -737- CZ 295843 B6 Trp Arg Leu Val Leu Ala Gin Arg 165 Ala Gly Ser Lys Met Gin Gly Leu 180 His Phe Val Thr Lys Cys Ala Phe 195 200 Phe Val Gin Thr Asn Ile Ser Arg 210 215 Leu Val Ala Leu Lys Pro Trp Ile 225 230 Leu Glu Leu Gin Cys Gin Pro Asp 245 Gly Gly Gly Thr Gin Asp Cys Ser 260 Asp Phe Ala Val Lys Ile Arg Glu 275 280 Tyr Pro Val Thr Val 290 Trp Met 170 Glu Arg Leu Lys Thr 175 Val Leu 185 Glu Arg Val Asn Thr 190 Glu Ile Gin Pro Pro Pro Ser 205 Cys Leu Arg Leu Leu Gin Glu 220 Thr Ser Glu Gin Thr Arg Gin 235 Asn Phe Ser Arg Cys 240 Ser Ser 250 Thr Leu Gly Gly Gly 255 Ser Phe 265 Gin His Ser Pro Ile 270 Ser Ser Leu Ser Asp Tyr Leu 285 Leu Gin Asp 20 (2) INFORMACE PRO SEQ ID NO:638: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 299 aminokyselin (B) TYP: aminokyselina 25 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 30 (xi) POPIS SEKVENCE: SEQ ID NO:638: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro •Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu 145 150 155 160 Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val 165 170 175 Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile 180 185 190 His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg 195 200 205 Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin 210 215 220 Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys 225 230 235 240 -738 - 5 10 15 20 25 30 35 40 45 50 55 CZ 295843 B6 Leu. Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser 245 250 255 Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe Gin 260 265 270 His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser 275 280 285 Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val 290 295 (2) INFORMACE PRO SEQ ID NO:639: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 307 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:639: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu 145 150 155 160 Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val 165 170 175 Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile 180 185 190 His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg 195 200 205 Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin 210 215 220 Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys 225 230 235 240 Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser 245 250 255 Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser 260 265 270 Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe 275 280 285 Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro 290 295 300 Val Thr Val -739- 305 60 CZ 295843 B6 (2) INFORMACE PRO SEQ ID NO:640: (i) CHARAKTERISTIKY SEKVENCE: 5 (A) DÉLKA: 292 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 10 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:640: Ala Asn Cys Ser Ile Met Ile 15 1 5 Pro Pro Asn Pro Leu Leu Asp 20 Asp Ile Leu Met Glu Arg Asn 35 20 Val Arg Ala Val Lys His Leu 50 55 Leu Arg Asn Leu Gin Pro Cys 65 70 Arg His Pro Ile Ile Ile Lys 25 85 Lys Leu Thr Phe Tyr Leu Val 100 Tyr Val Glu Gly Gly Gly Gly 115 30 Ser Thr Ile Asn Pro Ser Pro 130 135 Asn Met Ala Val Ala Gly Ser 145 150 Asn Thr Glu Ile His Phe Val 35 165 Ser Cys Leu Arg Phe Val Gin 180 Thr Ser Glu Gin Leu Val Ala 195 40 Phe Ser Arg Cys Leu Glu Leu 210 215 Gly Gly Gly Ser Gly Gly Thr 225 230 Ile Ser Ser Asp Phe Ala Val 45 245 Leu Gin Asp Tyr Pro Val Thr 260 Leu Cys Gly Gly Leu Trp Arg 275 50 Arg Leu Lys Thr 290 Asp Glu Ile Ile His His Leu Lys Arg 10 15 Pro Asn Asn Leu Asn Ser Glu Asp Met 25 30 Leu Arg Thr Pro Asn Leu Leu Ala Phe 40 45 Glu Asn Ala Ser Gly Ile Glu Ala Ile 60 Leu Pro Ser Ala Thr Ala Ala Pro Ser 75 80 Ala Gly Asp Trp Gin Glu Phe Arg Glu 90 95 Thr Leu Glu Gin Ala Gin Glu Gin Gin 105 110 Ser Pro Gly Glu Pro Ser Gly Pro Ile 120 125 Pro Ser Lys Glu Ser His Lys Ser Pro 140 Lys Met Gin Gly Leu Leu Glu Arg Val 155 160 Thr Lys Cys Ala Phe Gin Pro Pro Pro 170 175 Thr Asn Ile Ser Arg Leu Leu Gin Glu 185 190 Leu Lys Pro Trp Ile Thr Arg Gin Asn 200 205 Gin Cys Gin Pro Asp Ser Ser Thr Leu 220 Gin Asp Cys Ser Phe Gin His Ser Pro 235 240 Lys Ile Arg Glu Leu Ser Asp Tyr Leu 250 255 Val Ala Ser Asn Leu Gin Asp Glu Glu 265 270 Leu Val Leu Ala Gin Arg Trp Met Glu 280 285 (2) INFORMACE PRO SEQ ID NO:641: 55 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 293 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný -740- 60 5 10 15 20 25 30 35 40 CZ 295843 B6 (xi) POPIS SEKVENCE: SEQ ID NO:641: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val 145 150 155 160 Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro 165 170 175 Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu 180 185 190 Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn 195 200 205 Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 210 215 220 Gly Gly Gly Ser Gly Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser 225 230 235 240 Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr 245 250 255 Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu 260 265 270 Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met 275 280 285 Glu Arg Leu Lys Thr 290 (2) INFORMACE PRO SEQ ID NO:642: 45 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 299 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 50 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:642: 55 Ala 1 Asn Cys Ser Ile 5 Met Ile Asp Glu Ile 10 Ile His His Leu Lys 15 Arg Pro Pro Asn Pro 20 Leu Leu Asp Pro Asn 25 Asn Leu Asn Ser Glu 30 Asp Met Asp Ile Leu 35 Met Glu Arg Asn Leu 40 Arg Thr Pro Asn Leu 45 Leu Ala Phe -741 - 60 CZ 295843 B6 Val Arg Ala Val Lys His Leu Glu Asn <—1 Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val 145 150 155 160 Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro 165 170 175 Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu 180 185 190 Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn 195 200 205 Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 210 215 220 Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp 225 230 235 240 Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile 245 250 255 Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala 260 265 270 Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val 275 280 285 Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr 290 295 (2) INFORMACE PRO SEQ ID NO:643: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 307 aminokyselin (B) TYP: : aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:643: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu m Gly Gly Gly Gly Ser 1 on Pro Gly Glu Pro Ser 1 0 R Gly Pro Ile -742- 5 10 15 20 25 CZ 295843 B6 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val 145 150 155 160 Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro 165 170 175 Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu 180 185 190 Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn 195 200 205 Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 210 215 220 Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser 225 230 235 240 Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile 245 250 255 Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu 260 265 270 Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu 275 280 285 Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg 290 295 300 Leu Lys Thr 305 (2) INFORMACE PRO SEQ ID NO:644: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 292 aminokyselin 30 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 35 (xi) POPIS SEKVENCE: SEQ ID NO:644: 40 45 50 55 Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu 145 150 155 160 Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn 165 170 175 Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 180 185 190 -743- 60 5 10 15 CZ 295843 B6 Gly Gly Gly Ser Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro 195 200 205 Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu 210 215 220 Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu 225 230 235 240 Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu 245 250 255 Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg 260 265 270 Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro 275 280 285 Pro Ser Cys Leu 290 (2) INFORMACE PRO SEQ ID NO:645: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 293 aminokyselin 20 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 25 (xi) POPIS SEKVENCE: SEQ ID NO:645: 30 35 40 45 50 55 Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu 145 150 155 160 Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn 165 170 175 Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 180 185 190 Gly Gly Gly Ser Gly Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser 195 200 205 Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr 210 215 220 Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu 225 230 235 240 Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met 245 250 255 Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu 260 265 270 -744- 60 5 CZ 295843 B6 Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro 275 280 285 Pro Pro Ser Cys Leu 290 (2) INFORMACE PRO SEQ ID NO:646: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 299 aminokyselin 10 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:646: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 20 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 25 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 30 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 35 130 135 140 Asn Met Ala Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu 145 150 155 160 Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn 165 170 175 40 Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 180 185 190 Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp 195 200 205 Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile 45 210 215 220 Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala 225 230 235 240 Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val 245 250 255 50 Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys 260 265 270 Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr 275 280 285 Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu 55 2 9 0 2 9 5 (2) INFORMACE PRO SEQ ID NO:647: (i) CHARAKTERISTIKY SEKVENCE: 60 (A) DÉLKA: 307 aminokyselin (B) TYP: aminokyselina -745- CZ 295843 B6 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:647: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu 145 150 155 160 Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn 165 170 175 Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 180 185 190 Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser 195 200 205 Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile 210 215 220 Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu 225 230 235 240 Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu 245 250 255 Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg 260 265 270 Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val 275 280 285 Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro 290 295 300 Ser Cys Leu 305 (2) INFORMACE PRO SEQ ID NO:648: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 292 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:648: -746- CZ 295843 B6 Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 5 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 10 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 15 Tyr Val Glu Gly Gly Gly Ser Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin 20 145 150 155 160 Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys 165 170 175 Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser 180 185 190 25 Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp 195 200 205 Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr 210 215 220 Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly 30 225 230 235 240 Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr 245 250 255 Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu 260 265 270 35 Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu 275 280 285 Arg Phe Val Gin 290 40 (2) INFORMACE PRO SEQ ID NO:649: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 293 aminokyselin (B) TYP: aminokyselina 45 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 50 (xi) POPIS SEKVENCE: SEQ ID NO:649: Ala 1 Asn Cys Ser Ile 5 Met Ile Asp Glu Ile 10 Ile His His Leu Lys 15 Arg Pro Pro Asn Pro 20 Leu Leu Asp Pro Asn 25 Asn Leu Asn Ser Glu 30 Asp Met Asp Ile Leu 35 Met Glu Arg Asn Leu 40 Arg Thr Pro Asn Leu 45 Leu Ala Phe Val Arg 50 Ala Val Lys His Leu 55 Glu Asn Ala Ser Gly 60 Ile Glu Ala Ile Leu 65 Arg Asn Leu Gin Pro 70 Cys Leu Pro Ser Ala 75 Thr Ala Ala Pro Ser 80 -747- CZ 295843 B6 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Ser Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin 145 150 155 160 Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys 165 170 175 Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser 180 185 190 Gly Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser 195 200 205 Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp 210 215 220 Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly 225 230 235 240 Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys 245 250 255 Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr 260 265 270 Glu Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys 275 280 285 Leu Arg Phe Val Gin 290 (2) INFORMACE PRO SEQ ID NO:650: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 299 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:650: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Ser Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin 145 150 155 160 -748- 5 10 15 20 25 30 35 40 45 50 55 CZ 295843 B6 Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys 165 170 175 Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser 180 185 190 Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe Gin 195 200 205 His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser 210 215 220 Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin 225 230 235 240 Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg 245 250 255 Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu 260 265 270 Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala Phe 275 280 285 Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin 290 295 (2) INFORMACE PRO SEQ ID NO:651: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 307 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:651: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin 145 150 155 160 Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys 165 170 175 Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser 180 185 190 Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser 195 200 205 Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe 210 215 220 Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro 225 230 235 240 -749- 60 CZ 295843 B6 Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu 245 250 255 Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val 260 265 270 Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile 275 280 285 His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg 290 295 300 Phe Val Gin 305 (2) INFORMACE PRO SEQ ID NO:652: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 749 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:652: Gly Ser Thr Met Ser Arg Leu Pro Val Leu Leu Leu Leu Gin Leu Leu 1 5 10 15 Val Arg Pro Ala Met Ser Thr Asn Gin Asp Leu Pro Val Ile Lys Cys 20 25 30 Val Leu Ile Asn His Lys Asn Asn Asp Ser Ser Val Gly Lys Ser Ser 35 40 45 Ser Tyr Pro Met Val Ser Glu Ser Pro Glu Asp Leu Gly Cys Ala Leu 50 55 60 Arg Pro Gin Ser Ser Gly Thr Val Tyr Glu Ala Ala Ala Val Glu Val 65 70 75 80 Asp Val Ser Ala Ser Ile Thr Leu Gin Val Leu Val Asp Ala Pro Gly 85 90 95 Asn Ile Ser Cys Leu Trp Val Phe Lys His Ser Ser Leu Asn Cys Gin 100 105 110 Pro His Phe Asp Leu Gin Asn Arg Gly Val Val Ser Met Val Ile Leu 115 120 125 Lys Met Thr Glu Thr Gin Ala Gly Glu Tyr Leu Leu Phe Ile Gin Ser 130 135 140 Glu Ala Thr Asn Tyr Thr Ile Leu Phe Thr Val Ser Ile Arg Asn Thr 145 150 155 160 Leu Leu Tyr Thr Leu Arg Arg Pro Tyr Phe Arg Lys Met Glu Asn Gin 165 170 175 Asp Ala Leu Val Cys Ile Ser Glu Ser Val Pro Glu Pro Ile Val Glu 180 185 190 Trp Val Leu Cys Asp Ser Gin Gly Glu Ser Cys Lys Glu Glu Ser Pro 195 200 205 Ala Val Val Lys Lys Glu Glu Lys Val Leu His Glu Leu Phe Gly Met 210 215 220 Asp Ile Arg Cys Cys Ala Arg Asn Glu Leu Gly Arg Glu Cys Thr Arg 225 230 235 240 Leu Phe Thr Ile Asp Leu Asn Gin Thr Pro Gin Thr Thr Leu Pro Gin 245 250 255 Leu Phe Leu Lys Val Gly Glu Pro Leu Trp Ile Arg Cys Lys Ala Val 260 265 270 His Val Asn His Gly Phe Gly Leu Thr Trp Glu Leu Glu Asn Lys Ala 275 280 285 Leu Glu Glu Gly Asn Tyr Phe Glu Met Ser Thr Tyr Ser Thr Asn Arg 290 295 300 -750- CZ 295843 B6 Thr Met Ile Arg Ile Leu Phe Ala Phe Val Ser Ser Val Ala Arg Asn 305 310 315 320 Asp Thr Gly Tyr Tyr Thr Cys Ser Ser Ser Lys His Pro Ser Gin Ser 325 330 335 Ala Leu Val Thr Ile Val Glu Lys Gly Phe Ile Asn Ala Thr Asn Ser 340 345 350 Ser Glu Asp Tyr Glu Ile Asp Gin Tyr Glu Glu Phe Cys Phe Ser Val 355 360 365 Arg Phe Lys Ala Tyr Pro Gin Ile Arg Cys Thr Trp Thr Phe Ser Arg 370 375 380 Lys Ser Phe Pro Cys Glu Gin Lys Gly Leu Asp Asn Gly Tyr Ser Ile 385 390 395 400 Ser Lys Phe Cys Asn His Lys His Gin Pro Gly Glu Tyr Ile Phe His 405 410 415 Ala Glu Asn Asp Asp Ala Gin Phe Thr Lys Met Phe Thr Leu Asn Ile 420 425 430 Arg Arg Lys Pro Gin Val Leu Ala Glu Ala Ser Ala Ser Gin Ala Ser 435 440 445 Cys Phe Ser Asp Gly Tyr Pro Leu Pro Ser Trp Thr Trp Lys Lys Cys 450 455 460 Ser Asp Lys Ser Pro Asn Cys Thr Glu Glu Ile Thr Glu Gly Val Trp 465 470 475 480 Asn Arg Lys Ala Asn Arg Lys Val Phe Gly Gin Trp Val Ser Ser Ser 485 490 495 Thr Leu Asn Met Ser Glu Ala Ile Lys Gly Phe Leu Val Lys Cys Cys 500 505 510 Ala Tyr Asn Ser Leu Gly Thr Ser Cys Glu Thr Ile Leu Leu Asn Ser 515 520 525 Pro Gly Pro Phe Pro Phe Ile Gin Asp Asn Glu Phe Ile Ile Leu Gly 530 535 540 Leu Phe Gly Leu Leu Leu Leu Leu Thr Cys Leu Cys Gly Thr Ala Trp 545 550 555 560 Leu Cys Cys Ser Pro Asn Arg Lys Asn Pro Leu Trp Pro Ser Val Pro 565 570 575 Asp Pro Ala His Ser Ser Leu Gly Ser Trp Val Pro Thr Ile Met Glu 580 585 590 Glu Asp Ala Phe Gin Leu Pro Gly Leu Gly Thr Pro Pro Ile Thr Lys 595 600 605 Leu Thr Val Leu Glu Glu Asp Glu Lys Lys Pro Val Pro Trp Glu Ser 610 615 620 His Asn Ser Ser Glu Thr Cys Gly Leu Pro Thr Leu Val Gin Thr Tyr 625 630 635 640 Val Leu Gin Gly Asp Pro Arg Ala Val Ser Thr Gin Pro Gin Ser Gin 645 650 655 Ser Gly Thr Ser Asp Gin Val Leu Tyr Gly Gin Leu Leu Gly Ser Pro 660 665 670 Thr Ser Pro Gly Pro Gly His Tyr Leu Arg Cys Asp Ser Thr Gin Pro 675 680 685 Leu Leu Ala Gly Leu Thr Pro Ser Pro Lys Ser Tyr Glu Asn Leu Trp 690 695 700 Phe Gin Ala Ser Pro Leu Gly Thr Leu Val Thr Pro Ala Pro Ser Gin 705 710 715 720 Glu Asp Asp Cys Val Phe Gly Pro Leu Leu Asn Phe Pro Leu Leu Gin 725 730 735 Gly Ile Arg Val His Gly Met Glu Ala Leu Gly Ser Phe 740 745 (2) INFORMACE PRO SEQ ID NO:653: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 349 aminokyselin -751 - CZ 295843 B6 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 5 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:653: Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu 10 1 5 10 15 Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu 20 25 30 Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu 35 40 45 15 Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser 50 55 60 Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His 65 70 75 80 Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile 20 85 90 95 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala 100 105 110 Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala 115 120 125 25 Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala 130 135 140 Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser 145 150 155 160 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Tyr 30 165 170 175 Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser 180 185 190 Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn 195 200 205 35 Met Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp 210 215 220 Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr 225 230 235 240 Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly 40 245 250 255 Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr 260 265 270 Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu 275 280 285 45 Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu 290 295 300 Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu 305 310 315 320 Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg 50 325 330 335 Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 340 345 (2) INFORMACE PRO SEQ ID NO:654: 55 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 314 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché 60 (D) TOPOLOGIE: lineární -752- CZ 295843 B6 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:654: Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe 1 5 10 15 Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro 20 25 30 Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu 35 40 45 Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val 50 55 60 Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile 65 70 75 80 His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg 85 90 95 Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin 100 105 110 Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys 115 120 125 Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Tyr Val Glu Gly 130 135 140 Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn 145 150 155 160 Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr 165 170 175 Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val 180 185 190 Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr 195 200 205 Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg 210 215 220 Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly 225 230 235 240 Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe 245 250 255 Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val 260 265 270 Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val 275 280 285 Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu 290 295 300 Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 305 310 (2) INFORMACE PRO SEQ ID NO:655: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 349 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:655: Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe 15 10 15 Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro 20 25 30 -753- 5 10 15 20 25 30 35 40 CZ 295843 B6 Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu 35 40 45 Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val 50 55 60 Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile 65 70 75 80 His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg 85 90 95 Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin 100 105 110 Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys 115 120 125 Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Tyr Val Glu Gly 130 135 140 Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn 145 150 155 160 Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr 165 170 175 Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Cys 180 185 190 Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu 195 200 205 Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu 210 215 220 Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro 225 230 235 240 Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly 245 250 255 Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro 260 265 270 Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe 275 280 285 Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala 290 295 300 Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin 305 310 315 320 Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu 325 330 335 Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro 340 345 (2) INFORMACE PRO SEQ ID NO:656: (i) CHARAKTERIŠTIKY SEKVENCE: 45 (A) DÉLKA: 523 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 50 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:656: 55 Ala 1 Thr Pro Leu Gly 5 Pro Ala Ser Ser Leu 10 Pro Gin Ser Phe Leu 15 Leu Lys Ser Leu Glu 20 Gin Val Arg Lys Ile 25 Gin Gly Asp Gly Ala 30 Ala Leu Gin Glu Lys 35 Leu Cys Ala Thr Tyr 40 Lys Leu Cys His Pro 45 Glu Glu Leu Val Leu 50 Leu Gly His Ser Leu 55 Gly Ile Pro Trp Ala 60 Pro Leu Ser Ser -754- 60 CZ 295843 B6 Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His 65 70 75 80 Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile 85 90 95 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala 100 105 110 Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala 115 120 125 Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala 130 135 140 Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser 145 150 155 160 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Tyr 165 170 175 Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser 180 185 190 Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn 195 200 205 Met Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp 210 215 220 Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr 225 230 235 240 Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly 245 250 255 Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met. Glu Arg Leu Lys Thr 260 265 270 Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu 275 280 285 Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu 290 295 300 Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu 305 310 315 320 Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg 325 330 335 Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Tyr Val Glu 340 345 350 Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile 355 360 365 Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala 370 375 380 Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala 385 390 395 400 Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val 405 410 415 Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp 420 425 430 Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala 435 440 445 Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His 450 455 460 Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe 465 470 475 480 Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu 485 490 495 Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu 500 505 510 Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 515 520 -755 - CZ 295843 B6 (2) INFORMACE PRO SEQ ID NO:657: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 460 aminokyselin 5 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:657: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 20 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 25 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 30 130 135 140 Asn Met Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser 145 150 155 160 Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp 165 170 175 35 Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly 180 185 190 Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys 195 200 205 Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr 40 210 215 220 Glu Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys 225 230 235 240 Leu Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser 245 250 255 45 Glu Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser 260 265 270 Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Tyr Val 275 280 285 Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr 50 290 295 300 Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met 305 310 315 320 Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe 325 330 335 55 Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro 340 345 350 Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu 355 360 365 Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val 60 370 375 380 -756 - 5 10 CZ 295843 B6 Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile 385 390 395 400 His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg 405 410 415 Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin 420 425 430 Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys 435 440 445 Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 450 455 460 (2) INFORMACE PRO SEQ ID NO:658: (i) CHARAKTERISTIKY SEKVENCE: 15 (A) DÉLKA: 523 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 20 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:658: 25 30 35 40 45 50 55 Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe 1 5 10 15 Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro 20 25 30 Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu 35 40 45 Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val 50 55 60 Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile 65 70 75 80 His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg 85 90 95 Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin 100 105 110 Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys 115 120 125 Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Tyr Val Glu Gly 130 135 140 Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn 145 150 155 160 Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr 165 170 175 Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser 180 185 190 Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu 195 200 205 Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu 210 215 220 Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro 225 230 235 240 Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly 245 250 255 Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro 260 265 270 Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe 275 280 285, Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala 290 295 300 -757- 60 5 10 15 20 25 30 35 40 45 50 55 CZ 295843 B6 Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin 305 310 315 320 Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu 325 330 335 Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Tyr Val Glu 340 345 350 Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile 355 360 365 Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala 370 375 380 Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala 385 390 395 400 Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val 405 410 415 Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp 420 425 430 Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala 435 440 445 Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His 450 455 460 Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe 465 470 475 480 Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu 485 490 495 Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu 500 505 510 Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 515 520 (2) INFORMACE PRO SEQ ID NO:659: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 334 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:659: Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe 1 5 10 15 Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro 20 25 30 Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu 35 40 45 Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val 50 55 60 Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile 65 70 75 80 His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg 85 90 95 Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin 100 105 110 Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys 115 120 125 Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Tyr Val Glu Gly 130 135 140 Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala 145 150 155 160 -758- 60 5 CZ 295843 B6 10 15 20 25 30 35 40 45 50 55 Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys 165 170 175 Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin 180 185 190 Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val 195 200 205 Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys 210 215 220 Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser 225 230 235 240 Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser 245 250 255 Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp 260 265 270 Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro 275 280 285 Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe 290 295 300 Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe 305 310 315 320 Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro 325 330 (2) INFORMACE PRO SEQ ID NO:660: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 296 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:660: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu 145 150 155 160 Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met 165 170 175 Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu 180 185 190 Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro 195 200 205 -759- 60 5 10 CZ 295843 B6 Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu 210 215 220 Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg 225 230 235 240 Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser 245 250 255 Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Thr Gin Asp Cys 260 265 270 Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg 275 280 285 Glu Leu Ser Asp Tyr Leu Leu Gin 290 295 (2) INFORMACE PRO SEQ ID NO:661: 15 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 301 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché 20 (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:661: 25 30 35 40 45 50 55 Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu 145 150 155 160 Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met 165 170 175 Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu 180 185 190 Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro 195 200 205 Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu 210 215 220 Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg 225 230 235 240 Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser 245 250 255 Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly 260 265 270 Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe 275 280 285 -760- 60 CZ 295843 B6 Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin 290 295 300 (2) INFORMACE PRO SEQ ID NO:662: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 296 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:662: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu 145 150 155 160 Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val 165 170 175 Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile 180 185 190 His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg 195 200 205 Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin 210 215 220 Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys 225 230 235 240 Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser 245 250 255 Gly Gly Gly Ser Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro 260 265 270 Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu 275 280 285 Leu Gin Asp Tyr Pro Val Thr Val 290 295 (2) INFORMACE PRO SEQ ID NO:663: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 301 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární -761 - CZ 295843 B6 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:663: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu 145 150 155 160 Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val 165 170 175 Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile 180 185 190 His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg 195 200 205 Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin 210 215 220 Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys 225 230 235 240 Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser 245 250 255 Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gin Asp Cys Ser 260 265 270 Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu 275 280 285 Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val 290 295 300 (2) INFORMACE PRO SEQ ID NO:664: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 296 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:664: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 15 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 -762- 5 10 15 20 25 30 35 CZ 295843 B6 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val 145 150 155 160 Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro 165 170 175 Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu 180 185 190 Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn 195 200 205 Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 210 215 220 Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Thr Gin Asp Cys Ser Phe 225 230 235 240 Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu 245 250 255 Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu 260 265 270 Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 275 280 285 Arg Trp Met Glu Arg Leu Lys Thr 290 295 (2) INFORMACE PRO SEQ ID NO:665: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 301 aminokyselin 40 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 45 (xi) POPIS SEKVENCE: SEQ ID NO:665: 50 55 Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 -763 - 60 CZ 295843 B6 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val 145 150 155 160 Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro 165 170 175 Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu 180 185 190 Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn 195 200 205 Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 210 215 220 Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr 225 230 235 240 Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val 245 250 255 Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr 260 265 270 Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg 275 280 285 Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr 290 295 300 (2) INFORMACE PRO SEQ ID NO:666: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 296 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:666: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu 145 150 155 160 Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn 165 170 175 Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 180 185 190 -764- CZ 295843 B6 Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Thr Gin Asp Cys Ser Phe 195 200 205 Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu 210 215 220 Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu 225 230 235 240 Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 245 250 255 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly 260 265 270 Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala 275 280 285 Phe Gin Pro Pro Pro Ser Cys Leu 290 295 (2) INFORMACE PRO SEQ ID NO:667: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 301 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:667: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu 145 150 155 160 Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn 165 170 175 Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 180 185 190 Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr 195 200 205 Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val 210 215 220 Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr 225 230 235 240 Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg 245 250 255 Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly 260 265 270 -765- CZ 295843 B6 Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe 275 280 285 Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu 290 295 300 (2) INFORMACE PRO SEQ ID NO:668: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 296 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:668: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Ser Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met AI a Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin 145 150 155 160 Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys 165 170 175 Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser 180 185 190 Gly Gly Gly Ser Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro 195 200 205 Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu 210 215 220 Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu 225 230 235 240 Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu 245 250 255 Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg 260 265 270 Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro 275 280 285 Pro Ser Cys Leu Arg Phe Val Gin 290 295 (2) INFORMACE PRO SEQ ID NO:669: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 301 aminokyselin (B) TYP: aminokyselina CZ 295843 B6 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:669: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 10 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 15 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 20 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 25 130 135 140 Asn Met Ala Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin 145 150 155 160 Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys 165 170 175 30 Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser 180 185 190 Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gin Asp Cys Ser 195 200 205 Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu 35 210 215 220 Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn 225 230 235 240 Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala 245 250 255 40 Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin 260 265 270 Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys 275 280 285 Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin 45 290 295 300 (2) INFORMACE PRO SEQ ID NO:670: (i) CHARAKTERISTIKY SEKVENCE: 50 (A) DÉLKA: 307 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 55 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:670: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 60 1 5 10 15 -767- CZ 295843 B6 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 5 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 10 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 15 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Ser Asn • Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp 145 150 155 160 Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala 20 165 170 175 Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His 180 185 190 Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe 195 200 205 25 Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu 210 215 220 Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu 225 230 235 240 Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly 30 245 250 255 Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly 260 265 270 Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala 275 280 285 35 Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val 290 295 300 Thr Val Ala 305 40 (2) INFORMACE PRO SEQ ID NO:671: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 307 aminokyselin (B) TYP: aminokyselina 45 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:671: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 -768 - CZ 295843 B6 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg 145 150 155 160 Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly 165 170 175 Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe 180 185 190 Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val 195 200 205 Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val 210 215 220 Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu 225 230 235 240 Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly 245 250 255 Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr 260 265 270 Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val 275 280 285 Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr 290 295 300 Val Ala Ser 305 (2) INFORMACE PRO SEQ ID NO:672: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 307 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:672: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 -769- CZ 295843 B6 Asn 145 Met Ala Leu Gin Asp 150 Glu Val Leu Ala Gin Arg 165 Trp Met 5 Lys Met Gin Gly 180 Leu Leu Glu Thr Lys Cys 195 Ala Phe Gin Pro 10 Thr Asn 210 Ile Ser Arg Leu Leu 215 Leu 225 Lys Pro Trp Ile Thr 230 Arg Gin Cys Gin Pro Asp 245 Ser Ser 15 Ser Gly Gly Gly 260 Ser Gly Gly Asp Cys Ser 275 Phe Gin His Ser 20 Ile Ala 305 Arg 290 Ser Glu Asn Leu Ser Asp Tyr 295 25 Glu Leu Cys Gly Gly Leu Trp Arg Leu 155 160 Glu Arg Leu Lys Thr Val Ala Gly Ser 170 175 Arg Val Asn Thr Glu Ile His Phe Val 185 190 Pro Pro Ser Cys Leu Arg Phe Val Gin 200 205 Gin Glu Thr Ser Glu Gin Leu Val Ala 220 Gin Asn Phe Ser Arg Cys Leu Glu Leu 235 240 Thr Leu Gly Gly Gly Ser Gly Gly Gly 250 255 Gly Ser Gly Gly Gly Ser Gly Thr Gin 265 270 Pro Ile Ser Ser Asp Phe Ala Val Lys 280 285 Leu Leu Gin Asp Tyr Pro Val Thr Val 300 (2) INFORMACE PRO SEQ ID NO:673: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 307 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché 30 35 (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:673: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val 145 150 155 160 Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys 165 170 175 Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr 180 185 190 Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr 195 200 205 40 45 50 55 -770- 60 5 10 15 20 25 30 35 40 45 50 55 CZ 295843 B6 Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu 210 215 220 Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin 225 230 235 240 Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser 245 250 255 Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp 260 265 270 Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile 275 280 285 Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala 290 295 300 Ser Asn Leu 305 (2: ) INFORMACE ] PRO SEQ : ID NO:674: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 305 aminokyselin (B) TYP : aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY : žádný (xi) POPIS SEKVENCE: SEQ ID NO:674: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe Val Arg 35 40 45 Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg 50 55 60 Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His 65 70 75 80 Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu 85 90 95 Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val 100 105 110 Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr 115 120 125 Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met 130 135 140 Ala Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg 145 150 155 160 Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu 165 170 175 Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala Phe 180 185 190 Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser Arg 195 200 205 Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp Ile 210 215 220 Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp 225 230 235 240 Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser 245 250 255 Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe Gin 260 265 270 -771 - 60 CZ 295843 B6 His Ser Pro 275 Ile Ser Ser Asp Phe 280 Ala Val Lys Ile Arg 285 Glu Leu Ser Asp Tyr 290 Leu Leu Gin Asp Tyr 295 Pro Val Thr Val Ala 300 Ser Asn Leu Gin 5 Asp 305 (2) INFORMACE PRO SEQ ID NO:675: 10 15 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 307 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:675: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 145 150 155 160 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly 165 170 175 Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala 180 185 190 Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser 195 200 205 Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 210 215 220 Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro 225 230 235 240 Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 245 250 255 Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe 260 265 270 Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu 275 280 285 Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu 290 295 300 Gin Asp Glu 305 20 25 30 35 40 45 50 55 -772- 60 CZ 295843 B6 (2) INFORMACE PRO SEQ ID NO:676: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 307 aminokyselin 5 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:676: Ala Asn Cys Ser Ile Met Ile 1 5 15 Pro Pro Asn Pro Leu Leu Asp 20 Asp Ile Leu Met Glu Arg Asn 35 Val Arg Ala Val Lys His Leu 20 50 55 Leu Arg Asn Leu Gin Pro Cys 65 70 Arg His Pro Ile Ile Ile Lys 85 25 Lys Leu Thr Phe Tyr Leu Val 100 Tyr Val Glu Gly Gly Gly Gly 115 Ser Thr Ile Asn Pro Ser Pro 30 130 135 Asn Met Ala Leu Cys Gly Gly 145 150 Trp Met Glu Arg Leu Lys Thr 165 35 Leu Glu Arg Val Asn Thr Glu 180 Gin Pro Pro Pro Ser Cys Leu 195 Leu Leu Gin Glu Thr Ser Glu 40 210 215 Thr Arg Gin Asn Phe Ser Arg 225 230 Ser Ser Thr Leu Gly Gly Gly 245 45 Gly Gly Gly Ser Gly Gly Gly 260 His Ser Pro Ile Ser Ser Asp 275 Asp Tyr Leu Leu Gin Asp Tyr 50 290 295 Asp Glu Glu 305 Asp Glu Ile 10 Ile His His Leu Lys 15 Arg Pro Asn 25 Asn Leu Asn Ser Glu 30 Asp Met Leu 40 Arg Thr Pro Asn Leu 45 Leu Ala Phe Glu Asn Ala Ser Gly 60 Ile Glu Ala Ile Leu Pro Ser Ala 75 Thr Ala Ala Pro Ser 80 Ala Gly Asp 90 Trp Gin Glu Phe Arg 95 Glu Thr Leu 105 Glu Gin Ala Gin Glu 110 Gin Gin Ser 120 Pro Gly Glu Pro Ser 125 Gly Pro Ile Pro Ser Lys Glu Ser 140 His Lys Ser Pro Leu Trp Arg Leu 155 Val Leu Ala Gin Arg 160 Val Ala Gly 170 Ser Lys Met Gin Gly 175 Leu Ile His 185 Phe Val Thr Lys Cys 190 Ala Phe Arg 200 Phe Val Gin Thr Asn 205 Ile Ser Arg Gin Leu Val Ala Leu 220 Lys Pro Trp Ile Cys Leu Glu Leu 235 Gin Cys Gin Pro Asp 240 Ser Gly Gly Gly 250 Ser Gly Gly Gly 255 Ser Ser Gly 265 Thr Gin Asp Cys Ser 270 Phe Gin Phe 280 Ala Val Lys Ile Arg 285 Glu Leu Ser Pro Val Thr Val Ala 300 Ser Asn Leu Gin (2) INFORMACE PRO SEQ ID NO:677: 55 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 307 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární -773- 60 CZ 295843 B6 ID NO:677: Glu Ile Ile His His Leu Lys Arg 10 15 Asn Asn Leu Asn Ser Glu Asp Met 25 30 Arg Thr Pro Asn Leu Leu Ala Phe 45 Asn Ala Ser Gly Ile Glu Ala Ile 60 Pro Ser Ala Thr Ala Ala Pro Ser 75 80 Gly Asp Trp Gin Glu Phe Arg Glu 90 95 Leu Glu Gin Ala Gin Glu Gin Gin 105 110 Pro Gly Glu Pro Ser Gly Pro Ile 125 Ser Lys Glu Ser His Lys Ser Pro 140 Glu Glu Leu Cys Gly Gly Leu Trp 155 160 Met Glu Arg Leu Lys Thr Val Ala 170 175 Glu Arg Val Asn Thr Glu Ile His 185 190 Pro Pro Pro Ser Cys Leu Arg Phe 205 Leu Gin Glu Thr Ser Glu Gin Leu 220 Arg Gin Asn Phe Ser Arg Cys Leu 235 240 Ser Thr Leu Gly Gly Gly Ser Gly 250 255 Gly Gly Ser Gly Gly Gly Ser Gly 265 270 Ser Pro Ile Ser Ser Asp Ser Ala 285 Tyr Leu Leu Gin Asp Tyr Pro Val 300 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ 5 Ala Asn Cys Ser Ile Met Ile Asp 1 5 Pro Pro Asn Pro Leu Leu Asp Pro 20 Asp Ile Leu Met Glu Arg Asn Leu 10 35 40 Val Arg Ala Val Lys His Leu Glu 50 55 Leu Arg Asn Leu Gin Pro Cys Leu 65 70 15 Arg His Pro Ile Ile Ile Lys Ala 85 Lys Leu Thr Phe Tyr Leu Val Thr 100 Tyr Val Glu Gly Gly Gly Gly Ser 20 115 120 Ser Thr Ile Asn Pro Ser Pro Pro 130 135 Asn Met Ala Ser Asn Leu Gin Asp 145 150 25 Arg Leu Val Leu Ala Gin Arg Trp 165 Gly Ser Lys Met Gin Gly Leu Leu 180 Phe Val Thr Lys Cys Ala Phe Gin 30 195 200 Val Gin Thr Asn Ile Ser Arg Leu 210 215 Val Ala Leu Lys Pro Trp Ile Thr 225 230 35 Glu Leu Gin Cys Gin Pro Asp Ser 245 Gly Gly Ser Gly Gly Gly Ser Gly 260 Thr Gin Asp Cys Ser Phe Gin His 40 275 280 Val Lys Ile Arg Glu Leu Ser Asp 290 295 Thr Val Ala 305 45 (2) INFORMACE PRO SEQ ID NO:678: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 307 aminokyselin 50 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 55 (xi) POPIS SEKVENCE: SEQ ID NO:678: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 15 10 15 60 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 -774- CZ 295843 B6 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val 145 150 155 160 Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys 165 170 175 Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr 180 185 190 Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr 195 200 205 Asn Ile Ser Arg Leu Leu Arg Glu Thr Ser Glu Gin Pro Val Ala Leu 210 215 220 Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin 225 230 235 240 Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser 245 250 255 Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp 260 265 270 cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile 275 280 285 Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala 290 295 300 Ser Asn Leu 305 (2) INFORMACE PRO SEQ ID NO:679: 40 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 307 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 45 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:679: 50 55 Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 -775- 60 CZ 295843 B6 Lys Leu Thr Phe Tyr Leu Val Thr 100 Tyr Val Glu Gly Gly Gly Gly Ser 115 120 Ser Thr Ile Asn Pro Ser Pro Pro 130 135 Asn Met Ala Leu Cys Gly Gly Leu 145 150 Trp Met Glu Arg Leu Lys Thr Val 165 Leu Glu Arg Val Asn Thr Glu Ile 180 Gin Pro Pro Pro Ser Cys Leu Arg 195 200 Leu Leu Gin Glu Thr Ser Glu Gin 210 215 Thr Arg Gin Asn Phe Ser Arg Cys 225 230 Ser Ser Thr Leu Gly Gly Gly Ser 245 Gly Gly Gly Ser Gly Gly Gly Ser 260 His Ser Pro Ile Ser Ser Asp Phe 275 280 Asp Tyr Leu Leu Gin Asp Tyr Pro 290 295 Asp Glu Glu 305 Leu 105 Glu Gin Ala Gin Glu 110 Gin Gin Pro Gly Glu Pro Ser 125 Gly Pro Ile Ser Lys Glu Ser 140 His Lys Ser Pro Trp Arg Leu 155 Val Leu Ala Gin Arg 160 Ala Gly 170 Ser Lys Met Gin Gly 175 Leu His 185 Phe Val Thr Lys Cys 190 Ala Phe Phe Val Gin Thr Asn 205 Ile Ser Arg Leu Val Ala Leu 220 Lys Pro Trp Ile Leu Glu Leu 235 Gin Cys Arg Pro Asp 240 Gly Gly 250 Gly Ser Gly Gly Gly 255 Ser Gly 265 Thr Gin Asp Cys Ser 270 Phe Gin Ala Val Lys Ile Arg 285 Glu Leu Ser Val Thr Val Ala 300 Ser Asn Leu Gin (2) INFORMACE PRO SEQ ID NO:680: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 302 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:680: Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly 20 25 30 Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser 50 55 60 Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80 Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro 85 90 95 Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 100 105 110 Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe 115 120 125 Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu 130 135 140 Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Tyr Val Glu Gly 145 150 155 160 -776- 5 10 15 20 25 30 35 40 45 50 55 CZ 295843 B6 Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn 165 170 175 Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Asn 180 185 190 Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro 195 200 205 Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met Asp Ile 210 215 220 Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe Val Arg 225 230 235 240 Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg 245 250 255 Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His 260 265 270 Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu 275 280 285 Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 290 295 300 (2) INFORMACE PRO SEQ ID NO:681: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 296 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:681: Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly 20 25 30 Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser 50 55 60 Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Arg Pro Trp 65 70 75 80 Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro 85 90 95 Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Thr 100 105 110 Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val 115 120 125 Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr 130 135 140 Val Ala Ser Asn Leu Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly 145 150 155 160 Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys 165 170 175 Glu Ser His Lys Ser Pro Asn Met Ala Asn Cys Ser Ile Met Ile Asp 180 185 190 Glu Ile Ile His His Leu Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro 195 200 205 Asn Asn Leu Asn Ser Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu 210 215 220 Arg Thr Pro Asn Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu 225 230 235 240 -777- 60 5 10 15 20 25 30 35 40 45 50 55 CZ 295843 B6 Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu 245 250 255 Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala 260 265 270 Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr 275 280 285 Leu Glu Gin Ala Gin Glu Gin Gin 290 295 (2) INFORMACE PRO SEQ ID NO:682: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 301 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:682: Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly 20 25 30 Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser 50 55 60 Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80 Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro 85 90 95 Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 100 105 110 Ser Gly Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser 115 120 125 Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin 130 135 140 Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Tyr Val Glu Gly Gly 145 150 155 160 Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro 165 170 175 Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Asn Cys 180 185 190 Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Asn 195 200 205 Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met Asp Ile Leu 210 215 220 Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe Val Arg Ala 225 230 235 240 Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn 245 250 255 Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro 260 265 270 Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr 275 280 285 Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 290 295 300 -778- 60 CZ 295843 B6 (2) INFORMACE PRO SEQ ID NO:683: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 307 aminokyselin 5 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 10 (xi) POPIS SEKVENCE: SEQ ID NO:683: Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 1 5 10 15 15 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly 20 25 30 Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser 20 50 55 60 Arg’ Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80 Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro 85 90 95 25 Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 100 105 110 Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe 115 120 125 Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu 30 130 135 140 Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu 145 150 155 160 Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 165 170 175 35 Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 180 185 190 Pro Asn Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His 195 200 205 Leu Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser 40 210 215 220 Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu 225 230 235 240 Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile 245 250 255 45 Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala 260 265 270 Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu 275 280 285 Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin 50 290 295 300 Glu Gin Gin 305 (2) INFORMACE PRO SEQ ID NO:684: 55 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 301 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární -779- 60 5 CZ 295843 B6 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:684: 10 15 20 25 30 35 40 Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly 20 25 30 Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gin Pro Pro Pro Ser Cys Leu Arg Leu Val Gin Thr Asn Ile Ser 50 55 60 Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80 Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro 85 90 95 Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 100 105 110 Ser Gly Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser 115 120 125 Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin 130 135 140 Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Tyr Val Glu Gly Gly 145 150 155 160 Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro 165 170 175 Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Asn Cys 180 185 190 Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Asn 195 200 205 Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met Asp Ile Leu 210 215 220 Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe Val Arg Ala 225 230 235 240 Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn 245 250 255 Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro 260 265 270 Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr 275 280 285 Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 290 295 300 (2) INFORMACE PRO SEQ ID NO:685: 45 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 307 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché 50 (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:685: 55 Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 15 10 15 Arg Trp Met Gly Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly 20 25 30 Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala 35 40 45 -780- 60 5 10 15 20 25 30 35 CZ 295843 B6 Phe Gin Pro Pro Pro Ser Cys Leu Arg CL) x: CU Val Gin Thr Asn Ile Ser 50 55 60 Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80 Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro 85 90 95 Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 100 105 110 Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe 115 120 125 Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu 130 135 140 Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu 145 150 155 160 Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 165 170 175 Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 180 185 190 Pro Asn Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His 195 200 205 Leu Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser 210 215 220 Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu 225 230 235 240 Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile 245 250 255 Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala 260 265 270 Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu 275 280 285 Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin 290 295 300 Glu Gin Gin 305 (2) INFORMACE PRO SEQ ID NO:686: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 302 aminokyselin 40 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 45 (xi) POPIS SEKVENCE: SEQ ID NO:686: 50 55 Met Ala Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu 1 5 10 15 Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu 20 25 30 Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg 35 40 45 Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro 50 55 60 Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin 65 70 75 80 Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin 85 90 95 Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr 100 105 110 -781 - 60 CZ 295843 B6 Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 115 120 125 Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala 130 135 140 Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Tyr Val Glu Gly 145 150 155 160 Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn 165 170 175 Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Asn 180 185 190 Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro 195 200 205 Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met Asp Ile 210 215 220 Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe Val Arg 225 230 235 240 Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg 245 250 255 Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His 260 265 270 Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu 275 280 285 Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 290 295 300 (2) INFORMACE PRO SEQ ID NO:687: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 301 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:687: Ala Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg 1 5 10 15 Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly 20 25 30 Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe 35 40 45 Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val 50 55 60 Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val 65 70 75 80 Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu 85 90 95 Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly 100 105 110 Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gin Asp Cys Ser Phe Gin 115 120 125 His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser 130 135 140 Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Tyr Val Glu Gly Gly 145 150 155 160 Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro 165 170 175 Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Asn Cys 180 185 190 -782- 5 10 15 CZ 295843 B6 Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Asn 195 200 205 Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met Asp Ile Leu 210 215 220 Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe Val Arg Ala 225 230 235 240 Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn 245 250 255 Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro 260 265 270 Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr 275 280 285 Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 290 295 300 (2) INFORMACE PRO SEQ ID NO:688: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 301 aminokyselin 20 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 25 (xi) POPIS SEKVENCE: SEQ ID NO:688: 30 35 40 45 50 55 Ala Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr 1 5 10 15 Glu Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys 20 25 30 Leu Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser 35 40 45 Glu Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser 50 55 60 Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly 65 70 75 80 Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gin Asp 85 90 95 Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile 100 105 110 Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala 115 120 125 Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val 130 135 140 Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Tyr Val Glu Gly Gly 145 150 155 160 Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro 165 170 175 Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Asn Cys 180 185 190 Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Asn 195 200 205 Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met Asp Ile Leu 210 215 220 Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe Val Arg Ala 225 230 235 240 Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn 245 250 255 Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro 260 265 270 -783 - 60 5 CZ 295843 B6 Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr 275 280 285 Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 290 295 300 (2) INFORMACE PRO SEQ ID NO:689: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 301 aminokyselin 10 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 15 (xi) POPIS SEKVENCE: SEQ ID NO:689: 20 25 30 35 40 45 50 55 Ala Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His 1 5 10 15 Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe 20 25 30 Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu 35 40 45 Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu 50 55 60 Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly 65 70 75 80 Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gin Asp Cys Ser Phe 85 90 95 Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu 100 105 110 Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu 115 120 125 Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 130 135 140 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Tyr Val Glu Gly Gly 145 150 155 160 Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro 165 170 175 Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Asn Cys 180 185 190 Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Asn 195 200 205 Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met Asp Ile Leu 210 215 220 Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe Val Arg Ala 225 230 235 240 Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn 245 250 255 Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro 260 265 270 Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr 275 280 285 Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 290 295 300 (2) INFORMACE PRO SEQ ID NO:690: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 301 aminokyselin (B) TYP: aminokyselina -784- 60 CZ 295843 B6 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:690: Ala Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser Arg Leu 1 5 10 15 Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp Ile Thr 20 25 30 Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser 35 40 45 Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly 50 55 60 Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp 65 70 75 80 Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr 85 90 95 Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly 100 105 110 Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr 115 120 125 i—1 > Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu 130 135 140 Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro Tyr Val Glu Gly Gly 145 150 155 160 Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro 165 170 175 Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Asn Cys 180 185 190 Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Asn 195 200 205 Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met Asp Ile Leu 210 215 220 Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe Val Arg Ala 225 230 235 240 Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn 245 250 255 Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro 260 265 270 Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr 275 280 285 Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 290 295 300 (2) INFORMACE PRO SEQ ID NO:691: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 301 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:691: Ala Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val 15 10 15 -785 - CZ 295843 B6 Ala Leu Lys Pro 20 Trp Ile Thr Leu Gin Cys 35 Gin Pro Asp Ser 5 Gly Ser 50 Gly Gly Gly Ser Gly 55 His 65 Ser Pro Ile Ser Ser 70 Asp 10 Asp Tyr Leu Leu Gin 85 Asp Tyr Asp Glu Glu Leu 100 Cys Gly Gly Trp Met Glu 115 Arg Leu Lys Thr 15 Leu Glu 130 Arg Val Asn Thr Glu 135 Gin 145 Pro Pro Pro Ser Cys 150 Leu 20 Gly Gly Ser Pro Gly 165 Glu Pro Ser Pro Pro Ser 180 Lys Glu Ser Ser Ile Met 195 Ile Asp Glu Ile 25 Pro Leu 210 Leu Asp Pro Asn Asn 215 Met 225 Glu Arg Asn Leu Arg 230 Thr 30 Val Lys His Leu Glu 245 Asn Ala Leu Gin Pro Cys 260 Leu Pro Ser Ile Ile Ile 275 Lys Ala Gly Asp 35 Phe Tyr 290 Leu Val Thr Leu Glu 295 Arg Gin Asn Phe Ser Arg Cys Leu Glu 25 30 Ser Thr Leu Gly Gly Gly Ser Gly Gly 40 45 Gly Gly Thr Gin Asp Cys Ser Phe Gin 60 Phe Ala Val Lys Ile Arg Glu Leu Ser 75 80 Pro Val Thr Val Ala Ser Asn Leu Gin 90 95 Leu Trp Arg Leu Val Leu Ala Gin Arg 105 110 Val Ala Gly Ser Lys Met Gin Gly Leu 120 125 Ile His Phe Val Thr Lys Cys Ala Phe 140 Arg Phe Val Gin Tyr Val Glu Gly Gly 155 160 Ser Gly Pro Ile Ser Thr Ile Asn Pro 170 175 His Lys Ser Pro Asn Met Ala Asn Cys 185 190 Ile His His Leu Lys Arg Pro Pro Asn 200 205 Leu Asn Ser Glu Asp Met Asp Ile Leu 220 Pro Asn Leu Leu Ala Phe Val Arg Ala 235 240 Ser Gly Ile Glu Ala Ile Leu Arg Asn 250 255 Ala Thr Ala Ala Pro Ser Arg His Pro 265 270 Trp Gin Glu Phe Arg Glu Lys Leu Thr 280 285 Gin Ala Gin Glu Gin Gin 300 (2) INFORMACE PRO SEQ ID NO:692: 40 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 301 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 45 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:692: Ala Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser 1 5 10 15 Glu Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser 20 25 30 Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly 35 40 45 Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gin Asp 50 55 60 Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile 65 70 75 80 Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala 85 90 95 -786- 5 10 15 20 25 CZ 295843 B6 Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val 100 105 110 Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys 115 120 125 Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr 130 135 140 Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Phe Tyr Val Glu Gly Gly 145 150 155 160 Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro 165 170 175 Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Asn Cys 180 185 190 Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Asn 195 200 205 Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met Asp Ile Leu 210 215 220 Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe Val Arg Ala 225 230 235 240 Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn 245 250 255 Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro 260 265 270 Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr 275 280 285 Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 290 295 300 (2) INFORMACE PRO SEQ ID NO:693: 30 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 307 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 35 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:693: 40 45 50 55 Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu 1 5 10 15 Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser 20 25 30 Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val 35 40 45 Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin 50 55 60 Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala 65 70 75 80 Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu 85 90 95 Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly 100 105 110 Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin 115 120 125 Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys 130 135 140 Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val 145 150 155 160 Ala Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 165 170 175 -787- 60 10 15 20 25 30 35 40 45 50 55 CZ 295843 B6 Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 180 185 190 Pro Asn Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His 195 200 205 Leu Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser 210 215 220 Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu 225 230 235 240 Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile 245 250 255 Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala 260 265 270 Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu 275 280 285 Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin 290 295 300 Glu Gin Gin 305 (2) INFORMACE PRO SEQ ID NO:694: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA.: 307 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:694: Ala Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val 1 5 10 15 Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys 20 25 30 Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr 35 40 45 Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr 50 55 60 Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu 65 70 75 80 Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin 85 90 95 Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser 100 105 110 Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp 115 120 125 Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile 130 135 140 Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala 145 150 155 160 Ser Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 165 170 175 Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 180 185 190 Pro Asn Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His 195 200 205 Leu Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser 210 215 220 Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu 225 230 235 240 -788- 60 CZ 295843 B6 Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile 245 250 255 Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala 260 265 270 Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu 275 280 285 Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin 290 295 300 Glu Gin Gin 305 (2) INFORMACE PRO SEQ ID NO:695: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 307 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:695: Ala Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu 1 5 10 15 Ala Gin Arg Leu Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met 20 25 30 Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys 35 40 45 Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn 50 55 60 Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys 65 70 75 80 Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys 85 90 95 Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly 100 105 110 Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys 115 120 125 Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg 130 135 140 Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser 145 150 155 160 Asn Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 165 170 175 Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 180 185 190 Pro Asn Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His 195 200 205 Leu Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser 210 215 220 Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu 225 230 235 240 Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile 245 250 255 Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala 260 265 270 Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu 275 280 285 -789- CZ 295843 B6 Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin 290 295 300 Glu Gin Gin 305 (2) INFORMACE PRO SEQ ID NO:696: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 307 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:696: Ala Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala 1 5 10 15 Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin 20 25 30 Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys 35 40 45 Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile 50 55 60 Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro 65 70 75 80 Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin 85 90 95 Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly 100 105 110 Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser 115 120 125 Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu 130 135 140 Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn 145 150 155 160 Leu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 165 170 175 Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 180 185 190 Pro Asn Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His 195 200 205 Leu Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser 210 215 220 Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu 225 230 235 240 Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile 245 250 255 Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala 260 265 270 Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu 275 280 285 Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin 290 295 300 Glu Gin Gin 305 (2) INFORMACE PRO SEQ ID NO:697: (i) CHARAKTERISTIKY SEKVENCE: -790- 5 CZ 295843 B6 (A) DÉLKA: 307 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:697: 10 15 20 25 30 35 40 45 Ala Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg 1 5 10 15 Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu 20 25 30 Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala Phe 35 40 45 Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser Arg 50 55 60 Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp Ile 65 70 75 80 Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp 85 90 95 Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser 100 105 110 Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe Gin 115 120 125 His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser 130 135 140 Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin 145 150 155 160 Asp Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 165 170 175 Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 180 185 190 Pro Asn Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His 195 200 205 Leu Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser 210 215 220 Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu 225 230 235 240 Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile 245 250 255 Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala 260 265 270 Ala Pro Ser Arg His Pro Ile Ile Ile Lys AI a Gly Asp Trp Gin Glu 275 280 285 Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin 290 295 300 Glu Gin Gin 305 50 (2) INFORMACE PRO SEQ ID NO:698: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 307 aminokyselin 55 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:698: -791 - 60 CZ 295843 B6 Ala 1 Leu Cys Gly 5 Glu Arg Leu Lys 20 Arg Val Asn 35 Thr Pro Pro 50 Ser Cys 10 Gin 65 Glu Thr Ser Gin Asn Phe Ser 15 Thr Leu Gly Gly 100 Gly Ser Gly 115 Gly Pro Ile 130 Ser Ser 20 Leu 145 Leu Gin Asp Glu Tyr Val Glu 25 Ile Ser Thr Ile 180 Pro Asn Met 195 Ala Leu Lys 210 Arg Pro 30 Glu 225 Asp Met Asp Leu Ala Phe Val 35 Glu Ala Ile Leu 260 Ala Pro Ser 275 Arg Phe Arg 290 Glu Lys 40 Glu 305 Gin Gin Gly 5 Leu Trp Arg Leu Val 10 Thr Val Ala Gly Ser 25 Lys Glu Ile His Phe 40 Val Thr Leu Arg Phe 55 Val Gin Thr Glu Gin 70 Leu Val Ala Leu Arg 85 Cys Leu Glu Leu Gin 90 Gly Ser Gly Gly Gly 105 Ser Gly Ser Gly Thr 120 Gin Asp Asp Phe Ala 135 Val Lys Ile Tyr Pro 150 Val Thr Val Ala Gly 165 Gly Gly Gly Ser Pro 170 Asn Pro Ser Pro Pro 185 Ser Asn Cys Ser Ile 200 Met Ile Pro Asn Pro 215 Leu Leu Asp Ile Leu 230 Met Glu Arg Asn Arg 245 Ala Val Lys His Leu 250 Arg Asn Leu Gin Pro 265 Cys His Pro Ile Ile 280 Ile Lys Leu Thr Phe 295 Tyr Leu Val Leu Ala Gin Arg Trp 15 Met Met Gin Gly Leu 30 Leu Glu Lys Cys Ala 45 Phe Gin Pro Asn Ile 60 Ser Arg Leu Leu Lys 75 Pro Trp Ile Thr Arg 80 Cys Gin Pro Asp Ser 95 Ser Gly Gly Gly Ser 110 Gly Gly Cys Ser Phe 125 Gin His Ser Arg Glu 140 Leu Ser Asp Tyr Ser 155 Asn Leu Gin Asp Glu 160 Gly Glu Pro Ser Gly 175 Pro Lys Glu Ser His 190 Lys Ser Asp Glu Ile 205 Ile His His Pro Asn 220 Asn Leu Asn Ser Leu 235 Arg Thr Pro Asn Leu 240 Glu Asn Ala Ser Gly 255 Ile Leu Pro Ser Ala 270 Thr Ala Ala Gly Asp 285 Trp Gin Glu Thr Leu 300 Glu Gin Ala Gin (2) INFORMACE PRO SEQ ID NO:699: 45 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 307 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 50 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:699: Ala 1 Leu Cys Gly Gly 5 Leu Trp Arg Leu Val 10 Leu Ala Gin Arg Trp Met 15 Glu Arg Leu Lys 20 Thr Val Ala Gly Ser 25 Lys Met Gin Gly Leu 30 Leu Glu Arg Val Asn 35 Thr Glu Ile His Phe 40 Val Thr Lys Cys Ala 45 Phe Gin Pro 55 -792- 60 5 10 15 20 25 30 35 40 45 50 55 CZ 295843 B6 Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu 50 55 60 Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg 65 70 75 80 Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser 85 90 95 Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly 100 105 110 Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe Gin His Ser 115 120 125 Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr 130 135 140 Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu 145 150 155 160 Glu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 165 170 175 Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 180 185 190 Pro Asn Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His 195 200 205 Leu Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser 210 215 220 Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu 225 230 235 240 Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile 245 250 255 Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala 260 265 270 Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu 275 280 285 Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin 290 295 300 Glu Gin Gin 305 (2) INFORMACE PRO SEQ ID NO:700: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 307 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ !: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:700: Ala Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met 1 5 10 15 Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu 20 25 30 Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro 35 40 45 Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu 50 55 60 Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg 65 70 75 80 Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Arg Pro Asp Ser Ser 85 90 95 Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly 100 105 110 -793 - 60 CZ 295843 B6 Gly Ser Gly Gly Pro Ile 115 Ser Ser 5 Leu 130 Leu Gin Asp 145 Glu Tyr Val Glu Ile Ser Thr Ile 10 Pro Asn Met 180 Ala Leu Lys 195 Arg Pro 15 Glu 210 Asp Met Asp 225 Leu Ala Phe Val Glu Ala Ile Leu 20 Ala Pro Ser 260 Arg Phe Arg 275 Glu Lys 25 Glu 290 Gin Gin 305 Gly Ser Gly Thr 120 Gin Asp Asp Phe Ala 135 Val Lys Ile Tyr Pro 150 Val Thr Val Ala Gly 165 Gly Gly Gly Ser Pro 170 Asn Pro Ser Pro Pro 185 Ser Asn Cys Ser Ile 200 Met Ile Pro Asn Pro 215 Leu Leu Asp Ile Leu 230 Met Glu Arg Asn Arg 245 Ala Val Lys His Leu 250 Arg Asn Leu Gin Pro 265 Cys His Pro Ile Ile 280 Ile Lys Leu Thr Phe 295 Tyr Leu Val Cys Ser Phe 125 Gin His Ser Arg Glu 140 Leu Ser Asp Tyr Ser 155 Asn Leu Gin Asp Glu 160 Gly Glu Pro Ser Gly 175 Pro Lys Glu Ser His 190 Lys Ser Asp Glu Ile 205 Ile His His Pro Asn 220 Asn Leu Asn Ser Leu 235 Arg Thr Pro Asn Leu 240 Glu Asn Ala Ser Gly 255 Ile Leu Pro Ser Ala 270 Thr Ala Ala Gly Asp 285 Trp Gin Glu Thr Leu 300 Glu Gin Ala Gin (2) INFORMACE PRO SEQ ID NO:701: 30 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 301 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 35 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:701: Ala Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His 1 5 10 15 Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe 20 25 30 Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu 35 - 40 45 Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu 50 55 60 Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly 65 70 75 80 Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gin Asp Cys Ser Phe 85 90 95 Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu 100 105 110 Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu 115 120 125 Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 130 135 140 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Tyr Val Glu Gly Gly 145 150 155 160 Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro 165 170 175 40 45 50 55 -794- 60 5 10 15 CZ 295843 B6 Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Asn Cys 180 185 190 Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Asn 195 200 205 Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met Asp Ile Leu 210 215 220 Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe Val Arg Ala 225 230 235 240 Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn 245 250 255 Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro 260 265 270 Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr 275 280 285 Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 290 295 300 (2) INFORMACE PRO SEQ ID NO:702: 20 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 315 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 25 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:702: 30 35 40 45 50 55 Ala Gin Asp Asp Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala 1 5 10 15 Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin 20 25 30 Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys 35 40 45 Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile 50 55 60 Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro 65 70 75 80 Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin 85 90 95 Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly 100 105 110 Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly 115 120 125 Gly Ser Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser 130 135 140 Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp 145 150 155 160 Tyr Pro Val Thr Val Ala Ser Asn Leu Tyr Val Glu Gly Gly Gly Gly 165 170 175 Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro 180 185 190 Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Asn Cys Ser Ile 195 200 205 Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Asn Pro Leu 210 215 220 Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met Asp Ile Leu Met Glu 225 230 235 240 Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe Val Arg Ala Val Lys 245 250 255 -795 - 60 5 10 15 20 25 30 35 40 45 50 55 CZ 295843 B6 His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin 260 265 270 Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile 275 280 285 Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr 290 295 300 Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 305 310 315 (2) INFORMACE PRO SEQ ID NO:703: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 301 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:703: Ala Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala 1 5 10 15 Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin 20 25 30 Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys 35 40 45 Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile 50 55 60 Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro 65 70 75 80 Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin 85 90 95 Pro Asp Ser Ser Thr Leu Pro Pro Pro Trp Ser Pro Arg Pro Leu Gly 100 105 110 Ala Thr Ala Pro Thr Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile 115 120 125 Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu 130 135 140 Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Tyr Val Glu Gly Gly 145 150 155 160 Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro 165 170 175 Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Asn Cys 180 185 190 Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Asn 195 200 205 Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met Asp Ile Leu 210 215 220 Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe Val Arg Ala 225 230 235 240 Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn 245 250 255 Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro 260 265 270 Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr 275 280 285 Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 290 295 300 -796- 60 CZ 295843 B6 (2) INFORMACE PRO SEQ ID NO:704: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 307 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:704: Ala Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala 1 5 10 15 Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin 20 25 30 Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys 35 40 45 Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile 50 55 60 Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro 65 70 75 80 Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin 85 90 95 Pro Asp Ser Ser Thr Leu Pro Pro Pro Trp Ser Pro Arg Pro Leu Gly 100 105 110 Ala Thr Ala Pro Thr Ala Gly Gin Pro Pro Leu Thr Gin Asp Cys Ser 115 120 125 Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu 130 135 140 Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn 145 150 155 160 Leu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 165 170 175 Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 180 185 190 Pro Asn Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His 195 200 205 Leu Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser 210 215 220 Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu 225 230 235 240 Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile 245 250 255 Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala 260 265 270 Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu 275 280 285 Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin 290 295 300 Glu Gin Gin 305 (2) INFORMACE PRO SEQ ID NO:705: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 370 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární -797- CZ 295843 B6 (íi) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:705: 5 Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu 1 5 10 15 Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu 20 25 30 Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu 10 35 40 45 Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser 50 55 60 Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His 65 70 75 80 15 Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile 85 90 95 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala 100 105 110 Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala 20 115 120 125 Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala 130 135 140 Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser 145 150 155 160 25 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Tyr 165 170 175 Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser 180 185 190 Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn 30 195 200 205 Met Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala 210 215 220 Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin 225 230 235 240 35 Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys 245 250 255 Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile 260 265 270 Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro 40 275 280 285 Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin 290 295 300 Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly 305 310 315 320 45 Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser 325 330 335 Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu 340 345 350 Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn 50 Leu Gin 355 360 365 370 (2) INFORMACE PRO SEQ ID NO:706: 55 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 370 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární -798- 60 CZ 295843 B6 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:706: 5 Ala Thr Pro Leu Gly Pro Ala 1 5 Lys Ser Leu Glu Gin Val Arg 20 Gin Glu Lys Leu Cys Ala Thr 10 35 Val Leu Leu Gly His Ser Leu 50 55 Cys Pro Ser Gin Ala Leu Gin 65 70 15 Ser Gly Leu Phe Leu Tyr Gin 85 Ser Pro Glu Leu Gly Pro Thr 100 Asp Phe Ala Thr Thr Ile Trp 20 115 Pro Ala Leu Gin Pro Thr Gin 130 135 Phe Gin Arg Arg Ala Gly Gly 145 150 25 Phe Leu Glu Val Ser Tyr Arg 165 Val Glu Gly Gly Gly Gly Ser 180 Thr Ile Asn Pro Ser Pro Pro 30 195 Met Ala Asn Leu Gin Asp Glu 210 215 . Val Leu Ala Gin Arg Trp Met 225 230 35 Lys Met Gin Gly Leu Leu Glu 245 Thr Lys Cys Ala Phe Gin Pro 260 Ile Asn Ile Ser Arg Leu Leu 40 275 Leu Lys Pro Trp Ile Thr Arg 290 295 Gin Cys Gin Pro Asp Ser Ser 305 310 45 Ser Gly Gly Gly Ser Gly Gly 325 Asp Cys Ser Phe Gin His Ser 340 Ile Arg Glu Leu Ser Asp Tyr 50 Ala Ser 355 370 Ser Ser Leu Pro Gin Ser Phe Leu Leu 10 15 Lys Ile Gin Gly Asp Gly Ala Ala Leu 25 30 Tyr Lys Leu Cys His Pro Glu Glu Leu 40 45 Gly Ile Pro Trp Ala Pro Leu Ser Ser 60 Leu Ala Gly Cys Leu Ser Gin Leu His 75 80 Gly Leu Leu Gin Ala Leu Glu Gly Ile 90 95 Leu Asp Thr Leu Gin Leu Asp Val Ala 105 110 Gin Gin Met Glu Glu Leu Gly Met Ala 120 125 Gly Ala Met Pro Ala Phe Ala Ser Ala 140 Val Leu Val Ala Ser His Leu Gin Ser 155 160 Val Leu Arg His Leu Ala Gin Pro Tyr 170 175 Pro Gly Glu Pro Ser Gly Pro Ile Ser 185 190 Ser Lys Glu Ser His Lys Ser Pro Asn 200 205 Glu Leu Cys Gly Gly Leu Trp Arg Leu 220 Glu Arg Leu Lys Thr Val Ala Gly Ser 235 240 Arg Val Asn Thr Glu Ile His Phe Val 250 255 Pro Pro Ser Cys Leu Arg Phe Val Gin 265 270 Gin Glu Thr Ser Glu Gin Leu Val Ala 280 285 Gin Asn Phe Ser Arg Cys Leu Glu Leu 300 Thr Leu Gly Gly Gly Ser Gly Gly Gly 315 320 Gly Ser Gly Gly Gly Ser Gly Thr Gin 330 335 Pro Ile Ser Ser Asp Phe Ala Val Lys 345 350 Leu Leu Gin Asp Tyr Pro Val Thr Val 360 365 (2) INFORMACE PRO SEQ ID NO:707: 55 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 370 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární -799- 60 CZ 295843 B6 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:707: 5 Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu 1 5 10 15 Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu 20 25 30 Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu 10 35 40 45 Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser 50 55 60 Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His 65 70 75 80 15 Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile 85 90 95 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala 100 105 110 Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala 20 115 120 125 Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala 130 135 140 Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser 145 150 155 160 25 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Tyr 165 170 175 Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser 180 185 190 Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn 30 195 200 205 Met Ala Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser Arg 210 215 220 Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp Ile 225 230 235 240 35 Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp 245 250 255 Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser 260 265 270 Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe Gin 40 275 280 285 His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser 290 295 300 Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin 305 310 315 320 45 Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg 325 330 335 Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu 340 345 350 Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala Phe 50 Gin Pro 355 360 365 370 (2) INFORMACE PRO SEQ ID NO:708: 55 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 370 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární -800- 60 CZ 295843 B6 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:708: 5 Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu 1 5 10 15 Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu 20 25 30 Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu 10 35 40 45 Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser 50 55 60 Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His 65 70 75 80 15 Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile 85 90 95 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala 100 105 110 Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala 20 115 120 125 Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala 130 135 140 Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser 145 150 155 160 25 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Tyr 165 170 175 Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser 180 185 190 Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn 30 195 200 205 Met Ala Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val 210 215 220 Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys 225 230 235 240 35 Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr 245 250 255 Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr 260 265 270 Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu 40 275 280 285 Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin 290 295 300 Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser 305 310 315 320 45 Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp 325 330 335 Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile 340 345 350 Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala 50 Ser Asn 355 360 365 370 (2) INFORMACE PRO SEQ ID NO:709: 55 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 370 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární -801 - 60 CZ 295843 B6 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:709: Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu 1 5 10 15 Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu 20 25 30 Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu 35 40 45 Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser 50 55 60 Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His 65 70 75 80 Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile 85 90 95 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala 100 105 110 Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala 115 120 125 Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala 130 135 140 Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser 145 150 155 160 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Tyr 165 170 175 Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser 180 185 190 Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn 195 200 205 Met Ala Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu 210 215 220 Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met 225 230 235 240 Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys 245 250 255 Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn 260 265 270 Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys 275 280 285 Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys 290 295 300 Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly 305 310 315 320 Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys 325 330 335 Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg 340 345 350 Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser 355 360 365 Asn Leu 370 (2) INFORMACE PRO SEQ ID NO:710: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 370 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární -802- 5 CZ 295843 B6 (ii) TYP MOLEKULY: žádný 10 15 20 25 30 35 40 45 50 (xi) POPIS SEKVENCE: SEQ ID NO:710: Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu 1 5 10 15 Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu 20 25 30 Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu 35 40 45 Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser 50 55 60 Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His 65 70 75 80 Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile 85 90 95 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala 100 105 110 Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala 115 120 125 Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala 130 135 140 Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser 145 150 155 160 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Tyr 165 170 175 Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser 180 185 190 Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn 195 200 205 Met Ala Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 210 215 220 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly 225 230 235 240 Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala 245 250 255 Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser 260 265 270 Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 275 280 285 Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro 290 295 300 Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 305 310 315 320 Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe 325 330 335 Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu 340 345 350 Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu 355 360 365 Gin Asp 370 (2) INFORMACE PRO SEQ ID NO:711: 55 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 370 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché 60 (D) TOPOLOGIE: lineární i -803- CZ 295843 B6 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:711: 5 Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu I 5 10 15 Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu 20 25 30 Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu 10 35 40 45 Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser 50 55 60 Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His 65 70 75 80 15 Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile 85 90 95 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala 100 105 110 Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala 20 115 120 125 Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala 130 135 140 Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser 145 150 155 160 25 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Tyr 165 170 175 Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser 180 185 190 Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn 30 195 200 205 Met Ala Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Al a Gin Arg 210 215 220 Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu 225 230 235 240 35 Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala Phe 245 250 255 Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser Arg 260 265 270 Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp Ile 40 275 280 285 Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp 290 295 300 Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser 305 310 315 320 45 Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe Gin 325 330 335 His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser 340 345 350 Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin 50 Asp Glu 355 360 365 370 (2) INFORMACE PRO SEQ ID NO:712: 55 i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 370 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární -804- 60 CZ 295843 B6 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:712: 5 Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu 1 5 10 15 Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu 20 25 30 Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu 10 35 40 45 Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser 50 55 60 Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His 65 70 75 80 15 Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile 85 90 95 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala 100 105 110 Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala 20 115 120 125 Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala 130 135 140 Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser 145 150 155 160 25 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Tyr 165 170 175 Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser 180 185 190 Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn 30 195 200 205 Met Ala Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp 210 215 220 Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu 225 230 235 240 35 Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala Phe Gin 245 250 255 Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser Arg Leu 260 265 270 Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp Ile Thr 40 275 280 285 Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser 290 295 300 Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly 305 310 315 320 45 Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe Gin His 325 330 335 Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp 340 345 350 Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp 50 Glu Glu 355 360 365 370 (2) INFORMACE PRO SEQ ID NO:713: 55 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 364 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární - 805 - 60 5 CZ 295843 B6 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:713: 10 15 20 25 30 35 40 45 50 Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu 1 5 10 15 Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu 20 25 30 Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu 35 40 45 Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser 50 55 60 Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His 65 70 75 80 Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile 85 90 95 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala 100 105 110 Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala 115 120 125 Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala 130 135 140 Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser 145 150 155 160 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Tyr 165 170 175 Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser 180 185 190 Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn 195 200 205 Met Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala 210 215 220 Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin 225 230 235 240 Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys 245 250 255 Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile 260 265 270 Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro 275 280 285 Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin 290 295 300 Pro Asp Ser Ser Thr Leu Pro Pro Pro Trp Ser Pro Arg Pro Leu Gly 305 310 315 320 Ala Thr Ala Pro Thr Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile 325 330 335 Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu 340 345 350 Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin 355 360 (2) INFORMACE PRO SEQ ID NO:714: (i) CHARAKTERISTIKY SEKVENCE: 55 (A) DÉLKA: 378 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný -806- 60 CZ 295843 B6 (xi) POPIS SEKVENCE: SEQ ID NO:714: Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu 1 5 10 15 5 Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu 20 25 30 Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu 35 40 45 Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser 10 50 55 60 Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His 65 70 75 80 Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile 85 90 95 15 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala 100 105 110 Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala 115 120 125 Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala 20 130 135 140 Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser 145 150 155 160 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Tyr 165 170 175 25 Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser 180 185 190 Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn 195 200 205 Met Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala 30 210 215 220 Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin 225 230 235 240 Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys 245 250 255 35 Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile 260 265 270 Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro 275 280 285 Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin 40 290 295 300 Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly 305 310 315 320 Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly 325 330 335 45 Gly Ser Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser 340 345 350 Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp 355 360 365 Tyr Pro Val Thr Val Ala Ser Asn Leu Gin 50 370 375 (2) INFORMACE PRO SEQ ID NO:715: (i) CHARAKTERISTIKY SEKVENCE: 55 (A) DÉLKA: 370 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 60 (ii) TYP MOLEKULY: žádný -807- CZ 295843 B6 (xi) POPIS SEKVENCE: SEQ ID NO:715: Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu 1 5 10 15 5 Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu 20 25 30 Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu 35 40 45 Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser 10 50 55 60 Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His 65 70 75 80 Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile 85 90 95 15 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala 100 105 110 Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala 115 120 125 Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala 20 130 135 140 Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser 145 150 155 160 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Tyr 165 170 175 25 Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser 180 185 190 Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn 195 200 205 Met Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala 30 210 215 220 Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin 225 230 235 240 Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys 245 250 255 35 Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile 260 265 270 Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro 275 280 285 Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin 40 290 295 300 Pro Asp Ser Ser Thr Leu Pro Pro Pro Trp Ser Pro Arg Pro Leu Gly 305 310 315 320 Ala Thr Ala Pro Thr Ala Gly Gin Pro Pro Leu Thr Gin Asp Cys Ser 325 330 335 45 Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu 340 345 350 Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn 355 360 365 Leu Gin 50 370 (2) INFORMACE PRO SEQ ID NO:716: (i) CHARAKTERISTIKY SEKVENCE: 55 (A) DÉLKA: 155 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 60 (ii) TYP MOLEKULY: žádný -808- 5 CZ 295843 B6 10 15 20 25 30 35 40 45 50 55 (xi) POPIS SEKVENCE: SEQ ID NO:716: Ala Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu 1 5 10 15 Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg 20 25 30 Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val 35 40 45 Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro 50 55 60 Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu 65 70 75 80 Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn 85 90 95 Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 100 105 110 Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr 115 120 125 Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val 130 135 140 Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin 145 150 155 (2) INFORMACE PRO SEQ ID NO:717: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 155 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:717: Ala Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg 1 5 10 15 Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly 20 25 30 Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe 35 40 45 Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val 50 55 60 Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val 65 70 75 80 Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu 85 90 95 Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly 100 105 110 Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gin Asp Cys Ser Phe Gin 115 120 125 His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser 130 135 140 Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val 145 150 155 (2) INFORMACE PRO SEQ ID NO:718: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 155 aminokyselin (B) TYP: aminokyselina -809- 60 5 CZ 295843 B6 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:718: 10 15 20 25 Ala Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr 1 5 10 15 Glu Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys 20 25 30 Leu Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser 35 40 45 Glu Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser 50 55 60 Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly 65 70 75 80 Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gin Asp 85 90 95 Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile 100 105 110 Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala 115 120 125 Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val 130 135 140 Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr 145 150 155 30 35 (2) INFORMACE PRO SEQ ID NO:719: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 155 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:719: 40 45 50 55 Ala Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His 1 5 10 15 Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe 20 25 30 Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu 35 40 45 Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu 50 55 60 Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly 65 70 75 80 Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gin Asp Cys Ser Phe 85 90 95 Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu 100 105 110 Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu 115 120 125 Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 130 135 140 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly 145 150 155 -810- 60 5 CZ 295843 B6 (2) INFORMACE PRO SEQ ID NO:720: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 155 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 10 (xi) POPIS SEKVENCE: SEQ ID NO:720: 15 20 25 30 Ala Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser Arg Leu 1 5 10 15 Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp Ile Thr 20 25 30 Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser 35 40 45 Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly 50 55 60 Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp 65 70 75 80 Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr 85 90 95 Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly 100 105 110 Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr 115 120 125 Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu 130 135 140 Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro 145 150 155 (2) INFORMACE PRO SEQ ID NO:721: 35 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 155 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché 40 (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:721: 45 50 55 Ala Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser 1 5 10 15 Glu Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser 20 25 30 Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly 35 40 45 Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gin Asp 50 55 60 Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile 65 70 75 80 Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala 85 90 95 Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val 100 105 110 Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys 115 120 125 -811 - 60 5 CZ 295843 B6 Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr 130 135 140 Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu 145 150 155 (2) INFORMACE PRO SEQ ID NO:722: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 155 aminokyselin 10 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 15 (xi) POPIS SEKVENCE: SEQ ID NO:722: 20 25 30 35 Ala Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val 1 5 10 15 Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu 20 25 30 Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly 35 40 45 Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gin Asp Cys Ser Phe Gin 50 55 60 His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser 65 70 75 80 Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin 85 90 95 Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg 100 105 110 Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu 115 120 125 Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala Phe 130 135 140 Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin 145 150 155 (2) INFORMACE PRO SEQ ID NO:723: 40 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 370 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché 45 (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:723: 50 55 Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly 20 25 30 Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser 50 55 60 Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80 -812- 60 CZ 295843 B6 Ile Thr Arg Gin Asn 85 Phe Ser Asp Ser Ser Thr 100 Leu Gly Gly 5 Ser Gly Gly 115 Gly Ser Gly Gly Gin His 130 Ser Pro Ile Ser Ser 135 10 Ser 145 Asp Tyr Leu Leu Gin 150 Asp Gin Tyr Val Glu Gly 165 Gly Gly Ile Ser Thr Ile 180 Asn Pro Ser 15 Pro Asn Met 195 Ala Thr Pro Leu Phe Leu 210 Leu Lys Ser Leu Glu 215 20 Ala 225 Ala Leu Gin Glu Lys 230 Leu Glu Glu Leu Val Leu 245 Leu Gly Leu Ser Ser Cys 260 Pro Ser Gin 25 Gin Leu His 275 Ser Gly Leu Phe Glu Gly 290 Ile Ser Pro Glu Leu 295 30 Asp 305 Val Ala Asp Phe Ala 310 Thr Gly Met Ala Pro Ala 325 Leu Gin Ala Ser Ala Phe 340 Gin Arg Arg 35 Leu Gin Gin Pro 370 Ser 355 Phe Leu Glu Val Arg Cys Leu Glu Leu Gin Cys Gin Pro 90 95 Gly Ser Gly Gly Gly Ser Gly Gly Gly 105 110 Gly Ser Gly Thr Gin Asp Cys Ser Phe 120 125 Asp Phe Ala Val Lys Ile Arg Glu Leu 140 Tyr Pro Val Thr Val Ala Ser Asn Leu 155 160 Gly Ser Pro Gly Glu Pro Ser Gly Pro 170 175 Pro Pro Ser Lys Glu Ser His Lys Ser 185 190 Gly Pro Ala Ser Ser Leu Pro Gin Ser 200 205 Gin Val Arg Lys Ile Gin Gly Asp Gly 220 Cys Ala Thr Tyr Lys Leu Cys His Pro 235 240 His Ser Leu Gly Ile Pro Trp Ala Pro 250 255 Ala Leu Gin Leu Ala Gly Cys Leu Ser 265 270 Leu Tyr Gin Gly Leu Leu Gin Ala Leu 280 285 Gly Pro Thr Leu Asp Thr Leu Gin Leu 300 Thr Ile Trp Gin Gin Met Glu Glu Leu 315 320 Pro Thr Gin Gly Ala Met Pro Ala Phe 330 335 Ala Gly Gly Val Leu Val Ala Ser His 345 350 Ser Tyr Arg Val Leu Arg His Leu Ala 360 365 40 (2) INFORMACE PRO SEQ ID NO:724: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 370 aminokyselin (B) TYP: aminokyselina 45 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 50 (xi) POPIS SEKVENCE: SEQ ID NO:724: Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly 20 25 30 Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser 50 55 60 Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80 -813 - CZ 295843 B6 Ile Thr Arg Gin Asn 85 Phe Ser Asp Ser Ser Thr 100 Leu Gly Gly 5 Ser Gly Gly 115 Gly Ser Gly Gly Gin His 130 Ser Pro Ile Ser Ser 135 10 Ser 145 Asp Tyr Leu Leu Gin 150 Asp Gin Tyr Val Glu Gly 165 Gly Gly Ile Ser Thr Ile 180 Asn Pro Ser 15 Pro Asn Met 195 Ala Thr Pro Leu Phe Leu 210 Leu Lys Cys Leu Glu 215 20 Ala 225 Ala Leu Gin Glu Lys 230 Leu Glu Glu Leu Val Leu 245 Leu Gly Leu Ser Ser Cys 260 Pro Ser Gin 25 Gin Leu His 275 Ser Gly Leu Phe Glu Gly 290 Ile Ser Pro Glu Leu 295 30 Asp 305 Val Ala Asp Phe Ala 310 Thr Gly Met Ala Pro Ala 325 Leu Gin Ala Ser Ala Phe 340 Gin Arg Arg 35 Leu Gin Gin Pro 370 Ser 355 Phe Leu Glu Val Arg Cys Leu Glu Leu Gin Cys Gin Pro 90 95 Gly Ser Gly Gly Gly Ser Gly Gly Gly 105 110 Gly Ser Gly Thr Gin Asp Cys Ser Phe 120 125 Asp Phe Ala Val Lys Ile Arg Glu Leu 140 Tyr Pro Val Thr Val Ala Ser Asn Leu 155 160 Gly Ser Pro Gly Glu Pro Ser Gly Pro 170 175 Pro Pro Ser Lys Glu Ser His Lys Ser 185 190 Gly Pro Ala Ser Ser Leu Pro Gin Ser 200 205 Gin Val Arg Lys Ile Gin Gly Asp Gly 220 Cys Ala Thr Tyr Lys Leu Cys His Pro 235 240 His Ser Leu Gly Ile Pro Trp Ala Pro 250 255 Ala Leu Gin Leu Ala Gly Cys Leu Ser 265 270 Leu Tyr Gin Gly Leu Leu Gin Ala Leu 280 285 Gly Pro Thr Leu Asp Thr Leu Gin Leu 300 Thr Ile Trp Gin Gin Met Glu Glu Leu 315 320 Pro Thr Gin Gly Ala Met Pro Ala Phe 330 335 Ala Gly Gly Val Leu Val Ala Ser His 345 350 Ser Tyr Arg Val Leu Arg His Leu Ala 360 365 40 (2) INFORMACE PRO SEQ ID NO:725: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 354 aminokyselin (B) TYP: aminokyselina 45 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 50 (xi) POPIS SEKVENCE: SEQ ID NO:725: Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly 20 25 30 Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser 50 55 60 Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80 -814- CZ 295843 B6 Ile Thr Arg Gin Asp Ser Ser Thr 100 5 Thr Ala Pro Thr 115 Gin His Ser Pro 130 Ser Asp Tyr Leu 10 145 Tyr Val Glu Gly Ser Asn Met Ala 180 15 Phe Leu Leu Lys 195 Ala Ala Leu Gin 210 Glu Glu Leu Val 20 225 Leu Ser Ser Cys Gin Leu His Ser 260 25 Glu Gly Ile Ser 275 Asp Val Ala Asp 290 Gly Met Ala Pro 30 305 Ala Ser Ala Phe Leu Gin Ser Phe 340 35 Gin Pro Asn 85 Phe Ser Arg Cys Leu 90 Leu Pro Pro Pro Trp 105 Ser Ala Gly Gin Pro 120 Pro Leu Ile Ser Ser 135 Asp Phe Ala Leu Gin 150 Asp Tyr Pro Val Gly 165 Gly Gly Ser Pro Gly 170 Thr Pro Leu Gly Pro 185 Ala Ser Leu Glu Gin 200 Val Arg Glu Lys Leu 215 Cys Ala Thr Leu Leu 230 Gly His Ser Leu Pro 245 Ser Gin Ala Leu Gin 250 Gly Leu Phe Leu Tyr 265 Gin Pro Glu Leu Gly 280 Pro Thr Phe Ala Thr 295 Thr Ile Trp Ala Leu 310 Gin Pro Thr Gin Gin 325 Arg Arg Ala Gly Gly 330 Leu Glu Val Ser Tyr 345 Arg Glu Leu Gin Cys Gin 95 Pro Pro Arg Pro Leu 110 Gly Ala Thr Gin Asp 125 Cys Ser Phe Val Lys 140 Ile Arg Glu Leu Thr 155 Val Ala Ser Asn Leu 160 Gly Gly Ser Gly Gly 175 Gly Ser Ser Leu Pro 190 Gin Ser Lys Ile Gin 205 Gly Asp Gly Tyr Lys 220 Leu Cys His Pro Gly 235 Ile Pro Trp Ala Pro 240 Leu Ala Gly Cys Leu 255 Ser Gly Leu Leu Gin 270 Ala Leu Leu Asp Thr 285 Leu Gin Leu Gin Gin 300 Met Glu Glu Leu Gly Ala 315 Met Pro Ala Phe 320 Val Leu Val Ala Ser 335 His Val Leu Arg His 350 Leu Ala (2) INFORMACE PRO SEQ ID NO:726: (i) CHARAKTERISTIKY SEKVENCE: 40 (A) DÉLKA: 363 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 45 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:726: Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly 20 25 30 Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser 50 55 60 Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80 Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro 85 90 95 -815- 5 10 15 20 25 30 35 40 45 50 55 CZ 295843 B6 Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 100 105 110 Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 115 120 125 Ser Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp 130 135 140 Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr 145 150 155 160 Pro Val Thr Val Ala Ser Asn Leu Gin Tyr Val Glu Gly Gly Gly Gly 165 170 175 Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Thr Pro Leu 180 185 190 Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu 195 200 205 Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu 210 215 220 Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly 225 230 235 240 His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin 245 250 255 Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe 260 265 270 Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu 275 280 285 Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr 290 295 300 Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin 305 310 315 320 Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg 325 330 335 Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val 340 345 350 Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro 355 360 (2) INFORMACE PRO SEQ ID NO:727: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 348 aminokyselin (B) TYP: : aminokyselina (C) RETEZENI !: j ednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:727: Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly 20 25 30 Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser 50 55 60 Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80 Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro 85 90 95 Asp Ser Ser Thr Leu Pro Pro Pro Trp Ser Pro Arg Pro Leu Gly Ala 100 105 110 -816- 60 CZ 295843 B6 Thr Ala Pro Thr Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser 115 120 125 Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin 130 135 140 5 Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Tyr Val Glu Gly Gly Gly 145 150 155 160 Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Thr Pro 165 170 175 Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu 10 180 185 190 Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys 195 200 205 Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu 210 215 220 15 Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser 225 230 235 240 Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu 245 250 255 Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu 20 260 265 270 Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala 275 280 285 Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu 290 295 300 25 Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg 305 310 315 320 Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu 325 330 335 Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro 30 340 345 (2) INFORMACE PRO SEQ ID NO:728: (i) CHARAKTERISTIKY SEKVENCE: 35 (A) DÉLKA: 359 aminokyselin (B) TYP: : aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 40 (ii) TYP MOLEKULY: : žádný (xi) POPIS SEKVENCE: SEQ ID NO:728: Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 45 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly 20 25 30 Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala 35 40 45 50 Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser 50 55 60 Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Arg Pro Trp 65 70 75 80 Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro 55 85 90 95 Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Thr 100 105 110 Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val 115 120 125 60 Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr 130 135 140 -817- 5 10 15 20 25 30 35 40 45 50 55 CZ 295843 B6 Val Ala Ser Asn Leu Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly 145 150 155 160 Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys 165 170 175 Glu Ser His Lys Ser Pro Asn Met Ala Thr Pro Leu Gly Pro Ala Ser 180 185 190 Ser Leu Pro Gin Ser Phe Leu Leu Lys Cys Leu Glu Gin Val Arg Lys 195 200 205 Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr 210 215 220 Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly 225 230 235 240 Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu 245 250 255 Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly 260 265 270 Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu 275 280 285 Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin 290 295 300 Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly 305 310 315 320 Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val 325 330 335 Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val 340 345 350 Leu Arg His Leu Ala Gin Pro 355 (2) INFORMACE PRO SEQ ID NO:729: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 364 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:729: Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly 20 25 30 Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser 50 55 60 Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80 Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro 85 90 95 Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 100 105 110 Ser Gly Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser 115 120 125 Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin 130 135 140 Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Tyr Val Glu Gly Gly 145 150 155 160 -818- 60 5 10 15 20 25 CZ 295843 B6 Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro 165 170 175 Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Pro 180 185 190 Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Cys Leu 195 200 205 Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys 210 215 220 Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu 225 230 235 240 Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser 245 250 255 Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu 260 265 270 Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu 275 280 285 Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala 290 295 300 Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu 305 310 315 320 Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg 325 330 335 Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu 340 345 350 Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro 355 360 (2) INFORMACE PRO SEQ ID NO:730: 30 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 370 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 35 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:730: 40 45 50 55 Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly 20 25 30 Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser 50 55 60 Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80 Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro 85 90 95 Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 100 105 110 Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe 115 120 125 Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu 130 135 140 Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu 145 150 155 160 Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 165 170 175 -819- 60 CZ 295843 B6 Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 180 185 190 Pro Asn Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser 195 200 205 Phe Leu Leu Lys Cys Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly 210 215 220 Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro 225 230 235 240 Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro 245 250 255 Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser 260 265 270 Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu 275 280 285 Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu 290 295 300 Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu 305 310 315 320 Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe 325 330 335 Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His 340 345 350 Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Val Arg His Leu Ala 355 360 365 Gin Pro 370 (2) INFORMACE PRO SEQ ID NO:731: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 364 aminokyselin (B) TYP: : aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: : žádný (xi) POPIS SEKVENCE: SEQ ID NO:731: Ala Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser Arg Leu 1 5 10 15 Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp Ile Thr 20 25 30 Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser 35 40 45 Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly 50 55 60 Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp 65 70 75 80 Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr 85 90 95 Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly 100 105 110 Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr 115 120 125 Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu 130 135 140 Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro Tyr Val Glu Gly Gly 145 150 155 160 Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro 165 170 175 -820- 5 10 15 20 25 CZ 295843 B6 Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Pro 180 185 190 Leu Gly Pro Ala Ser Ser Val Pro Gin Ser Phe Leu Leu Lys Cys Leu 195 200 205 Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys 210 215 220 Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu 225 230 235 240 Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser 245 250 255 Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu 260 265 270 Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu 275 280 285 Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala 290 295 300 Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu 305 310 315 320 Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg 325 330 335 Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu 340 345 350 Val Ser Tyr Arg Val Ile Arg His Leu Ala Gin Pro 355 360 (2) INFORMACE PRO SEQ ID NO:732: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 370 aminokyselin 30 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 35 (xi) POPIS SEKVENCE: SEQ ID NO:732: 40 45 50 55 Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu 1 5 10 15 Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser 20 25 30 Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val 35 40 45 Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin 50 55 60 Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala 65 70 75 80 Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu 85 90 95 Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly 100 105 110 Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin 115 120 125 Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys 130 135 140 Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val 145 150 155 160 Ala Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 165 170 175 Ile Ser Thr Ile Asn Pro Ser His Pro Ser Lys Glu Ser His Lys Ser 180 185 190 -821 - 60 CZ 295843 B6 Pro Asn Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser 195 200 205 Phe Leu Leu Lys Cys Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly 210 215 220 Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro 225 230 235 240 Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro 245 250 255 Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser 260 265 270 Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu 275 280 285 Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu 290 295 300 Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu 305 310 315 320 Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe 325 330 335 Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His 340 345 350 Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala 355 360 365 Gin Pro 370 (2) INFORMACE PRO SEQ ID NO:733: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 370 aminokyselin (B) TYP : aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY : žádný (xi) POPIS SEKVENCE: SEQ ID NO:733: Ala Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val 1 5 10 15 Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys 20 25 30 Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr 35 40 45 Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr 50 55 60 Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu 65 70 75 80 Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin 85 90 95 Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser 100 105 110 Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp 115 120 125 Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile 130 135 140 Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala 145 150 155 160 Ser Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 165 170 175 Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 180 185 190 -822- CZ 295843 B6 Pro Asn Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser 195 200 205 Phe Leu Leu Lys Cys Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly 210 215 220 Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro 225 230 235 240 Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro 245 250 255 Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser 260 265 270 Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu 275 280 285 Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu 290 295 300 Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu 305 310 315 320 Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe 325 330 335 Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His 340 345 350 Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Ile Arg His Leu Ala 355 360 365 Gin Pro 370 (2) INFORMACE PRO SEQ ID NO:734: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 370 aminokyselin (B) TYP: : aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY : žádný (xi) POPIS SEKVENCE: SEQ ID NO:734: Ala Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu 1 5 10 15 Ala Gin Arg Leu Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met 20 25 30 Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys 35 40 45 Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn 50 55 60 Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys 65 70 75 80 Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys 85 90 95 Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly 100 105 110 Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys 115 120 125 Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg 130 135 140 Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser 14 5 150 155 160 Asn Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 165 170 175 Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 180 185 190 -823 - CZ 295843 B6 Pro Asn Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser 195 200 205 Phe Leu Leu Lys Cys Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly 210 215 220 Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro 225 230 235 240 Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro 245 250 255 Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser 260 265 270 Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu 275 280 285 Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu 290 295 300 Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu 305 310 315 320 Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe 325 330 335 Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His 340 345 350 Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala 355 360 365 Gin Pro 370 (2; i INFORMACE 1 PRO SEQ ID NO:735: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 370 aminokyselin (B) TYP: : aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY : žádný (xi) POPIS SEKVENCE: SEQ ID NO:735: Ala Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met 1 5 10 15 Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu 20 25 30 Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro 35 40 45 Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu 50 55 60 Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg 65 70 75 80 Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser 85 90 95 Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly 100 105 110 Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe Gin His Ser 115 120 125 Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr 130 135 140 Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu 145 150 155 160 Glu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 165 170 175 Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 180 185 190 -824- CZ 295843 B6 Pro Asn Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser 195 200 205 Phe Leu Leu Lys Cys Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly 210 215 220 Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro 225 230 235 240 Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro 245 250 255 Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser 260 265 270 Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu 275 280 285 Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu 290 295 300 Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu 305 310 315 320 Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe 325 330 335 Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His 340 345 350 Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala 355 360 365 Gin Pro 370 (2: ) INFORMACE ] PRO SEQ ID NO:736: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 364 aminokyselin (B) TYP: : aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY : žádný (xi) POPIS SEKVENCE: SEQ ID NO:736: Ala Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His 1 5 10 15 Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe 20 25 30 Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu 35 40 45 Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu 50 55 60 Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly 65 70 75 80 Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gin Asp Cys Ser Phe 85 90 95 Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu 100 105 110 Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu 115 120 125 Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 130 135 140 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Tyr Val Glu Gly Gly 145 150 155 160 Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro 165 170 175 Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Pro 180 185 190 - 825 - CZ 295843 B6 Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Cys Leu 195 200 205 Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys 210 215 220 Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu 225 230 235 240 Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser 245 250 255 Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu 260 265 270 Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu 275 280 285 Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala 290 295 300 Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu 305 310 315 320 Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg 325 330 335 Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu 340 345 350 Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro 355 360 (2) INFORMACE ] PRO SEQ ID NO:737: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 364 aminokyselin (B) TYP: ; aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: : lineární (ii) TYP MOLEKULY : žádný (xi) POPIS SEKVENCE: SEQ ID NO:737: Ala Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His 1 5 10 15 Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe 20 25 30 Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu 35 40 45 Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu 50 55 60 Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly 65 70 75 80 Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gin Asp Cys Ser Phe 85 90 95 Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu 100 105 110 Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu 115 120 125 Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 130 135 140 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Tyr Val Glu Gly Gly 145 150 155 160 Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro 165 170 175 Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Pro 180 185 190 Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Cys Leu 195 200 205 -826- CZ 295843 B6 Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys 210 215 220 Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu 225 230 235 240 5 Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser 245 250 255 Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu 260 265 270 Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu 10 275 280 285 Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala 290 295 300 Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu 305 310 315 320 15 Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg 325 330 335 Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu 340 345 350 Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro 20 355 360 (2 ) INFORMACE : PRO SEQ : ID NO:738: (i) CHARAKTERISTIKY SEKVENCE: 25 (A) DÉLKA: 370 i aminokyselin (B) TYP: : aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: ! Lineární 30 (ii) TYP MOLEKULY : žádný (xi) POPIS SEKVENCE: SEQ ID NO:738: Ala Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met 35 1 5 10 15 Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu 20 25 30 Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro 35 40 45 40 Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu 50 55 60 Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg 65 70 75 80 Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Arg Pro Asp Ser Ser 45 85 90 95 Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly 100 105 110 Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe Gin His Ser 115 120 125 50 Pro Ile Ser Ser Asn Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr 130 135 140 Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu 145 150 155 160 Glu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 55 165 170 175 Ile Phe Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 180 185 190 Pro Asn Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser 195 200 205 60 Phe Leu Leu Lys Cys Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly 210 215 220 -827- CZ 295843 B6 Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro 225 230 235 240 Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro 245 250 255 Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser 260 265 270 Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu 275 280 285 Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu 290 295 300 Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu 305 310 315 320 Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe 325 330 335 Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His 340 345 350 Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala 355 360 365 Gin Pro 370 (2) INFORMACE PRO SEQ ID NO:739: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 370 aminokyselin (B) TYP: : aminokyselina (C) RETEZENI: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY : žádný (xi) POPIS SEKVENCE: SEQ ID NO:739: Ala Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp 1 5 10 15 Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu 20 25 30 Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala Phe Gin 35 40 45 Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser Arg Leu 50 55 60 Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp Ile Thr 65 70 75 80 Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser 85 90 95 Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly 100 105 110 Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe Gin His 115 120 125 Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp 130 135 140 Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp 145 150 155 160 Glu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 165 170 175 Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 180 185 190 Pro Asn Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser 195 200 205 Phe Leu Leu Lys Cys Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly 210 215 220 -828- CZ 295843 B6 Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro 225 230 235 240 Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro 245 250 255 Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser 260 265 270 Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu 275 280 285 Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu 290 295 300 Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu 305 310 315 320 Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe 325 330 335 Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His 340 345 350 Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala 355 360 365 Gin Pro 370 (2) INFORMACE i PRO SEQ ID NO:740: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 370 aminokyselin (B) TYP: : aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY : žádný (xi) POPIS SEKVENCE: SEQ ID NO:740: AI a Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg 1 5 10 15 Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu 20 25 30 Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala Phe 35 40 45 Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser Arg 50 55 60 Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp Ile 65 70 75 80 Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp 85 90 95 Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser 100 105 110 Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe Gin 115 120 125 His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser 130 135 140 Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin 145 150 155 160 Asp Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 165 170 175 Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 180 185 190 Pro Asn Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser 195 200 205 Phe Leu Leu Lys Cys Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly 210 215 220 -829- CZ 295843 B6 Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro 225 230 235 240 Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro 245 250 255 Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser 260 265 270 Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu 275 280 285 Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu 290 295 300 Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu 305 310 315 320 Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe 325 330 335 Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His 340 345 350 Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala 355 360 365 Gin Pro 370 (2) INFORMACE ] PRO SEQ : ID NO:741: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 370 aminokyselin (B) TYP: : aminokyselina (C) RETEZENI: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY : žádný (xi) POPIS SEKVENCE: SEQ : ID NO:741: Ala Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala 1 5 10 15 Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin 20 25 30 Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys 35 40 45 Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile 50 55 60 Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro 65 70 75 80 Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin 85 90 95 Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly 100 105 110 Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser 115 120 125 Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu 130 135 140 Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn 145 150 155 160 Leu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 165 170 175 Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 180 185 190 Pro Asn Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser 195 200 205 Phe Leu Leu Lys Cys Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly 210 215 220 -830- CZ 295843 B6 Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro 225 230 235 240 Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro 245 250 255 5 Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser 260 265 270 Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu 275 280 285 Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu 10 290 295 300 Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu 305 310 315 320 Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe 325 330 335 15 Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His 340 345 350 Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala 355 360 365 Gin Pro 20 370 (2) INFORMACE ] PRO SEQ : ID NO:742: (i) CHARAKTERISTIKY SEKVENCE: 25 (A) DÉLKA: 364 aminokyselin (B) TYP: : aminokyselina (C) ŘETĚZENI: jednoduché (D) TOPOLOGIE: i Lineární 30 (ii) TYP MOLEKULY : žádný (xi) POPIS SEKVENCE: SEQ ID NO:745 ) . Ala Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val 35 1 5 10 15 Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu 20 25 30 Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly 35 40 45 40 Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gin Asp Cys Ser Phe Gin 50 55 60 His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser 65 70 75 80 Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin 45 85 90 95 Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg 100 105 110 Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu 115 120 125 50 Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala Phe 130 135 140 Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Tyr Val Glu Gly Gly 145 150 155 160 Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro 55 165 170 175 Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Pro 180 185 190 Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Cys Leu 195 200 205 60 Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys 210 215 220 - 831 - 5 10 15 20 25 30 35 40 45 50 55 CZ 295843 B6 Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu 225 230 235 240 Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser 245 250 255 Gin AI a Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu 260 265 270 Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu 275 280 285 Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala 290 295 300 Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu 305 310 315 320 Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg 325 330 335 Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu 340 345 350 Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro 355 360 (2) INFORMACE PRO SEQ ID NO:743: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 355 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:743: Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly 20 25 30 Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser 50 55 60 Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80 Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro 85 90 95 Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 100 105 110 Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe 115 120 125 Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu 130 135 140 Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu 145 150 155 160 Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly 165 170 175 Gly Ser Asn Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin 180 185 190 Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp 195 200 205 Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His 210 215 220 Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala 225 230 235 240 - 832 - 60 5 10 15 20 25 30 35 40 45 50 55 CZ 295843 B6 Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu 245 250 255 Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala 260 265 270 Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin 275 280 285 Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu 290 295 300 Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala 305 310 315 320 Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser 325 330 335 His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu 340 345 350 Ala Gin Pro 355 (2) INFORMACE : PRO SEQ : ID NO:744: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 370 aminokyselin (B) TYP: : aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: ! Lineární (ii) TYP MOLEKULY : žádný (xi) POPIS SEKVENCE: SEQ : ID NO:744: Ala Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala 1 5 10 15 Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin 20 25 30 Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys 35 40 45 Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile 50 55 60 Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro 65 70 75 80 Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin 85 90 95 Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly 100 105 110 Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser 115 120 125 Phe Gin His Ser Pro Ile Ser Ser Asp Ser Ala Val Lys Ile Arg Glu 130 135 140 Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn 145 150 155 160 Leu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 165 170 175 Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 180 185 190 Pro Asn Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser 195 200 205 Phe Leu Leu Lys Cys Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly 210 215 220 Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro 225 230 235 240 Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro 245 250 255 -833 - 60 CZ 295843 B6 Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser 260 265 270 Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu 275 280 285 Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu 290 295 300 Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu 305 310 315 320 Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe 325 330 335 Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His 340 345 350 Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala 355 360 365 Gin Pro 370 (2) INFORMACE ! PRO SEQ : ID NO:745: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 366 , aminokyselin (B) TYP: : aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: : lineární (ii) TYP MOLEKULY : žádný (xi) POPIS SEKVENCE: SEQ : ID NO:745: Ala Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met 1 5 10 15 Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu 20 25 30 Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Tyr Ala Phe Gin Pro 35 40 45 Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu 50 55 60 Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg 65 70 75 80 Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Arg Pro Asp Ser Ser 85 90 95 Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly 100 105 110 Gly Ser Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser 115 120 125 Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp 130 135 140 Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Tyr Val Glu 145 150 155 160 Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile 165 170 175 Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala 180 185 190 Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys 195 200 205 Cys Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin 210 215 220 Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val 225 230 235 240 Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys 245 250 255 - 834 - 5 10 15 20 25 30 35 40 45 50 55 CZ 295843 B6 Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser 260 265 270 Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser 275 280 285 Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp 290 295 300 Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro 305 310 315 320 Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe 325 330 335 Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe 340 345 350 Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro 355 360 365 (2) INFORMACE ] PRO : 3EQ : ID NO:74 6: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 364 ; aminokyselin (B) TYP: : aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY : žádný (xi) POPIS SEKVENCE: ! 3EQ : ID NO:746: Ala Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His 1 5 10 15 Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe 20 25 30 Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu 35 40 45 Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Phe Arg Cys Leu 50 55 60 Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly 65 70 75 80 Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gin Asp Cys Ser Phe 85 90 95 Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu 100 105 110 Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu 115 120 125 Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 130 135 140 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Tyr Val Glu Gly Gly 145 150 155 160 Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro 165 170 175 Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Pro 180 185 190 Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Cys Leu 195 200 205 Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys 210 215 220 Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu 225 230 235 240 Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser 245 250 255 Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu 260 265 270 - 835 - 60 5 10 15 20 25 30 35 40 45 50 55 CZ 295843 B6 Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu 275 280 285 Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala 290 295 300 Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu 305 310 315 320 Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg 325 330 335 Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu 340 345 350 Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro 355 360 (2) INFORMACE PRO i 3EQ : ID NO:747: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 378 , aminokyselin (B) TYP; : aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: . lineární (ii) TYP MOLEKULY : žádný (xi) POPIS SEKVENCE: : SEQ : ID NO:747: Ala Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala 1 5 10 15 Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin 20 25 30 Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys 35 40 45 Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile 50 55 60 Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro 65 70 75 80 Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin 85 90 95 Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly 100 105 110 Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly 115 120 125 Gly Ser Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser 130 135 140 Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp 145 150 155 160 Tyr Pro Val Thr Val Ala Ser Asn Leu Tyr Val Glu Gly Gly Gly Gly 165 170 175 Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro 180 185 190 Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Pro Leu Gly 195 200 205 Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Cys Leu Glu Gin 210 215 220 Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys 225 230 235 240 Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His 245 250 255 Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala 260 265 270 Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu 275 280 285 -836- 60 5 10 CZ 295843 B6 Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly 290 295 300 Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr 305 310 315 320 Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro 325 330 335 Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala 340 345 350 Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser 355 360 365 Tyr Arg Val Leu Arg His Leu Ala Gin Pro 370 375 (2) INFORMACE PRO SEQ ID NO:748: 15 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 364 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché 20 (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:748: 25 30 35 40 45 50 55 Ala Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala 1 5 10 15 Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin 20 25 30 Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys 35 40 45 Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile 50 55 60 Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro 65 70 75 80 Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin 85 90 95 Pro Asp Ser Ser Thr Leu Pro Pro Pro Trp Ser Pro Arg Pro Leu Gly 100 105 110 Ala Thr Ala Pro Thr Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile 115 120 125 Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu 130 135 140 Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Tyr Val Glu Gly Gly 145 150 155 160 Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro 165 170 175 Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Pro 180 185 190 Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Cys Leu 195 200 205 Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys 210 215 220 Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu 225 230 235 240 Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser 245 250 255 Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu 260 265 270 Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu 275 280 285 -837 - 60 CZ 295843 B6 Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala 290 295 300 Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu 305 310 315 320 5 Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg 325 330 335 Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu 340 345 350 Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro 10 355 360 (2) INFORMACE : PRO : SEQ : ID NO:749: (i) CHARAKTERISTIKY SEKVENCE: 15 (A) DÉLKA: : 370 , aminokyselin (B) TYP: : aminokyselina (C) ŘETĚZENI: jednoduché (D) TOPOLOGIE: : lineární 20 (ii) TYP MOLEKULY : žádný (xi) POPIS SEKVENCE: SEQ : ID NO:749: Ala Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala 25 1 5 10 15 Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin 20 25 30 Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys 35 40 45 30 Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile 50 55 60 Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro 65 70 75 80 Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin 35 85 90 95 Pro Asp Ser Ser Thr Leu Pro Pro Pro Trp Ser Pro Arg Pro Leu Gly 100 105 110 Ala Thr Ala Pro Thr Ala Gly Gin Pro Pro Leu Thr Gin Asp Cys Ser 115 120 125 40 Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu 130 135 140 Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn 145 150 155 160 Leu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 45 165 170 175 Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 180 185 190 Pro Asn Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser 195 200 205 50 Phe Leu Leu Lys Cys Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly 210 215 220 Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro 225 230 235 240 Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro 55 245 250 255 Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser 260 265 270 Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu 275 280 285 60 Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu 290 295 300 838 - CZ 295843 B6 Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu 305 310 315 320 Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe 325 330 335 5 Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His 340 345 350 Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala 355 360 365 Gin Pro 10 370 (2 ) INFORMACE : PRO : SEQ : ID NO:750: (i) CHARAKTERISTIKY SEKVENCE: 15 (A) DÉLKA: : 378 i aminokyselin (B) TYP : aminokysel: ina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: : lineární 20 (ii) ' TYP MOLEKULY : žádný (xi) POPIS SEKVENCE: : SEQ : ID NO:750: Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 25 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly 20 25 30 Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala 35 40 45 30 Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser 50 55 60 Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80 Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro 35 85 90 95 Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 100 105 110 Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 115 120 125 40 Ser Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp 130 135 140 Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr 145 150 155 160 Pro Val Thr Val Ala Ser Asn Leu Gin Tyr Val Glu Gly Gly Gly Gly 45 165 170 175 Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro 180 185 190 Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Pro Leu Gly 195 200 205 50 Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Cys Leu Glu Gin 210 215 220 Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys 225 230 235 240 Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His 55 245 250 255 Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala 260 265 270 Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu 275 280 285 60 Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly 290 295 300 -839- 5 10 CZ 295843 B6 O - Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr 305 310 315 320 Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro 325 330 335 Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala 340 345 350 Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser 355 360 365 Tyr Arg Val Leu Arg His Leu Ala Gin Pro 370 375 (2) INFORMACE PRO SEQ ID NO:751: (i) CHARAKTERISTIKY SEKVENCE: 15 (A) DÉLKA: 378 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 20 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:751: 25 30 35 40 45 50 55 Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 1 5 10 15 Arg Trp Met Glu Arg Pro Lys Thr Val Ala Gly Ser Lys Met Gin Gly 20 25 30 Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser 50 55 60 Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80 Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro 85 90 95 Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 100 105 110 Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 115 120 125 Ser Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp 130 135 140 Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr 145 150 155 160 Pro Val Thr Val Ala Ser Asn Leu Gin Tyr Val Glu Gly Gly Gly Gly 165 170 175 Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro 180 185 190 Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Pro Leu Gly 195 200 205 Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Cys Leu Glu Gin 210 215 220 Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys 225 230 235 240 Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His 245 250 255 Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala 260 265 270 Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu 275 280 285 Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly 290 295 300 -840- 60 5 10 CZ 295843 B6 Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr 305 310 315 320 Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro 325 330 335 Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala 340 345 350 Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser 355 360 365 Tyr Arg Val Leu Arg His Leu Ala Gin Pro 370 375 (2) INFORMACE PRO SEQ ID NO:752: (i) CHARAKTERISTIKY SEKVENCE: 15 (A) DÉLKA: 370 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 20 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:752: 25 30 35 40 45 50 55 Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly 20 25 30 Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser 50 55 60 Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80 Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro 85 90 95 Asp Ser Ser Thr Leu Pro Pro Pro Trp Ser Pro Arg Pro Leu Gly Ala 100 105 110 Thr Ala Pro Thr Ala Gly Gin Pro Pro Leu Thr Gin Asp Cys Ser Phe 115 120 125 Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu 130 135 140 Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu 145 150 155 160 Gin Tyr Val Glu Gly Gly Gly Gly Thr Pro Gly Glu Pro Ser Gly Pro 165 170 175 Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 180 185 190 Pro Asn Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser 195 200 205 Phe Leu Leu Lys Cys Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly 210 215 220 Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro 225 230 235 240 Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro 245 250 255 Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser 260 265 270 Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu 275 280 285 Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu 290 295 300 -841 - 60 CZ 295843 B6 Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu 305 310 315 320 Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe 325 330 335 Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His 340 345 350 Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala 355 360 365 Gin Pro 370 (2) INFORMACE PRO SEQ ID NO:753: (i) CHARAKTERISTIKY SEKVENCE: 15 (A) DÉLKA: 347 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 20 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:753: Ala Asp Glu Glu Leu Cys Gly 25 1 5 Arg Trp Met Glu Arg Leu Lys 20 Leu Leu Glu Arg Val Asn Thr 35 30 Phe Gin Pro Pro Pro Ser Cys 50 55 Arg Leu Leu Gin Glu Thr Ser 65 70 Ile Thr Arg Gin Asn Phe Ser 35 85 Val Glu Thr Val Phe His Arg 100 Thr Ser Thr Gin Asp Cys Ser 115 40 Phe Ala Val Lys Ile Arg Glu 130 135 Pro Val Thr Val Ala Ser Asn 145 150 Ser Pro Gly Gly Gly Ser Gly 45 165 Gly Pro Ala Ser Ser Leu Pro 180 Gin Val Arg Lys Ile Gin Gly 195 50 Cys Ala Thr Asn Lys Leu Cys 210 215 His Ser Leu Gly Ile Pro Trp 225 230 Ala Leu Gin Leu Ala Gly Cys 55 245 Leu Tyr Gin Gly Leu Leu Gin 260 Gly Pro Thr Leu Asp Thr Leu 275 60 Thr Ile Trp Gin Gin Met Glu 290 295 Gly Leu Trp Arg Leu Val Leu Ala Gin 10 15 Thr Val Ala Gly Ser Lys Met Gin Gly 25 30 Glu Ile His Phe Val Thr Lys Cys Ala 40 45 Leu Arg Phe Val Gin Thr Asn Ile Ser 60 Glu Gin Leu Val Ala Leu Lys Pro Trp 75 80 Arg Cys Leu Glu Leu Gin Cys Gin Pro 90 95 Val Ser Gin Asp Gly Leu Asp Leu Leu 105 110 Phe Gin His Ser Pro Ile Ser Ser Asp 120 125 Leu Ser Asp Tyr Leu Leu Gin Asp Tyr 140 Leu Gin Tyr Val Glu Gly Gly Gly Gly 155 160 Gly Gly Ser Asn Met Ala Thr Pro Leu 170 175 Gin Ser Phe Leu Leu Lys Ser Leu Glu 185 190 Asp Gly Ala Ala Leu Gin Glu Lys Leu 200 205 His Pro Glu Glu Leu Val Leu Leu Gly 220 Ala Pro Leu Ser Ser Cys Pro Ser Gin 235 240 Leu Ser Gin Leu His Ser Gly Leu Phe 250 255 Ala Leu Glu Gly Ile Ser Pro Glu Leu 265 270 Gin Leu Asp Val Ala Asp Phe Ala Thr 280 285 Glu Leu Gly Met Ala Pro Ala Leu Gin -842- 300 5 CZ 295843 B6 Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg 305 310 315 320 Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val 325 330 335 Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro 340 345 (2) INFORMACE PRO SEQ ID NO:754: 10 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 384 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 15 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:754: 20 25 30 35 40 45 50 55 Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly 20 25 30 Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser 50 55 60 Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80 Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro 85 90 95 Asp Ser Ser Thr Leu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu 100 105 110 Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu 115 120 125 Ser His Lys Ser Pro Asn Met Ala Thr Pro Leu Gly Pro Ala Ser Ser 130 135 140 Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile 145 150 155 160 Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys 165 170 175 Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile 180 185 190 Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala 195 200 205 Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu 210 215 220 Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp 225 230 235 240 Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin 245 250 255 Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala 260 265 270 Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu 275 280 285 Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu 290 295 300 Arg His Leu Ala Gin Pro Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly 305 310 315 320 Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys 325 330 335 - 843 - 60 CZ 295843 B6 Glu Ser His Lys Ser Pro Asn Met Ala Thr Gin Asp Cys Ser Phe Gin 340 345 350 His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser 355 360 365 Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin 370 375 380 (2 ) INFORMACE PRO ; SEQ ID NO:755: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 349 aminokyselin (B) TYP : aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) ' ΓΥΡ MOLEKULY : žádný (xi) : POPIS SEKVENCE: SEQ : ID NO:755: Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe 1 5 10 15 Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro 20 25 30 Val Thr Val Ala Ser Asn Leu Gin Glu Pro Lys Ser Pro Asp Thr His 35 40 45 Thr Ser Pro Pro Ser Pro Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro 50 55 60 Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly 65 70 75 80 Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys 85 90 95 His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp 100 105 110 Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys 115 120 125 Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin 130 135 140 Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu 145 150 155 160 Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu 165 170 175 Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro 180 185 190 Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala 195 200 205 Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His 210 215 220 Leu Ala Gin Pro Ser Ala Glu Pro Lys Ser Pro Asp Thr His Thr Ser 225 230 235 240 Pro Pro Ser Pro Gly Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly 245 250 255 Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr 260 265 270 Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu 275 280 285 Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu 290 295 300 Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu 305 310 315 320 Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg 325 330 335 -844- CZ 295843 B6 Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 340 345 (2) INFORMACE PRO SEQ ID NO:756: 5 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 347 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché 10 (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:756: 15 Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe 1 5 10 15 Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro 20 25 30 Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu 35 40 45 Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val 50 55 60 Ala Gly Ser Lys Met Gin Gly Trp Gin Gly Arg Val Asn Thr Glu Ile 65 70 75 80 His Phe Val Thr Lys Cys Ala Phe Pro Lys Ser Pro Asp Thr His Thr 85 90 95 Ser Pro Pro Ser Pro Gly Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro 100 105 110 Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly 115 120 125 Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Tyr Lys Leu Cys His 130 135 140 Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala 145 150 155 160 Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu 165 170 175 Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala 180 185 190 Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin 195 200 205 Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu 210 215 220 Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala 225 230 235 240 Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser 245 250 255 His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu 260 265 270 Ala Gin Pro Ser Ala Glu Pro Lys Ser Pro Asp Thr His Thr Ser Pro 275 280 285 Pro Ser Pro Gly Lys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe 290 295 300 Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu 305 310 315 320 Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu 325 330 335 Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 340 345 -845 - 60 CZ 295843 B6 (2) INFORMACE PRO SEQ ID NO:757: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 355 aminokyselin 5 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:757: Ala 1 Asp Glu Glu Leu 5 Cys Gly 15 Arg Trp Met Glu 20 Arg Leu Lys Leu Leu Glu Arg 35 Val Asn Thr 20 Phe Gin 50 Pro Pro Pro Ser Cys 55 Arg 65 Leu Leu Gin Glu Thr 70 Ser Ile Thr Arg Gin Asn 85 Phe Ser 25 Asp Ser Ser Thr 100 Leu Gly Gly Ser Gly Gly 115 Gly Ser Gly Gly 30 Gin His 130 Ser Pro Ile Ser Ser 135 Ser 145 Asp Tyr Leu Leu Gin 150 Asp Gin Tyr Val Glu Gly 165 Gly Gly 35 Gly Ser Asn Met 180 Ala Thr Pro Ser Phe Leu 195 Leu Lys Ser Leu 40 Gly Ala 210 Ala Leu Gin Glu Lys 215 Pro 225 Glu Glu Leu Val Leu 230 Leu Pro Leu Ser Ser Cys 245 Pro Ser 45 Ser Gin Leu His 260 Ser Gly Leu Leu Glu Gly 275 Ile Ser Pro Glu 50 Leu Asp 290 Val Ala Asp Phe Ala 295 Leu 305 Gly Met Ala Pro Ala 310 Leu Phe Ala Ser Ala Phe 325 Gin Arg 55 His Leu Gin Ser Phe Leu Glu 340 Gly Leu Trp Arg Leu Val Leu Ala Gin 10 15 Thr Val Ala Gly Ser Lys Met Gin Gly 25 30 Glu Ile His Phe Val Thr Lys Ser Ala 40 45 Leu Arg Phe Val Gin Thr Asn Ile Ser 60 Glu Gin Leu Val Ala Leu Lys Pro Trp 75 80 Arg Cys Leu Glu Leu Gin Cys Gin Pro 90 95 Gly Ser Gly Gly Gly Ser Gly Gly Gly 105 110 Gly Ser Gly Thr Gin Asp Ser Ser Phe 120 125 Asp Phe Ala Val Lys Ile Arg Glu Leu 140 Tyr Pro Val Thr Val Ala Ser Asn Leu 155 160 Gly Ser Pro Gly Gly Gly Ser Gly Gly 170 175 Leu Gly Pro Ala Ser Ser Leu Pro Gin 185 190 Glu Gin Val Arg Lys Ile Gin Gly Asp 200 205 Leu Cys Ala Thr Asn Lys Leu Cys His 220 Gly His Ser Leu Gly Ile Pro Trp Ala 235 240 Gin Ala Leu Gin Leu Ala Gly Cys Leu 250 255 Phe Leu Tyr Gin Gly Leu Leu Gin Ala 265 270 Leu Gly Pro Thr Leu Asp Thr Leu Gin 280 285 Thr Thr Ile Trp Gin Gin Met Glu Glu 300 Gin Pro Thr Gin Gly Ala Met Pro Ala 315 320 Arg Ala Gly Gly Val Leu Val Ala Ser 330 335 Val Ser Tyr Arg Val Leu Arg His Leu 345 350 Ala Gin Pro 355 CZ 295843 B6 (2) INFORMACE PRO SEQ ID NO:758: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 370 aminokyselin 5 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:758: 10 Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu 1 5 10 15 15 Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu 20 25 30 Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu 35 40 45 Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser 20 50 55 60 Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His 65 70 75 80 Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile 85 90 95 25 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala 100 105 110 Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala 115 120 125 Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala 30 130 135 140 Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser 145 150 155 160 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Tyr 165 170 175 35 Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser 180 185 190 Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn 195 200 205 Met Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala 40 210 215 220 Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin 225 230 235 240 Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Ser 245 250 255 45 Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile 260 265 270 Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro 275 280 285 Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin 50 290 295 300 Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly 305 310 315 320 Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Ser Ser 325 330 335 55 Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu 340 345 350 Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn 355 360 365 Leu Gin 60 3 7 0 -847- CZ 295843 B6 (2) INFORMACE PRO SEQ ID NO:759: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 355 aminokyselin 5 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:759: 10 Ala Asp Glu Glu 1 15 Arg Trp Met Glu 20 Leu Leu Glu Arg 35 Phe Gin Pro Pro 20 50 Arg Leu Leu Gin 65 Ile Thr Arg Gin 25 Asp Ser Ser Thr 100 Ser Gly Gly Gly 115 Gin His Ser Pro 30 130 Ser Asp Tyr Leu 145 Gin Tyr Val Glu 35 Gly Ser Asn Met 180 Ser Phe Leu Leu 195 Gly Ala Ala Leu 40 210 Pro Glu Glu Leu 225 Pro Leu Ser Ser 45 Ser Gin Leu His 260 Leu Glu Gly Ile 275 Leu Asp Val Ala 50 290 Leu Gly Met Ala 305 Phe Ala Ser Ala 55 His Leu Gin Ser 340 Ala Gin Pro Leu 5 Cys Gly Gly Leu Trp 10 Arg Leu Lys Thr Val 25 Ala Val Asn Thr Glu 40 Ile His Pro Ser Ser 55 Leu Arg Phe Glu Thr 70 Ser Glu Gin Leu Asn 85 Phe Ser Arg Cys Leu 90 Leu Gly Gly Gly Ser 105 Gly Ser Gly Gly Gly 120 Ser Gly Ile Ser Ser 135 Asp Phe Ala Leu Gin 150 Asp Tyr Pro Val Gly 165 Gly Gly Gly Ser Pro 170 Ala Thr Pro Leu Gly 185 Pro Lys Ser Leu Glu 200 Gin Val Gin Glu Lys 215 Leu Cys Ala Val Leu 230 Leu Gly His Ser Cys 245 Pro Ser Gin Ala Leu 250 Ser Gly Leu Phe Leu 265 Tyr Ser Pro Glu Leu 280 Gly Pro Asp Phe Ala 295 Thr Thr Ile Pro Ala 310 Leu Gin Pro Thr Phe 325 Gin Arg Arg Ala Gly 330 Phe Leu Glu Val Ser 345 Tyr Arg Leu Val Leu Ala 15 Gin Gly Ser Lys Met 30 Gin Gly Phe Val Thr 45 Lys Cys Ala Val Gin 60 Thr Asn Ile Ser Val 75 Ala Leu Lys Pro Trp 80 Glu Leu Gin Ser Gin 95 Pro Gly Gly Ser Gly 110 Gly Gly Thr Gin Asp 125 Cys Ser Phe Val Lys 140 Ile Arg Glu Leu Thr 155 Val Ala Ser Asn Leu 160 Gly Gly Gly Ser Gly Gly 175 Ala Ser Ser Leu 190 Pro Gin Arg Lys Ile 205 Gin Gly Asp Thr Asn 220 Lys Leu Cys His Leu 235 Gly Ile Pro Trp Ala 240 Gin Leu Ala Gly Cys 255 Leu Gin Gly Leu Leu 270 Gin Ala Thr Leu Asp 285 Thr Leu Gin Trp Gin 300 Gin Met Glu Glu Gin 315 Gly Ala Met Pro Ala 320 Gly Val Leu Val Ala 335 Ser Arg Val Leu Arg 350 His Leu -848- 355 CZ 295843 B6 (2) INFORMACE PRO SEQ ID NO:760: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 370 aminokyselin 5 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:760: Ala 1 Thr Pro Leu Gly 5 Pro Ala 15 Lys Ser Leu Glu 20 Gin Val Arg Gin Glu Lys 35 Leu Cys Ala Thr 20 Val Leu 50 Leu Gly His Ser Leu 55 Cys 65 Pro Ser Gin Ala Leu 70 Gin Ser Gly Leu Phe Leu 85 Tyr Gin 25 Ser Pro Glu Leu 100 Gly Pro Thr Asp Phe Ala 115 Thr Thr Ile Trp 30 Pro Ala 130 Leu Gin Pro Thr Gin 135 Phe 145 Gin Arg Arg Ala Gly 150 Gly Phe Leu Glu Val Ser 165 Tyr Arg 35 Val Glu Gly Gly 180 Gly Gly Ser Thr Ile Asn 195 Pro Ser Pro Pro 40 Met Ala 210 Asp Glu Glu Leu Cys 215 Gin 225 Arg Trp Met Glu Arg 230 Leu Gly Leu Leu Glu Arg 245 Val Asn 45 Ala Phe Gin Pro 260 Pro Pro Ser Ser Arg Leu 275 Leu Gin Glu Thr 50 Trp Ile 290 Thr Arg Gin Asn Phe 295 Pro 305 Asp Ser Ser Thr Leu 310 Gly Gly Ser Gly Gly Gly 325 Ser Gly 55 Phe Gin His Ser 340 Pro Ile Ser Leu Leu Ser Gin Asp 355 Tyr Leu Leu Gin 60 3 7 0 Ser Ser Leu Pro Gin Ser Phe Leu Leu 10 15 Lys Ile Gin Gly Asp Gly Ala Ala Leu 25 30 Tyr Lys Leu Cys His Pro Glu Glu Leu 40 45 Gly Ile Pro Trp Ala Pro Leu Ser Ser 60 Leu Ala Gly Cys Leu Ser Gin Leu His 75 80 Gly Leu Leu Gin Ala Leu Glu Gly Ile 90 95 Leu Asp Thr Leu Gin Leu Asp Val Ala 105 110 Gin Gin Met Glu Glu Leu Gly Met Ala 120 125 Gly Ala Met Pro Ala Phe Ala Ser Ala 140 Val Leu Val Ala Ser His Leu Gin Ser 155 160 Val Leu Arg His Leu Ala Gin Pro Tyr 170 175 Pro Gly Glu Pro Ser Gly Pro Ile Ser 185 190 Ser Lys Glu Ser His Lys Ser Pro Asn 200 205 Gly Gly Leu Trp Arg Leu Val Leu Ala 220 Lys Thr Val Ala Gly Ser Lys Met Gin 235 240 Thr Glu Ile His Phe Val Thr Lys Cys 250 255 Ser Leu Arg Phe Val Gin Thr Asn Ile 265 270 Ser Glu Gin Leu Val Ala Leu Lys Pro 280 285 Ser Arg Cys Leu Glu Leu Gin Ser Gin 300 Gly Gly Ser Gly Gly Gly Ser Gly Gly 315 320 Gly Gly Ser Gly Thr Gin Asp Cys Ser 330 335 Ser Asp Phe Ala Val Lys Ile Arg Glu 345 350 Asp Tyr Pro Val Thr Val Ala Ser Asn 360 365 -849- 5 CZ 295843 B6 (2) INFORMACE PRO SEQ ID NO:761: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 334 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 10 (xi) POPIS SEKVENCE: SEQ ID NO:761: 15 20 25 30 35 40 45 50 55 Ala Thr Gin Asp Ser Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe 1 5 10 15 Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro 20 25 30 Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu 35 40 45 Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val 50 55 60 Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile 65 70 75 80 His Phe Val Thr Lys Ser Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg 85 90 95 Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin 100 105 110 Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys 115 120 125 Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Tyr Val Glu Gly 130 135 140 Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala 145 150 155 160 Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys 165 170 175 Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin 180 185 190 Glu Lys Leu Cys Ala Thr Asn Lys Leu Cys His Pro Glu Glu Leu Val 195 200 205 Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys 210 215 220 Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser 225 230 235 240 Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser 245 250 255 Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp 260 265 270 Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro 275 280 285 Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe 290 295 300 Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe 305 310 315 320 Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro 325 330 (2) INFORMACE PRO SEQ ID NO:762: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 334 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché -850- 60 ID NO:762: His Ser Pro Ile Ser Ser Asp Phe 10 15 Asp Tyr Leu Leu Gin Asp Tyr Pro 25 30 Asp Glu Glu Leu Cys Gly Gly Leu 45 Trp Met Glu Arg Leu Lys Thr Val 60 Leu Glu Arg Val Asn Thr Glu Ile 75 80 Gin Pro Pro Pro Ser Ser Leu Arg 90 95 Leu Leu Gin Glu Thr Ser Glu Gin 105 110 Thr Arg Gin Asn Phe Ser Arg Cys 125 Ser Ser Thr Leu Tyr Val Glu Gly 140 Ser Gly Gly Gly Ser Asn Met Ala 155 160 Leu Pro Gin Ser Phe Leu Leu Lys 170 175 Gin Gly Asp Gly Ala Ala Leu Gin 185 190 Leu Cys His Pro Glu Glu Leu Val 205 Pro Trp Ala Pro Leu Ser Ser Cys 220 Gly Cys Leu Ser Gin Leu His Ser 235 240 Leu Gin Ala Leu Glu Gly Ile Ser 250 255 Thr Leu Gin Leu Asp Val Ala Asp 265 270 Met Glu Glu Leu Gly Met Ala Pro 285 Met Pro Ala Phe Ala Ser Ala Phe 300 Val Ala Ser His Leu Gin Ser Phe 315 320 Arg His Leu Ala Gin Pro 330 CZ 295843 B6 (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 5 (xi) POPIS SEKVENCE: SEQ Ala Thr Gin Asp Cys Ser Phe Gin 1 5 Ala Val Lys Ile Arg Glu Leu Ser 10 20 Val Thr Val Ala Ser Asn Leu Gin 35 40 Trp Arg Leu Val Leu Ala Gin Arg 50 55 15 Ala Gly Ser Lys Met Gin Gly Leu 65 70 His Phe Val Thr Lys Cys Ala Phe 85 Phe Val Gin Thr Asn Ile Ser Arg 20 100 Leu Val Ala Leu Lys Pro Trp Ile 115 120 Leu Glu Leu Gin Ser Gin Pro Asp 130 135 25 Gly Gly Gly Ser Pro Gly Gly Gly 145 150 Thr Pro Leu Gly Pro Ala Ser Ser 165 Ser Leu Glu Gin Val Arg Lys Ile 30 180 Glu Lys Leu Cys Ala Thr Asn Lys 195 200 Leu Leu Gly His Ser Leu Gly Ile 210 215 35 Pro Ser Gin Ala Leu Gin Leu Ala 225 230 Gly Leu Phe Leu Tyr Gin Gly Leu 245 Pro Glu Leu Gly Pro Thr Leu Asp 40 260 Phe Ala Thr Thr Ile Trp Gin Gin 275 280 Ala Leu Gin Pro Thr Gin Gly Ala 290 295 45 Gin Arg Arg Ala Gly Gly Val Leu 305 310 Leu Glu Val Ser Tyr Arg Val Leu 325 50 (2) INFORMACE PRO SEQ ID NO:763: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 326 aminokyselin (B) TYP: aminokyselina 55 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 60 (xi) POPIS SEKVENCE: SEQ ID NO:763: -851 - 5 10 15 20 25 30 35 40 CZ 295843 B6 Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe 1 5 10 15 Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro 20 25 30 Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu 35 40 45 Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val 50 55 60 Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile 65 70 75 80 His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg 85 90 95 Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin 100 105 110 Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys 115 120 125 Leu Glu Leu Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly 130 135 140 Ser Gly Gly Gly Ser Asn Met Ala Thr Pro Leu Gly Pro Ala Ser Ser 145 150 155 160 Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile 165 170 175 Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Asn Lys 180 185 190 Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile 195 200 205 Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu. Ala 210 215 220 Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu 225 230 235 340 Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp 245 250 255 Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin 260 265 270 Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala 275 280 285 Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu 290 295 300 Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu 305 310 315 320 Arg His Leu Ala Gin Pro 325 (2) INFORMACE PRO SEQ ID NO:764: 45 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 334 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché 50 (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:764: 55 Ala 1 Thr Gin Asp Cys 5 Ser Phe Gin His Ser 10 Pro Ile Ser Ser Asp 15 Phe Ala Val Lys Ile 20 Arg Glu Leu Ser Asp 25 Tyr Leu Leu Gin Asp 30 Tyr Pro Val Thr Val 35 Ala Ser Asn Leu Gin 40 Asp Glu Glu Leu Cys 45 Gly Gly Leu -852- 60 CZ 295843 B6 Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val 50 55 60 Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile 65 70 75 80 His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg 85 90 95 Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin 100 105 110 Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys 115 120 125 Leu Glu Leu Gin Ser Gin Pro Asp Ser Ser Thr Leu Tyr Val Glu Gly 130 135 140 Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala 145 150 155 160 Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys 165 170 175 Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin 180 185 190 Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val 195 200 205 Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys 210 215 220 Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser 225 230 235 240 Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser 245 250 255 Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp 260 265 270 Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro 275 280 285 Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe 290 295 300 Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe 305 310 315 320 Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro 325 330 (2) INFORMACE PRO SEQ ID NO:765: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 334 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:765: Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe 1 5 10 15 Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro 20 25 30 Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu 35 40 45 Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val 50 55 60 Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile 65 70 75 80 His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg 85 90 95 -853 - CZ 295843 B6 Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin 100 105 110 Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Arg 115 120 125 Leu Glu Leu Gin Ser Gin Pro Asp Ser Ser Thr Leu Tyr Val Glu Gly 130 135 140 Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala 145 150 155 160 Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys 165 170 175 Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin 180 185 190 Glu Lys Leu Cys Ala Thr Asn Lys Leu Cys His Pro Glu Glu Leu Val 195 200 205 Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys 210 215 220 Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser 225 230 235 240 Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser 245 250 255 Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp 260 265 270 Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro 275 280 285 Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe 290 295 300 Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe 305 310 315 320 Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro 325 330 (2) INFORMACE PRO SEQ ID NO:766: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 352 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:766: Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly 20 25 30 Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser 50 55 60 Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80 Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro 85 90 95 Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 100 105 110 Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe 115 120 125 Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu 130 135 140 -854- CZ 295843 B6 Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu 145 150 155 160 Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly 165 170 175 Gly Ser Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala 180 185 190 Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser 195 200 205 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser 210 215 220 Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin 225 230 235 240 Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys 245 250 255 Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His 260 265 270 Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala 275 280 285 Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu 290 295 300 Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly 305 310 315 320 Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr 325 330 335 Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro 340 345 350 (2) INFORMACE PRO SEQ ID NO:767: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 367 aminokyselin (B) TYP: : aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: : žádný (xi) POPIS SEKVENCE: SEQ ID NO:767: Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg 1 5 10 15 Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val 20 25 30 Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly 35 40 45 Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile 50 55 60 Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys 65 70 75 80 Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile 85 90 95 Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala 100 105 110 Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu 115 120 125 Leu Gin Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp 130 135 140 Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin 145 150 155 160 Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Tyr Val Glu Gly 165 170 175 -855- 5 10 15 20 25 CZ 295843 B6 Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn 180 185 190 Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Asp 195 200 205 Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp 210 215 220 Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu 225 230 235 240 Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala Phe Gin 245 250 255 Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser Arg Leu 260 265 270 Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp Ile Thr 275 280 285 Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser 290 295 300 Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly 305 310 315 320 Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe Gin His 325 330 335 Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp 340 345 350 Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin 355 360 365 (2) INFORMACE PRO SEQ ID NO:768: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 344 aminokyselin 30 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 35 (xi) POPIS SEKVENCE: SEQ ID NO:768: 40 45 50 55 Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly 20 25 30 Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser 50 55 60 Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80 Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro 85 90 95 Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 100 105 110 Ser Gly Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser 115 120 125 Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin 130 135 140 Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Tyr Val Glu Gly Gly 145 150 155 160 Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro 165 170 175 Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Asp Glu 180 185 190 - 856 - 60 5 5 10 15 20 CZ 295843 B6 Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met 195 200 205 Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu 210 215 220 Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro 225 230 235 240 Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu 245 250 255 Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg 260 265 270 Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser 275 280 285 Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly 290 295 300 Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe 305 310 315 320 Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro 325 330 335 Val Thr Val Ala Ser Asn Leu Gin 340 (2) INFORMACE PRO SEQ ID NO:769: (i) CHARAKTERISTIKY SEKVENCE: 25 (A) DÉLKA: 335 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 30 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:769: 35 40 45 50 55 Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly 20 25 30 Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser 50 55 60 Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80 Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro 85 90 95 Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 100 105 110 Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe 115 120 125 Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu 130 135 140 Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu 145 150 155 160 Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro 165 170 175 Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 180 185 190 Pro Asn Met Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser 195 200 205 Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin 210 215 220 - 857- 60 5 10 15 CZ 295843 B6 Asn Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys 225 230 235 240 Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu 245 250 255 Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn 260 265 270 Thr Glu Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser 275 280 285 Cys Leu Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr 290 295 300 Ser Glu Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe 305 310 315 320 Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 325 330 335 (2) INFORMACE PRO SEQ ID NO:770: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 550 aminokyselin 20 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 25 (xi) POPIS SEKVENCE: SEQ ID NO:770: 30 35 40 45 50 55 Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly 20 25 30 Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser 50 55 60 Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80 Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro 85 90 95 Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 100 105 110 Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe 115 120 125 Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu 130 135 140 Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu 145 150 155 160 Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly 165 170 175 Gly Ser Asn Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin 180 185 190 Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp 195 200 205 Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His 210 215 220 Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala 225 230 235 240 Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu 245 250 255 Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala 260 265 270 -858- 60 CZ 295843 B6 Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin 275 280 285 Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu 290 295 300 Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala 305 310 315 320 Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser 325 330 335 His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu 340 345 350 Ala Gin Pro Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser 355 360 365 Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His 370 375 380 Lys Ser Pro Asn Met Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg 385 390 395 400 Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly 405 410 415 Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe 420 425 430 Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val 435 440 445 Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val 450 455 460 Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu 465 470 475 480 Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly 485 490 495 Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr 500 505 510 Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val 515 520 525 Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr 530 535 540 Val Ala Ser Asn Leu Gin 545 550 (2) INFORMACE PRO SEQ ID NO:771: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 544 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:771 Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu 1 5 10 15 Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu 20 25 30 Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu 35 40 45 Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser 50 55 60 Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His 65 70 75 80 Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile 85 90 95 -859- CZ 295843 B6 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala 100 105 110 Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala 115 120 125 5 Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala 130 135 140 Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser 145 150 155 160 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Tyr 10 165 170 175 Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser 180 185 190 Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn 195 200 205 15 Met Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala 210 215 220 Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin 225 230 235 240 Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys 20 245 250 255 Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile 260 265 270 Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro 275 280 285 25 Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin 290 295 300 Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly 305 310 315 320 Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser 30 325 330 335 Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu 340 345 350 Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn 355 360 365 35 Leu Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly 370 375 380 Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys 385 390 395 400 Ser Pro Asn Met Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile 40 405 410 415 Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu 420 425 430 Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu 435 440 445 45 Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg 450 455 460 Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val 465 470 475 480 Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro 50 485 490 495 Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu 500 505 510 Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn 515 520 525 55 Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 530 535 540 (2) INFORMACE PRO SEQ ID NO:772: 60 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 565 aminokyselin - 860- CZ 295843 B6 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 5 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:772: Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu 10 1 5 10 15 Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu 20 25 30 Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu 35 40 45 15 Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser 50 55 60 Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His 65 70 75 80 Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile 20 85 90 95 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala 100 105 110 Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu Leu Gly Met Ala 115 120 125 25 Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala 130 135 140 Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser 145 150 155 160 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Tyr 30 165 170 175 Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser 180 185 190 Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn 195 200 205 35 Met Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala 210 215 220 Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin 225 230 235 240 Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys 40 245 250 255 Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile 260 265 270 Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro 275 280 285 45 Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin 290 295 300 Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly 305 310 315 320 Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser 50 325 330 335 Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu 340 345 350 Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn 355 360 365 55 Leu Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly 370 375 380 Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys 385 390 395 400 Ser Pro Asn Met Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu 60 405 410 415 -861 - 5 5 10 15 20 CZ 295843 B6 Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser 420 425 430 Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val 435 440 445 Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin 450 455 460 Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala 465 470 475 480 Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu 485 490 495 Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly 500 505 510 Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin 515 520 525 Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys 530 535 540 Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val 545 550 555 560 Ala Ser Asn Leu Gin 565 (2) INFORMACE PRO SEQ ID NO:773: (i) CHARAKTERISTIKY SEKVENCE: 25 (A) DÉLKA: 502 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 30 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:773: 35 40 45 50 55 Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu 145 150 155 160 Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met 165 170 175 Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys 180 185 190 Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn 195 200 205 Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys 210 215 220 -862- 60 5 10 15 20 25 30 35 CZ 295843 B6 Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys 225 230 235 240 Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly 245 250 255 Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys 260 265 270 Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg 275 280 285 Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser 290 295 300 Asn Leu Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser 305 310 315 320 Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His 325 330 335 Lys Ser Pro Asn Met Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg 340 345 350 Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly 355 360 365 Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe 370 375 380 Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val 385 390 395 400 Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val 405 410 415 Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu 420 425 430 Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly 435 440 445 Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr 450 455 460 Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val 465 470 475 480 Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr 485 490 495 Val Ala Ser Asn Leu Gin 500 (2) INFORMACE PRO SEQ ID NO:774: 40 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 562 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 45 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:774: 50 55 Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly 20 25 30 Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser 50 55 60 Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80 Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro 85 90 95 - 863 - 60 CZ 295843 B6 Asp Ser Ser Thr 100 Leu Gly Gly Ser Gly Gly 115 Gly Ser Gly Gly 5 Gin His 130 Ser Pro Ile Ser Ser 135 Ser 145 Asp Tyr Leu Leu Gin 150 Asp 10 Gin Tyr Val Glu Gly Gly 165 Gly Gly Ser Asn Met 180 Ala Asp Glu Val Leu Ala 195 Gin Arg Trp Met 15 Lys Met 210 Gin Gly Leu Leu Glu 215 Thr 225 Lys Cys Ala Phe Gin 230 Pro 20 Thr Asn Ile Ser Arg 245 Leu Leu Leu Lys Pro Trp 260 Ile Thr Arg Gin Cys Gin 275 Pro Asp Ser Ser 25 Ser Gly 290 Gly Gly Ser Gly Gly 295 Asp 305 Cys Ser Phe Gin His 310 Ser 30 Ile Arg Glu Leu Ser Asp 325 Tyr Ala Ser Asn Leu 340 Gin Tyr Val Pro Ser Gly 355 Pro Ile Ser Thr 35 Ser His 370 Lys Ser Pro Asn Met 375 Leu 385 Pro Gin Ser Phe Leu 390 Leu 40 Gin Gly Asp Gly Ala 405 Ala Leu Leu Cys His Pro 420 Glu Glu Leu Pro Trp Ala 435 Pro Leu Ser Ser 45 Gly Cys 450 Leu Ser Gin Leu His 455 Leu 4 65 Gin Ala Leu Glu Gly 470 Ile 50 Thr Leu Gin Leu Asp 485 Val Ala Met Glu Glu Leu 500 Gly Met Ala Met Pro Ala 515 Phe Ala Ser Ala 55 Val Ala 530 Ser His Leu Gin Ser 535 60 Arg 545 Gly His Ser Leu Ala Gin Pro 550 Ser Gly Ser Gly Gly Gly Ser Gly Gly Gly 105 110 Gly Ser Gly Thr Gin Asp Cys Ser Phe 120 125 Asp Phe Ala Val Lys Ile Arg Glu Leu 140 Tyr Pro Val Thr Val Ala Ser Asn Leu 155 160 Gly Ser Pro Gly Gly Gly Ser Gly Gly 170 175 Glu Leu Cys Gly Gly Leu Trp Arg Leu 185 190 Glu Arg Leu Lys Thr Val Ala Gly Ser 200 205 Arg Val Asn Thr Glu Ile His Phe Val 220 Pro Pro Ser Cys Leu Arg Phe Val Gin 235 240 Gin Glu Thr Ser Glu Gin Leu Val Ala 250 255 Gin Asn Phe Ser Arg Cys Leu Glu Leu 265 270 Thr Leu Gly Gly Gly Ser Gly Gly Gly 280 285 Gly Ser Gly, Gly Gly Ser Gly Thr Gin 300 Pro Ile Ser Ser Asp Phe Ala Val Lys 315 320 Leu Leu Gin Asp Tyr Pro Val Thr Val 330 335 Glu Gly Gly Gly Gly Ser Pro Gly Glu 345 350 Ile Asn Pro Ser Pro Pro Ser Lys Glu 360 365 Ala Thr Pro Leu Gly Pro Ala Ser Ser 380 Lys Cys Leu Glu Gin Val Arg Lys Ile 395 400 Gin Glu Lys Leu Cys Ala Thr Tyr Lys 410 415 Val Leu Leu Gly His Ser Leu Gly Ile 425 430 Cys Pro Ser Gin Ala Leu Gin Leu Ala 440 445 Ser Gly Leu Phe Leu Tyr Gin Gly Leu 460 Ser Pro Glu Leu Gly Pro Thr Leu Asp 475 480 Asp Phe Ala Thr Thr Ile Trp Gin Gin 490 495 Pro Ala Leu Gin Pro Thr Gin Gly Ala 505 510 Phe Gin Arg Arg Ala Gly Gly Val Leu 520 525 Phe Leu Glu Val Ser Tyr Arg Val Leu 540 Thr Pro Ser Thr Pro Gly Ser Glu Phe 555 560 -864- CZ 295843 B6 (2) INFORMACE PRO SEQ ID NO:775: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 490 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:775: Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly 20 25 30 Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser 50 55 60 Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80 Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro 85 90 95 Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 100 105 110 Ser Gly Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser 115 120 125 Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin 130 135 140 Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Tyr Val Glu Gly Gly 145 150 155 160 Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro 165 170 175 Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Asn Cys 180 185 190 Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Asn 195 200 205 Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met Asp Ile Leu 210 215 220 Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe Val Arg Ala 225 230 235 240 Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn 245 250 255 Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro 260 265 270 Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr 275 280 285 Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu 290 295 300 Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile 305 310 315 320 Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala 325 330 335 Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg 340 345 350 Trp Met Glu Arg Leu Lys Thr Val AI a Gly Ser Lys Met Gin Gly Leu 355 360 365 Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala Phe 370 375 380 - 865 - 5 10 15 CZ 295843 B6 Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser Arg 385 390 395 400 Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp Ile 405 410 415 Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp 420 425 430 Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser 435 440 445 Gly Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser 450 455 460 Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp 4 65 470 475 480 Tyr Pro Val Thr Val Ala Ser Asn Leu Gin 485 490 (2) INFORMACE PRO SEQ ID NO:776: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 398 aminokyselin 20 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 25 (xi) POPIS SEKVENCE: SEQ ID NO:776: 30 35 40 45 50 55 Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 1 5 10 15 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly 20 25 30 Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala 35 40 45 Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn Ile Ser 50 55 60 Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80 Ile Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro 85 90 95 Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 100 105 110 Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe 115 120 125 Gin His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu 130 135 140 Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu 145 150 155 160 Gin Glu Phe Lys Leu Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys Pro 165 170 175 Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser Val Phe 180 185 190 Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser Leu Ser Pro 195 200 205 Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro Asp Val 210 215 220 Gin Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala Gin Thr 225 230 235 240 Gin Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Ala Val Ser Ala 245 250 255 Leu Pro Ile Gin His Gin Asp Trp Met Ser Gly Lys Glu Phe Lys Cys 260 265 270 -866- 60 5 10 15 CZ 295843 B6 Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile Ser 275 280 285 Lys Pro Lys Gly Ser Val Arg Ala Pro Gin Val Tyr Val Leu Pro Pro 290 295 300 Pro Glu Glu Glu Met Thr Lys Lys Gin Val Thr Leu Thr Cys Met Val 305 310 315 320 Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn Gly 325 330 335 Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser Asp 340 345 350 Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn Trp 355 360 365 Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu Gly Leu His 370 375 380 Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys 385 390 395 (2) INFORMACE PRO SEQ ID NO:777: 20 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 377 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 25 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:777: 30 35 40 45 50 55 Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro Ile Ser Ser Asp Phe 1 5 10 15 Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro 20 25 30 Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu 35 40 45 Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val 50 55 60 Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu Ile 65 70 75 80 His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg 85 90 95 Phe Val Gin Thr Asn Ile Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin 100 105 110 Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gin Asn Phe Ser Arg Cys 115 120 125 Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Glu Phe Lys Leu 130 135 140 Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro 145 150 155 160 Ala Pro Asn Leu Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys 165 170 175 Ile Lys Asp Val Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val 180 185 190 Val Val Asp Val Ser Glu Asp Asp Pro Asp Val Gin Ile Ser Trp Phe 195 200 205 Val Asn Asn Val Glu Val His Thr Ala Gin Thr Gin Thr His Arg Glu 210 215 220 Asp Tyr Asn Ser Thr Leu Arg Ala Val Ser Ala Leu Pro Ile Gin His 225 230 235 240 Gin Asp Trp Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys 245 250 255 -867- 60 5 10 15 20 25 30 CZ 295843 B6 Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser 260 265 270 Val Arg Ala Pro Gin Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met 275 280 285 Thr Lys Lys Gin Val Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro 290 295 300 Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn 305 310 315 320 Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met 325 330 335 Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser 340 345 350 Tyr Ser Cys Ser Val Val His Glu Gly Leu His Asn His His Thr Thr 355 360 365 Lys Ser Phe Ser Arg Thr Pro Gly Lys 370 375 (2) INFORMACE PRO SEQ ID NO:778: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 4 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:778: Gly Gly Gly Ser 1 (2) INFORMACE PRO SEQ ID NO:779: 35 40 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 8 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:779: 45 Gly Gly Gly Ser Gly Gly Gly Ser 1 5 (2) INFORMACE PRO SEQ ID NO:780: 50 55 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 12 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:780: 60 Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser 15 10 -868- CZ 295843 B6 (2) INFORMACE PRO SEQ ID NO:781: (i) CHARAKTERISTIKY SEKVENCE: 5 (A) DÉLKA: 7 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 10 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:781: Ser Gly Gly Ser Gly Gly Ser 15 1 5 (2) INFORMACE PRO SEQ ID NO:782: (i) CHARAKTERISTIKY SEKVENCE: 20 (A) DÉLKA: 5 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 25 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:782: Glu Phe Gly Asn Met 30 1 5 (2) INFORMACE PRO SEQ ID NO:783: (i) CHARAKTERISTIKY SEKVENCE: 35 (A) DÉLKA: 6 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 40 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:783: Glu Phe Gly Gly Asn Met 45 1 5 (2) INFORMACE PRO SEQ ID NO:784: (i) CHARAKTERISTIKY SEKVENCE: 50 (A) DÉLKA: 9 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 55 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:784: Glu Phe Gly Gly Asn Gly Gly Asn Met 60 1 5 - 869- CZ 295843 B6 (2) INFORMACE PRO SEQ ID NO:785: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 7 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:785: Gly Gly Ser Asp Met Ala Gly 1 5 (2) INFORMACE PRO SEQ ID NO:786: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 5 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:786: Ser Gly Gly Asn Gly 1 5 (2) INFORMACE PRO SEQ ID NO:787: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 10 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:787: Ser Gly Gly Asn Gly Ser Gly Gly Asn Gly 15 10 (2) INFORMACE PRO SEQ ID NO:788: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 15 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:788: Ser Gly Gly Asn Gly Ser Gly Gly Asn Gly Ser Gly Gly Asn Gly 15 10 15 -870- 5 CZ 295843 B6 (2) INFORMACE PRO SEQ ID NO:789: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 10 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 10 (xi) POPIS SEKVENCE: SEQ ID NO:789: Ser Gly Gly Ser Gly Ser Gly Gly Ser Gly 15 10 15 (2) INFORMACE PRO SEQ ID NO:790: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 15 aminokyselin 20 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 25 (xi) POPIS SEKVENCE: SEQ ID NO:790: Ser Gly Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly Gly Ser Gly 15 10 15 30 (2) INFORMACE PRO SEQ ID NO:791: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 6 aminokyselin 35 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 40 (xi) POPIS SEKVENCE: SEQ ID NO:791: Gly Gly Gly Ser Gly Gly 1 5 45 (2) INFORMACE PRO SEQ ID NO:792: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 7 aminokyselin 50 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 55 (xi) POPIS SEKVENCE: SEQ ID NO:792: Gly Gly Gly Ser Gly Gly Gly 1 5 -871 - 5 CZ 295843 B6 (2) INFORMACE PRO SEQ ID NO:793: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 10 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 10 (xi) POPIS SEKVENCE: SEQ ID NO:793: Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly 15 10 15 (2) INFORMACE PRO SEQ ID NO:794: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 13 aminokyselin 20 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 25 (xi) POPIS SEKVENCE: SEQ ID NO:794: Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly 15 10 30 (2) INFORMACE PRO SEQ ID NO:795: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 15 aminokyselin 35 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 40 (xi) POPIS SEKVENCE: SEQ ID NO:795: Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 15 10 15 45 (2) INFORMACE PRO SEQ ID NO:796: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 21 aminokyselin 50 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 55 (xi) POPIS SEKVENCE: SEQ ID NO:796: Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser 15 10 15 60 Gly Gly Gly Ser Gly 20 872- CZ 295843 B6 (2) INFORMACE PRO SEQ ID NO:797: (i) CHARAKTERISTIKY SEKVENCE: 5 (A) DÉLKA: 21 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 10 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:797: Pro Pro Pro Trp Ser Pro Arg Pro Leu Gly Ala Thr Ala Pro Thr Ala 15 1 5 10 15 Gly Gin Pro Pro Leu 20 (2) INFORMACE PRO SEQ ID NO:798: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 15 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:798: o Pro Trp Ser Pro Arg Pro Leu Gly Ala Thr Ala Pro Thr 5 10 15 (2) INFORMACE PRO SEQ ID NO:799: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 16 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:799: 45 Val Glu Thr Val Phe His Arg Val Ser Gin Asp Gly Leu Leu Thr Ser 15 10 15 20 25 30 35 40 50 Pro Pr< 1 (2) INFORMACE PRO SEQ ID NO:800: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 36 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný -873- 55 CZ 295843 B6 (xi) POPIS SEKVENCE: SEQ ID NO:800: Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Glu Gly Gly Gly 15 10 15 5 Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly Ser 20 25 30 Gly Gly Gly Ser 35 10 (2) INFORMACE PRO SEQ ID NO:801: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 24 aminokyselin (B) TYP: aminokyselina 15 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný 20 (xi) POPIS SEKVENCE: SEQ ID NO:801: Ile Ser Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro 15 10 15 Ser Lys Glu Ser His Lys Ser Pro 25 20 (2) INFORMACE PRO SEQ ID NO:802: (i) CHARAKTERISTIKY SEKVENCE: 30 (A) DÉLKA: 28 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 35 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:802: Ile Glu Gly Arg Ile Ser Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn 40 1 5 10 15 Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 20 25 (2) INFORMACE PRO SEQ ID NO:803: 45 50 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 112 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:803: Ala 1 Asn Cys Ser Ile 5 Met Ile Asp Glu Ile 10 Ile His His Leu Lys 15 Arg Pro Pro Ala Pro 20 Leu Leu Asp Pro Asn 25 Asn Leu Asn Ala Glu 30 Asp Val Asp Ile Leu 35 Met Glu Arg Asn Leu Arg 40 Leu Pro Asn Leu 45 Glu Ser Phe -874- 5 CZ 295843 B6 Val Arg 50 Ala Val Lys Asn Leu 55 Glu Asn Ala Ser Gly 60 Ile Glu Ala Ile Leu 65 Arg Asn Leu Gin Pro 70 Cys Leu Pro Ser Ala 75 Thr Ala Ala Pro Ser 80 Arg His Pro Ile Ile 85 Ile Lys Ala Gly Asp 90 Trp Gin Glu Phe Arg 95 Glu Lys Leu Thr Phe 100 Tyr Leu Val Thr Leu 105 Glu Gin Ala Gin Glu 110 Gin Gin 10 15 20 (2) INFORMACE PRO SEQ ID NO:804: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 112 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:804: 25 30 35 Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg 1 5 10 15 Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 (2) INFORMACE PRO SEQ ID NO:805: (i) CHARAKTERISTIKY SEKVENCE: 40 (A) DÉLKA: 112 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 45 (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:805: 50 55 Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Val 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Ser Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn Leu Leu Ala Phe 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala AI a Pro Ser 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 - 875 - 60 5 CZ 295843 B6 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 (2) INFORMACE PRO SEQ ID NO:806: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 111 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché 10 (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: žádný (xi) POPIS SEKVENCE: SEQ ID NO:806: 15 20 25 Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro 1 5 10 15 Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser 20 25 30 Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val 35 40 45 Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu 50 55 60 Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg 65 70 75 80 His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys 85 90 95 Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 30 35 40 45 50 55 (2) INFORMACE PRO SEQ ID NO:807: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 33 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:807: CTGACCATGG CNACCCAGGA CTGCTCCTTC CAA (2) INFORMACE PRO SEQ ID NO:808: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 32 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:808: ACTGAAGCTT AGGGCTGACA CTGCAGCTCC AG (2) INFORMACE PRO SEQ ID NO:809: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 32 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární -876- 60 CZ 295843 B6 (xi) POPIS SEKVENCE: SEQ ID NO:809: ACTGAAGCTT ACAGGGTTGA GGAGTCGGGC TG (2) INFORMACE PRO SEQ ID NO:810: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 46 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:810: GACTGCCATG GCNACYCAGG AYTGYTCYTT YCAACACAGC CCCATC (2) INFORMACE PRO SEQ ID NO:811: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 46 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:811: GACTGCCATG GCNACYCAGG AYTGYTCYTT YCAACACAGC CCCATC (2) INFORMACE PRO SEQ ID NO:812: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 22 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:812: TGTCCAAACT CATCAATGTA TC (2) INFORMACE PRO SEQ ID NO:813: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 38 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:813: CATGGCCATG GCCGACGAGG AGCTCTGCGG GGGCCTCT (2) INFORMACE PRO SEQ ID NO:814: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 36 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární CZ 295843 B6 (xi) POPIS SEKVENCE: SEQ ID NO:814: GCTAGAAGCT TACTGCAGGT TGGAGGCCAC GGTGAC 5 (2) INFORMACE PRO SEQ ID NO:815: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 38 párů bází (B) TYP: nukleová kyselina 10 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:815: 15 CATGGCCATG GCCTCCAAGA TGCAAGGCTT GCTGGAGC (2) INFORMACE PRO SEQ ID NO:816: (i) CHARAKTERISTIKY SEKVENCE: 20 (A) DÉLKA: 36 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 25 (xi) POPIS SEKVENCE: SEQ ID NO:816: GCTAGAAGCT TACCCAGCGA CAGTCTTGAG CCGCTC (2) INFORMACE PRO SEQ ID NO:817: 30 35 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 36 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:817: CATGGCCATG GCCCCCCCCA GCTGTCTTCG CTTCGT 40 (2) INFORMACE PRO SEQ ID NO:818: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 37 párů bází 45 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:818: 50 GCTAGAAGCT TAGGGCTGAA AGGCACATTT GGTGACA (2) INFORMACE PRO SEQ ID NO:819: 55 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 42 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární - 878 - 60 CZ 295843 B6 (xi) POPIS SEKVENCE: SEQ ID NO:819: CCCTGTCTGG CGGCAACGGC ACCCAGGACT GCTCCTTCCA AC (2) INFORMACE PRO SEQ ID NO:820: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 48 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:820: GCGGTAACGG CAGTGGAGGT AATGGCACCC AGGACTGCTC CTTCCAAC (2) INFORMACE PRO SEQ ID NO:821: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 57 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:821: ACGGCAGTGG TGGCAATGGG AGCGGCGGAA ATGGAACCCA GGACTGCTCC TTCCAAC (2) INFORMACE PRO SEQ ID NO:822: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 38 párů bází (B) TYP: nukleová kyselina, (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:822: GTGCCGTTGC CGCCAGACAG GGTTGAGGAG TCGGGCTG (2) INFORMACE PRO SEQ ID NO:823: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 48 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:823: ATTACCTCCA CTGCCGTTAC CGCCTGACAG GGTTGAGGAG TCGGGCTG (2) INFORMACE PRO SEQ ID NO:824: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 54 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární CZ 295843 B6 (xi) POPIS SEKVENCE: SEQ ID NO:824: GCTCCCATTG CCACCACTGC CGTTACCTCC AGACAGGGTT GAGGAGTCGG GCTG 5 (2) INFORMACE PRO SEQ ID NO:825: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 60 párů bází (B) TYP: nukleová kyselina 10 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:825: 15 GATGAGGATC CGGTGGCAAT GGGAGCGGCG GAAATGGAAC CCAGGACTGC TCCTTCCACC (2) INFORMACE PRO SEQ ID NO:826: (i) CHARAKTERISTIKY SEKVENCE: 20 (A) DÉLKA: 45 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 25 (xi) POPIS SEKVENCE: SEQ ID NO:826: GATGACGGAT CCGTTACCTC CAGACAGGGT TGAGGAGTCG GGCTG (2) INFORMACE PRO SEQ ID NO:827: 30 35 40 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 46 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:827: GATGACGGAT CCGGAGGTAA TGGCACCCAG GACTGCTCCT TCCAAC (2) INFORMACE PRO SEQ ID NO:828: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 29 párů bází 45 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 50 (xi) POPIS SEKVENCE: SEQ ID NO:828: GACTGCCATG GCCGACGAGG AGCTCTGCG (2) INFORMACE PRO SEQ ID NO:829: 55 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 28 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární - 880- 60 CZ 295843 B6 (xi) POPIS SEKVENCE: SEQ ID NO:829: GACTCAAGCT TACTGCAGGT TGGAGGCC (2) INFORMACE PRO SEQ ID NO:830: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 39 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:830: GACTCGGGAT CCGGAGGTTC TGGCACCCAG GACTGCTCC (2) INFORMACE PRO SEQ ID NO:831: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 41 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:831: GACTGGGATC CGGTGGCAGT GGGAGCGGCG GATCTGGAAC C (2) INFORMACE PRO SEQ ID NO:832: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 39 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:832: GACTTGGGAT CCACTACCTC CAGACAGGGT TGAGGAGTC (2) INFORMACE PRO SEQ ID NO:833: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 39 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:833: ACTGACGGAT CCACCGCCCA GGGTTGAGGA GTCGGGCTG (2) INFORMACE PRO SEQ ID NO:834: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 51 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární CZ 295843 B6 (xi) POPIS SEKVENCE: SEQ ID NO:834: ACTGACGGAT CCACCTCCTG ACCCACCGCC CAGGGTTGAG GAGTCGGGCT G (2) INFORMACE PRO SEQ ID NO:835: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 63 párů bázi (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:835: ACTGACGGAT CCACCTCCTG ACCCACCTCC TGACCCACCG CCCAGGGTTG AGGAGTCGGG CTG (2) INFORMACE PRO SEQ ID NO:836: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 28 párů bázi (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:836: ACGTAAAGCT TACAGGGTTG AGGAGTCG (2) INFORMACE PRO SEQ ID NO:837: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 40 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:837: GTCAGTGGAT CCGGAGGTAC CCAGGACTGC TCCTTCCAAC (2) INFORMACE PRO SEQ ID NO:838: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 43 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:838: GTCAGTGGAT CCGGAGGTGG CACCCAGGAC TGCTCCTTCC AAC (2) INFORMACE PRO SEQ ID NO:839: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 60 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární -882 - CZ 295843 B6 (xi) POPIS SEKVENCE: SEQ ID NO:839: TCAGTGGATC CGGAGGTGGC TCAGGGGGAG GTAGTGGTAC CCAGGACTGC TCCTTCCAAC 5 (2) INFORMACE PRO SEQ ID NO:840: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 27 párů bází (B) TYP: nukleová kyselina 10 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:840: 15 TAGTCCATGG CCACCCAGGA CTGCTCC (2) INFORMACE PRO SEQ ID NO:841: (i) CHARAKTERISTIKY SEKVENCE: 20 (A) DÉLKA: 31 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 25 (xi) POPIS SEKVENCE: SEQ ID NO:841: GCATTACGTA GGGCTGACAC TGCAGCTCCA G (2) INFORMACE PRO SEQ ID NO:842: 30 35 40 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 31 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:842: GCATTACGTA CAGGGTTGAG GAGTCGGGCT G (2) INFORMACE PRO SEQ ID NO:843: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 37 párů bází 45 (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 50 (xi) POPIS SEKVENCE: SEQ ID NO:843: GTCAGACCAT GGCCGATTAC CCAGTCACCG TGGCCTC (2) INFORMACE PRO SEQ ID NO:844: 55 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 39 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární - 883 - 60 CZ 295843 B6 (xi) POPIS SEKVENCE: SEQ ID NO:844: TCTGACAAGC TTATTGAAGC AGGTAGTCAG ACAGCTCAC (2) INFORMACE PRO SEQ ID NO:845: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 37 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:845: GTCAGCCCAT GGCCGCCTCC AACCTGCAGG ACGAGGA (2) INFORMACE PRO SEQ ID NO:846: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 37 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:846: TCTGACAAGC TTACACGGTG ACTGGGTAAC TTGAAGC (2) INFORMACE PRO SEQ ID NO:847: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 38 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:847: GTCAGACCAT GGCCGTCGCT GGGTCCAAGA TGCAAGGC (2) INFORMACE PRO SEQ ID NO:848: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 37 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:848: TCTGACAAGC TTAAGTCTTG AGCCGCTCCA TCCAGCG (2) INFORMACE PRO SEQ ID NO:849: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 38 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární CZ 295843 B6 (xi) POPIS SEKVENCE: SEQ ID NO:849: GTCAGACCAT GGCCCGCTTC GTCCAGACCA ACATCTCC (2) INFORMACE PRO SEQ ID NO:850: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 36 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:850: TCTGACAAGC TTAAAGACAG CTGGGGGGGG GCTGAA (2) INFORMACE PRO SEQ ID NO:851: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 38 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:851: GTCAGACCAT GGCCACCAAC ATCTCCCGCC TCCTGCAG (2) INFORMACE PRO SEQ ID NO:852: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 37 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:852: CTCGACAAGC TTACTGGACG AAGCGAAGAC AGCTGGG (2) INFORMACE PRO SEQ ID NO:853: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 33 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:853: GATCACATGT CTACAAATCA AGATCTGCCT GTG (2) INFORMACE PRO SEQ ID NO:854: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 30 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární CZ 295843 B6 (xi) POPIS SEKVENCE: SEQ ID NO:854: GATCGAATTC GTTGTCTTGG ATGAAAGGGA 5 (2) INFORMACE PRO SEQ ID NO:855: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 32 párů bází (B) TYP: nukleová kyselina 10 (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:855: 15 ACTTGAATTC ATCATCCTGG GCCTGTTCGG GC (2) INFORMACE PRO SEQ ID NO:856: (i) CHARAKTERISTIKY SEKVENCE: 20 (A) DÉLKA: 30 párů bází (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 25 (xi) POPIS SEKVENCE: SEQ ID NO:856: ACTCAAGCTT AGAAGCTCCC CAGCGCCTCC (2) INFORMACE PRO SEQ ID NO:857: 30 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 64 párů bázi (B) TYP: nukleová kyselina (C) ŘETĚZENÍ: jednoduché 35 (D) TOPOLOGIE: lineární (xi) POPIS SEKVENCE: SEQ ID NO:857: GGATCCACCA TGAGCCGCCT GCCCGTCCTG CTCCTGCTCC AACTCCTGGT CCGCCCCGCC 40 ATGG (2) INFORMACE PRO SEQ ID NO:858: (i) CHARAKTERISTIKY SEKVENCE: 45 (A) DÉLKA: 174 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: neznámo (D) TOPOLOGIE: neznáma 50 (ii) TYP MOLEKULY: protein (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:1 55 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 1 je Thr, Ser, Arg, Tyr nebo Gly;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo 60 (B) UMÍSTĚNÍ: 2 - 886- 5 10 15 20 25 30 35 40 45 50 55 CZ 295843 B6 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 2 je Pro nebo Leu; " (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:3 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 3 je Leu, Arg, Tyr nebo Ser;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:13 (D) OSTATNÍ INFORMACE:/poznámka^ "Xaa v pozici 13 je Phe, Ser, His, Thr nebo Pro;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:16 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozicí 16 je Lys, Pro, Ser, Thr nebo His;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:17 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 17 je Cys, Ser, Gly, Ala, Ile, Tyr nebo Arg;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:18 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 18 je Leu, Thr, Pro, His, Ile nebo Cys;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:22 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 22 je Arg, Tyr, Ser, Thr nebo Ala;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:24 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 24 je Ile, Pro, Tyr nebo Leu;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:27 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 27 je Asp, nebo Gly;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:30 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 30 je Ala, Ile, Leu nebo Gly;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:34 -887- 60 5 10 15 20 25 30 35 40 45 50 55 CZ 295843 B6 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 34 je Lys nebo Ser;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:36 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 36 je Cys nebo Ser;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:42 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 42 je Cys nebo Ser;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:43 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 43 je His, Thr, Gly, Val, Lys, Trp, Ala, Arg, Cys, nebo Leu;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:44 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 44 je Pro, Gly, Arg, Asp, Val, Ala, His, Trp, Gin, nebo Thr;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:46 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 46 je Glu, Arg, Phe, Arg, Ile nebo Ala;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:47 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 47 je Leu nebo Thr;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:49 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 49 je Leu, Phe, Arg nebo Ser;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:50 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 50 je Leu, Ile, His, Pro nebo Tyr;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:54 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 54 je Leu nebo His;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:64 - 888 - 60 CZ 295843 B6 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 64 je Cys nebo Ser;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:67 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 67 je Gin, Lys, Leu nebo Cys;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:70 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 70 je Gin, Pro, Leu, Arg nebo Ser; ” (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:74 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 74 je Cys nebo Ser;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:104 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 104 je Asp, Gly nebo Val;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:108 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 108 je Leu, Ala, Val, Arg, Trp, Gin nebo Gly;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:115 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 115 je Thr, His, Leu nebo Ala;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:120 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 120 je Gin, Gly, Arg, Lys nebo His" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:123 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 123 je Glu, Arg, Phe nebo Thr" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:144 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 144 je Phe, His, Arg, Pro, Leu, Gin nebo Glu;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:146 - 889- 5 10 15 20 25 30 35 40 45 50 55 60 CZ 295843 B6 (D) OSTATNÍ INFORMACE:/poznámka» "Xaa v pozici 146 je Arg nebo Gin;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:147 (D) OSTATNÍ INFORMACE:/poznámka» "Xaa v pozici 147 je Arg nebo Gin;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:156 (D) OSTATNÍ INFORMACE:/poznámka» "Xaa v pozici 156 je His, Gly nebo Ser;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:159 (D) OSTATNÍ INFORMACE:/poznámka» "Xaa v pozici 159 je Ser, Arg, Thr, Tyr, Val nebo Gly;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:162 (D) OSTATNÍ INFORMACE:/poznámka» "Xaa v pozici 162 je Glu, Leu, Gly nebo Trp;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:163 (D) OSTATNÍ INFORMACE:/poznámka» "Xaa v pozici 163 je Val, Gly, Arg nebo Ala;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:169 (D) OSTATNÍ INFORMACE:/poznámka» "Xaa v pozici 169 je Arg, Ser, Leu, Arg nebo Cys;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:170 (D) OSTATNÍ INFORMACE:/poznámka» "Xaa v pozici 170 je His, Arg nebo Ser;" (xi) POPIS SEKVENCE: SEQ ID NO:858: Xaa Xaa Xaa Gly Pro Ala Ser Ser Leu Pro Gin Ser Xaa Leu Leu Xaa Xaa Xaa Glu Gin Val Xaa Lys Xaa Gin Gly Xaa Gly Ais Xaa Leu Gin 20 25 30 Glu Xaa Leu Xaa Ala Thr Tyr Lys Leu Xaa Xaa Xaa Glu Xaa Xaa Val 35 40 45 Xaa Xaa Gly His Ser Xaa Gly Ile Pro Trp Ala Pro Leu Ser Ser Xaa 50 55 60 Pro Ser Xaa Ala Leu Xaa Leu Ala Gly Xaa Leu Ser Gin Leu His Ser 65 70 75 80 -890- CZ 295843 B6 Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly Ile Ser 85 90 95 Pro Glu Leu Gly Pro Thr Leu Xaa Thr Leu Gin Xaa Asp Val Ala Asp 100 105 110 Phe Ala Xaa Thr Ile Trp Gin Gin Met Glu Xaa Xaa Gly Met Ala Pro 115 120 125 Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Xaa 130 135 140 Gin Xaa Xaa Ala Gly Gly Val Leu Val Ala Ser Xaa Leu Gin Xaa Phe 145 150 155 160 Leu Xaa Xaa Ser Tyr Arg Val Leu Xaa Xaa Leu Ala Gin Pro (2) INFORMACE PRO SEQ ID NO: 859: 20 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 133 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 25 (ii) TYP MOLEKULY: protein (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo 30 (B) UMÍSTĚNÍ:17 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 17 je Ser, Lys, Gly, Asp, Met, Gin, nebo Arg;" (ix) ZNAK: 35 (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:18 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 18 je Asn, His, Leu, Ile, Phe, Arg, nebo Gin;" 40 45 50 (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:19 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 19 je Met, Phe, Ile, Arg, Gly, Ala, nebo Cys;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:20 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 20 je Ile, Cys, Gin, Glu, Arg, Pro, nebo Ala;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:21 55 (D) OSTATNÍ INFORMACE:/poznámka^ "Xaa v pozici 21 je Asp, Phe, Lys, Arg, Ala, Gly, Glu, Gin, Asn, Thr, Ser nebo Val;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:22 -891 - 60 5 10 15 20 25 30 35 40 45 50 55 CZ 295843 B6 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 22 je Glu, Trp, Pro, Ser, Ala, His, Asp, Asn, Gin, Leu, Val nebo Gly; " (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:23 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 23 je Ile, Val, Ala, Gly, Trp, Lys, Phe, Leu, Ser, nebo Arg;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:24 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 24 je Ile, Gly, Val, Arg, Ser, Phe, Leu;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:25 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 25 je Thr, His, Gly, Gin, Arg, Pro, nebo Ala;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:26 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 26 je His, Thr, Phe, Gly, Arg, Ala, Trp;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:27 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 27 je Leu, Gly, Arg, Thr, Ser, nebo Ala;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:28 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 28 je Lys, Arg, Leu, Gin, Gly, Pro, Val nebo Trp;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:29 (D) OSTATNÍ INFORMACE:/poznámka^ "Xaa v pozici 29 je Gin, Asn, Leu, Pro, Arg, nebo Val;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:30 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 30 je Pro, His, Thr, Gly, Asp, Gin, Ser, Leu, nebo L..." (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:31 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 31 je Pro, Asp, Gly, Ala, Arg, Leu, nebo Gin;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:32 -892- 60 CZ 295843 B6 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 32 je Leu, Val, Arg, Gin, Asn, Gly, Ala, nebo Glu;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:33 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 33 je Pro, Leu, Gin, Ala, Thr, nebo Glu;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:34 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 34 je Leu, Val, Gly, Ser, Lys, Glu, Gin, Thr, Arg, Ala, Phe, Ile nebo Met;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:35 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 35 je Leu, Ala, Gly, Asn, Pro, Gin, nebo Val;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:36 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 36 je Asp, Leu, nebo Val;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:37 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 37 je Phe, Ser, Pro, Trp, nebo Ile;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:38 (D) OSTATNÍ INFORMACE:/poznámka^ "Xaa v pozici 38 je Asn, nebo Ala;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:40 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 40 je Leu, Trp, nebo Arg;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:41 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 41 je Asn, Cys, Arg, Leu, His, Met, nebo Pro;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:42 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 42 je Gly, Asp, Ser, Cys, Asn, Lys, Thr, Leu, Val, Glu, Phe, Tyr, Ile, Met nebo Ala;" -893 - 5 10 15 20 25 30 35 40 45 50 55 CZ 295843 B6 (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:43 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 43 je Glu, Asn, Tyr, Leu, Phe, Asp, Ala, Cys, Gin, Arg, Thr, Gly, nebo Ser;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:4 4 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 44 je Asp, Ser, Leu, Arg, Lys, Thr, Met, Trp, Glu, Asn, Gin, Ala nebo Pro;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:45 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 45 je Gin, Pro, Phe, Val, Met, Leu, Thr, Lys, Trp, Asp, Asn, Arg, Ser, Ala, Ile, Glu nebo His;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:46 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 46 je Asp, Phe, Ser, Thr, Cys, Glu, Asn, Gin, Lys, His, Ala, Tyr, Ile, Val nebo Gly;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:47 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 47 je Ile, Gly, Val, Ser, Arg, Pro, nebo His;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:4 8 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 48 je Leu, Ser, Cys, Arg, Ile, His, Phe, Glu, Lys, Thr, Ala, Met, Val nebo Asn;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:49 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 49 je Met, Arg, Ala, Gly, Pro, Asn, His, nebo Asp;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:50 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 50 je Glu, Leu, Thr, Asp, Tyr, Lys, Asn, Ser, Ala, Ile, Val, His, Phe, Met nebo Gin;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:51 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozicí 51 je Asn, Arg, Met, Pro, Ser, Thr, nebo His;" -894- 60 CZ 295843 B6 (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:52 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 52 je Asn, His, Arg, Leu, Gly, Ser, nebo Thr;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:53 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 53 je Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser, nebo M..." (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:54 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 54 je Arg, Asp, Ile, Ser, Val, Thr, Gin, Asn, Lys, His, Ala nebo Leu; " (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:55 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 55 je Arg, Thr, Val, Ser, Leu, nebo Gly;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:56 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 56 je Pro, Gly, Cys, Ser, Gin, Glu, Arg, His, Thr, Ala, Tyr, Phe, Leu, Val nebo Lys;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:57 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 57 je Asn nebo Gly;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:58 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 58 je Leu, Ser, Asp, Arg, Gin, Val, nebo Cys;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:59 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 59 je Glu, Tyr, His, Leu, Pro, nebo Arg;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:60 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 60 je Ala, Ser, Pro, Tyr, Asn, nebo Thr;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:61 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 61 je Phe, Asn, Glu, Pro, Lys, Arg, nebo Ser;" -895 - CZ 295843 B6 (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:62 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 62 je Asn, His, Val, Arg, Pro, Thr, Asp, nebo Ile;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:63 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 63 je Arg, Tyr, Trp, Lys, Ser, His, Pro, nebo Val;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:64 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 64 je Ala, Asn, Pro, Ser, nebo Lys;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:65 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 65 je Val, Thr, Pro, His, Leu, Phe, nebo Ser;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:66 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 66 je Lys, Ile, Arg, Val, Asn, Glu, nebo Ser;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:67 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 67 je Ser, Ala, Phe, Val, Gly, Asn, Ile, Pro, nebo His;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:68 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 68 je Leu, Val, Trp, Ser, Ile, Phe, Thr, nebo His;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:69 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 69 je Gin, Ala, Pro, Thr, Glu, Arg, Trp, Gly, nebo L..." (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:7 0 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 70 je Asn, Leu, Val, Trp, Pro, nebo Ala;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:71 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 71 je Ala, Met, Leu, Pro, Arg, Glu, Thr, Gin, Trp, nebo Asn;" -896- 5 10 15 20 25 30 35 40 45 50 55 CZ 295843 B6 (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:72 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 72 je Ser, Glu, Met, Ala, His, Asn, Arg, nebo Asp;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:7 3 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 73 je Ala, Glu, Asp, Leu, Ser, Gly, Thr, nebo Arg;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:74 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 74 je Ile, Met, Thr, Pro, Arg, Gly, Ala;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:75 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 75 je Glu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gin, nebo Leu;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:7 6 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 76 je Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly, nebo A..." (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:77 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 77 je Ile, Ser, Arg, Thr, nebo Leu;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:78 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 78 je Leu, Ala, Ser, Glu, Phe, Gly, nebo Arg;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:7 9 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 79 je Lys, Thr, Asn, Met, Arg, Ile, Gly, nebo Asp;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:80 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 80 je Asn, Trp, Val, Gly, Thr, Leu, Glu, nebo Arg;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:81 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 81 je Leu, Gin, Gly, Ala, Trp, Arg, Val, nebo Lys;" - 897- 60 5 10 15 20 25 30 35 40 45 50 55 CZ 295843 B6 (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:82 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 82 je Leu, Gin, Lys, Trp, Arg, Asp, Glu, Asn, His, Thr, Ser, Ala, Tyr, Phe, Ile, Met nebo Val;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:83 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 83 je Pro, Ala, Thr, Trp, Arg, nebo Met;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:84 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 84 je Cys, Glu, Gly, Arg, Met, nebo Val;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:85 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 85 je Leu, Asn, Val, nebo Gin;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:86 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 86 je Pro, Cys, Arg, Ala, nebo Lys;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:87 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 87 je Leu, Ser, Trp, nebo Gly;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:88 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 88 je Ala, Lys, Arg, Val, nebo Trp;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:89 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 89 je Thr, Asp, Cys, Leu, Val, Glu, His, Asn, nebo S..." (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:90 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 90 je Ala, Pro, Ser, Thr, Gly, Asp, Ile, nebo, Met;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:91 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 91 je Ala, Pro, Ser, Thr, Phe, Leu, Asp, nebo His;" 898 - 60 5 10 15 20 25 30 35 40 45 50 55 CZ 295843 B6 (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:92 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 92 je Pro, Phe, Arg, Ser, Lys, His, Ala, Gly, Ile nebo Leu;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:93 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 93 je Thr, Asp, Ser, Asn, Pro, Ala, Leu, nebo Arg;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:94 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 94 je Arg, Ile, Ser, Glu, Leu, Val, Gin, Lys, His, Ala, nebo Pro;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:95 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 95 je His, Gin, Pro, Arg, Val, Leu, Gly, Thr, Asn, Lys, Ser, Ala, Trp, Phe, Ile, nebo Tyr;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:96 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 96 je Pro, Lys, Tyr, Gly, Ile, nebo Thr;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:97 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 97 je Ile, Val, Lys, Ala, nebo Asn;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:98 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 98 je His, Ile, Asn, Leu, Asp, Ala, Thr, Glu, Gin, Ser, Phe, Met, Val, Lys, Arg, Tyr, nebo Pro;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:99 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 99 je Ile, Leu, Arg, Asp, Val, Pro, Gin, Gly, Ser, Phe, nebo His;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:100 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 100 je Lys, Tyr, Leu, His, Arg, Ile, Ser, Gin, nebo ..." (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:101 -899- 60 5 10 15 20 25 30 35 40 45 50 55 CZ 295843 B6 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 101 je Asp, Pro, Met, Lys, His, Thr, Val, Tyr, Glu, Asn, Ser, Ala, Gly, Ile, Leu, nebo Gin;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:102 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 102 je Gly, Leu, Glu, Lys, Ser, Tyr, nebo Pro;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:103 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 103 je Asp, nebo Ser;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:104 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 104 je Trp, Val, Cys, Tyr, Thr, Met, Pro, Leu, Gin, Lys, Ala, Phe, nebo Gly;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:105 (D) OSTATNÍ INFORMACE:/poznámka» "Xaa v pozici 105 je Asn, Pro, Ala, Phe, Ser, Trp, Gin, Tyr, Leu, Lys, Ile, Asp, nebo His;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:106 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 106 je Glu, Ser, Ala, Lys, Thr, Ile, Gly, nebo Pro;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:108 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 108 je Arg, Lys, Asp, Leu, Thr, Ile, Gin, His, Ser, Ala nebo Pro;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:109 (D) OSTATNÍ INFORMACE:/poznámka» "Xaa v pozici 109 je Arg, Thr, Pro, Glu, Tyr, Leu, Ser, nebo Gly;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:110 (D) OSTATNÍ INFORMACE:/poznámka» "Xaa v pozici 110 je Lys, Ala, Asn, Thr, Leu, Arg, Gin, His, Glu, Ser, nebo Trp; " (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:111 (D) OSTATNÍ INFORMACE:/poznámka» "Xaa v pozici 111 je Leu, Ile, Arg, Asp, nebo Met;" -900- 60 5 10 15 20 25 30 35 40 45 50 55 CZ 295843 B6 (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:112 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 112 je Thr, Val, Gin, Tyr, Glu, His, Ser, nebo Phe;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:113 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 113 je Phe, Ser, Cys, His, Gly, Trp, Tyr, Asp, Lys, Leu, Ile, Val nebo Asn;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:114 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 114 je Tyr, Cys, His, Ser, Trp, Arg, nebo Leu;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:115 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 115 je Leu, Asn, Val, Pro, Arg, Ala, His, Thr, Trp, nebo Met;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:116 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 116 je Lys, Leu, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp, Ser, Asn, His, Ala, Tyr, Phe, Gin, nebo Ile;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:117 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 117 je Thr, Ser, Asn, Ile, Trp, Lys, nebo Pro;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:118 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 118 je Leu, Ser, Pro, Ala, Glu, Cys, Asp, nebo Tyr;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:119 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 119 je Glu, Ser, Lys, Pro, Leu, Thr, Tyr, nebo Arg;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:120 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 120 je Asn, Ala, Pro, Leu, His, Val, nebo Gin;" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:121 (D) OSTATNÍ INFORMACE:/poznámka^ "Xaa v pozici 121 je Ala, Ser, Ile, Asn, Pro, Lys, Asp, nebo Gly;" -901 - 60 5 CZ 295843 B6 (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:122 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 122 je Gin, Ser, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr, nebo Cys;" (ix) ZNAK: 10 (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:123 (D) OSTATNÍ INFORMACE:/poznámka= "Xaa v pozici 123 je Ala, Met, Glu, His, Ser, Pro, Tyr, nebo Leu;" 15 (xi) POPIS SEKVENCE: SEQ ID NO: 859: Ala Pro Met Thr Gin Thr Thr Ser Leu Lys Thr Ser Trp Val Asn Cys 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 35 40 45 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 50 55 60 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 65 70 75 80 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 85 90 95 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Phe Xaa Xaa Xaa Xaa Xaa 100 105 110 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gin Gin Thr Thr Leu 115 120 125 Ser Leu Ala Ile Phe 130 20 25 30 35 40 (2) INFORMACE PRO SEQ ID NO:860: 45 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 153 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: neznámo 50 (D) TOPOLOGIE: neznáma (ii) TYP MOLEKULY: protein (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:112 (D) OSTATNÍ INFORMACE:/poznámka= "pozice 112 je odstraněna nebo Leu, Ala,Val, Ile, Pro, Phe, Trp nebo Met" -902- 55 5 CZ 295843 B6 (ίχ) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:113 (D) OSTATNÍ INFORMACE:/poznámka= "pozice 113 je odstraněna nebo Pro, Phe, Ala, Val, Leu, Ile, Trp nebo Met" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo (B) UMÍSTĚNÍ:114 10 (D) OSTATNÍ INFORMACE:/poznámka= "pozice 114 je odstraněna nebo Pro, Phe, Ala, Val, Leu, Ile, Trp nebo Met" (ix) ZNAK: (A) JMÉNO/ZNAČKA: Modifikované místo 15 (B) UMÍSTĚNÍ:115 (D) OSTATNÍ INFORMACE:/poznámka= "pozice 115 je odstraněna nebo Gin, Gly, Ser, Thr, Tyr, nebo Asn" (xi) POPIS SEKVENCE: SEQ ID NO:860: 20 Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu 1 5 10 15 Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gin Cys Pro Glu Val 25 20 25 30 His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu 35 40 45 30 Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala Gin Asp Ile Leu 50 55 60 Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gin 65 70 75 80 35 Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser Gly Gin 85 90 95 Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr Gin Xaa 40 100 105 110 Xaa Xaa Xaa Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala Ile Phe 115 120 125 45 Leu Ser Phe Gin His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu 130 135 140 Val Gly Gly Ser Thr Leu Cys Val Arg 145 150 50 (2) INFORMACE PRO SEQ ID NO:861: (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1 aminokyselin 55 (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: protein -903 - 60 CZ 295843 B6 (ix) ZNAK: (A) JMÉNO/ZNAČKA: Protein (B) UMÍSTĚNÍ:1 (D) OSTATNÍ INFORMACE:/poznámka= "kde x=(glyglyglyser)n a 5 kde n je celé číslo" (xi) POPIS SEKVENCE: SEQ ID NO:861: Xaa 10 1 (2) INFORMACE PRO SEQ ID NO:862: (i) CHARAKTERISTIKY SEKVENCE: 15 (A) DÉLKA: 1 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární 20 25 (ii) TYP MOLEKULY: protein (ix) ZNAK: (A) JMÉNO/ZNAČKA: Peptid (B) UMÍSTĚNÍ:1 (D) OSTATNÍ INFORMACE:/poznámka= "kde x=(glyglyglyglyser)n a kde n je celé číslo" (xi) POPIS SEKVENCE: SEQ ID NO:862: 30 Xaa 1 (2) INFORMACE PRO SEQ ID NO:863: 35 40 45 50 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární (ii) TYP MOLEKULY: protein (ix) ZNAK: (A) JMÉNO/ZNAČKA: Protein (B) UMÍSTĚNÍ:1 (D) OSTATNÍ INFORMACE:/poznámka= "kde x= (glyglyglyglyglyser)n a kde n je celé číslo" (xi) POPIS SEKVENCE: SEQ ID NO:863: Xaa 1 (2) INFORMACE PRO SEQ ID NO:864: 55 (i) CHARAKTERISTIKY SEKVENCE: (A) DÉLKA: 1 aminokyselin (B) TYP: aminokyselina (C) ŘETĚZENÍ: jednoduché (D) TOPOLOGIE: lineární -904- 60 CZ 295843 B6 (ii) TYP MOLEKULY: protein (ix) ZNAK: (A) 5 (B) (D) JMÉNO/ZNAČKA: Protein UMÍSTĚNÍ:! OSTATNÍ INFORMACE:/poznámka= "kde x=(gly n ser)n a kde n je celé číslo" (xi) POPIS SEKVENCE: SEQ ID NO:864 10 Xaa 1 (2) INFORMACE PRO SEQ ID NO:865: 15 (i) CHARAKTERISTIKY SEKVENCE (A) (B) (C) 20 (D) DÉLKA: 1 aminokyselin TYP: aminokyselina ŘETĚZENÍ: jednoduché TOPOLOGIE: lineární (ii) TYP MOLEKULY: protein (ix) ZNAK 25 (A) (B) (D) JMÉNO/ZNAČKA: Protein UMÍSTĚNÍ:1 OSTATNÍ INFORMACE:/poznámka= "kde x=(alaglyser)n a kde n je celé číslo" 30 (xi) POPIS SEKVENCE: SEQ ID NO:865 Xaa -905 -
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2962996P | 1996-10-25 | 1996-10-25 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CZ132399A3 CZ132399A3 (cs) | 1999-12-15 |
| CZ295843B6 true CZ295843B6 (cs) | 2005-11-16 |
Family
ID=21850035
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CZ19991323A CZ295843B6 (cs) | 1996-10-25 | 1997-10-23 | Multi-funkční chimérní agonisté hematopoietických receptorů |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP0935663A2 (cs) |
| JP (1) | JP2001504689A (cs) |
| KR (1) | KR100497423B1 (cs) |
| AR (1) | AR010041A1 (cs) |
| AU (1) | AU725547B2 (cs) |
| BR (1) | BR9713668A (cs) |
| CA (1) | CA2268742A1 (cs) |
| CZ (1) | CZ295843B6 (cs) |
| IL (1) | IL129565A0 (cs) |
| NO (1) | NO991948L (cs) |
| NZ (1) | NZ335382A (cs) |
| PL (1) | PL333023A1 (cs) |
| RO (1) | RO120919B1 (cs) |
| RU (2) | RU2245887C2 (cs) |
| TW (2) | TW591035B (cs) |
| WO (1) | WO1998017810A2 (cs) |
| ZA (1) | ZA979607B (cs) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5581476A (en) | 1993-01-28 | 1996-12-03 | Amgen Inc. | Computer-based methods and articles of manufacture for preparing G-CSF analogs |
| US20020137890A1 (en) * | 1997-03-31 | 2002-09-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| CA2284127A1 (en) * | 1997-04-11 | 1998-10-22 | G.D. Searle & Co. | Flt3 ligand chimeric proteins |
| BR9905867A (pt) * | 1998-11-06 | 2001-01-23 | Bio Sidus S A | Linhagem celular produtora de eritropoietina humana recombinante e a eritropoietina humana recombinante produzida por esta célula |
| WO2002101047A1 (en) * | 2001-06-12 | 2002-12-19 | Smithkline Beecham Corporation | Method of identifying compounds that modulate epo primary response gene 1, eprg1, activities |
| PL371781A1 (en) | 2001-07-11 | 2005-06-27 | Maxygen Holdings, Ltd. | G-csf conjugates |
| DE602004023956D1 (de) | 2003-08-18 | 2009-12-17 | Univ California | Polypeptid-display-bibliotheken und verfahren zur herstellung und verwendung davon |
| EP1888119B1 (en) | 2005-06-01 | 2011-03-09 | Maxygen, Inc. | Pegylated g-csf polypeptides and methods of producing same |
| US7550433B2 (en) * | 2005-06-03 | 2009-06-23 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
| EP2535346B1 (en) | 2005-08-31 | 2017-08-02 | The Regents of The University of California | Cellular libraries of peptide sequences (CLiPS) and methods of using the same |
| WO2007098548A1 (en) * | 2006-03-01 | 2007-09-07 | Apollo Life Sciences Limited | A molecule and chimeric molecules thereof |
| US8293685B2 (en) | 2007-07-26 | 2012-10-23 | The Regents Of The University Of California | Methods for enhancing bacterial cell display of proteins and peptides |
| US10071109B2 (en) | 2013-11-06 | 2018-09-11 | Molecular Templates, Inc. | Predictive biomarker for hypoxia-activated prodrug therapy |
| WO2020198659A1 (en) * | 2019-03-28 | 2020-10-01 | Orionis Biosciences, Inc. | Fms-like tyrosine kinase 3 ligand (flt3l)-based chimeric proteins |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2069746A1 (en) * | 1990-09-28 | 1992-03-29 | Jonathan I. Rosen | Hybrid growth factors |
| US5376367A (en) * | 1991-11-22 | 1994-12-27 | Immunex Corporation | Fusion proteins comprising MGF and IL-3 |
| US5738849A (en) * | 1992-11-24 | 1998-04-14 | G. D. Searle & Co. | Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them |
| US6057133A (en) * | 1992-11-24 | 2000-05-02 | G. D. Searle | Multivariant human IL-3 fusion proteins and their recombinant production |
| US5635599A (en) * | 1994-04-08 | 1997-06-03 | The United States Of America As Represented By The Department Of Health And Human Services | Fusion proteins comprising circularly permuted ligands |
-
1997
- 1997-10-23 NZ NZ335382A patent/NZ335382A/xx unknown
- 1997-10-23 CA CA002268742A patent/CA2268742A1/en not_active Abandoned
- 1997-10-23 AU AU51652/98A patent/AU725547B2/en not_active Ceased
- 1997-10-23 CZ CZ19991323A patent/CZ295843B6/cs not_active IP Right Cessation
- 1997-10-23 IL IL12956597A patent/IL129565A0/xx unknown
- 1997-10-23 WO PCT/US1997/020037 patent/WO1998017810A2/en not_active Ceased
- 1997-10-23 BR BR9713668-9A patent/BR9713668A/pt not_active Application Discontinuation
- 1997-10-23 EP EP97946495A patent/EP0935663A2/en not_active Withdrawn
- 1997-10-23 PL PL97333023A patent/PL333023A1/xx unknown
- 1997-10-23 KR KR10-1999-7003635A patent/KR100497423B1/ko not_active Expired - Fee Related
- 1997-10-23 RO RO99-00480A patent/RO120919B1/ro unknown
- 1997-10-23 JP JP51975498A patent/JP2001504689A/ja not_active Abandoned
- 1997-10-23 RU RU99111071/13A patent/RU2245887C2/ru not_active IP Right Cessation
- 1997-10-27 TW TW086116018A patent/TW591035B/zh not_active IP Right Cessation
- 1997-10-27 ZA ZA979607A patent/ZA979607B/xx unknown
- 1997-10-27 TW TW093111460A patent/TW200413407A/zh unknown
- 1997-10-28 AR ARP970104979A patent/AR010041A1/es unknown
-
1999
- 1999-04-23 NO NO991948A patent/NO991948L/no not_active Application Discontinuation
-
2005
- 2005-02-24 RU RU2005105360/13A patent/RU2005105360A/ru not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO991948D0 (no) | 1999-04-23 |
| TW591035B (en) | 2004-06-11 |
| CZ132399A3 (cs) | 1999-12-15 |
| WO1998017810A3 (en) | 1998-10-15 |
| NZ335382A (en) | 2001-03-30 |
| IL129565A0 (en) | 2000-02-29 |
| RU2005105360A (ru) | 2006-08-10 |
| BR9713668A (pt) | 2000-03-08 |
| PL333023A1 (en) | 1999-11-08 |
| WO1998017810A2 (en) | 1998-04-30 |
| RU2245887C2 (ru) | 2005-02-10 |
| AU5165298A (en) | 1998-05-15 |
| TW200413407A (en) | 2004-08-01 |
| AU725547B2 (en) | 2000-10-12 |
| AR010041A1 (es) | 2000-05-17 |
| NO991948L (no) | 1999-06-23 |
| RO120919B1 (ro) | 2006-09-29 |
| JP2001504689A (ja) | 2001-04-10 |
| KR20000052812A (ko) | 2000-08-25 |
| KR100497423B1 (ko) | 2005-07-07 |
| EP0935663A2 (en) | 1999-08-18 |
| CA2268742A1 (en) | 1998-04-30 |
| ZA979607B (en) | 1999-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CZ295843B6 (cs) | Multi-funkční chimérní agonisté hematopoietických receptorů | |
| CN113912737A (zh) | 白介素-2/白介素-2受体α融合蛋白和使用方法 | |
| US6730303B1 (en) | Fused G-CSF and IL-3 proteins and uses thereof | |
| AU705083B2 (en) | Multi-functional hematopoietic receptor agonists | |
| US20040127410A1 (en) | Circular permuteins of flt3 ligand | |
| AU717733B2 (en) | Novel G-CSF receptor agonists | |
| US6358505B1 (en) | G-CSF receptor agonists | |
| WO1997023639A1 (en) | Process for producing biologically active fused proteins | |
| US6967092B1 (en) | Multi-functional chimeric hematopoietic receptor agonists | |
| MXPA99003877A (en) | Multi-functional chimeric hematopoietic receptor agonists | |
| WO1997012978A1 (en) | NOVEL c-mpl RECEPTOR AGONISTS | |
| CN1242049A (zh) | 多功能嵌合造血受体激动剂 | |
| HK1025353A (en) | Multi-functional chimeric hematopoietic receptor agonists | |
| CZ346799A3 (cs) | Chimérické proteiny jako flt3 ligandy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PD00 | Pending as of 2000-06-30 in czech republic | ||
| MM4A | Patent lapsed due to non-payment of fee |
Effective date: 19971023 |